| Symbol | GSK |
|---|---|
| Name | GSK PLC |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | - |
| Address | TW8 9GS United Kingdom ENG 980 Great West Road Brentford |
| Telephone | +44 20 8047 5000 |
| Fax | — |
| — | |
| Website | http://GSK.Investor-Relations@gsk.com |
| Incorporation | GB |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001131399 |
| Description | In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. Additional info from NASDAQ: |
2026-05-07 12:00
Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT01131247 | PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CL… | Phase2 | Chronic Lymphocytic Leukemia (CLL) | Withdrawn | — | — | ClinicalTrials.gov |
| NCT01776996 | An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies In… | — | Infection, Human Immunodeficiency Virus | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT00244686 | This Record Contains Information About the Mepolizumab Compassionate Use (CU) P… | — | Hypereosinophilic Syndrome | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT02416232 | Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc)… | — | Melanoma | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT03763370 | Managed Access Program for Combination Treatment With Belantamab Mafodotin in M… | — | Multiple Myeloma | Available | — | — | ClinicalTrials.gov |
| NCT00022893 | Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of… | Na | Non-Hodgkin's Lymphoma | Unknown | — | — | ClinicalTrials.gov |
| NCT03702036 | Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carci… | — | Solid Tumours | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT00022893 | Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of… | Na | Non-Hodgkin's Lymphoma | Unknown | — | — | ClinicalTrials.gov |
| NCT00841451 | Pulmonary Vein Isolation Outcomes With Fish Oils | — | Atrial Fibrillation | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT00225342 | Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina | Phase4 | Angina Pectoris | Withdrawn | — | — | ClinicalTrials.gov |
| NCT02416232 | Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc)… | — | Melanoma | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT00474591 | Fondaparinux to Prevent Thrombotic Complications and Graft Failure in Patients … | Phase3 | Coronary Bypass Graft Failure/Occlusion | Unknown | — | — | ClinicalTrials.gov |
| NCT05448170 | Linerixibat Compassionate Use for Cholestatic Pruritus Adult Patients With Prim… | — | Pruritus | Available | — | — | ClinicalTrials.gov |
| NCT05582083 | Managed Access Program for Momelotinib in Myelofibrosis | — | Myelofibrosis | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT01317810 | A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication | — | Overactive Bladder (OAB) | Withdrawn | — | — | ClinicalTrials.gov |
| NCT00244686 | This Record Contains Information About the Mepolizumab Compassionate Use (CU) P… | — | Hypereosinophilic Syndrome | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT00357045 | Antidepressant Prophylaxis for Interferon-Induced Depression: Efficacy of Parox… | Phase4 | Major Depression | Completed | — | — | ClinicalTrials.gov |
| NCT01776996 | An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies In… | — | Infection, Human Immunodeficiency Virus | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT03025867 | Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer | — | Recurrent Ovarian Cancer | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT01317810 | A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication | — | Overactive Bladder (OAB) | Withdrawn | — | — | ClinicalTrials.gov |
| NCT03125486 | Compassionate Use for Subcutaneous (SC) Belimumab | — | Systemic Lupus Erythematosus | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT03702036 | Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carci… | — | Solid Tumours | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT00225342 | Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina | Phase4 | Angina Pectoris | Withdrawn | — | — | ClinicalTrials.gov |
| NCT00492414 | Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effe… | Phase4 | Panic Disorder | Unknown | — | — | ClinicalTrials.gov |
| NCT01131247 | PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CL… | Phase2 | Chronic Lymphocytic Leukemia (CLL) | Withdrawn | — | — | ClinicalTrials.gov |
| NCT03125486 | Compassionate Use for Subcutaneous (SC) Belimumab | — | Systemic Lupus Erythematosus | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT03025867 | Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer | — | Recurrent Ovarian Cancer | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT03763370 | Managed Access Program for Combination Treatment With Belantamab Mafodotin in M… | — | Multiple Myeloma | Available | — | — | ClinicalTrials.gov |
| NCT00841451 | Pulmonary Vein Isolation Outcomes With Fish Oils | — | Atrial Fibrillation | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT00357045 | Antidepressant Prophylaxis for Interferon-Induced Depression: Efficacy of Parox… | Phase4 | Major Depression | Completed | — | — | ClinicalTrials.gov |
| NCT00474591 | Fondaparinux to Prevent Thrombotic Complications and Graft Failure in Patients … | Phase3 | Coronary Bypass Graft Failure/Occlusion | Unknown | — | — | ClinicalTrials.gov |
| NCT05448170 | Linerixibat Compassionate Use for Cholestatic Pruritus Adult Patients With Prim… | — | Pruritus | Available | — | — | ClinicalTrials.gov |
| NCT00492414 | Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effe… | Phase4 | Panic Disorder | Unknown | — | — | ClinicalTrials.gov |
| NCT05582083 | Managed Access Program for Momelotinib in Myelofibrosis | — | Myelofibrosis | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT07498205 | Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis an… | Phase4 | Myelofibrosis | Not_Yet_Recruiting | 2026-08-08 | 2031-08-08 | ClinicalTrials.gov |
| NCT07498205 | Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis an… | Phase4 | Myelofibrosis | Not_Yet_Recruiting | 2026-08-08 | 2031-08-08 | ClinicalTrials.gov |
| NCT07406347 | A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumoc… | Phase1 | Pneumonia, Bacterial | Not_Yet_Recruiting | 2026-07-10 | 2028-04-03 | ClinicalTrials.gov |
| NCT07406347 | A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumoc… | Phase1 | Pneumonia, Bacterial | Not_Yet_Recruiting | 2026-07-10 | 2028-04-03 | ClinicalTrials.gov |
| NCT07585266 | A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants … | Phase3 | Gastrointestinal Stromal Neoplasms | Not_Yet_Recruiting | 2026-06-15 | 2032-09-28 | ClinicalTrials.gov |
| NCT07585266 | A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants … | Phase3 | Gastrointestinal Stromal Neoplasms | Not_Yet_Recruiting | 2026-06-15 | 2032-09-28 | ClinicalTrials.gov |
| NCT07286331 | A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants Wi… | Phase3 | Neoplasms, Endometrial | Not_Yet_Recruiting | 2026-06-09 | 2029-05-30 | ClinicalTrials.gov |
| NCT07286331 | A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants Wi… | Phase3 | Neoplasms, Endometrial | Not_Yet_Recruiting | 2026-06-09 | 2029-05-30 | ClinicalTrials.gov |
| NCT06412120 | Study Evaluating Safety, Tolerability, and Metabolism of Niraparib | Phase4 | Ovarian Cancer | Recruiting | 2026-06-01 | 2031-06-01 | ClinicalTrials.gov |
| NCT06412120 | Study Evaluating Safety, Tolerability, and Metabolism of Niraparib | Phase4 | Ovarian Cancer | Recruiting | 2026-06-01 | 2031-06-01 | ClinicalTrials.gov |
| NCT07406334 | A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumoc… | Phase1 | Pneumonia, Bacterial | Not_Yet_Recruiting | 2026-05-15 | 2027-02-22 | ClinicalTrials.gov |
| NCT07406334 | A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumoc… | Phase1 | Pneumonia, Bacterial | Not_Yet_Recruiting | 2026-05-15 | 2027-02-22 | ClinicalTrials.gov |
| NCT07285239 | Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexametha… | Phase3 | Multiple Myeloma | Not_Yet_Recruiting | 2026-05-01 | 2034-04-01 | ClinicalTrials.gov |
| NCT07285239 | Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexametha… | Phase3 | Multiple Myeloma | Not_Yet_Recruiting | 2026-05-01 | 2034-04-01 | ClinicalTrials.gov |
| NCT07371429 | A Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Conf… | Phase1 | Urinary Tract Infections | Not_Yet_Recruiting | 2026-04-29 | 2027-08-23 | ClinicalTrials.gov |
| NCT07371429 | A Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Conf… | Phase1 | Urinary Tract Infections | Not_Yet_Recruiting | 2026-04-29 | 2027-08-23 | ClinicalTrials.gov |
| NCT07408063 | A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to… | Phase2 | Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Recruiting | 2026-04-27 | 2031-03-01 | ClinicalTrials.gov |
| NCT07408063 | A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to… | Phase2 | Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Recruiting | 2026-04-27 | 2031-03-01 | ClinicalTrials.gov |
| NCT07545681 | A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With… | Phase2 | Malaria, Falciparum | Not_Yet_Recruiting | 2026-04-20 | 2027-07-22 | ClinicalTrials.gov |
| NCT07545681 | A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With… | Phase2 | Malaria, Falciparum | Not_Yet_Recruiting | 2026-04-20 | 2027-07-22 | ClinicalTrials.gov |
| NCT07227311 | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combinat… | Phase2 | Multiple Myeloma | Recruiting | 2026-04-15 | 2030-08-30 | ClinicalTrials.gov |
| NCT07227311 | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combinat… | Phase2 | Multiple Myeloma | Recruiting | 2026-04-15 | 2030-08-30 | ClinicalTrials.gov |
| NCT07406360 | A Study on the Immune Response and Safety of an Investigational Combined Measle… | Phase3 | Measles | Not_Yet_Recruiting | 2026-04-13 | 2028-06-22 | ClinicalTrials.gov |
| NCT07406360 | A Study on the Immune Response and Safety of an Investigational Combined Measle… | Phase3 | Measles | Not_Yet_Recruiting | 2026-04-13 | 2028-06-22 | ClinicalTrials.gov |
| NCT07519395 | A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placeb… | Phase2 | Irritable Bowel Syndrome | Not_Yet_Recruiting | 2026-04-06 | 2027-07-09 | ClinicalTrials.gov |
| NCT07519395 | A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placeb… | Phase2 | Irritable Bowel Syndrome | Not_Yet_Recruiting | 2026-04-06 | 2027-07-09 | ClinicalTrials.gov |
| NCT07286370 | A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TC… | Phase2 | Salmonella Infections | Recruiting | 2026-04-01 | 2028-04-27 | ClinicalTrials.gov |
| NCT07485283 | Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and D… | Phase4 | Cardiovascular Disease | Not_Yet_Recruiting | 2026-04-01 | 2029-04-01 | ClinicalTrials.gov |
| NCT07286370 | A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TC… | Phase2 | Salmonella Infections | Recruiting | 2026-04-01 | 2028-04-27 | ClinicalTrials.gov |
| NCT07485283 | Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and D… | Phase4 | Cardiovascular Disease | Not_Yet_Recruiting | 2026-04-01 | 2029-04-01 | ClinicalTrials.gov |
| NCT07502560 | A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis o… | Phase4 | Herpes Zoster | Recruiting | 2026-03-31 | 2037-03-31 | ClinicalTrials.gov |
| NCT07502560 | A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis o… | Phase4 | Herpes Zoster | Recruiting | 2026-03-31 | 2037-03-31 | ClinicalTrials.gov |
| NCT07438782 | First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Acti… | Phase1 | Neoplasms | Recruiting | 2026-03-23 | 2029-02-13 | ClinicalTrials.gov |
| NCT07438782 | First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Acti… | Phase1 | Neoplasms | Recruiting | 2026-03-23 | 2029-02-13 | ClinicalTrials.gov |
| NCT07224672 | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combinat… | Phase2 | Amyloidosis | Not_Yet_Recruiting | 2026-03-20 | 2032-12-13 | ClinicalTrials.gov |
| NCT07224672 | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combinat… | Phase2 | Amyloidosis | Not_Yet_Recruiting | 2026-03-20 | 2032-12-13 | ClinicalTrials.gov |
| NCT07428759 | Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal… | Phase1 | Pneumonia, Bacterial | Recruiting | 2026-03-10 | 2026-12-24 | ClinicalTrials.gov |
| NCT07428759 | Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal… | Phase1 | Pneumonia, Bacterial | Recruiting | 2026-03-10 | 2026-12-24 | ClinicalTrials.gov |
| NCT07464314 | A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/… | Phase1 | Influenza, Human+COVID-19 | Recruiting | 2026-03-09 | 2027-06-03 | ClinicalTrials.gov |
| NCT07464314 | A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/… | Phase1 | Influenza, Human+COVID-19 | Recruiting | 2026-03-09 | 2027-06-03 | ClinicalTrials.gov |
| NCT07335198 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenici… | Phase1 | Non-alcoholic Fatty Liver Disease | Recruiting | 2026-03-05 | 2026-08-17 | ClinicalTrials.gov |
| NCT07335198 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenici… | Phase1 | Non-alcoholic Fatty Liver Disease | Recruiting | 2026-03-05 | 2026-08-17 | ClinicalTrials.gov |
| NCT07104799 | Momelotinib During and After HCT in Myelofibrosis | Phase1 | Myelofibrosis | Recruiting | 2026-02-23 | 2030-01-01 | ClinicalTrials.gov |
| NCT07104799 | Momelotinib During and After HCT in Myelofibrosis | Phase1 | Myelofibrosis | Recruiting | 2026-02-23 | 2030-01-01 | ClinicalTrials.gov |
| NCT07268053 | A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targe… | Early_Phase1 | Glioblastoma (GBM) | Recruiting | 2026-02-11 | 2029-07-01 | ClinicalTrials.gov |
| NCT07268053 | A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targe… | Early_Phase1 | Glioblastoma (GBM) | Recruiting | 2026-02-11 | 2029-07-01 | ClinicalTrials.gov |
| NCT07332455 | First-Time-in-Human Study of GSK5471713 in Adults With mCRPC | Phase1 | Neoplasms, Prostate | Recruiting | 2026-02-10 | 2030-03-26 | ClinicalTrials.gov |
| NCT07332455 | First-Time-in-Human Study of GSK5471713 in Adults With mCRPC | Phase1 | Neoplasms, Prostate | Recruiting | 2026-02-10 | 2030-03-26 | ClinicalTrials.gov |
| NCT07371468 | A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic D… | Phase1 | Systemic Lupus Erythematosus | Recruiting | 2026-02-10 | 2028-03-15 | ClinicalTrials.gov |
| NCT07371468 | A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic D… | Phase1 | Systemic Lupus Erythematosus | Recruiting | 2026-02-10 | 2028-03-15 | ClinicalTrials.gov |
| NCT07320716 | Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Chi… | Phase2 | Diarrhoea | Not_Yet_Recruiting | 2026-01-02 | 2028-10-31 | ClinicalTrials.gov |
| NCT07320716 | Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Chi… | Phase2 | Diarrhoea | Not_Yet_Recruiting | 2026-01-02 | 2028-10-31 | ClinicalTrials.gov |
| NCT07050732 | Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons | Phase2 | Respiratory Syncytial Virus (RSV) | Recruiting | 2025-12-04 | 2028-04-01 | ClinicalTrials.gov |
| NCT07050732 | Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons | Phase2 | Respiratory Syncytial Virus (RSV) | Recruiting | 2025-12-04 | 2028-04-01 | ClinicalTrials.gov |
| NCT07218926 | A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gast… | Phase3 | Gastrointestinal Neoplasms | Recruiting | 2025-12-03 | 2030-11-29 | ClinicalTrials.gov |
| NCT07277270 | A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agent… | Phase1 | Neoplasms | Recruiting | 2025-12-03 | 2028-09-29 | ClinicalTrials.gov |
| NCT07277270 | A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agent… | Phase1 | Neoplasms | Recruiting | 2025-12-03 | 2028-09-29 | ClinicalTrials.gov |
| NCT07218926 | A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gast… | Phase3 | Gastrointestinal Neoplasms | Recruiting | 2025-12-03 | 2030-11-29 | ClinicalTrials.gov |
| NCT07263594 | A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors | Phase1 | Gastrointestinal Cancer | Not_Yet_Recruiting | 2025-12-01 | 2028-12-01 | ClinicalTrials.gov |
| NCT07263594 | A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors | Phase1 | Gastrointestinal Cancer | Not_Yet_Recruiting | 2025-12-01 | 2028-12-01 | ClinicalTrials.gov |
| NCT07108270 | A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Pa… | Phase2 | Neoplasms, Endometrial | Recruiting | 2025-11-27 | 2030-03-31 | ClinicalTrials.gov |
| NCT07108270 | A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Pa… | Phase2 | Neoplasms, Endometrial | Recruiting | 2025-11-27 | 2030-03-31 | ClinicalTrials.gov |
| NCT07098936 | Momelotinib in VEXAS Syndrome | Phase2 | VEXAS Syndome | Recruiting | 2025-11-25 | 2028-11-01 | ClinicalTrials.gov |
| NCT07098936 | Momelotinib in VEXAS Syndrome | Phase2 | VEXAS Syndome | Recruiting | 2025-11-25 | 2028-11-01 | ClinicalTrials.gov |
| NCT07444203 | Transformative Research in Diabetic Nephropathy 2.0 | — | Diabetic Nephropathies | Recruiting | 2025-11-12 | 2028-11-12 | ClinicalTrials.gov |
| NCT07444203 | Transformative Research in Diabetic Nephropathy 2.0 | — | Diabetic Nephropathies | Recruiting | 2025-11-12 | 2028-11-12 | ClinicalTrials.gov |
| NCT07220109 | A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncyt… | Phase3 | Respiratory Syncytial Virus Infections | Recruiting | 2025-10-29 | 2026-12-14 | ClinicalTrials.gov |
| NCT07220109 | A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncyt… | Phase3 | Respiratory Syncytial Virus Infections | Recruiting | 2025-10-29 | 2026-12-14 | ClinicalTrials.gov |
| NCT07221227 | A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With … | Phase3 | Non-alcoholic Fatty Liver Disease | Recruiting | 2025-10-24 | 2031-12-12 | ClinicalTrials.gov |
| NCT07221227 | A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With … | Phase3 | Non-alcoholic Fatty Liver Disease | Recruiting | 2025-10-24 | 2031-12-12 | ClinicalTrials.gov |
| NCT06489964 | Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies | Na | Preventable Disease, Vaccine | Recruiting | 2025-10-23 | 2026-12-01 | ClinicalTrials.gov |
| NCT06489964 | Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies | Na | Preventable Disease, Vaccine | Recruiting | 2025-10-23 | 2026-12-01 | ClinicalTrials.gov |
| NCT07213609 | A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone … | Phase1 | Neoplasms, Colorectal | Recruiting | 2025-10-20 | 2028-10-27 | ClinicalTrials.gov |
| NCT07177339 | eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN C… | Phase3 | Pulmonary Disease, Chronic Obstructive | Recruiting | 2025-10-20 | 2029-12-14 | ClinicalTrials.gov |
| NCT07213609 | A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone … | Phase1 | Neoplasms, Colorectal | Recruiting | 2025-10-20 | 2028-10-27 | ClinicalTrials.gov |
| NCT07177339 | eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN C… | Phase3 | Pulmonary Disease, Chronic Obstructive | Recruiting | 2025-10-20 | 2029-12-14 | ClinicalTrials.gov |
| NCT07204964 | A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in A… | Phase2 | Influenza, Human | Active_Not_Recruiting | 2025-10-07 | 2026-07-31 | ClinicalTrials.gov |
| NCT07204964 | A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in A… | Phase2 | Influenza, Human | Active_Not_Recruiting | 2025-10-07 | 2026-07-31 | ClinicalTrials.gov |
| NCT07115927 | pReOperative Dostarlimab and Novel Therapies in EndOmetrial Cancer | Phase2 | Endometrial Cancer | Not_Yet_Recruiting | 2025-09-30 | 2031-01-31 | ClinicalTrials.gov |
| NCT07115927 | pReOperative Dostarlimab and Novel Therapies in EndOmetrial Cancer | Phase2 | Endometrial Cancer | Not_Yet_Recruiting | 2025-09-30 | 2031-01-31 | ClinicalTrials.gov |
| NCT07201051 | A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Br… | Phase2 | Bronchiectasis | Not_Yet_Recruiting | 2025-09-26 | 2027-11-08 | ClinicalTrials.gov |
| NCT07362225 | MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, an… | — | Polycythemia Vera | Recruiting | 2025-09-26 | 2035-09-08 | ClinicalTrials.gov |
| NCT07201051 | A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Br… | Phase2 | Bronchiectasis | Not_Yet_Recruiting | 2025-09-26 | 2027-11-08 | ClinicalTrials.gov |
| NCT07362225 | MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, an… | — | Polycythemia Vera | Recruiting | 2025-09-26 | 2035-09-08 | ClinicalTrials.gov |
| NCT07168356 | A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Sev… | Phase1 | Hepatitis B | Recruiting | 2025-09-16 | 2026-08-18 | ClinicalTrials.gov |
| NCT07168356 | A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Sev… | Phase1 | Hepatitis B | Recruiting | 2025-09-16 | 2026-08-18 | ClinicalTrials.gov |
| NCT07121192 | A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza… | Phase2 | Influenza, Human | Active_Not_Recruiting | 2025-08-25 | 2026-05-15 | ClinicalTrials.gov |
| NCT07121192 | A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza… | Phase2 | Influenza, Human | Active_Not_Recruiting | 2025-08-25 | 2026-05-15 | ClinicalTrials.gov |
| NCT07105709 | Open-label Extension Study in Participants With Early Alzheimer's Disease | Phase2 | Alzheimer's Disease | Recruiting | 2025-08-14 | 2028-12-08 | ClinicalTrials.gov |
| NCT07105709 | Open-label Extension Study in Participants With Early Alzheimer's Disease | Phase2 | Alzheimer's Disease | Recruiting | 2025-08-14 | 2028-12-08 | ClinicalTrials.gov |
| NCT07105722 | A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumo… | Phase1 | Pneumonia, Bacterial | Active_Not_Recruiting | 2025-08-12 | 2026-06-09 | ClinicalTrials.gov |
| NCT07105722 | A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumo… | Phase1 | Pneumonia, Bacterial | Active_Not_Recruiting | 2025-08-12 | 2026-06-09 | ClinicalTrials.gov |
| NCT07099898 | A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCL… | Phase3 | Neoplasms, Lung | Recruiting | 2025-08-11 | 2029-09-28 | ClinicalTrials.gov |
| NCT07099898 | A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCL… | Phase3 | Neoplasms, Lung | Recruiting | 2025-08-11 | 2029-09-28 | ClinicalTrials.gov |
| NCT07036159 | A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in… | Phase2 | Malaria | Recruiting | 2025-08-06 | 2027-04-23 | ClinicalTrials.gov |
| NCT07036159 | A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in… | Phase2 | Malaria | Recruiting | 2025-08-06 | 2027-04-23 | ClinicalTrials.gov |
| NCT07092865 | A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respira… | Phase2 | Respiratory Syncytial Virus Infections | Recruiting | 2025-08-06 | 2027-07-16 | ClinicalTrials.gov |
| NCT07092865 | A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respira… | Phase2 | Respiratory Syncytial Virus Infections | Recruiting | 2025-08-06 | 2027-07-16 | ClinicalTrials.gov |
| NCT07085702 | A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-com… | Phase1 | Streptococcal Infections | Recruiting | 2025-07-31 | 2026-11-30 | ClinicalTrials.gov |
| NCT07085702 | A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-com… | Phase1 | Streptococcal Infections | Recruiting | 2025-07-31 | 2026-11-30 | ClinicalTrials.gov |
| NCT06897527 | A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India Wi… | Phase4 | Neoplasms, Endometrial | Not_Yet_Recruiting | 2025-07-15 | 2027-01-13 | ClinicalTrials.gov |
| NCT06897527 | A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India Wi… | Phase4 | Neoplasms, Endometrial | Not_Yet_Recruiting | 2025-07-15 | 2027-01-13 | ClinicalTrials.gov |
| NCT06995430 | A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Pri… | Phase3 | Meningitis | Completed | 2025-07-07 | 2025-12-15 | ClinicalTrials.gov |
| NCT06995430 | A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Pri… | Phase3 | Meningitis | Completed | 2025-07-07 | 2025-12-15 | ClinicalTrials.gov |
| NCT07017803 | Molecular Epidemiology, Strains Genotyping of Multi-drug Resistant Tuberculosis… | — | Tuberculosis, Multi Drug Resistant | Not_Yet_Recruiting | 2025-07-01 | 2026-01-31 | ClinicalTrials.gov |
| NCT07017803 | Molecular Epidemiology, Strains Genotyping of Multi-drug Resistant Tuberculosis… | — | Tuberculosis, Multi Drug Resistant | Not_Yet_Recruiting | 2025-07-01 | 2026-01-31 | ClinicalTrials.gov |
| NCT06961214 | Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic O… | Phase3 | Pulmonary Disease, Chronic Obstructive | Recruiting | 2025-06-23 | 2029-08-21 | ClinicalTrials.gov |
| NCT06961214 | Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic O… | Phase3 | Pulmonary Disease, Chronic Obstructive | Recruiting | 2025-06-23 | 2029-08-21 | ClinicalTrials.gov |
| NCT06959095 | Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic O… | Phase3 | Pulmonary Disease, Chronic Obstructive | Recruiting | 2025-06-20 | 2029-08-20 | ClinicalTrials.gov |
| NCT06959095 | Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic O… | Phase3 | Pulmonary Disease, Chronic Obstructive | Recruiting | 2025-06-20 | 2029-08-20 | ClinicalTrials.gov |
| NCT06990880 | A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Canc… | Phase1 | Neoplasms, Prostate | Recruiting | 2025-06-12 | 2028-08-09 | ClinicalTrials.gov |
| NCT06990880 | A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Canc… | Phase1 | Neoplasms, Prostate | Recruiting | 2025-06-12 | 2028-08-09 | ClinicalTrials.gov |
| NCT06885034 | A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other… | Phase1 | Gastrointestinal Neoplasms | Recruiting | 2025-06-11 | 2028-06-23 | ClinicalTrials.gov |
| NCT06885034 | A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other… | Phase1 | Gastrointestinal Neoplasms | Recruiting | 2025-06-11 | 2028-06-23 | ClinicalTrials.gov |
| NCT06847867 | A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome | Phase2 | Myelodysplastic Syndromes | Recruiting | 2025-06-05 | 2027-12-29 | ClinicalTrials.gov |
| NCT06847867 | A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome | Phase2 | Myelodysplastic Syndromes | Recruiting | 2025-06-05 | 2027-12-29 | ClinicalTrials.gov |
| NCT06979323 | Depemokimab Asthma Imaging and Bronchoscopy Sub-Study | Phase3 | Asthma | Recruiting | 2025-06-03 | 2028-02-11 | ClinicalTrials.gov |
| NCT06979323 | Depemokimab Asthma Imaging and Bronchoscopy Sub-Study | Phase3 | Asthma | Recruiting | 2025-06-03 | 2028-02-11 | ClinicalTrials.gov |
| NCT06806137 | A Study on the Immune Response and Safety of the Second Dose of an Investigatio… | Phase3 | Chickenpox | Recruiting | 2025-05-15 | 2027-05-03 | ClinicalTrials.gov |
| NCT06806137 | A Study on the Immune Response and Safety of the Second Dose of an Investigatio… | Phase3 | Chickenpox | Recruiting | 2025-05-15 | 2027-05-03 | ClinicalTrials.gov |
| NCT06747845 | Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Ad… | Phase2 | Pancreatic Adenocarcinoma Metastatic | Recruiting | 2025-05-07 | 2029-01-30 | ClinicalTrials.gov |
| NCT06747845 | Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Ad… | Phase2 | Pancreatic Adenocarcinoma Metastatic | Recruiting | 2025-05-07 | 2029-01-30 | ClinicalTrials.gov |
| NCT06855160 | A Study on the Immune Response and Safety of an Investigational Chickenpox Vacc… | Phase3 | Chickenpox | Recruiting | 2025-04-17 | 2027-02-02 | ClinicalTrials.gov |
| NCT06855160 | A Study on the Immune Response and Safety of an Investigational Chickenpox Vacc… | Phase3 | Chickenpox | Recruiting | 2025-04-17 | 2027-02-02 | ClinicalTrials.gov |
| NCT06920043 | A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (C… | Phase2 | Metabolic Dysfunction-Associated Steatohepatitis | Recruiting | 2025-04-09 | 2027-12-01 | ClinicalTrials.gov |
| NCT06920043 | A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (C… | Phase2 | Metabolic Dysfunction-Associated Steatohepatitis | Recruiting | 2025-04-09 | 2027-12-01 | ClinicalTrials.gov |
| NCT06911775 | Eosinophil Subpopulations in Eosinophilic-associated Diseases | — | Eosinophilic Asthma | Not_Yet_Recruiting | 2025-04-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT06911775 | Eosinophil Subpopulations in Eosinophilic-associated Diseases | — | Eosinophilic Asthma | Not_Yet_Recruiting | 2025-04-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT06702462 | A Study to Assess the Potential for Airway Sensitivity Reactions With Propellan… | Phase1 | Asthma | Completed | 2025-03-11 | 2025-06-04 | ClinicalTrials.gov |
| NCT06702462 | A Study to Assess the Potential for Airway Sensitivity Reactions With Propellan… | Phase1 | Asthma | Completed | 2025-03-11 | 2025-06-04 | ClinicalTrials.gov |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants… | Phase1 | Melanoma | Active_Not_Recruiting | 2025-03-06 | 2026-10-13 | ClinicalTrials.gov |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants… | Phase1 | Melanoma | Active_Not_Recruiting | 2025-03-06 | 2026-10-13 | ClinicalTrials.gov |
| NCT06702345 | Clostridioides Difficile Controlled Human Infection Model | Na | C. Difficile | Not_Yet_Recruiting | 2025-03-01 | 2026-12-31 | ClinicalTrials.gov |
| NCT06702345 | Clostridioides Difficile Controlled Human Infection Model | Na | C. Difficile | Not_Yet_Recruiting | 2025-03-01 | 2026-12-31 | ClinicalTrials.gov |
| NCT06517875 | Study of Momelotinib in Combination With Luspatercept in Participants With Tran… | Phase2 | Primary Myelofibrosis | Recruiting | 2025-02-28 | 2028-03-17 | ClinicalTrials.gov |
| NCT06517875 | Study of Momelotinib in Combination With Luspatercept in Participants With Tran… | Phase2 | Primary Myelofibrosis | Recruiting | 2025-02-28 | 2028-03-17 | ClinicalTrials.gov |
| NCT06757244 | DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 Wi… | Phase2 | Pancreas Neoplasms | Recruiting | 2025-02-18 | 2028-02-18 | ClinicalTrials.gov |
| NCT06757244 | DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 Wi… | Phase2 | Pancreas Neoplasms | Recruiting | 2025-02-18 | 2028-02-18 | ClinicalTrials.gov |
| NCT06567782 | A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) … | Phase2 | Neoplasms, Colon | Recruiting | 2025-02-17 | 2028-10-26 | ClinicalTrials.gov |
| NCT06567782 | A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) … | Phase2 | Neoplasms, Colon | Recruiting | 2025-02-17 | 2028-10-26 | ClinicalTrials.gov |
| NCT06748053 | A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 … | Phase2 | Asthma | Active_Not_Recruiting | 2025-02-10 | 2027-09-09 | ClinicalTrials.gov |
| NCT06748053 | A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 … | Phase2 | Asthma | Active_Not_Recruiting | 2025-02-10 | 2027-09-09 | ClinicalTrials.gov |
| NCT06365970 | Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers | Phase2 | MMR-D/MSI-H Colorectal Cancers | Withdrawn | 2025-01-31 | 2028-01-01 | ClinicalTrials.gov |
| NCT06365970 | Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers | Phase2 | MMR-D/MSI-H Colorectal Cancers | Withdrawn | 2025-01-31 | 2028-01-01 | ClinicalTrials.gov |
| NCT06740630 | A Study on the Immune Response and Safety of an Investigational Chickenpox Vacc… | Phase3 | Chickenpox | Recruiting | 2025-01-10 | 2027-05-13 | ClinicalTrials.gov |
| NCT06740630 | A Study on the Immune Response and Safety of an Investigational Chickenpox Vacc… | Phase3 | Chickenpox | Recruiting | 2025-01-10 | 2027-05-13 | ClinicalTrials.gov |
| NCT06763783 | Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Disea… | Phase4 | Systemic Vasculitis | Enrolling_By_Invitation | 2024-12-17 | 2034-06-30 | ClinicalTrials.gov |
| NCT06763783 | Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Disea… | Phase4 | Systemic Vasculitis | Enrolling_By_Invitation | 2024-12-17 | 2034-06-30 | ClinicalTrials.gov |
| NCT06679101 | A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide a… | Phase3 | Multiple Myeloma | Recruiting | 2024-12-16 | 2031-04-28 | ClinicalTrials.gov |
| NCT06679101 | A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide a… | Phase3 | Multiple Myeloma | Recruiting | 2024-12-16 | 2031-04-28 | ClinicalTrials.gov |
| NCT06710847 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiven… | Phase1 | Neoplasms, Colorectal | Active_Not_Recruiting | 2024-12-13 | 2026-06-22 | ClinicalTrials.gov |
| NCT06710847 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiven… | Phase1 | Neoplasms, Colorectal | Active_Not_Recruiting | 2024-12-13 | 2026-06-22 | ClinicalTrials.gov |
| NCT06716606 | A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults… | Phase3 | Connective Tissue Diseases | Recruiting | 2024-12-12 | 2029-12-27 | ClinicalTrials.gov |
| NCT06716606 | A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults… | Phase3 | Connective Tissue Diseases | Recruiting | 2024-12-12 | 2029-12-27 | ClinicalTrials.gov |
| NCT06381453 | Belimumab in Autoimmune Hepatitis | Phase2 | Autoimmune Hepatitis | Recruiting | 2024-12-11 | 2029-04-30 | ClinicalTrials.gov |
| NCT06381453 | Belimumab in Autoimmune Hepatitis | Phase2 | Autoimmune Hepatitis | Recruiting | 2024-12-11 | 2029-04-30 | ClinicalTrials.gov |
| NCT06468995 | Antiviral Long Acting Drugs Landing in People Living With HIV | Na | HIV | Active_Not_Recruiting | 2024-12-02 | 2026-07-01 | ClinicalTrials.gov |
| NCT06468995 | Antiviral Long Acting Drugs Landing in People Living With HIV | Na | HIV | Active_Not_Recruiting | 2024-12-02 | 2026-07-01 | ClinicalTrials.gov |
| NCT06693895 | A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to H… | Phase3 | Chickenpox | Recruiting | 2024-11-26 | 2026-11-23 | ClinicalTrials.gov |
| NCT06693895 | A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to H… | Phase3 | Chickenpox | Recruiting | 2024-11-26 | 2026-11-23 | ClinicalTrials.gov |
| NCT06727136 | A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pi… | Phase1 | Healthy Participants | Completed | 2024-11-20 | 2025-04-22 | ClinicalTrials.gov |
| NCT06727136 | A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pi… | Phase1 | Healthy Participants | Completed | 2024-11-20 | 2025-04-22 | ClinicalTrials.gov |
| NCT06702449 | A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Va… | Phase1 | Urinary Tract Infections | Recruiting | 2024-11-19 | 2027-05-31 | ClinicalTrials.gov |
| NCT06702449 | A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Va… | Phase1 | Urinary Tract Infections | Recruiting | 2024-11-19 | 2027-05-31 | ClinicalTrials.gov |
| NCT06681181 | A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacoki… | Phase1 | Colitis, Ulcerative | Active_Not_Recruiting | 2024-11-18 | 2027-02-25 | ClinicalTrials.gov |
| NCT06681181 | A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacoki… | Phase1 | Colitis, Ulcerative | Active_Not_Recruiting | 2024-11-18 | 2027-02-25 | ClinicalTrials.gov |
| NCT06663436 | A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine … | Phase2 | Diarrhoea | Completed | 2024-11-13 | 2025-10-21 | ClinicalTrials.gov |
| NCT06666491 | An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) … | Phase3 | Malaria, Vivax | Recruiting | 2024-11-13 | 2026-05-25 | ClinicalTrials.gov |
| NCT06663436 | A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine … | Phase2 | Diarrhoea | Completed | 2024-11-13 | 2025-10-21 | ClinicalTrials.gov |
| NCT06666491 | An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) … | Phase3 | Malaria, Vivax | Recruiting | 2024-11-13 | 2026-05-25 | ClinicalTrials.gov |
| NCT06680375 | A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Ad… | Phase1 | COVID-19 | Completed | 2024-11-11 | 2025-06-09 | ClinicalTrials.gov |
| NCT06537414 | A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed b… | Phase2 | Chronic Hepatitis B Virus Infection | Active_Not_Recruiting | 2024-11-11 | 2027-05-31 | ClinicalTrials.gov |
| NCT06680375 | A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Ad… | Phase1 | COVID-19 | Completed | 2024-11-11 | 2025-06-09 | ClinicalTrials.gov |
| NCT06537414 | A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed b… | Phase2 | Chronic Hepatitis B Virus Infection | Active_Not_Recruiting | 2024-11-11 | 2027-05-31 | ClinicalTrials.gov |
| NCT06640049 | A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal C… | Phase2 | Neoplasms, Rectal | Active_Not_Recruiting | 2024-10-17 | 2031-04-15 | ClinicalTrials.gov |
| NCT06640049 | A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal C… | Phase2 | Neoplasms, Rectal | Active_Not_Recruiting | 2024-10-17 | 2031-04-15 | ClinicalTrials.gov |
| NCT06533813 | Clinical Epidemiology in Contemporary Patients With Myelofibrosis. | — | Myelofibrosis | Recruiting | 2024-10-14 | 2028-12-31 | ClinicalTrials.gov |
| NCT06533813 | Clinical Epidemiology in Contemporary Patients With Myelofibrosis. | — | Myelofibrosis | Recruiting | 2024-10-14 | 2028-12-31 | ClinicalTrials.gov |
| NCT06625489 | A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Adm… | Phase1 | Idiopathic Pulmonary Fibrosis | Completed | 2024-10-07 | 2024-11-25 | ClinicalTrials.gov |
| NCT06625489 | A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Adm… | Phase1 | Idiopathic Pulmonary Fibrosis | Completed | 2024-10-07 | 2024-11-25 | ClinicalTrials.gov |
| NCT06527872 | Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults W… | — | Lupus Nephritis | Recruiting | 2024-10-04 | 2029-03-29 | ClinicalTrials.gov |
| NCT06527872 | Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults W… | — | Lupus Nephritis | Recruiting | 2024-10-04 | 2029-03-29 | ClinicalTrials.gov |
| NCT06614725 | A Study in India on the Immune Response and Safety of a Respiratory Syncytial V… | Phase3 | Respiratory Syncytial Virus Infections | Completed | 2024-10-01 | 2025-11-14 | ClinicalTrials.gov |
| NCT06224270 | Study of Response to Zoster Vaccine in Adults with Inflammatory Bowel Disease T… | Phase4 | Inflammatory Bowel Diseases | Withdrawn | 2024-10-01 | 2027-09-01 | ClinicalTrials.gov |
| NCT06224270 | Study of Response to Zoster Vaccine in Adults with Inflammatory Bowel Disease T… | Phase4 | Inflammatory Bowel Diseases | Withdrawn | 2024-10-01 | 2027-09-01 | ClinicalTrials.gov |
| NCT06614725 | A Study in India on the Immune Response and Safety of a Respiratory Syncytial V… | Phase3 | Respiratory Syncytial Virus Infections | Completed | 2024-10-01 | 2025-11-14 | ClinicalTrials.gov |
| NCT06573281 | A Study on the Safety and Immune Response to an mRNA-based RSV Investigational … | Phase1 | Respiratory Syncytial Virus Infections | Active_Not_Recruiting | 2024-09-30 | 2026-04-13 | ClinicalTrials.gov |
| NCT06551142 | A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTu… | Phase1 | Neoplasms | Recruiting | 2024-09-30 | 2027-05-19 | ClinicalTrials.gov |
| NCT06551142 | A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTu… | Phase1 | Neoplasms | Recruiting | 2024-09-30 | 2027-05-19 | ClinicalTrials.gov |
| NCT06573281 | A Study on the Safety and Immune Response to an mRNA-based RSV Investigational … | Phase1 | Respiratory Syncytial Virus Infections | Active_Not_Recruiting | 2024-09-30 | 2026-04-13 | ClinicalTrials.gov |
| NCT06613698 | A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Plac… | Phase2 | Liver Diseases, Alcoholic | Recruiting | 2024-09-27 | 2028-03-07 | ClinicalTrials.gov |
| NCT06613698 | A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Plac… | Phase2 | Liver Diseases, Alcoholic | Recruiting | 2024-09-27 | 2028-03-07 | ClinicalTrials.gov |
| NCT06594679 | A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of… | Phase1 | Ovarian Cancer | Recruiting | 2024-09-26 | 2027-09-18 | ClinicalTrials.gov |
| NCT06594679 | A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of… | Phase1 | Ovarian Cancer | Recruiting | 2024-09-26 | 2027-09-18 | ClinicalTrials.gov |
| NCT06597916 | RSV Vaccination in Immunocompromised Patients. | Phase2 | RSV Infection | Recruiting | 2024-09-19 | 2026-03-31 | ClinicalTrials.gov |
| NCT06597916 | RSV Vaccination in Immunocompromised Patients. | Phase2 | RSV Infection | Recruiting | 2024-09-19 | 2026-03-31 | ClinicalTrials.gov |
| NCT06497504 | Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus … | Phase2 | Hepatitis B | Active_Not_Recruiting | 2024-09-17 | 2027-04-22 | ClinicalTrials.gov |
| NCT06497504 | Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus … | Phase2 | Hepatitis B | Active_Not_Recruiting | 2024-09-17 | 2027-04-22 | ClinicalTrials.gov |
| NCT06572384 | A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lun… | Phase3 | Lung Diseases, Interstitial | Recruiting | 2024-09-11 | 2028-12-13 | ClinicalTrials.gov |
| NCT06572384 | A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lun… | Phase3 | Lung Diseases, Interstitial | Recruiting | 2024-09-11 | 2028-12-13 | ClinicalTrials.gov |
| NCT06577597 | Safety, Tolerability and Blood Sampling of GSK3923868 Administered Via Dry Powd… | Phase1 | Respiratory Tract Infections | Completed | 2024-09-02 | 2024-11-01 | ClinicalTrials.gov |
| NCT06576271 | A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SL… | Phase1 | Systemic Lupus Erythematosus | Recruiting | 2024-09-02 | 2028-01-11 | ClinicalTrials.gov |
| NCT06577597 | Safety, Tolerability and Blood Sampling of GSK3923868 Administered Via Dry Powd… | Phase1 | Respiratory Tract Infections | Completed | 2024-09-02 | 2024-11-01 | ClinicalTrials.gov |
| NCT06576271 | A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SL… | Phase1 | Systemic Lupus Erythematosus | Recruiting | 2024-09-02 | 2028-01-11 | ClinicalTrials.gov |
| NCT06258018 | Niraparib and Temozolomide in Patients Glioblastoma | Phase1 | Glioma, Malignant | Not_Yet_Recruiting | 2024-09-01 | 2027-09-01 | ClinicalTrials.gov |
| NCT06258018 | Niraparib and Temozolomide in Patients Glioblastoma | Phase1 | Glioma, Malignant | Not_Yet_Recruiting | 2024-09-01 | 2027-09-01 | ClinicalTrials.gov |
| NCT04876248 | Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in … | Phase2 | Plasma Cell Myeloma | Active_Not_Recruiting | 2024-08-19 | 2027-09-01 | ClinicalTrials.gov |
| NCT04876248 | Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in … | Phase2 | Plasma Cell Myeloma | Active_Not_Recruiting | 2024-08-19 | 2027-09-01 | ClinicalTrials.gov |
| NCT06433921 | A Study to Compare the Relative Potency of Salbutamol Administered Via Metered … | Phase1 | Asthma | Recruiting | 2024-08-14 | 2026-11-06 | ClinicalTrials.gov |
| NCT06433921 | A Study to Compare the Relative Potency of Salbutamol Administered Via Metered … | Phase1 | Asthma | Recruiting | 2024-08-14 | 2026-11-06 | ClinicalTrials.gov |
| NCT06278857 | SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient … | Phase2 | Endometrial Cancer Stage I | Recruiting | 2024-08-01 | 2028-06-30 | ClinicalTrials.gov |
| NCT06534892 | An Extension and Crossover Vaccination Study on the Immune Response and Safety … | Phase3 | Respiratory Syncytial Virus Infections | Active_Not_Recruiting | 2024-08-01 | 2026-09-30 | ClinicalTrials.gov |
| NCT06278857 | SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient … | Phase2 | Endometrial Cancer Stage I | Recruiting | 2024-08-01 | 2028-06-30 | ClinicalTrials.gov |
| NCT06534892 | An Extension and Crossover Vaccination Study on the Immune Response and Safety … | Phase3 | Respiratory Syncytial Virus Infections | Active_Not_Recruiting | 2024-08-01 | 2026-09-30 | ClinicalTrials.gov |
| NCT06333314 | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endom… | Phase2 | Pancreatic Adenocarcinoma | Recruiting | 2024-07-23 | 2030-09-01 | ClinicalTrials.gov |
| NCT06333314 | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endom… | Phase2 | Pancreatic Adenocarcinoma | Recruiting | 2024-07-23 | 2030-09-01 | ClinicalTrials.gov |
| NCT06422767 | Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed … | Phase1 | Hepatitis B | Completed | 2024-07-18 | 2025-04-28 | ClinicalTrials.gov |
| NCT06422767 | Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed … | Phase1 | Hepatitis B | Completed | 2024-07-18 | 2025-04-28 | ClinicalTrials.gov |
| NCT06431594 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Act… | Phase1 | Solid Tumors | Recruiting | 2024-07-02 | 2027-09-20 | ClinicalTrials.gov |
| NCT06431594 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Act… | Phase1 | Solid Tumors | Recruiting | 2024-07-02 | 2027-09-20 | ClinicalTrials.gov |
| NCT06488703 | Retrospective Analysis of Systemic Glucocorticoid Mediated Long-term Effects, P… | — | Asthma | Active_Not_Recruiting | 2024-07-01 | 2025-07-31 | ClinicalTrials.gov |
| NCT06488703 | Retrospective Analysis of Systemic Glucocorticoid Mediated Long-term Effects, P… | — | Asthma | Active_Not_Recruiting | 2024-07-01 | 2025-07-31 | ClinicalTrials.gov |
| NCT06388733 | A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-… | Phase3 | Glioblastoma | Recruiting | 2024-06-19 | 2028-03-01 | ClinicalTrials.gov |
| NCT06388733 | A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-… | Phase3 | Glioblastoma | Recruiting | 2024-06-19 | 2028-03-01 | ClinicalTrials.gov |
| NCT06472076 | A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizuma… | Phase3 | Lung Cancer, Non-Small Cell | Active_Not_Recruiting | 2024-06-10 | 2027-02-02 | ClinicalTrials.gov |
| NCT06472076 | A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizuma… | Phase3 | Lung Cancer, Non-Small Cell | Active_Not_Recruiting | 2024-06-10 | 2027-02-02 | ClinicalTrials.gov |
| NCT06411249 | A Study Describing the Efficacy and Safety of Belimumab Administered in Adult P… | Phase4 | Systemic Lupus Erythematosus | Recruiting | 2024-06-06 | 2029-05-29 | ClinicalTrials.gov |
| NCT06411249 | A Study Describing the Efficacy and Safety of Belimumab Administered in Adult P… | Phase4 | Systemic Lupus Erythematosus | Recruiting | 2024-06-06 | 2029-05-29 | ClinicalTrials.gov |
| NCT06447506 | Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis. | Phase2 | Dermatitis, Atopic | Terminated | 2024-06-05 | 2025-07-29 | ClinicalTrials.gov |
| NCT06447506 | Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis. | Phase2 | Dermatitis, Atopic | Terminated | 2024-06-05 | 2025-07-29 | ClinicalTrials.gov |
| NCT06433908 | A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Met… | Phase1 | Asthma | Completed | 2024-06-04 | 2024-10-22 | ClinicalTrials.gov |
| NCT06433908 | A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Met… | Phase1 | Asthma | Completed | 2024-06-04 | 2024-10-22 | ClinicalTrials.gov |
| NCT06413511 | A Study to Investigate the Safety and Pharmacological Effect of a Single Intrav… | Phase1 | Autoimmune Diseases | Withdrawn | 2024-06-03 | 2025-07-08 | ClinicalTrials.gov |
| NCT06413511 | A Study to Investigate the Safety and Pharmacological Effect of a Single Intrav… | Phase1 | Autoimmune Diseases | Withdrawn | 2024-06-03 | 2025-07-08 | ClinicalTrials.gov |
| NCT05922501 | Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma | Phase2 | Relapsed Cancer | Recruiting | 2024-05-31 | 2030-12-31 | ClinicalTrials.gov |
| NCT05922501 | Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma | Phase2 | Relapsed Cancer | Recruiting | 2024-05-31 | 2030-12-31 | ClinicalTrials.gov |
| NCT06261957 | A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment Wit… | Phase3 | Asthma | Completed | 2024-05-31 | 2025-09-02 | ClinicalTrials.gov |
| NCT06261957 | A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment Wit… | Phase3 | Asthma | Completed | 2024-05-31 | 2025-09-02 | ClinicalTrials.gov |
| NCT06431607 | A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine… | Phase2 | Influenza, Human | Completed | 2024-05-23 | 2025-06-04 | ClinicalTrials.gov |
| NCT06431607 | A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine… | Phase2 | Influenza, Human | Completed | 2024-05-23 | 2025-06-04 | ClinicalTrials.gov |
| NCT06134362 | Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure… | Phase3 | HIV Infections | Recruiting | 2024-05-14 | 2029-01-01 | ClinicalTrials.gov |
| NCT06134362 | Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure… | Phase3 | HIV Infections | Recruiting | 2024-05-14 | 2029-01-01 | ClinicalTrials.gov |
| NCT06317311 | A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese P… | Phase2 | Carcinoma | Active_Not_Recruiting | 2024-05-07 | 2027-08-31 | ClinicalTrials.gov |
| NCT06317311 | A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese P… | Phase2 | Carcinoma | Active_Not_Recruiting | 2024-05-07 | 2027-08-31 | ClinicalTrials.gov |
| NCT06389487 | A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncyt… | Phase3 | Respiratory Syncytial Virus Infections | Completed | 2024-04-29 | 2025-03-18 | ClinicalTrials.gov |
| NCT06389487 | A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncyt… | Phase3 | Respiratory Syncytial Virus Infections | Completed | 2024-04-29 | 2025-03-18 | ClinicalTrials.gov |
| NCT06382311 | A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immu… | Phase1 | Influenza, Human | Completed | 2024-04-18 | 2026-01-13 | ClinicalTrials.gov |
| NCT06382311 | A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immu… | Phase1 | Influenza, Human | Completed | 2024-04-18 | 2026-01-13 | ClinicalTrials.gov |
| NCT06372496 | Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta U… | Phase4 | Asthma | Active_Not_Recruiting | 2024-04-16 | 2027-03-31 | ClinicalTrials.gov |
| NCT06372496 | Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta U… | Phase4 | Asthma | Active_Not_Recruiting | 2024-04-16 | 2027-03-31 | ClinicalTrials.gov |
| NCT06354257 | A Study to Investigate the Pharmacokinetics of a Combined Oral Contraceptive Wh… | Phase1 | Tuberculosis | Completed | 2024-04-05 | 2024-07-01 | ClinicalTrials.gov |
| NCT06354257 | A Study to Investigate the Pharmacokinetics of a Combined Oral Contraceptive Wh… | Phase1 | Tuberculosis | Completed | 2024-04-05 | 2024-07-01 | ClinicalTrials.gov |
| NCT06317285 | A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With … | Phase2 | Idiopathic Pulmonary Fibrosis | Terminated | 2024-04-04 | 2025-10-01 | ClinicalTrials.gov |
| NCT06317285 | A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With … | Phase2 | Idiopathic Pulmonary Fibrosis | Terminated | 2024-04-04 | 2025-10-01 | ClinicalTrials.gov |
| NCT06331156 | A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IP… | Phase3 | Gastroenteritis | Completed | 2024-03-22 | 2024-10-22 | ClinicalTrials.gov |
| NCT06331156 | A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IP… | Phase3 | Gastroenteritis | Completed | 2024-03-22 | 2024-10-22 | ClinicalTrials.gov |
| NCT06256588 | A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants Wi… | Phase3 | Neoplasms, Head and Neck | Recruiting | 2024-03-21 | 2029-10-26 | ClinicalTrials.gov |
| NCT06256588 | A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants Wi… | Phase3 | Neoplasms, Head and Neck | Recruiting | 2024-03-21 | 2029-10-26 | ClinicalTrials.gov |
| NCT06041386 | REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on … | Phase4 | Asthma | Active_Not_Recruiting | 2024-03-20 | 2028-06-14 | ClinicalTrials.gov |
| NCT06041386 | REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on … | Phase4 | Asthma | Active_Not_Recruiting | 2024-03-20 | 2028-06-14 | ClinicalTrials.gov |
| NCT06238635 | Dostarlimab and Cobolimab in Advanced Cervical Cancer | Phase2 | Cervical Cancer | Active_Not_Recruiting | 2024-03-11 | 2027-07-15 | ClinicalTrials.gov |
| NCT06238635 | Dostarlimab and Cobolimab in Advanced Cervical Cancer | Phase2 | Cervical Cancer | Active_Not_Recruiting | 2024-03-11 | 2027-07-15 | ClinicalTrials.gov |
| NCT05659381 | Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary … | Phase3 | Stage III Ovarian Cancer | Recruiting | 2024-03-08 | 2034-08-01 | ClinicalTrials.gov |
| NCT05659381 | Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary … | Phase3 | Stage III Ovarian Cancer | Recruiting | 2024-03-08 | 2034-08-01 | ClinicalTrials.gov |
| NCT06206083 | Molecular Classification in Mexican Patients With Endometrial Cancer and Its Im… | — | Endometrial Cancer | Recruiting | 2024-03-01 | 2027-02-01 | ClinicalTrials.gov |
| NCT06206083 | Molecular Classification in Mexican Patients With Endometrial Cancer and Its Im… | — | Endometrial Cancer | Recruiting | 2024-03-01 | 2027-02-01 | ClinicalTrials.gov |
| NCT05145816 | Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidos… | Phase1 | AL Amyloidosis | Recruiting | 2024-02-15 | 2026-09-01 | ClinicalTrials.gov |
| NCT05145816 | Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidos… | Phase1 | AL Amyloidosis | Recruiting | 2024-02-15 | 2026-09-01 | ClinicalTrials.gov |
| NCT06298448 | eGPA and Local Inflammation Within the Ear, Nose and Throat Area | — | EGPA - Eosinophilic Granulomatosis With Polyangiitis | Recruiting | 2024-02-14 | 2028-12-01 | ClinicalTrials.gov |
| NCT06298448 | eGPA and Local Inflammation Within the Ear, Nose and Throat Area | — | EGPA - Eosinophilic Granulomatosis With Polyangiitis | Recruiting | 2024-02-14 | 2028-12-01 | ClinicalTrials.gov |
| NCT06214052 | VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1 | Phase2 | HIV Infections | Completed | 2024-02-07 | 2024-06-12 | ClinicalTrials.gov |
| NCT06214052 | VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1 | Phase2 | HIV Infections | Completed | 2024-02-07 | 2024-06-12 | ClinicalTrials.gov |
| NCT04274023 | Study on TSR-042 in Advanced Clear Cell Sarcoma | Phase2 | Sarcoma, Clear Cell | Terminated | 2024-01-29 | 2024-01-29 | ClinicalTrials.gov |
| NCT04274023 | Study on TSR-042 in Advanced Clear Cell Sarcoma | Phase2 | Sarcoma, Clear Cell | Terminated | 2024-01-29 | 2024-01-29 | ClinicalTrials.gov |
| NCT06161493 | ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Soli… | Phase1 | Ovarian Cancer | Withdrawn | 2024-01-23 | 2029-12-31 | ClinicalTrials.gov |
| NCT06161493 | ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Soli… | Phase1 | Ovarian Cancer | Withdrawn | 2024-01-23 | 2029-12-31 | ClinicalTrials.gov |
| NCT06023862 | A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab … | Phase2 | Ovarian Neoplasms | Recruiting | 2024-01-22 | 2029-12-31 | ClinicalTrials.gov |
| NCT06023862 | A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab … | Phase2 | Ovarian Neoplasms | Recruiting | 2024-01-22 | 2029-12-31 | ClinicalTrials.gov |
| NCT06213506 | A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMM… | Phase2 | Salmonella Infections | Unknown | 2024-01-15 | 2026-04-27 | ClinicalTrials.gov |
| NCT06213506 | A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMM… | Phase2 | Salmonella Infections | Unknown | 2024-01-15 | 2026-04-27 | ClinicalTrials.gov |
| NCT06188507 | A First Time in Human Study to Evaluate the Safety and Tolerability of GSK39964… | Phase1 | Systemic Lupus Erythematosus | Suspended | 2024-01-12 | 2026-07-14 | ClinicalTrials.gov |
| NCT06188507 | A First Time in Human Study to Evaluate the Safety and Tolerability of GSK39964… | Phase1 | Systemic Lupus Erythematosus | Suspended | 2024-01-12 | 2026-07-14 | ClinicalTrials.gov |
| NCT06114628 | Platform Assessing Regimens and Durations In a Global Multisite Consortium for … | Phase2 | Pulmonary Tuberculosis | Recruiting | 2024-01-09 | 2027-08-11 | ClinicalTrials.gov |
| NCT06114628 | Platform Assessing Regimens and Durations In a Global Multisite Consortium for … | Phase2 | Pulmonary Tuberculosis | Recruiting | 2024-01-09 | 2027-08-11 | ClinicalTrials.gov |
| NCT06272123 | Endotypic Stability in CRS | — | Chronic Sinusitis | Unknown | 2024-01-01 | 2026-01-31 | ClinicalTrials.gov |
| NCT06272123 | Endotypic Stability in CRS | — | Chronic Sinusitis | Unknown | 2024-01-01 | 2026-01-31 | ClinicalTrials.gov |
| NCT06147206 | Exacerbantes Study | — | COPD Exacerbation | Unknown | 2023-12-31 | 2025-03-31 | ClinicalTrials.gov |
| NCT06147206 | Exacerbantes Study | — | COPD Exacerbation | Unknown | 2023-12-31 | 2025-03-31 | ClinicalTrials.gov |
| NCT06059846 | A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intrave… | Phase3 | Urinary Tract Infection | Completed | 2023-12-21 | 2025-02-06 | ClinicalTrials.gov |
| NCT06059846 | A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intrave… | Phase3 | Urinary Tract Infection | Completed | 2023-12-21 | 2025-02-06 | ClinicalTrials.gov |
| NCT05718323 | Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensiv… | Phase2 | SCLC,Extensive Stage | Recruiting | 2023-12-20 | 2027-06-01 | ClinicalTrials.gov |
| NCT05718323 | Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensiv… | Phase2 | SCLC,Extensive Stage | Recruiting | 2023-12-20 | 2027-06-01 | ClinicalTrials.gov |
| NCT05648357 | A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influ… | Phase4 | Influenza, Human | Completed | 2023-12-14 | 2024-02-26 | ClinicalTrials.gov |
| NCT05648357 | A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influ… | Phase4 | Influenza, Human | Completed | 2023-12-14 | 2024-02-26 | ClinicalTrials.gov |
| NCT06190509 | Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine … | Phase1 | Recurrent Vulvovaginal Candidiasis | Active_Not_Recruiting | 2023-12-06 | 2027-04-30 | ClinicalTrials.gov |
| NCT06190509 | Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine … | Phase1 | Recurrent Vulvovaginal Candidiasis | Active_Not_Recruiting | 2023-12-06 | 2027-04-30 | ClinicalTrials.gov |
| NCT06014580 | Molecular and Epidemiological Characteristics of Endometrial Cancer in Brazil | — | Endometrial Cancer | Active_Not_Recruiting | 2023-11-27 | 2025-12-31 | ClinicalTrials.gov |
| NCT06014580 | Molecular and Epidemiological Characteristics of Endometrial Cancer in Brazil | — | Endometrial Cancer | Active_Not_Recruiting | 2023-11-27 | 2025-12-31 | ClinicalTrials.gov |
| NCT05999799 | A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 … | Phase2 | Dermatitis, Atopic | Terminated | 2023-11-16 | 2025-07-23 | ClinicalTrials.gov |
| NCT05999799 | A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 … | Phase2 | Dermatitis, Atopic | Terminated | 2023-11-16 | 2025-07-23 | ClinicalTrials.gov |
| NCT06062420 | A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in… | Phase2 | Neoplasms, Head and Neck | Active_Not_Recruiting | 2023-11-14 | 2027-12-31 | ClinicalTrials.gov |
| NCT06062420 | A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in… | Phase2 | Neoplasms, Head and Neck | Active_Not_Recruiting | 2023-11-14 | 2027-12-31 | ClinicalTrials.gov |
| NCT06113198 | A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis … | Phase4 | Meningitis, Meningococcal | Active_Not_Recruiting | 2023-11-10 | 2027-02-08 | ClinicalTrials.gov |
| NCT06113198 | A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis … | Phase4 | Meningitis, Meningococcal | Active_Not_Recruiting | 2023-11-10 | 2027-02-08 | ClinicalTrials.gov |
| NCT05784012 | Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Local… | Phase1 | Head and Neck Squamous Cell Carcinoma | Recruiting | 2023-11-08 | 2029-03-01 | ClinicalTrials.gov |
| NCT05784012 | Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Local… | Phase1 | Head and Neck Squamous Cell Carcinoma | Recruiting | 2023-11-08 | 2029-03-01 | ClinicalTrials.gov |
| NCT05126342 | Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed E… | Phase2 | Recurrent Ovarian Cancer | Withdrawn | 2023-11-01 | 2026-11-01 | ClinicalTrials.gov |
| NCT05126342 | Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed E… | Phase2 | Recurrent Ovarian Cancer | Withdrawn | 2023-11-01 | 2026-11-01 | ClinicalTrials.gov |
| NCT05999708 | A First Time in Human Study to Evaluate the Safety and Tolerability of GSK43814… | Phase1 | Colitis, Ulcerative | Withdrawn | 2023-10-31 | 2024-12-05 | ClinicalTrials.gov |
| NCT05999708 | A First Time in Human Study to Evaluate the Safety and Tolerability of GSK43814… | Phase1 | Colitis, Ulcerative | Withdrawn | 2023-10-31 | 2024-12-05 | ClinicalTrials.gov |
| NCT05952271 | Herpes Zoster Hospitalizations in Italy | — | Herpes Zoster | Unknown | 2023-10-26 | 2025-07-30 | ClinicalTrials.gov |
| NCT05952271 | Herpes Zoster Hospitalizations in Italy | — | Herpes Zoster | Unknown | 2023-10-26 | 2025-07-30 | ClinicalTrials.gov |
| NCT05775718 | Shingrix In Recipients of Allogeneic Transplants | Phase2 | Bone Marrow Transplant | Recruiting | 2023-10-24 | 2030-12-01 | ClinicalTrials.gov |
| NCT06077877 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Pre… | Phase1 | Neoplasms | Active_Not_Recruiting | 2023-10-24 | 2026-06-30 | ClinicalTrials.gov |
| NCT05775718 | Shingrix In Recipients of Allogeneic Transplants | Phase2 | Bone Marrow Transplant | Recruiting | 2023-10-24 | 2030-12-01 | ClinicalTrials.gov |
| NCT06077877 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Pre… | Phase1 | Neoplasms | Active_Not_Recruiting | 2023-10-24 | 2026-06-30 | ClinicalTrials.gov |
| NCT06079190 | Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer'… | Phase2 | Alzheimer's Disease | Active_Not_Recruiting | 2023-10-20 | 2026-11-23 | ClinicalTrials.gov |
| NCT06079190 | Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer'… | Phase2 | Alzheimer's Disease | Active_Not_Recruiting | 2023-10-20 | 2026-11-23 | ClinicalTrials.gov |
| NCT05340257 | A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP an… | Phase2 | Infections, Bacterial | Withdrawn | 2023-10-14 | 2024-07-08 | ClinicalTrials.gov |
| NCT05340257 | A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP an… | Phase2 | Infections, Bacterial | Withdrawn | 2023-10-14 | 2024-07-08 | ClinicalTrials.gov |
| NCT05666349 | Reirradiation and Niraparib in Patients With Recurrent Glioblastoma | Phase1 | Recurrent Glioblastoma | Withdrawn | 2023-10-13 | 2023-10-13 | ClinicalTrials.gov |
| NCT05666349 | Reirradiation and Niraparib in Patients With Recurrent Glioblastoma | Phase1 | Recurrent Glioblastoma | Withdrawn | 2023-10-13 | 2023-10-13 | ClinicalTrials.gov |
| NCT06065735 | Concentration-QT Study of Paroxetine in Healthy Adults | Phase1 | Anxiety Disorders | Completed | 2023-10-02 | 2024-01-08 | ClinicalTrials.gov |
| NCT06065735 | Concentration-QT Study of Paroxetine in Healthy Adults | Phase1 | Anxiety Disorders | Completed | 2023-10-02 | 2024-01-08 | ClinicalTrials.gov |
| NCT05838755 | A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Ne… | Phase2 | Pain | Terminated | 2023-09-20 | 2025-02-17 | ClinicalTrials.gov |
| NCT05838755 | A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Ne… | Phase2 | Pain | Terminated | 2023-09-20 | 2025-02-17 | ClinicalTrials.gov |
| NCT05986682 | Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Rela… | — | Multiple Myeloma | Completed | 2023-09-18 | 2023-11-07 | ClinicalTrials.gov |
| NCT05986682 | Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Rela… | — | Multiple Myeloma | Completed | 2023-09-18 | 2023-11-07 | ClinicalTrials.gov |
| NCT05878717 | A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Scleros… | Phase2 | Systemic Sclerosis Associated Interstitial Lung Disease | Recruiting | 2023-09-13 | 2029-07-12 | ClinicalTrials.gov |
| NCT05838742 | A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adult… | Phase2 | Pain | Terminated | 2023-09-13 | 2024-12-03 | ClinicalTrials.gov |
| NCT05878717 | A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Scleros… | Phase2 | Systemic Sclerosis Associated Interstitial Lung Disease | Recruiting | 2023-09-13 | 2029-07-12 | ClinicalTrials.gov |
| NCT05838742 | A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adult… | Phase2 | Pain | Terminated | 2023-09-13 | 2024-12-03 | ClinicalTrials.gov |
| NCT05895929 | The Role of IL5 in Epithelial Cell Integrity | Early_Phase1 | Chronic Rhinosinusitis With Nasal Polyps | Recruiting | 2023-09-05 | 2026-06-01 | ClinicalTrials.gov |
| NCT05895929 | The Role of IL5 in Epithelial Cell Integrity | Early_Phase1 | Chronic Rhinosinusitis With Nasal Polyps | Recruiting | 2023-09-05 | 2026-06-01 | ClinicalTrials.gov |
| NCT06327724 | Belimumab in SLE Synovial Inflammation and Lymph Nodes | — | Systemic Lupus Erythematosus | Unknown | 2023-09-01 | 2025-03-01 | ClinicalTrials.gov |
| NCT06025695 | Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals'… | Phase3 | Gastroenteritis | Completed | 2023-09-01 | 2024-10-23 | ClinicalTrials.gov |
| NCT06025695 | Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals'… | Phase3 | Gastroenteritis | Completed | 2023-09-01 | 2024-10-23 | ClinicalTrials.gov |
| NCT06327724 | Belimumab in SLE Synovial Inflammation and Lymph Nodes | — | Systemic Lupus Erythematosus | Unknown | 2023-09-01 | 2025-03-01 | ClinicalTrials.gov |
| NCT05660265 | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral G… | Phase1 | Hematologic Diseases | Terminated | 2023-08-26 | 2025-09-22 | ClinicalTrials.gov |
| NCT05660265 | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral G… | Phase1 | Hematologic Diseases | Terminated | 2023-08-26 | 2025-09-22 | ClinicalTrials.gov |
| NCT05961124 | Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Mai… | Phase2 | Ovarian Cancer | Recruiting | 2023-08-21 | 2027-09-01 | ClinicalTrials.gov |
| NCT06201559 | Bioequivalence Study Between Two Albendazole 400 mg Tablets in Healthy Adult Pa… | Phase1 | Intestinal Diseases | Completed | 2023-08-21 | 2023-09-12 | ClinicalTrials.gov |
| NCT05961124 | Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Mai… | Phase2 | Ovarian Cancer | Recruiting | 2023-08-21 | 2027-09-01 | ClinicalTrials.gov |
| NCT06201559 | Bioequivalence Study Between Two Albendazole 400 mg Tablets in Healthy Adult Pa… | Phase1 | Intestinal Diseases | Completed | 2023-08-21 | 2023-09-12 | ClinicalTrials.gov |
| NCT05980416 | Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 | Phase1 | Stomach Neoplasm | Terminated | 2023-08-10 | 2025-06-02 | ClinicalTrials.gov |
| NCT05980416 | Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 | Phase1 | Stomach Neoplasm | Terminated | 2023-08-10 | 2025-06-02 | ClinicalTrials.gov |
| NCT05989672 | A Study on the Reactogenicity, Safety and Immune Response of a Targeted Immunot… | Phase1 | Herpes Simplex | Completed | 2023-08-08 | 2024-04-24 | ClinicalTrials.gov |
| NCT05989672 | A Study on the Reactogenicity, Safety and Immune Response of a Targeted Immunot… | Phase1 | Herpes Simplex | Completed | 2023-08-08 | 2024-04-24 | ClinicalTrials.gov |
| NCT05975840 | Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/A… | Phase1 | Influenza, Human | Completed | 2023-08-03 | 2024-09-19 | ClinicalTrials.gov |
| NCT05975840 | Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/A… | Phase1 | Influenza, Human | Completed | 2023-08-03 | 2024-09-19 | ClinicalTrials.gov |
| NCT05960097 | A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vacc… | Phase2 | SARS-CoV-2 | Completed | 2023-08-01 | 2024-08-30 | ClinicalTrials.gov |
| NCT05960097 | A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vacc… | Phase2 | SARS-CoV-2 | Completed | 2023-08-01 | 2024-08-30 | ClinicalTrials.gov |
| NCT05979207 | Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Inf… | Phase1 | Infections | Completed | 2023-08-01 | 2023-10-30 | ClinicalTrials.gov |
| NCT05855200 | Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage… | Phase3 | Colonic Neoplasms | Recruiting | 2023-08-01 | 2031-03-27 | ClinicalTrials.gov |
| NCT05855200 | Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage… | Phase3 | Colonic Neoplasms | Recruiting | 2023-08-01 | 2031-03-27 | ClinicalTrials.gov |
| NCT05979207 | Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Inf… | Phase1 | Infections | Completed | 2023-08-01 | 2023-10-30 | ClinicalTrials.gov |
| NCT05966090 | A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Comb… | Phase3 | Respiratory Syncytial Viruses | Completed | 2023-07-28 | 2024-07-29 | ClinicalTrials.gov |
| NCT05966090 | A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Comb… | Phase3 | Respiratory Syncytial Viruses | Completed | 2023-07-28 | 2024-07-29 | ClinicalTrials.gov |
| NCT05855811 | PREventing Second Cancers With DOSTARlimab | Phase2 | Recurrent Cancer | Recruiting | 2023-07-26 | 2029-03-26 | ClinicalTrials.gov |
| NCT05855811 | PREventing Second Cancers With DOSTARlimab | Phase2 | Recurrent Cancer | Recruiting | 2023-07-26 | 2029-03-26 | ClinicalTrials.gov |
| NCT05857397 | A Collaborative Trial of Niraparib to Evaluate Patients With Ovarian Cancer in … | — | Ovarian Cancer | Active_Not_Recruiting | 2023-07-21 | 2025-05-31 | ClinicalTrials.gov |
| NCT05857397 | A Collaborative Trial of Niraparib to Evaluate Patients With Ovarian Cancer in … | — | Ovarian Cancer | Active_Not_Recruiting | 2023-07-21 | 2025-05-31 | ClinicalTrials.gov |
| NCT05573802 | A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in … | Phase1 | Multiple Myeloma | Recruiting | 2023-07-14 | 2026-10-31 | ClinicalTrials.gov |
| NCT05573802 | A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in … | Phase1 | Multiple Myeloma | Recruiting | 2023-07-14 | 2026-10-31 | ClinicalTrials.gov |
| NCT05917288 | A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Eryt… | Phase1 | Systemic Lupus Erythematosus | Completed | 2023-07-07 | 2024-10-30 | ClinicalTrials.gov |
| NCT05917288 | A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Eryt… | Phase1 | Systemic Lupus Erythematosus | Completed | 2023-07-07 | 2024-10-30 | ClinicalTrials.gov |
| NCT05951192 | A Prospective Interventional Study Assessing the Clinical and Operational Effec… | Phase4 | Anemia | Completed | 2023-07-01 | 2024-02-14 | ClinicalTrials.gov |
| NCT05913700 | Effect of Respiratory Virus Infection on EmeRgencY Admission Study (EVERY Study) | — | Respiratory Syncytial Virus (RSV) | Active_Not_Recruiting | 2023-07-01 | 2026-09-30 | ClinicalTrials.gov |
| NCT05913700 | Effect of Respiratory Virus Infection on EmeRgencY Admission Study (EVERY Study) | — | Respiratory Syncytial Virus (RSV) | Active_Not_Recruiting | 2023-07-01 | 2026-09-30 | ClinicalTrials.gov |
| NCT05951192 | A Prospective Interventional Study Assessing the Clinical and Operational Effec… | Phase4 | Anemia | Completed | 2023-07-01 | 2024-02-14 | ClinicalTrials.gov |
| NCT05714839 | A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment … | Phase1 | Multiple Myeloma | Recruiting | 2023-06-14 | 2029-12-03 | ClinicalTrials.gov |
| NCT05714839 | A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment … | Phase1 | Multiple Myeloma | Recruiting | 2023-06-14 | 2029-12-03 | ClinicalTrials.gov |
| NCT04923347 | A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclid… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2023-06-06 | 2024-03-14 | ClinicalTrials.gov |
| NCT04923347 | A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclid… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2023-06-06 | 2024-03-14 | ClinicalTrials.gov |
| NCT05789303 | Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone… | Phase2 | Multiple Myeloma | Recruiting | 2023-05-30 | 2028-07-01 | ClinicalTrials.gov |
| NCT05789303 | Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone… | Phase2 | Multiple Myeloma | Recruiting | 2023-05-30 | 2028-07-01 | ClinicalTrials.gov |
| NCT05879107 | Study to Assess the Immune Response, the Safety and the Reactogenicity of Respi… | Phase3 | Respiratory Syncytial Virus Infections | Completed | 2023-05-26 | 2024-05-07 | ClinicalTrials.gov |
| NCT05879107 | Study to Assess the Immune Response, the Safety and the Reactogenicity of Respi… | Phase3 | Respiratory Syncytial Virus Infections | Completed | 2023-05-26 | 2024-05-07 | ClinicalTrials.gov |
| NCT05879419 | Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases | Phase4 | Rheumatoid Arthritis | Active_Not_Recruiting | 2023-05-23 | 2032-06-30 | ClinicalTrials.gov |
| NCT05879419 | Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases | Phase4 | Rheumatoid Arthritis | Active_Not_Recruiting | 2023-05-23 | 2032-06-30 | ClinicalTrials.gov |
| NCT05406700 | Niraparib In Recurrent IDH 1/2 Gliomas | Early_Phase1 | Low-grade Glioma | Active_Not_Recruiting | 2023-05-18 | 2026-10-01 | ClinicalTrials.gov |
| NCT05406700 | Niraparib In Recurrent IDH 1/2 Gliomas | Early_Phase1 | Low-grade Glioma | Active_Not_Recruiting | 2023-05-18 | 2026-10-01 | ClinicalTrials.gov |
| NCT06389058 | Using NLP and Neural Networks to Autonomously Identify Severe Asthma and Determ… | — | Severe Asthma | Active_Not_Recruiting | 2023-05-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT06389058 | Using NLP and Neural Networks to Autonomously Identify Severe Asthma and Determ… | — | Severe Asthma | Active_Not_Recruiting | 2023-05-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT05823974 | A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza… | Phase1 | Influenza, Human | Completed | 2023-04-27 | 2024-12-18 | ClinicalTrials.gov |
| NCT05823974 | A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza… | Phase1 | Influenza, Human | Completed | 2023-04-27 | 2024-12-18 | ClinicalTrials.gov |
| NCT05757102 | A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/… | Phase3 | Asthma | Recruiting | 2023-04-25 | 2027-01-15 | ClinicalTrials.gov |
| NCT05757102 | A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/… | Phase3 | Asthma | Recruiting | 2023-04-25 | 2027-01-15 | ClinicalTrials.gov |
| NCT05807399 | PanACEA - STEP2C -01 | Phase2 | Pulmonary Tuberculosis | Recruiting | 2023-04-14 | 2027-12-30 | ClinicalTrials.gov |
| NCT05807399 | PanACEA - STEP2C -01 | Phase2 | Pulmonary Tuberculosis | Recruiting | 2023-04-14 | 2027-12-30 | ClinicalTrials.gov |
| NCT05760261 | Drug Interaction Assessment of GSK3882347 in Healthy Participants Aged 18 to 65… | Phase1 | Urinary Tract Infections | Completed | 2023-04-11 | 2024-08-20 | ClinicalTrials.gov |
| NCT05760261 | Drug Interaction Assessment of GSK3882347 in Healthy Participants Aged 18 to 65… | Phase1 | Urinary Tract Infections | Completed | 2023-04-11 | 2024-08-20 | ClinicalTrials.gov |
| NCT05723562 | A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer | Phase2 | Neoplasms, Rectal | Active_Not_Recruiting | 2023-04-03 | 2029-10-11 | ClinicalTrials.gov |
| NCT05791565 | Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy Participa… | Phase1 | Asthma | Completed | 2023-04-03 | 2023-05-21 | ClinicalTrials.gov |
| NCT05791565 | Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy Participa… | Phase1 | Asthma | Completed | 2023-04-03 | 2023-05-21 | ClinicalTrials.gov |
| NCT05723562 | A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer | Phase2 | Neoplasms, Rectal | Active_Not_Recruiting | 2023-04-03 | 2029-10-11 | ClinicalTrials.gov |
| NCT05762861 | Exploring Clinical Predictors of COPD Exacerbation in a Community Cohort | Na | COPD Exacerbation | Unknown | 2023-04-01 | 2025-04-01 | ClinicalTrials.gov |
| NCT05320939 | Immunological Basis for Mepolizumab Activity in COPD | Phase2 | COPD | Unknown | 2023-04-01 | 2025-05-01 | ClinicalTrials.gov |
| NCT05320939 | Immunological Basis for Mepolizumab Activity in COPD | Phase2 | COPD | Unknown | 2023-04-01 | 2025-05-01 | ClinicalTrials.gov |
| NCT05762861 | Exploring Clinical Predictors of COPD Exacerbation in a Community Cohort | Na | COPD Exacerbation | Unknown | 2023-04-01 | 2025-04-01 | ClinicalTrials.gov |
| NCT05626777 | Symptoms Control and adhErenCe Assessment During Treatment With MepolizUmab New… | Phase4 | Asthma | Active_Not_Recruiting | 2023-03-09 | 2026-07-01 | ClinicalTrials.gov |
| NCT05626777 | Symptoms Control and adhErenCe Assessment During Treatment With MepolizUmab New… | Phase4 | Asthma | Active_Not_Recruiting | 2023-03-09 | 2026-07-01 | ClinicalTrials.gov |
| NCT04128189 | Shingrix in Renal Transplant Recipients | Phase3 | Kidney Transplant Recipient Response to Shingrix Vaccine | Recruiting | 2023-03-02 | 2029-06-01 | ClinicalTrials.gov |
| NCT04128189 | Shingrix in Renal Transplant Recipients | Phase3 | Kidney Transplant Recipient Response to Shingrix Vaccine | Recruiting | 2023-03-02 | 2029-06-01 | ClinicalTrials.gov |
| NCT05405192 | Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia | Phase2 | Gestational Trophoblastic Neoplasia | Withdrawn | 2023-03-01 | 2028-12-01 | ClinicalTrials.gov |
| NCT05673083 | Impact of a Health Technology Intervention on Patient Activation in Multiple My… | — | Multiple Myeloma in Relapse | Active_Not_Recruiting | 2023-03-01 | 2026-03-01 | ClinicalTrials.gov |
| NCT05519670 | A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combinatio… | Phase1 | Breast Cancer | Not_Yet_Recruiting | 2023-03-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT05519670 | A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combinatio… | Phase1 | Breast Cancer | Not_Yet_Recruiting | 2023-03-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT05673083 | Impact of a Health Technology Intervention on Patient Activation in Multiple My… | — | Multiple Myeloma in Relapse | Active_Not_Recruiting | 2023-03-01 | 2026-03-01 | ClinicalTrials.gov |
| NCT05405192 | Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia | Phase2 | Gestational Trophoblastic Neoplasia | Withdrawn | 2023-03-01 | 2028-12-01 | ClinicalTrials.gov |
| NCT05065021 | Using Genetic Profile to Determine the Treatment for Patients With Ovarian Canc… | Phase2 | Ovarian Cancer | Unknown | 2023-02-23 | 2025-06-06 | ClinicalTrials.gov |
| NCT05065021 | Using Genetic Profile to Determine the Treatment for Patients With Ovarian Canc… | Phase2 | Ovarian Cancer | Unknown | 2023-02-23 | 2025-06-06 | ClinicalTrials.gov |
| NCT05523440 | Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovar… | Phase2 | Recurrent Endometrial Carcinoma | Terminated | 2023-02-15 | 2025-01-08 | ClinicalTrials.gov |
| NCT05523440 | Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovar… | Phase2 | Recurrent Endometrial Carcinoma | Terminated | 2023-02-15 | 2025-01-08 | ClinicalTrials.gov |
| NCT05304130 | A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokin… | Phase1 | Arthritis, Rheumatoid | Withdrawn | 2023-02-08 | 2023-05-04 | ClinicalTrials.gov |
| NCT05304130 | A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokin… | Phase1 | Arthritis, Rheumatoid | Withdrawn | 2023-02-08 | 2023-05-04 | ClinicalTrials.gov |
| NCT05705440 | A Follow-up Study to Describe the Safety of Study Participants Who Received RSV… | Phase3 | Respiratory Syncytial Virus Infections | Completed | 2023-02-07 | 2025-01-15 | ClinicalTrials.gov |
| NCT05705440 | A Follow-up Study to Describe the Safety of Study Participants Who Received RSV… | Phase3 | Respiratory Syncytial Virus Infections | Completed | 2023-02-07 | 2025-01-15 | ClinicalTrials.gov |
| NCT05404763 | Mepolizumab and Physical Activity in Severe Asthma | — | Asthma | Active_Not_Recruiting | 2023-02-02 | 2026-08-02 | ClinicalTrials.gov |
| NCT05404763 | Mepolizumab and Physical Activity in Severe Asthma | — | Asthma | Active_Not_Recruiting | 2023-02-02 | 2026-08-02 | ClinicalTrials.gov |
| NCT04305678 | Mepolizumab for Eosinophilic Fasciitis | Phase1 | Eosinophilic Fasciitis | Withdrawn | 2023-02-01 | 2023-02-15 | ClinicalTrials.gov |
| NCT04305678 | Mepolizumab for Eosinophilic Fasciitis | Phase1 | Eosinophilic Fasciitis | Withdrawn | 2023-02-01 | 2023-02-15 | ClinicalTrials.gov |
| NCT05677347 | Phase 1, Single and Repeat Dose Study to Assess Safety, Tolerability, and Pharm… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2023-01-23 | 2023-07-20 | ClinicalTrials.gov |
| NCT05677347 | Phase 1, Single and Repeat Dose Study to Assess Safety, Tolerability, and Pharm… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2023-01-23 | 2023-07-20 | ClinicalTrials.gov |
| NCT05583344 | Phase 2b Study of GSK4532990 in Adults With NASH | Phase2 | Nonalcoholic Fatty Liver Disease | Active_Not_Recruiting | 2023-01-02 | 2027-04-05 | ClinicalTrials.gov |
| NCT05583344 | Phase 2b Study of GSK4532990 in Adults With NASH | Phase2 | Nonalcoholic Fatty Liver Disease | Active_Not_Recruiting | 2023-01-02 | 2027-04-05 | ClinicalTrials.gov |
| NCT05526989 | Study of the Combination Dostarlimab With Niraparib In Patients With Penile Car… | Phase2 | Penile Carcinoma | Recruiting | 2022-12-28 | 2027-11-01 | ClinicalTrials.gov |
| NCT05526989 | Study of the Combination Dostarlimab With Niraparib In Patients With Penile Car… | Phase2 | Penile Carcinoma | Recruiting | 2022-12-28 | 2027-11-01 | ClinicalTrials.gov |
| NCT05630846 | A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella… | Phase2 | Measles; Mumps; Rubella; Chickenpox | Completed | 2022-12-14 | 2024-10-14 | ClinicalTrials.gov |
| NCT05630846 | A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella… | Phase2 | Measles; Mumps; Rubella; Chickenpox | Completed | 2022-12-14 | 2024-10-14 | ClinicalTrials.gov |
| NCT05602025 | A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With… | Phase1 | Asthma | Completed | 2022-12-13 | 2023-10-23 | ClinicalTrials.gov |
| NCT05602025 | A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With… | Phase1 | Asthma | Completed | 2022-12-13 | 2023-10-23 | ClinicalTrials.gov |
| NCT05501522 | Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-C… | Phase3 | COVID-19 | Completed | 2022-12-09 | 2024-08-17 | ClinicalTrials.gov |
| NCT05501522 | Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-C… | Phase3 | COVID-19 | Completed | 2022-12-09 | 2024-08-17 | ClinicalTrials.gov |
| NCT05630807 | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chron… | Phase3 | Chronic Hepatitis B | Active_Not_Recruiting | 2022-12-07 | 2026-05-05 | ClinicalTrials.gov |
| NCT05630807 | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chron… | Phase3 | Chronic Hepatitis B | Active_Not_Recruiting | 2022-12-07 | 2026-05-05 | ClinicalTrials.gov |
| NCT05473195 | A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and i… | Phase2 | Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis (TB) | Completed | 2022-12-06 | 2024-04-16 | ClinicalTrials.gov |
| NCT05473195 | A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and i… | Phase2 | Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis (TB) | Completed | 2022-12-06 | 2024-04-16 | ClinicalTrials.gov |
| NCT05630820 | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chron… | Phase3 | Chronic Hepatitis B | Active_Not_Recruiting | 2022-12-06 | 2026-04-29 | ClinicalTrials.gov |
| NCT05630820 | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chron… | Phase3 | Chronic Hepatitis B | Active_Not_Recruiting | 2022-12-06 | 2026-04-29 | ClinicalTrials.gov |
| NCT05630859 | Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vac… | Phase1 | Sexually Transmitted Diseases | Completed | 2022-11-28 | 2025-05-22 | ClinicalTrials.gov |
| NCT05613205 | Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi… | Phase1 | Typhoid Fever | Completed | 2022-11-28 | 2024-04-02 | ClinicalTrials.gov |
| NCT05613205 | Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi… | Phase1 | Typhoid Fever | Completed | 2022-11-28 | 2024-04-02 | ClinicalTrials.gov |
| NCT05630859 | Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vac… | Phase1 | Sexually Transmitted Diseases | Completed | 2022-11-28 | 2025-05-22 | ClinicalTrials.gov |
| NCT04494412 | An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neona… | Phase2 | Influenza, Human | Recruiting | 2022-11-21 | 2026-04-30 | ClinicalTrials.gov |
| NCT04494412 | An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neona… | Phase2 | Influenza, Human | Recruiting | 2022-11-21 | 2026-04-30 | ClinicalTrials.gov |
| NCT05338190 | Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituxim… | Phase3 | Primary Immune Thrombocytopenia (ITP) | Recruiting | 2022-11-14 | 2027-11-14 | ClinicalTrials.gov |
| NCT05338190 | Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituxim… | Phase3 | Primary Immune Thrombocytopenia (ITP) | Recruiting | 2022-11-14 | 2027-11-14 | ClinicalTrials.gov |
| NCT05896748 | Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Ac… | Phase3 | Human Immunodeficiency Virus Type 1 (HIV-1) | Completed | 2022-11-08 | 2023-09-14 | ClinicalTrials.gov |
| NCT05896748 | Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Ac… | Phase3 | Human Immunodeficiency Virus Type 1 (HIV-1) | Completed | 2022-11-08 | 2023-09-14 | ClinicalTrials.gov |
| NCT05590338 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmaco… | Phase1 | Dermatitis, Atopic | Completed | 2022-11-04 | 2023-12-28 | ClinicalTrials.gov |
| NCT05590338 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmaco… | Phase1 | Dermatitis, Atopic | Completed | 2022-11-04 | 2023-12-28 | ClinicalTrials.gov |
| NCT05008081 | The CATALINA Study | — | Chronic Obstructive Pulmonary Disease Exacerbation | Recruiting | 2022-10-25 | 2026-12-01 | ClinicalTrials.gov |
| NCT05008081 | The CATALINA Study | — | Chronic Obstructive Pulmonary Disease Exacerbation | Recruiting | 2022-10-25 | 2026-12-01 | ClinicalTrials.gov |
| NCT05559476 | A Study on the Immune Response and Safety Elicited by a Vaccine Against Respira… | Phase3 | Respiratory Syncytial Virus Infections | Completed | 2022-10-20 | 2023-08-15 | ClinicalTrials.gov |
| NCT05559476 | A Study on the Immune Response and Safety Elicited by a Vaccine Against Respira… | Phase3 | Respiratory Syncytial Virus Infections | Completed | 2022-10-20 | 2023-08-15 | ClinicalTrials.gov |
| NCT05581875 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin… | Phase1 | Multiple Myeloma | Not_Yet_Recruiting | 2022-10-20 | 2026-10-31 | ClinicalTrials.gov |
| NCT05581875 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin… | Phase1 | Multiple Myeloma | Not_Yet_Recruiting | 2022-10-20 | 2026-10-31 | ClinicalTrials.gov |
| NCT05568797 | A Study on the Immune Response and Safety of a Vaccine Against Respiratory Sync… | Phase3 | Respiratory Syncytial Virus Infections | Completed | 2022-10-14 | 2023-07-17 | ClinicalTrials.gov |
| NCT05568797 | A Study on the Immune Response and Safety of a Vaccine Against Respiratory Sync… | Phase3 | Respiratory Syncytial Virus Infections | Completed | 2022-10-14 | 2023-07-17 | ClinicalTrials.gov |
| NCT05565378 | A Platform Study of Novel Immunotherapy Combinations in Participants With Previ… | Phase2 | Lung Cancer, Non-Small Cell | Active_Not_Recruiting | 2022-10-14 | 2027-02-26 | ClinicalTrials.gov |
| NCT05535972 | To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromid… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2022-10-14 | 2023-09-25 | ClinicalTrials.gov |
| NCT05535972 | To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromid… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2022-10-14 | 2023-09-25 | ClinicalTrials.gov |
| NCT05565378 | A Platform Study of Novel Immunotherapy Combinations in Participants With Previ… | Phase2 | Lung Cancer, Non-Small Cell | Active_Not_Recruiting | 2022-10-14 | 2027-02-26 | ClinicalTrials.gov |
| NCT05561673 | A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Ant… | Phase1 | Hepatitis B | Completed | 2022-10-04 | 2024-11-29 | ClinicalTrials.gov |
| NCT05561673 | A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Ant… | Phase1 | Hepatitis B | Completed | 2022-10-04 | 2024-11-29 | ClinicalTrials.gov |
| NCT05480800 | A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TC… | Phase1 | Salmonella Infections | Completed | 2022-09-13 | 2025-01-07 | ClinicalTrials.gov |
| NCT05480800 | A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TC… | Phase1 | Salmonella Infections | Completed | 2022-09-13 | 2025-01-07 | ClinicalTrials.gov |
| NCT05334368 | Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safe… | Phase3 | Hypereosinophilic Syndrome | Recruiting | 2022-09-06 | 2028-12-19 | ClinicalTrials.gov |
| NCT05334368 | Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safe… | Phase3 | Hypereosinophilic Syndrome | Recruiting | 2022-09-06 | 2028-12-19 | ClinicalTrials.gov |
| NCT07150104 | Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combinatio… | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2022-08-31 | 2027-03-11 | ClinicalTrials.gov |
| NCT07150104 | Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combinatio… | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2022-08-31 | 2027-03-11 | ClinicalTrials.gov |
| NCT05515575 | A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in The… | Phase2 | Sarcoma,Soft Tissue | Active_Not_Recruiting | 2022-08-23 | 2026-08-01 | ClinicalTrials.gov |
| NCT05515575 | A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in The… | Phase2 | Sarcoma,Soft Tissue | Active_Not_Recruiting | 2022-08-23 | 2026-08-01 | ClinicalTrials.gov |
| NCT05496231 | A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus… | Phase1 | Cervical Intraepithelial Neoplasia | Completed | 2022-08-22 | 2024-02-25 | ClinicalTrials.gov |
| NCT05496231 | A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus… | Phase1 | Cervical Intraepithelial Neoplasia | Completed | 2022-08-22 | 2024-02-25 | ClinicalTrials.gov |
| NCT05477186 | Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501… | Phase1 | COVID-19 | Completed | 2022-08-12 | 2023-08-18 | ClinicalTrials.gov |
| NCT05477186 | Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501… | Phase1 | COVID-19 | Completed | 2022-08-12 | 2023-08-18 | ClinicalTrials.gov |
| NCT05371080 | A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of… | Phase3 | Herpes Zoster | Active_Not_Recruiting | 2022-08-10 | 2027-08-23 | ClinicalTrials.gov |
| NCT05371080 | A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of… | Phase3 | Herpes Zoster | Active_Not_Recruiting | 2022-08-10 | 2027-08-23 | ClinicalTrials.gov |
| NCT05446740 | A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against … | Phase1 | Influenza, Human | Completed | 2022-08-09 | 2024-03-26 | ClinicalTrials.gov |
| NCT05446740 | A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against … | Phase1 | Influenza, Human | Completed | 2022-08-09 | 2024-03-26 | ClinicalTrials.gov |
| NCT04651777 | Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma | Phase3 | Asthma | Active_Not_Recruiting | 2022-08-08 | 2025-12-01 | ClinicalTrials.gov |
| NCT04651777 | Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma | Phase3 | Asthma | Active_Not_Recruiting | 2022-08-08 | 2025-12-01 | ClinicalTrials.gov |
| NCT05208307 | Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-… | Phase2 | Plasma Cell Myeloma | Recruiting | 2022-07-21 | 2027-10-21 | ClinicalTrials.gov |
| NCT05208307 | Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-… | Phase2 | Plasma Cell Myeloma | Recruiting | 2022-07-21 | 2027-10-21 | ClinicalTrials.gov |
| NCT07150091 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat… | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2022-07-19 | 2027-03-11 | ClinicalTrials.gov |
| NCT05393076 | Phase I Study of Linerixibat in Adults With Moderate Hepatic Impairment and Hea… | Phase1 | Pruritus | Completed | 2022-07-19 | 2022-12-06 | ClinicalTrials.gov |
| NCT05393076 | Phase I Study of Linerixibat in Adults With Moderate Hepatic Impairment and Hea… | Phase1 | Pruritus | Completed | 2022-07-19 | 2022-12-06 | ClinicalTrials.gov |
| NCT07150091 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat… | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2022-07-19 | 2027-03-11 | ClinicalTrials.gov |
| NCT04965636 | Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE) | Phase3 | Hypereosinophilic Syndrome | Completed | 2022-07-11 | 2025-10-28 | ClinicalTrials.gov |
| NCT04965636 | Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE) | Phase3 | Hypereosinophilic Syndrome | Completed | 2022-07-11 | 2025-10-28 | ClinicalTrials.gov |
| NCT05305651 | Study to Monitor the Occurrence of Viral Variants in Patients With Compromised … | Phase4 | COVID-19 | Completed | 2022-07-01 | 2023-07-17 | ClinicalTrials.gov |
| NCT05305651 | Study to Monitor the Occurrence of Viral Variants in Patients With Compromised … | Phase4 | COVID-19 | Completed | 2022-07-01 | 2023-07-17 | ClinicalTrials.gov |
| NCT05292053 | Outcomes of Once-Daily ICS/LABA/LAMA + PRN Respiratory Therapy Treatments in Ho… | Phase4 | Copd | Completed | 2022-07-01 | 2025-02-09 | ClinicalTrials.gov |
| NCT05292053 | Outcomes of Once-Daily ICS/LABA/LAMA + PRN Respiratory Therapy Treatments in Ho… | Phase4 | Copd | Completed | 2022-07-01 | 2025-02-09 | ClinicalTrials.gov |
| NCT05349227 | Comprehensive Outcomes for After Cancer Health | Na | Ovarian Cancer | Recruiting | 2022-06-23 | 2027-05-01 | ClinicalTrials.gov |
| NCT05349227 | Comprehensive Outcomes for After Cancer Health | Na | Ovarian Cancer | Recruiting | 2022-06-23 | 2027-05-01 | ClinicalTrials.gov |
| NCT05412030 | A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AF… | Phase2 | Pneumonia, Bacterial | Completed | 2022-06-16 | 2025-09-18 | ClinicalTrials.gov |
| NCT05412030 | A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AF… | Phase2 | Pneumonia, Bacterial | Completed | 2022-06-16 | 2025-09-18 | ClinicalTrials.gov |
| NCT05297864 | PARP Inhibition for Gliomas (PI-4G or π4g) | Phase2 | Recurrent Glioblastoma | Terminated | 2022-06-09 | 2024-02-06 | ClinicalTrials.gov |
| NCT05297864 | PARP Inhibition for Gliomas (PI-4G or π4g) | Phase2 | Recurrent Glioblastoma | Terminated | 2022-06-09 | 2024-02-06 | ClinicalTrials.gov |
| NCT05357274 | A System to Classify Treatable Traits in Primary Care | — | Respiratory Disease | Unknown | 2022-05-16 | 2024-12-31 | ClinicalTrials.gov |
| NCT05357274 | A System to Classify Treatable Traits in Primary Care | — | Respiratory Disease | Unknown | 2022-05-16 | 2024-12-31 | ClinicalTrials.gov |
| NCT04600752 | Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength… | Phase4 | Otitis Media | Completed | 2022-05-07 | 2022-11-12 | ClinicalTrials.gov |
| NCT04600752 | Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength… | Phase4 | Otitis Media | Completed | 2022-05-07 | 2022-11-12 | ClinicalTrials.gov |
| NCT05289492 | Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma | Phase1 | Multiple Myeloma | Terminated | 2022-05-01 | 2023-11-29 | ClinicalTrials.gov |
| NCT05289492 | Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma | Phase1 | Multiple Myeloma | Terminated | 2022-05-01 | 2023-11-29 | ClinicalTrials.gov |
| NCT05274750 | Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rh… | Phase3 | Nasal Polyps | Completed | 2022-04-22 | 2024-08-27 | ClinicalTrials.gov |
| NCT05274750 | Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rh… | Phase3 | Nasal Polyps | Completed | 2022-04-22 | 2024-08-27 | ClinicalTrials.gov |
| NCT04964050 | A Bioequivalence Study Between Capozide Versus ACE-Hemmer-ratiopharm in Healthy… | Phase1 | Healthy Volunteers | Withdrawn | 2022-04-21 | 2022-05-26 | ClinicalTrials.gov |
| NCT05388448 | EBA, Safety and Tolerability of Sanfetrinem Cilexetil | Phase2 | Tuberculosis, Pulmonary | Completed | 2022-04-21 | 2024-08-19 | ClinicalTrials.gov |
| NCT05388448 | EBA, Safety and Tolerability of Sanfetrinem Cilexetil | Phase2 | Tuberculosis, Pulmonary | Completed | 2022-04-21 | 2024-08-19 | ClinicalTrials.gov |
| NCT04964050 | A Bioequivalence Study Between Capozide Versus ACE-Hemmer-ratiopharm in Healthy… | Phase1 | Healthy Volunteers | Withdrawn | 2022-04-21 | 2022-05-26 | ClinicalTrials.gov |
| NCT05281523 | Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rh… | Phase3 | Nasal Polyps | Completed | 2022-04-18 | 2024-08-06 | ClinicalTrials.gov |
| NCT05281523 | Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rh… | Phase3 | Nasal Polyps | Completed | 2022-04-18 | 2024-08-06 | ClinicalTrials.gov |
| NCT05201547 | Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlima… | Phase3 | Endometrial Cancer | Active_Not_Recruiting | 2022-04-15 | 2029-10-01 | ClinicalTrials.gov |
| NCT05201547 | Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlima… | Phase3 | Endometrial Cancer | Active_Not_Recruiting | 2022-04-15 | 2029-10-01 | ClinicalTrials.gov |
| NCT05330455 | Study of GSK3965193 in Healthy Participants and Participants Living With Chroni… | Phase1 | Hepatitis B | Terminated | 2022-04-14 | 2026-04-08 | ClinicalTrials.gov |
| NCT06964165 | A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoa… | Phase2 | Ovarian Neoplasms | Terminated | 2022-04-14 | 2025-03-31 | ClinicalTrials.gov |
| NCT05330455 | Study of GSK3965193 in Healthy Participants and Participants Living With Chroni… | Phase1 | Hepatitis B | Terminated | 2022-04-14 | 2026-04-08 | ClinicalTrials.gov |
| NCT06964165 | A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoa… | Phase2 | Ovarian Neoplasms | Terminated | 2022-04-14 | 2025-03-31 | ClinicalTrials.gov |
| NCT05280275 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin… | Phase1 | Multiple Myeloma | Unknown | 2022-04-13 | 2026-03-15 | ClinicalTrials.gov |
| NCT05280275 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin… | Phase1 | Multiple Myeloma | Unknown | 2022-04-13 | 2026-03-15 | ClinicalTrials.gov |
| NCT04992013 | Niraparib in Tumors Metastatic to the CNS | Phase2 | Metastatic Cancer | Active_Not_Recruiting | 2022-04-05 | 2027-06-01 | ClinicalTrials.gov |
| NCT04992013 | Niraparib in Tumors Metastatic to the CNS | Phase2 | Metastatic Cancer | Active_Not_Recruiting | 2022-04-05 | 2027-06-01 | ClinicalTrials.gov |
| NCT05280717 | Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab In… | Phase1 | Covid19 | Terminated | 2022-03-28 | 2023-11-06 | ClinicalTrials.gov |
| NCT05280717 | Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab In… | Phase1 | Covid19 | Terminated | 2022-03-28 | 2023-11-06 | ClinicalTrials.gov |
| NCT05297240 | Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients W… | — | RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA | Unknown | 2022-03-24 | 2022-12-01 | ClinicalTrials.gov |
| NCT05297240 | Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients W… | — | RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA | Unknown | 2022-03-24 | 2022-12-01 | ClinicalTrials.gov |
| NCT05260437 | Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against… | Phase1 | COVID-19 | Completed | 2022-03-24 | 2023-03-07 | ClinicalTrials.gov |
| NCT05260437 | Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against… | Phase1 | COVID-19 | Completed | 2022-03-24 | 2023-03-07 | ClinicalTrials.gov |
| NCT05277051 | First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tum… | Phase1 | Neoplasms | Active_Not_Recruiting | 2022-03-22 | 2027-08-31 | ClinicalTrials.gov |
| NCT05276297 | A Study on the Safety, Efficacy and Immune Response Following Sequential Treatm… | Phase2 | Hepatitis B, Chronic | Completed | 2022-03-22 | 2025-08-05 | ClinicalTrials.gov |
| NCT05277051 | First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tum… | Phase1 | Neoplasms | Active_Not_Recruiting | 2022-03-22 | 2027-08-31 | ClinicalTrials.gov |
| NCT05276297 | A Study on the Safety, Efficacy and Immune Response Following Sequential Treatm… | Phase2 | Hepatitis B, Chronic | Completed | 2022-03-22 | 2025-08-05 | ClinicalTrials.gov |
| NCT05169437 | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors | Phase2 | Solid Tumor | Terminated | 2022-03-15 | 2024-08-27 | ClinicalTrials.gov |
| NCT05169437 | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors | Phase2 | Solid Tumor | Terminated | 2022-03-15 | 2024-08-27 | ClinicalTrials.gov |
| NCT05229068 | A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination… | Phase3 | Respiratory Syncytial Virus Infections | Withdrawn | 2022-03-11 | 2024-10-24 | ClinicalTrials.gov |
| NCT05229068 | A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination… | Phase3 | Respiratory Syncytial Virus Infections | Withdrawn | 2022-03-11 | 2024-10-24 | ClinicalTrials.gov |
| NCT05298254 | A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targe… | Phase1 | Herpes Simplex | Completed | 2022-03-07 | 2025-06-12 | ClinicalTrials.gov |
| NCT05298254 | A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targe… | Phase1 | Herpes Simplex | Completed | 2022-03-07 | 2025-06-12 | ClinicalTrials.gov |
| NCT05064358 | Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Par… | Phase2 | Multiple Myeloma | Active_Not_Recruiting | 2022-03-03 | 2026-01-30 | ClinicalTrials.gov |
| NCT05064358 | Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Par… | Phase2 | Multiple Myeloma | Active_Not_Recruiting | 2022-03-03 | 2026-01-30 | ClinicalTrials.gov |
| NCT05243680 | An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who W… | Phase3 | Asthma | Completed | 2022-03-01 | 2025-05-19 | ClinicalTrials.gov |
| NCT05243680 | An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who W… | Phase3 | Asthma | Completed | 2022-03-01 | 2025-05-19 | ClinicalTrials.gov |
| NCT05002816 | Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic… | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2022-02-21 | 2026-12-01 | ClinicalTrials.gov |
| NCT05002816 | Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic… | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2022-02-21 | 2026-12-01 | ClinicalTrials.gov |
| NCT05174013 | Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in H… | Phase1 | Pain | Completed | 2022-02-14 | 2023-04-17 | ClinicalTrials.gov |
| NCT05174013 | Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in H… | Phase1 | Pain | Completed | 2022-02-14 | 2023-04-17 | ClinicalTrials.gov |
| NCT04878315 | Bioequivalence Study Between Capoten Versus Captopril Reference Product in Heal… | Phase1 | Healthy Volunteers | Withdrawn | 2022-02-13 | 2022-03-25 | ClinicalTrials.gov |
| NCT04878315 | Bioequivalence Study Between Capoten Versus Captopril Reference Product in Heal… | Phase1 | Healthy Volunteers | Withdrawn | 2022-02-13 | 2022-03-25 | ClinicalTrials.gov |
| NCT05252338 | A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CV… | Phase1 | Influenza | Completed | 2022-02-07 | 2022-09-27 | ClinicalTrials.gov |
| NCT05210101 | A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against CO… | Phase2 | SARS CoV 2 Infection | Completed | 2022-02-07 | 2023-02-28 | ClinicalTrials.gov |
| NCT05252338 | A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CV… | Phase1 | Influenza | Completed | 2022-02-07 | 2022-09-27 | ClinicalTrials.gov |
| NCT05210101 | A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against CO… | Phase2 | SARS CoV 2 Infection | Completed | 2022-02-07 | 2023-02-28 | ClinicalTrials.gov |
| NCT05219253 | A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in… | Phase3 | Herpes Zoster | Completed | 2022-02-02 | 2022-12-12 | ClinicalTrials.gov |
| NCT05169905 | A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Mater… | Phase3 | Respiratory Syncytial Virus Infections | Completed | 2022-02-02 | 2022-08-03 | ClinicalTrials.gov |
| NCT05169905 | A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Mater… | Phase3 | Respiratory Syncytial Virus Infections | Completed | 2022-02-02 | 2022-08-03 | ClinicalTrials.gov |
| NCT05219253 | A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in… | Phase3 | Herpes Zoster | Completed | 2022-02-02 | 2022-12-12 | ClinicalTrials.gov |
| NCT05069051 | Belimumab in Patients with Chronic Lymphocytic Leukemia | Phase2 | Chronic Lymphoid Leukemia in Relapse | Active_Not_Recruiting | 2022-01-19 | 2027-07-14 | ClinicalTrials.gov |
| NCT05069051 | Belimumab in Patients with Chronic Lymphocytic Leukemia | Phase2 | Chronic Lymphoid Leukemia in Relapse | Active_Not_Recruiting | 2022-01-19 | 2027-07-14 | ClinicalTrials.gov |
| NCT06926673 | Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants … | Phase2 | Neoplasms | Completed | 2021-12-23 | 2024-05-02 | ClinicalTrials.gov |
| NCT06926673 | Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants … | Phase2 | Neoplasms | Completed | 2021-12-23 | 2024-05-02 | ClinicalTrials.gov |
| NCT05124210 | Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in Hig… | Phase2 | COVID-19 | Terminated | 2021-12-16 | 2023-06-14 | ClinicalTrials.gov |
| NCT05124210 | Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in Hig… | Phase2 | COVID-19 | Terminated | 2021-12-16 | 2023-06-14 | ClinicalTrials.gov |
| NCT05100316 | Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell … | Phase2 | Neoplasms | Terminated | 2021-12-16 | 2022-10-04 | ClinicalTrials.gov |
| NCT05100316 | Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell … | Phase2 | Neoplasms | Terminated | 2021-12-16 | 2022-10-04 | ClinicalTrials.gov |
| NCT04954859 | Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previ… | Phase2 | Hepatitis B | Recruiting | 2021-12-14 | 2029-02-08 | ClinicalTrials.gov |
| NCT04954859 | Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previ… | Phase2 | Hepatitis B | Recruiting | 2021-12-14 | 2029-02-08 | ClinicalTrials.gov |
| NCT05140200 | Study of GSK3511294 in Healthy Chinese Participants | Phase1 | Asthma | Completed | 2021-12-10 | 2022-12-23 | ClinicalTrials.gov |
| NCT05140200 | Study of GSK3511294 in Healthy Chinese Participants | Phase1 | Asthma | Completed | 2021-12-10 | 2022-12-23 | ClinicalTrials.gov |
| NCT05169554 | Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease Thera… | Phase2 | Buruli Ulcer | Recruiting | 2021-12-01 | 2026-05-31 | ClinicalTrials.gov |
| NCT05169554 | Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease Thera… | Phase2 | Buruli Ulcer | Recruiting | 2021-12-01 | 2026-05-31 | ClinicalTrials.gov |
| NCT05082285 | A Study on the Safety, Tolerability and Immune Response of Meningococcal Combin… | Phase2 | Infections, Meningococcal | Completed | 2021-11-29 | 2025-03-31 | ClinicalTrials.gov |
| NCT05082285 | A Study on the Safety, Tolerability and Immune Response of Meningococcal Combin… | Phase2 | Infections, Meningococcal | Completed | 2021-11-29 | 2025-03-31 | ClinicalTrials.gov |
| NCT05087056 | Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different … | Phase2 | Meningitis, Meningococcal | Active_Not_Recruiting | 2021-11-18 | 2027-03-10 | ClinicalTrials.gov |
| NCT05087056 | Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different … | Phase2 | Meningitis, Meningococcal | Active_Not_Recruiting | 2021-11-18 | 2027-03-10 | ClinicalTrials.gov |
| NCT04975438 | Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis | Phase1 | Dermatitis, Atopic | Completed | 2021-11-18 | 2023-03-13 | ClinicalTrials.gov |
| NCT04975438 | Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis | Phase1 | Dermatitis, Atopic | Completed | 2021-11-18 | 2023-03-13 | ClinicalTrials.gov |
| NCT05131971 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics… | Phase1 | Multiple Sclerosis | Completed | 2021-11-01 | 2023-10-12 | ClinicalTrials.gov |
| NCT05131971 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics… | Phase1 | Multiple Sclerosis | Completed | 2021-11-01 | 2023-10-12 | ClinicalTrials.gov |
| NCT05076513 | Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurr… | Early_Phase1 | Glioblastoma | Active_Not_Recruiting | 2021-10-29 | 2027-03-01 | ClinicalTrials.gov |
| NCT05076513 | Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurr… | Early_Phase1 | Glioblastoma | Active_Not_Recruiting | 2021-10-29 | 2027-03-01 | ClinicalTrials.gov |
| NCT05045144 | A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational… | Phase3 | Respiratory Syncytial Virus Infections | Completed | 2021-10-26 | 2022-06-06 | ClinicalTrials.gov |
| NCT05045144 | A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational… | Phase3 | Respiratory Syncytial Virus Infections | Completed | 2021-10-26 | 2022-06-06 | ClinicalTrials.gov |
| NCT05089630 | A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus V… | Phase1 | Cytomegalovirus Infections | Completed | 2021-10-14 | 2025-04-02 | ClinicalTrials.gov |
| NCT05089630 | A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus V… | Phase1 | Cytomegalovirus Infections | Completed | 2021-10-14 | 2025-04-02 | ClinicalTrials.gov |
| NCT04895046 | Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma | Phase2 | HRD | Withdrawn | 2021-10-11 | 2023-09-01 | ClinicalTrials.gov |
| NCT04895046 | Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma | Phase2 | HRD | Withdrawn | 2021-10-11 | 2023-09-01 | ClinicalTrials.gov |
| NCT05073003 | A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine … | Phase1 | Diarrhoea | Completed | 2021-10-06 | 2025-06-24 | ClinicalTrials.gov |
| NCT05073003 | A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine … | Phase1 | Diarrhoea | Completed | 2021-10-06 | 2025-06-24 | ClinicalTrials.gov |
| NCT05059301 | A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial V… | Phase3 | Respiratory Syncytial Virus Infections | Completed | 2021-10-01 | 2022-06-30 | ClinicalTrials.gov |
| NCT04767698 | Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Scler… | Phase2 | Multiple Sclerosis | Terminated | 2021-10-01 | 2022-05-10 | ClinicalTrials.gov |
| NCT05059301 | A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial V… | Phase3 | Respiratory Syncytial Virus Infections | Completed | 2021-10-01 | 2022-06-30 | ClinicalTrials.gov |
| NCT04767698 | Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Scler… | Phase2 | Multiple Sclerosis | Terminated | 2021-10-01 | 2022-05-10 | ClinicalTrials.gov |
| NCT04914078 | Severe Asthma Exacerbations and Mepolizumab Treatment | — | Severe Asthma | Unknown | 2021-09-21 | 2023-12-01 | ClinicalTrials.gov |
| NCT04914078 | Severe Asthma Exacerbations and Mepolizumab Treatment | — | Severe Asthma | Unknown | 2021-09-21 | 2023-12-01 | ClinicalTrials.gov |
| NCT05082688 | Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHI… | Phase2 | Influenza | Completed | 2021-09-20 | 2023-05-17 | ClinicalTrials.gov |
| NCT05082688 | Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHI… | Phase2 | Influenza | Completed | 2021-09-20 | 2023-05-17 | ClinicalTrials.gov |
| NCT05044325 | A First Time in Human (FTIH) Study to Evaluate the Safety, Tolerability, Pharma… | Phase1 | Heart Failure | Terminated | 2021-09-20 | 2022-08-05 | ClinicalTrials.gov |
| NCT05044325 | A First Time in Human (FTIH) Study to Evaluate the Safety, Tolerability, Pharma… | Phase1 | Heart Failure | Terminated | 2021-09-20 | 2022-08-05 | ClinicalTrials.gov |
| NCT04971928 | Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impai… | Phase1 | Hepatitis B | Completed | 2021-09-07 | 2022-05-12 | ClinicalTrials.gov |
| NCT04971928 | Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impai… | Phase1 | Hepatitis B | Completed | 2021-09-07 | 2022-05-12 | ClinicalTrials.gov |
| NCT05060432 | Study of EOS-448 With Standard of Care and/or Investigational Therapies in Part… | Phase1 | Advanced Cancer | Active_Not_Recruiting | 2021-09-06 | 2025-07-01 | ClinicalTrials.gov |
| NCT05060432 | Study of EOS-448 With Standard of Care and/or Investigational Therapies in Part… | Phase1 | Advanced Cancer | Active_Not_Recruiting | 2021-09-06 | 2025-07-01 | ClinicalTrials.gov |
| NCT05007951 | Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vacci… | Phase3 | Covid19 | Completed | 2021-08-30 | 2023-10-02 | ClinicalTrials.gov |
| NCT05007951 | Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vacci… | Phase3 | Covid19 | Completed | 2021-08-30 | 2023-10-02 | ClinicalTrials.gov |
| NCT04950127 | Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholang… | Phase3 | Pruritus | Completed | 2021-08-27 | 2024-12-20 | ClinicalTrials.gov |
| NCT04950127 | Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholang… | Phase3 | Pruritus | Completed | 2021-08-27 | 2024-12-20 | ClinicalTrials.gov |
| NCT04980391 | A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vacci… | Phase3 | Respiratory Syncytial Virus Infections | Terminated | 2021-08-03 | 2023-05-30 | ClinicalTrials.gov |
| NCT04980391 | A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vacci… | Phase3 | Respiratory Syncytial Virus Infections | Terminated | 2021-08-03 | 2023-05-30 | ClinicalTrials.gov |
| NCT07217184 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab i… | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2021-07-29 | 2027-03-11 | ClinicalTrials.gov |
| NCT04937387 | Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)… | Phase3 | Asthma | Completed | 2021-07-29 | 2024-08-05 | ClinicalTrials.gov |
| NCT07217184 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab i… | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2021-07-29 | 2027-03-11 | ClinicalTrials.gov |
| NCT04937387 | Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)… | Phase3 | Asthma | Completed | 2021-07-29 | 2024-08-05 | ClinicalTrials.gov |
| NCT06868667 | Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodot… | Phase3 | Multiple Myeloma | Active_Not_Recruiting | 2021-07-28 | 2028-06-30 | ClinicalTrials.gov |
| NCT06868654 | China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin,… | Phase3 | Multiple Myeloma | Active_Not_Recruiting | 2021-07-28 | 2028-06-30 | ClinicalTrials.gov |
| NCT06868654 | China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin,… | Phase3 | Multiple Myeloma | Active_Not_Recruiting | 2021-07-28 | 2028-06-30 | ClinicalTrials.gov |
| NCT06868667 | Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodot… | Phase3 | Multiple Myeloma | Active_Not_Recruiting | 2021-07-28 | 2028-06-30 | ClinicalTrials.gov |
| NCT04988152 | A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placeb… | Phase1 | Covid19 | Completed | 2021-07-06 | 2021-12-07 | ClinicalTrials.gov |
| NCT04988152 | A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placeb… | Phase1 | Covid19 | Completed | 2021-07-06 | 2021-12-07 | ClinicalTrials.gov |
| NCT04959344 | Safety and Immunogenicity of a Klebsiella Pneumoniae Tetravalent Bioconjugate V… | Phase1 | Klebsiella Pneumoniae Infection | Completed | 2021-07-05 | 2022-09-26 | ClinicalTrials.gov |
| NCT04959344 | Safety and Immunogenicity of a Klebsiella Pneumoniae Tetravalent Bioconjugate V… | Phase1 | Klebsiella Pneumoniae Infection | Completed | 2021-07-05 | 2022-09-26 | ClinicalTrials.gov |
| NCT04808973 | DTG Plus 3TC for Prophylaxis of Mother-to-child Transmission of HIV Infection i… | Phase3 | HIV Infections | Completed | 2021-07-01 | 2023-09-10 | ClinicalTrials.gov |
| NCT04676360 | Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma | Phase2 | Relapsed Plasmablastic Lymphoma | Terminated | 2021-07-01 | 2024-11-26 | ClinicalTrials.gov |
| NCT04808973 | DTG Plus 3TC for Prophylaxis of Mother-to-child Transmission of HIV Infection i… | Phase3 | HIV Infections | Completed | 2021-07-01 | 2023-09-10 | ClinicalTrials.gov |
| NCT04961060 | Drivers of Eosinophilic COPD Exacerbations | — | COPD Exacerbation | Unknown | 2021-07-01 | 2025-01-01 | ClinicalTrials.gov |
| NCT04924478 | Evaluation of Volatile Organic Compounds in Mepolizumab Therapy | — | Asthma; Eosinophilic | Unknown | 2021-07-01 | 2022-12-01 | ClinicalTrials.gov |
| NCT04676360 | Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma | Phase2 | Relapsed Plasmablastic Lymphoma | Terminated | 2021-07-01 | 2024-11-26 | ClinicalTrials.gov |
| NCT04924478 | Evaluation of Volatile Organic Compounds in Mepolizumab Therapy | — | Asthma; Eosinophilic | Unknown | 2021-07-01 | 2022-12-01 | ClinicalTrials.gov |
| NCT04961060 | Drivers of Eosinophilic COPD Exacerbations | — | COPD Exacerbation | Unknown | 2021-07-01 | 2025-01-01 | ClinicalTrials.gov |
| NCT04276233 | Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) i… | Phase4 | Asthma | Completed | 2021-06-29 | 2023-10-28 | ClinicalTrials.gov |
| NCT04276233 | Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) i… | Phase4 | Asthma | Completed | 2021-06-29 | 2023-10-28 | ClinicalTrials.gov |
| NCT04915755 | Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Hum… | Phase3 | Neoplasms, Breast | Active_Not_Recruiting | 2021-06-28 | 2025-12-31 | ClinicalTrials.gov |
| NCT04915755 | Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Hum… | Phase3 | Neoplasms, Breast | Active_Not_Recruiting | 2021-06-28 | 2025-12-31 | ClinicalTrials.gov |
| NCT04886154 | A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combi… | Phase1 | Infections, Meningococcal | Completed | 2021-06-14 | 2024-02-02 | ClinicalTrials.gov |
| NCT04886154 | A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combi… | Phase1 | Infections, Meningococcal | Completed | 2021-06-14 | 2024-02-02 | ClinicalTrials.gov |
| NCT04913675 | Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19. | Phase3 | Covid19 | Terminated | 2021-06-10 | 2023-03-24 | ClinicalTrials.gov |
| NCT04913675 | Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19. | Phase3 | Covid19 | Terminated | 2021-06-10 | 2023-03-24 | ClinicalTrials.gov |
| NCT04676516 | A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early… | Phase2 | Breast Cancer | Completed | 2021-06-08 | 2022-08-15 | ClinicalTrials.gov |
| NCT04676516 | A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early… | Phase2 | Breast Cancer | Completed | 2021-06-08 | 2022-08-15 | ClinicalTrials.gov |
| NCT04481113 | Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor … | Phase1 | Anatomic Stage I Breast Cancer AJCC v8 | Completed | 2021-06-07 | 2025-06-20 | ClinicalTrials.gov |
| NCT04481113 | Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor … | Phase1 | Anatomic Stage I Breast Cancer AJCC v8 | Completed | 2021-06-07 | 2025-06-20 | ClinicalTrials.gov |
| NCT04680468 | Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant … | Phase2 | Myeloma | Active_Not_Recruiting | 2021-06-02 | 2026-07-11 | ClinicalTrials.gov |
| NCT04680468 | Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant … | Phase2 | Myeloma | Active_Not_Recruiting | 2021-06-02 | 2026-07-11 | ClinicalTrials.gov |
| NCT04655508 | Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation … | Phase3 | Stem Cell Transplant Complications | Terminated | 2021-05-21 | 2023-09-27 | ClinicalTrials.gov |
| NCT04655508 | Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation … | Phase3 | Stem Cell Transplant Complications | Terminated | 2021-05-21 | 2023-09-27 | ClinicalTrials.gov |
| NCT04723446 | Efficacy of Mouthwashes in Reducing Severe Acute Respiratory Syndrome Coronavir… | Na | Covid19 | Completed | 2021-05-19 | 2021-10-25 | ClinicalTrials.gov |
| NCT04822337 | Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in M… | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2021-05-19 | 2032-11-01 | ClinicalTrials.gov |
| NCT04723446 | Efficacy of Mouthwashes in Reducing Severe Acute Respiratory Syndrome Coronavir… | Na | Covid19 | Completed | 2021-05-19 | 2021-10-25 | ClinicalTrials.gov |
| NCT04822337 | Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in M… | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2021-05-19 | 2032-11-01 | ClinicalTrials.gov |
| NCT04869982 | Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Sh… | Phase4 | Herpes Zoster | Completed | 2021-05-14 | 2023-04-20 | ClinicalTrials.gov |
| NCT04869982 | Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Sh… | Phase4 | Herpes Zoster | Completed | 2021-05-14 | 2023-04-20 | ClinicalTrials.gov |
| NCT04714567 | Portuguese Severe Asthma Registry: Getting Answers for Severe Asthma Patients | — | Severe Asthma | Unknown | 2021-05-01 | 2022-12-01 | ClinicalTrials.gov |
| NCT04714567 | Portuguese Severe Asthma Registry: Getting Answers for Severe Asthma Patients | — | Severe Asthma | Unknown | 2021-05-01 | 2022-12-01 | ClinicalTrials.gov |
| NCT04841577 | A Study on the Immune Response and Safety Elicited by a Vaccine Against Respira… | Phase3 | Respiratory Syncytial Virus Infections | Completed | 2021-04-27 | 2022-02-08 | ClinicalTrials.gov |
| NCT04841577 | A Study on the Immune Response and Safety Elicited by a Vaccine Against Respira… | Phase3 | Respiratory Syncytial Virus Infections | Completed | 2021-04-27 | 2022-02-08 | ClinicalTrials.gov |
| NCT04607005 | Efficacy and Safety of Mepolizumab in Adults With Chronic Rhinosinusitis With N… | Phase3 | Nasal Polyps | Completed | 2021-04-22 | 2023-04-12 | ClinicalTrials.gov |
| NCT04607005 | Efficacy and Safety of Mepolizumab in Adults With Chronic Rhinosinusitis With N… | Phase3 | Nasal Polyps | Completed | 2021-04-22 | 2023-04-12 | ClinicalTrials.gov |
| NCT04641247 | A Long-term Treatment Extension Study of Niraparib in Participants Who Complete… | Phase2 | Ovarian Neoplasms | Recruiting | 2021-04-16 | 2026-11-13 | ClinicalTrials.gov |
| NCT04641247 | A Long-term Treatment Extension Study of Niraparib in Participants Who Complete… | Phase2 | Ovarian Neoplasms | Recruiting | 2021-04-16 | 2026-11-13 | ClinicalTrials.gov |
| NCT04813354 | A Comparison of Critical Errors, Overall Errors, Training/Teaching Time, and Pr… | Phase4 | Asthma | Completed | 2021-04-14 | 2021-07-08 | ClinicalTrials.gov |
| NCT04813354 | A Comparison of Critical Errors, Overall Errors, Training/Teaching Time, and Pr… | Phase4 | Asthma | Completed | 2021-04-14 | 2021-07-08 | ClinicalTrials.gov |
| NCT04802356 | Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Pa… | Phase2 | Multiple Myeloma | Active_Not_Recruiting | 2021-04-07 | 2026-06-01 | ClinicalTrials.gov |
| NCT04802356 | Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Pa… | Phase2 | Multiple Myeloma | Active_Not_Recruiting | 2021-04-07 | 2026-06-01 | ClinicalTrials.gov |
| NCT04151225 | Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Di… | Phase2 | Crohns Disease | Withdrawn | 2021-04-05 | 2025-05-26 | ClinicalTrials.gov |
| NCT04151225 | Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Di… | Phase2 | Crohns Disease | Withdrawn | 2021-04-05 | 2025-05-26 | ClinicalTrials.gov |
| NCT04774419 | Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After The… | Phase2 | Endometrial Cancer | Recruiting | 2021-04-02 | 2027-02-01 | ClinicalTrials.gov |
| NCT04774419 | Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After The… | Phase2 | Endometrial Cancer | Recruiting | 2021-04-02 | 2027-02-01 | ClinicalTrials.gov |
| NCT04641741 | Effect of Mepolizumab on Severe Eosinophilic Asthma | — | Asthma | Unknown | 2021-04-01 | 2025-03-01 | ClinicalTrials.gov |
| NCT04762901 | LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Met… | Phase1 | Breast Cancer | Withdrawn | 2021-04-01 | 2026-01-01 | ClinicalTrials.gov |
| NCT04641741 | Effect of Mepolizumab on Severe Eosinophilic Asthma | — | Asthma | Unknown | 2021-04-01 | 2025-03-01 | ClinicalTrials.gov |
| NCT04762901 | LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Met… | Phase1 | Breast Cancer | Withdrawn | 2021-04-01 | 2026-01-01 | ClinicalTrials.gov |
| NCT04670627 | Biomarkers in Nasal Samples of Seasonal Allergic Rhinitics | — | Seasonal Allergic Rhinitis | Completed | 2021-03-22 | 2023-04-27 | ClinicalTrials.gov |
| NCT04670627 | Biomarkers in Nasal Samples of Seasonal Allergic Rhinitics | — | Seasonal Allergic Rhinitis | Completed | 2021-03-22 | 2023-04-27 | ClinicalTrials.gov |
| NCT04719832 | Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Par… | Phase3 | Asthma | Completed | 2021-03-17 | 2023-11-21 | ClinicalTrials.gov |
| NCT04719832 | Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Par… | Phase3 | Asthma | Completed | 2021-03-17 | 2023-11-21 | ClinicalTrials.gov |
| NCT04789577 | A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biological… | Phase2 | Influenza, Human | Completed | 2021-03-16 | 2022-09-12 | ClinicalTrials.gov |
| NCT05001087 | A "Physician & Patient-powered" Cohort Registry (MY MYELOMA) | — | Multiple Myeloma | Recruiting | 2021-03-16 | 2027-03-31 | ClinicalTrials.gov |
| NCT04789577 | A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biological… | Phase2 | Influenza, Human | Completed | 2021-03-16 | 2022-09-12 | ClinicalTrials.gov |
| NCT05001087 | A "Physician & Patient-powered" Cohort Registry (MY MYELOMA) | — | Multiple Myeloma | Recruiting | 2021-03-16 | 2027-03-31 | ClinicalTrials.gov |
| NCT06655818 | Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combinatio… | Phase1 | Relapsed/Refractory Multiple Myeloma | Terminated | 2021-03-09 | 2024-02-14 | ClinicalTrials.gov |
| NCT06655818 | Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combinatio… | Phase1 | Relapsed/Refractory Multiple Myeloma | Terminated | 2021-03-09 | 2024-02-14 | ClinicalTrials.gov |
| NCT06790303 | Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants … | Phase2 | Neoplasms | Terminated | 2021-03-04 | 2021-09-23 | ClinicalTrials.gov |
| NCT06790303 | Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants … | Phase2 | Neoplasms | Terminated | 2021-03-04 | 2021-09-23 | ClinicalTrials.gov |
| NCT04762511 | A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against … | Phase1 | Herpes Simplex | Terminated | 2021-03-02 | 2021-05-26 | ClinicalTrials.gov |
| NCT04762511 | A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against … | Phase1 | Herpes Simplex | Terminated | 2021-03-02 | 2021-05-26 | ClinicalTrials.gov |
| NCT04617925 | A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyl… | Phase2 | AL Amyloidosis | Completed | 2021-02-26 | 2025-07-17 | ClinicalTrials.gov |
| NCT04617925 | A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyl… | Phase2 | AL Amyloidosis | Completed | 2021-02-26 | 2025-07-17 | ClinicalTrials.gov |
| NCT04762680 | Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as … | Phase2 | COVID-19 | Completed | 2021-02-24 | 2023-06-29 | ClinicalTrials.gov |
| NCT04762680 | Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as … | Phase2 | COVID-19 | Completed | 2021-02-24 | 2023-06-29 | ClinicalTrials.gov |
| NCT04808037 | Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With New… | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2021-02-22 | 2028-11-08 | ClinicalTrials.gov |
| NCT04808037 | Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With New… | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2021-02-22 | 2028-11-08 | ClinicalTrials.gov |
| NCT04870333 | PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V | Phase2 | Covid19 | Completed | 2021-02-19 | 2025-04-16 | ClinicalTrials.gov |
| NCT04870333 | PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V | Phase2 | Covid19 | Completed | 2021-02-19 | 2025-04-16 | ClinicalTrials.gov |
| NCT04779879 | Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Materia… | Phase2 | Covid19 | Completed | 2021-02-18 | 2022-04-06 | ClinicalTrials.gov |
| NCT04779879 | Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Materia… | Phase2 | Covid19 | Completed | 2021-02-18 | 2022-04-06 | ClinicalTrials.gov |
| NCT04758962 | A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Agai… | Phase1 | Virus Diseases | Completed | 2021-02-15 | 2022-04-19 | ClinicalTrials.gov |
| NCT04758962 | A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Agai… | Phase1 | Virus Diseases | Completed | 2021-02-15 | 2022-04-19 | ClinicalTrials.gov |
| NCT04737538 | A Proof-of-principle Clinical Study Investigating the Efficacy of an Experiment… | Phase2 | Gingivitis | Completed | 2021-02-10 | 2021-07-28 | ClinicalTrials.gov |
| NCT04737538 | A Proof-of-principle Clinical Study Investigating the Efficacy of an Experiment… | Phase2 | Gingivitis | Completed | 2021-02-10 | 2021-07-28 | ClinicalTrials.gov |
| NCT04718103 | A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an … | Phase3 | Asthma | Completed | 2021-02-04 | 2024-04-11 | ClinicalTrials.gov |
| NCT04718103 | A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an … | Phase3 | Asthma | Completed | 2021-02-04 | 2024-04-11 | ClinicalTrials.gov |
| NCT04750343 | Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adj… | Phase1 | COVID-19 (Healthy Volunteers) | Unknown | 2021-02-03 | 2022-06-01 | ClinicalTrials.gov |
| NCT04750343 | Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adj… | Phase1 | COVID-19 (Healthy Volunteers) | Unknown | 2021-02-03 | 2022-06-01 | ClinicalTrials.gov |
| NCT04676724 | Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With… | Phase2 | Hepatitis B | Completed | 2021-01-28 | 2023-02-17 | ClinicalTrials.gov |
| NCT04676724 | Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With… | Phase2 | Hepatitis B | Completed | 2021-01-28 | 2023-02-17 | ClinicalTrials.gov |
| NCT04718389 | A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab i… | Phase3 | Asthma | Completed | 2021-01-26 | 2025-09-14 | ClinicalTrials.gov |
| NCT04718389 | A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab i… | Phase3 | Asthma | Completed | 2021-01-26 | 2025-09-14 | ClinicalTrials.gov |
| NCT04707391 | Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescent… | Phase3 | Meningitis, Meningococcal | Completed | 2021-01-25 | 2023-09-29 | ClinicalTrials.gov |
| NCT04707391 | Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescent… | Phase3 | Meningitis, Meningococcal | Completed | 2021-01-25 | 2023-09-29 | ClinicalTrials.gov |
| NCT04727294 | MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey | — | Multiple Myeloma | Unknown | 2021-01-22 | 2021-12-01 | ClinicalTrials.gov |
| NCT04727294 | MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey | — | Multiple Myeloma | Unknown | 2021-01-22 | 2021-12-01 | ClinicalTrials.gov |
| NCT04657211 | Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) Participants | — | Pulmonary Disease, Chronic Obstructive | Completed | 2021-01-14 | 2024-07-01 | ClinicalTrials.gov |
| NCT04657211 | Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) Participants | — | Pulmonary Disease, Chronic Obstructive | Completed | 2021-01-14 | 2024-07-01 | ClinicalTrials.gov |
| NCT05441059 | Use of Nucala in Severe Asthma | — | Asthma Severe Persistent Uncontrolled | Completed | 2021-01-01 | 2022-05-01 | ClinicalTrials.gov |
| NCT05441059 | Use of Nucala in Severe Asthma | — | Asthma Severe Persistent Uncontrolled | Completed | 2021-01-01 | 2022-05-01 | ClinicalTrials.gov |
| NCT04260282 | Microbiome and Exacerbations in Neutrophilic Asthma | — | Asthma | Unknown | 2021-01-01 | 2025-01-01 | ClinicalTrials.gov |
| NCT04260282 | Microbiome and Exacerbations in Neutrophilic Asthma | — | Asthma | Unknown | 2021-01-01 | 2025-01-01 | ClinicalTrials.gov |
| NCT04549363 | Characterization of Corneal Epithelial Changes in Participants Treated With Bel… | Phase3 | Multiple Myeloma | Terminated | 2020-12-21 | 2022-11-21 | ClinicalTrials.gov |
| NCT04549363 | Characterization of Corneal Epithelial Changes in Participants Treated With Bel… | Phase3 | Multiple Myeloma | Terminated | 2020-12-21 | 2022-11-21 | ClinicalTrials.gov |
| NCT04584255 | Niraparib + Dostarlimab In BRCA Mutated Breast Cancer | Phase2 | Stage I Breast Cancer | Active_Not_Recruiting | 2020-12-18 | 2029-07-17 | ClinicalTrials.gov |
| NCT04584255 | Niraparib + Dostarlimab In BRCA Mutated Breast Cancer | Phase2 | Stage I Breast Cancer | Active_Not_Recruiting | 2020-12-18 | 2029-07-17 | ClinicalTrials.gov |
| NCT04640311 | Comparison of Daprodustat Formulations Produced by Two Methods of Manufacture f… | Phase1 | Anaemia | Completed | 2020-12-18 | 2021-05-18 | ClinicalTrials.gov |
| NCT04640311 | Comparison of Daprodustat Formulations Produced by Two Methods of Manufacture f… | Phase1 | Anaemia | Completed | 2020-12-18 | 2021-05-18 | ClinicalTrials.gov |
| NCT05780281 | VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) | Phase3 | COVID-19 | Completed | 2020-12-16 | 2022-10-04 | ClinicalTrials.gov |
| NCT04570306 | Transcriptional and Immune Parameters of Response to Belimumab | — | Systemic Lupus Erythematosus | Completed | 2020-12-16 | 2023-12-16 | ClinicalTrials.gov |
| NCT05780281 | VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) | Phase3 | COVID-19 | Completed | 2020-12-16 | 2022-10-04 | ClinicalTrials.gov |
| NCT04570306 | Transcriptional and Immune Parameters of Response to Belimumab | — | Systemic Lupus Erythematosus | Completed | 2020-12-16 | 2023-12-16 | ClinicalTrials.gov |
| NCT04551989 | Mepolizumab Long-term Study to Assess Real World Safety and Effectiveness of Eo… | — | Churg-Strauss Syndrome | Completed | 2020-12-11 | 2023-04-27 | ClinicalTrials.gov |
| NCT04551989 | Mepolizumab Long-term Study to Assess Real World Safety and Effectiveness of Eo… | — | Churg-Strauss Syndrome | Completed | 2020-12-11 | 2023-04-27 | ClinicalTrials.gov |
| NCT04311463 | Bioequivalence Study of Paroxetine and PAXIL Under Fasting Conditions in Health… | Phase1 | Anxiety Disorders | Completed | 2020-12-09 | 2021-01-02 | ClinicalTrials.gov |
| NCT04657198 | Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Do… | Phase2 | Respiratory Syncytial Virus Infections | Completed | 2020-12-09 | 2021-10-25 | ClinicalTrials.gov |
| NCT04657198 | Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Do… | Phase2 | Respiratory Syncytial Virus Infections | Completed | 2020-12-09 | 2021-10-25 | ClinicalTrials.gov |
| NCT04311463 | Bioequivalence Study of Paroxetine and PAXIL Under Fasting Conditions in Health… | Phase1 | Anxiety Disorders | Completed | 2020-12-09 | 2021-01-02 | ClinicalTrials.gov |
| NCT04655976 | Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Doc… | Phase3 | Lung Cancer, Non-Small Cell | Active_Not_Recruiting | 2020-12-08 | 2027-03-30 | ClinicalTrials.gov |
| NCT04655976 | Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Doc… | Phase3 | Lung Cancer, Non-Small Cell | Active_Not_Recruiting | 2020-12-08 | 2027-03-30 | ClinicalTrials.gov |
| NCT04606394 | Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD | Phase4 | COPD | Completed | 2020-12-02 | 2021-12-15 | ClinicalTrials.gov |
| NCT04606394 | Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD | Phase4 | COPD | Completed | 2020-12-02 | 2021-12-15 | ClinicalTrials.gov |
| NCT04605159 | A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Materna… | Phase3 | Respiratory Syncytial Virus Infections | Terminated | 2020-11-20 | 2023-06-14 | ClinicalTrials.gov |
| NCT04605159 | A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Materna… | Phase3 | Respiratory Syncytial Virus Infections | Terminated | 2020-11-20 | 2023-06-14 | ClinicalTrials.gov |
| NCT04581824 | Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus … | Phase2 | Lung Cancer, Non-Small Cell | Terminated | 2020-11-19 | 2024-09-10 | ClinicalTrials.gov |
| NCT04581824 | Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus … | Phase2 | Lung Cancer, Non-Small Cell | Terminated | 2020-11-19 | 2024-09-10 | ClinicalTrials.gov |
| NCT04661579 | Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Unin… | Phase2 | Plasmodium Falciparum | Completed | 2020-11-06 | 2022-08-17 | ClinicalTrials.gov |
| NCT04661579 | Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Unin… | Phase2 | Plasmodium Falciparum | Completed | 2020-11-06 | 2022-08-17 | ClinicalTrials.gov |
| NCT04604795 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK3915393 … | Phase1 | Celiac Disease | Completed | 2020-11-04 | 2021-06-29 | ClinicalTrials.gov |
| NCT04313504 | Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurre… | Phase2 | Head and Neck Cancer | Active_Not_Recruiting | 2020-11-04 | 2025-06-01 | ClinicalTrials.gov |
| NCT04604795 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK3915393 … | Phase1 | Celiac Disease | Completed | 2020-11-04 | 2021-06-29 | ClinicalTrials.gov |
| NCT04313504 | Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurre… | Phase2 | Head and Neck Cancer | Active_Not_Recruiting | 2020-11-04 | 2025-06-01 | ClinicalTrials.gov |
| NCT04634409 | A Study of Immune System Proteins in Participants With Mild to Moderate COVID-1… | Phase2 | COVID-19 | Completed | 2020-10-29 | 2021-10-18 | ClinicalTrials.gov |
| NCT04634409 | A Study of Immune System Proteins in Participants With Mild to Moderate COVID-1… | Phase2 | COVID-19 | Completed | 2020-10-29 | 2021-10-18 | ClinicalTrials.gov |
| NCT04349280 | A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monother… | Phase1 | Neoplasms | Terminated | 2020-10-15 | 2022-08-15 | ClinicalTrials.gov |
| NCT04349280 | A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monother… | Phase1 | Neoplasms | Terminated | 2020-10-15 | 2022-08-15 | ClinicalTrials.gov |
| NCT04557371 | A Study to Assess the Local Cutaneous and Ocular Tolerance of Three Development… | Na | Skin Care | Completed | 2020-10-12 | 2020-12-22 | ClinicalTrials.gov |
| NCT04557371 | A Study to Assess the Local Cutaneous and Ocular Tolerance of Three Development… | Na | Skin Care | Completed | 2020-10-12 | 2020-12-22 | ClinicalTrials.gov |
| NCT04585009 | Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in He… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2020-10-12 | 2022-06-16 | ClinicalTrials.gov |
| NCT04585009 | Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in He… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2020-10-12 | 2022-06-16 | ClinicalTrials.gov |
| NCT04544995 | Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paed… | Phase1 | Neoplasms | Terminated | 2020-10-06 | 2025-04-23 | ClinicalTrials.gov |
| NCT04544956 | A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Particip… | Phase2 | Hepatitis B | Completed | 2020-10-06 | 2023-11-30 | ClinicalTrials.gov |
| NCT04544995 | Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paed… | Phase1 | Neoplasms | Terminated | 2020-10-06 | 2025-04-23 | ClinicalTrials.gov |
| NCT04544956 | A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Particip… | Phase2 | Hepatitis B | Completed | 2020-10-06 | 2023-11-30 | ClinicalTrials.gov |
| NCT04473521 | A Clinical Study to Assess Force Required to Dislodge Upper Denture With and Wi… | Phase3 | Denture Retention | Withdrawn | 2020-10-04 | 2021-01-10 | ClinicalTrials.gov |
| NCT04473521 | A Clinical Study to Assess Force Required to Dislodge Upper Denture With and Wi… | Phase3 | Denture Retention | Withdrawn | 2020-10-04 | 2021-01-10 | ClinicalTrials.gov |
| NCT04484623 | Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib… | Phase3 | Multiple Myeloma | Active_Not_Recruiting | 2020-10-01 | 2029-10-25 | ClinicalTrials.gov |
| NCT06811155 | Non-Interventional Study to Describe the Clinical Management in Asthmatic Patie… | — | Asthma | Completed | 2020-10-01 | 2021-09-30 | ClinicalTrials.gov |
| NCT04484623 | Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib… | Phase3 | Multiple Myeloma | Active_Not_Recruiting | 2020-10-01 | 2029-10-25 | ClinicalTrials.gov |
| NCT06811155 | Non-Interventional Study to Describe the Clinical Management in Asthmatic Patie… | — | Asthma | Completed | 2020-10-01 | 2021-09-30 | ClinicalTrials.gov |
| NCT04504435 | Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in H… | Phase1 | Leishmaniasis | Completed | 2020-09-29 | 2024-01-11 | ClinicalTrials.gov |
| NCT04504435 | Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in H… | Phase1 | Leishmaniasis | Completed | 2020-09-29 | 2024-01-11 | ClinicalTrials.gov |
| NCT04316585 | A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe … | Phase1 | Psoriasis | Completed | 2020-09-28 | 2021-10-12 | ClinicalTrials.gov |
| NCT04316585 | A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe … | Phase1 | Psoriasis | Completed | 2020-09-28 | 2021-10-12 | ClinicalTrials.gov |
| NCT04371380 | Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular… | Phase1 | HIV Infections | Completed | 2020-09-16 | 2021-12-26 | ClinicalTrials.gov |
| NCT04371380 | Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular… | Phase1 | HIV Infections | Completed | 2020-09-16 | 2021-12-26 | ClinicalTrials.gov |
| NCT04075331 | Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial | Phase2 | COPD | Completed | 2020-09-07 | 2024-06-21 | ClinicalTrials.gov |
| NCT04075331 | Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial | Phase2 | COPD | Completed | 2020-09-07 | 2024-06-21 | ClinicalTrials.gov |
| NCT04537208 | Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy A… | Phase1 | COVID-19 (Healthy Volunteers) | Completed | 2020-09-03 | 2021-11-19 | ClinicalTrials.gov |
| NCT04537208 | Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy A… | Phase1 | COVID-19 (Healthy Volunteers) | Completed | 2020-09-03 | 2021-11-19 | ClinicalTrials.gov |
| NCT04545060 | VIR-7831 for the Early Treatment of COVID-19 in Outpatients | Phase2 | Covid19 | Completed | 2020-08-27 | 2021-09-02 | ClinicalTrials.gov |
| NCT04545060 | VIR-7831 for the Early Treatment of COVID-19 in Outpatients | Phase2 | Covid19 | Completed | 2020-08-27 | 2021-09-02 | ClinicalTrials.gov |
| NCT04341181 | ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Bas… | Phase2 | Cancer | Recruiting | 2020-08-24 | 2030-04-30 | ClinicalTrials.gov |
| NCT04502602 | Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advan… | Phase1 | Advanced Solid Tumor | Active_Not_Recruiting | 2020-08-24 | 2027-10-31 | ClinicalTrials.gov |
| NCT04341181 | ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Bas… | Phase2 | Cancer | Recruiting | 2020-08-24 | 2030-04-30 | ClinicalTrials.gov |
| NCT04502602 | Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advan… | Phase1 | Advanced Solid Tumor | Active_Not_Recruiting | 2020-08-24 | 2027-10-31 | ClinicalTrials.gov |
| NCT04488770 | Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy… | Phase1 | Urinary Tract Infections | Completed | 2020-08-24 | 2021-05-14 | ClinicalTrials.gov |
| NCT04488770 | Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy… | Phase1 | Urinary Tract Infections | Completed | 2020-08-24 | 2021-05-14 | ClinicalTrials.gov |
| NCT04502693 | Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Co… | Phase3 | Infections, Meningococcal | Completed | 2020-08-14 | 2022-09-13 | ClinicalTrials.gov |
| NCT04493931 | Drug-drug Interaction Study of Gepotidacin | Phase1 | Infections, Bacterial | Completed | 2020-08-14 | 2020-12-21 | ClinicalTrials.gov |
| NCT04502693 | Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Co… | Phase3 | Infections, Meningococcal | Completed | 2020-08-14 | 2022-09-13 | ClinicalTrials.gov |
| NCT04493931 | Drug-drug Interaction Study of Gepotidacin | Phase1 | Infections, Bacterial | Completed | 2020-08-14 | 2020-12-21 | ClinicalTrials.gov |
| NCT04428333 | Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemo… | Phase3 | Neoplasms, Head and Neck | Terminated | 2020-08-12 | 2023-09-19 | ClinicalTrials.gov |
| NCT04428333 | Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemo… | Phase3 | Neoplasms, Head and Neck | Terminated | 2020-08-12 | 2023-09-19 | ClinicalTrials.gov |
| NCT04501978 | ACTIV-3: Therapeutics for Inpatients With COVID-19 | Phase3 | Covid19 | Completed | 2020-08-04 | 2023-07-14 | ClinicalTrials.gov |
| NCT04501978 | ACTIV-3: Therapeutics for Inpatients With COVID-19 | Phase3 | Covid19 | Completed | 2020-08-04 | 2023-07-14 | ClinicalTrials.gov |
| NCT04224701 | A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1… | Phase1 | HIV Infections | Completed | 2020-08-01 | 2023-08-02 | ClinicalTrials.gov |
| NCT04224701 | A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1… | Phase1 | HIV Infections | Completed | 2020-08-01 | 2023-08-02 | ClinicalTrials.gov |
| NCT04449029 | A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB) | Phase2 | Hepatitis B | Completed | 2020-07-27 | 2022-03-18 | ClinicalTrials.gov |
| NCT04449029 | A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB) | Phase2 | Hepatitis B | Completed | 2020-07-27 | 2022-03-18 | ClinicalTrials.gov |
| NCT04374136 | A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Deme… | Phase3 | Frontotemporal Dementia | Terminated | 2020-07-23 | 2026-01-06 | ClinicalTrials.gov |
| NCT04409002 | Niraparib + Dostarlimab + RT in Pancreatic Cancer | Phase2 | Pancreatic Cancer | Completed | 2020-07-23 | 2022-02-25 | ClinicalTrials.gov |
| NCT04374136 | A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Deme… | Phase3 | Frontotemporal Dementia | Terminated | 2020-07-23 | 2026-01-06 | ClinicalTrials.gov |
| NCT04409002 | Niraparib + Dostarlimab + RT in Pancreatic Cancer | Phase2 | Pancreatic Cancer | Completed | 2020-07-23 | 2022-02-25 | ClinicalTrials.gov |
| NCT04366349 | A Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Phar… | Phase1 | Healthy Volunteers | Completed | 2020-07-21 | 2020-12-21 | ClinicalTrials.gov |
| NCT04366349 | A Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Phar… | Phase1 | Healthy Volunteers | Completed | 2020-07-21 | 2020-12-21 | ClinicalTrials.gov |
| NCT03651206 | Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib | Phase2 | Ovarian Carcinosarcoma | Recruiting | 2020-07-15 | 2027-06-01 | ClinicalTrials.gov |
| NCT03651206 | Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib | Phase2 | Ovarian Carcinosarcoma | Recruiting | 2020-07-15 | 2027-06-01 | ClinicalTrials.gov |
| NCT04167358 | Linerixibat Long-term Safety, and Tolerability Study | Phase3 | Cholestasis | Active_Not_Recruiting | 2020-07-14 | 2026-09-30 | ClinicalTrials.gov |
| NCT04167358 | Linerixibat Long-term Safety, and Tolerability Study | Phase3 | Cholestasis | Active_Not_Recruiting | 2020-07-14 | 2026-09-30 | ClinicalTrials.gov |
| NCT04617470 | Niraparib as Maintenance Treatment in Platinum Responsive Ovarian Cancer Patien… | — | Ovarian Cancer | Unknown | 2020-07-08 | 2022-01-01 | ClinicalTrials.gov |
| NCT04617470 | Niraparib as Maintenance Treatment in Platinum Responsive Ovarian Cancer Patien… | — | Ovarian Cancer | Unknown | 2020-07-08 | 2022-01-01 | ClinicalTrials.gov |
| NCT04449419 | Mitoquines in COPD | — | COPD Exacerbation | Unknown | 2020-07-01 | 2021-06-01 | ClinicalTrials.gov |
| NCT04449419 | Mitoquines in COPD | — | COPD Exacerbation | Unknown | 2020-07-01 | 2021-06-01 | ClinicalTrials.gov |
| NCT04446351 | Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanc… | Phase1 | Neoplasms | Active_Not_Recruiting | 2020-06-25 | 2026-12-31 | ClinicalTrials.gov |
| NCT04446351 | Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanc… | Phase1 | Neoplasms | Active_Not_Recruiting | 2020-06-25 | 2026-12-31 | ClinicalTrials.gov |
| NCT04240106 | Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HD… | Phase2 | Breast Cancer | Completed | 2020-06-15 | 2023-11-17 | ClinicalTrials.gov |
| NCT04240106 | Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HD… | Phase2 | Breast Cancer | Completed | 2020-06-15 | 2023-11-17 | ClinicalTrials.gov |
| NCT04139902 | Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhib… | Phase2 | Melanoma Stage III | Active_Not_Recruiting | 2020-06-12 | 2029-12-15 | ClinicalTrials.gov |
| NCT04139902 | Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhib… | Phase2 | Melanoma Stage III | Active_Not_Recruiting | 2020-06-12 | 2029-12-15 | ClinicalTrials.gov |
| NCT07084896 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat… | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2020-06-08 | 2027-03-11 | ClinicalTrials.gov |
| NCT07084896 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat… | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2020-06-08 | 2027-03-11 | ClinicalTrials.gov |
| NCT04376684 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disea… | Phase2 | Severe Acute Respiratory Syndrome | Completed | 2020-05-28 | 2021-08-16 | ClinicalTrials.gov |
| NCT04376684 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disea… | Phase2 | Severe Acute Respiratory Syndrome | Completed | 2020-05-28 | 2021-08-16 | ClinicalTrials.gov |
| NCT04333147 | Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheu… | Phase3 | Arthritis, Rheumatoid | Terminated | 2020-05-12 | 2023-02-24 | ClinicalTrials.gov |
| NCT04333147 | Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheu… | Phase3 | Arthritis, Rheumatoid | Terminated | 2020-05-12 | 2023-02-24 | ClinicalTrials.gov |
| NCT04246047 | Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexam… | Phase3 | Multiple Myeloma | Active_Not_Recruiting | 2020-05-07 | 2028-06-30 | ClinicalTrials.gov |
| NCT04246047 | Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexam… | Phase3 | Multiple Myeloma | Active_Not_Recruiting | 2020-05-07 | 2028-06-30 | ClinicalTrials.gov |
| NCT04187144 | Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurant… | Phase3 | Urinary Tract Infections | Completed | 2020-04-23 | 2022-12-01 | ClinicalTrials.gov |
| NCT04187144 | Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurant… | Phase3 | Urinary Tract Infections | Completed | 2020-04-23 | 2022-12-01 | ClinicalTrials.gov |
| NCT04853225 | Investigation of Chronic Obstructive Pulmonary Disease (COPD) Phenotypes and En… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2020-04-22 | 2024-06-25 | ClinicalTrials.gov |
| NCT04853225 | Investigation of Chronic Obstructive Pulmonary Disease (COPD) Phenotypes and En… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2020-04-22 | 2024-06-25 | ClinicalTrials.gov |
| NCT04162210 | Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose De… | Phase3 | Multiple Myeloma | Active_Not_Recruiting | 2020-04-02 | 2027-03-11 | ClinicalTrials.gov |
| NCT04162210 | Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose De… | Phase3 | Multiple Myeloma | Active_Not_Recruiting | 2020-04-02 | 2027-03-11 | ClinicalTrials.gov |
| NCT03949855 | Belimumab With Rituximab for Primary Membranous Nephropathy | Phase2 | Membranous Nephropathy | Recruiting | 2020-03-06 | 2030-03-01 | ClinicalTrials.gov |
| NCT03949855 | Belimumab With Rituximab for Primary Membranous Nephropathy | Phase2 | Membranous Nephropathy | Recruiting | 2020-03-06 | 2030-03-01 | ClinicalTrials.gov |
| NCT04267939 | ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advance… | Phase1 | Advanced Solid Tumors (Excluding Prostate Cancer) | Terminated | 2020-02-26 | 2023-12-01 | ClinicalTrials.gov |
| NCT04267939 | ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advance… | Phase1 | Advanced Solid Tumors (Excluding Prostate Cancer) | Terminated | 2020-02-26 | 2023-12-01 | ClinicalTrials.gov |
| NCT03984799 | Interleukin-5 Receptor Expression in COPD | Na | COPD | Completed | 2020-02-21 | 2022-04-30 | ClinicalTrials.gov |
| NCT03984799 | Interleukin-5 Receptor Expression in COPD | Na | COPD | Completed | 2020-02-21 | 2022-04-30 | ClinicalTrials.gov |
| NCT04295733 | Safety, Tolerability and Immunogenicity of 4CMenB Vaccine(2 Doses) in Adults Wi… | — | Acquired Immunodeficiency | Completed | 2020-02-06 | 2024-01-11 | ClinicalTrials.gov |
| NCT04295733 | Safety, Tolerability and Immunogenicity of 4CMenB Vaccine(2 Doses) in Adults Wi… | — | Acquired Immunodeficiency | Completed | 2020-02-06 | 2024-01-11 | ClinicalTrials.gov |
| NCT04237896 | Compliance With Clinical Guidelines and Effect on Patient Outcome of Treatment … | — | Pulmonary Disease, Chronic Obstructive | Unknown | 2020-01-27 | 2020-08-30 | ClinicalTrials.gov |
| NCT04237896 | Compliance With Clinical Guidelines and Effect on Patient Outcome of Treatment … | — | Pulmonary Disease, Chronic Obstructive | Unknown | 2020-01-27 | 2020-08-30 | ClinicalTrials.gov |
| NCT04318535 | Bioequivalence (BE) Study of Test Griseofulvin 500 Milligram (mg) Tablets Versu… | Phase1 | Antifungal Agents | Completed | 2020-01-13 | 2020-02-06 | ClinicalTrials.gov |
| NCT04318535 | Bioequivalence (BE) Study of Test Griseofulvin 500 Milligram (mg) Tablets Versu… | Phase1 | Antifungal Agents | Completed | 2020-01-13 | 2020-02-06 | ClinicalTrials.gov |
| NCT04080284 | Trial of Maintenance With Niraparib- Uterine Serous Carcinoma | Phase2 | Endometrial Cancer | Completed | 2019-12-30 | 2025-01-01 | ClinicalTrials.gov |
| NCT04221503 | Niraparib/TTFields in GBM | Phase2 | Glioblastoma | Active_Not_Recruiting | 2019-12-30 | 2026-01-01 | ClinicalTrials.gov |
| NCT04080284 | Trial of Maintenance With Niraparib- Uterine Serous Carcinoma | Phase2 | Endometrial Cancer | Completed | 2019-12-30 | 2025-01-01 | ClinicalTrials.gov |
| NCT04221503 | Niraparib/TTFields in GBM | Phase2 | Glioblastoma | Active_Not_Recruiting | 2019-12-30 | 2026-01-01 | ClinicalTrials.gov |
| NCT03680508 | TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With… | Phase2 | Adult Primary Liver Cancer | Active_Not_Recruiting | 2019-12-19 | 2027-10-01 | ClinicalTrials.gov |
| NCT03680508 | TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With… | Phase2 | Adult Primary Liver Cancer | Active_Not_Recruiting | 2019-12-19 | 2027-10-01 | ClinicalTrials.gov |
| NCT04091126 | Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Mu… | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2019-12-18 | 2026-12-31 | ClinicalTrials.gov |
| NCT04091126 | Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Mu… | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2019-12-18 | 2026-12-31 | ClinicalTrials.gov |
| NCT04165772 | Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Rep… | Phase2 | Rectal Adenocarcinoma | Recruiting | 2019-12-11 | 2026-11-30 | ClinicalTrials.gov |
| NCT04165772 | Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Rep… | Phase2 | Rectal Adenocarcinoma | Recruiting | 2019-12-11 | 2026-11-30 | ClinicalTrials.gov |
| NCT04176939 | A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Lo… | Phase3 | Herpes Zoster | Completed | 2019-12-09 | 2024-06-27 | ClinicalTrials.gov |
| NCT04176939 | A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Lo… | Phase3 | Herpes Zoster | Completed | 2019-12-09 | 2024-06-27 | ClinicalTrials.gov |
| NCT04138043 | Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of GSK2330811 in Healt… | Phase1 | Healthy Volunteers | Completed | 2019-12-05 | 2020-05-28 | ClinicalTrials.gov |
| NCT04138043 | Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of GSK2330811 in Healt… | Phase1 | Healthy Volunteers | Completed | 2019-12-05 | 2020-05-28 | ClinicalTrials.gov |
| NCT07217119 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab … | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2019-11-26 | 2027-03-11 | ClinicalTrials.gov |
| NCT07217119 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab … | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2019-11-26 | 2027-03-11 | ClinicalTrials.gov |
| NCT04128696 | Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (… | Phase3 | Neoplasms, Head and Neck | Terminated | 2019-11-21 | 2023-06-20 | ClinicalTrials.gov |
| NCT04128696 | Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (… | Phase3 | Neoplasms, Head and Neck | Terminated | 2019-11-21 | 2023-06-20 | ClinicalTrials.gov |
| NCT04021290 | Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current A… | Phase3 | HIV Infections | Completed | 2019-11-11 | 2022-09-09 | ClinicalTrials.gov |
| NCT04021290 | Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current A… | Phase3 | HIV Infections | Completed | 2019-11-11 | 2022-09-09 | ClinicalTrials.gov |
| NCT04126213 | Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Re… | Phase2 | Respiratory Syncytial Virus Infections | Completed | 2019-11-05 | 2021-05-14 | ClinicalTrials.gov |
| NCT04138056 | A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone… | Phase2 | Respiratory Syncytial Virus Infections | Completed | 2019-11-05 | 2021-11-22 | ClinicalTrials.gov |
| NCT04138056 | A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone… | Phase2 | Respiratory Syncytial Virus Infections | Completed | 2019-11-05 | 2021-11-22 | ClinicalTrials.gov |
| NCT04126213 | Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Re… | Phase2 | Respiratory Syncytial Virus Infections | Completed | 2019-11-05 | 2021-05-14 | ClinicalTrials.gov |
| NCT04133909 | Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Freq… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2019-10-30 | 2024-08-08 | ClinicalTrials.gov |
| NCT04133909 | Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Freq… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2019-10-30 | 2024-08-08 | ClinicalTrials.gov |
| NCT04136145 | Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimu… | Phase1 | Systemic Lupus Erythematosus | Completed | 2019-10-28 | 2020-01-14 | ClinicalTrials.gov |
| NCT04136145 | Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimu… | Phase1 | Systemic Lupus Erythematosus | Completed | 2019-10-28 | 2020-01-14 | ClinicalTrials.gov |
| NCT04006808 | A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Preve… | Phase1 | Herpes Zoster | Recruiting | 2019-10-25 | 2027-03-31 | ClinicalTrials.gov |
| NCT04006808 | A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Preve… | Phase1 | Herpes Zoster | Recruiting | 2019-10-25 | 2027-03-31 | ClinicalTrials.gov |
| NCT04052620 | Voltaren Emulgel 2% Acute Ankle Sprain Non Inferiority Study | Phase3 | Pain | Completed | 2019-10-24 | 2020-11-12 | ClinicalTrials.gov |
| NCT04052620 | Voltaren Emulgel 2% Acute Ankle Sprain Non Inferiority Study | Phase3 | Pain | Completed | 2019-10-24 | 2020-11-12 | ClinicalTrials.gov |
| NCT04020341 | A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Unco… | Phase3 | Urinary Tract Infections | Completed | 2019-10-17 | 2022-11-30 | ClinicalTrials.gov |
| NCT04020341 | A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Unco… | Phase3 | Urinary Tract Infections | Completed | 2019-10-17 | 2022-11-30 | ClinicalTrials.gov |
| NCT03983993 | Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Ca… | Phase2 | Advanced Microsatellite Stable Colorectal Carcinoma | Active_Not_Recruiting | 2019-10-15 | 2026-12-01 | ClinicalTrials.gov |
| NCT04114656 | Effects of Intravenous GSK3858279 on a Battery of Evoked Pain Tests in Healthy … | Phase1 | Pain | Terminated | 2019-10-15 | 2021-09-16 | ClinicalTrials.gov |
| NCT03983993 | Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Ca… | Phase2 | Advanced Microsatellite Stable Colorectal Carcinoma | Active_Not_Recruiting | 2019-10-15 | 2026-12-01 | ClinicalTrials.gov |
| NCT04114656 | Effects of Intravenous GSK3858279 on a Battery of Evoked Pain Tests in Healthy … | Phase1 | Pain | Terminated | 2019-10-15 | 2021-09-16 | ClinicalTrials.gov |
| NCT03425201 | Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Ur… | Phase1 | Urothelial Cancer | Completed | 2019-10-14 | 2024-07-31 | ClinicalTrials.gov |
| NCT03425201 | Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Ur… | Phase1 | Urothelial Cancer | Completed | 2019-10-14 | 2024-07-31 | ClinicalTrials.gov |
| NCT06160609 | Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX… | Phase1 | Relapsed/Refractory Multiple Myeloma | Terminated | 2019-10-07 | 2023-01-09 | ClinicalTrials.gov |
| NCT04050722 | A Clinical Study Investigating the Efficacy of a Stannous Fluoride Dentifrice i… | Phase4 | Gingivitis | Completed | 2019-10-07 | 2019-11-13 | ClinicalTrials.gov |
| NCT04050722 | A Clinical Study Investigating the Efficacy of a Stannous Fluoride Dentifrice i… | Phase4 | Gingivitis | Completed | 2019-10-07 | 2019-11-13 | ClinicalTrials.gov |
| NCT06160609 | Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX… | Phase1 | Relapsed/Refractory Multiple Myeloma | Terminated | 2019-10-07 | 2023-01-09 | ClinicalTrials.gov |
| NCT03955471 | Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and D… | Phase2 | Ovarian Neoplasms | Terminated | 2019-10-03 | 2022-01-12 | ClinicalTrials.gov |
| NCT03955471 | Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and D… | Phase2 | Ovarian Neoplasms | Terminated | 2019-10-03 | 2022-01-12 | ClinicalTrials.gov |
| NCT04095286 | Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Health… | Phase1 | Hypertension, Pulmonary | Completed | 2019-09-30 | 2019-12-17 | ClinicalTrials.gov |
| NCT04095286 | Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Health… | Phase1 | Hypertension, Pulmonary | Completed | 2019-09-30 | 2019-12-17 | ClinicalTrials.gov |
| NCT03987295 | A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal … | Phase2 | Frontotemporal Dementia | Completed | 2019-09-27 | 2024-06-05 | ClinicalTrials.gov |
| NCT03987295 | A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal … | Phase2 | Frontotemporal Dementia | Completed | 2019-09-27 | 2024-06-05 | ClinicalTrials.gov |
| NCT02964507 | Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestran… | Phase1 | Neoplasms | Terminated | 2019-09-26 | 2021-07-19 | ClinicalTrials.gov |
| NCT02964507 | Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestran… | Phase1 | Neoplasms | Terminated | 2019-09-26 | 2021-07-19 | ClinicalTrials.gov |
| NCT04090658 | A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candida… | Phase1 | Respiratory Syncytial Virus Infections | Completed | 2019-09-25 | 2020-12-11 | ClinicalTrials.gov |
| NCT04090658 | A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candida… | Phase1 | Respiratory Syncytial Virus Infections | Completed | 2019-09-25 | 2020-12-11 | ClinicalTrials.gov |
| NCT04091451 | Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vacc… | Phase3 | Herpes Zoster | Completed | 2019-09-17 | 2024-02-15 | ClinicalTrials.gov |
| NCT04091451 | Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vacc… | Phase3 | Herpes Zoster | Completed | 2019-09-17 | 2024-02-15 | ClinicalTrials.gov |
| NCT03368729 | Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer | Phase1 | Metastatic Breast Cancer | Active_Not_Recruiting | 2019-09-06 | 2027-12-30 | ClinicalTrials.gov |
| NCT03368729 | Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer | Phase1 | Metastatic Breast Cancer | Active_Not_Recruiting | 2019-09-06 | 2027-12-30 | ClinicalTrials.gov |
| NCT04079790 | Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects | Phase1 | Infections, Bacterial | Completed | 2019-09-04 | 2019-11-25 | ClinicalTrials.gov |
| NCT04079790 | Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects | Phase1 | Infections, Bacterial | Completed | 2019-09-04 | 2019-11-25 | ClinicalTrials.gov |
| NCT04007159 | To Evaluate Skin Irritation and Skin Sensitisation of Developmental Cosmetic Fa… | Na | Skin Care | Completed | 2019-08-30 | 2019-11-29 | ClinicalTrials.gov |
| NCT04007159 | To Evaluate Skin Irritation and Skin Sensitisation of Developmental Cosmetic Fa… | Na | Skin Care | Completed | 2019-08-30 | 2019-11-29 | ClinicalTrials.gov |
| NCT04006795 | A Photoxicity and Photoallergy Study of a Developmental Face Cream, Serum and L… | Na | Skin Care | Completed | 2019-08-28 | 2019-10-11 | ClinicalTrials.gov |
| NCT04006795 | A Photoxicity and Photoallergy Study of a Developmental Face Cream, Serum and L… | Na | Skin Care | Completed | 2019-08-28 | 2019-10-11 | ClinicalTrials.gov |
| NCT04053023 | Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Subjects | Phase1 | Cholestasis | Completed | 2019-08-27 | 2019-11-25 | ClinicalTrials.gov |
| NCT04053023 | Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Subjects | Phase1 | Cholestasis | Completed | 2019-08-27 | 2019-11-25 | ClinicalTrials.gov |
| NCT03945084 | Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1s… | Phase2 | Urothelial Carcinoma | Completed | 2019-08-27 | 2021-09-01 | ClinicalTrials.gov |
| NCT03945084 | Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1s… | Phase2 | Urothelial Carcinoma | Completed | 2019-08-27 | 2021-09-01 | ClinicalTrials.gov |
| NCT03457701 | Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor … | Phase2 | Anaemia | Completed | 2019-07-30 | 2022-07-05 | ClinicalTrials.gov |
| NCT03494881 | Mepolizumab for the Treatment of Chronic Spontaneous Urticaria | Early_Phase1 | Chronic Spontaneous Urticaria | Completed | 2019-07-30 | 2025-02-25 | ClinicalTrials.gov |
| NCT03494881 | Mepolizumab for the Treatment of Chronic Spontaneous Urticaria | Early_Phase1 | Chronic Spontaneous Urticaria | Completed | 2019-07-30 | 2025-02-25 | ClinicalTrials.gov |
| NCT03457701 | Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor … | Phase2 | Anaemia | Completed | 2019-07-30 | 2022-07-05 | ClinicalTrials.gov |
| NCT03844061 | Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutane… | Phase2 | Systemic Sclerosis | Recruiting | 2019-07-29 | 2026-06-30 | ClinicalTrials.gov |
| NCT03844061 | Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutane… | Phase2 | Systemic Sclerosis | Recruiting | 2019-07-29 | 2026-06-30 | ClinicalTrials.gov |
| NCT03954743 | Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563),… | Phase3 | Infections, Rotavirus | Completed | 2019-07-19 | 2020-11-30 | ClinicalTrials.gov |
| NCT03954743 | Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563),… | Phase3 | Infections, Rotavirus | Completed | 2019-07-19 | 2020-11-30 | ClinicalTrials.gov |
| NCT03981796 | A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus… | Phase3 | Neoplasms | Active_Not_Recruiting | 2019-07-18 | 2026-11-26 | ClinicalTrials.gov |
| NCT03981796 | A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus… | Phase3 | Neoplasms | Active_Not_Recruiting | 2019-07-18 | 2026-11-26 | ClinicalTrials.gov |
| NCT03644342 | Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carci… | Phase1 | Metastatic Carcinoma of the Cervix | Terminated | 2019-07-15 | 2023-09-27 | ClinicalTrials.gov |
| NCT03644342 | Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carci… | Phase1 | Metastatic Carcinoma of the Cervix | Terminated | 2019-07-15 | 2023-09-27 | ClinicalTrials.gov |
| NCT03945721 | A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in… | Phase1 | Triple Negative Breast Cancer | Active_Not_Recruiting | 2019-07-11 | 2028-12-31 | ClinicalTrials.gov |
| NCT03945721 | A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in… | Phase1 | Triple Negative Breast Cancer | Active_Not_Recruiting | 2019-07-11 | 2028-12-31 | ClinicalTrials.gov |
| NCT03840967 | A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously… | Phase2 | Esophageal Cancer | Terminated | 2019-07-09 | 2023-02-22 | ClinicalTrials.gov |
| NCT03840967 | A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously… | Phase2 | Esophageal Cancer | Terminated | 2019-07-09 | 2023-02-22 | ClinicalTrials.gov |
| NCT03992014 | Pharmacokinetics (PKs) and Metabolism of Radiolabelled Linerixibat | Phase1 | Cholestasis | Completed | 2019-07-08 | 2019-08-26 | ClinicalTrials.gov |
| NCT03809910 | Dental Plaque Removal Ability of Prototype Power Toothbrush Versus a Manual Too… | Phase2 | Dental Plaque | Completed | 2019-07-08 | 2019-08-09 | ClinicalTrials.gov |
| NCT03992014 | Pharmacokinetics (PKs) and Metabolism of Radiolabelled Linerixibat | Phase1 | Cholestasis | Completed | 2019-07-08 | 2019-08-26 | ClinicalTrials.gov |
| NCT03809910 | Dental Plaque Removal Ability of Prototype Power Toothbrush Versus a Manual Too… | Phase2 | Dental Plaque | Completed | 2019-07-08 | 2019-08-09 | ClinicalTrials.gov |
| NCT05779384 | The COPD Attack Study | — | Pulmonary Disease, Chronic Obstructive | Completed | 2019-07-07 | 2021-03-30 | ClinicalTrials.gov |
| NCT05779384 | The COPD Attack Study | — | Pulmonary Disease, Chronic Obstructive | Completed | 2019-07-07 | 2021-03-30 | ClinicalTrials.gov |
| NCT03833479 | TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cer… | Phase2 | Cervical Cancer | Active_Not_Recruiting | 2019-06-28 | 2025-12-01 | ClinicalTrials.gov |
| NCT03833479 | TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cer… | Phase2 | Cervical Cancer | Active_Not_Recruiting | 2019-06-28 | 2025-12-01 | ClinicalTrials.gov |
| NCT03949842 | Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effecti… | Phase4 | Pulmonary Disease, Chronic Obstructive | Withdrawn | 2019-06-27 | 2022-11-30 | ClinicalTrials.gov |
| NCT03949842 | Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effecti… | Phase4 | Pulmonary Disease, Chronic Obstructive | Withdrawn | 2019-06-27 | 2022-11-30 | ClinicalTrials.gov |
| NCT04063306 | Quality of Life of Taiwan People Living With HIV | — | HIV-1-infection | Unknown | 2019-06-20 | 2020-12-20 | ClinicalTrials.gov |
| NCT04063306 | Quality of Life of Taiwan People Living With HIV | — | HIV-1-infection | Unknown | 2019-06-20 | 2020-12-20 | ClinicalTrials.gov |
| NCT03957577 | Etiology of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOP… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2019-06-13 | 2022-06-30 | ClinicalTrials.gov |
| NCT03957577 | Etiology of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOP… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2019-06-13 | 2022-06-30 | ClinicalTrials.gov |
| NCT03965533 | Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK283… | Phase1 | Healthy Volunteers | Completed | 2019-06-10 | 2019-12-10 | ClinicalTrials.gov |
| NCT03965533 | Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK283… | Phase1 | Healthy Volunteers | Completed | 2019-06-10 | 2019-12-10 | ClinicalTrials.gov |
| NCT03891615 | Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer | Phase1 | Lung Cancer | Unknown | 2019-06-06 | 2024-04-30 | ClinicalTrials.gov |
| NCT03891615 | Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer | Phase1 | Lung Cancer | Unknown | 2019-06-06 | 2024-04-30 | ClinicalTrials.gov |
| NCT03970837 | Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participant… | Phase3 | Arthritis, Rheumatoid | Terminated | 2019-06-05 | 2023-01-18 | ClinicalTrials.gov |
| NCT03970837 | Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participant… | Phase3 | Arthritis, Rheumatoid | Terminated | 2019-06-05 | 2023-01-18 | ClinicalTrials.gov |
| NCT03018808 | Prevalence of Chronic Obstructive Pulmonary Disease (COPD) and Eosinophilia Amo… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2019-06-03 | 2021-10-04 | ClinicalTrials.gov |
| NCT03018808 | Prevalence of Chronic Obstructive Pulmonary Disease (COPD) and Eosinophilia Amo… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2019-06-03 | 2021-10-04 | ClinicalTrials.gov |
| NCT03614676 | A Study of Outcomes and Events of Interest in Pregnant Women, Neonates and Infa… | Na | Respiratory Syncytial Virus Infections | Completed | 2019-05-30 | 2021-07-27 | ClinicalTrials.gov |
| NCT03614676 | A Study of Outcomes and Events of Interest in Pregnant Women, Neonates and Infa… | Na | Respiratory Syncytial Virus Infections | Completed | 2019-05-30 | 2021-07-27 | ClinicalTrials.gov |
| NCT03980483 | Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participant… | Phase3 | Arthritis, Rheumatoid | Completed | 2019-05-16 | 2022-08-16 | ClinicalTrials.gov |
| NCT03980483 | Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participant… | Phase3 | Arthritis, Rheumatoid | Completed | 2019-05-16 | 2022-08-16 | ClinicalTrials.gov |
| NCT03591380 | CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant … | Phase2 | Kidney Transplantation | Terminated | 2019-05-14 | 2021-12-03 | ClinicalTrials.gov |
| NCT03591380 | CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant … | Phase2 | Kidney Transplantation | Terminated | 2019-05-14 | 2021-12-03 | ClinicalTrials.gov |
| NCT03984253 | Swiss Severe Asthma Register | — | Severe Asthma | Recruiting | 2019-05-13 | 2034-02-28 | ClinicalTrials.gov |
| NCT03943095 | Study to Characterize the Efficacy of a Dual Active Dentifrice for the Relief o… | Phase2 | Dentin Hypersensitivity | Completed | 2019-05-13 | 2019-08-28 | ClinicalTrials.gov |
| NCT03984253 | Swiss Severe Asthma Register | — | Severe Asthma | Recruiting | 2019-05-13 | 2034-02-28 | ClinicalTrials.gov |
| NCT03943095 | Study to Characterize the Efficacy of a Dual Active Dentifrice for the Relief o… | Phase2 | Dentin Hypersensitivity | Completed | 2019-05-13 | 2019-08-28 | ClinicalTrials.gov |
| NCT03893565 | Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Co… | Phase2 | Colitis, Ulcerative | Terminated | 2019-05-06 | 2021-05-17 | ClinicalTrials.gov |
| NCT03893565 | Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Co… | Phase2 | Colitis, Ulcerative | Terminated | 2019-05-06 | 2021-05-17 | ClinicalTrials.gov |
| NCT03874234 | Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in … | Phase1 | Leishmaniasis | Terminated | 2019-04-30 | 2019-10-17 | ClinicalTrials.gov |
| NCT03874234 | Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in … | Phase1 | Leishmaniasis | Terminated | 2019-04-30 | 2019-10-17 | ClinicalTrials.gov |
| NCT03797404 | Airway Remodeling During Mepolizumab Treatment | — | Asthma | Completed | 2019-04-24 | 2022-06-21 | ClinicalTrials.gov |
| NCT03797404 | Airway Remodeling During Mepolizumab Treatment | — | Asthma | Completed | 2019-04-24 | 2022-06-21 | ClinicalTrials.gov |
| NCT03894969 | Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine … | Phase2 | Respiratory Disorders | Completed | 2019-04-23 | 2021-08-13 | ClinicalTrials.gov |
| NCT03894969 | Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine … | Phase2 | Respiratory Disorders | Completed | 2019-04-23 | 2021-08-13 | ClinicalTrials.gov |
| NCT03703245 | Pooled Analysis of Clinical Data From Six GSK Studies to Investigate the Effica… | — | Gingivitis | Completed | 2019-04-17 | 2019-11-11 | ClinicalTrials.gov |
| NCT03703245 | Pooled Analysis of Clinical Data From Six GSK Studies to Investigate the Effica… | — | Gingivitis | Completed | 2019-04-17 | 2019-11-11 | ClinicalTrials.gov |
| NCT03826108 | ARTHR-IS (Arthroplasties' Infections Due to Staphylococcus Aureus) | — | Staphylococcus Aureus | Unknown | 2019-04-16 | 2020-12-31 | ClinicalTrials.gov |
| NCT03826108 | ARTHR-IS (Arthroplasties' Infections Due to Staphylococcus Aureus) | — | Staphylococcus Aureus | Unknown | 2019-04-16 | 2020-12-31 | ClinicalTrials.gov |
| NCT03636906 | Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and… | Phase1 | Respiratory Syncytial Virus Infections | Completed | 2019-04-08 | 2021-07-22 | ClinicalTrials.gov |
| NCT03636906 | Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and… | Phase1 | Respiratory Syncytial Virus Infections | Completed | 2019-04-08 | 2021-07-22 | ClinicalTrials.gov |
| NCT03889054 | Effect of Education and Respiratory Rehabilitation on Quality of Life in COPD P… | Na | COPD | Unknown | 2019-04-01 | 2020-05-01 | ClinicalTrials.gov |
| NCT03732703 | Myeloma-Developing Regimens Using Genomics (MyDRUG) | Phase1 | Relapsed Refractory Multiple Myeloma | Completed | 2019-04-01 | 2024-12-31 | ClinicalTrials.gov |
| NCT03732703 | Myeloma-Developing Regimens Using Genomics (MyDRUG) | Phase1 | Relapsed Refractory Multiple Myeloma | Completed | 2019-04-01 | 2024-12-31 | ClinicalTrials.gov |
| NCT03889054 | Effect of Education and Respiratory Rehabilitation on Quality of Life in COPD P… | Na | COPD | Unknown | 2019-04-01 | 2020-05-01 | ClinicalTrials.gov |
| NCT03866187 | Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and… | Phase1 | Hepatitis B, Chronic | Terminated | 2019-03-28 | 2024-10-07 | ClinicalTrials.gov |
| NCT03866187 | Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and… | Phase1 | Hepatitis B, Chronic | Terminated | 2019-03-28 | 2024-10-07 | ClinicalTrials.gov |
| NCT03557281 | An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjec… | Phase2 | Tuberculosis | Completed | 2019-03-22 | 2021-12-14 | ClinicalTrials.gov |
| NCT03557281 | An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjec… | Phase2 | Tuberculosis | Completed | 2019-03-22 | 2021-12-14 | ClinicalTrials.gov |
| NCT03855995 | A Study Assessing the Safety, Efficacy, and Impact of GlaxoSmithKline Biologica… | — | Malaria | Completed | 2019-03-21 | 2025-08-07 | ClinicalTrials.gov |
| NCT03855995 | A Study Assessing the Safety, Efficacy, and Impact of GlaxoSmithKline Biologica… | — | Malaria | Completed | 2019-03-21 | 2025-08-07 | ClinicalTrials.gov |
| NCT03925350 | Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Reco… | Phase2 | Metastatic Melanoma | Unknown | 2019-03-20 | 2023-02-01 | ClinicalTrials.gov |
| NCT03925350 | Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Reco… | Phase2 | Metastatic Melanoma | Unknown | 2019-03-20 | 2023-02-01 | ClinicalTrials.gov |
| NCT03848845 | Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Co… | Phase1 | Multiple Myeloma | Completed | 2019-03-14 | 2023-06-14 | ClinicalTrials.gov |
| NCT03848845 | Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Co… | Phase1 | Multiple Myeloma | Completed | 2019-03-14 | 2023-06-14 | ClinicalTrials.gov |
| NCT03843359 | A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants W… | Phase1 | Neoplasms | Active_Not_Recruiting | 2019-03-12 | 2026-03-31 | ClinicalTrials.gov |
| NCT03843359 | A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants W… | Phase1 | Neoplasms | Active_Not_Recruiting | 2019-03-12 | 2026-03-31 | ClinicalTrials.gov |
| NCT03830918 | Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Sol… | Phase1 | Advanced Malignant Solid Neoplasm | Active_Not_Recruiting | 2019-03-06 | 2027-01-03 | ClinicalTrials.gov |
| NCT03830918 | Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Sol… | Phase1 | Advanced Malignant Solid Neoplasm | Active_Not_Recruiting | 2019-03-06 | 2027-01-03 | ClinicalTrials.gov |
| NCT03697824 | Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically En… | Phase2 | Neoplasms | Withdrawn | 2019-02-25 | 2022-07-18 | ClinicalTrials.gov |
| NCT03697824 | Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically En… | Phase2 | Neoplasms | Withdrawn | 2019-02-25 | 2022-07-18 | ClinicalTrials.gov |
| NCT03681067 | A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moder… | Phase1 | Crohn Disease | Completed | 2019-02-20 | 2020-06-02 | ClinicalTrials.gov |
| NCT03681067 | A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moder… | Phase1 | Crohn Disease | Completed | 2019-02-20 | 2020-06-02 | ClinicalTrials.gov |
| NCT03973905 | Effectiveness of Maternal Immunization With Boostrix at Preventing Pertussis Am… | — | Whooping Cough | Completed | 2019-02-15 | 2019-05-15 | ClinicalTrials.gov |
| NCT03782753 | Molecular Pathology and Neuronal Networks in LRRK2 Parkinson's Disease | — | Parkinson Disease, PARK8 | Completed | 2019-02-15 | 2023-06-23 | ClinicalTrials.gov |
| NCT03973905 | Effectiveness of Maternal Immunization With Boostrix at Preventing Pertussis Am… | — | Whooping Cough | Completed | 2019-02-15 | 2019-05-15 | ClinicalTrials.gov |
| NCT03782753 | Molecular Pathology and Neuronal Networks in LRRK2 Parkinson's Disease | — | Parkinson Disease, PARK8 | Completed | 2019-02-15 | 2023-06-23 | ClinicalTrials.gov |
| NCT03824236 | A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Cha… | Phase2 | Malaria | Completed | 2019-02-05 | 2019-09-26 | ClinicalTrials.gov |
| NCT03824236 | A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Cha… | Phase2 | Malaria | Completed | 2019-02-05 | 2019-09-26 | ClinicalTrials.gov |
| NCT03771157 | Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With… | Early_Phase1 | Chronic Lymphocytic Leukemia (CLL) | Completed | 2019-02-01 | 2022-08-03 | ClinicalTrials.gov |
| NCT03967925 | Rituximab and Belimumab Combination Therapy in PR3 Vasculitis | Phase2 | ANCA Associated Vasculitis | Unknown | 2019-02-01 | 2023-11-01 | ClinicalTrials.gov |
| NCT03771157 | Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With… | Early_Phase1 | Chronic Lymphocytic Leukemia (CLL) | Completed | 2019-02-01 | 2022-08-03 | ClinicalTrials.gov |
| NCT03967925 | Rituximab and Belimumab Combination Therapy in PR3 Vasculitis | Phase2 | ANCA Associated Vasculitis | Unknown | 2019-02-01 | 2023-11-01 | ClinicalTrials.gov |
| NCT03654833 | Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Maligna… | Phase2 | Mesothelioma, Malignant | Unknown | 2019-01-28 | 2023-10-31 | ClinicalTrials.gov |
| NCT03654833 | Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Maligna… | Phase2 | Mesothelioma, Malignant | Unknown | 2019-01-28 | 2023-10-31 | ClinicalTrials.gov |
| NCT03739710 | Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants … | Phase2 | Neoplasms | Completed | 2019-01-24 | 2024-05-02 | ClinicalTrials.gov |
| NCT05553808 | Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants … | Phase2 | Neoplasms | Completed | 2019-01-24 | 2021-09-23 | ClinicalTrials.gov |
| NCT03739710 | Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants … | Phase2 | Neoplasms | Completed | 2019-01-24 | 2024-05-02 | ClinicalTrials.gov |
| NCT03803202 | A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Fin… | Phase1 | Pneumonia, Bacterial | Completed | 2019-01-24 | 2020-09-28 | ClinicalTrials.gov |
| NCT05553808 | Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants … | Phase2 | Neoplasms | Completed | 2019-01-24 | 2021-09-23 | ClinicalTrials.gov |
| NCT03803202 | A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Fin… | Phase1 | Pneumonia, Bacterial | Completed | 2019-01-24 | 2020-09-28 | ClinicalTrials.gov |
| NCT03804710 | To Evaluate the Effect of Moisturizing Creams on Skin Barrier Function | Na | Dry Skin | Completed | 2019-01-22 | 2019-04-16 | ClinicalTrials.gov |
| NCT03804710 | To Evaluate the Effect of Moisturizing Creams on Skin Barrier Function | Na | Dry Skin | Completed | 2019-01-22 | 2019-04-16 | ClinicalTrials.gov |
| NCT03814590 | A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithK… | Phase1 | Respiratory Syncytial Virus Infections | Completed | 2019-01-21 | 2020-11-30 | ClinicalTrials.gov |
| NCT03814590 | A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithK… | Phase1 | Respiratory Syncytial Virus Infections | Completed | 2019-01-21 | 2020-11-30 | ClinicalTrials.gov |
| NCT03707678 | A Safety and Efficacy Study of Intranasal GSK2245035 in Adults With Allergic As… | Phase2 | Asthma | Withdrawn | 2019-01-21 | 2019-12-23 | ClinicalTrials.gov |
| NCT03707678 | A Safety and Efficacy Study of Intranasal GSK2245035 in Adults With Allergic As… | Phase2 | Asthma | Withdrawn | 2019-01-21 | 2019-12-23 | ClinicalTrials.gov |
| NCT03376932 | Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Usi… | Phase3 | Asthma | Withdrawn | 2019-01-18 | 2021-02-03 | ClinicalTrials.gov |
| NCT03376932 | Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Usi… | Phase3 | Asthma | Withdrawn | 2019-01-18 | 2021-02-03 | ClinicalTrials.gov |
| NCT03446612 | Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Proly… | Phase2 | Anaemia | Terminated | 2019-01-10 | 2019-05-29 | ClinicalTrials.gov |
| NCT03446612 | Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Proly… | Phase2 | Anaemia | Terminated | 2019-01-10 | 2019-05-29 | ClinicalTrials.gov |
| NCT03709810 | A Study to Investigate Food Occlusion Efficacy of a Denture Adhesive in Denture… | Phase4 | Denture Retention | Completed | 2019-01-07 | 2019-01-24 | ClinicalTrials.gov |
| NCT03709810 | A Study to Investigate Food Occlusion Efficacy of a Denture Adhesive in Denture… | Phase4 | Denture Retention | Completed | 2019-01-07 | 2019-01-24 | ClinicalTrials.gov |
| NCT03709706 | Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-… | Phase1 | Neoplasms | Terminated | 2018-12-31 | 2022-11-04 | ClinicalTrials.gov |
| NCT03709706 | Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-… | Phase1 | Neoplasms | Terminated | 2018-12-31 | 2022-11-04 | ClinicalTrials.gov |
| NCT03699241 | A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clini… | Phase1 | HIV Infections | Completed | 2018-12-03 | 2023-07-11 | ClinicalTrials.gov |
| NCT03699241 | A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clini… | Phase1 | HIV Infections | Completed | 2018-12-03 | 2023-07-11 | ClinicalTrials.gov |
| NCT03715478 | Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex | Phase1 | Relapsed and/or Refractory Multiple Myeloma | Active_Not_Recruiting | 2018-11-26 | 2026-12-31 | ClinicalTrials.gov |
| NCT03715478 | Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex | Phase1 | Relapsed and/or Refractory Multiple Myeloma | Active_Not_Recruiting | 2018-11-26 | 2026-12-31 | ClinicalTrials.gov |
| NCT03281291 | Study to Assess the Vaccine Efficacy Against Malaria Infection, in Children Imm… | — | Malaria | Completed | 2018-11-19 | 2023-10-23 | ClinicalTrials.gov |
| NCT03281291 | Study to Assess the Vaccine Efficacy Against Malaria Infection, in Children Imm… | — | Malaria | Completed | 2018-11-19 | 2023-10-23 | ClinicalTrials.gov |
| NCT03681951 | First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Ot… | Phase2 | Neoplasms, Pancreatic | Terminated | 2018-11-16 | 2019-08-13 | ClinicalTrials.gov |
| NCT03681951 | First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Ot… | Phase2 | Neoplasms, Pancreatic | Terminated | 2018-11-16 | 2019-08-13 | ClinicalTrials.gov |
| NCT03574779 | A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in … | Phase2 | Ovarian Neoplasms | Completed | 2018-11-15 | 2025-03-31 | ClinicalTrials.gov |
| NCT05751629 | Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Nirapari… | Phase2 | Ovarian Neoplasm | Completed | 2018-11-15 | 2022-04-01 | ClinicalTrials.gov |
| NCT03574779 | A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in … | Phase2 | Ovarian Neoplasms | Completed | 2018-11-15 | 2025-03-31 | ClinicalTrials.gov |
| NCT05751629 | Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Nirapari… | Phase2 | Ovarian Neoplasm | Completed | 2018-11-15 | 2022-04-01 | ClinicalTrials.gov |
| NCT04585997 | Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma -… | Phase4 | Asthma | Unknown | 2018-11-03 | 2022-12-01 | ClinicalTrials.gov |
| NCT04585997 | Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma -… | Phase4 | Asthma | Unknown | 2018-11-03 | 2022-12-01 | ClinicalTrials.gov |
| NCT03674177 | A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals'… | Phase1 | Respiratory Syncytial Virus Infections | Completed | 2018-10-30 | 2019-09-02 | ClinicalTrials.gov |
| NCT03674177 | A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals'… | Phase1 | Respiratory Syncytial Virus Infections | Completed | 2018-10-30 | 2019-09-02 | ClinicalTrials.gov |
| NCT03666988 | First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumo… | Phase1 | Neoplasms | Terminated | 2018-10-22 | 2021-03-04 | ClinicalTrials.gov |
| NCT03666988 | First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumo… | Phase1 | Neoplasms | Terminated | 2018-10-22 | 2021-03-04 | ClinicalTrials.gov |
| NCT03640832 | A Clinical Study to Investigate the Dermal and Ocular Tolerance of a Developmen… | Na | Skin Care | Completed | 2018-10-15 | 2018-11-13 | ClinicalTrials.gov |
| NCT03640832 | A Clinical Study to Investigate the Dermal and Ocular Tolerance of a Developmen… | Na | Skin Care | Completed | 2018-10-15 | 2018-11-13 | ClinicalTrials.gov |
| NCT03602859 | A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standa… | Phase3 | Ovarian Neoplasms | Active_Not_Recruiting | 2018-10-11 | 2029-04-30 | ClinicalTrials.gov |
| NCT03602859 | A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standa… | Phase3 | Ovarian Neoplasms | Active_Not_Recruiting | 2018-10-11 | 2029-04-30 | ClinicalTrials.gov |
| NCT03688620 | Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal… | Phase4 | Influenza, Human | Completed | 2018-10-05 | 2019-01-04 | ClinicalTrials.gov |
| NCT03688620 | Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal… | Phase4 | Influenza, Human | Completed | 2018-10-05 | 2019-01-04 | ClinicalTrials.gov |
| NCT03816189 | Role of Eosinophil in Fibrogenesis of Systemic Sclerosis | — | Systemic Sclerosis | Completed | 2018-10-03 | 2022-04-05 | ClinicalTrials.gov |
| NCT03816189 | Role of Eosinophil in Fibrogenesis of Systemic Sclerosis | — | Systemic Sclerosis | Completed | 2018-10-03 | 2022-04-05 | ClinicalTrials.gov |
| NCT03671369 | A Post-marketing Surveillance Study to Assess the Safety of Cervarix (GlaxoSmit… | — | Neoplasms, Rectal | Completed | 2018-10-02 | 2020-12-01 | ClinicalTrials.gov |
| NCT03671369 | A Post-marketing Surveillance Study to Assess the Safety of Cervarix (GlaxoSmit… | — | Neoplasms, Rectal | Completed | 2018-10-02 | 2020-12-01 | ClinicalTrials.gov |
| NCT03747159 | Synergetic B-cell Immunomodulation in SLE - 2nd Study. | Phase3 | Lupus Erythematosus, Systemic | Active_Not_Recruiting | 2018-10-01 | 2026-06-07 | ClinicalTrials.gov |
| NCT03747159 | Synergetic B-cell Immunomodulation in SLE - 2nd Study. | Phase3 | Lupus Erythematosus, Systemic | Active_Not_Recruiting | 2018-10-01 | 2026-06-07 | ClinicalTrials.gov |
| NCT03649412 | A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Proto… | Phase1 | Autoimmune Diseases | Completed | 2018-09-26 | 2019-05-07 | ClinicalTrials.gov |
| NCT03649412 | A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Proto… | Phase1 | Autoimmune Diseases | Completed | 2018-09-26 | 2019-05-07 | ClinicalTrials.gov |
| NCT02588326 | Sensitivity of Pharmacokinetics to Differences in Particle Size Distribution of… | Phase1 | Hypersensitivity | Completed | 2018-09-21 | 2021-04-16 | ClinicalTrials.gov |
| NCT03595930 | Post-marketing Surveillance (PMS) Study to Observe the Safety and Effectiveness… | — | Asthma | Completed | 2018-09-21 | 2020-07-22 | ClinicalTrials.gov |
| NCT03595930 | Post-marketing Surveillance (PMS) Study to Observe the Safety and Effectiveness… | — | Asthma | Completed | 2018-09-21 | 2020-07-22 | ClinicalTrials.gov |
| NCT02588326 | Sensitivity of Pharmacokinetics to Differences in Particle Size Distribution of… | Phase1 | Hypersensitivity | Completed | 2018-09-21 | 2021-04-16 | ClinicalTrials.gov |
| NCT03544281 | To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Co… | Phase1 | Multiple Myeloma | Completed | 2018-09-20 | 2024-02-28 | ClinicalTrials.gov |
| NCT03544281 | To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Co… | Phase1 | Multiple Myeloma | Completed | 2018-09-20 | 2024-02-28 | ClinicalTrials.gov |
| NCT03652610 | A Study to Investigate the Safety and Immunogenicity of Different Formulations … | Phase2 | Infections, Meningococcal | Completed | 2018-09-07 | 2019-06-11 | ClinicalTrials.gov |
| NCT03652610 | A Study to Investigate the Safety and Immunogenicity of Different Formulations … | Phase2 | Infections, Meningococcal | Completed | 2018-09-07 | 2019-06-11 | ClinicalTrials.gov |
| NCT03400033 | Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prol… | Phase3 | Anaemia | Completed | 2018-09-05 | 2020-06-19 | ClinicalTrials.gov |
| NCT03400033 | Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prol… | Phase3 | Anaemia | Completed | 2018-09-05 | 2020-06-19 | ClinicalTrials.gov |
| NCT03433482 | A Study to Investigate the Safety and Immunogenicity of Different Formulations … | Phase2 | Meningitis, Meningococcal | Completed | 2018-08-30 | 2019-12-17 | ClinicalTrials.gov |
| NCT03433482 | A Study to Investigate the Safety and Immunogenicity of Different Formulations … | Phase2 | Meningitis, Meningococcal | Completed | 2018-08-30 | 2019-12-17 | ClinicalTrials.gov |
| NCT03527173 | A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Design… | Phase2 | Dysentery, Bacillary | Completed | 2018-08-29 | 2019-11-11 | ClinicalTrials.gov |
| NCT03527173 | A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Design… | Phase2 | Dysentery, Bacillary | Completed | 2018-08-29 | 2019-11-11 | ClinicalTrials.gov |
| NCT03629886 | Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Ty… | Phase4 | Cervical Intraepithelial Neoplasia | Completed | 2018-08-22 | 2020-02-28 | ClinicalTrials.gov |
| NCT03629886 | Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Ty… | Phase4 | Cervical Intraepithelial Neoplasia | Completed | 2018-08-22 | 2020-02-28 | ClinicalTrials.gov |
| NCT03207347 | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neop… | Phase2 | Mesothelioma | Completed | 2018-08-13 | 2022-08-30 | ClinicalTrials.gov |
| NCT03207347 | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neop… | Phase2 | Mesothelioma | Completed | 2018-08-13 | 2022-08-30 | ClinicalTrials.gov |
| NCT03244059 | Belimumab Treatment of Emphysema Patients With Anti-GRP78 Autoantibodies | Phase2 | Chronic Obstructive Pulmonary Disease | Completed | 2018-08-09 | 2022-04-01 | ClinicalTrials.gov |
| NCT03244059 | Belimumab Treatment of Emphysema Patients With Anti-GRP78 Autoantibodies | Phase2 | Chronic Obstructive Pulmonary Disease | Completed | 2018-08-09 | 2022-04-01 | ClinicalTrials.gov |
| NCT03621670 | Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pn… | Phase3 | Infections, Meningococcal | Completed | 2018-07-27 | 2024-12-27 | ClinicalTrials.gov |
| NCT03621670 | Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pn… | Phase3 | Infections, Meningococcal | Completed | 2018-07-27 | 2024-12-27 | ClinicalTrials.gov |
| NCT03568942 | Pharmacokinetic Study of Oral Gepotidacin (GSK2140944) in Subjects With Uncompl… | Phase2 | Infections, Bacterial | Completed | 2018-07-23 | 2019-01-07 | ClinicalTrials.gov |
| NCT03568942 | Pharmacokinetic Study of Oral Gepotidacin (GSK2140944) in Subjects With Uncompl… | Phase2 | Infections, Bacterial | Completed | 2018-07-23 | 2019-01-07 | ClinicalTrials.gov |
| NCT03543150 | BOTOX® Drug Use Investigation (Spasmodic Dysphonia) | — | Dysphonia | Unknown | 2018-07-20 | 2022-02-28 | ClinicalTrials.gov |
| NCT03543150 | BOTOX® Drug Use Investigation (Spasmodic Dysphonia) | — | Dysphonia | Unknown | 2018-07-20 | 2022-02-28 | ClinicalTrials.gov |
| NCT03590613 | Phase I Study of GSK2982772 in Japanese Healthy Male Participants | Phase1 | Autoimmune Diseases | Completed | 2018-07-19 | 2018-09-26 | ClinicalTrials.gov |
| NCT03590613 | Phase I Study of GSK2982772 in Japanese Healthy Male Participants | Phase1 | Autoimmune Diseases | Completed | 2018-07-19 | 2018-09-26 | ClinicalTrials.gov |
| NCT03497039 | A Study to Characterize Diclofenac's Plasma and Knee Exposure After Application… | Phase1 | Pain | Completed | 2018-07-19 | 2019-03-01 | ClinicalTrials.gov |
| NCT03497039 | A Study to Characterize Diclofenac's Plasma and Knee Exposure After Application… | Phase1 | Pain | Completed | 2018-07-19 | 2019-03-01 | ClinicalTrials.gov |
| NCT03567499 | Pro-arrhythmic Potential of GSK3039294 in Healthy Subjects | Phase1 | Amyloidosis | Withdrawn | 2018-07-12 | 2019-05-03 | ClinicalTrials.gov |
| NCT03567499 | Pro-arrhythmic Potential of GSK3039294 in Healthy Subjects | Phase1 | Amyloidosis | Withdrawn | 2018-07-12 | 2019-05-03 | ClinicalTrials.gov |
| NCT03587207 | Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biolog… | Phase2 | Meningitis, Meningococcal | Completed | 2018-07-09 | 2018-12-19 | ClinicalTrials.gov |
| NCT03587207 | Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biolog… | Phase2 | Meningitis, Meningococcal | Completed | 2018-07-09 | 2018-12-19 | ClinicalTrials.gov |
| NCT03004807 | Role of Centrum® Silver® in Improving Micronutrient Status in Older Men | Na | Vitamin Deficiency | Completed | 2018-07-01 | 2021-12-31 | ClinicalTrials.gov |
| NCT03004807 | Role of Centrum® Silver® in Improving Micronutrient Status in Older Men | Na | Vitamin Deficiency | Completed | 2018-07-01 | 2021-12-31 | ClinicalTrials.gov |
| NCT03478683 | A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/U… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2018-06-25 | 2019-03-14 | ClinicalTrials.gov |
| NCT03557060 | NUCALA® Special Drug Use Investigation (EGPA, Long-term) | — | Churg-Strauss Syndrome | Completed | 2018-06-25 | 2025-07-30 | ClinicalTrials.gov |
| NCT03478683 | A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/U… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2018-06-25 | 2019-03-14 | ClinicalTrials.gov |
| NCT03557060 | NUCALA® Special Drug Use Investigation (EGPA, Long-term) | — | Churg-Strauss Syndrome | Completed | 2018-06-25 | 2025-07-30 | ClinicalTrials.gov |
| NCT03525678 | A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Pa… | Phase2 | Multiple Myeloma | Completed | 2018-06-18 | 2024-09-12 | ClinicalTrials.gov |
| NCT03543137 | To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the … | Phase1 | Tobacco Use Disorder | Completed | 2018-06-18 | 2018-11-12 | ClinicalTrials.gov |
| NCT03541044 | A Bioequivalence Study of Two Nicotine Lozenges in Fasting Conditions in Health… | Phase1 | Tobacco Use Disorder | Completed | 2018-06-18 | 2019-03-24 | ClinicalTrials.gov |
| NCT03543137 | To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the … | Phase1 | Tobacco Use Disorder | Completed | 2018-06-18 | 2018-11-12 | ClinicalTrials.gov |
| NCT03525678 | A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Pa… | Phase2 | Multiple Myeloma | Completed | 2018-06-18 | 2024-09-12 | ClinicalTrials.gov |
| NCT03541044 | A Bioequivalence Study of Two Nicotine Lozenges in Fasting Conditions in Health… | Phase1 | Tobacco Use Disorder | Completed | 2018-06-18 | 2019-03-24 | ClinicalTrials.gov |
| NCT03562117 | Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With … | Phase1 | Infections, Bacterial | Completed | 2018-06-14 | 2018-12-26 | ClinicalTrials.gov |
| NCT03562117 | Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With … | Phase1 | Infections, Bacterial | Completed | 2018-06-14 | 2018-12-26 | ClinicalTrials.gov |
| NCT03501420 | Adelphi Primary Sjogren's Syndrome (pSS) Disease Specific Programme (DSP) | — | Sjogren's Syndrome | Completed | 2018-06-13 | 2018-10-30 | ClinicalTrials.gov |
| NCT03501420 | Adelphi Primary Sjogren's Syndrome (pSS) Disease Specific Programme (DSP) | — | Sjogren's Syndrome | Completed | 2018-06-13 | 2018-10-30 | ClinicalTrials.gov |
| NCT03212690 | Study of Renin-angiotensin System in Mechanically Ventilated Subjects | Na | Acute Lung Injury | Terminated | 2018-06-11 | 2019-07-08 | ClinicalTrials.gov |
| NCT03212690 | Study of Renin-angiotensin System in Mechanically Ventilated Subjects | Na | Acute Lung Injury | Terminated | 2018-06-11 | 2019-07-08 | ClinicalTrials.gov |
| NCT03503474 | COMBACTE-CDI Understanding the Burden of C. Difficile Infection | — | Clostridium Difficile Infection | Completed | 2018-06-11 | 2019-09-30 | ClinicalTrials.gov |
| NCT03503474 | COMBACTE-CDI Understanding the Burden of C. Difficile Infection | — | Clostridium Difficile Infection | Completed | 2018-06-11 | 2019-09-30 | ClinicalTrials.gov |
| NCT03518242 | Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breas… | Phase1 | Breast Cancer Female | Completed | 2018-06-06 | 2022-05-04 | ClinicalTrials.gov |
| NCT03518242 | Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breas… | Phase1 | Breast Cancer Female | Completed | 2018-06-06 | 2022-05-04 | ClinicalTrials.gov |
| NCT03563183 | A Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022 | — | Herpes Zoster | Completed | 2018-06-05 | 2019-04-30 | ClinicalTrials.gov |
| NCT03563183 | A Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022 | — | Herpes Zoster | Completed | 2018-06-05 | 2019-04-30 | ClinicalTrials.gov |
| NCT02671188 | A Study to Evaluate the Safety, Mode of Action and Clinical Efficacy of GSK3050… | Phase1 | Autoimmune Diseases | Withdrawn | 2018-06-01 | 2019-08-09 | ClinicalTrials.gov |
| NCT02671188 | A Study to Evaluate the Safety, Mode of Action and Clinical Efficacy of GSK3050… | Phase1 | Autoimmune Diseases | Withdrawn | 2018-06-01 | 2019-08-09 | ClinicalTrials.gov |
| NCT03438006 | A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKl… | — | Cervical Intraepithelial Neoplasia | Completed | 2018-05-31 | 2020-12-03 | ClinicalTrials.gov |
| NCT03543176 | Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness | — | Pulmonary Disease, Chronic Obstructive | Completed | 2018-05-31 | 2019-08-21 | ClinicalTrials.gov |
| NCT03438006 | A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKl… | — | Cervical Intraepithelial Neoplasia | Completed | 2018-05-31 | 2020-12-03 | ClinicalTrials.gov |
| NCT03543176 | Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness | — | Pulmonary Disease, Chronic Obstructive | Completed | 2018-05-31 | 2019-08-21 | ClinicalTrials.gov |
| NCT03329573 | Bioequivalence Study of Paroxetine Immediate Release (IR) Tablets Manufactured … | Phase1 | Anxiety Disorders | Completed | 2018-05-30 | 2018-08-03 | ClinicalTrials.gov |
| NCT03329573 | Bioequivalence Study of Paroxetine Immediate Release (IR) Tablets Manufactured … | Phase1 | Anxiety Disorders | Completed | 2018-05-30 | 2018-08-03 | ClinicalTrials.gov |
| NCT03188458 | Immunogenicity of a Single Dose of GSK Biologicals' Boostrix™ in Infants Prior … | Phase4 | Diphtheria-Tetanus-Acellular Pertussis | Terminated | 2018-05-29 | 2018-10-22 | ClinicalTrials.gov |
| NCT03188458 | Immunogenicity of a Single Dose of GSK Biologicals' Boostrix™ in Infants Prior … | Phase4 | Diphtheria-Tetanus-Acellular Pertussis | Terminated | 2018-05-29 | 2018-10-22 | ClinicalTrials.gov |
| NCT03555890 | Bioequivalence Study Between Levocetirizine Oral Disintegrating Tablet (ODT) an… | Phase1 | Rhinitis | Completed | 2018-05-18 | 2018-09-17 | ClinicalTrials.gov |
| NCT03555890 | Bioequivalence Study Between Levocetirizine Oral Disintegrating Tablet (ODT) an… | Phase1 | Rhinitis | Completed | 2018-05-18 | 2018-09-17 | ClinicalTrials.gov |
| NCT03485365 | A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study … | Phase1 | Pain, Inflammatory | Completed | 2018-05-17 | 2022-09-12 | ClinicalTrials.gov |
| NCT03485365 | A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study … | Phase1 | Pain, Inflammatory | Completed | 2018-05-17 | 2022-09-12 | ClinicalTrials.gov |
| NCT03207958 | Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogen… | Phase1 | Graft Vs Host Disease | Completed | 2018-05-16 | 2024-02-09 | ClinicalTrials.gov |
| NCT03207958 | Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogen… | Phase1 | Graft Vs Host Disease | Completed | 2018-05-16 | 2024-02-09 | ClinicalTrials.gov |
| NCT02826512 | A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast… | Phase2 | Breast Cancer | Terminated | 2018-05-15 | 2022-07-01 | ClinicalTrials.gov |
| NCT02826512 | A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast… | Phase2 | Breast Cancer | Terminated | 2018-05-15 | 2022-07-01 | ClinicalTrials.gov |
| NCT03183492 | Immunogenicity and Persistence of GlaxoSmithKline (GSK) Biologicals' Havrix® in… | Phase4 | Hepatitis A | Withdrawn | 2018-05-07 | 2019-01-28 | ClinicalTrials.gov |
| NCT03183492 | Immunogenicity and Persistence of GlaxoSmithKline (GSK) Biologicals' Havrix® in… | Phase4 | Hepatitis A | Withdrawn | 2018-05-07 | 2019-01-28 | ClinicalTrials.gov |
| NCT03441113 | Extended Access of Momelotinib in Adults With Myelofibrosis | Phase2 | Neoplasms | Active_Not_Recruiting | 2018-05-03 | 2026-12-11 | ClinicalTrials.gov |
| NCT03441113 | Extended Access of Momelotinib in Adults With Myelofibrosis | Phase2 | Neoplasms | Active_Not_Recruiting | 2018-05-03 | 2026-12-11 | ClinicalTrials.gov |
| NCT03318783 | Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial | Phase1 | Subarachnoid Hemorrhage, Aneurysmal | Completed | 2018-05-02 | 2020-01-09 | ClinicalTrials.gov |
| NCT03318783 | Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial | Phase1 | Subarachnoid Hemorrhage, Aneurysmal | Completed | 2018-05-02 | 2020-01-09 | ClinicalTrials.gov |
| NCT03493386 | Daprodustat Bioequivalence and Food Effect Study | Phase1 | Anaemia | Completed | 2018-04-24 | 2018-06-09 | ClinicalTrials.gov |
| NCT03493386 | Daprodustat Bioequivalence and Food Effect Study | Phase1 | Anaemia | Completed | 2018-04-24 | 2018-06-09 | ClinicalTrials.gov |
| NCT03465332 | Use of Diagnostic Measures in Chronic Obstructive Pulmonary Disease (COPD) in R… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2018-04-19 | 2018-08-30 | ClinicalTrials.gov |
| NCT03465332 | Use of Diagnostic Measures in Chronic Obstructive Pulmonary Disease (COPD) in R… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2018-04-19 | 2018-08-30 | ClinicalTrials.gov |
| NCT03393806 | Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma … | Phase2 | Asthma | Terminated | 2018-04-18 | 2020-01-06 | ClinicalTrials.gov |
| NCT03393806 | Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma … | Phase2 | Asthma | Terminated | 2018-04-18 | 2020-01-06 | ClinicalTrials.gov |
| NCT03152669 | The Extended Salford Lung Study ("Ex-SLS") Data Access Project | — | Asthma | Recruiting | 2018-04-15 | 2028-04-30 | ClinicalTrials.gov |
| NCT03152669 | The Extended Salford Lung Study ("Ex-SLS") Data Access Project | — | Asthma | Recruiting | 2018-04-15 | 2028-04-30 | ClinicalTrials.gov |
| NCT03463577 | The Safety of Boostrix Following Routine Immunization of Pregnant Women | — | Whooping Cough | Completed | 2018-04-13 | 2020-08-04 | ClinicalTrials.gov |
| NCT03463577 | The Safety of Boostrix Following Routine Immunization of Pregnant Women | — | Whooping Cough | Completed | 2018-04-13 | 2020-08-04 | ClinicalTrials.gov |
| NCT03329937 | Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant … | Phase1 | Neoplasms, Breast | Completed | 2018-04-12 | 2020-03-31 | ClinicalTrials.gov |
| NCT03439657 | Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK14… | Phase3 | Herpes Zoster | Completed | 2018-04-12 | 2020-03-03 | ClinicalTrials.gov |
| NCT03439657 | Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK14… | Phase3 | Herpes Zoster | Completed | 2018-04-12 | 2020-03-03 | ClinicalTrials.gov |
| NCT03329937 | Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant … | Phase1 | Neoplasms, Breast | Completed | 2018-04-12 | 2020-03-31 | ClinicalTrials.gov |
| NCT02802501 | Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartem… | Phase3 | Malaria, Vivax | Completed | 2018-04-08 | 2019-08-19 | ClinicalTrials.gov |
| NCT02802501 | Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartem… | Phase3 | Malaria, Vivax | Completed | 2018-04-08 | 2019-08-19 | ClinicalTrials.gov |
| NCT03417830 | Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging | Phase1 | Amyloidosis | Terminated | 2018-04-06 | 2018-07-20 | ClinicalTrials.gov |
| NCT03417830 | Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging | Phase1 | Amyloidosis | Terminated | 2018-04-06 | 2018-07-20 | ClinicalTrials.gov |
| NCT03372603 | A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participa… | Phase1 | Cough | Terminated | 2018-04-05 | 2018-10-08 | ClinicalTrials.gov |
| NCT03372603 | A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participa… | Phase1 | Cough | Terminated | 2018-04-05 | 2018-10-08 | ClinicalTrials.gov |
| NCT03447314 | Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advan… | Phase1 | Neoplasms | Completed | 2018-03-26 | 2022-03-11 | ClinicalTrials.gov |
| NCT03447314 | Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advan… | Phase1 | Neoplasms | Completed | 2018-03-26 | 2022-03-11 | ClinicalTrials.gov |
| NCT03443427 | A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Sm… | Phase2 | Respiratory Disorders | Completed | 2018-03-20 | 2020-09-23 | ClinicalTrials.gov |
| NCT03443427 | A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Sm… | Phase2 | Respiratory Disorders | Completed | 2018-03-20 | 2020-09-23 | ClinicalTrials.gov |
| NCT02899026 | Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica | Phase3 | Polymyalgia Rheumatica | Withdrawn | 2018-03-15 | 2021-08-26 | ClinicalTrials.gov |
| NCT02899026 | Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica | Phase3 | Polymyalgia Rheumatica | Withdrawn | 2018-03-15 | 2021-08-26 | ClinicalTrials.gov |
| NCT03493919 | A Sourcing Study to Collect Human Blood Samples From Healthy Adults | Phase4 | Meningitis, Meningococcal | Completed | 2018-03-08 | 2022-05-27 | ClinicalTrials.gov |
| NCT03493919 | A Sourcing Study to Collect Human Blood Samples From Healthy Adults | Phase4 | Meningitis, Meningococcal | Completed | 2018-03-08 | 2022-05-27 | ClinicalTrials.gov |
| NCT03363191 | The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate … | Phase4 | Asthma | Withdrawn | 2018-03-07 | 2019-05-29 | ClinicalTrials.gov |
| NCT03363191 | The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate … | Phase4 | Asthma | Withdrawn | 2018-03-07 | 2019-05-29 | ClinicalTrials.gov |
| NCT03409107 | Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prol… | Phase3 | Anaemia | Completed | 2018-03-05 | 2020-10-07 | ClinicalTrials.gov |
| NCT03409107 | Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prol… | Phase3 | Anaemia | Completed | 2018-03-05 | 2020-10-07 | ClinicalTrials.gov |
| NCT03312907 | A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combin… | Phase3 | Systemic Lupus Erythematosus | Completed | 2018-03-01 | 2021-07-07 | ClinicalTrials.gov |
| NCT03415243 | To Investigate the Gastrointestinal Behaviour of Two Triple Combination Product… | Phase1 | Common Cold | Completed | 2018-03-01 | 2018-03-29 | ClinicalTrials.gov |
| NCT03312907 | A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combin… | Phase3 | Systemic Lupus Erythematosus | Completed | 2018-03-01 | 2021-07-07 | ClinicalTrials.gov |
| NCT03415243 | To Investigate the Gastrointestinal Behaviour of Two Triple Combination Product… | Phase1 | Common Cold | Completed | 2018-03-01 | 2018-03-29 | ClinicalTrials.gov |
| NCT03355820 | A Follow-up Extension Study to Evaluate the Persistence of Immune Response to G… | Phase3 | Cervical Intraepithelial Neoplasia | Completed | 2018-02-28 | 2018-06-29 | ClinicalTrials.gov |
| NCT03359473 | Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen… | Phase2 | Cachexia | Completed | 2018-02-28 | 2019-11-19 | ClinicalTrials.gov |
| NCT03359473 | Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen… | Phase2 | Cachexia | Completed | 2018-02-28 | 2019-11-19 | ClinicalTrials.gov |
| NCT03355820 | A Follow-up Extension Study to Evaluate the Persistence of Immune Response to G… | Phase3 | Cervical Intraepithelial Neoplasia | Completed | 2018-02-28 | 2018-06-29 | ClinicalTrials.gov |
| NCT03441984 | To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and La… | Phase1 | HIV Infections | Completed | 2018-02-26 | 2018-04-28 | ClinicalTrials.gov |
| NCT03441984 | To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and La… | Phase1 | HIV Infections | Completed | 2018-02-26 | 2018-04-28 | ClinicalTrials.gov |
| NCT03359850 | Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic I… | Phase1 | Ovarian Neoplasms | Completed | 2018-02-20 | 2020-06-24 | ClinicalTrials.gov |
| NCT03359850 | Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic I… | Phase1 | Ovarian Neoplasms | Completed | 2018-02-20 | 2020-06-24 | ClinicalTrials.gov |
| NCT03192371 | A Study to Evaluate the One Year Long-term Persistence of Immune Responses Foll… | Phase4 | Virus Diseases | Withdrawn | 2018-02-15 | 2019-05-12 | ClinicalTrials.gov |
| NCT03192371 | A Study to Evaluate the One Year Long-term Persistence of Immune Responses Foll… | Phase4 | Virus Diseases | Withdrawn | 2018-02-15 | 2019-05-12 | ClinicalTrials.gov |
| NCT03408392 | Bioequivalence Study Between SKF101804 Cefixime 200 Milligram (mg)/5 Milliliter… | Phase1 | Infections, Bacterial | Completed | 2018-02-06 | 2018-03-13 | ClinicalTrials.gov |
| NCT03408392 | Bioequivalence Study Between SKF101804 Cefixime 200 Milligram (mg)/5 Milliliter… | Phase1 | Infections, Bacterial | Completed | 2018-02-06 | 2018-03-13 | ClinicalTrials.gov |
| NCT03404960 | Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcino… | Phase1 | Pancreatic Adenocarcinoma | Completed | 2018-01-31 | 2024-10-09 | ClinicalTrials.gov |
| NCT03404960 | Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcino… | Phase1 | Pancreatic Adenocarcinoma | Completed | 2018-01-31 | 2024-10-09 | ClinicalTrials.gov |
| NCT03242434 | Investigation of Thermal Injury on Intestinal Permeability in Both Thermal Inju… | Phase1 | Burns | Terminated | 2018-01-29 | 2018-03-26 | ClinicalTrials.gov |
| NCT03242434 | Investigation of Thermal Injury on Intestinal Permeability in Both Thermal Inju… | Phase1 | Burns | Terminated | 2018-01-29 | 2018-03-26 | ClinicalTrials.gov |
| NCT03311659 | Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boo… | Phase3 | Diphtheria-Tetanus-acellular Pertussis Vaccines | Completed | 2018-01-26 | 2018-08-31 | ClinicalTrials.gov |
| NCT03311659 | Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boo… | Phase3 | Diphtheria-Tetanus-acellular Pertussis Vaccines | Completed | 2018-01-26 | 2018-08-31 | ClinicalTrials.gov |
| NCT03399461 | Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (… | — | Wiskott-Aldrich Syndrome | Completed | 2018-01-24 | 2018-09-14 | ClinicalTrials.gov |
| NCT03399461 | Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (… | — | Wiskott-Aldrich Syndrome | Completed | 2018-01-24 | 2018-09-14 | ClinicalTrials.gov |
| NCT03312712 | Validation of the Analysis Methodology Behind the Use of Quantitative 18F-FDG P… | — | Lung Inflammation | Unknown | 2018-01-23 | 2022-01-01 | ClinicalTrials.gov |
| NCT03312712 | Validation of the Analysis Methodology Behind the Use of Quantitative 18F-FDG P… | — | Lung Inflammation | Unknown | 2018-01-23 | 2022-01-01 | ClinicalTrials.gov |
| NCT03202004 | GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis | Phase3 | Psoriasis | Withdrawn | 2018-01-22 | 2018-09-28 | ClinicalTrials.gov |
| NCT03202004 | GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis | Phase3 | Psoriasis | Withdrawn | 2018-01-22 | 2018-09-28 | ClinicalTrials.gov |
| NCT03883568 | A 2-year, European Multicentre Study to Describe, Validate, and Predict Phenoty… | — | Knee Osteoarthritis | Completed | 2018-01-19 | 2021-12-01 | ClinicalTrials.gov |
| NCT03883568 | A 2-year, European Multicentre Study to Describe, Validate, and Predict Phenoty… | — | Knee Osteoarthritis | Completed | 2018-01-19 | 2021-12-01 | ClinicalTrials.gov |
| NCT03398421 | A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of … | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2018-01-17 | 2018-03-12 | ClinicalTrials.gov |
| NCT03398421 | A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of … | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2018-01-17 | 2018-03-12 | ClinicalTrials.gov |
| NCT03122223 | Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuv… | Phase1 | HIV Infections | Completed | 2018-01-16 | 2020-07-30 | ClinicalTrials.gov |
| NCT03122223 | Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuv… | Phase1 | HIV Infections | Completed | 2018-01-16 | 2020-07-30 | ClinicalTrials.gov |
| NCT03370263 | BENLYSTA® Special Drug Use Investigation | — | Systemic Lupus Erythematosus | Completed | 2018-01-15 | 2025-09-26 | ClinicalTrials.gov |
| NCT03370263 | BENLYSTA® Special Drug Use Investigation | — | Systemic Lupus Erythematosus | Completed | 2018-01-15 | 2025-09-26 | ClinicalTrials.gov |
| NCT03329547 | A Bioequivalence Study of SKF101804 Cefixime Versus Cefixime Reference Formulat… | Phase1 | Infections, Bacterial | Withdrawn | 2018-01-11 | 2018-02-02 | ClinicalTrials.gov |
| NCT03329547 | A Bioequivalence Study of SKF101804 Cefixime Versus Cefixime Reference Formulat… | Phase1 | Infections, Bacterial | Withdrawn | 2018-01-11 | 2018-02-02 | ClinicalTrials.gov |
| NCT03273946 | Post-marketing Safety Monitoring Program of Fluticasone Propionate (FP) in Chin… | — | Asthma | Completed | 2018-01-09 | 2018-09-27 | ClinicalTrials.gov |
| NCT03273946 | Post-marketing Safety Monitoring Program of Fluticasone Propionate (FP) in Chin… | — | Asthma | Completed | 2018-01-09 | 2018-09-27 | ClinicalTrials.gov |
| NCT03351140 | Patient-Reported Outcome Measurement Information System (PROMIS) Physical Funct… | — | Neoplasms | Completed | 2017-12-20 | 2020-05-08 | ClinicalTrials.gov |
| NCT03351140 | Patient-Reported Outcome Measurement Information System (PROMIS) Physical Funct… | — | Neoplasms | Completed | 2017-12-20 | 2020-05-08 | ClinicalTrials.gov |
| NCT03383783 | Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model | Phase3 | Caries | Completed | 2017-12-19 | 2018-05-02 | ClinicalTrials.gov |
| NCT03383783 | Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model | Phase3 | Caries | Completed | 2017-12-19 | 2018-05-02 | ClinicalTrials.gov |
| NCT03201978 | A Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of GSK2894512… | Phase1 | Psoriasis | Withdrawn | 2017-12-14 | 2018-05-15 | ClinicalTrials.gov |
| NCT03201978 | A Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of GSK2894512… | Phase1 | Psoriasis | Withdrawn | 2017-12-14 | 2018-05-15 | ClinicalTrials.gov |
| NCT03368053 | Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461) | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2017-12-14 | 2018-01-30 | ClinicalTrials.gov |
| NCT03368053 | Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461) | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2017-12-14 | 2018-01-30 | ClinicalTrials.gov |
| NCT03336567 | Perceptions of Cell and Gene Therapies (CGT) for the Treatment of Cancer | — | Neoplasms | Completed | 2017-12-04 | 2018-06-12 | ClinicalTrials.gov |
| NCT03336567 | Perceptions of Cell and Gene Therapies (CGT) for the Treatment of Cancer | — | Neoplasms | Completed | 2017-12-04 | 2018-06-12 | ClinicalTrials.gov |
| NCT03128489 | Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infa… | Phase3 | Diphtheria | Withdrawn | 2017-12-01 | 2018-08-01 | ClinicalTrials.gov |
| NCT03344406 | A Study to Evaluate Conceptual Saturation of Evaluating Respiratory Symptoms (E… | — | Asthma | Completed | 2017-12-01 | 2018-09-10 | ClinicalTrials.gov |
| NCT03344406 | A Study to Evaluate Conceptual Saturation of Evaluating Respiratory Symptoms (E… | — | Asthma | Completed | 2017-12-01 | 2018-09-10 | ClinicalTrials.gov |
| NCT03128489 | Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infa… | Phase3 | Diphtheria | Withdrawn | 2017-12-01 | 2018-08-01 | ClinicalTrials.gov |
| NCT03345407 | Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Modera… | Phase2 | Pulmonary Disease, Chronic Obstructive | Terminated | 2017-11-28 | 2019-01-10 | ClinicalTrials.gov |
| NCT03345407 | Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Modera… | Phase2 | Pulmonary Disease, Chronic Obstructive | Terminated | 2017-11-28 | 2019-01-10 | ClinicalTrials.gov |
| NCT03281876 | A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary… | Phase2 | Respiratory Disorders | Completed | 2017-11-27 | 2020-03-26 | ClinicalTrials.gov |
| NCT03266159 | A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharm… | Phase2 | Solid Tumours | Withdrawn | 2017-11-27 | 2020-08-19 | ClinicalTrials.gov |
| NCT03266159 | A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharm… | Phase2 | Solid Tumours | Withdrawn | 2017-11-27 | 2020-08-19 | ClinicalTrials.gov |
| NCT03281876 | A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary… | Phase2 | Respiratory Disorders | Completed | 2017-11-27 | 2020-03-26 | ClinicalTrials.gov |
| NCT03137043 | Prevalence of Severe Asthma in Spanish Hospitals | — | Asthma | Completed | 2017-11-22 | 2020-06-02 | ClinicalTrials.gov |
| NCT03137043 | Prevalence of Severe Asthma in Spanish Hospitals | — | Asthma | Completed | 2017-11-22 | 2020-06-02 | ClinicalTrials.gov |
| NCT03345108 | A Study to Investigate a Method to Measure Food Occlusion by Denture Adhesives … | Na | Denture Retention | Completed | 2017-11-20 | 2017-12-15 | ClinicalTrials.gov |
| NCT03345108 | A Study to Investigate a Method to Measure Food Occlusion by Denture Adhesives … | Na | Denture Retention | Completed | 2017-11-20 | 2017-12-15 | ClinicalTrials.gov |
| NCT03310268 | A Clinical Study to Evaluate a Stannous Fluoride Toothpaste for the Relief of D… | Na | Dentin Sensitivity | Completed | 2017-11-18 | 2018-02-02 | ClinicalTrials.gov |
| NCT03310268 | A Clinical Study to Evaluate a Stannous Fluoride Toothpaste for the Relief of D… | Na | Dentin Sensitivity | Completed | 2017-11-18 | 2018-02-02 | ClinicalTrials.gov |
| NCT03250689 | Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular… | Phase2 | Pulmonary Disease, Chronic Obstructive | Terminated | 2017-11-15 | 2018-10-08 | ClinicalTrials.gov |
| NCT03250689 | Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular… | Phase2 | Pulmonary Disease, Chronic Obstructive | Terminated | 2017-11-15 | 2018-10-08 | ClinicalTrials.gov |
| NCT03315559 | Absorption & Elimination of Radiolabelled GSK2269557 | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2017-11-14 | 2017-12-22 | ClinicalTrials.gov |
| NCT03315559 | Absorption & Elimination of Radiolabelled GSK2269557 | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2017-11-14 | 2017-12-22 | ClinicalTrials.gov |
| NCT03296072 | In Situ Erosion Study to Investigate the Effectiveness of an Experimental Tooth… | Phase3 | Tooth Erosion | Completed | 2017-11-13 | 2018-01-16 | ClinicalTrials.gov |
| NCT03306043 | A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects W… | Phase3 | Hypereosinophilic Syndrome | Completed | 2017-11-13 | 2019-12-30 | ClinicalTrials.gov |
| NCT03296072 | In Situ Erosion Study to Investigate the Effectiveness of an Experimental Tooth… | Phase3 | Tooth Erosion | Completed | 2017-11-13 | 2018-01-16 | ClinicalTrials.gov |
| NCT03306043 | A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects W… | Phase3 | Hypereosinophilic Syndrome | Completed | 2017-11-13 | 2019-12-30 | ClinicalTrials.gov |
| NCT03292588 | A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerba… | Phase2 | Asthma | Completed | 2017-11-07 | 2021-04-20 | ClinicalTrials.gov |
| NCT03292588 | A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerba… | Phase2 | Asthma | Completed | 2017-11-07 | 2021-04-20 | ClinicalTrials.gov |
| NCT03016338 | Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer | Phase2 | Endometrial Cancer | Unknown | 2017-11-06 | 2025-12-01 | ClinicalTrials.gov |
| NCT03016338 | Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer | Phase2 | Endometrial Cancer | Unknown | 2017-11-06 | 2025-12-01 | ClinicalTrials.gov |
| NCT03248128 | Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose … | Phase3 | Asthma | Completed | 2017-10-20 | 2022-03-21 | ClinicalTrials.gov |
| NCT03248128 | Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose … | Phase3 | Asthma | Completed | 2017-10-20 | 2022-03-21 | ClinicalTrials.gov |
| NCT03287310 | First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenici… | Phase1 | Asthma | Completed | 2017-10-17 | 2019-07-31 | ClinicalTrials.gov |
| NCT03287310 | First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenici… | Phase1 | Asthma | Completed | 2017-10-17 | 2019-07-31 | ClinicalTrials.gov |
| NCT03170232 | A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmo… | Phase2 | Pulmonary Disease, Chronic Obstructive | Terminated | 2017-10-16 | 2018-11-15 | ClinicalTrials.gov |
| NCT03170232 | A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmo… | Phase2 | Pulmonary Disease, Chronic Obstructive | Terminated | 2017-10-16 | 2018-11-15 | ClinicalTrials.gov |
| NCT03209401 | Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient … | Phase1 | Solid Tumor, Adult | Terminated | 2017-10-13 | 2023-10-16 | ClinicalTrials.gov |
| NCT03209401 | Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient … | Phase1 | Solid Tumor, Adult | Terminated | 2017-10-13 | 2023-10-16 | ClinicalTrials.gov |
| NCT03307785 | Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemothera… | Phase1 | Neoplasms | Completed | 2017-10-12 | 2024-12-11 | ClinicalTrials.gov |
| NCT03307785 | Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemothera… | Phase1 | Neoplasms | Completed | 2017-10-12 | 2024-12-11 | ClinicalTrials.gov |
| NCT03305419 | A Safety and Pharmacokinetic (PK) Study of GSK2982772 in Healthy Subjects | Phase1 | Autoimmune Diseases | Completed | 2017-10-11 | 2018-10-15 | ClinicalTrials.gov |
| NCT03305419 | A Safety and Pharmacokinetic (PK) Study of GSK2982772 in Healthy Subjects | Phase1 | Autoimmune Diseases | Completed | 2017-10-11 | 2018-10-15 | ClinicalTrials.gov |
| NCT03300050 | Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed b… | Phase1 | Influenza | Completed | 2017-10-10 | 2019-08-09 | ClinicalTrials.gov |
| NCT03300050 | Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed b… | Phase1 | Influenza | Completed | 2017-10-10 | 2019-08-09 | ClinicalTrials.gov |
| NCT03239522 | Absorption and Elimination of Radiolabeled Daprodustat | Phase1 | Anaemia | Completed | 2017-10-10 | 2017-11-28 | ClinicalTrials.gov |
| NCT03239522 | Absorption and Elimination of Radiolabeled Daprodustat | Phase1 | Anaemia | Completed | 2017-10-10 | 2017-11-28 | ClinicalTrials.gov |
| NCT05491902 | Pilot PET Study of Regional Cerebral Protein Synthesis in Alzheimer's | — | Alzheimer Disease | Terminated | 2017-10-09 | 2020-10-15 | ClinicalTrials.gov |
| NCT05491902 | Pilot PET Study of Regional Cerebral Protein Synthesis in Alzheimer's | — | Alzheimer Disease | Terminated | 2017-10-09 | 2020-10-15 | ClinicalTrials.gov |
| NCT03294135 | The Aim of This Study is to Investigate the Persistence of Antibody Response in… | Phase4 | Virus Diseases | Completed | 2017-10-05 | 2021-10-25 | ClinicalTrials.gov |
| NCT03294135 | The Aim of This Study is to Investigate the Persistence of Antibody Response in… | Phase4 | Virus Diseases | Completed | 2017-10-05 | 2021-10-25 | ClinicalTrials.gov |
| NCT03258710 | A Study of Switching From Entecavir to Tenofovir Disoproxil Fumarate in Subject… | Phase4 | Hepatitis B, Chronic | Completed | 2017-10-02 | 2019-11-25 | ClinicalTrials.gov |
| NCT03258710 | A Study of Switching From Entecavir to Tenofovir Disoproxil Fumarate in Subject… | Phase4 | Hepatitis B, Chronic | Completed | 2017-10-02 | 2019-11-25 | ClinicalTrials.gov |
| NCT02130661 | Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapl… | Phase1 | Alzheimer's Disease | Withdrawn | 2017-10-01 | 2018-01-01 | ClinicalTrials.gov |
| NCT02130661 | Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapl… | Phase1 | Alzheimer's Disease | Withdrawn | 2017-10-01 | 2018-01-01 | ClinicalTrials.gov |
| NCT03258762 | Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects | Phase1 | Toxoplasmosis | Completed | 2017-09-25 | 2017-11-19 | ClinicalTrials.gov |
| NCT03258762 | Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects | Phase1 | Toxoplasmosis | Completed | 2017-09-25 | 2017-11-19 | ClinicalTrials.gov |
| NCT03267511 | A Study to Investigate the Stain and Plaque Removal Capability of Two Experimen… | Phase2 | Oral Hygiene | Completed | 2017-09-25 | 2017-12-02 | ClinicalTrials.gov |
| NCT03267511 | A Study to Investigate the Stain and Plaque Removal Capability of Two Experimen… | Phase2 | Oral Hygiene | Completed | 2017-09-25 | 2017-12-02 | ClinicalTrials.gov |
| NCT03227445 | Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used Wi… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2017-09-20 | 2018-01-04 | ClinicalTrials.gov |
| NCT03227445 | Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used Wi… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2017-09-20 | 2018-01-04 | ClinicalTrials.gov |
| NCT03231943 | GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2017-09-19 | 2018-09-09 | ClinicalTrials.gov |
| NCT03231943 | GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2017-09-19 | 2018-09-09 | ClinicalTrials.gov |
| NCT03239600 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of M… | Phase2 | Autoimmune Diseases | Withdrawn | 2017-09-19 | 2017-10-12 | ClinicalTrials.gov |
| NCT03239600 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of M… | Phase2 | Autoimmune Diseases | Withdrawn | 2017-09-19 | 2017-10-12 | ClinicalTrials.gov |
| NCT03207243 | Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asth… | Phase2 | Asthma | Completed | 2017-09-14 | 2019-05-15 | ClinicalTrials.gov |
| NCT03207750 | This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the R… | Phase3 | Rotavirus Infection | Completed | 2017-09-14 | 2019-03-01 | ClinicalTrials.gov |
| NCT03207243 | Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asth… | Phase2 | Asthma | Completed | 2017-09-14 | 2019-05-15 | ClinicalTrials.gov |
| NCT03207750 | This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the R… | Phase3 | Rotavirus Infection | Completed | 2017-09-14 | 2019-03-01 | ClinicalTrials.gov |
| NCT03275389 | A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmith… | Phase1 | Influenza, Human | Completed | 2017-09-08 | 2020-03-26 | ClinicalTrials.gov |
| NCT03275389 | A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmith… | Phase1 | Influenza, Human | Completed | 2017-09-08 | 2020-03-26 | ClinicalTrials.gov |
| NCT03219255 | RELVAR® 100 ELLIPTA® Special Drug Use Investigation (COPD, Long-term) | — | Pulmonary Disease, Chronic Obstructive | Completed | 2017-08-30 | 2021-03-30 | ClinicalTrials.gov |
| NCT03219255 | RELVAR® 100 ELLIPTA® Special Drug Use Investigation (COPD, Long-term) | — | Pulmonary Disease, Chronic Obstructive | Completed | 2017-08-30 | 2021-03-30 | ClinicalTrials.gov |
| NCT03151395 | Occurrence of Potential Bacterial and Viral Pathogens in Stable Chronic Obstruc… | Na | Respiratory Disorders | Completed | 2017-08-25 | 2020-04-06 | ClinicalTrials.gov |
| NCT03151395 | Occurrence of Potential Bacterial and Viral Pathogens in Stable Chronic Obstruc… | Na | Respiratory Disorders | Completed | 2017-08-25 | 2020-04-06 | ClinicalTrials.gov |
| NCT03245619 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Investigation of G… | Phase1 | Pancreatitis, Acute Necrotizing | Terminated | 2017-08-22 | 2018-05-19 | ClinicalTrials.gov |
| NCT03245619 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Investigation of G… | Phase1 | Pancreatitis, Acute Necrotizing | Terminated | 2017-08-22 | 2018-05-19 | ClinicalTrials.gov |
| NCT03184480 | Arnuity® Ellipta® Drug Use Investigation | — | Asthma | Completed | 2017-08-19 | 2021-03-17 | ClinicalTrials.gov |
| NCT03184480 | Arnuity® Ellipta® Drug Use Investigation | — | Asthma | Completed | 2017-08-19 | 2021-03-17 | ClinicalTrials.gov |
| NCT03168438 | Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembro… | Phase1 | Neoplasms | Terminated | 2017-08-18 | 2020-11-05 | ClinicalTrials.gov |
| NCT03168438 | Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembro… | Phase1 | Neoplasms | Terminated | 2017-08-18 | 2020-11-05 | ClinicalTrials.gov |
| NCT03015519 | A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Ped… | Phase3 | Diabetes Mellitus, Type 2 | Withdrawn | 2017-08-14 | 2020-04-20 | ClinicalTrials.gov |
| NCT03015519 | A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Ped… | Phase3 | Diabetes Mellitus, Type 2 | Withdrawn | 2017-08-14 | 2020-04-20 | ClinicalTrials.gov |
| NCT03153007 | Study of Subjects With Diabetic Foot Ulcer (DFU) | — | Diabetic Foot | Completed | 2017-08-11 | 2017-12-06 | ClinicalTrials.gov |
| NCT03153007 | Study of Subjects With Diabetic Foot Ulcer (DFU) | — | Diabetic Foot | Completed | 2017-08-11 | 2017-12-06 | ClinicalTrials.gov |
| NCT03306589 | Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (G… | Phase1 | Arthritis, Rheumatoid | Completed | 2017-08-11 | 2018-06-20 | ClinicalTrials.gov |
| NCT03306589 | Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (G… | Phase1 | Arthritis, Rheumatoid | Completed | 2017-08-11 | 2018-06-20 | ClinicalTrials.gov |
| NCT03250832 | Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Partic… | Phase1 | Neoplasms | Completed | 2017-08-08 | 2023-02-13 | ClinicalTrials.gov |
| NCT03250832 | Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Partic… | Phase1 | Neoplasms | Completed | 2017-08-08 | 2023-02-13 | ClinicalTrials.gov |
| NCT03238352 | A Study to Assess Efficacy of an Experimental Oral Rinse in Providing Long Term… | Phase2 | Dentin Sensitivity | Completed | 2017-08-07 | 2017-10-27 | ClinicalTrials.gov |
| NCT03238352 | A Study to Assess Efficacy of an Experimental Oral Rinse in Providing Long Term… | Phase2 | Dentin Sensitivity | Completed | 2017-08-07 | 2017-10-27 | ClinicalTrials.gov |
| NCT03261167 | A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects… | Phase3 | Spasticity, Post-Stroke | Completed | 2017-08-02 | 2019-01-10 | ClinicalTrials.gov |
| NCT03234036 | A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2017-08-02 | 2017-11-10 | ClinicalTrials.gov |
| NCT03234036 | A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2017-08-02 | 2017-11-10 | ClinicalTrials.gov |
| NCT03261167 | A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects… | Phase3 | Spasticity, Post-Stroke | Completed | 2017-08-02 | 2019-01-10 | ClinicalTrials.gov |
| NCT03150082 | Bioequivalence Study Between GR37547 500 Milligrams (mg) Tablet Versus Ciproflo… | Phase1 | Infections, Bacterial | Completed | 2017-08-01 | 2017-08-28 | ClinicalTrials.gov |
| NCT03150082 | Bioequivalence Study Between GR37547 500 Milligrams (mg) Tablet Versus Ciproflo… | Phase1 | Infections, Bacterial | Completed | 2017-08-01 | 2017-08-28 | ClinicalTrials.gov |
| NCT02929498 | Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of … | Phase1 | Myelodysplastic Syndrome | Terminated | 2017-07-31 | 2018-01-31 | ClinicalTrials.gov |
| NCT02929498 | Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of … | Phase1 | Myelodysplastic Syndrome | Terminated | 2017-07-31 | 2018-01-31 | ClinicalTrials.gov |
| NCT03221192 | Qualitative Analysis of Subject Experience of Nasal Polyps | — | Nasal Polyps | Completed | 2017-07-31 | 2018-02-28 | ClinicalTrials.gov |
| NCT03221192 | Qualitative Analysis of Subject Experience of Nasal Polyps | — | Nasal Polyps | Completed | 2017-07-31 | 2018-02-28 | ClinicalTrials.gov |
| NCT03029247 | Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl… | Phase2 | Anaemia | Completed | 2017-07-27 | 2020-07-09 | ClinicalTrials.gov |
| NCT03029247 | Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl… | Phase2 | Anaemia | Completed | 2017-07-27 | 2020-07-09 | ClinicalTrials.gov |
| NCT02542865 | A Study to Investigate the Impact of Fortified Malt Based on Immunity Outcomes … | Na | Growth and Development | Completed | 2017-07-24 | 2018-07-06 | ClinicalTrials.gov |
| NCT03223337 | Daprodustat Hepatic Impairment Study | Phase1 | Anaemia | Completed | 2017-07-24 | 2018-08-20 | ClinicalTrials.gov |
| NCT02542865 | A Study to Investigate the Impact of Fortified Malt Based on Immunity Outcomes … | Na | Growth and Development | Completed | 2017-07-24 | 2018-07-06 | ClinicalTrials.gov |
| NCT03223337 | Daprodustat Hepatic Impairment Study | Phase1 | Anaemia | Completed | 2017-07-24 | 2018-08-20 | ClinicalTrials.gov |
| NCT03150056 | Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Andro… | Phase1 | Solid Tumours | Terminated | 2017-07-18 | 2021-06-22 | ClinicalTrials.gov |
| NCT03150056 | Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Andro… | Phase1 | Solid Tumours | Terminated | 2017-07-18 | 2021-06-22 | ClinicalTrials.gov |
| NCT03131908 | Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembr… | Phase1 | Melanoma and Other Malignant Neoplasms of Skin | Active_Not_Recruiting | 2017-07-17 | 2027-12-31 | ClinicalTrials.gov |
| NCT03131908 | Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembr… | Phase1 | Melanoma and Other Malignant Neoplasms of Skin | Active_Not_Recruiting | 2017-07-17 | 2027-12-31 | ClinicalTrials.gov |
| NCT03235726 | Study of Safety and Drug Levels of CCI15106 Inhalation Powder in Healthy Adults… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2017-07-13 | 2018-06-19 | ClinicalTrials.gov |
| NCT03235726 | Study of Safety and Drug Levels of CCI15106 Inhalation Powder in Healthy Adults… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2017-07-13 | 2018-06-19 | ClinicalTrials.gov |
| NCT03191383 | A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoS… | Phase2 | Respiratory Syncytial Virus Infections | Withdrawn | 2017-07-11 | 2017-07-14 | ClinicalTrials.gov |
| NCT03191383 | A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoS… | Phase2 | Respiratory Syncytial Virus Infections | Withdrawn | 2017-07-11 | 2017-07-14 | ClinicalTrials.gov |
| NCT03044353 | Multiple Treatment Session Study to Assess GSK2398852 Administered Following an… | Phase2 | Amyloidosis | Terminated | 2017-07-10 | 2019-01-03 | ClinicalTrials.gov |
| NCT03160703 | Study to Investigate the Stain Control of Two Stannous Fluoride Dentifrices | Na | Extrinsic Dental Stain | Completed | 2017-07-10 | 2017-08-25 | ClinicalTrials.gov |
| NCT02889809 | Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubert… | Phase4 | Asthma | Completed | 2017-07-10 | 2021-06-04 | ClinicalTrials.gov |
| NCT02889809 | Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubert… | Phase4 | Asthma | Completed | 2017-07-10 | 2021-06-04 | ClinicalTrials.gov |
| NCT03160703 | Study to Investigate the Stain Control of Two Stannous Fluoride Dentifrices | Na | Extrinsic Dental Stain | Completed | 2017-07-10 | 2017-08-25 | ClinicalTrials.gov |
| NCT03044353 | Multiple Treatment Session Study to Assess GSK2398852 Administered Following an… | Phase2 | Amyloidosis | Terminated | 2017-07-10 | 2019-01-03 | ClinicalTrials.gov |
| NCT03271203 | Subject Insights to Understand the Hand Osteoarthritis (HOA) | — | Osteoarthritis | Completed | 2017-07-03 | 2017-10-30 | ClinicalTrials.gov |
| NCT03285191 | Subject Insights to Understand Rheumatoid Arthritis (RA) | — | Arthritis, Rheumatoid | Completed | 2017-07-03 | 2017-08-17 | ClinicalTrials.gov |
| NCT03271203 | Subject Insights to Understand the Hand Osteoarthritis (HOA) | — | Osteoarthritis | Completed | 2017-07-03 | 2017-10-30 | ClinicalTrials.gov |
| NCT03285191 | Subject Insights to Understand Rheumatoid Arthritis (RA) | — | Arthritis, Rheumatoid | Completed | 2017-07-03 | 2017-08-17 | ClinicalTrials.gov |
| NCT04471493 | Pediatric and Ambulatory Research in Infectious Diseases | — | Otitis | Recruiting | 2017-06-26 | 2030-08-02 | ClinicalTrials.gov |
| NCT04471493 | Pediatric and Ambulatory Research in Infectious Diseases | — | Otitis | Recruiting | 2017-06-26 | 2030-08-02 | ClinicalTrials.gov |
| NCT03184987 | A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/… | Phase3 | Asthma | Completed | 2017-06-22 | 2019-06-25 | ClinicalTrials.gov |
| NCT03184987 | A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/… | Phase3 | Asthma | Completed | 2017-06-22 | 2019-06-25 | ClinicalTrials.gov |
| NCT03157583 | A Study to Measure the Sun Protection Factor (SPF) and Ultraviolet-A Protection… | Na | Sunscreening Agents | Completed | 2017-06-21 | 2017-07-07 | ClinicalTrials.gov |
| NCT03157583 | A Study to Measure the Sun Protection Factor (SPF) and Ultraviolet-A Protection… | Na | Sunscreening Agents | Completed | 2017-06-21 | 2017-07-07 | ClinicalTrials.gov |
| NCT03284710 | Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine | Phase1 | HIV Infections | Completed | 2017-06-19 | 2019-12-12 | ClinicalTrials.gov |
| NCT03284710 | Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine | Phase1 | HIV Infections | Completed | 2017-06-19 | 2019-12-12 | ClinicalTrials.gov |
| NCT03235401 | The PAH Disability and Bothersomeness Questionnaire | — | Pulmonary Arterial Hypertension (PAH) | Unknown | 2017-06-16 | 2018-02-01 | ClinicalTrials.gov |
| NCT03235401 | The PAH Disability and Bothersomeness Questionnaire | — | Pulmonary Arterial Hypertension (PAH) | Unknown | 2017-06-16 | 2018-02-01 | ClinicalTrials.gov |
| NCT03034915 | A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeter… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2017-06-16 | 2018-06-18 | ClinicalTrials.gov |
| NCT03034915 | A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeter… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2017-06-16 | 2018-06-18 | ClinicalTrials.gov |
| NCT03189589 | Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy S… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2017-06-15 | 2017-07-24 | ClinicalTrials.gov |
| NCT03189589 | Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy S… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2017-06-15 | 2017-07-24 | ClinicalTrials.gov |
| NCT03069989 | Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants … | Phase1 | Idiopathic Pulmonary Fibrosis | Terminated | 2017-06-13 | 2018-07-18 | ClinicalTrials.gov |
| NCT03069989 | Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants … | Phase1 | Idiopathic Pulmonary Fibrosis | Terminated | 2017-06-13 | 2018-07-18 | ClinicalTrials.gov |
| NCT03114969 | Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and … | — | Pulmonary Disease, Chronic Obstructive | Completed | 2017-06-08 | 2018-03-09 | ClinicalTrials.gov |
| NCT03114969 | Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and … | — | Pulmonary Disease, Chronic Obstructive | Completed | 2017-06-08 | 2018-03-09 | ClinicalTrials.gov |
| NCT03149848 | Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Sub… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2017-06-06 | 2017-09-07 | ClinicalTrials.gov |
| NCT03149848 | Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Sub… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2017-06-06 | 2017-09-07 | ClinicalTrials.gov |
| NCT02778204 | Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infant… | Phase1 | HIV Infections | Completed | 2017-06-05 | 2019-11-20 | ClinicalTrials.gov |
| NCT03041025 | Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis | Phase2 | Scleroderma, Systemic | Completed | 2017-06-05 | 2020-07-07 | ClinicalTrials.gov |
| NCT03041025 | Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis | Phase2 | Scleroderma, Systemic | Completed | 2017-06-05 | 2020-07-07 | ClinicalTrials.gov |
| NCT02778204 | Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infant… | Phase1 | HIV Infections | Completed | 2017-06-05 | 2019-11-20 | ClinicalTrials.gov |
| NCT03161587 | Patient Characteristics and Treatment Modalities in COPD Patients in China | — | Pulmonary Disease, Chronic Obstructive | Completed | 2017-05-31 | 2018-12-31 | ClinicalTrials.gov |
| NCT03161587 | Patient Characteristics and Treatment Modalities in COPD Patients in China | — | Pulmonary Disease, Chronic Obstructive | Completed | 2017-05-31 | 2018-12-31 | ClinicalTrials.gov |
| NCT03136107 | Determination of the Sun Protection Factor (SPF) of a Cosmetic Daily De-fence S… | Na | Sunscreening Agents | Completed | 2017-05-30 | 2017-06-30 | ClinicalTrials.gov |
| NCT03136107 | Determination of the Sun Protection Factor (SPF) of a Cosmetic Daily De-fence S… | Na | Sunscreening Agents | Completed | 2017-05-30 | 2017-06-30 | ClinicalTrials.gov |
| NCT03085797 | Effect of Mepolizumab in Severe Bilateral Nasal Polyps | Phase3 | Nasal Polyps | Completed | 2017-05-25 | 2019-12-11 | ClinicalTrials.gov |
| NCT03085797 | Effect of Mepolizumab in Severe Bilateral Nasal Polyps | Phase3 | Nasal Polyps | Completed | 2017-05-25 | 2019-12-11 | ClinicalTrials.gov |
| NCT03155269 | To Investigate the Impact of a Nutritional Supplement on Bone Turnover Markers … | Na | Growth and Development | Completed | 2017-05-25 | 2018-01-16 | ClinicalTrials.gov |
| NCT03155269 | To Investigate the Impact of a Nutritional Supplement on Bone Turnover Markers … | Na | Growth and Development | Completed | 2017-05-25 | 2018-01-16 | ClinicalTrials.gov |
| NCT03162614 | Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria… | Phase2 | Malaria | Completed | 2017-05-24 | 2018-09-24 | ClinicalTrials.gov |
| NCT03162614 | Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria… | Phase2 | Malaria | Completed | 2017-05-24 | 2018-09-24 | ClinicalTrials.gov |
| NCT03233009 | To Investigate Primary Irritation Potential of Four Skin Serum Products on Huma… | Na | Skin Care | Completed | 2017-05-22 | 2017-05-26 | ClinicalTrials.gov |
| NCT03233009 | To Investigate Primary Irritation Potential of Four Skin Serum Products on Huma… | Na | Skin Care | Completed | 2017-05-22 | 2017-05-26 | ClinicalTrials.gov |
| NCT03000686 | Study of GSK2586881 on Acute Hypoxia and Exercise | Phase1 | Healthy Volunteers | Terminated | 2017-05-17 | 2019-01-04 | ClinicalTrials.gov |
| NCT03000686 | Study of GSK2586881 on Acute Hypoxia and Exercise | Phase1 | Healthy Volunteers | Terminated | 2017-05-17 | 2019-01-04 | ClinicalTrials.gov |
| NCT03154086 | A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarrange… | Phase1 | Irritable Bowel Syndrome | Completed | 2017-05-17 | 2018-03-05 | ClinicalTrials.gov |
| NCT03154086 | A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarrange… | Phase1 | Irritable Bowel Syndrome | Completed | 2017-05-17 | 2018-03-05 | ClinicalTrials.gov |
| NCT03029208 | Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prol… | Phase3 | Anaemia | Completed | 2017-05-11 | 2020-09-24 | ClinicalTrials.gov |
| NCT03029208 | Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prol… | Phase3 | Anaemia | Completed | 2017-05-11 | 2020-09-24 | ClinicalTrials.gov |
| NCT02699099 | Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine G… | Phase3 | Malaria | Completed | 2017-05-10 | 2020-10-07 | ClinicalTrials.gov |
| NCT02699099 | Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine G… | Phase3 | Malaria | Completed | 2017-05-10 | 2020-10-07 | ClinicalTrials.gov |
| NCT03103906 | Evaluation of the Cosmetic Benefit of a Skin Cream in Healthy Females With Mild… | Na | Skin Care | Completed | 2017-05-10 | 2017-07-19 | ClinicalTrials.gov |
| NCT03136380 | Study of Danirixin in Japanese Healthy Elderly Male Subjects | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2017-05-10 | 2017-07-31 | ClinicalTrials.gov |
| NCT03136380 | Study of Danirixin in Japanese Healthy Elderly Male Subjects | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2017-05-10 | 2017-07-31 | ClinicalTrials.gov |
| NCT03103906 | Evaluation of the Cosmetic Benefit of a Skin Cream in Healthy Females With Mild… | Na | Skin Care | Completed | 2017-05-10 | 2017-07-19 | ClinicalTrials.gov |
| NCT03146754 | A Study to Evaluate Lung Ultrasound as a Method to Measure Changes in Extravasc… | Na | Acute Decompensated Heart Failure | Completed | 2017-05-04 | 2023-01-01 | ClinicalTrials.gov |
| NCT03099096 | Study of Mepolizumab Autoinjector in Asthmatics | Phase3 | Asthma | Completed | 2017-05-04 | 2017-11-30 | ClinicalTrials.gov |
| NCT03099096 | Study of Mepolizumab Autoinjector in Asthmatics | Phase3 | Asthma | Completed | 2017-05-04 | 2017-11-30 | ClinicalTrials.gov |
| NCT03146754 | A Study to Evaluate Lung Ultrasound as a Method to Measure Changes in Extravasc… | Na | Acute Decompensated Heart Failure | Completed | 2017-05-04 | 2023-01-01 | ClinicalTrials.gov |
| NCT03095638 | Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional… | Phase1 | HIV Infections | Completed | 2017-05-03 | 2017-06-23 | ClinicalTrials.gov |
| NCT03095638 | Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional… | Phase1 | HIV Infections | Completed | 2017-05-03 | 2017-06-23 | ClinicalTrials.gov |
| NCT02939846 | Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subje… | Phase1 | Cancer | Withdrawn | 2017-05-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT02447939 | Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabr… | Phase1 | Melanoma | Withdrawn | 2017-05-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT02447939 | Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabr… | Phase1 | Melanoma | Withdrawn | 2017-05-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT02939846 | Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subje… | Phase1 | Cancer | Withdrawn | 2017-05-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT03075410 | First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656… | Phase1 | Tuberculosis | Completed | 2017-04-02 | 2017-08-04 | ClinicalTrials.gov |
| NCT03075410 | First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656… | Phase1 | Tuberculosis | Completed | 2017-04-02 | 2017-08-04 | ClinicalTrials.gov |
| NCT03183518 | To Assess the Photosensitisation and Photoallergy Potential of a Cosmetic Facia… | Na | Skin Care | Completed | 2017-03-27 | 2017-05-19 | ClinicalTrials.gov |
| NCT03078556 | Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and L… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2017-03-27 | 2017-08-18 | ClinicalTrials.gov |
| NCT03078556 | Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and L… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2017-03-27 | 2017-08-18 | ClinicalTrials.gov |
| NCT03183518 | To Assess the Photosensitisation and Photoallergy Potential of a Cosmetic Facia… | Na | Skin Care | Completed | 2017-03-27 | 2017-05-19 | ClinicalTrials.gov |
| NCT03175562 | To Assess the Cutaneous Irritation and Sensitization Potential of a Cosmetic Fa… | Na | Skin Care | Completed | 2017-03-27 | 2017-05-19 | ClinicalTrials.gov |
| NCT03175562 | To Assess the Cutaneous Irritation and Sensitization Potential of a Cosmetic Fa… | Na | Skin Care | Completed | 2017-03-27 | 2017-05-19 | ClinicalTrials.gov |
| NCT03180645 | Proof of Concept Anti-ageing Clinical Study in Healthy Subjects | Na | Skin Aging | Completed | 2017-03-20 | 2017-04-21 | ClinicalTrials.gov |
| NCT03180645 | Proof of Concept Anti-ageing Clinical Study in Healthy Subjects | Na | Skin Aging | Completed | 2017-03-20 | 2017-04-21 | ClinicalTrials.gov |
| NCT03031496 | Bioequivalence Study Between GSK3542503 Hydrochlorothiazide + Amiloride Hydroch… | Phase1 | Hypertension | Completed | 2017-03-17 | 2017-04-10 | ClinicalTrials.gov |
| NCT03045861 | Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1… | Phase2 | Infection, Human Immunodeficiency Virus | Completed | 2017-03-17 | 2018-04-23 | ClinicalTrials.gov |
| NCT03031496 | Bioequivalence Study Between GSK3542503 Hydrochlorothiazide + Amiloride Hydroch… | Phase1 | Hypertension | Completed | 2017-03-17 | 2017-04-10 | ClinicalTrials.gov |
| NCT03045861 | Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1… | Phase2 | Infection, Human Immunodeficiency Virus | Completed | 2017-03-17 | 2018-04-23 | ClinicalTrials.gov |
| NCT03089879 | A Study to Evaluate Safety and Immunogenicity of 1 Booster Dose of 1790GAHB Vac… | Phase1 | Dysentery, Bacillary | Completed | 2017-03-16 | 2017-08-31 | ClinicalTrials.gov |
| NCT03089879 | A Study to Evaluate Safety and Immunogenicity of 1 Booster Dose of 1790GAHB Vac… | Phase1 | Dysentery, Bacillary | Completed | 2017-03-16 | 2017-08-31 | ClinicalTrials.gov |
| NCT03028207 | A Cross-sectional Study on COPD Prevalence | — | Pulmonary Disease, Chronic Obstructive | Completed | 2017-03-09 | 2019-03-01 | ClinicalTrials.gov |
| NCT03028207 | A Cross-sectional Study on COPD Prevalence | — | Pulmonary Disease, Chronic Obstructive | Completed | 2017-03-09 | 2019-03-01 | ClinicalTrials.gov |
| NCT02836496 | Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophi… | Phase3 | Hypereosinophilic Syndrome | Completed | 2017-03-07 | 2019-08-08 | ClinicalTrials.gov |
| NCT02937870 | A Bite Force Study Comparing Two New Test Adhesives With Currently Marketed Den… | Na | Denture Retention | Completed | 2017-03-07 | 2017-04-05 | ClinicalTrials.gov |
| NCT02836496 | Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophi… | Phase3 | Hypereosinophilic Syndrome | Completed | 2017-03-07 | 2019-08-08 | ClinicalTrials.gov |
| NCT02937870 | A Bite Force Study Comparing Two New Test Adhesives With Currently Marketed Den… | Na | Denture Retention | Completed | 2017-03-07 | 2017-04-05 | ClinicalTrials.gov |
| NCT03076164 | A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung… | Phase1 | Lung Adenocarcinoma | Completed | 2017-03-01 | 2020-12-18 | ClinicalTrials.gov |
| NCT03076164 | A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung… | Phase1 | Lung Adenocarcinoma | Completed | 2017-03-01 | 2020-12-18 | ClinicalTrials.gov |
| NCT02981602 | Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in… | Phase2 | Hepatitis B | Completed | 2017-02-24 | 2019-12-26 | ClinicalTrials.gov |
| NCT02981602 | Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in… | Phase2 | Hepatitis B | Completed | 2017-02-24 | 2019-12-26 | ClinicalTrials.gov |
| NCT03216265 | A Proof of Concept Clinical Study to Investigate the Effects of an Experimental… | Na | Skin Care | Completed | 2017-02-23 | 2017-04-24 | ClinicalTrials.gov |
| NCT03216265 | A Proof of Concept Clinical Study to Investigate the Effects of an Experimental… | Na | Skin Care | Completed | 2017-02-23 | 2017-04-24 | ClinicalTrials.gov |
| NCT02987465 | Evaluating the Effect of Standard-of-care Erythropoiesis-stimulating Agents on … | — | Cardiovascular Diseases | Completed | 2017-02-20 | 2018-05-21 | ClinicalTrials.gov |
| NCT03046069 | FF/UMEC/VI Inhaler: Qualitative Analysis and Subject Preference Survey | — | Pulmonary Disease, Chronic Obstructive | Completed | 2017-02-20 | 2018-02-23 | ClinicalTrials.gov |
| NCT03046069 | FF/UMEC/VI Inhaler: Qualitative Analysis and Subject Preference Survey | — | Pulmonary Disease, Chronic Obstructive | Completed | 2017-02-20 | 2018-02-23 | ClinicalTrials.gov |
| NCT02987465 | Evaluating the Effect of Standard-of-care Erythropoiesis-stimulating Agents on … | — | Cardiovascular Diseases | Completed | 2017-02-20 | 2018-05-21 | ClinicalTrials.gov |
| NCT02868970 | Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfacti… | Phase4 | Healthy | Completed | 2017-02-15 | 2021-07-05 | ClinicalTrials.gov |
| NCT02868970 | Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfacti… | Phase4 | Healthy | Completed | 2017-02-15 | 2021-07-05 | ClinicalTrials.gov |
| NCT03020745 | A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacod… | Phase2 | Hepatitis B | Completed | 2017-02-14 | 2019-11-06 | ClinicalTrials.gov |
| NCT03020745 | A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacod… | Phase2 | Hepatitis B | Completed | 2017-02-14 | 2019-11-06 | ClinicalTrials.gov |
| NCT03037307 | A Clinical Bite Force Study of Two Marketed Adhesives Against no Adhesive | Na | Denture Retention | Completed | 2017-02-13 | 2017-05-04 | ClinicalTrials.gov |
| NCT03004846 | A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis | Phase1 | Psoriasis | Completed | 2017-02-13 | 2017-05-05 | ClinicalTrials.gov |
| NCT03037307 | A Clinical Bite Force Study of Two Marketed Adhesives Against no Adhesive | Na | Denture Retention | Completed | 2017-02-13 | 2017-05-04 | ClinicalTrials.gov |
| NCT03004846 | A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis | Phase1 | Psoriasis | Completed | 2017-02-13 | 2017-05-05 | ClinicalTrials.gov |
| NCT02991859 | Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for … | Phase2 | Asthma | Completed | 2017-02-09 | 2018-12-20 | ClinicalTrials.gov |
| NCT02991859 | Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for … | Phase2 | Asthma | Completed | 2017-02-09 | 2018-12-20 | ClinicalTrials.gov |
| NCT03348774 | Scrutinizing the Heterogeneity of SLE: Defining Phenotypes | — | Systemic Lupus Erythematosus | Unknown | 2017-02-09 | 2018-07-30 | ClinicalTrials.gov |
| NCT03348774 | Scrutinizing the Heterogeneity of SLE: Defining Phenotypes | — | Systemic Lupus Erythematosus | Unknown | 2017-02-09 | 2018-07-30 | ClinicalTrials.gov |
| NCT02563496 | A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric … | Phase2 | Malaria, Vivax | Completed | 2017-02-06 | 2020-02-17 | ClinicalTrials.gov |
| NCT03045887 | Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292… | Phase1 | Asthma | Completed | 2017-02-06 | 2017-08-16 | ClinicalTrials.gov |
| NCT03045887 | Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292… | Phase1 | Asthma | Completed | 2017-02-06 | 2017-08-16 | ClinicalTrials.gov |
| NCT02563496 | A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric … | Phase2 | Malaria, Vivax | Completed | 2017-02-06 | 2020-02-17 | ClinicalTrials.gov |
| NCT02730364 | An Efficacy and Safety Study of Theraflu Night Powder as Oral Solution for Cold… | Phase3 | Infections, Respiratory Tract | Withdrawn | 2017-02-01 | 2017-04-01 | ClinicalTrials.gov |
| NCT02730364 | An Efficacy and Safety Study of Theraflu Night Powder as Oral Solution for Cold… | Phase3 | Infections, Respiratory Tract | Withdrawn | 2017-02-01 | 2017-04-01 | ClinicalTrials.gov |
| NCT02979626 | Evaluation of Moderate to Severe Influenza Outcomes in Children | — | Influenza | Completed | 2017-01-30 | 2018-05-05 | ClinicalTrials.gov |
| NCT02979626 | Evaluation of Moderate to Severe Influenza Outcomes in Children | — | Influenza | Completed | 2017-01-30 | 2018-05-05 | ClinicalTrials.gov |
| NCT03012061 | Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With … | Phase2 | Asthma | Completed | 2017-01-25 | 2018-05-30 | ClinicalTrials.gov |
| NCT03012061 | Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With … | Phase2 | Asthma | Completed | 2017-01-25 | 2018-05-30 | ClinicalTrials.gov |
| NCT03028467 | Evaluation of Pharmacokinetics and Safety of GSK3196165 in Combination With Met… | Phase1 | Arthritis, Rheumatoid | Completed | 2017-01-24 | 2017-12-20 | ClinicalTrials.gov |
| NCT03028467 | Evaluation of Pharmacokinetics and Safety of GSK3196165 in Combination With Met… | Phase1 | Arthritis, Rheumatoid | Completed | 2017-01-24 | 2017-12-20 | ClinicalTrials.gov |
| NCT02880852 | Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus | Phase1 | Systemic Lupus Erythematosus | Completed | 2017-01-23 | 2017-09-08 | ClinicalTrials.gov |
| NCT03408678 | Determinants of Type 2 Diabetes Risk in Middle-aged Black South African Men and… | — | Diabetes Mellitus, Type 2 | Completed | 2017-01-23 | 2018-07-31 | ClinicalTrials.gov |
| NCT02880852 | Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus | Phase1 | Systemic Lupus Erythematosus | Completed | 2017-01-23 | 2017-09-08 | ClinicalTrials.gov |
| NCT03408678 | Determinants of Type 2 Diabetes Risk in Middle-aged Black South African Men and… | — | Diabetes Mellitus, Type 2 | Completed | 2017-01-23 | 2018-07-31 | ClinicalTrials.gov |
| NCT02927431 | Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Ose… | Phase2 | Virus Diseases | Terminated | 2017-01-19 | 2017-05-24 | ClinicalTrials.gov |
| NCT02927431 | Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Ose… | Phase2 | Virus Diseases | Terminated | 2017-01-19 | 2017-05-24 | ClinicalTrials.gov |
| NCT02979639 | Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After … | Phase3 | Herpes Zoster | Completed | 2017-01-16 | 2018-05-24 | ClinicalTrials.gov |
| NCT02979639 | Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After … | Phase3 | Herpes Zoster | Completed | 2017-01-16 | 2018-05-24 | ClinicalTrials.gov |
| NCT02927457 | Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of… | Phase1 | Lupus Erythematosus, Cutaneous | Completed | 2017-01-13 | 2018-06-12 | ClinicalTrials.gov |
| NCT02927457 | Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of… | Phase1 | Lupus Erythematosus, Cutaneous | Completed | 2017-01-13 | 2018-06-12 | ClinicalTrials.gov |
| NCT02966834 | Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants… | Phase2 | Cholestasis | Completed | 2017-01-11 | 2020-04-15 | ClinicalTrials.gov |
| NCT03028480 | Long Term Special Drug Use Investigation of Mepolizumab | — | Asthma | Completed | 2017-01-11 | 2023-11-22 | ClinicalTrials.gov |
| NCT02927873 | A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biological… | Phase1 | Respiratory Syncytial Virus Infections | Completed | 2017-01-11 | 2020-11-26 | ClinicalTrials.gov |
| NCT02966834 | Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants… | Phase2 | Cholestasis | Completed | 2017-01-11 | 2020-04-15 | ClinicalTrials.gov |
| NCT02927873 | A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biological… | Phase1 | Respiratory Syncytial Virus Infections | Completed | 2017-01-11 | 2020-11-26 | ClinicalTrials.gov |
| NCT03028480 | Long Term Special Drug Use Investigation of Mepolizumab | — | Asthma | Completed | 2017-01-11 | 2023-11-22 | ClinicalTrials.gov |
| NCT02798978 | A Phase I, 2-part (Part 1 Being a Single Dose Escalation and Part 2, a Parallel… | Phase1 | Cancer | Completed | 2017-01-10 | 2017-10-13 | ClinicalTrials.gov |
| NCT02798978 | A Phase I, 2-part (Part 1 Being a Single Dose Escalation and Part 2, a Parallel… | Phase1 | Cancer | Completed | 2017-01-10 | 2017-10-13 | ClinicalTrials.gov |
| NCT03178968 | Can Surface Roughness Predict Progression of Tooth Wear? | Na | Tooth Wear | Completed | 2017-01-10 | 2017-05-29 | ClinicalTrials.gov |
| NCT03178968 | Can Surface Roughness Predict Progression of Tooth Wear? | Na | Tooth Wear | Completed | 2017-01-10 | 2017-05-29 | ClinicalTrials.gov |
| NCT03014674 | A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Sa… | Phase3 | Asthma | Completed | 2017-01-06 | 2017-08-11 | ClinicalTrials.gov |
| NCT03014674 | A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Sa… | Phase3 | Asthma | Completed | 2017-01-06 | 2017-08-11 | ClinicalTrials.gov |
| NCT02982187 | A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Prefere… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2016-12-30 | 2017-06-19 | ClinicalTrials.gov |
| NCT02982187 | A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Prefere… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2016-12-30 | 2017-06-19 | ClinicalTrials.gov |
| NCT03005067 | To Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Participants … | Phase2 | Common Cold | Completed | 2016-12-29 | 2017-06-07 | ClinicalTrials.gov |
| NCT03005067 | To Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Participants … | Phase2 | Common Cold | Completed | 2016-12-29 | 2017-06-07 | ClinicalTrials.gov |
| NCT02965599 | Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK311… | Phase2 | Arthritis, Rheumatoid | Terminated | 2016-12-27 | 2017-11-14 | ClinicalTrials.gov |
| NCT02965599 | Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK311… | Phase2 | Arthritis, Rheumatoid | Terminated | 2016-12-27 | 2017-11-14 | ClinicalTrials.gov |
| NCT02991872 | A Study to Evaluate Persistence of Immune Responses After Post-exposure Prophyl… | Phase4 | Virus Diseases | Completed | 2016-12-16 | 2017-03-12 | ClinicalTrials.gov |
| NCT02991872 | A Study to Evaluate Persistence of Immune Responses After Post-exposure Prophyl… | Phase4 | Virus Diseases | Completed | 2016-12-16 | 2017-03-12 | ClinicalTrials.gov |
| NCT02992743 | Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants Wi… | Phase2 | Neoplasms | Completed | 2016-12-06 | 2022-03-22 | ClinicalTrials.gov |
| NCT02992743 | Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants Wi… | Phase2 | Neoplasms | Completed | 2016-12-06 | 2022-03-22 | ClinicalTrials.gov |
| NCT02833974 | Effect of the GSK2245035 on the Allergen-induced Asthmatic Response | Phase2 | Asthma | Completed | 2016-12-05 | 2018-05-04 | ClinicalTrials.gov |
| NCT02833974 | Effect of the GSK2245035 on the Allergen-induced Asthmatic Response | Phase2 | Asthma | Completed | 2016-12-05 | 2018-05-04 | ClinicalTrials.gov |
| NCT02977078 | Improving Asthma Treatment Using Inhaler Technology | Na | Asthma | Unknown | 2016-12-01 | 2018-04-01 | ClinicalTrials.gov |
| NCT02977078 | Improving Asthma Treatment Using Inhaler Technology | Na | Asthma | Unknown | 2016-12-01 | 2018-04-01 | ClinicalTrials.gov |
| NCT02986984 | Transformative Research in Diabetic Nephropathy | — | Diabetic Nephropathies | Recruiting | 2016-12-01 | 2027-06-01 | ClinicalTrials.gov |
| NCT02986984 | Transformative Research in Diabetic Nephropathy | — | Diabetic Nephropathies | Recruiting | 2016-12-01 | 2027-06-01 | ClinicalTrials.gov |
| NCT02999100 | Comparison of Inhaled Oxytocin (IH) With Intramuscular (IM) Oxytocin in Pregnan… | Phase1 | Postpartum Hemorrhage | Terminated | 2016-11-23 | 2019-03-04 | ClinicalTrials.gov |
| NCT02999100 | Comparison of Inhaled Oxytocin (IH) With Intramuscular (IM) Oxytocin in Pregnan… | Phase1 | Postpartum Hemorrhage | Terminated | 2016-11-23 | 2019-03-04 | ClinicalTrials.gov |
| NCT02937623 | To Evaluate the Efficacy of an Experimental Dissolvable Strip in Rapidly Reliev… | Na | Dentin Sensitivity | Completed | 2016-11-21 | 2016-12-22 | ClinicalTrials.gov |
| NCT02937623 | To Evaluate the Efficacy of an Experimental Dissolvable Strip in Rapidly Reliev… | Na | Dentin Sensitivity | Completed | 2016-11-21 | 2016-12-22 | ClinicalTrials.gov |
| NCT02903966 | GSK2982772 Study in Subjects With Ulcerative Colitis | Phase2 | Colitis, Ulcerative | Completed | 2016-11-15 | 2019-06-17 | ClinicalTrials.gov |
| NCT02903966 | GSK2982772 Study in Subjects With Ulcerative Colitis | Phase2 | Colitis, Ulcerative | Completed | 2016-11-15 | 2019-06-17 | ClinicalTrials.gov |
| NCT02946385 | Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Y… | Phase2 | Infections, Meningococcal | Completed | 2016-11-15 | 2018-02-13 | ClinicalTrials.gov |
| NCT02946385 | Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Y… | Phase2 | Infections, Meningococcal | Completed | 2016-11-15 | 2018-02-13 | ClinicalTrials.gov |
| NCT02956837 | A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologica… | Phase2 | Respiratory Syncytial Virus Infections | Completed | 2016-11-10 | 2018-02-05 | ClinicalTrials.gov |
| NCT02956837 | A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologica… | Phase2 | Respiratory Syncytial Virus Infections | Completed | 2016-11-10 | 2018-02-05 | ClinicalTrials.gov |
| NCT02924350 | The Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hyper… | Na | Dentin Sensitivity | Completed | 2016-11-07 | 2017-03-17 | ClinicalTrials.gov |
| NCT02924350 | The Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hyper… | Na | Dentin Sensitivity | Completed | 2016-11-07 | 2017-03-17 | ClinicalTrials.gov |
| NCT02974114 | Exploratory Study to Investigate Cognition Function and Mobility in Individuals… | Phase4 | Pain | Terminated | 2016-10-31 | 2017-02-06 | ClinicalTrials.gov |
| NCT02974114 | Exploratory Study to Investigate Cognition Function and Mobility in Individuals… | Phase4 | Pain | Terminated | 2016-10-31 | 2017-02-06 | ClinicalTrials.gov |
| NCT02951052 | Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-ac… | Phase3 | Infection, Human Immunodeficiency Virus | Active_Not_Recruiting | 2016-10-28 | 2029-12-31 | ClinicalTrials.gov |
| NCT02951052 | Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-ac… | Phase3 | Infection, Human Immunodeficiency Virus | Active_Not_Recruiting | 2016-10-28 | 2029-12-31 | ClinicalTrials.gov |
| NCT02938520 | Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramu… | Phase3 | HIV Infections | Active_Not_Recruiting | 2016-10-27 | 2029-12-31 | ClinicalTrials.gov |
| NCT02938520 | Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramu… | Phase3 | HIV Infections | Active_Not_Recruiting | 2016-10-27 | 2029-12-31 | ClinicalTrials.gov |
| NCT02914184 | Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals'… | Phase3 | Infections, Rotavirus | Completed | 2016-10-27 | 2018-11-26 | ClinicalTrials.gov |
| NCT02914184 | Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals'… | Phase3 | Infections, Rotavirus | Completed | 2016-10-27 | 2018-11-26 | ClinicalTrials.gov |
| NCT02968849 | Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and … | Phase2 | HIV Infections | Completed | 2016-10-26 | 2021-11-16 | ClinicalTrials.gov |
| NCT02968849 | Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and … | Phase2 | HIV Infections | Completed | 2016-10-26 | 2021-11-16 | ClinicalTrials.gov |
| NCT02663102 | Evaluation of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal I… | — | Influenza, Human | Completed | 2016-10-20 | 2021-02-05 | ClinicalTrials.gov |
| NCT02663102 | Evaluation of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal I… | — | Influenza, Human | Completed | 2016-10-20 | 2021-02-05 | ClinicalTrials.gov |
| NCT02858492 | Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Effic… | Phase2 | Arthritis, Rheumatoid | Completed | 2016-10-17 | 2018-10-22 | ClinicalTrials.gov |
| NCT02858492 | Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Effic… | Phase2 | Arthritis, Rheumatoid | Completed | 2016-10-17 | 2018-10-22 | ClinicalTrials.gov |
| NCT02924688 | A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerabili… | Phase3 | Asthma | Completed | 2016-10-13 | 2019-02-22 | ClinicalTrials.gov |
| NCT02924688 | A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerabili… | Phase3 | Asthma | Completed | 2016-10-13 | 2019-02-22 | ClinicalTrials.gov |
| NCT02849418 | Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incon… | Phase3 | Urinary Bladder, Overactive | Completed | 2016-10-11 | 2018-12-20 | ClinicalTrials.gov |
| NCT02923895 | To Investigate the Efficacy of an Occluding Dentifrice in Dentinal Hypersensiti… | Phase4 | Dentin Sensitivity | Completed | 2016-10-11 | 2016-12-16 | ClinicalTrials.gov |
| NCT02849418 | Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incon… | Phase3 | Urinary Bladder, Overactive | Completed | 2016-10-11 | 2018-12-20 | ClinicalTrials.gov |
| NCT02923895 | To Investigate the Efficacy of an Occluding Dentifrice in Dentinal Hypersensiti… | Phase4 | Dentin Sensitivity | Completed | 2016-10-11 | 2016-12-16 | ClinicalTrials.gov |
| NCT03478644 | Oral and Dermal Tolerability Clinical Study of an Experimental Denture Wipe | Na | Denture Cleansers | Completed | 2016-10-10 | 2016-10-31 | ClinicalTrials.gov |
| NCT03478644 | Oral and Dermal Tolerability Clinical Study of an Experimental Denture Wipe | Na | Denture Cleansers | Completed | 2016-10-10 | 2016-10-31 | ClinicalTrials.gov |
| NCT02972905 | Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Ja… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2016-10-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02925546 | A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets | Phase1 | Heart Failure, Congestive | Completed | 2016-10-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02972905 | Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Ja… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2016-10-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02925546 | A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets | Phase1 | Heart Failure, Congestive | Completed | 2016-10-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02879305 | Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hyd… | Phase3 | Anaemia | Completed | 2016-09-28 | 2020-11-09 | ClinicalTrials.gov |
| NCT02879305 | Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hyd… | Phase3 | Anaemia | Completed | 2016-09-28 | 2020-11-09 | ClinicalTrials.gov |
| NCT02861664 | Assessment of the Efficacy of an Experimental Occlusion Technology Dentifrice i… | Na | Dentin Sensitivity | Completed | 2016-09-21 | 2016-12-24 | ClinicalTrials.gov |
| NCT02861664 | Assessment of the Efficacy of an Experimental Occlusion Technology Dentifrice i… | Na | Dentin Sensitivity | Completed | 2016-09-21 | 2016-12-24 | ClinicalTrials.gov |
| NCT02802514 | A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Ac… | Phase4 | Diabetes Mellitus | Terminated | 2016-09-20 | 2017-09-07 | ClinicalTrials.gov |
| NCT02802514 | A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Ac… | Phase4 | Diabetes Mellitus | Terminated | 2016-09-20 | 2017-09-07 | ClinicalTrials.gov |
| NCT02853929 | Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in … | Phase4 | Diphtheria | Completed | 2016-09-19 | 2019-03-19 | ClinicalTrials.gov |
| NCT02853929 | Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in … | Phase4 | Diphtheria | Completed | 2016-09-19 | 2019-03-19 | ClinicalTrials.gov |
| NCT02907216 | Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis a… | Phase4 | Rotavirus | Completed | 2016-09-16 | 2017-05-29 | ClinicalTrials.gov |
| NCT02907216 | Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis a… | Phase4 | Rotavirus | Completed | 2016-09-16 | 2017-05-29 | ClinicalTrials.gov |
| NCT03005041 | Consumer Perception of an Experimental Mouthwash After a Single Use in Dry Mout… | Na | Xerostomia | Completed | 2016-08-31 | 2016-10-19 | ClinicalTrials.gov |
| NCT03005041 | Consumer Perception of an Experimental Mouthwash After a Single Use in Dry Mout… | Na | Xerostomia | Completed | 2016-08-31 | 2016-10-19 | ClinicalTrials.gov |
| NCT02776033 | Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repea… | Phase2 | Psoriasis | Completed | 2016-08-30 | 2018-01-04 | ClinicalTrials.gov |
| NCT02776033 | Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repea… | Phase2 | Psoriasis | Completed | 2016-08-30 | 2018-01-04 | ClinicalTrials.gov |
| NCT02723786 | Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of GSK1070806 for… | Phase2 | Kidney Transplantation (Status Post) | Terminated | 2016-08-27 | 2018-03-06 | ClinicalTrials.gov |
| NCT02723786 | Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of GSK1070806 for… | Phase2 | Kidney Transplantation (Status Post) | Terminated | 2016-08-27 | 2018-03-06 | ClinicalTrials.gov |
| NCT02868281 | Asthma Control Test Guided Treatment in Chinese Subjects | Phase4 | Asthma | Completed | 2016-08-26 | 2019-08-09 | ClinicalTrials.gov |
| NCT02868281 | Asthma Control Test Guided Treatment in Chinese Subjects | Phase4 | Asthma | Completed | 2016-08-26 | 2019-08-09 | ClinicalTrials.gov |
| NCT02829307 | A Positron Emission Tomography (PET) Imaging Study to Investigate the Biodistri… | Phase1 | Drug-Related Side Effects and Adverse Reactions | Completed | 2016-08-23 | 2017-01-27 | ClinicalTrials.gov |
| NCT02798952 | A Study to Evaluate Persistence of Hepatitis B Antibodies, Immunogenicity and S… | Phase4 | Hepatitis B | Completed | 2016-08-23 | 2017-07-05 | ClinicalTrials.gov |
| NCT02829307 | A Positron Emission Tomography (PET) Imaging Study to Investigate the Biodistri… | Phase1 | Drug-Related Side Effects and Adverse Reactions | Completed | 2016-08-23 | 2017-01-27 | ClinicalTrials.gov |
| NCT02798952 | A Study to Evaluate Persistence of Hepatitis B Antibodies, Immunogenicity and S… | Phase4 | Hepatitis B | Completed | 2016-08-23 | 2017-07-05 | ClinicalTrials.gov |
| NCT02794480 | Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Mete… | Phase4 | Asthma | Completed | 2016-08-22 | 2016-12-15 | ClinicalTrials.gov |
| NCT02794480 | Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Mete… | Phase4 | Asthma | Completed | 2016-08-22 | 2016-12-15 | ClinicalTrials.gov |
| NCT02820844 | Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder | Phase3 | Urinary Bladder, Overactive | Completed | 2016-08-10 | 2018-11-12 | ClinicalTrials.gov |
| NCT02820844 | Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder | Phase3 | Urinary Bladder, Overactive | Completed | 2016-08-10 | 2018-11-12 | ClinicalTrials.gov |
| NCT02829320 | Efficacy and Safety Study of GSK1278863 in Japanese Hemodialysis Subjects With … | Phase3 | Anaemia | Completed | 2016-08-08 | 2017-10-17 | ClinicalTrials.gov |
| NCT02829320 | Efficacy and Safety Study of GSK1278863 in Japanese Hemodialysis Subjects With … | Phase3 | Anaemia | Completed | 2016-08-08 | 2017-10-17 | ClinicalTrials.gov |
| NCT02676895 | A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine … | Phase2 | Shigella Sonnei Infection | Completed | 2016-08-08 | 2017-03-10 | ClinicalTrials.gov |
| NCT02676895 | A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine … | Phase2 | Shigella Sonnei Infection | Completed | 2016-08-08 | 2017-03-10 | ClinicalTrials.gov |
| NCT02853435 | To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tabl… | Phase1 | Infections, Bacterial | Completed | 2016-08-04 | 2017-10-17 | ClinicalTrials.gov |
| NCT02853435 | To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tabl… | Phase1 | Infections, Bacterial | Completed | 2016-08-04 | 2017-10-17 | ClinicalTrials.gov |
| NCT02925234 | The Drug Rediscovery Protocol (DRUP Trial) | Phase2 | Cancer | Recruiting | 2016-08-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT02985450 | A Prospective Study of HBV Immunity and HBV Vaccination in Patients With NAFLD … | — | Non-Alcoholic Fatty Liver Disease | Completed | 2016-08-01 | 2021-01-01 | ClinicalTrials.gov |
| NCT02985450 | A Prospective Study of HBV Immunity and HBV Vaccination in Patients With NAFLD … | — | Non-Alcoholic Fatty Liver Disease | Completed | 2016-08-01 | 2021-01-01 | ClinicalTrials.gov |
| NCT02925234 | The Drug Rediscovery Protocol (DRUP Trial) | Phase2 | Cancer | Recruiting | 2016-08-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT02928380 | Evaluation of a Experimental Denture Adhesive to Prevent Food Ingress | Na | Denture Retention | Completed | 2016-07-25 | 2016-09-16 | ClinicalTrials.gov |
| NCT02801942 | Immune Profile in Subjects With New Onset Type 1 Diabetes | Na | Diabetes Mellitus, Type 1 | Completed | 2016-07-25 | 2017-12-21 | ClinicalTrials.gov |
| NCT02928380 | Evaluation of a Experimental Denture Adhesive to Prevent Food Ingress | Na | Denture Retention | Completed | 2016-07-25 | 2016-09-16 | ClinicalTrials.gov |
| NCT02801942 | Immune Profile in Subjects With New Onset Type 1 Diabetes | Na | Diabetes Mellitus, Type 1 | Completed | 2016-07-25 | 2017-12-21 | ClinicalTrials.gov |
| NCT02593539 | Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of … | Phase2 | Activated PI3K-delta Syndrome | Completed | 2016-07-22 | 2020-06-04 | ClinicalTrials.gov |
| NCT02593539 | Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of … | Phase2 | Activated PI3K-delta Syndrome | Completed | 2016-07-22 | 2020-06-04 | ClinicalTrials.gov |
| NCT02831673 | An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivud… | Phase3 | Infection, Human Immunodeficiency Virus | Completed | 2016-07-21 | 2022-08-15 | ClinicalTrials.gov |
| NCT02831673 | An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivud… | Phase3 | Infection, Human Immunodeficiency Virus | Completed | 2016-07-21 | 2022-08-15 | ClinicalTrials.gov |
| NCT02799784 | An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2016-07-14 | 2017-04-27 | ClinicalTrials.gov |
| NCT02757950 | A Post-marketing, Observational, Retrospective Study to Assess the Safety of Re… | — | Diphtheria | Completed | 2016-07-14 | 2017-05-31 | ClinicalTrials.gov |
| NCT02799784 | An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2016-07-14 | 2017-04-27 | ClinicalTrials.gov |
| NCT02757950 | A Post-marketing, Observational, Retrospective Study to Assess the Safety of Re… | — | Diphtheria | Completed | 2016-07-14 | 2017-05-31 | ClinicalTrials.gov |
| NCT02766088 | This Study Will Describe the Burden of DENgue Fever Virus (DENV) Illness Among … | Na | Dengue | Terminated | 2016-07-14 | 2018-12-14 | ClinicalTrials.gov |
| NCT02766088 | This Study Will Describe the Burden of DENgue Fever Virus (DENV) Illness Among … | Na | Dengue | Terminated | 2016-07-14 | 2018-12-14 | ClinicalTrials.gov |
| NCT02655016 | A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Ad… | Phase3 | Ovarian Neoplasms | Active_Not_Recruiting | 2016-07-11 | 2026-05-29 | ClinicalTrials.gov |
| NCT02655016 | A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Ad… | Phase3 | Ovarian Neoplasms | Active_Not_Recruiting | 2016-07-11 | 2026-05-29 | ClinicalTrials.gov |
| NCT02817633 | A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) | Phase1 | Neoplasms | Active_Not_Recruiting | 2016-07-08 | 2027-03-01 | ClinicalTrials.gov |
| NCT02817633 | A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) | Phase1 | Neoplasms | Active_Not_Recruiting | 2016-07-08 | 2027-03-01 | ClinicalTrials.gov |
| NCT02719743 | A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologi… | Phase2 | Influenza | Completed | 2016-07-07 | 2018-02-13 | ClinicalTrials.gov |
| NCT02719743 | A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologi… | Phase2 | Influenza | Completed | 2016-07-07 | 2018-02-13 | ClinicalTrials.gov |
| NCT02768194 | Dentine Tubule Occlusion Assessment in a Modified in Situ Model | Na | Dentin Sensitivity | Completed | 2016-07-06 | 2016-09-21 | ClinicalTrials.gov |
| NCT02768194 | Dentine Tubule Occlusion Assessment in a Modified in Situ Model | Na | Dentin Sensitivity | Completed | 2016-07-06 | 2016-09-21 | ClinicalTrials.gov |
| NCT02794467 | Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis | Phase2 | Adenomyosis | Withdrawn | 2016-07-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02794467 | Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis | Phase2 | Adenomyosis | Withdrawn | 2016-07-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02729038 | Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal … | Phase1 | Infections, Bacterial | Completed | 2016-06-29 | 2017-06-20 | ClinicalTrials.gov |
| NCT02729051 | Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilan… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2016-06-29 | 2017-05-23 | ClinicalTrials.gov |
| NCT02729051 | Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilan… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2016-06-29 | 2017-05-23 | ClinicalTrials.gov |
| NCT02729038 | Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal … | Phase1 | Infections, Bacterial | Completed | 2016-06-29 | 2017-06-20 | ClinicalTrials.gov |
| NCT02786927 | Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2016-06-21 | 2016-10-04 | ClinicalTrials.gov |
| NCT02786927 | Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2016-06-21 | 2016-10-04 | ClinicalTrials.gov |
| NCT02780661 | Frequency of Denture Cleanser Use and Denture Cleanliness | Na | Denture Cleansers | Completed | 2016-06-20 | 2016-11-15 | ClinicalTrials.gov |
| NCT02780661 | Frequency of Denture Cleanser Use and Denture Cleanliness | Na | Denture Cleansers | Completed | 2016-06-20 | 2016-11-15 | ClinicalTrials.gov |
| NCT02742753 | Impact of Pneumococcal Conjugate Vaccines on Otitis Media and Acute Otitis Medi… | — | Acute Otitis Media | Completed | 2016-06-16 | 2017-09-14 | ClinicalTrials.gov |
| NCT02742753 | Impact of Pneumococcal Conjugate Vaccines on Otitis Media and Acute Otitis Medi… | — | Acute Otitis Media | Completed | 2016-06-16 | 2017-09-14 | ClinicalTrials.gov |
| NCT02832362 | Local Nasal Tolerability and Safety Study of 1146A in Healthy Adult Participants | Phase1 | Common Cold | Completed | 2016-06-11 | 2016-07-18 | ClinicalTrials.gov |
| NCT02832362 | Local Nasal Tolerability and Safety Study of 1146A in Healthy Adult Participants | Phase1 | Common Cold | Completed | 2016-06-11 | 2016-07-18 | ClinicalTrials.gov |
| NCT02791763 | Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dial… | Phase3 | Anaemia | Completed | 2016-06-06 | 2018-10-26 | ClinicalTrials.gov |
| NCT02791763 | Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dial… | Phase3 | Anaemia | Completed | 2016-06-06 | 2018-10-26 | ClinicalTrials.gov |
| NCT02800655 | Digital Health Feedback System for Longitudinal Measurement of Medication Adher… | Phase4 | HIV | Unknown | 2016-06-01 | 2023-12-01 | ClinicalTrials.gov |
| NCT02551627 | A Study to Investigate the Impact of a Multiple Micronutrient (MMN) Beverage Po… | Na | Growth and Development | Withdrawn | 2016-06-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT02712359 | This Study Will Evaluate the Persistence of Hepatitis A Antibodies, 8 Years and… | Na | Hepatitis A Vaccine | Completed | 2016-06-01 | 2018-08-22 | ClinicalTrials.gov |
| NCT02799264 | A Study to Evaluate the Effect of High Fat Meal on Cabotegravir | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2016-06-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02551627 | A Study to Investigate the Impact of a Multiple Micronutrient (MMN) Beverage Po… | Na | Growth and Development | Withdrawn | 2016-06-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT02799264 | A Study to Evaluate the Effect of High Fat Meal on Cabotegravir | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2016-06-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02800655 | Digital Health Feedback System for Longitudinal Measurement of Medication Adher… | Phase4 | HIV | Unknown | 2016-06-01 | 2023-12-01 | ClinicalTrials.gov |
| NCT02731846 | A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual The… | Phase3 | Pulmonary Disease, Chronic Obstructive | Withdrawn | 2016-06-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02570152 | A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity… | Na | Dengue | Completed | 2016-06-01 | 2019-06-28 | ClinicalTrials.gov |
| NCT02712359 | This Study Will Evaluate the Persistence of Hepatitis A Antibodies, 8 Years and… | Na | Hepatitis A Vaccine | Completed | 2016-06-01 | 2018-08-22 | ClinicalTrials.gov |
| NCT02570152 | A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity… | Na | Dengue | Completed | 2016-06-01 | 2019-06-28 | ClinicalTrials.gov |
| NCT02731846 | A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual The… | Phase3 | Pulmonary Disease, Chronic Obstructive | Withdrawn | 2016-06-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02730351 | Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily V… | Phase4 | Asthma | Completed | 2016-05-25 | 2017-02-03 | ClinicalTrials.gov |
| NCT02730351 | Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily V… | Phase4 | Asthma | Completed | 2016-05-25 | 2017-02-03 | ClinicalTrials.gov |
| NCT02752958 | Impact of Long Term Management of Dentine Hypersensitivity (DH) With a Daily Us… | Na | Dentin Sensitivity | Completed | 2016-05-23 | 2017-02-03 | ClinicalTrials.gov |
| NCT02698553 | A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Extended-relea… | Phase1 | Depressive Disorder, Major | Completed | 2016-05-23 | 2016-06-29 | ClinicalTrials.gov |
| NCT02698553 | A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Extended-relea… | Phase1 | Depressive Disorder, Major | Completed | 2016-05-23 | 2016-06-29 | ClinicalTrials.gov |
| NCT02752958 | Impact of Long Term Management of Dentine Hypersensitivity (DH) With a Daily Us… | Na | Dentin Sensitivity | Completed | 2016-05-23 | 2017-02-03 | ClinicalTrials.gov |
| NCT03293641 | Zinc Supplementation in Children With Sickle Cell Disease in Western Kenya | Na | Sickle Cell Disease | Completed | 2016-05-20 | 2017-01-19 | ClinicalTrials.gov |
| NCT03293641 | Zinc Supplementation in Children With Sickle Cell Disease in Western Kenya | Na | Sickle Cell Disease | Completed | 2016-05-20 | 2017-01-19 | ClinicalTrials.gov |
| NCT02839135 | A Comparative Bioavailability and Adhesion Performance Study, Comparing a New S… | Phase1 | Motion Sickness | Completed | 2016-05-13 | 2016-08-10 | ClinicalTrials.gov |
| NCT02839135 | A Comparative Bioavailability and Adhesion Performance Study, Comparing a New S… | Phase1 | Motion Sickness | Completed | 2016-05-13 | 2016-08-10 | ClinicalTrials.gov |
| NCT02757963 | Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subject… | Phase4 | Prostatic Hyperplasia | Completed | 2016-05-12 | 2017-02-27 | ClinicalTrials.gov |
| NCT02603172 | A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic A… | Phase1 | Amyloidosis | Terminated | 2016-05-12 | 2017-05-10 | ClinicalTrials.gov |
| NCT02757963 | Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subject… | Phase4 | Prostatic Hyperplasia | Completed | 2016-05-12 | 2017-02-27 | ClinicalTrials.gov |
| NCT02603172 | A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic A… | Phase1 | Amyloidosis | Terminated | 2016-05-12 | 2017-05-10 | ClinicalTrials.gov |
| NCT02184611 | A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic … | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2016-05-09 | 2017-11-08 | ClinicalTrials.gov |
| NCT02184611 | A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic … | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2016-05-09 | 2017-11-08 | ClinicalTrials.gov |
| NCT02706535 | A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the… | Phase1 | Drug Interactions | Completed | 2016-05-05 | 2017-01-06 | ClinicalTrials.gov |
| NCT02706535 | A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the… | Phase1 | Drug Interactions | Completed | 2016-05-05 | 2017-01-06 | ClinicalTrials.gov |
| NCT02738931 | Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combi… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2016-05-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02751294 | A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of… | Phase1 | Malaria, Vivax | Completed | 2016-05-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02705807 | Evaluation of a New Thermostable Formulation of FLOLAN in Japanese Subjects | Phase4 | Cardiovascular Disease | Completed | 2016-05-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT02705807 | Evaluation of a New Thermostable Formulation of FLOLAN in Japanese Subjects | Phase4 | Cardiovascular Disease | Completed | 2016-05-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT02738931 | Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combi… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2016-05-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02751294 | A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of… | Phase1 | Malaria, Vivax | Completed | 2016-05-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02712047 | A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients. | Phase2 | Asthma | Completed | 2016-04-29 | 2017-02-21 | ClinicalTrials.gov |
| NCT02712047 | A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients. | Phase2 | Asthma | Completed | 2016-04-29 | 2017-02-21 | ClinicalTrials.gov |
| NCT02737007 | A Microdose Study in Healthy Subjects to Describe Intravenous Pharmacokinetics … | Phase1 | Malaria, Falciparum | Completed | 2016-04-18 | 2016-05-12 | ClinicalTrials.gov |
| NCT02737007 | A Microdose Study in Healthy Subjects to Describe Intravenous Pharmacokinetics … | Phase1 | Malaria, Falciparum | Completed | 2016-04-18 | 2016-05-12 | ClinicalTrials.gov |
| NCT02723773 | A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 1… | Phase3 | Herpes Zoster | Completed | 2016-04-16 | 2024-01-30 | ClinicalTrials.gov |
| NCT02723773 | A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 1… | Phase3 | Herpes Zoster | Completed | 2016-04-16 | 2024-01-30 | ClinicalTrials.gov |
| NCT02657889 | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Br… | Phase1 | Neoplasms | Completed | 2016-04-15 | 2021-09-17 | ClinicalTrials.gov |
| NCT02657889 | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Br… | Phase1 | Neoplasms | Completed | 2016-04-15 | 2021-09-17 | ClinicalTrials.gov |
| NCT02497937 | A Study to Evaluate the Effect of the Transient Receptor Potential Vanilloid 4 … | Phase2 | Heart Failure | Completed | 2016-04-13 | 2017-08-21 | ClinicalTrials.gov |
| NCT02497937 | A Study to Evaluate the Effect of the Transient Receptor Potential Vanilloid 4 … | Phase2 | Heart Failure | Completed | 2016-04-13 | 2017-08-21 | ClinicalTrials.gov |
| NCT02735915 | Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster S… | Phase3 | Herpes Zoster | Completed | 2016-04-11 | 2018-10-08 | ClinicalTrials.gov |
| NCT02735915 | Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster S… | Phase3 | Herpes Zoster | Completed | 2016-04-11 | 2018-10-08 | ClinicalTrials.gov |
| NCT02715479 | A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravi… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2016-04-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT02428270 | A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer | Phase2 | Pancreatic Cancer | Completed | 2016-04-01 | 2022-10-27 | ClinicalTrials.gov |
| NCT02715479 | A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravi… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2016-04-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT02428270 | A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer | Phase2 | Pancreatic Cancer | Completed | 2016-04-01 | 2022-10-27 | ClinicalTrials.gov |
| NCT02753413 | Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investiga… | Phase2 | Respiratory Syncytial Virus Infections | Completed | 2016-04-01 | 2016-06-28 | ClinicalTrials.gov |
| NCT02753413 | Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investiga… | Phase2 | Respiratory Syncytial Virus Infections | Completed | 2016-04-01 | 2016-06-28 | ClinicalTrials.gov |
| NCT02690181 | Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of… | Phase2 | Bacterial Infection Due to Streptococcus, Group B | Completed | 2016-03-29 | 2016-11-02 | ClinicalTrials.gov |
| NCT02690181 | Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of… | Phase2 | Bacterial Infection Due to Streptococcus, Group B | Completed | 2016-03-29 | 2016-11-02 | ClinicalTrials.gov |
| NCT02688387 | A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose… | Phase1 | Hypertension, Pulmonary | Completed | 2016-03-18 | 2017-08-04 | ClinicalTrials.gov |
| NCT02688387 | A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose… | Phase1 | Hypertension, Pulmonary | Completed | 2016-03-18 | 2017-08-04 | ClinicalTrials.gov |
| NCT02690207 | Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vacci… | Phase3 | Herpes Zoster | Completed | 2016-03-16 | 2019-03-15 | ClinicalTrials.gov |
| NCT02690207 | Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vacci… | Phase3 | Herpes Zoster | Completed | 2016-03-16 | 2019-03-15 | ClinicalTrials.gov |
| NCT02683746 | Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2016-03-16 | 2017-05-15 | ClinicalTrials.gov |
| NCT02683746 | Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2016-03-16 | 2017-05-15 | ClinicalTrials.gov |
| NCT02742766 | Safety, Tolerability and Preliminary Pharmacokinetics (PK) and Pharmacodynamics… | Phase1 | Healthy Volunteers | Completed | 2016-03-14 | 2017-06-16 | ClinicalTrials.gov |
| NCT02691325 | Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 A… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2016-03-14 | 2016-06-05 | ClinicalTrials.gov |
| NCT02691325 | Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 A… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2016-03-14 | 2016-06-05 | ClinicalTrials.gov |
| NCT02742766 | Safety, Tolerability and Preliminary Pharmacokinetics (PK) and Pharmacodynamics… | Phase1 | Healthy Volunteers | Completed | 2016-03-14 | 2017-06-16 | ClinicalTrials.gov |
| NCT02860169 | Motivation, Brain Function and Mood in Individuals With Cold and/or Flu | Na | Cognition | Terminated | 2016-03-11 | 2016-11-24 | ClinicalTrials.gov |
| NCT02860169 | Motivation, Brain Function and Mood in Individuals With Cold and/or Flu | Na | Cognition | Terminated | 2016-03-11 | 2016-11-24 | ClinicalTrials.gov |
| NCT02641912 | Potential of an Experimental Mouthwash Formulation to Reduce Dry Mouth Symptoms | Na | Xerostomia | Completed | 2016-03-09 | 2016-04-15 | ClinicalTrials.gov |
| NCT02641912 | Potential of an Experimental Mouthwash Formulation to Reduce Dry Mouth Symptoms | Na | Xerostomia | Completed | 2016-03-09 | 2016-04-15 | ClinicalTrials.gov |
| NCT02715284 | Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal An… | Phase1 | Neoplasms | Active_Not_Recruiting | 2016-03-07 | 2027-01-25 | ClinicalTrials.gov |
| NCT02715284 | Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal An… | Phase1 | Neoplasms | Active_Not_Recruiting | 2016-03-07 | 2027-01-25 | ClinicalTrials.gov |
| NCT02673619 | A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerabilit… | Phase2 | Hyperhidrosis | Completed | 2016-03-07 | 2016-12-08 | ClinicalTrials.gov |
| NCT02673619 | A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerabilit… | Phase2 | Hyperhidrosis | Completed | 2016-03-07 | 2016-12-08 | ClinicalTrials.gov |
| NCT02795754 | Single and Repeated Dose Escalation Study of GSK2838232 | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2016-03-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02795754 | Single and Repeated Dose Escalation Study of GSK2838232 | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2016-03-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02705716 | Study Investigating Efficacy of an Occluding Dentifrice for Dentine Hypersensit… | Na | Dentin Sensitivity | Completed | 2016-03-01 | 2016-05-20 | ClinicalTrials.gov |
| NCT02177734 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza… | Phase1 | Influenza | Withdrawn | 2016-03-01 | 2017-05-01 | ClinicalTrials.gov |
| NCT02177734 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza… | Phase1 | Influenza | Withdrawn | 2016-03-01 | 2017-05-01 | ClinicalTrials.gov |
| NCT02705716 | Study Investigating Efficacy of an Occluding Dentifrice for Dentine Hypersensit… | Na | Dentin Sensitivity | Completed | 2016-03-01 | 2016-05-20 | ClinicalTrials.gov |
| NCT02377466 | A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo f… | Phase3 | Obstetric Labour, Premature | Terminated | 2016-02-29 | 2017-07-24 | ClinicalTrials.gov |
| NCT02377466 | A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo f… | Phase3 | Obstetric Labour, Premature | Terminated | 2016-02-29 | 2017-07-24 | ClinicalTrials.gov |
| NCT02674581 | A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjec… | Phase1 | HIV Infections | Completed | 2016-02-26 | 2016-05-24 | ClinicalTrials.gov |
| NCT02674581 | A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjec… | Phase1 | HIV Infections | Completed | 2016-02-26 | 2016-05-24 | ClinicalTrials.gov |
| NCT02688361 | A Bioequivalence Study of an Acetylcysteine 2% Oral Solution Versus a Reference… | Phase1 | Infections, Respiratory Tract | Completed | 2016-02-22 | 2016-04-13 | ClinicalTrials.gov |
| NCT02688361 | A Bioequivalence Study of an Acetylcysteine 2% Oral Solution Versus a Reference… | Phase1 | Infections, Respiratory Tract | Completed | 2016-02-22 | 2016-04-13 | ClinicalTrials.gov |
| NCT02689206 | Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Week… | Phase2 | Anaemia | Completed | 2016-02-17 | 2017-01-25 | ClinicalTrials.gov |
| NCT02689206 | Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Week… | Phase2 | Anaemia | Completed | 2016-02-17 | 2017-01-25 | ClinicalTrials.gov |
| NCT02856282 | Drug Utilization Study for Pirinase Hayfever Relief | — | Rhinitis, Allergic, Seasonal | Completed | 2016-02-15 | 2018-03-31 | ClinicalTrials.gov |
| NCT02856282 | Drug Utilization Study for Pirinase Hayfever Relief | — | Rhinitis, Allergic, Seasonal | Completed | 2016-02-15 | 2018-03-31 | ClinicalTrials.gov |
| NCT03243760 | Dose Escalating Study of CCI15106 Inhalation Capsules in Healthy Subjects and M… | Phase1 | Pulmonary Disease, Chronic Obstructive | Terminated | 2016-02-10 | 2016-08-20 | ClinicalTrials.gov |
| NCT03243760 | Dose Escalating Study of CCI15106 Inhalation Capsules in Healthy Subjects and M… | Phase1 | Pulmonary Disease, Chronic Obstructive | Terminated | 2016-02-10 | 2016-08-20 | ClinicalTrials.gov |
| NCT02663089 | A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metaboli… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2016-02-08 | 2016-03-17 | ClinicalTrials.gov |
| NCT02663089 | A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metaboli… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2016-02-08 | 2016-03-17 | ClinicalTrials.gov |
| NCT02658435 | Assessment of Any Potential Retinal Effects of Tafenoquine (TQ) | Phase1 | Malaria, Vivax | Completed | 2016-02-02 | 2017-09-14 | ClinicalTrials.gov |
| NCT02658435 | Assessment of Any Potential Retinal Effects of Tafenoquine (TQ) | Phase1 | Malaria, Vivax | Completed | 2016-02-02 | 2017-09-14 | ClinicalTrials.gov |
| NCT02660736 | Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2016-02-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02292732 | A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosi… | Phase1 | Cancer | Withdrawn | 2016-02-01 | 2017-05-01 | ClinicalTrials.gov |
| NCT02588612 | Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-S… | Phase1 | Neoplasms | Completed | 2016-02-01 | 2020-08-10 | ClinicalTrials.gov |
| NCT02751320 | Efficacy of Three Toothpastes Using an in Situ Caries Model | Na | Dental Caries | Completed | 2016-02-01 | 2016-08-11 | ClinicalTrials.gov |
| NCT01563146 | Number of Rotavirus (RV) Related Hospitalizations in Belgium - Season 2006-2007 | — | Infections, Rotavirus | Completed | 2016-02-01 | 2017-12-31 | ClinicalTrials.gov |
| NCT02588612 | Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-S… | Phase1 | Neoplasms | Completed | 2016-02-01 | 2020-08-10 | ClinicalTrials.gov |
| NCT02292732 | A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosi… | Phase1 | Cancer | Withdrawn | 2016-02-01 | 2017-05-01 | ClinicalTrials.gov |
| NCT02660736 | Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2016-02-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT01563146 | Number of Rotavirus (RV) Related Hospitalizations in Belgium - Season 2006-2007 | — | Infections, Rotavirus | Completed | 2016-02-01 | 2017-12-31 | ClinicalTrials.gov |
| NCT02751320 | Efficacy of Three Toothpastes Using an in Situ Caries Model | Na | Dental Caries | Completed | 2016-02-01 | 2016-08-11 | ClinicalTrials.gov |
| NCT02640677 | Safety of 4CMenB Exposure During Pregnancy | — | Infections, Meningococcal | Completed | 2016-01-31 | 2019-11-30 | ClinicalTrials.gov |
| NCT02640677 | Safety of 4CMenB Exposure During Pregnancy | — | Infections, Meningococcal | Completed | 2016-01-31 | 2019-11-30 | ClinicalTrials.gov |
| NCT02666053 | A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the B… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2016-01-27 | 2016-02-22 | ClinicalTrials.gov |
| NCT02666053 | A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the B… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2016-01-27 | 2016-02-22 | ClinicalTrials.gov |
| NCT02422264 | Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mot… | Phase4 | Acellular Pertussis | Completed | 2016-01-22 | 2018-03-07 | ClinicalTrials.gov |
| NCT02422264 | Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mot… | Phase4 | Acellular Pertussis | Completed | 2016-01-22 | 2018-03-07 | ClinicalTrials.gov |
| NCT02487472 | Burden of Herpes Zoster and Post-herpetic Neuralgia Among People ≥ 50 Years Old… | — | Herpes Zoster | Completed | 2016-01-19 | 2017-08-28 | ClinicalTrials.gov |
| NCT02487472 | Burden of Herpes Zoster and Post-herpetic Neuralgia Among People ≥ 50 Years Old… | — | Herpes Zoster | Completed | 2016-01-19 | 2017-08-28 | ClinicalTrials.gov |
| NCT02555371 | Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic A… | Phase3 | Asthma | Completed | 2016-01-07 | 2019-07-24 | ClinicalTrials.gov |
| NCT02555371 | Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic A… | Phase3 | Asthma | Completed | 2016-01-07 | 2019-07-24 | ClinicalTrials.gov |
| NCT02651467 | A Study to Investigate Efficacy of Two Experimental Oral Rinses in Providing Lo… | Na | Dentin Sensitivity | Completed | 2016-01-04 | 2016-04-22 | ClinicalTrials.gov |
| NCT02651467 | A Study to Investigate Efficacy of Two Experimental Oral Rinses in Providing Lo… | Na | Dentin Sensitivity | Completed | 2016-01-04 | 2016-04-22 | ClinicalTrials.gov |
| NCT02627820 | The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels … | Phase2 | Amyloidosis | Withdrawn | 2016-01-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT02616289 | Emollient Therapy for Severe Acute Malnutrition | Na | Child Malnutrition | Completed | 2016-01-01 | 2019-12-31 | ClinicalTrials.gov |
| NCT03083509 | A Physiological Profile of Recovery From Resistance, Endurance, and Mixed Exerc… | Na | Sports Nutritional Sciences | Completed | 2016-01-01 | 2016-07-29 | ClinicalTrials.gov |
| NCT03083509 | A Physiological Profile of Recovery From Resistance, Endurance, and Mixed Exerc… | Na | Sports Nutritional Sciences | Completed | 2016-01-01 | 2016-07-29 | ClinicalTrials.gov |
| NCT02634073 | A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interac… | Phase4 | Infection, Human Immunodeficiency Virus | Completed | 2016-01-01 | 2016-03-11 | ClinicalTrials.gov |
| NCT02627820 | The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels … | Phase2 | Amyloidosis | Withdrawn | 2016-01-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT02773758 | Study to Investigate the Efficacy of an Occluding Dentifrice in Providing Relie… | Phase4 | Dentin Sensitivity | Completed | 2016-01-01 | 2016-03-11 | ClinicalTrials.gov |
| NCT02616289 | Emollient Therapy for Severe Acute Malnutrition | Na | Child Malnutrition | Completed | 2016-01-01 | 2019-12-31 | ClinicalTrials.gov |
| NCT04184336 | Enhanced Population-based Core Surveillance of Meningococcal Invasive Infection… | — | Invasive Meningococcal Disease | Unknown | 2016-01-01 | 2022-12-31 | ClinicalTrials.gov |
| NCT04184336 | Enhanced Population-based Core Surveillance of Meningococcal Invasive Infection… | — | Invasive Meningococcal Disease | Unknown | 2016-01-01 | 2022-12-31 | ClinicalTrials.gov |
| NCT02773758 | Study to Investigate the Efficacy of an Occluding Dentifrice in Providing Relie… | Phase4 | Dentin Sensitivity | Completed | 2016-01-01 | 2016-03-11 | ClinicalTrials.gov |
| NCT02634073 | A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interac… | Phase4 | Infection, Human Immunodeficiency Virus | Completed | 2016-01-01 | 2016-03-11 | ClinicalTrials.gov |
| NCT02613910 | Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris | Phase3 | Pemphigus | Terminated | 2015-12-23 | 2016-03-23 | ClinicalTrials.gov |
| NCT02613910 | Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris | Phase3 | Pemphigus | Terminated | 2015-12-23 | 2016-03-23 | ClinicalTrials.gov |
| NCT02647281 | First Time in Human Study to Assess the Safety, Tolerability and Pharmacokineti… | Phase1 | Hepatitis B | Completed | 2015-12-17 | 2017-01-03 | ClinicalTrials.gov |
| NCT02647281 | First Time in Human Study to Assess the Safety, Tolerability and Pharmacokineti… | Phase1 | Hepatitis B | Completed | 2015-12-17 | 2017-01-03 | ClinicalTrials.gov |
| NCT02612051 | First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopa… | Phase1 | Idiopathic Pulmonary Fibrosis | Completed | 2015-12-04 | 2016-06-02 | ClinicalTrials.gov |
| NCT02612051 | First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopa… | Phase1 | Idiopathic Pulmonary Fibrosis | Completed | 2015-12-04 | 2016-06-02 | ClinicalTrials.gov |
| NCT02573870 | Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary … | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2015-12-01 | 2016-07-05 | ClinicalTrials.gov |
| NCT01528865 | Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA … | Phase1 | Lymphoma | Withdrawn | 2015-12-01 | — | ClinicalTrials.gov |
| NCT01528865 | Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA … | Phase1 | Lymphoma | Withdrawn | 2015-12-01 | — | ClinicalTrials.gov |
| NCT02564055 | A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD) | Phase2 | Dermatitis, Atopic | Completed | 2015-12-01 | 2017-01-12 | ClinicalTrials.gov |
| NCT02622581 | Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (No… | — | Metastatic Non-small Cell Lung Cancer (NSCLC) | Recruiting | 2015-12-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT02622581 | Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (No… | — | Metastatic Non-small Cell Lung Cancer (NSCLC) | Recruiting | 2015-12-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT02564055 | A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD) | Phase2 | Dermatitis, Atopic | Completed | 2015-12-01 | 2017-01-12 | ClinicalTrials.gov |
| NCT02573870 | Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary … | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2015-12-01 | 2016-07-05 | ClinicalTrials.gov |
| NCT02727283 | A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation St… | Phase1 | Irritable Bowel Syndrome | Completed | 2015-11-26 | 2016-03-18 | ClinicalTrials.gov |
| NCT02727283 | A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation St… | Phase1 | Irritable Bowel Syndrome | Completed | 2015-11-26 | 2016-03-18 | ClinicalTrials.gov |
| NCT02564042 | A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis | Phase2 | Psoriasis | Completed | 2015-11-23 | 2016-10-05 | ClinicalTrials.gov |
| NCT02563899 | Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidin… | Phase2 | Hyperhidrosis | Completed | 2015-11-23 | 2016-02-25 | ClinicalTrials.gov |
| NCT02564042 | A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis | Phase2 | Psoriasis | Completed | 2015-11-23 | 2016-10-05 | ClinicalTrials.gov |
| NCT02563899 | Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidin… | Phase2 | Hyperhidrosis | Completed | 2015-11-23 | 2016-02-25 | ClinicalTrials.gov |
| NCT02594332 | Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients Wit… | Phase3 | Asthma | Terminated | 2015-11-17 | 2017-05-22 | ClinicalTrials.gov |
| NCT02446743 | Combined Study - Phase 3b MenB Long Term Persistence in Adolescents | Phase3 | Infections, Meningococcal | Completed | 2015-11-17 | 2016-09-23 | ClinicalTrials.gov |
| NCT02594332 | Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients Wit… | Phase3 | Asthma | Terminated | 2015-11-17 | 2017-05-22 | ClinicalTrials.gov |
| NCT02446743 | Combined Study - Phase 3b MenB Long Term Persistence in Adolescents | Phase3 | Infections, Meningococcal | Completed | 2015-11-17 | 2016-09-23 | ClinicalTrials.gov |
| NCT02856880 | A Study to Investigate the Antimicrobial Activity of 2 Test Toothpastes | Na | Dental Plaque | Completed | 2015-11-09 | 2015-12-11 | ClinicalTrials.gov |
| NCT02548078 | A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine … | Phase2 | Virus Diseases | Completed | 2015-11-09 | 2017-05-15 | ClinicalTrials.gov |
| NCT02856880 | A Study to Investigate the Antimicrobial Activity of 2 Test Toothpastes | Na | Dental Plaque | Completed | 2015-11-09 | 2015-12-11 | ClinicalTrials.gov |
| NCT02548078 | A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine … | Phase2 | Virus Diseases | Completed | 2015-11-09 | 2017-05-15 | ClinicalTrials.gov |
| NCT02522299 | A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Bloo… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2015-11-04 | 2018-06-22 | ClinicalTrials.gov |
| NCT02522299 | A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Bloo… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2015-11-04 | 2018-06-22 | ClinicalTrials.gov |
| NCT03271593 | Impact of Rotavirus Vaccination on Hospital Pressures at a Large Paediatric Hos… | — | Gastroenteritis | Completed | 2015-11-02 | 2016-09-23 | ClinicalTrials.gov |
| NCT03271593 | Impact of Rotavirus Vaccination on Hospital Pressures at a Large Paediatric Hos… | — | Gastroenteritis | Completed | 2015-11-02 | 2016-09-23 | ClinicalTrials.gov |
| NCT02612064 | The Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hyper… | Na | Dentin Sensitivity | Completed | 2015-11-01 | 2016-06-03 | ClinicalTrials.gov |
| NCT02750943 | Potential of Stannous Fluoride Toothpaste to Reduce Gum Disease | Na | Gingivitis | Completed | 2015-11-01 | 2016-03-04 | ClinicalTrials.gov |
| NCT02750943 | Potential of Stannous Fluoride Toothpaste to Reduce Gum Disease | Na | Gingivitis | Completed | 2015-11-01 | 2016-03-04 | ClinicalTrials.gov |
| NCT02612064 | The Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hyper… | Na | Dentin Sensitivity | Completed | 2015-11-01 | 2016-06-03 | ClinicalTrials.gov |
| NCT02637206 | Skin Irritation Study of GSK2894512 Cream | Phase1 | Dermatitis, Atopic | Completed | 2015-10-27 | 2015-12-02 | ClinicalTrials.gov |
| NCT02637206 | Skin Irritation Study of GSK2894512 Cream | Phase1 | Dermatitis, Atopic | Completed | 2015-10-27 | 2015-12-02 | ClinicalTrials.gov |
| NCT02548052 | Study of Safety and Efficacy of Topical GSK2981278 Ointment in Plaque Psoriasis | Phase1 | Psoriasis | Completed | 2015-10-22 | 2016-02-19 | ClinicalTrials.gov |
| NCT02548052 | Study of Safety and Efficacy of Topical GSK2981278 Ointment in Plaque Psoriasis | Phase1 | Psoriasis | Completed | 2015-10-22 | 2016-02-19 | ClinicalTrials.gov |
| NCT02576119 | A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electroc… | Phase1 | Infection, Human Immunodeficiency Virus | Terminated | 2015-10-19 | 2016-10-14 | ClinicalTrials.gov |
| NCT02576119 | A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electroc… | Phase1 | Infection, Human Immunodeficiency Virus | Terminated | 2015-10-19 | 2016-10-14 | ClinicalTrials.gov |
| NCT02377349 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™… | Phase4 | Diphtheria-Tetanus-acellular Pertussis Vaccines | Completed | 2015-10-14 | 2017-10-24 | ClinicalTrials.gov |
| NCT02377349 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™… | Phase4 | Diphtheria-Tetanus-acellular Pertussis Vaccines | Completed | 2015-10-14 | 2017-10-24 | ClinicalTrials.gov |
| NCT03197597 | EUpertstrain 4 Study of Bordetella Pertussis Isolates | — | Bordetella Pertussis, Whooping Cough | Completed | 2015-10-12 | 2016-12-31 | ClinicalTrials.gov |
| NCT03197597 | EUpertstrain 4 Study of Bordetella Pertussis Isolates | — | Bordetella Pertussis, Whooping Cough | Completed | 2015-10-12 | 2016-12-31 | ClinicalTrials.gov |
| NCT02483975 | Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-a… | Phase3 | Asthma | Completed | 2015-10-09 | 2016-06-21 | ClinicalTrials.gov |
| NCT02483975 | Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-a… | Phase3 | Asthma | Completed | 2015-10-09 | 2016-06-21 | ClinicalTrials.gov |
| NCT02557399 | DUAC® Early Onset Efficacy Study in Japanese Subjects | Phase4 | Acne Vulgaris | Completed | 2015-10-07 | 2016-02-17 | ClinicalTrials.gov |
| NCT02557399 | DUAC® Early Onset Efficacy Study in Japanese Subjects | Phase4 | Acne Vulgaris | Completed | 2015-10-07 | 2016-02-17 | ClinicalTrials.gov |
| NCT02545517 | A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability … | Phase3 | Virus Diseases | Completed | 2015-10-05 | 2022-12-23 | ClinicalTrials.gov |
| NCT02545517 | A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability … | Phase3 | Virus Diseases | Completed | 2015-10-05 | 2022-12-23 | ClinicalTrials.gov |
| NCT02569879 | Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussi… | — | Diphtheria | Completed | 2015-10-01 | 2018-04-14 | ClinicalTrials.gov |
| NCT02567721 | Post-authorisation Safety Study (PASS) of Influenza Vaccine in United Kingdom (… | — | Influenza | Completed | 2015-10-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02567747 | Vaccination Impact Against Pneumococcal Disease on Acute Otitis Media Morbidity… | — | Acute Otitis Media | Completed | 2015-10-01 | 2018-02-23 | ClinicalTrials.gov |
| NCT02567708 | A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses o… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2015-10-01 | 2016-09-28 | ClinicalTrials.gov |
| NCT02586506 | Study of the Ease of Use and Correct Use of Placebo ELLIPTA® Inhaler in Subject… | Phase4 | Asthma | Completed | 2015-10-01 | 2016-02-04 | ClinicalTrials.gov |
| NCT02380313 | Dose-Finding Study of Afuresertib Administered in Combination With Either Enzal… | Phase1 | Cancer | Withdrawn | 2015-10-01 | 2017-05-01 | ClinicalTrials.gov |
| NCT02586493 | Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2015-10-01 | 2016-03-15 | ClinicalTrials.gov |
| NCT02586506 | Study of the Ease of Use and Correct Use of Placebo ELLIPTA® Inhaler in Subject… | Phase4 | Asthma | Completed | 2015-10-01 | 2016-02-04 | ClinicalTrials.gov |
| NCT02586493 | Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2015-10-01 | 2016-03-15 | ClinicalTrials.gov |
| NCT02380313 | Dose-Finding Study of Afuresertib Administered in Combination With Either Enzal… | Phase1 | Cancer | Withdrawn | 2015-10-01 | 2017-05-01 | ClinicalTrials.gov |
| NCT03141814 | Asthma Origins and Remission Study | — | Asthma | Unknown | 2015-10-01 | 2018-10-01 | ClinicalTrials.gov |
| NCT02567708 | A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses o… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2015-10-01 | 2016-09-28 | ClinicalTrials.gov |
| NCT02567721 | Post-authorisation Safety Study (PASS) of Influenza Vaccine in United Kingdom (… | — | Influenza | Completed | 2015-10-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02567747 | Vaccination Impact Against Pneumococcal Disease on Acute Otitis Media Morbidity… | — | Acute Otitis Media | Completed | 2015-10-01 | 2018-02-23 | ClinicalTrials.gov |
| NCT02533466 | In Vivo Investigation of Initial Stages of Enamel Erosion | Na | Tooth Erosion | Completed | 2015-10-01 | 2015-11-06 | ClinicalTrials.gov |
| NCT02533466 | In Vivo Investigation of Initial Stages of Enamel Erosion | Na | Tooth Erosion | Completed | 2015-10-01 | 2015-11-06 | ClinicalTrials.gov |
| NCT03141814 | Asthma Origins and Remission Study | — | Asthma | Unknown | 2015-10-01 | 2018-10-01 | ClinicalTrials.gov |
| NCT02569879 | Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussi… | — | Diphtheria | Completed | 2015-10-01 | 2018-04-14 | ClinicalTrials.gov |
| NCT02424539 | A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays … | Phase4 | Rhinitis, Allergic, Perennial and Seasonal | Completed | 2015-09-30 | 2017-10-25 | ClinicalTrials.gov |
| NCT02424539 | A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays … | Phase4 | Rhinitis, Allergic, Perennial and Seasonal | Completed | 2015-09-30 | 2017-10-25 | ClinicalTrials.gov |
| NCT02523014 | Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating… | Phase2 | Intracranial Meningioma | Recruiting | 2015-09-28 | 2028-01-01 | ClinicalTrials.gov |
| NCT02523014 | Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating… | Phase2 | Intracranial Meningioma | Recruiting | 2015-09-28 | 2028-01-01 | ClinicalTrials.gov |
| NCT02619357 | Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko f… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2015-09-21 | 2016-03-16 | ClinicalTrials.gov |
| NCT02619357 | Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko f… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2015-09-21 | 2016-03-16 | ClinicalTrials.gov |
| NCT03841344 | Repeatability and Sensitivity to Change of Non-invasive Endpoints in PAH | Na | Pulmonary Arterial Hypertension | Unknown | 2015-09-15 | 2019-05-20 | ClinicalTrials.gov |
| NCT03841344 | Repeatability and Sensitivity to Change of Non-invasive Endpoints in PAH | Na | Pulmonary Arterial Hypertension | Unknown | 2015-09-15 | 2019-05-20 | ClinicalTrials.gov |
| NCT02542813 | Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Adm… | Phase1 | Postpartum Hemorrhage | Completed | 2015-09-14 | 2015-12-16 | ClinicalTrials.gov |
| NCT02542813 | Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Adm… | Phase1 | Postpartum Hemorrhage | Completed | 2015-09-14 | 2015-12-16 | ClinicalTrials.gov |
| NCT02528357 | GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tum… | Phase1 | Neoplasms | Completed | 2015-09-11 | 2020-04-29 | ClinicalTrials.gov |
| NCT02528357 | GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tum… | Phase1 | Neoplasms | Completed | 2015-09-11 | 2020-04-29 | ClinicalTrials.gov |
| NCT02753075 | A Study in Dentinal Hypersensitivity (DH) Participants to Assess the Efficacy o… | Na | Dentin Sensitivity | Completed | 2015-09-08 | 2015-12-18 | ClinicalTrials.gov |
| NCT02753075 | A Study in Dentinal Hypersensitivity (DH) Participants to Assess the Efficacy o… | Na | Dentin Sensitivity | Completed | 2015-09-08 | 2015-12-18 | ClinicalTrials.gov |
| NCT02513654 | Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healt… | Phase1 | Bipolar Disorder | Completed | 2015-09-06 | 2015-11-11 | ClinicalTrials.gov |
| NCT02513654 | Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healt… | Phase1 | Bipolar Disorder | Completed | 2015-09-06 | 2015-11-11 | ClinicalTrials.gov |
| NCT02502812 | Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative t… | Phase1 | Cardiovascular Disease | Completed | 2015-09-04 | 2015-09-24 | ClinicalTrials.gov |
| NCT02502812 | Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative t… | Phase1 | Cardiovascular Disease | Completed | 2015-09-04 | 2015-09-24 | ClinicalTrials.gov |
| NCT02548156 | Intra Oral Kinetics of Fluoride Containing Dentifrices | Na | Tooth Erosion | Completed | 2015-09-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02750189 | The Economic Burden of Chronic Obstructive Pulmonary Disease(COPD) in South Kor… | — | COPD | Completed | 2015-09-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT02567773 | Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK288… | Phase1 | Cachexia | Completed | 2015-09-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02567773 | Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK288… | Phase1 | Cachexia | Completed | 2015-09-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02750189 | The Economic Burden of Chronic Obstructive Pulmonary Disease(COPD) in South Kor… | — | COPD | Completed | 2015-09-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT02548156 | Intra Oral Kinetics of Fluoride Containing Dentifrices | Na | Tooth Erosion | Completed | 2015-09-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02547974 | A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Invest… | Phase1 | Respiratory Disorders | Completed | 2015-08-31 | 2017-03-31 | ClinicalTrials.gov |
| NCT02547974 | A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Invest… | Phase1 | Respiratory Disorders | Completed | 2015-08-31 | 2017-03-31 | ClinicalTrials.gov |
| NCT02377427 | Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneousl… | Phase2 | Asthma | Completed | 2015-08-25 | 2018-01-31 | ClinicalTrials.gov |
| NCT02377427 | Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneousl… | Phase2 | Asthma | Completed | 2015-08-25 | 2018-01-31 | ClinicalTrials.gov |
| NCT02555540 | Placebo Controlled Study to Generate Data Characterising Safety Parameters and … | Phase4 | Prevention of Infections With Bordetella Pertussis | Completed | 2015-08-24 | 2016-12-15 | ClinicalTrials.gov |
| NCT02555540 | Placebo Controlled Study to Generate Data Characterising Safety Parameters and … | Phase4 | Prevention of Infections With Bordetella Pertussis | Completed | 2015-08-24 | 2016-12-15 | ClinicalTrials.gov |
| NCT02658422 | Bioequivalence of GW483100 10 Milligram (mg) Tablets in Healthy Subjects Under … | Phase1 | Respiratory Disorders | Completed | 2015-08-18 | 2015-09-21 | ClinicalTrials.gov |
| NCT02658422 | Bioequivalence of GW483100 10 Milligram (mg) Tablets in Healthy Subjects Under … | Phase1 | Respiratory Disorders | Completed | 2015-08-18 | 2015-09-21 | ClinicalTrials.gov |
| NCT02350426 | A Study to Assess Inflammation in Rheumatoid Arthritis Using Molecular Imaging … | Phase1 | Arthritis, Rheumatoid | Terminated | 2015-08-12 | 2016-10-26 | ClinicalTrials.gov |
| NCT02350426 | A Study to Assess Inflammation in Rheumatoid Arthritis Using Molecular Imaging … | Phase1 | Arthritis, Rheumatoid | Terminated | 2015-08-12 | 2016-10-26 | ClinicalTrials.gov |
| NCT02508064 | Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Exten… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2015-08-03 | 2015-11-05 | ClinicalTrials.gov |
| NCT02508064 | Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Exten… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2015-08-03 | 2015-11-05 | ClinicalTrials.gov |
| NCT02229240 | Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects … | Phase3 | Diabetes Mellitus, Type 2 | Withdrawn | 2015-08-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02504775 | Bioequivalence Study for Mejoral 500 Product | Na | Pain | Completed | 2015-08-01 | 2015-08-19 | ClinicalTrials.gov |
| NCT02421367 | Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant a… | Phase1 | Dengue | Completed | 2015-08-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT02504775 | Bioequivalence Study for Mejoral 500 Product | Na | Pain | Completed | 2015-08-01 | 2015-08-19 | ClinicalTrials.gov |
| NCT02421367 | Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant a… | Phase1 | Dengue | Completed | 2015-08-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT02229240 | Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects … | Phase3 | Diabetes Mellitus, Type 2 | Withdrawn | 2015-08-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02509104 | Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosi… | Phase1 | Prostatic Hyperplasia | Completed | 2015-07-30 | 2015-10-10 | ClinicalTrials.gov |
| NCT02509104 | Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosi… | Phase1 | Prostatic Hyperplasia | Completed | 2015-07-30 | 2015-10-10 | ClinicalTrials.gov |
| NCT02504671 | Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Su… | Phase2 | Arthritis, Rheumatoid | Completed | 2015-07-23 | 2017-12-29 | ClinicalTrials.gov |
| NCT02504671 | Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Su… | Phase2 | Arthritis, Rheumatoid | Completed | 2015-07-23 | 2017-12-29 | ClinicalTrials.gov |
| NCT02568332 | A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive In… | Phase1 | Hepatitis C Infection | Completed | 2015-07-21 | 2017-10-31 | ClinicalTrials.gov |
| NCT02568332 | A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive In… | Phase1 | Hepatitis C Infection | Completed | 2015-07-21 | 2017-10-31 | ClinicalTrials.gov |
| NCT02485301 | A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine … | Phase2 | Virus Diseases | Completed | 2015-07-15 | 2016-12-23 | ClinicalTrials.gov |
| NCT02485301 | A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine … | Phase2 | Virus Diseases | Completed | 2015-07-15 | 2016-12-23 | ClinicalTrials.gov |
| NCT02446691 | Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations | Phase4 | Infections, Meningococcal | Completed | 2015-07-13 | 2017-12-28 | ClinicalTrials.gov |
| NCT02446691 | Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations | Phase4 | Infections, Meningococcal | Completed | 2015-07-13 | 2017-12-28 | ClinicalTrials.gov |
| NCT02446418 | A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Po… | Phase3 | Asthma | Completed | 2015-07-09 | 2017-07-20 | ClinicalTrials.gov |
| NCT02446418 | A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Po… | Phase3 | Asthma | Completed | 2015-07-09 | 2017-07-20 | ClinicalTrials.gov |
| NCT02480894 | A Open-label, Drug-Drug Interaction With Maraviroc (DDI) | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2015-07-07 | 2015-09-21 | ClinicalTrials.gov |
| NCT02480881 | A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Hea… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2015-07-07 | 2016-01-11 | ClinicalTrials.gov |
| NCT02480881 | A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Hea… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2015-07-07 | 2016-01-11 | ClinicalTrials.gov |
| NCT02480894 | A Open-label, Drug-Drug Interaction With Maraviroc (DDI) | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2015-07-07 | 2015-09-21 | ClinicalTrials.gov |
| NCT02465515 | Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies,… | Phase4 | Diabetes Mellitus | Completed | 2015-07-01 | 2018-03-14 | ClinicalTrials.gov |
| NCT02411435 | Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2015-07-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02411435 | Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2015-07-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02465515 | Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies,… | Phase4 | Diabetes Mellitus | Completed | 2015-07-01 | 2018-03-14 | ClinicalTrials.gov |
| NCT02929043 | Psychophysical Characterization and Brain Correlates of Dentine Hypersensitivity | — | Dentine Hypersensitivity | Completed | 2015-07-01 | 2017-06-30 | ClinicalTrials.gov |
| NCT02929043 | Psychophysical Characterization and Brain Correlates of Dentine Hypersensitivity | — | Dentine Hypersensitivity | Completed | 2015-07-01 | 2017-06-30 | ClinicalTrials.gov |
| NCT02447952 | Exploratory Study of Biotelemetry in Amyotrophic Lateral Sclerosis | Na | Amyotrophic Lateral Sclerosis | Completed | 2015-06-30 | 2017-06-01 | ClinicalTrials.gov |
| NCT02447952 | Exploratory Study of Biotelemetry in Amyotrophic Lateral Sclerosis | Na | Amyotrophic Lateral Sclerosis | Completed | 2015-06-30 | 2017-06-01 | ClinicalTrials.gov |
| NCT02446613 | Follow-up Study to Investigate the Effect of GSK2245035 on Nasal Allergic React… | Phase2 | Asthma and Rhinitis | Completed | 2015-06-22 | 2015-08-10 | ClinicalTrials.gov |
| NCT02446613 | Follow-up Study to Investigate the Effect of GSK2245035 on Nasal Allergic React… | Phase2 | Asthma and Rhinitis | Completed | 2015-06-22 | 2015-08-10 | ClinicalTrials.gov |
| NCT02354950 | A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects W… | Phase1 | HIV Infections | Completed | 2015-06-22 | 2016-09-16 | ClinicalTrials.gov |
| NCT02354950 | A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects W… | Phase1 | HIV Infections | Completed | 2015-06-22 | 2016-09-16 | ClinicalTrials.gov |
| NCT02478632 | Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Ad… | Phase3 | HIV Infections | Completed | 2015-06-12 | 2018-08-17 | ClinicalTrials.gov |
| NCT02478632 | Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Ad… | Phase3 | HIV Infections | Completed | 2015-06-12 | 2018-08-17 | ClinicalTrials.gov |
| NCT02496221 | A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy… | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2015-06-11 | 2015-10-13 | ClinicalTrials.gov |
| NCT02496221 | A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy… | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2015-06-11 | 2015-10-13 | ClinicalTrials.gov |
| NCT02331498 | Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Gl… | Phase1 | Glioblastoma Multiforme | Recruiting | 2015-06-01 | 2030-08-01 | ClinicalTrials.gov |
| NCT02367651 | Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tiss… | Phase2 | Sarcoma, Soft Tissue | Withdrawn | 2015-06-01 | 2018-05-01 | ClinicalTrials.gov |
| NCT02367651 | Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tiss… | Phase2 | Sarcoma, Soft Tissue | Withdrawn | 2015-06-01 | 2018-05-01 | ClinicalTrials.gov |
| NCT02500251 | Belimumab Impacting Transplant Eligibility | Phase1 | Renal Transplant Rejection | Completed | 2015-06-01 | 2018-08-01 | ClinicalTrials.gov |
| NCT02450552 | Clinical Trial of Ezogabine (Retigabine) in ALS Subjects | Phase2 | Amyotrophic Lateral Sclerosis | Completed | 2015-06-01 | 2018-02-01 | ClinicalTrials.gov |
| NCT02459756 | Anthocyanin-rich Blackcurrant and Vascular Function | Na | Vascular Stiffness | Completed | 2015-06-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02458599 | Efficacy Study of Protein Supplementation in Attenuating the Decline in Perform… | Na | Sports Nutritional Sciences | Completed | 2015-06-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02459756 | Anthocyanin-rich Blackcurrant and Vascular Function | Na | Vascular Stiffness | Completed | 2015-06-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02792595 | In Vivo Sun Protection Factor Determination | Na | Skin Care | Completed | 2015-06-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT02331498 | Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Gl… | Phase1 | Glioblastoma Multiforme | Recruiting | 2015-06-01 | 2030-08-01 | ClinicalTrials.gov |
| NCT02292784 | Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children… | Phase3 | Obstetric Labour, Premature | Completed | 2015-06-01 | 2019-09-02 | ClinicalTrials.gov |
| NCT02469298 | Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza | Phase2 | Virus Diseases | Completed | 2015-06-01 | 2016-04-25 | ClinicalTrials.gov |
| NCT02292784 | Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children… | Phase3 | Obstetric Labour, Premature | Completed | 2015-06-01 | 2019-09-02 | ClinicalTrials.gov |
| NCT02500251 | Belimumab Impacting Transplant Eligibility | Phase1 | Renal Transplant Rejection | Completed | 2015-06-01 | 2018-08-01 | ClinicalTrials.gov |
| NCT02450552 | Clinical Trial of Ezogabine (Retigabine) in ALS Subjects | Phase2 | Amyotrophic Lateral Sclerosis | Completed | 2015-06-01 | 2018-02-01 | ClinicalTrials.gov |
| NCT02792595 | In Vivo Sun Protection Factor Determination | Na | Skin Care | Completed | 2015-06-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT02469298 | Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza | Phase2 | Virus Diseases | Completed | 2015-06-01 | 2016-04-25 | ClinicalTrials.gov |
| NCT02458599 | Efficacy Study of Protein Supplementation in Attenuating the Decline in Perform… | Na | Sports Nutritional Sciences | Completed | 2015-06-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02466152 | Pharmacokinetic Study of Topical GSK2894512 Cream | Phase1 | Dermatitis, Atopic | Completed | 2015-05-28 | 2015-10-27 | ClinicalTrials.gov |
| NCT02466152 | Pharmacokinetic Study of Topical GSK2894512 Cream | Phase1 | Dermatitis, Atopic | Completed | 2015-05-28 | 2015-10-27 | ClinicalTrials.gov |
| NCT02453022 | A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Re… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2015-05-18 | 2015-07-31 | ClinicalTrials.gov |
| NCT02453022 | A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Re… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2015-05-18 | 2015-07-31 | ClinicalTrials.gov |
| NCT02415595 | Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults | Phase2 | Infection, Human Immunodeficiency Virus | Terminated | 2015-05-12 | 2017-08-21 | ClinicalTrials.gov |
| NCT02415595 | Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults | Phase2 | Infection, Human Immunodeficiency Virus | Terminated | 2015-05-12 | 2017-08-21 | ClinicalTrials.gov |
| NCT02424565 | Effect of Topical Application of Iodex® Balm on Local Surface Temperature | Phase4 | Pain | Completed | 2015-05-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02124785 | Evaluation of the Long-term Persistence of Hepatitis A Antibodies in Healthy Ad… | Phase4 | Hepatitis A | Withdrawn | 2015-05-01 | 2019-07-01 | ClinicalTrials.gov |
| NCT02003703 | Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Vi… | Phase3 | Hepatitis B | Completed | 2015-05-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT02003703 | Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Vi… | Phase3 | Hepatitis B | Completed | 2015-05-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT02434861 | An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitan… | Phase1 | Chemotherapy-induced Nausea and Vomiting | Completed | 2015-05-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02428127 | Efficacy of a Carbohydrate Drink on Speed, Agility and Power in School Going Ch… | Na | Growth and Development | Completed | 2015-05-01 | 2015-05-30 | ClinicalTrials.gov |
| NCT02135666 | Evaluation of the Long-term Hepatitis A and B Antibody Persistence in Healthy A… | Phase4 | Hepatitis B | Withdrawn | 2015-05-01 | 2019-10-01 | ClinicalTrials.gov |
| NCT02434861 | An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitan… | Phase1 | Chemotherapy-induced Nausea and Vomiting | Completed | 2015-05-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02424565 | Effect of Topical Application of Iodex® Balm on Local Surface Temperature | Phase4 | Pain | Completed | 2015-05-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02428127 | Efficacy of a Carbohydrate Drink on Speed, Agility and Power in School Going Ch… | Na | Growth and Development | Completed | 2015-05-01 | 2015-05-30 | ClinicalTrials.gov |
| NCT02124785 | Evaluation of the Long-term Persistence of Hepatitis A Antibodies in Healthy Ad… | Phase4 | Hepatitis A | Withdrawn | 2015-05-01 | 2019-07-01 | ClinicalTrials.gov |
| NCT02135666 | Evaluation of the Long-term Hepatitis A and B Antibody Persistence in Healthy A… | Phase4 | Hepatitis B | Withdrawn | 2015-05-01 | 2019-10-01 | ClinicalTrials.gov |
| NCT02369341 | Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadriv… | Phase3 | Influenza | Completed | 2015-04-29 | 2015-06-03 | ClinicalTrials.gov |
| NCT02369341 | Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadriv… | Phase3 | Influenza | Completed | 2015-04-29 | 2015-06-03 | ClinicalTrials.gov |
| NCT02221037 | Study of GSK2862277 in Subjects Undergoing Oesophagectomy Surgery | Phase2 | Lung Injury, Acute and Respiratory Distress Syndrome, Adult | Terminated | 2015-04-28 | 2017-06-28 | ClinicalTrials.gov |
| NCT02377401 | Pharmacokinetics of Zanamivir After Single and Repeated Dose Infusion Administr… | Phase1 | Influenza, Human | Completed | 2015-04-28 | 2015-06-19 | ClinicalTrials.gov |
| NCT02377401 | Pharmacokinetics of Zanamivir After Single and Repeated Dose Infusion Administr… | Phase1 | Influenza, Human | Completed | 2015-04-28 | 2015-06-19 | ClinicalTrials.gov |
| NCT02221037 | Study of GSK2862277 in Subjects Undergoing Oesophagectomy Surgery | Phase2 | Lung Injury, Acute and Respiratory Distress Syndrome, Adult | Terminated | 2015-04-28 | 2017-06-28 | ClinicalTrials.gov |
| NCT02422797 | Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regime… | Phase3 | HIV Infections | Completed | 2015-04-21 | 2023-05-25 | ClinicalTrials.gov |
| NCT02422797 | Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regime… | Phase3 | HIV Infections | Completed | 2015-04-21 | 2023-05-25 | ClinicalTrials.gov |
| NCT02294682 | A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK21… | Phase2 | Gonorrhea | Completed | 2015-04-15 | 2016-07-27 | ClinicalTrials.gov |
| NCT02294682 | A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK21… | Phase2 | Gonorrhea | Completed | 2015-04-15 | 2016-07-27 | ClinicalTrials.gov |
| NCT03298061 | Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in … | Phase3 | Churg-Strauss Syndrome | Completed | 2015-04-14 | 2023-02-16 | ClinicalTrials.gov |
| NCT03298061 | Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in … | Phase3 | Churg-Strauss Syndrome | Completed | 2015-04-14 | 2023-02-16 | ClinicalTrials.gov |
| NCT02429791 | Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regime… | Phase3 | HIV Infections | Completed | 2015-04-14 | 2023-05-30 | ClinicalTrials.gov |
| NCT02429791 | Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regime… | Phase3 | HIV Infections | Completed | 2015-04-14 | 2023-05-30 | ClinicalTrials.gov |
| NCT02399163 | Evaluation of Oral Hygiene Products in an In Situ Caries Model | Na | Dental Caries | Completed | 2015-04-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02383290 | The Implementation of Pharmacogenomics Into Primary Care in British Columbia | Na | Pharmacogenetics | Completed | 2015-04-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02399163 | Evaluation of Oral Hygiene Products in an In Situ Caries Model | Na | Dental Caries | Completed | 2015-04-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02383290 | The Implementation of Pharmacogenomics Into Primary Care in British Columbia | Na | Pharmacogenetics | Completed | 2015-04-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02294734 | An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acut… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2015-03-31 | 2016-04-25 | ClinicalTrials.gov |
| NCT01563159 | Number of Rotavirus (RV) Related Hospitalizations in Belgium - Season 2010-2011 | — | Infections, Rotavirus | Completed | 2015-03-31 | 2017-12-31 | ClinicalTrials.gov |
| NCT01563159 | Number of Rotavirus (RV) Related Hospitalizations in Belgium - Season 2010-2011 | — | Infections, Rotavirus | Completed | 2015-03-31 | 2017-12-31 | ClinicalTrials.gov |
| NCT02294734 | An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acut… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2015-03-31 | 2016-04-25 | ClinicalTrials.gov |
| NCT02224456 | Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chr… | Phase4 | Hepatitis B, Chronic | Completed | 2015-03-25 | 2020-12-04 | ClinicalTrials.gov |
| NCT02224456 | Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chr… | Phase4 | Hepatitis B, Chronic | Completed | 2015-03-25 | 2020-12-04 | ClinicalTrials.gov |
| NCT02354586 | A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or… | Phase2 | Ovarian Neoplasms | Completed | 2015-03-23 | 2021-08-23 | ClinicalTrials.gov |
| NCT02354586 | A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or… | Phase2 | Ovarian Neoplasms | Completed | 2015-03-23 | 2021-08-23 | ClinicalTrials.gov |
| NCT02357810 | Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With M… | Phase2 | Adult Liposarcoma | Completed | 2015-03-21 | 2021-10-12 | ClinicalTrials.gov |
| NCT02357810 | Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With M… | Phase2 | Adult Liposarcoma | Completed | 2015-03-21 | 2021-10-12 | ClinicalTrials.gov |
| NCT02360475 | Safety, Reactogenicity and Immunogenicity Study of Different Formulations of Gl… | Phase2 | Respiratory Syncytial Virus Infections | Completed | 2015-03-20 | 2016-06-21 | ClinicalTrials.gov |
| NCT02360475 | Safety, Reactogenicity and Immunogenicity Study of Different Formulations of Gl… | Phase2 | Respiratory Syncytial Virus Infections | Completed | 2015-03-20 | 2016-06-21 | ClinicalTrials.gov |
| NCT02345174 | Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human … | Phase1 | Cancer | Completed | 2015-03-19 | 2016-06-02 | ClinicalTrials.gov |
| NCT02345174 | Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human … | Phase1 | Cancer | Completed | 2015-03-19 | 2016-06-02 | ClinicalTrials.gov |
| NCT02195518 | Tenofovir Disoproxil Fumarate (TDF) 300mg 3 Years RD Therapy Chinese Chronic He… | Phase4 | Hepatitis B, Chronic | Completed | 2015-03-18 | 2018-08-14 | ClinicalTrials.gov |
| NCT02195518 | Tenofovir Disoproxil Fumarate (TDF) 300mg 3 Years RD Therapy Chinese Chronic He… | Phase4 | Hepatitis B, Chronic | Completed | 2015-03-18 | 2018-08-14 | ClinicalTrials.gov |
| NCT02551614 | Neutrophil Imaging in Healthy Subjects Following Lipopolysaccharide or Saline C… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2015-03-17 | 2016-05-24 | ClinicalTrials.gov |
| NCT02551614 | Neutrophil Imaging in Healthy Subjects Following Lipopolysaccharide or Saline C… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2015-03-17 | 2016-05-24 | ClinicalTrials.gov |
| NCT02292771 | A Randomized Study Comparing the Efficacy and Safety of Retosiban Versus Atosib… | Phase3 | Obstetric Labour, Premature | Terminated | 2015-03-16 | 2017-08-25 | ClinicalTrials.gov |
| NCT02292771 | A Randomized Study Comparing the Efficacy and Safety of Retosiban Versus Atosib… | Phase3 | Obstetric Labour, Premature | Terminated | 2015-03-16 | 2017-08-25 | ClinicalTrials.gov |
| NCT02377414 | Study to Investigate the Pharmacokinetics (PK), Safety and Tolerability of Reto… | Phase1 | Obstetric Labour, Premature | Completed | 2015-03-02 | 2015-04-17 | ClinicalTrials.gov |
| NCT02377414 | Study to Investigate the Pharmacokinetics (PK), Safety and Tolerability of Reto… | Phase1 | Obstetric Labour, Premature | Completed | 2015-03-02 | 2015-04-17 | ClinicalTrials.gov |
| NCT02403999 | A Tolerability Assessment Study of Three Wash Products in Infants | Na | Skin Care | Completed | 2015-03-01 | 2015-04-27 | ClinicalTrials.gov |
| NCT02301975 | An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram… | Phase3 | Asthma | Completed | 2015-03-01 | 2016-11-25 | ClinicalTrials.gov |
| NCT02403999 | A Tolerability Assessment Study of Three Wash Products in Infants | Na | Skin Care | Completed | 2015-03-01 | 2015-04-27 | ClinicalTrials.gov |
| NCT02301975 | An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram… | Phase3 | Asthma | Completed | 2015-03-01 | 2016-11-25 | ClinicalTrials.gov |
| NCT02204371 | Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Te… | Phase2 | Telangiectasia, Hereditary Hemorrhagic | Terminated | 2015-02-25 | 2016-02-10 | ClinicalTrials.gov |
| NCT02204371 | Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Te… | Phase2 | Telangiectasia, Hereditary Hemorrhagic | Terminated | 2015-02-25 | 2016-02-10 | ClinicalTrials.gov |
| NCT02339155 | Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed | Phase4 | Infections, Bacterial | Completed | 2015-02-24 | 2017-06-06 | ClinicalTrials.gov |
| NCT02339155 | Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed | Phase4 | Infections, Bacterial | Completed | 2015-02-24 | 2017-06-06 | ClinicalTrials.gov |
| NCT02322671 | Relative Bioavailability Study of Two Montelukast Sodium (GW483100) 5 Milligram… | Phase1 | Respiratory Disorders | Completed | 2015-02-23 | 2015-04-20 | ClinicalTrials.gov |
| NCT02322671 | Relative Bioavailability Study of Two Montelukast Sodium (GW483100) 5 Milligram… | Phase1 | Respiratory Disorders | Completed | 2015-02-23 | 2015-04-20 | ClinicalTrials.gov |
| NCT02082665 | Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin … | Phase1 | Cancer | Completed | 2015-02-19 | 2016-08-01 | ClinicalTrials.gov |
| NCT02082665 | Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin … | Phase1 | Cancer | Completed | 2015-02-19 | 2016-08-01 | ClinicalTrials.gov |
| NCT02371603 | Drug-drug Interaction Study of GSK1278863 With Pioglitazone, Rosuvastatin and T… | Phase1 | Anaemia | Completed | 2015-02-11 | 2015-08-12 | ClinicalTrials.gov |
| NCT02371603 | Drug-drug Interaction Study of GSK1278863 With Pioglitazone, Rosuvastatin and T… | Phase1 | Anaemia | Completed | 2015-02-11 | 2015-08-12 | ClinicalTrials.gov |
| NCT02191397 | Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochlor… | Phase3 | Depressive Disorder, Major | Completed | 2015-02-10 | 2016-10-25 | ClinicalTrials.gov |
| NCT02191397 | Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochlor… | Phase3 | Depressive Disorder, Major | Completed | 2015-02-10 | 2016-10-25 | ClinicalTrials.gov |
| NCT02404311 | A Safety and Immune Response Study of 2 Experimental HIV Vaccines | Phase1 | HIV Infection | Completed | 2015-02-02 | 2018-08-07 | ClinicalTrials.gov |
| NCT02404311 | A Safety and Immune Response Study of 2 Experimental HIV Vaccines | Phase1 | HIV Infection | Completed | 2015-02-02 | 2018-08-07 | ClinicalTrials.gov |
| NCT02476552 | Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailab… | Phase1 | Cancer | Completed | 2015-02-01 | 2018-01-01 | ClinicalTrials.gov |
| NCT02447978 | Duration of Protection: GSK DTaP Vaccines | — | Diphtheria | Completed | 2015-02-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01991899 | Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mum… | Phase3 | Measles | Completed | 2015-02-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT02082639 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Pap… | Phase3 | Infections, Papillomavirus | Withdrawn | 2015-02-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02082639 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Pap… | Phase3 | Infections, Papillomavirus | Withdrawn | 2015-02-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02373930 | Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dol… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2015-02-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02476552 | Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailab… | Phase1 | Cancer | Completed | 2015-02-01 | 2018-01-01 | ClinicalTrials.gov |
| NCT02373930 | Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dol… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2015-02-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02447978 | Duration of Protection: GSK DTaP Vaccines | — | Diphtheria | Completed | 2015-02-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01991899 | Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mum… | Phase3 | Measles | Completed | 2015-02-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT02355665 | Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Ther… | Phase3 | Tobacco Dependence | Completed | 2015-01-31 | 2016-02-10 | ClinicalTrials.gov |
| NCT02355665 | Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Ther… | Phase3 | Tobacco Dependence | Completed | 2015-01-31 | 2016-02-10 | ClinicalTrials.gov |
| NCT02467335 | Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subj… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2015-01-29 | 2015-10-03 | ClinicalTrials.gov |
| NCT02467335 | Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subj… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2015-01-29 | 2015-10-03 | ClinicalTrials.gov |
| NCT02275052 | A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vi… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2015-01-23 | 2016-06-02 | ClinicalTrials.gov |
| NCT02275052 | A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vi… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2015-01-23 | 2016-06-02 | ClinicalTrials.gov |
| NCT02178592 | Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodefic… | Phase3 | Infection, Human Immunodeficiency Virus | Completed | 2015-01-23 | 2020-03-06 | ClinicalTrials.gov |
| NCT02178592 | Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodefic… | Phase3 | Infection, Human Immunodeficiency Virus | Completed | 2015-01-23 | 2020-03-06 | ClinicalTrials.gov |
| NCT02231190 | GSK1278863 Effects on Eccentric Exercise-Induced Muscle Damage | Phase1 | Tendon Injuries | Completed | 2015-01-15 | 2015-06-12 | ClinicalTrials.gov |
| NCT02231190 | GSK1278863 Effects on Eccentric Exercise-Induced Muscle Damage | Phase1 | Tendon Injuries | Completed | 2015-01-15 | 2015-06-12 | ClinicalTrials.gov |
| NCT02262689 | To Evaluate Effects of GSK2256294 on Pulmonary Artery Pressure in Healthy Volun… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2015-01-08 | 2015-04-24 | ClinicalTrials.gov |
| NCT02262689 | To Evaluate Effects of GSK2256294 on Pulmonary Artery Pressure in Healthy Volun… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2015-01-08 | 2015-04-24 | ClinicalTrials.gov |
| NCT02323217 | I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers | Early_Phase1 | Healthy Volunteers | Completed | 2015-01-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT02382666 | A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability… | Phase1 | Chemotherapy-induced Nausea and Vomiting | Completed | 2015-01-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02100618 | Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS… | Phase3 | Infections, Papillomavirus | Withdrawn | 2015-01-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT01890447 | Assessing Contacts' Decision Making on Reducing the Risk of Pertussis Transmiss… | — | Pertussis | Completed | 2015-01-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02302417 | Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With F… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2015-01-01 | 2015-05-28 | ClinicalTrials.gov |
| NCT02311881 | A 12-Week Efficacy Study of Paracetamol 1000mg Sustained-release Tablets in Pat… | Phase3 | Pain | Completed | 2015-01-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02323217 | I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers | Early_Phase1 | Healthy Volunteers | Completed | 2015-01-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT02347891 | Belimumab in Idiopathic Inflammatory Myositis | Phase2 | Myositis | Completed | 2015-01-01 | 2020-11-01 | ClinicalTrials.gov |
| NCT02311881 | A 12-Week Efficacy Study of Paracetamol 1000mg Sustained-release Tablets in Pat… | Phase3 | Pain | Completed | 2015-01-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02382666 | A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability… | Phase1 | Chemotherapy-induced Nausea and Vomiting | Completed | 2015-01-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02302417 | Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With F… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2015-01-01 | 2015-05-28 | ClinicalTrials.gov |
| NCT02246166 | The Effect of Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydr… | Phase4 | Common Cold | Completed | 2015-01-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT02100618 | Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS… | Phase3 | Infections, Papillomavirus | Withdrawn | 2015-01-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02246166 | The Effect of Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydr… | Phase4 | Common Cold | Completed | 2015-01-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01890447 | Assessing Contacts' Decision Making on Reducing the Risk of Pertussis Transmiss… | — | Pertussis | Completed | 2015-01-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02347891 | Belimumab in Idiopathic Inflammatory Myositis | Phase2 | Myositis | Completed | 2015-01-01 | 2020-11-01 | ClinicalTrials.gov |
| NCT02298179 | A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies … | Phase1 | Respiratory Syncytial Virus (RSV) | Completed | 2014-12-19 | 2017-03-27 | ClinicalTrials.gov |
| NCT02110355 | A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma | Phase1 | Advanced Malignancy | Completed | 2014-12-19 | 2018-12-27 | ClinicalTrials.gov |
| NCT02110355 | A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma | Phase1 | Advanced Malignancy | Completed | 2014-12-19 | 2018-12-27 | ClinicalTrials.gov |
| NCT02298179 | A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies … | Phase1 | Respiratory Syncytial Virus (RSV) | Completed | 2014-12-19 | 2017-03-27 | ClinicalTrials.gov |
| NCT02257359 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban i… | Phase1 | Embryo Transfer | Completed | 2014-12-18 | 2015-01-29 | ClinicalTrials.gov |
| NCT02257359 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban i… | Phase1 | Embryo Transfer | Completed | 2014-12-18 | 2015-01-29 | ClinicalTrials.gov |
| NCT02075593 | ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno… | Phase3 | Infection, Human Immunodeficiency Virus | Completed | 2014-12-17 | 2021-09-15 | ClinicalTrials.gov |
| NCT02075593 | ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno… | Phase3 | Infection, Human Immunodeficiency Virus | Completed | 2014-12-17 | 2021-09-15 | ClinicalTrials.gov |
| NCT02227238 | Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir i… | Phase3 | HIV Infections | Completed | 2014-12-11 | 2022-02-14 | ClinicalTrials.gov |
| NCT02281318 | Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants Wit… | Phase3 | Asthma | Completed | 2014-12-11 | 2016-06-10 | ClinicalTrials.gov |
| NCT02227238 | Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir i… | Phase3 | HIV Infections | Completed | 2014-12-11 | 2022-02-14 | ClinicalTrials.gov |
| NCT02281318 | Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants Wit… | Phase3 | Asthma | Completed | 2014-12-11 | 2016-06-10 | ClinicalTrials.gov |
| NCT02112890 | Study to Assess Seroprevalence of Hepatitis A, Hepatitis B and Bordetella Pertu… | — | Hepatitis A | Completed | 2014-12-10 | 2016-05-02 | ClinicalTrials.gov |
| NCT02112890 | Study to Assess Seroprevalence of Hepatitis A, Hepatitis B and Bordetella Pertu… | — | Hepatitis A | Completed | 2014-12-10 | 2016-05-02 | ClinicalTrials.gov |
| NCT02299375 | Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating P… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-12-09 | 2016-06-30 | ClinicalTrials.gov |
| NCT02299375 | Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating P… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-12-09 | 2016-06-30 | ClinicalTrials.gov |
| NCT02254447 | Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions | Phase1 | Cardiovascular Disease | Completed | 2014-12-02 | 2015-01-08 | ClinicalTrials.gov |
| NCT02254447 | Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions | Phase1 | Cardiovascular Disease | Completed | 2014-12-02 | 2015-01-08 | ClinicalTrials.gov |
| NCT01978223 | Effectiveness of RotarixTM Vaccine in Children Aged Between 12 Weeks to < 5 Yea… | — | Infections, Rotavirus | Withdrawn | 2014-12-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02293265 | Cross-sectional Study for Identification and Description of Severe Asthma Patie… | Phase3 | Asthma | Completed | 2014-12-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT01978223 | Effectiveness of RotarixTM Vaccine in Children Aged Between 12 Weeks to < 5 Yea… | — | Infections, Rotavirus | Withdrawn | 2014-12-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02287688 | Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study | — | Meningococcal Disease | Completed | 2014-12-01 | 2017-11-29 | ClinicalTrials.gov |
| NCT02285777 | Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY V… | Phase2 | Meningococcal Disease | Completed | 2014-12-01 | 2015-06-11 | ClinicalTrials.gov |
| NCT02293265 | Cross-sectional Study for Identification and Description of Severe Asthma Patie… | Phase3 | Asthma | Completed | 2014-12-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02285777 | Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY V… | Phase2 | Meningococcal Disease | Completed | 2014-12-01 | 2015-06-11 | ClinicalTrials.gov |
| NCT02287688 | Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study | — | Meningococcal Disease | Completed | 2014-12-01 | 2017-11-29 | ClinicalTrials.gov |
| NCT02289482 | A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and With… | Phase1 | Infection, Human Immunodeficiency Virus | Terminated | 2014-11-17 | 2015-03-10 | ClinicalTrials.gov |
| NCT02424799 | Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetic… | Phase1 | Urticaria | Completed | 2014-11-17 | 2017-11-10 | ClinicalTrials.gov |
| NCT02293148 | Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 … | Phase1 | Anaemia | Completed | 2014-11-17 | 2015-03-10 | ClinicalTrials.gov |
| NCT02289482 | A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and With… | Phase1 | Infection, Human Immunodeficiency Virus | Terminated | 2014-11-17 | 2015-03-10 | ClinicalTrials.gov |
| NCT02424799 | Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetic… | Phase1 | Urticaria | Completed | 2014-11-17 | 2017-11-10 | ClinicalTrials.gov |
| NCT02293148 | Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 … | Phase1 | Anaemia | Completed | 2014-11-17 | 2015-03-10 | ClinicalTrials.gov |
| NCT02233803 | A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOT… | Phase4 | Asthma | Completed | 2014-11-14 | 2015-12-11 | ClinicalTrials.gov |
| NCT02233803 | A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOT… | Phase4 | Asthma | Completed | 2014-11-14 | 2015-12-11 | ClinicalTrials.gov |
| NCT02215096 | Dose-finding Study of GSK2636771 When Administered in Combination With Enzaluta… | Phase1 | Neoplasms | Completed | 2014-11-13 | 2019-10-03 | ClinicalTrials.gov |
| NCT02215096 | Dose-finding Study of GSK2636771 When Administered in Combination With Enzaluta… | Phase1 | Neoplasms | Completed | 2014-11-13 | 2019-10-03 | ClinicalTrials.gov |
| NCT02293161 | Single Ascending Doses Study of Anti- Interleukin-7 Receptor α Monoclonal Antib… | Phase1 | Autoimmune Diseases | Completed | 2014-11-11 | 2015-09-01 | ClinicalTrials.gov |
| NCT02293161 | Single Ascending Doses Study of Anti- Interleukin-7 Receptor α Monoclonal Antib… | Phase1 | Autoimmune Diseases | Completed | 2014-11-11 | 2015-09-01 | ClinicalTrials.gov |
| NCT02281370 | Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects | Phase1 | Purpura, Thrombocytopenic, Idiopathic | Completed | 2014-11-05 | 2014-12-24 | ClinicalTrials.gov |
| NCT02277600 | A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI) | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2014-11-05 | 2015-01-12 | ClinicalTrials.gov |
| NCT02281370 | Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects | Phase1 | Purpura, Thrombocytopenic, Idiopathic | Completed | 2014-11-05 | 2014-12-24 | ClinicalTrials.gov |
| NCT02277600 | A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI) | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2014-11-05 | 2015-01-12 | ClinicalTrials.gov |
| NCT02195284 | To Study Device Attributes by Investigating Errors Made in Use, Ease of Use and… | Phase4 | Asthma | Completed | 2014-11-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02195284 | To Study Device Attributes by Investigating Errors Made in Use, Ease of Use and… | Phase4 | Asthma | Completed | 2014-11-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02218723 | Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using … | Phase1 | Asthma | Completed | 2014-10-28 | 2014-12-19 | ClinicalTrials.gov |
| NCT02218723 | Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using … | Phase1 | Asthma | Completed | 2014-10-28 | 2014-12-19 | ClinicalTrials.gov |
| NCT02273947 | Food Effect Study With BMS-955176 | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2014-10-23 | 2016-08-15 | ClinicalTrials.gov |
| NCT02273947 | Food Effect Study With BMS-955176 | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2014-10-23 | 2016-08-15 | ClinicalTrials.gov |
| NCT02251704 | Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa | Phase4 | Malaria | Completed | 2014-10-22 | 2024-07-06 | ClinicalTrials.gov |
| NCT02251704 | Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa | Phase4 | Malaria | Completed | 2014-10-22 | 2024-07-06 | ClinicalTrials.gov |
| NCT02257385 | Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combinat… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-10-15 | 2015-05-04 | ClinicalTrials.gov |
| NCT02257385 | Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combinat… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-10-15 | 2015-05-04 | ClinicalTrials.gov |
| NCT02284009 | Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Di… | Phase2 | Diabetes Mellitus, Type 1 | Completed | 2014-10-10 | 2017-10-18 | ClinicalTrials.gov |
| NCT02284009 | Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Di… | Phase2 | Diabetes Mellitus, Type 1 | Completed | 2014-10-10 | 2017-10-18 | ClinicalTrials.gov |
| NCT02230553 | Lapatinib Plus Trametinib in KRAS Mutant NSCLC | Phase1 | Colorectal Cancer | Completed | 2014-10-07 | 2019-08-06 | ClinicalTrials.gov |
| NCT02230553 | Lapatinib Plus Trametinib in KRAS Mutant NSCLC | Phase1 | Colorectal Cancer | Completed | 2014-10-07 | 2019-08-06 | ClinicalTrials.gov |
| NCT02523287 | Placebo Controlled Study to Generate Data Characterising Clinical Events, Physi… | Phase4 | Safety Markers of Adjuvanted Influenza Vaccine | Completed | 2014-10-02 | 2016-08-01 | ClinicalTrials.gov |
| NCT02523287 | Placebo Controlled Study to Generate Data Characterising Clinical Events, Physi… | Phase4 | Safety Markers of Adjuvanted Influenza Vaccine | Completed | 2014-10-02 | 2016-08-01 | ClinicalTrials.gov |
| NCT02218697 | Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biological… | Phase3 | Influenza | Completed | 2014-10-01 | 2015-05-04 | ClinicalTrials.gov |
| NCT02289027 | A Clinical Trial on the Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switze… | Phase1 | Ebola Vaccines | Completed | 2014-10-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02289027 | A Clinical Trial on the Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switze… | Phase1 | Ebola Vaccines | Completed | 2014-10-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02218762 | A Study in Patients With Moderate Asthma to Compare Pharmacokinetics and Pharma… | Phase1 | Asthma | Withdrawn | 2014-10-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02201238 | Pharmacokinetics Study Comparing Topical Diclofenac/Menthol Gels With Voltaren … | Phase1 | Pain | Completed | 2014-10-01 | 2014-11-21 | ClinicalTrials.gov |
| NCT02218762 | A Study in Patients With Moderate Asthma to Compare Pharmacokinetics and Pharma… | Phase1 | Asthma | Withdrawn | 2014-10-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02218697 | Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biological… | Phase3 | Influenza | Completed | 2014-10-01 | 2015-05-04 | ClinicalTrials.gov |
| NCT02519751 | New Method Using Deuterium Labelled Creatine to Measure Total Body Skeletal Mus… | Na | Sports Nutritional Sciences | Completed | 2014-10-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT02324218 | This Study Aims to Determine the Incidence, of Hepatitis B Diagnosis Among Diab… | — | Hepatitis B | Completed | 2014-10-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT02201238 | Pharmacokinetics Study Comparing Topical Diclofenac/Menthol Gels With Voltaren … | Phase1 | Pain | Completed | 2014-10-01 | 2014-11-21 | ClinicalTrials.gov |
| NCT02519751 | New Method Using Deuterium Labelled Creatine to Measure Total Body Skeletal Mus… | Na | Sports Nutritional Sciences | Completed | 2014-10-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT02324218 | This Study Aims to Determine the Incidence, of Hepatitis B Diagnosis Among Diab… | — | Hepatitis B | Completed | 2014-10-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT02345187 | fMRI Study to Investigate Hemodynamic Changes in Brain Resulting From Supplemen… | Na | Growth and Development | Completed | 2014-10-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02345187 | fMRI Study to Investigate Hemodynamic Changes in Brain Resulting From Supplemen… | Na | Growth and Development | Completed | 2014-10-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02257372 | A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-09-30 | 2015-03-24 | ClinicalTrials.gov |
| NCT02257372 | A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-09-30 | 2015-03-24 | ClinicalTrials.gov |
| NCT02371616 | Clinical Study to Evaluate the Efficacy of Two Dentifrices for Dentine Hypersen… | Na | Dentine Sensitivity | Completed | 2014-09-29 | 2014-12-18 | ClinicalTrials.gov |
| NCT02371616 | Clinical Study to Evaluate the Efficacy of Two Dentifrices for Dentine Hypersen… | Na | Dentine Sensitivity | Completed | 2014-09-29 | 2014-12-18 | ClinicalTrials.gov |
| NCT02236611 | A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microg… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-09-26 | 2015-06-02 | ClinicalTrials.gov |
| NCT02236611 | A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microg… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-09-26 | 2015-06-02 | ClinicalTrials.gov |
| NCT01990196 | Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without S… | Phase2 | Prostate Cancer | Active_Not_Recruiting | 2014-09-23 | 2026-09-30 | ClinicalTrials.gov |
| NCT01990196 | Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without S… | Phase2 | Prostate Cancer | Active_Not_Recruiting | 2014-09-23 | 2026-09-30 | ClinicalTrials.gov |
| NCT02207816 | An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term E… | Phase3 | Malaria | Completed | 2014-09-18 | 2017-01-31 | ClinicalTrials.gov |
| NCT02207816 | An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term E… | Phase3 | Malaria | Completed | 2014-09-18 | 2017-01-31 | ClinicalTrials.gov |
| NCT01899742 | The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-09-15 | 2015-07-22 | ClinicalTrials.gov |
| NCT01899742 | The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-09-15 | 2015-07-22 | ClinicalTrials.gov |
| NCT02173704 | Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B… | Phase3 | Meningococcal Disease | Completed | 2014-09-11 | 2016-06-17 | ClinicalTrials.gov |
| NCT02173704 | Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B… | Phase3 | Meningococcal Disease | Completed | 2014-09-11 | 2016-06-17 | ClinicalTrials.gov |
| NCT02234882 | Study on Pharmacokinetics | Phase1 | HIV Infections | Completed | 2014-09-05 | 2014-10-31 | ClinicalTrials.gov |
| NCT02234882 | Study on Pharmacokinetics | Phase1 | HIV Infections | Completed | 2014-09-05 | 2014-10-31 | ClinicalTrials.gov |
| NCT02158507 | Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Meta… | Na | Metastatic Triple Negative Breast Cancer | Completed | 2014-09-04 | 2021-07-22 | ClinicalTrials.gov |
| NCT02158507 | Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Meta… | Na | Metastatic Triple Negative Breast Cancer | Completed | 2014-09-04 | 2021-07-22 | ClinicalTrials.gov |
| NCT02226562 | Clinical Study Investigating the Efficacy of a Mouthwash in Providing Long Term… | Phase2 | Dentin Sensitivity | Completed | 2014-09-02 | 2014-12-05 | ClinicalTrials.gov |
| NCT02226562 | Clinical Study Investigating the Efficacy of a Mouthwash in Providing Long Term… | Phase2 | Dentin Sensitivity | Completed | 2014-09-02 | 2014-12-05 | ClinicalTrials.gov |
| NCT02285647 | An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenou… | Phase1 | Chemotherapy-induced Nausea and Vomiting | Completed | 2014-09-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02152605 | A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-09-01 | 2015-03-05 | ClinicalTrials.gov |
| NCT02207829 | A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared Wi… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-09-01 | 2015-06-15 | ClinicalTrials.gov |
| NCT02207829 | A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared Wi… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-09-01 | 2015-06-15 | ClinicalTrials.gov |
| NCT02285647 | An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenou… | Phase1 | Chemotherapy-induced Nausea and Vomiting | Completed | 2014-09-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02152605 | A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-09-01 | 2015-03-05 | ClinicalTrials.gov |
| NCT02254434 | A Pharmacokinetic Study of Eltrombopag 50 Milligram (mg) in Healthy Volunteers … | Phase1 | Cirrhosis, Liver | Completed | 2014-08-28 | 2014-09-08 | ClinicalTrials.gov |
| NCT02213029 | A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentration… | Phase1 | Embryo Transfer | Terminated | 2014-08-28 | 2016-02-07 | ClinicalTrials.gov |
| NCT02213029 | A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentration… | Phase1 | Embryo Transfer | Terminated | 2014-08-28 | 2016-02-07 | ClinicalTrials.gov |
| NCT02254434 | A Pharmacokinetic Study of Eltrombopag 50 Milligram (mg) in Healthy Volunteers … | Phase1 | Cirrhosis, Liver | Completed | 2014-08-28 | 2014-09-08 | ClinicalTrials.gov |
| NCT02210000 | A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1… | Phase2 | Gastroparesis | Completed | 2014-08-27 | 2015-08-24 | ClinicalTrials.gov |
| NCT02202161 | A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynami… | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2014-08-27 | 2015-01-30 | ClinicalTrials.gov |
| NCT02210000 | A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1… | Phase2 | Gastroparesis | Completed | 2014-08-27 | 2015-08-24 | ClinicalTrials.gov |
| NCT02177812 | A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Le… | Phase1 | Leukaemia, Myelocytic, Acute | Terminated | 2014-08-27 | 2017-12-08 | ClinicalTrials.gov |
| NCT02177812 | A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Le… | Phase1 | Leukaemia, Myelocytic, Acute | Terminated | 2014-08-27 | 2017-12-08 | ClinicalTrials.gov |
| NCT02202161 | A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynami… | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2014-08-27 | 2015-01-30 | ClinicalTrials.gov |
| NCT02207400 | To Evaluate Efficacy and Tolerability of Sodium Bicarbonate Toothpaste and Its … | Phase2 | Oral Hygiene | Completed | 2014-08-25 | 2015-04-30 | ClinicalTrials.gov |
| NCT02184572 | Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, … | Phase3 | Measles; Mumps; Rubella | Completed | 2014-08-25 | 2015-12-22 | ClinicalTrials.gov |
| NCT02184572 | Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, … | Phase3 | Measles; Mumps; Rubella | Completed | 2014-08-25 | 2015-12-22 | ClinicalTrials.gov |
| NCT02207400 | To Evaluate Efficacy and Tolerability of Sodium Bicarbonate Toothpaste and Its … | Phase2 | Oral Hygiene | Completed | 2014-08-25 | 2015-04-30 | ClinicalTrials.gov |
| NCT02212457 | Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals'… | Phase2 | Infections, Meningococcal | Completed | 2014-08-21 | 2016-03-03 | ClinicalTrials.gov |
| NCT02212457 | Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals'… | Phase2 | Infections, Meningococcal | Completed | 2014-08-21 | 2016-03-03 | ClinicalTrials.gov |
| NCT01755598 | Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate … | Phase2 | Tuberculosis | Completed | 2014-08-19 | 2018-11-16 | ClinicalTrials.gov |
| NCT01755598 | Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate … | Phase2 | Tuberculosis | Completed | 2014-08-19 | 2018-11-16 | ClinicalTrials.gov |
| NCT02207413 | A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biol… | Phase3 | Influenza | Completed | 2014-08-18 | 2015-04-18 | ClinicalTrials.gov |
| NCT02207413 | A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biol… | Phase3 | Influenza | Completed | 2014-08-18 | 2015-04-18 | ClinicalTrials.gov |
| NCT02075515 | Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologica… | Phase3 | Herpes Zoster | Completed | 2014-08-13 | 2016-04-25 | ClinicalTrials.gov |
| NCT02075515 | Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologica… | Phase3 | Herpes Zoster | Completed | 2014-08-13 | 2016-04-25 | ClinicalTrials.gov |
| NCT02058953 | CNS and Extracranial Tumor Tissues, CSF, and Blood From Patients With Melanoma … | — | Melanoma | Completed | 2014-08-12 | 2019-08-19 | ClinicalTrials.gov |
| NCT02058953 | CNS and Extracranial Tumor Tissues, CSF, and Blood From Patients With Melanoma … | — | Melanoma | Completed | 2014-08-12 | 2019-08-19 | ClinicalTrials.gov |
| NCT02206711 | Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class … | Phase1 | HIV Infections | Completed | 2014-08-08 | 2014-09-09 | ClinicalTrials.gov |
| NCT02206711 | Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class … | Phase1 | HIV Infections | Completed | 2014-08-08 | 2014-09-09 | ClinicalTrials.gov |
| NCT02323178 | A Study of Eltrombopag in Patients With CMML and Thrombocytopenia | Phase1 | CMML | Completed | 2014-08-07 | 2021-04-01 | ClinicalTrials.gov |
| NCT02323178 | A Study of Eltrombopag in Patients With CMML and Thrombocytopenia | Phase1 | CMML | Completed | 2014-08-07 | 2021-04-01 | ClinicalTrials.gov |
| NCT01803399 | A Study to Evaluate the Effect of GSK1322322 on Cardiac Conduction as Assessed … | Phase1 | Infections, Bacterial | Withdrawn | 2014-08-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02097095 | Substudy of Protocol TB-018 (NCT01755598): Collection and Storage of Biological… | — | Tuberculosis | Completed | 2014-08-01 | 2016-11-30 | ClinicalTrials.gov |
| NCT01803399 | A Study to Evaluate the Effect of GSK1322322 on Cardiac Conduction as Assessed … | Phase1 | Infections, Bacterial | Withdrawn | 2014-08-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02367222 | A Database Study to Estimate the Risk of Multiple Sclerosis Following Vaccinati… | — | Multiple Sclerosis | Completed | 2014-08-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02174978 | Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evalua… | Phase1 | Malaria | Completed | 2014-08-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02207907 | To Evaluate the Efficacy and Tolerability of Sodium Bicarbonate Toothpaste | Phase2 | Oral Hygiene | Completed | 2014-08-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT02207907 | To Evaluate the Efficacy and Tolerability of Sodium Bicarbonate Toothpaste | Phase2 | Oral Hygiene | Completed | 2014-08-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01953809 | A Pharmacokinetics, Pharmacodynamics, and Safety Study of an Oral Contraceptive… | Phase1 | Infections, Bacterial | Withdrawn | 2014-08-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01953809 | A Pharmacokinetics, Pharmacodynamics, and Safety Study of an Oral Contraceptive… | Phase1 | Infections, Bacterial | Withdrawn | 2014-08-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT02174978 | Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evalua… | Phase1 | Malaria | Completed | 2014-08-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02097095 | Substudy of Protocol TB-018 (NCT01755598): Collection and Storage of Biological… | — | Tuberculosis | Completed | 2014-08-01 | 2016-11-30 | ClinicalTrials.gov |
| NCT02367222 | A Database Study to Estimate the Risk of Multiple Sclerosis Following Vaccinati… | — | Multiple Sclerosis | Completed | 2014-08-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02130635 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Respon… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-07-31 | 2015-08-18 | ClinicalTrials.gov |
| NCT02130635 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Respon… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-07-31 | 2015-08-18 | ClinicalTrials.gov |
| NCT02184637 | A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-adm… | Phase1 | Malaria, Vivax | Completed | 2014-07-31 | 2015-04-08 | ClinicalTrials.gov |
| NCT02184637 | A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-adm… | Phase1 | Malaria, Vivax | Completed | 2014-07-31 | 2015-04-08 | ClinicalTrials.gov |
| NCT02135861 | A Method Validation Study for Evaluation of Novel Treatments Limiting Pulmonary… | Phase1 | Heart Failure, Congestive | Completed | 2014-07-30 | 2017-02-22 | ClinicalTrials.gov |
| NCT02135861 | A Method Validation Study for Evaluation of Novel Treatments Limiting Pulmonary… | Phase1 | Heart Failure, Congestive | Completed | 2014-07-30 | 2017-02-22 | ClinicalTrials.gov |
| NCT02064387 | Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodyna… | Phase1 | Multiple Myeloma | Completed | 2014-07-29 | 2019-08-01 | ClinicalTrials.gov |
| NCT02064387 | Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodyna… | Phase1 | Multiple Myeloma | Completed | 2014-07-29 | 2019-08-01 | ClinicalTrials.gov |
| NCT02184585 | Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of… | Phase1 | Prostatic Hyperplasia | Completed | 2014-07-10 | 2015-02-23 | ClinicalTrials.gov |
| NCT02184585 | Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of… | Phase1 | Prostatic Hyperplasia | Completed | 2014-07-10 | 2015-02-23 | ClinicalTrials.gov |
| NCT02075541 | A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmith… | Phase2 | Respiratory Disorders | Completed | 2014-07-08 | 2017-04-19 | ClinicalTrials.gov |
| NCT02075541 | A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmith… | Phase2 | Respiratory Disorders | Completed | 2014-07-08 | 2017-04-19 | ClinicalTrials.gov |
| NCT02014584 | Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia | Phase3 | Alopecia | Completed | 2014-07-02 | 2016-03-19 | ClinicalTrials.gov |
| NCT02014584 | Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia | Phase3 | Alopecia | Completed | 2014-07-02 | 2016-03-19 | ClinicalTrials.gov |
| NCT02058563 | Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Va… | Phase3 | Rubella | Completed | 2014-07-01 | 2015-09-17 | ClinicalTrials.gov |
| NCT02546349 | Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS… | Phase4 | COPD | Unknown | 2014-07-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT02164539 | Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in C… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-07-01 | 2015-07-18 | ClinicalTrials.gov |
| NCT02416245 | Impact of Beverage Powder With Micronutrients and Brahmi Extract on Cognitive V… | Na | Cognition | Completed | 2014-07-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT02416245 | Impact of Beverage Powder With Micronutrients and Brahmi Extract on Cognitive V… | Na | Cognition | Completed | 2014-07-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT02164539 | Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in C… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-07-01 | 2015-07-18 | ClinicalTrials.gov |
| NCT02188238 | Effect of Oral Health Ingredients on the Acquired Salivary Pellicle | — | Healthy | Completed | 2014-07-01 | 2018-12-31 | ClinicalTrials.gov |
| NCT02546349 | Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS… | Phase4 | COPD | Unknown | 2014-07-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT02058563 | Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Va… | Phase3 | Rubella | Completed | 2014-07-01 | 2015-09-17 | ClinicalTrials.gov |
| NCT02188238 | Effect of Oral Health Ingredients on the Acquired Salivary Pellicle | — | Healthy | Completed | 2014-07-01 | 2018-12-31 | ClinicalTrials.gov |
| NCT02250729 | Allergy to Neuromuscular Blocking Agents and Pholcodine Exposure | Na | Neuromuscular Blocking Agents Anaphylaxis | Unknown | 2014-07-01 | 2020-07-01 | ClinicalTrials.gov |
| NCT02250729 | Allergy to Neuromuscular Blocking Agents and Pholcodine Exposure | Na | Neuromuscular Blocking Agents Anaphylaxis | Unknown | 2014-07-01 | 2020-07-01 | ClinicalTrials.gov |
| NCT02164513 | A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combinati… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-06-30 | 2017-07-17 | ClinicalTrials.gov |
| NCT02164513 | A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combinati… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-06-30 | 2017-07-17 | ClinicalTrials.gov |
| NCT02106000 | A Non-investigational Product (IP) Study to Investigate Lung Function in Women … | — | Haemorrhage | Completed | 2014-06-24 | 2014-12-20 | ClinicalTrials.gov |
| NCT02164045 | Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529 | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2014-06-24 | 2014-07-25 | ClinicalTrials.gov |
| NCT02164045 | Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529 | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2014-06-24 | 2014-07-25 | ClinicalTrials.gov |
| NCT02106000 | A Non-investigational Product (IP) Study to Investigate Lung Function in Women … | — | Haemorrhage | Completed | 2014-06-24 | 2014-12-20 | ClinicalTrials.gov |
| NCT02153346 | Indirect Cost of Illness Study of Moderate and Severe Asthma in Quebec | Na | Asthma | Completed | 2014-06-22 | 2016-04-22 | ClinicalTrials.gov |
| NCT02153346 | Indirect Cost of Illness Study of Moderate and Severe Asthma in Quebec | Na | Asthma | Completed | 2014-06-22 | 2016-04-22 | ClinicalTrials.gov |
| NCT02169583 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and … | Phase1 | Infections, Respiratory Tract | Completed | 2014-06-12 | 2014-08-28 | ClinicalTrials.gov |
| NCT02169583 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and … | Phase1 | Infections, Respiratory Tract | Completed | 2014-06-12 | 2014-08-28 | ClinicalTrials.gov |
| NCT02119260 | A First Time in Human Study to Evaluate the Safety, Tolerability, Pharmacokinet… | Phase2 | Oedema, Pulmonary | Completed | 2014-06-09 | 2016-12-25 | ClinicalTrials.gov |
| NCT02119260 | A First Time in Human Study to Evaluate the Safety, Tolerability, Pharmacokinet… | Phase2 | Oedema, Pulmonary | Completed | 2014-06-09 | 2016-12-25 | ClinicalTrials.gov |
| NCT02106390 | Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B … | Phase3 | Infections, Meningococcal | Completed | 2014-06-05 | 2016-10-14 | ClinicalTrials.gov |
| NCT02106390 | Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B … | Phase3 | Infections, Meningococcal | Completed | 2014-06-05 | 2016-10-14 | ClinicalTrials.gov |
| NCT02145468 | A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Car… | Phase3 | Acute Coronary Syndrome | Completed | 2014-06-03 | 2015-12-14 | ClinicalTrials.gov |
| NCT02145468 | A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Car… | Phase3 | Acute Coronary Syndrome | Completed | 2014-06-03 | 2015-12-14 | ClinicalTrials.gov |
| NCT02157467 | Study of Combined Oral Contraceptive Effects in Female Subjects | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2014-06-02 | 2014-08-25 | ClinicalTrials.gov |
| NCT02157467 | Study of Combined Oral Contraceptive Effects in Female Subjects | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2014-06-02 | 2014-08-25 | ClinicalTrials.gov |
| NCT02169154 | A Safety Study to Investigate the Skin Irritancy Potential of Diclofenac-Mentho… | Phase1 | Pain | Completed | 2014-06-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT02169154 | A Safety Study to Investigate the Skin Irritancy Potential of Diclofenac-Mentho… | Phase1 | Pain | Completed | 2014-06-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT02135133 | A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL… | Phase2 | Chronic Lymphocytic Leukemia | Completed | 2014-06-01 | 2020-10-06 | ClinicalTrials.gov |
| NCT02135718 | ELLIPTA™ vs. MDI Inhaler Preference Study, in Adult Subjects With Asthma | — | Asthma | Completed | 2014-06-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT02195583 | The Effect of Experimental Dentifrices on Remineralization of Caries Lesions In… | Na | Oral Hygiene | Completed | 2014-06-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT02135718 | ELLIPTA™ vs. MDI Inhaler Preference Study, in Adult Subjects With Asthma | — | Asthma | Completed | 2014-06-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT02135133 | A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL… | Phase2 | Chronic Lymphocytic Leukemia | Completed | 2014-06-01 | 2020-10-06 | ClinicalTrials.gov |
| NCT02195583 | The Effect of Experimental Dentifrices on Remineralization of Caries Lesions In… | Na | Oral Hygiene | Completed | 2014-06-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT02135692 | A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in A… | Phase3 | Asthma | Completed | 2014-05-29 | 2017-10-05 | ClinicalTrials.gov |
| NCT02135692 | A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in A… | Phase3 | Asthma | Completed | 2014-05-29 | 2017-10-05 | ClinicalTrials.gov |
| NCT02124798 | A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliabilit… | Phase2 | Systemic Lupus Erythematosus | Completed | 2014-05-20 | 2015-04-13 | ClinicalTrials.gov |
| NCT02124798 | A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliabilit… | Phase2 | Systemic Lupus Erythematosus | Completed | 2014-05-20 | 2015-04-13 | ClinicalTrials.gov |
| NCT02138084 | Drug-drug Interaction (DDI) Rifabutin | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2014-05-14 | 2014-07-24 | ClinicalTrials.gov |
| NCT01943851 | A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharm… | Phase2 | Neoplasms | Completed | 2014-05-14 | 2020-04-30 | ClinicalTrials.gov |
| NCT01943851 | A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharm… | Phase2 | Neoplasms | Completed | 2014-05-14 | 2020-04-30 | ClinicalTrials.gov |
| NCT02138084 | Drug-drug Interaction (DDI) Rifabutin | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2014-05-14 | 2014-07-24 | ClinicalTrials.gov |
| NCT02119156 | Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients | Phase3 | Systemic Lupus Erythematosus | Completed | 2014-05-13 | 2018-12-14 | ClinicalTrials.gov |
| NCT02119156 | Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients | Phase3 | Systemic Lupus Erythematosus | Completed | 2014-05-13 | 2018-12-14 | ClinicalTrials.gov |
| NCT01962454 | A Study to Evaluate a Skeletal-muscle Microbiopsy Technique With Dynamic Proteo… | Phase1 | Cachexia | Completed | 2014-05-05 | 2015-03-20 | ClinicalTrials.gov |
| NCT01962454 | A Study to Evaluate a Skeletal-muscle Microbiopsy Technique With Dynamic Proteo… | Phase1 | Cachexia | Completed | 2014-05-05 | 2015-03-20 | ClinicalTrials.gov |
| NCT02114333 | Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 a… | Phase1 | Shingles | Completed | 2014-05-01 | 2020-05-01 | ClinicalTrials.gov |
| NCT02106403 | A Study to Evaluate the Cooling Sensation and Consumer Liking of a Skin Disinfe… | Na | Skin Care | Completed | 2014-05-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01934894 | Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cance… | Phase2 | Metastatic Breast Cancer With Intracranial Metastases | Terminated | 2014-05-01 | 2017-04-01 | ClinicalTrials.gov |
| NCT01934894 | Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cance… | Phase2 | Metastatic Breast Cancer With Intracranial Metastases | Terminated | 2014-05-01 | 2017-04-01 | ClinicalTrials.gov |
| NCT02140762 | Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Adminis… | Phase2 | Meningococcal Disease | Completed | 2014-05-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT02113436 | Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) H… | Phase4 | Asthma | Completed | 2014-05-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02140762 | Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Adminis… | Phase2 | Meningococcal Disease | Completed | 2014-05-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT02106403 | A Study to Evaluate the Cooling Sensation and Consumer Liking of a Skin Disinfe… | Na | Skin Care | Completed | 2014-05-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT02114333 | Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 a… | Phase1 | Shingles | Completed | 2014-05-01 | 2020-05-01 | ClinicalTrials.gov |
| NCT02113436 | Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) H… | Phase4 | Asthma | Completed | 2014-05-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02120352 | A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenan… | Phase2 | Infection, Human Immunodeficiency Virus | Completed | 2014-04-28 | 2023-04-20 | ClinicalTrials.gov |
| NCT02120352 | A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenan… | Phase2 | Infection, Human Immunodeficiency Virus | Completed | 2014-04-28 | 2023-04-20 | ClinicalTrials.gov |
| NCT02082977 | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clini… | Phase1 | Cancer | Terminated | 2014-04-24 | 2017-06-20 | ClinicalTrials.gov |
| NCT01376167 | Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse | Phase2 | Malaria, Vivax | Completed | 2014-04-24 | 2016-11-18 | ClinicalTrials.gov |
| NCT02014519 | A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in Hu… | Na | Pertussis | Completed | 2014-04-24 | 2015-04-24 | ClinicalTrials.gov |
| NCT02082977 | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clini… | Phase1 | Cancer | Terminated | 2014-04-24 | 2017-06-20 | ClinicalTrials.gov |
| NCT01376167 | Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse | Phase2 | Malaria, Vivax | Completed | 2014-04-24 | 2016-11-18 | ClinicalTrials.gov |
| NCT02014519 | A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in Hu… | Na | Pertussis | Completed | 2014-04-24 | 2015-04-24 | ClinicalTrials.gov |
| NCT02105961 | Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructiv… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-04-24 | 2017-01-16 | ClinicalTrials.gov |
| NCT02105961 | Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructiv… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-04-24 | 2017-01-16 | ClinicalTrials.gov |
| NCT02065063 | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti… | Phase1 | Cancer | Completed | 2014-04-22 | 2016-06-23 | ClinicalTrials.gov |
| NCT02065063 | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti… | Phase1 | Cancer | Completed | 2014-04-22 | 2016-06-23 | ClinicalTrials.gov |
| NCT02094924 | A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of G… | Phase1 | Hypertension | Completed | 2014-04-17 | 2014-05-23 | ClinicalTrials.gov |
| NCT02094924 | A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of G… | Phase1 | Hypertension | Completed | 2014-04-17 | 2014-05-23 | ClinicalTrials.gov |
| NCT02096263 | Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biolo… | Phase3 | Poliomyelitis | Completed | 2014-04-16 | 2015-11-13 | ClinicalTrials.gov |
| NCT02096263 | Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biolo… | Phase3 | Poliomyelitis | Completed | 2014-04-16 | 2015-11-13 | ClinicalTrials.gov |
| NCT02105948 | Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbatin… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-04-15 | 2017-01-17 | ClinicalTrials.gov |
| NCT01978301 | Study to Evaluate Fractional Collagen Synthesis Within Keloid Scars and Identif… | Phase1 | Fibrosis | Terminated | 2014-04-15 | 2015-02-05 | ClinicalTrials.gov |
| NCT02105948 | Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbatin… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-04-15 | 2017-01-17 | ClinicalTrials.gov |
| NCT01978301 | Study to Evaluate Fractional Collagen Synthesis Within Keloid Scars and Identif… | Phase1 | Fibrosis | Terminated | 2014-04-15 | 2015-02-05 | ClinicalTrials.gov |
| NCT02100644 | Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine… | Phase4 | Epilepsy | Completed | 2014-04-12 | 2015-05-11 | ClinicalTrials.gov |
| NCT02100644 | Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine… | Phase4 | Epilepsy | Completed | 2014-04-12 | 2015-05-11 | ClinicalTrials.gov |
| NCT02105974 | Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inha… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-04-07 | 2015-07-08 | ClinicalTrials.gov |
| NCT02105974 | Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inha… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-04-07 | 2015-07-08 | ClinicalTrials.gov |
| NCT02019472 | A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Mo… | Phase3 | Arthritis, Rheumatoid | Completed | 2014-04-04 | 2016-08-17 | ClinicalTrials.gov |
| NCT01934192 | Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIAT… | Phase2 | Gastroparesis | Terminated | 2014-04-04 | 2016-07-08 | ClinicalTrials.gov |
| NCT01934192 | Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIAT… | Phase2 | Gastroparesis | Terminated | 2014-04-04 | 2016-07-08 | ClinicalTrials.gov |
| NCT02019472 | A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Mo… | Phase3 | Arthritis, Rheumatoid | Completed | 2014-04-04 | 2016-08-17 | ClinicalTrials.gov |
| NCT02034097 | A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer | Phase2 | Cancer | Withdrawn | 2014-04-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02116504 | Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Releva… | Na | Rheumatoid Arthritis | Unknown | 2014-04-01 | 2017-11-01 | ClinicalTrials.gov |
| NCT02034097 | A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer | Phase2 | Cancer | Withdrawn | 2014-04-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02105987 | A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a … | Phase3 | Infection, Human Immunodeficiency Virus | Completed | 2014-04-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02105987 | A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a … | Phase3 | Infection, Human Immunodeficiency Virus | Completed | 2014-04-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02116504 | Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Releva… | Na | Rheumatoid Arthritis | Unknown | 2014-04-01 | 2017-11-01 | ClinicalTrials.gov |
| NCT02446496 | A Bioequivalence Study of Cefadroxil Film Coated Tablets After A Single Oral Do… | Phase4 | Infections, Urinary Tract | Completed | 2014-03-31 | 2014-04-08 | ClinicalTrials.gov |
| NCT02096276 | Boostrix® Pregnancy Registry | — | Pertussis | Completed | 2014-03-31 | 2019-08-02 | ClinicalTrials.gov |
| NCT02446496 | A Bioequivalence Study of Cefadroxil Film Coated Tablets After A Single Oral Do… | Phase4 | Infections, Urinary Tract | Completed | 2014-03-31 | 2014-04-08 | ClinicalTrials.gov |
| NCT02096276 | Boostrix® Pregnancy Registry | — | Pertussis | Completed | 2014-03-31 | 2019-08-02 | ClinicalTrials.gov |
| NCT02076178 | Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Inje… | Phase2 | Infection, Human Immunodeficiency Virus | Completed | 2014-03-27 | 2016-02-23 | ClinicalTrials.gov |
| NCT02094937 | A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg … | Phase3 | Asthma | Completed | 2014-03-27 | 2015-08-28 | ClinicalTrials.gov |
| NCT02076178 | Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Inje… | Phase2 | Infection, Human Immunodeficiency Virus | Completed | 2014-03-27 | 2016-02-23 | ClinicalTrials.gov |
| NCT02094937 | A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg … | Phase3 | Asthma | Completed | 2014-03-27 | 2015-08-28 | ClinicalTrials.gov |
| NCT02095886 | Relative Bioavailability Study With BMS-955176 | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2014-03-25 | 2014-07-07 | ClinicalTrials.gov |
| NCT02095886 | Relative Bioavailability Study With BMS-955176 | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2014-03-25 | 2014-07-07 | ClinicalTrials.gov |
| NCT02075619 | Relative Bioavailability Study of One Amlodipine 10mg Tablet and One Rosuvastat… | Phase1 | Hypertension | Completed | 2014-03-24 | 2014-07-11 | ClinicalTrials.gov |
| NCT02045797 | Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or… | Phase2 | Infections, Bacterial | Completed | 2014-03-24 | 2015-06-29 | ClinicalTrials.gov |
| NCT02045797 | Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or… | Phase2 | Infections, Bacterial | Completed | 2014-03-24 | 2015-06-29 | ClinicalTrials.gov |
| NCT02075619 | Relative Bioavailability Study of One Amlodipine 10mg Tablet and One Rosuvastat… | Phase1 | Hypertension | Completed | 2014-03-24 | 2014-07-11 | ClinicalTrials.gov |
| NCT02058589 | Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster S… | Phase3 | Herpes Zoster | Completed | 2014-03-20 | 2017-04-13 | ClinicalTrials.gov |
| NCT02058589 | Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster S… | Phase3 | Herpes Zoster | Completed | 2014-03-20 | 2017-04-13 | ClinicalTrials.gov |
| NCT02446483 | A Bioequivalence Study of Idiazole 20mg DR Tabs and PARIET® 20 mg DR Tabs After… | Phase4 | Gastrointestinal Diseases | Completed | 2014-03-19 | 2014-03-26 | ClinicalTrials.gov |
| NCT02446483 | A Bioequivalence Study of Idiazole 20mg DR Tabs and PARIET® 20 mg DR Tabs After… | Phase4 | Gastrointestinal Diseases | Completed | 2014-03-19 | 2014-03-26 | ClinicalTrials.gov |
| NCT02046148 | Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healt… | Phase2 | GBS Disease | Completed | 2014-03-18 | 2016-03-26 | ClinicalTrials.gov |
| NCT02046148 | Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healt… | Phase2 | GBS Disease | Completed | 2014-03-18 | 2016-03-26 | ClinicalTrials.gov |
| NCT02000817 | Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus… | Phase1 | Diabetes Mellitus, Type 1 | Completed | 2014-03-12 | 2018-09-27 | ClinicalTrials.gov |
| NCT02000817 | Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus… | Phase1 | Diabetes Mellitus, Type 1 | Completed | 2014-03-12 | 2018-09-27 | ClinicalTrials.gov |
| NCT01899703 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmac… | Phase2 | Cholestasis, Intrahepatic | Completed | 2014-03-10 | 2015-10-07 | ClinicalTrials.gov |
| NCT01899703 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmac… | Phase2 | Cholestasis, Intrahepatic | Completed | 2014-03-10 | 2015-10-07 | ClinicalTrials.gov |
| NCT02045836 | Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zo… | Phase3 | Herpes Zoster | Completed | 2014-03-05 | 2016-06-17 | ClinicalTrials.gov |
| NCT02045836 | Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zo… | Phase3 | Herpes Zoster | Completed | 2014-03-05 | 2016-06-17 | ClinicalTrials.gov |
| NCT02076386 | A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of C… | — | Infection, Human Immunodeficiency Virus | Completed | 2014-03-04 | 2017-07-05 | ClinicalTrials.gov |
| NCT02076386 | A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of C… | — | Infection, Human Immunodeficiency Virus | Completed | 2014-03-04 | 2017-07-05 | ClinicalTrials.gov |
| NCT02079545 | Bioavailability and Pharmacokinetics Study of Sirukumab in Healthy Male Partici… | Phase1 | Healthy | Completed | 2014-03-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT02010645 | Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS) | Phase2 | Leukemia | Terminated | 2014-03-01 | 2019-01-02 | ClinicalTrials.gov |
| NCT02477306 | A Bioequivalence Study of Rabeprazole From Idiazole 20mg DR Tabs (GSK, Egypt) a… | Phase1 | Healthy | Completed | 2014-03-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT02010645 | Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS) | Phase2 | Leukemia | Terminated | 2014-03-01 | 2019-01-02 | ClinicalTrials.gov |
| NCT02079545 | Bioavailability and Pharmacokinetics Study of Sirukumab in Healthy Male Partici… | Phase1 | Healthy | Completed | 2014-03-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT02477306 | A Bioequivalence Study of Rabeprazole From Idiazole 20mg DR Tabs (GSK, Egypt) a… | Phase1 | Healthy | Completed | 2014-03-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT02058641 | Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects W… | Phase1 | Atherosclerosis | Completed | 2014-02-26 | 2014-08-18 | ClinicalTrials.gov |
| NCT02058641 | Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects W… | Phase1 | Atherosclerosis | Completed | 2014-02-26 | 2014-08-18 | ClinicalTrials.gov |
| NCT01905592 | A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germ… | Phase3 | Neoplasms, Breast | Terminated | 2014-02-25 | 2021-10-26 | ClinicalTrials.gov |
| NCT01905592 | A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germ… | Phase3 | Neoplasms, Breast | Terminated | 2014-02-25 | 2021-10-26 | ClinicalTrials.gov |
| NCT01988857 | Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccin… | Phase3 | Diphtheria | Completed | 2014-02-22 | 2014-05-10 | ClinicalTrials.gov |
| NCT01988857 | Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccin… | Phase3 | Diphtheria | Completed | 2014-02-22 | 2014-05-10 | ClinicalTrials.gov |
| NCT02058628 | Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formula… | Phase4 | Acne Vulgaris | Completed | 2014-02-21 | 2014-09-08 | ClinicalTrials.gov |
| NCT02058628 | Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formula… | Phase4 | Acne Vulgaris | Completed | 2014-02-21 | 2014-09-08 | ClinicalTrials.gov |
| NCT02064504 | Study to Determine the Pharmacokinetics of GSK961081 and Fluticasone Furoate Wh… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-02-19 | 2014-05-20 | ClinicalTrials.gov |
| NCT02052713 | Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin Hydroc… | Phase1 | Urologic Diseases | Completed | 2014-02-19 | 2014-12-29 | ClinicalTrials.gov |
| NCT02064504 | Study to Determine the Pharmacokinetics of GSK961081 and Fluticasone Furoate Wh… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-02-19 | 2014-05-20 | ClinicalTrials.gov |
| NCT02052713 | Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin Hydroc… | Phase1 | Urologic Diseases | Completed | 2014-02-19 | 2014-12-29 | ClinicalTrials.gov |
| NCT02052661 | This Study Aims to Determine the Long-term Persistence of Antibodies Against He… | Phase4 | Hepatitis B | Completed | 2014-02-18 | 2014-09-23 | ClinicalTrials.gov |
| NCT01751139 | An Epidemiological Surveillance Study to Evaluate the Incidence of Dengue in Br… | Na | Dengue | Terminated | 2014-02-18 | 2018-12-20 | ClinicalTrials.gov |
| NCT01751139 | An Epidemiological Surveillance Study to Evaluate the Incidence of Dengue in Br… | Na | Dengue | Terminated | 2014-02-18 | 2018-12-20 | ClinicalTrials.gov |
| NCT02052661 | This Study Aims to Determine the Long-term Persistence of Antibodies Against He… | Phase4 | Hepatitis B | Completed | 2014-02-18 | 2014-09-23 | ClinicalTrials.gov |
| NCT02058576 | Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin HCl Co… | Phase1 | Urologic Diseases | Completed | 2014-02-11 | 2015-01-02 | ClinicalTrials.gov |
| NCT02058576 | Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin HCl Co… | Phase1 | Urologic Diseases | Completed | 2014-02-11 | 2015-01-02 | ClinicalTrials.gov |
| NCT02058368 | Study to Compare the Efficacy and Safety of Combination Treatment With Dutaster… | Phase3 | Prostatic Hyperplasia | Completed | 2014-02-10 | 2017-03-03 | ClinicalTrials.gov |
| NCT02058368 | Study to Compare the Efficacy and Safety of Combination Treatment With Dutaster… | Phase3 | Prostatic Hyperplasia | Completed | 2014-02-10 | 2017-03-03 | ClinicalTrials.gov |
| NCT02052596 | Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologic… | Phase3 | Herpes Zoster | Completed | 2014-02-07 | 2016-04-21 | ClinicalTrials.gov |
| NCT02052596 | Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologic… | Phase3 | Herpes Zoster | Completed | 2014-02-07 | 2016-04-21 | ClinicalTrials.gov |
| NCT02040480 | Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Rele… | Phase1 | Cancer | Completed | 2014-02-05 | 2014-04-04 | ClinicalTrials.gov |
| NCT02040480 | Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Rele… | Phase1 | Cancer | Completed | 2014-02-05 | 2014-04-04 | ClinicalTrials.gov |
| NCT02201316 | A Pilot Study to Determine the Relative Bioavailability of Mosapride 5mg From T… | Phase1 | Gastritis | Completed | 2014-02-03 | 2014-03-18 | ClinicalTrials.gov |
| NCT02201316 | A Pilot Study to Determine the Relative Bioavailability of Mosapride 5mg From T… | Phase1 | Gastritis | Completed | 2014-02-03 | 2014-03-18 | ClinicalTrials.gov |
| NCT02064374 | Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2014-02-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT02064374 | Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2014-02-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT02052752 | A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatmen… | Phase4 | Skin Diseases | Completed | 2014-02-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT02153333 | Serologic Response to Porcine Circovirus Type 1 (PCV-1) in Infants Following Ad… | — | Infections, Rotavirus | Completed | 2014-02-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02052752 | A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatmen… | Phase4 | Skin Diseases | Completed | 2014-02-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01978093 | Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biolog… | Phase3 | Neisseria Meningitidis | Completed | 2014-02-01 | 2016-03-18 | ClinicalTrials.gov |
| NCT02153333 | Serologic Response to Porcine Circovirus Type 1 (PCV-1) in Infants Following Ad… | — | Infections, Rotavirus | Completed | 2014-02-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01978093 | Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biolog… | Phase3 | Neisseria Meningitidis | Completed | 2014-02-01 | 2016-03-18 | ClinicalTrials.gov |
| NCT02006537 | A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of GSK2… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-01-31 | 2014-05-27 | ClinicalTrials.gov |
| NCT02006537 | A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of GSK2… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-01-31 | 2014-05-27 | ClinicalTrials.gov |
| NCT02045953 | A Study to Assess the Systemic Exposure of FLIXOTIDE™ (Fluticasone Propionate) … | Phase1 | Asthma | Completed | 2014-01-29 | 2014-03-13 | ClinicalTrials.gov |
| NCT02045953 | A Study to Assess the Systemic Exposure of FLIXOTIDE™ (Fluticasone Propionate) … | Phase1 | Asthma | Completed | 2014-01-29 | 2014-03-13 | ClinicalTrials.gov |
| NCT01957150 | Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalati… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-01-28 | 2018-03-26 | ClinicalTrials.gov |
| NCT02058407 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacody… | Phase1 | Bronchiectasis | Terminated | 2014-01-28 | 2014-10-31 | ClinicalTrials.gov |
| NCT02045849 | Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food … | Phase1 | Infections, Bacterial | Completed | 2014-01-28 | 2014-08-21 | ClinicalTrials.gov |
| NCT02045849 | Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food … | Phase1 | Infections, Bacterial | Completed | 2014-01-28 | 2014-08-21 | ClinicalTrials.gov |
| NCT02058407 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacody… | Phase1 | Bronchiectasis | Terminated | 2014-01-28 | 2014-10-31 | ClinicalTrials.gov |
| NCT01957150 | Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalati… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2014-01-28 | 2018-03-26 | ClinicalTrials.gov |
| NCT02052297 | A Validation and Dosimetry Study of GSK2634673F PET Ligand | Phase1 | Idiopathic Pulmonary Fibrosis | Terminated | 2014-01-24 | 2016-04-21 | ClinicalTrials.gov |
| NCT02052297 | A Validation and Dosimetry Study of GSK2634673F PET Ligand | Phase1 | Idiopathic Pulmonary Fibrosis | Terminated | 2014-01-24 | 2016-04-21 | ClinicalTrials.gov |
| NCT01894022 | A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of… | Phase3 | Hypertension | Terminated | 2014-01-23 | 2015-11-18 | ClinicalTrials.gov |
| NCT01894022 | A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of… | Phase3 | Hypertension | Terminated | 2014-01-23 | 2015-11-18 | ClinicalTrials.gov |
| NCT02033668 | Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers | Phase1 | Atrophy, Geographic | Completed | 2014-01-22 | 2014-07-15 | ClinicalTrials.gov |
| NCT02033668 | Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers | Phase1 | Atrophy, Geographic | Completed | 2014-01-22 | 2014-07-15 | ClinicalTrials.gov |
| NCT02045940 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of GSK288107… | Phase1 | Cachexia | Completed | 2014-01-20 | 2015-03-26 | ClinicalTrials.gov |
| NCT02045940 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of GSK288107… | Phase1 | Cachexia | Completed | 2014-01-20 | 2015-03-26 | ClinicalTrials.gov |
| NCT02201303 | Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression | Phase1 | Infections, Respiratory Syncytial Virus | Completed | 2014-01-13 | 2015-07-02 | ClinicalTrials.gov |
| NCT02201303 | Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression | Phase1 | Infections, Respiratory Syncytial Virus | Completed | 2014-01-13 | 2015-07-02 | ClinicalTrials.gov |
| NCT01984047 | Single Dose Escalation Trial to Evaluate the Safety, Tolerability Pharmacokinet… | Phase1 | Colitis, Ulcerative | Completed | 2014-01-10 | 2015-02-23 | ClinicalTrials.gov |
| NCT01984047 | Single Dose Escalation Trial to Evaluate the Safety, Tolerability Pharmacokinet… | Phase1 | Colitis, Ulcerative | Completed | 2014-01-10 | 2015-02-23 | ClinicalTrials.gov |
| NCT02014467 | Denosumab China Phase III Study | Phase3 | Osteoporosis, Postmenopausal | Completed | 2014-01-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02014467 | Denosumab China Phase III Study | Phase3 | Osteoporosis, Postmenopausal | Completed | 2014-01-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT01890798 | Drisapersen Duchenne Muscular Dystrophy (DMD) Treatment Protocol | Phase3 | Muscular Dystrophies | Withdrawn | 2014-01-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT01890798 | Drisapersen Duchenne Muscular Dystrophy (DMD) Treatment Protocol | Phase3 | Muscular Dystrophies | Withdrawn | 2014-01-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT01915914 | A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing … | Phase4 | Skin Diseases | Completed | 2013-12-23 | 2015-02-15 | ClinicalTrials.gov |
| NCT01915914 | A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing … | Phase4 | Skin Diseases | Completed | 2013-12-23 | 2015-02-15 | ClinicalTrials.gov |
| NCT01954043 | A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabraf… | Phase1 | Cancer | Completed | 2013-12-20 | 2016-02-29 | ClinicalTrials.gov |
| NCT01954043 | A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabraf… | Phase1 | Cancer | Completed | 2013-12-20 | 2016-02-29 | ClinicalTrials.gov |
| NCT02000453 | Safety and Tolerability Study of GSK2586184 in Patients With Moderate to Severe… | Phase1 | Colitis, Ulcerative | Terminated | 2013-12-20 | 2014-08-08 | ClinicalTrials.gov |
| NCT02000453 | Safety and Tolerability Study of GSK2586184 in Patients With Moderate to Severe… | Phase1 | Colitis, Ulcerative | Terminated | 2013-12-20 | 2014-08-08 | ClinicalTrials.gov |
| NCT01995175 | A Prospective, Epidemiological Study to Assess the Disease Burden of Respirator… | Na | Respiratory Syncytial Virus | Completed | 2013-12-12 | 2021-11-03 | ClinicalTrials.gov |
| NCT01995175 | A Prospective, Epidemiological Study to Assess the Disease Burden of Respirator… | Na | Respiratory Syncytial Virus | Completed | 2013-12-12 | 2021-11-03 | ClinicalTrials.gov |
| NCT01888471 | Feasibility Study for Identifying Anti Capsular Antibody Protection Against Inv… | Na | Streptococcus Agalactiae | Completed | 2013-12-11 | 2014-07-14 | ClinicalTrials.gov |
| NCT01888471 | Feasibility Study for Identifying Anti Capsular Antibody Protection Against Inv… | Na | Streptococcus Agalactiae | Completed | 2013-12-11 | 2014-07-14 | ClinicalTrials.gov |
| NCT02006589 | Bioavailability Study of Candesartan Cilexetil 8mg Tablet Under Fasting Conditi… | Phase1 | Hypertension | Completed | 2013-12-11 | 2014-01-22 | ClinicalTrials.gov |
| NCT02006589 | Bioavailability Study of Candesartan Cilexetil 8mg Tablet Under Fasting Conditi… | Phase1 | Hypertension | Completed | 2013-12-11 | 2014-01-22 | ClinicalTrials.gov |
| NCT01995981 | Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic resp… | — | Sarcoma, Soft Tissue | Completed | 2013-12-01 | 2017-11-10 | ClinicalTrials.gov |
| NCT02058654 | A Clinical Study to Investigate the Effects of Creatine Supplementation on Musc… | Phase1 | Nutritional Status | Completed | 2013-12-01 | 2014-06-24 | ClinicalTrials.gov |
| NCT02094781 | Effect of Using Whey Protein and Creatine Supplements on Muscular Strength in W… | Phase1 | Nutritional Status | Completed | 2013-12-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01995981 | Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic resp… | — | Sarcoma, Soft Tissue | Completed | 2013-12-01 | 2017-11-10 | ClinicalTrials.gov |
| NCT01592838 | Impact on Quality of Hospital Care During Pre- and Post- Rotavirus (RV) Vaccina… | — | Infections, Rotavirus | Completed | 2013-12-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT02094781 | Effect of Using Whey Protein and Creatine Supplements on Muscular Strength in W… | Phase1 | Nutritional Status | Completed | 2013-12-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT02058654 | A Clinical Study to Investigate the Effects of Creatine Supplementation on Musc… | Phase1 | Nutritional Status | Completed | 2013-12-01 | 2014-06-24 | ClinicalTrials.gov |
| NCT01592838 | Impact on Quality of Hospital Care During Pre- and Post- Rotavirus (RV) Vaccina… | — | Infections, Rotavirus | Completed | 2013-12-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01966445 | Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmaco… | Phase1 | Cancer | Completed | 2013-11-26 | 2017-09-18 | ClinicalTrials.gov |
| NCT01966445 | Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmaco… | Phase1 | Cancer | Completed | 2013-11-26 | 2017-09-18 | ClinicalTrials.gov |
| NCT01999842 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza… | Phase1 | Influenza | Completed | 2013-11-25 | 2015-01-19 | ClinicalTrials.gov |
| NCT01999842 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza… | Phase1 | Influenza | Completed | 2013-11-25 | 2015-01-19 | ClinicalTrials.gov |
| NCT01978327 | GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers | Phase1 | Alzheimer's Disease | Terminated | 2013-11-22 | 2014-03-03 | ClinicalTrials.gov |
| NCT01978327 | GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers | Phase1 | Alzheimer's Disease | Terminated | 2013-11-22 | 2014-03-03 | ClinicalTrials.gov |
| NCT01938443 | A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combi… | Phase1 | Cancer | Completed | 2013-11-18 | 2016-06-23 | ClinicalTrials.gov |
| NCT01938443 | A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combi… | Phase1 | Cancer | Completed | 2013-11-18 | 2016-06-23 | ClinicalTrials.gov |
| NCT01978145 | A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of F… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-11-14 | 2015-04-16 | ClinicalTrials.gov |
| NCT01978145 | A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of F… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-11-14 | 2015-04-16 | ClinicalTrials.gov |
| NCT02314143 | Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib… | Phase2 | Melanoma | Terminated | 2013-11-13 | 2017-01-19 | ClinicalTrials.gov |
| NCT02314143 | Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib… | Phase2 | Melanoma | Terminated | 2013-11-13 | 2017-01-19 | ClinicalTrials.gov |
| NCT02000765 | A Study to Investigate the Recovery, Excretion and Pharmacokinetics of [14C]-GS… | Phase1 | Infections, Respiratory Tract | Completed | 2013-11-08 | 2013-11-30 | ClinicalTrials.gov |
| NCT02000765 | A Study to Investigate the Recovery, Excretion and Pharmacokinetics of [14C]-GS… | Phase1 | Infections, Respiratory Tract | Completed | 2013-11-08 | 2013-11-30 | ClinicalTrials.gov |
| NCT01978119 | A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of C… | Phase3 | Asthma | Completed | 2013-11-06 | 2015-01-28 | ClinicalTrials.gov |
| NCT01978119 | A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of C… | Phase3 | Asthma | Completed | 2013-11-06 | 2015-01-28 | ClinicalTrials.gov |
| NCT02019719 | Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Ja… | Phase2 | Anaemia | Completed | 2013-11-05 | 2014-08-06 | ClinicalTrials.gov |
| NCT02019719 | Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Ja… | Phase2 | Anaemia | Completed | 2013-11-05 | 2014-08-06 | ClinicalTrials.gov |
| NCT01899768 | GSK2339345 Hypertussive Challenge Study | Phase2 | Cough | Completed | 2013-11-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT02113449 | Market Potential of Carbon Dioxide Nasal Spray | Phase2 | Nasal Congestion | Completed | 2013-11-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01899768 | GSK2339345 Hypertussive Challenge Study | Phase2 | Cough | Completed | 2013-11-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01977482 | Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in … | Phase2 | Anaemia | Completed | 2013-11-01 | 2015-02-06 | ClinicalTrials.gov |
| NCT02000466 | FluLaval® Quadrivalent Pregnancy Registry | — | Influenza | Withdrawn | 2013-11-01 | 2018-05-01 | ClinicalTrials.gov |
| NCT02113449 | Market Potential of Carbon Dioxide Nasal Spray | Phase2 | Nasal Congestion | Completed | 2013-11-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT02100670 | A Multicenter Efficacy Study of a Diclofenac+Menthol Gel in Subjects With Ankle… | Phase3 | Pain | Completed | 2013-11-01 | 2015-03-22 | ClinicalTrials.gov |
| NCT02100670 | A Multicenter Efficacy Study of a Diclofenac+Menthol Gel in Subjects With Ankle… | Phase3 | Pain | Completed | 2013-11-01 | 2015-03-22 | ClinicalTrials.gov |
| NCT02039960 | PRJ2215: Assessment of Buproprion Misuse/Abuse 2004-2011 | — | Depressive Disorder, Major | Completed | 2013-11-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT02000466 | FluLaval® Quadrivalent Pregnancy Registry | — | Influenza | Withdrawn | 2013-11-01 | 2018-05-01 | ClinicalTrials.gov |
| NCT01977482 | Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in … | Phase2 | Anaemia | Completed | 2013-11-01 | 2015-02-06 | ClinicalTrials.gov |
| NCT02039960 | PRJ2215: Assessment of Buproprion Misuse/Abuse 2004-2011 | — | Depressive Disorder, Major | Completed | 2013-11-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01920594 | Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic A… | Phase2 | Surgical Procedures | Completed | 2013-10-31 | 2014-10-08 | ClinicalTrials.gov |
| NCT01977573 | A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent… | Phase2 | Anaemia | Completed | 2013-10-31 | 2015-06-15 | ClinicalTrials.gov |
| NCT01938482 | Study to Evaluate the Safety, Tolerability and Pharmacokinetic of Single and 14… | Phase1 | Acne Vulgaris | Completed | 2013-10-31 | 2015-02-17 | ClinicalTrials.gov |
| NCT01938482 | Study to Evaluate the Safety, Tolerability and Pharmacokinetic of Single and 14… | Phase1 | Acne Vulgaris | Completed | 2013-10-31 | 2015-02-17 | ClinicalTrials.gov |
| NCT01977573 | A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent… | Phase2 | Anaemia | Completed | 2013-10-31 | 2015-06-15 | ClinicalTrials.gov |
| NCT01920594 | Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic A… | Phase2 | Surgical Procedures | Completed | 2013-10-31 | 2014-10-08 | ClinicalTrials.gov |
| NCT01957189 | This Will be an Open-label, Three-period, Fixed-sequence Study to Evaluate the … | Phase1 | Prostatic Hyperplasia | Completed | 2013-10-25 | 2014-01-22 | ClinicalTrials.gov |
| NCT01957189 | This Will be an Open-label, Three-period, Fixed-sequence Study to Evaluate the … | Phase1 | Prostatic Hyperplasia | Completed | 2013-10-25 | 2014-01-22 | ClinicalTrials.gov |
| NCT02000804 | Darapladib China PK | Phase1 | Atherosclerosis | Completed | 2013-10-23 | 2014-01-04 | ClinicalTrials.gov |
| NCT01974895 | Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biological… | Phase2 | Influenza | Completed | 2013-10-23 | 2014-07-03 | ClinicalTrials.gov |
| NCT02000804 | Darapladib China PK | Phase1 | Atherosclerosis | Completed | 2013-10-23 | 2014-01-04 | ClinicalTrials.gov |
| NCT01974895 | Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biological… | Phase2 | Influenza | Completed | 2013-10-23 | 2014-07-03 | ClinicalTrials.gov |
| NCT01837316 | A Study to Assess the Bronchodilator Effect of a Single Dose of Fluticasone Fur… | Phase1 | Asthma | Completed | 2013-10-21 | 2014-08-08 | ClinicalTrials.gov |
| NCT01837316 | A Study to Assess the Bronchodilator Effect of a Single Dose of Fluticasone Fur… | Phase1 | Asthma | Completed | 2013-10-21 | 2014-08-08 | ClinicalTrials.gov |
| NCT01984086 | Study to Evaluate the Pharmacokinetic Profile of Salbutamol Delivered by Unit D… | Phase1 | Asthma | Completed | 2013-10-21 | 2014-05-26 | ClinicalTrials.gov |
| NCT01984086 | Study to Evaluate the Pharmacokinetic Profile of Salbutamol Delivered by Unit D… | Phase1 | Asthma | Completed | 2013-10-21 | 2014-05-26 | ClinicalTrials.gov |
| NCT02275078 | Innovations in Treating COPD Exacerbations: Pilot Project on Action Plans Using… | Na | COPD | Completed | 2013-10-15 | 2017-11-29 | ClinicalTrials.gov |
| NCT02275078 | Innovations in Treating COPD Exacerbations: Pilot Project on Action Plans Using… | Na | COPD | Completed | 2013-10-15 | 2017-11-29 | ClinicalTrials.gov |
| NCT01984801 | Study to Investigate the Irritation Potential of GSK1940029 Gel | Phase1 | Acne Vulgaris | Completed | 2013-10-14 | 2015-04-10 | ClinicalTrials.gov |
| NCT01894360 | A Study to Estimate the Relative Bioavailability, Tolerability and Safety of a … | Phase1 | Systemic Lupus Erythematosus | Completed | 2013-10-14 | 2014-05-13 | ClinicalTrials.gov |
| NCT01894360 | A Study to Estimate the Relative Bioavailability, Tolerability and Safety of a … | Phase1 | Systemic Lupus Erythematosus | Completed | 2013-10-14 | 2014-05-13 | ClinicalTrials.gov |
| NCT01984801 | Study to Investigate the Irritation Potential of GSK1940029 Gel | Phase1 | Acne Vulgaris | Completed | 2013-10-14 | 2015-04-10 | ClinicalTrials.gov |
| NCT01962467 | A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine | Phase1 | Rhinitis, Allergic, Perennial and Seasonal | Completed | 2013-10-11 | 2014-02-27 | ClinicalTrials.gov |
| NCT01962467 | A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine | Phase1 | Rhinitis, Allergic, Perennial and Seasonal | Completed | 2013-10-11 | 2014-02-27 | ClinicalTrials.gov |
| NCT01953835 | A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586… | Phase1 | Systemic Lupus Erythematosus | Completed | 2013-10-04 | 2014-03-10 | ClinicalTrials.gov |
| NCT01953835 | A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586… | Phase1 | Systemic Lupus Erythematosus | Completed | 2013-10-04 | 2014-03-10 | ClinicalTrials.gov |
| NCT01954251 | Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biolog… | Phase3 | Herpes Zoster | Completed | 2013-10-03 | 2015-03-20 | ClinicalTrials.gov |
| NCT01954251 | Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biolog… | Phase3 | Herpes Zoster | Completed | 2013-10-03 | 2015-03-20 | ClinicalTrials.gov |
| NCT01964924 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Tr… | Phase2 | Estrogen Receptor Negative | Completed | 2013-10-02 | 2018-04-23 | ClinicalTrials.gov |
| NCT01964924 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Tr… | Phase2 | Estrogen Receptor Negative | Completed | 2013-10-02 | 2018-04-23 | ClinicalTrials.gov |
| NCT01957215 | Efficacy of Topical Indomethacin Patch Over Placebo in Ankle Sprain Pain Relief | Phase4 | Ankle Sprain | Completed | 2013-10-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01949051 | A Study to Assess Intranasal Repeat Dose Effect of Levocabastine in the Subject… | Phase2 | Rhinitis, Allergic, Perennial and Seasonal | Completed | 2013-10-01 | 2014-02-04 | ClinicalTrials.gov |
| NCT02119286 | Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Fur… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-10-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01967771 | Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subje… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2013-10-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01893372 | Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent F… | Phase2 | Leukemia | Completed | 2013-10-01 | 2019-01-06 | ClinicalTrials.gov |
| NCT02425241 | Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Va… | Phase1 | HIV | Completed | 2013-10-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT01957202 | A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabas… | Phase2 | Rhinitis, Allergic, Perennial and Seasonal | Completed | 2013-10-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01957163 | Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Fur… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-10-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01953822 | Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed t… | — | Infections, Papillomavirus | Completed | 2013-10-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01949051 | A Study to Assess Intranasal Repeat Dose Effect of Levocabastine in the Subject… | Phase2 | Rhinitis, Allergic, Perennial and Seasonal | Completed | 2013-10-01 | 2014-02-04 | ClinicalTrials.gov |
| NCT01940562 | Eltrombopag for Enhancing Platelet Engraftment in Pediatric Patients Undergoing… | Phase2 | Pediatric Patients Undergoing Allogeneic Cord Blood Transplantation. | Unknown | 2013-10-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT01938456 | Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese… | Phase1 | Lung Cancer, Non-Small Cell | Withdrawn | 2013-10-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01967771 | Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subje… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2013-10-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01957215 | Efficacy of Topical Indomethacin Patch Over Placebo in Ankle Sprain Pain Relief | Phase4 | Ankle Sprain | Completed | 2013-10-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01957202 | A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabas… | Phase2 | Rhinitis, Allergic, Perennial and Seasonal | Completed | 2013-10-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT02119286 | Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Fur… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-10-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01957163 | Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Fur… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-10-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01953822 | Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed t… | — | Infections, Papillomavirus | Completed | 2013-10-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01938456 | Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese… | Phase1 | Lung Cancer, Non-Small Cell | Withdrawn | 2013-10-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01940562 | Eltrombopag for Enhancing Platelet Engraftment in Pediatric Patients Undergoing… | Phase2 | Pediatric Patients Undergoing Allogeneic Cord Blood Transplantation. | Unknown | 2013-10-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT01893372 | Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent F… | Phase2 | Leukemia | Completed | 2013-10-01 | 2019-01-06 | ClinicalTrials.gov |
| NCT02425241 | Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Va… | Phase1 | HIV | Completed | 2013-10-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT01891357 | Phase II Trial to Validate Markers for a Response Evaluation of a Combined Ther… | Phase2 | Carcinoma, Ductal, Breast | Terminated | 2013-09-30 | 2016-11-16 | ClinicalTrials.gov |
| NCT01953510 | Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam | Phase2 | Pneumococcal Vaccines | Completed | 2013-09-30 | 2021-11-08 | ClinicalTrials.gov |
| NCT01953510 | Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam | Phase2 | Pneumococcal Vaccines | Completed | 2013-09-30 | 2021-11-08 | ClinicalTrials.gov |
| NCT01891357 | Phase II Trial to Validate Markers for a Response Evaluation of a Combined Ther… | Phase2 | Carcinoma, Ductal, Breast | Terminated | 2013-09-30 | 2016-11-16 | ClinicalTrials.gov |
| NCT01949090 | Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (G… | Phase2 | Influenza | Completed | 2013-09-25 | 2014-10-23 | ClinicalTrials.gov |
| NCT01934205 | To Evaluate Plasma and Pulmonary Pharmacokinetics of GSK2140944 | Phase1 | Infections, Bacterial | Completed | 2013-09-25 | 2013-12-21 | ClinicalTrials.gov |
| NCT01949090 | Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (G… | Phase2 | Influenza | Completed | 2013-09-25 | 2014-10-23 | ClinicalTrials.gov |
| NCT01934205 | To Evaluate Plasma and Pulmonary Pharmacokinetics of GSK2140944 | Phase1 | Infections, Bacterial | Completed | 2013-09-25 | 2013-12-21 | ClinicalTrials.gov |
| NCT02838407 | Identification and Characterization of Bacteria in the Lungs of Children From 6… | Na | Infections, Streptococcal | Completed | 2013-09-23 | 2015-09-23 | ClinicalTrials.gov |
| NCT01929330 | Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Cap… | Phase1 | Alopecia | Completed | 2013-09-23 | 2014-01-09 | ClinicalTrials.gov |
| NCT01929330 | Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Cap… | Phase1 | Alopecia | Completed | 2013-09-23 | 2014-01-09 | ClinicalTrials.gov |
| NCT02838407 | Identification and Characterization of Bacteria in the Lungs of Children From 6… | Na | Infections, Streptococcal | Completed | 2013-09-23 | 2015-09-23 | ClinicalTrials.gov |
| NCT01943864 | A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment … | Phase2 | Cancer | Completed | 2013-09-19 | 2016-02-01 | ClinicalTrials.gov |
| NCT01943864 | A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment … | Phase2 | Cancer | Completed | 2013-09-19 | 2016-02-01 | ClinicalTrials.gov |
| NCT03494985 | A Clinical Study to Evaluate the Efficacy of Three Dry Mouth Relief Products Ve… | Na | Xerostomia | Completed | 2013-09-17 | 2014-01-10 | ClinicalTrials.gov |
| NCT03494985 | A Clinical Study to Evaluate the Efficacy of Three Dry Mouth Relief Products Ve… | Na | Xerostomia | Completed | 2013-09-17 | 2014-01-10 | ClinicalTrials.gov |
| NCT01750931 | This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GS… | Na | Arthritis, Rheumatoid | Completed | 2013-09-12 | 2013-10-01 | ClinicalTrials.gov |
| NCT01750931 | This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GS… | Na | Arthritis, Rheumatoid | Completed | 2013-09-12 | 2013-10-01 | ClinicalTrials.gov |
| NCT01934153 | Characterization of Exposure From Topical Administration of [14C] Umeclidinium … | Phase1 | Hyperhidrosis | Completed | 2013-09-02 | 2014-02-19 | ClinicalTrials.gov |
| NCT01934153 | Characterization of Exposure From Topical Administration of [14C] Umeclidinium … | Phase1 | Hyperhidrosis | Completed | 2013-09-02 | 2014-02-19 | ClinicalTrials.gov |
| NCT01884675 | Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension. | Phase3 | Hypertension | Terminated | 2013-09-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01884675 | Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension. | Phase3 | Hypertension | Terminated | 2013-09-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01765413 | Training Study to Characterize Biomarkers to Chickenpox and Yellow Fever Vaccin… | Na | Healthy | Completed | 2013-09-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01772225 | NSCLC Burden of Illness Study | — | Lung Cancer, Non-Small Cell | Completed | 2013-09-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT02076269 | Severe Chronic Obstructive Pulmonary Disease Inhalation Profiles Comparison | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-09-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01772225 | NSCLC Burden of Illness Study | — | Lung Cancer, Non-Small Cell | Completed | 2013-09-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT02076269 | Severe Chronic Obstructive Pulmonary Disease Inhalation Profiles Comparison | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-09-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01536379 | A Study of Belimumab in the Prevention of Kidney Transplant Rejection | Phase2 | Transplantation, Organ | Completed | 2013-09-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT01765413 | Training Study to Characterize Biomarkers to Chickenpox and Yellow Fever Vaccin… | Na | Healthy | Completed | 2013-09-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01962493 | An Efficacy Study of Stain Control of a 67% Sodium Bicarbonate Containing Tooth… | Phase4 | Oral Hygiene | Completed | 2013-09-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01536379 | A Study of Belimumab in the Prevention of Kidney Transplant Rejection | Phase2 | Transplantation, Organ | Completed | 2013-09-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT01962493 | An Efficacy Study of Stain Control of a 67% Sodium Bicarbonate Containing Tooth… | Phase4 | Oral Hygiene | Completed | 2013-09-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01934231 | Study to Assess the Efficacy and Safety of Potassium Clavulanate/Amoxicillin in… | Phase3 | Sinusitis, Acute | Completed | 2013-08-30 | 2013-11-07 | ClinicalTrials.gov |
| NCT01934231 | Study to Assess the Efficacy and Safety of Potassium Clavulanate/Amoxicillin in… | Phase3 | Sinusitis, Acute | Completed | 2013-08-30 | 2013-11-07 | ClinicalTrials.gov |
| NCT01929317 | A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Releas… | Phase3 | Parkinson Disease | Terminated | 2013-08-28 | 2015-06-09 | ClinicalTrials.gov |
| NCT01929317 | A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Releas… | Phase3 | Parkinson Disease | Terminated | 2013-08-28 | 2015-06-09 | ClinicalTrials.gov |
| NCT01934127 | Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (G… | Phase1 | Influenza | Completed | 2013-08-26 | 2014-10-20 | ClinicalTrials.gov |
| NCT01934127 | Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (G… | Phase1 | Influenza | Completed | 2013-08-26 | 2014-10-20 | ClinicalTrials.gov |
| NCT01907802 | Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfuncti… | Phase1 | BRAF Gene Mutation | Terminated | 2013-08-23 | 2015-12-16 | ClinicalTrials.gov |
| NCT01907802 | Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfuncti… | Phase1 | BRAF Gene Mutation | Terminated | 2013-08-23 | 2015-12-16 | ClinicalTrials.gov |
| NCT01910402 | A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (D… | Phase3 | Infection, Human Immunodeficiency Virus | Completed | 2013-08-22 | 2022-08-18 | ClinicalTrials.gov |
| NCT01910402 | A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (D… | Phase3 | Infection, Human Immunodeficiency Virus | Completed | 2013-08-22 | 2022-08-18 | ClinicalTrials.gov |
| NCT01924858 | A Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribu… | Phase1 | Alzheimer's Disease | Terminated | 2013-08-19 | 2014-03-03 | ClinicalTrials.gov |
| NCT01924858 | A Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribu… | Phase1 | Alzheimer's Disease | Terminated | 2013-08-19 | 2014-03-03 | ClinicalTrials.gov |
| NCT01934101 | Phase 1 Dose Escalating Study to Assess Safety, Tolerability, Food Effect and P… | Phase1 | Arthritis, Rheumatoid | Terminated | 2013-08-12 | 2014-05-28 | ClinicalTrials.gov |
| NCT01934101 | Phase 1 Dose Escalating Study to Assess Safety, Tolerability, Food Effect and P… | Phase1 | Arthritis, Rheumatoid | Terminated | 2013-08-12 | 2014-05-28 | ClinicalTrials.gov |
| NCT01818011 | A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics o… | Phase1 | Infections, Bacterial | Terminated | 2013-08-07 | 2013-10-18 | ClinicalTrials.gov |
| NCT01818011 | A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics o… | Phase1 | Infections, Bacterial | Terminated | 2013-08-07 | 2013-10-18 | ClinicalTrials.gov |
| NCT01856309 | Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing S… | Phase3 | Arthritis, Rheumatoid | Completed | 2013-08-07 | 2018-04-30 | ClinicalTrials.gov |
| NCT01856309 | Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing S… | Phase3 | Arthritis, Rheumatoid | Completed | 2013-08-07 | 2018-04-30 | ClinicalTrials.gov |
| NCT02275364 | Functional Magnetic Resonance Imaging (fMRI) Study of Nasal Strips in Nasal Con… | Phase4 | Nasal Congestion | Completed | 2013-08-05 | 2013-10-30 | ClinicalTrials.gov |
| NCT02275364 | Functional Magnetic Resonance Imaging (fMRI) Study of Nasal Strips in Nasal Con… | Phase4 | Nasal Congestion | Completed | 2013-08-05 | 2013-10-30 | ClinicalTrials.gov |
| NCT01925222 | Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage | — | Nasopharyngeal Carriage of Streptococcus Pneumoniae | Completed | 2013-08-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01920568 | A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metasta… | Phase3 | Fractures, Bone | Completed | 2013-08-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01916226 | A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine… | Phase4 | Rhinitis, Allergic, Perennial and Seasonal | Completed | 2013-08-01 | 2013-10-17 | ClinicalTrials.gov |
| NCT01925222 | Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage | — | Nasopharyngeal Carriage of Streptococcus Pneumoniae | Completed | 2013-08-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01916226 | A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine… | Phase4 | Rhinitis, Allergic, Perennial and Seasonal | Completed | 2013-08-01 | 2013-10-17 | ClinicalTrials.gov |
| NCT01920568 | A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metasta… | Phase3 | Fractures, Bone | Completed | 2013-08-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01929863 | Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamic… | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2013-08-01 | 2013-11-21 | ClinicalTrials.gov |
| NCT01911221 | A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Sa… | Phase3 | Prevention of the Meningococcal Disease | Completed | 2013-08-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01929863 | Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamic… | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2013-08-01 | 2013-11-21 | ClinicalTrials.gov |
| NCT01911221 | A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Sa… | Phase3 | Prevention of the Meningococcal Disease | Completed | 2013-08-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01905215 | Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKl… | Phase1 | Infections, Respiratory Syncytial Virus | Completed | 2013-07-22 | 2015-03-16 | ClinicalTrials.gov |
| NCT01905215 | Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKl… | Phase1 | Infections, Respiratory Syncytial Virus | Completed | 2013-07-22 | 2015-03-16 | ClinicalTrials.gov |
| NCT01847430 | Evaluation of the Long-term Persistence of Immunity to Hepatitis B, in Adolesce… | Phase4 | Hepatitis B | Completed | 2013-07-19 | 2014-02-21 | ClinicalTrials.gov |
| NCT01847430 | Evaluation of the Long-term Persistence of Immunity to Hepatitis B, in Adolesce… | Phase4 | Hepatitis B | Completed | 2013-07-19 | 2014-02-21 | ClinicalTrials.gov |
| NCT01878825 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Trivalent… | Phase3 | Influenza | Completed | 2013-07-18 | 2013-08-09 | ClinicalTrials.gov |
| NCT01878825 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Trivalent… | Phase3 | Influenza | Completed | 2013-07-18 | 2013-08-09 | ClinicalTrials.gov |
| NCT01894386 | Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Flu… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-07-15 | 2013-09-26 | ClinicalTrials.gov |
| NCT01894386 | Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Flu… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-07-15 | 2013-09-26 | ClinicalTrials.gov |
| NCT01878812 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Quadrival… | Phase3 | Influenza | Completed | 2013-07-11 | 2013-08-05 | ClinicalTrials.gov |
| NCT01878812 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Quadrival… | Phase3 | Influenza | Completed | 2013-07-11 | 2013-08-05 | ClinicalTrials.gov |
| NCT01899755 | A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunog… | Phase1 | Psoriasis | Completed | 2013-07-10 | 2014-04-03 | ClinicalTrials.gov |
| NCT01899755 | A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunog… | Phase1 | Psoriasis | Completed | 2013-07-10 | 2014-04-03 | ClinicalTrials.gov |
| NCT01884519 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza… | Phase3 | Influenza | Completed | 2013-07-01 | 2013-08-02 | ClinicalTrials.gov |
| NCT01890850 | Study to Analyze the Risk Factors Associated With Pertussis/Whooping Cough Infe… | — | Diphtheria | Completed | 2013-07-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01884519 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza… | Phase3 | Influenza | Completed | 2013-07-01 | 2013-08-02 | ClinicalTrials.gov |
| NCT01848145 | Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lympho… | Phase2 | Chronic Lymphocytic Leukemia | Completed | 2013-07-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT01890850 | Study to Analyze the Risk Factors Associated With Pertussis/Whooping Cough Infe… | — | Diphtheria | Completed | 2013-07-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01848145 | Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lympho… | Phase2 | Chronic Lymphocytic Leukemia | Completed | 2013-07-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT01873365 | A Study to Assess the Burden of Herpes Zoster and Postherpetic Neuralgia in Jap… | — | Herpes Zoster | Completed | 2013-06-29 | 2015-02-04 | ClinicalTrials.gov |
| NCT01873365 | A Study to Assess the Burden of Herpes Zoster and Postherpetic Neuralgia in Jap… | — | Herpes Zoster | Completed | 2013-06-29 | 2015-02-04 | ClinicalTrials.gov |
| NCT01855724 | Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopa… | Phase2 | Cholangiocarcinoma | Terminated | 2013-06-28 | 2018-09-28 | ClinicalTrials.gov |
| NCT01855724 | Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopa… | Phase2 | Cholangiocarcinoma | Terminated | 2013-06-28 | 2018-09-28 | ClinicalTrials.gov |
| NCT01847274 | A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sen… | Phase3 | Ovarian Neoplasms | Completed | 2013-06-21 | 2021-12-26 | ClinicalTrials.gov |
| NCT01847274 | A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sen… | Phase3 | Ovarian Neoplasms | Completed | 2013-06-21 | 2021-12-26 | ClinicalTrials.gov |
| NCT01746108 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococ… | Phase3 | Infections, Streptococcal | Completed | 2013-06-18 | 2015-06-29 | ClinicalTrials.gov |
| NCT01746108 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococ… | Phase3 | Infections, Streptococcal | Completed | 2013-06-18 | 2015-06-29 | ClinicalTrials.gov |
| NCT01831804 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and… | Phase1 | Wound Healing | Completed | 2013-06-17 | 2017-02-10 | ClinicalTrials.gov |
| NCT01777321 | Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/s… | Phase3 | Herpes Zoster | Completed | 2013-06-17 | 2014-11-11 | ClinicalTrials.gov |
| NCT01831804 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and… | Phase1 | Wound Healing | Completed | 2013-06-17 | 2017-02-10 | ClinicalTrials.gov |
| NCT01777321 | Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/s… | Phase3 | Herpes Zoster | Completed | 2013-06-17 | 2014-11-11 | ClinicalTrials.gov |
| NCT01879462 | A First Time in Human Study to Investigate the Safety, Tolerability and Pharmac… | Phase1 | Hepatitis C, Chronic | Completed | 2013-06-14 | 2014-01-10 | ClinicalTrials.gov |
| NCT01879462 | A First Time in Human Study to Investigate the Safety, Tolerability and Pharmac… | Phase1 | Hepatitis C, Chronic | Completed | 2013-06-14 | 2014-01-10 | ClinicalTrials.gov |
| NCT01879410 | A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Flut… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-06-13 | 2014-01-09 | ClinicalTrials.gov |
| NCT01879410 | A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Flut… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-06-13 | 2014-01-09 | ClinicalTrials.gov |
| NCT01894919 | Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meni… | Phase3 | Meningoccocal Disease | Completed | 2013-06-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT01894919 | Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meni… | Phase3 | Meningoccocal Disease | Completed | 2013-06-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02498288 | A Study to Determine Bioequivalence of Isotretinoin in Healthy Male Subjects Un… | Phase1 | Acne Vulgaris | Completed | 2013-05-31 | 2013-07-15 | ClinicalTrials.gov |
| NCT02498288 | A Study to Determine Bioequivalence of Isotretinoin in Healthy Male Subjects Un… | Phase1 | Acne Vulgaris | Completed | 2013-05-31 | 2013-07-15 | ClinicalTrials.gov |
| NCT04123665 | A Phase 3 Clinical Study Investigating the Gingivitis Efficacy of a Test Dentif… | Phase3 | Gingivitis | Completed | 2013-05-28 | 2013-12-11 | ClinicalTrials.gov |
| NCT01827657 | Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects Wit… | Phase1 | Hepatitis C | Completed | 2013-05-28 | 2014-03-20 | ClinicalTrials.gov |
| NCT04123665 | A Phase 3 Clinical Study Investigating the Gingivitis Efficacy of a Test Dentif… | Phase3 | Gingivitis | Completed | 2013-05-28 | 2013-12-11 | ClinicalTrials.gov |
| NCT01827657 | Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects Wit… | Phase1 | Hepatitis C | Completed | 2013-05-28 | 2014-03-20 | ClinicalTrials.gov |
| NCT01842607 | A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects | Phase3 | Asthma | Completed | 2013-05-27 | 2015-03-13 | ClinicalTrials.gov |
| NCT01842607 | A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects | Phase3 | Asthma | Completed | 2013-05-27 | 2015-03-13 | ClinicalTrials.gov |
| NCT01797926 | Study to Determine the Bioequivalence of Two Fixed Dose Combination (FDC) Table… | Phase1 | Hypertension | Completed | 2013-05-23 | 2013-07-25 | ClinicalTrials.gov |
| NCT01797926 | Study to Determine the Bioequivalence of Two Fixed Dose Combination (FDC) Table… | Phase1 | Hypertension | Completed | 2013-05-23 | 2013-07-25 | ClinicalTrials.gov |
| NCT01857869 | Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' … | Phase2 | Malaria | Completed | 2013-05-20 | 2014-12-16 | ClinicalTrials.gov |
| NCT01899638 | Pharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomize… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-05-20 | 2013-07-25 | ClinicalTrials.gov |
| NCT01857869 | Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' … | Phase2 | Malaria | Completed | 2013-05-20 | 2014-12-16 | ClinicalTrials.gov |
| NCT01899638 | Pharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomize… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-05-20 | 2013-07-25 | ClinicalTrials.gov |
| NCT01808261 | Proof of Concept (POC) in Patients With Ischaemic Stroke | Phase2 | Cerebrovascular Accident | Terminated | 2013-05-18 | 2014-07-28 | ClinicalTrials.gov |
| NCT01808261 | Proof of Concept (POC) in Patients With Ischaemic Stroke | Phase2 | Cerebrovascular Accident | Terminated | 2013-05-18 | 2014-07-28 | ClinicalTrials.gov |
| NCT01743482 | Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors | Phase2 | Germ Cell Tumors | Completed | 2013-05-17 | 2016-07-27 | ClinicalTrials.gov |
| NCT01743482 | Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors | Phase2 | Germ Cell Tumors | Completed | 2013-05-17 | 2016-07-27 | ClinicalTrials.gov |
| NCT01857895 | Feasibility Study of Exenatide by Continuous Subcutaneous Infusion | Phase1 | Obesity | Completed | 2013-05-16 | 2013-11-01 | ClinicalTrials.gov |
| NCT01847417 | Comparative Bioavailability Study of Two Test Products of Fixed Dose Combinatio… | Phase1 | Ulcers, Duodenal and Gastric | Completed | 2013-05-16 | 2013-07-01 | ClinicalTrials.gov |
| NCT01847417 | Comparative Bioavailability Study of Two Test Products of Fixed Dose Combinatio… | Phase1 | Ulcers, Duodenal and Gastric | Completed | 2013-05-16 | 2013-07-01 | ClinicalTrials.gov |
| NCT01857895 | Feasibility Study of Exenatide by Continuous Subcutaneous Infusion | Phase1 | Obesity | Completed | 2013-05-16 | 2013-11-01 | ClinicalTrials.gov |
| NCT01847404 | Comparative Bioavailability Study of Two Test Products of Fixed Dose Combinatio… | Phase1 | Ulcers, Duodenal and Gastric | Completed | 2013-05-14 | 2013-06-28 | ClinicalTrials.gov |
| NCT01852565 | Study to Determine the Effect of Repeated Administration of Diltiazem on the Ph… | Phase1 | Atherosclerosis | Completed | 2013-05-14 | 2013-09-30 | ClinicalTrials.gov |
| NCT01847404 | Comparative Bioavailability Study of Two Test Products of Fixed Dose Combinatio… | Phase1 | Ulcers, Duodenal and Gastric | Completed | 2013-05-14 | 2013-06-28 | ClinicalTrials.gov |
| NCT01852565 | Study to Determine the Effect of Repeated Administration of Diltiazem on the Ph… | Phase1 | Atherosclerosis | Completed | 2013-05-14 | 2013-09-30 | ClinicalTrials.gov |
| NCT01777243 | A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK23156… | Phase1 | Amyloidosis | Completed | 2013-05-13 | 2015-12-22 | ClinicalTrials.gov |
| NCT01777243 | A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK23156… | Phase1 | Amyloidosis | Completed | 2013-05-13 | 2015-12-22 | ClinicalTrials.gov |
| NCT01777308 | Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals'… | Phase3 | Infections, Meningococcal | Completed | 2013-05-03 | 2016-04-20 | ClinicalTrials.gov |
| NCT01777308 | Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals'… | Phase3 | Infections, Meningococcal | Completed | 2013-05-03 | 2016-04-20 | ClinicalTrials.gov |
| NCT01847443 | Comparison of Pharmacokinetic Profiles of Two Nicotine Gum Formulations | Phase1 | Smoking Cessation | Completed | 2013-05-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01817777 | An Open Study to Evaluate Whether Pack Size Affects Compliance of Metformin Tre… | Phase4 | Diabetes Mellitus, Type 2 | Terminated | 2013-05-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01868009 | DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Dis… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-05-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01868009 | DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Dis… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-05-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01847443 | Comparison of Pharmacokinetic Profiles of Two Nicotine Gum Formulations | Phase1 | Smoking Cessation | Completed | 2013-05-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01817777 | An Open Study to Evaluate Whether Pack Size Affects Compliance of Metformin Tre… | Phase4 | Diabetes Mellitus, Type 2 | Terminated | 2013-05-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01879423 | The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 5mg×5 Comp… | Phase1 | Epilepsy | Completed | 2013-04-28 | 2013-06-06 | ClinicalTrials.gov |
| NCT01879423 | The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 5mg×5 Comp… | Phase1 | Epilepsy | Completed | 2013-04-28 | 2013-06-06 | ClinicalTrials.gov |
| NCT01827644 | Bioavailability and Food Effect of the Original Gelatin Formulation and Two New… | Phase1 | Cancer | Completed | 2013-04-24 | 2013-07-12 | ClinicalTrials.gov |
| NCT01827644 | Bioavailability and Food Effect of the Original Gelatin Formulation and Two New… | Phase1 | Cancer | Completed | 2013-04-24 | 2013-07-12 | ClinicalTrials.gov |
| NCT01831791 | A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subje… | Phase3 | Alopecia | Completed | 2013-04-14 | 2014-07-19 | ClinicalTrials.gov |
| NCT01831791 | A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subje… | Phase3 | Alopecia | Completed | 2013-04-14 | 2014-07-19 | ClinicalTrials.gov |
| NCT01777139 | A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-r… | Phase3 | Epilepsy | Completed | 2013-04-11 | 2017-09-13 | ClinicalTrials.gov |
| NCT01777139 | A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-r… | Phase3 | Epilepsy | Completed | 2013-04-11 | 2017-09-13 | ClinicalTrials.gov |
| NCT01822899 | A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol … | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-04-04 | 2013-10-07 | ClinicalTrials.gov |
| NCT01822899 | A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol … | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-04-04 | 2013-10-07 | ClinicalTrials.gov |
| NCT01822639 | A Fixed Dose Combination Amlodipine + Enalapril Bioavailability Study | Phase1 | Hypertension | Completed | 2013-04-03 | 2013-05-24 | ClinicalTrials.gov |
| NCT01822639 | A Fixed Dose Combination Amlodipine + Enalapril Bioavailability Study | Phase1 | Hypertension | Completed | 2013-04-03 | 2013-05-24 | ClinicalTrials.gov |
| NCT01551537 | Post-marketing Surveillance of GSK Biologicals' Cervarix™ When Administered to … | — | Human Papillomavirus Infection | Withdrawn | 2013-04-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01762852 | Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects W… | Phase2 | Glomerulonephritis, Membranous | Withdrawn | 2013-04-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01915732 | A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Tr… | Phase3 | Acne Vulgaris | Completed | 2013-04-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01803425 | Post-marketing Safety Study of GlaxoSmithKline (GSK) Biologicals' Synflorix™ Va… | — | Immunisation Against Streptococcus Pneumoniae | Withdrawn | 2013-04-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01920464 | Place of Flixovate® in the Treatment Pathway and Its Conditions of Use in Infan… | — | Dermatitis, Atopic | Completed | 2013-04-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01551537 | Post-marketing Surveillance of GSK Biologicals' Cervarix™ When Administered to … | — | Human Papillomavirus Infection | Withdrawn | 2013-04-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01821625 | Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C | Phase2 | Thrombocytopenia | Terminated | 2013-04-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01721603 | Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets | Phase2 | BRAFV600E Melanoma Patients | Terminated | 2013-04-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01543802 | Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Sof… | Phase2 | Sarcoma, Soft-tissue | Terminated | 2013-04-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT01803425 | Post-marketing Safety Study of GlaxoSmithKline (GSK) Biologicals' Synflorix™ Va… | — | Immunisation Against Streptococcus Pneumoniae | Withdrawn | 2013-04-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01480596 | The Evaluation of Belimumab in Myasthenia Gravis (MG) | Phase2 | Myasthaenia Gravis | Completed | 2013-04-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01543802 | Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Sof… | Phase2 | Sarcoma, Soft-tissue | Terminated | 2013-04-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT01721603 | Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets | Phase2 | BRAFV600E Melanoma Patients | Terminated | 2013-04-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01821625 | Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C | Phase2 | Thrombocytopenia | Terminated | 2013-04-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01762852 | Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects W… | Phase2 | Glomerulonephritis, Membranous | Withdrawn | 2013-04-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01915732 | A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Tr… | Phase3 | Acne Vulgaris | Completed | 2013-04-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01480596 | The Evaluation of Belimumab in Myasthenia Gravis (MG) | Phase2 | Myasthaenia Gravis | Completed | 2013-04-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01920464 | Place of Flixovate® in the Treatment Pathway and Its Conditions of Use in Infan… | — | Dermatitis, Atopic | Completed | 2013-04-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01607346 | An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Ex… | Phase4 | Epilepsy | Terminated | 2013-03-27 | 2016-11-16 | ClinicalTrials.gov |
| NCT01607346 | An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Ex… | Phase4 | Epilepsy | Terminated | 2013-03-27 | 2016-11-16 | ClinicalTrials.gov |
| NCT01788228 | Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adult… | Phase3 | Influenza | Completed | 2013-03-22 | 2015-02-25 | ClinicalTrials.gov |
| NCT01788228 | Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adult… | Phase3 | Influenza | Completed | 2013-03-22 | 2015-02-25 | ClinicalTrials.gov |
| NCT02141217 | AUGMENTIN™ in Dental Infections | Phase4 | Focal Infection, Dental | Completed | 2013-03-21 | 2013-12-28 | ClinicalTrials.gov |
| NCT02141217 | AUGMENTIN™ in Dental Infections | Phase4 | Focal Infection, Dental | Completed | 2013-03-21 | 2013-12-28 | ClinicalTrials.gov |
| NCT01663623 | Belimumab in Remission of VASculitis | Phase3 | Vasculitis | Completed | 2013-03-20 | 2017-02-06 | ClinicalTrials.gov |
| NCT01663623 | Belimumab in Remission of VASculitis | Phase3 | Vasculitis | Completed | 2013-03-20 | 2017-02-06 | ClinicalTrials.gov |
| NCT01711658 | TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating… | Phase2 | Non-HPV Locally Advanced Head and Neck Cancer | Completed | 2013-03-15 | 2022-09-21 | ClinicalTrials.gov |
| NCT01766206 | Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 M… | Phase4 | Meningococcal Disease | Completed | 2013-03-15 | 2018-01-22 | ClinicalTrials.gov |
| NCT01711658 | TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating… | Phase2 | Non-HPV Locally Advanced Head and Neck Cancer | Completed | 2013-03-15 | 2022-09-21 | ClinicalTrials.gov |
| NCT01766206 | Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 M… | Phase4 | Meningococcal Disease | Completed | 2013-03-15 | 2018-01-22 | ClinicalTrials.gov |
| NCT01808482 | A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (P… | Phase1 | Multiple Sclerosis, Relapsing-Remitting | Terminated | 2013-03-13 | 2013-08-06 | ClinicalTrials.gov |
| NCT01842620 | OXEMET™ 1000 mg Coated Tablets (Metformin Hydrochloride) Bioequivalence Study. … | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2013-03-13 | 2013-05-04 | ClinicalTrials.gov |
| NCT01808482 | A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (P… | Phase1 | Multiple Sclerosis, Relapsing-Remitting | Terminated | 2013-03-13 | 2013-08-06 | ClinicalTrials.gov |
| NCT01842620 | OXEMET™ 1000 mg Coated Tablets (Metformin Hydrochloride) Bioequivalence Study. … | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2013-03-13 | 2013-05-04 | ClinicalTrials.gov |
| NCT01751165 | Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK… | Phase3 | Herpes Zoster | Completed | 2013-03-12 | 2015-04-08 | ClinicalTrials.gov |
| NCT01751165 | Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK… | Phase3 | Herpes Zoster | Completed | 2013-03-12 | 2015-04-08 | ClinicalTrials.gov |
| NCT01725139 | A Proof of Mechanism Study With GSK2126458 in Patients With Idiopathic Pulmonar… | Phase1 | Idiopathic Pulmonary Fibrosis | Completed | 2013-03-08 | 2016-07-12 | ClinicalTrials.gov |
| NCT01725139 | A Proof of Mechanism Study With GSK2126458 in Patients With Idiopathic Pulmonar… | Phase1 | Idiopathic Pulmonary Fibrosis | Completed | 2013-03-08 | 2016-07-12 | ClinicalTrials.gov |
| NCT01777256 | An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety a… | Phase2 | Systemic Lupus Erythematosus | Terminated | 2013-03-01 | 2014-03-31 | ClinicalTrials.gov |
| NCT01055600 | Milk-only Lactation Study for Patients on Eltrombopag | Phase4 | Thrombocytopaenia | Withdrawn | 2013-03-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01330147 | HPV Prevalence in the Mouth and Oropharynx of the Tonsillectomy Population | — | Chronic Tonsillitis | Completed | 2013-03-01 | 2015-09-28 | ClinicalTrials.gov |
| NCT01813136 | Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid … | Phase2 | Thyroid Carcinoma | Completed | 2013-03-01 | 2019-01-01 | ClinicalTrials.gov |
| NCT01440361 | A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocyt… | Phase2 | Purpura, Thrombocytopaenic, Idiopathic | Withdrawn | 2013-03-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT01055600 | Milk-only Lactation Study for Patients on Eltrombopag | Phase4 | Thrombocytopaenia | Withdrawn | 2013-03-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT02020902 | Post Marketing Surveillance for Contac Bien Z in Japan | — | Allergic Rhinitis | Completed | 2013-03-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01330147 | HPV Prevalence in the Mouth and Oropharynx of the Tonsillectomy Population | — | Chronic Tonsillitis | Completed | 2013-03-01 | 2015-09-28 | ClinicalTrials.gov |
| NCT02020902 | Post Marketing Surveillance for Contac Bien Z in Japan | — | Allergic Rhinitis | Completed | 2013-03-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01767467 | Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologic… | Phase3 | Herpes Zoster | Completed | 2013-03-01 | 2017-01-06 | ClinicalTrials.gov |
| NCT01767467 | Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologic… | Phase3 | Herpes Zoster | Completed | 2013-03-01 | 2017-01-06 | ClinicalTrials.gov |
| NCT01808339 | To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Ev… | Phase2 | Asthma | Completed | 2013-03-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01808339 | To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Ev… | Phase2 | Asthma | Completed | 2013-03-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01777256 | An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety a… | Phase2 | Systemic Lupus Erythematosus | Terminated | 2013-03-01 | 2014-03-31 | ClinicalTrials.gov |
| NCT01440361 | A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocyt… | Phase2 | Purpura, Thrombocytopaenic, Idiopathic | Withdrawn | 2013-03-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT01788813 | To Investigate the Safety, Pharmacodynamics and Effect on Allergic Reactivity o… | Phase2 | Mild Asthma and Allergic Rhinitis | Completed | 2013-03-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01813136 | Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid … | Phase2 | Thyroid Carcinoma | Completed | 2013-03-01 | 2019-01-01 | ClinicalTrials.gov |
| NCT01788813 | To Investigate the Safety, Pharmacodynamics and Effect on Allergic Reactivity o… | Phase2 | Mild Asthma and Allergic Rhinitis | Completed | 2013-03-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01777295 | Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated … | Phase2 | Hepatitis B | Completed | 2013-02-25 | 2016-09-13 | ClinicalTrials.gov |
| NCT01777295 | Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated … | Phase2 | Hepatitis B | Completed | 2013-02-25 | 2016-09-13 | ClinicalTrials.gov |
| NCT01777282 | A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combin… | Phase3 | Diabetes Mellitus | Completed | 2013-02-23 | 2015-01-27 | ClinicalTrials.gov |
| NCT01777282 | A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combin… | Phase3 | Diabetes Mellitus | Completed | 2013-02-23 | 2015-01-27 | ClinicalTrials.gov |
| NCT01910662 | Characterisation of T-cell Response to Keyhole Limpet Hemocyanin (KLH) and Tube… | Phase1 | Dermatitis | Completed | 2013-02-22 | 2013-11-26 | ClinicalTrials.gov |
| NCT01818024 | A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacody… | Phase1 | Respiratory Disorders | Completed | 2013-02-22 | 2013-10-25 | ClinicalTrials.gov |
| NCT01818024 | A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacody… | Phase1 | Respiratory Disorders | Completed | 2013-02-22 | 2013-10-25 | ClinicalTrials.gov |
| NCT01910662 | Characterisation of T-cell Response to Keyhole Limpet Hemocyanin (KLH) and Tube… | Phase1 | Dermatitis | Completed | 2013-02-22 | 2013-11-26 | ClinicalTrials.gov |
| NCT01729455 | Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosu… | — | Systemic Lupus Erythematosus | Completed | 2013-02-21 | 2025-02-28 | ClinicalTrials.gov |
| NCT01729455 | Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosu… | — | Systemic Lupus Erythematosus | Completed | 2013-02-21 | 2025-02-28 | ClinicalTrials.gov |
| NCT01632241 | Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Ery… | Phase4 | Systemic Lupus Erythematosus | Completed | 2013-02-19 | 2019-01-28 | ClinicalTrials.gov |
| NCT01632241 | Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Ery… | Phase4 | Systemic Lupus Erythematosus | Completed | 2013-02-19 | 2019-01-28 | ClinicalTrials.gov |
| NCT01802918 | Single Dose Escalation Study of GSK2838232 in Healthy Subjects | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2013-02-18 | 2013-11-21 | ClinicalTrials.gov |
| NCT01777269 | Prospective Sexual Function Study for BPH Subjects | Phase4 | Prostatic Hyperplasia | Completed | 2013-02-18 | 2016-04-05 | ClinicalTrials.gov |
| NCT01777269 | Prospective Sexual Function Study for BPH Subjects | Phase4 | Prostatic Hyperplasia | Completed | 2013-02-18 | 2016-04-05 | ClinicalTrials.gov |
| NCT01802918 | Single Dose Escalation Study of GSK2838232 in Healthy Subjects | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2013-02-18 | 2013-11-21 | ClinicalTrials.gov |
| NCT01767454 | Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K M… | Phase1 | Solid Tumours | Completed | 2013-02-12 | 2015-09-04 | ClinicalTrials.gov |
| NCT01767454 | Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K M… | Phase1 | Solid Tumours | Completed | 2013-02-12 | 2015-09-04 | ClinicalTrials.gov |
| NCT01725126 | To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in H… | Phase2 | Obesity | Completed | 2013-02-10 | 2013-09-12 | ClinicalTrials.gov |
| NCT01725126 | To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in H… | Phase2 | Obesity | Completed | 2013-02-10 | 2013-09-12 | ClinicalTrials.gov |
| NCT02254460 | Investigation of Iron Uptake From Micronutrient Fortified Powder Versus From Ta… | Na | Growth and Development | Completed | 2013-02-06 | 2013-03-08 | ClinicalTrials.gov |
| NCT02254460 | Investigation of Iron Uptake From Micronutrient Fortified Powder Versus From Ta… | Na | Growth and Development | Completed | 2013-02-06 | 2013-03-08 | ClinicalTrials.gov |
| NCT01725100 | A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trameti… | Phase1 | Cancer | Completed | 2013-02-05 | 2015-01-30 | ClinicalTrials.gov |
| NCT01725100 | A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trameti… | Phase1 | Cancer | Completed | 2013-02-05 | 2015-01-30 | ClinicalTrials.gov |
| NCT03292094 | The African-PREDICT Study | — | Cardiovascular Diseases | Active_Not_Recruiting | 2013-02-04 | 2027-12-03 | ClinicalTrials.gov |
| NCT03292094 | The African-PREDICT Study | — | Cardiovascular Diseases | Active_Not_Recruiting | 2013-02-04 | 2027-12-03 | ClinicalTrials.gov |
| NCT01716533 | Evaluation of the Immune Response to Clostridium Difficile in Adults With Clost… | Na | Infections, Clostridium Difficile | Completed | 2013-02-02 | 2015-06-01 | ClinicalTrials.gov |
| NCT01716533 | Evaluation of the Immune Response to Clostridium Difficile in Adults With Clost… | Na | Infections, Clostridium Difficile | Completed | 2013-02-02 | 2015-06-01 | ClinicalTrials.gov |
| NCT01827670 | Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From D… | Phase3 | Dentine Hypersensitivity | Completed | 2013-02-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01751113 | A 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiot… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-02-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01827670 | Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From D… | Phase3 | Dentine Hypersensitivity | Completed | 2013-02-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01772199 | Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Rela… | Phase2 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2013-02-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01769508 | Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Trea… | Phase2 | HER2 Positive Esophagogastric Cancer | Terminated | 2013-02-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01938560 | REMS Retigabine Study | — | Epilepsy | Completed | 2013-02-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT02014480 | A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umec… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-02-01 | 2013-06-11 | ClinicalTrials.gov |
| NCT01762800 | Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bro… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-02-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01762800 | Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bro… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-02-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01658605 | A Study to Investigate the Efficacy and Safety of GSK1605786 for Treatment of P… | Phase2 | Colitis, Ulcerative | Withdrawn | 2013-02-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01772199 | Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Rela… | Phase2 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2013-02-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01751113 | A 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiot… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-02-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01769508 | Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Trea… | Phase2 | HER2 Positive Esophagogastric Cancer | Terminated | 2013-02-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01658605 | A Study to Investigate the Efficacy and Safety of GSK1605786 for Treatment of P… | Phase2 | Colitis, Ulcerative | Withdrawn | 2013-02-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01938560 | REMS Retigabine Study | — | Epilepsy | Completed | 2013-02-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT02014480 | A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umec… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-02-01 | 2013-06-11 | ClinicalTrials.gov |
| NCT01738477 | Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vacci… | Phase3 | Tetanus | Completed | 2013-01-31 | 2014-04-02 | ClinicalTrials.gov |
| NCT01738477 | Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vacci… | Phase3 | Tetanus | Completed | 2013-01-31 | 2014-04-02 | ClinicalTrials.gov |
| NCT01692496 | Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcom… | Phase2 | Advanced and / or Metastatic Liposarcoma | Completed | 2013-01-29 | 2018-03-02 | ClinicalTrials.gov |
| NCT01692496 | Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcom… | Phase2 | Advanced and / or Metastatic Liposarcoma | Completed | 2013-01-29 | 2018-03-02 | ClinicalTrials.gov |
| NCT01777334 | The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) o… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-01-23 | 2013-09-24 | ClinicalTrials.gov |
| NCT01777334 | The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) o… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-01-23 | 2013-09-24 | ClinicalTrials.gov |
| NCT01738451 | A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac R… | Phase1 | Cancer | Completed | 2013-01-22 | 2014-11-28 | ClinicalTrials.gov |
| NCT01738451 | A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac R… | Phase1 | Cancer | Completed | 2013-01-22 | 2014-11-28 | ClinicalTrials.gov |
| NCT01762774 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynami… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-01-16 | 2014-05-01 | ClinicalTrials.gov |
| NCT01762774 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynami… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-01-16 | 2014-05-01 | ClinicalTrials.gov |
| NCT01716208 | Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma | Phase2 | Chronic Lymphocytic Leukemia | Completed | 2013-01-14 | 2020-10-01 | ClinicalTrials.gov |
| NCT01716208 | Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma | Phase2 | Chronic Lymphocytic Leukemia | Completed | 2013-01-14 | 2020-10-01 | ClinicalTrials.gov |
| NCT01755689 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningoco… | Phase3 | Infections, Meningococcal | Completed | 2013-01-11 | 2014-04-29 | ClinicalTrials.gov |
| NCT01755689 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningoco… | Phase3 | Infections, Meningococcal | Completed | 2013-01-11 | 2014-04-29 | ClinicalTrials.gov |
| NCT01756495 | A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared … | Phase1 | Acute Coronary Syndrome | Completed | 2013-01-10 | 2013-04-23 | ClinicalTrials.gov |
| NCT01767376 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningoco… | Phase3 | Infections, Meningococcal | Completed | 2013-01-10 | 2014-01-16 | ClinicalTrials.gov |
| NCT01756495 | A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared … | Phase1 | Acute Coronary Syndrome | Completed | 2013-01-10 | 2013-04-23 | ClinicalTrials.gov |
| NCT01767376 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningoco… | Phase3 | Infections, Meningococcal | Completed | 2013-01-10 | 2014-01-16 | ClinicalTrials.gov |
| NCT01802931 | GSK239512 DDI Study | Phase1 | Multiple Sclerosis | Completed | 2013-01-07 | 2013-04-15 | ClinicalTrials.gov |
| NCT01802931 | GSK239512 DDI Study | Phase1 | Multiple Sclerosis | Completed | 2013-01-07 | 2013-04-15 | ClinicalTrials.gov |
| NCT02019732 | Study to Assess the Burden of Mild Outcomes (Physician Office Visits) Due to In… | — | Influenza | Completed | 2013-01-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT02262702 | Panadol Osteo Pharmaceuticals Benefit Scheme (PBS) Claims Cohort Study | — | Osteoarthritis | Withdrawn | 2013-01-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01772134 | Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-01-01 | 2013-07-22 | ClinicalTrials.gov |
| NCT01754116 | A Randomized Study to Assess the Relative Bioavailability of New Formulations o… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2013-01-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01866267 | Switching Undetectables to Selzentry | Phase4 | Human Immunodeficiency Virus | Completed | 2013-01-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT02019732 | Study to Assess the Burden of Mild Outcomes (Physician Office Visits) Due to In… | — | Influenza | Completed | 2013-01-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT02070055 | Dietary Correlates of the Maximal Capacity for Fat Oxidation | — | Maximal Rate of Fat Oxidation | Completed | 2013-01-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01772134 | Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2013-01-01 | 2013-07-22 | ClinicalTrials.gov |
| NCT01831817 | Exploratory Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in … | Phase2 | Dentinal Hypersensitivity | Completed | 2013-01-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01754116 | A Randomized Study to Assess the Relative Bioavailability of New Formulations o… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2013-01-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT02262702 | Panadol Osteo Pharmaceuticals Benefit Scheme (PBS) Claims Cohort Study | — | Osteoarthritis | Withdrawn | 2013-01-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT02070055 | Dietary Correlates of the Maximal Capacity for Fat Oxidation | — | Maximal Rate of Fat Oxidation | Completed | 2013-01-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01866267 | Switching Undetectables to Selzentry | Phase4 | Human Immunodeficiency Virus | Completed | 2013-01-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01831817 | Exploratory Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in … | Phase2 | Dentinal Hypersensitivity | Completed | 2013-01-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01753076 | Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic… | Phase2 | Amyotrophic Lateral Sclerosis | Completed | 2012-12-20 | 2015-01-22 | ClinicalTrials.gov |
| NCT01753076 | Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic… | Phase2 | Amyotrophic Lateral Sclerosis | Completed | 2012-12-20 | 2015-01-22 | ClinicalTrials.gov |
| NCT01751074 | To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmaco… | Phase1 | Atherosclerosis | Completed | 2012-12-17 | 2013-03-14 | ClinicalTrials.gov |
| NCT01751074 | To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmaco… | Phase1 | Atherosclerosis | Completed | 2012-12-17 | 2013-03-14 | ClinicalTrials.gov |
| NCT01738867 | To Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor G… | Phase1 | Alcoholism | Completed | 2012-12-12 | 2014-05-27 | ClinicalTrials.gov |
| NCT01738867 | To Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor G… | Phase1 | Alcoholism | Completed | 2012-12-12 | 2014-05-27 | ClinicalTrials.gov |
| NCT01577732 | Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Tod… | Phase3 | Acellular Pertussis | Completed | 2012-12-08 | 2013-04-09 | ClinicalTrials.gov |
| NCT01577732 | Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Tod… | Phase3 | Acellular Pertussis | Completed | 2012-12-08 | 2013-04-09 | ClinicalTrials.gov |
| NCT01591577 | Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Ne… | Phase2 | Newly Diagnosed Glioblastoma Multiforme | Completed | 2012-12-07 | 2024-05-07 | ClinicalTrials.gov |
| NCT01591577 | Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Ne… | Phase2 | Newly Diagnosed Glioblastoma Multiforme | Completed | 2012-12-07 | 2024-05-07 | ClinicalTrials.gov |
| NCT01711463 | Relovair PD PK in Chinese Healthy Subjects | Phase1 | Asthma | Completed | 2012-12-05 | 2013-06-04 | ClinicalTrials.gov |
| NCT01711463 | Relovair PD PK in Chinese Healthy Subjects | Phase1 | Asthma | Completed | 2012-12-05 | 2013-06-04 | ClinicalTrials.gov |
| NCT01729949 | The Acute and Chronic Effects of Fruit Polyphenols on Chronic Disease (PPF) | Na | Nutritional and Metabolic Disease | Completed | 2012-12-01 | 2018-06-26 | ClinicalTrials.gov |
| NCT01817790 | Assessment of Fluticasone Propionate on Ocular Allergy Symptoms | Phase3 | Allergic Rhinitis | Completed | 2012-12-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01729949 | The Acute and Chronic Effects of Fruit Polyphenols on Chronic Disease (PPF) | Na | Nutritional and Metabolic Disease | Completed | 2012-12-01 | 2018-06-26 | ClinicalTrials.gov |
| NCT01710059 | Using Mobile Phones to Improve Adherence to Inhaled Steroids | Na | Asthma | Completed | 2012-12-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01693185 | Remifentanil Only vs. Midazolam and Meperidine During Elective Colonoscopy | Phase4 | Diagnostic Colonoscopy Screening | Completed | 2012-12-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01817790 | Assessment of Fluticasone Propionate on Ocular Allergy Symptoms | Phase3 | Allergic Rhinitis | Completed | 2012-12-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01693185 | Remifentanil Only vs. Midazolam and Meperidine During Elective Colonoscopy | Phase4 | Diagnostic Colonoscopy Screening | Completed | 2012-12-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01762995 | A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Ph… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2012-12-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01710059 | Using Mobile Phones to Improve Adherence to Inhaled Steroids | Na | Asthma | Completed | 2012-12-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01808313 | Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hyper… | Phase3 | Vascular Disease | Completed | 2012-12-01 | 2014-08-15 | ClinicalTrials.gov |
| NCT01733849 | A Study to Estimate the Occurrence of Rotavirus Gastroenteritis in Children < 5… | — | Infections, Rotavirus | Completed | 2012-12-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01762995 | A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Ph… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2012-12-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01808313 | Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hyper… | Phase3 | Vascular Disease | Completed | 2012-12-01 | 2014-08-15 | ClinicalTrials.gov |
| NCT01733849 | A Study to Estimate the Occurrence of Rotavirus Gastroenteritis in Children < 5… | — | Infections, Rotavirus | Completed | 2012-12-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01733862 | Study to Assess the Impact of Vaccination on Hospitalizations and Outpatient Vi… | — | Infections, Rotavirus | Completed | 2012-11-27 | 2017-02-08 | ClinicalTrials.gov |
| NCT01733862 | Study to Assess the Impact of Vaccination on Hospitalizations and Outpatient Vi… | — | Infections, Rotavirus | Completed | 2012-11-27 | 2017-02-08 | ClinicalTrials.gov |
| NCT01684397 | Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Un… | Phase1 | Clear Cell Renal Cell Carcinoma | Active_Not_Recruiting | 2012-11-21 | 2026-08-20 | ClinicalTrials.gov |
| NCT01684397 | Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Un… | Phase1 | Clear Cell Renal Cell Carcinoma | Active_Not_Recruiting | 2012-11-21 | 2026-08-20 | ClinicalTrials.gov |
| NCT01687296 | Nebulized Fluticasone Propionate VS Oral Prednisone in Chinese Pediatric and Ad… | Phase3 | Asthma | Completed | 2012-11-12 | 2013-06-21 | ClinicalTrials.gov |
| NCT01687296 | Nebulized Fluticasone Propionate VS Oral Prednisone in Chinese Pediatric and Ad… | Phase3 | Asthma | Completed | 2012-11-12 | 2013-06-21 | ClinicalTrials.gov |
| NCT01725685 | To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Ume… | Phase1 | Asthma | Completed | 2012-11-08 | 2013-01-02 | ClinicalTrials.gov |
| NCT01725685 | To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Ume… | Phase1 | Asthma | Completed | 2012-11-08 | 2013-01-02 | ClinicalTrials.gov |
| NCT01802892 | Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Response… | Phase1 | Transplantation, Stem Cell | Completed | 2012-11-02 | 2013-04-02 | ClinicalTrials.gov |
| NCT01802892 | Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Response… | Phase1 | Transplantation, Stem Cell | Completed | 2012-11-02 | 2013-04-02 | ClinicalTrials.gov |
| NCT01905462 | Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Wome… | — | Infections, Papillomavirus | Completed | 2012-11-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01744106 | A Multicenter Study of Pseudoephedrine for the Temporary Relief of Nasal Conges… | Phase3 | Nasal Congestion Associated With the Common Cold | Completed | 2012-11-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01702857 | A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Ina… | Phase1 | Dengue Fever | Completed | 2012-11-01 | 2017-03-23 | ClinicalTrials.gov |
| NCT01031329 | Study to Identify and Characterize Bacteria Causing Acute Otitis Media in Young… | — | Infections, Streptococcal | Withdrawn | 2012-11-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01700010 | Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer | Phase2 | Urothelial Cancer | Withdrawn | 2012-11-01 | 2019-01-01 | ClinicalTrials.gov |
| NCT01706198 | An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol … | Phase3 | Asthma | Completed | 2012-11-01 | 2016-12-16 | ClinicalTrials.gov |
| NCT01691885 | RELOVAIR® Lung Deflation Study | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2012-11-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01702857 | A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Ina… | Phase1 | Dengue Fever | Completed | 2012-11-01 | 2017-03-23 | ClinicalTrials.gov |
| NCT01706224 | Sero-prevalence of Anti-pertussis Antibodies and Disease Awareness Among Spanis… | — | Pertussis | Completed | 2012-11-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01691885 | RELOVAIR® Lung Deflation Study | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2012-11-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01689532 | A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patient… | Phase3 | Arthritis, Rheumatoid | Completed | 2012-11-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01767363 | WEUSKOP5723: Prostate Cancer Study | — | Prostatic Hyperplasia | Completed | 2012-11-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT01706198 | An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol … | Phase3 | Asthma | Completed | 2012-11-01 | 2016-12-16 | ClinicalTrials.gov |
| NCT01744106 | A Multicenter Study of Pseudoephedrine for the Temporary Relief of Nasal Conges… | Phase3 | Nasal Congestion Associated With the Common Cold | Completed | 2012-11-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01767363 | WEUSKOP5723: Prostate Cancer Study | — | Prostatic Hyperplasia | Completed | 2012-11-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT01905462 | Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Wome… | — | Infections, Papillomavirus | Completed | 2012-11-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01031329 | Study to Identify and Characterize Bacteria Causing Acute Otitis Media in Young… | — | Infections, Streptococcal | Withdrawn | 2012-11-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01445600 | ALTARGO(Retapamulin) PMS(Post-marketing Surveillance) | — | Skin Infections, Bacterial | Completed | 2012-11-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT01445600 | ALTARGO(Retapamulin) PMS(Post-marketing Surveillance) | — | Skin Infections, Bacterial | Completed | 2012-11-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT01700010 | Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer | Phase2 | Urothelial Cancer | Withdrawn | 2012-11-01 | 2019-01-01 | ClinicalTrials.gov |
| NCT01706224 | Sero-prevalence of Anti-pertussis Antibodies and Disease Awareness Among Spanis… | — | Pertussis | Completed | 2012-11-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01689532 | A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patient… | Phase3 | Arthritis, Rheumatoid | Completed | 2012-11-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01711723 | A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral … | Phase1 | Atherosclerosis | Completed | 2012-10-29 | 2013-03-25 | ClinicalTrials.gov |
| NCT01711723 | A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral … | Phase1 | Atherosclerosis | Completed | 2012-10-29 | 2013-03-25 | ClinicalTrials.gov |
| NCT01702467 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Esc… | Phase1 | Alzheimer's Disease | Completed | 2012-10-19 | 2013-05-15 | ClinicalTrials.gov |
| NCT01702467 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Esc… | Phase1 | Alzheimer's Disease | Completed | 2012-10-19 | 2013-05-15 | ClinicalTrials.gov |
| NCT01706315 | This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profil… | Phase1 | Infections, Respiratory Tract | Completed | 2012-10-17 | 2013-12-13 | ClinicalTrials.gov |
| NCT01706315 | This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profil… | Phase1 | Infections, Respiratory Tract | Completed | 2012-10-17 | 2013-12-13 | ClinicalTrials.gov |
| NCT01681992 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined … | Phase3 | Measles | Completed | 2012-10-10 | 2015-08-18 | ClinicalTrials.gov |
| NCT01681992 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined … | Phase3 | Measles | Completed | 2012-10-10 | 2015-08-18 | ClinicalTrials.gov |
| NCT01691521 | Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Se… | Phase3 | Asthma | Completed | 2012-10-08 | 2014-01-18 | ClinicalTrials.gov |
| NCT01691521 | Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Se… | Phase3 | Asthma | Completed | 2012-10-08 | 2014-01-18 | ClinicalTrials.gov |
| NCT01682876 | Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or… | Phase3 | Meningococcal Disease | Completed | 2012-10-07 | 2014-05-30 | ClinicalTrials.gov |
| NCT01682876 | Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or… | Phase3 | Meningococcal Disease | Completed | 2012-10-07 | 2014-05-30 | ClinicalTrials.gov |
| NCT01691820 | A Study in Adolescent Females to Explore Cytomegalovirus Infection | Na | Infections, Cytomegalovirus | Completed | 2012-10-05 | 2017-04-08 | ClinicalTrials.gov |
| NCT01691820 | A Study in Adolescent Females to Explore Cytomegalovirus Infection | Na | Infections, Cytomegalovirus | Completed | 2012-10-05 | 2017-04-08 | ClinicalTrials.gov |
| NCT01691508 | Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma | Phase3 | Asthma | Completed | 2012-10-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01716520 | Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2012-10-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01691495 | ARIXTRA® Adherence in SVT Patients. | — | Thrombosis, Venous | Completed | 2012-10-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01691508 | Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma | Phase3 | Asthma | Completed | 2012-10-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01621204 | A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune… | Phase3 | Immune Thrombocytopenic Purpura | Completed | 2012-10-01 | 2019-08-01 | ClinicalTrials.gov |
| NCT01626352 | Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed D… | Phase2 | Diffuse Large B-Cell Lymphoma | Completed | 2012-10-01 | 2017-04-01 | ClinicalTrials.gov |
| NCT01621204 | A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune… | Phase3 | Immune Thrombocytopenic Purpura | Completed | 2012-10-01 | 2019-08-01 | ClinicalTrials.gov |
| NCT01500538 | A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With… | Phase2 | Follicular Lymphoma | Terminated | 2012-10-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01160055 | Study to Characterize and Identify Bacteria Causing Acute Otitis Media in Young… | — | Infections, Streptococcal | Withdrawn | 2012-10-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01751178 | An Efficacy Study of Chlorhexidine Mouthwashes | Phase4 | Gingivitis | Completed | 2012-10-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01716520 | Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2012-10-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01160055 | Study to Characterize and Identify Bacteria Causing Acute Otitis Media in Young… | — | Infections, Streptococcal | Withdrawn | 2012-10-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01715792 | Assess the Risk of Solid Organ Transplant Rejection Following Vaccination With … | — | Influenza | Completed | 2012-10-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01706302 | Burden of Respiratory Syncytial Virus (RSV) in the United Kingdom From 1995 to … | — | Respiratory Syncyctial Virus Vaccines | Completed | 2012-10-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01500538 | A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With… | Phase2 | Follicular Lymphoma | Terminated | 2012-10-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01691495 | ARIXTRA® Adherence in SVT Patients. | — | Thrombosis, Venous | Completed | 2012-10-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01626352 | Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed D… | Phase2 | Diffuse Large B-Cell Lymphoma | Completed | 2012-10-01 | 2017-04-01 | ClinicalTrials.gov |
| NCT01751178 | An Efficacy Study of Chlorhexidine Mouthwashes | Phase4 | Gingivitis | Completed | 2012-10-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01715792 | Assess the Risk of Solid Organ Transplant Rejection Following Vaccination With … | — | Influenza | Completed | 2012-10-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01706302 | Burden of Respiratory Syncytial Virus (RSV) in the United Kingdom From 1995 to … | — | Respiratory Syncyctial Virus Vaccines | Completed | 2012-10-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01691859 | MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmat… | Phase3 | Asthma | Completed | 2012-09-28 | 2017-05-31 | ClinicalTrials.gov |
| NCT01691859 | MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmat… | Phase3 | Asthma | Completed | 2012-09-28 | 2017-05-31 | ClinicalTrials.gov |
| NCT01725672 | Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose C… | Phase1 | Diabetes Mellitus, Type 2 | Terminated | 2012-09-27 | 2013-08-21 | ClinicalTrials.gov |
| NCT01343043 | A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-… | Phase1 | Neoplasms | Completed | 2012-09-27 | 2019-06-18 | ClinicalTrials.gov |
| NCT01343043 | A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-… | Phase1 | Neoplasms | Completed | 2012-09-27 | 2019-06-18 | ClinicalTrials.gov |
| NCT01725672 | Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose C… | Phase1 | Diabetes Mellitus, Type 2 | Terminated | 2012-09-27 | 2013-08-21 | ClinicalTrials.gov |
| NCT01696604 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Cachexia | Completed | 2012-09-26 | 2013-05-03 | ClinicalTrials.gov |
| NCT01696604 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Cachexia | Completed | 2012-09-26 | 2013-05-03 | ClinicalTrials.gov |
| NCT01686633 | An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 M… | Phase3 | Asthma | Completed | 2012-09-20 | 2013-10-15 | ClinicalTrials.gov |
| NCT01686633 | An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 M… | Phase3 | Asthma | Completed | 2012-09-20 | 2013-10-15 | ClinicalTrials.gov |
| NCT01658553 | A Study to Look at the Electrical Activity of the Heart in Subjects With Solid … | Phase1 | Cancer | Completed | 2012-09-19 | 2014-04-05 | ClinicalTrials.gov |
| NCT01658553 | A Study to Look at the Electrical Activity of the Heart in Subjects With Solid … | Phase1 | Cancer | Completed | 2012-09-19 | 2014-04-05 | ClinicalTrials.gov |
| NCT01641042 | Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for M… | Phase3 | Infections, Meningococcal | Completed | 2012-09-10 | 2015-03-03 | ClinicalTrials.gov |
| NCT01641042 | Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for M… | Phase3 | Infections, Meningococcal | Completed | 2012-09-10 | 2015-03-03 | ClinicalTrials.gov |
| NCT01649765 | Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy | Phase2 | Systemic Lupus Erythematosus | Completed | 2012-09-07 | 2025-09-30 | ClinicalTrials.gov |
| NCT01649765 | Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy | Phase2 | Systemic Lupus Erythematosus | Completed | 2012-09-07 | 2025-09-30 | ClinicalTrials.gov |
| NCT01641133 | Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and… | Phase3 | Infections, Streptococcal | Completed | 2012-09-04 | 2014-05-07 | ClinicalTrials.gov |
| NCT01668654 | Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatr… | Phase3 | Epilepsy | Terminated | 2012-09-04 | 2013-06-18 | ClinicalTrials.gov |
| NCT01668654 | Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatr… | Phase3 | Epilepsy | Terminated | 2012-09-04 | 2013-06-18 | ClinicalTrials.gov |
| NCT01641133 | Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and… | Phase3 | Infections, Streptococcal | Completed | 2012-09-04 | 2014-05-07 | ClinicalTrials.gov |
| NCT01340846 | A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects … | Phase1 | Cancer | Completed | 2012-09-03 | 2012-11-14 | ClinicalTrials.gov |
| NCT01340846 | A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects … | Phase1 | Cancer | Completed | 2012-09-03 | 2012-11-14 | ClinicalTrials.gov |
| NCT01619774 | An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in… | Phase2 | Melanoma | Completed | 2012-09-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT01701869 | Microbiology & Immunology of the Chronically-inflamed Airway | — | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2012-09-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01619774 | An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in… | Phase2 | Melanoma | Completed | 2012-09-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT01767389 | Glucagon-like Peptide (GLP) Utilization and Safety | — | Diabetes Mellitus, Type 2 | Completed | 2012-09-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01666652 | A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Ina… | Phase1 | Dengue Fever | Completed | 2012-09-01 | 2017-11-01 | ClinicalTrials.gov |
| NCT01694329 | Impact of Introduction of PHiD-CV for Nunavik Children, Quebec, Canada | — | Acute Upper Respiratory Infection | Unknown | 2012-09-01 | 2017-12-31 | ClinicalTrials.gov |
| NCT01721213 | Trobalt™ Products Risk Survey | — | Epilepsy | Completed | 2012-09-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01767389 | Glucagon-like Peptide (GLP) Utilization and Safety | — | Diabetes Mellitus, Type 2 | Completed | 2012-09-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01666652 | A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Ina… | Phase1 | Dengue Fever | Completed | 2012-09-01 | 2017-11-01 | ClinicalTrials.gov |
| NCT01702532 | Nicotine Mouth Film for Craving Relief. | Phase3 | Smoking Cessation | Completed | 2012-09-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01721213 | Trobalt™ Products Risk Survey | — | Epilepsy | Completed | 2012-09-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01694329 | Impact of Introduction of PHiD-CV for Nunavik Children, Quebec, Canada | — | Acute Upper Respiratory Infection | Unknown | 2012-09-01 | 2017-12-31 | ClinicalTrials.gov |
| NCT01702532 | Nicotine Mouth Film for Craving Relief. | Phase3 | Smoking Cessation | Completed | 2012-09-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01701869 | Microbiology & Immunology of the Chronically-inflamed Airway | — | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2012-09-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01657851 | Bioequivalence - Duodart Against Avodart & Omnic | Phase1 | Prostatic Hyperplasia | Completed | 2012-08-23 | 2012-12-05 | ClinicalTrials.gov |
| NCT01657851 | Bioequivalence - Duodart Against Avodart & Omnic | Phase1 | Prostatic Hyperplasia | Completed | 2012-08-23 | 2012-12-05 | ClinicalTrials.gov |
| NCT01659086 | Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biolog… | Phase1 | Influenza | Completed | 2012-08-22 | 2014-03-19 | ClinicalTrials.gov |
| NCT01659086 | Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biolog… | Phase1 | Influenza | Completed | 2012-08-22 | 2014-03-19 | ClinicalTrials.gov |
| NCT01669096 | Study in Healthy Adults to Evaluate Gene Activation After Vaccination With Glax… | Phase2 | Tuberculosis | Completed | 2012-08-21 | 2013-05-24 | ClinicalTrials.gov |
| NCT01669096 | Study in Healthy Adults to Evaluate Gene Activation After Vaccination With Glax… | Phase2 | Tuberculosis | Completed | 2012-08-21 | 2013-05-24 | ClinicalTrials.gov |
| NCT01669083 | Study to Evaluate the Pharmacokinetics, Safety and Tolerability of GSK557296 in… | Phase1 | Embryo Transfer | Completed | 2012-08-16 | 2013-03-09 | ClinicalTrials.gov |
| NCT01669083 | Study to Evaluate the Pharmacokinetics, Safety and Tolerability of GSK557296 in… | Phase1 | Embryo Transfer | Completed | 2012-08-16 | 2013-03-09 | ClinicalTrials.gov |
| NCT01669070 | A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Propor… | Phase1 | Asthma | Completed | 2012-08-15 | 2012-11-16 | ClinicalTrials.gov |
| NCT01604343 | A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With … | Phase3 | Arthritis, Rheumatoid | Completed | 2012-08-15 | 2016-12-06 | ClinicalTrials.gov |
| NCT01669070 | A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Propor… | Phase1 | Asthma | Completed | 2012-08-15 | 2012-11-16 | ClinicalTrials.gov |
| NCT01604343 | A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With … | Phase3 | Arthritis, Rheumatoid | Completed | 2012-08-15 | 2016-12-06 | ClinicalTrials.gov |
| NCT01663389 | A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GS… | Phase1 | Infections, Bacterial | Completed | 2012-08-10 | 2012-10-05 | ClinicalTrials.gov |
| NCT01663389 | A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GS… | Phase1 | Infections, Bacterial | Completed | 2012-08-10 | 2012-10-05 | ClinicalTrials.gov |
| NCT01657526 | Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals'… | Phase1 | Respiratory Disorders | Completed | 2012-08-08 | 2013-11-25 | ClinicalTrials.gov |
| NCT01657526 | Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals'… | Phase1 | Respiratory Disorders | Completed | 2012-08-08 | 2013-11-25 | ClinicalTrials.gov |
| NCT01606761 | A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Adminis… | Phase3 | Arthritis, Rheumatoid | Completed | 2012-08-06 | 2016-01-12 | ClinicalTrials.gov |
| NCT01648231 | Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose C… | Phase1 | Hypertension | Completed | 2012-08-06 | 2012-09-25 | ClinicalTrials.gov |
| NCT01606761 | A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Adminis… | Phase3 | Arthritis, Rheumatoid | Completed | 2012-08-06 | 2016-01-12 | ClinicalTrials.gov |
| NCT01648231 | Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose C… | Phase1 | Hypertension | Completed | 2012-08-06 | 2012-09-25 | ClinicalTrials.gov |
| NCT01301794 | Lovaza Mechanisms of Action | Phase4 | Moderate Hypertriglyceridemia. | Unknown | 2012-08-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01657552 | Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study I… | Phase1 | Thrombocytopaenia | Completed | 2012-08-01 | 2012-10-26 | ClinicalTrials.gov |
| NCT01648140 | Dose Ranging of GSK2336805 in Combination Therapy | Phase2 | Hepatitis C, Chronic | Completed | 2012-08-01 | 2014-07-16 | ClinicalTrials.gov |
| NCT01702363 | Long-term Safety Study for GSK573719 in Japanese | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2012-08-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01710540 | BE Study of Metformin GSK 850mg | Phase2 | Diabetic Foot | Completed | 2012-08-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01648153 | Investigate the Efficacy and Safety of GSK1070806 in Obese Subjects With T2DM | Phase2 | Diabetes Mellitus | Completed | 2012-08-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01682005 | Study to Analyze the Clinical and Cost Impact of Complete and Incomplete Rotavi… | — | Infections, Rotavirus | Completed | 2012-08-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01542047 | A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies | Phase1 | Cancer, Metastatic | Terminated | 2012-08-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01657552 | Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study I… | Phase1 | Thrombocytopaenia | Completed | 2012-08-01 | 2012-10-26 | ClinicalTrials.gov |
| NCT02552472 | A Study of Inhaler Use in the Community | — | Asthma | Completed | 2012-08-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01648140 | Dose Ranging of GSK2336805 in Combination Therapy | Phase2 | Hepatitis C, Chronic | Completed | 2012-08-01 | 2014-07-16 | ClinicalTrials.gov |
| NCT01542047 | A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies | Phase1 | Cancer, Metastatic | Terminated | 2012-08-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01648153 | Investigate the Efficacy and Safety of GSK1070806 in Obese Subjects With T2DM | Phase2 | Diabetes Mellitus | Completed | 2012-08-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01691560 | Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentin… | Phase2 | Dentine Hypersensitivity | Completed | 2012-08-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01710540 | BE Study of Metformin GSK 850mg | Phase2 | Diabetic Foot | Completed | 2012-08-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01691560 | Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentin… | Phase2 | Dentine Hypersensitivity | Completed | 2012-08-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01602510 | Lamotrigine Phase III Study in Bipolar I Disorder | Phase3 | Bipolar Disorder | Completed | 2012-08-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01301794 | Lovaza Mechanisms of Action | Phase4 | Moderate Hypertriglyceridemia. | Unknown | 2012-08-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01682005 | Study to Analyze the Clinical and Cost Impact of Complete and Incomplete Rotavi… | — | Infections, Rotavirus | Completed | 2012-08-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01602510 | Lamotrigine Phase III Study in Bipolar I Disorder | Phase3 | Bipolar Disorder | Completed | 2012-08-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01702363 | Long-term Safety Study for GSK573719 in Japanese | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2012-08-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT02552472 | A Study of Inhaler Use in the Community | — | Asthma | Completed | 2012-08-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01647659 | Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation | Phase1 | Cancer | Completed | 2012-07-30 | 2012-11-12 | ClinicalTrials.gov |
| NCT01647659 | Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation | Phase1 | Cancer | Completed | 2012-07-30 | 2012-11-12 | ClinicalTrials.gov |
| NCT01648192 | Phase I Study of GW856553 (Losmapimod) | Phase1 | Acute Coronary Syndrome | Completed | 2012-07-24 | 2012-10-26 | ClinicalTrials.gov |
| NCT01627340 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-… | Phase4 | Hepatitis B | Completed | 2012-07-24 | 2013-12-18 | ClinicalTrials.gov |
| NCT01648192 | Phase I Study of GW856553 (Losmapimod) | Phase1 | Acute Coronary Syndrome | Completed | 2012-07-24 | 2012-10-26 | ClinicalTrials.gov |
| NCT01627340 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-… | Phase4 | Hepatitis B | Completed | 2012-07-24 | 2013-12-18 | ClinicalTrials.gov |
| NCT01691482 | A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking … | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2012-07-23 | 2012-10-22 | ClinicalTrials.gov |
| NCT01691482 | A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking … | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2012-07-23 | 2012-10-22 | ClinicalTrials.gov |
| NCT01626820 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral®… | Phase3 | Influenza | Completed | 2012-07-19 | 2012-08-10 | ClinicalTrials.gov |
| NCT01626820 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral®… | Phase3 | Influenza | Completed | 2012-07-19 | 2012-08-10 | ClinicalTrials.gov |
| NCT01532310 | Belimumab (BENLYSTA®) Pregnancy Registry | — | Systemic Lupus Erythematosus | Completed | 2012-07-16 | 2022-11-11 | ClinicalTrials.gov |
| NCT01532310 | Belimumab (BENLYSTA®) Pregnancy Registry | — | Systemic Lupus Erythematosus | Completed | 2012-07-16 | 2022-11-11 | ClinicalTrials.gov |
| NCT01639339 | Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis | Phase3 | Lupus Nephritis | Completed | 2012-07-12 | 2020-03-12 | ClinicalTrials.gov |
| NCT01639339 | Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis | Phase3 | Lupus Nephritis | Completed | 2012-07-12 | 2020-03-12 | ClinicalTrials.gov |
| NCT01616459 | Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal … | Phase2 | Infections, Streptococcal | Completed | 2012-07-11 | 2014-01-22 | ClinicalTrials.gov |
| NCT01616459 | Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal … | Phase2 | Infections, Streptococcal | Completed | 2012-07-11 | 2014-01-22 | ClinicalTrials.gov |
| NCT01681979 | WEUSRTP4850: Phase II: ICS/LABA Use in Pregnancy and Outcomes | — | Asthma | Completed | 2012-07-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01627223 | Comparison Between Lamivudine and Entecavir Treatment in Spontaneous Severe Acu… | Phase4 | Chronic Hepatitis B | Terminated | 2012-07-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01763463 | WEUSKOP6416: Evaluating Pneumonia in Chronic Obstructive Pulmonary Disease (COP… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2012-07-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01763463 | WEUSKOP6416: Evaluating Pneumonia in Chronic Obstructive Pulmonary Disease (COP… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2012-07-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01710553 | BE STUDY OF METFORMIN GSK 1000mg | Phase2 | Diabetic Foot | Completed | 2012-07-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01608009 | [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer | Phase1 | Ovarian Neoplasm | Completed | 2012-07-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01656252 | Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complet… | Phase1 | Acute Myeloid Leukemia | Terminated | 2012-07-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT01653509 | An Exploratory Study to Investigate the Inflammatory Response During a Cold Sor… | Phase1 | Herpes Labialis | Completed | 2012-07-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01636778 | Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients | Phase2 | Hepatitis C, Chronic | Completed | 2012-07-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01636739 | Special Drug Use Investigation for ROTARIX® | — | Infections, Rotavirus | Completed | 2012-07-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT01636713 | A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/2… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2012-07-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01627223 | Comparison Between Lamivudine and Entecavir Treatment in Spontaneous Severe Acu… | Phase4 | Chronic Hepatitis B | Terminated | 2012-07-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01610492 | A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy | Phase2 | Glomerulonephritis, Membranous | Completed | 2012-07-01 | 2016-09-14 | ClinicalTrials.gov |
| NCT01608009 | [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer | Phase1 | Ovarian Neoplasm | Completed | 2012-07-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01602549 | A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokineti… | Phase2 | Gastroparesis | Completed | 2012-07-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01602549 | A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokineti… | Phase2 | Gastroparesis | Completed | 2012-07-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01710553 | BE STUDY OF METFORMIN GSK 1000mg | Phase2 | Diabetic Foot | Completed | 2012-07-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01534897 | Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroi… | Na | Papillary Thyroid Carcinoma | Completed | 2012-07-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01610492 | A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy | Phase2 | Glomerulonephritis, Membranous | Completed | 2012-07-01 | 2016-09-14 | ClinicalTrials.gov |
| NCT02626923 | Study of Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in ART-Naive & First … | — | Drug-induced Hypotension | Completed | 2012-07-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01681979 | WEUSRTP4850: Phase II: ICS/LABA Use in Pregnancy and Outcomes | — | Asthma | Completed | 2012-07-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01636713 | A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/2… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2012-07-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT02626923 | Study of Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in ART-Naive & First … | — | Drug-induced Hypotension | Completed | 2012-07-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01636739 | Special Drug Use Investigation for ROTARIX® | — | Infections, Rotavirus | Completed | 2012-07-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT01636778 | Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients | Phase2 | Hepatitis C, Chronic | Completed | 2012-07-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01534897 | Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroi… | Na | Papillary Thyroid Carcinoma | Completed | 2012-07-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01656252 | Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complet… | Phase1 | Acute Myeloid Leukemia | Terminated | 2012-07-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT01653509 | An Exploratory Study to Investigate the Inflammatory Response During a Cold Sor… | Phase1 | Herpes Labialis | Completed | 2012-07-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01673490 | Safety and Efficacy of 0.5mg Dutasteride and 0.4mg Tamsulosin Combination Once … | Phase4 | Prostatic Hyperplasia | Terminated | 2012-06-29 | 2015-03-20 | ClinicalTrials.gov |
| NCT01673490 | Safety and Efficacy of 0.5mg Dutasteride and 0.4mg Tamsulosin Combination Once … | Phase4 | Prostatic Hyperplasia | Terminated | 2012-06-29 | 2015-03-20 | ClinicalTrials.gov |
| NCT01610427 | Study to Optimize the Quality of Samples for Cell-mediated Immunity (CMI) in AR… | Na | AIDS | Completed | 2012-06-25 | 2012-10-30 | ClinicalTrials.gov |
| NCT01610427 | Study to Optimize the Quality of Samples for Cell-mediated Immunity (CMI) in AR… | Na | AIDS | Completed | 2012-06-25 | 2012-10-30 | ClinicalTrials.gov |
| NCT01621802 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined … | Phase3 | Measles-Mumps-Rubella | Completed | 2012-06-21 | 2015-11-09 | ClinicalTrials.gov |
| NCT01621802 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined … | Phase3 | Measles-Mumps-Rubella | Completed | 2012-06-21 | 2015-11-09 | ClinicalTrials.gov |
| NCT01597687 | Pertussis Infection in Adolescents and Adults With Prolonged Cough | Na | Pertussis | Completed | 2012-06-20 | 2013-05-02 | ClinicalTrials.gov |
| NCT01597687 | Pertussis Infection in Adolescents and Adults With Prolonged Cough | Na | Pertussis | Completed | 2012-06-20 | 2013-05-02 | ClinicalTrials.gov |
| NCT01536873 | Dolutegravir Expanded Access Study | Na | Infection, Human Immunodeficiency Virus | Completed | 2012-06-14 | 2016-09-23 | ClinicalTrials.gov |
| NCT01536873 | Dolutegravir Expanded Access Study | Na | Infection, Human Immunodeficiency Virus | Completed | 2012-06-14 | 2016-09-23 | ClinicalTrials.gov |
| NCT01597622 | BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Er… | Phase3 | Systemic Lupus Erythematosus | Completed | 2012-06-11 | 2018-09-13 | ClinicalTrials.gov |
| NCT01597622 | BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Er… | Phase3 | Systemic Lupus Erythematosus | Completed | 2012-06-11 | 2018-09-13 | ClinicalTrials.gov |
| NCT01622491 | Effectiveness of H1N1 Influenza Vaccines in Manitoba, Canada | — | Influenza | Unknown | 2012-06-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01622231 | Study FFR116365, an Open-label Study of GW685698X in Paediatric Subjects With P… | Phase3 | Rhinitis | Completed | 2012-06-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01622491 | Effectiveness of H1N1 Influenza Vaccines in Manitoba, Canada | — | Influenza | Unknown | 2012-06-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01612351 | Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to T… | Phase2 | Head and Neck Cancer | Completed | 2012-06-01 | 2025-05-19 | ClinicalTrials.gov |
| NCT01622660 | Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastat… | Phase2 | Bladder Cancer | Terminated | 2012-06-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT01622790 | Evaluation of the Bioequivalence of a Combined Formulated Tablet | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2012-06-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01541852 | Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibr… | Phase2 | Chronic Obstructive Pulmonary Disease | Completed | 2012-06-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01636193 | Drug Use Investigation for ROTARIX® | — | Infections, Rotavirus | Completed | 2012-06-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01669122 | Pharmacokinetic Study of 4 mg Nicotine Lozenge. | Phase2 | Smoking Cessation | Completed | 2012-06-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01669122 | Pharmacokinetic Study of 4 mg Nicotine Lozenge. | Phase2 | Smoking Cessation | Completed | 2012-06-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01612351 | Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to T… | Phase2 | Head and Neck Cancer | Completed | 2012-06-01 | 2025-05-19 | ClinicalTrials.gov |
| NCT01541852 | Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibr… | Phase2 | Chronic Obstructive Pulmonary Disease | Completed | 2012-06-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01622231 | Study FFR116365, an Open-label Study of GW685698X in Paediatric Subjects With P… | Phase3 | Rhinitis | Completed | 2012-06-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01636193 | Drug Use Investigation for ROTARIX® | — | Infections, Rotavirus | Completed | 2012-06-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01622790 | Evaluation of the Bioequivalence of a Combined Formulated Tablet | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2012-06-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01622660 | Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastat… | Phase2 | Bladder Cancer | Terminated | 2012-06-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT01597492 | A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects Wi… | Phase4 | Systemic Lupus Erythematosus | Completed | 2012-05-31 | 2015-09-24 | ClinicalTrials.gov |
| NCT01597492 | A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects Wi… | Phase4 | Systemic Lupus Erythematosus | Completed | 2012-05-31 | 2015-09-24 | ClinicalTrials.gov |
| NCT01418937 | Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Con… | Phase3 | Infections, Papillomavirus | Completed | 2012-05-29 | 2015-01-09 | ClinicalTrials.gov |
| NCT01418937 | Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Con… | Phase3 | Infections, Papillomavirus | Completed | 2012-05-29 | 2015-01-09 | ClinicalTrials.gov |
| NCT01587924 | 4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated W… | Phase2 | Anaemia | Completed | 2012-05-23 | 2013-05-27 | ClinicalTrials.gov |
| NCT01587924 | 4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated W… | Phase2 | Anaemia | Completed | 2012-05-23 | 2013-05-27 | ClinicalTrials.gov |
| NCT01545375 | Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children | Phase2 | Infections, Streptococcal | Completed | 2012-05-21 | 2016-07-26 | ClinicalTrials.gov |
| NCT01568060 | Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among … | — | Acellular Pertussis | Completed | 2012-05-21 | 2015-12-15 | ClinicalTrials.gov |
| NCT01545375 | Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children | Phase2 | Infections, Streptococcal | Completed | 2012-05-21 | 2016-07-26 | ClinicalTrials.gov |
| NCT01568060 | Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among … | — | Acellular Pertussis | Completed | 2012-05-21 | 2015-12-15 | ClinicalTrials.gov |
| NCT01607385 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of D… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2012-05-18 | 2012-12-03 | ClinicalTrials.gov |
| NCT01607385 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of D… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2012-05-18 | 2012-12-03 | ClinicalTrials.gov |
| NCT01587898 | 4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney … | Phase2 | Anaemia | Completed | 2012-05-17 | 2013-05-07 | ClinicalTrials.gov |
| NCT01587898 | 4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney … | Phase2 | Anaemia | Completed | 2012-05-17 | 2013-05-07 | ClinicalTrials.gov |
| NCT01673555 | Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers | Phase1 | Anaemia | Completed | 2012-05-15 | 2012-11-19 | ClinicalTrials.gov |
| NCT01673555 | Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers | Phase1 | Anaemia | Completed | 2012-05-15 | 2012-11-19 | ClinicalTrials.gov |
| NCT01582997 | A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Pro… | Phase1 | Cancer | Completed | 2012-05-11 | 2015-04-16 | ClinicalTrials.gov |
| NCT01582997 | A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Pro… | Phase1 | Cancer | Completed | 2012-05-11 | 2015-04-16 | ClinicalTrials.gov |
| NCT01710527 | BE Study of Metformin GSK 500mg | Phase2 | Diabetic Foot | Completed | 2012-05-09 | 2012-05-18 | ClinicalTrials.gov |
| NCT01710527 | BE Study of Metformin GSK 500mg | Phase2 | Diabetic Foot | Completed | 2012-05-09 | 2012-05-18 | ClinicalTrials.gov |
| NCT01602562 | Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantatio… | Phase3 | Herpes Simplex | Completed | 2012-05-07 | 2013-05-24 | ClinicalTrials.gov |
| NCT01602562 | Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantatio… | Phase3 | Herpes Simplex | Completed | 2012-05-07 | 2013-05-24 | ClinicalTrials.gov |
| NCT01641692 | A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With… | Phase2 | Asthma | Completed | 2012-05-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01657864 | WEUSKOP6166: Lamotrigine and Aseptic Meningitis | — | Epilepsy | Completed | 2012-05-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01550185 | Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid… | Phase1 | Adult Acute Basophilic Leukemia | Terminated | 2012-05-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01499160 | Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Ca… | Phase2 | Breast Neoplasms | Terminated | 2012-05-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01657877 | Anti-caries Potential of a Sodium Monofluorophosphate and Calcium Sodium Phosph… | Phase2 | Caries | Completed | 2012-05-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01292213 | A Study to Identify and Characterise Bacteria Causing Chronic Cough Among Child… | — | Infections, Respiratory Tract | Terminated | 2012-05-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01600573 | Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ) | Phase1 | Ovarian Cancer | Unknown | 2012-05-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT01600573 | Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ) | Phase1 | Ovarian Cancer | Unknown | 2012-05-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT01593046 | A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat … | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2012-05-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01550185 | Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid… | Phase1 | Adult Acute Basophilic Leukemia | Terminated | 2012-05-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01607398 | ADOAIR250 Anti-inflammatory Effects in Japanese Subjects With Chronic Obstructi… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2012-05-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01499160 | Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Ca… | Phase2 | Breast Neoplasms | Terminated | 2012-05-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01593046 | A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat … | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2012-05-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01607398 | ADOAIR250 Anti-inflammatory Effects in Japanese Subjects With Chronic Obstructi… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2012-05-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01584843 | Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Str… | Phase3 | Strabismus | Completed | 2012-05-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01657877 | Anti-caries Potential of a Sodium Monofluorophosphate and Calcium Sodium Phosph… | Phase2 | Caries | Completed | 2012-05-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01292213 | A Study to Identify and Characterise Bacteria Causing Chronic Cough Among Child… | — | Infections, Respiratory Tract | Terminated | 2012-05-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01584843 | Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Str… | Phase3 | Strabismus | Completed | 2012-05-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01641692 | A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With… | Phase2 | Asthma | Completed | 2012-05-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01657864 | WEUSKOP6166: Lamotrigine and Aseptic Meningitis | — | Epilepsy | Completed | 2012-05-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01687309 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacod… | Phase1 | Systemic Lupus Erythematosus | Completed | 2012-04-30 | 2012-07-31 | ClinicalTrials.gov |
| NCT01687309 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacod… | Phase1 | Systemic Lupus Erythematosus | Completed | 2012-04-30 | 2012-07-31 | ClinicalTrials.gov |
| NCT01466972 | Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib | Phase2 | Breast Cancer | Completed | 2012-04-27 | 2019-10-02 | ClinicalTrials.gov |
| NCT01466972 | Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib | Phase2 | Breast Cancer | Completed | 2012-04-27 | 2019-10-02 | ClinicalTrials.gov |
| NCT01587716 | A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2339… | Phase1 | Cough | Completed | 2012-04-23 | 2012-07-30 | ClinicalTrials.gov |
| NCT01587716 | A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2339… | Phase1 | Cough | Completed | 2012-04-23 | 2012-07-30 | ClinicalTrials.gov |
| NCT01568892 | Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to… | Phase3 | HIV Infections | Completed | 2012-04-18 | 2013-12-16 | ClinicalTrials.gov |
| NCT01568892 | Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to… | Phase3 | HIV Infections | Completed | 2012-04-18 | 2013-12-16 | ClinicalTrials.gov |
| NCT01353703 | Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infa… | Phase3 | Poliomyelitis | Completed | 2012-04-16 | 2013-02-25 | ClinicalTrials.gov |
| NCT01353703 | Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infa… | Phase3 | Poliomyelitis | Completed | 2012-04-16 | 2013-02-25 | ClinicalTrials.gov |
| NCT01956487 | Bioequivalence of RYTHMOL SR® Manufactured at Two Different Sites | Phase1 | Arrhythmia, Cardiac | Completed | 2012-04-11 | 2012-06-27 | ClinicalTrials.gov |
| NCT01956487 | Bioequivalence of RYTHMOL SR® Manufactured at Two Different Sites | Phase1 | Arrhythmia, Cardiac | Completed | 2012-04-11 | 2012-06-27 | ClinicalTrials.gov |
| NCT01462669 | Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Tai… | Phase1 | Epilepsy | Completed | 2012-04-10 | 2012-06-27 | ClinicalTrials.gov |
| NCT01462669 | Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Tai… | Phase1 | Epilepsy | Completed | 2012-04-10 | 2012-06-27 | ClinicalTrials.gov |
| NCT01602601 | A Study to Test the Possibility of Cross Reaction Induced by the Idursulfase Dr… | — | Mucopolysaccharidosis II | Completed | 2012-04-09 | 2012-06-11 | ClinicalTrials.gov |
| NCT01602601 | A Study to Test the Possibility of Cross Reaction Induced by the Idursulfase Dr… | — | Mucopolysaccharidosis II | Completed | 2012-04-09 | 2012-06-11 | ClinicalTrials.gov |
| NCT01573624 | Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination Wit… | Phase2 | Asthma | Completed | 2012-04-03 | 2013-02-04 | ClinicalTrials.gov |
| NCT01573624 | Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination Wit… | Phase2 | Asthma | Completed | 2012-04-03 | 2013-02-04 | ClinicalTrials.gov |
| NCT01592851 | Clinical Efficacy of a Toothpaste in Providing Relief From the Pain of Dentinal… | Phase3 | Dentine Hypersensitivity | Completed | 2012-04-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01573767 | Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children | Phase2 | Asthma | Completed | 2012-04-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01580995 | Herpes Simplex Type 1 Suppression in Hepatitis C | Phase2 | Chronic Hepatitis C Infection | Completed | 2012-04-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01580995 | Herpes Simplex Type 1 Suppression in Hepatitis C | Phase2 | Chronic Hepatitis C Infection | Completed | 2012-04-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01457261 | IPF Drug Deposition Study | Phase1 | Idiopathic Pulmonary Fibrosis | Completed | 2012-04-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01616472 | WEUKBRE5716: Steroid-related Damage in Systemic Lupus Erythematosus (Hopkins) | — | Systemic Lupus Erythematosus | Completed | 2012-04-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01573767 | Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children | Phase2 | Asthma | Completed | 2012-04-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01491594 | Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia | Phase1 | Sarcoma, Soft Tissue | Terminated | 2012-04-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01563068 | Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use i… | Phase1 | Psoriasis | Completed | 2012-04-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT01616472 | WEUKBRE5716: Steroid-related Damage in Systemic Lupus Erythematosus (Hopkins) | — | Systemic Lupus Erythematosus | Completed | 2012-04-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01858831 | Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablet… | Phase1 | Malaria | Completed | 2012-04-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01592851 | Clinical Efficacy of a Toothpaste in Providing Relief From the Pain of Dentinal… | Phase3 | Dentine Hypersensitivity | Completed | 2012-04-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01491594 | Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia | Phase1 | Sarcoma, Soft Tissue | Terminated | 2012-04-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01536067 | Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Walden… | Phase2 | Waldenström Macroglobulinemia | Terminated | 2012-04-01 | — | ClinicalTrials.gov |
| NCT01563068 | Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use i… | Phase1 | Psoriasis | Completed | 2012-04-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT01457261 | IPF Drug Deposition Study | Phase1 | Idiopathic Pulmonary Fibrosis | Completed | 2012-04-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01755637 | Bioequivalence Study of Albendazole 400 mg Tablets in Chinese Population | Phase1 | Helminthiasis | Completed | 2012-04-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01755637 | Bioequivalence Study of Albendazole 400 mg Tablets in Chinese Population | Phase1 | Helminthiasis | Completed | 2012-04-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01858831 | Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablet… | Phase1 | Malaria | Completed | 2012-04-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01536067 | Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Walden… | Phase2 | Waldenström Macroglobulinemia | Terminated | 2012-04-01 | — | ClinicalTrials.gov |
| NCT01587807 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacod… | Phase1 | Respiratory Disorders | Completed | 2012-03-28 | 2012-11-19 | ClinicalTrials.gov |
| NCT01587807 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacod… | Phase1 | Respiratory Disorders | Completed | 2012-03-28 | 2012-11-19 | ClinicalTrials.gov |
| NCT01551758 | A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/V… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2012-03-13 | 2015-11-24 | ClinicalTrials.gov |
| NCT01551758 | A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/V… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2012-03-13 | 2015-11-24 | ClinicalTrials.gov |
| NCT01562444 | Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Boost… | Phase4 | Tick Borne Encephalitis | Completed | 2012-03-08 | 2016-09-30 | ClinicalTrials.gov |
| NCT01562444 | Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Boost… | Phase4 | Tick Borne Encephalitis | Completed | 2012-03-08 | 2016-09-30 | ClinicalTrials.gov |
| NCT03072719 | The Efficacy of a Dentifrice in Providing Relief From Immediate and Short Term … | Phase3 | Dentine Hypersensitivity | Completed | 2012-03-01 | 2012-06-12 | ClinicalTrials.gov |
| NCT01521286 | Study to Estimate the Burden of Herpes Zoster and Postherpetic Neuralgia in Spa… | — | Herpes Zoster | Completed | 2012-03-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT01592864 | The Efficacy of a Dentifrice in Providing Relief From the Pain of Dentinal Hype… | Phase3 | Dentine Hypersensitivity | Completed | 2012-03-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT03315468 | French Clinical Datbase of Melanoma Patients (RIC-Mel) | — | Melanoma (Skin) | Recruiting | 2012-03-01 | 2030-03-01 | ClinicalTrials.gov |
| NCT01563328 | A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pha… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2012-03-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT03072719 | The Efficacy of a Dentifrice in Providing Relief From Immediate and Short Term … | Phase3 | Dentine Hypersensitivity | Completed | 2012-03-01 | 2012-06-12 | ClinicalTrials.gov |
| NCT01563328 | A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pha… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2012-03-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01592864 | The Efficacy of a Dentifrice in Providing Relief From the Pain of Dentinal Hype… | Phase3 | Dentine Hypersensitivity | Completed | 2012-03-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01437995 | Long-acting Beta Agonist Step Down Study | Phase4 | Asthma | Completed | 2012-03-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01428544 | Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Veno… | — | Ataxia | Completed | 2012-03-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01636726 | WEUKBRE5554: IMI PROTECT(Work Package 2): Beta2 Agonists and Acute Myocardial I… | — | Asthma | Completed | 2012-03-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01636726 | WEUKBRE5554: IMI PROTECT(Work Package 2): Beta2 Agonists and Acute Myocardial I… | — | Asthma | Completed | 2012-03-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01428544 | Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Veno… | — | Ataxia | Completed | 2012-03-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01641237 | Effect of Fluoride in a Dentifrice on Remineralization of Erosive Lesions | Phase3 | Enamel Erosion | Completed | 2012-03-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01648179 | A Study to Assess the Relative Bioavailability of Three Formulations and Food E… | Phase1 | Infections, Bacterial | Completed | 2012-03-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01437995 | Long-acting Beta Agonist Step Down Study | Phase4 | Asthma | Completed | 2012-03-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01641237 | Effect of Fluoride in a Dentifrice on Remineralization of Erosive Lesions | Phase3 | Enamel Erosion | Completed | 2012-03-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01521286 | Study to Estimate the Burden of Herpes Zoster and Postherpetic Neuralgia in Spa… | — | Herpes Zoster | Completed | 2012-03-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT01702519 | A Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers | Phase1 | Smoking | Completed | 2012-03-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01702519 | A Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers | Phase1 | Smoking | Completed | 2012-03-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01648179 | A Study to Assess the Relative Bioavailability of Three Formulations and Food E… | Phase1 | Infections, Bacterial | Completed | 2012-03-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT03315468 | French Clinical Datbase of Melanoma Patients (RIC-Mel) | — | Melanoma (Skin) | Recruiting | 2012-03-01 | 2030-03-01 | ClinicalTrials.gov |
| NCT01527123 | A Study to Evaluate the Pharmacokinetics of Benzoic Acid and Hippuric Acid Afte… | Phase1 | Acne Vulgaris | Completed | 2012-02-28 | 2012-06-01 | ClinicalTrials.gov |
| NCT01527123 | A Study to Evaluate the Pharmacokinetics of Benzoic Acid and Hippuric Acid Afte… | Phase1 | Acne Vulgaris | Completed | 2012-02-28 | 2012-06-01 | ClinicalTrials.gov |
| NCT01453491 | A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Diff… | Phase1 | Colitis, Ulcerative | Completed | 2012-02-13 | 2013-03-18 | ClinicalTrials.gov |
| NCT01563042 | A Single Dose Pharmacokinetics (PK) Study of GSK2434735 in Healthy Male Volunte… | Phase1 | Asthma | Completed | 2012-02-13 | 2012-05-23 | ClinicalTrials.gov |
| NCT01453491 | A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Diff… | Phase1 | Colitis, Ulcerative | Completed | 2012-02-13 | 2013-03-18 | ClinicalTrials.gov |
| NCT01563042 | A Single Dose Pharmacokinetics (PK) Study of GSK2434735 in Healthy Male Volunte… | Phase1 | Asthma | Completed | 2012-02-13 | 2012-05-23 | ClinicalTrials.gov |
| NCT01506193 | Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conj… | Phase3 | Rubella | Completed | 2012-02-06 | 2014-03-31 | ClinicalTrials.gov |
| NCT01506193 | Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conj… | Phase3 | Rubella | Completed | 2012-02-06 | 2014-03-31 | ClinicalTrials.gov |
| NCT01584765 | Rechallenge, Potential Drug Induced Liver Injury (Kaiser) | — | Drug-induced Liver Injury | Completed | 2012-02-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01562548 | Exploratory Efficacy Study of Guaifenesin in Upper Back Pain | Na | Upper Back Pain | Completed | 2012-02-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01506895 | A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With … | Phase2 | Retinopathy, Diabetic | Completed | 2012-02-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01584765 | Rechallenge, Potential Drug Induced Liver Injury (Kaiser) | — | Drug-induced Liver Injury | Completed | 2012-02-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01500226 | Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Rec… | Phase3 | Chemotherapy-induced Nausea and Vomiting | Completed | 2012-02-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01500213 | Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects … | Phase3 | Chemotherapy-induced Nausea and Vomiting | Completed | 2012-02-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01822665 | Gastrointestinal Safety Evaluation of Two Over the Counter Analgesics | Phase4 | Gastrointestinal Mucosal Damage | Completed | 2012-02-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01529086 | For Cause Prostate Biopsy in REDUCE Population Trial | — | Prostate Cancer | Completed | 2012-02-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01467037 | Vaccine Effectiveness of RV1 in a Naïve Population | — | Rotavirus Infections | Completed | 2012-02-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01607411 | A Clinical Study to Evaluate Experimental Children's Toothpastes in an In-Situ … | Phase3 | Dental Caries | Completed | 2012-02-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01562548 | Exploratory Efficacy Study of Guaifenesin in Upper Back Pain | Na | Upper Back Pain | Completed | 2012-02-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01516437 | A Study to Assess Immunity to Specific Microbial Antigens in Healthy Smokers an… | Na | Respiratory Disorders | Completed | 2012-02-01 | 2012-12-20 | ClinicalTrials.gov |
| NCT01506895 | A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With … | Phase2 | Retinopathy, Diabetic | Completed | 2012-02-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01467037 | Vaccine Effectiveness of RV1 in a Naïve Population | — | Rotavirus Infections | Completed | 2012-02-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01762982 | Patch Test of Benzalkonium Chloride Disinfectant Spray | Na | Wound Healing | Completed | 2012-02-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01529086 | For Cause Prostate Biopsy in REDUCE Population Trial | — | Prostate Cancer | Completed | 2012-02-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01762982 | Patch Test of Benzalkonium Chloride Disinfectant Spray | Na | Wound Healing | Completed | 2012-02-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01500226 | Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Rec… | Phase3 | Chemotherapy-induced Nausea and Vomiting | Completed | 2012-02-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01516437 | A Study to Assess Immunity to Specific Microbial Antigens in Healthy Smokers an… | Na | Respiratory Disorders | Completed | 2012-02-01 | 2012-12-20 | ClinicalTrials.gov |
| NCT01500213 | Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects … | Phase3 | Chemotherapy-induced Nausea and Vomiting | Completed | 2012-02-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01607411 | A Clinical Study to Evaluate Experimental Children's Toothpastes in an In-Situ … | Phase3 | Dental Caries | Completed | 2012-02-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01822665 | Gastrointestinal Safety Evaluation of Two Over the Counter Analgesics | Phase4 | Gastrointestinal Mucosal Damage | Completed | 2012-02-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01561976 | Evaluation of Food Effect on the Pharmacokinetics of Sustained Release Metformi… | Na | Diabetes Mellitus, Type 2 | Completed | 2012-01-30 | 2012-02-21 | ClinicalTrials.gov |
| NCT01561976 | Evaluation of Food Effect on the Pharmacokinetics of Sustained Release Metformi… | Na | Diabetes Mellitus, Type 2 | Completed | 2012-01-30 | 2012-02-21 | ClinicalTrials.gov |
| NCT01340898 | Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vac… | Phase3 | Meningococcal Infection | Completed | 2012-01-27 | 2015-10-19 | ClinicalTrials.gov |
| NCT01340898 | Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vac… | Phase3 | Meningococcal Infection | Completed | 2012-01-27 | 2015-10-19 | ClinicalTrials.gov |
| NCT01540708 | A Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation… | Phase1 | Asthma | Completed | 2012-01-16 | 2012-09-04 | ClinicalTrials.gov |
| NCT01583036 | An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin A… | Phase1 | Epilepsy | Completed | 2012-01-16 | 2012-04-17 | ClinicalTrials.gov |
| NCT01583036 | An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin A… | Phase1 | Epilepsy | Completed | 2012-01-16 | 2012-04-17 | ClinicalTrials.gov |
| NCT01540708 | A Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation… | Phase1 | Asthma | Completed | 2012-01-16 | 2012-09-04 | ClinicalTrials.gov |
| NCT01597700 | Acotral® Versus Zetia® Ezetimibe Bioequivalance Study. | Phase1 | Hypercholesterolaemia | Completed | 2012-01-13 | 2012-01-30 | ClinicalTrials.gov |
| NCT01597700 | Acotral® Versus Zetia® Ezetimibe Bioequivalance Study. | Phase1 | Hypercholesterolaemia | Completed | 2012-01-13 | 2012-01-30 | ClinicalTrials.gov |
| NCT01520051 | Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations | Phase3 | Asthma | Unknown | 2012-01-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01499199 | A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the C… | Phase3 | Infection, Human Immunodeficiency Virus | Completed | 2012-01-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01495000 | A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Effica… | Phase3 | Osteoporosis, Postmenopausal | Completed | 2012-01-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01498653 | Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatat… | Phase3 | Asthma | Completed | 2012-01-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01520051 | Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations | Phase3 | Asthma | Unknown | 2012-01-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01435902 | A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exerci… | Phase3 | Asthma | Withdrawn | 2012-01-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01498653 | Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatat… | Phase3 | Asthma | Completed | 2012-01-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01491802 | Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderat… | Phase3 | COPD | Completed | 2012-01-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01498172 | BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non M… | Phase1 | Bladder Cancer | Completed | 2012-01-01 | — | ClinicalTrials.gov |
| NCT01527110 | A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With… | Phase3 | Influenza, Human | Completed | 2012-01-01 | 2013-03-29 | ClinicalTrials.gov |
| NCT01467310 | Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 | Early_Phase1 | Breast Cancer | Completed | 2012-01-01 | 2016-03-21 | ClinicalTrials.gov |
| NCT01536678 | Bioequivalence of Two Levothyroxine Tablet Formulations in Healthy Indian Volun… | Phase4 | Hypothyroidism | Completed | 2012-01-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01498679 | Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatat… | Phase3 | Asthma | Completed | 2012-01-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01435902 | A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exerci… | Phase3 | Asthma | Withdrawn | 2012-01-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01467310 | Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 | Early_Phase1 | Breast Cancer | Completed | 2012-01-01 | 2016-03-21 | ClinicalTrials.gov |
| NCT01498172 | BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non M… | Phase1 | Bladder Cancer | Completed | 2012-01-01 | — | ClinicalTrials.gov |
| NCT01491802 | Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderat… | Phase3 | COPD | Completed | 2012-01-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01527110 | A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With… | Phase3 | Influenza, Human | Completed | 2012-01-01 | 2013-03-29 | ClinicalTrials.gov |
| NCT01499199 | A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the C… | Phase3 | Infection, Human Immunodeficiency Virus | Completed | 2012-01-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01498679 | Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatat… | Phase3 | Asthma | Completed | 2012-01-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01495000 | A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Effica… | Phase3 | Osteoporosis, Postmenopausal | Completed | 2012-01-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01536678 | Bioequivalence of Two Levothyroxine Tablet Formulations in Healthy Indian Volun… | Phase4 | Hypothyroidism | Completed | 2012-01-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01521377 | QTc Study GSK573719+GW642444 | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-12-19 | 2012-06-05 | ClinicalTrials.gov |
| NCT01495065 | A Study to Evaluate Single and Repeat Doses of IV GSK2251052 in Healthy Male Ja… | Phase1 | Community-acquired Infection | Terminated | 2011-12-19 | 2012-02-17 | ClinicalTrials.gov |
| NCT01521377 | QTc Study GSK573719+GW642444 | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-12-19 | 2012-06-05 | ClinicalTrials.gov |
| NCT01495065 | A Study to Evaluate Single and Repeat Doses of IV GSK2251052 in Healthy Male Ja… | Phase1 | Community-acquired Infection | Terminated | 2011-12-19 | 2012-02-17 | ClinicalTrials.gov |
| NCT01627587 | A Two Cohort Study to Look at the Metabolites of GSK221149, the Metabolism of G… | Phase1 | Obstetric Labour, Premature | Completed | 2011-12-12 | 2012-02-09 | ClinicalTrials.gov |
| NCT01465659 | Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pan… | Phase1 | Pancreatic Alpha Cell Carcinoma | Completed | 2011-12-12 | 2021-01-27 | ClinicalTrials.gov |
| NCT01465659 | Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pan… | Phase1 | Pancreatic Alpha Cell Carcinoma | Completed | 2011-12-12 | 2021-01-27 | ClinicalTrials.gov |
| NCT01485406 | Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococ… | Phase1 | Infections, Streptococcal | Completed | 2011-12-12 | 2012-03-15 | ClinicalTrials.gov |
| NCT01627587 | A Two Cohort Study to Look at the Metabolites of GSK221149, the Metabolism of G… | Phase1 | Obstetric Labour, Premature | Completed | 2011-12-12 | 2012-02-09 | ClinicalTrials.gov |
| NCT01485406 | Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococ… | Phase1 | Infections, Streptococcal | Completed | 2011-12-12 | 2012-03-15 | ClinicalTrials.gov |
| NCT01476111 | Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer | — | Neoplasms, Breast | Terminated | 2011-12-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01485042 | Dose Escalation Study of Pazopanib Plus TH-302 | Phase1 | Solid Tumors | Completed | 2011-12-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01465334 | Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzum… | Phase2 | CLL | Terminated | 2011-12-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT01475851 | Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Wit… | Phase3 | Hepatitis B, Chronic | Completed | 2011-12-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01678430 | A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who… | Phase3 | Chronic Lymphocytic Leukaemia | Unknown | 2011-12-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT01602913 | Type II Diabetes Mellitus in Patients Exposed to Pravastatin and Paroxetine | — | Depression, Postpartum | Completed | 2011-12-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01498861 | Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containin… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2011-12-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01475734 | Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2011-12-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01607333 | WEUKBRE5557: IMI PROTECT(Work Package 2): Antiepileptics & Suicide | — | Epilepsy | Completed | 2011-12-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01328054 | A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Inter… | Phase4 | Cancer | Completed | 2011-12-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01413113 | Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent an… | Phase1 | Recurrent Thyroid Cancer | Completed | 2011-12-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01328054 | A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Inter… | Phase4 | Cancer | Completed | 2011-12-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01498861 | Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containin… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2011-12-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01678430 | A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who… | Phase3 | Chronic Lymphocytic Leukaemia | Unknown | 2011-12-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT01413113 | Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent an… | Phase1 | Recurrent Thyroid Cancer | Completed | 2011-12-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01467518 | Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study. | Phase1 | Infections, Human Immunodeficiency Virus and Hepatitis | Completed | 2011-12-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01495013 | A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvas… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2011-12-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01465334 | Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzum… | Phase2 | CLL | Terminated | 2011-12-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT01607333 | WEUKBRE5557: IMI PROTECT(Work Package 2): Antiepileptics & Suicide | — | Epilepsy | Completed | 2011-12-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01485042 | Dose Escalation Study of Pazopanib Plus TH-302 | Phase1 | Solid Tumors | Completed | 2011-12-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01467518 | Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study. | Phase1 | Infections, Human Immunodeficiency Virus and Hepatitis | Completed | 2011-12-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01602913 | Type II Diabetes Mellitus in Patients Exposed to Pravastatin and Paroxetine | — | Depression, Postpartum | Completed | 2011-12-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01475734 | Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2011-12-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01475851 | Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Wit… | Phase3 | Hepatitis B, Chronic | Completed | 2011-12-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01476111 | Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer | — | Neoplasms, Breast | Terminated | 2011-12-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01495013 | A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvas… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2011-12-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01462604 | Pilot Study of Patient's Adherence to TYKERB™/TYVERB™ + Capecitabine in Metasta… | — | Cancer | Completed | 2011-11-23 | 2013-01-24 | ClinicalTrials.gov |
| NCT01462604 | Pilot Study of Patient's Adherence to TYKERB™/TYVERB™ + Capecitabine in Metasta… | — | Cancer | Completed | 2011-11-23 | 2013-01-24 | ClinicalTrials.gov |
| NCT01602900 | Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a… | Phase1 | Huntington Disease | Completed | 2011-11-22 | 2012-04-12 | ClinicalTrials.gov |
| NCT01602900 | Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a… | Phase1 | Huntington Disease | Completed | 2011-11-22 | 2012-04-12 | ClinicalTrials.gov |
| NCT01462357 | Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papilloma… | Phase3 | Infections, Papillomavirus | Completed | 2011-11-21 | 2015-10-27 | ClinicalTrials.gov |
| NCT01462357 | Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papilloma… | Phase3 | Infections, Papillomavirus | Completed | 2011-11-21 | 2015-10-27 | ClinicalTrials.gov |
| NCT01516528 | Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease (COPD) in … | — | Pulmonary Disease, Chronic Obstructive | Completed | 2011-11-17 | 2015-06-12 | ClinicalTrials.gov |
| NCT01462344 | 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old | Phase4 | Asthma | Completed | 2011-11-17 | 2015-11-03 | ClinicalTrials.gov |
| NCT01345240 | Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologic… | Phase3 | Malaria | Completed | 2011-11-17 | 2017-02-09 | ClinicalTrials.gov |
| NCT01345240 | Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologic… | Phase3 | Malaria | Completed | 2011-11-17 | 2017-02-09 | ClinicalTrials.gov |
| NCT01516528 | Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease (COPD) in … | — | Pulmonary Disease, Chronic Obstructive | Completed | 2011-11-17 | 2015-06-12 | ClinicalTrials.gov |
| NCT01462344 | 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old | Phase4 | Asthma | Completed | 2011-11-17 | 2015-11-03 | ClinicalTrials.gov |
| NCT01484496 | A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupu… | Phase3 | Systemic Lupus Erythematosus | Completed | 2011-11-16 | 2015-10-01 | ClinicalTrials.gov |
| NCT01484496 | A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupu… | Phase3 | Systemic Lupus Erythematosus | Completed | 2011-11-16 | 2015-10-01 | ClinicalTrials.gov |
| NCT01458067 | A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanc… | Phase1 | Cancer | Completed | 2011-11-10 | 2016-02-25 | ClinicalTrials.gov |
| NCT01458067 | A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanc… | Phase1 | Cancer | Completed | 2011-11-10 | 2016-02-25 | ClinicalTrials.gov |
| NCT01458366 | Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin an… | Phase1 | Non-Hodgkin's Lymphoma | Completed | 2011-11-09 | 2020-07-23 | ClinicalTrials.gov |
| NCT01458366 | Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin an… | Phase1 | Non-Hodgkin's Lymphoma | Completed | 2011-11-09 | 2020-07-23 | ClinicalTrials.gov |
| NCT01545570 | A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Hea… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2011-11-07 | 2012-12-23 | ClinicalTrials.gov |
| NCT01545570 | A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Hea… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2011-11-07 | 2012-12-23 | ClinicalTrials.gov |
| NCT01495026 | A Study Assessing a Range of Formulations of the Fixed Dose Combination Product… | Phase1 | Prostatic Hyperplasia | Completed | 2011-11-06 | 2012-04-03 | ClinicalTrials.gov |
| NCT01495026 | A Study Assessing a Range of Formulations of the Fixed Dose Combination Product… | Phase1 | Prostatic Hyperplasia | Completed | 2011-11-06 | 2012-04-03 | ClinicalTrials.gov |
| NCT01462565 | Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmon… | Phase4 | Hypertension, Pulmonary | Completed | 2011-11-01 | 2012-11-08 | ClinicalTrials.gov |
| NCT01480284 | Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Unt… | Phase3 | Hepatitis B, Chronic | Completed | 2011-11-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01479491 | Study on the Incidence of Intussusception (IS) in Children Aged < 12 Months in … | — | Intussusception | Completed | 2011-11-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01657903 | Evaluation of Efficacy of Experimental Gel to Foam Dentifrices in Dental Erosion | Na | Dental Erosion | Completed | 2011-11-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01473030 | Long-term Effects of Dutasteride on Architectural and Nuclear Morphometric Feat… | — | Benign Prostate Tissue | Completed | 2011-11-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT01459315 | GSK1349572 Exposure in Blood, Seminal Fluid, and Rectal Fluid and Tissue in Hea… | Phase1 | Healthy | Completed | 2011-11-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01517191 | Sentinel Surveillance for Influenza Requiring Hospital Admission Canadian Adults | — | Influenza | Completed | 2011-11-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01456936 | Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoki… | Phase4 | Smoking Cessation | Completed | 2011-11-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01445587 | A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple… | Phase2 | Cancer | Withdrawn | 2011-11-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT06035289 | Register Schweres Asthma - German Asthma Net e.V. | — | Severe Asthma | Recruiting | 2011-11-01 | 2026-11-01 | ClinicalTrials.gov |
| NCT01445587 | A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple… | Phase2 | Cancer | Withdrawn | 2011-11-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01686646 | Effects of Two Doses of a Common Cold Treatment on Alertness | Phase3 | Common Cold | Completed | 2011-11-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01456936 | Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoki… | Phase4 | Smoking Cessation | Completed | 2011-11-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01459315 | GSK1349572 Exposure in Blood, Seminal Fluid, and Rectal Fluid and Tissue in Hea… | Phase1 | Healthy | Completed | 2011-11-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01587729 | IMI PROTECT(WP2): Antidepressants & Fractures | — | Depression, Postpartum | Completed | 2011-11-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01587742 | IMI PROTECT (Work Package 2): Calcium Channel Blockers and Cancer | — | Hypertension | Completed | 2011-11-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01587768 | WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics | — | Infections, Bacterial | Completed | 2011-11-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01462565 | Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmon… | Phase4 | Hypertension, Pulmonary | Completed | 2011-11-01 | 2012-11-08 | ClinicalTrials.gov |
| NCT01587833 | WEUKBRE5559: IMI PROTECT: Benzodiazepines & Fracture | — | Anxiety Disorders | Completed | 2011-11-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT06035289 | Register Schweres Asthma - German Asthma Net e.V. | — | Severe Asthma | Recruiting | 2011-11-01 | 2026-11-01 | ClinicalTrials.gov |
| NCT01473030 | Long-term Effects of Dutasteride on Architectural and Nuclear Morphometric Feat… | — | Benign Prostate Tissue | Completed | 2011-11-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT01479491 | Study on the Incidence of Intussusception (IS) in Children Aged < 12 Months in … | — | Intussusception | Completed | 2011-11-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01480284 | Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Unt… | Phase3 | Hepatitis B, Chronic | Completed | 2011-11-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01597648 | A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared… | Phase1 | Infection, Human Immunodeficiency Virus I | Completed | 2011-11-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01517191 | Sentinel Surveillance for Influenza Requiring Hospital Admission Canadian Adults | — | Influenza | Completed | 2011-11-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01587729 | IMI PROTECT(WP2): Antidepressants & Fractures | — | Depression, Postpartum | Completed | 2011-11-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01587742 | IMI PROTECT (Work Package 2): Calcium Channel Blockers and Cancer | — | Hypertension | Completed | 2011-11-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01587768 | WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics | — | Infections, Bacterial | Completed | 2011-11-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01587833 | WEUKBRE5559: IMI PROTECT: Benzodiazepines & Fracture | — | Anxiety Disorders | Completed | 2011-11-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01597648 | A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared… | Phase1 | Infection, Human Immunodeficiency Virus I | Completed | 2011-11-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01657903 | Evaluation of Efficacy of Experimental Gel to Foam Dentifrices in Dental Erosion | Na | Dental Erosion | Completed | 2011-11-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01686646 | Effects of Two Doses of a Common Cold Treatment on Alertness | Phase3 | Common Cold | Completed | 2011-11-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01449929 | Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nu… | Phase3 | Infection, Human Immunodeficiency Virus | Completed | 2011-10-31 | 2016-12-26 | ClinicalTrials.gov |
| NCT01449929 | Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nu… | Phase3 | Infection, Human Immunodeficiency Virus | Completed | 2011-10-31 | 2016-12-26 | ClinicalTrials.gov |
| NCT01466335 | An Adaptive Phase I Study to Evaluate the Safety, Efficacy and Dose Responses o… | Phase1 | Bone Marrow Transplantation | Completed | 2011-10-27 | 2012-03-05 | ClinicalTrials.gov |
| NCT01466335 | An Adaptive Phase I Study to Evaluate the Safety, Efficacy and Dose Responses o… | Phase1 | Bone Marrow Transplantation | Completed | 2011-10-27 | 2012-03-05 | ClinicalTrials.gov |
| NCT01476137 | A Study of the Safety and Activity of the MEK Inhibitor Given Together With the… | Phase1 | Cancer | Completed | 2011-10-26 | 2013-03-12 | ClinicalTrials.gov |
| NCT01476137 | A Study of the Safety and Activity of the MEK Inhibitor Given Together With the… | Phase1 | Cancer | Completed | 2011-10-26 | 2013-03-12 | ClinicalTrials.gov |
| NCT01702350 | A Four Part Study to Investigate Relative Bioavailability, Safety and Tolerabil… | Phase1 | Community-acquired Infection | Terminated | 2011-10-21 | 2011-12-08 | ClinicalTrials.gov |
| NCT01702350 | A Four Part Study to Investigate Relative Bioavailability, Safety and Tolerabil… | Phase1 | Community-acquired Infection | Terminated | 2011-10-21 | 2011-12-08 | ClinicalTrials.gov |
| NCT01494636 | The Safety, Tolerability, PK and PD of GSK2339345 in Healthy Subjects | Phase1 | Cough | Completed | 2011-10-17 | 2012-03-15 | ClinicalTrials.gov |
| NCT01494636 | The Safety, Tolerability, PK and PD of GSK2339345 in Healthy Subjects | Phase1 | Cough | Completed | 2011-10-17 | 2012-03-15 | ClinicalTrials.gov |
| NCT01453998 | Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKl… | Phase2 | Acellular Pertussis | Completed | 2011-10-14 | 2012-11-12 | ClinicalTrials.gov |
| NCT01453998 | Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKl… | Phase2 | Acellular Pertussis | Completed | 2011-10-14 | 2012-11-12 | ClinicalTrials.gov |
| NCT01406314 | SAP Depleter Dose Assessment Study in Patients | Phase1 | Amyloidosis | Completed | 2011-10-13 | 2012-11-14 | ClinicalTrials.gov |
| NCT01406314 | SAP Depleter Dose Assessment Study in Patients | Phase1 | Amyloidosis | Completed | 2011-10-13 | 2012-11-14 | ClinicalTrials.gov |
| NCT01521390 | Assessment of Lung Function After Single Inhalations of a Bronchodilator From 2… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-10-12 | 2011-12-16 | ClinicalTrials.gov |
| NCT01453478 | A Study to Look at How GSK1325756 is Taken up by the Body When Given by Mouth W… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-10-12 | 2011-12-19 | ClinicalTrials.gov |
| NCT01453478 | A Study to Look at How GSK1325756 is Taken up by the Body When Given by Mouth W… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-10-12 | 2011-12-19 | ClinicalTrials.gov |
| NCT01521390 | Assessment of Lung Function After Single Inhalations of a Bronchodilator From 2… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-10-12 | 2011-12-16 | ClinicalTrials.gov |
| NCT01437605 | Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI … | Phase2 | Melanoma | Terminated | 2011-10-11 | 2018-07-18 | ClinicalTrials.gov |
| NCT01485185 | Gabapentin and Donepezil Combination on Experimental Human Pain Models | Phase1 | Pain, Neuropathic | Completed | 2011-10-11 | 2012-07-03 | ClinicalTrials.gov |
| NCT01437605 | Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI … | Phase2 | Melanoma | Terminated | 2011-10-11 | 2018-07-18 | ClinicalTrials.gov |
| NCT01485185 | Gabapentin and Donepezil Combination on Experimental Human Pain Models | Phase1 | Pain, Neuropathic | Completed | 2011-10-11 | 2012-07-03 | ClinicalTrials.gov |
| NCT01430572 | Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients | Phase1 | Advanced Cancers | Completed | 2011-10-07 | 2020-05-12 | ClinicalTrials.gov |
| NCT01430572 | Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients | Phase1 | Advanced Cancers | Completed | 2011-10-07 | 2020-05-12 | ClinicalTrials.gov |
| NCT01636271 | SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Effica… | — | Coronary Heart Disease | Completed | 2011-10-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT02343055 | COPE With COPD Trial | Na | Chronic Obstructive Pulmonary Disease | Completed | 2011-10-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01137994 | A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus … | Phase2 | Neoplasms, Breast | Withdrawn | 2011-10-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT01449812 | Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Polior… | Phase3 | Acellular Pertussis | Completed | 2011-10-01 | 2012-01-16 | ClinicalTrials.gov |
| NCT01485159 | Airflow Limitation in Cardiac Diseases in Europe | — | Pulmonary Disease, Chronic Obstructive | Completed | 2011-10-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01453023 | Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study | Phase2 | Asthma | Completed | 2011-10-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01453348 | Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vacci… | Phase3 | Meningococcal Disease | Completed | 2011-10-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01636271 | SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Effica… | — | Coronary Heart Disease | Completed | 2011-10-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01455051 | Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients… | Phase2 | Chronic Lymphocytic Leukemia | Completed | 2011-10-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT01455051 | Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients… | Phase2 | Chronic Lymphocytic Leukemia | Completed | 2011-10-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT01137994 | A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus … | Phase2 | Neoplasms, Breast | Withdrawn | 2011-10-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT01439360 | An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vac… | Phase3 | Influenza | Completed | 2011-10-01 | 2014-12-31 | ClinicalTrials.gov |
| NCT01481220 | Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic … | Phase1 | Myelodysplastic Syndrome | Completed | 2011-10-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01485159 | Airflow Limitation in Cardiac Diseases in Europe | — | Pulmonary Disease, Chronic Obstructive | Completed | 2011-10-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT02343055 | COPE With COPD Trial | Na | Chronic Obstructive Pulmonary Disease | Completed | 2011-10-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01453348 | Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vacci… | Phase3 | Meningococcal Disease | Completed | 2011-10-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01453023 | Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study | Phase2 | Asthma | Completed | 2011-10-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01449812 | Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Polior… | Phase3 | Acellular Pertussis | Completed | 2011-10-01 | 2012-01-16 | ClinicalTrials.gov |
| NCT01397591 | Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, … | Phase2 | Recurrent Adult Diffuse Large Cell Lymphoma | Terminated | 2011-10-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01439360 | An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vac… | Phase3 | Influenza | Completed | 2011-10-01 | 2014-12-31 | ClinicalTrials.gov |
| NCT01397591 | Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, … | Phase2 | Recurrent Adult Diffuse Large Cell Lymphoma | Terminated | 2011-10-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01481220 | Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic … | Phase1 | Myelodysplastic Syndrome | Completed | 2011-10-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01440387 | A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-… | Phase3 | Influenza | Completed | 2011-09-30 | 2011-10-22 | ClinicalTrials.gov |
| NCT01440387 | A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-… | Phase3 | Influenza | Completed | 2011-09-30 | 2011-10-22 | ClinicalTrials.gov |
| NCT01458054 | Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Ad… | Phase1 | Hepatitis C | Completed | 2011-09-27 | 2011-11-28 | ClinicalTrials.gov |
| NCT01458054 | Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Ad… | Phase1 | Hepatitis C | Completed | 2011-09-27 | 2011-11-28 | ClinicalTrials.gov |
| NCT02202187 | A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers | Phase1 | Infections, Respiratory Tract | Completed | 2011-09-26 | 2012-02-15 | ClinicalTrials.gov |
| NCT02202187 | A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers | Phase1 | Infections, Respiratory Tract | Completed | 2011-09-26 | 2012-02-15 | ClinicalTrials.gov |
| NCT01489943 | A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and… | Phase1 | Crohn's Disease | Completed | 2011-09-19 | 2011-11-10 | ClinicalTrials.gov |
| NCT01489943 | A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and… | Phase1 | Crohn's Disease | Completed | 2011-09-19 | 2011-11-10 | ClinicalTrials.gov |
| NCT01610388 | A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral an… | Phase1 | Infections, Bacterial | Completed | 2011-09-13 | 2012-01-26 | ClinicalTrials.gov |
| NCT01610388 | A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral an… | Phase1 | Infections, Bacterial | Completed | 2011-09-13 | 2012-01-26 | ClinicalTrials.gov |
| NCT01190176 | Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects | Phase3 | Infections, Papillomavirus | Completed | 2011-09-12 | 2017-09-20 | ClinicalTrials.gov |
| NCT01190176 | Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects | Phase3 | Infections, Papillomavirus | Completed | 2011-09-12 | 2017-09-20 | ClinicalTrials.gov |
| NCT01435993 | Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis | Phase1 | Multiple Sclerosis, Relapsing-Remitting | Terminated | 2011-09-08 | 2012-01-23 | ClinicalTrials.gov |
| NCT01435993 | Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis | Phase1 | Multiple Sclerosis, Relapsing-Remitting | Terminated | 2011-09-08 | 2012-01-23 | ClinicalTrials.gov |
| NCT01391819 | Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden o… | Na | Dengue | Completed | 2011-09-06 | 2015-01-30 | ClinicalTrials.gov |
| NCT01391819 | Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden o… | Na | Dengue | Completed | 2011-09-06 | 2015-01-30 | ClinicalTrials.gov |
| NCT01497626 | Lapatinib and Bortezomib in Patients With Advanced Malignancies | Phase1 | Advanced Solid Tumors | Terminated | 2011-09-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01681563 | Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patie… | Phase2 | Chronic Lymphocytic Leukemia | Completed | 2011-09-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01597661 | Bupropion & Cardio Birth Defect (Slone) | — | Depressive Disorder | Completed | 2011-09-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01506908 | Provoked Craving Assessment | Phase2 | Smoking Dependence | Completed | 2011-09-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01497626 | Lapatinib and Bortezomib in Patients With Advanced Malignancies | Phase1 | Advanced Solid Tumors | Terminated | 2011-09-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01494649 | Pilot Study to Investigate the Efficacy of a Toothpaste in Providing Relief Fro… | Na | Dentinal Sensitivity | Completed | 2011-09-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01480245 | Open Label Study of GSK2402968 in Subjects With Duchenne Muscular Dystrophy | Phase3 | Muscular Dystrophies | Terminated | 2011-09-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01453062 | Phase IV Observational Study in Chronic Lymphocytic Leukemia | — | Leukaemia, Lymphocytic, Chronic | Completed | 2011-09-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01437709 | Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma … | Phase2 | Mantle Cell Lymphoma | Completed | 2011-09-01 | 2023-09-12 | ClinicalTrials.gov |
| NCT01436110 | Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Flutic… | Phase3 | Asthma | Completed | 2011-09-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01436071 | Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People … | Phase3 | Asthma | Completed | 2011-09-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01435967 | Observational Study on Rotavirus Gastroenteritis Epidemiology, Impact of Lyophi… | — | Infections, Rotavirus | Completed | 2011-09-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01431963 | Clinical Study of Lamotrigine to Treat Newly Diagnosed Epilepsy | Phase3 | Epilepsy | Completed | 2011-09-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01431950 | Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of A… | Phase3 | Asthma | Completed | 2011-09-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01425099 | Drug Interaction Study Between Dolutegravir and Prednisone | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2011-09-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01681563 | Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patie… | Phase2 | Chronic Lymphocytic Leukemia | Completed | 2011-09-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01380145 | MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoin… | Phase1 | Multiple Myeloma | Completed | 2011-09-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01362296 | An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-muta… | Phase2 | Lung Cancer, Non-Small Cell | Completed | 2011-09-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01597661 | Bupropion & Cardio Birth Defect (Slone) | — | Depressive Disorder | Completed | 2011-09-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01506908 | Provoked Craving Assessment | Phase2 | Smoking Dependence | Completed | 2011-09-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01494649 | Pilot Study to Investigate the Efficacy of a Toothpaste in Providing Relief Fro… | Na | Dentinal Sensitivity | Completed | 2011-09-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01480245 | Open Label Study of GSK2402968 in Subjects With Duchenne Muscular Dystrophy | Phase3 | Muscular Dystrophies | Terminated | 2011-09-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01453062 | Phase IV Observational Study in Chronic Lymphocytic Leukemia | — | Leukaemia, Lymphocytic, Chronic | Completed | 2011-09-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01437709 | Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma … | Phase2 | Mantle Cell Lymphoma | Completed | 2011-09-01 | 2023-09-12 | ClinicalTrials.gov |
| NCT01436110 | Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Flutic… | Phase3 | Asthma | Completed | 2011-09-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01436071 | Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People … | Phase3 | Asthma | Completed | 2011-09-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01435967 | Observational Study on Rotavirus Gastroenteritis Epidemiology, Impact of Lyophi… | — | Infections, Rotavirus | Completed | 2011-09-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01431963 | Clinical Study of Lamotrigine to Treat Newly Diagnosed Epilepsy | Phase3 | Epilepsy | Completed | 2011-09-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01431950 | Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of A… | Phase3 | Asthma | Completed | 2011-09-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01425099 | Drug Interaction Study Between Dolutegravir and Prednisone | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2011-09-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01380145 | MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoin… | Phase1 | Multiple Myeloma | Completed | 2011-09-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01362296 | An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-muta… | Phase2 | Lung Cancer, Non-Small Cell | Completed | 2011-09-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01406340 | Assessment of the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subj… | Phase1 | Anaemia | Terminated | 2011-08-30 | 2013-08-31 | ClinicalTrials.gov |
| NCT01416376 | Effect of Multiple Dose Levels of SRT2379 on Endotoxin-Induced Inflammation | Phase1 | Sepsis | Completed | 2011-08-30 | 2011-12-12 | ClinicalTrials.gov |
| NCT01416376 | Effect of Multiple Dose Levels of SRT2379 on Endotoxin-Induced Inflammation | Phase1 | Sepsis | Completed | 2011-08-30 | 2011-12-12 | ClinicalTrials.gov |
| NCT01406340 | Assessment of the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subj… | Phase1 | Anaemia | Terminated | 2011-08-30 | 2013-08-31 | ClinicalTrials.gov |
| NCT01863615 | Bioequivalence Study for an Isotretinoin | Phase1 | Skin Infections (Acne) | Completed | 2011-08-26 | 2011-09-23 | ClinicalTrials.gov |
| NCT01863615 | Bioequivalence Study for an Isotretinoin | Phase1 | Skin Infections (Acne) | Completed | 2011-08-26 | 2011-09-23 | ClinicalTrials.gov |
| NCT01449188 | To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as C… | Phase1 | Nausea and Vomiting, Chemotherapy-Induced | Completed | 2011-08-16 | 2011-12-19 | ClinicalTrials.gov |
| NCT01449188 | To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as C… | Phase1 | Nausea and Vomiting, Chemotherapy-Induced | Completed | 2011-08-16 | 2011-12-19 | ClinicalTrials.gov |
| NCT01416571 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalen… | Phase2 | Influenza | Completed | 2011-08-12 | 2012-09-28 | ClinicalTrials.gov |
| NCT01416571 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalen… | Phase2 | Influenza | Completed | 2011-08-12 | 2012-09-28 | ClinicalTrials.gov |
| NCT01366534 | Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in He… | Phase2 | Malaria | Completed | 2011-08-10 | 2012-07-03 | ClinicalTrials.gov |
| NCT01366534 | Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in He… | Phase2 | Malaria | Completed | 2011-08-10 | 2012-07-03 | ClinicalTrials.gov |
| NCT01471327 | Japanese Phase 1 Study of Mepolizumab | Phase1 | Asthma | Completed | 2011-08-09 | 2012-04-27 | ClinicalTrials.gov |
| NCT01471327 | Japanese Phase 1 Study of Mepolizumab | Phase1 | Asthma | Completed | 2011-08-09 | 2012-04-27 | ClinicalTrials.gov |
| NCT02012400 | Effects of Regular Exercise on Adult Asthma | Na | Asthma | Completed | 2011-08-01 | 2015-06-30 | ClinicalTrials.gov |
| NCT02012400 | Effects of Regular Exercise on Adult Asthma | Na | Asthma | Completed | 2011-08-01 | 2015-06-30 | ClinicalTrials.gov |
| NCT01376388 | Long-term Safety Study for GSK573719/GW642444 in Japanese | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-08-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01376388 | Long-term Safety Study for GSK573719/GW642444 in Japanese | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-08-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01426880 | Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-pos… | Phase2 | Tubular Breast Cancer Stage II | Completed | 2011-08-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01416597 | A Systematic Review of Studies of the Effect of Influenza Vaccine Against Misma… | — | Influenza | Completed | 2011-08-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01435356 | Safety and Efficacy Study of MAGE-A3 + AS-15 in Patients With Muscle-invasive B… | Phase2 | Urinary Bladder Neoplasms | Terminated | 2011-08-01 | 2017-04-07 | ClinicalTrials.gov |
| NCT01404806 | GSK1349572 Exposure in Blood, Cervicovaginal Fluid, and Cervical and Vaginal Ti… | Phase1 | Healthy Adult Females | Completed | 2011-08-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01426880 | Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-pos… | Phase2 | Tubular Breast Cancer Stage II | Completed | 2011-08-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01404806 | GSK1349572 Exposure in Blood, Cervicovaginal Fluid, and Cervical and Vaginal Ti… | Phase1 | Healthy Adult Females | Completed | 2011-08-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01390922 | Special Drug Use Investigation for Botox® (Botulinum) Spasticity (BOTOX is a Re… | — | Mumps | Completed | 2011-08-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01390922 | Special Drug Use Investigation for Botox® (Botulinum) Spasticity (BOTOX is a Re… | — | Mumps | Completed | 2011-08-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01435356 | Safety and Efficacy Study of MAGE-A3 + AS-15 in Patients With Muscle-invasive B… | Phase2 | Urinary Bladder Neoplasms | Terminated | 2011-08-01 | 2017-04-07 | ClinicalTrials.gov |
| NCT01416597 | A Systematic Review of Studies of the Effect of Influenza Vaccine Against Misma… | — | Influenza | Completed | 2011-08-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01458132 | Drug Exposure Registry for GSK2248761, an Investigational NNRTI | — | HIV Infections | Completed | 2011-07-29 | 2013-04-30 | ClinicalTrials.gov |
| NCT01458132 | Drug Exposure Registry for GSK2248761, an Investigational NNRTI | — | HIV Infections | Completed | 2011-07-29 | 2013-04-30 | ClinicalTrials.gov |
| NCT01379937 | A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of … | Phase3 | Influenza | Completed | 2011-07-28 | 2012-10-05 | ClinicalTrials.gov |
| NCT01379937 | A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of … | Phase3 | Influenza | Completed | 2011-07-28 | 2012-10-05 | ClinicalTrials.gov |
| NCT01928914 | Tafenoquine Thorough QTc Study in Healthy Subjects | Phase1 | Malaria, Vivax | Completed | 2011-07-26 | 2012-06-04 | ClinicalTrials.gov |
| NCT01928914 | Tafenoquine Thorough QTc Study in Healthy Subjects | Phase1 | Malaria, Vivax | Completed | 2011-07-26 | 2012-06-04 | ClinicalTrials.gov |
| NCT01462617 | Study to Investigate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics … | Phase1 | Asthma | Completed | 2011-07-24 | 2012-03-26 | ClinicalTrials.gov |
| NCT01462617 | Study to Investigate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics … | Phase1 | Asthma | Completed | 2011-07-24 | 2012-03-26 | ClinicalTrials.gov |
| NCT01439438 | Topiramate Bioequivalence Study Brazil - Fast | Phase1 | Epilepsy, Tonic-Clonic | Completed | 2011-07-22 | 2011-09-11 | ClinicalTrials.gov |
| NCT01439438 | Topiramate Bioequivalence Study Brazil - Fast | Phase1 | Epilepsy, Tonic-Clonic | Completed | 2011-07-22 | 2011-09-11 | ClinicalTrials.gov |
| NCT01400906 | Inhalation of Corticosteroids in Smoking and Non-smoking Asthmatics. | Phase2 | Asthma | Completed | 2011-07-20 | 2012-12-12 | ClinicalTrials.gov |
| NCT01400906 | Inhalation of Corticosteroids in Smoking and Non-smoking Asthmatics. | Phase2 | Asthma | Completed | 2011-07-20 | 2012-12-12 | ClinicalTrials.gov |
| NCT01376323 | A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Tr… | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2011-07-13 | 2012-09-17 | ClinicalTrials.gov |
| NCT01449799 | An Investigation of the Pharmacokinetics of GSK961081 and Fluticasone Propionat… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-07-13 | 2011-09-21 | ClinicalTrials.gov |
| NCT01394211 | Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Br… | Phase2 | Estrogen Receptor-positive Breast Cancer | Terminated | 2011-07-13 | 2012-04-12 | ClinicalTrials.gov |
| NCT01449799 | An Investigation of the Pharmacokinetics of GSK961081 and Fluticasone Propionat… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-07-13 | 2011-09-21 | ClinicalTrials.gov |
| NCT01394211 | Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Br… | Phase2 | Estrogen Receptor-positive Breast Cancer | Terminated | 2011-07-13 | 2012-04-12 | ClinicalTrials.gov |
| NCT01376323 | A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Tr… | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2011-07-13 | 2012-09-17 | ClinicalTrials.gov |
| NCT01513187 | Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Re… | Phase1 | Advanced Renal Cell Carcinoma | Completed | 2011-07-11 | 2019-02-22 | ClinicalTrials.gov |
| NCT01513187 | Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Re… | Phase1 | Advanced Renal Cell Carcinoma | Completed | 2011-07-11 | 2019-02-22 | ClinicalTrials.gov |
| NCT01439373 | Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterfer… | Phase2 | Hepatitis C, Chronic | Completed | 2011-07-07 | 2011-12-05 | ClinicalTrials.gov |
| NCT01362348 | 12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD) | Phase2 | Macular Degeneration | Terminated | 2011-07-07 | 2012-04-16 | ClinicalTrials.gov |
| NCT01362348 | 12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD) | Phase2 | Macular Degeneration | Terminated | 2011-07-07 | 2012-04-16 | ClinicalTrials.gov |
| NCT01439373 | Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterfer… | Phase2 | Hepatitis C, Chronic | Completed | 2011-07-07 | 2011-12-05 | ClinicalTrials.gov |
| NCT01258933 | Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy | Phase2 | Leukemia | Terminated | 2011-07-06 | 2024-10-18 | ClinicalTrials.gov |
| NCT01406262 | Albiglutide Thorough ECG Study in Healthy Volunteers | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2011-07-06 | 2011-12-29 | ClinicalTrials.gov |
| NCT01258933 | Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy | Phase2 | Leukemia | Terminated | 2011-07-06 | 2024-10-18 | ClinicalTrials.gov |
| NCT01406262 | Albiglutide Thorough ECG Study in Healthy Volunteers | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2011-07-06 | 2011-12-29 | ClinicalTrials.gov |
| NCT01387230 | Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder … | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-07-01 | 2012-02-13 | ClinicalTrials.gov |
| NCT01428505 | [18F]PBR111 and Microglial Activation in Multiple Sclerosis | Phase2 | Multiple Sclerosis | Terminated | 2011-07-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01357889 | Pharmacokinetics/Pharmacodynamics of Albiglutide | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2011-07-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01476085 | Evaluating the Utility of the Apoptosis Imaging Biomarker 18F]ML10 in Patients … | Phase1 | Cancer | Terminated | 2011-07-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01462487 | Safety of Inhaled Zanamivir in Pregnancy | — | Influenza, Human | Completed | 2011-07-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01536704 | Nicotine Lozenge Bioequivalence Study | Phase1 | Smoking Cessation | Completed | 2011-07-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01428505 | [18F]PBR111 and Microglial Activation in Multiple Sclerosis | Phase2 | Multiple Sclerosis | Terminated | 2011-07-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01353768 | Zanamivir Aqueous Solution Compassionate Use Program Retrospective Chart Review… | — | Infections, Respiratory Tract | Completed | 2011-07-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01391611 | Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors … | Phase2 | Gastrointestinal Stromal Tumor (GIST) | Terminated | 2011-07-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01357889 | Pharmacokinetics/Pharmacodynamics of Albiglutide | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2011-07-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01372410 | A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Do… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-07-01 | 2011-10-27 | ClinicalTrials.gov |
| NCT01389076 | Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, … | Phase2 | Follicular Lymphoma | Terminated | 2011-07-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT01389076 | Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, … | Phase2 | Follicular Lymphoma | Terminated | 2011-07-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT01400932 | Study STF115288, a Clinical Confirmation Study of GI148512 in the Treatment of … | Phase3 | Acne Vulgaris | Completed | 2011-07-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01387230 | Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder … | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-07-01 | 2012-02-13 | ClinicalTrials.gov |
| NCT01362322 | Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Ol… | Phase4 | Diphtheria | Completed | 2011-07-01 | 2012-09-03 | ClinicalTrials.gov |
| NCT01536704 | Nicotine Lozenge Bioequivalence Study | Phase1 | Smoking Cessation | Completed | 2011-07-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01476085 | Evaluating the Utility of the Apoptosis Imaging Biomarker 18F]ML10 in Patients … | Phase1 | Cancer | Terminated | 2011-07-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01391611 | Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors … | Phase2 | Gastrointestinal Stromal Tumor (GIST) | Terminated | 2011-07-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01372410 | A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Do… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-07-01 | 2011-10-27 | ClinicalTrials.gov |
| NCT01400932 | Study STF115288, a Clinical Confirmation Study of GI148512 in the Treatment of … | Phase3 | Acne Vulgaris | Completed | 2011-07-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01362322 | Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Ol… | Phase4 | Diphtheria | Completed | 2011-07-01 | 2012-09-03 | ClinicalTrials.gov |
| NCT01462487 | Safety of Inhaled Zanamivir in Pregnancy | — | Influenza, Human | Completed | 2011-07-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01353768 | Zanamivir Aqueous Solution Compassionate Use Program Retrospective Chart Review… | — | Infections, Respiratory Tract | Completed | 2011-07-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01395888 | A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium … | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-06-30 | 2012-08-06 | ClinicalTrials.gov |
| NCT01360398 | Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly | Na | Respiratory Disorders | Completed | 2011-06-30 | 2014-06-27 | ClinicalTrials.gov |
| NCT01471678 | Bioavailability of Two Combination Products of Dutasteride (0.5mg) and Tamsulos… | Phase1 | Prostatic Hyperplasia | Completed | 2011-06-30 | 2011-09-07 | ClinicalTrials.gov |
| NCT01395888 | A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium … | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-06-30 | 2012-08-06 | ClinicalTrials.gov |
| NCT01471678 | Bioavailability of Two Combination Products of Dutasteride (0.5mg) and Tamsulos… | Phase1 | Prostatic Hyperplasia | Completed | 2011-06-30 | 2011-09-07 | ClinicalTrials.gov |
| NCT01360398 | Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly | Na | Respiratory Disorders | Completed | 2011-06-30 | 2014-06-27 | ClinicalTrials.gov |
| NCT01381549 | GSK2251052 in Complicated Urinary Tract Infection | Phase2 | Infections, Urinary Tract | Terminated | 2011-06-28 | 2012-03-06 | ClinicalTrials.gov |
| NCT01381549 | GSK2251052 in Complicated Urinary Tract Infection | Phase2 | Infections, Urinary Tract | Terminated | 2011-06-28 | 2012-03-06 | ClinicalTrials.gov |
| NCT01357915 | Evaluation of the Long-term Persistence of GlaxoSmithKline (GSK) Biologicals' C… | Na | Infections, Cytomegalovirus | Completed | 2011-06-24 | 2012-09-13 | ClinicalTrials.gov |
| NCT01357915 | Evaluation of the Long-term Persistence of GlaxoSmithKline (GSK) Biologicals' C… | Na | Infections, Cytomegalovirus | Completed | 2011-06-24 | 2012-09-13 | ClinicalTrials.gov |
| NCT01342952 | Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated i… | Phase2 | Hypertension, Pulmonary | Completed | 2011-06-21 | 2022-06-09 | ClinicalTrials.gov |
| NCT01342952 | Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated i… | Phase2 | Hypertension, Pulmonary | Completed | 2011-06-21 | 2022-06-09 | ClinicalTrials.gov |
| NCT01416337 | Absolute Bioavialability of GSK1120212 | Phase1 | Cancer | Completed | 2011-06-20 | 2011-12-17 | ClinicalTrials.gov |
| NCT01416337 | Absolute Bioavialability of GSK1120212 | Phase1 | Cancer | Completed | 2011-06-20 | 2011-12-17 | ClinicalTrials.gov |
| NCT01755611 | Bioequivalence Minocycline Bioequivalence | Phase1 | Skin Infections (Acne) | Completed | 2011-06-17 | 2011-06-25 | ClinicalTrials.gov |
| NCT01755611 | Bioequivalence Minocycline Bioequivalence | Phase1 | Skin Infections (Acne) | Completed | 2011-06-17 | 2011-06-25 | ClinicalTrials.gov |
| NCT01416324 | First Time in Human Study Using GSK2330672 | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2011-06-15 | 2011-09-09 | ClinicalTrials.gov |
| NCT01416324 | First Time in Human Study Using GSK2330672 | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2011-06-15 | 2011-09-09 | ClinicalTrials.gov |
| NCT01382706 | Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder | Phase2 | Recurrent Bladder Cancer | Terminated | 2011-06-13 | 2017-12-15 | ClinicalTrials.gov |
| NCT01382706 | Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder | Phase2 | Recurrent Bladder Cancer | Terminated | 2011-06-13 | 2017-12-15 | ClinicalTrials.gov |
| NCT01340833 | Determination of the Absolute Bioavailability of GSK2118436 Following a Single … | Phase1 | Cancer | Completed | 2011-06-08 | 2011-09-12 | ClinicalTrials.gov |
| NCT01340833 | Determination of the Absolute Bioavailability of GSK2118436 Following a Single … | Phase1 | Cancer | Completed | 2011-06-08 | 2011-09-12 | ClinicalTrials.gov |
| NCT01248247 | BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously T… | Phase2 | Lung Cancer | Completed | 2011-06-02 | 2020-11-30 | ClinicalTrials.gov |
| NCT01248247 | BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously T… | Phase2 | Lung Cancer | Completed | 2011-06-02 | 2020-11-30 | ClinicalTrials.gov |
| NCT01394614 | Risk of Narcolepsy Associated With Administration of H1N1 Vaccine | — | Narcolepsy | Completed | 2011-06-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01385228 | Pazopanib, Docetaxel, Prednisone Prostate | Phase1 | Prostate Cancer | Completed | 2011-06-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT01385228 | Pazopanib, Docetaxel, Prednisone Prostate | Phase1 | Prostate Cancer | Completed | 2011-06-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT01342926 | Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patient… | Phase2 | Atrophy, Geographic | Completed | 2011-06-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01382238 | Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegrav… | Phase1 | Infections, Human Immunodeficiency Virus and Herpesviridae | Completed | 2011-06-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01342926 | Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patient… | Phase2 | Atrophy, Geographic | Completed | 2011-06-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01521416 | Cost of Illness Associated With Influenza in the UK | — | Influenza | Completed | 2011-06-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01361711 | Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic … | Phase2 | Stage I Chronic Lymphocytic Leukemia | Active_Not_Recruiting | 2011-06-01 | 2027-05-01 | ClinicalTrials.gov |
| NCT01377298 | Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell … | Phase2 | Head and Neck Squamous Cell Carcinoma | Unknown | 2011-06-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01353716 | Dolutegravir Renal Impairment Study | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2011-06-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01471665 | GSK2190915 Neutrophilic Asthma Study | Phase2 | Asthma | Completed | 2011-06-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01366547 | Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixe… | Phase1 | Healthy Subjects | Completed | 2011-06-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01394614 | Risk of Narcolepsy Associated With Administration of H1N1 Vaccine | — | Narcolepsy | Completed | 2011-06-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01361711 | Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic … | Phase2 | Stage I Chronic Lymphocytic Leukemia | Active_Not_Recruiting | 2011-06-01 | 2027-05-01 | ClinicalTrials.gov |
| NCT01361113 | Neoadjuvant Pazopanib in Renal Cell Carcinoma | Phase2 | Renal Cell Carcinoma | Completed | 2011-06-01 | 2017-02-15 | ClinicalTrials.gov |
| NCT01446237 | U0289-405: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of … | Na | Acne Vulgaris | Completed | 2011-06-01 | 2011-12-15 | ClinicalTrials.gov |
| NCT01446237 | U0289-405: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of … | Na | Acne Vulgaris | Completed | 2011-06-01 | 2011-12-15 | ClinicalTrials.gov |
| NCT01421251 | H1N1 Vaccine Safety in Manitoba, Canada | — | H1N1 Influenza | Unknown | 2011-06-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01366547 | Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixe… | Phase1 | Healthy Subjects | Completed | 2011-06-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01521416 | Cost of Illness Associated With Influenza in the UK | — | Influenza | Completed | 2011-06-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01377298 | Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell … | Phase2 | Head and Neck Squamous Cell Carcinoma | Unknown | 2011-06-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01353716 | Dolutegravir Renal Impairment Study | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2011-06-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01382238 | Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegrav… | Phase1 | Infections, Human Immunodeficiency Virus and Herpesviridae | Completed | 2011-06-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01308957 | Fish Oil and Muscle Function | Na | Sarcopenia | Completed | 2011-06-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01421251 | H1N1 Vaccine Safety in Manitoba, Canada | — | H1N1 Influenza | Unknown | 2011-06-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01175083 | Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococc… | Phase3 | Infections, Streptococcal | Completed | 2011-06-01 | 2013-05-23 | ClinicalTrials.gov |
| NCT01471665 | GSK2190915 Neutrophilic Asthma Study | Phase2 | Asthma | Completed | 2011-06-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01361113 | Neoadjuvant Pazopanib in Renal Cell Carcinoma | Phase2 | Renal Cell Carcinoma | Completed | 2011-06-01 | 2017-02-15 | ClinicalTrials.gov |
| NCT01308957 | Fish Oil and Muscle Function | Na | Sarcopenia | Completed | 2011-06-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01263418 | Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B… | Phase2 | Lymphoma, Non-Hodgkin | Withdrawn | 2011-06-01 | 2018-01-01 | ClinicalTrials.gov |
| NCT01263418 | Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B… | Phase2 | Lymphoma, Non-Hodgkin | Withdrawn | 2011-06-01 | 2018-01-01 | ClinicalTrials.gov |
| NCT01175083 | Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococc… | Phase3 | Infections, Streptococcal | Completed | 2011-06-01 | 2013-05-23 | ClinicalTrials.gov |
| NCT01380054 | Pulmonary Hypertension, Quality of Life and Psychosocial Factors | — | Pulmonary Hypertension | Completed | 2011-05-31 | 2016-05-20 | ClinicalTrials.gov |
| NCT01380054 | Pulmonary Hypertension, Quality of Life and Psychosocial Factors | — | Pulmonary Hypertension | Completed | 2011-05-31 | 2016-05-20 | ClinicalTrials.gov |
| NCT01358825 | Study to Evaluate Antibody Persistence in Children Previously Vaccinated With I… | Phase4 | Tetanus | Completed | 2011-05-30 | 2011-07-15 | ClinicalTrials.gov |
| NCT01480271 | An Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodyna… | Phase1 | Rhinitis, Allergic, Seasonal | Completed | 2011-05-30 | 2011-09-30 | ClinicalTrials.gov |
| NCT01358825 | Study to Evaluate Antibody Persistence in Children Previously Vaccinated With I… | Phase4 | Tetanus | Completed | 2011-05-30 | 2011-07-15 | ClinicalTrials.gov |
| NCT01480271 | An Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodyna… | Phase1 | Rhinitis, Allergic, Seasonal | Completed | 2011-05-30 | 2011-09-30 | ClinicalTrials.gov |
| NCT01431989 | Amoxicillin Bioequivalence Study Brazil - Fast | Phase1 | Infections, Bacterial | Completed | 2011-05-27 | 2011-06-11 | ClinicalTrials.gov |
| NCT01431989 | Amoxicillin Bioequivalence Study Brazil - Fast | Phase1 | Infections, Bacterial | Completed | 2011-05-27 | 2011-06-11 | ClinicalTrials.gov |
| NCT01352312 | Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chroni… | Phase1 | Chronic Lymphocytic Leukemia | Terminated | 2011-05-25 | 2018-05-10 | ClinicalTrials.gov |
| NCT01352312 | Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chroni… | Phase1 | Chronic Lymphocytic Leukemia | Terminated | 2011-05-25 | 2018-05-10 | ClinicalTrials.gov |
| NCT01345253 | GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subj… | Phase3 | Systemic Lupus Erythematosus | Completed | 2011-05-23 | 2018-09-21 | ClinicalTrials.gov |
| NCT01345253 | GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subj… | Phase3 | Systemic Lupus Erythematosus | Completed | 2011-05-23 | 2018-09-21 | ClinicalTrials.gov |
| NCT01416363 | Healthy Volunteer Study Using 3 Different Formulations of Firategrast | Phase1 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2011-05-20 | 2011-09-17 | ClinicalTrials.gov |
| NCT01416363 | Healthy Volunteer Study Using 3 Different Formulations of Firategrast | Phase1 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2011-05-20 | 2011-09-17 | ClinicalTrials.gov |
| NCT01323972 | Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate… | Phase3 | Malaria | Completed | 2011-05-16 | 2012-05-04 | ClinicalTrials.gov |
| NCT01323972 | Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate… | Phase3 | Malaria | Completed | 2011-05-16 | 2012-05-04 | ClinicalTrials.gov |
| NCT01352286 | Redirected Auto T Cells for Advanced Myeloma | Phase2 | Multiple Myeloma | Completed | 2011-05-13 | 2019-07-08 | ClinicalTrials.gov |
| NCT01352286 | Redirected Auto T Cells for Advanced Myeloma | Phase2 | Multiple Myeloma | Completed | 2011-05-13 | 2019-07-08 | ClinicalTrials.gov |
| NCT01316939 | GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease | Phase3 | Crohn's Disease | Terminated | 2011-05-09 | 2013-10-23 | ClinicalTrials.gov |
| NCT01316939 | GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease | Phase3 | Crohn's Disease | Terminated | 2011-05-09 | 2013-10-23 | ClinicalTrials.gov |
| NCT01160211 | A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combina… | Phase3 | Neoplasms, Breast | Completed | 2011-05-05 | 2022-06-06 | ClinicalTrials.gov |
| NCT01160211 | A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combina… | Phase3 | Neoplasms, Breast | Completed | 2011-05-05 | 2022-06-06 | ClinicalTrials.gov |
| NCT01262898 | Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male … | Phase2 | Gastroparesis | Completed | 2011-05-03 | 2013-02-26 | ClinicalTrials.gov |
| NCT01262898 | Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male … | Phase2 | Gastroparesis | Completed | 2011-05-03 | 2013-02-26 | ClinicalTrials.gov |
| NCT01371487 | GSK1120212 Food-effect Study | Phase1 | Cancer | Completed | 2011-05-02 | 2011-09-30 | ClinicalTrials.gov |
| NCT01371487 | GSK1120212 Food-effect Study | Phase1 | Cancer | Completed | 2011-05-02 | 2011-09-30 | ClinicalTrials.gov |
| NCT01332539 | An Observational Study to Assess the Burden of Drug-resistant Partial Epilepsy … | — | Epilepsy, Partial | Completed | 2011-05-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01858792 | A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) … | — | Lupus Erythematosus, Discoid | Completed | 2011-05-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01458080 | WEUSKOP5410: Observational Study in ENABLE Clinical Trials | — | Hepatitis C | Completed | 2011-05-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01332539 | An Observational Study to Assess the Burden of Drug-resistant Partial Epilepsy … | — | Epilepsy, Partial | Completed | 2011-05-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01332578 | A Comparison of Solid and Soluble Forms of Cold and Influenza Remedies | Phase4 | Influenza | Completed | 2011-05-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01393470 | Evaluation of Long-term HPV Vaccine Efficacy | — | Uterine Cervical Cancer | Unknown | 2011-05-01 | 2024-12-01 | ClinicalTrials.gov |
| NCT01393470 | Evaluation of Long-term HPV Vaccine Efficacy | — | Uterine Cervical Cancer | Unknown | 2011-05-01 | 2024-12-01 | ClinicalTrials.gov |
| NCT01231542 | Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Ri… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2011-05-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01858792 | A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) … | — | Lupus Erythematosus, Discoid | Completed | 2011-05-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01458080 | WEUSKOP5410: Observational Study in ENABLE Clinical Trials | — | Hepatitis C | Completed | 2011-05-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01329562 | CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in … | Phase4 | Menstrual Migraine | Completed | 2011-05-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01328041 | A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure … | Phase3 | Infection, Human Immunodeficiency Virus | Completed | 2011-05-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT01329562 | CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in … | Phase4 | Menstrual Migraine | Completed | 2011-05-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT00920140 | Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212… | Phase2 | Cancer | Completed | 2011-05-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01328041 | A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure … | Phase3 | Infection, Human Immunodeficiency Virus | Completed | 2011-05-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT01231542 | Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Ri… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2011-05-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01348880 | Vardenafil ODT (Orally Disintegrating Tablet) - Nifedipine Interaction Study | Phase1 | Erectile Dysfunction | Completed | 2011-05-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01348880 | Vardenafil ODT (Orally Disintegrating Tablet) - Nifedipine Interaction Study | Phase1 | Erectile Dysfunction | Completed | 2011-05-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01332578 | A Comparison of Solid and Soluble Forms of Cold and Influenza Remedies | Phase4 | Influenza | Completed | 2011-05-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT00920140 | Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212… | Phase2 | Cancer | Completed | 2011-05-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01362257 | A Study to Determine the Excretion Balance and Pharmacokinetics of 14C-GSK573719 | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-04-29 | 2011-06-22 | ClinicalTrials.gov |
| NCT01362257 | A Study to Determine the Excretion Balance and Pharmacokinetics of 14C-GSK573719 | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-04-29 | 2011-06-22 | ClinicalTrials.gov |
| NCT01323647 | Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously V… | Phase3 | Poliomyelitis | Completed | 2011-04-25 | 2011-09-19 | ClinicalTrials.gov |
| NCT01323647 | Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously V… | Phase3 | Poliomyelitis | Completed | 2011-04-25 | 2011-09-19 | ClinicalTrials.gov |
| NCT01475695 | GSK2251052 Mass Balance in Healthy Adult Subjects | Phase1 | Community-acquired Infection | Completed | 2011-04-21 | 2011-05-19 | ClinicalTrials.gov |
| NCT01475695 | GSK2251052 Mass Balance in Healthy Adult Subjects | Phase1 | Community-acquired Infection | Completed | 2011-04-21 | 2011-05-19 | ClinicalTrials.gov |
| NCT01273610 | Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 o… | Phase2 | Breast Neoplasms | Active_Not_Recruiting | 2011-04-20 | 2026-05-19 | ClinicalTrials.gov |
| NCT01273610 | Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 o… | Phase2 | Breast Neoplasms | Active_Not_Recruiting | 2011-04-20 | 2026-05-19 | ClinicalTrials.gov |
| NCT01357902 | Lamotrigine Bioequivalence Study to Compare Dispersible Tables With Compressed … | Phase1 | Epilepsy | Completed | 2011-04-18 | 2011-05-23 | ClinicalTrials.gov |
| NCT01357902 | Lamotrigine Bioequivalence Study to Compare Dispersible Tables With Compressed … | Phase1 | Epilepsy | Completed | 2011-04-18 | 2011-05-23 | ClinicalTrials.gov |
| NCT01381445 | A Study Assessing GW870086's Potential to Cause Skin Thinning | Phase1 | Dermatitis, Atopic | Completed | 2011-04-14 | 2011-07-07 | ClinicalTrials.gov |
| NCT01381445 | A Study Assessing GW870086's Potential to Cause Skin Thinning | Phase1 | Dermatitis, Atopic | Completed | 2011-04-14 | 2011-07-07 | ClinicalTrials.gov |
| NCT01424397 | Intranasal SB-705498 in Allergic Rhinitis (AR) Patients | Phase2 | Rhinitis | Completed | 2011-04-14 | 2011-07-07 | ClinicalTrials.gov |
| NCT01424397 | Intranasal SB-705498 in Allergic Rhinitis (AR) Patients | Phase2 | Rhinitis | Completed | 2011-04-14 | 2011-07-07 | ClinicalTrials.gov |
| NCT01220128 | Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant T… | Phase2 | Neoplasms, Breast | Terminated | 2011-04-11 | 2014-11-14 | ClinicalTrials.gov |
| NCT01220128 | Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant T… | Phase2 | Neoplasms, Breast | Terminated | 2011-04-11 | 2014-11-14 | ClinicalTrials.gov |
| NCT01286038 | Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia | Phase1 | Myelodysplastic Syndrome (MDS) | Terminated | 2011-04-06 | 2018-11-03 | ClinicalTrials.gov |
| NCT01286038 | Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia | Phase1 | Myelodysplastic Syndrome (MDS) | Terminated | 2011-04-06 | 2018-11-03 | ClinicalTrials.gov |
| NCT01311024 | Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage | — | Pneumococcal Infections | Completed | 2011-04-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT01476098 | A Study to Investigate the Effect of SB-705498 on Chronic Cough | Phase2 | Rhinitis | Completed | 2011-04-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01318993 | Open-Label Extension Study of GSK1605786A | Phase3 | Crohn's Disease | Terminated | 2011-04-01 | 2013-10-29 | ClinicalTrials.gov |
| NCT01323959 | Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previo… | Phase4 | Acellular Pertussis | Completed | 2011-04-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01171378 | Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With… | Phase2 | Richter's Syndrome | Completed | 2011-04-01 | 2016-04-19 | ClinicalTrials.gov |
| NCT01311024 | Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage | — | Pneumococcal Infections | Completed | 2011-04-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT01323959 | Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previo… | Phase4 | Acellular Pertussis | Completed | 2011-04-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01171378 | Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With… | Phase2 | Richter's Syndrome | Completed | 2011-04-01 | 2016-04-19 | ClinicalTrials.gov |
| NCT01476098 | A Study to Investigate the Effect of SB-705498 on Chronic Cough | Phase2 | Rhinitis | Completed | 2011-04-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01332565 | A Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2011-04-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01318993 | Open-Label Extension Study of GSK1605786A | Phase3 | Crohn's Disease | Terminated | 2011-04-01 | 2013-10-29 | ClinicalTrials.gov |
| NCT01332565 | A Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2011-04-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT02348372 | Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single … | Phase1 | Anaemia | Completed | 2011-03-31 | 2011-06-03 | ClinicalTrials.gov |
| NCT02348372 | Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single … | Phase1 | Anaemia | Completed | 2011-03-31 | 2011-06-03 | ClinicalTrials.gov |
| NCT01300234 | Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Sub… | Phase3 | Hepatitis B | Completed | 2011-03-30 | 2016-12-06 | ClinicalTrials.gov |
| NCT01300234 | Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Sub… | Phase3 | Hepatitis B | Completed | 2011-03-30 | 2016-12-06 | ClinicalTrials.gov |
| NCT01371812 | GSK2239633 FTIH Study | Phase1 | Asthma | Completed | 2011-03-29 | 2011-07-01 | ClinicalTrials.gov |
| NCT01371812 | GSK2239633 FTIH Study | Phase1 | Asthma | Completed | 2011-03-29 | 2011-07-01 | ClinicalTrials.gov |
| NCT01772238 | Bioequivalence Study of an Amoxicillin-Clavulanic | Phase1 | Infections, Respiratory Tract | Completed | 2011-03-22 | 2011-03-30 | ClinicalTrials.gov |
| NCT01772238 | Bioequivalence Study of an Amoxicillin-Clavulanic | Phase1 | Infections, Respiratory Tract | Completed | 2011-03-22 | 2011-03-30 | ClinicalTrials.gov |
| NCT01323621 | Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate … | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-03-18 | 2012-01-24 | ClinicalTrials.gov |
| NCT01323634 | Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-03-18 | 2011-12-14 | ClinicalTrials.gov |
| NCT01323634 | Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-03-18 | 2011-12-14 | ClinicalTrials.gov |
| NCT01323621 | Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate … | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-03-18 | 2012-01-24 | ClinicalTrials.gov |
| NCT01190202 | Epidemiology Study of Malaria Transmission Intensity in Africa | Na | Malaria | Completed | 2011-03-14 | 2013-12-20 | ClinicalTrials.gov |
| NCT01190202 | Epidemiology Study of Malaria Transmission Intensity in Africa | Na | Malaria | Completed | 2011-03-14 | 2013-12-20 | ClinicalTrials.gov |
| NCT01476046 | Safety Study of GSK1995057 Given as Single and Repeat Intravenous Doses in Heal… | Phase1 | Respiratory Disorders | Completed | 2011-03-08 | 2012-06-17 | ClinicalTrials.gov |
| NCT01476046 | Safety Study of GSK1995057 Given as Single and Repeat Intravenous Doses in Heal… | Phase1 | Respiratory Disorders | Completed | 2011-03-08 | 2012-06-17 | ClinicalTrials.gov |
| NCT01310413 | Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age | Phase3 | Influenza | Completed | 2011-03-07 | 2014-01-26 | ClinicalTrials.gov |
| NCT01310413 | Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age | Phase3 | Influenza | Completed | 2011-03-07 | 2014-01-26 | ClinicalTrials.gov |
| NCT01336608 | A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-03-04 | 2014-11-04 | ClinicalTrials.gov |
| NCT01336608 | A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-03-04 | 2014-11-04 | ClinicalTrials.gov |
| NCT01309646 | Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vac… | Phase3 | Poliomyelitis | Completed | 2011-03-04 | 2012-02-24 | ClinicalTrials.gov |
| NCT01309646 | Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vac… | Phase3 | Poliomyelitis | Completed | 2011-03-04 | 2012-02-24 | ClinicalTrials.gov |
| NCT01381601 | Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell C… | — | Carcinoma, Renal Cell | Completed | 2011-03-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01243190 | Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic L… | Phase2 | Chronic Lymphocytic Leukemia | Completed | 2011-03-01 | 2023-03-28 | ClinicalTrials.gov |
| NCT01647737 | Green Tea Lozenges for the Management of Dry Mouth | Phase1 | Xerostomia | Completed | 2011-03-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01454479 | A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Tr… | Phase1 | Recurrent Endometrial Cancer | Unknown | 2011-03-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01243190 | Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic L… | Phase2 | Chronic Lymphocytic Leukemia | Completed | 2011-03-01 | 2023-03-28 | ClinicalTrials.gov |
| NCT01283100 | A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacoki… | Phase1 | Infection, Human Immunodeficiency Virus I | Withdrawn | 2011-03-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01283100 | A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacoki… | Phase1 | Infection, Human Immunodeficiency Virus I | Withdrawn | 2011-03-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01296698 | Study to Determine if a New Nicotine Replacement Therapy Can Safely Help Smoker… | Phase3 | Tobacco Dependence | Terminated | 2011-03-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01313637 | A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-03-01 | 2012-04-19 | ClinicalTrials.gov |
| NCT01313650 | A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-03-01 | 2012-04-05 | ClinicalTrials.gov |
| NCT01316900 | 24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-03-01 | 2012-04-24 | ClinicalTrials.gov |
| NCT01296698 | Study to Determine if a New Nicotine Replacement Therapy Can Safely Help Smoker… | Phase3 | Tobacco Dependence | Terminated | 2011-03-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01313637 | A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-03-01 | 2012-04-19 | ClinicalTrials.gov |
| NCT01313650 | A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-03-01 | 2012-04-05 | ClinicalTrials.gov |
| NCT01316900 | 24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-03-01 | 2012-04-24 | ClinicalTrials.gov |
| NCT01328444 | An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obs… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-03-01 | 2012-06-14 | ClinicalTrials.gov |
| NCT01328444 | An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obs… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-03-01 | 2012-06-14 | ClinicalTrials.gov |
| NCT01339221 | Epidemiological, Observational and Post Marketing Study of Rotarix™ in Children… | — | Infections, Rotavirus | Completed | 2011-03-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01647737 | Green Tea Lozenges for the Management of Dry Mouth | Phase1 | Xerostomia | Completed | 2011-03-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01339221 | Epidemiological, Observational and Post Marketing Study of Rotarix™ in Children… | — | Infections, Rotavirus | Completed | 2011-03-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01352884 | Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Pa… | Phase1 | Cancer | Completed | 2011-03-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01352884 | Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Pa… | Phase1 | Cancer | Completed | 2011-03-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01381601 | Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell C… | — | Carcinoma, Renal Cell | Completed | 2011-03-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01454479 | A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Tr… | Phase1 | Recurrent Endometrial Cancer | Unknown | 2011-03-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01390935 | SUrvey of Guideline Adherence for Treatment of Systolic Heart Failure in Real W… | — | Heart Failure, Congestive | Completed | 2011-03-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01395875 | Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initia… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2011-03-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01395875 | Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initia… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2011-03-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01390935 | SUrvey of Guideline Adherence for Treatment of Systolic Heart Failure in Real W… | — | Heart Failure, Congestive | Completed | 2011-03-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01319006 | Relative Bioavailability Study for GSK1278863A | Phase1 | Anaemia | Completed | 2011-02-25 | 2011-04-18 | ClinicalTrials.gov |
| NCT01319006 | Relative Bioavailability Study for GSK1278863A | Phase1 | Anaemia | Completed | 2011-02-25 | 2011-04-18 | ClinicalTrials.gov |
| NCT01772212 | Bioequivalence Study for Terbinafine 250 mg | Phase1 | Mycoses | Completed | 2011-02-24 | 2011-03-15 | ClinicalTrials.gov |
| NCT01772212 | Bioequivalence Study for Terbinafine 250 mg | Phase1 | Mycoses | Completed | 2011-02-24 | 2011-03-15 | ClinicalTrials.gov |
| NCT01266603 | High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI | Phase2 | Melanoma | Completed | 2011-02-22 | 2018-11-01 | ClinicalTrials.gov |
| NCT01266603 | High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI | Phase2 | Melanoma | Completed | 2011-02-22 | 2018-11-01 | ClinicalTrials.gov |
| NCT01353742 | Lamivudine and Adefovir Dipivoxil Fixed Dose Combination | Phase1 | Hepatitis B, Chronic | Completed | 2011-02-21 | 2011-04-12 | ClinicalTrials.gov |
| NCT01336621 | Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Thera… | Phase3 | Epilepsy | Completed | 2011-02-21 | 2017-09-13 | ClinicalTrials.gov |
| NCT01353742 | Lamivudine and Adefovir Dipivoxil Fixed Dose Combination | Phase1 | Hepatitis B, Chronic | Completed | 2011-02-21 | 2011-04-12 | ClinicalTrials.gov |
| NCT01336621 | Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Thera… | Phase3 | Epilepsy | Completed | 2011-02-21 | 2017-09-13 | ClinicalTrials.gov |
| NCT01277042 | Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Health… | Phase3 | Infections, Papillomavirus | Completed | 2011-02-17 | 2012-02-28 | ClinicalTrials.gov |
| NCT01153841 | Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy… | Phase3 | Infections, Streptococcal | Completed | 2011-02-17 | 2011-07-26 | ClinicalTrials.gov |
| NCT01277042 | Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Health… | Phase3 | Infections, Papillomavirus | Completed | 2011-02-17 | 2012-02-28 | ClinicalTrials.gov |
| NCT01153841 | Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy… | Phase3 | Infections, Streptococcal | Completed | 2011-02-17 | 2011-07-26 | ClinicalTrials.gov |
| NCT01387204 | Study to Investigate the Absorption, Distribution, Metabolism and Elimination o… | Phase1 | Cancer | Completed | 2011-02-15 | 2011-07-18 | ClinicalTrials.gov |
| NCT01387204 | Study to Investigate the Absorption, Distribution, Metabolism and Elimination o… | Phase1 | Cancer | Completed | 2011-02-15 | 2011-07-18 | ClinicalTrials.gov |
| NCT01332513 | An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Perf… | Phase1 | Epilepsy | Completed | 2011-02-10 | 2011-05-23 | ClinicalTrials.gov |
| NCT01332513 | An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Perf… | Phase1 | Epilepsy | Completed | 2011-02-10 | 2011-05-23 | ClinicalTrials.gov |
| NCT01262872 | Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety … | Phase2 | Infections, Streptococcal | Completed | 2011-02-09 | 2013-03-18 | ClinicalTrials.gov |
| NCT01262872 | Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety … | Phase2 | Infections, Streptococcal | Completed | 2011-02-09 | 2013-03-18 | ClinicalTrials.gov |
| NCT01258608 | Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced He… | Phase1 | Carcinoma, Hepatocellular | Completed | 2011-02-08 | 2017-11-29 | ClinicalTrials.gov |
| NCT01258608 | Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced He… | Phase1 | Carcinoma, Hepatocellular | Completed | 2011-02-08 | 2017-11-29 | ClinicalTrials.gov |
| NCT01321723 | Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Table… | Phase2 | Postmenopausal Osteoporosis | Completed | 2011-02-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01313663 | A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Settin… | Phase2 | Lung Cancer, Small Cell | Terminated | 2011-02-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01466348 | Effects of a Common Cold Treatment on Cognitive Function | Phase4 | Common Cold | Completed | 2011-02-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01313663 | A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Settin… | Phase2 | Lung Cancer, Small Cell | Terminated | 2011-02-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01263015 | A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripl… | Phase3 | Infection, Human Immunodeficiency Virus I | Completed | 2011-02-01 | 2015-12-03 | ClinicalTrials.gov |
| NCT01283789 | Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer | Phase2 | Metastatic Breast Cancer | Unknown | 2011-02-01 | 2017-04-01 | ClinicalTrials.gov |
| NCT01466348 | Effects of a Common Cold Treatment on Cognitive Function | Phase4 | Common Cold | Completed | 2011-02-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01366521 | Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in As… | Phase2 | Asthma | Completed | 2011-02-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT02247583 | Investigating Patient Satisfaction With Oral Anti-Cancer Treatment | — | Clear Cell Renal Cell Carcinoma | Completed | 2011-02-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01445262 | Drug Use Investigation for XYZAL® | — | Rhinitis, Allergic, Perennial and Seasonal | Completed | 2011-02-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01583530 | Study of Belimumab Administered Subcutaneously to Healthy Subjects | Phase1 | Healthy | Completed | 2011-02-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01342913 | A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoat… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-02-01 | 2011-10-19 | ClinicalTrials.gov |
| NCT01445262 | Drug Use Investigation for XYZAL® | — | Rhinitis, Allergic, Perennial and Seasonal | Completed | 2011-02-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01342913 | A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoat… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-02-01 | 2011-10-19 | ClinicalTrials.gov |
| NCT01283789 | Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer | Phase2 | Metastatic Breast Cancer | Unknown | 2011-02-01 | 2017-04-01 | ClinicalTrials.gov |
| NCT01321723 | Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Table… | Phase2 | Postmenopausal Osteoporosis | Completed | 2011-02-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT02247583 | Investigating Patient Satisfaction With Oral Anti-Cancer Treatment | — | Clear Cell Renal Cell Carcinoma | Completed | 2011-02-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01366521 | Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in As… | Phase2 | Asthma | Completed | 2011-02-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01583530 | Study of Belimumab Administered Subcutaneously to Healthy Subjects | Phase1 | Healthy | Completed | 2011-02-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01263015 | A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripl… | Phase3 | Infection, Human Immunodeficiency Virus I | Completed | 2011-02-01 | 2015-12-03 | ClinicalTrials.gov |
| NCT01213472 | Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and… | Phase1 | Melanoma | Completed | 2011-01-31 | 2018-04-17 | ClinicalTrials.gov |
| NCT01213472 | Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and… | Phase1 | Melanoma | Completed | 2011-01-31 | 2018-04-17 | ClinicalTrials.gov |
| NCT01767571 | Bioequivalence Study of Cephalexin Suspension 250 | Phase1 | Infections, Respiratory Tract | Completed | 2011-01-30 | 2011-02-08 | ClinicalTrials.gov |
| NCT01767571 | Bioequivalence Study of Cephalexin Suspension 250 | Phase1 | Infections, Respiratory Tract | Completed | 2011-01-30 | 2011-02-08 | ClinicalTrials.gov |
| NCT01767532 | Bioequivalence Study of Cephalexin Suspension 125 | Phase1 | Infections, Respiratory Tract | Completed | 2011-01-30 | 2011-02-08 | ClinicalTrials.gov |
| NCT01767532 | Bioequivalence Study of Cephalexin Suspension 125 | Phase1 | Infections, Respiratory Tract | Completed | 2011-01-30 | 2011-02-08 | ClinicalTrials.gov |
| NCT01262963 | An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Or… | Phase1 | Cancer | Completed | 2011-01-26 | 2011-04-08 | ClinicalTrials.gov |
| NCT01262963 | An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Or… | Phase1 | Cancer | Completed | 2011-01-26 | 2011-04-08 | ClinicalTrials.gov |
| NCT01313676 | Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in S… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-01-25 | 2015-07-15 | ClinicalTrials.gov |
| NCT01313676 | Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in S… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-01-25 | 2015-07-15 | ClinicalTrials.gov |
| NCT01324258 | Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects… | Phase1 | Solid Tumours | Completed | 2011-01-24 | 2013-07-08 | ClinicalTrials.gov |
| NCT01324258 | Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects… | Phase1 | Solid Tumours | Completed | 2011-01-24 | 2013-07-08 | ClinicalTrials.gov |
| NCT01262976 | Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Human Im… | Phase2 | Tuberculosis | Completed | 2011-01-17 | 2015-06-04 | ClinicalTrials.gov |
| NCT01262976 | Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Human Im… | Phase2 | Tuberculosis | Completed | 2011-01-17 | 2015-06-04 | ClinicalTrials.gov |
| NCT01231620 | A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolesce… | Phase3 | Influenza, Human | Completed | 2011-01-15 | 2015-03-18 | ClinicalTrials.gov |
| NCT01231620 | A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolesce… | Phase3 | Influenza, Human | Completed | 2011-01-15 | 2015-03-18 | ClinicalTrials.gov |
| NCT01738893 | Bioequivalence Study of 300 mg Gabapentin | Phase1 | Epilepsy | Completed | 2011-01-14 | 2011-01-22 | ClinicalTrials.gov |
| NCT01332552 | A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetic… | Phase1 | Hepatitis C | Terminated | 2011-01-14 | 2011-04-06 | ClinicalTrials.gov |
| NCT01738893 | Bioequivalence Study of 300 mg Gabapentin | Phase1 | Epilepsy | Completed | 2011-01-14 | 2011-01-22 | ClinicalTrials.gov |
| NCT01332552 | A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetic… | Phase1 | Hepatitis C | Terminated | 2011-01-14 | 2011-04-06 | ClinicalTrials.gov |
| NCT01428479 | Phase1 Study of GR121167, Single and Multiple Dose Study in Healthy Japanese Ma… | Phase1 | Influenza, Human | Completed | 2011-01-07 | 2011-04-04 | ClinicalTrials.gov |
| NCT01428479 | Phase1 Study of GR121167, Single and Multiple Dose Study in Healthy Japanese Ma… | Phase1 | Influenza, Human | Completed | 2011-01-07 | 2011-04-04 | ClinicalTrials.gov |
| NCT01323985 | SAP Depleter Dose Escalation Study in Healthy Volunteers | Phase1 | Amyloidosis | Completed | 2011-01-06 | 2011-06-30 | ClinicalTrials.gov |
| NCT01323985 | SAP Depleter Dose Escalation Study in Healthy Volunteers | Phase1 | Amyloidosis | Completed | 2011-01-06 | 2011-06-30 | ClinicalTrials.gov |
| NCT01411111 | A Repeat Dose Study to Investigate the Interaction of GSK2190915 on the Pharmac… | Phase1 | Asthma | Completed | 2011-01-06 | 2011-02-23 | ClinicalTrials.gov |
| NCT01411111 | A Repeat Dose Study to Investigate the Interaction of GSK2190915 on the Pharmac… | Phase1 | Asthma | Completed | 2011-01-06 | 2011-02-23 | ClinicalTrials.gov |
| NCT01332331 | Efficacy and Safety of Ambrisentan in Children 8-18yrs | Phase2 | Hypertension, Pulmonary | Terminated | 2011-01-04 | 2013-11-12 | ClinicalTrials.gov |
| NCT01332331 | Efficacy and Safety of Ambrisentan in Children 8-18yrs | Phase2 | Hypertension, Pulmonary | Terminated | 2011-01-04 | 2013-11-12 | ClinicalTrials.gov |
| NCT01266993 | Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134… | Phase3 | Infections, Meningococcal | Completed | 2011-01-03 | 2014-05-17 | ClinicalTrials.gov |
| NCT01266993 | Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134… | Phase3 | Infections, Meningococcal | Completed | 2011-01-03 | 2014-05-17 | ClinicalTrials.gov |
| NCT01578941 | An Investigation of the Safety and Utility of Treximet in the Treatment of Mens… | Phase4 | Menstrual Migraine | Completed | 2011-01-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01277679 | Evaluation of MRI Measures of Lung Water With Posture Changes in Healthy Volunt… | Phase1 | Heart Failure, Congestive | Completed | 2011-01-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01273103 | A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK… | Phase1 | Infection, Human Immunodeficiency Virus | Withdrawn | 2011-01-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01184326 | Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previous… | Phase1 | Solid Tumor | Completed | 2011-01-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT01970189 | The International ITP Registry | — | Thrombocytopenia | Unknown | 2011-01-01 | 2020-12-01 | ClinicalTrials.gov |
| NCT01107613 | The Lung Attack Alert Study | Na | Chronic Obstructive Pulmonary Disease | Completed | 2011-01-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01045564 | Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influen… | Phase2 | Influenza | Withdrawn | 2011-01-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01184326 | Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previous… | Phase1 | Solid Tumor | Completed | 2011-01-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT01316887 | A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Contr… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-01-01 | 2012-07-21 | ClinicalTrials.gov |
| NCT01273103 | A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK… | Phase1 | Infection, Human Immunodeficiency Virus | Withdrawn | 2011-01-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01316887 | A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Contr… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2011-01-01 | 2012-07-21 | ClinicalTrials.gov |
| NCT01970189 | The International ITP Registry | — | Thrombocytopenia | Unknown | 2011-01-01 | 2020-12-01 | ClinicalTrials.gov |
| NCT01277679 | Evaluation of MRI Measures of Lung Water With Posture Changes in Healthy Volunt… | Phase1 | Heart Failure, Congestive | Completed | 2011-01-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01045564 | Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influen… | Phase2 | Influenza | Withdrawn | 2011-01-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01578941 | An Investigation of the Safety and Utility of Treximet in the Treatment of Mens… | Phase4 | Menstrual Migraine | Completed | 2011-01-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01107613 | The Lung Attack Alert Study | Na | Chronic Obstructive Pulmonary Disease | Completed | 2011-01-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01227889 | A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subj… | Phase3 | Cancer | Completed | 2010-12-23 | 2016-09-16 | ClinicalTrials.gov |
| NCT01227889 | A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subj… | Phase3 | Cancer | Completed | 2010-12-23 | 2016-09-16 | ClinicalTrials.gov |
| NCT01466322 | A Study to Assess the Relative Bioavailability of Different Formulations of GSK… | Phase1 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2010-12-22 | 2011-02-15 | ClinicalTrials.gov |
| NCT01294592 | Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus… | Phase4 | Prostatic Hyperplasia | Completed | 2010-12-22 | 2013-10-17 | ClinicalTrials.gov |
| NCT01466322 | A Study to Assess the Relative Bioavailability of Different Formulations of GSK… | Phase1 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2010-12-22 | 2011-02-15 | ClinicalTrials.gov |
| NCT01294592 | Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus… | Phase4 | Prostatic Hyperplasia | Completed | 2010-12-22 | 2013-10-17 | ClinicalTrials.gov |
| NCT01277666 | A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment … | Phase3 | Crohn's Disease | Completed | 2010-12-20 | 2013-07-11 | ClinicalTrials.gov |
| NCT01277666 | A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment … | Phase3 | Crohn's Disease | Completed | 2010-12-20 | 2013-07-11 | ClinicalTrials.gov |
| NCT01258530 | A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsule… | Phase1 | Influenza, Human | Completed | 2010-12-20 | 2011-02-03 | ClinicalTrials.gov |
| NCT01258530 | A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsule… | Phase1 | Influenza, Human | Completed | 2010-12-20 | 2011-02-03 | ClinicalTrials.gov |
| NCT01406327 | Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hyperten… | — | Hypertension, Pulmonary | Completed | 2010-12-14 | 2020-02-28 | ClinicalTrials.gov |
| NCT01406327 | Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hyperten… | — | Hypertension, Pulmonary | Completed | 2010-12-14 | 2020-02-28 | ClinicalTrials.gov |
| NCT01218308 | A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Child… | Phase3 | Influenza | Completed | 2010-12-09 | 2012-01-09 | ClinicalTrials.gov |
| NCT01248884 | Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' D… | Phase2 | Tetanus | Completed | 2010-12-09 | 2012-01-05 | ClinicalTrials.gov |
| NCT01218308 | A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Child… | Phase3 | Influenza | Completed | 2010-12-09 | 2012-01-09 | ClinicalTrials.gov |
| NCT01251744 | Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to Foe… | Na | Infections, Cytomegalovirus | Completed | 2010-12-09 | 2015-06-17 | ClinicalTrials.gov |
| NCT01251744 | Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to Foe… | Na | Infections, Cytomegalovirus | Completed | 2010-12-09 | 2015-06-17 | ClinicalTrials.gov |
| NCT01248884 | Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' D… | Phase2 | Tetanus | Completed | 2010-12-09 | 2012-01-05 | ClinicalTrials.gov |
| NCT01745562 | Bioequivalence Trial of Alprazolam 0.5 mg Tablets | Phase1 | Anxiety Disorders | Completed | 2010-12-07 | 2010-12-17 | ClinicalTrials.gov |
| NCT01745562 | Bioequivalence Trial of Alprazolam 0.5 mg Tablets | Phase1 | Anxiety Disorders | Completed | 2010-12-07 | 2010-12-17 | ClinicalTrials.gov |
| NCT01094171 | Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix … | Phase4 | Poliomyelitis | Completed | 2010-12-03 | 2012-10-27 | ClinicalTrials.gov |
| NCT01094171 | Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix … | Phase4 | Poliomyelitis | Completed | 2010-12-03 | 2012-10-27 | ClinicalTrials.gov |
| NCT01248858 | Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinic… | Phase1 | Cancer | Terminated | 2010-12-03 | 2015-04-23 | ClinicalTrials.gov |
| NCT01248858 | Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinic… | Phase1 | Cancer | Terminated | 2010-12-03 | 2015-04-23 | ClinicalTrials.gov |
| NCT01853956 | Bioequivalence Trial of Alprazolam 0.25 mg Tablets | Phase1 | Anxiety Disorders | Completed | 2010-12-02 | 2010-12-10 | ClinicalTrials.gov |
| NCT01853956 | Bioequivalence Trial of Alprazolam 0.25 mg Tablets | Phase1 | Anxiety Disorders | Completed | 2010-12-02 | 2010-12-10 | ClinicalTrials.gov |
| NCT01446224 | Cardiovascular and Torsades de Pointes Monitoring for Pazopanib | — | Carcinoma, Renal Cell | Completed | 2010-12-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01446224 | Cardiovascular and Torsades de Pointes Monitoring for Pazopanib | — | Carcinoma, Renal Cell | Completed | 2010-12-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01449825 | Hepatic Monitoring for Pazopanib | — | Carcinoma, Renal Cell | Completed | 2010-12-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01245426 | A Study in Asthmatics to Determine the Efficacy and Dose Response of Repeat Dos… | Phase2 | Asthma | Completed | 2010-12-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01239394 | Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma | Phase2 | Follicular Lymphoma | Completed | 2010-12-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT02714335 | The Correlation Between MAGE-A3, PRAME Polymorphism and Expression Levels of MA… | — | Carcinoma, Non-Small-Cell Lung | Completed | 2010-12-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01462552 | Physician Liver Function Test (LFT) Monitoring for Tykerb Pts | — | Cancer | Completed | 2010-12-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01244009 | A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002) | Phase2 | Lymphoma | Withdrawn | 2010-12-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT03243110 | The Economic Burden of Asthma in Canada | — | Asthma | Completed | 2010-12-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT01263340 | Characterisation of People With COPD | — | Chronic Obstructive Pulmonary Disease | Completed | 2010-12-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01248975 | Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/… | Phase2 | Asthma | Completed | 2010-12-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01248988 | Post Marketing Surveillance of Synflorix Vaccine Safety Among Infants in Korea | — | Infections, Streptococcal | Completed | 2010-12-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01299610 | A Study to Test the Effect of 2 Different Doses of Topical GW870086X on Atopic … | Phase2 | Dermatitis, Atopic | Completed | 2010-12-01 | 2011-04-14 | ClinicalTrials.gov |
| NCT01420822 | Special Drug Use Investigation for ALLERMIST (Long Term) | — | Rhinitis | Completed | 2010-12-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01205217 | Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients W… | Phase2 | Neoplasms, Breast | Withdrawn | 2010-12-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01248975 | Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/… | Phase2 | Asthma | Completed | 2010-12-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01424514 | SB705498 Proof of Concept Chamber Challenge in Subjects With Non Allergic Rhini… | Phase2 | Rhinitis | Completed | 2010-12-01 | 2011-04-18 | ClinicalTrials.gov |
| NCT02714335 | The Correlation Between MAGE-A3, PRAME Polymorphism and Expression Levels of MA… | — | Carcinoma, Non-Small-Cell Lung | Completed | 2010-12-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01462552 | Physician Liver Function Test (LFT) Monitoring for Tykerb Pts | — | Cancer | Completed | 2010-12-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01273077 | Evaluation of Universal Rotavirus Vaccination Program | — | Gastrointestinal Diseases | Completed | 2010-12-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01300546 | Treximet Trademark (TM) in the Prevention and Modification of Disease Progressi… | Phase4 | Migraine | Completed | 2010-12-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01424527 | Korean Chronic Obstructive Pulmonary Disease(COPD) Assessment Test Validation S… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2010-12-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01299610 | A Study to Test the Effect of 2 Different Doses of Topical GW870086X on Atopic … | Phase2 | Dermatitis, Atopic | Completed | 2010-12-01 | 2011-04-14 | ClinicalTrials.gov |
| NCT01248988 | Post Marketing Surveillance of Synflorix Vaccine Safety Among Infants in Korea | — | Infections, Streptococcal | Completed | 2010-12-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01239394 | Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma | Phase2 | Follicular Lymphoma | Completed | 2010-12-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01449825 | Hepatic Monitoring for Pazopanib | — | Carcinoma, Renal Cell | Completed | 2010-12-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01244009 | A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002) | Phase2 | Lymphoma | Withdrawn | 2010-12-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT03243110 | The Economic Burden of Asthma in Canada | — | Asthma | Completed | 2010-12-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT01420822 | Special Drug Use Investigation for ALLERMIST (Long Term) | — | Rhinitis | Completed | 2010-12-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01300546 | Treximet Trademark (TM) in the Prevention and Modification of Disease Progressi… | Phase4 | Migraine | Completed | 2010-12-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01262820 | Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Th… | Phase2 | Lung Cancer | Completed | 2010-12-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01424527 | Korean Chronic Obstructive Pulmonary Disease(COPD) Assessment Test Validation S… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2010-12-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01424514 | SB705498 Proof of Concept Chamber Challenge in Subjects With Non Allergic Rhini… | Phase2 | Rhinitis | Completed | 2010-12-01 | 2011-04-18 | ClinicalTrials.gov |
| NCT01205217 | Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients W… | Phase2 | Neoplasms, Breast | Withdrawn | 2010-12-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01245426 | A Study in Asthmatics to Determine the Efficacy and Dose Response of Repeat Dos… | Phase2 | Asthma | Completed | 2010-12-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01262820 | Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Th… | Phase2 | Lung Cancer | Completed | 2010-12-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01488565 | A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Ac… | Phase2 | Myelodysplastic Syndromes (MDS) | Completed | 2010-12-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT01263340 | Characterisation of People With COPD | — | Chronic Obstructive Pulmonary Disease | Completed | 2010-12-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01488565 | A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Ac… | Phase2 | Myelodysplastic Syndromes (MDS) | Completed | 2010-12-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT01273077 | Evaluation of Universal Rotavirus Vaccination Program | — | Gastrointestinal Diseases | Completed | 2010-12-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01235975 | Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given… | Phase3 | Infections, Meningococcal | Completed | 2010-11-30 | 2011-08-03 | ClinicalTrials.gov |
| NCT01235975 | Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given… | Phase3 | Infections, Meningococcal | Completed | 2010-11-30 | 2011-08-03 | ClinicalTrials.gov |
| NCT01294566 | FTIH to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Dose… | Phase1 | Gastroparesis | Completed | 2010-11-29 | 2011-03-23 | ClinicalTrials.gov |
| NCT01294566 | FTIH to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Dose… | Phase1 | Gastroparesis | Completed | 2010-11-29 | 2011-03-23 | ClinicalTrials.gov |
| NCT01015625 | Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer | Na | Synchronous Metastasized Breast Cancer | Completed | 2010-11-24 | 2022-07-01 | ClinicalTrials.gov |
| NCT01015625 | Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer | Na | Synchronous Metastasized Breast Cancer | Completed | 2010-11-24 | 2022-07-01 | ClinicalTrials.gov |
| NCT01245062 | GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-posi… | Phase3 | Melanoma | Completed | 2010-11-22 | 2016-12-16 | ClinicalTrials.gov |
| NCT01222078 | Investigating Re-Dosing With Otelixizumab in Adults With Newly-Diagnosed Type 1… | Phase2 | Diabetes Mellitus, Type 1 | Terminated | 2010-11-22 | 2011-05-19 | ClinicalTrials.gov |
| NCT01245062 | GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-posi… | Phase3 | Melanoma | Completed | 2010-11-22 | 2016-12-16 | ClinicalTrials.gov |
| NCT01222078 | Investigating Re-Dosing With Otelixizumab in Adults With Newly-Diagnosed Type 1… | Phase2 | Diabetes Mellitus, Type 1 | Terminated | 2010-11-22 | 2011-05-19 | ClinicalTrials.gov |
| NCT01231529 | GSK1349572 Hepatic Impairment Study | Phase1 | Healthy Subjects | Completed | 2010-11-19 | 2011-06-04 | ClinicalTrials.gov |
| NCT01231529 | GSK1349572 Hepatic Impairment Study | Phase1 | Healthy Subjects | Completed | 2010-11-19 | 2011-06-04 | ClinicalTrials.gov |
| NCT01266980 | A Study to Assess the Effects of Repeat Doses of Fluticasone Furoate and GW6424… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2010-11-18 | 2011-03-22 | ClinicalTrials.gov |
| NCT01266980 | A Study to Assess the Effects of Repeat Doses of Fluticasone Furoate and GW6424… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2010-11-18 | 2011-03-22 | ClinicalTrials.gov |
| NCT01323673 | Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in … | Phase4 | Dermatitis, Chronic | Completed | 2010-11-15 | 2011-03-29 | ClinicalTrials.gov |
| NCT01323673 | Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in … | Phase4 | Dermatitis, Chronic | Completed | 2010-11-15 | 2011-03-29 | ClinicalTrials.gov |
| NCT01235949 | Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and… | Phase4 | Infections, Streptococcal | Completed | 2010-11-12 | 2012-12-08 | ClinicalTrials.gov |
| NCT01235949 | Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and… | Phase4 | Infections, Streptococcal | Completed | 2010-11-12 | 2012-12-08 | ClinicalTrials.gov |
| NCT01198769 | Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received… | Phase4 | Infections, Rotavirus | Completed | 2010-11-11 | 2011-04-18 | ClinicalTrials.gov |
| NCT01198769 | Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received… | Phase4 | Infections, Rotavirus | Completed | 2010-11-11 | 2011-04-18 | ClinicalTrials.gov |
| NCT01376232 | Study to Assess the Pharmacokinetics of GSK1278863A Coadministered With a High … | Phase1 | Anaemia | Completed | 2010-11-08 | 2010-12-20 | ClinicalTrials.gov |
| NCT01218113 | Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (A… | Phase2 | AIDS | Completed | 2010-11-08 | 2012-11-05 | ClinicalTrials.gov |
| NCT01376232 | Study to Assess the Pharmacokinetics of GSK1278863A Coadministered With a High … | Phase1 | Anaemia | Completed | 2010-11-08 | 2010-12-20 | ClinicalTrials.gov |
| NCT01218113 | Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (A… | Phase2 | AIDS | Completed | 2010-11-08 | 2012-11-05 | ClinicalTrials.gov |
| NCT03549130 | A Pivotal Study to Assess the Effectiveness of Nasal Dilator (Breathe Right Nas… | Phase2 | Congestion, Nasal | Completed | 2010-11-04 | 2011-02-17 | ClinicalTrials.gov |
| NCT03549130 | A Pivotal Study to Assess the Effectiveness of Nasal Dilator (Breathe Right Nas… | Phase2 | Congestion, Nasal | Completed | 2010-11-04 | 2011-02-17 | ClinicalTrials.gov |
| NCT01277692 | A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Sing… | Phase1 | Hepatitis C | Completed | 2010-11-03 | 2011-05-09 | ClinicalTrials.gov |
| NCT01277692 | A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Sing… | Phase1 | Hepatitis C | Completed | 2010-11-03 | 2011-05-09 | ClinicalTrials.gov |
| NCT01286844 | GSK2190915 Pediatric Study | Phase2 | Asthma | Withdrawn | 2010-11-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01227941 | MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants Wit… | Phase1 | Ovarian Cancer | Terminated | 2010-11-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT00958633 | Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar … | Phase3 | Bipolar I Disorder | Terminated | 2010-11-01 | 2020-05-20 | ClinicalTrials.gov |
| NCT01246011 | Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft P… | Phase4 | Coronary Artery Bypass Graft Surgery | Terminated | 2010-11-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01286844 | GSK2190915 Pediatric Study | Phase2 | Asthma | Withdrawn | 2010-11-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01252290 | Breast Cancer Risk Biomarkers in Postmenopausal Women | Phase2 | Breast Cancer | Completed | 2010-11-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01439321 | Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients S… | — | Immune Thrombocytopenic Purpura | Completed | 2010-11-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01252290 | Breast Cancer Risk Biomarkers in Postmenopausal Women | Phase2 | Breast Cancer | Completed | 2010-11-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01216982 | Effects of Omega-3 EPA/DHA for Soldiers at Risk for Mood Disorders | Phase2 | Mood Disorders | Unknown | 2010-11-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01246011 | Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft P… | Phase4 | Coronary Artery Bypass Graft Surgery | Terminated | 2010-11-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01216982 | Effects of Omega-3 EPA/DHA for Soldiers at Risk for Mood Disorders | Phase2 | Mood Disorders | Unknown | 2010-11-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01439321 | Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients S… | — | Immune Thrombocytopenic Purpura | Completed | 2010-11-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01227941 | MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants Wit… | Phase1 | Ovarian Cancer | Terminated | 2010-11-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01328106 | Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uvea… | Phase2 | GNA11 Mutation-positive Metastatic Melanoma | Withdrawn | 2010-11-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01328106 | Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uvea… | Phase2 | GNA11 Mutation-positive Metastatic Melanoma | Withdrawn | 2010-11-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT00958633 | Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar … | Phase3 | Bipolar I Disorder | Terminated | 2010-11-01 | 2020-05-20 | ClinicalTrials.gov |
| NCT01231607 | Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia | Phase3 | Androgenetic Alopecia | Completed | 2010-10-28 | 2012-02-28 | ClinicalTrials.gov |
| NCT01231607 | Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia | Phase3 | Androgenetic Alopecia | Completed | 2010-10-28 | 2012-02-28 | ClinicalTrials.gov |
| NCT01138384 | Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Br… | Phase1 | Breast Cancer | Completed | 2010-10-27 | 2015-02-13 | ClinicalTrials.gov |
| NCT01138384 | Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Br… | Phase1 | Breast Cancer | Completed | 2010-10-27 | 2015-02-13 | ClinicalTrials.gov |
| NCT01231516 | A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Backg… | Phase3 | Infection, Human Immunodeficiency Virus | Completed | 2010-10-26 | 2021-02-02 | ClinicalTrials.gov |
| NCT01031069 | Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine… | Phase4 | Infections, Papillomavirus | Completed | 2010-10-26 | 2017-04-19 | ClinicalTrials.gov |
| NCT01031069 | Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine… | Phase4 | Infections, Papillomavirus | Completed | 2010-10-26 | 2017-04-19 | ClinicalTrials.gov |
| NCT01231516 | A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Backg… | Phase3 | Infection, Human Immunodeficiency Virus | Completed | 2010-10-26 | 2021-02-02 | ClinicalTrials.gov |
| NCT03549117 | A Pivotal Subjective Sleep Study of a Nasal Dilator (Breathe Right Tan) | Phase2 | Congestion, Nasal | Completed | 2010-10-25 | 2011-01-14 | ClinicalTrials.gov |
| NCT01494610 | Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate… | Phase1 | Asthma | Completed | 2010-10-25 | 2011-06-08 | ClinicalTrials.gov |
| NCT03549117 | A Pivotal Subjective Sleep Study of a Nasal Dilator (Breathe Right Tan) | Phase2 | Congestion, Nasal | Completed | 2010-10-25 | 2011-01-14 | ClinicalTrials.gov |
| NCT01494610 | Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate… | Phase1 | Asthma | Completed | 2010-10-25 | 2011-06-08 | ClinicalTrials.gov |
| NCT01449838 | Phase I Study of Colistin Methanesulfonate Sodium | Phase1 | Infections, Pseudomonas | Completed | 2010-10-23 | 2010-12-09 | ClinicalTrials.gov |
| NCT01449838 | Phase I Study of Colistin Methanesulfonate Sodium | Phase1 | Infections, Pseudomonas | Completed | 2010-10-23 | 2010-12-09 | ClinicalTrials.gov |
| NCT01231568 | An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size… | Phase1 | Cancer | Completed | 2010-10-21 | 2011-05-13 | ClinicalTrials.gov |
| NCT01231568 | An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size… | Phase1 | Cancer | Completed | 2010-10-21 | 2011-05-13 | ClinicalTrials.gov |
| NCT01227824 | A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily | Phase3 | Infection, Human Immunodeficiency Virus I | Completed | 2010-10-19 | 2016-12-27 | ClinicalTrials.gov |
| NCT01227824 | A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily | Phase3 | Infection, Human Immunodeficiency Virus I | Completed | 2010-10-19 | 2016-12-27 | ClinicalTrials.gov |
| NCT01266941 | A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination … | Phase1 | Asthma | Completed | 2010-10-18 | 2011-07-15 | ClinicalTrials.gov |
| NCT01266941 | A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination … | Phase1 | Asthma | Completed | 2010-10-18 | 2011-07-15 | ClinicalTrials.gov |
| NCT01200589 | Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgk… | Phase3 | Non-Hodgkin's Lymphoma | Terminated | 2010-10-11 | 2016-12-19 | ClinicalTrials.gov |
| NCT01200589 | Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgk… | Phase3 | Non-Hodgkin's Lymphoma | Terminated | 2010-10-11 | 2016-12-19 | ClinicalTrials.gov |
| NCT01431937 | Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers | Phase1 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2010-10-10 | 2011-03-29 | ClinicalTrials.gov |
| NCT01431937 | Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers | Phase1 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2010-10-10 | 2011-03-29 | ClinicalTrials.gov |
| NCT01262885 | A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolera… | Phase1 | Infections, Bacterial | Completed | 2010-10-07 | 2011-08-25 | ClinicalTrials.gov |
| NCT01262885 | A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolera… | Phase1 | Infections, Bacterial | Completed | 2010-10-07 | 2011-08-25 | ClinicalTrials.gov |
| NCT01199731 | Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects… | Phase2 | Infection, Human Immunodeficiency Virus | Terminated | 2010-10-05 | 2011-07-19 | ClinicalTrials.gov |
| NCT01199731 | Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects… | Phase2 | Infection, Human Immunodeficiency Virus | Terminated | 2010-10-05 | 2011-07-19 | ClinicalTrials.gov |
| NCT01190215 | Immunogenicity and Safety Study of FluarixTM Vaccine in Children Who Have Previ… | Phase4 | Influenza | Completed | 2010-10-04 | 2011-07-07 | ClinicalTrials.gov |
| NCT01190215 | Immunogenicity and Safety Study of FluarixTM Vaccine in Children Who Have Previ… | Phase4 | Influenza | Completed | 2010-10-04 | 2011-07-07 | ClinicalTrials.gov |
| NCT01153893 | Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK102… | Phase3 | Infections, Streptococcal | Completed | 2010-10-04 | 2011-02-16 | ClinicalTrials.gov |
| NCT01196988 | Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Admi… | Phase3 | Influenza | Completed | 2010-10-04 | 2011-06-15 | ClinicalTrials.gov |
| NCT01204671 | Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidat… | Phase3 | Influenza | Completed | 2010-10-04 | 2011-06-06 | ClinicalTrials.gov |
| NCT01213849 | Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilant… | Phase1 | Asthma | Completed | 2010-10-04 | 2010-11-25 | ClinicalTrials.gov |
| NCT01153893 | Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK102… | Phase3 | Infections, Streptococcal | Completed | 2010-10-04 | 2011-02-16 | ClinicalTrials.gov |
| NCT01196988 | Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Admi… | Phase3 | Influenza | Completed | 2010-10-04 | 2011-06-15 | ClinicalTrials.gov |
| NCT01204671 | Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidat… | Phase3 | Influenza | Completed | 2010-10-04 | 2011-06-06 | ClinicalTrials.gov |
| NCT01213849 | Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilant… | Phase1 | Asthma | Completed | 2010-10-04 | 2010-11-25 | ClinicalTrials.gov |
| NCT01214993 | A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK13… | Phase1 | Infections, Human Immunodeficiency Virus and Tuberculosis | Completed | 2010-10-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01431911 | Outcomes Associated With Early or Delayed Maintenance Treatment Post-Chronic Ob… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2010-10-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT01214993 | A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK13… | Phase1 | Infections, Human Immunodeficiency Virus and Tuberculosis | Completed | 2010-10-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01431924 | Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate o… | — | Asthma | Completed | 2010-10-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01376258 | Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enla… | — | Prostatic Hyperplasia | Completed | 2010-10-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01205412 | An Observational Study on the Prevalence of Human Papillomavirus Types in Women… | — | Human Papillomavirus Infection | Completed | 2010-10-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01357876 | Effect of Metformin on Gut Peptides , Bile Acids and Lipid Profiles in Type 2 D… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2010-10-01 | 2011-07-07 | ClinicalTrials.gov |
| NCT01642173 | Assessment of Coronary Plaque Composition Using Optical Coherence Tomography | Phase1 | Coronary Atherosclerosis | Completed | 2010-10-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01357876 | Effect of Metformin on Gut Peptides , Bile Acids and Lipid Profiles in Type 2 D… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2010-10-01 | 2011-07-07 | ClinicalTrials.gov |
| NCT01196975 | A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal … | Phase3 | Influenza | Completed | 2010-10-01 | 2011-06-24 | ClinicalTrials.gov |
| NCT01202812 | A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD) | Phase2 | Sickle Cell Disease | Unknown | 2010-10-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01337336 | Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Pat… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2010-10-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT01337336 | Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Pat… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2010-10-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT01550679 | Early Detection of COPD Patients in GOLD 0 (Smokers) Population | — | COPD | Completed | 2010-10-01 | 2020-04-01 | ClinicalTrials.gov |
| NCT01198756 | A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal … | Phase3 | Influenza | Completed | 2010-10-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01642173 | Assessment of Coronary Plaque Composition Using Optical Coherence Tomography | Phase1 | Coronary Atherosclerosis | Completed | 2010-10-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01037023 | Regulatory Hycamtin(Oral) PMS | — | Lung Cancer, Small Cell | Completed | 2010-10-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01550679 | Early Detection of COPD Patients in GOLD 0 (Smokers) Population | — | COPD | Completed | 2010-10-01 | 2020-04-01 | ClinicalTrials.gov |
| NCT02284074 | Nasal LPS Challenge in Healthy Volunteers | Na | Healthy | Completed | 2010-10-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01196975 | A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal … | Phase3 | Influenza | Completed | 2010-10-01 | 2011-06-24 | ClinicalTrials.gov |
| NCT01178073 | A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects… | Phase3 | Hypertension, Pulmonary | Completed | 2010-10-01 | 2014-07-31 | ClinicalTrials.gov |
| NCT01287065 | A Study in Asthmatic Patients to Determine if There is Any Difference in Dosing… | Phase2 | Asthma | Completed | 2010-10-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01178073 | A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects… | Phase3 | Hypertension, Pulmonary | Completed | 2010-10-01 | 2014-07-31 | ClinicalTrials.gov |
| NCT01198756 | A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal … | Phase3 | Influenza | Completed | 2010-10-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01037023 | Regulatory Hycamtin(Oral) PMS | — | Lung Cancer, Small Cell | Completed | 2010-10-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01287065 | A Study in Asthmatic Patients to Determine if There is Any Difference in Dosing… | Phase2 | Asthma | Completed | 2010-10-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01376258 | Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enla… | — | Prostatic Hyperplasia | Completed | 2010-10-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01286285 | Surveillance of Influenza in Paediatric Intensive Care Units in Bavaria | — | Influenza | Unknown | 2010-10-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01286285 | Surveillance of Influenza in Paediatric Intensive Care Units in Bavaria | — | Influenza | Unknown | 2010-10-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01202812 | A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD) | Phase2 | Sickle Cell Disease | Unknown | 2010-10-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01238029 | Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine i… | Phase1 | Metastatic Breast Cancer | Terminated | 2010-10-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT02284074 | Nasal LPS Challenge in Healthy Volunteers | Na | Healthy | Completed | 2010-10-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01205412 | An Observational Study on the Prevalence of Human Papillomavirus Types in Women… | — | Human Papillomavirus Infection | Completed | 2010-10-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01158209 | An Observational, Epidemiological Study on the Prevalence of Human Papillomavir… | — | Human Papillomavirus Infection | Completed | 2010-10-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01153906 | Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccinat… | — | Infections, Papillomavirus | Completed | 2010-10-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01153906 | Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccinat… | — | Infections, Papillomavirus | Completed | 2010-10-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01158209 | An Observational, Epidemiological Study on the Prevalence of Human Papillomavir… | — | Human Papillomavirus Infection | Completed | 2010-10-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01431911 | Outcomes Associated With Early or Delayed Maintenance Treatment Post-Chronic Ob… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2010-10-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT01431924 | Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate o… | — | Asthma | Completed | 2010-10-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01238029 | Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine i… | Phase1 | Metastatic Breast Cancer | Terminated | 2010-10-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01204658 | Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With D… | Phase2 | Infections, Streptococcal | Completed | 2010-09-27 | 2012-10-01 | ClinicalTrials.gov |
| NCT01204658 | Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With D… | Phase2 | Infections, Streptococcal | Completed | 2010-09-27 | 2012-10-01 | ClinicalTrials.gov |
| NCT01407562 | Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid… | Phase1 | Unspecified Adult Solid Tumor - Protocol Specific | Terminated | 2010-09-17 | 2016-03-29 | ClinicalTrials.gov |
| NCT01407562 | Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid… | Phase1 | Unspecified Adult Solid Tumor - Protocol Specific | Terminated | 2010-09-17 | 2016-03-29 | ClinicalTrials.gov |
| NCT01357850 | A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 an… | Phase2 | Heart Failure, Congestive | Completed | 2010-09-15 | 2012-09-18 | ClinicalTrials.gov |
| NCT01196026 | Immunogenicity and Safety Study of Fluarix™ Vaccine in Children Who Have Previo… | Phase4 | Influenza | Completed | 2010-09-15 | 2011-05-26 | ClinicalTrials.gov |
| NCT01357850 | A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 an… | Phase2 | Heart Failure, Congestive | Completed | 2010-09-15 | 2012-09-18 | ClinicalTrials.gov |
| NCT01196026 | Immunogenicity and Safety Study of Fluarix™ Vaccine in Children Who Have Previo… | Phase4 | Influenza | Completed | 2010-09-15 | 2011-05-26 | ClinicalTrials.gov |
| NCT01195974 | A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-admin… | Phase1 | Infection, Human Immunodeficiency Virus | Terminated | 2010-09-14 | 2011-02-09 | ClinicalTrials.gov |
| NCT01192165 | Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination Wi… | Phase1 | Cancer | Completed | 2010-09-14 | 2013-10-07 | ClinicalTrials.gov |
| NCT01192165 | Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination Wi… | Phase1 | Cancer | Completed | 2010-09-14 | 2013-10-07 | ClinicalTrials.gov |
| NCT01218204 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacod… | Phase2 | Dyslipidaemias | Completed | 2010-09-14 | 2011-06-29 | ClinicalTrials.gov |
| NCT01195974 | A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-admin… | Phase1 | Infection, Human Immunodeficiency Virus | Terminated | 2010-09-14 | 2011-02-09 | ClinicalTrials.gov |
| NCT01218204 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacod… | Phase2 | Dyslipidaemias | Completed | 2010-09-14 | 2011-06-29 | ClinicalTrials.gov |
| NCT01254071 | A Study to Determine the Bioavailability of a Fixed Dose Combination Product of… | Phase1 | Prostatic Hyperplasia | Completed | 2010-09-10 | 2010-12-21 | ClinicalTrials.gov |
| NCT01254071 | A Study to Determine the Bioavailability of a Fixed Dose Combination Product of… | Phase1 | Prostatic Hyperplasia | Completed | 2010-09-10 | 2010-12-21 | ClinicalTrials.gov |
| NCT01160224 | Oral GW766944 (Oral CCR3 Antagonist) | Phase2 | Asthma | Completed | 2010-09-08 | 2011-08-29 | ClinicalTrials.gov |
| NCT01160224 | Oral GW766944 (Oral CCR3 Antagonist) | Phase2 | Asthma | Completed | 2010-09-08 | 2011-08-29 | ClinicalTrials.gov |
| NCT01536574 | Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528 | Phase3 | Parkinson Disease | Completed | 2010-09-02 | 2012-03-28 | ClinicalTrials.gov |
| NCT01536574 | Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528 | Phase3 | Parkinson Disease | Completed | 2010-09-02 | 2012-03-28 | ClinicalTrials.gov |
| NCT01227928 | Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in O… | Phase2 | Neoplasms, Ovarian | Completed | 2010-09-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01187927 | Drug Use Investigation for Cervarix® | — | Infections, Papillomavirus | Completed | 2010-09-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01153932 | Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With … | Phase2 | Muscular Dystrophies | Completed | 2010-09-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01721135 | A Study to Evaluate the Effect of Two Different Repeat Doses of GSK2190915 on t… | Phase1 | Asthma | Withdrawn | 2010-09-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01202201 | A Retrospective Survey of the Burden of Rotavirus Gastroenteritis (RV GE) and N… | — | Nosocomial Rotavirus Gastroenteritis | Completed | 2010-09-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01381458 | Risk of Re-Hospitalization in Patients With Chronic Obstructive Pulmonary Disea… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2010-09-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT01195792 | A 35 Day Study to Investigate the Effects of GSK1521498 on Bodyweight in Obese … | Phase2 | Obesity | Completed | 2010-09-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01205451 | A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1… | Phase3 | Spasticity, Post-Stroke | Completed | 2010-09-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01209065 | GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir | Phase1 | Infections, Human Immunodeficiency Virus and Herpesviridae | Completed | 2010-09-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01381458 | Risk of Re-Hospitalization in Patients With Chronic Obstructive Pulmonary Disea… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2010-09-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT01587339 | Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy | — | Epilepsy | Completed | 2010-09-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01195792 | A 35 Day Study to Investigate the Effects of GSK1521498 on Bodyweight in Obese … | Phase2 | Obesity | Completed | 2010-09-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01721135 | A Study to Evaluate the Effect of Two Different Repeat Doses of GSK2190915 on t… | Phase1 | Asthma | Withdrawn | 2010-09-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01187927 | Drug Use Investigation for Cervarix® | — | Infections, Papillomavirus | Completed | 2010-09-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01180621 | Evaluation of Seasonal Influenza Vaccine for 2010-2011 in Young Children | Phase2 | Seasonal Influenza | Completed | 2010-09-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01180621 | Evaluation of Seasonal Influenza Vaccine for 2010-2011 in Young Children | Phase2 | Seasonal Influenza | Completed | 2010-09-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01090050 | Treximet in the Treatment of Chronic Migraine | Phase4 | Chronic Migraine | Completed | 2010-09-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01466361 | Evaluation of the Nicotine Lozenge in Relief of Provoked Acute Craving | Phase2 | Smoking | Completed | 2010-09-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01209065 | GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir | Phase1 | Infections, Human Immunodeficiency Virus and Herpesviridae | Completed | 2010-09-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00864994 | Multiorgan Pathology in Chronic Obstructive Pulmonary Disease (COPD) | — | Chronic Obstructive Pulmonary Disease | Unknown | 2010-09-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT01090050 | Treximet in the Treatment of Chronic Migraine | Phase4 | Chronic Migraine | Completed | 2010-09-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01105936 | Assess the Blood-Oxygen-Level-Dependent (BOLD) Signal Changes in the Brain by P… | Phase4 | Osteoarthritis, Knee | Completed | 2010-09-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01105936 | Assess the Blood-Oxygen-Level-Dependent (BOLD) Signal Changes in the Brain by P… | Phase4 | Osteoarthritis, Knee | Completed | 2010-09-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01156792 | Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticostero… | Phase2 | Asthma | Completed | 2010-09-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01110694 | Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study | — | Idiopathic Pulmonary Fibrosis | Completed | 2010-09-01 | 2018-09-01 | ClinicalTrials.gov |
| NCT01153932 | Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With … | Phase2 | Muscular Dystrophies | Completed | 2010-09-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01110694 | Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study | — | Idiopathic Pulmonary Fibrosis | Completed | 2010-09-01 | 2018-09-01 | ClinicalTrials.gov |
| NCT01205230 | VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole o… | Phase4 | Cancer | Completed | 2010-09-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01587339 | Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy | — | Epilepsy | Completed | 2010-09-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01202201 | A Retrospective Survey of the Burden of Rotavirus Gastroenteritis (RV GE) and N… | — | Nosocomial Rotavirus Gastroenteritis | Completed | 2010-09-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01337323 | Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patt… | — | Rhinitis, Allergic, Seasonal | Terminated | 2010-09-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01156792 | Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticostero… | Phase2 | Asthma | Completed | 2010-09-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01337323 | Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patt… | — | Rhinitis, Allergic, Seasonal | Terminated | 2010-09-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01227928 | Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in O… | Phase2 | Neoplasms, Ovarian | Completed | 2010-09-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01205230 | VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole o… | Phase4 | Cancer | Completed | 2010-09-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT00864994 | Multiorgan Pathology in Chronic Obstructive Pulmonary Disease (COPD) | — | Chronic Obstructive Pulmonary Disease | Unknown | 2010-09-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT01205451 | A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1… | Phase3 | Spasticity, Post-Stroke | Completed | 2010-09-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01466361 | Evaluation of the Nicotine Lozenge in Relief of Provoked Acute Craving | Phase2 | Smoking | Completed | 2010-09-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01366560 | Effect of GSK962040 on Oesophageal Function | Phase1 | Gastrointestinal Motility | Completed | 2010-08-31 | 2010-10-22 | ClinicalTrials.gov |
| NCT01366560 | Effect of GSK962040 on Oesophageal Function | Phase1 | Gastrointestinal Motility | Completed | 2010-08-31 | 2010-10-22 | ClinicalTrials.gov |
| NCT01171963 | Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavir… | Phase3 | Infections, Rotavirus | Completed | 2010-08-29 | 2012-05-12 | ClinicalTrials.gov |
| NCT01171963 | Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavir… | Phase3 | Infections, Rotavirus | Completed | 2010-08-29 | 2012-05-12 | ClinicalTrials.gov |
| NCT01165138 | Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642… | Phase3 | Asthma | Completed | 2010-08-20 | 2011-10-19 | ClinicalTrials.gov |
| NCT01165138 | Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642… | Phase3 | Asthma | Completed | 2010-08-20 | 2011-10-19 | ClinicalTrials.gov |
| NCT01171989 | Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vac… | Phase2 | Tetanus | Completed | 2010-08-18 | 2010-12-03 | ClinicalTrials.gov |
| NCT01171989 | Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vac… | Phase2 | Tetanus | Completed | 2010-08-18 | 2010-12-03 | ClinicalTrials.gov |
| NCT01209078 | GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin S… | Phase2 | Skin Infections, Bacterial | Completed | 2010-08-17 | 2011-01-18 | ClinicalTrials.gov |
| NCT01762787 | Phase I Methodology Study to Validate the Cantharidin Blister Model in Healthy … | Phase1 | Inflammation | Completed | 2010-08-17 | 2011-01-14 | ClinicalTrials.gov |
| NCT01762787 | Phase I Methodology Study to Validate the Cantharidin Blister Model in Healthy … | Phase1 | Inflammation | Completed | 2010-08-17 | 2011-01-14 | ClinicalTrials.gov |
| NCT01248897 | Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients T… | — | Neoplasms, Metastasis | Completed | 2010-08-17 | 2014-09-05 | ClinicalTrials.gov |
| NCT01248897 | Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients T… | — | Neoplasms, Metastasis | Completed | 2010-08-17 | 2014-09-05 | ClinicalTrials.gov |
| NCT01209078 | GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin S… | Phase2 | Skin Infections, Bacterial | Completed | 2010-08-17 | 2011-01-18 | ClinicalTrials.gov |
| NCT01154062 | A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-rela… | Phase1 | Macular Degeneration | Completed | 2010-08-16 | 2011-04-29 | ClinicalTrials.gov |
| NCT01154062 | A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-rela… | Phase1 | Macular Degeneration | Completed | 2010-08-16 | 2011-04-29 | ClinicalTrials.gov |
| NCT01153763 | A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma | Phase2 | Melanoma | Completed | 2010-08-09 | 2016-06-01 | ClinicalTrials.gov |
| NCT01153763 | A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma | Phase2 | Melanoma | Completed | 2010-08-09 | 2016-06-01 | ClinicalTrials.gov |
| NCT02207452 | Helium-3 MRI Imaging Study in COPD | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2010-08-05 | 2011-07-04 | ClinicalTrials.gov |
| NCT02207452 | Helium-3 MRI Imaging Study in COPD | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2010-08-05 | 2011-07-04 | ClinicalTrials.gov |
| NCT01165177 | Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpe… | Phase3 | Herpes Zoster | Completed | 2010-08-02 | 2015-07-27 | ClinicalTrials.gov |
| NCT01165229 | Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) … | Phase3 | Herpes Zoster | Completed | 2010-08-02 | 2015-07-24 | ClinicalTrials.gov |
| NCT01165177 | Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpe… | Phase3 | Herpes Zoster | Completed | 2010-08-02 | 2015-07-27 | ClinicalTrials.gov |
| NCT01165229 | Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) … | Phase3 | Herpes Zoster | Completed | 2010-08-02 | 2015-07-24 | ClinicalTrials.gov |
| NCT01192191 | A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subje… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2010-08-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01180764 | Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in… | Phase4 | Hypertriglyceridemia | Withdrawn | 2010-08-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01435954 | Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated… | — | Benign Prostatic Hyperplasia | Completed | 2010-08-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT01254032 | Predictive Ability of the Chronic Obstructive Pulmonary Disease (COPD) Assessme… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2010-08-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01453296 | Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects | Phase2 | Asthma | Completed | 2010-08-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01191190 | Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocyti… | Phase2 | CLL | Completed | 2010-08-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01192178 | Fall Epidemic Viral Pediatric Study | Phase4 | Asthma | Completed | 2010-08-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01191190 | Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocyti… | Phase2 | CLL | Completed | 2010-08-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01180764 | Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in… | Phase4 | Hypertriglyceridemia | Withdrawn | 2010-08-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01453296 | Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects | Phase2 | Asthma | Completed | 2010-08-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01107665 | Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable… | Phase2 | Stage III Melanoma | Completed | 2010-08-01 | 2018-02-01 | ClinicalTrials.gov |
| NCT01107665 | Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable… | Phase2 | Stage III Melanoma | Completed | 2010-08-01 | 2018-02-01 | ClinicalTrials.gov |
| NCT01160237 | Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit … | Phase3 | Influenza | Terminated | 2010-08-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01128686 | Lamivudine(LAM) Good Responder Study | — | Hepatitis B, Chronic | Completed | 2010-08-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01140009 | Safety and Protectiveness of the Seasonal Influenza Vaccine for 2010-2011 | Phase2 | Influenza | Completed | 2010-08-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT01254032 | Predictive Ability of the Chronic Obstructive Pulmonary Disease (COPD) Assessme… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2010-08-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01128686 | Lamivudine(LAM) Good Responder Study | — | Hepatitis B, Chronic | Completed | 2010-08-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01231581 | Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic … | Phase2 | Cancer | Completed | 2010-08-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01231581 | Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic … | Phase2 | Cancer | Completed | 2010-08-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01140009 | Safety and Protectiveness of the Seasonal Influenza Vaccine for 2010-2011 | Phase2 | Influenza | Completed | 2010-08-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT01160237 | Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit … | Phase3 | Influenza | Terminated | 2010-08-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01435954 | Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated… | — | Benign Prostatic Hyperplasia | Completed | 2010-08-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT01192191 | A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subje… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2010-08-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01192178 | Fall Epidemic Viral Pediatric Study | Phase4 | Asthma | Completed | 2010-08-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01148459 | Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine i… | Phase3 | Malaria | Completed | 2010-07-30 | 2013-05-24 | ClinicalTrials.gov |
| NCT01148459 | Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine i… | Phase3 | Malaria | Completed | 2010-07-30 | 2013-05-24 | ClinicalTrials.gov |
| NCT01160003 | A Blinded, Dose Ascending Study to Assess the Pharmacokinetics, Safety and Toll… | Phase1 | Asthma | Completed | 2010-07-29 | 2010-11-05 | ClinicalTrials.gov |
| NCT01160003 | A Blinded, Dose Ascending Study to Assess the Pharmacokinetics, Safety and Toll… | Phase1 | Asthma | Completed | 2010-07-29 | 2010-11-05 | ClinicalTrials.gov |
| NCT01138033 | Study of a Focal Adhesion Kinase Inhibitor in Subjects With Solid Tumors | Phase1 | Cancer | Completed | 2010-07-27 | 2015-12-21 | ClinicalTrials.gov |
| NCT01138033 | Study of a Focal Adhesion Kinase Inhibitor in Subjects With Solid Tumors | Phase1 | Cancer | Completed | 2010-07-27 | 2015-12-21 | ClinicalTrials.gov |
| NCT01611805 | Japanese Phase I of GSK1605786 | Phase1 | Crohn's Disease | Completed | 2010-07-22 | 2010-10-06 | ClinicalTrials.gov |
| NCT01611805 | Japanese Phase I of GSK1605786 | Phase1 | Crohn's Disease | Completed | 2010-07-22 | 2010-10-06 | ClinicalTrials.gov |
| NCT01159964 | Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung C… | Phase1 | Lung Cancer, Non-Small Cell | Terminated | 2010-07-20 | 2014-09-10 | ClinicalTrials.gov |
| NCT01381536 | Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythemato… | Phase1 | Systemic Lupus Erythematosus | Completed | 2010-07-20 | 2010-11-27 | ClinicalTrials.gov |
| NCT01159964 | Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung C… | Phase1 | Lung Cancer, Non-Small Cell | Terminated | 2010-07-20 | 2014-09-10 | ClinicalTrials.gov |
| NCT01381536 | Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythemato… | Phase1 | Systemic Lupus Erythematosus | Completed | 2010-07-20 | 2010-11-27 | ClinicalTrials.gov |
| NCT01160172 | A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biolog… | Phase1 | Infections, Staphylococcal | Completed | 2010-07-19 | 2012-08-23 | ClinicalTrials.gov |
| NCT01124422 | Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise End… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2010-07-19 | 2011-05-02 | ClinicalTrials.gov |
| NCT01124422 | Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise End… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2010-07-19 | 2011-05-02 | ClinicalTrials.gov |
| NCT01160172 | A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biolog… | Phase1 | Infections, Staphylococcal | Completed | 2010-07-19 | 2012-08-23 | ClinicalTrials.gov |
| NCT01357863 | Role of Early Versus Late Switch to Lapatinib-Capecitabine | — | Cancer | Terminated | 2010-07-15 | 2010-12-13 | ClinicalTrials.gov |
| NCT01357863 | Role of Early Versus Late Switch to Lapatinib-Capecitabine | — | Cancer | Terminated | 2010-07-15 | 2010-12-13 | ClinicalTrials.gov |
| NCT01119625 | Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Im… | Phase3 | Infections, Streptococcal | Completed | 2010-07-12 | 2011-02-17 | ClinicalTrials.gov |
| NCT01119625 | Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Im… | Phase3 | Infections, Streptococcal | Completed | 2010-07-12 | 2011-02-17 | ClinicalTrials.gov |
| NCT01098474 | Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy … | Phase2 | Tuberculosis | Completed | 2010-07-07 | 2012-03-16 | ClinicalTrials.gov |
| NCT01098474 | Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy … | Phase2 | Tuberculosis | Completed | 2010-07-07 | 2012-03-16 | ClinicalTrials.gov |
| NCT01114503 | A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease | Phase2 | Graves Ophthalmopathy | Terminated | 2010-07-07 | 2012-08-29 | ClinicalTrials.gov |
| NCT01114503 | A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease | Phase2 | Graves Ophthalmopathy | Terminated | 2010-07-07 | 2012-08-29 | ClinicalTrials.gov |
| NCT01149343 | Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer | Phase1 | Melanoma | Completed | 2010-07-02 | 2016-12-19 | ClinicalTrials.gov |
| NCT01149343 | Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer | Phase1 | Melanoma | Completed | 2010-07-02 | 2016-12-19 | ClinicalTrials.gov |
| NCT01178346 | Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies | Phase3 | Smoking Cessation | Completed | 2010-07-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01059656 | Phase II Pazopanib Study in Advanced Dermatofibrosarcomas | Phase2 | Dermatofibrosarcomas of DARIER FERRAND(DFSP) | Terminated | 2010-07-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01072227 | Study to Identify and Characterize the Bacteria Causing Acute Otitis Media Epis… | — | Acute Otitis Media | Terminated | 2010-07-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01059656 | Phase II Pazopanib Study in Advanced Dermatofibrosarcomas | Phase2 | Dermatofibrosarcomas of DARIER FERRAND(DFSP) | Terminated | 2010-07-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01101542 | Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Fem… | — | Infections, Papillomavirus | Completed | 2010-07-01 | 2014-02-20 | ClinicalTrials.gov |
| NCT01110603 | A Study of MK-4827 in Combination With Standard Chemotherapy in Participants Wi… | Phase1 | Cancer: Solid Tumors | Terminated | 2010-07-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01134822 | Prospective Study of Fibrosis In the Lung Endpoints (PROFILE - Central England) | — | Idiopathic Pulmonary Fibrosis | Completed | 2010-07-01 | 2017-09-05 | ClinicalTrials.gov |
| NCT01244984 | A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanes… | Phase3 | Asthma | Completed | 2010-07-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01147861 | A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist,… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2010-07-01 | 2010-09-07 | ClinicalTrials.gov |
| NCT01148017 | Evaluation of Meningococcal Immune Response Among Children Who Previously Recei… | Phase3 | Meningococcal Meningitis | Completed | 2010-07-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01169883 | Coping Peer Intervention for Adherence | Na | Asthma | Completed | 2010-07-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01154114 | Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects | Phase1 | Atherosclerosis | Completed | 2010-07-01 | 2010-10-15 | ClinicalTrials.gov |
| NCT01167829 | ORAL T-8 Oral Testosterone for Male Hormonal Contraception | Phase1 | Healthy | Completed | 2010-07-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01165125 | A Drug Interaction Study With Fluticasone Furoate/GW642444 Inhalation Powder an… | Phase1 | Asthma | Completed | 2010-07-01 | 2010-08-28 | ClinicalTrials.gov |
| NCT01161160 | Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and… | Phase2 | Influenza | Completed | 2010-07-01 | 2011-01-31 | ClinicalTrials.gov |
| NCT01157897 | Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults | Phase1 | Malaria | Completed | 2010-07-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01154114 | Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects | Phase1 | Atherosclerosis | Completed | 2010-07-01 | 2010-10-15 | ClinicalTrials.gov |
| NCT01157897 | Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults | Phase1 | Malaria | Completed | 2010-07-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01148017 | Evaluation of Meningococcal Immune Response Among Children Who Previously Recei… | Phase3 | Meningococcal Meningitis | Completed | 2010-07-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01147861 | A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist,… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2010-07-01 | 2010-09-07 | ClinicalTrials.gov |
| NCT01134822 | Prospective Study of Fibrosis In the Lung Endpoints (PROFILE - Central England) | — | Idiopathic Pulmonary Fibrosis | Completed | 2010-07-01 | 2017-09-05 | ClinicalTrials.gov |
| NCT01110603 | A Study of MK-4827 in Combination With Standard Chemotherapy in Participants Wi… | Phase1 | Cancer: Solid Tumors | Terminated | 2010-07-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01161160 | Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and… | Phase2 | Influenza | Completed | 2010-07-01 | 2011-01-31 | ClinicalTrials.gov |
| NCT01101542 | Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Fem… | — | Infections, Papillomavirus | Completed | 2010-07-01 | 2014-02-20 | ClinicalTrials.gov |
| NCT01165125 | A Drug Interaction Study With Fluticasone Furoate/GW642444 Inhalation Powder an… | Phase1 | Asthma | Completed | 2010-07-01 | 2010-08-28 | ClinicalTrials.gov |
| NCT01167829 | ORAL T-8 Oral Testosterone for Male Hormonal Contraception | Phase1 | Healthy | Completed | 2010-07-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01169883 | Coping Peer Intervention for Adherence | Na | Asthma | Completed | 2010-07-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01178346 | Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies | Phase3 | Smoking Cessation | Completed | 2010-07-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01072227 | Study to Identify and Characterize the Bacteria Causing Acute Otitis Media Epis… | — | Acute Otitis Media | Terminated | 2010-07-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01244984 | A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanes… | Phase3 | Asthma | Completed | 2010-07-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01159912 | Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in … | Phase3 | Asthma | Completed | 2010-06-30 | 2012-01-16 | ClinicalTrials.gov |
| NCT01159912 | Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in … | Phase3 | Asthma | Completed | 2010-06-30 | 2012-01-16 | ClinicalTrials.gov |
| NCT01147744 | Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administere… | Phase2 | Asthma | Completed | 2010-06-28 | 2011-10-06 | ClinicalTrials.gov |
| NCT01435915 | Ropinirole PR Pharmacokinetics Study Among Chinese Healthy Subjects | Phase1 | Parkinson Disease | Completed | 2010-06-28 | 2010-08-05 | ClinicalTrials.gov |
| NCT01435915 | Ropinirole PR Pharmacokinetics Study Among Chinese Healthy Subjects | Phase1 | Parkinson Disease | Completed | 2010-06-28 | 2010-08-05 | ClinicalTrials.gov |
| NCT01147744 | Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administere… | Phase2 | Asthma | Completed | 2010-06-28 | 2011-10-06 | ClinicalTrials.gov |
| NCT01209026 | Corrected QT (QTc) Study With Flucticasone Furoate and GW642444 | Phase1 | Asthma | Completed | 2010-06-23 | 2011-01-04 | ClinicalTrials.gov |
| NCT01209026 | Corrected QT (QTc) Study With Flucticasone Furoate and GW642444 | Phase1 | Asthma | Completed | 2010-06-23 | 2011-01-04 | ClinicalTrials.gov |
| NCT01000974 | Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Ver… | Phase3 | Haemophilus Influenzae Type b | Completed | 2010-06-18 | 2013-07-17 | ClinicalTrials.gov |
| NCT01000974 | Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Ver… | Phase3 | Haemophilus Influenzae Type b | Completed | 2010-06-18 | 2013-07-17 | ClinicalTrials.gov |
| NCT01138007 | A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (… | Phase3 | Depressive Disorder, Major | Completed | 2010-06-17 | 2012-08-07 | ClinicalTrials.gov |
| NCT01138007 | A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (… | Phase3 | Depressive Disorder, Major | Completed | 2010-06-17 | 2012-08-07 | ClinicalTrials.gov |
| NCT01147900 | Evaluation of Boostrix™10 Years After Previous Booster Vaccination | Phase4 | Acellular Pertussis | Completed | 2010-06-15 | 2012-05-08 | ClinicalTrials.gov |
| NCT01147900 | Evaluation of Boostrix™10 Years After Previous Booster Vaccination | Phase4 | Acellular Pertussis | Completed | 2010-06-15 | 2012-05-08 | ClinicalTrials.gov |
| NCT01267071 | A Study to Evaluate the Pharmacokinetics and Absolute Bioavailability of GSK962… | Phase1 | Gastroparesis | Completed | 2010-06-14 | 2010-09-01 | ClinicalTrials.gov |
| NCT01267071 | A Study to Evaluate the Pharmacokinetics and Absolute Bioavailability of GSK962… | Phase1 | Gastroparesis | Completed | 2010-06-14 | 2010-09-01 | ClinicalTrials.gov |
| NCT01119651 | A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic React… | Phase1 | Acne Vulgaris | Completed | 2010-06-14 | 2010-06-26 | ClinicalTrials.gov |
| NCT01119651 | A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic React… | Phase1 | Acne Vulgaris | Completed | 2010-06-14 | 2010-06-26 | ClinicalTrials.gov |
| NCT01147718 | A Drug Interaction Study of Albiglutide and Digoxin | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2010-06-11 | 2010-11-29 | ClinicalTrials.gov |
| NCT01147718 | A Drug Interaction Study of Albiglutide and Digoxin | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2010-06-11 | 2010-11-29 | ClinicalTrials.gov |
| NCT01094860 | Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients W… | Phase1 | Leukemia | Completed | 2010-06-08 | 2018-08-09 | ClinicalTrials.gov |
| NCT01094860 | Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients W… | Phase1 | Leukemia | Completed | 2010-06-08 | 2018-08-09 | ClinicalTrials.gov |
| NCT01138098 | Evaluation of Antibody Persistence and Immune Memory Against the Hepatitis B An… | Phase4 | Hepatitis B | Completed | 2010-06-07 | 2010-11-26 | ClinicalTrials.gov |
| NCT01138098 | Evaluation of Antibody Persistence and Immune Memory Against the Hepatitis B An… | Phase4 | Hepatitis B | Completed | 2010-06-07 | 2010-11-26 | ClinicalTrials.gov |
| NCT01147731 | A Drug Interaction Study With Albiglutide and Warfarin | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2010-06-04 | 2010-09-09 | ClinicalTrials.gov |
| NCT01147731 | A Drug Interaction Study With Albiglutide and Warfarin | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2010-06-04 | 2010-09-09 | ClinicalTrials.gov |
| NCT01134042 | Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642… | Phase3 | Asthma | Completed | 2010-06-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01129518 | Can we Reduce the Number of Vaccine Injections for Children? | Phase4 | Invasive Meningococcal Disease | Completed | 2010-06-01 | — | ClinicalTrials.gov |
| NCT01167504 | Factors Controlling the Formation of Salivary Films | — | Healthy | Completed | 2010-06-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01165255 | Bupropion and Specific Cardiovascular Malformations | — | Depressive Disorder | Completed | 2010-06-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00924794 | Study of Natural History of Human Papillomavirus (HPV) Infections in Adult Wome… | — | Infections, Papillomavirus | Terminated | 2010-06-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01147809 | Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag | Phase2 | Thrombocytopaenia | Completed | 2010-06-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01165255 | Bupropion and Specific Cardiovascular Malformations | — | Depressive Disorder | Completed | 2010-06-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01167504 | Factors Controlling the Formation of Salivary Films | — | Healthy | Completed | 2010-06-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01155336 | The Effects of Lovaza® in Acute Myocardial Infarction | Phase1 | Myocardial Infarction | Terminated | 2010-06-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01147848 | HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in A… | Phase3 | Asthma | Completed | 2010-06-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01147848 | HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in A… | Phase3 | Asthma | Completed | 2010-06-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01147809 | Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag | Phase2 | Thrombocytopaenia | Completed | 2010-06-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01985295 | Combined Modality Treatment of Sarcomas of the Extremities | Phase1 | Sarcoma,Soft Tissue | Completed | 2010-06-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01138072 | A Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and G… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2010-06-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01138072 | A Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and G… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2010-06-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00981799 | Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and … | Phase1 | Relapsed T-Cell Acute Lymphoblastic Leukemia | Terminated | 2010-06-01 | 2016-07-18 | ClinicalTrials.gov |
| NCT01134055 | Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degene… | Phase2 | Macular Degeneration | Completed | 2010-06-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01134042 | Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642… | Phase3 | Asthma | Completed | 2010-06-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01129518 | Can we Reduce the Number of Vaccine Injections for Children? | Phase4 | Invasive Meningococcal Disease | Completed | 2010-06-01 | — | ClinicalTrials.gov |
| NCT01184482 | Lapatinib and Cetuximab in Patients With Solid Tumors | Phase1 | Colorectal Cancer | Completed | 2010-06-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT00964678 | Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hype… | Phase1 | Pulmonary Arterial Hypertension | Completed | 2010-06-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01381510 | Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Valida… | — | Prostatic Hyperplasia | Completed | 2010-06-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01985295 | Combined Modality Treatment of Sarcomas of the Extremities | Phase1 | Sarcoma,Soft Tissue | Completed | 2010-06-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT00981799 | Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and … | Phase1 | Relapsed T-Cell Acute Lymphoblastic Leukemia | Terminated | 2010-06-01 | 2016-07-18 | ClinicalTrials.gov |
| NCT01134055 | Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degene… | Phase2 | Macular Degeneration | Completed | 2010-06-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01155336 | The Effects of Lovaza® in Acute Myocardial Infarction | Phase1 | Myocardial Infarction | Terminated | 2010-06-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT00964678 | Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hype… | Phase1 | Pulmonary Arterial Hypertension | Completed | 2010-06-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT00924794 | Study of Natural History of Human Papillomavirus (HPV) Infections in Adult Wome… | — | Infections, Papillomavirus | Terminated | 2010-06-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01184482 | Lapatinib and Cetuximab in Patients With Solid Tumors | Phase1 | Colorectal Cancer | Completed | 2010-06-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01381510 | Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Valida… | — | Prostatic Hyperplasia | Completed | 2010-06-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01031108 | A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascul… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2010-05-28 | 2011-10-12 | ClinicalTrials.gov |
| NCT01031108 | A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascul… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2010-05-28 | 2011-10-12 | ClinicalTrials.gov |
| NCT01387217 | GSK2018682 FTIH in Healthy Volunteers | Phase1 | Multiple Sclerosis | Completed | 2010-05-21 | 2010-12-20 | ClinicalTrials.gov |
| NCT01387217 | GSK2018682 FTIH in Healthy Volunteers | Phase1 | Multiple Sclerosis | Completed | 2010-05-21 | 2010-12-20 | ClinicalTrials.gov |
| NCT01147692 | A Drug Interaction Study of Simvastatin and Albiglutide | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2010-05-19 | 2010-08-27 | ClinicalTrials.gov |
| NCT01147692 | A Drug Interaction Study of Simvastatin and Albiglutide | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2010-05-19 | 2010-08-27 | ClinicalTrials.gov |
| NCT01286831 | A Single Dose Study to Determine the Excretion, Balance and Metabolic Dispositi… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2010-05-18 | 2010-07-09 | ClinicalTrials.gov |
| NCT01286831 | A Single Dose Study to Determine the Excretion, Balance and Metabolic Dispositi… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2010-05-18 | 2010-07-09 | ClinicalTrials.gov |
| NCT01090453 | Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants | Phase2 | Tetanus | Completed | 2010-05-17 | 2011-10-11 | ClinicalTrials.gov |
| NCT01090453 | Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants | Phase2 | Tetanus | Completed | 2010-05-17 | 2011-10-11 | ClinicalTrials.gov |
| NCT01299558 | Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate an… | Phase1 | Asthma | Completed | 2010-05-17 | 2010-07-15 | ClinicalTrials.gov |
| NCT01299558 | Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate an… | Phase1 | Asthma | Completed | 2010-05-17 | 2010-07-15 | ClinicalTrials.gov |
| NCT01943942 | Bioequivalence Study of Montelukast 10 mg Tablets | Phase1 | Asthma | Completed | 2010-05-16 | 2010-05-26 | ClinicalTrials.gov |
| NCT01943942 | Bioequivalence Study of Montelukast 10 mg Tablets | Phase1 | Asthma | Completed | 2010-05-16 | 2010-05-26 | ClinicalTrials.gov |
| NCT01863654 | Bioequivalence Study of Montelukast 5 mg Chewable | Phase1 | Asthma | Completed | 2010-05-16 | 2010-05-26 | ClinicalTrials.gov |
| NCT01863654 | Bioequivalence Study of Montelukast 5 mg Chewable | Phase1 | Asthma | Completed | 2010-05-16 | 2010-05-26 | ClinicalTrials.gov |
| NCT01110031 | Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic… | Phase1 | Leukaemia, Lymphocytic, Chronic | Completed | 2010-05-13 | 2012-06-26 | ClinicalTrials.gov |
| NCT01110031 | Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic… | Phase1 | Leukaemia, Lymphocytic, Chronic | Completed | 2010-05-13 | 2012-06-26 | ClinicalTrials.gov |
| NCT01138085 | Safety, Pharmacokinetics (PK) of AKT and MEK Combination | Phase1 | Cancer | Completed | 2010-05-04 | 2014-11-19 | ClinicalTrials.gov |
| NCT01138085 | Safety, Pharmacokinetics (PK) of AKT and MEK Combination | Phase1 | Cancer | Completed | 2010-05-04 | 2014-11-19 | ClinicalTrials.gov |
| NCT01150123 | Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women | Phase1 | Group B Streptococcus | Completed | 2010-05-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01139580 | The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Cal… | Phase3 | Psoriasis | Completed | 2010-05-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01128894 | A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Li… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2010-05-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01128595 | Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF … | Phase2 | Asthma | Completed | 2010-05-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01128400 | Fat Perception in Humans (09-0873) | — | Obesity | Completed | 2010-05-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01125787 | Clinical Protocol for the Treatment of Patients With Previously Untreated Chron… | Phase2 | Chronic Lymphocytic Leukemia (CLL) | Terminated | 2010-05-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01123356 | Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rit… | Phase2 | Chronic Lymphocytic Leukemia | Completed | 2010-05-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01139580 | The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Cal… | Phase3 | Psoriasis | Completed | 2010-05-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01121770 | "Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction" | Phase1 | Renal Insufficiency | Completed | 2010-05-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01128894 | A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Li… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2010-05-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01128595 | Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF … | Phase2 | Asthma | Completed | 2010-05-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01128400 | Fat Perception in Humans (09-0873) | — | Obesity | Completed | 2010-05-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01125787 | Clinical Protocol for the Treatment of Patients With Previously Untreated Chron… | Phase2 | Chronic Lymphocytic Leukemia (CLL) | Terminated | 2010-05-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01123356 | Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rit… | Phase2 | Chronic Lymphocytic Leukemia | Completed | 2010-05-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01121770 | "Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction" | Phase1 | Renal Insufficiency | Completed | 2010-05-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01107834 | Heart Function in HIV-Negative Children Exposed to HIV and HAART | — | HIV Infections | Completed | 2010-05-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01371513 | Korean Practice Patterns for Screening PCA(Prostate Cancer) | — | Neoplasms, Prostate | Completed | 2010-05-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01107834 | Heart Function in HIV-Negative Children Exposed to HIV and HAART | — | HIV Infections | Completed | 2010-05-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01098539 | A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabe… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2010-05-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01098487 | A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Ad… | Phase4 | Purpura, Thrombocytopaenic, Idiopathic | Completed | 2010-05-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01098539 | A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabe… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2010-05-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01098487 | A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Ad… | Phase4 | Purpura, Thrombocytopaenic, Idiopathic | Completed | 2010-05-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT00866580 | A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine | Phase3 | Influenza | Withdrawn | 2010-05-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00866580 | A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine | Phase3 | Influenza | Withdrawn | 2010-05-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01046097 | Post-marketing Surveillance Study With GSK Biologicals' Pneumococcal Vaccine in… | — | Infections, Streptococcal | Terminated | 2010-05-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01001130 | Regulatory AVAMYS Nasal Spray PMS | — | Rhinitis, Allergic, Perennial and Seasonal | Completed | 2010-05-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01053507 | Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dy… | Phase4 | Post-Traumatic Headache | Terminated | 2010-05-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01053507 | Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dy… | Phase4 | Post-Traumatic Headache | Terminated | 2010-05-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01046097 | Post-marketing Surveillance Study With GSK Biologicals' Pneumococcal Vaccine in… | — | Infections, Streptococcal | Terminated | 2010-05-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01551797 | A Pharmacokinetic Study to Compare Sustained Release and Standard Paracetamol F… | Phase1 | Pain | Completed | 2010-05-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT01332474 | JCP Study of Investigation of Patient Background Characteristics | — | Spasticity, Post-Stroke | Completed | 2010-05-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01332474 | JCP Study of Investigation of Patient Background Characteristics | — | Spasticity, Post-Stroke | Completed | 2010-05-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01551797 | A Pharmacokinetic Study to Compare Sustained Release and Standard Paracetamol F… | Phase1 | Pain | Completed | 2010-05-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT01001130 | Regulatory AVAMYS Nasal Spray PMS | — | Rhinitis, Allergic, Perennial and Seasonal | Completed | 2010-05-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01651247 | Assessment of the Serologic Response to Porcine Circovirus Type 1 (PCV-1) in th… | — | Presence of Materials From PCV-1 | Completed | 2010-05-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01651247 | Assessment of the Serologic Response to Porcine Circovirus Type 1 (PCV-1) in th… | — | Presence of Materials From PCV-1 | Completed | 2010-05-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01371513 | Korean Practice Patterns for Screening PCA(Prostate Cancer) | — | Neoplasms, Prostate | Completed | 2010-05-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01150123 | Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women | Phase1 | Group B Streptococcus | Completed | 2010-05-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01110200 | Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2010-04-30 | 2012-05-08 | ClinicalTrials.gov |
| NCT01110200 | Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2010-04-30 | 2012-05-08 | ClinicalTrials.gov |
| NCT01098006 | A Study in Adult Subjects With Chronic Hepatitis B Infection to Support the Dev… | Na | Immunologic Tests | Completed | 2010-04-29 | 2012-02-20 | ClinicalTrials.gov |
| NCT01098006 | A Study in Adult Subjects With Chronic Hepatitis B Infection to Support the Dev… | Na | Immunologic Tests | Completed | 2010-04-29 | 2012-02-20 | ClinicalTrials.gov |
| NCT01110018 | GSK573719 IV Enabling Study | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2010-04-28 | 2010-06-09 | ClinicalTrials.gov |
| NCT01077531 | Safety, Pharmacodynamics and Pharmacokinetics of GSK2136525 Repeat Dose in Rheu… | Phase1 | Arthritis, Rheumatoid | Terminated | 2010-04-28 | 2013-03-19 | ClinicalTrials.gov |
| NCT01077531 | Safety, Pharmacodynamics and Pharmacokinetics of GSK2136525 Repeat Dose in Rheu… | Phase1 | Arthritis, Rheumatoid | Terminated | 2010-04-28 | 2013-03-19 | ClinicalTrials.gov |
| NCT01110018 | GSK573719 IV Enabling Study | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2010-04-28 | 2010-06-09 | ClinicalTrials.gov |
| NCT01424462 | Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of… | Phase1 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2010-04-19 | 2010-07-06 | ClinicalTrials.gov |
| NCT01424462 | Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of… | Phase1 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2010-04-19 | 2010-07-06 | ClinicalTrials.gov |
| NCT01209104 | Pharmacokinetics and Safety of GSK1325756 in Elderly Subjects and Adult Subject… | Phase1 | Nutritional Status | Completed | 2010-04-14 | 2010-05-24 | ClinicalTrials.gov |
| NCT01101568 | A Study to Investigate the Interaction of GSK1292263 With Rosuvastatin and Simv… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2010-04-14 | 2010-06-24 | ClinicalTrials.gov |
| NCT01101568 | A Study to Investigate the Interaction of GSK1292263 With Rosuvastatin and Simv… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2010-04-14 | 2010-06-24 | ClinicalTrials.gov |
| NCT01209104 | Pharmacokinetics and Safety of GSK1325756 in Elderly Subjects and Adult Subject… | Phase1 | Nutritional Status | Completed | 2010-04-14 | 2010-05-24 | ClinicalTrials.gov |
| NCT01107587 | Study to Assess the Safety of GSK Biologicals' Liquid Human Rotavirus Vaccine i… | Phase1 | Infections, Rotavirus | Completed | 2010-04-13 | 2010-06-28 | ClinicalTrials.gov |
| NCT01107587 | Study to Assess the Safety of GSK Biologicals' Liquid Human Rotavirus Vaccine i… | Phase1 | Infections, Rotavirus | Completed | 2010-04-13 | 2010-06-28 | ClinicalTrials.gov |
| NCT01096056 | Trial to Evaluate the Safety and the Immunogenicity of GSK Biologicals' Influen… | Phase1 | Influenza | Completed | 2010-04-05 | 2010-12-13 | ClinicalTrials.gov |
| NCT01096056 | Trial to Evaluate the Safety and the Immunogenicity of GSK Biologicals' Influen… | Phase1 | Influenza | Completed | 2010-04-05 | 2010-12-13 | ClinicalTrials.gov |
| NCT01098513 | GSK1349572 Relative Bioavailability Study | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2010-04-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01150760 | Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus … | — | Ileus | Completed | 2010-04-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01168388 | Movement Disorder Survey in East China | — | Primary Dystonia | Completed | 2010-04-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01098461 | Dose Ranging Study of Albiglutide in Japanese Subjects | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2010-04-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01122862 | Effect of a Commercial Cosmetic Mouth Rinse on Plaque Re-growth | Phase2 | Healthy Subjects | Completed | 2010-04-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01110044 | Study of a Birth Dose of GlaxoSmithKline Biologicals' 251154 Vaccine | Phase2 | Infections, Rotavirus | Withdrawn | 2010-04-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01108055 | Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urotheli… | Phase2 | Bladder Cancer | Completed | 2010-04-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT01381640 | A Study to Compare Two Paracetamol Tablets | Phase1 | Healthy Subjects | Withdrawn | 2010-04-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01115322 | A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When A… | Phase1 | Acne Vulgaris | Completed | 2010-04-01 | 2010-04-10 | ClinicalTrials.gov |
| NCT01476072 | 31P MRS Ischaemic Exercise Optimisation and COPD | Phase1 | Atrophy, Muscular | Completed | 2010-04-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01109537 | Altered Brain GABA and Glutamate in Restless Legs Syndrome | — | Restless Legs Syndrome | Completed | 2010-04-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01333644 | The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk | — | HIV Infection | Completed | 2010-04-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01334723 | Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor … | — | Prostatic Hyperplasia | Completed | 2010-04-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01333644 | The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk | — | HIV Infection | Completed | 2010-04-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01334723 | Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor … | — | Prostatic Hyperplasia | Completed | 2010-04-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01010568 | Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia… | Phase2 | Chronic Lymphocytic Leukemia | Terminated | 2010-04-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01453049 | An Efficacy and Safety Study of Fixed-dose Rosiglitazone/Glimepiride to Treat C… | Phase3 | Diabetes Mellitus, Type 2 | Terminated | 2010-04-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT01110044 | Study of a Birth Dose of GlaxoSmithKline Biologicals' 251154 Vaccine | Phase2 | Infections, Rotavirus | Withdrawn | 2010-04-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01128738 | GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary Hy… | Phase3 | Hyperhidrosis | Completed | 2010-04-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01767428 | Pharmacokinetic Study to Compare Two Formulations of Paracetamol | Phase1 | Fever | Completed | 2010-04-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT01126268 | Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue … | Phase4 | Impetigo | Completed | 2010-04-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01476072 | 31P MRS Ischaemic Exercise Optimisation and COPD | Phase1 | Atrophy, Muscular | Completed | 2010-04-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01767428 | Pharmacokinetic Study to Compare Two Formulations of Paracetamol | Phase1 | Fever | Completed | 2010-04-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT01153815 | A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate t… | Phase3 | Cerebrovascular Accident | Completed | 2010-04-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01098513 | GSK1349572 Relative Bioavailability Study | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2010-04-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01128738 | GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary Hy… | Phase3 | Hyperhidrosis | Completed | 2010-04-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01098461 | Dose Ranging Study of Albiglutide in Japanese Subjects | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2010-04-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01453049 | An Efficacy and Safety Study of Fixed-dose Rosiglitazone/Glimepiride to Treat C… | Phase3 | Diabetes Mellitus, Type 2 | Terminated | 2010-04-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT01099488 | A Study in Healthy Adults Having Received a Single Vaccine Administration to Su… | Na | Immunologic Tests | Completed | 2010-04-01 | 2010-12-07 | ClinicalTrials.gov |
| NCT01099488 | A Study in Healthy Adults Having Received a Single Vaccine Administration to Su… | Na | Immunologic Tests | Completed | 2010-04-01 | 2010-12-07 | ClinicalTrials.gov |
| NCT01115322 | A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When A… | Phase1 | Acne Vulgaris | Completed | 2010-04-01 | 2010-04-10 | ClinicalTrials.gov |
| NCT01108055 | Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urotheli… | Phase2 | Bladder Cancer | Completed | 2010-04-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT01109537 | Altered Brain GABA and Glutamate in Restless Legs Syndrome | — | Restless Legs Syndrome | Completed | 2010-04-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01010568 | Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia… | Phase2 | Chronic Lymphocytic Leukemia | Terminated | 2010-04-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01323998 | Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan | — | Prostatic Hyperplasia | Completed | 2010-04-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01126268 | Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue … | Phase4 | Impetigo | Completed | 2010-04-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01150760 | Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus … | — | Ileus | Completed | 2010-04-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01168388 | Movement Disorder Survey in East China | — | Primary Dystonia | Completed | 2010-04-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01323998 | Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan | — | Prostatic Hyperplasia | Completed | 2010-04-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01381640 | A Study to Compare Two Paracetamol Tablets | Phase1 | Healthy Subjects | Withdrawn | 2010-04-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01122862 | Effect of a Commercial Cosmetic Mouth Rinse on Plaque Re-growth | Phase2 | Healthy Subjects | Completed | 2010-04-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01153815 | A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate t… | Phase3 | Cerebrovascular Accident | Completed | 2010-04-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01114841 | A Study To Evaluate The Contact Sensitization Potential Of Tazarotene Foam On S… | Phase1 | Acne Vulgaris | Completed | 2010-03-31 | 2010-06-26 | ClinicalTrials.gov |
| NCT01114841 | A Study To Evaluate The Contact Sensitization Potential Of Tazarotene Foam On S… | Phase1 | Acne Vulgaris | Completed | 2010-03-31 | 2010-06-26 | ClinicalTrials.gov |
| NCT01060384 | Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractor… | Phase1 | Non-Hodgkin's Lymphoma | Completed | 2010-03-29 | 2018-01-01 | ClinicalTrials.gov |
| NCT01060384 | Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractor… | Phase1 | Non-Hodgkin's Lymphoma | Completed | 2010-03-29 | 2018-01-01 | ClinicalTrials.gov |
| NCT01745575 | Bioequivalence Trial of Alprazolam 2 mg Tablets | Phase1 | Anxiety Disorders | Completed | 2010-03-28 | 2010-04-05 | ClinicalTrials.gov |
| NCT01745575 | Bioequivalence Trial of Alprazolam 2 mg Tablets | Phase1 | Anxiety Disorders | Completed | 2010-03-28 | 2010-04-05 | ClinicalTrials.gov |
| NCT01112787 | A Study to Evaluate the Irritation Potential of Tazarotene Foam on Skin in Heal… | Phase1 | Acne Vulgaris | Completed | 2010-03-26 | 2010-04-26 | ClinicalTrials.gov |
| NCT01112787 | A Study to Evaluate the Irritation Potential of Tazarotene Foam on Skin in Heal… | Phase1 | Acne Vulgaris | Completed | 2010-03-26 | 2010-04-26 | ClinicalTrials.gov |
| NCT01092611 | Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine | Phase1 | AIDS | Completed | 2010-03-22 | 2014-05-19 | ClinicalTrials.gov |
| NCT01092611 | Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine | Phase1 | AIDS | Completed | 2010-03-22 | 2014-05-19 | ClinicalTrials.gov |
| NCT01098526 | GSK1349572 Drug Interaction Study With Efavirenz | Phase1 | Infections, Human Immunodeficiency Virus and Herpesviridae | Completed | 2010-03-16 | 2010-05-26 | ClinicalTrials.gov |
| NCT01098526 | GSK1349572 Drug Interaction Study With Efavirenz | Phase1 | Infections, Human Immunodeficiency Virus and Herpesviridae | Completed | 2010-03-16 | 2010-05-26 | ClinicalTrials.gov |
| NCT01077505 | An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When … | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2010-03-15 | 2010-11-24 | ClinicalTrials.gov |
| NCT01077505 | An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When … | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2010-03-15 | 2010-11-24 | ClinicalTrials.gov |
| NCT01072214 | A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers | Phase1 | Macular Degeneration | Completed | 2010-03-09 | 2010-06-28 | ClinicalTrials.gov |
| NCT01072214 | A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers | Phase1 | Macular Degeneration | Completed | 2010-03-09 | 2010-06-28 | ClinicalTrials.gov |
| NCT01128634 | Pharmacokinetic and Safety of GSK573719 and GW642444 Administered Individually … | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2010-03-04 | 2010-04-26 | ClinicalTrials.gov |
| NCT01128634 | Pharmacokinetic and Safety of GSK573719 and GW642444 Administered Individually … | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2010-03-04 | 2010-04-26 | ClinicalTrials.gov |
| NCT01086449 | Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in… | Phase1 | Herpes Zoster | Completed | 2010-03-04 | 2010-11-25 | ClinicalTrials.gov |
| NCT01086449 | Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in… | Phase1 | Herpes Zoster | Completed | 2010-03-04 | 2010-11-25 | ClinicalTrials.gov |
| NCT01018017 | A Clinical Study to Assess the Safety, Tolerability, and Activity of Oral SRT21… | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2010-03-03 | 2010-12-25 | ClinicalTrials.gov |
| NCT01018017 | A Clinical Study to Assess the Safety, Tolerability, and Activity of Oral SRT21… | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2010-03-03 | 2010-12-25 | ClinicalTrials.gov |
| NCT01179269 | Pazopanib and Paclitaxel for Non-Small Cell Lung Cancer | Phase2 | Non-small Cell Lung Cancer | Withdrawn | 2010-03-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01047397 | Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia | Phase2 | Kidney Disease | Completed | 2010-03-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT02686424 | Tumor Markers Study in Gastric Cancer for Cancer Immunotherapy (ONCO-RD 010 CRT) | — | Stomach Neoplasms | Suspended | 2010-03-01 | — | ClinicalTrials.gov |
| NCT00997620 | Fluticasone Furoate Treatment of Daytime Somnolence and Cognitive Performance i… | Phase4 | Seasonal Allergic Rhinitis | Completed | 2010-03-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT01004939 | Retrospective Study of Patients Who Were Treated With Fondaparinux Pre-, Peri- … | — | Thromboembolism | Completed | 2010-03-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01016678 | Treximet Early Intervention Adolescent Migraine | Phase2 | Migraine | Completed | 2010-03-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01047397 | Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia | Phase2 | Kidney Disease | Completed | 2010-03-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01064336 | Promacta Pregnancy Registry | — | Purpura, Thrombocytopaenic, Idiopathic | Completed | 2010-03-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01086410 | Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypo… | Phase3 | Asthma | Completed | 2010-03-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT01086423 | Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine | Phase3 | Tetanus | Completed | 2010-03-01 | 2010-11-19 | ClinicalTrials.gov |
| NCT01088009 | Efficacy Optimizing Research of Lamivudine Therapy | Phase4 | Compensated Chronic Hepatitis B | Completed | 2010-03-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01092390 | Go Fish: Omega-3 Fatty Acid Supplementation in Diabetes-Related Kidney Disease | Phase3 | Diabetes | Completed | 2010-03-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01138124 | Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD) | — | Renal Pelvis Cancer | Completed | 2010-03-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01162590 | Study to Evaluate the Reactogenicity and Safety of Rotarix™ in Chinese Adults | Phase1 | Infections, Rotavirus | Completed | 2010-03-01 | 2010-03-31 | ClinicalTrials.gov |
| NCT01179269 | Pazopanib and Paclitaxel for Non-Small Cell Lung Cancer | Phase2 | Non-small Cell Lung Cancer | Withdrawn | 2010-03-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01381497 | Impact of Migraine on Work Productivity in Patients Treated With a Combination … | — | Migraine Disorders | Completed | 2010-03-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT02686424 | Tumor Markers Study in Gastric Cancer for Cancer Immunotherapy (ONCO-RD 010 CRT) | — | Stomach Neoplasms | Suspended | 2010-03-01 | — | ClinicalTrials.gov |
| NCT01381497 | Impact of Migraine on Work Productivity in Patients Treated With a Combination … | — | Migraine Disorders | Completed | 2010-03-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01162590 | Study to Evaluate the Reactogenicity and Safety of Rotarix™ in Chinese Adults | Phase1 | Infections, Rotavirus | Completed | 2010-03-01 | 2010-03-31 | ClinicalTrials.gov |
| NCT01138124 | Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD) | — | Renal Pelvis Cancer | Completed | 2010-03-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01092390 | Go Fish: Omega-3 Fatty Acid Supplementation in Diabetes-Related Kidney Disease | Phase3 | Diabetes | Completed | 2010-03-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01088009 | Efficacy Optimizing Research of Lamivudine Therapy | Phase4 | Compensated Chronic Hepatitis B | Completed | 2010-03-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01086423 | Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine | Phase3 | Tetanus | Completed | 2010-03-01 | 2010-11-19 | ClinicalTrials.gov |
| NCT01086410 | Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypo… | Phase3 | Asthma | Completed | 2010-03-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT01064336 | Promacta Pregnancy Registry | — | Purpura, Thrombocytopaenic, Idiopathic | Completed | 2010-03-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT00997620 | Fluticasone Furoate Treatment of Daytime Somnolence and Cognitive Performance i… | Phase4 | Seasonal Allergic Rhinitis | Completed | 2010-03-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT01004939 | Retrospective Study of Patients Who Were Treated With Fondaparinux Pre-, Peri- … | — | Thromboembolism | Completed | 2010-03-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01016678 | Treximet Early Intervention Adolescent Migraine | Phase2 | Migraine | Completed | 2010-03-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01086384 | Asthma Exacerbation Study | Phase3 | Asthma | Completed | 2010-02-22 | 2011-09-15 | ClinicalTrials.gov |
| NCT01086384 | Asthma Exacerbation Study | Phase3 | Asthma | Completed | 2010-02-22 | 2011-09-15 | ClinicalTrials.gov |
| NCT01154166 | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study… | Phase3 | Parkinson Disease | Completed | 2010-02-15 | 2011-09-29 | ClinicalTrials.gov |
| NCT01068925 | Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy V… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2010-02-15 | 2010-04-05 | ClinicalTrials.gov |
| NCT01068925 | Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy V… | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2010-02-15 | 2010-04-05 | ClinicalTrials.gov |
| NCT01154166 | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study… | Phase3 | Parkinson Disease | Completed | 2010-02-15 | 2011-09-29 | ClinicalTrials.gov |
| NCT01424423 | NOGO-A in Multiple Sclerosis FTIH | Phase1 | Multiple Sclerosis | Terminated | 2010-02-11 | 2010-08-26 | ClinicalTrials.gov |
| NCT01424423 | NOGO-A in Multiple Sclerosis FTIH | Phase1 | Multiple Sclerosis | Terminated | 2010-02-11 | 2010-08-26 | ClinicalTrials.gov |
| NCT01067339 | Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary… | Phase3 | Endothelial Dysfunction | Completed | 2010-02-04 | 2015-11-01 | ClinicalTrials.gov |
| NCT01067339 | Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary… | Phase3 | Endothelial Dysfunction | Completed | 2010-02-04 | 2015-11-01 | ClinicalTrials.gov |
| NCT01039961 | PK Study of IV Formulation of GW856553 | Phase1 | Cardiovascular Disease | Completed | 2010-02-02 | 2010-04-15 | ClinicalTrials.gov |
| NCT01039961 | PK Study of IV Formulation of GW856553 | Phase1 | Cardiovascular Disease | Completed | 2010-02-02 | 2010-04-15 | ClinicalTrials.gov |
| NCT01702337 | Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrival… | — | Human Papillomavirus Infection | Completed | 2010-02-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT01702337 | Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrival… | — | Human Papillomavirus Infection | Completed | 2010-02-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT01332448 | Meta-analysis of Orlistat Laboratory Data From Placebo-controlled Clinical Tria… | — | Obesity | Completed | 2010-02-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00979771 | A Study to Investigate the Ability of GSK706769 to Maintain Clinical Remission … | Phase2 | Arthritis, Rheumatoid | Withdrawn | 2010-02-01 | 2011-04-28 | ClinicalTrials.gov |
| NCT01064947 | Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily I… | Phase4 | Atopic Dermatitis | Completed | 2010-02-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01811615 | Efficacy of New Alcohol Free Mouthrinses | Na | Gum Disease | Completed | 2010-02-01 | — | ClinicalTrials.gov |
| NCT01444612 | Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post C… | — | Thrombosis, Venous | Completed | 2010-02-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01035749 | Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Childr… | Phase2 | Influenza | Completed | 2010-02-01 | 2011-05-10 | ClinicalTrials.gov |
| NCT01345266 | Characterisation of Healthy Volunteers, Asthma and Chronic Obstructive Pulmonar… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2010-02-01 | 2010-06-28 | ClinicalTrials.gov |
| NCT00974805 | An Investigation of the Mechanism of Action of Seretide in Chronic Obstructive … | Phase4 | Chronic Obstructive Pulmonary Disease | Completed | 2010-02-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT00979771 | A Study to Investigate the Ability of GSK706769 to Maintain Clinical Remission … | Phase2 | Arthritis, Rheumatoid | Withdrawn | 2010-02-01 | 2011-04-28 | ClinicalTrials.gov |
| NCT01345266 | Characterisation of Healthy Volunteers, Asthma and Chronic Obstructive Pulmonar… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2010-02-01 | 2010-06-28 | ClinicalTrials.gov |
| NCT01002040 | Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV | Phase4 | HIV Infections | Completed | 2010-02-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01002040 | Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV | Phase4 | HIV Infections | Completed | 2010-02-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01035749 | Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Childr… | Phase2 | Influenza | Completed | 2010-02-01 | 2011-05-10 | ClinicalTrials.gov |
| NCT01546116 | Adefovir and Lamivudine for Entecavir Resistance (ALTER Study) | Phase4 | Chronic Hepatitis B | Completed | 2010-02-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01077648 | Brain Metastasis in Breast Cancer Patients | — | Cancer | Completed | 2010-02-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01546116 | Adefovir and Lamivudine for Entecavir Resistance (ALTER Study) | Phase4 | Chronic Hepatitis B | Completed | 2010-02-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01072890 | Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors | Phase1 | Solid Tumors | Completed | 2010-02-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01077648 | Brain Metastasis in Breast Cancer Patients | — | Cancer | Completed | 2010-02-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01072890 | Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors | Phase1 | Solid Tumors | Completed | 2010-02-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01444612 | Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post C… | — | Thrombosis, Venous | Completed | 2010-02-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00974805 | An Investigation of the Mechanism of Action of Seretide in Chronic Obstructive … | Phase4 | Chronic Obstructive Pulmonary Disease | Completed | 2010-02-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01064947 | Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily I… | Phase4 | Atopic Dermatitis | Completed | 2010-02-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01811615 | Efficacy of New Alcohol Free Mouthrinses | Na | Gum Disease | Completed | 2010-02-01 | — | ClinicalTrials.gov |
| NCT01332448 | Meta-analysis of Orlistat Laboratory Data From Placebo-controlled Clinical Tria… | — | Obesity | Completed | 2010-02-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01037114 | Long-term Persistence Study in Healthy Adults Previously Vaccinated With Twinri… | Phase4 | Hepatitis A | Completed | 2010-01-27 | 2014-02-28 | ClinicalTrials.gov |
| NCT01037114 | Long-term Persistence Study in Healthy Adults Previously Vaccinated With Twinri… | Phase4 | Hepatitis A | Completed | 2010-01-27 | 2014-02-28 | ClinicalTrials.gov |
| NCT01086462 | Intravenous Microdose Pharmacokinetic (PK) Study With [14C]-GSK2239633 | Phase1 | Asthma | Completed | 2010-01-21 | 2010-02-22 | ClinicalTrials.gov |
| NCT01086462 | Intravenous Microdose Pharmacokinetic (PK) Study With [14C]-GSK2239633 | Phase1 | Asthma | Completed | 2010-01-21 | 2010-02-22 | ClinicalTrials.gov |
| NCT01068587 | MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydroc… | Phase1 | Lung Cancer | Completed | 2010-01-21 | 2015-02-13 | ClinicalTrials.gov |
| NCT01068587 | MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydroc… | Phase1 | Lung Cancer | Completed | 2010-01-21 | 2015-02-13 | ClinicalTrials.gov |
| NCT01299597 | A Single-centre Open Label Study to Investigate the Effect of Repeat Doses of S… | Phase1 | Sleep Disorders | Completed | 2010-01-18 | 2010-02-26 | ClinicalTrials.gov |
| NCT01299597 | A Single-centre Open Label Study to Investigate the Effect of Repeat Doses of S… | Phase1 | Sleep Disorders | Completed | 2010-01-18 | 2010-02-26 | ClinicalTrials.gov |
| NCT01072162 | Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation … | Phase1 | Purpura, Thrombocytopaenic, Idiopathic | Completed | 2010-01-12 | 2010-04-07 | ClinicalTrials.gov |
| NCT01051700 | A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is A… | Phase1 | Macular Degeneration | Completed | 2010-01-12 | 2010-05-27 | ClinicalTrials.gov |
| NCT01072162 | Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation … | Phase1 | Purpura, Thrombocytopaenic, Idiopathic | Completed | 2010-01-12 | 2010-04-07 | ClinicalTrials.gov |
| NCT01051700 | A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is A… | Phase1 | Macular Degeneration | Completed | 2010-01-12 | 2010-05-27 | ClinicalTrials.gov |
| NCT01110057 | Efficacy Study in Lumbosacral Radiculopathy | Phase2 | Pain, Neuropathic | Completed | 2010-01-07 | 2010-08-23 | ClinicalTrials.gov |
| NCT01110057 | Efficacy Study in Lumbosacral Radiculopathy | Phase2 | Pain, Neuropathic | Completed | 2010-01-07 | 2010-08-23 | ClinicalTrials.gov |
| NCT01018030 | Dose Finding Study of Fluticasone Furoate Nasal Spray for Uncomplicated Acute R… | Phase2 | Sinusitis, Acute | Completed | 2010-01-06 | 2010-07-16 | ClinicalTrials.gov |
| NCT01018030 | Dose Finding Study of Fluticasone Furoate Nasal Spray for Uncomplicated Acute R… | Phase2 | Sinusitis, Acute | Completed | 2010-01-06 | 2010-07-16 | ClinicalTrials.gov |
| NCT01035645 | First Time in Human Study of Intravenous Interleukin-18 Antibody | Phase1 | Inflammatory Bowel Diseases | Completed | 2010-01-05 | 2012-07-11 | ClinicalTrials.gov |
| NCT01035645 | First Time in Human Study of Intravenous Interleukin-18 Antibody | Phase1 | Inflammatory Bowel Diseases | Completed | 2010-01-05 | 2012-07-11 | ClinicalTrials.gov |
| NCT01262989 | SECOTEX® (Tamsulosin Hydrochloride) Bioequivalence Study Brazil - Fast Admin | Phase1 | Prostatic Hyperplasia | Completed | 2010-01-04 | 2010-01-26 | ClinicalTrials.gov |
| NCT01262989 | SECOTEX® (Tamsulosin Hydrochloride) Bioequivalence Study Brazil - Fast Admin | Phase1 | Prostatic Hyperplasia | Completed | 2010-01-04 | 2010-01-26 | ClinicalTrials.gov |
| NCT01337258 | Economic Analyses of the REDUCE Trial | — | Neoplasms, Prostate | Completed | 2010-01-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00936195 | Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in … | Phase3 | HIV Infection | Withdrawn | 2010-01-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00920348 | The Canadian Cohort Obstructive Lung Disease | — | COPD | Unknown | 2010-01-01 | 2022-12-01 | ClinicalTrials.gov |
| NCT01035658 | Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian … | Phase1 | Ovarian Cancer | Terminated | 2010-01-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01387243 | Survey on the Pharmacy Follow-up of Alli Purchasers | — | Overweight | Completed | 2010-01-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01376271 | Special Drug Use Investigation for PAXIL (Paroxetine) Social Anxiety Disorder (… | — | Social Phobia | Completed | 2010-01-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01376219 | European Cost of Asthma Treatment | — | Asthma | Completed | 2010-01-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01072149 | A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), a… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2010-01-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00920348 | The Canadian Cohort Obstructive Lung Disease | — | COPD | Unknown | 2010-01-01 | 2022-12-01 | ClinicalTrials.gov |
| NCT00936195 | Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in … | Phase3 | HIV Infection | Withdrawn | 2010-01-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01064362 | Hemorrhage Risk Prescribed Arixtra | — | Thrombosis, Venous | Completed | 2010-01-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00944229 | The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure | Phase3 | Heart Failure | Terminated | 2010-01-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01039675 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination … | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2010-01-01 | 2010-04-20 | ClinicalTrials.gov |
| NCT00975988 | Regulatory TYKERB® Tablets PMS | — | Cancer | Completed | 2010-01-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01085461 | Assessment of Suicidality in Epilepsy - Rating Tools | — | Epilepsy | Completed | 2010-01-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01072149 | A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), a… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2010-01-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01064362 | Hemorrhage Risk Prescribed Arixtra | — | Thrombosis, Venous | Completed | 2010-01-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01048502 | Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia | Na | Cardiovascular Disease | Completed | 2010-01-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01044576 | Patient Research Cohort: Rapidly Evolving Multiple Sclerosis | — | Relapsing-remitting Multiple Sclerosis | Completed | 2010-01-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01039675 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination … | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2010-01-01 | 2010-04-20 | ClinicalTrials.gov |
| NCT01035658 | Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian … | Phase1 | Ovarian Cancer | Terminated | 2010-01-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01048502 | Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia | Na | Cardiovascular Disease | Completed | 2010-01-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01028326 | PCV10 Reactogenicity and Immunogenicity Study - Malindi | Phase4 | Pneumococcal Pneumonia | Unknown | 2010-01-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT01027598 | Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in P… | Phase2 | Non Small Cell Lung Cancer | Completed | 2010-01-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01337258 | Economic Analyses of the REDUCE Trial | — | Neoplasms, Prostate | Completed | 2010-01-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01085461 | Assessment of Suicidality in Epilepsy - Rating Tools | — | Epilepsy | Completed | 2010-01-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00975988 | Regulatory TYKERB® Tablets PMS | — | Cancer | Completed | 2010-01-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01376219 | European Cost of Asthma Treatment | — | Asthma | Completed | 2010-01-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01376271 | Special Drug Use Investigation for PAXIL (Paroxetine) Social Anxiety Disorder (… | — | Social Phobia | Completed | 2010-01-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01027598 | Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in P… | Phase2 | Non Small Cell Lung Cancer | Completed | 2010-01-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01028326 | PCV10 Reactogenicity and Immunogenicity Study - Malindi | Phase4 | Pneumococcal Pneumonia | Unknown | 2010-01-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT01387243 | Survey on the Pharmacy Follow-up of Alli Purchasers | — | Overweight | Completed | 2010-01-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00944229 | The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure | Phase3 | Heart Failure | Terminated | 2010-01-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01044576 | Patient Research Cohort: Rapidly Evolving Multiple Sclerosis | — | Relapsing-remitting Multiple Sclerosis | Completed | 2010-01-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01004874 | Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topo… | Phase2 | Malignant Glioma | Completed | 2009-12-30 | 2021-11-02 | ClinicalTrials.gov |
| NCT01004874 | Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topo… | Phase2 | Malignant Glioma | Completed | 2009-12-30 | 2021-11-02 | ClinicalTrials.gov |
| NCT01021553 | A Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodyna… | Phase2 | Premature Ejaculation | Completed | 2009-12-23 | 2011-05-05 | ClinicalTrials.gov |
| NCT01021553 | A Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodyna… | Phase2 | Premature Ejaculation | Completed | 2009-12-23 | 2011-05-05 | ClinicalTrials.gov |
| NCT01031472 | A Study to Assess Relative Bioavailability and Food Effect of New Formulations … | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2009-12-21 | 2010-03-11 | ClinicalTrials.gov |
| NCT01031472 | A Study to Assess Relative Bioavailability and Food Effect of New Formulations … | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2009-12-21 | 2010-03-11 | ClinicalTrials.gov |
| NCT01371799 | A Study to Examine the Pharmacodynamic Effects of GSK1034702 on Neurophysiologi… | Phase1 | Mental Disorders | Completed | 2009-12-17 | 2010-06-18 | ClinicalTrials.gov |
| NCT01371799 | A Study to Examine the Pharmacodynamic Effects of GSK1034702 on Neurophysiologi… | Phase1 | Mental Disorders | Completed | 2009-12-17 | 2010-06-18 | ClinicalTrials.gov |
| NCT01030965 | 28-day Repeat Dose Study of GSK573719 | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2009-12-15 | 2010-07-04 | ClinicalTrials.gov |
| NCT01030965 | 28-day Repeat Dose Study of GSK573719 | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2009-12-15 | 2010-07-04 | ClinicalTrials.gov |
| NCT01079910 | To Investigate the Clinical Efficacy of an Experimental Toothpaste | Phase1 | Gingivitis | Withdrawn | 2009-12-09 | 2009-12-10 | ClinicalTrials.gov |
| NCT01079910 | To Investigate the Clinical Efficacy of an Experimental Toothpaste | Phase1 | Gingivitis | Withdrawn | 2009-12-09 | 2009-12-10 | ClinicalTrials.gov |
| NCT01051063 | Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia P… | Phase1 | Leukaemia, Myelocytic, Acute | Completed | 2009-12-09 | 2016-04-26 | ClinicalTrials.gov |
| NCT01014117 | Effect of SRT2104 on Endotoxin-induced Inflammation | Phase1 | Sepsis | Completed | 2009-12-09 | 2010-05-10 | ClinicalTrials.gov |
| NCT01014117 | Effect of SRT2104 on Endotoxin-induced Inflammation | Phase1 | Sepsis | Completed | 2009-12-09 | 2010-05-10 | ClinicalTrials.gov |
| NCT01051063 | Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia P… | Phase1 | Leukaemia, Myelocytic, Acute | Completed | 2009-12-09 | 2016-04-26 | ClinicalTrials.gov |
| NCT01027845 | Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A in … | Phase3 | Infections, Streptococcal | Completed | 2009-12-08 | 2011-09-17 | ClinicalTrials.gov |
| NCT01027845 | Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A in … | Phase3 | Infections, Streptococcal | Completed | 2009-12-08 | 2011-09-17 | ClinicalTrials.gov |
| NCT01018628 | A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2009-12-07 | 2010-08-06 | ClinicalTrials.gov |
| NCT01018628 | A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2009-12-07 | 2010-08-06 | ClinicalTrials.gov |
| NCT01540721 | Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a… | Phase1 | Healthy Subjects | Completed | 2009-12-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT01039805 | Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral… | Phase2 | Gastroparesis | Completed | 2009-12-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01262469 | Evaluating Lapatinib + Capecitabine in Patients Aged 70 and Over With HER2 Meta… | Phase2 | Metastatic Breast Cancer | Completed | 2009-12-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01450995 | Migraine Treatment Satisfaction With Treximet Versus Concomitant 2 Aleve and Im… | Phase4 | Migraine | Completed | 2009-12-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01196273 | Cardiovascular Diseases in HIV-infected Patients HIV-HEART Study: 5 Years Follo… | — | Coronary Heart Disease | Completed | 2009-12-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00972725 | Evaluation of the Immune Response of a HIV Candidate Vaccine After Administrati… | Phase2 | AIDS | Completed | 2009-12-01 | 2010-10-04 | ClinicalTrials.gov |
| NCT01439308 | Intranasal SB-705498 in Non-allergic Rhinitis Patients | Phase2 | Rhinitis | Completed | 2009-12-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01262469 | Evaluating Lapatinib + Capecitabine in Patients Aged 70 and Over With HER2 Meta… | Phase2 | Metastatic Breast Cancer | Completed | 2009-12-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01428440 | PET Study to Study Tumour Apoptosis | Phase2 | Cancer | Terminated | 2009-12-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00972725 | Evaluation of the Immune Response of a HIV Candidate Vaccine After Administrati… | Phase2 | AIDS | Completed | 2009-12-01 | 2010-10-04 | ClinicalTrials.gov |
| NCT01376206 | Drug Use Investigation for ALLERMIST | — | Rhinitis | Completed | 2009-12-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01439308 | Intranasal SB-705498 in Non-allergic Rhinitis Patients | Phase2 | Rhinitis | Completed | 2009-12-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01450995 | Migraine Treatment Satisfaction With Treximet Versus Concomitant 2 Aleve and Im… | Phase4 | Migraine | Completed | 2009-12-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01916395 | Comparison of Treximet & Imitrex as They Affect the Levels of Inflammatory Mark… | — | Migraine | Completed | 2009-12-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01592227 | A Study to Compare Two Paracetamol Formulations. | Phase1 | Pain | Completed | 2009-12-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT01039805 | Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral… | Phase2 | Gastroparesis | Completed | 2009-12-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01012362 | Study of Pazopanib and Ixabepilone in Patients With Solid Tumors | Phase1 | Breast Cancer | Terminated | 2009-12-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01014091 | Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Cand… | Phase3 | Influenza | Terminated | 2009-12-01 | 2011-01-14 | ClinicalTrials.gov |
| NCT01916395 | Comparison of Treximet & Imitrex as They Affect the Levels of Inflammatory Mark… | — | Migraine | Completed | 2009-12-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01016444 | Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms | — | Acute Asthma | Completed | 2009-12-01 | 2011-07-29 | ClinicalTrials.gov |
| NCT01540721 | Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a… | Phase1 | Healthy Subjects | Completed | 2009-12-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT01196273 | Cardiovascular Diseases in HIV-infected Patients HIV-HEART Study: 5 Years Follo… | — | Coronary Heart Disease | Completed | 2009-12-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01332370 | Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti … | — | Diabetes Mellitus, Type 2 | Completed | 2009-12-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01376206 | Drug Use Investigation for ALLERMIST | — | Rhinitis | Completed | 2009-12-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01012362 | Study of Pazopanib and Ixabepilone in Patients With Solid Tumors | Phase1 | Breast Cancer | Terminated | 2009-12-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01014091 | Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Cand… | Phase3 | Influenza | Terminated | 2009-12-01 | 2011-01-14 | ClinicalTrials.gov |
| NCT01016444 | Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms | — | Acute Asthma | Completed | 2009-12-01 | 2011-07-29 | ClinicalTrials.gov |
| NCT01428440 | PET Study to Study Tumour Apoptosis | Phase2 | Cancer | Terminated | 2009-12-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01592227 | A Study to Compare Two Paracetamol Formulations. | Phase1 | Pain | Completed | 2009-12-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT01332370 | Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti … | — | Diabetes Mellitus, Type 2 | Completed | 2009-12-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01021293 | Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vacci… | Phase3 | Poliomyelitis | Completed | 2009-11-28 | 2010-07-05 | ClinicalTrials.gov |
| NCT01021293 | Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vacci… | Phase3 | Poliomyelitis | Completed | 2009-11-28 | 2010-07-05 | ClinicalTrials.gov |
| NCT01009814 | Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment … | Phase2 | HIV Infections | Completed | 2009-11-23 | 2010-06-25 | ClinicalTrials.gov |
| NCT01128621 | A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate … | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2009-11-23 | 2010-04-12 | ClinicalTrials.gov |
| NCT01128621 | A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate … | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2009-11-23 | 2010-04-12 | ClinicalTrials.gov |
| NCT01009814 | Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment … | Phase2 | HIV Infections | Completed | 2009-11-23 | 2010-06-25 | ClinicalTrials.gov |
| NCT00992121 | An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell … | Phase1 | Carcinoma, Renal Cell | Completed | 2009-11-18 | 2013-11-01 | ClinicalTrials.gov |
| NCT00992121 | An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell … | Phase1 | Carcinoma, Renal Cell | Completed | 2009-11-18 | 2013-11-01 | ClinicalTrials.gov |
| NCT01003418 | Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influe… | Phase2 | Influenza | Terminated | 2009-11-17 | 2010-11-25 | ClinicalTrials.gov |
| NCT01003418 | Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influe… | Phase2 | Influenza | Terminated | 2009-11-17 | 2010-11-25 | ClinicalTrials.gov |
| NCT00985465 | Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK102… | Phase3 | Infections, Streptococcal | Completed | 2009-11-12 | 2010-07-26 | ClinicalTrials.gov |
| NCT04912297 | Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With P… | — | Pneumococcal Infections | Completed | 2009-11-12 | 2013-05-07 | ClinicalTrials.gov |
| NCT00985465 | Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK102… | Phase3 | Infections, Streptococcal | Completed | 2009-11-12 | 2010-07-26 | ClinicalTrials.gov |
| NCT04912297 | Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With P… | — | Pneumococcal Infections | Completed | 2009-11-12 | 2013-05-07 | ClinicalTrials.gov |
| NCT00996762 | A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formul… | Phase1 | Neoplasms, Breast | Completed | 2009-11-12 | 2012-09-18 | ClinicalTrials.gov |
| NCT00996762 | A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formul… | Phase1 | Neoplasms, Breast | Completed | 2009-11-12 | 2012-09-18 | ClinicalTrials.gov |
| NCT01181908 | Alcohol Interaction Study | Phase1 | Alcoholism | Completed | 2009-11-11 | 2009-12-30 | ClinicalTrials.gov |
| NCT01181908 | Alcohol Interaction Study | Phase1 | Alcoholism | Completed | 2009-11-11 | 2009-12-30 | ClinicalTrials.gov |
| NCT00979602 | Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 1… | Phase3 | Influenza | Completed | 2009-11-09 | 2011-02-01 | ClinicalTrials.gov |
| NCT00969436 | Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus Priorix… | Phase3 | Varicella | Completed | 2009-11-09 | 2011-02-21 | ClinicalTrials.gov |
| NCT00979602 | Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 1… | Phase3 | Influenza | Completed | 2009-11-09 | 2011-02-01 | ClinicalTrials.gov |
| NCT00969436 | Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus Priorix… | Phase3 | Varicella | Completed | 2009-11-09 | 2011-02-21 | ClinicalTrials.gov |
| NCT01000324 | Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated Wi… | Phase4 | Hepatitis A | Completed | 2009-11-06 | 2014-07-25 | ClinicalTrials.gov |
| NCT01000324 | Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated Wi… | Phase4 | Hepatitis A | Completed | 2009-11-06 | 2014-07-25 | ClinicalTrials.gov |
| NCT01009255 | Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease | Phase2 | Alzheimer's Disease | Completed | 2009-11-02 | 2010-11-10 | ClinicalTrials.gov |
| NCT01009255 | Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease | Phase2 | Alzheimer's Disease | Completed | 2009-11-02 | 2010-11-10 | ClinicalTrials.gov |
| NCT01014988 | Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Pat… | Phase2 | Influenza, Human | Completed | 2009-11-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01199744 | Relenza® Sentinel Site Monitoring Program in Japan | — | Influenza, Human | Completed | 2009-11-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT01050322 | Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Tax… | Phase2 | BRMS1 | Completed | 2009-11-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01199744 | Relenza® Sentinel Site Monitoring Program in Japan | — | Influenza, Human | Completed | 2009-11-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT01014988 | Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Pat… | Phase2 | Influenza, Human | Completed | 2009-11-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01128946 | Enamel Remineralization Potential of Dentifrices in Situ | Phase4 | Dental Caries | Completed | 2009-11-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT01476189 | A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulatio… | Phase1 | Healthy Subjects | Completed | 2009-11-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT01476215 | A Pharmacokinetic Study Investigating the Rate and Extent of Paracetamol Absorp… | Phase1 | Healthy Subjects | Completed | 2009-11-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT01075243 | Post-operative Dental Pain Study Comparing Two Different Dosage of Analgesic Ef… | Phase4 | Post-surgical Dental Pain | Completed | 2009-11-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00997061 | SCOT Registry: Small Cell Lung Cancer Treatment and Outcome | — | Lung Cancer, Small Cell | Completed | 2009-11-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01075243 | Post-operative Dental Pain Study Comparing Two Different Dosage of Analgesic Ef… | Phase4 | Post-surgical Dental Pain | Completed | 2009-11-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00977301 | Interaction Between Fosamprenavir/Ritonavir and a Single-dose Olanzapine (FORZA) | Phase1 | HIV Infections | Completed | 2009-11-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01777074 | Acceptability of Hepatitis B Vaccination in General Practitioners and Paediatri… | — | Hepatitis B | Completed | 2009-11-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01332435 | Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database … | — | Prostatic Hyperplasia | Completed | 2009-11-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT01050322 | Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Tax… | Phase2 | BRMS1 | Completed | 2009-11-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01039610 | A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safe… | Phase1 | Infections, Bacterial | Withdrawn | 2009-11-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01332461 | Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2009-11-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01037127 | Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Me… | Phase2 | Cancer | Completed | 2009-11-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01777074 | Acceptability of Hepatitis B Vaccination in General Practitioners and Paediatri… | — | Hepatitis B | Completed | 2009-11-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01013701 | Compare the Effects of Fluticasone Furoate Nasal Spray vs Placebo in Patients W… | Phase4 | Patients With Nasal Polyps | Terminated | 2009-11-01 | 2010-07-29 | ClinicalTrials.gov |
| NCT01013701 | Compare the Effects of Fluticasone Furoate Nasal Spray vs Placebo in Patients W… | Phase4 | Patients With Nasal Polyps | Terminated | 2009-11-01 | 2010-07-29 | ClinicalTrials.gov |
| NCT01000506 | Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma | Phase2 | Asthma | Completed | 2009-11-01 | 2012-03-23 | ClinicalTrials.gov |
| NCT00997061 | SCOT Registry: Small Cell Lung Cancer Treatment and Outcome | — | Lung Cancer, Small Cell | Completed | 2009-11-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01037127 | Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Me… | Phase2 | Cancer | Completed | 2009-11-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01476215 | A Pharmacokinetic Study Investigating the Rate and Extent of Paracetamol Absorp… | Phase1 | Healthy Subjects | Completed | 2009-11-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT01476189 | A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulatio… | Phase1 | Healthy Subjects | Completed | 2009-11-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00977301 | Interaction Between Fosamprenavir/Ritonavir and a Single-dose Olanzapine (FORZA) | Phase1 | HIV Infections | Completed | 2009-11-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01000506 | Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma | Phase2 | Asthma | Completed | 2009-11-01 | 2012-03-23 | ClinicalTrials.gov |
| NCT01039610 | A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safe… | Phase1 | Infections, Bacterial | Withdrawn | 2009-11-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01332461 | Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2009-11-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01332435 | Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database … | — | Prostatic Hyperplasia | Completed | 2009-11-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT01128946 | Enamel Remineralization Potential of Dentifrices in Situ | Phase4 | Dental Caries | Completed | 2009-11-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00996853 | Post-Authorization Safety Study of GSK Biologicals' Pandemic Influenza Vaccine … | — | Influenza | Completed | 2009-10-31 | 2011-04-06 | ClinicalTrials.gov |
| NCT00996853 | Post-Authorization Safety Study of GSK Biologicals' Pandemic Influenza Vaccine … | — | Influenza | Completed | 2009-10-31 | 2011-04-06 | ClinicalTrials.gov |
| NCT00984659 | Validation of a New Shortness of Breath With Daily Activities Questionnaire in … | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2009-10-29 | 2010-07-01 | ClinicalTrials.gov |
| NCT00984659 | Validation of a New Shortness of Breath With Daily Activities Questionnaire in … | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2009-10-29 | 2010-07-01 | ClinicalTrials.gov |
| NCT00996125 | Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299… | Phase3 | Infections, Papillomavirus | Completed | 2009-10-24 | 2010-12-08 | ClinicalTrials.gov |
| NCT00996125 | Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299… | Phase3 | Infections, Papillomavirus | Completed | 2009-10-24 | 2010-12-08 | ClinicalTrials.gov |
| NCT00945282 | Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretro… | Phase2 | Infection, Human Immunodeficiency Virus | Completed | 2009-10-20 | 2009-11-28 | ClinicalTrials.gov |
| NCT01339247 | Paxil CR Bioequivalence Study Brazil - Fed Administration | Phase1 | Depressive Disorder | Completed | 2009-10-20 | 2009-11-16 | ClinicalTrials.gov |
| NCT01339247 | Paxil CR Bioequivalence Study Brazil - Fed Administration | Phase1 | Depressive Disorder | Completed | 2009-10-20 | 2009-11-16 | ClinicalTrials.gov |
| NCT00976820 | Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Th… | Phase2 | Influenza | Completed | 2009-10-20 | 2011-03-21 | ClinicalTrials.gov |
| NCT00976820 | Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Th… | Phase2 | Influenza | Completed | 2009-10-20 | 2011-03-21 | ClinicalTrials.gov |
| NCT00945282 | Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretro… | Phase2 | Infection, Human Immunodeficiency Virus | Completed | 2009-10-20 | 2009-11-28 | ClinicalTrials.gov |
| NCT00976261 | A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Eval… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2009-10-17 | 2010-09-05 | ClinicalTrials.gov |
| NCT00976261 | A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Eval… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2009-10-17 | 2010-09-05 | ClinicalTrials.gov |
| NCT01209052 | First Time in Human Study With GSK1325756 | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2009-10-15 | 2010-03-02 | ClinicalTrials.gov |
| NCT00996268 | An Open-label Single Dose Randomized, Parallel Group Study Followed by Single-b… | Phase1 | Cardiovascular Disease | Completed | 2009-10-15 | 2010-01-04 | ClinicalTrials.gov |
| NCT00996268 | An Open-label Single Dose Randomized, Parallel Group Study Followed by Single-b… | Phase1 | Cardiovascular Disease | Completed | 2009-10-15 | 2010-01-04 | ClinicalTrials.gov |
| NCT00992784 | Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals'… | Phase3 | Influenza | Completed | 2009-10-15 | 2010-05-27 | ClinicalTrials.gov |
| NCT01209052 | First Time in Human Study With GSK1325756 | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2009-10-15 | 2010-03-02 | ClinicalTrials.gov |
| NCT00992784 | Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals'… | Phase3 | Influenza | Completed | 2009-10-15 | 2010-05-27 | ClinicalTrials.gov |
| NCT00992511 | Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza… | Phase3 | Influenza | Completed | 2009-10-14 | 2010-11-09 | ClinicalTrials.gov |
| NCT00992511 | Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza… | Phase3 | Influenza | Completed | 2009-10-14 | 2010-11-09 | ClinicalTrials.gov |
| NCT00979407 | Study to Evaluate Immunological Equivalence Between Two Investigational Influen… | Phase3 | Influenza | Completed | 2009-10-12 | 2010-11-04 | ClinicalTrials.gov |
| NCT00989404 | Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics o… | Phase1 | Influenza A Virus, H1N1 Subtype | Completed | 2009-10-12 | 2009-12-07 | ClinicalTrials.gov |
| NCT00979407 | Study to Evaluate Immunological Equivalence Between Two Investigational Influen… | Phase3 | Influenza | Completed | 2009-10-12 | 2010-11-04 | ClinicalTrials.gov |
| NCT00984139 | Persistence of Immunity Against Hepatitis B in 12-13 Year Old Adolescents After… | Phase4 | Hepatitis B | Completed | 2009-10-12 | 2010-04-07 | ClinicalTrials.gov |
| NCT00989404 | Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics o… | Phase1 | Influenza A Virus, H1N1 Subtype | Completed | 2009-10-12 | 2009-12-07 | ClinicalTrials.gov |
| NCT00984139 | Persistence of Immunity Against Hepatitis B in 12-13 Year Old Adolescents After… | Phase4 | Hepatitis B | Completed | 2009-10-12 | 2010-04-07 | ClinicalTrials.gov |
| NCT00985088 | Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older | Phase2 | Influenza | Completed | 2009-10-11 | 2010-12-16 | ClinicalTrials.gov |
| NCT00985088 | Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older | Phase2 | Influenza | Completed | 2009-10-11 | 2010-12-16 | ClinicalTrials.gov |
| NCT00985790 | Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Inf… | Phase2 | Influenza | Completed | 2009-10-08 | 2010-05-21 | ClinicalTrials.gov |
| NCT00910962 | A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effe… | Phase2 | Acute Coronary Syndrome | Completed | 2009-10-08 | 2012-03-06 | ClinicalTrials.gov |
| NCT00910962 | A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effe… | Phase2 | Acute Coronary Syndrome | Completed | 2009-10-08 | 2012-03-06 | ClinicalTrials.gov |
| NCT00985790 | Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Inf… | Phase2 | Influenza | Completed | 2009-10-08 | 2010-05-21 | ClinicalTrials.gov |
| NCT01013974 | A Study of GSK573719 in Healthy Japanese Male Subjects | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2009-10-05 | 2009-12-18 | ClinicalTrials.gov |
| NCT01013974 | A Study of GSK573719 in Healthy Japanese Male Subjects | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2009-10-05 | 2009-12-18 | ClinicalTrials.gov |
| NCT01053988 | A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2009-10-05 | 2011-04-14 | ClinicalTrials.gov |
| NCT01053988 | A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2009-10-05 | 2011-04-14 | ClinicalTrials.gov |
| NCT01016977 | A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Effi… | Phase4 | Acne Vulgaris | Completed | 2009-10-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT01289418 | Surveillance for Adverse Events Following Pandemic H1N1 Immunization | — | Novel Influenza A/H1N1 | Completed | 2009-10-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01195259 | Malignancy Meta Analysis for BRL49653 | — | Diabetes Mellitus, Type 2 | Completed | 2009-10-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT01008813 | Clinical Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N… | Phase2 | HIV Infections | Completed | 2009-10-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01077661 | Regulatory Nebilet PMS | — | Hypertension | Completed | 2009-10-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT01001325 | Does Seasonal Influenza Vaccination Affect the Incidence of pH1N1 Influenza? | Phase3 | Influenza | Completed | 2009-10-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01082081 | Post-operative Dental Pain Study Comparing Analgesic Efficacy | Phase4 | Post-surgical Dental Pain | Completed | 2009-10-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT01001325 | Does Seasonal Influenza Vaccination Affect the Incidence of pH1N1 Influenza? | Phase3 | Influenza | Completed | 2009-10-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01001169 | Safety and Immunogenocity Study of GSK Biologicals' Pandemic Influenza (H1N1) C… | Phase2 | Influenza | Completed | 2009-10-01 | 2010-05-17 | ClinicalTrials.gov |
| NCT01485237 | Severe Pandemic H1N1 Infection in ICU: Comparative Resource Utilization | — | Novel H1N1 Influenzal Acute Respiratory Infection | Completed | 2009-10-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00931879 | Lovaza® and Microvascular Function in Type 2 Diabetes | Phase4 | Hypertriglyceridemia | Completed | 2009-10-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01485237 | Severe Pandemic H1N1 Infection in ICU: Comparative Resource Utilization | — | Novel H1N1 Influenzal Acute Respiratory Infection | Completed | 2009-10-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01429376 | Pulmonary Function, Chronic Obstructive Pulmonary Disease (COPD) Prevalence, an… | Na | Heart Failure | Completed | 2009-10-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT00991523 | Overnight Post-Exercise Recovery After Protein Ingestion Prior to Sleep | Na | Exercise | Completed | 2009-10-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00989612 | Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vac… | Phase2 | Influenza | Completed | 2009-10-01 | 2010-04-19 | ClinicalTrials.gov |
| NCT00985673 | Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal I… | Phase2 | Influenza | Completed | 2009-10-01 | 2010-12-29 | ClinicalTrials.gov |
| NCT00931879 | Lovaza® and Microvascular Function in Type 2 Diabetes | Phase4 | Hypertriglyceridemia | Completed | 2009-10-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01221987 | Cross-sectional Study on Human Papillomavirus Type Distribution in Adult Women … | — | Neoplasms, Uterine Cervix | Completed | 2009-10-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00832364 | Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Pla… | Phase4 | Plaque Psoriasis | Withdrawn | 2009-10-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT01001169 | Safety and Immunogenocity Study of GSK Biologicals' Pandemic Influenza (H1N1) C… | Phase2 | Influenza | Completed | 2009-10-01 | 2010-05-17 | ClinicalTrials.gov |
| NCT01289418 | Surveillance for Adverse Events Following Pandemic H1N1 Immunization | — | Novel Influenza A/H1N1 | Completed | 2009-10-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01016977 | A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Effi… | Phase4 | Acne Vulgaris | Completed | 2009-10-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00985673 | Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal I… | Phase2 | Influenza | Completed | 2009-10-01 | 2010-12-29 | ClinicalTrials.gov |
| NCT01082081 | Post-operative Dental Pain Study Comparing Analgesic Efficacy | Phase4 | Post-surgical Dental Pain | Completed | 2009-10-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00989612 | Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vac… | Phase2 | Influenza | Completed | 2009-10-01 | 2010-04-19 | ClinicalTrials.gov |
| NCT01195259 | Malignancy Meta Analysis for BRL49653 | — | Diabetes Mellitus, Type 2 | Completed | 2009-10-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00991523 | Overnight Post-Exercise Recovery After Protein Ingestion Prior to Sleep | Na | Exercise | Completed | 2009-10-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01366508 | A Study to Characterize Event Related Potential Markers of Attentional Bias Tow… | Phase1 | Obesity | Terminated | 2009-10-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT01008813 | Clinical Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N… | Phase2 | HIV Infections | Completed | 2009-10-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01017146 | A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjec… | Phase3 | Acne Vulgaris | Completed | 2009-10-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01221987 | Cross-sectional Study on Human Papillomavirus Type Distribution in Adult Women … | — | Neoplasms, Uterine Cervix | Completed | 2009-10-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT01366508 | A Study to Characterize Event Related Potential Markers of Attentional Bias Tow… | Phase1 | Obesity | Terminated | 2009-10-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT01017120 | A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjec… | Phase3 | Acne Vulgaris | Completed | 2009-10-01 | 2010-11-09 | ClinicalTrials.gov |
| NCT01429376 | Pulmonary Function, Chronic Obstructive Pulmonary Disease (COPD) Prevalence, an… | Na | Heart Failure | Completed | 2009-10-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01077661 | Regulatory Nebilet PMS | — | Hypertension | Completed | 2009-10-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00832364 | Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Pla… | Phase4 | Plaque Psoriasis | Withdrawn | 2009-10-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT01017146 | A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjec… | Phase3 | Acne Vulgaris | Completed | 2009-10-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01017120 | A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjec… | Phase3 | Acne Vulgaris | Completed | 2009-10-01 | 2010-11-09 | ClinicalTrials.gov |
| NCT00908037 | Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocyto… | Phase2 | Purpura, Thrombocytopaenic, Idiopathic | Completed | 2009-09-30 | 2014-02-01 | ClinicalTrials.gov |
| NCT00908037 | Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocyto… | Phase2 | Purpura, Thrombocytopaenic, Idiopathic | Completed | 2009-09-30 | 2014-02-01 | ClinicalTrials.gov |
| NCT00953576 | Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Ca… | Phase1 | Prostate Cancer | Terminated | 2009-09-29 | 2013-04-11 | ClinicalTrials.gov |
| NCT00953576 | Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Ca… | Phase1 | Prostate Cancer | Terminated | 2009-09-29 | 2013-04-11 | ClinicalTrials.gov |
| NCT00972517 | Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza… | Phase3 | Influenza | Completed | 2009-09-29 | 2010-11-22 | ClinicalTrials.gov |
| NCT00972517 | Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza… | Phase3 | Influenza | Completed | 2009-09-29 | 2010-11-22 | ClinicalTrials.gov |
| NCT00963937 | Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Tre… | Phase3 | Migraine Disorders | Completed | 2009-09-28 | 2010-12-03 | ClinicalTrials.gov |
| NCT00903201 | 28 Day Repeat Dose in Cystic Fibrosis Patients | Phase2 | Cystic Fibrosis | Completed | 2009-09-28 | 2010-12-29 | ClinicalTrials.gov |
| NCT00963937 | Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Tre… | Phase3 | Migraine Disorders | Completed | 2009-09-28 | 2010-12-03 | ClinicalTrials.gov |
| NCT00903201 | 28 Day Repeat Dose in Cystic Fibrosis Patients | Phase2 | Cystic Fibrosis | Completed | 2009-09-28 | 2010-12-29 | ClinicalTrials.gov |
| NCT01009463 | A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW64244… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2009-09-25 | 2011-10-31 | ClinicalTrials.gov |
| NCT01009463 | A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW64244… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2009-09-25 | 2011-10-31 | ClinicalTrials.gov |
| NCT03105297 | To Characterize the Performance of the Nasal Dilator Strip in Lowering Nasal Re… | Phase2 | Sleep Disordered Breathing | Completed | 2009-09-25 | 2010-08-10 | ClinicalTrials.gov |
| NCT01017952 | A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengt… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2009-09-25 | 2011-10-17 | ClinicalTrials.gov |
| NCT00976560 | Clinical Study to Test a New Drug to Treat Major Depression | Phase2 | Depressive Disorder, Major | Completed | 2009-09-25 | 2010-07-07 | ClinicalTrials.gov |
| NCT01017952 | A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengt… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2009-09-25 | 2011-10-17 | ClinicalTrials.gov |
| NCT00976560 | Clinical Study to Test a New Drug to Treat Major Depression | Phase2 | Depressive Disorder, Major | Completed | 2009-09-25 | 2010-07-07 | ClinicalTrials.gov |
| NCT03105297 | To Characterize the Performance of the Nasal Dilator Strip in Lowering Nasal Re… | Phase2 | Sleep Disordered Breathing | Completed | 2009-09-25 | 2010-08-10 | ClinicalTrials.gov |
| NCT00976105 | Effects of Repeat Dosing of GSK1521498 | Phase1 | Obesity | Completed | 2009-09-22 | 2010-03-09 | ClinicalTrials.gov |
| NCT00976105 | Effects of Repeat Dosing of GSK1521498 | Phase1 | Obesity | Completed | 2009-09-22 | 2010-03-09 | ClinicalTrials.gov |
| NCT00947115 | Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HP… | Phase3 | Infections, Papillomavirus | Completed | 2009-09-22 | 2015-02-03 | ClinicalTrials.gov |
| NCT00947115 | Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HP… | Phase3 | Infections, Papillomavirus | Completed | 2009-09-22 | 2015-02-03 | ClinicalTrials.gov |
| NCT01039974 | GSK962040 Drug-drug Interaction Study With Ketoconazole | Phase1 | Gastroparesis | Completed | 2009-09-18 | 2009-11-30 | ClinicalTrials.gov |
| NCT01371682 | A Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Rop… | Phase1 | Parkinson Disease | Completed | 2009-09-18 | 2009-12-02 | ClinicalTrials.gov |
| NCT01371682 | A Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Rop… | Phase1 | Parkinson Disease | Completed | 2009-09-18 | 2009-12-02 | ClinicalTrials.gov |
| NCT01039974 | GSK962040 Drug-drug Interaction Study With Ketoconazole | Phase1 | Gastroparesis | Completed | 2009-09-18 | 2009-11-30 | ClinicalTrials.gov |
| NCT00968890 | Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Flu… | Phase2 | Influenza | Completed | 2009-09-12 | 2010-09-23 | ClinicalTrials.gov |
| NCT00968890 | Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Flu… | Phase2 | Influenza | Completed | 2009-09-12 | 2010-09-23 | ClinicalTrials.gov |
| NCT01316926 | Paxil CR Bioequivalence Study Brazil | Phase1 | Depressive Disorder | Completed | 2009-09-09 | 2009-10-05 | ClinicalTrials.gov |
| NCT01316926 | Paxil CR Bioequivalence Study Brazil | Phase1 | Depressive Disorder | Completed | 2009-09-09 | 2009-10-05 | ClinicalTrials.gov |
| NCT00971425 | Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candid… | Phase3 | Influenza | Completed | 2009-09-08 | 2010-10-08 | ClinicalTrials.gov |
| NCT00968526 | Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vac… | Phase3 | Influenza | Completed | 2009-09-08 | 2010-09-23 | ClinicalTrials.gov |
| NCT00968526 | Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vac… | Phase3 | Influenza | Completed | 2009-09-08 | 2010-09-23 | ClinicalTrials.gov |
| NCT00971425 | Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candid… | Phase3 | Influenza | Completed | 2009-09-08 | 2010-10-08 | ClinicalTrials.gov |
| NCT00968539 | Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza V… | Phase3 | Influenza | Completed | 2009-09-08 | 2010-09-28 | ClinicalTrials.gov |
| NCT00968539 | Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza V… | Phase3 | Influenza | Completed | 2009-09-08 | 2010-09-28 | ClinicalTrials.gov |
| NCT00996216 | Clinical Trial for Non-responders Who Previously Participated in Eltrombopag St… | Phase3 | Hepatitis C | Completed | 2009-09-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01766544 | Asthma & COPD Guideline Implementation | Early_Phase1 | Asthma | Terminated | 2009-09-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT01766544 | Asthma & COPD Guideline Implementation | Early_Phase1 | Asthma | Terminated | 2009-09-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT01390896 | Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal General Sur… | — | Cardiovascular Disease | Completed | 2009-09-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01231464 | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy a… | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2009-09-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01154244 | Insulin Resistance as Primary Pathogenesis in Newly Diagnosed, Drug naïve Type … | — | Diabetes Mellitus, Type 2 | Completed | 2009-09-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01115452 | Efficacy of Potassium Nitrate Solution in Reducing Dentinal Hypersensitivity | Phase2 | Dentine Hypersensitivity | Completed | 2009-09-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT01105949 | An Evaluation of Two Novel Nasal Strip Prototypes on Nasal Patency | Phase1 | Healthy Volunteer | Completed | 2009-09-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT01086358 | Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Re… | Phase4 | Workplace Migraine Treatment | Completed | 2009-09-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT01077622 | A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Pati… | Phase2 | Leukaemia, Lymphocytic, Chronic | Completed | 2009-09-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00996216 | Clinical Trial for Non-responders Who Previously Participated in Eltrombopag St… | Phase3 | Hepatitis C | Completed | 2009-09-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT00996021 | Study to Assess Cardiac Conduction of GSK1349572 | Phase1 | Healthy Subjects | Completed | 2009-09-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00980200 | Efficacy and Safety Study in Subjects With Asthma | Phase2 | Asthma | Completed | 2009-09-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00974363 | Study to Evaluate Persistence of Antibodies After Vaccination With Meningococca… | Phase3 | Infections, Meningococcal | Completed | 2009-09-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT00973739 | Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and… | Phase2 | Neurofibromatosis 2 | Completed | 2009-09-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT00950807 | GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2009-09-01 | 2010-03-15 | ClinicalTrials.gov |
| NCT00941642 | Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Live… | Phase4 | Non-Alcoholic Fatty Liver Disease | Unknown | 2009-09-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT00891761 | A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Ci… | Phase3 | Cancer | Withdrawn | 2009-09-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01390896 | Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal General Sur… | — | Cardiovascular Disease | Completed | 2009-09-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT00996021 | Study to Assess Cardiac Conduction of GSK1349572 | Phase1 | Healthy Subjects | Completed | 2009-09-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00980200 | Efficacy and Safety Study in Subjects With Asthma | Phase2 | Asthma | Completed | 2009-09-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00974363 | Study to Evaluate Persistence of Antibodies After Vaccination With Meningococca… | Phase3 | Infections, Meningococcal | Completed | 2009-09-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT00973739 | Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and… | Phase2 | Neurofibromatosis 2 | Completed | 2009-09-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT00950807 | GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2009-09-01 | 2010-03-15 | ClinicalTrials.gov |
| NCT00941642 | Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Live… | Phase4 | Non-Alcoholic Fatty Liver Disease | Unknown | 2009-09-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01231464 | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy a… | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2009-09-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00891761 | A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Ci… | Phase3 | Cancer | Withdrawn | 2009-09-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01077622 | A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Pati… | Phase2 | Leukaemia, Lymphocytic, Chronic | Completed | 2009-09-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01154244 | Insulin Resistance as Primary Pathogenesis in Newly Diagnosed, Drug naïve Type … | — | Diabetes Mellitus, Type 2 | Completed | 2009-09-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01086358 | Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Re… | Phase4 | Workplace Migraine Treatment | Completed | 2009-09-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT01105949 | An Evaluation of Two Novel Nasal Strip Prototypes on Nasal Patency | Phase1 | Healthy Volunteer | Completed | 2009-09-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT01115452 | Efficacy of Potassium Nitrate Solution in Reducing Dentinal Hypersensitivity | Phase2 | Dentine Hypersensitivity | Completed | 2009-09-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00972686 | Dose-Escalation Study of GSK2126458 | Phase1 | Solid Tumours | Completed | 2009-08-31 | 2015-03-31 | ClinicalTrials.gov |
| NCT00972686 | Dose-Escalation Study of GSK2126458 | Phase1 | Solid Tumours | Completed | 2009-08-31 | 2015-03-31 | ClinicalTrials.gov |
| NCT00964106 | Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation | Phase1 | Drug Interactions | Completed | 2009-08-26 | 2011-08-29 | ClinicalTrials.gov |
| NCT00964106 | Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation | Phase1 | Drug Interactions | Completed | 2009-08-26 | 2011-08-29 | ClinicalTrials.gov |
| NCT00969228 | Study to Evaluate Immunogenicity, Reactogenicity and Safety of Rotarix™ Vaccine… | Phase4 | Infections, Rotavirus | Completed | 2009-08-25 | 2010-07-23 | ClinicalTrials.gov |
| NCT00955682 | Study to Evaluate Persistence of Antibodies After Vaccination With Meningococca… | Phase3 | Infections, Meningococcal | Completed | 2009-08-25 | 2012-09-10 | ClinicalTrials.gov |
| NCT00955682 | Study to Evaluate Persistence of Antibodies After Vaccination With Meningococca… | Phase3 | Infections, Meningococcal | Completed | 2009-08-25 | 2012-09-10 | ClinicalTrials.gov |
| NCT00969228 | Study to Evaluate Immunogenicity, Reactogenicity and Safety of Rotarix™ Vaccine… | Phase4 | Infections, Rotavirus | Completed | 2009-08-25 | 2010-07-23 | ClinicalTrials.gov |
| NCT01014962 | A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail … | Phase1 | Onychomycosis | Completed | 2009-08-24 | 2009-12-04 | ClinicalTrials.gov |
| NCT00950586 | Safety, Blood Levels, Drug Interaction and Effects of Repeated Doses of GSK1034… | Phase1 | Cognitive Disorders | Completed | 2009-08-24 | 2009-12-24 | ClinicalTrials.gov |
| NCT00950586 | Safety, Blood Levels, Drug Interaction and Effects of Repeated Doses of GSK1034… | Phase1 | Cognitive Disorders | Completed | 2009-08-24 | 2009-12-24 | ClinicalTrials.gov |
| NCT01014962 | A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail … | Phase1 | Onychomycosis | Completed | 2009-08-24 | 2009-12-04 | ClinicalTrials.gov |
| NCT00937326 | Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 D… | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2009-08-19 | 2010-09-18 | ClinicalTrials.gov |
| NCT00937326 | Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 D… | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2009-08-19 | 2010-09-18 | ClinicalTrials.gov |
| NCT00955773 | A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects | Phase1 | Cancer | Completed | 2009-08-17 | 2011-11-08 | ClinicalTrials.gov |
| NCT00955773 | A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects | Phase1 | Cancer | Completed | 2009-08-17 | 2011-11-08 | ClinicalTrials.gov |
| NCT00942162 | A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unr… | Phase2 | Melanoma | Completed | 2009-08-14 | 2015-04-01 | ClinicalTrials.gov |
| NCT00942162 | A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unr… | Phase2 | Melanoma | Completed | 2009-08-14 | 2015-04-01 | ClinicalTrials.gov |
| NCT01013766 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2009-08-13 | 2009-11-20 | ClinicalTrials.gov |
| NCT01013766 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2009-08-13 | 2009-11-20 | ClinicalTrials.gov |
| NCT00970307 | Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Heal… | Phase2 | Tetanus | Completed | 2009-08-13 | 2010-01-27 | ClinicalTrials.gov |
| NCT00970307 | Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Heal… | Phase2 | Tetanus | Completed | 2009-08-13 | 2010-01-27 | ClinicalTrials.gov |
| NCT01428427 | Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors | Phase1 | Leukaemia, Myelocytic, Acute | Completed | 2009-08-12 | 2011-07-18 | ClinicalTrials.gov |
| NCT00920192 | Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer | Phase1 | Carcinoma, Hepatocellular | Completed | 2009-08-12 | 2015-03-24 | ClinicalTrials.gov |
| NCT00935831 | Single Dose Safety Study for Compound to Treat Anemia in Patients With Renal Im… | Phase1 | Kidney Disease | Completed | 2009-08-12 | 2010-04-27 | ClinicalTrials.gov |
| NCT00920192 | Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer | Phase1 | Carcinoma, Hepatocellular | Completed | 2009-08-12 | 2015-03-24 | ClinicalTrials.gov |
| NCT01428427 | Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors | Phase1 | Leukaemia, Myelocytic, Acute | Completed | 2009-08-12 | 2011-07-18 | ClinicalTrials.gov |
| NCT00935831 | Single Dose Safety Study for Compound to Treat Anemia in Patients With Renal Im… | Phase1 | Kidney Disease | Completed | 2009-08-12 | 2010-04-27 | ClinicalTrials.gov |
| NCT00951041 | Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza… | Phase2 | Influenza | Completed | 2009-08-11 | 2010-08-30 | ClinicalTrials.gov |
| NCT00951041 | Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza… | Phase2 | Influenza | Completed | 2009-08-11 | 2010-08-30 | ClinicalTrials.gov |
| NCT00937950 | Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects | Phase3 | Infections, Papillomavirus | Completed | 2009-08-05 | 2014-01-20 | ClinicalTrials.gov |
| NCT00937950 | Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects | Phase3 | Infections, Papillomavirus | Completed | 2009-08-05 | 2014-01-20 | ClinicalTrials.gov |
| NCT00937404 | Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine… | Phase1 | Poliomyelitis | Completed | 2009-08-04 | 2009-11-13 | ClinicalTrials.gov |
| NCT00937404 | Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine… | Phase1 | Poliomyelitis | Completed | 2009-08-04 | 2009-11-13 | ClinicalTrials.gov |
| NCT00938327 | Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix™ (Human… | — | Infections, Rotavirus | Completed | 2009-08-03 | 2010-04-23 | ClinicalTrials.gov |
| NCT00938327 | Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix™ (Human… | — | Infections, Rotavirus | Completed | 2009-08-03 | 2010-04-23 | ClinicalTrials.gov |
| NCT00969059 | Study in Neuropathic Pain Patients With Peripheral Nerve Injury | Phase2 | Pain, Neuropathic | Completed | 2009-08-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01209091 | Utility and Work Productivity Data for Economic Evaluation of Breast Cancer The… | — | Solid Tumours | Completed | 2009-08-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00980707 | Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarkers … | Phase4 | Allergic Asthma | Completed | 2009-08-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01015638 | Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clind… | Phase4 | Acne Vulgaris | Completed | 2009-08-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00969059 | Study in Neuropathic Pain Patients With Peripheral Nerve Injury | Phase2 | Pain, Neuropathic | Completed | 2009-08-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01706263 | U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerabilit… | Phase4 | Acne Vulgaris | Completed | 2009-08-01 | 2009-11-20 | ClinicalTrials.gov |
| NCT00950859 | A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Pers… | Phase2 | Infection, Human Immunodeficiency Virus | Completed | 2009-08-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT00946400 | Validating 4Ts for Heparin Induced Thrombocytopenia (HIT) | — | Heparin-Induced Thrombocytopenia | Unknown | 2009-08-01 | — | ClinicalTrials.gov |
| NCT01381471 | Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chroni… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2009-08-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01332409 | Special Drug Use Investigation for ADOAIR DISKUS COPD (Salmeterol and Fluticaso… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2009-08-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01235988 | Meta-analysis - Eltrombopag | — | Thrombocytopaenia | Completed | 2009-08-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT01332409 | Special Drug Use Investigation for ADOAIR DISKUS COPD (Salmeterol and Fluticaso… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2009-08-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01236014 | Indirect Comparison Between Eltrombopag & Romiplostim | — | Thrombocytopaenia | Completed | 2009-08-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT01128972 | Evaluation of a Test Mouthwash and Dentifrice Regimen in an In-situ Model of De… | Phase2 | Tooth Erosion | Completed | 2009-08-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT01236014 | Indirect Comparison Between Eltrombopag & Romiplostim | — | Thrombocytopaenia | Completed | 2009-08-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT01128972 | Evaluation of a Test Mouthwash and Dentifrice Regimen in an In-situ Model of De… | Phase2 | Tooth Erosion | Completed | 2009-08-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT01235988 | Meta-analysis - Eltrombopag | — | Thrombocytopaenia | Completed | 2009-08-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT01381471 | Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chroni… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2009-08-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01706263 | U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerabilit… | Phase4 | Acne Vulgaris | Completed | 2009-08-01 | 2009-11-20 | ClinicalTrials.gov |
| NCT00950859 | A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Pers… | Phase2 | Infection, Human Immunodeficiency Virus | Completed | 2009-08-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT00946400 | Validating 4Ts for Heparin Induced Thrombocytopenia (HIT) | — | Heparin-Induced Thrombocytopenia | Unknown | 2009-08-01 | — | ClinicalTrials.gov |
| NCT01209091 | Utility and Work Productivity Data for Economic Evaluation of Breast Cancer The… | — | Solid Tumours | Completed | 2009-08-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT01015638 | Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clind… | Phase4 | Acne Vulgaris | Completed | 2009-08-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00980707 | Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarkers … | Phase4 | Allergic Asthma | Completed | 2009-08-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00951015 | A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive … | Phase2 | Infection, Human Immunodeficiency Virus | Completed | 2009-07-30 | 2016-12-22 | ClinicalTrials.gov |
| NCT00938392 | Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza… | Phase3 | Influenza | Completed | 2009-07-30 | 2009-10-05 | ClinicalTrials.gov |
| NCT00938392 | Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza… | Phase3 | Influenza | Completed | 2009-07-30 | 2009-10-05 | ClinicalTrials.gov |
| NCT00951015 | A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive … | Phase2 | Infection, Human Immunodeficiency Virus | Completed | 2009-07-30 | 2016-12-22 | ClinicalTrials.gov |
| NCT00976144 | Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of GSK573719 … | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2009-07-29 | 2009-09-22 | ClinicalTrials.gov |
| NCT00976144 | Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of GSK573719 … | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2009-07-29 | 2009-09-22 | ClinicalTrials.gov |
| NCT00937846 | Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study | Phase1 | Cognitive Disorders | Completed | 2009-07-15 | 2009-08-28 | ClinicalTrials.gov |
| NCT00937846 | Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study | Phase1 | Cognitive Disorders | Completed | 2009-07-15 | 2009-08-28 | ClinicalTrials.gov |
| NCT00938184 | Single Dose Study of Controlled-Release Paroxetine Tablets in Healthy Japanese … | Phase1 | Depressive Disorder | Completed | 2009-07-14 | 2009-09-02 | ClinicalTrials.gov |
| NCT00920218 | Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1… | Phase2 | Herpes Zoster | Completed | 2009-07-14 | 2012-03-21 | ClinicalTrials.gov |
| NCT00938184 | Single Dose Study of Controlled-Release Paroxetine Tablets in Healthy Japanese … | Phase1 | Depressive Disorder | Completed | 2009-07-14 | 2009-09-02 | ClinicalTrials.gov |
| NCT00920218 | Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1… | Phase2 | Herpes Zoster | Completed | 2009-07-14 | 2012-03-21 | ClinicalTrials.gov |
| NCT01199757 | A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering C… | — | Rhinitis, Allergic, Perennial | Completed | 2009-07-10 | 2009-08-01 | ClinicalTrials.gov |
| NCT01199757 | A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering C… | — | Rhinitis, Allergic, Perennial | Completed | 2009-07-10 | 2009-08-01 | ClinicalTrials.gov |
| NCT00866528 | Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer | Phase1 | Lung Cancer, Non-Small Cell | Completed | 2009-07-09 | 2012-10-25 | ClinicalTrials.gov |
| NCT00866528 | Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer | Phase1 | Lung Cancer, Non-Small Cell | Completed | 2009-07-09 | 2012-10-25 | ClinicalTrials.gov |
| NCT00833989 | Safety Escalating Repeat IV, in Stroke Patients | Phase2 | Ischaemic Attack, Transient | Completed | 2009-07-08 | 2011-01-31 | ClinicalTrials.gov |
| NCT00833989 | Safety Escalating Repeat IV, in Stroke Patients | Phase2 | Ischaemic Attack, Transient | Completed | 2009-07-08 | 2011-01-31 | ClinicalTrials.gov |
| NCT01205178 | G6PD (Glucose-6-phosphate Dehydrogenase) Study to Evaluate Hemolysis Potential … | Phase1 | Malaria | Completed | 2009-07-02 | 2013-04-01 | ClinicalTrials.gov |
| NCT01205178 | G6PD (Glucose-6-phosphate Dehydrogenase) Study to Evaluate Hemolysis Potential … | Phase1 | Malaria | Completed | 2009-07-02 | 2013-04-01 | ClinicalTrials.gov |
| NCT01156701 | Prophylactic Efficacy of Relenza Against Influenza A and B | — | Pulmonary Disease, Chronic Obstructive | Completed | 2009-07-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00920296 | DDI Study of Etravirine and GSK1265744 | Phase1 | Healthy Subjects | Completed | 2009-07-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00964366 | Study to Determine and Compare the Tolerance and Irritation Potential of Topica… | Phase4 | Acne Vulgaris | Completed | 2009-07-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00920296 | DDI Study of Etravirine and GSK1265744 | Phase1 | Healthy Subjects | Completed | 2009-07-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00934219 | Triglyceride Lowering Study | Phase4 | Hypertriglyceridemia | Unknown | 2009-07-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01156701 | Prophylactic Efficacy of Relenza Against Influenza A and B | — | Pulmonary Disease, Chronic Obstructive | Completed | 2009-07-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01755702 | Paracetamol With Caffeine to Treat Episodic Tension Type Headache | Phase2 | Headache, Tension-Type | Terminated | 2009-07-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00942136 | GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Stu… | Phase1 | Healthy Volunteer | Completed | 2009-07-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00945932 | A Study to Evaluate the Effect of Repeat Doses of GW870086X in Mild to Moderate… | Phase2 | Asthma | Completed | 2009-07-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00939120 | Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptom… | Phase4 | Benign Prostatic Hyperplasia (BPH) | Completed | 2009-07-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT00915902 | Fish Oil Study for High Triglyceride Levels in Children | Phase2 | Hypertriglyceridemia | Completed | 2009-07-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01159925 | Surveillance Study to Determine the Trends in Acute Hepatitis A Among Panamania… | — | Acute Hepatitis A | Completed | 2009-07-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01914770 | Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Eryth… | — | Systemic Lupus Erythematosus | Completed | 2009-07-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00934219 | Triglyceride Lowering Study | Phase4 | Hypertriglyceridemia | Unknown | 2009-07-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00849472 | Treatment With Pazopanib for Neoadjuvant Breast Cancer | Phase2 | Neoplasms, Breast | Completed | 2009-07-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT00849472 | Treatment With Pazopanib for Neoadjuvant Breast Cancer | Phase2 | Neoplasms, Breast | Completed | 2009-07-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT00915902 | Fish Oil Study for High Triglyceride Levels in Children | Phase2 | Hypertriglyceridemia | Completed | 2009-07-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT00944034 | Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine … | Phase2 | Meningococcal Disease | Completed | 2009-07-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01346852 | Predictive Ability of Therapeutic Risk Factors in Pediatric and Adult Asthma Pa… | — | Asthma | Completed | 2009-07-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00942136 | GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Stu… | Phase1 | Healthy Volunteer | Completed | 2009-07-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT01347060 | Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol … | — | Asthma | Completed | 2009-07-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT01346852 | Predictive Ability of Therapeutic Risk Factors in Pediatric and Adult Asthma Pa… | — | Asthma | Completed | 2009-07-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT01209039 | A Repeat Dose Positron Emission Tomography Study With GSK1144814 | Phase1 | Schizophrenia | Completed | 2009-07-01 | 2009-10-25 | ClinicalTrials.gov |
| NCT00939120 | Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptom… | Phase4 | Benign Prostatic Hyperplasia (BPH) | Completed | 2009-07-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT00964223 | A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment … | Phase4 | Acne Vulgaris | Completed | 2009-07-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00964223 | A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment … | Phase4 | Acne Vulgaris | Completed | 2009-07-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00964366 | Study to Determine and Compare the Tolerance and Irritation Potential of Topica… | Phase4 | Acne Vulgaris | Completed | 2009-07-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT01332500 | Treximet ™ Pharmacy Budget Impact Model Database Validation Study | — | Migraine Disorders | Completed | 2009-07-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT01871038 | Effectiveness of Monovalent Rotavirus Vaccine (RV1) | — | Rotavirus | Completed | 2009-07-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT00871403 | Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer | Phase2 | Lung Cancer, Non-Small Cell | Completed | 2009-07-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00952692 | Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib t… | Phase1 | Metastatic Breast Cancer | Completed | 2009-07-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01209039 | A Repeat Dose Positron Emission Tomography Study With GSK1144814 | Phase1 | Schizophrenia | Completed | 2009-07-01 | 2009-10-25 | ClinicalTrials.gov |
| NCT01201252 | Study to Estimate the Disease Burden of Acute Rotavirus Gastroenteritis in Chil… | — | Rotaviral Gastroenteritis | Completed | 2009-07-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00952692 | Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib t… | Phase1 | Metastatic Breast Cancer | Completed | 2009-07-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01871038 | Effectiveness of Monovalent Rotavirus Vaccine (RV1) | — | Rotavirus | Completed | 2009-07-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01914770 | Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Eryth… | — | Systemic Lupus Erythematosus | Completed | 2009-07-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01347060 | Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol … | — | Asthma | Completed | 2009-07-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00945932 | A Study to Evaluate the Effect of Repeat Doses of GW870086X in Mild to Moderate… | Phase2 | Asthma | Completed | 2009-07-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT01159925 | Surveillance Study to Determine the Trends in Acute Hepatitis A Among Panamania… | — | Acute Hepatitis A | Completed | 2009-07-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00944034 | Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine … | Phase2 | Meningococcal Disease | Completed | 2009-07-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01201252 | Study to Estimate the Disease Burden of Acute Rotavirus Gastroenteritis in Chil… | — | Rotaviral Gastroenteritis | Completed | 2009-07-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01755702 | Paracetamol With Caffeine to Treat Episodic Tension Type Headache | Phase2 | Headache, Tension-Type | Terminated | 2009-07-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT01476176 | A Pharmacokinetic Study of an Experimental Paracetamol Formulation | Phase1 | Headache, Tension-Type | Completed | 2009-07-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT01331694 | Outcomes and Costs Associated With Initiating Maintenance Treatment With Flutic… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2009-07-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01476176 | A Pharmacokinetic Study of an Experimental Paracetamol Formulation | Phase1 | Headache, Tension-Type | Completed | 2009-07-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00871403 | Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer | Phase2 | Lung Cancer, Non-Small Cell | Completed | 2009-07-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT01331694 | Outcomes and Costs Associated With Initiating Maintenance Treatment With Flutic… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2009-07-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01332500 | Treximet ™ Pharmacy Budget Impact Model Database Validation Study | — | Migraine Disorders | Completed | 2009-07-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00871338 | Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course … | Phase2 | Neisseria Meningitidis | Completed | 2009-06-24 | 2010-12-09 | ClinicalTrials.gov |
| NCT00871338 | Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course … | Phase2 | Neisseria Meningitidis | Completed | 2009-06-24 | 2010-12-09 | ClinicalTrials.gov |
| NCT00907777 | Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted Wi… | Phase3 | Infections, Streptococcal | Completed | 2009-06-23 | 2009-10-05 | ClinicalTrials.gov |
| NCT00907777 | Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted Wi… | Phase3 | Infections, Streptococcal | Completed | 2009-06-23 | 2009-10-05 | ClinicalTrials.gov |
| NCT00920257 | A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2… | Phase1 | Cancer | Completed | 2009-06-16 | 2013-04-17 | ClinicalTrials.gov |
| NCT00920374 | A Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Infl… | Phase3 | Influenza | Completed | 2009-06-16 | 2009-07-08 | ClinicalTrials.gov |
| NCT00920374 | A Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Infl… | Phase3 | Influenza | Completed | 2009-06-16 | 2009-07-08 | ClinicalTrials.gov |
| NCT00920257 | A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2… | Phase1 | Cancer | Completed | 2009-06-16 | 2013-04-17 | ClinicalTrials.gov |
| NCT00903617 | Study to Test GSK256073 in Patients With Dyslipidemia | Phase2 | Dyslipidaemias | Completed | 2009-06-15 | 2010-02-16 | ClinicalTrials.gov |
| NCT00903617 | Study to Test GSK256073 in Patients With Dyslipidemia | Phase2 | Dyslipidaemias | Completed | 2009-06-15 | 2010-02-16 | ClinicalTrials.gov |
| NCT00911144 | Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With t… | Phase3 | Infections, Streptococcal | Completed | 2009-06-11 | 2010-01-11 | ClinicalTrials.gov |
| NCT00911144 | Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With t… | Phase3 | Infections, Streptococcal | Completed | 2009-06-11 | 2010-01-11 | ClinicalTrials.gov |
| NCT00920426 | Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in… | Phase2 | Infection, Human Immunodeficiency Virus | Completed | 2009-06-09 | 2009-08-13 | ClinicalTrials.gov |
| NCT00920426 | Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in… | Phase2 | Infection, Human Immunodeficiency Virus | Completed | 2009-06-09 | 2009-08-13 | ClinicalTrials.gov |
| NCT00861744 | Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Rou… | Phase2 | Rubella | Completed | 2009-06-03 | 2012-06-18 | ClinicalTrials.gov |
| NCT00861744 | Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Rou… | Phase2 | Rubella | Completed | 2009-06-03 | 2012-06-18 | ClinicalTrials.gov |
| NCT00892775 | Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated Wit… | Phase2 | Measles | Completed | 2009-06-03 | 2010-12-13 | ClinicalTrials.gov |
| NCT00892775 | Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated Wit… | Phase2 | Measles | Completed | 2009-06-03 | 2010-12-13 | ClinicalTrials.gov |
| NCT00893737 | "Completeness of Response" Following Treatment With Treximet™ for Migraine | Phase4 | Migraine | Completed | 2009-06-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00920088 | Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK224… | Phase1 | Healthy Subjects | Completed | 2009-06-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00972504 | 723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover | Phase2 | Rhinitis, Allergic, Seasonal | Completed | 2009-06-01 | 2009-08-14 | ClinicalTrials.gov |
| NCT00861809 | The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I … | Phase2 | Gastroparesis | Completed | 2009-06-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00863122 | Concentration and Activity of Lapatinib in Vestibular Schwannomas | Early_Phase1 | Vestibular Schwannoma | Completed | 2009-06-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT00930527 | Omega-3-Fatty Acid on Joint Symptoms Inducted by Aromatase Inhibitors | Phase2 | Breast Cancer | Terminated | 2009-06-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01204385 | Study to Identify and Characterize the Bacteria Causing Acute Otitis Media Epis… | — | Infections, Streptococcal | Completed | 2009-06-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT00921466 | Pilot Study to Assess Feasibility, Reliability and Validity of the e-SSRS-IVR | — | Healthy | Unknown | 2009-06-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00920439 | Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (Po… | Phase3 | Poliomyelitis | Completed | 2009-06-01 | 2009-08-03 | ClinicalTrials.gov |
| NCT01332357 | Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department … | — | Asthma | Completed | 2009-06-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01328964 | Comparison of Asthma-related Outcomes and Costs in Pediatric Subjects That Rece… | — | Asthma | Completed | 2009-06-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01332357 | Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department … | — | Asthma | Completed | 2009-06-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00894283 | Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in… | Early_Phase1 | Deep Venous Thrombosis | Completed | 2009-06-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT00893737 | "Completeness of Response" Following Treatment With Treximet™ for Migraine | Phase4 | Migraine | Completed | 2009-06-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00929526 | Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vac… | Phase3 | Infections, Papillomavirus | Completed | 2009-06-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00440115 | Disease Management for Smoking Cessation | Phase3 | Smoking Cessation | Completed | 2009-06-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00861809 | The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I … | Phase2 | Gastroparesis | Completed | 2009-06-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00921466 | Pilot Study to Assess Feasibility, Reliability and Validity of the e-SSRS-IVR | — | Healthy | Unknown | 2009-06-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT01345279 | Indirect Comparison Topotecan Cervical Carcinoma | — | Cervical Intraepithelial Neoplasia | Completed | 2009-06-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT01332344 | Outcomes in Patients Taking Fluticasone Propionate/Salmeterol Combination or Ot… | — | Asthma | Completed | 2009-06-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01332344 | Outcomes in Patients Taking Fluticasone Propionate/Salmeterol Combination or Ot… | — | Asthma | Completed | 2009-06-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00930527 | Omega-3-Fatty Acid on Joint Symptoms Inducted by Aromatase Inhibitors | Phase2 | Breast Cancer | Terminated | 2009-06-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01204385 | Study to Identify and Characterize the Bacteria Causing Acute Otitis Media Epis… | — | Infections, Streptococcal | Completed | 2009-06-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT00440115 | Disease Management for Smoking Cessation | Phase3 | Smoking Cessation | Completed | 2009-06-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01328964 | Comparison of Asthma-related Outcomes and Costs in Pediatric Subjects That Rece… | — | Asthma | Completed | 2009-06-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00929526 | Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vac… | Phase3 | Infections, Papillomavirus | Completed | 2009-06-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01345279 | Indirect Comparison Topotecan Cervical Carcinoma | — | Cervical Intraepithelial Neoplasia | Completed | 2009-06-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00972504 | 723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover | Phase2 | Rhinitis, Allergic, Seasonal | Completed | 2009-06-01 | 2009-08-14 | ClinicalTrials.gov |
| NCT00920439 | Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (Po… | Phase3 | Poliomyelitis | Completed | 2009-06-01 | 2009-08-03 | ClinicalTrials.gov |
| NCT00920088 | Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK224… | Phase1 | Healthy Subjects | Completed | 2009-06-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00863122 | Concentration and Activity of Lapatinib in Vestibular Schwannomas | Early_Phase1 | Vestibular Schwannoma | Completed | 2009-06-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT00894283 | Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in… | Early_Phase1 | Deep Venous Thrombosis | Completed | 2009-06-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT00866697 | Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in O… | Phase3 | Ovarian Cancer | Completed | 2009-05-26 | 2017-08-24 | ClinicalTrials.gov |
| NCT01171157 | Effectiveness of Flu Vaccination and Burden of Illness Among Community-dwelling… | — | Influenza | Terminated | 2009-05-26 | 2009-06-29 | ClinicalTrials.gov |
| NCT01171157 | Effectiveness of Flu Vaccination and Burden of Illness Among Community-dwelling… | — | Influenza | Terminated | 2009-05-26 | 2009-06-29 | ClinicalTrials.gov |
| NCT00866697 | Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in O… | Phase3 | Ovarian Cancer | Completed | 2009-05-26 | 2017-08-24 | ClinicalTrials.gov |
| NCT00896480 | Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With… | Phase2 | Melanoma | Completed | 2009-05-19 | 2014-11-03 | ClinicalTrials.gov |
| NCT00896480 | Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With… | Phase2 | Melanoma | Completed | 2009-05-19 | 2014-11-03 | ClinicalTrials.gov |
| NCT00896064 | Evaluation of a Booster Dose of Pneumococcal Vaccine Formulations in Young Adul… | Phase2 | Infections, Streptococcal | Completed | 2009-05-18 | 2009-08-05 | ClinicalTrials.gov |
| NCT00896064 | Evaluation of a Booster Dose of Pneumococcal Vaccine Formulations in Young Adul… | Phase2 | Infections, Streptococcal | Completed | 2009-05-18 | 2009-08-05 | ClinicalTrials.gov |
| NCT00907985 | A Study to Evaluate the Effect of Single Doses of Drug A (Lamotrigine) and Drug… | Phase1 | Bipolar Disorder | Terminated | 2009-05-15 | 2010-06-10 | ClinicalTrials.gov |
| NCT00907985 | A Study to Evaluate the Effect of Single Doses of Drug A (Lamotrigine) and Drug… | Phase1 | Bipolar Disorder | Terminated | 2009-05-15 | 2010-06-10 | ClinicalTrials.gov |
| NCT00891176 | Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Men… | Phase3 | Neisseria Meningitidis | Completed | 2009-05-14 | 2012-11-21 | ClinicalTrials.gov |
| NCT00891176 | Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Men… | Phase3 | Neisseria Meningitidis | Completed | 2009-05-14 | 2012-11-21 | ClinicalTrials.gov |
| NCT00903422 | Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodyspla… | Phase1 | Myelodysplastic Syndrome | Completed | 2009-05-14 | 2013-12-05 | ClinicalTrials.gov |
| NCT00903422 | Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodyspla… | Phase1 | Myelodysplastic Syndrome | Completed | 2009-05-14 | 2013-12-05 | ClinicalTrials.gov |
| NCT01362244 | Mepolizumab in Nasal Polyposis | Phase2 | Nasal Polyps | Completed | 2009-05-12 | 2014-12-05 | ClinicalTrials.gov |
| NCT01362244 | Mepolizumab in Nasal Polyposis | Phase2 | Nasal Polyps | Completed | 2009-05-12 | 2014-12-05 | ClinicalTrials.gov |
| NCT00877877 | Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HP… | Phase3 | Infections, Papillomavirus | Completed | 2009-05-07 | 2015-01-06 | ClinicalTrials.gov |
| NCT00877877 | Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HP… | Phase3 | Infections, Papillomavirus | Completed | 2009-05-07 | 2015-01-06 | ClinicalTrials.gov |
| NCT01064349 | Breast Cancer With Over-expression of erbB2-BRAINSTORM | — | Cancer | Completed | 2009-05-06 | 2011-06-03 | ClinicalTrials.gov |
| NCT01064349 | Breast Cancer With Over-expression of erbB2-BRAINSTORM | — | Cancer | Completed | 2009-05-06 | 2011-06-03 | ClinicalTrials.gov |
| NCT00861380 | Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine … | Phase3 | Infections, Streptococcal | Completed | 2009-05-04 | 2013-10-05 | ClinicalTrials.gov |
| NCT00861380 | Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine … | Phase3 | Infections, Streptococcal | Completed | 2009-05-04 | 2013-10-05 | ClinicalTrials.gov |
| NCT00856089 | Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus … | Phase4 | Methicillin-resistant Staphylococcus Aureus | Withdrawn | 2009-05-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT01055327 | Birth Defects Associated With Exposure to Lamotrigine in Pregnancy (EUROCAT) | — | Epilepsy | Completed | 2009-05-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00879970 | Thiazolidinedione Intervention With Vitamin D Evaluation | Phase4 | Diabetes Mellitus, Type 2 | Terminated | 2009-05-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00875485 | Evaluation of Antibody Persistence & Immune Memory in Subjects Vaccinated Durin… | Phase4 | Hepatitis B | Completed | 2009-05-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01031082 | Study to Identify and Characterize Bacteria Causing Acute Otitis Media in South… | — | Acute Otitis Media | Completed | 2009-05-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01332383 | Special Drug Use Investigation for AMERGE® Tablet (Long-term) | — | Migraine Disorders | Completed | 2009-05-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT00908362 | Impact of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers | Phase1 | Smoke-related Lung Diseases | Completed | 2009-05-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00888901 | Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With El… | Phase4 | Idiopathic Thrombocytopenic Purpura | Completed | 2009-05-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT00985985 | Efficacy and Safety Study of Nicotine Mint Lozenge (2mg and 4mg) in Smoking Ces… | Phase3 | Smoking | Completed | 2009-05-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00871208 | Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Lo… | Phase4 | Atopic Dermatitis | Withdrawn | 2009-05-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00894010 | Photosensitivity Proof of Concept Trial | Phase2 | Photosensitive Epilepsy | Completed | 2009-05-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01055327 | Birth Defects Associated With Exposure to Lamotrigine in Pregnancy (EUROCAT) | — | Epilepsy | Completed | 2009-05-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01390870 | Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Sympt… | — | Prostatic Hyperplasia | Completed | 2009-05-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00985985 | Efficacy and Safety Study of Nicotine Mint Lozenge (2mg and 4mg) in Smoking Ces… | Phase3 | Smoking | Completed | 2009-05-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00823719 | Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or D… | Phase2 | Lymphoma, Large-Cell, Diffuse | Completed | 2009-05-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01782794 | Acceptability of Hepatitis B Vaccination in General Population | — | Hepatitis B | Completed | 2009-05-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT00908362 | Impact of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers | Phase1 | Smoke-related Lung Diseases | Completed | 2009-05-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT01366599 | CV Events in Emetogenic Chemotherapy | — | Vomiting | Completed | 2009-05-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00856089 | Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus … | Phase4 | Methicillin-resistant Staphylococcus Aureus | Withdrawn | 2009-05-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT01782794 | Acceptability of Hepatitis B Vaccination in General Population | — | Hepatitis B | Completed | 2009-05-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT00823719 | Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or D… | Phase2 | Lymphoma, Large-Cell, Diffuse | Completed | 2009-05-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01366599 | CV Events in Emetogenic Chemotherapy | — | Vomiting | Completed | 2009-05-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT01031082 | Study to Identify and Characterize Bacteria Causing Acute Otitis Media in South… | — | Acute Otitis Media | Completed | 2009-05-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00871208 | Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Lo… | Phase4 | Atopic Dermatitis | Withdrawn | 2009-05-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00875485 | Evaluation of Antibody Persistence & Immune Memory in Subjects Vaccinated Durin… | Phase4 | Hepatitis B | Completed | 2009-05-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT00879970 | Thiazolidinedione Intervention With Vitamin D Evaluation | Phase4 | Diabetes Mellitus, Type 2 | Terminated | 2009-05-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01390870 | Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Sympt… | — | Prostatic Hyperplasia | Completed | 2009-05-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00926367 | Two-week Study to Compare the Tolerance and Irritation Potential of Two Combina… | Phase4 | Acne Vulgaris | Completed | 2009-05-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00888901 | Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With El… | Phase4 | Idiopathic Thrombocytopenic Purpura | Completed | 2009-05-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT00894010 | Photosensitivity Proof of Concept Trial | Phase2 | Photosensitive Epilepsy | Completed | 2009-05-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT00926367 | Two-week Study to Compare the Tolerance and Irritation Potential of Two Combina… | Phase4 | Acne Vulgaris | Completed | 2009-05-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT01332383 | Special Drug Use Investigation for AMERGE® Tablet (Long-term) | — | Migraine Disorders | Completed | 2009-05-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT00924911 | Relative Bioavailability Study in Healthy Subjects | Phase1 | Infections, Bacterial | Completed | 2009-04-27 | 2009-07-09 | ClinicalTrials.gov |
| NCT00924911 | Relative Bioavailability Study in Healthy Subjects | Phase1 | Infections, Bacterial | Completed | 2009-04-27 | 2009-07-09 | ClinicalTrials.gov |
| NCT00896363 | Safety and Efficacy Study in Patients With Major Depressive Disorder | Phase2 | Depressive Disorder | Completed | 2009-04-23 | 2010-02-09 | ClinicalTrials.gov |
| NCT00896363 | Safety and Efficacy Study in Patients With Major Depressive Disorder | Phase2 | Depressive Disorder | Completed | 2009-04-23 | 2010-02-09 | ClinicalTrials.gov |
| NCT00875641 | Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to C… | — | Infections, Rotavirus | Completed | 2009-04-20 | 2016-11-04 | ClinicalTrials.gov |
| NCT02224521 | GSK2190915A - Bioavailability Study | Phase1 | Asthma | Completed | 2009-04-20 | 2010-06-08 | ClinicalTrials.gov |
| NCT00875641 | Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to C… | — | Infections, Rotavirus | Completed | 2009-04-20 | 2016-11-04 | ClinicalTrials.gov |
| NCT02224521 | GSK2190915A - Bioavailability Study | Phase1 | Asthma | Completed | 2009-04-20 | 2010-06-08 | ClinicalTrials.gov |
| NCT00867048 | Strategic Timing of Antiretroviral Treatment | Phase4 | HIV Infection | Completed | 2009-04-15 | 2022-07-27 | ClinicalTrials.gov |
| NCT00867048 | Strategic Timing of Antiretroviral Treatment | Phase4 | HIV Infection | Completed | 2009-04-15 | 2022-07-27 | ClinicalTrials.gov |
| NCT00883909 | ARI103094-Follow-Up Study for REDUCE Study Subjects | — | Neoplasms, Prostate | Completed | 2009-04-09 | 2010-12-29 | ClinicalTrials.gov |
| NCT00883909 | ARI103094-Follow-Up Study for REDUCE Study Subjects | — | Neoplasms, Prostate | Completed | 2009-04-09 | 2010-12-29 | ClinicalTrials.gov |
| NCT01767584 | Bioequivalence Study of Cephalexin Tablets 1g | Phase1 | Infections, Respiratory Tract | Completed | 2009-04-06 | 2009-04-14 | ClinicalTrials.gov |
| NCT00920660 | Clinical Study to Assess the Effects of SRT2104 and Prednisolone on Biomarkers … | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2009-04-06 | 2009-06-12 | ClinicalTrials.gov |
| NCT00920660 | Clinical Study to Assess the Effects of SRT2104 and Prednisolone on Biomarkers … | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2009-04-06 | 2009-06-12 | ClinicalTrials.gov |
| NCT01767584 | Bioequivalence Study of Cephalexin Tablets 1g | Phase1 | Infections, Respiratory Tract | Completed | 2009-04-06 | 2009-04-14 | ClinicalTrials.gov |
| NCT01153802 | An Open Label Positron Emission Tomography Study in Healthy Male Subjects to In… | Phase1 | Depressive Disorder | Completed | 2009-04-03 | 2009-10-12 | ClinicalTrials.gov |
| NCT01153802 | An Open Label Positron Emission Tomography Study in Healthy Male Subjects to In… | Phase1 | Depressive Disorder | Completed | 2009-04-03 | 2009-10-12 | ClinicalTrials.gov |
| NCT00871741 | Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Health… | Phase2 | Tetanus | Terminated | 2009-04-01 | 2009-06-25 | ClinicalTrials.gov |
| NCT00931086 | Expanded Access Trial of Belimumab Antibody in RA Patients Who Were Previously … | — | Rheumatoid Arthritis | No_Longer_Available | 2009-04-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00891982 | A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retin… | Phase3 | Acne Vulgaris | Completed | 2009-04-01 | 2009-06-05 | ClinicalTrials.gov |
| NCT00891436 | Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Sy… | Phase4 | Allergic Conjunctivitis to Tree Pollen or Grass Pollen | Completed | 2009-04-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00883935 | GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and Atazanavir | Phase1 | Healthy Volunteer | Completed | 2009-04-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00871000 | Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6… | Phase3 | Acellular Pertussis | Completed | 2009-04-01 | 2009-11-18 | ClinicalTrials.gov |
| NCT01376193 | Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet | — | Migraine Disorders | Completed | 2009-04-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00857714 | Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast | Na | Ductal Carcinoma in Situ | Terminated | 2009-04-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00852540 | Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA | Phase3 | Skin Infections, Bacterial | Completed | 2009-04-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00849381 | Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Sub… | Phase3 | Infections, Papillomavirus | Completed | 2009-04-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01001767 | Pilot Placebo Controlled Study With Lovaza in Cardiovascular Disease | Phase2 | HIV Infections | Completed | 2009-04-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00800345 | Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurren… | Phase1 | Gynecologic Tumors | Completed | 2009-04-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01587638 | Use of Beta-blockers and Risk of New Onset Diabetes | — | Hypertension | Completed | 2009-04-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT01128543 | Lapatinib in Combination With Vinorelbine | Phase2 | Cancer | Completed | 2009-04-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00931086 | Expanded Access Trial of Belimumab Antibody in RA Patients Who Were Previously … | — | Rheumatoid Arthritis | No_Longer_Available | 2009-04-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01376193 | Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet | — | Migraine Disorders | Completed | 2009-04-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00891982 | A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retin… | Phase3 | Acne Vulgaris | Completed | 2009-04-01 | 2009-06-05 | ClinicalTrials.gov |
| NCT01128543 | Lapatinib in Combination With Vinorelbine | Phase2 | Cancer | Completed | 2009-04-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00891436 | Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Sy… | Phase4 | Allergic Conjunctivitis to Tree Pollen or Grass Pollen | Completed | 2009-04-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00883935 | GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and Atazanavir | Phase1 | Healthy Volunteer | Completed | 2009-04-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00871741 | Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Health… | Phase2 | Tetanus | Terminated | 2009-04-01 | 2009-06-25 | ClinicalTrials.gov |
| NCT00871000 | Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6… | Phase3 | Acellular Pertussis | Completed | 2009-04-01 | 2009-11-18 | ClinicalTrials.gov |
| NCT01587638 | Use of Beta-blockers and Risk of New Onset Diabetes | — | Hypertension | Completed | 2009-04-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00857714 | Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast | Na | Ductal Carcinoma in Situ | Terminated | 2009-04-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00852540 | Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA | Phase3 | Skin Infections, Bacterial | Completed | 2009-04-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00849381 | Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Sub… | Phase3 | Infections, Papillomavirus | Completed | 2009-04-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01863602 | Special Drug Use Investigation for LAMICTAL® (Long Term) | — | Epilepsy | Completed | 2009-04-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT01863602 | Special Drug Use Investigation for LAMICTAL® (Long Term) | — | Epilepsy | Completed | 2009-04-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT00800345 | Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurren… | Phase1 | Gynecologic Tumors | Completed | 2009-04-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01001767 | Pilot Placebo Controlled Study With Lovaza in Cardiovascular Disease | Phase2 | HIV Infections | Completed | 2009-04-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00871117 | Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With … | Phase3 | Tetanus | Completed | 2009-03-31 | 2010-06-15 | ClinicalTrials.gov |
| NCT00871117 | Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With … | Phase3 | Tetanus | Completed | 2009-03-31 | 2010-06-15 | ClinicalTrials.gov |
| NCT00866619 | Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria D… | Phase3 | Malaria | Completed | 2009-03-27 | 2014-01-31 | ClinicalTrials.gov |
| NCT00866619 | Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria D… | Phase3 | Malaria | Completed | 2009-03-27 | 2014-01-31 | ClinicalTrials.gov |
| NCT00871156 | Tafenoquine/Chloroquine DDI Study | Phase1 | Malaria | Completed | 2009-03-24 | 2009-08-26 | ClinicalTrials.gov |
| NCT00871156 | Tafenoquine/Chloroquine DDI Study | Phase1 | Malaria | Completed | 2009-03-24 | 2009-08-26 | ClinicalTrials.gov |
| NCT00933062 | Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT21… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2009-03-23 | 2009-05-12 | ClinicalTrials.gov |
| NCT00933062 | Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT21… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2009-03-23 | 2009-05-12 | ClinicalTrials.gov |
| NCT00861029 | VEG111485: A QTc Study of Pazopanib | Phase1 | Carcinoma, Renal Cell | Completed | 2009-03-19 | 2010-02-15 | ClinicalTrials.gov |
| NCT00861029 | VEG111485: A QTc Study of Pazopanib | Phase1 | Carcinoma, Renal Cell | Completed | 2009-03-19 | 2010-02-15 | ClinicalTrials.gov |
| NCT00840320 | Repeat Dose Safety Study for Compound to Treat Anemia | Phase1 | Kidney Disease | Completed | 2009-03-13 | 2009-09-02 | ClinicalTrials.gov |
| NCT00840320 | Repeat Dose Safety Study for Compound to Treat Anemia | Phase1 | Kidney Disease | Completed | 2009-03-13 | 2009-09-02 | ClinicalTrials.gov |
| NCT00849069 | Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vacc… | Phase1 | Haemophilus Influenzae | Terminated | 2009-03-12 | 2009-04-07 | ClinicalTrials.gov |
| NCT00849069 | Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vacc… | Phase1 | Haemophilus Influenzae | Terminated | 2009-03-12 | 2009-04-07 | ClinicalTrials.gov |
| NCT00849329 | A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orall… | Phase1 | Neoplasms, Breast | Completed | 2009-03-10 | 2009-11-24 | ClinicalTrials.gov |
| NCT00849329 | A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orall… | Phase1 | Neoplasms, Breast | Completed | 2009-03-10 | 2009-11-24 | ClinicalTrials.gov |
| NCT00814710 | Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Chil… | Phase3 | Infections, Streptococcal | Completed | 2009-03-07 | 2009-11-13 | ClinicalTrials.gov |
| NCT00814710 | Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Chil… | Phase3 | Infections, Streptococcal | Completed | 2009-03-07 | 2009-11-13 | ClinicalTrials.gov |
| NCT00880399 | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Stud… | Phase2 | Depressive Disorder, Major | Terminated | 2009-03-01 | 2010-06-16 | ClinicalTrials.gov |
| NCT01386983 | Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for En… | — | Prostatic Hyperplasia | Completed | 2009-03-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00805870 | The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soren… | Phase2 | Muscle Damage | Completed | 2009-03-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00891553 | CR9112792, a Follow-up of Study CR9108963 | — | Osteoporosis | Completed | 2009-03-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT01054638 | HIV Treatment and CVD Events | — | HIV Infection | Completed | 2009-03-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00949455 | A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of t… | Phase2 | Bladder Cancer | Unknown | 2009-03-01 | — | ClinicalTrials.gov |
| NCT01054638 | HIV Treatment and CVD Events | — | HIV Infection | Completed | 2009-03-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00823836 | Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Ta… | Phase3 | Parkinson Disease | Completed | 2009-03-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01386983 | Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for En… | — | Prostatic Hyperplasia | Completed | 2009-03-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00880399 | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Stud… | Phase2 | Depressive Disorder, Major | Terminated | 2009-03-01 | 2010-06-16 | ClinicalTrials.gov |
| NCT00866554 | Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Pro… | Phase2 | Prostate Cancer | Completed | 2009-03-01 | 2019-12-01 | ClinicalTrials.gov |
| NCT00853697 | Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastati… | Phase2 | Prostate Cancer | Completed | 2009-03-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT00852761 | A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the … | Phase4 | Plaque-Type Psoriasis | Completed | 2009-03-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00891553 | CR9112792, a Follow-up of Study CR9108963 | — | Osteoporosis | Completed | 2009-03-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00852761 | A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the … | Phase4 | Plaque-Type Psoriasis | Completed | 2009-03-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00853697 | Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastati… | Phase2 | Prostate Cancer | Completed | 2009-03-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT00823836 | Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Ta… | Phase3 | Parkinson Disease | Completed | 2009-03-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00805870 | The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soren… | Phase2 | Muscle Damage | Completed | 2009-03-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00866554 | Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Pro… | Phase2 | Prostate Cancer | Completed | 2009-03-01 | 2019-12-01 | ClinicalTrials.gov |
| NCT00949455 | A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of t… | Phase2 | Bladder Cancer | Unknown | 2009-03-01 | — | ClinicalTrials.gov |
| NCT01133912 | Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb®)… | Phase1 | Breast Cancer | Completed | 2009-03-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01133912 | Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb®)… | Phase1 | Breast Cancer | Completed | 2009-03-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00839254 | Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pne… | Phase3 | Infections, Streptococcal | Completed | 2009-02-18 | 2012-01-31 | ClinicalTrials.gov |
| NCT00839254 | Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pne… | Phase3 | Infections, Streptococcal | Completed | 2009-02-18 | 2012-01-31 | ClinicalTrials.gov |
| NCT00835237 | Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With… | Phase3 | Tetanus | Completed | 2009-02-17 | 2009-10-15 | ClinicalTrials.gov |
| NCT00835237 | Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With… | Phase3 | Tetanus | Completed | 2009-02-17 | 2009-10-15 | ClinicalTrials.gov |
| NCT00829010 | Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infect… | Phase3 | Infections, Streptococcal | Completed | 2009-02-17 | 2012-06-27 | ClinicalTrials.gov |
| NCT00829010 | Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infect… | Phase3 | Infections, Streptococcal | Completed | 2009-02-17 | 2012-06-27 | ClinicalTrials.gov |
| NCT00857857 | A Study to Evaluate the Effect of GW870086X on Allergen Challenge in Mild Asthm… | Phase2 | Asthma | Completed | 2009-02-16 | 2009-11-03 | ClinicalTrials.gov |
| NCT00857857 | A Study to Evaluate the Effect of GW870086X on Allergen Challenge in Mild Asthm… | Phase2 | Asthma | Completed | 2009-02-16 | 2009-11-03 | ClinicalTrials.gov |
| NCT00814762 | Safety of the HIV Vaccine 732462 in HIV Infected Subjects Aged 18 to 55 Years O… | Phase1 | AIDS | Completed | 2009-02-03 | 2010-08-18 | ClinicalTrials.gov |
| NCT00814762 | Safety of the HIV Vaccine 732462 in HIV Infected Subjects Aged 18 to 55 Years O… | Phase1 | AIDS | Completed | 2009-02-03 | 2010-08-18 | ClinicalTrials.gov |
| NCT01013948 | Prevalence of Chronic Airway Obstruction in Subjects With a History of Cigarett… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2009-02-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT01550926 | A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms | Phase1 | Overweight | Completed | 2009-02-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00866671 | Observational Study of Nelarabine in Children and Young Adults | — | Leukaemia, Lymphoblastic, Acute | Completed | 2009-02-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT00887484 | A Comparative Study of the Tolerability of Two Combination Therapies for the Tr… | Phase4 | Acne Vulgaris | Completed | 2009-02-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00828763 | GSK1349572 Mass Balance Study | Phase1 | Healthy Volunteer | Completed | 2009-02-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00841828 | Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients | Phase2 | Breast Cancer | Completed | 2009-02-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00839527 | A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Ty… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2009-02-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01550926 | A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms | Phase1 | Overweight | Completed | 2009-02-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00837044 | Treximet in Acute Migraine Headache: Assessing Cognitive Function | Na | Migraine Headache | Unknown | 2009-02-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00856297 | Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among A… | Phase3 | Meningococcal Meningitis | Completed | 2009-02-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT00858286 | A Follow-up Survey to Compare Stable Dosing (SERETIDE) With SYMBICORT, SMART, M… | Phase4 | Asthma | Completed | 2009-02-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00837044 | Treximet in Acute Migraine Headache: Assessing Cognitive Function | Na | Migraine Headache | Unknown | 2009-02-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00872963 | An Extended Follow up of a RTS,S/AS01E Malaria Vaccine Trial | — | Malaria | Unknown | 2009-02-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT00790907 | Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization i… | Phase4 | Acute Coronary Syndrome | Completed | 2009-02-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00858286 | A Follow-up Survey to Compare Stable Dosing (SERETIDE) With SYMBICORT, SMART, M… | Phase4 | Asthma | Completed | 2009-02-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00856297 | Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among A… | Phase3 | Meningococcal Meningitis | Completed | 2009-02-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01013948 | Prevalence of Chronic Airway Obstruction in Subjects With a History of Cigarett… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2009-02-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00828763 | GSK1349572 Mass Balance Study | Phase1 | Healthy Volunteer | Completed | 2009-02-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00887484 | A Comparative Study of the Tolerability of Two Combination Therapies for the Tr… | Phase4 | Acne Vulgaris | Completed | 2009-02-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT01587950 | The Effects of Potassium Nitrate in Reducing Dentinal Hypersensitivity | Phase1 | Dentinal Hypersensitivity | Completed | 2009-02-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00850863 | Systemic Inflammation in Chronic Obstructive Pulmonary Disease (COPD) | — | Chronic Obstructive Pulmonary Disease | Unknown | 2009-02-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT00850863 | Systemic Inflammation in Chronic Obstructive Pulmonary Disease (COPD) | — | Chronic Obstructive Pulmonary Disease | Unknown | 2009-02-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01587950 | The Effects of Potassium Nitrate in Reducing Dentinal Hypersensitivity | Phase1 | Dentinal Hypersensitivity | Completed | 2009-02-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00839527 | A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Ty… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2009-02-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT00872963 | An Extended Follow up of a RTS,S/AS01E Malaria Vaccine Trial | — | Malaria | Unknown | 2009-02-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT00841828 | Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients | Phase2 | Breast Cancer | Completed | 2009-02-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00866671 | Observational Study of Nelarabine in Children and Young Adults | — | Leukaemia, Lymphoblastic, Acute | Completed | 2009-02-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT00790907 | Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization i… | Phase4 | Acute Coronary Syndrome | Completed | 2009-02-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00748410 | Study to Evaluate the Pharmacodynamics of SB-656933 in Patients With Ulcerative… | Phase2 | Colitis, Ulcerative | Terminated | 2009-01-22 | 2009-12-12 | ClinicalTrials.gov |
| NCT00748410 | Study to Evaluate the Pharmacodynamics of SB-656933 in Patients With Ulcerative… | Phase2 | Colitis, Ulcerative | Terminated | 2009-01-22 | 2009-12-12 | ClinicalTrials.gov |
| NCT00938275 | A Clinical Study to Assess the Effect of Food and Gender on the Pharmacokinetic… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2009-01-20 | 2009-03-27 | ClinicalTrials.gov |
| NCT00938275 | A Clinical Study to Assess the Effect of Food and Gender on the Pharmacokinetic… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2009-01-20 | 2009-03-27 | ClinicalTrials.gov |
| NCT00823940 | A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Health… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2009-01-13 | 2009-04-27 | ClinicalTrials.gov |
| NCT00823940 | A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Health… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2009-01-13 | 2009-04-27 | ClinicalTrials.gov |
| NCT00814489 | Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vacci… | Phase1 | Streptococcus Pneumoniae | Completed | 2009-01-08 | 2010-06-10 | ClinicalTrials.gov |
| NCT00814489 | Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vacci… | Phase1 | Streptococcus Pneumoniae | Completed | 2009-01-08 | 2010-06-10 | ClinicalTrials.gov |
| NCT00808444 | Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Chil… | Phase3 | Infections, Streptococcal | Completed | 2009-01-05 | 2009-11-02 | ClinicalTrials.gov |
| NCT00808444 | Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Chil… | Phase3 | Infections, Streptococcal | Completed | 2009-01-05 | 2009-11-02 | ClinicalTrials.gov |
| NCT00802737 | Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Pati… | Phase4 | Leukaemia, Lymphocytic, Chronic | Completed | 2009-01-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT00817765 | Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir | Phase1 | HIV Infection | Completed | 2009-01-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00802737 | Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Pati… | Phase4 | Leukaemia, Lymphocytic, Chronic | Completed | 2009-01-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT00731770 | Comparing Fluticasone-salmeterol in Chronic Obstructive Pulmonary Disease (COPD… | Phase4 | COPD | Completed | 2009-01-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00799825 | Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Sub… | Phase3 | Infections, Papillomavirus | Completed | 2009-01-01 | 2012-08-02 | ClinicalTrials.gov |
| NCT00731770 | Comparing Fluticasone-salmeterol in Chronic Obstructive Pulmonary Disease (COPD… | Phase4 | COPD | Completed | 2009-01-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00861601 | Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Sub… | Phase2 | Liver Diseases | Completed | 2009-01-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00858455 | A Study to Evaluate the Effect of Antacid and Multivitamin and Mineral Tablet o… | Phase1 | Healthy Volunteer | Completed | 2009-01-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00849017 | Safety and Efficacy Study of Albiglutide in Type 2 Diabetes | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2009-01-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01133860 | Efficacy of Eltrombopag to Improve Thrombocytopenia of MYH9-related Disease | Phase2 | Blood Platelet Disorders | Completed | 2009-01-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01133860 | Efficacy of Eltrombopag to Improve Thrombocytopenia of MYH9-related Disease | Phase2 | Blood Platelet Disorders | Completed | 2009-01-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01054586 | Fosamprenavir in Pts With Hepatic Impairment | — | Infection, Human Immunodeficiency Virus | Completed | 2009-01-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00902018 | Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic… | Phase2 | Immune Thrombocytopenia | Completed | 2009-01-01 | 2015-09-07 | ClinicalTrials.gov |
| NCT00849017 | Safety and Efficacy Study of Albiglutide in Type 2 Diabetes | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2009-01-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01159951 | Analysis of Trends Over Time of Hepatitis Related Incidence in Panama | — | Hepatitis | Completed | 2009-01-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01159951 | Analysis of Trends Over Time of Hepatitis Related Incidence in Panama | — | Hepatitis | Completed | 2009-01-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT00858455 | A Study to Evaluate the Effect of Antacid and Multivitamin and Mineral Tablet o… | Phase1 | Healthy Volunteer | Completed | 2009-01-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00861601 | Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Sub… | Phase2 | Liver Diseases | Completed | 2009-01-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00817765 | Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir | Phase1 | HIV Infection | Completed | 2009-01-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00902018 | Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic… | Phase2 | Immune Thrombocytopenia | Completed | 2009-01-01 | 2015-09-07 | ClinicalTrials.gov |
| NCT00805701 | Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving U… | Phase4 | Prostate Cancer | Completed | 2009-01-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT00803543 | Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding | Na | HIV | Completed | 2009-01-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT00799825 | Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Sub… | Phase3 | Infections, Papillomavirus | Completed | 2009-01-01 | 2012-08-02 | ClinicalTrials.gov |
| NCT00805701 | Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving U… | Phase4 | Prostate Cancer | Completed | 2009-01-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01054586 | Fosamprenavir in Pts With Hepatic Impairment | — | Infection, Human Immunodeficiency Virus | Completed | 2009-01-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00803543 | Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding | Na | HIV | Completed | 2009-01-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01563172 | Effect of Dentifrice Usage Regime on Delivery and Efficacy of Fluoride | Phase4 | Dental Caries | Completed | 2009-01-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT01563172 | Effect of Dentifrice Usage Regime on Delivery and Efficacy of Fluoride | Phase4 | Dental Caries | Completed | 2009-01-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00866515 | Drug Interaction Study to Investigate Co-administration of GW642444M With Ketoc… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-12-22 | 2009-03-27 | ClinicalTrials.gov |
| NCT00866515 | Drug Interaction Study to Investigate Co-administration of GW642444M With Ketoc… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-12-22 | 2009-03-27 | ClinicalTrials.gov |
| NCT00805389 | Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With… | Phase2 | Hepatitis B | Completed | 2008-12-15 | 2011-07-14 | ClinicalTrials.gov |
| NCT00805389 | Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With… | Phase2 | Hepatitis B | Completed | 2008-12-15 | 2011-07-14 | ClinicalTrials.gov |
| NCT00811356 | A First Time in Human Study in Healthy Volunteers to Investigate a New Medicine… | Phase1 | Malaria | Terminated | 2008-12-11 | 2009-03-30 | ClinicalTrials.gov |
| NCT00811356 | A First Time in Human Study in Healthy Volunteers to Investigate a New Medicine… | Phase1 | Malaria | Terminated | 2008-12-11 | 2009-03-30 | ClinicalTrials.gov |
| NCT00843193 | Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma | Phase2 | Asthma | Completed | 2008-12-09 | 2010-07-25 | ClinicalTrials.gov |
| NCT00843193 | Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma | Phase2 | Asthma | Completed | 2008-12-09 | 2010-07-25 | ClinicalTrials.gov |
| NCT00814957 | An Open Label Positron Emission Tomography (PET) Study of GSK618334 in Healthy … | Phase1 | Substance Dependence | Completed | 2008-12-08 | 2009-06-11 | ClinicalTrials.gov |
| NCT01929278 | W0265-103: A Single-Center, Evaluator-Blinded, Randomized, Placebo Controlled, … | Phase1 | Acne Vulgaris | Completed | 2008-12-08 | 2008-12-19 | ClinicalTrials.gov |
| NCT01929278 | W0265-103: A Single-Center, Evaluator-Blinded, Randomized, Placebo Controlled, … | Phase1 | Acne Vulgaris | Completed | 2008-12-08 | 2008-12-19 | ClinicalTrials.gov |
| NCT00814957 | An Open Label Positron Emission Tomography (PET) Study of GSK618334 in Healthy … | Phase1 | Substance Dependence | Completed | 2008-12-08 | 2009-06-11 | ClinicalTrials.gov |
| NCT00792909 | Vaccination Course in Primed Children and Age-matched Unprimed Children With Pn… | Phase3 | Infections, Streptococcal | Completed | 2008-12-02 | 2009-07-02 | ClinicalTrials.gov |
| NCT00792909 | Vaccination Course in Primed Children and Age-matched Unprimed Children With Pn… | Phase3 | Infections, Streptococcal | Completed | 2008-12-02 | 2009-07-02 | ClinicalTrials.gov |
| NCT00796445 | A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in… | Phase3 | Melanoma | Terminated | 2008-12-01 | 2016-01-27 | ClinicalTrials.gov |
| NCT00793468 | Relapse Prevention Study in Newly Abstinent Smokers | Phase2 | Substance Dependence | Withdrawn | 2008-12-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00791518 | Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obs… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2008-12-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00784550 | A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 2… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-12-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00524134 | P-glycoprotein Inhibition as Adjunct Treatment for Medically Refractory Epileps… | Phase2 | Epilepsy | Terminated | 2008-12-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00784550 | A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 2… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-12-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00843024 | Migraine Study in Adolescent Patients | Phase3 | Migraine Disorders | Completed | 2008-12-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00524134 | P-glycoprotein Inhibition as Adjunct Treatment for Medically Refractory Epileps… | Phase2 | Epilepsy | Terminated | 2008-12-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00799760 | Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir | Phase3 | Gastric Influenza | Terminated | 2008-12-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01075256 | Dose Response of a Tubule Occlusion Agent | Phase4 | Dentine Hypersensitivity | Completed | 2008-12-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00791518 | Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obs… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2008-12-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00843024 | Migraine Study in Adolescent Patients | Phase3 | Migraine Disorders | Completed | 2008-12-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01153880 | United States Pharmacovigilence Retapamulin-Prescribing | — | Skin Infections, Bacterial | Completed | 2008-12-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01568749 | A Study Investigating the Pharmacokinetic Profiles of Four Extended Release Par… | Phase1 | Analgesia | Completed | 2008-12-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00748306 | Study in Mild Asthmatic Patients | Phase2 | Asthma | Completed | 2008-12-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00793468 | Relapse Prevention Study in Newly Abstinent Smokers | Phase2 | Substance Dependence | Withdrawn | 2008-12-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT01075256 | Dose Response of a Tubule Occlusion Agent | Phase4 | Dentine Hypersensitivity | Completed | 2008-12-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00748306 | Study in Mild Asthmatic Patients | Phase2 | Asthma | Completed | 2008-12-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT01153880 | United States Pharmacovigilence Retapamulin-Prescribing | — | Skin Infections, Bacterial | Completed | 2008-12-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT00796445 | A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in… | Phase3 | Melanoma | Terminated | 2008-12-01 | 2016-01-27 | ClinicalTrials.gov |
| NCT01376180 | Drug Use Investigation for LAMICTAL | — | Epilepsy | Completed | 2008-12-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT01376180 | Drug Use Investigation for LAMICTAL | — | Epilepsy | Completed | 2008-12-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT01390883 | Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal (Urology,Ob… | — | Cardiovascular Disease | Completed | 2008-12-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT00799903 | The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy… | Phase3 | Atherosclerosis | Completed | 2008-12-01 | 2013-10-17 | ClinicalTrials.gov |
| NCT01390883 | Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal (Urology,Ob… | — | Cardiovascular Disease | Completed | 2008-12-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT00799903 | The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy… | Phase3 | Atherosclerosis | Completed | 2008-12-01 | 2013-10-17 | ClinicalTrials.gov |
| NCT01568749 | A Study Investigating the Pharmacokinetic Profiles of Four Extended Release Par… | Phase1 | Analgesia | Completed | 2008-12-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00799760 | Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir | Phase3 | Gastric Influenza | Terminated | 2008-12-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00861484 | Proof of Mechanism in ELT | Phase1 | Premature Ejaculation | Completed | 2008-11-26 | 2009-12-11 | ClinicalTrials.gov |
| NCT00861484 | Proof of Mechanism in ELT | Phase1 | Premature Ejaculation | Completed | 2008-11-26 | 2009-12-11 | ClinicalTrials.gov |
| NCT00912275 | Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer | Phase1 | Metastatic Breast Cancer | Completed | 2008-11-24 | 2017-07-07 | ClinicalTrials.gov |
| NCT00912275 | Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer | Phase1 | Metastatic Breast Cancer | Completed | 2008-11-24 | 2017-07-07 | ClinicalTrials.gov |
| NCT00937872 | A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailabil… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2008-11-22 | 2008-12-22 | ClinicalTrials.gov |
| NCT00937872 | A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailabil… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2008-11-22 | 2008-12-22 | ClinicalTrials.gov |
| NCT00849134 | First Time in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics… | Phase1 | Pain, Inflammatory | Completed | 2008-11-17 | 2009-04-06 | ClinicalTrials.gov |
| NCT00857883 | A First-Time-In-Human Study in Healthy Subjects | Phase1 | Obesity | Completed | 2008-11-17 | 2009-08-01 | ClinicalTrials.gov |
| NCT00857883 | A First-Time-In-Human Study in Healthy Subjects | Phase1 | Obesity | Completed | 2008-11-17 | 2009-08-01 | ClinicalTrials.gov |
| NCT00849134 | First Time in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics… | Phase1 | Pain, Inflammatory | Completed | 2008-11-17 | 2009-04-06 | ClinicalTrials.gov |
| NCT00812981 | A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine. | Phase3 | Influenza | Completed | 2008-11-15 | 2009-06-07 | ClinicalTrials.gov |
| NCT00812981 | A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine. | Phase3 | Influenza | Completed | 2008-11-15 | 2009-06-07 | ClinicalTrials.gov |
| NCT00828867 | Single Dose Escalation First Time in Human PK Study | Phase1 | Infections, Bacterial | Completed | 2008-11-14 | 2009-12-07 | ClinicalTrials.gov |
| NCT00828867 | Single Dose Escalation First Time in Human PK Study | Phase1 | Infections, Bacterial | Completed | 2008-11-14 | 2009-12-07 | ClinicalTrials.gov |
| NCT00783003 | A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-11-10 | 2009-02-06 | ClinicalTrials.gov |
| NCT00907933 | Intranasal SB-705498 in Healthy Volunteers | Phase1 | Rhinitis | Completed | 2008-11-10 | 2009-02-11 | ClinicalTrials.gov |
| NCT00907933 | Intranasal SB-705498 in Healthy Volunteers | Phase1 | Rhinitis | Completed | 2008-11-10 | 2009-02-11 | ClinicalTrials.gov |
| NCT00783003 | A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-11-10 | 2009-02-06 | ClinicalTrials.gov |
| NCT00791089 | Effects of Fish Oil on Post Ablation Arrhythmias | Phase4 | Atrial Fibrillation | Terminated | 2008-11-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00789113 | Determination of Absorption and Elimination of Lamotrigine-XR | Phase1 | Epilepsy | Completed | 2008-11-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00791089 | Effects of Fish Oil on Post Ablation Arrhythmias | Phase4 | Atrial Fibrillation | Terminated | 2008-11-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01346475 | Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versu… | Phase4 | Genital Herpes | Completed | 2008-11-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT00774995 | Immune Response of Healthy Subjects Who Received Neonatal Vaccination Course Wi… | Phase4 | Hepatitis B | Completed | 2008-11-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00695305 | An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo … | Phase2 | Atherosclerosis | Completed | 2008-11-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00911196 | Analysis of Expression of Specific Markers and Their Prognostic Significance in… | — | Hepatocellular Carcinoma | Completed | 2008-11-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT01153828 | EU PV for Retapamulin-Prescribing | — | Impetigo | Completed | 2008-11-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT00695305 | An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo … | Phase2 | Atherosclerosis | Completed | 2008-11-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01044485 | Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advance… | Phase1 | Metastatic Breast Cancer | Completed | 2008-11-01 | — | ClinicalTrials.gov |
| NCT01005966 | In Situ Caries Model of Fluoride Toothpastes | Phase3 | Caries | Completed | 2008-11-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00771914 | The Effects of Omega-3 Fatty Acids on Aspirin Resistance | Phase1 | Increased Drug Resistance | Completed | 2008-11-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT01005966 | In Situ Caries Model of Fluoride Toothpastes | Phase3 | Caries | Completed | 2008-11-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT01044485 | Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advance… | Phase1 | Metastatic Breast Cancer | Completed | 2008-11-01 | — | ClinicalTrials.gov |
| NCT00771914 | The Effects of Omega-3 Fatty Acids on Aspirin Resistance | Phase1 | Increased Drug Resistance | Completed | 2008-11-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00791973 | Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Na… | Phase4 | Allergic Rhinitis | Completed | 2008-11-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00774995 | Immune Response of Healthy Subjects Who Received Neonatal Vaccination Course Wi… | Phase4 | Hepatitis B | Completed | 2008-11-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01153828 | EU PV for Retapamulin-Prescribing | — | Impetigo | Completed | 2008-11-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT00784784 | Zanamivir Versus Trivalent Split Virus Influenza Vaccine | Phase3 | Influenza | Completed | 2008-11-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT01346475 | Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versu… | Phase4 | Genital Herpes | Completed | 2008-11-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT00784784 | Zanamivir Versus Trivalent Split Virus Influenza Vaccine | Phase3 | Influenza | Completed | 2008-11-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00825994 | Omega-3 for Peri- and Postmenopausal Depression | Na | Depression | Completed | 2008-11-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00825994 | Omega-3 for Peri- and Postmenopausal Depression | Na | Depression | Completed | 2008-11-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00789113 | Determination of Absorption and Elimination of Lamotrigine-XR | Phase1 | Epilepsy | Completed | 2008-11-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00791973 | Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Na… | Phase4 | Allergic Rhinitis | Completed | 2008-11-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00911196 | Analysis of Expression of Specific Markers and Their Prognostic Significance in… | — | Hepatocellular Carcinoma | Completed | 2008-11-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00758264 | Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine G… | Phase3 | Infections, Meningococcal | Completed | 2008-10-30 | 2009-11-02 | ClinicalTrials.gov |
| NCT00758264 | Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine G… | Phase3 | Infections, Meningococcal | Completed | 2008-10-30 | 2009-11-02 | ClinicalTrials.gov |
| NCT00779766 | Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine … | Phase3 | Infections, Papillomavirus | Completed | 2008-10-22 | 2016-02-28 | ClinicalTrials.gov |
| NCT00779766 | Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine … | Phase3 | Infections, Papillomavirus | Completed | 2008-10-22 | 2016-02-28 | ClinicalTrials.gov |
| NCT00711126 | A Study To Investigate Safety, Blood Levels And Effects Of Giving GW642444, By … | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-10-21 | 2008-12-17 | ClinicalTrials.gov |
| NCT00711126 | A Study To Investigate Safety, Blood Levels And Effects Of Giving GW642444, By … | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-10-21 | 2008-12-17 | ClinicalTrials.gov |
| NCT00718666 | The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GS… | Phase2 | Infections, Meningococcal | Completed | 2008-10-20 | 2014-03-28 | ClinicalTrials.gov |
| NCT00718666 | The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GS… | Phase2 | Infections, Meningococcal | Completed | 2008-10-20 | 2014-03-28 | ClinicalTrials.gov |
| NCT00771615 | Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Age… | Phase2 | Influenza | Completed | 2008-10-16 | 2009-12-04 | ClinicalTrials.gov |
| NCT00771615 | Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Age… | Phase2 | Influenza | Completed | 2008-10-16 | 2009-12-04 | ClinicalTrials.gov |
| NCT00765076 | Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2… | Phase3 | Influenza | Completed | 2008-10-16 | 2009-12-04 | ClinicalTrials.gov |
| NCT00765076 | Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2… | Phase3 | Influenza | Completed | 2008-10-16 | 2009-12-04 | ClinicalTrials.gov |
| NCT00772889 | Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877… | Phase3 | Influenza | Completed | 2008-10-09 | 2009-12-15 | ClinicalTrials.gov |
| NCT00772889 | Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877… | Phase3 | Influenza | Completed | 2008-10-09 | 2009-12-15 | ClinicalTrials.gov |
| NCT00760617 | Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine G… | Phase3 | Influenza | Completed | 2008-10-06 | 2009-05-15 | ClinicalTrials.gov |
| NCT00760617 | Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine G… | Phase3 | Influenza | Completed | 2008-10-06 | 2009-05-15 | ClinicalTrials.gov |
| NCT00751348 | Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubell… | Phase3 | Measles | Completed | 2008-10-01 | 2010-05-27 | ClinicalTrials.gov |
| NCT00776919 | Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne | Phase3 | Acne Vulgaris | Completed | 2008-10-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00774735 | GSK1349572 Drug Interaction Study With Protease Inhibitors | Phase1 | Healthy Subjects | Completed | 2008-10-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00776919 | Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne | Phase3 | Acne Vulgaris | Completed | 2008-10-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00995995 | Evaluation of the Duration of Oral Combination Therapy in Type 2 Diabetes, Prio… | — | Diabetes Mellitus, Type 2 | Completed | 2008-10-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00774735 | GSK1349572 Drug Interaction Study With Protease Inhibitors | Phase1 | Healthy Subjects | Completed | 2008-10-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00774111 | GSK1349572 Drug Interaction Study With Etravirine | Phase1 | Healthy Subjects | Completed | 2008-10-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00774111 | GSK1349572 Drug Interaction Study With Etravirine | Phase1 | Healthy Subjects | Completed | 2008-10-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00732472 | A Study to Assess the Safety and Tolerability of Once Daily Inhaled Doses of GS… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-10-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00828464 | Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate fo… | Phase4 | Hand Dermatosis | Completed | 2008-10-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00732940 | Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemi… | Phase2 | Systemic Lupus Erythematosus | Terminated | 2008-10-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00766090 | Safety and Efficacy of GW685698X an Inhaled Corticosteroid Once Daily and Twice… | Phase2 | Asthma | Completed | 2008-10-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00764790 | Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licens… | Phase3 | Influenza | Completed | 2008-10-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00764790 | Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licens… | Phase3 | Influenza | Completed | 2008-10-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00766090 | Safety and Efficacy of GW685698X an Inhaled Corticosteroid Once Daily and Twice… | Phase2 | Asthma | Completed | 2008-10-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00725283 | Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patie… | Phase1 | Leukaemia, Myelocytic, Acute | Completed | 2008-10-01 | 2016-06-22 | ClinicalTrials.gov |
| NCT01077635 | PENTA Fosamprenavir Study | — | Infection, Human Immunodeficiency Virus | Completed | 2008-10-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01077635 | PENTA Fosamprenavir Study | — | Infection, Human Immunodeficiency Virus | Completed | 2008-10-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT00828464 | Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate fo… | Phase4 | Hand Dermatosis | Completed | 2008-10-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00995995 | Evaluation of the Duration of Oral Combination Therapy in Type 2 Diabetes, Prio… | — | Diabetes Mellitus, Type 2 | Completed | 2008-10-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00725283 | Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patie… | Phase1 | Leukaemia, Myelocytic, Acute | Completed | 2008-10-01 | 2016-06-22 | ClinicalTrials.gov |
| NCT00732940 | Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemi… | Phase2 | Systemic Lupus Erythematosus | Terminated | 2008-10-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00751348 | Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubell… | Phase3 | Measles | Completed | 2008-10-01 | 2010-05-27 | ClinicalTrials.gov |
| NCT00732472 | A Study to Assess the Safety and Tolerability of Once Daily Inhaled Doses of GS… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-10-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00706238 | MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive … | Phase2 | Melanoma | Terminated | 2008-09-29 | 2011-01-19 | ClinicalTrials.gov |
| NCT00887367 | EtOH Interaction Study | Phase1 | Substance Dependence | Completed | 2008-09-29 | 2008-12-03 | ClinicalTrials.gov |
| NCT00887367 | EtOH Interaction Study | Phase1 | Substance Dependence | Completed | 2008-09-29 | 2008-12-03 | ClinicalTrials.gov |
| NCT00706238 | MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive … | Phase2 | Melanoma | Terminated | 2008-09-29 | 2011-01-19 | ClinicalTrials.gov |
| NCT00732420 | Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors | Phase1 | Solid Tumours | Completed | 2008-09-24 | 2013-06-12 | ClinicalTrials.gov |
| NCT00972673 | A Study of GW685698X in Healthy Japanese Male Subjects | Phase1 | Asthma | Completed | 2008-09-24 | 2008-12-19 | ClinicalTrials.gov |
| NCT00732420 | Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors | Phase1 | Solid Tumours | Completed | 2008-09-24 | 2013-06-12 | ClinicalTrials.gov |
| NCT00972673 | A Study of GW685698X in Healthy Japanese Male Subjects | Phase1 | Asthma | Completed | 2008-09-24 | 2008-12-19 | ClinicalTrials.gov |
| NCT00733551 | Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Dose… | Phase1 | Gastroparesis | Completed | 2008-09-23 | 2009-07-20 | ClinicalTrials.gov |
| NCT00733551 | Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Dose… | Phase1 | Gastroparesis | Completed | 2008-09-23 | 2009-07-20 | ClinicalTrials.gov |
| NCT00753649 | Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants | Phase4 | Hepatitis B | Completed | 2008-09-23 | 2013-03-12 | ClinicalTrials.gov |
| NCT00753649 | Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants | Phase4 | Hepatitis B | Completed | 2008-09-23 | 2013-03-12 | ClinicalTrials.gov |
| NCT00964249 | Phase I Study of GW642444M in Healthy Japanese Male Subjects | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-09-20 | 2008-12-01 | ClinicalTrials.gov |
| NCT00964405 | Phase I Study of GSK233705 in Healthy Japanese Male Subjects | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-09-20 | 2008-12-20 | ClinicalTrials.gov |
| NCT00964249 | Phase I Study of GW642444M in Healthy Japanese Male Subjects | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-09-20 | 2008-12-01 | ClinicalTrials.gov |
| NCT00964405 | Phase I Study of GSK233705 in Healthy Japanese Male Subjects | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-09-20 | 2008-12-20 | ClinicalTrials.gov |
| NCT00742144 | Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chron… | Phase1 | Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular | Completed | 2008-09-19 | 2009-11-18 | ClinicalTrials.gov |
| NCT00742144 | Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chron… | Phase1 | Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular | Completed | 2008-09-19 | 2009-11-18 | ClinicalTrials.gov |
| NCT01424384 | Emotional Processing in Healthy Volunteers in the Presence of an Investigationa… | Phase1 | Depressive Disorder and Anxiety Disorders | Completed | 2008-09-19 | 2009-04-30 | ClinicalTrials.gov |
| NCT01424384 | Emotional Processing in Healthy Volunteers in the Presence of an Investigationa… | Phase1 | Depressive Disorder and Anxiety Disorders | Completed | 2008-09-19 | 2009-04-30 | ClinicalTrials.gov |
| NCT00730847 | A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biolog… | Phase4 | Human Papillomavirus Infection Leading to Cervical Cancer | Terminated | 2008-09-17 | 2012-01-16 | ClinicalTrials.gov |
| NCT00730847 | A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biolog… | Phase4 | Human Papillomavirus Infection Leading to Cervical Cancer | Terminated | 2008-09-17 | 2012-01-16 | ClinicalTrials.gov |
| NCT00757523 | Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and … | Phase4 | Acne Vulgaris | Completed | 2008-09-10 | 2009-06-24 | ClinicalTrials.gov |
| NCT00757523 | Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and … | Phase4 | Acne Vulgaris | Completed | 2008-09-10 | 2009-06-24 | ClinicalTrials.gov |
| NCT00783549 | A Study in Healthy Volunteers of Single Doses of Orally Administered Investigat… | Phase1 | Dyslipidaemias | Completed | 2008-09-04 | 2009-03-31 | ClinicalTrials.gov |
| NCT00783549 | A Study in Healthy Volunteers of Single Doses of Orally Administered Investigat… | Phase1 | Dyslipidaemias | Completed | 2008-09-04 | 2009-03-31 | ClinicalTrials.gov |
| NCT00867737 | Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbi… | Phase4 | Asthma | Unknown | 2008-09-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00749502 | A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Mal… | Phase1 | Solid Tumors | Completed | 2008-09-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01231490 | Acute Osteoarthritis Experimental Model Study. | Phase2 | Osteoarthritis | Completed | 2008-09-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00867737 | Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbi… | Phase4 | Asthma | Unknown | 2008-09-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00752869 | Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement | Phase4 | Hypogonadism | Completed | 2008-09-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00851344 | Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With … | Phase2 | Rhinitis, Allergic, Seasonal | Completed | 2008-09-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00749502 | A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Mal… | Phase1 | Solid Tumors | Completed | 2008-09-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00742885 | Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candida… | Phase2 | Influenza | Completed | 2008-09-01 | 2009-03-07 | ClinicalTrials.gov |
| NCT00819910 | Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL) | Phase4 | Hypertriglyceridemia in Type 4 Hyperlipidemia | Terminated | 2008-09-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01231490 | Acute Osteoarthritis Experimental Model Study. | Phase2 | Osteoarthritis | Completed | 2008-09-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00819910 | Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL) | Phase4 | Hypertriglyceridemia in Type 4 Hyperlipidemia | Terminated | 2008-09-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00851344 | Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With … | Phase2 | Rhinitis, Allergic, Seasonal | Completed | 2008-09-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT01216735 | Effect of an Inhaled Glucocorticosteroid (ICS) on Endothelial Dysfunction in Ci… | Na | Tobacco Abuse Smoke | Completed | 2008-09-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00752869 | Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement | Phase4 | Hypogonadism | Completed | 2008-09-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00742885 | Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candida… | Phase2 | Influenza | Completed | 2008-09-01 | 2009-03-07 | ClinicalTrials.gov |
| NCT01216735 | Effect of an Inhaled Glucocorticosteroid (ICS) on Endothelial Dysfunction in Ci… | Na | Tobacco Abuse Smoke | Completed | 2008-09-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00843011 | Food and Relative Bioavailability Study | Phase1 | Depressive Disorder | Completed | 2008-08-28 | 2008-10-23 | ClinicalTrials.gov |
| NCT00742508 | A Phase I/II Clinical Study of SK&F-105517-D in Japanese Patients With Chronic … | Phase1 | Heart Failure, Congestive | Completed | 2008-08-28 | 2009-08-21 | ClinicalTrials.gov |
| NCT00843011 | Food and Relative Bioavailability Study | Phase1 | Depressive Disorder | Completed | 2008-08-28 | 2008-10-23 | ClinicalTrials.gov |
| NCT00742508 | A Phase I/II Clinical Study of SK&F-105517-D in Japanese Patients With Chronic … | Phase1 | Heart Failure, Congestive | Completed | 2008-08-28 | 2009-08-21 | ClinicalTrials.gov |
| NCT00734032 | A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients | Phase2 | Atherosclerosis | Completed | 2008-08-26 | 2009-01-16 | ClinicalTrials.gov |
| NCT00734032 | A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients | Phase2 | Atherosclerosis | Completed | 2008-08-26 | 2009-01-16 | ClinicalTrials.gov |
| NCT00920803 | A Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics o… | Phase1 | Neoplasms, Colorectal | Completed | 2008-08-19 | 2009-11-11 | ClinicalTrials.gov |
| NCT00920803 | A Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics o… | Phase1 | Neoplasms, Colorectal | Completed | 2008-08-19 | 2009-11-11 | ClinicalTrials.gov |
| NCT00733785 | PK, Dose Proportionality, Food Effect And Repeat Dose Study Of Rosiglitazone XR… | Phase1 | Alzheimer's Disease | Completed | 2008-08-13 | 2008-11-28 | ClinicalTrials.gov |
| NCT00733785 | PK, Dose Proportionality, Food Effect And Repeat Dose Study Of Rosiglitazone XR… | Phase1 | Alzheimer's Disease | Completed | 2008-08-13 | 2008-11-28 | ClinicalTrials.gov |
| NCT00742261 | A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors | Phase1 | Solid Tumours | Completed | 2008-08-11 | 2009-06-24 | ClinicalTrials.gov |
| NCT00733577 | A Study to Test How SB756050 Affects Subjects With Type 2 Diabetes Mellitus Aft… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2008-08-11 | 2009-03-03 | ClinicalTrials.gov |
| NCT00742261 | A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors | Phase1 | Solid Tumours | Completed | 2008-08-11 | 2009-06-24 | ClinicalTrials.gov |
| NCT00733577 | A Study to Test How SB756050 Affects Subjects With Type 2 Diabetes Mellitus Aft… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2008-08-11 | 2009-03-03 | ClinicalTrials.gov |
| NCT00741767 | The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD | Na | Chronic Obstructive Pulmonary Disease | Withdrawn | 2008-08-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT00742209 | Prevention Study in Adult Patients Suffering From Migraine Headaches | Phase2 | Migraine Disorders | Completed | 2008-08-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00726336 | GSK1349572 Drug Interaction With Tenofovir | Phase1 | Healthy Subjects | Completed | 2008-08-01 | — | ClinicalTrials.gov |
| NCT00724867 | A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C10… | Phase3 | Systemic Lupus Erythematosus | Completed | 2008-08-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT00726336 | GSK1349572 Drug Interaction With Tenofovir | Phase1 | Healthy Subjects | Completed | 2008-08-01 | — | ClinicalTrials.gov |
| NCT00742209 | Prevention Study in Adult Patients Suffering From Migraine Headaches | Phase2 | Migraine Disorders | Completed | 2008-08-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00724867 | A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C10… | Phase3 | Systemic Lupus Erythematosus | Completed | 2008-08-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT00729430 | Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Ma… | Phase3 | Myocardial Infarction | Completed | 2008-08-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT00741767 | The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD | Na | Chronic Obstructive Pulmonary Disease | Withdrawn | 2008-08-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01498627 | Cervarix Long-term Safety Surveillance | — | Infections, Papillomavirus | Completed | 2008-08-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT00729430 | Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Ma… | Phase3 | Myocardial Infarction | Completed | 2008-08-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT00731822 | A Study To Assess Single Dosage Strength Of GW685698/GW642444 Chronic Obstructi… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-08-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00731822 | A Study To Assess Single Dosage Strength Of GW685698/GW642444 Chronic Obstructi… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-08-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT01498627 | Cervarix Long-term Safety Surveillance | — | Infections, Papillomavirus | Completed | 2008-08-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT00678886 | Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus … | Phase3 | Diabetes Mellitus, Type 1 | Completed | 2008-07-29 | 2012-01-31 | ClinicalTrials.gov |
| NCT00678886 | Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus … | Phase3 | Diabetes Mellitus, Type 1 | Completed | 2008-07-29 | 2012-01-31 | ClinicalTrials.gov |
| NCT00687622 | Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120… | Phase1 | Solid Tumours | Completed | 2008-07-28 | 2011-11-08 | ClinicalTrials.gov |
| NCT00728208 | GSK372475 PK Study in Healthy Volunteers | Phase1 | Depressive Disorder | Completed | 2008-07-28 | 2008-12-29 | ClinicalTrials.gov |
| NCT00728208 | GSK372475 PK Study in Healthy Volunteers | Phase1 | Depressive Disorder | Completed | 2008-07-28 | 2008-12-29 | ClinicalTrials.gov |
| NCT00687622 | Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120… | Phase1 | Solid Tumours | Completed | 2008-07-28 | 2011-11-08 | ClinicalTrials.gov |
| NCT00723775 | GSK706769/KALETRA Drug-drug Interaction Study | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2008-07-24 | 2008-11-08 | ClinicalTrials.gov |
| NCT00723775 | GSK706769/KALETRA Drug-drug Interaction Study | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2008-07-24 | 2008-11-08 | ClinicalTrials.gov |
| NCT00731250 | A Study To Assess The Effect Of SB-705498 In A Capsaicin Challenge Model | Phase1 | Rhinitis | Completed | 2008-07-22 | 2009-03-31 | ClinicalTrials.gov |
| NCT00731250 | A Study To Assess The Effect Of SB-705498 In A Capsaicin Challenge Model | Phase1 | Rhinitis | Completed | 2008-07-22 | 2009-03-31 | ClinicalTrials.gov |
| NCT00718120 | Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Seas… | Phase3 | Influenza Vaccines | Completed | 2008-07-18 | 2008-08-09 | ClinicalTrials.gov |
| NCT00718120 | Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Seas… | Phase3 | Influenza Vaccines | Completed | 2008-07-18 | 2008-08-09 | ClinicalTrials.gov |
| NCT00714285 | Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults. | Phase1 | Influenza | Completed | 2008-07-14 | 2009-01-28 | ClinicalTrials.gov |
| NCT00714285 | Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults. | Phase1 | Influenza | Completed | 2008-07-14 | 2009-01-28 | ClinicalTrials.gov |
| NCT01607086 | Compare the Properties and Characteristics of an Investigational Formulation of… | Phase1 | Mental Disorders | Completed | 2008-07-11 | 2008-07-18 | ClinicalTrials.gov |
| NCT00719043 | Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Age… | Phase2 | Influenza | Completed | 2008-07-11 | 2011-02-18 | ClinicalTrials.gov |
| NCT01607086 | Compare the Properties and Characteristics of an Investigational Formulation of… | Phase1 | Mental Disorders | Completed | 2008-07-11 | 2008-07-18 | ClinicalTrials.gov |
| NCT00719043 | Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Age… | Phase2 | Influenza | Completed | 2008-07-11 | 2011-02-18 | ClinicalTrials.gov |
| NCT00750256 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacod… | Phase1 | Anaemia | Completed | 2008-07-07 | 2008-12-12 | ClinicalTrials.gov |
| NCT00876018 | Nutrition, Physical Performance & Fitness in Indian School Children | Phase4 | Physical Fitness | Completed | 2008-07-07 | 2008-12-19 | ClinicalTrials.gov |
| NCT00706563 | A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ / Influ… | Phase3 | Influenza | Completed | 2008-07-07 | 2008-07-30 | ClinicalTrials.gov |
| NCT00749359 | PAXIL CR Bioequivalence Study | Phase1 | Depressive Disorder | Completed | 2008-07-07 | 2008-09-16 | ClinicalTrials.gov |
| NCT00750256 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacod… | Phase1 | Anaemia | Completed | 2008-07-07 | 2008-12-12 | ClinicalTrials.gov |
| NCT00876018 | Nutrition, Physical Performance & Fitness in Indian School Children | Phase4 | Physical Fitness | Completed | 2008-07-07 | 2008-12-19 | ClinicalTrials.gov |
| NCT00749359 | PAXIL CR Bioequivalence Study | Phase1 | Depressive Disorder | Completed | 2008-07-07 | 2008-09-16 | ClinicalTrials.gov |
| NCT00706563 | A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ / Influ… | Phase3 | Influenza | Completed | 2008-07-07 | 2008-07-30 | ClinicalTrials.gov |
| NCT00708552 | Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderat… | Phase2 | Alzheimer's Disease | Completed | 2008-07-04 | 2010-03-09 | ClinicalTrials.gov |
| NCT00708552 | Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderat… | Phase2 | Alzheimer's Disease | Completed | 2008-07-04 | 2010-03-09 | ClinicalTrials.gov |
| NCT00728897 | A Healthy Volunteer Study to Investigate the Relative Bioavailability of Two Fo… | Phase1 | Substance Dependence | Completed | 2008-07-02 | 2008-07-29 | ClinicalTrials.gov |
| NCT00728897 | A Healthy Volunteer Study to Investigate the Relative Bioavailability of Two Fo… | Phase1 | Substance Dependence | Completed | 2008-07-02 | 2008-07-29 | ClinicalTrials.gov |
| NCT00721630 | Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the … | Phase2 | Breast Cancer | Completed | 2008-07-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT00723450 | Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients | Phase3 | Bipolar Disorder | Completed | 2008-07-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT00699608 | An Evaluation of Potential Next-day Residual Effects of Eszopiclone in Healthy … | Phase3 | Healthy Subjects | Completed | 2008-07-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00698516 | Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer | Phase2 | Recurrent Small-cell Lung Cancer (SCLC) | Completed | 2008-07-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00751686 | Estimation of the Burden of Rotavirus Gastroenteritis (RV GE) in Children Less … | — | Rotavirus Gastroenteritis | Completed | 2008-07-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00710684 | A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate … | Phase2 | Alzheimer's Disease | Completed | 2008-07-01 | 2010-11-16 | ClinicalTrials.gov |
| NCT00710684 | A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate … | Phase2 | Alzheimer's Disease | Completed | 2008-07-01 | 2010-11-16 | ClinicalTrials.gov |
| NCT01387178 | Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salme… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2008-07-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00929370 | A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokin… | Phase1 | Schizophrenia | Terminated | 2008-07-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00727597 | A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT | Phase3 | Human Immunodeficiency Virus Infections | Completed | 2008-07-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00929370 | A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokin… | Phase1 | Schizophrenia | Terminated | 2008-07-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT01381406 | Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combinati… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2008-07-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00699608 | An Evaluation of Potential Next-day Residual Effects of Eszopiclone in Healthy … | Phase3 | Healthy Subjects | Completed | 2008-07-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00715910 | The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GS… | Phase2 | Infections, Meningococcal | Completed | 2008-07-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT00715910 | The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GS… | Phase2 | Infections, Meningococcal | Completed | 2008-07-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT00716651 | Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome | Phase2 | Churg Strauss Syndrome | Completed | 2008-07-01 | — | ClinicalTrials.gov |
| NCT00716651 | Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome | Phase2 | Churg Strauss Syndrome | Completed | 2008-07-01 | — | ClinicalTrials.gov |
| NCT01381406 | Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combinati… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2008-07-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00751686 | Estimation of the Burden of Rotavirus Gastroenteritis (RV GE) in Children Less … | — | Rotavirus Gastroenteritis | Completed | 2008-07-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00721630 | Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the … | Phase2 | Breast Cancer | Completed | 2008-07-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT00723450 | Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients | Phase3 | Bipolar Disorder | Completed | 2008-07-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01387178 | Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salme… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2008-07-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00698516 | Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer | Phase2 | Recurrent Small-cell Lung Cancer (SCLC) | Completed | 2008-07-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00727597 | A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT | Phase3 | Human Immunodeficiency Virus Infections | Completed | 2008-07-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00707967 | Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-posit… | Phase2 | Tuberculosis | Completed | 2008-06-30 | 2009-05-27 | ClinicalTrials.gov |
| NCT00707798 | Evaluation of Pneumococcal Vaccine Formulations in Young Adults | Phase1 | Infections, Streptococcal | Completed | 2008-06-30 | 2009-01-15 | ClinicalTrials.gov |
| NCT00707967 | Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-posit… | Phase2 | Tuberculosis | Completed | 2008-06-30 | 2009-05-27 | ClinicalTrials.gov |
| NCT00707798 | Evaluation of Pneumococcal Vaccine Formulations in Young Adults | Phase1 | Infections, Streptococcal | Completed | 2008-06-30 | 2009-01-15 | ClinicalTrials.gov |
| NCT00733304 | An Extension to Study MD7108240 | Phase2 | Macular Degeneration | Completed | 2008-06-25 | 2009-09-09 | ClinicalTrials.gov |
| NCT00733304 | An Extension to Study MD7108240 | Phase2 | Macular Degeneration | Completed | 2008-06-25 | 2009-09-09 | ClinicalTrials.gov |
| NCT00695448 | Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid … | Phase1 | Solid Tumours | Terminated | 2008-06-24 | 2009-03-31 | ClinicalTrials.gov |
| NCT00695448 | Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid … | Phase1 | Solid Tumours | Terminated | 2008-06-24 | 2009-03-31 | ClinicalTrials.gov |
| NCT00678301 | Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1… | Phase3 | Infections, Streptococcal | Completed | 2008-06-18 | 2009-12-10 | ClinicalTrials.gov |
| NCT00659178 | Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Ep… | Phase1 | Neoplasms, Ovarian | Completed | 2008-06-18 | 2011-02-18 | ClinicalTrials.gov |
| NCT00678301 | Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1… | Phase3 | Infections, Streptococcal | Completed | 2008-06-18 | 2009-12-10 | ClinicalTrials.gov |
| NCT00659178 | Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Ep… | Phase1 | Neoplasms, Ovarian | Completed | 2008-06-18 | 2011-02-18 | ClinicalTrials.gov |
| NCT00680914 | Primary Vaccination Course in Children Receiving Pneumococcal Conjugate Vaccine… | Phase3 | Infections, Streptococcal | Completed | 2008-06-10 | 2009-05-08 | ClinicalTrials.gov |
| NCT00680914 | Primary Vaccination Course in Children Receiving Pneumococcal Conjugate Vaccine… | Phase3 | Infections, Streptococcal | Completed | 2008-06-10 | 2009-05-08 | ClinicalTrials.gov |
| NCT00728052 | A Human Volunteer Study Investigating Single Oral Doses of GSK598809 in Otherwi… | Phase1 | Substance Dependence | Completed | 2008-06-09 | 2008-08-19 | ClinicalTrials.gov |
| NCT00728052 | A Human Volunteer Study Investigating Single Oral Doses of GSK598809 in Otherwi… | Phase1 | Substance Dependence | Completed | 2008-06-09 | 2008-08-19 | ClinicalTrials.gov |
| NCT00696423 | Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children | Phase3 | Acellular Pertussis | Completed | 2008-06-07 | 2008-07-26 | ClinicalTrials.gov |
| NCT00696423 | Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children | Phase3 | Acellular Pertussis | Completed | 2008-06-07 | 2008-07-26 | ClinicalTrials.gov |
| NCT00695669 | A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vac… | Phase2 | Influenza | Completed | 2008-06-05 | 2009-01-08 | ClinicalTrials.gov |
| NCT00695669 | A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vac… | Phase2 | Influenza | Completed | 2008-06-05 | 2009-01-08 | ClinicalTrials.gov |
| NCT00693706 | Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 13… | Phase1 | Influenza | Completed | 2008-06-02 | 2009-03-26 | ClinicalTrials.gov |
| NCT00633022 | A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed F… | Phase2 | Atherosclerosis | Completed | 2008-06-02 | 2009-12-03 | ClinicalTrials.gov |
| NCT00693706 | Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 13… | Phase1 | Influenza | Completed | 2008-06-02 | 2009-03-26 | ClinicalTrials.gov |
| NCT00633022 | A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed F… | Phase2 | Atherosclerosis | Completed | 2008-06-02 | 2009-12-03 | ClinicalTrials.gov |
| NCT01227369 | Quality of Life(QoL) in Korean Postmenopausal Osteoporosis Patients With Bispho… | — | Osteoporosis, Postmenopausal | Completed | 2008-06-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00703846 | STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2% | Phase4 | Dermatitis, Seborrheic | Completed | 2008-06-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00712855 | A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced … | Phase1 | Hepatocellular Carcinoma | Completed | 2008-06-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT00679224 | An Observational Study For Ambrisentan | — | Hypertension, Pulmonary | Completed | 2008-06-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT00709618 | Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastati… | Phase2 | Neoplasms, Breast | Terminated | 2008-06-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT00708305 | Evaluation of Plaque Fluid Fluoride Retention From Fluoride Toothpastes | Phase3 | Dental Caries | Completed | 2008-06-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00708110 | Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults | Phase2 | Infection, Human Immunodeficiency Virus | Completed | 2008-06-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00682643 | A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For T… | Phase4 | Rhinitis, Allergic, Perennial | Completed | 2008-06-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00694746 | Study of Fish Oil to Reduce ALT Levels in Adolescents | Phase1 | Non-alcoholic Fatty Liver Disease | Terminated | 2008-06-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT00695071 | Study to Assess Blood Levels of Itraconazole During a Two-Week Period | Phase1 | Healthy | Completed | 2008-06-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00812318 | Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Admini… | Phase1 | HIV Infection | Completed | 2008-06-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00703846 | STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2% | Phase4 | Dermatitis, Seborrheic | Completed | 2008-06-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00911157 | The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux So… | Phase3 | Thrombosis, Venous | Completed | 2008-06-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00820924 | Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary T… | Phase2 | Neoplasms, Breast | Terminated | 2008-06-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00824356 | Allergen Challenge Chamber Study With Single Dose Intranasal GSK1004723 Compare… | Phase2 | Allergic Rhinitis | Completed | 2008-06-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00820924 | Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary T… | Phase2 | Neoplasms, Breast | Terminated | 2008-06-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00911651 | Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obs… | Phase4 | COPD | Completed | 2008-06-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00824356 | Allergen Challenge Chamber Study With Single Dose Intranasal GSK1004723 Compare… | Phase2 | Allergic Rhinitis | Completed | 2008-06-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00695071 | Study to Assess Blood Levels of Itraconazole During a Two-Week Period | Phase1 | Healthy | Completed | 2008-06-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00812318 | Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Admini… | Phase1 | HIV Infection | Completed | 2008-06-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00694746 | Study of Fish Oil to Reduce ALT Levels in Adolescents | Phase1 | Non-alcoholic Fatty Liver Disease | Terminated | 2008-06-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT00708110 | Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults | Phase2 | Infection, Human Immunodeficiency Virus | Completed | 2008-06-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00708305 | Evaluation of Plaque Fluid Fluoride Retention From Fluoride Toothpastes | Phase3 | Dental Caries | Completed | 2008-06-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00709618 | Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastati… | Phase2 | Neoplasms, Breast | Terminated | 2008-06-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT00911157 | The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux So… | Phase3 | Thrombosis, Venous | Completed | 2008-06-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00911651 | Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obs… | Phase4 | COPD | Completed | 2008-06-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00682643 | A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For T… | Phase4 | Rhinitis, Allergic, Perennial | Completed | 2008-06-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00712855 | A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced … | Phase1 | Hepatocellular Carcinoma | Completed | 2008-06-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01227369 | Quality of Life(QoL) in Korean Postmenopausal Osteoporosis Patients With Bispho… | — | Osteoporosis, Postmenopausal | Completed | 2008-06-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00679224 | An Observational Study For Ambrisentan | — | Hypertension, Pulmonary | Completed | 2008-06-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT00712933 | A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1… | Phase3 | Systemic Lupus Erythematosus | Completed | 2008-05-30 | 2016-12-09 | ClinicalTrials.gov |
| NCT00712933 | A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1… | Phase3 | Systemic Lupus Erythematosus | Completed | 2008-05-30 | 2016-12-09 | ClinicalTrials.gov |
| NCT00684671 | Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administ… | Phase4 | Hepatitis A | Completed | 2008-05-26 | 2008-11-03 | ClinicalTrials.gov |
| NCT00694902 | Single Dose Escalation Study FTIM in Order to Assess Safety and Tolerability of… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-05-26 | 2008-09-23 | ClinicalTrials.gov |
| NCT00684671 | Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administ… | Phase4 | Hepatitis A | Completed | 2008-05-26 | 2008-11-03 | ClinicalTrials.gov |
| NCT00694902 | Single Dose Escalation Study FTIM in Order to Assess Safety and Tolerability of… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-05-26 | 2008-09-23 | ClinicalTrials.gov |
| NCT01597609 | A Study to Characterise the Physiology of Weight Loss and Regain Under Dietary,… | Phase1 | Obesity | Completed | 2008-05-22 | 2010-03-04 | ClinicalTrials.gov |
| NCT01597609 | A Study to Characterise the Physiology of Weight Loss and Regain Under Dietary,… | Phase1 | Obesity | Completed | 2008-05-22 | 2010-03-04 | ClinicalTrials.gov |
| NCT00945503 | Positron Emission Tomography (PET) Study to Describe the Relationship Between P… | Phase1 | Schizophrenia | Completed | 2008-05-19 | 2008-12-22 | ClinicalTrials.gov |
| NCT00945503 | Positron Emission Tomography (PET) Study to Describe the Relationship Between P… | Phase1 | Schizophrenia | Completed | 2008-05-19 | 2008-12-22 | ClinicalTrials.gov |
| NCT00676052 | Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-05-16 | 2008-12-22 | ClinicalTrials.gov |
| NCT00676052 | Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-05-16 | 2008-12-22 | ClinicalTrials.gov |
| NCT00711386 | GSK706769 Repeat Dose Study | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2008-05-16 | 2008-09-12 | ClinicalTrials.gov |
| NCT00711386 | GSK706769 Repeat Dose Study | Phase1 | Infection, Human Immunodeficiency Virus | Completed | 2008-05-16 | 2008-09-12 | ClinicalTrials.gov |
| NCT00674583 | Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed M… | Phase3 | Infections, Meningococcal | Completed | 2008-05-09 | 2009-01-08 | ClinicalTrials.gov |
| NCT00674583 | Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed M… | Phase3 | Infections, Meningococcal | Completed | 2008-05-09 | 2009-01-08 | ClinicalTrials.gov |
| NCT00875784 | An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pha… | Phase1 | Migraine Disorders | Completed | 2008-05-06 | 2008-06-14 | ClinicalTrials.gov |
| NCT00875784 | An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pha… | Phase1 | Migraine Disorders | Completed | 2008-05-06 | 2008-06-14 | ClinicalTrials.gov |
| NCT00803673 | A Healthy Volunteer Study With Inhaled GSK573719 and Placebo | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-05-05 | 2008-10-16 | ClinicalTrials.gov |
| NCT00803673 | A Healthy Volunteer Study With Inhaled GSK573719 and Placebo | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-05-05 | 2008-10-16 | ClinicalTrials.gov |
| NCT00675064 | Single-Blind, Placebo-Controlled, Randomized Study Testing Single Ascending Dos… | Phase1 | Malaria | Completed | 2008-05-02 | 2008-10-12 | ClinicalTrials.gov |
| NCT00743405 | Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects | Phase1 | Cognitive Disorders | Completed | 2008-05-02 | 2008-12-15 | ClinicalTrials.gov |
| NCT00743405 | Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects | Phase1 | Cognitive Disorders | Completed | 2008-05-02 | 2008-12-15 | ClinicalTrials.gov |
| NCT00675064 | Single-Blind, Placebo-Controlled, Randomized Study Testing Single Ascending Dos… | Phase1 | Malaria | Completed | 2008-05-02 | 2008-10-12 | ClinicalTrials.gov |
| NCT00684177 | Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL) | Phase3 | Skin Infections, Bacterial | Completed | 2008-05-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00638222 | Carvedilol and Micro T-Wave Alternans in Hypertensives With Chronic Kidney Dise… | Na | Vascular Disease | Terminated | 2008-05-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00704431 | A Study With Darapladib to Collect Tolerability Information | Phase1 | Atherosclerosis | Completed | 2008-05-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00933530 | A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2008-05-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00566020 | A Clinical Evaluation Of BW430C (Lamotrigine) In Bipolar I Disorder- Long-term … | Phase3 | Bipolar Disorder | Completed | 2008-05-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00684177 | Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL) | Phase3 | Skin Infections, Bacterial | Completed | 2008-05-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00828750 | Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpu… | Phase3 | Idiopathic Thrombocytopenic Purpura | Completed | 2008-05-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00638222 | Carvedilol and Micro T-Wave Alternans in Hypertensives With Chronic Kidney Dise… | Na | Vascular Disease | Terminated | 2008-05-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00548184 | Lapatinib and Trastuzumab With or Without Endocrine Therapy | Phase2 | Breast Cancer | Completed | 2008-05-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT00740064 | Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in T… | Phase4 | HIV Infections | Unknown | 2008-05-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00640328 | Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patien… | Phase2 | Multiple Sclerosis | Completed | 2008-05-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00548184 | Lapatinib and Trastuzumab With or Without Endocrine Therapy | Phase2 | Breast Cancer | Completed | 2008-05-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT00740064 | Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in T… | Phase4 | HIV Infections | Unknown | 2008-05-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00933530 | A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2008-05-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00566020 | A Clinical Evaluation Of BW430C (Lamotrigine) In Bipolar I Disorder- Long-term … | Phase3 | Bipolar Disorder | Completed | 2008-05-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00640328 | Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patien… | Phase2 | Multiple Sclerosis | Completed | 2008-05-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00704431 | A Study With Darapladib to Collect Tolerability Information | Phase1 | Atherosclerosis | Completed | 2008-05-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00828750 | Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpu… | Phase3 | Idiopathic Thrombocytopenic Purpura | Completed | 2008-05-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00685750 | Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melano… | Na | Lung Cancer, Non-Small Cell | Terminated | 2008-04-28 | 2013-12-17 | ClinicalTrials.gov |
| NCT00685750 | Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melano… | Na | Lung Cancer, Non-Small Cell | Terminated | 2008-04-28 | 2013-12-17 | ClinicalTrials.gov |
| NCT00702910 | A Study to Investigate the Effect of Inhaling Single Doses of Different Formula… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-04-27 | 2008-10-04 | ClinicalTrials.gov |
| NCT00702910 | A Study to Investigate the Effect of Inhaling Single Doses of Different Formula… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-04-27 | 2008-10-04 | ClinicalTrials.gov |
| NCT00650910 | Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In… | Phase1 | Neoplasms, Breast | Completed | 2008-04-23 | 2009-07-10 | ClinicalTrials.gov |
| NCT00650910 | Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In… | Phase1 | Neoplasms, Breast | Completed | 2008-04-23 | 2009-07-10 | ClinicalTrials.gov |
| NCT00679939 | Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes… | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2008-04-21 | 2010-09-16 | ClinicalTrials.gov |
| NCT00679939 | Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes… | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2008-04-21 | 2010-09-16 | ClinicalTrials.gov |
| NCT00664365 | FTIH Study With GSK958108 | Phase1 | Premature Ejaculation | Completed | 2008-04-12 | 2008-08-22 | ClinicalTrials.gov |
| NCT00664365 | FTIH Study With GSK958108 | Phase1 | Premature Ejaculation | Completed | 2008-04-12 | 2008-08-22 | ClinicalTrials.gov |
| NCT00711776 | Bioequivalence Study of Aciclovir 5% Cream in Japanese Healthy Volunteers | Phase1 | Herpes Labialis | Completed | 2008-04-10 | 2008-08-17 | ClinicalTrials.gov |
| NCT00711776 | Bioequivalence Study of Aciclovir 5% Cream in Japanese Healthy Volunteers | Phase1 | Herpes Labialis | Completed | 2008-04-10 | 2008-08-17 | ClinicalTrials.gov |
| NCT00652938 | Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine C… | Phase3 | Infections, Papillomavirus | Completed | 2008-04-09 | 2010-01-08 | ClinicalTrials.gov |
| NCT00652938 | Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine C… | Phase3 | Infections, Papillomavirus | Completed | 2008-04-09 | 2010-01-08 | ClinicalTrials.gov |
| NCT00659555 | Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single … | Phase1 | Macular Degeneration | Completed | 2008-04-04 | 2008-05-10 | ClinicalTrials.gov |
| NCT00659555 | Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single … | Phase1 | Macular Degeneration | Completed | 2008-04-04 | 2008-05-10 | ClinicalTrials.gov |
| NCT00621322 | Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (69234… | Phase2 | Tuberculosis | Completed | 2008-04-03 | 2009-04-03 | ClinicalTrials.gov |
| NCT00621322 | Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (69234… | Phase2 | Tuberculosis | Completed | 2008-04-03 | 2009-04-03 | ClinicalTrials.gov |
| NCT00678977 | A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and G… | Phase1 | Lung Cancer, Non-Small Cell | Completed | 2008-04-03 | 2011-06-30 | ClinicalTrials.gov |
| NCT00678977 | A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and G… | Phase1 | Lung Cancer, Non-Small Cell | Completed | 2008-04-03 | 2011-06-30 | ClinicalTrials.gov |
| NCT00615524 | Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In … | Phase2 | Hormone-receptor Positive Breast Cancer | Withdrawn | 2008-04-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT00655187 | Effectiveness of Human Rotavirus Vaccine, Rotarix™ Against Rotavirus Severe Gas… | — | Rotavirus Severe Gastroenteritis | Completed | 2008-04-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00657241 | Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril | Phase3 | Hypertension | Completed | 2008-04-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00655629 | Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dy… | Phase3 | Erectile Dysfunction | Completed | 2008-04-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00669279 | Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pres… | Phase4 | Hypertension | Completed | 2008-04-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00652951 | Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co… | Phase3 | Infections, Streptococcal | Completed | 2008-04-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00689117 | A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational… | Phase3 | Acne Vulgaris | Completed | 2008-04-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00655187 | Effectiveness of Human Rotavirus Vaccine, Rotarix™ Against Rotavirus Severe Gas… | — | Rotavirus Severe Gastroenteritis | Completed | 2008-04-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00655629 | Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dy… | Phase3 | Erectile Dysfunction | Completed | 2008-04-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00657241 | Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril | Phase3 | Hypertension | Completed | 2008-04-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00657657 | Safety and Immunogenicity of a Booster Dose of GlaxoSmithKline (GSK) Biological… | Phase4 | Hepatitis B | Completed | 2008-04-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00666081 | Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refra… | Phase1 | Cancer | Withdrawn | 2008-04-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00674817 | An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And … | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-04-01 | 2008-10-19 | ClinicalTrials.gov |
| NCT00709878 | Histological Characterization and Differentiation of Rash From Other Epidermal … | — | Skin Rash | Completed | 2008-04-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00513253 | A Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formu… | Phase1 | Healthy Subjects | Withdrawn | 2008-04-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00708097 | In Situ Caries Efficacy of Fluoride Toothpastes | Phase3 | Caries | Completed | 2008-04-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00666081 | Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refra… | Phase1 | Cancer | Withdrawn | 2008-04-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00666380 | A Study to Determine the Effects of an Investigational Malaria Vaccine Given to… | Phase1 | Malaria | Completed | 2008-04-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00669279 | Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pres… | Phase4 | Hypertension | Completed | 2008-04-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00672633 | Trial of Lovaza in Adolescents With Mild to Moderately Elevated Triglycerides | Phase2 | Hypertriglyceridemia | Terminated | 2008-04-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00674817 | An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And … | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-04-01 | 2008-10-19 | ClinicalTrials.gov |
| NCT00708097 | In Situ Caries Efficacy of Fluoride Toothpastes | Phase3 | Caries | Completed | 2008-04-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT02602002 | Experimental Medicine Study to Validate Pharmacodynamic Pain Assessments in Hea… | Phase1 | Pain | Completed | 2008-04-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00631969 | Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction | Phase3 | Erectile Dysfunction | Completed | 2008-04-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT02458092 | Evaluate the Safety and Efficacy of Plasmodium Falciparum Malaria Protein 010 (… | Phase1 | Malaria | Completed | 2008-04-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00674635 | Phase II Study Evaluating the Safety and Efficacy of GSK315234A in Patients Wit… | Phase2 | Arthritis, Rheumatoid | Completed | 2008-04-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00689117 | A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational… | Phase3 | Acne Vulgaris | Completed | 2008-04-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00657657 | Safety and Immunogenicity of a Booster Dose of GlaxoSmithKline (GSK) Biological… | Phase4 | Hepatitis B | Completed | 2008-04-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT02602002 | Experimental Medicine Study to Validate Pharmacodynamic Pain Assessments in Hea… | Phase1 | Pain | Completed | 2008-04-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00709878 | Histological Characterization and Differentiation of Rash From Other Epidermal … | — | Skin Rash | Completed | 2008-04-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00672633 | Trial of Lovaza in Adolescents With Mild to Moderately Elevated Triglycerides | Phase2 | Hypertriglyceridemia | Terminated | 2008-04-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00615524 | Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In … | Phase2 | Hormone-receptor Positive Breast Cancer | Withdrawn | 2008-04-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT00513253 | A Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formu… | Phase1 | Healthy Subjects | Withdrawn | 2008-04-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00674635 | Phase II Study Evaluating the Safety and Efficacy of GSK315234A in Patients Wit… | Phase2 | Arthritis, Rheumatoid | Completed | 2008-04-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00666380 | A Study to Determine the Effects of an Investigational Malaria Vaccine Given to… | Phase1 | Malaria | Completed | 2008-04-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00652951 | Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co… | Phase3 | Infections, Streptococcal | Completed | 2008-04-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00631969 | Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction | Phase3 | Erectile Dysfunction | Completed | 2008-04-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT02458092 | Evaluate the Safety and Efficacy of Plasmodium Falciparum Malaria Protein 010 (… | Phase1 | Malaria | Completed | 2008-04-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00575159 | A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type… | Phase2 | Diabetes Mellitus, Type 1 | Completed | 2008-03-31 | 2008-12-18 | ClinicalTrials.gov |
| NCT00575159 | A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type… | Phase2 | Diabetes Mellitus, Type 1 | Completed | 2008-03-31 | 2008-12-18 | ClinicalTrials.gov |
| NCT00615576 | Repeat Dose Study in Male Healthy Volunteer Smokers | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-03-26 | 2008-07-24 | ClinicalTrials.gov |
| NCT00615576 | Repeat Dose Study in Male Healthy Volunteer Smokers | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-03-26 | 2008-07-24 | ClinicalTrials.gov |
| NCT00652743 | Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at … | Phase3 | Influenza | Completed | 2008-03-23 | 2011-06-08 | ClinicalTrials.gov |
| NCT00652743 | Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at … | Phase3 | Influenza | Completed | 2008-03-23 | 2011-06-08 | ClinicalTrials.gov |
| NCT02447393 | Phase 1 Study of Levocetirizine | Phase1 | Dermatitis | Completed | 2008-03-18 | 2008-04-30 | ClinicalTrials.gov |
| NCT02447393 | Phase 1 Study of Levocetirizine | Phase1 | Dermatitis | Completed | 2008-03-18 | 2008-04-30 | ClinicalTrials.gov |
| NCT00637195 | Immunogenicity and Safety of a Commercially Available Vaccine Co-administered W… | Phase3 | Infections, Papillomavirus | Completed | 2008-03-11 | 2009-06-18 | ClinicalTrials.gov |
| NCT00637195 | Immunogenicity and Safety of a Commercially Available Vaccine Co-administered W… | Phase3 | Infections, Papillomavirus | Completed | 2008-03-11 | 2009-06-18 | ClinicalTrials.gov |
| NCT00687700 | A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy Volu… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-03-10 | 2008-05-27 | ClinicalTrials.gov |
| NCT00601172 | A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And … | Phase3 | Nausea and Vomiting, Chemotherapy-Induced | Completed | 2008-03-10 | 2009-04-13 | ClinicalTrials.gov |
| NCT00687700 | A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy Volu… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-03-10 | 2008-05-27 | ClinicalTrials.gov |
| NCT00601172 | A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And … | Phase3 | Nausea and Vomiting, Chemotherapy-Induced | Completed | 2008-03-10 | 2009-04-13 | ClinicalTrials.gov |
| NCT00612456 | To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Dro… | Phase2 | Macular Degeneration | Completed | 2008-03-05 | 2009-06-17 | ClinicalTrials.gov |
| NCT00612456 | To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Dro… | Phase2 | Macular Degeneration | Completed | 2008-03-05 | 2009-06-17 | ClinicalTrials.gov |
| NCT00624819 | Assessment of Antibody Persistence in Children Previously Vaccinated With Pneum… | Phase3 | Infections, Streptococcal | Completed | 2008-03-03 | 2008-06-02 | ClinicalTrials.gov |
| NCT00633074 | Non-inferiority Study of GSK Biologicals' Influenza Vaccine GSK576389A Using Di… | Phase2 | Influenza | Completed | 2008-03-03 | 2008-04-11 | ClinicalTrials.gov |
| NCT00624819 | Assessment of Antibody Persistence in Children Previously Vaccinated With Pneum… | Phase3 | Infections, Streptococcal | Completed | 2008-03-03 | 2008-06-02 | ClinicalTrials.gov |
| NCT00633074 | Non-inferiority Study of GSK Biologicals' Influenza Vaccine GSK576389A Using Di… | Phase2 | Influenza | Completed | 2008-03-03 | 2008-04-11 | ClinicalTrials.gov |
| NCT00671424 | A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide O… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2008-03-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00730756 | A Pilot Study In Adults And Adolescents With Irritant (Non-Allergic) Rhinitis | Phase2 | Rhinitis, Allergic, Perennial | Completed | 2008-03-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT01406301 | Fondaparinux EU-RMP (Adherence) | — | Acute Coronary Syndrome | Completed | 2008-03-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01376128 | Special Drug Use Investigation for PAXIL Tablet (Pediatric Panic Disorder) | — | Panic Disorder | Completed | 2008-03-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00624065 | Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo I… | Phase3 | Hypertension | Completed | 2008-03-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT01406301 | Fondaparinux EU-RMP (Adherence) | — | Acute Coronary Syndrome | Completed | 2008-03-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00888810 | Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Ca… | Phase2 | Cancer | Terminated | 2008-03-01 | — | ClinicalTrials.gov |
| NCT00637351 | A Study in Elderly Subjects With Pneumonia to Support the Development of Bacter… | — | Infections, Streptococcal | Completed | 2008-03-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00639678 | A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subje… | Phase3 | Healthy | Completed | 2008-03-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT01376128 | Special Drug Use Investigation for PAXIL Tablet (Pediatric Panic Disorder) | — | Panic Disorder | Completed | 2008-03-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00526669 | Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine … | Phase2 | Neoplasms, Gastrointestinal Tract | Completed | 2008-03-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT00730756 | A Pilot Study In Adults And Adolescents With Irritant (Non-Allergic) Rhinitis | Phase2 | Rhinitis, Allergic, Perennial | Completed | 2008-03-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00671424 | A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide O… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2008-03-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00526669 | Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine … | Phase2 | Neoplasms, Gastrointestinal Tract | Completed | 2008-03-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT00624065 | Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo I… | Phase3 | Hypertension | Completed | 2008-03-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00888810 | Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Ca… | Phase2 | Cancer | Terminated | 2008-03-01 | — | ClinicalTrials.gov |
| NCT00688519 | Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis O… | Phase3 | Psoriasis | Completed | 2008-03-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00689481 | Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis T… | Phase3 | Psoriasis | Completed | 2008-03-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00637351 | A Study in Elderly Subjects With Pneumonia to Support the Development of Bacter… | — | Infections, Streptococcal | Completed | 2008-03-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00639678 | A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subje… | Phase3 | Healthy | Completed | 2008-03-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00689481 | Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis T… | Phase3 | Psoriasis | Completed | 2008-03-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00688519 | Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis O… | Phase3 | Psoriasis | Completed | 2008-03-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT01567995 | Randomised, Double-blind, Placebo-controlled Study of Topical Clobetasone Butyr… | Phase3 | Eczema | Completed | 2008-02-28 | 2009-02-10 | ClinicalTrials.gov |
| NCT01567995 | Randomised, Double-blind, Placebo-controlled Study of Topical Clobetasone Butyr… | Phase3 | Eczema | Completed | 2008-02-28 | 2009-02-10 | ClinicalTrials.gov |
| NCT00609596 | A Study To Compare 3 Different Formulations Of Tamsulosin At Steady State. | Phase1 | Prostatic Hyperplasia | Completed | 2008-02-26 | 2008-04-23 | ClinicalTrials.gov |
| NCT00609596 | A Study To Compare 3 Different Formulations Of Tamsulosin At Steady State. | Phase1 | Prostatic Hyperplasia | Completed | 2008-02-26 | 2008-04-23 | ClinicalTrials.gov |
| NCT00605241 | A Study To Assess The Effects Of A Single Dose Of GSK598809 In Modulating Nicot… | Phase1 | Substance Dependence | Completed | 2008-02-25 | 2009-03-20 | ClinicalTrials.gov |
| NCT00605241 | A Study To Assess The Effects Of A Single Dose Of GSK598809 In Modulating Nicot… | Phase1 | Substance Dependence | Completed | 2008-02-25 | 2009-03-20 | ClinicalTrials.gov |
| NCT01177826 | Effectiveness Study of GSK Biologicals' Rotarix TM Vaccine in Hospitalized Chil… | — | Infections, Rotavirus | Completed | 2008-02-23 | 2010-06-11 | ClinicalTrials.gov |
| NCT01177826 | Effectiveness Study of GSK Biologicals' Rotarix TM Vaccine in Hospitalized Chil… | — | Infections, Rotavirus | Completed | 2008-02-23 | 2010-06-11 | ClinicalTrials.gov |
| NCT00675090 | Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Dis… | Phase1 | Alzheimer's Disease | Completed | 2008-02-21 | 2009-06-16 | ClinicalTrials.gov |
| NCT00675090 | Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Dis… | Phase1 | Alzheimer's Disease | Completed | 2008-02-21 | 2009-06-16 | ClinicalTrials.gov |
| NCT00614614 | Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months P… | Phase3 | Infections, Meningococcal | Completed | 2008-02-13 | 2009-09-17 | ClinicalTrials.gov |
| NCT00614614 | Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months P… | Phase3 | Infections, Meningococcal | Completed | 2008-02-13 | 2009-09-17 | ClinicalTrials.gov |
| NCT00600782 | Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Hea… | Phase2 | Tuberculosis (TB) | Completed | 2008-02-05 | 2008-12-19 | ClinicalTrials.gov |
| NCT00600782 | Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Hea… | Phase2 | Tuberculosis (TB) | Completed | 2008-02-05 | 2008-12-19 | ClinicalTrials.gov |
| NCT00627575 | AED/Statin Interaction Study | Phase1 | Epilepsy | Completed | 2008-02-04 | 2008-09-12 | ClinicalTrials.gov |
| NCT00627575 | AED/Statin Interaction Study | Phase1 | Epilepsy | Completed | 2008-02-04 | 2008-09-12 | ClinicalTrials.gov |
| NCT00659191 | A Healthy Volunteer And Patient Study To Assess The Safety, Tolerability And Ph… | Phase1 | HIV Infection | Completed | 2008-02-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00549263 | Bioequivalence Study of SB797620 in Healthy Japanese Volunteers | Phase1 | Healthy Subjects | Withdrawn | 2008-02-01 | — | ClinicalTrials.gov |
| NCT00651352 | A Single Dose Bioequivalence Study OfTwo Formulations Of Nicotine Lozenges | Phase1 | Healthy Volunteer Smokers | Completed | 2008-02-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00612118 | A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride i… | Phase2 | Allergic Rhinitis | Completed | 2008-02-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00573170 | TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Tr… | Phase3 | Migraine Disorders | Completed | 2008-02-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00651079 | GSK1247303 First Time in Human Study | Phase1 | Healthy Subjects | Terminated | 2008-02-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00635128 | Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio … | Phase4 | Poliomyelitis | Completed | 2008-02-01 | 2008-07-08 | ClinicalTrials.gov |
| NCT00606684 | A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subject… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-02-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00635128 | Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio … | Phase4 | Poliomyelitis | Completed | 2008-02-01 | 2008-07-08 | ClinicalTrials.gov |
| NCT00549328 | Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer | Phase2 | Lung Cancer, Non-Small Cell | Terminated | 2008-02-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00605761 | SD Cystic Fibrosis Study | Phase1 | Cystic Fibrosis | Completed | 2008-02-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT01253967 | Surveillance Study to Estimate the Proportion of Rotavirus Gastroenteritis in C… | — | Infections, Rotavirus | Completed | 2008-02-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00627458 | Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/H… | Phase2 | Acellular Pertussis | Completed | 2008-02-01 | 2008-08-18 | ClinicalTrials.gov |
| NCT00549263 | Bioequivalence Study of SB797620 in Healthy Japanese Volunteers | Phase1 | Healthy Subjects | Withdrawn | 2008-02-01 | — | ClinicalTrials.gov |
| NCT00549328 | Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer | Phase2 | Lung Cancer, Non-Small Cell | Terminated | 2008-02-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00651079 | GSK1247303 First Time in Human Study | Phase1 | Healthy Subjects | Terminated | 2008-02-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00651352 | A Single Dose Bioequivalence Study OfTwo Formulations Of Nicotine Lozenges | Phase1 | Healthy Volunteer Smokers | Completed | 2008-02-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00659191 | A Healthy Volunteer And Patient Study To Assess The Safety, Tolerability And Ph… | Phase1 | HIV Infection | Completed | 2008-02-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00554619 | A Study to Evaluate GSK1325760A - a Long-Term Extension Study | Phase3 | Pulmonary Arterial Hypertension | Completed | 2008-02-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00554619 | A Study to Evaluate GSK1325760A - a Long-Term Extension Study | Phase3 | Pulmonary Arterial Hypertension | Completed | 2008-02-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00605761 | SD Cystic Fibrosis Study | Phase1 | Cystic Fibrosis | Completed | 2008-02-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT01253967 | Surveillance Study to Estimate the Proportion of Rotavirus Gastroenteritis in C… | — | Infections, Rotavirus | Completed | 2008-02-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00573170 | TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Tr… | Phase3 | Migraine Disorders | Completed | 2008-02-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00606684 | A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subject… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-02-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00679796 | The Effectiveness of Varicella Vaccination in Children in Germany | — | Varicella (Chickenpox) | Completed | 2008-02-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00679796 | The Effectiveness of Varicella Vaccination in Children in Germany | — | Varicella (Chickenpox) | Completed | 2008-02-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00627458 | Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/H… | Phase2 | Acellular Pertussis | Completed | 2008-02-01 | 2008-08-18 | ClinicalTrials.gov |
| NCT00612118 | A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride i… | Phase2 | Allergic Rhinitis | Completed | 2008-02-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT02016963 | An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of… | Phase2 | Therapeutic Treatment of Inhalation Anthrax | Completed | 2008-01-31 | 2008-05-31 | ClinicalTrials.gov |
| NCT02016963 | An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of… | Phase2 | Therapeutic Treatment of Inhalation Anthrax | Completed | 2008-01-31 | 2008-05-31 | ClinicalTrials.gov |
| NCT00703547 | A First Time in Human Study of GSK586529 in Healthy Volunteers | Phase1 | Depressive Disorder and Anxiety Disorders | Completed | 2008-01-28 | 2008-04-11 | ClinicalTrials.gov |
| NCT00703547 | A First Time in Human Study of GSK586529 in Healthy Volunteers | Phase1 | Depressive Disorder and Anxiety Disorders | Completed | 2008-01-28 | 2008-04-11 | ClinicalTrials.gov |
| NCT01002118 | Feasibility Study of Omega-3 Fatty Acids in Dialysis Patients | Na | Cardiovascular Disease | Terminated | 2008-01-25 | 2011-02-23 | ClinicalTrials.gov |
| NCT01002118 | Feasibility Study of Omega-3 Fatty Acids in Dialysis Patients | Na | Cardiovascular Disease | Terminated | 2008-01-25 | 2011-02-23 | ClinicalTrials.gov |
| NCT00599612 | To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-01-17 | 2008-02-18 | ClinicalTrials.gov |
| NCT00599612 | To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2008-01-17 | 2008-02-18 | ClinicalTrials.gov |
| NCT01706185 | Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With P… | — | Neoplasms, Urinary Bladder | Completed | 2008-01-15 | 2008-01-15 | ClinicalTrials.gov |
| NCT01706185 | Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With P… | — | Neoplasms, Urinary Bladder | Completed | 2008-01-15 | 2008-01-15 | ClinicalTrials.gov |
| NCT00546078 | Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580… | Phase2 | Infections, Papillomavirus | Completed | 2008-01-14 | 2009-12-01 | ClinicalTrials.gov |
| NCT00546078 | Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580… | Phase2 | Infections, Papillomavirus | Completed | 2008-01-14 | 2009-12-01 | ClinicalTrials.gov |
| NCT00615212 | Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2008-01-02 | 2008-02-15 | ClinicalTrials.gov |
| NCT00615212 | Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2008-01-02 | 2008-02-15 | ClinicalTrials.gov |
| NCT00603252 | Study to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Mo… | Phase4 | Hepatitis B | Completed | 2008-01-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00611455 | Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA… | Phase3 | Arthritis, Rheumatoid | Terminated | 2008-01-01 | 2013-07-15 | ClinicalTrials.gov |
| NCT00612820 | A Phase II Study Evaluating Intranasal GSK256066 and Fluticasone Propionate in … | Phase2 | Rhinitis, Allergic, Seasonal | Completed | 2008-01-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00614978 | Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HE… | Phase1 | Metastatic Breast Cancer | Completed | 2008-01-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT00614991 | An Interaction Study to Assess Drug Levels in Healthy Adult Subjects | Na | Healthy | Completed | 2008-01-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00621842 | Lamotrigine for Symptoms of Geriatric Bipolar Depression | Phase3 | Bipolar Disorder | Completed | 2008-01-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00622830 | Phase I Study of SB-480848(Darapladib) -Repeat Dose Study in Healthy Japanese M… | Phase1 | Atherosclerosis | Completed | 2008-01-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT01077609 | Flixonase Safety in Patients With Allergic Rhinitis (AR) | — | Rhinitis, Allergic, Perennial | Completed | 2008-01-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00655824 | Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Pa… | Phase2 | Arthritis, Rheumatoid | Terminated | 2008-01-01 | 2013-03-19 | ClinicalTrials.gov |
| NCT00659399 | Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreat… | Phase1 | Ovarian Carcinoma | Withdrawn | 2008-01-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00880672 | Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate | Phase4 | Benign Prostatic Hyperplasia | Completed | 2008-01-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00605449 | A Drug Interaction Study Between Simvastatin and GSK376501 | Phase1 | Type 2 Diabetes Mellitus | Completed | 2008-01-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00659399 | Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreat… | Phase1 | Ovarian Carcinoma | Withdrawn | 2008-01-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00655824 | Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Pa… | Phase2 | Arthritis, Rheumatoid | Terminated | 2008-01-01 | 2013-03-19 | ClinicalTrials.gov |
| NCT00622830 | Phase I Study of SB-480848(Darapladib) -Repeat Dose Study in Healthy Japanese M… | Phase1 | Atherosclerosis | Completed | 2008-01-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00603525 | Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA… | Phase3 | Arthritis, Rheumatoid | Terminated | 2008-01-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT00621842 | Lamotrigine for Symptoms of Geriatric Bipolar Depression | Phase3 | Bipolar Disorder | Completed | 2008-01-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00614991 | An Interaction Study to Assess Drug Levels in Healthy Adult Subjects | Na | Healthy | Completed | 2008-01-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00614978 | Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HE… | Phase1 | Metastatic Breast Cancer | Completed | 2008-01-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT00612820 | A Phase II Study Evaluating Intranasal GSK256066 and Fluticasone Propionate in … | Phase2 | Rhinitis, Allergic, Seasonal | Completed | 2008-01-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00611455 | Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA… | Phase3 | Arthritis, Rheumatoid | Terminated | 2008-01-01 | 2013-07-15 | ClinicalTrials.gov |
| NCT00880672 | Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate | Phase4 | Benign Prostatic Hyperplasia | Completed | 2008-01-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT01406275 | Special Drug Use Investigation for CLAVAMOX® (Amoxicillin/Clavulanate) Pediatri… | — | Otitis Maedia | Completed | 2008-01-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00605449 | A Drug Interaction Study Between Simvastatin and GSK376501 | Phase1 | Type 2 Diabetes Mellitus | Completed | 2008-01-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00579982 | An Open-Label Trial Measuring Satisfaction And Convenience Of Two Formulations … | Phase3 | Mood Disorders | Completed | 2008-01-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00603525 | Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA… | Phase3 | Arthritis, Rheumatoid | Terminated | 2008-01-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT00603252 | Study to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Mo… | Phase4 | Hepatitis B | Completed | 2008-01-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00600743 | Effect of a CCK-1R Agonist on Food Intake in Humans | Phase2 | Bulimia | Terminated | 2008-01-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00595205 | Intussusception Surveillance After Rotarix Introduction in Mexico | — | Intussusception (IS) | Completed | 2008-01-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT01077609 | Flixonase Safety in Patients With Allergic Rhinitis (AR) | — | Rhinitis, Allergic, Perennial | Completed | 2008-01-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00595205 | Intussusception Surveillance After Rotarix Introduction in Mexico | — | Intussusception (IS) | Completed | 2008-01-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00579982 | An Open-Label Trial Measuring Satisfaction And Convenience Of Two Formulations … | Phase3 | Mood Disorders | Completed | 2008-01-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00600743 | Effect of a CCK-1R Agonist on Food Intake in Humans | Phase2 | Bulimia | Terminated | 2008-01-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT01406275 | Special Drug Use Investigation for CLAVAMOX® (Amoxicillin/Clavulanate) Pediatri… | — | Otitis Maedia | Completed | 2008-01-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00606697 | A Study With GW597599 And GR205171: Potential New Drugs For The Treatment Of Pr… | Phase2 | Sleep Initiation and Maintenance Disorders | Completed | 2007-12-19 | 2008-05-07 | ClinicalTrials.gov |
| NCT00606697 | A Study With GW597599 And GR205171: Potential New Drugs For The Treatment Of Pr… | Phase2 | Sleep Initiation and Maintenance Disorders | Completed | 2007-12-19 | 2008-05-07 | ClinicalTrials.gov |
| NCT00578227 | Evaluation of Safety and Immunogenicity of Co-administering Human Papillomaviru… | Phase3 | Infections, Papillomavirus | Completed | 2007-12-15 | 2009-04-28 | ClinicalTrials.gov |
| NCT00578227 | Evaluation of Safety and Immunogenicity of Co-administering Human Papillomaviru… | Phase3 | Infections, Papillomavirus | Completed | 2007-12-15 | 2009-04-28 | ClinicalTrials.gov |
| NCT00586469 | A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made W… | Phase4 | Influenza Vaccines | Completed | 2007-12-14 | 2008-01-14 | ClinicalTrials.gov |
| NCT00586469 | A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made W… | Phase4 | Influenza Vaccines | Completed | 2007-12-14 | 2008-01-14 | ClinicalTrials.gov |
| NCT00555022 | Effect of GSK1160724 In Healthy Volunteers | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-12-12 | 2008-04-07 | ClinicalTrials.gov |
| NCT00555022 | Effect of GSK1160724 In Healthy Volunteers | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-12-12 | 2008-04-07 | ClinicalTrials.gov |
| NCT00549900 | A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Pa… | Phase1 | Infections, Papillomavirus | Completed | 2007-12-02 | 2008-07-12 | ClinicalTrials.gov |
| NCT00549900 | A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Pa… | Phase1 | Infections, Papillomavirus | Completed | 2007-12-02 | 2008-07-12 | ClinicalTrials.gov |
| NCT00531843 | The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patie… | Phase2 | Venous Thromboembolism | Completed | 2007-12-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00608699 | A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volun… | Phase1 | Healthy Subjects | Completed | 2007-12-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00586612 | Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix … | Phase3 | Haemophilus Influenzae Type b | Completed | 2007-12-01 | 2008-12-30 | ClinicalTrials.gov |
| NCT00527618 | Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive… | Phase4 | Genital Herpes | Completed | 2007-12-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00586612 | Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix … | Phase3 | Haemophilus Influenzae Type b | Completed | 2007-12-01 | 2008-12-30 | ClinicalTrials.gov |
| NCT00603746 | A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Dr… | Phase2 | Asthma | Completed | 2007-12-01 | 2008-09-20 | ClinicalTrials.gov |
| NCT00600171 | Efficacy And Safety Of GW642444M Comparing Placebo In Adolescent And Adult Subj… | Phase2 | Asthma | Completed | 2007-12-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00456313 | No Resistance After Long Term Treatment SERETIDE | Phase4 | Asthma | Withdrawn | 2007-12-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00603278 | A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Dr… | Phase2 | Asthma | Completed | 2007-12-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00622388 | Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma… | Phase2 | Lymphoma, Large-Cell, Diffuse | Completed | 2007-12-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT00603278 | A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Dr… | Phase2 | Asthma | Completed | 2007-12-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00622388 | Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma… | Phase2 | Lymphoma, Large-Cell, Diffuse | Completed | 2007-12-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT00558103 | Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammat… | Phase2 | Neoplasms, Breast | Completed | 2007-12-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00608699 | A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volun… | Phase1 | Healthy Subjects | Completed | 2007-12-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00527618 | Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive… | Phase4 | Genital Herpes | Completed | 2007-12-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00456313 | No Resistance After Long Term Treatment SERETIDE | Phase4 | Asthma | Withdrawn | 2007-12-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00558103 | Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammat… | Phase2 | Neoplasms, Breast | Completed | 2007-12-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00531843 | The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patie… | Phase2 | Venous Thromboembolism | Completed | 2007-12-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00600171 | Efficacy And Safety Of GW642444M Comparing Placebo In Adolescent And Adult Subj… | Phase2 | Asthma | Completed | 2007-12-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00603746 | A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Dr… | Phase2 | Asthma | Completed | 2007-12-01 | 2008-09-20 | ClinicalTrials.gov |
| NCT00550225 | Succinate Salt Version of GSK961081 for Healthy Volunteers | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-11-29 | 2008-01-08 | ClinicalTrials.gov |
| NCT00550225 | Succinate Salt Version of GSK961081 for Healthy Volunteers | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-11-29 | 2008-01-08 | ClinicalTrials.gov |
| NCT00524576 | Challenge Dose of Hepatitis B Vaccine in Subjects Who Previously Received Enger… | Phase4 | Hepatitis B | Completed | 2007-11-28 | 2008-05-14 | ClinicalTrials.gov |
| NCT00524576 | Challenge Dose of Hepatitis B Vaccine in Subjects Who Previously Received Enger… | Phase4 | Hepatitis B | Completed | 2007-11-28 | 2008-05-14 | ClinicalTrials.gov |
| NCT00570492 | Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth S… | Phase4 | Rhinitis, Allergic, Perennial | Completed | 2007-11-26 | 2011-03-17 | ClinicalTrials.gov |
| NCT00570492 | Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth S… | Phase4 | Rhinitis, Allergic, Perennial | Completed | 2007-11-26 | 2011-03-17 | ClinicalTrials.gov |
| NCT00578175 | Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQ… | Phase2 | Varicella | Completed | 2007-11-20 | 2009-03-17 | ClinicalTrials.gov |
| NCT00578175 | Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQ… | Phase2 | Varicella | Completed | 2007-11-20 | 2009-03-17 | ClinicalTrials.gov |
| NCT00549744 | Clinical Endpoint Trial Investigating Once Daily and Bronchodilator Dosing | Phase2 | Asthma | Completed | 2007-11-16 | 2008-08-27 | ClinicalTrials.gov |
| NCT00607906 | First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamic… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2007-11-16 | 2008-03-10 | ClinicalTrials.gov |
| NCT00549744 | Clinical Endpoint Trial Investigating Once Daily and Bronchodilator Dosing | Phase2 | Asthma | Completed | 2007-11-16 | 2008-08-27 | ClinicalTrials.gov |
| NCT00607906 | First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamic… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2007-11-16 | 2008-03-10 | ClinicalTrials.gov |
| NCT00619424 | A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients Wi… | Phase1 | Lung Cancer, Non-Small Cell | Completed | 2007-11-15 | 2009-09-04 | ClinicalTrials.gov |
| NCT00619424 | A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients Wi… | Phase1 | Lung Cancer, Non-Small Cell | Completed | 2007-11-15 | 2009-09-04 | ClinicalTrials.gov |
| NCT00552279 | Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (… | Phase3 | Infections, Papillomavirus | Completed | 2007-11-12 | 2009-07-20 | ClinicalTrials.gov |
| NCT00552279 | Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (… | Phase3 | Infections, Papillomavirus | Completed | 2007-11-12 | 2009-07-20 | ClinicalTrials.gov |
| NCT00548171 | Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vac… | Phase4 | Acellular Pertussis | Completed | 2007-11-05 | 2008-04-30 | ClinicalTrials.gov |
| NCT00548171 | Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vac… | Phase4 | Acellular Pertussis | Completed | 2007-11-05 | 2008-04-30 | ClinicalTrials.gov |
| NCT00554762 | Dose Response and Efficacy of GW842166 in Pain | Phase1 | Healthy Subjects | Withdrawn | 2007-11-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00559884 | A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2007-11-01 | — | ClinicalTrials.gov |
| NCT00568334 | Study of Two Formulations of GSK Biologicals' Varicella Vaccine | Phase2 | Varicella | Completed | 2007-11-01 | 2008-04-29 | ClinicalTrials.gov |
| NCT00559299 | Patient Tolerability Study of GSK163090 | Phase1 | Depressive Disorder, Major | Completed | 2007-11-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00559884 | A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2007-11-01 | — | ClinicalTrials.gov |
| NCT00531791 | Effects of Advair® in Outpatients With Chronic Obstructive Pulmonary Disease (C… | Phase3 | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2007-11-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00708123 | In Situ Caries of Fluoride Toothpastes | Phase3 | Healthy Subjects | Completed | 2007-11-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00527826 | Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-11-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT01376102 | BONVIVA(Ibandronate) Injection PMS(Post-marketing Surveillance) | — | Osteoporosis | Completed | 2007-11-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT00518336 | Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) … | Phase2 | Infections, Papillomavirus | Completed | 2007-11-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00436345 | Pharmacoeconomic Consequences Of Analgesia in the Intensive Care Unit (ICU) | Phase3 | Analgesia | Terminated | 2007-11-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00555035 | GSK1349572 First Time in Human Study | Phase1 | Healthy Subjects | Completed | 2007-11-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00518336 | Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) … | Phase2 | Infections, Papillomavirus | Completed | 2007-11-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00479856 | Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Can… | Phase2 | Relapsed Breast Cancer | Terminated | 2007-11-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00527826 | Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-11-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00842153 | Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compa… | Phase4 | Psoriasis | Completed | 2007-11-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00436345 | Pharmacoeconomic Consequences Of Analgesia in the Intensive Care Unit (ICU) | Phase3 | Analgesia | Terminated | 2007-11-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT01395862 | Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol) | — | Respiratory Disorders | Completed | 2007-11-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01376102 | BONVIVA(Ibandronate) Injection PMS(Post-marketing Surveillance) | — | Osteoporosis | Completed | 2007-11-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT00531791 | Effects of Advair® in Outpatients With Chronic Obstructive Pulmonary Disease (C… | Phase3 | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2007-11-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT01395862 | Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol) | — | Respiratory Disorders | Completed | 2007-11-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT00552084 | Evaluating the Effectiveness of Fish Oil Supplements at Reducing the Recurrence… | Phase4 | Atrial Fibrillation | Completed | 2007-11-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT00842153 | Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compa… | Phase4 | Psoriasis | Completed | 2007-11-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00568334 | Study of Two Formulations of GSK Biologicals' Varicella Vaccine | Phase2 | Varicella | Completed | 2007-11-01 | 2008-04-29 | ClinicalTrials.gov |
| NCT00550407 | An Evaluation Of BW430C (Lamotrigine) Versus Placebo In The Prevention Of Mood … | Phase3 | Bipolar Disorder | Completed | 2007-11-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00555035 | GSK1349572 First Time in Human Study | Phase1 | Healthy Subjects | Completed | 2007-11-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00557128 | Study to Examine the Effect of Food on the Pharmacokinetics of the Fixed Dose C… | Phase1 | Hypertension | Completed | 2007-11-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00554762 | Dose Response and Efficacy of GW842166 in Pain | Phase1 | Healthy Subjects | Withdrawn | 2007-11-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00558363 | ARTS - AVODART After Radical Therapy For Prostate Cancer Study | Phase2 | Neoplasms, Prostate | Completed | 2007-11-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00552084 | Evaluating the Effectiveness of Fish Oil Supplements at Reducing the Recurrence… | Phase4 | Atrial Fibrillation | Completed | 2007-11-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT00559299 | Patient Tolerability Study of GSK163090 | Phase1 | Depressive Disorder, Major | Completed | 2007-11-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00557128 | Study to Examine the Effect of Food on the Pharmacokinetics of the Fixed Dose C… | Phase1 | Hypertension | Completed | 2007-11-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00479856 | Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Can… | Phase2 | Relapsed Breast Cancer | Terminated | 2007-11-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00558363 | ARTS - AVODART After Radical Therapy For Prostate Cancer Study | Phase2 | Neoplasms, Prostate | Completed | 2007-11-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00550407 | An Evaluation Of BW430C (Lamotrigine) Versus Placebo In The Prevention Of Mood … | Phase3 | Bipolar Disorder | Completed | 2007-11-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00708123 | In Situ Caries of Fluoride Toothpastes | Phase3 | Healthy Subjects | Completed | 2007-11-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00605852 | Investigation Of a New Oral Anti-Histamine in Healthy Male Subjects | Phase1 | Rhinitis, Allergic, Seasonal | Completed | 2007-10-29 | 2008-05-03 | ClinicalTrials.gov |
| NCT00605852 | Investigation Of a New Oral Anti-Histamine in Healthy Male Subjects | Phase1 | Rhinitis, Allergic, Seasonal | Completed | 2007-10-29 | 2008-05-03 | ClinicalTrials.gov |
| NCT00547248 | Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previousl… | Phase3 | Infections, Streptococcal | Completed | 2007-10-22 | 2008-10-07 | ClinicalTrials.gov |
| NCT00547248 | Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previousl… | Phase3 | Infections, Streptococcal | Completed | 2007-10-22 | 2008-10-07 | ClinicalTrials.gov |
| NCT00537654 | A Study To Compare Giving AVODART And FLOMAX Together Or In A Combination Capsu… | Phase1 | Prostatic Hyperplasia | Completed | 2007-10-18 | 2008-02-22 | ClinicalTrials.gov |
| NCT00537654 | A Study To Compare Giving AVODART And FLOMAX Together Or In A Combination Capsu… | Phase1 | Prostatic Hyperplasia | Completed | 2007-10-18 | 2008-02-22 | ClinicalTrials.gov |
| NCT00541970 | Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vacc… | Phase1 | Infections, Papillomavirus | Completed | 2007-10-17 | 2013-03-18 | ClinicalTrials.gov |
| NCT00541970 | Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vacc… | Phase1 | Infections, Papillomavirus | Completed | 2007-10-17 | 2013-03-18 | ClinicalTrials.gov |
| NCT00545025 | Revaccination With Influenza Vaccine GSK1247446A | Phase2 | Influenza | Completed | 2007-10-15 | 2007-12-12 | ClinicalTrials.gov |
| NCT00538213 | Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK57638… | Phase2 | Influenza | Completed | 2007-10-15 | 2007-11-28 | ClinicalTrials.gov |
| NCT00545025 | Revaccination With Influenza Vaccine GSK1247446A | Phase2 | Influenza | Completed | 2007-10-15 | 2007-12-12 | ClinicalTrials.gov |
| NCT00538213 | Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK57638… | Phase2 | Influenza | Completed | 2007-10-15 | 2007-11-28 | ClinicalTrials.gov |
| NCT00404768 | The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36… | Phase2 | Obstetric Labour, Premature | Completed | 2007-10-12 | 2011-07-07 | ClinicalTrials.gov |
| NCT00404768 | The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36… | Phase2 | Obstetric Labour, Premature | Completed | 2007-10-12 | 2011-07-07 | ClinicalTrials.gov |
| NCT00540592 | Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biolo… | Phase2 | Influenza | Completed | 2007-10-08 | 2008-06-10 | ClinicalTrials.gov |
| NCT00551811 | Evaluate the Effects of the Drug (SB-656933-AAA) on the Body After a Single Dos… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-10-08 | 2008-07-22 | ClinicalTrials.gov |
| NCT00540592 | Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biolo… | Phase2 | Influenza | Completed | 2007-10-08 | 2008-06-10 | ClinicalTrials.gov |
| NCT00551811 | Evaluate the Effects of the Drug (SB-656933-AAA) on the Body After a Single Dos… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-10-08 | 2008-07-22 | ClinicalTrials.gov |
| NCT00540228 | Study to Evaluate an Influenza Vaccine Candidate | Phase2 | Influenza | Completed | 2007-10-05 | 2008-05-08 | ClinicalTrials.gov |
| NCT00540228 | Study to Evaluate an Influenza Vaccine Candidate | Phase2 | Influenza | Completed | 2007-10-05 | 2008-05-08 | ClinicalTrials.gov |
| NCT00534638 | Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580… | Phase4 | Infections, Papillomavirus | Completed | 2007-10-04 | 2014-12-17 | ClinicalTrials.gov |
| NCT00534638 | Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580… | Phase4 | Infections, Papillomavirus | Completed | 2007-10-04 | 2014-12-17 | ClinicalTrials.gov |
| NCT00549679 | Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive P… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-10-04 | 2008-12-15 | ClinicalTrials.gov |
| NCT00480025 | GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Pa… | Phase3 | Lung Cancer, Non-Small Cell | Terminated | 2007-10-04 | 2014-09-23 | ClinicalTrials.gov |
| NCT00549679 | Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive P… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-10-04 | 2008-12-15 | ClinicalTrials.gov |
| NCT00480025 | GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Pa… | Phase3 | Lung Cancer, Non-Small Cell | Terminated | 2007-10-04 | 2014-09-23 | ClinicalTrials.gov |
| NCT00538057 | Comparing Two Respiratory Drugs When Used In Combination And Separately From A … | Phase1 | Asthma | Completed | 2007-10-02 | 2007-12-01 | ClinicalTrials.gov |
| NCT00538057 | Comparing Two Respiratory Drugs When Used In Combination And Separately From A … | Phase1 | Asthma | Completed | 2007-10-02 | 2007-12-01 | ClinicalTrials.gov |
| NCT00540501 | A Study to Evaluate Orally-Administered Oseltamivir and Intravenous Zanamivir i… | Phase1 | Healthy Subjects | Withdrawn | 2007-10-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00450203 | Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesopha… | Phase2 | Oesophagogastric Cancer | Unknown | 2007-10-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT00481767 | Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papilloma… | Phase3 | Human Papillomavirus (HPV) Infection | Completed | 2007-10-01 | 2010-07-26 | ClinicalTrials.gov |
| NCT00503009 | Study Of RV-39 In Patients Who Also Have Asthma | Phase4 | Asthma | Terminated | 2007-10-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00516321 | Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects… | Phase3 | Hepatitis C, Chronic | Completed | 2007-10-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT00527605 | Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic H… | Phase3 | Benign Prostatic Hyperplasia | Completed | 2007-10-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00534872 | A Clinical Study to Evaluate the Pharmacokinetic Profile of SB-649868 in Elderl… | Phase1 | Insomnia | Withdrawn | 2007-10-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00537043 | A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With… | Phase1 | Hypertension | Completed | 2007-10-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00540501 | A Study to Evaluate Orally-Administered Oseltamivir and Intravenous Zanamivir i… | Phase1 | Healthy Subjects | Withdrawn | 2007-10-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00549211 | A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296. | Phase1 | Obstetric Labour, Premature | Completed | 2007-10-01 | — | ClinicalTrials.gov |
| NCT00549510 | Study to Investigate Dose Proportionality of the Fixed Dose Combination of CORE… | Phase1 | Hypertension | Completed | 2007-10-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00551694 | A Second Study to Determine the Effect of GSK256073A on HVTs | Phase1 | Healthy Subjects | Completed | 2007-10-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT01395849 | Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol) | — | Respiratory Disorders | Completed | 2007-10-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00450203 | Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesopha… | Phase2 | Oesophagogastric Cancer | Unknown | 2007-10-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT00481767 | Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papilloma… | Phase3 | Human Papillomavirus (HPV) Infection | Completed | 2007-10-01 | 2010-07-26 | ClinicalTrials.gov |
| NCT00503009 | Study Of RV-39 In Patients Who Also Have Asthma | Phase4 | Asthma | Terminated | 2007-10-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00516321 | Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects… | Phase3 | Hepatitis C, Chronic | Completed | 2007-10-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT00527605 | Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic H… | Phase3 | Benign Prostatic Hyperplasia | Completed | 2007-10-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00534872 | A Clinical Study to Evaluate the Pharmacokinetic Profile of SB-649868 in Elderl… | Phase1 | Insomnia | Withdrawn | 2007-10-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00537043 | A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With… | Phase1 | Hypertension | Completed | 2007-10-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00549211 | A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296. | Phase1 | Obstetric Labour, Premature | Completed | 2007-10-01 | — | ClinicalTrials.gov |
| NCT00549510 | Study to Investigate Dose Proportionality of the Fixed Dose Combination of CORE… | Phase1 | Hypertension | Completed | 2007-10-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00551694 | A Second Study to Determine the Effect of GSK256073A on HVTs | Phase1 | Healthy Subjects | Completed | 2007-10-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT01395849 | Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol) | — | Respiratory Disorders | Completed | 2007-10-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00515268 | Endotoxin Challenge Study For Healthy Men and Women | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-09-27 | 2008-04-23 | ClinicalTrials.gov |
| NCT00515268 | Endotoxin Challenge Study For Healthy Men and Women | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-09-27 | 2008-04-23 | ClinicalTrials.gov |
| NCT00536809 | Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine … | Phase1 | Neoplasms, Colorectal | Completed | 2007-09-26 | 2008-10-31 | ClinicalTrials.gov |
| NCT00536809 | Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine … | Phase1 | Neoplasms, Colorectal | Completed | 2007-09-26 | 2008-10-31 | ClinicalTrials.gov |
| NCT00532298 | Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults … | Phase2 | Influenza | Completed | 2007-09-20 | 2007-11-02 | ClinicalTrials.gov |
| NCT00532298 | Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults … | Phase2 | Influenza | Completed | 2007-09-20 | 2007-11-02 | ClinicalTrials.gov |
| NCT00548496 | A Phase IIa Study Of Men And Post-Menopausal Women With A Fractured Distal Radi… | Phase2 | Fracture Healing | Terminated | 2007-09-20 | 2008-11-26 | ClinicalTrials.gov |
| NCT00548496 | A Phase IIa Study Of Men And Post-Menopausal Women With A Fractured Distal Radi… | Phase2 | Fracture Healing | Terminated | 2007-09-20 | 2008-11-26 | ClinicalTrials.gov |
| NCT00514904 | Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Yea… | Phase3 | Infections, Meningococcal | Completed | 2007-09-18 | 2009-01-06 | ClinicalTrials.gov |
| NCT00533507 | Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Chil… | Phase3 | Infections, Rotavirus | Completed | 2007-09-18 | 2008-06-06 | ClinicalTrials.gov |
| NCT00533507 | Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Chil… | Phase3 | Infections, Rotavirus | Completed | 2007-09-18 | 2008-06-06 | ClinicalTrials.gov |
| NCT00514904 | Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Yea… | Phase3 | Infections, Meningococcal | Completed | 2007-09-18 | 2009-01-06 | ClinicalTrials.gov |
| NCT00513565 | A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotiona… | Phase1 | Depressive Disorder and Anxiety Disorders | Completed | 2007-09-13 | 2009-05-14 | ClinicalTrials.gov |
| NCT00513565 | A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotiona… | Phase1 | Depressive Disorder and Anxiety Disorders | Completed | 2007-09-13 | 2009-05-14 | ClinicalTrials.gov |
| NCT00569062 | A Study of GW856553X For the Treatment of Depression | Phase2 | Depressive Disorder, Major | Terminated | 2007-09-12 | 2008-06-25 | ClinicalTrials.gov |
| NCT00569062 | A Study of GW856553X For the Treatment of Depression | Phase2 | Depressive Disorder, Major | Terminated | 2007-09-12 | 2008-06-25 | ClinicalTrials.gov |
| NCT00519480 | A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A To… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2007-09-11 | 2008-04-01 | ClinicalTrials.gov |
| NCT00519480 | A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A To… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2007-09-11 | 2008-04-01 | ClinicalTrials.gov |
| NCT00516672 | Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese … | Phase1 | Carcinoma, Renal Cell | Completed | 2007-09-10 | 2015-10-14 | ClinicalTrials.gov |
| NCT00562848 | A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric … | Phase1 | Gastroparesis | Completed | 2007-09-10 | 2008-06-27 | ClinicalTrials.gov |
| NCT00562848 | A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric … | Phase1 | Gastroparesis | Completed | 2007-09-10 | 2008-06-27 | ClinicalTrials.gov |
| NCT00516672 | Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese … | Phase1 | Carcinoma, Renal Cell | Completed | 2007-09-10 | 2015-10-14 | ClinicalTrials.gov |
| NCT00539760 | A Phase I Rheumatoid Arthritis Study in Healthy Volunteers | Phase1 | Arthritis, Rheumatoid | Completed | 2007-09-05 | 2008-04-05 | ClinicalTrials.gov |
| NCT00539760 | A Phase I Rheumatoid Arthritis Study in Healthy Volunteers | Phase1 | Arthritis, Rheumatoid | Completed | 2007-09-05 | 2008-04-05 | ClinicalTrials.gov |
| NCT00536497 | Relative Bioavailability Study on a Single Dose of GW842166X in Healthy Male an… | Phase1 | Healthy Subjects | Withdrawn | 2007-09-01 | — | ClinicalTrials.gov |
| NCT00475332 | Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Be… | Phase2 | Non-Hodgkin's Lymphoma | Terminated | 2007-09-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00532610 | A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, … | Phase1 | Type 2 Diabetes Mellitus | Completed | 2007-09-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00539825 | Effect of GSK704838 In Healthy Volunteers | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-09-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00527566 | Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome | Phase1 | Churg Strauss Syndrome | Completed | 2007-09-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00539201 | GSK706769 A First Time in Human Study For Males and Females | Phase1 | Healthy Subjects | Terminated | 2007-09-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00523770 | Exploratory Study in Healthy Elderly Subjects to Collect Urine for Development … | — | Infections, Streptococcal | Completed | 2007-09-01 | — | ClinicalTrials.gov |
| NCT00521885 | Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patie… | Na | Venous Thrombosis | Terminated | 2007-09-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00657020 | Functional Magnetic Resonance Imaging (fMRI) Investigation of Nicotine Withdraw… | Phase4 | Smoking | Completed | 2007-09-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00540423 | Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purp… | Phase3 | Chronic Idiopathic Thrombocytopenic Purpura | Completed | 2007-09-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00527566 | Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome | Phase1 | Churg Strauss Syndrome | Completed | 2007-09-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00536497 | Relative Bioavailability Study on a Single Dose of GW842166X in Healthy Male an… | Phase1 | Healthy Subjects | Withdrawn | 2007-09-01 | — | ClinicalTrials.gov |
| NCT00561795 | Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecologic… | Phase2 | Primary Peritoneal Carcinoma | Completed | 2007-09-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00752089 | Experimental Dentifrice Remineralization/Fluoride Uptake in an in Situ Model | Phase2 | Dental Erosion | Completed | 2007-09-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00561795 | Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecologic… | Phase2 | Primary Peritoneal Carcinoma | Completed | 2007-09-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00532610 | A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, … | Phase1 | Type 2 Diabetes Mellitus | Completed | 2007-09-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00552708 | A Study Investigating the Bioequivalence of the Fixed Dose Combination of COREG… | Phase1 | Hypertension | Completed | 2007-09-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00539994 | Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Au… | Phase2 | Infections, Bacterial | Completed | 2007-09-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00549497 | A Randomized Study Evaluating Steroid Hormone Levels, Safety And Tolerability O… | Phase1 | Asthma | Completed | 2007-09-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00523770 | Exploratory Study in Healthy Elderly Subjects to Collect Urine for Development … | — | Infections, Streptococcal | Completed | 2007-09-01 | — | ClinicalTrials.gov |
| NCT00752089 | Experimental Dentifrice Remineralization/Fluoride Uptake in an in Situ Model | Phase2 | Dental Erosion | Completed | 2007-09-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00521885 | Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patie… | Na | Venous Thrombosis | Terminated | 2007-09-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00549497 | A Randomized Study Evaluating Steroid Hormone Levels, Safety And Tolerability O… | Phase1 | Asthma | Completed | 2007-09-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00475332 | Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Be… | Phase2 | Non-Hodgkin's Lymphoma | Terminated | 2007-09-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00552708 | A Study Investigating the Bioequivalence of the Fixed Dose Combination of COREG… | Phase1 | Hypertension | Completed | 2007-09-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00682461 | Oral Tolerability Of Two Nicotine Dosage Forms | Phase1 | Healthy Volunteer Smokers | Completed | 2007-09-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00540423 | Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purp… | Phase3 | Chronic Idiopathic Thrombocytopenic Purpura | Completed | 2007-09-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00539994 | Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Au… | Phase2 | Infections, Bacterial | Completed | 2007-09-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00539825 | Effect of GSK704838 In Healthy Volunteers | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-09-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00539201 | GSK706769 A First Time in Human Study For Males and Females | Phase1 | Healthy Subjects | Terminated | 2007-09-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00657020 | Functional Magnetic Resonance Imaging (fMRI) Investigation of Nicotine Withdraw… | Phase4 | Smoking | Completed | 2007-09-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00682461 | Oral Tolerability Of Two Nicotine Dosage Forms | Phase1 | Healthy Volunteer Smokers | Completed | 2007-09-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00519649 | Long-term Persistence of Immunity Against Hepatitis B in 7-8 Years Old Children… | Phase4 | Hepatitis B Vaccine | Completed | 2007-08-31 | 2007-12-31 | ClinicalTrials.gov |
| NCT00519649 | Long-term Persistence of Immunity Against Hepatitis B in 7-8 Years Old Children… | Phase4 | Hepatitis B Vaccine | Completed | 2007-08-31 | 2007-12-31 | ClinicalTrials.gov |
| NCT00725764 | Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cance… | Phase2 | Neoplasms, Head and Neck | Completed | 2007-08-27 | 2009-05-02 | ClinicalTrials.gov |
| NCT00725764 | Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cance… | Phase2 | Neoplasms, Head and Neck | Completed | 2007-08-27 | 2009-05-02 | ClinicalTrials.gov |
| NCT00530790 | Clinical Evaluation of Ropinirole CR-RLS ( SK&F101468)Tablets in Restless Legs … | Phase2 | Restless Legs Syndrome | Completed | 2007-08-23 | 2008-02-01 | ClinicalTrials.gov |
| NCT00530790 | Clinical Evaluation of Ropinirole CR-RLS ( SK&F101468)Tablets in Restless Legs … | Phase2 | Restless Legs Syndrome | Completed | 2007-08-23 | 2008-02-01 | ClinicalTrials.gov |
| NCT00513409 | Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given … | Phase2 | Infections, Streptococcal | Completed | 2007-08-22 | 2008-08-28 | ClinicalTrials.gov |
| NCT00513409 | Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given … | Phase2 | Infections, Streptococcal | Completed | 2007-08-22 | 2008-08-28 | ClinicalTrials.gov |
| NCT00495469 | Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-… | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2007-08-17 | 2008-06-05 | ClinicalTrials.gov |
| NCT00495469 | Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-… | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2007-08-17 | 2008-06-05 | ClinicalTrials.gov |
| NCT00549120 | Optimising the Propranolol Block Model | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-08-15 | 2007-10-26 | ClinicalTrials.gov |
| NCT00549120 | Optimising the Propranolol Block Model | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-08-15 | 2007-10-26 | ClinicalTrials.gov |
| NCT00527020 | First Time in Human Study With GSK1018921 | Phase1 | Schizophrenia | Completed | 2007-08-10 | 2008-07-12 | ClinicalTrials.gov |
| NCT00527020 | First Time in Human Study With GSK1018921 | Phase1 | Schizophrenia | Completed | 2007-08-10 | 2008-07-12 | ClinicalTrials.gov |
| NCT00490568 | Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subject… | Phase3 | Alzheimer's Disease | Terminated | 2007-08-08 | 2009-06-01 | ClinicalTrials.gov |
| NCT00490568 | Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subject… | Phase3 | Alzheimer's Disease | Terminated | 2007-08-08 | 2009-06-01 | ClinicalTrials.gov |
| NCT00540436 | Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatm… | Phase2 | Hypertension, Pulmonary | Completed | 2007-08-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00506350 | Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vac… | Phase2 | Influenza | Completed | 2007-08-01 | 2009-10-12 | ClinicalTrials.gov |
| NCT00539006 | Comparator Study Evaluating Patient Preference Of FFNS vs. FPNS | Phase4 | Rhinitis, Allergic, Perennial | Completed | 2007-08-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00532077 | A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Cal… | Phase1 | Osteoporosis | Completed | 2007-08-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00716430 | European Quality Improvement Programme for Acute Coronary Syndromes | Na | Acute Coronary Syndrome | Unknown | 2007-08-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00841776 | Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatm… | Phase4 | Acne | Completed | 2007-08-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00622609 | Anti-MAG First Administration to Human | Phase1 | Cerebrovascular Accident | Completed | 2007-08-01 | 2009-04-09 | ClinicalTrials.gov |
| NCT00837213 | Comparative Efficacy and Safety of Benzoyl Peroxide Used in Combination With Cl… | Phase4 | Acne | Completed | 2007-08-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00501670 | VZV PCR Sampling Validation Study | — | Herpes Zoster | Completed | 2007-08-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00502775 | Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine | Phase4 | Rhinitis, Allergic, Seasonal | Completed | 2007-08-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00483600 | Pharmacokinetic Study of Fondaparinux in Outpatients With Renal Dysfunction | Na | Kidney Diseases | Withdrawn | 2007-08-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00506350 | Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vac… | Phase2 | Influenza | Completed | 2007-08-01 | 2009-10-12 | ClinicalTrials.gov |
| NCT00508261 | Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus… | Phase3 | Infections, Meningococcal | Completed | 2007-08-01 | 2008-10-27 | ClinicalTrials.gov |
| NCT00501670 | VZV PCR Sampling Validation Study | — | Herpes Zoster | Completed | 2007-08-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00551772 | A Study To Assess The Pharmacokinetics Of SB-742457 Formulated As A Capsule And… | Phase1 | Alzheimer's Disease | Completed | 2007-08-01 | — | ClinicalTrials.gov |
| NCT00841776 | Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatm… | Phase4 | Acne | Completed | 2007-08-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00716430 | European Quality Improvement Programme for Acute Coronary Syndromes | Na | Acute Coronary Syndrome | Unknown | 2007-08-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00837213 | Comparative Efficacy and Safety of Benzoyl Peroxide Used in Combination With Cl… | Phase4 | Acne | Completed | 2007-08-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00511563 | A Study In Patients With Irritable Bowel Syndrome To Measure Hormone Response A… | Phase2 | Irritable Bowel Syndrome | Withdrawn | 2007-08-01 | — | ClinicalTrials.gov |
| NCT00540553 | Study to Test Safety, Tolerability and Blood Levels of GSK971086 After 1 Dose &… | Phase1 | Healthy Subjects | Completed | 2007-08-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00540436 | Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatm… | Phase2 | Hypertension, Pulmonary | Completed | 2007-08-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT01837511 | Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Pro… | — | Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer (NSCLC) | Completed | 2007-08-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00539006 | Comparator Study Evaluating Patient Preference Of FFNS vs. FPNS | Phase4 | Rhinitis, Allergic, Perennial | Completed | 2007-08-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00502775 | Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine | Phase4 | Rhinitis, Allergic, Seasonal | Completed | 2007-08-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00532077 | A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Cal… | Phase1 | Osteoporosis | Completed | 2007-08-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00530309 | Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2007-08-01 | 2008-04-17 | ClinicalTrials.gov |
| NCT00524303 | Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer The… | Phase2 | Neoplasms, Breast | Completed | 2007-08-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT00516139 | Lamotrigine Extended-Release In Elderly Patients With Epilepsy | Phase3 | Epilepsy | Completed | 2007-08-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00519636 | Comparator Study Evaluating Patient Experience And Preference Of FFNS vs. FPNS | Phase4 | Rhinitis, Allergic, Perennial | Completed | 2007-08-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00519376 | A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In COP… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-08-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00517543 | A Study to Examine the Effect of Particle Size on Bioequivalence and Bioavailab… | Phase1 | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2007-08-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT01837511 | Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Pro… | — | Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer (NSCLC) | Completed | 2007-08-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00517634 | Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects | Phase4 | Asthma | Completed | 2007-08-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00622609 | Anti-MAG First Administration to Human | Phase1 | Cerebrovascular Accident | Completed | 2007-08-01 | 2009-04-09 | ClinicalTrials.gov |
| NCT00517543 | A Study to Examine the Effect of Particle Size on Bioequivalence and Bioavailab… | Phase1 | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2007-08-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00516139 | Lamotrigine Extended-Release In Elderly Patients With Epilepsy | Phase3 | Epilepsy | Completed | 2007-08-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00517634 | Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects | Phase4 | Asthma | Completed | 2007-08-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00519376 | A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In COP… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-08-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00483600 | Pharmacokinetic Study of Fondaparinux in Outpatients With Renal Dysfunction | Na | Kidney Diseases | Withdrawn | 2007-08-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00519636 | Comparator Study Evaluating Patient Experience And Preference Of FFNS vs. FPNS | Phase4 | Rhinitis, Allergic, Perennial | Completed | 2007-08-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00551772 | A Study To Assess The Pharmacokinetics Of SB-742457 Formulated As A Capsule And… | Phase1 | Alzheimer's Disease | Completed | 2007-08-01 | — | ClinicalTrials.gov |
| NCT00524303 | Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer The… | Phase2 | Neoplasms, Breast | Completed | 2007-08-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT00511563 | A Study In Patients With Irritable Bowel Syndrome To Measure Hormone Response A… | Phase2 | Irritable Bowel Syndrome | Withdrawn | 2007-08-01 | — | ClinicalTrials.gov |
| NCT00530309 | Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2007-08-01 | 2008-04-17 | ClinicalTrials.gov |
| NCT00540553 | Study to Test Safety, Tolerability and Blood Levels of GSK971086 After 1 Dose &… | Phase1 | Healthy Subjects | Completed | 2007-08-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00508261 | Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus… | Phase3 | Infections, Meningococcal | Completed | 2007-08-01 | 2008-10-27 | ClinicalTrials.gov |
| NCT00500058 | A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity o… | Phase1 | Lymphoma, Non-Hodgkin | Completed | 2007-07-31 | 2010-03-04 | ClinicalTrials.gov |
| NCT00500058 | A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity o… | Phase1 | Lymphoma, Non-Hodgkin | Completed | 2007-07-31 | 2010-03-04 | ClinicalTrials.gov |
| NCT00551564 | Study to Determine the Utility of Novel Technologies and Biomarkers to Measure … | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2007-07-31 | 2008-09-08 | ClinicalTrials.gov |
| NCT00551564 | Study to Determine the Utility of Novel Technologies and Biomarkers to Measure … | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2007-07-31 | 2008-09-08 | ClinicalTrials.gov |
| NCT00510874 | Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Infl… | Phase1 | Influenza | Completed | 2007-07-28 | 2008-10-24 | ClinicalTrials.gov |
| NCT00510874 | Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Infl… | Phase1 | Influenza | Completed | 2007-07-28 | 2008-10-24 | ClinicalTrials.gov |
| NCT00478725 | Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034 | Phase1 | Carcinoma, Renal Cell | Completed | 2007-07-18 | 2008-07-01 | ClinicalTrials.gov |
| NCT00478725 | Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034 | Phase1 | Carcinoma, Renal Cell | Completed | 2007-07-18 | 2008-07-01 | ClinicalTrials.gov |
| NCT00604825 | Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study) | Phase2 | Menopausal and Female Climacteric States | Completed | 2007-07-17 | 2008-07-23 | ClinicalTrials.gov |
| NCT00604825 | Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study) | Phase2 | Menopausal and Female Climacteric States | Completed | 2007-07-17 | 2008-07-23 | ClinicalTrials.gov |
| NCT00540943 | Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line M… | Phase1 | Neoplasms, Colorectal | Completed | 2007-07-13 | 2010-05-03 | ClinicalTrials.gov |
| NCT00540943 | Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line M… | Phase1 | Neoplasms, Colorectal | Completed | 2007-07-13 | 2010-05-03 | ClinicalTrials.gov |
| NCT00488514 | Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adol… | Phase3 | Migraine Disorders | Completed | 2007-07-13 | 2009-08-20 | ClinicalTrials.gov |
| NCT00488514 | Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adol… | Phase3 | Migraine Disorders | Completed | 2007-07-13 | 2009-08-20 | ClinicalTrials.gov |
| NCT00479427 | A Study Of The Effects Of CB2 Compound Of GW842166 In Patients With Osteoarthri… | Phase2 | Osteoarthritis | Completed | 2007-07-06 | 2007-10-09 | ClinicalTrials.gov |
| NCT00479427 | A Study Of The Effects Of CB2 Compound Of GW842166 In Patients With Osteoarthri… | Phase2 | Osteoarthritis | Completed | 2007-07-06 | 2007-10-09 | ClinicalTrials.gov |
| NCT00471081 | Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Do… | Phase2 | Infections, Meningococcal | Completed | 2007-07-05 | 2008-11-26 | ClinicalTrials.gov |
| NCT00471081 | Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Do… | Phase2 | Infections, Meningococcal | Completed | 2007-07-05 | 2008-11-26 | ClinicalTrials.gov |
| NCT00496015 | Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumo… | Phase3 | Infections, Streptococcal | Completed | 2007-07-02 | 2009-02-17 | ClinicalTrials.gov |
| NCT00492544 | Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Jap… | Phase3 | Infections, Papillomavirus | Completed | 2007-07-02 | 2008-03-28 | ClinicalTrials.gov |
| NCT00492544 | Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Jap… | Phase3 | Infections, Papillomavirus | Completed | 2007-07-02 | 2008-03-28 | ClinicalTrials.gov |
| NCT00496015 | Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumo… | Phase3 | Infections, Streptococcal | Completed | 2007-07-02 | 2009-02-17 | ClinicalTrials.gov |
| NCT00505453 | A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogen… | Phase3 | Influenza | Completed | 2007-07-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00815685 | A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia | Na | Cancer Cachexia | Completed | 2007-07-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00469378 | Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients Wit… | Phase2 | Multiple Sclerosis | Completed | 2007-07-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00815685 | A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia | Na | Cancer Cachexia | Completed | 2007-07-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00345683 | Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at … | Phase3 | Haemophilus Influenzae Type b | Completed | 2007-07-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00474864 | Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Comp… | Phase2 | Healthy Subjects | Completed | 2007-07-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00551317 | A Study Investigating the Concentrations of Darapladib in Blood and the Safety … | Phase1 | Atherosclerosis | Completed | 2007-07-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00517673 | To Evaluate Safety, Tolerability, Pharmacokinetics, And Food Effect Of Single D… | Phase1 | Healthy Subjects | Completed | 2007-07-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00514033 | A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Chi… | — | Poliomyelitis | Completed | 2007-07-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00551317 | A Study Investigating the Concentrations of Darapladib in Blood and the Safety … | Phase1 | Atherosclerosis | Completed | 2007-07-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00509275 | A Study to Evaluate Efficacy and Safety of Three W0027 Regimens in the Treatmen… | Phase1 | Tinea Pedis | Completed | 2007-07-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00508534 | A Study To Evaluate The Effects Of Repeat Dosing Of Esomeprazole On The Pharmac… | Phase1 | Osteoporosis | Completed | 2007-07-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00486668 | A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapat… | Phase3 | Invasive Breast Cancer | Unknown | 2007-07-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT00486954 | Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplifie… | Phase3 | Neoplasms, Gastrointestinal Tract | Completed | 2007-07-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00488098 | GSK372475 Bioequivalence Study | Phase1 | Healthy Subjects | Completed | 2007-07-01 | — | ClinicalTrials.gov |
| NCT00517673 | To Evaluate Safety, Tolerability, Pharmacokinetics, And Food Effect Of Single D… | Phase1 | Healthy Subjects | Completed | 2007-07-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00514033 | A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Chi… | — | Poliomyelitis | Completed | 2007-07-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00490061 | Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cann… | Phase2 | Head and Neck Cancer | Terminated | 2007-07-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT00509275 | A Study to Evaluate Efficacy and Safety of Three W0027 Regimens in the Treatmen… | Phase1 | Tinea Pedis | Completed | 2007-07-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00501462 | A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2007-07-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00508534 | A Study To Evaluate The Effects Of Repeat Dosing Of Esomeprazole On The Pharmac… | Phase1 | Osteoporosis | Completed | 2007-07-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00505453 | A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogen… | Phase3 | Influenza | Completed | 2007-07-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00501462 | A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2007-07-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00345683 | Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at … | Phase3 | Haemophilus Influenzae Type b | Completed | 2007-07-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00469378 | Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients Wit… | Phase2 | Multiple Sclerosis | Completed | 2007-07-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00493896 | Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients | Phase3 | Venous Thromboembolism | Terminated | 2007-07-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00493896 | Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients | Phase3 | Venous Thromboembolism | Terminated | 2007-07-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00490061 | Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cann… | Phase2 | Head and Neck Cancer | Terminated | 2007-07-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT00488098 | GSK372475 Bioequivalence Study | Phase1 | Healthy Subjects | Completed | 2007-07-01 | — | ClinicalTrials.gov |
| NCT00486954 | Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplifie… | Phase3 | Neoplasms, Gastrointestinal Tract | Completed | 2007-07-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00486668 | A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapat… | Phase3 | Invasive Breast Cancer | Unknown | 2007-07-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT00474864 | Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Comp… | Phase2 | Healthy Subjects | Completed | 2007-07-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00513279 | To Investigate If Single Doses Of GSK618334 Are Safe And To Investigate Blood L… | Phase1 | Substance Dependence | Completed | 2007-06-28 | 2007-10-04 | ClinicalTrials.gov |
| NCT00513279 | To Investigate If Single Doses Of GSK618334 Are Safe And To Investigate Blood L… | Phase1 | Substance Dependence | Completed | 2007-06-28 | 2007-10-04 | ClinicalTrials.gov |
| NCT00466947 | COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Medi… | Phase3 | Infections, Streptococcal | Completed | 2007-06-28 | 2011-07-28 | ClinicalTrials.gov |
| NCT00466947 | COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Medi… | Phase3 | Infections, Streptococcal | Completed | 2007-06-28 | 2011-07-28 | ClinicalTrials.gov |
| NCT00504790 | Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK… | Phase1 | Cancer | Completed | 2007-06-25 | 2012-05-08 | ClinicalTrials.gov |
| NCT00504790 | Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK… | Phase1 | Cancer | Completed | 2007-06-25 | 2012-05-08 | ClinicalTrials.gov |
| NCT00492648 | Month 30 & 42 Extension Studies of CRD-004 Primary Study | Phase2 | Herpes Zoster | Completed | 2007-06-25 | 2008-06-23 | ClinicalTrials.gov |
| NCT00492648 | Month 30 & 42 Extension Studies of CRD-004 Primary Study | Phase2 | Herpes Zoster | Completed | 2007-06-25 | 2008-06-23 | ClinicalTrials.gov |
| NCT00483860 | A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function | Phase1 | Solid Tumours | Completed | 2007-06-20 | 2012-02-06 | ClinicalTrials.gov |
| NCT00483860 | A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function | Phase1 | Solid Tumours | Completed | 2007-06-20 | 2012-02-06 | ClinicalTrials.gov |
| NCT00511654 | 28-day Repeat Dose and Drug Interaction Study With Orvepitant (GW823296) | Phase1 | Depressive Disorder | Completed | 2007-06-12 | 2008-01-11 | ClinicalTrials.gov |
| NCT00511654 | 28-day Repeat Dose and Drug Interaction Study With Orvepitant (GW823296) | Phase1 | Depressive Disorder | Completed | 2007-06-12 | 2008-01-11 | ClinicalTrials.gov |
| NCT00508911 | A Study To Evaluate The Effect Of GW876008 On The Pharmacokinetics Of Oral Cont… | Phase1 | Social Phobia | Terminated | 2007-06-08 | 2007-10-22 | ClinicalTrials.gov |
| NCT00520663 | Radiolabel Study In Healthy Volunteers For Insomnia-Targeting Drug | Phase1 | Sleep Initiation and Maintenance Disorders | Completed | 2007-06-08 | 2007-08-10 | ClinicalTrials.gov |
| NCT00508911 | A Study To Evaluate The Effect Of GW876008 On The Pharmacokinetics Of Oral Cont… | Phase1 | Social Phobia | Terminated | 2007-06-08 | 2007-10-22 | ClinicalTrials.gov |
| NCT00520663 | Radiolabel Study In Healthy Volunteers For Insomnia-Targeting Drug | Phase1 | Sleep Initiation and Maintenance Disorders | Completed | 2007-06-08 | 2007-08-10 | ClinicalTrials.gov |
| NCT00474266 | Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Pri… | Phase3 | Infections, Meningococcal | Completed | 2007-06-05 | 2008-03-26 | ClinicalTrials.gov |
| NCT00474266 | Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Pri… | Phase3 | Infections, Meningococcal | Completed | 2007-06-05 | 2008-03-26 | ClinicalTrials.gov |
| NCT00500461 | Study To Examine Safety, Tolerability And Pharmacokinetics Of Intravenous Doses… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-06-04 | 2007-07-25 | ClinicalTrials.gov |
| NCT00504439 | A Study To Evaluate The Safety And Tolerability Of SB-656933-AAA Following Repe… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-06-04 | 2007-09-06 | ClinicalTrials.gov |
| NCT00504439 | A Study To Evaluate The Safety And Tolerability Of SB-656933-AAA Following Repe… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-06-04 | 2007-09-06 | ClinicalTrials.gov |
| NCT00500461 | Study To Examine Safety, Tolerability And Pharmacokinetics Of Intravenous Doses… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-06-04 | 2007-07-25 | ClinicalTrials.gov |
| NCT00377091 | Is Using Fondaparinux (Blood Thinner) to Treat Lung Clot Cheaper Than Tradition… | Phase4 | Pulmonary Embolism | Withdrawn | 2007-06-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00484874 | Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refrac… | Phase1 | Hodgkin's Disease | Completed | 2007-06-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT00481390 | Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 In HIV-1 Infe… | — | Infection, Human Immunodeficiency Virus I | Completed | 2007-06-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00489970 | Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Followin… | Phase3 | Acellular Pertussis | Completed | 2007-06-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT00584987 | Intranasal Steroids and Oxymetazoline in Allergic Rhinitis | Phase4 | Allergic Rhinitis | Completed | 2007-06-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00478738 | A 2 Part Study Examining Doses Of GSK961081 In Healthy Volunteers And Then In C… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-06-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00680485 | Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Dose… | Phase1 | Bacterial Infection | Terminated | 2007-06-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00477464 | Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic… | Phase2 | Metastatic Breast Cancer | Completed | 2007-06-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00476307 | Immunogenicity and Reactogenicity of Fluarix™ (Influsplit SSW®) 2007/2008 in Pe… | Phase3 | Influenza | Completed | 2007-06-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00489970 | Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Followin… | Phase3 | Acellular Pertussis | Completed | 2007-06-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT00549198 | KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects | Phase4 | Infection, Human Immunodeficiency Virus I | Completed | 2007-06-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00488449 | Study Of Pharmacokinetics and Pharmacodynamics Effects Of GSK256073A On Healthy… | Phase1 | Healthy Subjects | Completed | 2007-06-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00478738 | A 2 Part Study Examining Doses Of GSK961081 In Healthy Volunteers And Then In C… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-06-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00473668 | Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations o… | Phase3 | Whole Cell Pertussis | Completed | 2007-06-01 | 2008-01-30 | ClinicalTrials.gov |
| NCT00476307 | Immunogenicity and Reactogenicity of Fluarix™ (Influsplit SSW®) 2007/2008 in Pe… | Phase3 | Influenza | Completed | 2007-06-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00477464 | Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic… | Phase2 | Metastatic Breast Cancer | Completed | 2007-06-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00555438 | Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinu… | Phase4 | Major Orthopaedic Surgery and Renal Impairment | Completed | 2007-06-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00584987 | Intranasal Steroids and Oxymetazoline in Allergic Rhinitis | Phase4 | Allergic Rhinitis | Completed | 2007-06-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00834457 | A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi'… | Phase2 | AIDS-related Kaposi's Sarcoma | Completed | 2007-06-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00481390 | Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 In HIV-1 Infe… | — | Infection, Human Immunodeficiency Virus I | Completed | 2007-06-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00680485 | Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Dose… | Phase1 | Bacterial Infection | Terminated | 2007-06-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00485069 | REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study | Phase4 | Parkinson Disease | Completed | 2007-06-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00501267 | A Study To Test The Interaction of Two Medications for Treatment of Overactive … | Phase1 | Overactive Bladder | Completed | 2007-06-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00501267 | A Study To Test The Interaction of Two Medications for Treatment of Overactive … | Phase1 | Overactive Bladder | Completed | 2007-06-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00495014 | Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subje… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2007-06-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00494780 | Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, P… | Phase2 | Lymphoma, Follicular | Completed | 2007-06-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00495014 | Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subje… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2007-06-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT01381393 | BONVIVA(Ibandronate) PMS(Post-marketing Surveillance ) | — | Osteoporosis | Completed | 2007-06-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00473668 | Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations o… | Phase3 | Whole Cell Pertussis | Completed | 2007-06-01 | 2008-01-30 | ClinicalTrials.gov |
| NCT00834457 | A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi'… | Phase2 | AIDS-related Kaposi's Sarcoma | Completed | 2007-06-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00494780 | Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, P… | Phase2 | Lymphoma, Follicular | Completed | 2007-06-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00485069 | REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study | Phase4 | Parkinson Disease | Completed | 2007-06-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00549198 | KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects | Phase4 | Infection, Human Immunodeficiency Virus I | Completed | 2007-06-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00488449 | Study Of Pharmacokinetics and Pharmacodynamics Effects Of GSK256073A On Healthy… | Phase1 | Healthy Subjects | Completed | 2007-06-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00377091 | Is Using Fondaparinux (Blood Thinner) to Treat Lung Clot Cheaper Than Tradition… | Phase4 | Pulmonary Embolism | Withdrawn | 2007-06-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT01381393 | BONVIVA(Ibandronate) PMS(Post-marketing Surveillance ) | — | Osteoporosis | Completed | 2007-06-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00484874 | Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refrac… | Phase1 | Hodgkin's Disease | Completed | 2007-06-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT00555438 | Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinu… | Phase4 | Major Orthopaedic Surgery and Renal Impairment | Completed | 2007-06-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00478621 | Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adu… | Phase1 | Infections, Papillomavirus | Completed | 2007-05-25 | 2008-10-13 | ClinicalTrials.gov |
| NCT00478621 | Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adu… | Phase1 | Infections, Papillomavirus | Completed | 2007-05-25 | 2008-10-13 | ClinicalTrials.gov |
| NCT00500201 | A Healthy Volunteer Study to Assess the Relative Bioavailability of 2 Forms of … | Phase1 | Schizophrenia | Completed | 2007-05-24 | 2007-07-25 | ClinicalTrials.gov |
| NCT00500201 | A Healthy Volunteer Study to Assess the Relative Bioavailability of 2 Forms of … | Phase1 | Schizophrenia | Completed | 2007-05-24 | 2007-07-25 | ClinicalTrials.gov |
| NCT00470704 | Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metas… | Phase2 | Breast Cancer | Completed | 2007-05-14 | 2024-08-20 | ClinicalTrials.gov |
| NCT00475436 | A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK5… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-05-14 | 2007-09-18 | ClinicalTrials.gov |
| NCT00471237 | A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosi… | Phase2 | Osteoporosis | Terminated | 2007-05-14 | 2008-12-26 | ClinicalTrials.gov |
| NCT00470704 | Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metas… | Phase2 | Breast Cancer | Completed | 2007-05-14 | 2024-08-20 | ClinicalTrials.gov |
| NCT00475436 | A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK5… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-05-14 | 2007-09-18 | ClinicalTrials.gov |
| NCT00471237 | A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosi… | Phase2 | Osteoporosis | Terminated | 2007-05-14 | 2008-12-26 | ClinicalTrials.gov |
| NCT00455572 | Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-an… | Phase1 | Lung Cancer, Non-Small Cell | Terminated | 2007-05-11 | 2013-08-08 | ClinicalTrials.gov |
| NCT00455572 | Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-an… | Phase1 | Lung Cancer, Non-Small Cell | Terminated | 2007-05-11 | 2013-08-08 | ClinicalTrials.gov |
| NCT00449774 | Bioequivalence And Effect Of Food And Water On Lamotrigine in Healthy Volunteers | Phase1 | Mental Disorders | Completed | 2007-05-07 | 2007-06-19 | ClinicalTrials.gov |
| NCT00449774 | Bioequivalence And Effect Of Food And Water On Lamotrigine in Healthy Volunteers | Phase1 | Mental Disorders | Completed | 2007-05-07 | 2007-06-19 | ClinicalTrials.gov |
| NCT00440128 | The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Su… | Phase1 | Nausea and Vomiting, Chemotherapy-Induced | Completed | 2007-05-04 | 2008-07-17 | ClinicalTrials.gov |
| NCT00440128 | The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Su… | Phase1 | Nausea and Vomiting, Chemotherapy-Induced | Completed | 2007-05-04 | 2008-07-17 | ClinicalTrials.gov |
| NCT00464815 | Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Ye… | Phase3 | Infections, Meningococcal | Completed | 2007-05-02 | 2008-09-10 | ClinicalTrials.gov |
| NCT00464815 | Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Ye… | Phase3 | Infections, Meningococcal | Completed | 2007-05-02 | 2008-09-10 | ClinicalTrials.gov |
| NCT00470834 | Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Th… | Phase4 | Neoplasms, Prostate | Completed | 2007-05-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT00702507 | Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates … | Phase4 | Diaper Rash | Completed | 2007-05-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00551655 | Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairmen… | — | Human Immunodeficiency Viruses | Completed | 2007-05-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00551473 | Open-label Comparison of 24hr Gastric pH on Days 1, 2, 7 With Once-daily Admini… | Phase1 | Gastroesophageal Reflux Disease | Completed | 2007-05-01 | — | ClinicalTrials.gov |
| NCT00702507 | Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates … | Phase4 | Diaper Rash | Completed | 2007-05-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00551655 | Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairmen… | — | Human Immunodeficiency Viruses | Completed | 2007-05-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00551473 | Open-label Comparison of 24hr Gastric pH on Days 1, 2, 7 With Once-daily Admini… | Phase1 | Gastroesophageal Reflux Disease | Completed | 2007-05-01 | — | ClinicalTrials.gov |
| NCT01231230 | Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Ai… | Na | Asthma | Completed | 2007-05-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00479167 | A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patient… | Phase2 | Follicular Lymphoma | Terminated | 2007-05-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00471861 | Inflammatory Markers in Patients With Active Migraine Headaches | — | Migraine | Completed | 2007-05-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00460564 | Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity | Phase3 | Post-Stroke Spasticity | Completed | 2007-05-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00460525 | Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali | Phase2 | Plasmodium Falciparum Malaria | Completed | 2007-05-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00452699 | A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Co… | Phase4 | Asthma | Completed | 2007-05-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00452348 | A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Co… | Phase4 | Asthma | Completed | 2007-05-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00447226 | Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With D… | Phase2 | Cancer | Terminated | 2007-05-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00479167 | A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patient… | Phase2 | Follicular Lymphoma | Terminated | 2007-05-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00471861 | Inflammatory Markers in Patients With Active Migraine Headaches | — | Migraine | Completed | 2007-05-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00470834 | Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Th… | Phase4 | Neoplasms, Prostate | Completed | 2007-05-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT00424476 | A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) | Phase3 | Systemic Lupus Erythematosus | Completed | 2007-05-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00460564 | Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity | Phase3 | Post-Stroke Spasticity | Completed | 2007-05-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00460525 | Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali | Phase2 | Plasmodium Falciparum Malaria | Completed | 2007-05-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00452699 | A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Co… | Phase4 | Asthma | Completed | 2007-05-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00452348 | A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Co… | Phase4 | Asthma | Completed | 2007-05-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00447226 | Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With D… | Phase2 | Cancer | Terminated | 2007-05-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00394836 | HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Ritu… | Phase2 | Lymphoma, Follicular | Completed | 2007-05-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT00424476 | A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) | Phase3 | Systemic Lupus Erythematosus | Completed | 2007-05-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT01231230 | Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Ai… | Na | Asthma | Completed | 2007-05-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00394836 | HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Ritu… | Phase2 | Lymphoma, Follicular | Completed | 2007-05-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT00436007 | Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, Whe… | Phase2 | Malaria | Completed | 2007-04-30 | 2009-10-07 | ClinicalTrials.gov |
| NCT00436007 | Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, Whe… | Phase2 | Malaria | Completed | 2007-04-30 | 2009-10-07 | ClinicalTrials.gov |
| NCT00548769 | Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients | Phase1 | Multiple Sclerosis | Completed | 2007-04-21 | 2007-11-26 | ClinicalTrials.gov |
| NCT00548769 | Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients | Phase1 | Multiple Sclerosis | Completed | 2007-04-21 | 2007-11-26 | ClinicalTrials.gov |
| NCT00495729 | 15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoen… | Phase1 | Sleep Initiation and Maintenance Disorders | Completed | 2007-04-18 | 2007-08-04 | ClinicalTrials.gov |
| NCT00495729 | 15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoen… | Phase1 | Sleep Initiation and Maintenance Disorders | Completed | 2007-04-18 | 2007-08-04 | ClinicalTrials.gov |
| NCT00460707 | A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazol… | Phase1 | Nausea and Vomiting, Chemotherapy-Induced | Completed | 2007-04-16 | 2007-08-27 | ClinicalTrials.gov |
| NCT00460707 | A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazol… | Phase1 | Nausea and Vomiting, Chemotherapy-Induced | Completed | 2007-04-16 | 2007-08-27 | ClinicalTrials.gov |
| NCT00465816 | Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologic… | Phase3 | Infections, Meningococcal | Completed | 2007-04-11 | 2008-04-28 | ClinicalTrials.gov |
| NCT00465816 | Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologic… | Phase3 | Infections, Meningococcal | Completed | 2007-04-11 | 2008-04-28 | ClinicalTrials.gov |
| NCT00434304 | Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's … | Phase2 | Parkinson Disease | Completed | 2007-04-09 | 2009-03-10 | ClinicalTrials.gov |
| NCT00434304 | Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's … | Phase2 | Parkinson Disease | Completed | 2007-04-09 | 2009-03-10 | ClinicalTrials.gov |
| NCT00504816 | A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pil… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2007-04-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00456625 | Immune Response to Hepatitis B Vaccine Challenge Dose in Subjects Who Received … | Phase4 | Hepatitis B | Completed | 2007-04-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00473915 | Intranasal Steroids and the Nasal Ocular Response | Phase4 | Seasonal Allergic Rhinitis | Completed | 2007-04-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00460148 | Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And E… | Phase2 | Parkinson Disease | Completed | 2007-04-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00777114 | Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's … | Phase1 | Non-Hodgkin's Lymphoma | Completed | 2007-04-01 | 2012-12-18 | ClinicalTrials.gov |
| NCT00468689 | Evaluation Of SB-751689 Administered At Supratherapeutic Dose Levels In Healthy… | Phase1 | Osteoporosis | Completed | 2007-04-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00470847 | Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastas… | Phase1 | Breast Cancer | Completed | 2007-04-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT00456807 | Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) … | Phase3 | Infections, Papillomavirus | Completed | 2007-04-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00436358 | Implementing Hospital-based Active Surveillance Procedures for Vaccine Safety M… | — | Intussusception | Completed | 2007-04-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00422903 | Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breas… | Phase2 | Neoplasms, Breast | Completed | 2007-04-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00470847 | Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastas… | Phase1 | Breast Cancer | Completed | 2007-04-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT00512954 | Causes, Characteristics and Mechanisms of Infective Exacerbations in Subjects W… | — | Asthma | Completed | 2007-04-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00518115 | Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no D… | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2007-04-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00499928 | A Study To Investigate The Metabolism And Excretion Of 14C SB-751689 Given To H… | Phase1 | Osteoporosis | Completed | 2007-04-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00456807 | Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) … | Phase3 | Infections, Papillomavirus | Completed | 2007-04-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00448435 | Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Ast… | Phase3 | Bronchial Asthma | Completed | 2007-04-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00448058 | A Study Of New Medicine (GSK 372475) For The Treatment Of Depression | Phase2 | Depressive Disorder | Completed | 2007-04-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00447486 | A Study of GW842166 in Adults With Osteoarthritis Pain | Phase2 | Osteoarthritis, Knee | Completed | 2007-04-01 | — | ClinicalTrials.gov |
| NCT00512954 | Causes, Characteristics and Mechanisms of Infective Exacerbations in Subjects W… | — | Asthma | Completed | 2007-04-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00777114 | Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's … | Phase1 | Non-Hodgkin's Lymphoma | Completed | 2007-04-01 | 2012-12-18 | ClinicalTrials.gov |
| NCT00456625 | Immune Response to Hepatitis B Vaccine Challenge Dose in Subjects Who Received … | Phase4 | Hepatitis B | Completed | 2007-04-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00442468 | Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2007-04-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00459056 | The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese… | Phase3 | Abdominal Obesity | Completed | 2007-04-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00405015 | The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Sci… | Phase2 | Ischemia-Reperfusion Injury | Completed | 2007-04-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00448435 | Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Ast… | Phase3 | Bronchial Asthma | Completed | 2007-04-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00448058 | A Study Of New Medicine (GSK 372475) For The Treatment Of Depression | Phase2 | Depressive Disorder | Completed | 2007-04-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00518115 | Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no D… | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2007-04-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00370682 | A Phase II Trial of a Live Attenuated Virus Tetravalent Dengue Vaccine in Healt… | Phase2 | Dengue | Completed | 2007-04-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00468689 | Evaluation Of SB-751689 Administered At Supratherapeutic Dose Levels In Healthy… | Phase1 | Osteoporosis | Completed | 2007-04-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00460148 | Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And E… | Phase2 | Parkinson Disease | Completed | 2007-04-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00539942 | Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoi… | Phase3 | Venous Thrombosis | Terminated | 2007-04-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00436358 | Implementing Hospital-based Active Surveillance Procedures for Vaccine Safety M… | — | Intussusception | Completed | 2007-04-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00540878 | A Study to Estimate the Effect of Formulation on the Relative Absorption of SB-… | Phase1 | Osteoporosis | Completed | 2007-04-01 | — | ClinicalTrials.gov |
| NCT00422903 | Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breas… | Phase2 | Neoplasms, Breast | Completed | 2007-04-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00447486 | A Study of GW842166 in Adults With Osteoarthritis Pain | Phase2 | Osteoarthritis, Knee | Completed | 2007-04-01 | — | ClinicalTrials.gov |
| NCT00442468 | Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2007-04-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00499928 | A Study To Investigate The Metabolism And Excretion Of 14C SB-751689 Given To H… | Phase1 | Osteoporosis | Completed | 2007-04-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00501930 | A Study to Evaluate and Study Drug Levels in Blood Plasma When Giving High Dose… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2007-04-01 | — | ClinicalTrials.gov |
| NCT00493818 | Open-label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynam… | Phase1 | Cancer | Terminated | 2007-04-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00493818 | Open-label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynam… | Phase1 | Cancer | Terminated | 2007-04-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00539942 | Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoi… | Phase3 | Venous Thrombosis | Terminated | 2007-04-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00473915 | Intranasal Steroids and the Nasal Ocular Response | Phase4 | Seasonal Allergic Rhinitis | Completed | 2007-04-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00540878 | A Study to Estimate the Effect of Formulation on the Relative Absorption of SB-… | Phase1 | Osteoporosis | Completed | 2007-04-01 | — | ClinicalTrials.gov |
| NCT00370682 | A Phase II Trial of a Live Attenuated Virus Tetravalent Dengue Vaccine in Healt… | Phase2 | Dengue | Completed | 2007-04-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00501930 | A Study to Evaluate and Study Drug Levels in Blood Plasma When Giving High Dose… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2007-04-01 | — | ClinicalTrials.gov |
| NCT00504816 | A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pil… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2007-04-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00405015 | The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Sci… | Phase2 | Ischemia-Reperfusion Injury | Completed | 2007-04-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00459056 | The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese… | Phase3 | Abdominal Obesity | Completed | 2007-04-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00725712 | Study of GSK1363089 in Metastatic Gastric Cancer | Phase2 | Neoplasms, Gastrointestinal Tract | Completed | 2007-03-31 | 2009-11-30 | ClinicalTrials.gov |
| NCT00725712 | Study of GSK1363089 in Metastatic Gastric Cancer | Phase2 | Neoplasms, Gastrointestinal Tract | Completed | 2007-03-31 | 2009-11-30 | ClinicalTrials.gov |
| NCT00464568 | A 5-way Treatment Period Trial of Single Doses of Intranasal GSK256066 in Patie… | Phase2 | Rhinitis, Allergic, Seasonal | Completed | 2007-03-28 | 2007-05-16 | ClinicalTrials.gov |
| NCT00464568 | A 5-way Treatment Period Trial of Single Doses of Intranasal GSK256066 in Patie… | Phase2 | Rhinitis, Allergic, Seasonal | Completed | 2007-03-28 | 2007-05-16 | ClinicalTrials.gov |
| NCT00453479 | A Dose Ascending, Study To Examine The Safety, Tolerability, Pharmacokinetics A… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-03-28 | 2007-10-11 | ClinicalTrials.gov |
| NCT00453479 | A Dose Ascending, Study To Examine The Safety, Tolerability, Pharmacokinetics A… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-03-28 | 2007-10-11 | ClinicalTrials.gov |
| NCT00555139 | A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects Wi… | Phase1 | Social Phobia | Completed | 2007-03-27 | 2008-01-10 | ClinicalTrials.gov |
| NCT00555139 | A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects Wi… | Phase1 | Social Phobia | Completed | 2007-03-27 | 2008-01-10 | ClinicalTrials.gov |
| NCT00443131 | Characterisation of the Immune Responses of 2 Experimental Malaria Vaccines | Phase2 | Malaria | Completed | 2007-03-26 | 2007-07-13 | ClinicalTrials.gov |
| NCT00443131 | Characterisation of the Immune Responses of 2 Experimental Malaria Vaccines | Phase2 | Malaria | Completed | 2007-03-26 | 2007-07-13 | ClinicalTrials.gov |
| NCT00449670 | Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic I… | Phase3 | Influenza | Completed | 2007-03-24 | 2008-06-10 | ClinicalTrials.gov |
| NCT00449670 | Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic I… | Phase3 | Influenza | Completed | 2007-03-24 | 2008-06-10 | ClinicalTrials.gov |
| NCT00405392 | Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronat… | Phase4 | Osteoporosis, Postmenopausal | Completed | 2007-03-22 | 2008-05-27 | ClinicalTrials.gov |
| NCT00405392 | Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronat… | Phase4 | Osteoporosis, Postmenopausal | Completed | 2007-03-22 | 2008-05-27 | ClinicalTrials.gov |
| NCT00468897 | A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs… | Phase1 | Alzheimer's Disease | Completed | 2007-03-21 | 2007-05-02 | ClinicalTrials.gov |
| NCT00468897 | A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs… | Phase1 | Alzheimer's Disease | Completed | 2007-03-21 | 2007-05-02 | ClinicalTrials.gov |
| NCT00437840 | A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809 | Phase1 | Substance Dependence | Completed | 2007-03-20 | 2007-06-20 | ClinicalTrials.gov |
| NCT00453440 | Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 | — | Infection, Human Immunodeficiency Virus | Completed | 2007-03-20 | 2007-08-10 | ClinicalTrials.gov |
| NCT00453440 | Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 | — | Infection, Human Immunodeficiency Virus | Completed | 2007-03-20 | 2007-08-10 | ClinicalTrials.gov |
| NCT00437840 | A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809 | Phase1 | Substance Dependence | Completed | 2007-03-20 | 2007-06-20 | ClinicalTrials.gov |
| NCT00441688 | Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infec… | Phase4 | Infection, Human Immunodeficiency Virus | Completed | 2007-03-15 | 2007-06-01 | ClinicalTrials.gov |
| NCT00441688 | Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infec… | Phase4 | Infection, Human Immunodeficiency Virus | Completed | 2007-03-15 | 2007-06-01 | ClinicalTrials.gov |
| NCT00459550 | A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK9337… | Phase1 | Alzheimer's Disease | Completed | 2007-03-12 | 2011-05-30 | ClinicalTrials.gov |
| NCT00459550 | A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK9337… | Phase1 | Alzheimer's Disease | Completed | 2007-03-12 | 2011-05-30 | ClinicalTrials.gov |
| NCT00453687 | A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK2… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-03-09 | 2007-05-16 | ClinicalTrials.gov |
| NCT00453687 | A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK2… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-03-09 | 2007-05-16 | ClinicalTrials.gov |
| NCT00424177 | Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Pur… | Phase2 | Purpura, Thrombocytopaenic, Idiopathic | Completed | 2007-03-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00449709 | A Study To Assess The Pharmacokinetics Of Different Modified Release Formulatio… | Phase1 | Obstetric Labour, Premature | Terminated | 2007-03-01 | — | ClinicalTrials.gov |
| NCT00450580 | HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in An… | Phase3 | Infection, Human Immunodeficiency Virus I | Completed | 2007-03-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00452686 | Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vac… | Phase3 | Diphtheria | Completed | 2007-03-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00517946 | A Study To Investigate If MRI Scanning Is Effective At Seeing What Hayfever Dru… | — | Seasonal Allergic Rhinitis | Completed | 2007-03-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00452686 | Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vac… | Phase3 | Diphtheria | Completed | 2007-03-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00450580 | HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in An… | Phase3 | Infection, Human Immunodeficiency Virus I | Completed | 2007-03-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00449709 | A Study To Assess The Pharmacokinetics Of Different Modified Release Formulatio… | Phase1 | Obstetric Labour, Premature | Terminated | 2007-03-01 | — | ClinicalTrials.gov |
| NCT00553878 | Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablatio… | Phase2 | Prostate Cancer | Completed | 2007-03-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00482391 | Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapat… | Phase2 | Breast Cancer | Completed | 2007-03-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00443053 | Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Dai… | Phase3 | Thrombosis, Venous | Completed | 2007-03-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00482391 | Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapat… | Phase2 | Breast Cancer | Completed | 2007-03-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00440947 | Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixe… | Phase3 | Infection, Human Immunodeficiency Virus I | Completed | 2007-03-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00517946 | A Study To Investigate If MRI Scanning Is Effective At Seeing What Hayfever Dru… | — | Seasonal Allergic Rhinitis | Completed | 2007-03-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00437632 | Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated A… | Phase1 | Substance Dependence | Completed | 2007-03-01 | 2008-08-22 | ClinicalTrials.gov |
| NCT00421421 | Effects Of Dutasteride On Risk Reduction Of Acute Urinary Retention Relapse Fol… | Phase4 | Benign Prostatic Hyperplasia | Terminated | 2007-03-01 | — | ClinicalTrials.gov |
| NCT00435838 | A Study of Patient Management in HIV-1 Infected Patients Found to Have the Gene… | — | HIV Infection | Completed | 2007-03-01 | — | ClinicalTrials.gov |
| NCT00460226 | Lamictal Bipolar Observational Study | — | Bipolar Disorder | Completed | 2007-03-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00460226 | Lamictal Bipolar Observational Study | — | Bipolar Disorder | Completed | 2007-03-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00553878 | Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablatio… | Phase2 | Prostate Cancer | Completed | 2007-03-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00424177 | Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Pur… | Phase2 | Purpura, Thrombocytopaenic, Idiopathic | Completed | 2007-03-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00435838 | A Study of Patient Management in HIV-1 Infected Patients Found to Have the Gene… | — | HIV Infection | Completed | 2007-03-01 | — | ClinicalTrials.gov |
| NCT00421421 | Effects Of Dutasteride On Risk Reduction Of Acute Urinary Retention Relapse Fol… | Phase4 | Benign Prostatic Hyperplasia | Terminated | 2007-03-01 | — | ClinicalTrials.gov |
| NCT00437632 | Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated A… | Phase1 | Substance Dependence | Completed | 2007-03-01 | 2008-08-22 | ClinicalTrials.gov |
| NCT02028676 | Efficacy Study of Different Laboratory Management Strategies and Drug Regimens … | Phase4 | Human Immunodeficiency Virus | Completed | 2007-03-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT00440947 | Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixe… | Phase3 | Infection, Human Immunodeficiency Virus I | Completed | 2007-03-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT02028676 | Efficacy Study of Different Laboratory Management Strategies and Drug Regimens … | Phase4 | Human Immunodeficiency Virus | Completed | 2007-03-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT00443053 | Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Dai… | Phase3 | Thrombosis, Venous | Completed | 2007-03-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00469040 | Safety, Blood Levels and Effects of GW642444 | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-02-28 | 2007-04-16 | ClinicalTrials.gov |
| NCT00469040 | Safety, Blood Levels and Effects of GW642444 | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2007-02-28 | 2007-04-16 | ClinicalTrials.gov |
| NCT00428090 | Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild T… | Phase3 | Alzheimer's Disease | Completed | 2007-02-27 | 2008-09-05 | ClinicalTrials.gov |
| NCT00428090 | Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild T… | Phase3 | Alzheimer's Disease | Completed | 2007-02-27 | 2008-09-05 | ClinicalTrials.gov |
| NCT00435396 | Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-s… | Phase1 | Infections, Cytomegalovirus | Completed | 2007-02-22 | 2008-08-27 | ClinicalTrials.gov |
| NCT00435396 | Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-s… | Phase1 | Infections, Cytomegalovirus | Completed | 2007-02-22 | 2008-08-27 | ClinicalTrials.gov |
| NCT00434512 | Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732… | Phase2 | AIDS | Completed | 2007-02-20 | 2008-06-13 | ClinicalTrials.gov |
| NCT00434512 | Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732… | Phase2 | AIDS | Completed | 2007-02-20 | 2008-06-13 | ClinicalTrials.gov |
| NCT00434577 | Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects | Phase2 | Herpes Zoster | Completed | 2007-02-14 | 2010-07-14 | ClinicalTrials.gov |
| NCT00434577 | Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects | Phase2 | Herpes Zoster | Completed | 2007-02-14 | 2010-07-14 | ClinicalTrials.gov |
| NCT00426361 | Evaluation of Safety and Immunogenicity of Co-administering Human Papillomaviru… | Phase3 | Infections, Papillomavirus | Completed | 2007-02-13 | 2008-07-25 | ClinicalTrials.gov |
| NCT00426361 | Evaluation of Safety and Immunogenicity of Co-administering Human Papillomaviru… | Phase3 | Infections, Papillomavirus | Completed | 2007-02-13 | 2008-07-25 | ClinicalTrials.gov |
| NCT00420316 | Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming W… | Phase3 | Infections, Rotavirus | Completed | 2007-02-12 | 2007-08-08 | ClinicalTrials.gov |
| NCT00420316 | Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming W… | Phase3 | Infections, Rotavirus | Completed | 2007-02-12 | 2007-08-08 | ClinicalTrials.gov |
| NCT00427908 | Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of … | Phase2 | Infections, Meningococcal | Completed | 2007-02-07 | 2007-12-03 | ClinicalTrials.gov |
| NCT00427908 | Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of … | Phase2 | Infections, Meningococcal | Completed | 2007-02-07 | 2007-12-03 | ClinicalTrials.gov |
| NCT00412191 | Bioequivalence And Lack Of Food Effects Of 300mg Lamotrigine XR | Phase1 | Epilepsy | Completed | 2007-02-06 | 2007-04-27 | ClinicalTrials.gov |
| NCT00412191 | Bioequivalence And Lack Of Food Effects Of 300mg Lamotrigine XR | Phase1 | Epilepsy | Completed | 2007-02-06 | 2007-04-27 | ClinicalTrials.gov |
| NCT00430521 | Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pa… | Phase2 | Influenza | Completed | 2007-02-05 | 2008-10-20 | ClinicalTrials.gov |
| NCT00430521 | Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pa… | Phase2 | Influenza | Completed | 2007-02-05 | 2008-10-20 | ClinicalTrials.gov |
| NCT00390143 | Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Bi… | Phase2 | Infections, Meningococcal | Completed | 2007-02-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00501397 | A Study of the Effects of Ketoconazole Taken Orally Has on the PK Profiles of a… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2007-02-01 | — | ClinicalTrials.gov |
| NCT00501397 | A Study of the Effects of Ketoconazole Taken Orally Has on the PK Profiles of a… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2007-02-01 | — | ClinicalTrials.gov |
| NCT00450892 | Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer | Phase1 | Breast Cancer | Completed | 2007-02-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT00541320 | Phase IIa Venous Thromboembolism (VTE) Prevention Study In Total Knee Replaceme… | Phase2 | Venous Thromboembolism | Withdrawn | 2007-02-01 | — | ClinicalTrials.gov |
| NCT00548418 | Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer | Phase2 | Cervical Cancer | Completed | 2007-02-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00643929 | LENS - Long-term Eltrombopag Observational Study | — | Purpura, Thrombocytopaenic, Idiopathic | Completed | 2007-02-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00436787 | Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication … | Phase2 | Venous Thrombosis | Completed | 2007-02-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00541320 | Phase IIa Venous Thromboembolism (VTE) Prevention Study In Total Knee Replaceme… | Phase2 | Venous Thromboembolism | Withdrawn | 2007-02-01 | — | ClinicalTrials.gov |
| NCT00434629 | Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-C… | Phase1 | B-cell Lymphoma | Completed | 2007-02-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT00548418 | Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer | Phase2 | Cervical Cancer | Completed | 2007-02-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00430040 | Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI. | Phase4 | Diabetes Mellitus, Type 2 | Terminated | 2007-02-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT00752167 | Diagnosis of Exercise-induced Bronchospasm (EIB) and Asthma in National Collegi… | — | Exercise Induced Bronchospasm, Asthma | Completed | 2007-02-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00424281 | Effectiveness of Blood Clot Medication With Concomitant Blood Pressure Medicati… | — | ICU Patients 18 Years or Older. | Unknown | 2007-02-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00643929 | LENS - Long-term Eltrombopag Observational Study | — | Purpura, Thrombocytopaenic, Idiopathic | Completed | 2007-02-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00421343 | Secondary Prevention of Osteoporosis | Phase3 | Osteoporosis | Completed | 2007-02-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00752167 | Diagnosis of Exercise-induced Bronchospasm (EIB) and Asthma in National Collegi… | — | Exercise Induced Bronchospasm, Asthma | Completed | 2007-02-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00450892 | Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer | Phase1 | Breast Cancer | Completed | 2007-02-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT00390143 | Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Bi… | Phase2 | Infections, Meningococcal | Completed | 2007-02-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00436787 | Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication … | Phase2 | Venous Thrombosis | Completed | 2007-02-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00434629 | Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-C… | Phase1 | B-cell Lymphoma | Completed | 2007-02-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT00430040 | Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI. | Phase4 | Diabetes Mellitus, Type 2 | Terminated | 2007-02-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT00424281 | Effectiveness of Blood Clot Medication With Concomitant Blood Pressure Medicati… | — | ICU Patients 18 Years or Older. | Unknown | 2007-02-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00421343 | Secondary Prevention of Osteoporosis | Phase3 | Osteoporosis | Completed | 2007-02-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00461682 | Sb-705498 Rectal Pain Study | Phase2 | Irritable Colon | Terminated | 2007-01-26 | 2007-09-01 | ClinicalTrials.gov |
| NCT00461682 | Sb-705498 Rectal Pain Study | Phase2 | Irritable Colon | Terminated | 2007-01-26 | 2007-09-01 | ClinicalTrials.gov |
| NCT00423046 | Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vacci… | Phase3 | Infections, Papillomavirus | Completed | 2007-01-24 | 2012-05-14 | ClinicalTrials.gov |
| NCT00423046 | Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vacci… | Phase3 | Infections, Papillomavirus | Completed | 2007-01-24 | 2012-05-14 | ClinicalTrials.gov |
| NCT00500331 | Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM) | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2007-01-23 | 2008-02-14 | ClinicalTrials.gov |
| NCT00396630 | A Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vacc… | Phase3 | Infections, Rotavirus | Completed | 2007-01-23 | 2008-02-13 | ClinicalTrials.gov |
| NCT00396630 | A Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vacc… | Phase3 | Infections, Rotavirus | Completed | 2007-01-23 | 2008-02-13 | ClinicalTrials.gov |
| NCT00500331 | Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM) | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2007-01-23 | 2008-02-14 | ClinicalTrials.gov |
| NCT00470483 | A Study To Compare Emotional Changes In Subjects With Social Anxiety Disorder | Phase1 | Social Phobia | Completed | 2007-01-22 | 2009-01-07 | ClinicalTrials.gov |
| NCT00470483 | A Study To Compare Emotional Changes In Subjects With Social Anxiety Disorder | Phase1 | Social Phobia | Completed | 2007-01-22 | 2009-01-07 | ClinicalTrials.gov |
| NCT00440323 | Disturbed Sleep Model Study. | Phase1 | Sleep Initiation and Maintenance Disorders | Completed | 2007-01-05 | 2007-07-03 | ClinicalTrials.gov |
| NCT00440323 | Disturbed Sleep Model Study. | Phase1 | Sleep Initiation and Maintenance Disorders | Completed | 2007-01-05 | 2007-07-03 | ClinicalTrials.gov |
| NCT00412854 | Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs… | Phase3 | Tetanus | Completed | 2007-01-03 | 2007-06-25 | ClinicalTrials.gov |
| NCT00412854 | Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs… | Phase3 | Tetanus | Completed | 2007-01-03 | 2007-06-25 | ClinicalTrials.gov |
| NCT00380393 | Efficacy of RTS,S/AS01 Vaccine Against Episodes of Malaria Due to P. Falciparum… | Phase2 | Malaria | Completed | 2007-01-03 | 2008-11-11 | ClinicalTrials.gov |
| NCT00380393 | Efficacy of RTS,S/AS01 Vaccine Against Episodes of Malaria Due to P. Falciparum… | Phase2 | Malaria | Completed | 2007-01-03 | 2008-11-11 | ClinicalTrials.gov |
| NCT00916149 | Cognitive Effects of Treatment of Interictal Discharges | Na | Epilepsy | Completed | 2007-01-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00410163 | Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients | Phase2 | Leukaemia, Lymphocytic, Chronic | Completed | 2007-01-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT00397839 | The Effect Of Oral Ibandronate In Male Osteoporosis | Phase3 | Male Osteoporosis | Completed | 2007-01-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00460915 | Efficacy and Safety of Lacidipine and Amlodipine on Blood Pressure in Korean IS… | Phase4 | Hypertension | Completed | 2007-01-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00441675 | A Long Term Prospective Follow Up Study For The CATO Study (SAS30018/SER9702) | — | Asthma | Completed | 2007-01-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00916149 | Cognitive Effects of Treatment of Interictal Discharges | Na | Epilepsy | Completed | 2007-01-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00329745 | Year 3 Extension for Efficacy Follow-up in Subjects Vaccinated in Studies Rota-… | Phase3 | Infections, Rotavirus | Completed | 2007-01-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00421720 | A Study Comparing Two Analgesia/Sedation Regimens, Remifentanil/Propofol Versus… | Phase4 | Analgesia | Terminated | 2007-01-01 | — | ClinicalTrials.gov |
| NCT00423683 | Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous… | Phase3 | Cancer | Terminated | 2007-01-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00424034 | A Study of GSK1325760A in Healthy Japanese Subjects | Phase1 | Healthy Subjects | Completed | 2007-01-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00579436 | Effects of Fish Oils on Inflammation and Insulin Resistance | Na | Metabolic Syndrome | Completed | 2007-01-01 | 2015-01-15 | ClinicalTrials.gov |
| NCT01390792 | Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis) | — | Influenza, Human | Completed | 2007-01-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00430157 | Trial With Allergic Rhinitis Patients Taking GSK256066 Versus Placebo In A Poll… | Phase2 | Rhinitis, Allergic, Seasonal | Completed | 2007-01-01 | — | ClinicalTrials.gov |
| NCT00460915 | Efficacy and Safety of Lacidipine and Amlodipine on Blood Pressure in Korean IS… | Phase4 | Hypertension | Completed | 2007-01-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00430157 | Trial With Allergic Rhinitis Patients Taking GSK256066 Versus Placebo In A Poll… | Phase2 | Rhinitis, Allergic, Seasonal | Completed | 2007-01-01 | — | ClinicalTrials.gov |
| NCT00424034 | A Study of GSK1325760A in Healthy Japanese Subjects | Phase1 | Healthy Subjects | Completed | 2007-01-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00423683 | Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous… | Phase3 | Cancer | Terminated | 2007-01-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00421720 | A Study Comparing Two Analgesia/Sedation Regimens, Remifentanil/Propofol Versus… | Phase4 | Analgesia | Terminated | 2007-01-01 | — | ClinicalTrials.gov |
| NCT00329745 | Year 3 Extension for Efficacy Follow-up in Subjects Vaccinated in Studies Rota-… | Phase3 | Infections, Rotavirus | Completed | 2007-01-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00579436 | Effects of Fish Oils on Inflammation and Insulin Resistance | Na | Metabolic Syndrome | Completed | 2007-01-01 | 2015-01-15 | ClinicalTrials.gov |
| NCT01390792 | Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis) | — | Influenza, Human | Completed | 2007-01-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00410163 | Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients | Phase2 | Leukaemia, Lymphocytic, Chronic | Completed | 2007-01-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT00406562 | Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (B… | Phase3 | Tetanus | Completed | 2007-01-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00441675 | A Long Term Prospective Follow Up Study For The CATO Study (SAS30018/SER9702) | — | Asthma | Completed | 2007-01-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00404261 | Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter I… | Phase4 | Asthma | Completed | 2007-01-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00397839 | The Effect Of Oral Ibandronate In Male Osteoporosis | Phase3 | Male Osteoporosis | Completed | 2007-01-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00490490 | Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy | Phase2 | Lymphoma, Non-Hodgkin | Terminated | 2007-01-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT00490490 | Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy | Phase2 | Lymphoma, Non-Hodgkin | Terminated | 2007-01-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT00460070 | Study of Hormonal Sideeffects in Patients Taking Levetiracetam, Carbamazepine o… | — | Epilepsy | Completed | 2007-01-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00404261 | Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter I… | Phase4 | Asthma | Completed | 2007-01-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00460070 | Study of Hormonal Sideeffects in Patients Taking Levetiracetam, Carbamazepine o… | — | Epilepsy | Completed | 2007-01-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00406562 | Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (B… | Phase3 | Tetanus | Completed | 2007-01-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00410371 | Study to Compare Two Formulations of Lamotrigine in Healthy Subjects | Phase1 | Mental Disorders | Completed | 2006-12-28 | 2007-01-25 | ClinicalTrials.gov |
| NCT00410371 | Study to Compare Two Formulations of Lamotrigine in Healthy Subjects | Phase1 | Mental Disorders | Completed | 2006-12-28 | 2007-01-25 | ClinicalTrials.gov |
| NCT00356369 | Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Yea… | Phase2 | Infections, Meningococcal | Completed | 2006-12-23 | 2008-02-28 | ClinicalTrials.gov |
| NCT00356369 | Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Yea… | Phase2 | Infections, Meningococcal | Completed | 2006-12-23 | 2008-02-28 | ClinicalTrials.gov |
| NCT00435461 | Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine | Phase4 | Rhinitis, Allergic, Seasonal | Completed | 2006-12-20 | 2007-02-28 | ClinicalTrials.gov |
| NCT00435461 | Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine | Phase4 | Rhinitis, Allergic, Seasonal | Completed | 2006-12-20 | 2007-02-28 | ClinicalTrials.gov |
| NCT00420641 | MDD POC Study GSK372475 Subjects Depressive Disease | Phase2 | Depressive Disorder | Completed | 2006-12-19 | 2008-10-15 | ClinicalTrials.gov |
| NCT00420641 | MDD POC Study GSK372475 Subjects Depressive Disease | Phase2 | Depressive Disorder | Completed | 2006-12-19 | 2008-10-15 | ClinicalTrials.gov |
| NCT00441116 | A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6… | Phase3 | Alopecia | Completed | 2006-12-15 | 2008-01-21 | ClinicalTrials.gov |
| NCT00441116 | A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6… | Phase3 | Alopecia | Completed | 2006-12-15 | 2008-01-21 | ClinicalTrials.gov |
| NCT00385099 | Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome | Phase2 | Irritable Colon | Completed | 2006-12-08 | 2007-10-15 | ClinicalTrials.gov |
| NCT00385099 | Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome | Phase2 | Irritable Colon | Completed | 2006-12-08 | 2007-10-15 | ClinicalTrials.gov |
| NCT00370513 | A Phase I Study of Pazopanib in Adult Patients With Liver Cancer | Phase1 | Carcinoma, Hepatocellular | Completed | 2006-12-06 | 2009-04-08 | ClinicalTrials.gov |
| NCT00370513 | A Phase I Study of Pazopanib in Adult Patients With Liver Cancer | Phase1 | Carcinoma, Hepatocellular | Completed | 2006-12-06 | 2009-04-08 | ClinicalTrials.gov |
| NCT00346749 | ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISK… | Phase4 | Pulmonary Disease, Chronic Obstructive | Terminated | 2006-12-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00411073 | Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of … | Phase1 | Atherosclerosis | Completed | 2006-12-01 | — | ClinicalTrials.gov |
| NCT00398476 | Fluticasone Nasal Spray Patient Preference Study | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2006-12-01 | 2006-12-04 | ClinicalTrials.gov |
| NCT00410384 | A Study of Belimumab in Subjects With Systemic Lupus Erythematosus | Phase3 | Systemic Lupus Erythematosus | Completed | 2006-12-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00382993 | A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in M… | Phase3 | Migraine Disorders | Completed | 2006-12-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00411697 | Persistence of Hepatitis B Antibody Levels & Immune Response to a Hepatitis B V… | Phase4 | Hepatitis B | Completed | 2006-12-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00411073 | Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of … | Phase1 | Atherosclerosis | Completed | 2006-12-01 | — | ClinicalTrials.gov |
| NCT00410384 | A Study of Belimumab in Subjects With Systemic Lupus Erythematosus | Phase3 | Systemic Lupus Erythematosus | Completed | 2006-12-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00398476 | Fluticasone Nasal Spray Patient Preference Study | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2006-12-01 | 2006-12-04 | ClinicalTrials.gov |
| NCT00346749 | ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISK… | Phase4 | Pulmonary Disease, Chronic Obstructive | Terminated | 2006-12-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00423761 | An Investigation To Determine The Potential Interaction Effect Between GW876008… | Phase1 | Healthy Subjects | Completed | 2006-12-01 | — | ClinicalTrials.gov |
| NCT00424255 | Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Su… | Phase3 | Neoplasms, Head and Neck | Completed | 2006-12-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT00370032 | Study to Assess the Effect Of Alosetron On Mucosal Blood Flow | Phase4 | Irritable Colon | Completed | 2006-12-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00441974 | Adefovir Dipivoxil For The Treatment Of Chinese Compensated Chronic Hepatitis B… | Phase4 | Chronic Hepatitis B | Completed | 2006-12-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00390806 | Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastas… | Phase3 | Lung Cancer, Non-Small Cell | Completed | 2006-12-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT00426816 | To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Pri… | Phase2 | Sleep Initiation and Maintenance Disorders | Completed | 2006-12-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00426816 | To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Pri… | Phase2 | Sleep Initiation and Maintenance Disorders | Completed | 2006-12-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00370032 | Study to Assess the Effect Of Alosetron On Mucosal Blood Flow | Phase4 | Irritable Colon | Completed | 2006-12-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00350727 | Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Maligna… | Phase2 | Glioma | Completed | 2006-12-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00423761 | An Investigation To Determine The Potential Interaction Effect Between GW876008… | Phase1 | Healthy Subjects | Completed | 2006-12-01 | — | ClinicalTrials.gov |
| NCT00392743 | A Study to Compare Two Different Brain Imaging Techniques in Healthy Volunteers… | — | Schizophrenia | Completed | 2006-12-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00394056 | Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And… | Phase2 | Tinnitus | Completed | 2006-12-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00394056 | Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And… | Phase2 | Tinnitus | Completed | 2006-12-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00390806 | Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastas… | Phase3 | Lung Cancer, Non-Small Cell | Completed | 2006-12-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT00392743 | A Study to Compare Two Different Brain Imaging Techniques in Healthy Volunteers… | — | Schizophrenia | Completed | 2006-12-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00382993 | A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in M… | Phase3 | Migraine Disorders | Completed | 2006-12-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00424255 | Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Su… | Phase3 | Neoplasms, Head and Neck | Completed | 2006-12-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT00350727 | Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Maligna… | Phase2 | Glioma | Completed | 2006-12-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00368303 | A Local Register Study For Major Depression Of Paroxetine Controlled Release | Phase3 | Depressive Disorder, Major | Completed | 2006-12-01 | — | ClinicalTrials.gov |
| NCT00368303 | A Local Register Study For Major Depression Of Paroxetine Controlled Release | Phase3 | Depressive Disorder, Major | Completed | 2006-12-01 | — | ClinicalTrials.gov |
| NCT00411697 | Persistence of Hepatitis B Antibody Levels & Immune Response to a Hepatitis B V… | Phase4 | Hepatitis B | Completed | 2006-12-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00395317 | Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Mul… | Phase2 | Multiple Sclerosis | Completed | 2006-12-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00441974 | Adefovir Dipivoxil For The Treatment Of Chinese Compensated Chronic Hepatitis B… | Phase4 | Chronic Hepatitis B | Completed | 2006-12-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00395317 | Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Mul… | Phase2 | Multiple Sclerosis | Completed | 2006-12-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00353366 | To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine … | — | Infections, Rotavirus | Completed | 2006-11-16 | 2010-07-17 | ClinicalTrials.gov |
| NCT00353366 | To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine … | — | Infections, Rotavirus | Completed | 2006-11-16 | 2010-07-17 | ClinicalTrials.gov |
| NCT00397943 | Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 G… | Phase2 | Tuberculosis | Completed | 2006-11-15 | 2009-12-01 | ClinicalTrials.gov |
| NCT00398645 | A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Dr… | Phase2 | Asthma | Completed | 2006-11-15 | 2007-08-30 | ClinicalTrials.gov |
| NCT00398645 | A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Dr… | Phase2 | Asthma | Completed | 2006-11-15 | 2007-08-30 | ClinicalTrials.gov |
| NCT00397943 | Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 G… | Phase2 | Tuberculosis | Completed | 2006-11-15 | 2009-12-01 | ClinicalTrials.gov |
| NCT00397722 | Treatment Of Patients With Social Anxiety Disorder | Phase2 | Social Phobia | Completed | 2006-11-09 | 2007-09-05 | ClinicalTrials.gov |
| NCT00397722 | Treatment Of Patients With Social Anxiety Disorder | Phase2 | Social Phobia | Completed | 2006-11-09 | 2007-09-05 | ClinicalTrials.gov |
| NCT00372112 | A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chro… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2006-11-03 | 2007-05-10 | ClinicalTrials.gov |
| NCT00372112 | A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chro… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2006-11-03 | 2007-05-10 | ClinicalTrials.gov |
| NCT00383123 | Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza… | Phase3 | Influenza | Completed | 2006-11-02 | 2007-10-19 | ClinicalTrials.gov |
| NCT00383123 | Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza… | Phase3 | Influenza | Completed | 2006-11-02 | 2007-10-19 | ClinicalTrials.gov |
| NCT00429728 | A Study To Investigate The Metabolism Of GW876008 In Smokers Compared To Non-Sm… | Phase1 | Healthy Subjects | Completed | 2006-11-01 | — | ClinicalTrials.gov |
| NCT00408785 | A Study Of BOTOX For The Treatment Of Glabellar Lines | Phase3 | Glabellar Lines | Completed | 2006-11-01 | 2007-05-09 | ClinicalTrials.gov |
| NCT00435695 | Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using … | Phase1 | Healthy Subjects | Completed | 2006-11-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00387127 | Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In … | Phase2 | Neoplasms, Head and Neck | Completed | 2006-11-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT00429728 | A Study To Investigate The Metabolism Of GW876008 In Smokers Compared To Non-Sm… | Phase1 | Healthy Subjects | Completed | 2006-11-01 | — | ClinicalTrials.gov |
| NCT00448890 | Evaluation of Single and Repeat Doses of GSK729327 in Healthy Volunteers | Phase1 | Schizophrenia | Completed | 2006-11-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00430781 | Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Sub… | Phase2 | Neoplasms, Uterine Cervix | Completed | 2006-11-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00430781 | Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Sub… | Phase2 | Neoplasms, Uterine Cervix | Completed | 2006-11-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00370331 | RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) … | Phase3 | Purpura, Thrombocytopaenic, Idiopathic | Completed | 2006-11-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00383162 | A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in M… | Phase3 | Migraine Disorders | Completed | 2006-11-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00448890 | Evaluation of Single and Repeat Doses of GSK729327 in Healthy Volunteers | Phase1 | Schizophrenia | Completed | 2006-11-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00402363 | Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recu… | Phase3 | Fibrillation, Atrial | Completed | 2006-11-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00399243 | Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache | Phase4 | Episodic Cluster Headache | Unknown | 2006-11-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00383162 | A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in M… | Phase3 | Migraine Disorders | Completed | 2006-11-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00367679 | Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Ce… | Phase2 | Non-Small Cell Lung Cancer | Completed | 2006-11-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT01029015 | Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time… | — | Bladder Function | Completed | 2006-11-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00807014 | Evaluation of Quality of Life, Efficacy, and Tolerance of Duac® Gel Compared to… | Phase4 | Acne Vulgaris | Completed | 2006-11-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00366080 | Effectiveness Of The Drug GSK189254 In Treating Patients With Narcolepsy | Phase2 | Narcolepsy | Terminated | 2006-11-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00443170 | A Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of O… | Phase1 | Healthy Subjects | Completed | 2006-11-01 | — | ClinicalTrials.gov |
| NCT00443170 | A Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of O… | Phase1 | Healthy Subjects | Completed | 2006-11-01 | — | ClinicalTrials.gov |
| NCT00387127 | Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In … | Phase2 | Neoplasms, Head and Neck | Completed | 2006-11-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT00399165 | Oral Androgens in Man-4: (Short Title: Oral T-4) | Phase1 | Contraception | Completed | 2006-11-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00411814 | A Study Of GSK679586A When Infused Into Healthy And Mild Asthmatic Volunteers | Phase1 | Asthma | Completed | 2006-11-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00411372 | Shortness Of Breath Questionnaire Validation Study | Phase3 | Pulmonary Disease, Chronic Obstructive | Withdrawn | 2006-11-01 | — | ClinicalTrials.gov |
| NCT00398125 | Monotherapy Versus Placebo Over 10 Days in Integrase Naive HIV-1 Infected Adults | Phase2 | Infection, Human Immunodeficiency Virus | Completed | 2006-11-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT01029015 | Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time… | — | Bladder Function | Completed | 2006-11-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00376896 | Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndr… | Phase1 | Irritable Colon | Completed | 2006-11-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00408785 | A Study Of BOTOX For The Treatment Of Glabellar Lines | Phase3 | Glabellar Lines | Completed | 2006-11-01 | 2007-05-09 | ClinicalTrials.gov |
| NCT00411372 | Shortness Of Breath Questionnaire Validation Study | Phase3 | Pulmonary Disease, Chronic Obstructive | Withdrawn | 2006-11-01 | — | ClinicalTrials.gov |
| NCT00435695 | Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using … | Phase1 | Healthy Subjects | Completed | 2006-11-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00404274 | A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking War… | Phase1 | Nausea and Vomiting, Chemotherapy-Induced | Completed | 2006-11-01 | 2007-03-18 | ClinicalTrials.gov |
| NCT00370331 | RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) … | Phase3 | Purpura, Thrombocytopaenic, Idiopathic | Completed | 2006-11-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00411814 | A Study Of GSK679586A When Infused Into Healthy And Mild Asthmatic Volunteers | Phase1 | Asthma | Completed | 2006-11-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT01150981 | Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue | Phase2 | Metabolic Syndrome | Completed | 2006-11-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00402363 | Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recu… | Phase3 | Fibrillation, Atrial | Completed | 2006-11-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00366080 | Effectiveness Of The Drug GSK189254 In Treating Patients With Narcolepsy | Phase2 | Narcolepsy | Terminated | 2006-11-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00807014 | Evaluation of Quality of Life, Efficacy, and Tolerance of Duac® Gel Compared to… | Phase4 | Acne Vulgaris | Completed | 2006-11-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00399243 | Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache | Phase4 | Episodic Cluster Headache | Unknown | 2006-11-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00399165 | Oral Androgens in Man-4: (Short Title: Oral T-4) | Phase1 | Contraception | Completed | 2006-11-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT01150981 | Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue | Phase2 | Metabolic Syndrome | Completed | 2006-11-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00404274 | A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking War… | Phase1 | Nausea and Vomiting, Chemotherapy-Induced | Completed | 2006-11-01 | 2007-03-18 | ClinicalTrials.gov |
| NCT00398125 | Monotherapy Versus Placebo Over 10 Days in Integrase Naive HIV-1 Infected Adults | Phase2 | Infection, Human Immunodeficiency Virus | Completed | 2006-11-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00376896 | Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndr… | Phase1 | Irritable Colon | Completed | 2006-11-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00367679 | Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Ce… | Phase2 | Non-Small Cell Lung Cancer | Completed | 2006-11-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00385840 | Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With th… | Phase2 | Influenza | Completed | 2006-10-20 | 2007-02-05 | ClinicalTrials.gov |
| NCT00404378 | Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The … | Phase1 | Nausea and Vomiting, Chemotherapy-Induced | Completed | 2006-10-20 | 2007-01-05 | ClinicalTrials.gov |
| NCT00404378 | Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The … | Phase1 | Nausea and Vomiting, Chemotherapy-Induced | Completed | 2006-10-20 | 2007-01-05 | ClinicalTrials.gov |
| NCT00385840 | Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With th… | Phase2 | Influenza | Completed | 2006-10-20 | 2007-02-05 | ClinicalTrials.gov |
| NCT00411190 | Study To Determine The Effects Of Doses Of Relacatib On The Metabolism Of Aceta… | Phase1 | Osteoarthritis | Completed | 2006-10-19 | 2006-12-15 | ClinicalTrials.gov |
| NCT00411190 | Study To Determine The Effects Of Doses Of Relacatib On The Metabolism Of Aceta… | Phase1 | Osteoarthritis | Completed | 2006-10-19 | 2006-12-15 | ClinicalTrials.gov |
| NCT00386113 | Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuv… | Phase2 | Influenza | Completed | 2006-10-16 | 2006-11-14 | ClinicalTrials.gov |
| NCT00386113 | Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuv… | Phase2 | Influenza | Completed | 2006-10-16 | 2006-11-14 | ClinicalTrials.gov |
| NCT00421707 | Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 … | Phase2 | Irritable Bowel Syndrome (IBS) | Completed | 2006-10-14 | 2008-06-25 | ClinicalTrials.gov |
| NCT00421707 | Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 … | Phase2 | Irritable Bowel Syndrome (IBS) | Completed | 2006-10-14 | 2008-06-25 | ClinicalTrials.gov |
| NCT00411866 | Effects Of The Drug Ketoconazole On How The Body Handles The Drug SB773812 | Phase1 | Schizophrenia | Completed | 2006-10-13 | 2007-10-10 | ClinicalTrials.gov |
| NCT00411866 | Effects Of The Drug Ketoconazole On How The Body Handles The Drug SB773812 | Phase1 | Schizophrenia | Completed | 2006-10-13 | 2007-10-10 | ClinicalTrials.gov |
| NCT00426608 | To Investigate Effects GSK561679 on Part of the Body's System That Controls the… | Phase1 | Depressive Disorder and Anxiety Disorders | Completed | 2006-10-06 | 2007-01-08 | ClinicalTrials.gov |
| NCT00426608 | To Investigate Effects GSK561679 on Part of the Body's System That Controls the… | Phase1 | Depressive Disorder and Anxiety Disorders | Completed | 2006-10-06 | 2007-01-08 | ClinicalTrials.gov |
| NCT00377611 | Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 … | Phase4 | Influenza | Completed | 2006-10-05 | 2007-06-20 | ClinicalTrials.gov |
| NCT00377611 | Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 … | Phase4 | Influenza | Completed | 2006-10-05 | 2007-06-20 | ClinicalTrials.gov |
| NCT00374842 | Study to Evaluate the Immunogenicity and Safety of 2 Formulations of GlaxoSmith… | Phase2 | Influenza | Completed | 2006-10-03 | 2006-11-30 | ClinicalTrials.gov |
| NCT00374842 | Study to Evaluate the Immunogenicity and Safety of 2 Formulations of GlaxoSmith… | Phase2 | Influenza | Completed | 2006-10-03 | 2006-11-30 | ClinicalTrials.gov |
| NCT00387413 | A Study Of GSK189254 And Duloxetine In The Electrical Hyperalgesia Model Of Hea… | Phase1 | Hyperalgesia | Completed | 2006-10-02 | 2007-05-31 | ClinicalTrials.gov |
| NCT00363077 | Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza … | Phase2 | Influenza | Completed | 2006-10-02 | 2006-11-17 | ClinicalTrials.gov |
| NCT00387413 | A Study Of GSK189254 And Duloxetine In The Electrical Hyperalgesia Model Of Hea… | Phase1 | Hyperalgesia | Completed | 2006-10-02 | 2007-05-31 | ClinicalTrials.gov |
| NCT00363077 | Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza … | Phase2 | Influenza | Completed | 2006-10-02 | 2006-11-17 | ClinicalTrials.gov |
| NCT00439881 | A Study To Look At The Safety Of SB-681323 In Healthy Adult Subjects After Intr… | Phase1 | Arthritis, Rheumatoid | Completed | 2006-10-01 | — | ClinicalTrials.gov |
| NCT00437242 | Odiparcil QT Definitive Study | Phase1 | Fibrillation, Atrial | Terminated | 2006-10-01 | — | ClinicalTrials.gov |
| NCT00386347 | A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjec… | Phase1 | HIV Infection | Completed | 2006-10-01 | — | ClinicalTrials.gov |
| NCT00387257 | Effect Of Rilapladib (SB-659032) On Platelet Aggregation | Phase1 | Healthy Subjects | Completed | 2006-10-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00404066 | Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatini… | Phase2 | Breast Cancer | Completed | 2006-10-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00404066 | Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatini… | Phase2 | Breast Cancer | Completed | 2006-10-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00395239 | Asthma/Steroid Withdrawal Study | Phase4 | Asthma | Terminated | 2006-10-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT00457925 | Absorption, Distribution, Metabolism And Excretion Study For GSK221149A | Phase1 | Obstetric Labour, Premature | Completed | 2006-10-01 | — | ClinicalTrials.gov |
| NCT00395239 | Asthma/Steroid Withdrawal Study | Phase4 | Asthma | Terminated | 2006-10-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT00400608 | A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spa… | Phase4 | Asthma | Completed | 2006-10-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00487578 | Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognit… | Phase4 | Post Traumatic Headache | Terminated | 2006-10-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00457925 | Absorption, Distribution, Metabolism And Excretion Study For GSK221149A | Phase1 | Obstetric Labour, Premature | Completed | 2006-10-01 | — | ClinicalTrials.gov |
| NCT00439881 | A Study To Look At The Safety Of SB-681323 In Healthy Adult Subjects After Intr… | Phase1 | Arthritis, Rheumatoid | Completed | 2006-10-01 | — | ClinicalTrials.gov |
| NCT00422604 | Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Compara… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2006-10-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00390910 | Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Con… | Phase3 | Infections, Streptococcal | Completed | 2006-10-01 | 2008-05-02 | ClinicalTrials.gov |
| NCT00400335 | Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone … | Phase1 | Hypogonadism | Completed | 2006-10-01 | — | ClinicalTrials.gov |
| NCT00401479 | A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal … | Phase1 | Irritable Bowel Syndrome (IBS) | Completed | 2006-10-01 | — | ClinicalTrials.gov |
| NCT00401479 | A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal … | Phase1 | Irritable Bowel Syndrome (IBS) | Completed | 2006-10-01 | — | ClinicalTrials.gov |
| NCT00444769 | Dental Pain 3rd Molar Tooth Extraction GW842166 | Phase2 | Pain | Completed | 2006-10-01 | — | ClinicalTrials.gov |
| NCT00400608 | A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spa… | Phase4 | Asthma | Completed | 2006-10-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00444769 | Dental Pain 3rd Molar Tooth Extraction GW842166 | Phase2 | Pain | Completed | 2006-10-01 | — | ClinicalTrials.gov |
| NCT00487578 | Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognit… | Phase4 | Post Traumatic Headache | Terminated | 2006-10-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00422604 | Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Compara… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2006-10-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00393146 | A Study To Investigate The Effect Of 28 Days Of Dosing With GW856553 On Patient… | Phase2 | Arthritis, Rheumatoid | Completed | 2006-10-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00376779 | Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Mon… | Phase2 | Acellular Pertussis | Completed | 2006-10-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00386347 | A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjec… | Phase1 | HIV Infection | Completed | 2006-10-01 | — | ClinicalTrials.gov |
| NCT00390910 | Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Con… | Phase3 | Infections, Streptococcal | Completed | 2006-10-01 | 2008-05-02 | ClinicalTrials.gov |
| NCT00393146 | A Study To Investigate The Effect Of 28 Days Of Dosing With GW856553 On Patient… | Phase2 | Arthritis, Rheumatoid | Completed | 2006-10-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00346697 | Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients | Phase4 | HIV Infections | Completed | 2006-10-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00387257 | Effect Of Rilapladib (SB-659032) On Platelet Aggregation | Phase1 | Healthy Subjects | Completed | 2006-10-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00398580 | 28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men | Phase2 | Hypogonadism | Completed | 2006-10-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00426751 | Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary… | Phase3 | Infarction, Myocardial | Completed | 2006-10-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00373542 | 12-week Polysomnography Study of Ropinirole Controlled Release for Restless Leg… | Phase4 | Restless Legs Syndrome (RLS) | Completed | 2006-10-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00427141 | A Three-Part Study Of GSK580416 In Healthy Subjects | Phase1 | Respiratory Tract Infection | Completed | 2006-10-01 | — | ClinicalTrials.gov |
| NCT00437242 | Odiparcil QT Definitive Study | Phase1 | Fibrillation, Atrial | Terminated | 2006-10-01 | — | ClinicalTrials.gov |
| NCT00370227 | Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent… | Phase3 | Infections, Streptococcal | Completed | 2006-10-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00346697 | Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients | Phase4 | HIV Infections | Completed | 2006-10-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00373542 | 12-week Polysomnography Study of Ropinirole Controlled Release for Restless Leg… | Phase4 | Restless Legs Syndrome (RLS) | Completed | 2006-10-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00376779 | Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Mon… | Phase2 | Acellular Pertussis | Completed | 2006-10-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00439959 | Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infect… | Phase1 | Hepatitis C, Chronic | Terminated | 2006-10-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00398580 | 28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men | Phase2 | Hypogonadism | Completed | 2006-10-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00426751 | Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary… | Phase3 | Infarction, Myocardial | Completed | 2006-10-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00370227 | Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent… | Phase3 | Infections, Streptococcal | Completed | 2006-10-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00439959 | Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infect… | Phase1 | Hepatitis C, Chronic | Terminated | 2006-10-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00427141 | A Three-Part Study Of GSK580416 In Healthy Subjects | Phase1 | Respiratory Tract Infection | Completed | 2006-10-01 | — | ClinicalTrials.gov |
| NCT00400335 | Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone … | Phase1 | Hypogonadism | Completed | 2006-10-01 | — | ClinicalTrials.gov |
| NCT00494767 | Investigation Of Weight Loss And Body Composition Changes After Dosing With Eit… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2006-09-29 | 2007-06-07 | ClinicalTrials.gov |
| NCT00494767 | Investigation Of Weight Loss And Body Composition Changes After Dosing With Eit… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2006-09-29 | 2007-06-07 | ClinicalTrials.gov |
| NCT00289185 | Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in … | Phase2 | Malaria | Completed | 2006-09-27 | 2009-01-15 | ClinicalTrials.gov |
| NCT00289185 | Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in … | Phase2 | Malaria | Completed | 2006-09-27 | 2009-01-15 | ClinicalTrials.gov |
| NCT00369824 | Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Ot… | Phase3 | Infections, Papillomavirus | Completed | 2006-09-26 | 2008-02-13 | ClinicalTrials.gov |
| NCT00369824 | Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Ot… | Phase3 | Infections, Papillomavirus | Completed | 2006-09-26 | 2008-02-13 | ClinicalTrials.gov |
| NCT00370396 | Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent… | Phase3 | Infections, Streptococcal | Completed | 2006-09-25 | 2007-11-06 | ClinicalTrials.gov |
| NCT00345878 | Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccin… | Phase3 | Infections, Papillomavirus | Completed | 2006-09-25 | 2007-12-21 | ClinicalTrials.gov |
| NCT00370396 | Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent… | Phase3 | Infections, Streptococcal | Completed | 2006-09-25 | 2007-11-06 | ClinicalTrials.gov |
| NCT00345878 | Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccin… | Phase3 | Infections, Papillomavirus | Completed | 2006-09-25 | 2007-12-21 | ClinicalTrials.gov |
| NCT00377585 | Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vacc… | Phase2 | Influenza | Completed | 2006-09-22 | 2007-01-30 | ClinicalTrials.gov |
| NCT00377585 | Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vacc… | Phase2 | Influenza | Completed | 2006-09-22 | 2007-01-30 | ClinicalTrials.gov |
| NCT00363194 | A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazo… | Phase1 | Carcinoma, Renal Cell | Completed | 2006-09-21 | 2009-06-19 | ClinicalTrials.gov |
| NCT00363194 | A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazo… | Phase1 | Carcinoma, Renal Cell | Completed | 2006-09-21 | 2009-06-19 | ClinicalTrials.gov |
| NCT00345358 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent… | Phase3 | Infections, Streptococcal | Completed | 2006-09-18 | 2007-11-15 | ClinicalTrials.gov |
| NCT00345358 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent… | Phase3 | Infections, Streptococcal | Completed | 2006-09-18 | 2007-11-15 | ClinicalTrials.gov |
| NCT00359619 | Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Wom… | Phase2 | Infections, Papillomavirus | Completed | 2006-09-12 | 2007-01-30 | ClinicalTrials.gov |
| NCT00359619 | Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Wom… | Phase2 | Infections, Papillomavirus | Completed | 2006-09-12 | 2007-01-30 | ClinicalTrials.gov |
| NCT00358813 | Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairme… | Phase1 | Vomiting | Completed | 2006-09-08 | 2008-08-22 | ClinicalTrials.gov |
| NCT00358813 | Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairme… | Phase1 | Vomiting | Completed | 2006-09-08 | 2008-08-22 | ClinicalTrials.gov |
| NCT00379977 | Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccin… | Phase3 | Tetanus | Completed | 2006-09-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00388765 | Normal Control Cohort Sample Bank | — | Healthy | Completed | 2006-09-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00186693 | How Airway Remodeling and Hyperresponsiveness Contribute to Airflow Obstruction… | — | Asthma | Withdrawn | 2006-09-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00363870 | A Study to Demonstrate the Efficacy of GSK Biologicals' Influenza Vaccine in Ad… | Phase4 | Influenza | Completed | 2006-09-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00186693 | How Airway Remodeling and Hyperresponsiveness Contribute to Airflow Obstruction… | — | Asthma | Withdrawn | 2006-09-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00831129 | A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs | Phase2 | Pre-diabetes | Completed | 2006-09-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00388765 | Normal Control Cohort Sample Bank | — | Healthy | Completed | 2006-09-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00363870 | A Study to Demonstrate the Efficacy of GSK Biologicals' Influenza Vaccine in Ad… | Phase4 | Influenza | Completed | 2006-09-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00345579 | Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at … | Phase3 | Haemophilus Influenzae Type b | Completed | 2006-09-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00370318 | Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate… | Phase3 | Infections, Rotavirus | Completed | 2006-09-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00380211 | Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in … | Phase3 | Influenza | Completed | 2006-09-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00387881 | TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migrai… | Phase3 | Migraine, Without Aura | Completed | 2006-09-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00387764 | Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Meta… | Phase3 | Carcinoma, Renal Cell | Completed | 2006-09-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00345579 | Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at … | Phase3 | Haemophilus Influenzae Type b | Completed | 2006-09-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00359983 | Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK B… | Phase3 | Neisseria Meningitidis | Completed | 2006-09-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT02075632 | Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropi… | Phase2 | Eczema | Completed | 2006-09-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT01216956 | Metabolic Effects of an 8 Week Niaspan Treatment in Patients With Abdominal Obe… | Na | Insulin Sensitivity | Completed | 2006-09-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00387881 | TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migrai… | Phase3 | Migraine, Without Aura | Completed | 2006-09-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00359983 | Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK B… | Phase3 | Neisseria Meningitidis | Completed | 2006-09-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT00387764 | Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Meta… | Phase3 | Carcinoma, Renal Cell | Completed | 2006-09-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00385047 | A Study to Determine Whether 2 Investigational Malaria Vaccines Are Safe, Prote… | Phase1 | Malaria | Completed | 2006-09-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00379977 | Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccin… | Phase3 | Tetanus | Completed | 2006-09-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00380211 | Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in … | Phase3 | Influenza | Completed | 2006-09-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00380354 | Study To Evaluate GSK256066 In Subjects With Mild Bronchial Asthma | Phase2 | Asthma | Completed | 2006-09-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00831129 | A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs | Phase2 | Pre-diabetes | Completed | 2006-09-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT02075632 | Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropi… | Phase2 | Eczema | Completed | 2006-09-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00380354 | Study To Evaluate GSK256066 In Subjects With Mild Bronchial Asthma | Phase2 | Asthma | Completed | 2006-09-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00370318 | Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate… | Phase3 | Infections, Rotavirus | Completed | 2006-09-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00385047 | A Study to Determine Whether 2 Investigational Malaria Vaccines Are Safe, Prote… | Phase1 | Malaria | Completed | 2006-09-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT01216956 | Metabolic Effects of an 8 Week Niaspan Treatment in Patients With Abdominal Obe… | Na | Insulin Sensitivity | Completed | 2006-09-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00360230 | Partially-blind (Observer-blind) Study of Safety and Immunogenicity of Two Mala… | Phase2 | Malaria | Completed | 2006-08-30 | 2008-05-30 | ClinicalTrials.gov |
| NCT00406757 | Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or… | Phase1 | Leukaemia, Lymphoblastic, Acute and Lymphoma, Lymphoblastic | Completed | 2006-08-30 | 2009-07-15 | ClinicalTrials.gov |
| NCT00390845 | P38 Mitogen-activated Protein (Map) Kinase Inhibitor (SB-681323)Study In Patien… | Phase2 | Pain, Neuropathic | Completed | 2006-08-30 | 2008-08-11 | ClinicalTrials.gov |
| NCT00370097 | FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects | Phase1 | Asthma | Completed | 2006-08-30 | 2007-04-12 | ClinicalTrials.gov |
| NCT00370097 | FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects | Phase1 | Asthma | Completed | 2006-08-30 | 2007-04-12 | ClinicalTrials.gov |
| NCT00406757 | Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or… | Phase1 | Leukaemia, Lymphoblastic, Acute and Lymphoma, Lymphoblastic | Completed | 2006-08-30 | 2009-07-15 | ClinicalTrials.gov |
| NCT00390845 | P38 Mitogen-activated Protein (Map) Kinase Inhibitor (SB-681323)Study In Patien… | Phase2 | Pain, Neuropathic | Completed | 2006-08-30 | 2008-08-11 | ClinicalTrials.gov |
| NCT00360230 | Partially-blind (Observer-blind) Study of Safety and Immunogenicity of Two Mala… | Phase2 | Malaria | Completed | 2006-08-30 | 2008-05-30 | ClinicalTrials.gov |
| NCT00419692 | Restless Legs Patient Study On Absorption, Distribution, Metabolism And Excreti… | Phase1 | Restless Legs Syndrome | Completed | 2006-08-24 | 2006-12-12 | ClinicalTrials.gov |
| NCT00419692 | Restless Legs Patient Study On Absorption, Distribution, Metabolism And Excreti… | Phase1 | Restless Legs Syndrome | Completed | 2006-08-24 | 2006-12-12 | ClinicalTrials.gov |
| NCT00376714 | Safety And Tolerability Study In Patients With Chronic Obstructive Pulmonary Di… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2006-08-16 | 2007-04-03 | ClinicalTrials.gov |
| NCT00376714 | Safety And Tolerability Study In Patients With Chronic Obstructive Pulmonary Di… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2006-08-16 | 2007-04-03 | ClinicalTrials.gov |
| NCT00743067 | A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Forme… | Phase1 | Solid Tumours | Completed | 2006-08-09 | 2009-11-09 | ClinicalTrials.gov |
| NCT00743067 | A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Forme… | Phase1 | Solid Tumours | Completed | 2006-08-09 | 2009-11-09 | ClinicalTrials.gov |
| NCT00344318 | Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent… | Phase3 | Infections, Streptococcal | Completed | 2006-08-07 | 2007-10-17 | ClinicalTrials.gov |
| NCT00395694 | Clinical Evaluation of BW430C in Epilepsy | Phase3 | Epilepsy | Completed | 2006-08-07 | 2009-03-26 | ClinicalTrials.gov |
| NCT00395694 | Clinical Evaluation of BW430C in Epilepsy | Phase3 | Epilepsy | Completed | 2006-08-07 | 2009-03-26 | ClinicalTrials.gov |
| NCT00344318 | Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent… | Phase3 | Infections, Streptococcal | Completed | 2006-08-07 | 2007-10-17 | ClinicalTrials.gov |
| NCT00381394 | A Study Evaluating Sitamaquine Compared With Amphotericin B In The Treatment Of… | Phase2 | Leishmaniasis, Visceral | Completed | 2006-08-04 | 2007-09-14 | ClinicalTrials.gov |
| NCT00381394 | A Study Evaluating Sitamaquine Compared With Amphotericin B In The Treatment Of… | Phase2 | Leishmaniasis, Visceral | Completed | 2006-08-04 | 2007-09-14 | ClinicalTrials.gov |
| NCT00333450 | Immune Memory Evaluation in Children Following a Primary Vaccination With Pneum… | Phase3 | Infections, Streptococcal | Completed | 2006-08-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00429299 | Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer | Phase2 | Neoplasms, Breast | Completed | 2006-08-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT00365482 | Bipolar Disorder in Epilepsy | — | Epilepsy | Completed | 2006-08-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00426296 | SHARE: Simple HAART With Abacavir, Reyataz, and Epivir | Phase4 | HIV Infections | Unknown | 2006-08-01 | — | ClinicalTrials.gov |
| NCT00331292 | A Methodology Study To Look At Genes In Lung Cells And Tissue From Asthmatic Pa… | — | Asthma | Terminated | 2006-08-01 | — | ClinicalTrials.gov |
| NCT00429299 | Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer | Phase2 | Neoplasms, Breast | Completed | 2006-08-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT00368576 | A Study To Determine The Effect Of SB-480848 On Asthma | Phase1 | Atherosclerosis | Completed | 2006-08-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00368576 | A Study To Determine The Effect Of SB-480848 On Asthma | Phase1 | Atherosclerosis | Completed | 2006-08-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00426296 | SHARE: Simple HAART With Abacavir, Reyataz, and Epivir | Phase4 | HIV Infections | Unknown | 2006-08-01 | — | ClinicalTrials.gov |
| NCT00394186 | A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS) | Phase2 | Irritable Bowel Syndrome (IBS) | Completed | 2006-08-01 | — | ClinicalTrials.gov |
| NCT00471588 | Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And Anta… | Phase1 | Obsessive-Compulsive Disorder | Completed | 2006-08-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00218465 | Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of R… | Phase2 | Nicotine Dependence | Completed | 2006-08-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00218465 | Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of R… | Phase2 | Nicotine Dependence | Completed | 2006-08-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00376038 | Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 T… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2006-08-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00471588 | Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And Anta… | Phase1 | Obsessive-Compulsive Disorder | Completed | 2006-08-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00331292 | A Methodology Study To Look At Genes In Lung Cells And Tissue From Asthmatic Pa… | — | Asthma | Terminated | 2006-08-01 | — | ClinicalTrials.gov |
| NCT00376038 | Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 T… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2006-08-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00365482 | Bipolar Disorder in Epilepsy | — | Epilepsy | Completed | 2006-08-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00333450 | Immune Memory Evaluation in Children Following a Primary Vaccination With Pneum… | Phase3 | Infections, Streptococcal | Completed | 2006-08-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00394186 | A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS) | Phase2 | Irritable Bowel Syndrome (IBS) | Completed | 2006-08-01 | — | ClinicalTrials.gov |
| NCT00401583 | A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes | Phase1 | Carcinoma, Renal Cell | Completed | 2006-07-28 | 2008-02-20 | ClinicalTrials.gov |
| NCT00401583 | A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes | Phase1 | Carcinoma, Renal Cell | Completed | 2006-07-28 | 2008-02-20 | ClinicalTrials.gov |
| NCT00348140 | Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With… | Phase3 | Alzheimer's Disease | Completed | 2006-07-12 | 2009-03-20 | ClinicalTrials.gov |
| NCT00348140 | Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With… | Phase3 | Alzheimer's Disease | Completed | 2006-07-12 | 2009-03-20 | ClinicalTrials.gov |
| NCT00310388 | Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 1… | Phase3 | Epilepsy | Terminated | 2006-07-05 | 2018-05-24 | ClinicalTrials.gov |
| NCT00310388 | Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 1… | Phase3 | Epilepsy | Terminated | 2006-07-05 | 2018-05-24 | ClinicalTrials.gov |
| NCT00356564 | Persistence of the Immune Response to Hepatitis B in 7-9 Years Old Children Pre… | Phase4 | Hepatitis B | Completed | 2006-07-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00403585 | Study of Adefovir Dipivoxil for Korean Patients With Chronic Hepatitis B(CHB) W… | Phase4 | Hepatitis B, Chronic | Completed | 2006-07-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00356915 | Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of … | Phase3 | Onychomycosis | Completed | 2006-07-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00366834 | Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy I… | Phase3 | Vomiting | Completed | 2006-07-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00368589 | Effects Of Atorvastatin On Macrophage Activity And Plaque Inflammation Using Ma… | — | Atherosclerotic Carotid Disease | Completed | 2006-07-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00367744 | Rosiglitazone Effect on Mitochondria and Lipoatrophy | Phase2 | HIV Infections | Completed | 2006-07-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00347360 | The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) … | Phase3 | Hypertension | Completed | 2006-07-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00345904 | Study to Evaluate the Safety and Immunogenicity of Fluarix™ 2006/2007 in Adults… | Phase3 | Influenza | Completed | 2006-07-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00337922 | Pharmacokinetic Study Of EPZICOM Tablet | Phase4 | HIV Infection | Completed | 2006-07-01 | — | ClinicalTrials.gov |
| NCT00334698 | Study to Assess the Effect of a Combination of Cetirizine With Pseudoephedrine … | Na | Seasonal Allergic Rhinitis | Completed | 2006-07-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00567424 | GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial S… | Phase2 | Epilepsy | Withdrawn | 2006-07-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00298155 | Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer | Phase2 | Cancer | Completed | 2006-07-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT00545480 | SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in W… | Phase4 | Post Menopausal Osteoporosis | Completed | 2006-07-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00567424 | GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial S… | Phase2 | Epilepsy | Withdrawn | 2006-07-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00334698 | Study to Assess the Effect of a Combination of Cetirizine With Pseudoephedrine … | Na | Seasonal Allergic Rhinitis | Completed | 2006-07-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00545480 | SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in W… | Phase4 | Post Menopausal Osteoporosis | Completed | 2006-07-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00403585 | Study of Adefovir Dipivoxil for Korean Patients With Chronic Hepatitis B(CHB) W… | Phase4 | Hepatitis B, Chronic | Completed | 2006-07-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00337922 | Pharmacokinetic Study Of EPZICOM Tablet | Phase4 | HIV Infection | Completed | 2006-07-01 | — | ClinicalTrials.gov |
| NCT00345904 | Study to Evaluate the Safety and Immunogenicity of Fluarix™ 2006/2007 in Adults… | Phase3 | Influenza | Completed | 2006-07-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00347360 | The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) … | Phase3 | Hypertension | Completed | 2006-07-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00298155 | Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer | Phase2 | Cancer | Completed | 2006-07-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT00356564 | Persistence of the Immune Response to Hepatitis B in 7-9 Years Old Children Pre… | Phase4 | Hepatitis B | Completed | 2006-07-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00439179 | A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobili… | Phase1 | Metastatic Pancreatic Cancer | Completed | 2006-07-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00356915 | Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of … | Phase3 | Onychomycosis | Completed | 2006-07-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00368589 | Effects Of Atorvastatin On Macrophage Activity And Plaque Inflammation Using Ma… | — | Atherosclerotic Carotid Disease | Completed | 2006-07-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00367744 | Rosiglitazone Effect on Mitochondria and Lipoatrophy | Phase2 | HIV Infections | Completed | 2006-07-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00366834 | Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy I… | Phase3 | Vomiting | Completed | 2006-07-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00439179 | A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobili… | Phase1 | Metastatic Pancreatic Cancer | Completed | 2006-07-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00726323 | A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcin… | Phase2 | Carcinoma, Renal Cell | Completed | 2006-06-30 | 2010-08-18 | ClinicalTrials.gov |
| NCT00726323 | A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcin… | Phase2 | Carcinoma, Renal Cell | Completed | 2006-06-30 | 2010-08-18 | ClinicalTrials.gov |
| NCT00381238 | Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects Wi… | Phase2 | Alzheimer's Disease | Completed | 2006-06-20 | 2009-02-03 | ClinicalTrials.gov |
| NCT00356603 | Study Of Sumatriptan Succinate Injection Kit In Patients With Migraine or Clust… | Phase3 | Migraine Disorders | Completed | 2006-06-20 | 2006-08-07 | ClinicalTrials.gov |
| NCT00381238 | Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects Wi… | Phase2 | Alzheimer's Disease | Completed | 2006-06-20 | 2009-02-03 | ClinicalTrials.gov |
| NCT00356603 | Study Of Sumatriptan Succinate Injection Kit In Patients With Migraine or Clust… | Phase3 | Migraine Disorders | Completed | 2006-06-20 | 2006-08-07 | ClinicalTrials.gov |
| NCT00357097 | The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate … | Phase3 | Restless Legs Syndrome | Completed | 2006-06-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00349349 | HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Flud… | Phase2 | Leukaemia, Lymphocytic, Chronic | Completed | 2006-06-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT00357097 | The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate … | Phase3 | Restless Legs Syndrome | Completed | 2006-06-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00334607 | Study of 2 Doses of HRV Vaccine Given Concomitantly or Separately With Routine … | Phase3 | Infections, Rotavirus | Completed | 2006-06-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00242593 | Rosiglitazone Effects on Cognition for Adults in Later Life | Phase2 | Mild Cognitive Impairment | Unknown | 2006-06-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00344006 | Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria | Phase3 | Malaria, Falciparum | Completed | 2006-06-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00343395 | Rosiglitazone and Metformin: Outcomes Trial in Nondiabetic Patients With Stable… | Phase4 | Coronary Artery Disease | Terminated | 2006-06-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00337818 | Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in You… | Phase3 | Papillomavirus Type 16/18 Infection | Completed | 2006-06-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00335881 | Persistence of the Immune Response to Hepatitis B in 4-6 Years Old Children Pre… | Phase4 | Hepatitis B | Completed | 2006-06-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT01376154 | Special Drug Use Investigation for ZEFIX (Lamivudine) Tablet (HBV Cirrhosis) | — | Hepatitis B, Chronic | Completed | 2006-06-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00334607 | Study of 2 Doses of HRV Vaccine Given Concomitantly or Separately With Routine … | Phase3 | Infections, Rotavirus | Completed | 2006-06-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00827814 | Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prost… | Phase4 | Benign Prostatic Hyperplasia | Completed | 2006-06-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00335881 | Persistence of the Immune Response to Hepatitis B in 4-6 Years Old Children Pre… | Phase4 | Hepatitis B | Completed | 2006-06-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00337818 | Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in You… | Phase3 | Papillomavirus Type 16/18 Infection | Completed | 2006-06-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00343395 | Rosiglitazone and Metformin: Outcomes Trial in Nondiabetic Patients With Stable… | Phase4 | Coronary Artery Disease | Terminated | 2006-06-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00344006 | Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria | Phase3 | Malaria, Falciparum | Completed | 2006-06-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00349349 | HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Flud… | Phase2 | Leukaemia, Lymphocytic, Chronic | Completed | 2006-06-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT00242593 | Rosiglitazone Effects on Cognition for Adults in Later Life | Phase2 | Mild Cognitive Impairment | Unknown | 2006-06-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00611468 | Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refract… | Phase1 | Metastatic Solid Tumor | Completed | 2006-06-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00827814 | Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prost… | Phase4 | Benign Prostatic Hyperplasia | Completed | 2006-06-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00445510 | This Study Will Examine the Effects of GSK256066 to Protect Mild Steroid-naive … | Phase2 | Asthma | Completed | 2006-06-01 | — | ClinicalTrials.gov |
| NCT00445510 | This Study Will Examine the Effects of GSK256066 to Protect Mild Steroid-naive … | Phase2 | Asthma | Completed | 2006-06-01 | — | ClinicalTrials.gov |
| NCT01376154 | Special Drug Use Investigation for ZEFIX (Lamivudine) Tablet (HBV Cirrhosis) | — | Hepatitis B, Chronic | Completed | 2006-06-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00326118 | Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC &… | Phase3 | Haemophilus Influenzae Type b | Completed | 2006-06-01 | 2007-11-06 | ClinicalTrials.gov |
| NCT00611468 | Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refract… | Phase1 | Metastatic Solid Tumor | Completed | 2006-06-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00326118 | Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC &… | Phase3 | Haemophilus Influenzae Type b | Completed | 2006-06-01 | 2007-11-06 | ClinicalTrials.gov |
| NCT00358540 | Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adria… | Phase1 | Thrombocytopaenia | Completed | 2006-06-01 | 2010-10-22 | ClinicalTrials.gov |
| NCT00358540 | Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adria… | Phase1 | Thrombocytopaenia | Completed | 2006-06-01 | 2010-10-22 | ClinicalTrials.gov |
| NCT00432679 | A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy … | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2006-05-24 | 2007-03-28 | ClinicalTrials.gov |
| NCT00432679 | A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy … | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2006-05-24 | 2007-03-28 | ClinicalTrials.gov |
| NCT01059578 | First Study in Humans With GSK206136 | Phase1 | Depressive Disorder and Anxiety Disorders | Completed | 2006-05-23 | 2006-12-18 | ClinicalTrials.gov |
| NCT00347139 | Repeat Doses Of A New Medication (GW642444) In Asthmatic Patients | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2006-05-23 | 2007-01-10 | ClinicalTrials.gov |
| NCT01059578 | First Study in Humans With GSK206136 | Phase1 | Depressive Disorder and Anxiety Disorders | Completed | 2006-05-23 | 2006-12-18 | ClinicalTrials.gov |
| NCT00347139 | Repeat Doses Of A New Medication (GW642444) In Asthmatic Patients | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2006-05-23 | 2007-01-10 | ClinicalTrials.gov |
| NCT00379756 | A Study Evaluating Vardenafil Compared to Placebo in Subjects With Erectile Dys… | Phase4 | Erectile Dysfunction | Completed | 2006-05-22 | 2007-05-17 | ClinicalTrials.gov |
| NCT00379756 | A Study Evaluating Vardenafil Compared to Placebo in Subjects With Erectile Dys… | Phase4 | Erectile Dysfunction | Completed | 2006-05-22 | 2007-05-17 | ClinicalTrials.gov |
| NCT00363480 | Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data | Phase4 | Asthma | Completed | 2006-05-17 | 2007-09-14 | ClinicalTrials.gov |
| NCT00363480 | Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data | Phase4 | Asthma | Completed | 2006-05-17 | 2007-09-14 | ClinicalTrials.gov |
| NCT00321373 | Study to Evaluate an Influenza Vaccine Candidate | Phase2 | Influenza | Completed | 2006-05-11 | 2006-07-18 | ClinicalTrials.gov |
| NCT00321373 | Study to Evaluate an Influenza Vaccine Candidate | Phase2 | Influenza | Completed | 2006-05-11 | 2006-07-18 | ClinicalTrials.gov |
| NCT00331630 | Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage II… | Early_Phase1 | Breast Cancer | Completed | 2006-05-04 | 2010-08-05 | ClinicalTrials.gov |
| NCT00331630 | Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage II… | Early_Phase1 | Breast Cancer | Completed | 2006-05-04 | 2010-08-05 | ClinicalTrials.gov |
| NCT00346775 | Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Spra… | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2006-05-01 | 2006-06-29 | ClinicalTrials.gov |
| NCT00363142 | A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-I… | Phase3 | HIV Infection | Completed | 2006-05-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00356811 | Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified… | Phase2 | Neoplasms, Breast | Completed | 2006-05-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00355082 | Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment … | Phase3 | Epilepsy, Partial | Completed | 2006-05-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00354809 | Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Be… | Phase2 | Sleep Initiation and Maintenance Disorders | Completed | 2006-05-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00348192 | SB-742457 And Donepezil In Alzheimer's Disease | Phase2 | Alzheimer's Disease | Completed | 2006-05-01 | — | ClinicalTrials.gov |
| NCT00346775 | Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Spra… | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2006-05-01 | 2006-06-29 | ClinicalTrials.gov |
| NCT00344994 | SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole | Phase4 | Restless Legs Syndrome | Completed | 2006-05-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00387972 | Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM) | Phase2 | Type 2 Diabetes Mellitus | Withdrawn | 2006-05-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00343486 | Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overact… | Phase2 | Overactive Bladder | Completed | 2006-05-01 | — | ClinicalTrials.gov |
| NCT00333021 | Abdominal Surgery Study Of GSK576428 (Fondaparinux Sodium)In Japanese Patients | Phase3 | Venous Thromboembolism | Completed | 2006-05-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00330616 | Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Ja… | Phase2 | Major Depressive Disorder (MDD) | Completed | 2006-05-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00329576 | Evaluate Immune Response Approximately 5 to 6 Years After Receiving Different F… | Phase4 | Hepatitis B | Completed | 2006-05-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00329459 | Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrua… | Phase3 | Migraine Disorders | Completed | 2006-05-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00329355 | Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA) | Phase3 | Migraine | Completed | 2006-05-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00327665 | Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococ… | Phase1 | Infections, Streptococcal | Completed | 2006-05-01 | 2007-01-08 | ClinicalTrials.gov |
| NCT00319098 | Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine… | Phase3 | Influenza | Completed | 2006-05-01 | 2007-07-31 | ClinicalTrials.gov |
| NCT00405119 | A Study To Investigate The Effectiveness Of AH234844 (Lavoltidine) Compared Wit… | Phase2 | Gastroesophageal Reflux Disease | Completed | 2006-05-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00312013 | Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer | Phase3 | Thrombosis, Venous | Completed | 2006-05-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00310375 | Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial | Phase3 | Epilepsy | Completed | 2006-05-01 | 2017-03-15 | ClinicalTrials.gov |
| NCT00387972 | Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM) | Phase2 | Type 2 Diabetes Mellitus | Withdrawn | 2006-05-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00363142 | A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-I… | Phase3 | HIV Infection | Completed | 2006-05-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00405119 | A Study To Investigate The Effectiveness Of AH234844 (Lavoltidine) Compared Wit… | Phase2 | Gastroesophageal Reflux Disease | Completed | 2006-05-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00472251 | One-year Prospective Observational Study of BMI Change Effect of 5-alpha Reduct… | — | Benign Prostatic Hyperplasia | Completed | 2006-05-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00356811 | Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified… | Phase2 | Neoplasms, Breast | Completed | 2006-05-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00484666 | Platinum-Resistant, Recurrent Epithelial Ovarian Cancer | — | Ovarian Cancer | Withdrawn | 2006-05-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00355082 | Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment … | Phase3 | Epilepsy, Partial | Completed | 2006-05-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00354809 | Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Be… | Phase2 | Sleep Initiation and Maintenance Disorders | Completed | 2006-05-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00472251 | One-year Prospective Observational Study of BMI Change Effect of 5-alpha Reduct… | — | Benign Prostatic Hyperplasia | Completed | 2006-05-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00348192 | SB-742457 And Donepezil In Alzheimer's Disease | Phase2 | Alzheimer's Disease | Completed | 2006-05-01 | — | ClinicalTrials.gov |
| NCT00484666 | Platinum-Resistant, Recurrent Epithelial Ovarian Cancer | — | Ovarian Cancer | Withdrawn | 2006-05-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00344994 | SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole | Phase4 | Restless Legs Syndrome | Completed | 2006-05-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00343486 | Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overact… | Phase2 | Overactive Bladder | Completed | 2006-05-01 | — | ClinicalTrials.gov |
| NCT00525564 | Effects of Salmeterol on Walking Capacity in Patients With COPD | Phase4 | Chronic Obstructive Pulmonary Disease | Completed | 2006-05-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00545051 | A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-I… | Phase4 | Postmenopausal Osteoporosis | Completed | 2006-05-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00333021 | Abdominal Surgery Study Of GSK576428 (Fondaparinux Sodium)In Japanese Patients | Phase3 | Venous Thromboembolism | Completed | 2006-05-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00330616 | Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Ja… | Phase2 | Major Depressive Disorder (MDD) | Completed | 2006-05-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00329576 | Evaluate Immune Response Approximately 5 to 6 Years After Receiving Different F… | Phase4 | Hepatitis B | Completed | 2006-05-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00329459 | Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrua… | Phase3 | Migraine Disorders | Completed | 2006-05-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00329355 | Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA) | Phase3 | Migraine | Completed | 2006-05-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00327665 | Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococ… | Phase1 | Infections, Streptococcal | Completed | 2006-05-01 | 2007-01-08 | ClinicalTrials.gov |
| NCT00525564 | Effects of Salmeterol on Walking Capacity in Patients With COPD | Phase4 | Chronic Obstructive Pulmonary Disease | Completed | 2006-05-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00663845 | Assessing Efficacy and Safety of Flexible Dosing With Vardenafil in Subjects Wi… | Phase4 | Erectile Dysfunction | Completed | 2006-05-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00319098 | Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine… | Phase3 | Influenza | Completed | 2006-05-01 | 2007-07-31 | ClinicalTrials.gov |
| NCT00312013 | Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer | Phase3 | Thrombosis, Venous | Completed | 2006-05-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00310375 | Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial | Phase3 | Epilepsy | Completed | 2006-05-01 | 2017-03-15 | ClinicalTrials.gov |
| NCT00545051 | A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-I… | Phase4 | Postmenopausal Osteoporosis | Completed | 2006-05-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00663845 | Assessing Efficacy and Safety of Flexible Dosing With Vardenafil in Subjects Wi… | Phase4 | Erectile Dysfunction | Completed | 2006-05-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00896987 | Lamotrigine Cognitive Function Study in Adult Untreated Epilepsies | Phase4 | Epilepsy | Completed | 2006-05-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00896987 | Lamotrigine Cognitive Function Study in Adult Untreated Epilepsies | Phase4 | Epilepsy | Completed | 2006-05-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00321763 | Study to Demonstrate the Lot-to-lot Consistency and to Evaluate the Safety of a… | Phase2 | Influenza | Completed | 2006-04-27 | 2006-07-07 | ClinicalTrials.gov |
| NCT00321763 | Study to Demonstrate the Lot-to-lot Consistency and to Evaluate the Safety of a… | Phase2 | Influenza | Completed | 2006-04-27 | 2006-07-07 | ClinicalTrials.gov |
| NCT00316693 | Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Saf… | Phase2 | Infections, Papillomavirus | Completed | 2006-04-26 | 2009-02-10 | ClinicalTrials.gov |
| NCT00316693 | Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Saf… | Phase2 | Infections, Papillomavirus | Completed | 2006-04-26 | 2009-02-10 | ClinicalTrials.gov |
| NCT00317109 | Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m… | Phase3 | Infections, Meningococcal | Completed | 2006-04-19 | 2007-05-17 | ClinicalTrials.gov |
| NCT00317109 | Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m… | Phase3 | Infections, Meningococcal | Completed | 2006-04-19 | 2007-05-17 | ClinicalTrials.gov |
| NCT00359463 | Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or … | Phase1 | Purpura, Thrombocytopaenic, Idiopathic | Completed | 2006-04-18 | 2007-03-07 | ClinicalTrials.gov |
| NCT00359463 | Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or … | Phase1 | Purpura, Thrombocytopaenic, Idiopathic | Completed | 2006-04-18 | 2007-03-07 | ClinicalTrials.gov |
| NCT00371488 | GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-… | Phase1 | Neoplasms, Breast | Completed | 2006-04-06 | 2007-12-10 | ClinicalTrials.gov |
| NCT00371488 | GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-… | Phase1 | Neoplasms, Breast | Completed | 2006-04-06 | 2007-12-10 | ClinicalTrials.gov |
| NCT00309166 | Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV… | Phase2 | Infections, Papillomavirus | Completed | 2006-04-05 | 2007-06-19 | ClinicalTrials.gov |
| NCT00350337 | Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalen… | Phase2 | Dengue | Completed | 2006-04-05 | 2008-03-13 | ClinicalTrials.gov |
| NCT00239577 | A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Vir… | Phase2 | Dengue | Completed | 2006-04-05 | 2007-06-19 | ClinicalTrials.gov |
| NCT00350337 | Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalen… | Phase2 | Dengue | Completed | 2006-04-05 | 2008-03-13 | ClinicalTrials.gov |
| NCT00239577 | A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Vir… | Phase2 | Dengue | Completed | 2006-04-05 | 2007-06-19 | ClinicalTrials.gov |
| NCT00309166 | Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV… | Phase2 | Infections, Papillomavirus | Completed | 2006-04-05 | 2007-06-19 | ClinicalTrials.gov |
| NCT00340080 | Clinical Utility Of Genetic Screening For HLA-B*5701, On Susceptibility To Abac… | Phase4 | HIV Infection | Completed | 2006-04-01 | — | ClinicalTrials.gov |
| NCT00358488 | Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic P… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2006-04-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00422994 | A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis … | Phase1 | Restless Legs Syndrome | Completed | 2006-04-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT01371474 | Special Drug Use Investigation for PAXIL Tablet (Investigation in Case of Admin… | — | Panic Disorder | Completed | 2006-04-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00385463 | Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Receiv… | Na | Asthma | Withdrawn | 2006-04-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00370942 | GW823093C For The Treatment Of Type 2 Diabetes Mellitus | Phase2 | Diabetes Mellitus, Type 2 | Terminated | 2006-04-01 | 2006-11-25 | ClinicalTrials.gov |
| NCT00320463 | Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-… | Phase3 | Diphtheria | Completed | 2006-04-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00312702 | Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of … | Phase1 | Malaria | Completed | 2006-04-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00320463 | Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-… | Phase3 | Diphtheria | Completed | 2006-04-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00312702 | Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of … | Phase1 | Malaria | Completed | 2006-04-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00315380 | Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis | — | Eosinophilic Granulomatosis With Polyangiitis | Recruiting | 2006-04-01 | 2028-12-01 | ClinicalTrials.gov |
| NCT00370942 | GW823093C For The Treatment Of Type 2 Diabetes Mellitus | Phase2 | Diabetes Mellitus, Type 2 | Terminated | 2006-04-01 | 2006-11-25 | ClinicalTrials.gov |
| NCT01327339 | REQUIP RLS Post Marketing Surveillance | — | Restless Legs Syndrome | Completed | 2006-04-01 | 2009-11-30 | ClinicalTrials.gov |
| NCT00331045 | Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptom… | Phase2 | Cancer | Terminated | 2006-04-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT01371474 | Special Drug Use Investigation for PAXIL Tablet (Investigation in Case of Admin… | — | Panic Disorder | Completed | 2006-04-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00358488 | Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic P… | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2006-04-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00327184 | Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence … | Phase3 | Neisseria Meningitidis | Completed | 2006-04-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00422994 | A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis … | Phase1 | Restless Legs Syndrome | Completed | 2006-04-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00385463 | Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Receiv… | Na | Asthma | Withdrawn | 2006-04-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT01327339 | REQUIP RLS Post Marketing Surveillance | — | Restless Legs Syndrome | Completed | 2006-04-01 | 2009-11-30 | ClinicalTrials.gov |
| NCT00331045 | Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptom… | Phase2 | Cancer | Terminated | 2006-04-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00327184 | Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence … | Phase3 | Neisseria Meningitidis | Completed | 2006-04-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00334282 | Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma | Phase3 | Carcinoma, Renal Cell | Completed | 2006-04-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT00334282 | Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma | Phase3 | Carcinoma, Renal Cell | Completed | 2006-04-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT00315380 | Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis | — | Eosinophilic Granulomatosis With Polyangiitis | Recruiting | 2006-04-01 | 2028-12-01 | ClinicalTrials.gov |
| NCT00340080 | Clinical Utility Of Genetic Screening For HLA-B*5701, On Susceptibility To Abac… | Phase4 | HIV Infection | Completed | 2006-04-01 | — | ClinicalTrials.gov |
| NCT00309647 | Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) I… | Phase1 | Influenza | Completed | 2006-03-29 | 2006-11-16 | ClinicalTrials.gov |
| NCT00309647 | Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) I… | Phase1 | Influenza | Completed | 2006-03-29 | 2006-11-16 | ClinicalTrials.gov |
| NCT00309634 | Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine… | Phase1 | Influenza | Completed | 2006-03-27 | 2006-10-28 | ClinicalTrials.gov |
| NCT00309634 | Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine… | Phase1 | Influenza | Completed | 2006-03-27 | 2006-10-28 | ClinicalTrials.gov |
| NCT00406003 | Single Dose Pharmacokinetic (PK) Study Of Paroxetine CR(12.5-37.5mg) In Healthy… | Phase1 | Depressive Disorder | Completed | 2006-03-24 | 2006-04-26 | ClinicalTrials.gov |
| NCT00406003 | Single Dose Pharmacokinetic (PK) Study Of Paroxetine CR(12.5-37.5mg) In Healthy… | Phase1 | Depressive Disorder | Completed | 2006-03-24 | 2006-04-26 | ClinicalTrials.gov |
| NCT00372957 | Study Of GW823093 In Japanese Subjects With Type 2 Diabetes Mellitus | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2006-03-22 | 2006-06-28 | ClinicalTrials.gov |
| NCT00372957 | Study Of GW823093 In Japanese Subjects With Type 2 Diabetes Mellitus | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2006-03-22 | 2006-06-28 | ClinicalTrials.gov |
| NCT00379730 | Prednisolone Novel Endpoint Study in Patients With Chronic Obstructive Pulmonar… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2006-03-21 | 2007-05-03 | ClinicalTrials.gov |
| NCT00379730 | Prednisolone Novel Endpoint Study in Patients With Chronic Obstructive Pulmonar… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2006-03-21 | 2007-05-03 | ClinicalTrials.gov |
| NCT00371566 | A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With… | Phase2 | Squamous Cell Carcinoma of Head and Neck | Completed | 2006-03-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00323037 | A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Su… | Phase3 | Congestive Heart Failure | Completed | 2006-03-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00316680 | Immuno & Safety Study With 2 Formulations of DTPw-HBV/HIB When Given at Birth W… | Phase3 | Haemophilus Influenzae Type b | Terminated | 2006-03-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00305942 | Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensiv… | Phase2 | Carcinoma, Small Cell | Completed | 2006-03-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00329602 | Long-term Study Of Ropinirole In Restless Legs Syndrome | Phase4 | Restless Legs Syndrome | Completed | 2006-03-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00334152 | Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women | Phase3 | Nausea and Vomiting, Postoperative | Completed | 2006-03-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00291902 | A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Un… | Phase2 | Coronary Heart Disease | Completed | 2006-03-01 | — | ClinicalTrials.gov |
| NCT00277641 | Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity | Phase3 | Binge Eating Disorder | Completed | 2006-03-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00281632 | A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With… | Phase2 | Peritoneal Cancer | Completed | 2006-03-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00326248 | Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Wo… | Phase3 | Nausea and Vomiting, Postoperative | Completed | 2006-03-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00329602 | Long-term Study Of Ropinirole In Restless Legs Syndrome | Phase4 | Restless Legs Syndrome | Completed | 2006-03-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00297856 | Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine | — | Diphtheria | Completed | 2006-03-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00297856 | Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine | — | Diphtheria | Completed | 2006-03-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00351923 | Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): … | Phase3 | Measles | Completed | 2006-03-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00306241 | A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vacci… | Phase3 | Infections, Papillomavirus | Completed | 2006-03-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00305942 | Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensiv… | Phase2 | Carcinoma, Small Cell | Completed | 2006-03-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00316680 | Immuno & Safety Study With 2 Formulations of DTPw-HBV/HIB When Given at Birth W… | Phase3 | Haemophilus Influenzae Type b | Terminated | 2006-03-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00315861 | Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies | Phase1 | Ovarian Cancer | Completed | 2006-03-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00353288 | Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) … | Phase2 | Varicella | Completed | 2006-03-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00315861 | Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies | Phase1 | Ovarian Cancer | Completed | 2006-03-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00281632 | A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With… | Phase2 | Peritoneal Cancer | Completed | 2006-03-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00335270 | A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two… | Phase4 | HIV | Completed | 2006-03-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00323037 | A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Su… | Phase3 | Congestive Heart Failure | Completed | 2006-03-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00891293 | A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to As… | Phase4 | Hypertriglyceridemia | Completed | 2006-03-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00306241 | A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vacci… | Phase3 | Infections, Papillomavirus | Completed | 2006-03-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00351923 | Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): … | Phase3 | Measles | Completed | 2006-03-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00334152 | Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women | Phase3 | Nausea and Vomiting, Postoperative | Completed | 2006-03-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00891293 | A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to As… | Phase4 | Hypertriglyceridemia | Completed | 2006-03-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00277641 | Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity | Phase3 | Binge Eating Disorder | Completed | 2006-03-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00335270 | A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two… | Phase4 | HIV | Completed | 2006-03-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00326248 | Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Wo… | Phase3 | Nausea and Vomiting, Postoperative | Completed | 2006-03-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00291902 | A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Un… | Phase2 | Coronary Heart Disease | Completed | 2006-03-01 | — | ClinicalTrials.gov |
| NCT00371566 | A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With… | Phase2 | Squamous Cell Carcinoma of Head and Neck | Completed | 2006-03-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00353288 | Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) … | Phase2 | Varicella | Completed | 2006-03-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00289783 | Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hi… | Phase3 | Haemophilus Influenzae Type b | Completed | 2006-02-22 | 2008-02-26 | ClinicalTrials.gov |
| NCT00289783 | Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hi… | Phase3 | Haemophilus Influenzae Type b | Completed | 2006-02-22 | 2008-02-26 | ClinicalTrials.gov |
| NCT00331058 | Comparison Of Molecular Targets In Mild To Severe Asthmatics And Healthy Subjec… | Phase1 | Asthma | Terminated | 2006-02-18 | 2011-07-07 | ClinicalTrials.gov |
| NCT00331058 | Comparison Of Molecular Targets In Mild To Severe Asthmatics And Healthy Subjec… | Phase1 | Asthma | Terminated | 2006-02-18 | 2011-07-07 | ClinicalTrials.gov |
| NCT00368979 | Dutasteride (GI198745) In Benign Prostatic Hyperplasia Subjects | Phase3 | Prostatic Hyperplasia | Completed | 2006-02-17 | 2007-12-06 | ClinicalTrials.gov |
| NCT00368979 | Dutasteride (GI198745) In Benign Prostatic Hyperplasia Subjects | Phase3 | Prostatic Hyperplasia | Completed | 2006-02-17 | 2007-12-06 | ClinicalTrials.gov |
| NCT00294047 | Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy A… | Phase3 | Infections, Papillomavirus | Completed | 2006-02-16 | 2014-01-29 | ClinicalTrials.gov |
| NCT00320424 | Hip Fracture Study of GSK576428 (Fondaparinux Sodium) | Phase3 | Thromboembolism | Completed | 2006-02-16 | 2006-10-26 | ClinicalTrials.gov |
| NCT00320424 | Hip Fracture Study of GSK576428 (Fondaparinux Sodium) | Phase3 | Thromboembolism | Completed | 2006-02-16 | 2006-10-26 | ClinicalTrials.gov |
| NCT00294047 | Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy A… | Phase3 | Infections, Papillomavirus | Completed | 2006-02-16 | 2014-01-29 | ClinicalTrials.gov |
| NCT00289172 | Assess the Immunogenicity & Safety of 2 Doses of Oral Live Attenuated Human Rot… | Phase3 | Infections, Rotavirus | Completed | 2006-02-10 | 2006-09-08 | ClinicalTrials.gov |
| NCT00289172 | Assess the Immunogenicity & Safety of 2 Doses of Oral Live Attenuated Human Rot… | Phase3 | Infections, Rotavirus | Completed | 2006-02-10 | 2006-09-08 | ClinicalTrials.gov |
| NCT00453791 | The Safety and Tolerability of GW805858 in Healthy Volunteers and Mild Asthmati… | Phase1 | Asthma | Terminated | 2006-02-07 | 2006-04-10 | ClinicalTrials.gov |
| NCT00289198 | Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial… | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2006-02-07 | 2006-07-04 | ClinicalTrials.gov |
| NCT00453791 | The Safety and Tolerability of GW805858 in Healthy Volunteers and Mild Asthmati… | Phase1 | Asthma | Terminated | 2006-02-07 | 2006-04-10 | ClinicalTrials.gov |
| NCT00289198 | Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial… | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2006-02-07 | 2006-07-04 | ClinicalTrials.gov |
| NCT00291941 | A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvan… | Phase3 | Hepatitis B | Completed | 2006-02-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00291343 | Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed … | Phase3 | Infections, Meningococcal | Completed | 2006-02-01 | 2007-03-15 | ClinicalTrials.gov |
| NCT00291941 | A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvan… | Phase3 | Hepatitis B | Completed | 2006-02-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00294190 | Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage … | Phase2 | Small Cell Lung Cancer | Completed | 2006-02-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00354536 | In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2006-02-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00197275 | Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tr… | Phase3 | Tetanus | Completed | 2006-02-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00314860 | RLS In Adults: Comparing Immediate Release Formulation With Extended Release Fo… | Phase3 | Restless Legs Syndrome | Completed | 2006-02-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00354536 | In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2006-02-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00197275 | Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tr… | Phase3 | Tetanus | Completed | 2006-02-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00583232 | Protein and Energy Metabolism in Pediatric Crohn's Disease | Phase1 | Crohn's Disease | Completed | 2006-02-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00314860 | RLS In Adults: Comparing Immediate Release Formulation With Extended Release Fo… | Phase3 | Restless Legs Syndrome | Completed | 2006-02-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00294190 | Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage … | Phase2 | Small Cell Lung Cancer | Completed | 2006-02-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00291343 | Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed … | Phase3 | Infections, Meningococcal | Completed | 2006-02-01 | 2007-03-15 | ClinicalTrials.gov |
| NCT00583232 | Protein and Energy Metabolism in Pediatric Crohn's Disease | Phase1 | Crohn's Disease | Completed | 2006-02-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00320398 | Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium) | Phase3 | Thrombosis, Venous | Completed | 2006-01-30 | 2006-07-18 | ClinicalTrials.gov |
| NCT00320398 | Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium) | Phase3 | Thrombosis, Venous | Completed | 2006-01-30 | 2006-07-18 | ClinicalTrials.gov |
| NCT00282295 | US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licens… | Phase4 | Acellular Pertussis | Completed | 2006-01-25 | 2006-08-08 | ClinicalTrials.gov |
| NCT00282295 | US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licens… | Phase4 | Acellular Pertussis | Completed | 2006-01-25 | 2006-08-08 | ClinicalTrials.gov |
| NCT00136604 | Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m… | Phase3 | Whole Cell Pertussis | Completed | 2006-01-22 | 2006-04-23 | ClinicalTrials.gov |
| NCT00136604 | Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m… | Phase3 | Whole Cell Pertussis | Completed | 2006-01-22 | 2006-04-23 | ClinicalTrials.gov |
| NCT00354965 | Pharmacokinetic Profiles Of Amoxicillin 2000 mg And Clavulanate 125 mg In Adole… | Phase1 | Infections, Respiratory Tract | Completed | 2006-01-19 | 2007-04-02 | ClinicalTrials.gov |
| NCT00296517 | Study In Patients With Depression Not Responding to Selective Serotonin Re-upta… | Phase3 | Depressive Disorder | Completed | 2006-01-19 | 2008-03-28 | ClinicalTrials.gov |
| NCT00354965 | Pharmacokinetic Profiles Of Amoxicillin 2000 mg And Clavulanate 125 mg In Adole… | Phase1 | Infections, Respiratory Tract | Completed | 2006-01-19 | 2007-04-02 | ClinicalTrials.gov |
| NCT00296517 | Study In Patients With Depression Not Responding to Selective Serotonin Re-upta… | Phase3 | Depressive Disorder | Completed | 2006-01-19 | 2008-03-28 | ClinicalTrials.gov |
| NCT00290329 | Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipin… | Phase4 | Infections, Meningococcal | Completed | 2006-01-14 | 2006-10-17 | ClinicalTrials.gov |
| NCT00290329 | Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipin… | Phase4 | Infections, Meningococcal | Completed | 2006-01-14 | 2006-10-17 | ClinicalTrials.gov |
| NCT00297063 | BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2006-01-11 | 2007-05-31 | ClinicalTrials.gov |
| NCT00297063 | BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2006-01-11 | 2007-05-31 | ClinicalTrials.gov |
| NCT00273052 | COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dysl… | Phase3 | Hypertension | Completed | 2006-01-05 | 2007-12-28 | ClinicalTrials.gov |
| NCT00273052 | COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dysl… | Phase3 | Hypertension | Completed | 2006-01-05 | 2007-12-28 | ClinicalTrials.gov |
| NCT00275275 | Pramipexole Conversion to Ropinirole Controlled Release (CR) | Phase3 | Parkinson Disease | Completed | 2006-01-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00280436 | Effects Of GW679769 On Sleep Onset And Maintenance,And Next Day Functioning In … | Phase2 | Sleep Initiation and Maintenance Disorders | Completed | 2006-01-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00316719 | Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients | Phase3 | Chronic Hepatitis B | Completed | 2006-01-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00460005 | Clinical Study Of Migraine Evolution | — | Migraine Headache | Completed | 2006-01-01 | — | ClinicalTrials.gov |
| NCT00379990 | A Study To Investigate GW274150 Or Prednisolone In Rheumatoid Arthritis Taken R… | Phase2 | Arthritis, Rheumatoid | Completed | 2006-01-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00379990 | A Study To Investigate GW274150 Or Prednisolone In Rheumatoid Arthritis Taken R… | Phase2 | Arthritis, Rheumatoid | Completed | 2006-01-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00465296 | Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS | Phase3 | Metabolic Syndrome | Terminated | 2006-01-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00465296 | Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS | Phase3 | Metabolic Syndrome | Terminated | 2006-01-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00274417 | Dutasteride for Improving Peri-Operative and Long-Term Outcomes of Photoselecti… | Na | Benign Prostatic Hyperplasia | Unknown | 2006-01-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00269061 | Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylure… | Phase1 | Non-Insulin-Dependent Diabetes Mellitus | Completed | 2006-01-01 | — | ClinicalTrials.gov |
| NCT00274417 | Dutasteride for Improving Peri-Operative and Long-Term Outcomes of Photoselecti… | Na | Benign Prostatic Hyperplasia | Unknown | 2006-01-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00275275 | Pramipexole Conversion to Ropinirole Controlled Release (CR) | Phase3 | Parkinson Disease | Completed | 2006-01-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00460005 | Clinical Study Of Migraine Evolution | — | Migraine Headache | Completed | 2006-01-01 | — | ClinicalTrials.gov |
| NCT00324961 | Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative… | Phase4 | Chronic Hepatitis B | Completed | 2006-01-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00358410 | An Exploratory Study Examining The Effects Of Taking GW679769 Once-Daily For 4 … | Phase2 | Nonulcer Dyspepsia | Completed | 2006-01-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00269061 | Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylure… | Phase1 | Non-Insulin-Dependent Diabetes Mellitus | Completed | 2006-01-01 | — | ClinicalTrials.gov |
| NCT00280436 | Effects Of GW679769 On Sleep Onset And Maintenance,And Next Day Functioning In … | Phase2 | Sleep Initiation and Maintenance Disorders | Completed | 2006-01-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00285727 | Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of M… | Na | Depressive Disorder, Major | Completed | 2006-01-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00298805 | A Quality of Life Study in Patients With Migraines | — | Migraine | Terminated | 2006-01-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT00285727 | Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of M… | Na | Depressive Disorder, Major | Completed | 2006-01-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00332319 | Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladde… | Phase2 | Incontinence, Urinary and Urinary Bladder, Overactive | Terminated | 2006-01-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00291356 | GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2006-01-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00298805 | A Quality of Life Study in Patients With Migraines | — | Migraine | Terminated | 2006-01-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT00332046 | fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With S… | Phase1 | Social Anxiety Disorder | Completed | 2006-01-01 | — | ClinicalTrials.gov |
| NCT00332319 | Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladde… | Phase2 | Incontinence, Urinary and Urinary Bladder, Overactive | Terminated | 2006-01-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00324961 | Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative… | Phase4 | Chronic Hepatitis B | Completed | 2006-01-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00358410 | An Exploratory Study Examining The Effects Of Taking GW679769 Once-Daily For 4 … | Phase2 | Nonulcer Dyspepsia | Completed | 2006-01-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00291356 | GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2006-01-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00332046 | fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With S… | Phase1 | Social Anxiety Disorder | Completed | 2006-01-01 | — | ClinicalTrials.gov |
| NCT00316719 | Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients | Phase3 | Chronic Hepatitis B | Completed | 2006-01-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00279019 | Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructiv… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2005-12-12 | 2006-06-13 | ClinicalTrials.gov |
| NCT00279019 | Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructiv… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2005-12-12 | 2006-06-13 | ClinicalTrials.gov |
| NCT00235755 | Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in E… | Phase3 | Seizures | Completed | 2005-12-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00359177 | Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subje… | Phase1 | Vomiting | Completed | 2005-12-01 | 2006-10-12 | ClinicalTrials.gov |
| NCT00325169 | SERETIDE Plus Tiotropium Versus Individual Components | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2005-12-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00321477 | A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder | Phase2 | Incontinence, Urinary and Urinary Bladder, Overactive | Completed | 2005-12-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00319137 | An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine | Phase2 | Migraine Disorders | Completed | 2005-12-01 | — | ClinicalTrials.gov |
| NCT00318669 | Social Anxiety Disorder Study Of Paroxetine | Phase3 | Social Phobia | Completed | 2005-12-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00316147 | Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian In… | Phase3 | Diphtheria | Completed | 2005-12-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00309855 | Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men | Phase1 | Aging | Completed | 2005-12-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00292552 | Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Id… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2005-12-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00285831 | Mild Depression 2 Week Observational Study | — | Depressive Disorder | Completed | 2005-12-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00264667 | Study In Patients With Dyslipidaemia | Phase2 | Metabolic Syndrome X | Completed | 2005-12-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00122603 | Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral … | Phase2 | HIV Infections | Completed | 2005-12-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00359177 | Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subje… | Phase1 | Vomiting | Completed | 2005-12-01 | 2006-10-12 | ClinicalTrials.gov |
| NCT00325169 | SERETIDE Plus Tiotropium Versus Individual Components | Phase2 | Pulmonary Disease, Chronic Obstructive | Completed | 2005-12-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00321477 | A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder | Phase2 | Incontinence, Urinary and Urinary Bladder, Overactive | Completed | 2005-12-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00319137 | An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine | Phase2 | Migraine Disorders | Completed | 2005-12-01 | — | ClinicalTrials.gov |
| NCT00318669 | Social Anxiety Disorder Study Of Paroxetine | Phase3 | Social Phobia | Completed | 2005-12-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00316147 | Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian In… | Phase3 | Diphtheria | Completed | 2005-12-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00309855 | Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men | Phase1 | Aging | Completed | 2005-12-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00292552 | Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Id… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2005-12-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00285831 | Mild Depression 2 Week Observational Study | — | Depressive Disorder | Completed | 2005-12-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00264667 | Study In Patients With Dyslipidaemia | Phase2 | Metabolic Syndrome X | Completed | 2005-12-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00235755 | Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in E… | Phase3 | Seizures | Completed | 2005-12-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00122603 | Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral … | Phase2 | HIV Infections | Completed | 2005-12-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00320411 | GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast… | Phase2 | Neoplasms, Breast | Completed | 2005-11-28 | 2009-04-01 | ClinicalTrials.gov |
| NCT00320411 | GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast… | Phase2 | Neoplasms, Breast | Completed | 2005-11-28 | 2009-04-01 | ClinicalTrials.gov |
| NCT00400660 | A First Time In Human Study To Assess The Compound GSK615915 | Phase1 | Bronchospasm | Completed | 2005-11-23 | 2006-07-03 | ClinicalTrials.gov |
| NCT00400660 | A First Time In Human Study To Assess The Compound GSK615915 | Phase1 | Bronchospasm | Completed | 2005-11-23 | 2006-07-03 | ClinicalTrials.gov |
| NCT00258050 | To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Mi… | Phase1 | Neoplasms, Breast | Completed | 2005-11-21 | 2007-02-08 | ClinicalTrials.gov |
| NCT00258050 | To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Mi… | Phase1 | Neoplasms, Breast | Completed | 2005-11-21 | 2007-02-08 | ClinicalTrials.gov |
| NCT00372255 | Study on the Immunogenicity and Tolerability of Influsplit SSW® 2005/2006 in Ch… | Phase4 | Influenza | Completed | 2005-11-17 | 2006-03-28 | ClinicalTrials.gov |
| NCT00372255 | Study on the Immunogenicity and Tolerability of Influsplit SSW® 2005/2006 in Ch… | Phase4 | Influenza | Completed | 2005-11-17 | 2006-03-28 | ClinicalTrials.gov |
| NCT00256854 | Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Rele… | Phase3 | Restless Legs Syndrome | Completed | 2005-11-14 | 2006-09-21 | ClinicalTrials.gov |
| NCT00256854 | Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Rele… | Phase3 | Restless Legs Syndrome | Completed | 2005-11-14 | 2006-09-21 | ClinicalTrials.gov |
| NCT00268996 | Integrated Biomarker And Imaging Study - 2 | Phase2 | Atherosclerosis | Completed | 2005-11-10 | 2007-08-28 | ClinicalTrials.gov |
| NCT00268996 | Integrated Biomarker And Imaging Study - 2 | Phase2 | Atherosclerosis | Completed | 2005-11-10 | 2007-08-28 | ClinicalTrials.gov |
| NCT00887406 | Study of GSK961081 in Healthy Volunteer Subjects | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2005-11-07 | 2006-10-04 | ClinicalTrials.gov |
| NCT00887406 | Study of GSK961081 in Healthy Volunteer Subjects | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2005-11-07 | 2006-10-04 | ClinicalTrials.gov |
| NCT00338338 | The Efficacy And Safety Of Lacidipine And Amlodipine Once-Daily Treatment In Hy… | Phase4 | Uncomplicated Hypertension | Completed | 2005-11-07 | 2007-09-14 | ClinicalTrials.gov |
| NCT00338338 | The Efficacy And Safety Of Lacidipine And Amlodipine Once-Daily Treatment In Hy… | Phase4 | Uncomplicated Hypertension | Completed | 2005-11-07 | 2007-09-14 | ClinicalTrials.gov |
| NCT00259909 | Observational Study Of An Electronic Questionnaire In Patients With Chronic Obs… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2005-11-02 | 2006-11-07 | ClinicalTrials.gov |
| NCT00259909 | Observational Study Of An Electronic Questionnaire In Patients With Chronic Obs… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2005-11-02 | 2006-11-07 | ClinicalTrials.gov |
| NCT00307567 | Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals'… | Phase2 | Acellular Pertussis | Completed | 2005-11-01 | 2006-03-01 | ClinicalTrials.gov |
| NCT00307554 | A Lot-to-lot Consistency (3 Lots of GSK Biologicals' 10-valent Pneumococcal Con… | Phase3 | Infections, Streptococcal | Completed | 2005-11-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00523913 | A Study Of BRL49653C For The Treatment Of Type 2 Diabetes | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2005-11-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00246701 | Evaluation of Efficacy and Safety of Combined Omacor (Omega-3-acid Ethyl Esters… | Phase3 | Hypertriglyceridemia | Completed | 2005-11-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00244309 | Study of Tamsulosin and/or Dutasteride to Relieve Urinary Symptoms After Brachy… | Phase3 | Prostate Cancer | Completed | 2005-11-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00291382 | Airway Hyper-responsiveness Study In Asthma Using Salmeterol/Fluticasone Propio… | Phase4 | Asthma | Completed | 2005-11-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00320450 | SB-681323 In Subjects With Rheumatoid Arthritis | Phase2 | Arthritis, Rheumatoid | Completed | 2005-11-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00240643 | Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At… | Phase2 | Fibrillation, Atrial | Completed | 2005-11-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00290277 | Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female … | Phase3 | Infections, Papillomavirus | Completed | 2005-11-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00240643 | Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At… | Phase2 | Fibrillation, Atrial | Completed | 2005-11-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00269048 | SB-480848 In Subjects With Coronary Heart Disease | Phase2 | Atherosclerosis | Completed | 2005-11-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00246701 | Evaluation of Efficacy and Safety of Combined Omacor (Omega-3-acid Ethyl Esters… | Phase3 | Hypertriglyceridemia | Completed | 2005-11-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00320385 | Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subje… | Phase3 | Neoplasms, Breast | Completed | 2005-11-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00318656 | 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes | Phase4 | Non-Insulin-Dependent Diabetes Mellitus | Completed | 2005-11-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00127010 | Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rube… | Phase3 | Measles | Completed | 2005-11-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00730782 | Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutc… | Phase1 | Plasmodium Falciparum Malaria | Completed | 2005-11-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00317434 | Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent O… | Phase1 | Ovarian Cancer | Terminated | 2005-11-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00320450 | SB-681323 In Subjects With Rheumatoid Arthritis | Phase2 | Arthritis, Rheumatoid | Completed | 2005-11-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00126308 | Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic… | Phase4 | HIV-Associated Lipodystrophy | Terminated | 2005-11-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00523913 | A Study Of BRL49653C For The Treatment Of Type 2 Diabetes | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2005-11-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00291382 | Airway Hyper-responsiveness Study In Asthma Using Salmeterol/Fluticasone Propio… | Phase4 | Asthma | Completed | 2005-11-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00290277 | Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female … | Phase3 | Infections, Papillomavirus | Completed | 2005-11-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00127010 | Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rube… | Phase3 | Measles | Completed | 2005-11-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00318656 | 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes | Phase4 | Non-Insulin-Dependent Diabetes Mellitus | Completed | 2005-11-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00269048 | SB-480848 In Subjects With Coronary Heart Disease | Phase2 | Atherosclerosis | Completed | 2005-11-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00317434 | Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent O… | Phase1 | Ovarian Cancer | Terminated | 2005-11-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00260793 | Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Di… | Phase3 | Parkinson's Disease | Unknown | 2005-11-01 | — | ClinicalTrials.gov |
| NCT00259987 | Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The… | Phase2 | Adenocarcinoma | Completed | 2005-11-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00307567 | Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals'… | Phase2 | Acellular Pertussis | Completed | 2005-11-01 | 2006-03-01 | ClinicalTrials.gov |
| NCT00307554 | A Lot-to-lot Consistency (3 Lots of GSK Biologicals' 10-valent Pneumococcal Con… | Phase3 | Infections, Streptococcal | Completed | 2005-11-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00259987 | Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The… | Phase2 | Adenocarcinoma | Completed | 2005-11-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00260793 | Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Di… | Phase3 | Parkinson's Disease | Unknown | 2005-11-01 | — | ClinicalTrials.gov |
| NCT00730782 | Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutc… | Phase1 | Plasmodium Falciparum Malaria | Completed | 2005-11-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00320385 | Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subje… | Phase3 | Neoplasms, Breast | Completed | 2005-11-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00126308 | Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic… | Phase4 | HIV-Associated Lipodystrophy | Terminated | 2005-11-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00244309 | Study of Tamsulosin and/or Dutasteride to Relieve Urinary Symptoms After Brachy… | Phase3 | Prostate Cancer | Completed | 2005-11-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00250276 | Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Ma… | Phase3 | Infections, Papillomavirus | Completed | 2005-10-28 | 2007-03-01 | ClinicalTrials.gov |
| NCT00250276 | Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Ma… | Phase3 | Infections, Papillomavirus | Completed | 2005-10-28 | 2007-03-01 | ClinicalTrials.gov |
| NCT00307541 | Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate … | Phase3 | Infections, Streptococcal | Completed | 2005-10-27 | 2006-04-07 | ClinicalTrials.gov |
| NCT00307541 | Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate … | Phase3 | Infections, Streptococcal | Completed | 2005-10-27 | 2006-04-07 | ClinicalTrials.gov |
| NCT00373243 | A Study Of GW406381 In Volunteers With Moderate Hepatic Impairment | Phase1 | Pain | Completed | 2005-10-19 | 2006-09-26 | ClinicalTrials.gov |
| NCT00373243 | A Study Of GW406381 In Volunteers With Moderate Hepatic Impairment | Phase1 | Pain | Completed | 2005-10-19 | 2006-09-26 | ClinicalTrials.gov |
| NCT00318149 | Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease … | Phase2 | Influenza | Completed | 2005-10-10 | 2006-05-14 | ClinicalTrials.gov |
| NCT00318149 | Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease … | Phase2 | Influenza | Completed | 2005-10-10 | 2006-05-14 | ClinicalTrials.gov |
| NCT00483899 | Examine the Effect of Repeat Inhaled Doses of GW870086X on Lung Function in Mil… | Phase1 | Asthma | Completed | 2005-10-07 | 2006-12-15 | ClinicalTrials.gov |
| NCT00483899 | Examine the Effect of Repeat Inhaled Doses of GW870086X on Lung Function in Mil… | Phase1 | Asthma | Completed | 2005-10-07 | 2006-12-15 | ClinicalTrials.gov |
| NCT00318058 | Safety Study of an Adjuvanted Candidate Influenza Vaccine to Prevent Influenza … | Phase1 | Influenza | Completed | 2005-10-03 | 2005-11-04 | ClinicalTrials.gov |
| NCT00318058 | Safety Study of an Adjuvanted Candidate Influenza Vaccine to Prevent Influenza … | Phase1 | Influenza | Completed | 2005-10-03 | 2005-11-04 | ClinicalTrials.gov |
| NCT00563134 | A Randomised Trial on the Saftely and Efficacy of GR270774 in the Treatment of … | Na | Gram-Negative Bacterial Infections | Suspended | 2005-10-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00240630 | Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute… | Phase3 | Migraine Disorders | Completed | 2005-10-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00240617 | Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multipl… | Phase3 | Migraine Disorders | Completed | 2005-10-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00244764 | GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell… | Phase2 | Carcinoma, Renal Cell | Completed | 2005-10-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT00246636 | Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-… | Phase4 | Hypertriglyceridemia | Completed | 2005-10-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00246753 | Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hor… | Phase2 | Prostate Cancer | Completed | 2005-10-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT00197288 | Study Comparing the Immune Response of Fluarix and Fluzone Influenza Vaccines | Phase3 | Influenza | Completed | 2005-10-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00259896 | In-patient Study in Patients With Type 2 Diabetes Mellitus | Phase1 | Type 2 Diabetes Mellitus | Completed | 2005-10-01 | — | ClinicalTrials.gov |
| NCT00264615 | Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended… | Phase3 | Epilepsy | Completed | 2005-10-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00264628 | GW679769 In Fibromyalgia | — | Depressive Disorder | Completed | 2005-10-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00264654 | Long-term Study Of Paroxetine in Women and Men | Phase3 | Social Phobia | Completed | 2005-10-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00267488 | Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometri… | Phase2 | Neoplasms, Endometrial | Completed | 2005-10-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00197288 | Study Comparing the Immune Response of Fluarix and Fluzone Influenza Vaccines | Phase3 | Influenza | Completed | 2005-10-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00243152 | Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI | Na | Facial Neuropathy | Completed | 2005-10-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00240617 | Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multipl… | Phase3 | Migraine Disorders | Completed | 2005-10-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00240630 | Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute… | Phase3 | Migraine Disorders | Completed | 2005-10-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00241644 | Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childho… | Phase3 | Infections, Rotavirus | Completed | 2005-10-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00272805 | Drug Compliance and Quality of Life in Patients With Heart Failure Dosed With E… | Phase3 | Chronic Heart Failure | Completed | 2005-10-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00242866 | Use Of GW274150 In The Prophylactic Treatment Of Migraine | Phase2 | Migraine Disorders | Completed | 2005-10-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00243152 | Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI | Na | Facial Neuropathy | Completed | 2005-10-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00244764 | GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell… | Phase2 | Carcinoma, Renal Cell | Completed | 2005-10-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT00246636 | Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-… | Phase4 | Hypertriglyceridemia | Completed | 2005-10-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00246753 | Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hor… | Phase2 | Prostate Cancer | Completed | 2005-10-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT00259896 | In-patient Study in Patients With Type 2 Diabetes Mellitus | Phase1 | Type 2 Diabetes Mellitus | Completed | 2005-10-01 | — | ClinicalTrials.gov |
| NCT01197729 | OPTAMI (Optimized Therapy of Acute Myocardial Infarction) - Registry | — | Myocardial Infarction | Completed | 2005-10-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00264615 | Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended… | Phase3 | Epilepsy | Completed | 2005-10-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00264628 | GW679769 In Fibromyalgia | — | Depressive Disorder | Completed | 2005-10-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00264654 | Long-term Study Of Paroxetine in Women and Men | Phase3 | Social Phobia | Completed | 2005-10-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00267488 | Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometri… | Phase2 | Neoplasms, Endometrial | Completed | 2005-10-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00272805 | Drug Compliance and Quality of Life in Patients With Heart Failure Dosed With E… | Phase3 | Chronic Heart Failure | Completed | 2005-10-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00242866 | Use Of GW274150 In The Prophylactic Treatment Of Migraine | Phase2 | Migraine Disorders | Completed | 2005-10-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00674674 | Phase 1 Intrathecal Topotecan for Neoplastic Meningitis | Phase1 | Neoplastic Meningitis | Completed | 2005-10-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00328718 | Pediatric ADVAIR DISKUS Versus Oral Montelukast Chewable Tablets | Phase3 | Asthma | Completed | 2005-10-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00563134 | A Randomised Trial on the Saftely and Efficacy of GR270774 in the Treatment of … | Na | Gram-Negative Bacterial Infections | Suspended | 2005-10-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT01197729 | OPTAMI (Optimized Therapy of Acute Myocardial Infarction) - Registry | — | Myocardial Infarction | Completed | 2005-10-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00674674 | Phase 1 Intrathecal Topotecan for Neoplastic Meningitis | Phase1 | Neoplastic Meningitis | Completed | 2005-10-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00241644 | Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childho… | Phase3 | Infections, Rotavirus | Completed | 2005-10-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00328718 | Pediatric ADVAIR DISKUS Versus Oral Montelukast Chewable Tablets | Phase3 | Asthma | Completed | 2005-10-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00355641 | Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome | Phase3 | Restless Legs Syndrome | Completed | 2005-10-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00355641 | Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome | Phase3 | Restless Legs Syndrome | Completed | 2005-10-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00360126 | An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder | Phase4 | Bipolar Disorder | Completed | 2005-10-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00360126 | An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder | Phase4 | Bipolar Disorder | Completed | 2005-10-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00358384 | Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034 | Phase1 | Psoriasis | Completed | 2005-09-26 | 2006-02-24 | ClinicalTrials.gov |
| NCT00358384 | Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034 | Phase1 | Psoriasis | Completed | 2005-09-26 | 2006-02-24 | ClinicalTrials.gov |
| NCT00232596 | Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Ref… | Phase3 | Seizures | Completed | 2005-09-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00262587 | Elite Sport and Development of Asthma | Phase4 | Asthma | Completed | 2005-09-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00296530 | Study Of Patients With Allergic Rhinitis And Asthma | Phase4 | Asthma | Completed | 2005-09-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00180843 | Assessment of Ventilation-perfusion Abnormalities in Patients With Stable Smoki… | Na | Chronic Obstructive Pulmonary Disease | Terminated | 2005-09-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00145990 | The Impact of Dosimeter on Measurement of Airway Responsiveness to Methacholine | Na | Asthma | Completed | 2005-09-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00259870 | SB-773812 Administered In Adults With Schizophrenia | Phase2 | Schizophrenia | Completed | 2005-09-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT01299584 | ULTIVA Post Marketing Surveillance | — | Analgesia | Completed | 2005-09-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00314678 | Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial O… | Phase2 | Epithelial Ovarian Cancer | Completed | 2005-09-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00262587 | Elite Sport and Development of Asthma | Phase4 | Asthma | Completed | 2005-09-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00314821 | Ropinirole in the Treatment of Bipolar Depression | Phase4 | Bipolar Disorder | Completed | 2005-09-01 | 2008-03-17 | ClinicalTrials.gov |
| NCT00131664 | Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study) | Phase3 | Type 2 Diabetes Mellitus | Completed | 2005-09-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00319332 | A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibri… | Phase3 | Lymphoma, Small Cleaved-Cell, Follicular | Withdrawn | 2005-09-01 | 2021-02-01 | ClinicalTrials.gov |
| NCT00320307 | Comparison of Abacavir Following Once-Daily And Twice-Daily Administration In H… | Phase1 | HIV Infection | Completed | 2005-09-01 | — | ClinicalTrials.gov |
| NCT00736801 | Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations… | Na | Allergic Asthma | Completed | 2005-09-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00296491 | Study Of Allergic Rhinitis In Patients Who Also Have Asthma | Phase4 | Asthma | Completed | 2005-09-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00296530 | Study Of Patients With Allergic Rhinitis And Asthma | Phase4 | Asthma | Completed | 2005-09-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00197223 | Post-marketing Study to Evaluate the Efficacy of Influenza Vaccine | Phase3 | Influenza | Completed | 2005-09-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00314678 | Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial O… | Phase2 | Epithelial Ovarian Cancer | Completed | 2005-09-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00314821 | Ropinirole in the Treatment of Bipolar Depression | Phase4 | Bipolar Disorder | Completed | 2005-09-01 | 2008-03-17 | ClinicalTrials.gov |
| NCT00259870 | SB-773812 Administered In Adults With Schizophrenia | Phase2 | Schizophrenia | Completed | 2005-09-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00736801 | Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations… | Na | Allergic Asthma | Completed | 2005-09-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00244725 | Odiparcil For The Prevention Of Venous Thromboembolism | Phase2 | Deep Vein Thrombosis | Completed | 2005-09-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00319332 | A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibri… | Phase3 | Lymphoma, Small Cleaved-Cell, Follicular | Withdrawn | 2005-09-01 | 2021-02-01 | ClinicalTrials.gov |
| NCT00320307 | Comparison of Abacavir Following Once-Daily And Twice-Daily Administration In H… | Phase1 | HIV Infection | Completed | 2005-09-01 | — | ClinicalTrials.gov |
| NCT00131664 | Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study) | Phase3 | Type 2 Diabetes Mellitus | Completed | 2005-09-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00196989 | Study In People With Type 2 Diabetes | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2005-09-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00197223 | Post-marketing Study to Evaluate the Efficacy of Influenza Vaccine | Phase3 | Influenza | Completed | 2005-09-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT01299584 | ULTIVA Post Marketing Surveillance | — | Analgesia | Completed | 2005-09-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00232596 | Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Ref… | Phase3 | Seizures | Completed | 2005-09-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00196989 | Study In People With Type 2 Diabetes | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2005-09-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00145990 | The Impact of Dosimeter on Measurement of Airway Responsiveness to Methacholine | Na | Asthma | Completed | 2005-09-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00180843 | Assessment of Ventilation-perfusion Abnormalities in Patients With Stable Smoki… | Na | Chronic Obstructive Pulmonary Disease | Terminated | 2005-09-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00296491 | Study Of Allergic Rhinitis In Patients Who Also Have Asthma | Phase4 | Asthma | Completed | 2005-09-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00244725 | Odiparcil For The Prevention Of Venous Thromboembolism | Phase2 | Deep Vein Thrombosis | Completed | 2005-09-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00197028 | Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to … | Phase2 | Malaria | Completed | 2005-08-23 | 2007-12-27 | ClinicalTrials.gov |
| NCT00197028 | Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to … | Phase2 | Malaria | Completed | 2005-08-23 | 2007-12-27 | ClinicalTrials.gov |
| NCT00256867 | A Study In Patients With Type 2 Diabetes Mellitus | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2005-08-18 | 2006-10-31 | ClinicalTrials.gov |
| NCT00256867 | A Study In Patients With Type 2 Diabetes Mellitus | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2005-08-18 | 2006-10-31 | ClinicalTrials.gov |
| NCT00327197 | Assessment Of Disease Pathology And Key Therapeutic Targets In Severe Asthma | Phase1 | Asthma | Terminated | 2005-08-02 | 2011-06-06 | ClinicalTrials.gov |
| NCT00327197 | Assessment Of Disease Pathology And Key Therapeutic Targets In Severe Asthma | Phase1 | Asthma | Terminated | 2005-08-02 | 2011-06-06 | ClinicalTrials.gov |
| NCT00135200 | Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Mul… | Phase2 | Multiple Myeloma | Completed | 2005-08-01 | 2024-09-04 | ClinicalTrials.gov |
| NCT00257569 | Study Of Atopic Dermatitis In Pediatrics | Phase3 | Dermatitis, Atopic | Completed | 2005-08-01 | — | ClinicalTrials.gov |
| NCT00370435 | Study Of 90mg Of GW274150 In Subjects Over 50 Years, Who Have Rheumatoid Arthri… | Phase2 | Arthritis, Rheumatoid | Completed | 2005-08-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00256932 | Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer … | Phase3 | Bowel Dysfunction | Completed | 2005-08-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00257582 | Study Of Cutaneous Disease Accompanied With Pruritus In Pediatrics | Phase3 | Pruritus | Completed | 2005-08-01 | — | ClinicalTrials.gov |
| NCT00197262 | Once-Daily Investigational Nasal Spray In Adults And Adolescents With Seasonal … | Phase3 | Rhinitis, Allergic, Seasonal | Completed | 2005-08-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT02948881 | A Study To Assess The Quality Of Bone In Patients Taking Oral Ibandronate Versu… | Phase4 | Osteoporosis | Completed | 2005-08-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00137930 | Study of Immunogenicity & Safety of 2 Different Formulations of Human Rotavirus… | Phase2 | Infections, Rotavirus | Completed | 2005-08-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00257569 | Study Of Atopic Dermatitis In Pediatrics | Phase3 | Dermatitis, Atopic | Completed | 2005-08-01 | — | ClinicalTrials.gov |
| NCT00126945 | Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conju… | Phase2 | Infections, Meningococcal | Completed | 2005-08-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00135200 | Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Mul… | Phase2 | Multiple Myeloma | Completed | 2005-08-01 | 2024-09-04 | ClinicalTrials.gov |
| NCT00256932 | Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer … | Phase3 | Bowel Dysfunction | Completed | 2005-08-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00372801 | Effectiveness Of Single Doses Of Ibuprofen In Patients With Osteoarthritis Of T… | Phase1 | Osteoarthritis | Completed | 2005-08-01 | — | ClinicalTrials.gov |
| NCT00120796 | Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chron… | Phase3 | Hepatitis B | Terminated | 2005-08-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00197262 | Once-Daily Investigational Nasal Spray In Adults And Adolescents With Seasonal … | Phase3 | Rhinitis, Allergic, Seasonal | Completed | 2005-08-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00257595 | Perennial Allergic Rhinitis In Pediatric Subjects | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2005-08-01 | — | ClinicalTrials.gov |
| NCT00257582 | Study Of Cutaneous Disease Accompanied With Pruritus In Pediatrics | Phase3 | Pruritus | Completed | 2005-08-01 | — | ClinicalTrials.gov |
| NCT02948881 | A Study To Assess The Quality Of Bone In Patients Taking Oral Ibandronate Versu… | Phase4 | Osteoporosis | Completed | 2005-08-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00126945 | Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conju… | Phase2 | Infections, Meningococcal | Completed | 2005-08-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00370435 | Study Of 90mg Of GW274150 In Subjects Over 50 Years, Who Have Rheumatoid Arthri… | Phase2 | Arthritis, Rheumatoid | Completed | 2005-08-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00241722 | Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being T… | Phase3 | Bowel Dysfunction | Completed | 2005-08-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00257595 | Perennial Allergic Rhinitis In Pediatric Subjects | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2005-08-01 | — | ClinicalTrials.gov |
| NCT00241722 | Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being T… | Phase3 | Bowel Dysfunction | Completed | 2005-08-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00316407 | Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer… | Phase1 | Ovarian Epithelial Cancer Stage III | Completed | 2005-08-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00137930 | Study of Immunogenicity & Safety of 2 Different Formulations of Human Rotavirus… | Phase2 | Infections, Rotavirus | Completed | 2005-08-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00120796 | Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chron… | Phase3 | Hepatitis B | Terminated | 2005-08-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00259922 | Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Pers… | Phase3 | Bowel Dysfunction | Completed | 2005-08-01 | — | ClinicalTrials.gov |
| NCT00316407 | Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer… | Phase1 | Ovarian Epithelial Cancer Stage III | Completed | 2005-08-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00259922 | Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Pers… | Phase3 | Bowel Dysfunction | Completed | 2005-08-01 | — | ClinicalTrials.gov |
| NCT00372801 | Effectiveness Of Single Doses Of Ibuprofen In Patients With Osteoarthritis Of T… | Phase1 | Osteoarthritis | Completed | 2005-08-01 | — | ClinicalTrials.gov |
| NCT00351143 | A Comparative Study To Determine If Motivating Asthma Education (Compliance Enh… | Phase4 | Asthma | Completed | 2005-07-26 | 2007-06-13 | ClinicalTrials.gov |
| NCT00351143 | A Comparative Study To Determine If Motivating Asthma Education (Compliance Enh… | Phase4 | Asthma | Completed | 2005-07-26 | 2007-06-13 | ClinicalTrials.gov |
| NCT00318630 | The Effect Of AVANDIA On The Late Asthmatic Response | Phase1 | Asthma | Completed | 2005-07-22 | 2006-06-30 | ClinicalTrials.gov |
| NCT00318630 | The Effect Of AVANDIA On The Late Asthmatic Response | Phase1 | Asthma | Completed | 2005-07-22 | 2006-06-30 | ClinicalTrials.gov |
| NCT00117325 | Study Of Adults And Adolescents With Vasomotor Rhinitis | Phase3 | Rhinitis, Vasomotor | Completed | 2005-07-11 | 2006-02-09 | ClinicalTrials.gov |
| NCT00117325 | Study Of Adults And Adolescents With Vasomotor Rhinitis | Phase3 | Rhinitis, Vasomotor | Completed | 2005-07-11 | 2006-02-09 | ClinicalTrials.gov |
| NCT00343278 | Pharmacokinetic Study Of Valaciclovir Hydrochloride Tablets | Phase4 | Virus Diseases | Completed | 2005-07-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00118703 | Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor… | Phase3 | Vasomotor Rhinitis | Completed | 2005-07-01 | 2006-02-09 | ClinicalTrials.gov |
| NCT00364429 | SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patie… | Phase1 | Schizophrenia | Terminated | 2005-07-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00134732 | Study of 2 Doses of Oral Live Attenuated Human Rotavirus (HRV) Vaccine for the … | Phase3 | Infections, Rotavirus | Completed | 2005-07-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00126984 | Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations o… | Phase2 | Infections, Meningococcal | Completed | 2005-07-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00119496 | Rosiglitazone Versus Theophylline in Asthmatic Smokers | Phase2 | Asthma | Completed | 2005-07-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00123903 | COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hyp… | Phase3 | Heart Failure, Congestive and Microalbuminuria | Terminated | 2005-07-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00297076 | Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experi… | Phase3 | HIV Infection | Terminated | 2005-07-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00306943 | Annual Study for Fluarix Registration | Phase3 | Influenza | Completed | 2005-07-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00119496 | Rosiglitazone Versus Theophylline in Asthmatic Smokers | Phase2 | Asthma | Completed | 2005-07-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00123903 | COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hyp… | Phase3 | Heart Failure, Congestive and Microalbuminuria | Terminated | 2005-07-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00118703 | Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor… | Phase3 | Vasomotor Rhinitis | Completed | 2005-07-01 | 2006-02-09 | ClinicalTrials.gov |
| NCT00197054 | Safety, Immunogenicity of RTS,S/AS02A, and RTS,S/AS01B Malaria Vaccines in Mala… | Phase2 | Plasmodium Falciparum | Completed | 2005-07-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00146744 | Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mt… | Phase2 | Tuberculosis (TB) | Completed | 2005-07-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00126984 | Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations o… | Phase2 | Infections, Meningococcal | Completed | 2005-07-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00253058 | Study Of Perennial Allergic Rhinitis In Pediatrics | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2005-07-01 | — | ClinicalTrials.gov |
| NCT00321438 | Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeabl… | — | HIV Infection | Terminated | 2005-07-01 | — | ClinicalTrials.gov |
| NCT00322920 | Efficacy Study of Weekly Topotecan With Cisplatin in Advanced Stage or Recurren… | Phase1 | Cervix Cancer | Terminated | 2005-07-01 | — | ClinicalTrials.gov |
| NCT00321438 | Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeabl… | — | HIV Infection | Terminated | 2005-07-01 | — | ClinicalTrials.gov |
| NCT00364429 | SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patie… | Phase1 | Schizophrenia | Terminated | 2005-07-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00322920 | Efficacy Study of Weekly Topotecan With Cisplatin in Advanced Stage or Recurren… | Phase1 | Cervix Cancer | Terminated | 2005-07-01 | — | ClinicalTrials.gov |
| NCT00253058 | Study Of Perennial Allergic Rhinitis In Pediatrics | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2005-07-01 | — | ClinicalTrials.gov |
| NCT00297076 | Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experi… | Phase3 | HIV Infection | Terminated | 2005-07-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00306943 | Annual Study for Fluarix Registration | Phase3 | Influenza | Completed | 2005-07-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00146744 | Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mt… | Phase2 | Tuberculosis (TB) | Completed | 2005-07-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00197197 | Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Trea… | Phase3 | HIV Infection | Terminated | 2005-07-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00197054 | Safety, Immunogenicity of RTS,S/AS02A, and RTS,S/AS01B Malaria Vaccines in Mala… | Phase2 | Plasmodium Falciparum | Completed | 2005-07-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00197197 | Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Trea… | Phase3 | HIV Infection | Terminated | 2005-07-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00343278 | Pharmacokinetic Study Of Valaciclovir Hydrochloride Tablets | Phase4 | Virus Diseases | Completed | 2005-07-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00134732 | Study of 2 Doses of Oral Live Attenuated Human Rotavirus (HRV) Vaccine for the … | Phase3 | Infections, Rotavirus | Completed | 2005-07-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00269035 | SPECT Study With SB-773812 In Schizophrenic Patients | Phase1 | Schizophrenia | Completed | 2005-06-21 | 2007-05-26 | ClinicalTrials.gov |
| NCT00134693 | A Single Dose Of Compound SB-681323 Compared To Prednisolone On A Protein That … | Phase2 | Arthritis, Rheumatoid | Completed | 2005-06-21 | 2006-08-03 | ClinicalTrials.gov |
| NCT00358475 | Study Of Perennial Allergic Rhinitis | Phase3 | Rhinitis, Allergic, Seasonal | Completed | 2005-06-21 | 2005-10-12 | ClinicalTrials.gov |
| NCT00358475 | Study Of Perennial Allergic Rhinitis | Phase3 | Rhinitis, Allergic, Seasonal | Completed | 2005-06-21 | 2005-10-12 | ClinicalTrials.gov |
| NCT00269035 | SPECT Study With SB-773812 In Schizophrenic Patients | Phase1 | Schizophrenia | Completed | 2005-06-21 | 2007-05-26 | ClinicalTrials.gov |
| NCT00134693 | A Single Dose Of Compound SB-681323 Compared To Prednisolone On A Protein That … | Phase2 | Arthritis, Rheumatoid | Completed | 2005-06-21 | 2006-08-03 | ClinicalTrials.gov |
| NCT00577629 | Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Ce… | Phase2 | Lymphoma, B-Cell | Completed | 2005-06-18 | 2016-11-03 | ClinicalTrials.gov |
| NCT00577629 | Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Ce… | Phase2 | Lymphoma, B-Cell | Completed | 2005-06-18 | 2016-11-03 | ClinicalTrials.gov |
| NCT00228917 | Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax … | Phase3 | Whole Cell Pertussis | Completed | 2005-06-16 | 2006-01-20 | ClinicalTrials.gov |
| NCT00228917 | Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax … | Phase3 | Whole Cell Pertussis | Completed | 2005-06-16 | 2006-01-20 | ClinicalTrials.gov |
| NCT00140712 | Ropinirole Tablets In Young Patients With Restless Legs Syndrome | Phase1 | Restless Legs Syndrome | Completed | 2005-06-10 | 2008-02-28 | ClinicalTrials.gov |
| NCT00140712 | Ropinirole Tablets In Young Patients With Restless Legs Syndrome | Phase1 | Restless Legs Syndrome | Completed | 2005-06-10 | 2008-02-28 | ClinicalTrials.gov |
| NCT00127608 | Detection and Characterisation of Varicella Zoster Virus From Dermal Lesions of… | Phase3 | Varicella | Completed | 2005-06-07 | 2006-07-13 | ClinicalTrials.gov |
| NCT00127608 | Detection and Characterisation of Varicella Zoster Virus From Dermal Lesions of… | Phase3 | Varicella | Completed | 2005-06-07 | 2006-07-13 | ClinicalTrials.gov |
| NCT00259883 | Combination Of PAXIL Tablet And Benzodiazepines | Phase4 | Mental Disorders | Completed | 2005-06-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00237991 | Safety of GlaxoSmithKline (GSK) Biologicals Hepatitis A Vaccine in Korean Popul… | — | Hepatitis A | Completed | 2005-06-01 | — | ClinicalTrials.gov |
| NCT00110630 | Smoking Treatment of Prisoners | Phase3 | Tobacco Use Cessation | Completed | 2005-06-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00413023 | Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Dep… | Phase2 | Depressive Disorder, Major | Completed | 2005-06-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00197080 | Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome | Phase3 | Restless Legs Syndrome | Completed | 2005-06-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT03324633 | Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With … | — | HIV | Completed | 2005-06-01 | 2022-12-01 | ClinicalTrials.gov |
| NCT00380133 | Study of SB681323 and Prednisolone on Biomarkers in COPD (Chronic Obstructive P… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2005-06-01 | 2006-04-01 | ClinicalTrials.gov |
| NCT00110630 | Smoking Treatment of Prisoners | Phase3 | Tobacco Use Cessation | Completed | 2005-06-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00259883 | Combination Of PAXIL Tablet And Benzodiazepines | Phase4 | Mental Disorders | Completed | 2005-06-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00117429 | Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic H… | Phase1 | HIV Infections | Completed | 2005-06-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00123890 | Screening Protocol To Determine Eligibility For Studies Of The Chemokine Corece… | Phase3 | HIV Infection | Terminated | 2005-06-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00237991 | Safety of GlaxoSmithKline (GSK) Biologicals Hepatitis A Vaccine in Korean Popul… | — | Hepatitis A | Completed | 2005-06-01 | — | ClinicalTrials.gov |
| NCT00413023 | Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Dep… | Phase2 | Depressive Disorder, Major | Completed | 2005-06-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00197080 | Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome | Phase3 | Restless Legs Syndrome | Completed | 2005-06-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00123890 | Screening Protocol To Determine Eligibility For Studies Of The Chemokine Corece… | Phase3 | HIV Infection | Terminated | 2005-06-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00227422 | Assess the Non-inferiority of GSK Biologicals' Mencevax™ ACWY (Manufactured by … | Phase4 | Infections, Meningococcal | Completed | 2005-06-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00139334 | A Study to Test 2 Doses of the HRV Vaccine Given With or Without OPV in Healthy… | Phase2 | Infections, Rotavirus | Completed | 2005-06-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00227422 | Assess the Non-inferiority of GSK Biologicals' Mencevax™ ACWY (Manufactured by … | Phase4 | Infections, Meningococcal | Completed | 2005-06-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00197106 | Treatment Of Symptomatic Asthma In Children | Phase4 | Asthma | Completed | 2005-06-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00117429 | Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic H… | Phase1 | HIV Infections | Completed | 2005-06-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00197106 | Treatment Of Symptomatic Asthma In Children | Phase4 | Asthma | Completed | 2005-06-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00380133 | Study of SB681323 and Prednisolone on Biomarkers in COPD (Chronic Obstructive P… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2005-06-01 | 2006-04-01 | ClinicalTrials.gov |
| NCT00139334 | A Study to Test 2 Doses of the HRV Vaccine Given With or Without OPV in Healthy… | Phase2 | Infections, Rotavirus | Completed | 2005-06-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT03324633 | Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With … | — | HIV | Completed | 2005-06-01 | 2022-12-01 | ClinicalTrials.gov |
| NCT00583362 | A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have C… | Phase2 | Systemic Lupus Erythematosus | Completed | 2005-05-04 | 2016-02-23 | ClinicalTrials.gov |
| NCT00583362 | A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have C… | Phase2 | Systemic Lupus Erythematosus | Completed | 2005-05-04 | 2016-02-23 | ClinicalTrials.gov |
| NCT00225823 | Study In Adults And Adolescents With Seasonal Allergic Rhinitis. | Phase3 | Rhinitis, Allergic, Seasonal | Completed | 2005-05-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00126373 | A Trial of Wellbutrin for Crohn's Disease | Phase2 | Crohn Disease | Completed | 2005-05-01 | 2006-03-01 | ClinicalTrials.gov |
| NCT00126997 | Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubell… | Phase4 | Mumps | Completed | 2005-05-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00127023 | Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rube… | Phase3 | Mumps | Completed | 2005-05-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00225823 | Study In Adults And Adolescents With Seasonal Allergic Rhinitis. | Phase3 | Rhinitis, Allergic, Seasonal | Completed | 2005-05-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00126373 | A Trial of Wellbutrin for Crohn's Disease | Phase2 | Crohn Disease | Completed | 2005-05-01 | 2006-03-01 | ClinicalTrials.gov |
| NCT00126997 | Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubell… | Phase4 | Mumps | Completed | 2005-05-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00127023 | Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rube… | Phase3 | Mumps | Completed | 2005-05-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00347009 | Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Relat… | Phase4 | Hepatitis B, Chronic | Completed | 2005-05-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00419809 | SB-681323-Methotrexate Interaction Study | Phase1 | Arthritis, Rheumatoid | Completed | 2005-05-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00347009 | Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Relat… | Phase4 | Hepatitis B, Chronic | Completed | 2005-05-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00419809 | SB-681323-Methotrexate Interaction Study | Phase1 | Arthritis, Rheumatoid | Completed | 2005-05-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00111800 | A New Oral Treatment For Type II Diabetes Mellitus | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2005-04-28 | 2006-07-21 | ClinicalTrials.gov |
| NCT00111800 | A New Oral Treatment For Type II Diabetes Mellitus | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2005-04-28 | 2006-07-21 | ClinicalTrials.gov |
| NCT00134719 | Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup… | Phase2 | Neisseria Meningitidis | Completed | 2005-04-11 | 2007-02-21 | ClinicalTrials.gov |
| NCT00134719 | Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup… | Phase2 | Neisseria Meningitidis | Completed | 2005-04-11 | 2007-02-21 | ClinicalTrials.gov |
| NCT00111787 | Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Dia… | Phase2 | Neoplasms, Breast | Completed | 2005-04-11 | 2006-11-01 | ClinicalTrials.gov |
| NCT00111787 | Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Dia… | Phase2 | Neoplasms, Breast | Completed | 2005-04-11 | 2006-11-01 | ClinicalTrials.gov |
| NCT00118729 | Study In Adolescent And Adult Subjects 12 Years Of Age And Older With Seasonal … | Phase3 | Rhinitis, Allergic, Seasonal | Completed | 2005-04-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00109486 | Safety Study To Assess Growth In Children With Seasonal Allergic And/Or Perenni… | Phase3 | Rhinitis, Allergic, Perennial and Seasonal | Completed | 2005-04-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00110799 | SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With T… | Phase2 | Hepatitis C, Chronic | Completed | 2005-04-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00327990 | Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthl… | Phase4 | Osteoporosis | Completed | 2005-04-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00109486 | Safety Study To Assess Growth In Children With Seasonal Allergic And/Or Perenni… | Phase3 | Rhinitis, Allergic, Perennial and Seasonal | Completed | 2005-04-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00118729 | Study In Adolescent And Adult Subjects 12 Years Of Age And Older With Seasonal … | Phase3 | Rhinitis, Allergic, Seasonal | Completed | 2005-04-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00110799 | SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With T… | Phase2 | Hepatitis C, Chronic | Completed | 2005-04-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00348361 | Exploration Of Key Targets And Biomarkers Involved In An Allergic Response In S… | Phase1 | Allergic Rhinitis | Completed | 2005-04-01 | — | ClinicalTrials.gov |
| NCT00327990 | Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthl… | Phase4 | Osteoporosis | Completed | 2005-04-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00348361 | Exploration Of Key Targets And Biomarkers Involved In An Allergic Response In S… | Phase1 | Allergic Rhinitis | Completed | 2005-04-01 | — | ClinicalTrials.gov |
| NCT00158769 | A Study To Compare The Effects Of The Infusion Of A Sepsis Drug Between Healthy… | Phase1 | Sepsis | Completed | 2005-03-31 | 2005-10-26 | ClinicalTrials.gov |
| NCT00158769 | A Study To Compare The Effects Of The Infusion Of A Sepsis Drug Between Healthy… | Phase1 | Sepsis | Completed | 2005-03-31 | 2005-10-26 | ClinicalTrials.gov |
| NCT00116844 | VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropos… | Phase4 | Infections, Herpesviridae | Completed | 2005-03-29 | 2006-01-10 | ClinicalTrials.gov |
| NCT00116844 | VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropos… | Phase4 | Infections, Herpesviridae | Completed | 2005-03-29 | 2006-01-10 | ClinicalTrials.gov |
| NCT00196976 | Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5… | Phase2 | Infections, Meningococcal | Completed | 2005-03-24 | 2006-03-03 | ClinicalTrials.gov |
| NCT00196976 | Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5… | Phase2 | Infections, Meningococcal | Completed | 2005-03-24 | 2006-03-03 | ClinicalTrials.gov |
| NCT00742131 | A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Forme… | Phase1 | Solid Tumours | Completed | 2005-03-17 | 2011-08-29 | ClinicalTrials.gov |
| NCT00742131 | A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Forme… | Phase1 | Solid Tumours | Completed | 2005-03-17 | 2011-08-29 | ClinicalTrials.gov |
| NCT00140738 | Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive… | Phase1 | Neoplasms, Breast | Completed | 2005-03-10 | 2009-09-29 | ClinicalTrials.gov |
| NCT00140738 | Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive… | Phase1 | Neoplasms, Breast | Completed | 2005-03-10 | 2009-09-29 | ClinicalTrials.gov |
| NCT00107757 | Seasonal Allergic Rhinitis In Pediatric Subjects | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2005-03-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00562081 | The Virtual Asthma Clinic | Phase4 | Asthma | Terminated | 2005-03-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00105950 | Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast … | Phase2 | Neoplasms, Breast | Completed | 2005-03-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00197158 | Comparison of Monodose and Multidose Presentations of GSK Biologicals' Hepatiti… | Phase4 | Hepatitis B | Completed | 2005-03-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00369993 | Spacer Comparison In Adult Asthmatics | Phase2 | Asthma | Completed | 2005-03-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00144833 | Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of … | Phase3 | HIV-1 | Terminated | 2005-03-01 | — | ClinicalTrials.gov |
| NCT00316173 | Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian C… | Phase2 | Ovarian Cancer | Completed | 2005-03-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00144833 | Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of … | Phase3 | HIV-1 | Terminated | 2005-03-01 | — | ClinicalTrials.gov |
| NCT00197158 | Comparison of Monodose and Multidose Presentations of GSK Biologicals' Hepatiti… | Phase4 | Hepatitis B | Completed | 2005-03-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00117832 | Nasal Ocular Reflexes Contribute to Eye Symptoms | Na | Rhinitis, Allergic, Seasonal | Completed | 2005-03-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00562081 | The Virtual Asthma Clinic | Phase4 | Asthma | Terminated | 2005-03-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00194675 | TRADE-Testosterone Replacement and Dutasteride Effectiveness | Phase4 | Hypogonadism | Completed | 2005-03-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00107757 | Seasonal Allergic Rhinitis In Pediatric Subjects | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2005-03-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00263653 | Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK… | Phase3 | Haemophilus Influenzae Type b | Completed | 2005-03-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00316173 | Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian C… | Phase2 | Ovarian Cancer | Completed | 2005-03-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00169416 | Evaluation Of Valaciclovir In Patients With Chickenpox | Phase3 | Varicella | Completed | 2005-03-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00117832 | Nasal Ocular Reflexes Contribute to Eye Symptoms | Na | Rhinitis, Allergic, Seasonal | Completed | 2005-03-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00161421 | Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone | Phase2 | Contraception | Completed | 2005-03-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00194675 | TRADE-Testosterone Replacement and Dutasteride Effectiveness | Phase4 | Hypogonadism | Completed | 2005-03-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00161421 | Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone | Phase2 | Contraception | Completed | 2005-03-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00369993 | Spacer Comparison In Adult Asthmatics | Phase2 | Asthma | Completed | 2005-03-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00105950 | Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast … | Phase2 | Neoplasms, Breast | Completed | 2005-03-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00169416 | Evaluation Of Valaciclovir In Patients With Chickenpox | Phase3 | Varicella | Completed | 2005-03-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00169455 | Assess the Immunogenicity of the Human Rotavirus (HRV) Vaccine After Reconstitu… | Phase3 | Rotavirus Gastroenteritis | Completed | 2005-03-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00263653 | Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK… | Phase3 | Haemophilus Influenzae Type b | Completed | 2005-03-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00169455 | Assess the Immunogenicity of the Human Rotavirus (HRV) Vaccine After Reconstitu… | Phase3 | Rotavirus Gastroenteritis | Completed | 2005-03-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00363740 | Study of GW685698X In Patients With Seasonal Allergic Rhinitis | Phase3 | Rhinitis, Allergic, Seasonal | Completed | 2005-02-19 | 2005-04-13 | ClinicalTrials.gov |
| NCT00363740 | Study of GW685698X In Patients With Seasonal Allergic Rhinitis | Phase3 | Rhinitis, Allergic, Seasonal | Completed | 2005-02-19 | 2005-04-13 | ClinicalTrials.gov |
| NCT00169442 | Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & R… | Phase3 | Whole Cell Pertussis | Completed | 2005-02-10 | 2006-03-10 | ClinicalTrials.gov |
| NCT00169442 | Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & R… | Phase3 | Whole Cell Pertussis | Completed | 2005-02-10 | 2006-03-10 | ClinicalTrials.gov |
| NCT01843621 | A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus A… | Phase1 | Dengue | Completed | 2005-02-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00424762 | Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocar… | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2005-02-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00316654 | Persistence of Antibody Response to N. Meningitidis Group C in Children | Phase4 | Prevention of Meningococcal Infection | Completed | 2005-02-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00295776 | Lamictal in the Treatment of Post-Herpetic Neuralgia | Phase2 | Neuralgia, Postherpetic | Terminated | 2005-02-01 | — | ClinicalTrials.gov |
| NCT00291928 | HuMax-CD20 in Active Rheumatoid Arthritis, Phase I/II | Phase2 | Arthritis, Rheumatoid | Completed | 2005-02-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00287911 | Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced … | Phase1 | Cervical Cancer | Completed | 2005-02-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00274690 | Post-Operative Nausea And Vomiting Study In Female Patients | Phase2 | Postoperative Nausea and Vomiting | Completed | 2005-02-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00316654 | Persistence of Antibody Response to N. Meningitidis Group C in Children | Phase4 | Prevention of Meningococcal Infection | Completed | 2005-02-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00108914 | Perennial Allergic Rhinitis Study In Pediatric Subjects | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2005-02-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00169572 | Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogen… | Phase2 | Nausea and Vomiting | Completed | 2005-02-01 | — | ClinicalTrials.gov |
| NCT00116883 | A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In Pediat… | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2005-02-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00102726 | SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer… | Phase2 | Thrombocytopaenia | Completed | 2005-02-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00424762 | Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocar… | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2005-02-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00295776 | Lamictal in the Treatment of Post-Herpetic Neuralgia | Phase2 | Neuralgia, Postherpetic | Terminated | 2005-02-01 | — | ClinicalTrials.gov |
| NCT00291928 | HuMax-CD20 in Active Rheumatoid Arthritis, Phase I/II | Phase2 | Arthritis, Rheumatoid | Completed | 2005-02-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT01843621 | A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus A… | Phase1 | Dengue | Completed | 2005-02-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT01863589 | Drug Use Investigation for HEPSERA (Adefovir) Tablet | — | Hepatitis B | Completed | 2005-02-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT00102739 | SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With … | Phase2 | Purpura, Thrombocytopaenic, Idiopathic | Completed | 2005-02-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00287911 | Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced … | Phase1 | Cervical Cancer | Completed | 2005-02-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00274690 | Post-Operative Nausea And Vomiting Study In Female Patients | Phase2 | Postoperative Nausea and Vomiting | Completed | 2005-02-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00169572 | Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogen… | Phase2 | Nausea and Vomiting | Completed | 2005-02-01 | — | ClinicalTrials.gov |
| NCT00116883 | A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In Pediat… | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2005-02-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00108914 | Perennial Allergic Rhinitis Study In Pediatric Subjects | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2005-02-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00102739 | SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With … | Phase2 | Purpura, Thrombocytopaenic, Idiopathic | Completed | 2005-02-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00102726 | SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer… | Phase2 | Thrombocytopaenia | Completed | 2005-02-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT01863589 | Drug Use Investigation for HEPSERA (Adefovir) Tablet | — | Hepatitis B | Completed | 2005-02-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT00269087 | GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysem… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2005-01-28 | 2006-10-25 | ClinicalTrials.gov |
| NCT00269087 | GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysem… | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2005-01-28 | 2006-10-25 | ClinicalTrials.gov |
| NCT00419237 | Investigating The Pharmacokinetics Of An Inhaled Dose Of A New Corticosteroid I… | Phase1 | Asthma | Completed | 2005-01-13 | 2005-04-15 | ClinicalTrials.gov |
| NCT00419237 | Investigating The Pharmacokinetics Of An Inhaled Dose Of A New Corticosteroid I… | Phase1 | Asthma | Completed | 2005-01-13 | 2005-04-15 | ClinicalTrials.gov |
| NCT00449436 | Study To Evaluate Long Term Maintenance With TRIZIVIR After Boosted Protease In… | Phase4 | HIV Infections | Completed | 2005-01-10 | 2007-12-13 | ClinicalTrials.gov |
| NCT00449436 | Study To Evaluate Long Term Maintenance With TRIZIVIR After Boosted Protease In… | Phase4 | HIV Infections | Completed | 2005-01-10 | 2007-12-13 | ClinicalTrials.gov |
| NCT00148941 | Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Ca… | Phase3 | Tetanus | Completed | 2005-01-06 | 2006-12-04 | ClinicalTrials.gov |
| NCT00148941 | Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Ca… | Phase3 | Tetanus | Completed | 2005-01-06 | 2006-12-04 | ClinicalTrials.gov |
| NCT00358371 | Bioavailability Of Flucloxacillin Capsules (250 mg and 500 mg) | Phase1 | Infections, Bacterial | Completed | 2005-01-06 | 2005-02-08 | ClinicalTrials.gov |
| NCT00358371 | Bioavailability Of Flucloxacillin Capsules (250 mg and 500 mg) | Phase1 | Infections, Bacterial | Completed | 2005-01-06 | 2005-02-08 | ClinicalTrials.gov |
| NCT00400855 | Study on the Effects of an AMP Challenge on Asthmatic Patients Following Treatm… | Phase2 | Asthma | Completed | 2005-01-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00158808 | Immune Memory Foll Pry Vaccination With DTPw-HBV/Hib Vaccine Formulation; Immun… | Phase2 | Hib Disease | Completed | 2005-01-01 | 2005-04-01 | ClinicalTrials.gov |
| NCT00158795 | Assess Safety & Reactogenicity of GSK Biologicals' Hib Vaccine Co-administered … | Phase4 | Haemophilus Influenzae Type b Disease | Completed | 2005-01-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00465205 | HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1 Co-infected Persons | Phase3 | HIV Infections | Completed | 2005-01-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00354874 | Investigation Of A New Medication (GW642444) In Asthmatic Patients | Phase2 | Asthma | Completed | 2005-01-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00116831 | Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patien… | Phase3 | Atherosclerosis | Completed | 2005-01-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00116818 | A Study of GW685698X for the Treatment Of Perennial Allergic Rhinitis in Adoles… | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2005-01-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00116402 | A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preven… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2005-01-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00465205 | HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1 Co-infected Persons | Phase3 | HIV Infections | Completed | 2005-01-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00256880 | Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma | Phase2 | Carcinoma, Renal Cell | Completed | 2005-01-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00116818 | A Study of GW685698X for the Treatment Of Perennial Allergic Rhinitis in Adoles… | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2005-01-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT01389479 | Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ in Heal… | Phase3 | Influenza | Completed | 2005-01-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00116831 | Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patien… | Phase3 | Atherosclerosis | Completed | 2005-01-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT01389479 | Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ in Heal… | Phase3 | Influenza | Completed | 2005-01-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00225862 | A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syn… | Phase3 | Restless Legs Syndrome | Completed | 2005-01-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00289588 | An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Au… | Na | Community-Acquired MRSA Infections | Completed | 2005-01-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00158808 | Immune Memory Foll Pry Vaccination With DTPw-HBV/Hib Vaccine Formulation; Immun… | Phase2 | Hib Disease | Completed | 2005-01-01 | 2005-04-01 | ClinicalTrials.gov |
| NCT00158795 | Assess Safety & Reactogenicity of GSK Biologicals' Hib Vaccine Co-administered … | Phase4 | Haemophilus Influenzae Type b Disease | Completed | 2005-01-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00292877 | The Prednisone-sparing Effect of Anti-IL-5 Antibody (SB-240563) | Phase2 | Asthma | Completed | 2005-01-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00289588 | An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Au… | Na | Community-Acquired MRSA Infections | Completed | 2005-01-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00400855 | Study on the Effects of an AMP Challenge on Asthmatic Patients Following Treatm… | Phase2 | Asthma | Completed | 2005-01-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00292877 | The Prednisone-sparing Effect of Anti-IL-5 Antibody (SB-240563) | Phase2 | Asthma | Completed | 2005-01-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00108082 | The CLEVER Study - Coreg And Left Ventricular Mass Regression | Phase3 | Hypertrophy, Left Ventricular | Completed | 2005-01-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00116402 | A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preven… | Phase1 | Pulmonary Disease, Chronic Obstructive | Completed | 2005-01-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00225862 | A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syn… | Phase3 | Restless Legs Syndrome | Completed | 2005-01-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00354874 | Investigation Of A New Medication (GW642444) In Asthmatic Patients | Phase2 | Asthma | Completed | 2005-01-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00256880 | Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma | Phase2 | Carcinoma, Renal Cell | Completed | 2005-01-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00108082 | The CLEVER Study - Coreg And Left Ventricular Mass Regression | Phase3 | Hypertrophy, Left Ventricular | Completed | 2005-01-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT01205165 | An Open Label, Multi Centre Phase IV Study of Adefovir Dipivoxil in Korean Pati… | Phase4 | Hepatitis B, Chronic | Completed | 2004-12-17 | 2006-04-28 | ClinicalTrials.gov |
| NCT01205165 | An Open Label, Multi Centre Phase IV Study of Adefovir Dipivoxil in Korean Pati… | Phase4 | Hepatitis B, Chronic | Completed | 2004-12-17 | 2006-04-28 | ClinicalTrials.gov |
| NCT00094523 | Fosamprenavir Versus Other Protease Inhibitors | Phase3 | Infection, Human Immunodeficiency Virus I | Completed | 2004-12-14 | 2007-06-29 | ClinicalTrials.gov |
| NCT00094523 | Fosamprenavir Versus Other Protease Inhibitors | Phase3 | Infection, Human Immunodeficiency Virus I | Completed | 2004-12-14 | 2007-06-29 | ClinicalTrials.gov |
| NCT00214890 | Viral Dynamics and Pharmacokinetics of Abacavir and Tenofovir | Phase2 | HIV Infections | Completed | 2004-12-07 | 2010-04-27 | ClinicalTrials.gov |
| NCT00214890 | Viral Dynamics and Pharmacokinetics of Abacavir and Tenofovir | Phase2 | HIV Infections | Completed | 2004-12-07 | 2010-04-27 | ClinicalTrials.gov |
| NCT00104416 | Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Tre… | Phase3 | Epilepsy, Tonic-Clonic | Completed | 2004-12-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00104403 | Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately E… | Phase2 | Nausea and Vomiting, Chemotherapy-Induced | Completed | 2004-12-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00103727 | Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia | Phase2 | Schizophrenia | Completed | 2004-12-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00097409 | Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ova… | Phase2 | Ovarian Cancer | Completed | 2004-12-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00114049 | Dental Pain (Following Third Molar Tooth Extraction) Study | Phase3 | Dental Pain | Completed | 2004-12-01 | 2005-04-01 | ClinicalTrials.gov |
| NCT00115492 | Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Dise… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2004-12-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00115622 | Study In Adults And Adolescents With Seasonal Allergic Rhinitis | Phase3 | Hayfever | Completed | 2004-12-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT01381432 | Special Drug Use Investigation for IMURAN (Azathioprine) Tablet (Pulmones Trans… | — | Liver Diseases | Completed | 2004-12-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01299571 | AVODART(Dutasteride) Post-marketing Surveillance(PMS) | — | Benign Prostatic Hyperplasia | Completed | 2004-12-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00634062 | Study of Lamotrigine Treatment of Affective Instability in Borderline Personali… | Phase4 | Borderline Personality Disorder | Completed | 2004-12-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00600990 | Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Na… | Phase2 | Postoperative Nausea and Vomiting | Completed | 2004-12-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00593593 | Pharmacovigilance Study To Evaluate Safety Of AVODART In Subjects With Benign P… | — | Benign Prostatic Hyperplasia | Completed | 2004-12-01 | — | ClinicalTrials.gov |
| NCT00135512 | Study Of 323U66 SR In Major Depressive Disorder | Phase2 | Depressive Disorder | Completed | 2004-12-01 | 2007-05-28 | ClinicalTrials.gov |
| NCT00160394 | Comparison of Duac® Gel And Differin® Gel in Mild to Moderate Acne Vulgaris | Phase4 | Acne Vulgaris | Completed | 2004-12-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00300963 | Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In … | Phase2 | Schizophrenia | Completed | 2004-12-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00334568 | Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisa… | Phase2 | Alzheimer's Disease | Terminated | 2004-12-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00343135 | AUGMENTIN 1gm In Skin And Soft Tissue Infection | Phase4 | Skin Diseases, Infectious | Completed | 2004-12-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00388180 | An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body… | — | Hypercholesterolemia | Completed | 2004-12-01 | — | ClinicalTrials.gov |
| NCT00388180 | An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body… | — | Hypercholesterolemia | Completed | 2004-12-01 | — | ClinicalTrials.gov |
| NCT01381432 | Special Drug Use Investigation for IMURAN (Azathioprine) Tablet (Pulmones Trans… | — | Liver Diseases | Completed | 2004-12-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01299571 | AVODART(Dutasteride) Post-marketing Surveillance(PMS) | — | Benign Prostatic Hyperplasia | Completed | 2004-12-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00343135 | AUGMENTIN 1gm In Skin And Soft Tissue Infection | Phase4 | Skin Diseases, Infectious | Completed | 2004-12-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00334568 | Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisa… | Phase2 | Alzheimer's Disease | Terminated | 2004-12-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00593593 | Pharmacovigilance Study To Evaluate Safety Of AVODART In Subjects With Benign P… | — | Benign Prostatic Hyperplasia | Completed | 2004-12-01 | — | ClinicalTrials.gov |
| NCT00600990 | Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Na… | Phase2 | Postoperative Nausea and Vomiting | Completed | 2004-12-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00634062 | Study of Lamotrigine Treatment of Affective Instability in Borderline Personali… | Phase4 | Borderline Personality Disorder | Completed | 2004-12-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00300963 | Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In … | Phase2 | Schizophrenia | Completed | 2004-12-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00160394 | Comparison of Duac® Gel And Differin® Gel in Mild to Moderate Acne Vulgaris | Phase4 | Acne Vulgaris | Completed | 2004-12-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00135512 | Study Of 323U66 SR In Major Depressive Disorder | Phase2 | Depressive Disorder | Completed | 2004-12-01 | 2007-05-28 | ClinicalTrials.gov |
| NCT00115622 | Study In Adults And Adolescents With Seasonal Allergic Rhinitis | Phase3 | Hayfever | Completed | 2004-12-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00115492 | Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Dise… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2004-12-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00114049 | Dental Pain (Following Third Molar Tooth Extraction) Study | Phase3 | Dental Pain | Completed | 2004-12-01 | 2005-04-01 | ClinicalTrials.gov |
| NCT00104416 | Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Tre… | Phase3 | Epilepsy, Tonic-Clonic | Completed | 2004-12-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00104403 | Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately E… | Phase2 | Nausea and Vomiting, Chemotherapy-Induced | Completed | 2004-12-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00103727 | Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia | Phase2 | Schizophrenia | Completed | 2004-12-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00097409 | Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ova… | Phase2 | Ovarian Cancer | Completed | 2004-12-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00107718 | Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastat… | Phase2 | Melanoma | Completed | 2004-11-15 | 2006-05-19 | ClinicalTrials.gov |
| NCT00107718 | Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastat… | Phase2 | Melanoma | Completed | 2004-11-15 | 2006-05-19 | ClinicalTrials.gov |
| NCT00273026 | Study In Asthma Control | Phase4 | Asthma | Terminated | 2004-11-08 | 2006-03-28 | ClinicalTrials.gov |
| NCT00273026 | Study In Asthma Control | Phase4 | Asthma | Terminated | 2004-11-08 | 2006-03-28 | ClinicalTrials.gov |
| NCT00315744 | Viapaed Study In Children And Adolescents With Asthma | Phase4 | Asthma | Completed | 2004-11-04 | 2007-04-12 | ClinicalTrials.gov |
| NCT00315744 | Viapaed Study In Children And Adolescents With Asthma | Phase4 | Asthma | Completed | 2004-11-04 | 2007-04-12 | ClinicalTrials.gov |
| NCT00325156 | Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4… | Phase4 | Diphtheria | Completed | 2004-11-02 | 2007-08-23 | ClinicalTrials.gov |
| NCT00325156 | Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4… | Phase4 | Diphtheria | Completed | 2004-11-02 | 2007-08-23 | ClinicalTrials.gov |
| NCT00102765 | Study Of Asthma In Patients Of African Descent | Phase4 | Asthma | Completed | 2004-11-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00144872 | LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures | Phase1 | Seizure, Absence | Completed | 2004-11-01 | 2006-04-22 | ClinicalTrials.gov |
| NCT00256893 | Fibromyalgia Study In Adults | Phase2 | Fibromyalgia Syndrome, Primary | Completed | 2004-11-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00103922 | Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease) | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2004-11-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00102765 | Study Of Asthma In Patients Of African Descent | Phase4 | Asthma | Completed | 2004-11-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00283322 | Heparin Antibodies in Intensive Care Unit Patients (HAICU) | — | Heparin-Induced Thrombocytopenia | Completed | 2004-11-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00256893 | Fibromyalgia Study In Adults | Phase2 | Fibromyalgia Syndrome, Primary | Completed | 2004-11-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00328965 | Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diab… | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2004-11-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00289718 | Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vacci… | Phase3 | Hepatitis B | Completed | 2004-11-01 | 2005-03-02 | ClinicalTrials.gov |
| NCT00328965 | Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diab… | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2004-11-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00315211 | Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer | Phase2 | Mediastinal Neoplasms | Terminated | 2004-11-01 | 2007-11-08 | ClinicalTrials.gov |
| NCT00323050 | Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Giv… | Phase3 | Neisseria Meningitidis | Completed | 2004-11-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00343941 | Tucaresol As Add-On To HAART (Highly Active Antiretroviral Therapy) In Chronic … | Phase2 | HIV Infection | Completed | 2004-11-01 | — | ClinicalTrials.gov |
| NCT00343707 | PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of … | Phase2 | Depressive Disorder and Anxiety Disorders | Completed | 2004-11-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00231855 | Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN)… | Phase2 | Ovarian Neoplasms | Completed | 2004-11-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00231855 | Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN)… | Phase2 | Ovarian Neoplasms | Completed | 2004-11-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00343941 | Tucaresol As Add-On To HAART (Highly Active Antiretroviral Therapy) In Chronic … | Phase2 | HIV Infection | Completed | 2004-11-01 | — | ClinicalTrials.gov |
| NCT00403962 | A Combination Therapy In Patients With Social Anxiety Disorder | Phase2 | Social Phobia | Completed | 2004-11-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00323050 | Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Giv… | Phase3 | Neisseria Meningitidis | Completed | 2004-11-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00343707 | PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of … | Phase2 | Depressive Disorder and Anxiety Disorders | Completed | 2004-11-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00403962 | A Combination Therapy In Patients With Social Anxiety Disorder | Phase2 | Social Phobia | Completed | 2004-11-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00349713 | FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali | Phase1 | Malaria | Completed | 2004-11-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00103922 | Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease) | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2004-11-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00289718 | Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vacci… | Phase3 | Hepatitis B | Completed | 2004-11-01 | 2005-03-02 | ClinicalTrials.gov |
| NCT00349713 | FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali | Phase1 | Malaria | Completed | 2004-11-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00283322 | Heparin Antibodies in Intensive Care Unit Patients (HAICU) | — | Heparin-Induced Thrombocytopenia | Completed | 2004-11-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00315211 | Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer | Phase2 | Mediastinal Neoplasms | Terminated | 2004-11-01 | 2007-11-08 | ClinicalTrials.gov |
| NCT00144872 | LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures | Phase1 | Seizure, Absence | Completed | 2004-11-01 | 2006-04-22 | ClinicalTrials.gov |
| NCT00108095 | A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nau… | Phase2 | Postoperative Nausea and Vomiting | Completed | 2004-10-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00101946 | Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active… | Phase2 | Crohn's Disease | Completed | 2004-10-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00268983 | Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR… | Phase3 | Lymphoma, Non-Hodgkin | Completed | 2004-10-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00113165 | Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Tre… | Phase3 | Epilepsy | Completed | 2004-10-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00108095 | A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nau… | Phase2 | Postoperative Nausea and Vomiting | Completed | 2004-10-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00102492 | Study Of GW679769 In Major Depressive Disorder | Phase2 | Depressive Disorder, Major | Completed | 2004-10-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00144911 | ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DI… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2004-10-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00367055 | Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination O… | Phase4 | Type 2 Diabetes Mellitus | Completed | 2004-10-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00367055 | Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination O… | Phase4 | Type 2 Diabetes Mellitus | Completed | 2004-10-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00317122 | Assess the Immune Response Following Primary Vaccination With GSK Biologicals' … | Phase3 | Diphtheria; Haemophilus Influenzae Type b; Hepatitis B; Tetanus; Whole Cell Pertussis | Completed | 2004-10-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00242853 | A Study To Investigate Markers Of Inflammation In Rheumatoid Arthritis | — | Rheumatoid Arthritis | Completed | 2004-10-01 | — | ClinicalTrials.gov |
| NCT00113165 | Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Tre… | Phase3 | Epilepsy | Completed | 2004-10-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00242853 | A Study To Investigate Markers Of Inflammation In Rheumatoid Arthritis | — | Rheumatoid Arthritis | Completed | 2004-10-01 | — | ClinicalTrials.gov |
| NCT00093314 | HuMax-CD20 in Chronic Lymphocytic Leukemia | Phase1 | Chronic Lymphocytic Leukemia | Withdrawn | 2004-10-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00268983 | Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR… | Phase3 | Lymphoma, Non-Hodgkin | Completed | 2004-10-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00101946 | Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active… | Phase2 | Crohn's Disease | Completed | 2004-10-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00101985 | Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndro… | Phase2 | Irritable Colon | Completed | 2004-10-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00102492 | Study Of GW679769 In Major Depressive Disorder | Phase2 | Depressive Disorder, Major | Completed | 2004-10-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00169481 | A Study in Children With Different Formulations of GSK Biologicals' 11 Valent P… | Phase2 | Streptococcal Infections | Completed | 2004-10-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00093314 | HuMax-CD20 in Chronic Lymphocytic Leukemia | Phase1 | Chronic Lymphocytic Leukemia | Withdrawn | 2004-10-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00317122 | Assess the Immune Response Following Primary Vaccination With GSK Biologicals' … | Phase3 | Diphtheria; Haemophilus Influenzae Type b; Hepatitis B; Tetanus; Whole Cell Pertussis | Completed | 2004-10-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00102882 | Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propion… | Phase4 | Asthma | Completed | 2004-10-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00102882 | Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propion… | Phase4 | Asthma | Completed | 2004-10-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00144911 | ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DI… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2004-10-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00169481 | A Study in Children With Different Formulations of GSK Biologicals' 11 Valent P… | Phase2 | Streptococcal Infections | Completed | 2004-10-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00101985 | Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndro… | Phase2 | Irritable Colon | Completed | 2004-10-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00097370 | Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophi… | Phase3 | Hypereosinophilic Syndrome | Terminated | 2004-09-30 | 2010-09-29 | ClinicalTrials.gov |
| NCT00097370 | Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophi… | Phase3 | Hypereosinophilic Syndrome | Terminated | 2004-09-30 | 2010-09-29 | ClinicalTrials.gov |
| NCT00158782 | Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Pat… | Phase1 | Carcinoma, Renal Cell | Completed | 2004-09-28 | 2007-08-21 | ClinicalTrials.gov |
| NCT00158782 | Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Pat… | Phase1 | Carcinoma, Renal Cell | Completed | 2004-09-28 | 2007-08-21 | ClinicalTrials.gov |
| NCT00317772 | Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Can… | Phase1 | Ovarian Cancer | Completed | 2004-09-02 | 2020-11-04 | ClinicalTrials.gov |
| NCT00317772 | Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Can… | Phase1 | Ovarian Cancer | Completed | 2004-09-02 | 2020-11-04 | ClinicalTrials.gov |
| NCT00135577 | Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bow… | Phase2 | Cancer | Completed | 2004-09-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT01750827 | A Study to Assess the Effect of SB 659032 on Platelet Function | Phase1 | Atherosclerosis | Completed | 2004-09-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT01571661 | A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetic… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2004-09-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00490009 | Phase 2 Study of Bexxar in Relapsed/Refractory DLCL | Phase2 | Lymphoma | Completed | 2004-09-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00663728 | Assessment of Duration of Erection With Vardenafil 10 mg | Phase4 | Erectile Dysfunction | Completed | 2004-09-01 | 2005-04-01 | ClinicalTrials.gov |
| NCT00490009 | Phase 2 Study of Bexxar in Relapsed/Refractory DLCL | Phase2 | Lymphoma | Completed | 2004-09-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00197093 | In-Patient Study In Schizophrenic Patients | Phase1 | Schizophrenia | Completed | 2004-09-01 | — | ClinicalTrials.gov |
| NCT00667979 | Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED… | Phase4 | Erectile Dysfunction | Completed | 2004-09-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00089986 | GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis… | Phase2 | Sepsis | Completed | 2004-09-01 | 2007-04-15 | ClinicalTrials.gov |
| NCT00097331 | Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclero… | Phase2 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2004-09-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00092274 | Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular L… | Phase1 | Lymphoma, Follicular | Withdrawn | 2004-09-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00097331 | Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclero… | Phase2 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2004-09-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00092274 | Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular L… | Phase1 | Lymphoma, Follicular | Withdrawn | 2004-09-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00663728 | Assessment of Duration of Erection With Vardenafil 10 mg | Phase4 | Erectile Dysfunction | Completed | 2004-09-01 | 2005-04-01 | ClinicalTrials.gov |
| NCT00089986 | GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis… | Phase2 | Sepsis | Completed | 2004-09-01 | 2007-04-15 | ClinicalTrials.gov |
| NCT00135577 | Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bow… | Phase2 | Cancer | Completed | 2004-09-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00667979 | Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED… | Phase4 | Erectile Dysfunction | Completed | 2004-09-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00216229 | Twinrix Alternative Schedule Study | Phase4 | Antibody Response After Vaccination | Unknown | 2004-09-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00295243 | Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies | Phase1 | Advanced Solid Malignancies | Completed | 2004-09-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00297011 | Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis | Phase2 | Herpes Labialis | Completed | 2004-09-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00316160 | Sexual Functioning Study With Antidepressants | Phase4 | Depressive Disorder, Major | Completed | 2004-09-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00140686 | To Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) … | Phase3 | Infections, Rotavirus | Completed | 2004-09-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00140686 | To Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) … | Phase3 | Infections, Rotavirus | Completed | 2004-09-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00144846 | Inhaled Albuterol Sulfate For Acute Wheezing Due To Obstructive Airways Disease… | Phase3 | Asthma | Completed | 2004-09-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00158873 | Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects | Phase4 | Sedation | Completed | 2004-09-01 | — | ClinicalTrials.gov |
| NCT00316160 | Sexual Functioning Study With Antidepressants | Phase4 | Depressive Disorder, Major | Completed | 2004-09-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT01571661 | A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetic… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2004-09-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00169494 | Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Ad… | Phase3 | Infections, Papillomavirus | Completed | 2004-09-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00144846 | Inhaled Albuterol Sulfate For Acute Wheezing Due To Obstructive Airways Disease… | Phase3 | Asthma | Completed | 2004-09-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00169494 | Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Ad… | Phase3 | Infections, Papillomavirus | Completed | 2004-09-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00297011 | Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis | Phase2 | Herpes Labialis | Completed | 2004-09-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT01750827 | A Study to Assess the Effect of SB 659032 on Platelet Function | Phase1 | Atherosclerosis | Completed | 2004-09-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00295243 | Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies | Phase1 | Advanced Solid Malignancies | Completed | 2004-09-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00197093 | In-Patient Study In Schizophrenic Patients | Phase1 | Schizophrenia | Completed | 2004-09-01 | — | ClinicalTrials.gov |
| NCT00158873 | Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects | Phase4 | Sedation | Completed | 2004-09-01 | — | ClinicalTrials.gov |
| NCT00216229 | Twinrix Alternative Schedule Study | Phase4 | Antibody Response After Vaccination | Unknown | 2004-09-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00169533 | Rollover Study Of Lapatinib In Cancer Patients | Phase1 | Neoplasms, Breast | Completed | 2004-08-19 | 2009-05-05 | ClinicalTrials.gov |
| NCT00169533 | Rollover Study Of Lapatinib In Cancer Patients | Phase1 | Neoplasms, Breast | Completed | 2004-08-19 | 2009-05-05 | ClinicalTrials.gov |
| NCT00158899 | GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol | Phase2 | Dyslipidaemias | Completed | 2004-08-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00665054 | BAY38-9456, 5/10/20mg, vs.Placebo in Erectile Dysfunction | Phase4 | Erectile Dysfunction | Completed | 2004-08-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00158899 | GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol | Phase2 | Dyslipidaemias | Completed | 2004-08-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00317161 | Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6… | Phase3 | Diphtheria | Completed | 2004-08-01 | 2005-04-01 | ClinicalTrials.gov |
| NCT00206427 | Neoadjuvant GW572016 to Treat Breast Cancer | Phase2 | Breast Cancer | Completed | 2004-08-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT00317161 | Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6… | Phase3 | Diphtheria | Completed | 2004-08-01 | 2005-04-01 | ClinicalTrials.gov |
| NCT00665054 | BAY38-9456, 5/10/20mg, vs.Placebo in Erectile Dysfunction | Phase4 | Erectile Dysfunction | Completed | 2004-08-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00206427 | Neoadjuvant GW572016 to Treat Breast Cancer | Phase2 | Breast Cancer | Completed | 2004-08-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT00129129 | Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or… | Phase2 | Haemophilus Influenzae Type b | Completed | 2004-08-01 | 2006-03-29 | ClinicalTrials.gov |
| NCT01329419 | HEPSERA Post Marketing Surveillance | — | Hepatitis B | Completed | 2004-08-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00129129 | Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or… | Phase2 | Haemophilus Influenzae Type b | Completed | 2004-08-01 | 2006-03-29 | ClinicalTrials.gov |
| NCT01329419 | HEPSERA Post Marketing Surveillance | — | Hepatitis B | Completed | 2004-08-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00354042 | Effects Of Repeat Inhaled Doses Of GW597901X On Patient Safety And Lung Functio… | Phase1 | Asthma | Completed | 2004-08-01 | — | ClinicalTrials.gov |
| NCT00354042 | Effects Of Repeat Inhaled Doses Of GW597901X On Patient Safety And Lung Functio… | Phase1 | Asthma | Completed | 2004-08-01 | — | ClinicalTrials.gov |
| NCT00650871 | A Study to Evaluate the Effects of GW679769 on Sleep and Cognitive Function in … | Phase2 | Sleep Initiation and Maintenance Disorders | Completed | 2004-07-30 | 2005-08-30 | ClinicalTrials.gov |
| NCT00650871 | A Study to Evaluate the Effects of GW679769 on Sleep and Cognitive Function in … | Phase2 | Sleep Initiation and Maintenance Disorders | Completed | 2004-07-30 | 2005-08-30 | ClinicalTrials.gov |
| NCT00089583 | 48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pedia… | Phase2 | Infection, Human Immunodeficiency Virus I | Completed | 2004-07-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT02712203 | MMR and MMRV Vaccines: Effect of Age at First Dose on Safety and Immunogenicity… | — | Measles | Unknown | 2004-07-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT00406211 | Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicel… | Phase3 | Rubella | Completed | 2004-07-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00406211 | Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicel… | Phase3 | Rubella | Completed | 2004-07-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00291889 | Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mt… | Phase1 | Tuberculosis (TB) | Completed | 2004-07-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00089583 | 48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pedia… | Phase2 | Infection, Human Immunodeficiency Virus I | Completed | 2004-07-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT02712203 | MMR and MMRV Vaccines: Effect of Age at First Dose on Safety and Immunogenicity… | — | Measles | Unknown | 2004-07-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT00291889 | Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mt… | Phase1 | Tuberculosis (TB) | Completed | 2004-07-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00128661 | Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in You… | Phase3 | Cervical Cancer | Completed | 2004-06-30 | 2010-12-31 | ClinicalTrials.gov |
| NCT00089973 | Study Of Ispinesib In Subjects With Breast Cancer | Phase2 | Neoplasms, Breast | Completed | 2004-06-30 | 2006-08-25 | ClinicalTrials.gov |
| NCT00462956 | GW572016 In Patients With Advanced Or Metastatic Breast Cancer | Phase1 | Neoplasms, Breast | Completed | 2004-06-30 | 2006-12-20 | ClinicalTrials.gov |
| NCT00462956 | GW572016 In Patients With Advanced Or Metastatic Breast Cancer | Phase1 | Neoplasms, Breast | Completed | 2004-06-30 | 2006-12-20 | ClinicalTrials.gov |
| NCT00089973 | Study Of Ispinesib In Subjects With Breast Cancer | Phase2 | Neoplasms, Breast | Completed | 2004-06-30 | 2006-08-25 | ClinicalTrials.gov |
| NCT00128661 | Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in You… | Phase3 | Cervical Cancer | Completed | 2004-06-30 | 2010-12-31 | ClinicalTrials.gov |
| NCT00359190 | Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Tr… | Phase1 | Neoplasms, Breast | Completed | 2004-06-29 | 2008-01-09 | ClinicalTrials.gov |
| NCT00359190 | Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Tr… | Phase1 | Neoplasms, Breast | Completed | 2004-06-29 | 2008-01-09 | ClinicalTrials.gov |
| NCT00158860 | A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression … | Phase4 | Herpes Genitalis | Completed | 2004-06-21 | 2006-07-26 | ClinicalTrials.gov |
| NCT00158860 | A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression … | Phase4 | Herpes Genitalis | Completed | 2004-06-21 | 2006-07-26 | ClinicalTrials.gov |
| NCT00317187 | Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) Af… | Phase3 | Hepatitis B | Completed | 2004-06-08 | 2005-01-16 | ClinicalTrials.gov |
| NCT00317187 | Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) Af… | Phase3 | Hepatitis B | Completed | 2004-06-08 | 2005-01-16 | ClinicalTrials.gov |
| NCT00193362 | Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinore… | Phase3 | Lung Cancer | Completed | 2004-06-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00205842 | Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dys… | Phase3 | Ileus | Completed | 2004-06-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00093288 | Major Depressive Disorder In The Elderly | Phase3 | Depressive Disorder, Major | Completed | 2004-06-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00196924 | Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolesce… | Phase3 | Infections, Papillomavirus | Completed | 2004-06-01 | 2006-03-01 | ClinicalTrials.gov |
| NCT00093288 | Major Depressive Disorder In The Elderly | Phase3 | Depressive Disorder, Major | Completed | 2004-06-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00193362 | Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinore… | Phase3 | Lung Cancer | Completed | 2004-06-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00186446 | Treatment of Nicotine Dependence and Acute Depression | Phase4 | Major Depressive Disorder | Completed | 2004-06-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00123604 | Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With … | Phase4 | Hypertension | Completed | 2004-06-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00169520 | SB-715992 In Combination With Docetaxel In Patients With Solid Tumors | Phase1 | Solid Tumor Cancer | Completed | 2004-06-01 | — | ClinicalTrials.gov |
| NCT00169520 | SB-715992 In Combination With Docetaxel In Patients With Solid Tumors | Phase1 | Solid Tumor Cancer | Completed | 2004-06-01 | — | ClinicalTrials.gov |
| NCT00186446 | Treatment of Nicotine Dependence and Acute Depression | Phase4 | Major Depressive Disorder | Completed | 2004-06-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00196924 | Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolesce… | Phase3 | Infections, Papillomavirus | Completed | 2004-06-01 | 2006-03-01 | ClinicalTrials.gov |
| NCT00205842 | Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dys… | Phase3 | Ileus | Completed | 2004-06-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT01294553 | An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to … | — | Diabetes Mellitus, Type 2 | Completed | 2004-06-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00851630 | Tuberculosis and Human Immunodeficiency Virus (HIV) Immune Reconstitution Syndr… | Phase4 | HIV | Completed | 2004-06-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00851630 | Tuberculosis and Human Immunodeficiency Virus (HIV) Immune Reconstitution Syndr… | Phase4 | HIV | Completed | 2004-06-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00123604 | Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With … | Phase4 | Hypertension | Completed | 2004-06-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00662805 | Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chr… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2004-06-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT01294553 | An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to … | — | Diabetes Mellitus, Type 2 | Completed | 2004-06-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00662805 | Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chr… | — | Pulmonary Disease, Chronic Obstructive | Completed | 2004-06-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00265148 | Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease | Phase2 | Alzheimer's Disease | Completed | 2004-05-18 | 2008-07-10 | ClinicalTrials.gov |
| NCT00265148 | Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease | Phase2 | Alzheimer's Disease | Completed | 2004-05-18 | 2008-07-10 | ClinicalTrials.gov |
| NCT00122681 | Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer … | Phase3 | Infections, Papillomavirus | Completed | 2004-05-06 | 2009-11-26 | ClinicalTrials.gov |
| NCT00122681 | Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer … | Phase3 | Infections, Papillomavirus | Completed | 2004-05-06 | 2009-11-26 | ClinicalTrials.gov |
| NCT00248209 | Female Orgasmic Disorder (FOD) and Wellbutrin XL | Phase2 | Orgasmic Disorder | Completed | 2004-05-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00252889 | Doxil Topotecan Doublet Cancer Study | Phase1 | Small Cell Lung Cancer | Completed | 2004-05-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00085943 | KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Sub… | Phase3 | HIV Infection | Completed | 2004-05-01 | — | ClinicalTrials.gov |
| NCT00086593 | Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophre… | Phase3 | Schizophrenia | Completed | 2004-05-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00086593 | Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophre… | Phase3 | Schizophrenia | Completed | 2004-05-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00085943 | KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Sub… | Phase3 | HIV Infection | Completed | 2004-05-01 | — | ClinicalTrials.gov |
| NCT00248209 | Female Orgasmic Disorder (FOD) and Wellbutrin XL | Phase2 | Orgasmic Disorder | Completed | 2004-05-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00252889 | Doxil Topotecan Doublet Cancer Study | Phase1 | Small Cell Lung Cancer | Completed | 2004-05-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00355342 | Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disea… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2004-04-28 | 2007-09-06 | ClinicalTrials.gov |
| NCT00355342 | Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disea… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2004-04-28 | 2007-09-06 | ClinicalTrials.gov |
| NCT00343915 | Immuno & Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B… | Phase3 | Hepatitis B | Completed | 2004-04-21 | 2008-01-10 | ClinicalTrials.gov |
| NCT00343915 | Immuno & Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B… | Phase3 | Hepatitis B | Completed | 2004-04-21 | 2008-01-10 | ClinicalTrials.gov |
| NCT00224484 | Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Fem… | Phase3 | Herpes Simplex | Completed | 2004-04-07 | 2007-07-24 | ClinicalTrials.gov |
| NCT00224484 | Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Fem… | Phase3 | Herpes Simplex | Completed | 2004-04-07 | 2007-07-24 | ClinicalTrials.gov |
| NCT00663130 | Evaluating the Efficacy Vardenafil 10 mg vs Tadalafil 10 mg in in Subjects With… | Phase4 | Erectile Dysfunction | Completed | 2004-04-01 | 2004-07-01 | ClinicalTrials.gov |
| NCT00240565 | Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non… | Phase2 | Lymphoma, Non-Hodgkin | Completed | 2004-04-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT00085904 | Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To … | Phase1 | Solid Tumor Cancer | Completed | 2004-04-01 | — | ClinicalTrials.gov |
| NCT00090077 | Monotherapy Versus Placebo Over 7 Days-Non-Nucleoside Reverse Transcriptase Inh… | Phase1 | HIV Infections | Completed | 2004-04-01 | — | ClinicalTrials.gov |
| NCT00090077 | Monotherapy Versus Placebo Over 7 Days-Non-Nucleoside Reverse Transcriptase Inh… | Phase1 | HIV Infections | Completed | 2004-04-01 | — | ClinicalTrials.gov |
| NCT00085904 | Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To … | Phase1 | Solid Tumor Cancer | Completed | 2004-04-01 | — | ClinicalTrials.gov |
| NCT00663130 | Evaluating the Efficacy Vardenafil 10 mg vs Tadalafil 10 mg in in Subjects With… | Phase4 | Erectile Dysfunction | Completed | 2004-04-01 | 2004-07-01 | ClinicalTrials.gov |
| NCT00240565 | Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non… | Phase2 | Lymphoma, Non-Hodgkin | Completed | 2004-04-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT00086658 | Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES) | Phase3 | Hypereosinophilia | Completed | 2004-03-23 | 2006-05-01 | ClinicalTrials.gov |
| NCT00086658 | Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES) | Phase3 | Hypereosinophilia | Completed | 2004-03-23 | 2006-05-01 | ClinicalTrials.gov |
| NCT00197067 | A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate… | Phase1 | Malaria | Completed | 2004-03-15 | 2005-04-26 | ClinicalTrials.gov |
| NCT00197067 | A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate… | Phase1 | Malaria | Completed | 2004-03-15 | 2005-04-26 | ClinicalTrials.gov |
| NCT00229528 | Effect of Paroxetine on COAT-Platelet Production in Normal Volunteers and Patie… | Phase4 | Coronary Artery Disease | Completed | 2004-03-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00738023 | Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes | Phase4 | Type 2 Diabetes | Completed | 2004-03-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00648284 | Cardiovascular (CV) Risk Evaluation In Type 2 Diabetes Subjects | — | Type 2 Diabetes Mellitus | Completed | 2004-03-01 | — | ClinicalTrials.gov |
| NCT00078572 | Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refra… | Phase3 | Breast Cancer | Completed | 2004-03-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00229528 | Effect of Paroxetine on COAT-Platelet Production in Normal Volunteers and Patie… | Phase4 | Coronary Artery Disease | Completed | 2004-03-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00078572 | Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refra… | Phase3 | Breast Cancer | Completed | 2004-03-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00648284 | Cardiovascular (CV) Risk Evaluation In Type 2 Diabetes Subjects | — | Type 2 Diabetes Mellitus | Completed | 2004-03-01 | — | ClinicalTrials.gov |
| NCT00738023 | Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes | Phase4 | Type 2 Diabetes | Completed | 2004-03-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00289744 | Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vacci… | Phase3 | Hepatitis B | Completed | 2004-02-16 | 2009-04-15 | ClinicalTrials.gov |
| NCT00289744 | Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vacci… | Phase3 | Hepatitis B | Completed | 2004-02-16 | 2009-04-15 | ClinicalTrials.gov |
| NCT00632736 | An Open-label Continuation Study Evaluating the Long-term Safety of Extended Re… | Phase3 | Parkinson Disease | Completed | 2004-02-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00158743 | Efficacy Study of Digibind for Treatment of Severe Preeclampsia | Phase2 | Pre-eclampsia | Completed | 2004-02-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00746174 | Insulin Resistance and Intramyocellular Lipid Content in Glucose Intolerant Sub… | Phase4 | Insulin Sensitivity | Completed | 2004-02-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00632736 | An Open-label Continuation Study Evaluating the Long-term Safety of Extended Re… | Phase3 | Parkinson Disease | Completed | 2004-02-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00080171 | Osteoarthritis Initiative (OAI): A Knee Health Study | — | Osteoarthritis | Completed | 2004-02-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT00158743 | Efficacy Study of Digibind for Treatment of Severe Preeclampsia | Phase2 | Pre-eclampsia | Completed | 2004-02-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00176228 | Lamotrigine Monotherapy in Pediatric Bipolar Disorder | Phase2 | Bipolar Disorder | Completed | 2004-02-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00080171 | Osteoarthritis Initiative (OAI): A Knee Health Study | — | Osteoarthritis | Completed | 2004-02-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT00322049 | A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus … | Phase1 | Dengue | Completed | 2004-02-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00330889 | Effects Of Prednisolone On Rheumatoid Arthritis Patients | — | Arthritis, Rheumatoid | Completed | 2004-02-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00322049 | A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus … | Phase1 | Dengue | Completed | 2004-02-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00330889 | Effects Of Prednisolone On Rheumatoid Arthritis Patients | — | Arthritis, Rheumatoid | Completed | 2004-02-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00359112 | AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled T… | Phase3 | Non-Insulin-Dependent Diabetes Mellitus | Completed | 2004-02-01 | — | ClinicalTrials.gov |
| NCT00176228 | Lamotrigine Monotherapy in Pediatric Bipolar Disorder | Phase2 | Bipolar Disorder | Completed | 2004-02-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00746174 | Insulin Resistance and Intramyocellular Lipid Content in Glucose Intolerant Sub… | Phase4 | Insulin Sensitivity | Completed | 2004-02-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00359112 | AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled T… | Phase3 | Non-Insulin-Dependent Diabetes Mellitus | Completed | 2004-02-01 | — | ClinicalTrials.gov |
| NCT00307528 | Safety and Efficacy Study of Investigational Pneumococcal Vaccine in Elderly Po… | Phase2 | Prophylaxis Invasive Pneumococcal Diseases and Pneumonia | Completed | 2004-01-20 | 2005-03-30 | ClinicalTrials.gov |
| NCT00307528 | Safety and Efficacy Study of Investigational Pneumococcal Vaccine in Elderly Po… | Phase2 | Prophylaxis Invasive Pneumococcal Diseases and Pneumonia | Completed | 2004-01-20 | 2005-03-30 | ClinicalTrials.gov |
| NCT00193167 | Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer | Phase2 | Colon Cancer | Completed | 2004-01-01 | 2006-04-01 | ClinicalTrials.gov |
| NCT00480649 | Successful Control and Clinical Effectiveness Of SERETIDE(Salmeterol/Fluticason… | Phase4 | Asthma | Completed | 2004-01-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00120744 | Oral Disintegrating Ondansetron Tablet to Reduce Vomiting From Gastroenteritis … | Na | Gastroenteritis | Completed | 2004-01-01 | 2005-04-01 | ClinicalTrials.gov |
| NCT00075270 | Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women … | Phase3 | Neoplasms, Breast | Completed | 2004-01-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00730795 | Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD… | Phase1 | Tuberculosis (TB) | Completed | 2004-01-01 | — | ClinicalTrials.gov |
| NCT00193167 | Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer | Phase2 | Colon Cancer | Completed | 2004-01-01 | 2006-04-01 | ClinicalTrials.gov |
| NCT00291876 | Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepati… | Phase4 | Hepatitis A | Completed | 2004-01-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00291876 | Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepati… | Phase4 | Hepatitis A | Completed | 2004-01-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00289757 | Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepati… | Phase4 | Hepatitis A | Completed | 2004-01-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00257816 | Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma | Phase2 | Cervical Cancer | Completed | 2004-01-01 | 2007-12-17 | ClinicalTrials.gov |
| NCT01406704 | Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologica… | Phase4 | NASH (Non-alcoholic Steato-hepatitis) | Terminated | 2004-01-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00159185 | Epidemiology Study in Major Orthopaedic Surgery | — | Thrombosis | Completed | 2004-01-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00107081 | Low-risk Fever and Neutropenia in Children With Cancer: Safety and Efficacy of … | Phase3 | Fever | Terminated | 2004-01-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00107081 | Low-risk Fever and Neutropenia in Children With Cancer: Safety and Efficacy of … | Phase3 | Fever | Terminated | 2004-01-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00490620 | Study of Combivir for Patients With Primary Biliary Cirrhosis | Phase2 | Primary Biliary Cirrhosis | Completed | 2004-01-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00289757 | Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepati… | Phase4 | Hepatitis A | Completed | 2004-01-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00257816 | Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma | Phase2 | Cervical Cancer | Completed | 2004-01-01 | 2007-12-17 | ClinicalTrials.gov |
| NCT00480649 | Successful Control and Clinical Effectiveness Of SERETIDE(Salmeterol/Fluticason… | Phase4 | Asthma | Completed | 2004-01-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00490620 | Study of Combivir for Patients With Primary Biliary Cirrhosis | Phase2 | Primary Biliary Cirrhosis | Completed | 2004-01-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT01371461 | Special Drug Use Investigation for PAXIL Tablet (20mg-Clinical Symptom Progress… | — | Mental Disorders | Completed | 2004-01-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00075270 | Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women … | Phase3 | Neoplasms, Breast | Completed | 2004-01-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01371461 | Special Drug Use Investigation for PAXIL Tablet (20mg-Clinical Symptom Progress… | — | Mental Disorders | Completed | 2004-01-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT01406704 | Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologica… | Phase4 | NASH (Non-alcoholic Steato-hepatitis) | Terminated | 2004-01-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00730795 | Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD… | Phase1 | Tuberculosis (TB) | Completed | 2004-01-01 | — | ClinicalTrials.gov |
| NCT00120744 | Oral Disintegrating Ondansetron Tablet to Reduce Vomiting From Gastroenteritis … | Na | Gastroenteritis | Completed | 2004-01-01 | 2005-04-01 | ClinicalTrials.gov |
| NCT00159185 | Epidemiology Study in Major Orthopaedic Surgery | — | Thrombosis | Completed | 2004-01-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00317135 | Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) A… | Phase3 | Diphtheria | Completed | 2003-12-11 | 2004-10-23 | ClinicalTrials.gov |
| NCT00317135 | Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) A… | Phase3 | Diphtheria | Completed | 2003-12-11 | 2004-10-23 | ClinicalTrials.gov |
| NCT00139347 | Study of 2 Doses of HRV Vaccine Given Concomitantly With Routine EPI Vaccinatio… | Phase3 | Infections, Rotavirus | Completed | 2003-12-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00197210 | A Study to Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotaviru… | Phase3 | Infections, Rotavirus | Completed | 2003-12-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00325143 | Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in … | Phase3 | Haemophilus Influenzae Type b | Completed | 2003-12-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00363727 | Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Ad… | Phase3 | Parkinson's Disease | Completed | 2003-12-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00363727 | Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Ad… | Phase3 | Parkinson's Disease | Completed | 2003-12-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00682019 | Study Evaluation the Efficacy and Safety of Vardenafil in Subjects With Erectil… | Phase3 | Erectile Dysfunction | Completed | 2003-12-01 | 2004-08-01 | ClinicalTrials.gov |
| NCT00325143 | Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in … | Phase3 | Haemophilus Influenzae Type b | Completed | 2003-12-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00682019 | Study Evaluation the Efficacy and Safety of Vardenafil in Subjects With Erectil… | Phase3 | Erectile Dysfunction | Completed | 2003-12-01 | 2004-08-01 | ClinicalTrials.gov |
| NCT00901407 | Lamotrigine Augmentation in Resistant Depression | Na | Unipolar Depression | Completed | 2003-12-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00901407 | Lamotrigine Augmentation in Resistant Depression | Na | Unipolar Depression | Completed | 2003-12-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT01045590 | Glibenclamide (Dose to be Titrated From Starting Dose of 5mg om) Plus Rosiglita… | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2003-12-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00118690 | A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Ast… | Phase4 | Bronchospasm | Completed | 2003-12-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00224471 | Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots… | Phase3 | Herpes Simplex | Completed | 2003-12-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00197210 | A Study to Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotaviru… | Phase3 | Infections, Rotavirus | Completed | 2003-12-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00139347 | Study of 2 Doses of HRV Vaccine Given Concomitantly With Routine EPI Vaccinatio… | Phase3 | Infections, Rotavirus | Completed | 2003-12-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT01045590 | Glibenclamide (Dose to be Titrated From Starting Dose of 5mg om) Plus Rosiglita… | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2003-12-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00118690 | A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Ast… | Phase4 | Bronchospasm | Completed | 2003-12-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00075049 | Safety and Efficacy Study of RTS,S AS02A/AS01B Vaccine to Prevent Malaria | Phase1 | Malaria | Completed | 2003-12-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00085813 | Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer | Phase2 | Non-Small-Cell Lung Cancer | Completed | 2003-12-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00085813 | Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer | Phase2 | Non-Small-Cell Lung Cancer | Completed | 2003-12-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00075049 | Safety and Efficacy Study of RTS,S AS02A/AS01B Vaccine to Prevent Malaria | Phase1 | Malaria | Completed | 2003-12-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00224471 | Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots… | Phase3 | Herpes Simplex | Completed | 2003-12-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00289731 | Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B V… | Phase4 | Hepatitis B | Completed | 2003-11-24 | 2004-12-21 | ClinicalTrials.gov |
| NCT00289731 | Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B V… | Phase4 | Hepatitis B | Completed | 2003-11-24 | 2004-12-21 | ClinicalTrials.gov |
| NCT00197236 | Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus… | Phase3 | Hepatitis A | Completed | 2003-11-11 | 2007-12-03 | ClinicalTrials.gov |
| NCT00197236 | Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus… | Phase3 | Hepatitis A | Completed | 2003-11-11 | 2007-12-03 | ClinicalTrials.gov |
| NCT00120848 | Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prev… | Phase2 | Infections, Papillomavirus | Completed | 2003-11-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00549146 | Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2003-11-01 | 2006-04-01 | ClinicalTrials.gov |
| NCT00197184 | Long Term Follow-up Study at Years 2, 3, 4 and 5 Where 2 Dosing Schedules of th… | Phase3 | Hepatitis B | Completed | 2003-11-01 | 2004-03-10 | ClinicalTrials.gov |
| NCT00090103 | Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination … | Phase3 | Prostatic Hyperplasia | Completed | 2003-11-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00169559 | Dyslipidemia Study Investigating The Increase In "Good Cholesterol" | Phase2 | Dyslipidaemias | Completed | 2003-11-01 | 2005-04-01 | ClinicalTrials.gov |
| NCT00274677 | Depression And Bipolar Disorder | Phase3 | Bipolar Disorder | Completed | 2003-11-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT02989727 | Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine | Phase4 | Depression | Completed | 2003-11-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT00073008 | A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer | Phase2 | Lung Cancer, Non-Small Cell | Terminated | 2003-11-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00211263 | Bipolar Disorder Research Study for Ages 12 and Older | Na | Bipolar Disorder | Completed | 2003-11-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00062686 | GW572016 For Treatment Of Refractory Metastatic Breast Cancer | Phase2 | Neoplasms, Breast | Completed | 2003-11-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00422955 | Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy. | Phase3 | Neuropathy, Diabetic | Completed | 2003-11-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00422955 | Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy. | Phase3 | Neuropathy, Diabetic | Completed | 2003-11-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00073008 | A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer | Phase2 | Lung Cancer, Non-Small Cell | Terminated | 2003-11-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00274677 | Depression And Bipolar Disorder | Phase3 | Bipolar Disorder | Completed | 2003-11-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00197184 | Long Term Follow-up Study at Years 2, 3, 4 and 5 Where 2 Dosing Schedules of th… | Phase3 | Hepatitis B | Completed | 2003-11-01 | 2004-03-10 | ClinicalTrials.gov |
| NCT00090103 | Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination … | Phase3 | Prostatic Hyperplasia | Completed | 2003-11-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00120848 | Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prev… | Phase2 | Infections, Papillomavirus | Completed | 2003-11-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00263679 | Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster… | Phase3 | Acellular Pertussis | Completed | 2003-11-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00263679 | Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster… | Phase3 | Acellular Pertussis | Completed | 2003-11-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00169559 | Dyslipidemia Study Investigating The Increase In "Good Cholesterol" | Phase2 | Dyslipidaemias | Completed | 2003-11-01 | 2005-04-01 | ClinicalTrials.gov |
| NCT00214019 | The Effect of Salmeterol on Eosinophil (EOS) Function | Na | Allergic Asthma | Completed | 2003-11-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT02989727 | Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine | Phase4 | Depression | Completed | 2003-11-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT00062686 | GW572016 For Treatment Of Refractory Metastatic Breast Cancer | Phase2 | Neoplasms, Breast | Completed | 2003-11-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00549146 | Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2003-11-01 | 2006-04-01 | ClinicalTrials.gov |
| NCT00214019 | The Effect of Salmeterol on Eosinophil (EOS) Function | Na | Allergic Asthma | Completed | 2003-11-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00211263 | Bipolar Disorder Research Study for Ages 12 and Older | Na | Bipolar Disorder | Completed | 2003-11-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00071760 | Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Inf… | Phase2 | Infection, Human Immunodeficiency Virus | Completed | 2003-10-23 | 2022-03-29 | ClinicalTrials.gov |
| NCT00071760 | Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Inf… | Phase2 | Infection, Human Immunodeficiency Virus | Completed | 2003-10-23 | 2022-03-29 | ClinicalTrials.gov |
| NCT00067951 | A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2003-10-17 | 2004-11-30 | ClinicalTrials.gov |
| NCT00067951 | A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2003-10-17 | 2004-11-30 | ClinicalTrials.gov |
| NCT00499707 | Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone a… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2003-10-08 | 2004-12-16 | ClinicalTrials.gov |
| NCT00499707 | Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone a… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2003-10-08 | 2004-12-16 | ClinicalTrials.gov |
| NCT00197015 | Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Ru… | Phase3 | Hepatitis A | Completed | 2003-10-06 | 2009-06-09 | ClinicalTrials.gov |
| NCT00197015 | Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Ru… | Phase3 | Hepatitis A | Completed | 2003-10-06 | 2009-06-09 | ClinicalTrials.gov |
| NCT00750360 | Study to Monitor the Safety and Reactogenicity of Fluarix™ in Korean Subjects A… | Phase4 | Influenza | Completed | 2003-10-03 | 2007-12-28 | ClinicalTrials.gov |
| NCT00750360 | Study to Monitor the Safety and Reactogenicity of Fluarix™ in Korean Subjects A… | Phase4 | Influenza | Completed | 2003-10-03 | 2007-12-28 | ClinicalTrials.gov |
| NCT00240526 | LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in … | Phase4 | Hepatitis B | Completed | 2003-10-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00101998 | Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain … | Phase2 | Constipation | Completed | 2003-10-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT01457547 | Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ … | Phase4 | Hepatitis B | Completed | 2003-10-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00062790 | Effect Of Dutasteride On Intraprostatic Dihydrotestosterone (DHT) Levels | Phase4 | Prostatic Hyperplasia | Completed | 2003-10-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT01767402 | Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal… | Phase1 | Pneumococcal Disease | Completed | 2003-10-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00240526 | LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in … | Phase4 | Hepatitis B | Completed | 2003-10-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00240591 | Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Tositumo… | — | Lymphoma, Non-Hodgkin | Completed | 2003-10-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00240539 | Long Term Follow-Up Study 16-20 Years After Hepatitis B Vaccination in Newborns… | Phase4 | Hepatitis B | Completed | 2003-10-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00240591 | Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Tositumo… | — | Lymphoma, Non-Hodgkin | Completed | 2003-10-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00240539 | Long Term Follow-Up Study 16-20 Years After Hepatitis B Vaccination in Newborns… | Phase4 | Hepatitis B | Completed | 2003-10-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00240500 | Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Ne… | Phase4 | Hepatitis B | Completed | 2003-10-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00240500 | Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Ne… | Phase4 | Hepatitis B | Completed | 2003-10-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00062790 | Effect Of Dutasteride On Intraprostatic Dihydrotestosterone (DHT) Levels | Phase4 | Prostatic Hyperplasia | Completed | 2003-10-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT01457547 | Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ … | Phase4 | Hepatitis B | Completed | 2003-10-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00429832 | A RCT of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting i… | Phase4 | Nausea | Completed | 2003-10-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00307008 | Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Po… | Phase2 | Streptococcus Pneumoniae Vaccines | Completed | 2003-10-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00101998 | Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain … | Phase2 | Constipation | Completed | 2003-10-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT01767402 | Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal… | Phase1 | Pneumococcal Disease | Completed | 2003-10-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00429832 | A RCT of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting i… | Phase4 | Nausea | Completed | 2003-10-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00307008 | Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Po… | Phase2 | Streptococcus Pneumoniae Vaccines | Completed | 2003-10-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00069459 | Seasonal Affective Depression (SAD) Study | Phase1 | Depressive Disorder | Completed | 2003-09-23 | 2004-06-03 | ClinicalTrials.gov |
| NCT00069459 | Seasonal Affective Depression (SAD) Study | Phase1 | Depressive Disorder | Completed | 2003-09-23 | 2004-06-03 | ClinicalTrials.gov |
| NCT01855711 | Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe … | Phase2 | Irritable Colon | Completed | 2003-09-18 | 2005-05-10 | ClinicalTrials.gov |
| NCT01855711 | Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe … | Phase2 | Irritable Colon | Completed | 2003-09-18 | 2005-05-10 | ClinicalTrials.gov |
| NCT01290601 | Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of P… | Phase2 | Malaria | Terminated | 2003-09-15 | 2005-01-10 | ClinicalTrials.gov |
| NCT01290601 | Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of P… | Phase2 | Malaria | Terminated | 2003-09-15 | 2005-01-10 | ClinicalTrials.gov |
| NCT00197002 | Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumoc… | Phase3 | Hepatitis A | Completed | 2003-09-11 | 2006-01-16 | ClinicalTrials.gov |
| NCT00197002 | Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumoc… | Phase3 | Hepatitis A | Completed | 2003-09-11 | 2006-01-16 | ClinicalTrials.gov |
| NCT00203632 | Glitazones and Endothelial Function (GATE) | Phase3 | Diabetes Mellitus | Terminated | 2003-09-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00279032 | GW406381 In Patients With Peripheral Nerve Injury | Phase1 | Hyperalgesia | Completed | 2003-09-01 | — | ClinicalTrials.gov |
| NCT00197171 | Long Term F/U Studies at Y5&6 to Demonstrate the Equivalence of 2 Vaccination S… | Phase3 | Hepatitis B | Completed | 2003-09-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00279032 | GW406381 In Patients With Peripheral Nerve Injury | Phase1 | Hyperalgesia | Completed | 2003-09-01 | — | ClinicalTrials.gov |
| NCT00039858 | Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulan… | Phase4 | Thrombocytopenia | Completed | 2003-09-01 | 2006-03-01 | ClinicalTrials.gov |
| NCT00169728 | Vaccination of Children Following Allogeneic Stem Cell Transplantation | Phase3 | Allogeneic Haematopoietic Stem Cell Transplantation | Completed | 2003-09-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00662441 | Evaluating of the Efficacy and Safety of Vardenafil in Subjects With Erectile D… | Phase4 | Erectile Dysfunction | Completed | 2003-09-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00203632 | Glitazones and Endothelial Function (GATE) | Phase3 | Diabetes Mellitus | Terminated | 2003-09-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00039858 | Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulan… | Phase4 | Thrombocytopenia | Completed | 2003-09-01 | 2006-03-01 | ClinicalTrials.gov |
| NCT00197171 | Long Term F/U Studies at Y5&6 to Demonstrate the Equivalence of 2 Vaccination S… | Phase3 | Hepatitis B | Completed | 2003-09-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00662441 | Evaluating of the Efficacy and Safety of Vardenafil in Subjects With Erectile D… | Phase4 | Erectile Dysfunction | Completed | 2003-09-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00169728 | Vaccination of Children Following Allogeneic Stem Cell Transplantation | Phase3 | Allogeneic Haematopoietic Stem Cell Transplantation | Completed | 2003-09-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00065182 | Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage II… | Phase2 | Lung Cancer, Non-Small Cell | Completed | 2003-08-14 | 2007-08-30 | ClinicalTrials.gov |
| NCT00065182 | Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage II… | Phase2 | Lung Cancer, Non-Small Cell | Completed | 2003-08-14 | 2007-08-30 | ClinicalTrials.gov |
| NCT00140673 | A Study to Test 2 Doses of the HRV Vaccine in Healthy Infants. | Phase3 | Infections, Rotavirus | Completed | 2003-08-05 | 2005-10-20 | ClinicalTrials.gov |
| NCT00140673 | A Study to Test 2 Doses of the HRV Vaccine in Healthy Infants. | Phase3 | Infections, Rotavirus | Completed | 2003-08-05 | 2005-10-20 | ClinicalTrials.gov |
| NCT00153062 | PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes | Phase4 | Stroke | Completed | 2003-08-01 | — | ClinicalTrials.gov |
| NCT00969072 | Extension Study of GI198745 to Treat Benign Prostatic Hyperplasia | Phase2 | Benign Prostatic Hyperplasia | Completed | 2003-08-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00969072 | Extension Study of GI198745 to Treat Benign Prostatic Hyperplasia | Phase2 | Benign Prostatic Hyperplasia | Completed | 2003-08-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00064428 | OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Pat… | Phase3 | Thromboembolism | Completed | 2003-08-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00067938 | Bipolar Study in Adults at Least 18 Years of Age | Phase4 | Bipolar Disorder | Completed | 2003-08-01 | 2004-08-01 | ClinicalTrials.gov |
| NCT00384670 | A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flaviviru… | Phase1 | Dengue Fever | Completed | 2003-08-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT00071747 | Clinical Study Of Schizophrenia in Both Men and Women | Phase3 | Schizophrenia | Completed | 2003-08-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00363857 | A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndro… | Phase3 | Restless Legs Syndrome (RLS) | Completed | 2003-08-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT00071747 | Clinical Study Of Schizophrenia in Both Men and Women | Phase3 | Schizophrenia | Completed | 2003-08-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00378976 | HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1, HSV-2 Co-infected Men. | Phase3 | HIV Infection | Completed | 2003-08-01 | 2004-07-01 | ClinicalTrials.gov |
| NCT00067938 | Bipolar Study in Adults at Least 18 Years of Age | Phase4 | Bipolar Disorder | Completed | 2003-08-01 | 2004-08-01 | ClinicalTrials.gov |
| NCT00064428 | OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Pat… | Phase3 | Thromboembolism | Completed | 2003-08-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00363857 | A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndro… | Phase3 | Restless Legs Syndrome (RLS) | Completed | 2003-08-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT00378976 | HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1, HSV-2 Co-infected Men. | Phase3 | HIV Infection | Completed | 2003-08-01 | 2004-07-01 | ClinicalTrials.gov |
| NCT00757770 | Assessment of Clinical Consistency of Three Production Lots of GSK Biologicals'… | Phase3 | Infections, Rotavirus | Completed | 2003-08-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT00384670 | A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flaviviru… | Phase1 | Dengue Fever | Completed | 2003-08-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT01061541 | Immunogenicity, Safety & Reactogenicity of GSK Vaccine Tritanrix™-HepB/Hib2.5 C… | Phase2 | Haemophilus Influenzae Type b | Completed | 2003-08-01 | 2004-08-01 | ClinicalTrials.gov |
| NCT00757770 | Assessment of Clinical Consistency of Three Production Lots of GSK Biologicals'… | Phase3 | Infections, Rotavirus | Completed | 2003-08-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT00153062 | PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes | Phase4 | Stroke | Completed | 2003-08-01 | — | ClinicalTrials.gov |
| NCT01061541 | Immunogenicity, Safety & Reactogenicity of GSK Vaccine Tritanrix™-HepB/Hib2.5 C… | Phase2 | Haemophilus Influenzae Type b | Completed | 2003-08-01 | 2004-08-01 | ClinicalTrials.gov |
| NCT00240552 | Fosamprenavir Expanded Access | Phase4 | Infection, Human Immunodeficiency Virus | Completed | 2003-07-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00317174 | A Study to Assess Antibody Persistence, Boostability & Safety in Previously Pri… | Phase2 | Haemophilus Influenzae Type b | Completed | 2003-07-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00197041 | A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline … | Phase2 | Malaria | Completed | 2003-07-01 | 2005-04-01 | ClinicalTrials.gov |
| NCT00240552 | Fosamprenavir Expanded Access | Phase4 | Infection, Human Immunodeficiency Virus | Completed | 2003-07-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00317174 | A Study to Assess Antibody Persistence, Boostability & Safety in Previously Pri… | Phase2 | Haemophilus Influenzae Type b | Completed | 2003-07-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00308061 | Safety Study of Candidate Malaria Vaccine FMP1/AS02A in Healthy Adults in Bandi… | Phase1 | Malaria | Completed | 2003-07-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00308061 | Safety Study of Candidate Malaria Vaccine FMP1/AS02A in Healthy Adults in Bandi… | Phase1 | Malaria | Completed | 2003-07-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00197041 | A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline … | Phase2 | Malaria | Completed | 2003-07-01 | 2005-04-01 | ClinicalTrials.gov |
| NCT00241605 | AVANDAMET Versus Metformin For Type 2 Diabetes Mellitus | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2003-06-25 | 2005-12-16 | ClinicalTrials.gov |
| NCT00241605 | AVANDAMET Versus Metformin For Type 2 Diabetes Mellitus | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2003-06-25 | 2005-12-16 | ClinicalTrials.gov |
| NCT00317473 | Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children | Phase1 | Plasmodium Falciparum Malaria | Completed | 2003-06-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00658177 | Study Evaluating the Efficacy and Safety of Flexible-dose Vardenafil in Subject… | Phase3 | Erectile Dysfunction | Completed | 2003-06-01 | 2004-02-01 | ClinicalTrials.gov |
| NCT00317473 | Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children | Phase1 | Plasmodium Falciparum Malaria | Completed | 2003-06-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00062738 | Treatment of Depression in Parkinson's Disease Trial | Phase2 | Parkinson Disease | Completed | 2003-06-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00067561 | Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having… | Phase3 | Irritable Colon | Completed | 2003-06-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00381472 | Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa | Phase3 | Parkinson Disease | Completed | 2003-06-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00361959 | SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Ch… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2003-06-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00067457 | Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having… | Phase3 | Irritable Colon | Completed | 2003-06-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00519467 | Safety and Efficacy Dose of Artesunate Used in Combination With LAPDAP Treatmen… | Phase2 | Malaria | Completed | 2003-06-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00361959 | SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Ch… | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 2003-06-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00658177 | Study Evaluating the Efficacy and Safety of Flexible-dose Vardenafil in Subject… | Phase3 | Erectile Dysfunction | Completed | 2003-06-01 | 2004-02-01 | ClinicalTrials.gov |
| NCT00156819 | The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial | Phase4 | Asthma | Completed | 2003-06-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00067561 | Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having… | Phase3 | Irritable Colon | Completed | 2003-06-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00381472 | Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa | Phase3 | Parkinson Disease | Completed | 2003-06-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00661297 | Study Evaluating the Efficacy, Safety, and Reliability of Vardenafil | Phase3 | Erectile Dysfunction | Completed | 2003-06-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT00067457 | Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having… | Phase3 | Irritable Colon | Completed | 2003-06-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00519467 | Safety and Efficacy Dose of Artesunate Used in Combination With LAPDAP Treatmen… | Phase2 | Malaria | Completed | 2003-06-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00156819 | The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial | Phase4 | Asthma | Completed | 2003-06-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00062738 | Treatment of Depression in Parkinson's Disease Trial | Phase2 | Parkinson Disease | Completed | 2003-06-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00661297 | Study Evaluating the Efficacy, Safety, and Reliability of Vardenafil | Phase3 | Erectile Dysfunction | Completed | 2003-06-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT00135525 | Study Of Generalized Anxiety Disorder | Phase2 | Anxiety Disorder | Completed | 2003-05-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00123643 | Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients | Phase4 | Type 2 Diabetes Mellitus | Completed | 2003-05-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00135525 | Study Of Generalized Anxiety Disorder | Phase2 | Anxiety Disorder | Completed | 2003-05-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00544271 | Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFAN… | Phase4 | Acellular Pertussis | Terminated | 2003-05-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT00123643 | Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients | Phase4 | Type 2 Diabetes Mellitus | Completed | 2003-05-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00631800 | Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW… | Phase2 | Staphylococcal Sepsis | Completed | 2003-05-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00193583 | Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for… | Phase1 | Cancer | Completed | 2003-05-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00125008 | Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever | Phase4 | Typhoid | Completed | 2003-05-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00544271 | Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFAN… | Phase4 | Acellular Pertussis | Terminated | 2003-05-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT00631800 | Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW… | Phase2 | Staphylococcal Sepsis | Completed | 2003-05-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00193583 | Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for… | Phase1 | Cancer | Completed | 2003-05-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00125008 | Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever | Phase4 | Typhoid | Completed | 2003-05-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00148902 | Effects Of GW572016 In Combination With Docetaxel (TAXOTERE) | Phase1 | Neoplasms, Breast | Completed | 2003-04-28 | 2006-01-21 | ClinicalTrials.gov |
| NCT00148902 | Effects Of GW572016 In Combination With Docetaxel (TAXOTERE) | Phase1 | Neoplasms, Breast | Completed | 2003-04-28 | 2006-01-21 | ClinicalTrials.gov |
| NCT00146835 | Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine | — | Hepatitis B | Completed | 2003-04-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00139815 | Michelangelo - Oasis 5 | Phase3 | Thromboembolism | Completed | 2003-04-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00139815 | Michelangelo - Oasis 5 | Phase3 | Thromboembolism | Completed | 2003-04-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT01294605 | Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (… | Phase4 | Acellular Pertussis | Completed | 2003-04-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00307970 | Impact of Anti-static Chamber/Mask | Phase4 | Asthma | Completed | 2003-04-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00307970 | Impact of Anti-static Chamber/Mask | Phase4 | Asthma | Completed | 2003-04-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00230477 | Hepsera Versus Hepsera Plus Lamivudine for Treatment of Chronic Hepatitis B in … | Phase4 | Hepatitis B | Completed | 2003-04-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00230477 | Hepsera Versus Hepsera Plus Lamivudine for Treatment of Chronic Hepatitis B in … | Phase4 | Hepatitis B | Completed | 2003-04-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT01294605 | Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (… | Phase4 | Acellular Pertussis | Completed | 2003-04-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00146835 | Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine | — | Hepatitis B | Completed | 2003-04-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00161434 | A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons | Phase4 | Herpes Simplex | Completed | 2003-03-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00057226 | An 8 Week Study Of Adults Diagnosed With Major Depressive Disorder | Phase2 | Depressive Disorder, Major | Completed | 2003-03-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00057213 | An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder | Phase2 | Depressive Disorder, Major | Completed | 2003-03-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00057239 | An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder | Phase2 | Major Depressive Disorder (MDD) | Completed | 2003-03-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT00057226 | An 8 Week Study Of Adults Diagnosed With Major Depressive Disorder | Phase2 | Depressive Disorder, Major | Completed | 2003-03-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00057213 | An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder | Phase2 | Depressive Disorder, Major | Completed | 2003-03-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00057239 | An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder | Phase2 | Major Depressive Disorder (MDD) | Completed | 2003-03-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT00056407 | "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer… | Phase3 | Neoplasms, Prostate | Completed | 2003-03-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00127855 | Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Sero… | Phase2 | Haemophilus Influenzae Type b | Completed | 2003-03-01 | 2004-02-12 | ClinicalTrials.gov |
| NCT00129116 | 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine C… | Phase2 | Haemophilus Influenzae Type b | Completed | 2003-03-01 | 2003-12-16 | ClinicalTrials.gov |
| NCT00256815 | Combination of Weekly Chest Radiotherapy and Oral Navelbine for the Palliation … | Phase1 | Carcinoma, Non-Small-Cell Lung | Completed | 2003-03-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00129116 | 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine C… | Phase2 | Haemophilus Influenzae Type b | Completed | 2003-03-01 | 2003-12-16 | ClinicalTrials.gov |
| NCT00256815 | Combination of Weekly Chest Radiotherapy and Oral Navelbine for the Palliation … | Phase1 | Carcinoma, Non-Small-Cell Lung | Completed | 2003-03-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00161434 | A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons | Phase4 | Herpes Simplex | Completed | 2003-03-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00127855 | Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Sero… | Phase2 | Haemophilus Influenzae Type b | Completed | 2003-03-01 | 2004-02-12 | ClinicalTrials.gov |
| NCT00056407 | "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer… | Phase3 | Neoplasms, Prostate | Completed | 2003-03-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00056277 | Bipolar Disorder Study for Men and Women | Phase3 | Bipolar Disorder | Completed | 2003-02-27 | 2005-12-14 | ClinicalTrials.gov |
| NCT00056277 | Bipolar Disorder Study for Men and Women | Phase3 | Bipolar Disorder | Completed | 2003-02-27 | 2005-12-14 | ClinicalTrials.gov |
| NCT00053638 | A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Hav… | Phase3 | HIV Infection | Completed | 2003-02-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00920543 | GSK BHR Study (Sont) | Phase4 | Asthma | Completed | 2003-02-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00920543 | GSK BHR Study (Sont) | Phase4 | Asthma | Completed | 2003-02-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00308932 | Effect of Age and Device on Delivery of Fluticasone | Phase4 | Asthma | Completed | 2003-02-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00308932 | Effect of Age and Device on Delivery of Fluticasone | Phase4 | Asthma | Completed | 2003-02-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00053638 | A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Hav… | Phase3 | HIV Infection | Completed | 2003-02-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00297206 | A Safety And Tolerability Study Of Valaciclovir Oral Suspension In Infants And … | Phase1 | Herpes Simplex | Completed | 2003-01-25 | 2007-02-28 | ClinicalTrials.gov |
| NCT00297206 | A Safety And Tolerability Study Of Valaciclovir Oral Suspension In Infants And … | Phase1 | Herpes Simplex | Completed | 2003-01-25 | 2007-02-28 | ClinicalTrials.gov |
| NCT00057330 | HerpeVac Trial for Young Women | Phase3 | Herpes Simplex Infection | Completed | 2003-01-14 | 2009-08-22 | ClinicalTrials.gov |
| NCT00057330 | HerpeVac Trial for Young Women | Phase3 | Herpes Simplex Infection | Completed | 2003-01-14 | 2009-08-22 | ClinicalTrials.gov |
| NCT01916720 | Study to Determine the Effect of 14 Days Dosing With Darapladib (SB-480848) on … | Phase2 | Atherosclerosis | Completed | 2003-01-01 | 2003-07-01 | ClinicalTrials.gov |
| NCT00051272 | Effects Of Antidepressants On Sexual Functioning In Adults | Phase3 | Major Depressive Disorder (MDD) | Completed | 2003-01-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00051259 | Effects of Antidepressants on Sexual Functioning | Phase3 | Major Depressive Disorder (MDD) | Completed | 2003-01-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00051272 | Effects Of Antidepressants On Sexual Functioning In Adults | Phase3 | Major Depressive Disorder (MDD) | Completed | 2003-01-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00169546 | Study In Airway Physiology In Children SERETIDE DISKUS ® Inhlaer and FLIXOTIDE®… | Phase4 | Asthma | Completed | 2003-01-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT01916720 | Study to Determine the Effect of 14 Days Dosing With Darapladib (SB-480848) on … | Phase2 | Atherosclerosis | Completed | 2003-01-01 | 2003-07-01 | ClinicalTrials.gov |
| NCT00169546 | Study In Airway Physiology In Children SERETIDE DISKUS ® Inhlaer and FLIXOTIDE®… | Phase4 | Asthma | Completed | 2003-01-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00051259 | Effects of Antidepressants on Sexual Functioning | Phase3 | Major Depressive Disorder (MDD) | Completed | 2003-01-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00344513 | Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients Wit… | Phase4 | Heart Failure, Congestive | Completed | 2002-12-16 | 2005-06-30 | ClinicalTrials.gov |
| NCT00344513 | Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients Wit… | Phase4 | Heart Failure, Congestive | Completed | 2002-12-16 | 2005-06-30 | ClinicalTrials.gov |
| NCT00215163 | Paroxetine-CR to Treat Post-Traumatic Stress Disorder (PTSD) Symptomatic After … | Phase2 | Stress Disorders, Post-Traumatic | Completed | 2002-12-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00857675 | A Efficacy and Safety Study of Adefovir Dipivoxil to Treat Chinese Patients Wit… | Phase3 | Chronic Hepatitis B | Completed | 2002-12-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00215163 | Paroxetine-CR to Treat Post-Traumatic Stress Disorder (PTSD) Symptomatic After … | Phase2 | Stress Disorders, Post-Traumatic | Completed | 2002-12-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00370591 | Study Of Airway Physiology In Adults. SERETIDE DISKUS® Inhaler and FLIXOTIDE® I… | Phase4 | Asthma | Completed | 2002-12-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00857675 | A Efficacy and Safety Study of Adefovir Dipivoxil to Treat Chinese Patients Wit… | Phase3 | Chronic Hepatitis B | Completed | 2002-12-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00370591 | Study Of Airway Physiology In Adults. SERETIDE DISKUS® Inhaler and FLIXOTIDE® I… | Phase4 | Asthma | Completed | 2002-12-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00048204 | A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Dis… | Phase2 | Depressive Disorder, Major | Completed | 2002-11-04 | 2003-09-30 | ClinicalTrials.gov |
| NCT00048204 | A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Dis… | Phase2 | Depressive Disorder, Major | Completed | 2002-11-04 | 2003-09-30 | ClinicalTrials.gov |
| NCT00453778 | A Study To Investigate The Effect Of Inhaled Fluticasone Propionate On The Bron… | Phase4 | Asthma | Completed | 2002-11-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT00376454 | The Study of GW493838, an Adenosine A1 Agonist, in Peripheral Neuropathic Pain | Phase2 | Neuropathic Pain | Completed | 2002-11-01 | 2003-06-01 | ClinicalTrials.gov |
| NCT00479739 | CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adju… | Phase4 | Asthma | Completed | 2002-11-01 | 2004-07-01 | ClinicalTrials.gov |
| NCT00263692 | Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separ… | Phase2 | Diphtheria | Completed | 2002-11-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00187031 | A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor | Phase2 | Wilms Tumor | Completed | 2002-11-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00187031 | A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor | Phase2 | Wilms Tumor | Completed | 2002-11-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00263692 | Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separ… | Phase2 | Diphtheria | Completed | 2002-11-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00479739 | CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adju… | Phase4 | Asthma | Completed | 2002-11-01 | 2004-07-01 | ClinicalTrials.gov |
| NCT00376454 | The Study of GW493838, an Adenosine A1 Agonist, in Peripheral Neuropathic Pain | Phase2 | Neuropathic Pain | Completed | 2002-11-01 | 2003-06-01 | ClinicalTrials.gov |
| NCT00453778 | A Study To Investigate The Effect Of Inhaled Fluticasone Propionate On The Bron… | Phase4 | Asthma | Completed | 2002-11-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT00654680 | Evaluating the Efficacy and Safety of Vardenafil in Patients Erectile Dysfuncti… | Phase3 | Erectile Dysfunction | Completed | 2002-10-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT00133081 | Study to Improve the Treatment of Epilepsy (SITE) | Phase4 | Epilepsy | Unknown | 2002-10-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00656188 | Placebo-controlled Study Evaluating the Efficacy and Safety of Vardenafil in Su… | Phase2 | Erectile Dysfunction | Completed | 2002-10-01 | 2003-05-01 | ClinicalTrials.gov |
| NCT00306696 | Examining the Effect of Different Diuretics on Fluid Retention in Diabetics Tre… | Phase4 | Diabetes Mellitus | Completed | 2002-10-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT00268177 | Airway Inflammation In Patients With Chronic Obstructive Pulmonary Disease | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2002-10-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00225225 | Rosiglitazone-Induced Weight Gain | Na | Diabetes Mellitus, Type 2 | Terminated | 2002-10-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00197132 | Study In Patients With Insulin Resistance | Phase3 | Insulin Resistance | Completed | 2002-10-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00048360 | Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults | Phase3 | Attention Deficit Disorder | Completed | 2002-10-01 | 2003-06-01 | ClinicalTrials.gov |
| NCT00049946 | Schizophrenia Study In Adults | Phase2 | Schizophrenia | Completed | 2002-10-01 | 2003-04-01 | ClinicalTrials.gov |
| NCT00051103 | Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-l… | Phase2 | Metastatic Breast Cancer | Completed | 2002-10-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00306696 | Examining the Effect of Different Diuretics on Fluid Retention in Diabetics Tre… | Phase4 | Diabetes Mellitus | Completed | 2002-10-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT00133081 | Study to Improve the Treatment of Epilepsy (SITE) | Phase4 | Epilepsy | Unknown | 2002-10-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00225225 | Rosiglitazone-Induced Weight Gain | Na | Diabetes Mellitus, Type 2 | Terminated | 2002-10-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00268177 | Airway Inflammation In Patients With Chronic Obstructive Pulmonary Disease | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2002-10-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00197132 | Study In Patients With Insulin Resistance | Phase3 | Insulin Resistance | Completed | 2002-10-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00051103 | Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-l… | Phase2 | Metastatic Breast Cancer | Completed | 2002-10-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00049946 | Schizophrenia Study In Adults | Phase2 | Schizophrenia | Completed | 2002-10-01 | 2003-04-01 | ClinicalTrials.gov |
| NCT00048360 | Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults | Phase3 | Attention Deficit Disorder | Completed | 2002-10-01 | 2003-06-01 | ClinicalTrials.gov |
| NCT00654680 | Evaluating the Efficacy and Safety of Vardenafil in Patients Erectile Dysfuncti… | Phase3 | Erectile Dysfunction | Completed | 2002-10-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT00656188 | Placebo-controlled Study Evaluating the Efficacy and Safety of Vardenafil in Su… | Phase2 | Erectile Dysfunction | Completed | 2002-10-01 | 2003-05-01 | ClinicalTrials.gov |
| NCT00731029 | Reacto & Immunogenicity of TF Formulation of Influsplit SSW® 2002/03 v/s Std Fo… | Phase3 | Influenza | Completed | 2002-09-01 | — | ClinicalTrials.gov |
| NCT00285584 | Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With M… | Phase1 | HIV Infections | Completed | 2002-09-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00353886 | Study of Antiepileptic Drug Effects on Child Development | — | Epilepsy | Completed | 2002-09-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00285584 | Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With M… | Phase1 | HIV Infections | Completed | 2002-09-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00329225 | Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Co… | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2002-09-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00049972 | Major Depressive Disorder Study In Adults | Phase4 | Major Depressive Disorder | Completed | 2002-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00065065 | A Trial of Rosiglitazone for Ulcerative Colitis | Phase2 | Ulcerative Colitis | Completed | 2002-09-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00046449 | Prevention of Seasonal Affective Disorder | Phase3 | Seasonal Affective Disorder (SAD) | Completed | 2002-09-01 | 2003-06-01 | ClinicalTrials.gov |
| NCT00046449 | Prevention of Seasonal Affective Disorder | Phase3 | Seasonal Affective Disorder (SAD) | Completed | 2002-09-01 | 2003-06-01 | ClinicalTrials.gov |
| NCT00044343 | GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With… | Phase2 | Colorectal Cancer | Completed | 2002-09-01 | 2003-10-01 | ClinicalTrials.gov |
| NCT00353886 | Study of Antiepileptic Drug Effects on Child Development | — | Epilepsy | Completed | 2002-09-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00049972 | Major Depressive Disorder Study In Adults | Phase4 | Major Depressive Disorder | Completed | 2002-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00231387 | Rosiglitazone And Plaque Study for Type 2 Diabetes Mellitus | Phase3 | Non-insulin-dependent Diabetes Mellitus | Completed | 2002-09-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00193388 | Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer | Phase2 | Lung Cancer | Completed | 2002-09-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00731029 | Reacto & Immunogenicity of TF Formulation of Influsplit SSW® 2002/03 v/s Std Fo… | Phase3 | Influenza | Completed | 2002-09-01 | — | ClinicalTrials.gov |
| NCT00329225 | Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Co… | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2002-09-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00193388 | Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer | Phase2 | Lung Cancer | Completed | 2002-09-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00231387 | Rosiglitazone And Plaque Study for Type 2 Diabetes Mellitus | Phase3 | Non-insulin-dependent Diabetes Mellitus | Completed | 2002-09-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00065065 | A Trial of Rosiglitazone for Ulcerative Colitis | Phase2 | Ulcerative Colitis | Completed | 2002-09-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00044343 | GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With… | Phase2 | Colorectal Cancer | Completed | 2002-09-01 | 2003-10-01 | ClinicalTrials.gov |
| NCT01390766 | Drug Use Investigation for IMURAN (Azathioprine) Tablet (Hepatic Transplantatio… | — | Liver Diseases | Completed | 2002-08-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT00320359 | Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive … | Phase3 | Lung Cancer, Small Cell | Completed | 2002-08-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00238888 | Randomised Controlled Trial of a Multi-faceted Community-based Intervention to … | Phase4 | Asthma | Completed | 2002-08-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01390766 | Drug Use Investigation for IMURAN (Azathioprine) Tablet (Hepatic Transplantatio… | — | Liver Diseases | Completed | 2002-08-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT00320359 | Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive … | Phase3 | Lung Cancer, Small Cell | Completed | 2002-08-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00238888 | Randomised Controlled Trial of a Multi-faceted Community-based Intervention to … | Phase4 | Asthma | Completed | 2002-08-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00043862 | The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly … | Phase2 | Lung Cancer, Small Cell | Completed | 2002-08-01 | — | ClinicalTrials.gov |
| NCT00043862 | The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly … | Phase2 | Lung Cancer, Small Cell | Completed | 2002-08-01 | — | ClinicalTrials.gov |
| NCT00137917 | Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a… | Phase2 | Infections, Meningococcal | Completed | 2002-07-01 | 2003-06-01 | ClinicalTrials.gov |
| NCT00137917 | Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a… | Phase2 | Infections, Meningococcal | Completed | 2002-07-01 | 2003-06-01 | ClinicalTrials.gov |
| NCT00046332 | A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients | Phase2 | HIV Infections | Completed | 2002-06-01 | 2003-01-01 | ClinicalTrials.gov |
| NCT00046332 | A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients | Phase2 | HIV Infections | Completed | 2002-06-01 | 2003-01-01 | ClinicalTrials.gov |
| NCT00290355 | Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell… | Phase2 | Lung Cancer, Non-Small Cell | Completed | 2002-05-28 | 2011-07-19 | ClinicalTrials.gov |
| NCT00290355 | Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell… | Phase2 | Lung Cancer, Non-Small Cell | Completed | 2002-05-28 | 2011-07-19 | ClinicalTrials.gov |
| NCT00650104 | Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly R… | Phase3 | Parkinson Disease | Completed | 2002-05-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00306644 | Effect Of Rosiglitazone On Carotid Intima Media Thickness In Patients With Insu… | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2002-05-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00044460 | Efficacy and Safety In Poorly Controlled Type 2 Diabetics | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2002-05-01 | 2003-04-10 | ClinicalTrials.gov |
| NCT00650104 | Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly R… | Phase3 | Parkinson Disease | Completed | 2002-05-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00197249 | Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix … | Phase3 | Hepatitis A | Completed | 2002-05-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00044460 | Efficacy and Safety In Poorly Controlled Type 2 Diabetics | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2002-05-01 | 2003-04-10 | ClinicalTrials.gov |
| NCT00306644 | Effect Of Rosiglitazone On Carotid Intima Media Thickness In Patients With Insu… | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2002-05-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00839397 | BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder | Phase3 | Post-Traumatic Stress Disorder | Completed | 2002-05-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00839397 | BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder | Phase3 | Post-Traumatic Stress Disorder | Completed | 2002-05-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00197249 | Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix … | Phase3 | Hepatitis A | Completed | 2002-05-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00383591 | Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pr… | Phase3 | Hepatitis B | Completed | 2002-03-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT00135486 | Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-Me… | Phase2 | Infections, Meningococcal | Completed | 2002-03-01 | 2003-01-01 | ClinicalTrials.gov |
| NCT00135486 | Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-Me… | Phase2 | Infections, Meningococcal | Completed | 2002-03-01 | 2003-01-01 | ClinicalTrials.gov |
| NCT00383591 | Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pr… | Phase3 | Hepatitis B | Completed | 2002-03-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT00407264 | Randomized Trial of Fluticasone in Bronchial Premalignancy | Phase2 | Bronchogenic Carcinoma | Completed | 2002-02-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00193570 | Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tum… | Phase1 | Cancer | Completed | 2002-02-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00457665 | Mechanisms of Lipodystrophy in HIV-Infected Pateints | Phase4 | HIV Infections | Completed | 2002-02-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT00193297 | Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced … | Phase2 | Ovary Cancer | Completed | 2002-02-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00407264 | Randomized Trial of Fluticasone in Bronchial Premalignancy | Phase2 | Bronchogenic Carcinoma | Completed | 2002-02-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00193297 | Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced … | Phase2 | Ovary Cancer | Completed | 2002-02-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00193570 | Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tum… | Phase1 | Cancer | Completed | 2002-02-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00549874 | Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes | Na | Type 2 Diabetes | Completed | 2002-02-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00457665 | Mechanisms of Lipodystrophy in HIV-Infected Pateints | Phase4 | HIV Infections | Completed | 2002-02-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT00549874 | Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes | Na | Type 2 Diabetes | Completed | 2002-02-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00043914 | Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Pat… | Phase4 | Epilepsy | Completed | 2002-01-14 | 2003-01-29 | ClinicalTrials.gov |
| NCT00043914 | Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Pat… | Phase4 | Epilepsy | Completed | 2002-01-14 | 2003-01-29 | ClinicalTrials.gov |
| NCT00610909 | Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (I… | Phase4 | Irritable Bowel Syndrome | Completed | 2002-01-01 | 2002-12-01 | ClinicalTrials.gov |
| NCT01277705 | Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids a… | Phase3 | Tetanus | Completed | 2002-01-01 | 2002-04-01 | ClinicalTrials.gov |
| NCT00129363 | Study to Evaluate the Safety of Twice Daily Oral Carvedilol | Phase3 | Congestive Heart Failure | Completed | 2002-01-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00041509 | ThromboEmbolism Prevention Efficacy and Safety Trial (TEMPEST) | Phase2 | Arthroplasty | Completed | 2002-01-01 | 2003-05-01 | ClinicalTrials.gov |
| NCT00388401 | Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dys… | Phase3 | Ileus | Completed | 2002-01-01 | 2003-06-01 | ClinicalTrials.gov |
| NCT00610909 | Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (I… | Phase4 | Irritable Bowel Syndrome | Completed | 2002-01-01 | 2002-12-01 | ClinicalTrials.gov |
| NCT02522754 | Development of an Intranasal Proteosome Influenza Vaccine | Phase1 | Influenza | Completed | 2002-01-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT01277705 | Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids a… | Phase3 | Tetanus | Completed | 2002-01-01 | 2002-04-01 | ClinicalTrials.gov |
| NCT00041509 | ThromboEmbolism Prevention Efficacy and Safety Trial (TEMPEST) | Phase2 | Arthroplasty | Completed | 2002-01-01 | 2003-05-01 | ClinicalTrials.gov |
| NCT00129363 | Study to Evaluate the Safety of Twice Daily Oral Carvedilol | Phase3 | Congestive Heart Failure | Completed | 2002-01-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00388401 | Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dys… | Phase3 | Ileus | Completed | 2002-01-01 | 2003-06-01 | ClinicalTrials.gov |
| NCT02522754 | Development of an Intranasal Proteosome Influenza Vaccine | Phase1 | Influenza | Completed | 2002-01-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT01059604 | Sumatriptan and Naratriptan Pregnancy Registry | — | Migraine Disorders | Completed | 2001-12-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT00388479 | Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dys… | Phase3 | Ileus | Completed | 2001-12-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT01059604 | Sumatriptan and Naratriptan Pregnancy Registry | — | Migraine Disorders | Completed | 2001-12-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT00151086 | Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory P… | Phase1 | Prostate Cancer | Completed | 2001-12-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00151086 | Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory P… | Phase1 | Prostate Cancer | Completed | 2001-12-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00388479 | Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dys… | Phase3 | Ileus | Completed | 2001-12-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT00131820 | Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Viet… | Phase4 | Typhoid | Completed | 2001-12-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00131820 | Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Viet… | Phase4 | Typhoid | Completed | 2001-12-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00325416 | Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue i… | Phase1 | Multiple Myeloma | Completed | 2001-11-19 | 2018-01-30 | ClinicalTrials.gov |
| NCT00325416 | Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue i… | Phase1 | Multiple Myeloma | Completed | 2001-11-19 | 2018-01-30 | ClinicalTrials.gov |
| NCT00158886 | Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer | Phase1 | Carcinoma, Renal Cell | Terminated | 2001-11-08 | 2006-08-11 | ClinicalTrials.gov |
| NCT00158886 | Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer | Phase1 | Carcinoma, Renal Cell | Terminated | 2001-11-08 | 2006-08-11 | ClinicalTrials.gov |
| NCT00215956 | A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With … | Phase1 | Rectal Neoplasms | Completed | 2001-11-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00041496 | Prevention Of Recurrence Of Atrial Fibrillation | Phase2 | Fibrillation, Atrial | Completed | 2001-11-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00215956 | A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With … | Phase1 | Rectal Neoplasms | Completed | 2001-11-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00920959 | Advair Pediatric Once-Daily | Phase3 | Asthma | Completed | 2001-11-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT01064297 | Lamotrigine Pregnancy Registry (LAM05) | — | Epilepsy | Completed | 2001-11-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00346892 | To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine … | Phase2 | Rotavirus Infections | Completed | 2001-11-01 | — | ClinicalTrials.gov |
| NCT00038961 | A Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used Wi… | Phase3 | Thromboembolism | Completed | 2001-11-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00038961 | A Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used Wi… | Phase3 | Thromboembolism | Completed | 2001-11-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00346892 | To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine … | Phase2 | Rotavirus Infections | Completed | 2001-11-01 | — | ClinicalTrials.gov |
| NCT00631878 | Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110 | Phase1 | Neonatal Staphylococcal Sepsis | Completed | 2001-11-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00041496 | Prevention Of Recurrence Of Atrial Fibrillation | Phase2 | Fibrillation, Atrial | Completed | 2001-11-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00631878 | Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110 | Phase1 | Neonatal Staphylococcal Sepsis | Completed | 2001-11-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00296504 | A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infecte… | Phase3 | Infection, Human Immunodeficiency Virus | Completed | 2001-11-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00296504 | A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infecte… | Phase3 | Infection, Human Immunodeficiency Virus | Completed | 2001-11-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT01064297 | Lamotrigine Pregnancy Registry (LAM05) | — | Epilepsy | Completed | 2001-11-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00920959 | Advair Pediatric Once-Daily | Phase3 | Asthma | Completed | 2001-11-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT00299793 | Observational Study of Lamotrigine | — | Epilepsy | Completed | 2001-10-01 | — | ClinicalTrials.gov |
| NCT00125047 | Combined Vi Vaccination and Health Education Program on the Burden of Typhoid i… | Phase4 | Typhoid | Completed | 2001-10-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00034840 | Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Follow… | Phase4 | Hypertension | Completed | 2001-10-01 | 2002-08-01 | ClinicalTrials.gov |
| NCT00333385 | Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis | Phase4 | Cystic Fibrosis | Terminated | 2001-10-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00125047 | Combined Vi Vaccination and Health Education Program on the Burden of Typhoid i… | Phase4 | Typhoid | Completed | 2001-10-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00049998 | Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small C… | Phase3 | Non-Small-Cell Lung Cancer | Completed | 2001-10-01 | — | ClinicalTrials.gov |
| NCT00299793 | Observational Study of Lamotrigine | — | Epilepsy | Completed | 2001-10-01 | — | ClinicalTrials.gov |
| NCT00333385 | Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis | Phase4 | Cystic Fibrosis | Terminated | 2001-10-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00049998 | Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small C… | Phase3 | Non-Small-Cell Lung Cancer | Completed | 2001-10-01 | — | ClinicalTrials.gov |
| NCT00034840 | Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Follow… | Phase4 | Hypertension | Completed | 2001-10-01 | 2002-08-01 | ClinicalTrials.gov |
| NCT00540098 | Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Dis… | Phase4 | Panic Disorder | Completed | 2001-09-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT01376141 | Drug Use Investigation for IMIGRAN Tablet | — | Migraine Disorders | Completed | 2001-09-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00540098 | Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Dis… | Phase4 | Panic Disorder | Completed | 2001-09-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00046111 | A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With A… | Phase1 | Lung Cancer, Small Cell | Completed | 2001-09-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00366366 | To Evaluate Immunogenicity & Safety of GSK Bio's DTPa-HBV-IPV/Hib (Mixed Vaccin… | Phase3 | Hepatitis B | Completed | 2001-09-01 | 2002-09-01 | ClinicalTrials.gov |
| NCT00046111 | A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With A… | Phase1 | Lung Cancer, Small Cell | Completed | 2001-09-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00366366 | To Evaluate Immunogenicity & Safety of GSK Bio's DTPa-HBV-IPV/Hib (Mixed Vaccin… | Phase3 | Hepatitis B | Completed | 2001-09-01 | 2002-09-01 | ClinicalTrials.gov |
| NCT01376141 | Drug Use Investigation for IMIGRAN Tablet | — | Migraine Disorders | Completed | 2001-09-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00143702 | D4T or Abacavir Plus Vitamin Enhancement in HIV-Infected Patients (DAVE) | Phase2 | Acidosis, Lactic | Completed | 2001-08-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00146549 | Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Pat… | Phase3 | Breast Cancer | Completed | 2001-08-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00143702 | D4T or Abacavir Plus Vitamin Enhancement in HIV-Infected Patients (DAVE) | Phase2 | Acidosis, Lactic | Completed | 2001-08-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00146549 | Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Pat… | Phase3 | Breast Cancer | Completed | 2001-08-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00287469 | A Safety and Efficacy Study of the Hepatitis E Vaccine in Nepal. | Phase2 | Hepatitis | Completed | 2001-07-09 | 2005-01-01 | ClinicalTrials.gov |
| NCT00287469 | A Safety and Efficacy Study of the Hepatitis E Vaccine in Nepal. | Phase2 | Hepatitis | Completed | 2001-07-09 | 2005-01-01 | ClinicalTrials.gov |
| NCT00095654 | The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medica… | Phase3 | Impaired Glucose Tolerance | Completed | 2001-07-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00910689 | Drug and Non-Drug Treatment Of Severe Migraine | Phase4 | Migraine Headache | Completed | 2001-07-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00910689 | Drug and Non-Drug Treatment Of Severe Migraine | Phase4 | Migraine Headache | Completed | 2001-07-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00095654 | The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medica… | Phase3 | Impaired Glucose Tolerance | Completed | 2001-07-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00992992 | Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreate… | Phase2 | Lymphoma, Mantle-Cell | Completed | 2001-06-28 | 2013-06-30 | ClinicalTrials.gov |
| NCT00992992 | Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreate… | Phase2 | Lymphoma, Mantle-Cell | Completed | 2001-06-28 | 2013-06-30 | ClinicalTrials.gov |
| NCT00501020 | Comparison of the Efficacy and Tolerability of the Addition of AVANDIA to Subma… | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2001-06-05 | 2003-02-13 | ClinicalTrials.gov |
| NCT00501020 | Comparison of the Efficacy and Tolerability of the Addition of AVANDIA to Subma… | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2001-06-05 | 2003-02-13 | ClinicalTrials.gov |
| NCT00060931 | Effect Of Carvedilol Versus Metoprolol On Glycemic Control In Patients With Typ… | Phase4 | Hypertension | Completed | 2001-06-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00060931 | Effect Of Carvedilol Versus Metoprolol On Glycemic Control In Patients With Typ… | Phase4 | Hypertension | Completed | 2001-06-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00060918 | Glycemic Control Of Carvedilol Versus Metoprolol In Patients With Type II Diabe… | Phase4 | Hypertension | Completed | 2001-06-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00060918 | Glycemic Control Of Carvedilol Versus Metoprolol In Patients With Type II Diabe… | Phase4 | Hypertension | Completed | 2001-06-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00385320 | Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After… | Phase2 | Infections, Rotavirus | Completed | 2001-05-31 | 2003-04-30 | ClinicalTrials.gov |
| NCT00385320 | Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After… | Phase2 | Infections, Rotavirus | Completed | 2001-05-31 | 2003-04-30 | ClinicalTrials.gov |
| NCT04807712 | Pediatric Pertussis in Ambulatory Settings | — | Pertussis/Whooping Cough | Recruiting | 2001-05-30 | 2030-01-01 | ClinicalTrials.gov |
| NCT04807712 | Pediatric Pertussis in Ambulatory Settings | — | Pertussis/Whooping Cough | Recruiting | 2001-05-30 | 2030-01-01 | ClinicalTrials.gov |
| NCT03619590 | Twinrix Pregnancy Registry | — | Hepatitis | Completed | 2001-05-18 | 2017-09-15 | ClinicalTrials.gov |
| NCT03619590 | Twinrix Pregnancy Registry | — | Hepatitis | Completed | 2001-05-18 | 2017-09-15 | ClinicalTrials.gov |
| NCT00510263 | Scandinavian Bell's Palsy Study | Phase4 | Bell's Palsy | Completed | 2001-05-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00025727 | Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritona… | Phase3 | HIV Infections | Unknown | 2001-05-01 | — | ClinicalTrials.gov |
| NCT00510263 | Scandinavian Bell's Palsy Study | Phase4 | Bell's Palsy | Completed | 2001-05-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00025727 | Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritona… | Phase3 | HIV Infections | Unknown | 2001-05-01 | — | ClinicalTrials.gov |
| NCT01371448 | Special Drug Use Investigation for PAXIL Tablet (Long-term) | — | Mental Disorders | Completed | 2001-05-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT01371448 | Special Drug Use Investigation for PAXIL Tablet (Long-term) | — | Mental Disorders | Completed | 2001-05-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00379769 | RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemi… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2001-04-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT01556945 | Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Me… | Phase1 | Malaria, Falciparum | Completed | 2001-04-01 | — | ClinicalTrials.gov |
| NCT01371435 | Drug Use Investigation for PAXIL Tablet | — | Mental Disorders | Completed | 2001-04-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT01371435 | Drug Use Investigation for PAXIL Tablet | — | Mental Disorders | Completed | 2001-04-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT01556945 | Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Me… | Phase1 | Malaria, Falciparum | Completed | 2001-04-01 | — | ClinicalTrials.gov |
| NCT00043927 | Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus C… | Phase3 | Small Cell Lung Cancer | Completed | 2001-04-01 | — | ClinicalTrials.gov |
| NCT00193089 | Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metast… | Phase2 | Breast Cancer | Completed | 2001-04-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00379769 | RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemi… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2001-04-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00193089 | Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metast… | Phase2 | Breast Cancer | Completed | 2001-04-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00043927 | Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus C… | Phase3 | Small Cell Lung Cancer | Completed | 2001-04-01 | — | ClinicalTrials.gov |
| NCT00262717 | Can Resistance Enhance Selection of Treatment? (CREST) | Na | HIV Infection | Completed | 2001-03-01 | 2006-07-31 | ClinicalTrials.gov |
| NCT00388258 | Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dys… | Phase3 | Ileus | Completed | 2001-03-01 | 2002-12-01 | ClinicalTrials.gov |
| NCT00226135 | Prophylactic Effect of Lamotrigine Compared With Lithium in Bipolar Disorder | Phase3 | Bipolar Disorder | Completed | 2001-03-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00388258 | Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dys… | Phase3 | Ileus | Completed | 2001-03-01 | 2002-12-01 | ClinicalTrials.gov |
| NCT00262717 | Can Resistance Enhance Selection of Treatment? (CREST) | Na | HIV Infection | Completed | 2001-03-01 | 2006-07-31 | ClinicalTrials.gov |
| NCT00226135 | Prophylactic Effect of Lamotrigine Compared With Lithium in Bipolar Disorder | Phase3 | Bipolar Disorder | Completed | 2001-03-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00041470 | Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I -… | Phase1 | Breast Cancer | Terminated | 2001-03-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00041470 | Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I -… | Phase1 | Breast Cancer | Terminated | 2001-03-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00011895 | Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efav… | Phase4 | HIV Infections | Unknown | 2001-02-01 | — | ClinicalTrials.gov |
| NCT00011895 | Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efav… | Phase4 | HIV Infections | Unknown | 2001-02-01 | — | ClinicalTrials.gov |
| NCT00880477 | Immunogenicity and Safety of Primary and Booster Vaccination With DTPa-HBV-IPV/… | Phase3 | Hepatitis B | Completed | 2001-01-01 | 2002-11-01 | ClinicalTrials.gov |
| NCT00304993 | Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia | Phase4 | Metabolic Syndrome X | Completed | 2001-01-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00880477 | Immunogenicity and Safety of Primary and Booster Vaccination With DTPa-HBV-IPV/… | Phase3 | Hepatitis B | Completed | 2001-01-01 | 2002-11-01 | ClinicalTrials.gov |
| NCT00689741 | Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 C… | Phase2 | Infections, Papillomavirus | Completed | 2001-01-01 | 2003-04-01 | ClinicalTrials.gov |
| NCT00440687 | Withdrawal of Inhaled Corticosteroids in Patients With COPD in Primary Care | Phase4 | Chronic Obstructive Pulmonary Disease | Completed | 2001-01-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00440687 | Withdrawal of Inhaled Corticosteroids in Patients With COPD in Primary Care | Phase4 | Chronic Obstructive Pulmonary Disease | Completed | 2001-01-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00304993 | Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia | Phase4 | Metabolic Syndrome X | Completed | 2001-01-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00292838 | Relative Potency of Inhaled Corticosteroids | Phase4 | Asthma | Completed | 2001-01-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00689741 | Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 C… | Phase2 | Infections, Papillomavirus | Completed | 2001-01-01 | 2003-04-01 | ClinicalTrials.gov |
| NCT00429481 | Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HR… | Phase2 | Hepatitis B | Completed | 2001-01-01 | 2003-04-01 | ClinicalTrials.gov |
| NCT00292838 | Relative Potency of Inhaled Corticosteroids | Phase4 | Asthma | Completed | 2001-01-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00429481 | Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HR… | Phase2 | Hepatitis B | Completed | 2001-01-01 | 2003-04-01 | ClinicalTrials.gov |
| NCT00157560 | Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed… | Phase2 | Ovarian Cancer | Completed | 2000-12-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00157560 | Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed… | Phase2 | Ovarian Cancer | Completed | 2000-12-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00043901 | Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational … | Phase4 | Epilepsy, Tonic-Clonic | Completed | 2000-12-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00043901 | Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational … | Phase4 | Epilepsy, Tonic-Clonic | Completed | 2000-12-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00388440 | Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at… | Phase4 | Rubella | Completed | 2000-11-01 | 2001-04-01 | ClinicalTrials.gov |
| NCT00193245 | Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung… | Phase2 | Lung Cancer | Completed | 2000-11-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00193245 | Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung… | Phase2 | Lung Cancer | Completed | 2000-11-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00276276 | Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients … | Phase3 | Lung Cancer, Small Cell | Completed | 2000-11-01 | — | ClinicalTrials.gov |
| NCT00388440 | Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at… | Phase4 | Rubella | Completed | 2000-11-01 | 2001-04-01 | ClinicalTrials.gov |
| NCT00276276 | Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients … | Phase3 | Lung Cancer, Small Cell | Completed | 2000-11-01 | — | ClinicalTrials.gov |
| NCT00119743 | A Efficacy Against Otitis Media in Children With 11 Valent Pneumococcal Vaccine | Phase3 | Hepatitis A | Terminated | 2000-10-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00693615 | Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuva… | Phase2 | Infections, Papillomavirus | Completed | 2000-10-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00119743 | A Efficacy Against Otitis Media in Children With 11 Valent Pneumococcal Vaccine | Phase3 | Hepatitis A | Terminated | 2000-10-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00693615 | Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuva… | Phase2 | Infections, Papillomavirus | Completed | 2000-10-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00516113 | A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in … | Phase4 | Premenstrual Dysphoric Disorder | Completed | 2000-10-01 | 2002-11-01 | ClinicalTrials.gov |
| NCT00516113 | A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in … | Phase4 | Premenstrual Dysphoric Disorder | Completed | 2000-10-01 | 2002-11-01 | ClinicalTrials.gov |
| NCT00268216 | Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD) | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2000-09-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00268216 | Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD) | Phase3 | Pulmonary Disease, Chronic Obstructive | Completed | 2000-09-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00044278 | Pediatric Epilepsy Study in Subjects 1-24 Months | Phase2 | Epilepsy | Completed | 2000-09-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT01798992 | Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Fai… | Phase4 | Idiopathic Dilated Cardiomyopathy | Completed | 2000-09-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00879827 | Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When… | Phase3 | Diphtheria | Completed | 2000-09-01 | 2001-05-01 | ClinicalTrials.gov |
| NCT01798992 | Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Fai… | Phase4 | Idiopathic Dilated Cardiomyopathy | Completed | 2000-09-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00044278 | Pediatric Epilepsy Study in Subjects 1-24 Months | Phase2 | Epilepsy | Completed | 2000-09-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00879827 | Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When… | Phase3 | Diphtheria | Completed | 2000-09-01 | 2001-05-01 | ClinicalTrials.gov |
| NCT00425737 | Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HR… | Phase2 | Infections, Rotavirus | Completed | 2000-08-01 | 2001-07-01 | ClinicalTrials.gov |
| NCT00697866 | Consistency of 3 Consecutive Lots of a Novel HBV Vaccine With Single-blind Safe… | Phase3 | Hepatitis B | Completed | 2000-08-01 | — | ClinicalTrials.gov |
| NCT00425737 | Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HR… | Phase2 | Infections, Rotavirus | Completed | 2000-08-01 | 2001-07-01 | ClinicalTrials.gov |
| NCT00697866 | Consistency of 3 Consecutive Lots of a Novel HBV Vaccine With Single-blind Safe… | Phase3 | Hepatitis B | Completed | 2000-08-01 | — | ClinicalTrials.gov |
| NCT00333723 | AVANDIA With Glyburide In African American And Hispanic Patients With Type 2 Di… | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2000-07-28 | 2003-01-06 | ClinicalTrials.gov |
| NCT00333723 | AVANDIA With Glyburide In African American And Hispanic Patients With Type 2 Di… | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2000-07-28 | 2003-01-06 | ClinicalTrials.gov |
| NCT00043875 | Pediatric Epilepsy Trial in Subjects 1-24 Months | Phase2 | Epilepsy | Completed | 2000-05-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT00043875 | Pediatric Epilepsy Trial in Subjects 1-24 Months | Phase2 | Epilepsy | Completed | 2000-05-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT00352170 | Calcium and Vitamin D Malnutrition in Elderly Women | Phase3 | Osteoporosis | Completed | 2000-05-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00352170 | Calcium and Vitamin D Malnutrition in Elderly Women | Phase3 | Osteoporosis | Completed | 2000-05-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00500955 | Rosiglitazone on Microalbuminuria in Type 2 Diabetics | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2000-04-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00158847 | Modification Of Disease Outcome In COPD | Phase4 | Chronic Obstructive Pulmonary Disease | Terminated | 2000-04-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00140725 | Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positiv… | Phase3 | Chronic Hepatitis B | Completed | 2000-04-01 | — | ClinicalTrials.gov |
| NCT00158847 | Modification Of Disease Outcome In COPD | Phase4 | Chronic Obstructive Pulmonary Disease | Terminated | 2000-04-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00140725 | Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positiv… | Phase3 | Chronic Hepatitis B | Completed | 2000-04-01 | — | ClinicalTrials.gov |
| NCT00500955 | Rosiglitazone on Microalbuminuria in Type 2 Diabetics | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2000-04-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00628225 | Smoking Cessation in Patients With COPD (SMOCC) in General Practice | Phase4 | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2000-03-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00508833 | Safety and Efficacy of SmithKline Beecham (GlaxoSmithKline [GSK]) Biologicals' … | Phase1 | Hepatitis B Disease | Completed | 2000-03-01 | — | ClinicalTrials.gov |
| NCT00628225 | Smoking Cessation in Patients With COPD (SMOCC) in General Practice | Phase4 | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2000-03-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00508833 | Safety and Efficacy of SmithKline Beecham (GlaxoSmithKline [GSK]) Biologicals' … | Phase1 | Hepatitis B Disease | Completed | 2000-03-01 | — | ClinicalTrials.gov |
| NCT01663714 | Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for… | Phase2 | Lymphoma, Non-Hodgkin | Completed | 2000-02-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01457560 | Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the S… | Phase3 | Hepatitis B | Completed | 2000-02-01 | 2001-04-01 | ClinicalTrials.gov |
| NCT01663714 | Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for… | Phase2 | Lymphoma, Non-Hodgkin | Completed | 2000-02-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT00194896 | Preferred Treatment of Type 1.5 Diabetes | Na | Type 2 Diabetes Mellitus | Completed | 2000-02-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT01457560 | Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the S… | Phase3 | Hepatitis B | Completed | 2000-02-01 | 2001-04-01 | ClinicalTrials.gov |
| NCT00194896 | Preferred Treatment of Type 1.5 Diabetes | Na | Type 2 Diabetes Mellitus | Completed | 2000-02-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00279045 | Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Gli… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2000-01-03 | 2006-06-19 | ClinicalTrials.gov |
| NCT00279045 | Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Gli… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2000-01-03 | 2006-06-19 | ClinicalTrials.gov |
| NCT00383383 | Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pr… | Phase3 | Hepatitis B | Completed | 1999-12-01 | — | ClinicalTrials.gov |
| NCT00383383 | Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pr… | Phase3 | Hepatitis B | Completed | 1999-12-01 | — | ClinicalTrials.gov |
| NCT00383227 | Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pr… | Phase3 | Hepatitis B | Completed | 1999-12-01 | 2000-11-01 | ClinicalTrials.gov |
| NCT00383227 | Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pr… | Phase3 | Hepatitis B | Completed | 1999-12-01 | 2000-11-01 | ClinicalTrials.gov |
| NCT00263744 | Study to Evaluate the Safety and Immunogenicity of MEDI-517P in Healthy Adult F… | Phase1 | Healthy | Completed | 1999-11-01 | 2001-06-01 | ClinicalTrials.gov |
| NCT00158834 | Pediatric Asthma Study Using Stepwise Treatment With Two Food And Drug Administ… | Phase3 | Asthma | Completed | 1999-11-01 | — | ClinicalTrials.gov |
| NCT00263744 | Study to Evaluate the Safety and Immunogenicity of MEDI-517P in Healthy Adult F… | Phase1 | Healthy | Completed | 1999-11-01 | 2001-06-01 | ClinicalTrials.gov |
| NCT00158834 | Pediatric Asthma Study Using Stepwise Treatment With Two Food And Drug Administ… | Phase3 | Asthma | Completed | 1999-11-01 | — | ClinicalTrials.gov |
| NCT00179426 | Effect of Antiseizure Medication on Hormone Levels and Sexual Function in Men W… | — | Seizure Disorder | Completed | 1999-10-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00693966 | Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GS… | Phase2 | Infections, Papillomavirus | Completed | 1999-10-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00181818 | Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease | Phase4 | Smoking | Completed | 1999-10-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00179426 | Effect of Antiseizure Medication on Hormone Levels and Sexual Function in Men W… | — | Seizure Disorder | Completed | 1999-10-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00693966 | Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GS… | Phase2 | Infections, Papillomavirus | Completed | 1999-10-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00181818 | Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease | Phase4 | Smoking | Completed | 1999-10-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT01387191 | Drug Use Investigation for FLOLAN (Epoprostenol) Injection 0.5mg・1.5mg | — | Cardiovascular Disease | Completed | 1999-08-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT01387191 | Drug Use Investigation for FLOLAN (Epoprostenol) Injection 0.5mg・1.5mg | — | Cardiovascular Disease | Completed | 1999-08-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00022880 | Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocyti… | Phase1 | Chronic Lymphocytic Leukemia | Unknown | 1999-07-01 | — | ClinicalTrials.gov |
| NCT00022880 | Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocyti… | Phase1 | Chronic Lymphocytic Leukemia | Unknown | 1999-07-01 | — | ClinicalTrials.gov |
| NCT00992758 | Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (… | Phase1 | Lymphoma, Non-Hodgkin | Completed | 1999-05-28 | 2012-06-07 | ClinicalTrials.gov |
| NCT00992758 | Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (… | Phase1 | Lymphoma, Non-Hodgkin | Completed | 1999-05-28 | 2012-06-07 | ClinicalTrials.gov |
| NCT00022906 | Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greate… | Phase1 | Non-Hodgkin's Lymphoma | Unknown | 1999-05-01 | — | ClinicalTrials.gov |
| NCT00022906 | Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greate… | Phase1 | Non-Hodgkin's Lymphoma | Unknown | 1999-05-01 | — | ClinicalTrials.gov |
| NCT00697749 | Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Healthy Voluntee… | Phase3 | Hepatitis B | Completed | 1999-04-01 | 2000-01-01 | ClinicalTrials.gov |
| NCT00696917 | Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Eng… | Phase3 | Hepatitis B | Completed | 1999-04-01 | — | ClinicalTrials.gov |
| NCT00697749 | Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Healthy Voluntee… | Phase3 | Hepatitis B | Completed | 1999-04-01 | 2000-01-01 | ClinicalTrials.gov |
| NCT00696917 | Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Eng… | Phase3 | Hepatitis B | Completed | 1999-04-01 | — | ClinicalTrials.gov |
| NCT00003635 | 506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Resp… | Phase2 | Leukemia | Completed | 1999-01-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00003635 | 506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Resp… | Phase2 | Leukemia | Completed | 1999-01-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00184977 | COPD on Primary Care Treatment (COOPT) | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 1998-12-01 | 2003-01-01 | ClinicalTrials.gov |
| NCT00184977 | COPD on Primary Care Treatment (COOPT) | Phase4 | Pulmonary Disease, Chronic Obstructive | Completed | 1998-12-01 | 2003-01-01 | ClinicalTrials.gov |
| NCT00697853 | Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of… | Phase2 | Hepatitis B | Completed | 1998-11-01 | — | ClinicalTrials.gov |
| NCT00697853 | Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of… | Phase2 | Hepatitis B | Completed | 1998-11-01 | — | ClinicalTrials.gov |
| NCT00201474 | Acute, Affective, Organic Disorders. | — | Depressive Disorders | Completed | 1998-10-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00201474 | Acute, Affective, Organic Disorders. | — | Depressive Disorders | Completed | 1998-10-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00178048 | Paroxetine in the Treatment of Chronic Primary Insomnia | Phase4 | Primary Insomnia | Completed | 1998-09-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00268203 | Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Ho… | Phase2 | Lymphoma, Non-Hodgkin | Completed | 1998-09-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT00268203 | Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Ho… | Phase2 | Lymphoma, Non-Hodgkin | Completed | 1998-09-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT00178048 | Paroxetine in the Treatment of Chronic Primary Insomnia | Phase4 | Primary Insomnia | Completed | 1998-09-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT01457495 | Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV … | Phase2 | Hepatitis B | Completed | 1998-09-01 | 1999-09-01 | ClinicalTrials.gov |
| NCT00022958 | Expanded Access Study of Iodine-131 Anti-B1 Antibody | Na | Non-Hodgkin's Lymphoma | Unknown | 1998-09-01 | — | ClinicalTrials.gov |
| NCT00022958 | Expanded Access Study of Iodine-131 Anti-B1 Antibody | Na | Non-Hodgkin's Lymphoma | Unknown | 1998-09-01 | — | ClinicalTrials.gov |
| NCT01457495 | Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV … | Phase2 | Hepatitis B | Completed | 1998-09-01 | 1999-09-01 | ClinicalTrials.gov |
| NCT00933335 | Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles… | Phase2 | Lymphoma, Non-Hodgkin | Completed | 1998-08-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00933335 | Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles… | Phase2 | Lymphoma, Non-Hodgkin | Completed | 1998-08-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00996593 | Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma W… | Phase2 | Lymphoma, Non-Hodgkin | Completed | 1998-07-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00996593 | Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma W… | Phase2 | Lymphoma, Non-Hodgkin | Completed | 1998-07-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00938041 | Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Respond… | Phase2 | Lymphoma, Non-Hodgkin | Completed | 1998-04-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00938041 | Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Respond… | Phase2 | Lymphoma, Non-Hodgkin | Completed | 1998-04-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00697775 | Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to E… | Phase2 | Hepatitis B | Completed | 1998-03-01 | — | ClinicalTrials.gov |
| NCT00697775 | Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to E… | Phase2 | Hepatitis B | Completed | 1998-03-01 | — | ClinicalTrials.gov |
| NCT01559753 | Early-onset Ventilator-associated Pneumonia in Adults: Comparison of 8 Versus 1… | Phase4 | Pneumonia Ventilator Associated | Completed | 1998-01-01 | 2002-11-01 | ClinicalTrials.gov |
| NCT01559753 | Early-onset Ventilator-associated Pneumonia in Adults: Comparison of 8 Versus 1… | Phase4 | Pneumonia Ventilator Associated | Completed | 1998-01-01 | 2002-11-01 | ClinicalTrials.gov |
| NCT00698906 | Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccin… | Phase2 | Hepatitis B | Completed | 1997-06-01 | — | ClinicalTrials.gov |
| NCT00696891 | Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Bios' HBV-MPL … | Phase3 | Hepatitis B | Completed | 1997-06-01 | — | ClinicalTrials.gov |
| NCT00696891 | Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Bios' HBV-MPL … | Phase3 | Hepatitis B | Completed | 1997-06-01 | — | ClinicalTrials.gov |
| NCT00698906 | Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccin… | Phase2 | Hepatitis B | Completed | 1997-06-01 | — | ClinicalTrials.gov |
| NCT00697931 | Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Va… | Phase3 | Hepatitis B | Completed | 1997-05-01 | 1998-06-01 | ClinicalTrials.gov |
| NCT00697931 | Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Va… | Phase3 | Hepatitis B | Completed | 1997-05-01 | 1998-06-01 | ClinicalTrials.gov |
| NCT00697216 | Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in… | Phase3 | Hepatitis B | Completed | 1997-03-01 | — | ClinicalTrials.gov |
| NCT00698555 | Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccin… | Phase2 | Hepatitis B | Completed | 1997-03-01 | — | ClinicalTrials.gov |
| NCT00697216 | Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in… | Phase3 | Hepatitis B | Completed | 1997-03-01 | — | ClinicalTrials.gov |
| NCT00698555 | Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccin… | Phase2 | Hepatitis B | Completed | 1997-03-01 | — | ClinicalTrials.gov |
| NCT01657097 | Allergic Inflammation in Rhinitis Patients Following Nasal Allergen Challenge | Phase4 | Allergic Rhinitis | Completed | 1997-02-01 | 1997-04-01 | ClinicalTrials.gov |
| NCT01657097 | Allergic Inflammation in Rhinitis Patients Following Nasal Allergen Challenge | Phase4 | Allergic Rhinitis | Completed | 1997-02-01 | 1997-04-01 | ClinicalTrials.gov |
| NCT00698568 | Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in H… | Phase3 | Prophylaxis for Herpes Simplex | Completed | 1996-10-01 | 1999-04-01 | ClinicalTrials.gov |
| NCT00698568 | Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in H… | Phase3 | Prophylaxis for Herpes Simplex | Completed | 1996-10-01 | 1999-04-01 | ClinicalTrials.gov |
| NCT00139113 | Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young… | Phase4 | Hepatitis A | Completed | 1996-09-01 | 2001-06-01 | ClinicalTrials.gov |
| NCT00139113 | Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young… | Phase4 | Hepatitis A | Completed | 1996-09-01 | 2001-06-01 | ClinicalTrials.gov |
| NCT00996996 | Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Prev… | Phase2 | Lymphoma, Non-Hodgkin | Completed | 1996-06-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00996996 | Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Prev… | Phase2 | Lymphoma, Non-Hodgkin | Completed | 1996-06-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00699764 | Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy t… | Phase3 | Herpes Simplex | Completed | 1996-03-01 | 1999-10-01 | ClinicalTrials.gov |
| NCT00699764 | Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy t… | Phase3 | Herpes Simplex | Completed | 1996-03-01 | 1999-10-01 | ClinicalTrials.gov |
| NCT00002767 | Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metas… | Phase3 | Melanoma (Skin) | Unknown | 1996-01-01 | — | ClinicalTrials.gov |
| NCT00002767 | Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metas… | Phase3 | Melanoma (Skin) | Unknown | 1996-01-01 | — | ClinicalTrials.gov |
| NCT01224821 | Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for… | Phase2 | Lymphoma, Non-Hodgkin | Completed | 1995-12-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT01224821 | Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for… | Phase2 | Lymphoma, Non-Hodgkin | Completed | 1995-12-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00698490 | Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines … | Phase1 | Prophylaxis Herpes Simplex | Completed | 1995-08-01 | 1997-01-01 | ClinicalTrials.gov |
| NCT00698490 | Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines … | Phase1 | Prophylaxis Herpes Simplex | Completed | 1995-08-01 | 1997-01-01 | ClinicalTrials.gov |
| NCT00697840 | Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (A… | Phase3 | Hepatitis B | Completed | 1995-06-01 | 1996-01-01 | ClinicalTrials.gov |
| NCT00697840 | Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (A… | Phase3 | Hepatitis B | Completed | 1995-06-01 | 1996-01-01 | ClinicalTrials.gov |
| NCT00698087 | Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant … | Phase3 | Hepatitis B | Completed | 1995-01-01 | 1996-02-01 | ClinicalTrials.gov |
| NCT00698087 | Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant … | Phase3 | Hepatitis B | Completed | 1995-01-01 | 1996-02-01 | ClinicalTrials.gov |
| NCT00530400 | Study of the Efficacy of Preoperative Cefuroxime Prophylaxis to Prevent Surgica… | Phase4 | Surgical Wound Infection | Completed | 1994-04-01 | 2000-03-01 | ClinicalTrials.gov |
| NCT00530400 | Study of the Efficacy of Preoperative Cefuroxime Prophylaxis to Prevent Surgica… | Phase4 | Surgical Wound Infection | Completed | 1994-04-01 | 2000-03-01 | ClinicalTrials.gov |
| NCT00697242 | Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With… | Phase3 | Hepatitis B | Completed | 1994-01-01 | 1995-11-01 | ClinicalTrials.gov |
| NCT00697242 | Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With… | Phase3 | Hepatitis B | Completed | 1994-01-01 | 1995-11-01 | ClinicalTrials.gov |
| NCT00697567 | Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) … | Phase2 | Prophylaxis Herpes Simplex | Completed | 1992-09-01 | 1997-12-01 | ClinicalTrials.gov |
| NCT00697229 | Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Ad… | Phase2 | Hepatitis B | Completed | 1992-09-01 | 1998-12-01 | ClinicalTrials.gov |
| NCT00697229 | Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Ad… | Phase2 | Hepatitis B | Completed | 1992-09-01 | 1998-12-01 | ClinicalTrials.gov |
| NCT00697567 | Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) … | Phase2 | Prophylaxis Herpes Simplex | Completed | 1992-09-01 | 1997-12-01 | ClinicalTrials.gov |
| NCT00698893 | Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy He… | Phase1 | Herpes Simplex | Completed | 1992-05-01 | 1992-07-01 | ClinicalTrials.gov |
| NCT00698893 | Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy He… | Phase1 | Herpes Simplex | Completed | 1992-05-01 | 1992-07-01 | ClinicalTrials.gov |
| NCT01536561 | Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell L… | Phase1 | Lymphoma, Non-Hodgkin | Completed | 1990-04-24 | 2009-10-16 | ClinicalTrials.gov |
| NCT01536561 | Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell L… | Phase1 | Lymphoma, Non-Hodgkin | Completed | 1990-04-24 | 2009-10-16 | ClinicalTrials.gov |
Total clinical trials: 8032
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Dostarlimab | Other | Phase PHASE2 | Stage I Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04584255 |
| Niraparib | Other | Phase PHASE2 | Stage I Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04584255 |
| Hypofractionated IMRT | Other | Phase PHASE2 | Endometrial Cancer | RECRUITING | NCT04774419 |
| Dostarlimab | Other | Phase PHASE2 | Endometrial Cancer | RECRUITING | NCT04774419 |
| Intensity modulated radiation therapy (IMRT) | Drug | Phase PHASE2 | Endometrial Cancer | RECRUITING | NCT04774419 |
| Bepirovirsen | Other | Phase PHASE1 | Hepatitis B | TERMINATED | NCT05330455 |
| Placebo to match GSK3965193 | Other | Phase PHASE1 | Hepatitis B | TERMINATED | NCT05330455 |
| GSK3965193 | Other | Phase PHASE1 | Hepatitis B | TERMINATED | NCT05330455 |
| Belantamab mafodotin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05002816 |
| Elotuzumab | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05002816 |
| Intensity Modulated Radiation Therapy (IMRT) | Drug | Phase PHASE2 | Rectal Adenocarcinoma | RECRUITING | NCT04165772 |
| capecitabine or 5-FU | Other | Phase PHASE2 | Rectal Adenocarcinoma | RECRUITING | NCT04165772 |
| TSR-042 or Dostarlimab | Other | Phase PHASE2 | Rectal Adenocarcinoma | RECRUITING | NCT04165772 |
| Imatinib | Other | Phase PHASE3 | Gastrointestinal Stromal Neoplasms | NOT_YET_RECRUITING | NCT07585266 |
| Velzatinib | Other | Phase PHASE3 | Gastrointestinal Stromal Neoplasms | NOT_YET_RECRUITING | NCT07585266 |
| Salmeterol/ fluticasone propionate | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00480649 |
| Part B | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT00291928 |
| Part A | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT00291928 |
| Stool sampling | Other | Preclinical | Rotaviral Gastroenteritis | COMPLETED | NCT01201252 |
| Endocervical samples | Other | Preclinical | Human Papillomavirus Infection | COMPLETED | NCT01205412 |
| Endocervical samples | Other | Preclinical | Human Papillomavirus Infection | COMPLETED | NCT01205412 |
| Serum sample | Other | Preclinical | Acute Hepatitis A | COMPLETED | NCT01159925 |
| Serum sample | Other | Preclinical | Acute Hepatitis A | COMPLETED | NCT01159925 |
| amoxicillin/clavulanate potassium 1gm | Other | Phase PHASE4 | Skin Diseases, Infectious | COMPLETED | NCT00343135 |
| Eptifibatide | Other | Phase PHASE3 | Infarction, Myocardial | COMPLETED | NCT00426751 |
| Abciximab | Other | Phase PHASE3 | Infarction, Myocardial | COMPLETED | NCT00426751 |
| Eptifibatide | Other | Phase PHASE3 | Infarction, Myocardial | COMPLETED | NCT00426751 |
| Abciximab | Other | Phase PHASE3 | Infarction, Myocardial | COMPLETED | NCT00426751 |
| CARBOPLATIN | Other | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT00316173 |
| topotecan | Other | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT00316173 |
| guideline adherence | Other | Preclinical | Heart Failure, Congestive | COMPLETED | NCT01390935 |
| Ibandronate | Other | Preclinical | Osteoporosis | COMPLETED | NCT01381393 |
| Ibandronate | Other | Preclinical | Osteoporosis | COMPLETED | NCT01381393 |
| Placebo nasal spray | Other | Phase PHASE4 | Allergic Conjunctivitis to Tree Pollen or Grass Pollen | COMPLETED | NCT00891436 |
| Fluticasone furoate nasal spray | Other | Phase PHASE4 | Allergic Conjunctivitis to Tree Pollen or Grass Pollen | COMPLETED | NCT00891436 |
| Paracetamol 750 mg | Other | Phase PHASE1 | Pain | COMPLETED | NCT01551797 |
| Paracetamol 1000 mg | Other | Phase PHASE1 | Pain | COMPLETED | NCT01551797 |
| Paracetamol 500 mg | Other | Phase PHASE1 | Pain | COMPLETED | NCT01551797 |
| lapatinib and Vinorelbine | Other | Phase PHASE2 | Cancer | COMPLETED | NCT01128543 |
| lapatinib and Vinorelbine | Other | Phase PHASE2 | Cancer | COMPLETED | NCT01128543 |
| SB659032 | Other | Phase PHASE1 | Atherosclerosis | COMPLETED | NCT01750827 |
| Vaccines | Other | Preclinical | Influenza | COMPLETED | NCT01416597 |
| Non-interventional study. | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00442468 |
| TISG | Other | Phase EARLY_PHASE1 | Asthma | TERMINATED | NCT01766544 |
| Standard Practice Group (SPG) | Other | Phase EARLY_PHASE1 | Asthma | TERMINATED | NCT01766544 |
| TISG | Other | Phase EARLY_PHASE1 | Asthma | TERMINATED | NCT01766544 |
| Standard Practice Group (SPG) | Other | Phase EARLY_PHASE1 | Asthma | TERMINATED | NCT01766544 |
| Paracetamol | Other | Phase PHASE1 | Fever | COMPLETED | NCT01767428 |
| NaCl | Other | Phase PHASE1 | Pneumococcal Disease | COMPLETED | NCT01767402 |
| Pneumovax 23TM | Other | Phase PHASE1 | Pneumococcal Disease | COMPLETED | NCT01767402 |
| PhtD vaccine with/without adjuvant | Other | Phase PHASE1 | Pneumococcal Disease | COMPLETED | NCT01767402 |
| Placebo | Other | Phase PHASE2 | Alzheimer's Disease | TERMINATED | NCT00334568 |
| Rosiglitazone XR (extended release) oral tablets | Other | Phase PHASE2 | Alzheimer's Disease | TERMINATED | NCT00334568 |
| Placebo | Other | Phase PHASE2 | Alzheimer's Disease | TERMINATED | NCT00334568 |
| Rosiglitazone XR (extended release) oral tablets | Other | Phase PHASE2 | Alzheimer's Disease | TERMINATED | NCT00334568 |
| Lapatinib and Paclitaxel | Other | Phase PHASE2 | Urothelial Cancer | WITHDRAWN | NCT01700010 |
| Lapatinib and Paclitaxel | Other | Phase PHASE2 | Urothelial Cancer | WITHDRAWN | NCT01700010 |
| orlistat experimental dose | Other | Phase PHASE1 | Overweight | COMPLETED | NCT01550926 |
| 60 mg orlistat | Other | Phase PHASE1 | Overweight | COMPLETED | NCT01550926 |
| 120 mg orlistat | Other | Phase PHASE1 | Overweight | COMPLETED | NCT01550926 |
| orlistat experimental dose | Other | Phase PHASE1 | Overweight | COMPLETED | NCT01550926 |
| 60 mg orlistat | Other | Phase PHASE1 | Overweight | COMPLETED | NCT01550926 |
| 120 mg orlistat | Other | Phase PHASE1 | Overweight | COMPLETED | NCT01550926 |
| Data collection | Other | Preclinical | Hepatitis B | COMPLETED | NCT01782794 |
| Data collection | Other | Preclinical | Hepatitis B | COMPLETED | NCT01782794 |
| Data collection | Other | Preclinical | Hepatitis B | COMPLETED | NCT01777074 |
| Data collection | Other | Preclinical | Hepatitis B | COMPLETED | NCT01777074 |
| Pazopanib | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00558103 |
| lapatinib | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00558103 |
| Pazopanib | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00558103 |
| lapatinib | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00558103 |
| naratriptan HCl | Other | Phase PHASE4 | Post Traumatic Headache | TERMINATED | NCT00487578 |
| FLIXOTIDE Diskus 500 mcg (Fluticasone Propionate) | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00453778 |
| FLIXOTIDE Diskus 500 mcg (Fluticasone Propionate) | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00453778 |
| GW493838 | Other | Phase PHASE2 | Neuropathic Pain | COMPLETED | NCT00376454 |
| GW493838 | Other | Phase PHASE2 | Neuropathic Pain | COMPLETED | NCT00376454 |
| Extended-release bupropion hydrochloride | Other | Phase PHASE3 | Attention Deficit Disorder | COMPLETED | NCT00048360 |
| Talnetant | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT00300963 |
| Data collection | Other | Preclinical | Rotavirus Gastroenteritis | COMPLETED | NCT00751686 |
| Stool sample | Other | Preclinical | Rotavirus Gastroenteritis | COMPLETED | NCT00751686 |
| carvedilol | Other | Phase PHASE3 | Chronic Heart Failure | COMPLETED | NCT00272805 |
| carvedilol | Other | Phase PHASE3 | Chronic Heart Failure | COMPLETED | NCT00272805 |
| GW810781 | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00046332 |
| GW810781 | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00046332 |
| Low-dose fixed dose fluticasone propionate/salmeterol xinafoate combination | Other | Preclinical | Asthma | COMPLETED | NCT01431924 |
| Higher-dose inhaled corticosteroids | Other | Preclinical | Asthma | COMPLETED | NCT01431924 |
| Omega 3 fatty acid (Lovaza) | Other | Phase PHASE4 | Moderate Hypertriglyceridemia. | UNKNOWN | NCT01301794 |
| Lamotrigine polytherapy without valproate | Drug | Preclinical | Epilepsy | COMPLETED | NCT01064297 |
| Lamotrigine polytherapy including valproate | Drug | Preclinical | Epilepsy | COMPLETED | NCT01064297 |
| Lamotrigine monotherapy | Drug | Preclinical | Epilepsy | COMPLETED | NCT01064297 |
| placebo | Other | Phase PHASE4 | Hypogonadism | COMPLETED | NCT00752869 |
| dutasteride | Other | Phase PHASE4 | Hypogonadism | COMPLETED | NCT00752869 |
| Nicotine | Other | Phase PHASE1 | Healthy Volunteer Smokers | COMPLETED | NCT00682461 |
| topotecan | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | COMPLETED | NCT00049998 |
| Vinorelbine | Other | Phase PHASE2 | Neoplasms, Breast | WITHDRAWN | NCT01137994 |
| Paclitaxel | Other | Phase PHASE2 | Neoplasms, Breast | WITHDRAWN | NCT01137994 |
| Docetaxel | Other | Phase PHASE2 | Neoplasms, Breast | WITHDRAWN | NCT01137994 |
| Trastuzumab | Other | Phase PHASE2 | Neoplasms, Breast | WITHDRAWN | NCT01137994 |
| Lapatinib | Other | Phase PHASE2 | Neoplasms, Breast | WITHDRAWN | NCT01137994 |
| Vinorelbine | Other | Phase PHASE2 | Neoplasms, Breast | WITHDRAWN | NCT01137994 |
| Paclitaxel | Other | Phase PHASE2 | Neoplasms, Breast | WITHDRAWN | NCT01137994 |
| Docetaxel | Other | Phase PHASE2 | Neoplasms, Breast | WITHDRAWN | NCT01137994 |
| Trastuzumab | Other | Phase PHASE2 | Neoplasms, Breast | WITHDRAWN | NCT01137994 |
| Lapatinib | Other | Phase PHASE2 | Neoplasms, Breast | WITHDRAWN | NCT01137994 |
| Lamictal in the treatment of Post-Herpetic Neuralgia | Drug | Phase PHASE2 | Neuralgia, Postherpetic | TERMINATED | NCT00295776 |
| alcohol-containing mouth rinsing | Other | Approved | Gum Disease | COMPLETED | NCT01811615 |
| alcohol-free experimental mouth rinse | Other | Approved | Gum Disease | COMPLETED | NCT01811615 |
| GW273225 | Other | Phase PHASE2 | Epilepsy | WITHDRAWN | NCT00567424 |
| GW273225 | Other | Phase PHASE2 | Epilepsy | WITHDRAWN | NCT00567424 |
| GW813893 | Other | Phase PHASE2 | Venous Thromboembolism | WITHDRAWN | NCT00541320 |
| Paroxetine hydrochloride hydrate | Other | Phase PHASE3 | Social Phobia | COMPLETED | NCT00318669 |
| Pneumovax 23™ | Other | Phase PHASE2 | Streptococcus Pneumoniae Vaccines | COMPLETED | NCT00307008 |
| Pneumovax 23™ | Other | Phase PHASE2 | Streptococcus Pneumoniae Vaccines | COMPLETED | NCT00307008 |
| topotecan | Other | Phase PHASE3 | Lung Cancer, Small Cell | COMPLETED | NCT00276276 |
| topotecan | Other | Phase PHASE3 | Lung Cancer, Small Cell | COMPLETED | NCT00276276 |
| paroxetine hydrochloride hydrate | Other | Phase PHASE3 | Social Phobia | COMPLETED | NCT00264654 |
| BRL29060A | Other | Phase PHASE3 | Social Phobia | COMPLETED | NCT00264654 |
| SB497115 | Other | Phase PHASE2 | Purpura, Thrombocytopaenic, Idiopathic | COMPLETED | NCT00102739 |
| SB497115 | Other | Phase PHASE2 | Purpura, Thrombocytopaenic, Idiopathic | COMPLETED | NCT00102739 |
| Metformin | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00131664 |
| Avandia and Amaryl | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00131664 |
| Avandamet | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00131664 |
| lapatinib | Other | Phase PHASE2 | Glioma | COMPLETED | NCT00350727 |
| pazopanib | Other | Phase PHASE2 | Glioma | COMPLETED | NCT00350727 |
| lapatinib | Other | Phase PHASE2 | Glioma | COMPLETED | NCT00350727 |
| pazopanib | Other | Phase PHASE2 | Glioma | COMPLETED | NCT00350727 |
| ritonavir | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00296504 |
| fosamprenavir (GW433908) | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00296504 |
| Ferrous Fumarate 324 mg | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01762995 |
| Calcium Carbonate 1200 mg | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01762995 |
| Dolutegravir 50 mg | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01762995 |
| Data acquisition and analysis | Other | Preclinical | Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer (NSCLC) | COMPLETED | NCT01837511 |
| Data collection | Other | Preclinical | Respiratory Syncyctial Virus Vaccines | COMPLETED | NCT01706302 |
| Eltrombopag | Other | Phase PHASE1 | Myelodysplastic Syndrome | COMPLETED | NCT01481220 |
| Ropinirole XL (formerly CR) | Other | Phase PHASE3 | Parkinson Disease | COMPLETED | NCT00650104 |
| Ropinirole XL (formerly CR) | Other | Phase PHASE3 | Parkinson Disease | COMPLETED | NCT00650104 |
| Cetirizine Dry Syrup | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00257595 |
| Cetirizine Dry Syrup | Other | Phase PHASE3 | Pruritus | COMPLETED | NCT00257582 |
| Cetirizine Dry Syrup | Other | Phase PHASE3 | Pruritus | COMPLETED | NCT00257582 |
| Cetirizine Dry Syrup | Other | Phase PHASE3 | Dermatitis, Atopic | COMPLETED | NCT00257569 |
| Cetirizine Dry Syrup | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00253058 |
| Intervention E | Other | Preclinical | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01054586 |
| Intervention D | Other | Preclinical | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01054586 |
| Intervention C | Other | Preclinical | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01054586 |
| Intervention B Reduced Dose | Other | Preclinical | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01054586 |
| Intervention A Standard dose | Other | Preclinical | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01054586 |
| abacavir/lamivudine as Epzicom | Other | Phase PHASE4 | HIV | COMPLETED | NCT00335270 |
| fos-amprenavir calcium, ritonavir | Other | Phase PHASE4 | HIV | COMPLETED | NCT00335270 |
| Naratriptan | Other | Preclinical | Migraine Disorders | COMPLETED | NCT01376193 |
| Naproxen Sodium | Other | Phase PHASE4 | Migraine | COMPLETED | NCT01300546 |
| Sumatriptan/Naproxen Sodium | Other | Phase PHASE4 | Migraine | COMPLETED | NCT01300546 |
| Fondaparinux | Other | Phase PHASE4 | Pulmonary Embolism | WITHDRAWN | NCT00377091 |
| Cognitive-behavioral therapy and paroxetine-CR | Drug | Phase PHASE2 | Stress Disorders, Post-Traumatic | COMPLETED | NCT00215163 |
| Placebo toothpaste | Other | Phase PHASE4 | Dentine Hypersensitivity | COMPLETED | NCT01075256 |
| 7.5% calcium sodium phosphosilicate toothpaste | Other | Phase PHASE4 | Dentine Hypersensitivity | COMPLETED | NCT01075256 |
| 5% calcium sodium phosphosilicate toothpaste | Other | Phase PHASE4 | Dentine Hypersensitivity | COMPLETED | NCT01075256 |
| fluticasone furoate | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00473915 |
| fluticasone furoate | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00473915 |
| Gemcitabine Lapatinib | Other | Phase PHASE2 | BRMS1 | COMPLETED | NCT01050322 |
| Lapatinib Capecitabine | Other | Phase PHASE2 | BRMS1 | COMPLETED | NCT01050322 |
| Lapatinib Vinorelbine | Other | Phase PHASE2 | BRMS1 | COMPLETED | NCT01050322 |
| Salmeterol and Fluticasone | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01332409 |
| Salmeterol and Fluticasone | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01332409 |
| Co-prescription of retapamulin and topical mupirocin | Other | Preclinical | Skin Infections, Bacterial | COMPLETED | NCT01153880 |
| Retapamulin | Other | Preclinical | Skin Infections, Bacterial | COMPLETED | NCT01153880 |
| Co-prescription of retapamulin and topical mupirocin | Other | Preclinical | Skin Infections, Bacterial | COMPLETED | NCT01153880 |
| Retapamulin | Other | Preclinical | Skin Infections, Bacterial | COMPLETED | NCT01153880 |
| Co-prescription of retapamulin and topical fusidic acid | Other | Preclinical | Impetigo | COMPLETED | NCT01153828 |
| Co-prescription of retapamulin and topical mupirocin | Other | Preclinical | Impetigo | COMPLETED | NCT01153828 |
| Retapamulin | Other | Preclinical | Impetigo | COMPLETED | NCT01153828 |
| Co-prescription of retapamulin and topical fusidic acid | Other | Preclinical | Impetigo | COMPLETED | NCT01153828 |
| Co-prescription of retapamulin and topical mupirocin | Other | Preclinical | Impetigo | COMPLETED | NCT01153828 |
| Retapamulin | Other | Preclinical | Impetigo | COMPLETED | NCT01153828 |
| dutasteride | Other | Phase PHASE4 | Benign Prostatic Hyperplasia | COMPLETED | NCT00880672 |
| dutasteride | Other | Phase PHASE4 | Benign Prostatic Hyperplasia | COMPLETED | NCT00880672 |
| pemetrexed and cisplatin | Other | Phase PHASE2 | Lung Cancer, Non-Small Cell | COMPLETED | NCT00871403 |
| pazopanib and pemetrexed | Other | Phase PHASE2 | Lung Cancer, Non-Small Cell | COMPLETED | NCT00871403 |
| Placebo | Other | Phase PHASE4 | Irritable Bowel Syndrome | COMPLETED | NCT00610909 |
| Paroxetine CR | Other | Phase PHASE4 | Irritable Bowel Syndrome | COMPLETED | NCT00610909 |
| Paclitaxel | Other | Phase PHASE3 | Neoplasms, Gastrointestinal Tract | COMPLETED | NCT00486954 |
| Lapatinib | Other | Phase PHASE3 | Neoplasms, Gastrointestinal Tract | COMPLETED | NCT00486954 |
| Placebo | Other | Phase PHASE2 | Colitis, Ulcerative | WITHDRAWN | NCT01658605 |
| GSK1605786 | Other | Phase PHASE2 | Colitis, Ulcerative | WITHDRAWN | NCT01658605 |
| Placebo | Other | Phase PHASE2 | Colitis, Ulcerative | WITHDRAWN | NCT01658605 |
| GSK1605786 | Other | Phase PHASE2 | Colitis, Ulcerative | WITHDRAWN | NCT01658605 |
| ML10 | Other | Phase PHASE1 | Cancer | TERMINATED | NCT01476085 |
| MRI scan | Other | Phase PHASE1 | Atrophy, Muscular | COMPLETED | NCT01476072 |
| Boosted Lexiva | Other | Phase PHASE3 | Human Immunodeficiency Virus Infections | COMPLETED | NCT00727597 |
| Efavirenz 600mg | Other | Phase PHASE3 | Human Immunodeficiency Virus Infections | COMPLETED | NCT00727597 |
| Naproxen Sodium | Other | Phase PHASE4 | Chronic Migraine | COMPLETED | NCT01090050 |
| Sumatriptan/Naproxen Sodium | Other | Phase PHASE4 | Chronic Migraine | COMPLETED | NCT01090050 |
| dolutegravir | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01459315 |
| GSK1349572 (dolutegravir) | Other | Phase PHASE1 | Healthy Adult Females | COMPLETED | NCT01404806 |
| Albendazole | Other | Phase PHASE1 | Helminthiasis | COMPLETED | NCT01755637 |
| glyburide | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT00123643 |
| rosiglitazone | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT00123643 |
| nelarabine | Other | Phase PHASE2 | Leukemia | COMPLETED | NCT00003635 |
| Placebo | Other | Phase PHASE2 | Migraine Disorders | COMPLETED | NCT00742209 |
| GSK1838262 | Other | Phase PHASE2 | Migraine Disorders | COMPLETED | NCT00742209 |
| MK-4827 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00749502 |
| MK-4827 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00749502 |
| 675 ppmf toothpaste | Other | Phase PHASE3 | Caries | COMPLETED | NCT01005966 |
| Placebo | Other | Phase PHASE3 | Caries | COMPLETED | NCT01005966 |
| Sodium monofluorophosphate/Sodium Fluoride Toothpaste | Other | Phase PHASE3 | Caries | COMPLETED | NCT01005966 |
| Amine Fluoride Toothpaste | Other | Phase PHASE3 | Caries | COMPLETED | NCT01005966 |
| Sodium Fluoride Toothpaste | Other | Phase PHASE3 | Caries | COMPLETED | NCT01005966 |
| eltrombopag | Other | Phase PHASE2 | Purpura, Thrombocytopaenic, Idiopathic | COMPLETED | NCT00424177 |
| Intermittent, sub-chronic and chronic use of intranasal steroids other than Flixonase | Other | Preclinical | Rhinitis, Allergic, Perennial | COMPLETED | NCT01077609 |
| Intermittent, sub-chronic and chronic Flixonase use | Other | Preclinical | Rhinitis, Allergic, Perennial | COMPLETED | NCT01077609 |
| sumatriptan and Treximet | Other | Preclinical | Migraine | COMPLETED | NCT01916395 |
| Multiple Dose Group: Belimumab SC 1 x 200 mg weekly | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01583530 |
| Multiple Dose Group: Belimumab SC 2 x 120 mg weekly | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01583530 |
| Single Dose Group: Belimumab SC 1 x 200 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01583530 |
| Single Dose Group: Belimumab SC 1 x 240 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01583530 |
| Single Dose Group: Belimumab SC 2 x 120 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01583530 |
| Single Dose Group: Belimumab IV 240 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01583530 |
| Multiple Dose Group: Belimumab SC 1 x 200 mg weekly | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01583530 |
| Multiple Dose Group: Belimumab SC 2 x 120 mg weekly | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01583530 |
| Single Dose Group: Belimumab SC 1 x 200 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01583530 |
| Single Dose Group: Belimumab SC 1 x 240 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01583530 |
| Single Dose Group: Belimumab SC 2 x 120 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01583530 |
| Single Dose Group: Belimumab IV 240 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01583530 |
| Belimumab 100 mg SC | Other | Phase PHASE2 | Systemic Lupus Erythematosus | TERMINATED | NCT00732940 |
| Belimumab 100 mg SC | Other | Phase PHASE2 | Systemic Lupus Erythematosus | TERMINATED | NCT00732940 |
| GSK2190915 placebo | Other | Phase PHASE1 | Asthma | WITHDRAWN | NCT01721135 |
| moxifloxacin placebo | Other | Phase PHASE1 | Asthma | WITHDRAWN | NCT01721135 |
| moxifloxacin 400mg | Other | Phase PHASE1 | Asthma | WITHDRAWN | NCT01721135 |
| GSK2190915 200mg | Other | Phase PHASE1 | Asthma | WITHDRAWN | NCT01721135 |
| GSK2190915 100mg | Other | Phase PHASE1 | Asthma | WITHDRAWN | NCT01721135 |
| Salmeterol and Fluticasone | Other | Preclinical | Respiratory Disorders | COMPLETED | NCT01395862 |
| Matching Placebo | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00465205 |
| Valacyclovir | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00465205 |
| matching placebo | Other | Phase PHASE3 | HIV Infection | COMPLETED | NCT00378976 |
| valacyclovir | Other | Phase PHASE3 | HIV Infection | COMPLETED | NCT00378976 |
| Data collection | Other | Preclinical | Influenza | COMPLETED | NCT01521416 |
| cetirizine hydrochloride | Other | Preclinical | Seasonal Allergic Rhinitis | COMPLETED | NCT00517946 |
| pseudoephedrine hydrochloride | Other | Preclinical | Seasonal Allergic Rhinitis | COMPLETED | NCT00517946 |
| bupropion XL | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT00093288 |
| Azelastine nasal spray | Other | Approved | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00117832 |
| Acyline | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01167829 |
| Oral Testosterone | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01167829 |
| Synflorix™ data collection | Other | Preclinical | Immunisation Against Streptococcus Pneumoniae | WITHDRAWN | NCT01803425 |
| Data Collection | Other | Preclinical | Human Papillomavirus Infection | WITHDRAWN | NCT01551537 |
| Cervarix data collection | Other | Preclinical | Human Papillomavirus Infection | WITHDRAWN | NCT01551537 |
| Data Collection | Other | Preclinical | Human Papillomavirus Infection | WITHDRAWN | NCT01551537 |
| Cervarix data collection | Other | Preclinical | Human Papillomavirus Infection | WITHDRAWN | NCT01551537 |
| Sterile water | Other | Phase PHASE2 | Healthy Subjects | COMPLETED | NCT01122862 |
| Cosmetic mouthrinse | Other | Phase PHASE2 | Healthy Subjects | COMPLETED | NCT01122862 |
| 0.12% chlorhexidine mouthrinse | Other | Phase PHASE2 | Healthy Subjects | COMPLETED | NCT01122862 |
| Placebo | Other | Preclinical | Systemic Lupus Erythematosus | COMPLETED | NCT01914770 |
| Belimumab 10 mg/kg | Other | Preclinical | Systemic Lupus Erythematosus | COMPLETED | NCT01914770 |
| Belimumab 1 mg/kg | Other | Preclinical | Systemic Lupus Erythematosus | COMPLETED | NCT01914770 |
| Placebo | Other | Preclinical | Systemic Lupus Erythematosus | COMPLETED | NCT01914770 |
| Belimumab 10 mg/kg | Other | Preclinical | Systemic Lupus Erythematosus | COMPLETED | NCT01914770 |
| Belimumab 1 mg/kg | Other | Preclinical | Systemic Lupus Erythematosus | COMPLETED | NCT01914770 |
| eslicarbazepine | Other | Preclinical | Epilepsy | COMPLETED | NCT01587339 |
| pregabalin | Other | Preclinical | Epilepsy | COMPLETED | NCT01587339 |
| zonisamide | Other | Preclinical | Epilepsy | COMPLETED | NCT01587339 |
| lacosamide | Other | Preclinical | Epilepsy | COMPLETED | NCT01587339 |
| retigabine/ezogabine | Other | Preclinical | Epilepsy | COMPLETED | NCT01587339 |
| nebulized saline | Other | Approved | Chronic Obstructive Pulmonary Disease | TERMINATED | NCT00180843 |
| salbutamol + ipratropium bromide nebules | Other | Approved | Chronic Obstructive Pulmonary Disease | TERMINATED | NCT00180843 |
| Placebo | Other | Phase PHASE2 | Cancer | COMPLETED | NCT01231581 |
| Gemcitabine | Other | Phase PHASE2 | Cancer | COMPLETED | NCT01231581 |
| GSK1120212 | Other | Phase PHASE2 | Cancer | COMPLETED | NCT01231581 |
| Cervarix | Other | Preclinical | Infections, Papillomavirus | COMPLETED | NCT01905462 |
| Data Collection | Other | Preclinical | Infections, Papillomavirus | COMPLETED | NCT01905462 |
| allocation of treatment with metformin or rosiglitazone | Drug | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT01195259 |
| lamivudine, adefovir | Other | Phase PHASE4 | Compensated Chronic Hepatitis B | COMPLETED | NCT01088009 |
| lamivudine | Other | Phase PHASE4 | Compensated Chronic Hepatitis B | COMPLETED | NCT01088009 |
| cetuximab and lapatinib | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT01184482 |
| telmisartan, valsartan | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT00034840 |
| SB-681323 | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT00320450 |
| placebo | Other | Phase PHASE3 | Hepatitis C, Chronic | COMPLETED | NCT00516321 |
| eltrombopag | Other | Phase PHASE3 | Hepatitis C, Chronic | COMPLETED | NCT00516321 |
| placebo | Other | Phase PHASE3 | Hepatitis C, Chronic | COMPLETED | NCT00516321 |
| eltrombopag | Other | Phase PHASE3 | Hepatitis C, Chronic | COMPLETED | NCT00516321 |
| Placebo | Other | Phase PHASE2 | Kidney Disease | COMPLETED | NCT01047397 |
| 1278863A | Other | Phase PHASE2 | Kidney Disease | COMPLETED | NCT01047397 |
| Paracetamol | Other | Phase PHASE4 | Common Cold | COMPLETED | NCT01466348 |
| Paracetamol and Caffeine | Other | Phase PHASE4 | Common Cold | COMPLETED | NCT01466348 |
| Paracetamol | Other | Phase PHASE4 | Common Cold | COMPLETED | NCT01466348 |
| Paracetamol and Caffeine | Other | Phase PHASE4 | Common Cold | COMPLETED | NCT01466348 |
| Placebo | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00708110 |
| GSK1349572 | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00708110 |
| Placebo | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00708110 |
| GSK1349572 | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00708110 |
| Lisinopril + HCTZ | Other | Phase PHASE3 | Abdominal Obesity | COMPLETED | NCT00459056 |
| Carvedilol CR + Lisinopril | Other | Phase PHASE3 | Abdominal Obesity | COMPLETED | NCT00459056 |
| Placebo Oxymetazoline | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT00584987 |
| Oxymetazoline | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT00584987 |
| Placebo Fluticasone furoate | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT00584987 |
| Fluticasone furoate | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT00584987 |
| surgery | Procedure | Phase PHASE1 | Rectal Neoplasms | COMPLETED | NCT00215956 |
| radiation | Other | Phase PHASE1 | Rectal Neoplasms | COMPLETED | NCT00215956 |
| topotecan | Other | Phase PHASE1 | Rectal Neoplasms | COMPLETED | NCT00215956 |
| surgery | Procedure | Phase PHASE1 | Rectal Neoplasms | COMPLETED | NCT00215956 |
| radiation | Other | Phase PHASE1 | Rectal Neoplasms | COMPLETED | NCT00215956 |
| topotecan | Other | Phase PHASE1 | Rectal Neoplasms | COMPLETED | NCT00215956 |
| sequential compression devices | Device | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT00531843 |
| fondaparinux sodium | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT00531843 |
| Saliva sample collection | Other | Preclinical | Healthy | COMPLETED | NCT01167504 |
| Saliva sample collection | Other | Preclinical | Healthy | COMPLETED | NCT01167504 |
| recombinant interferon alfa | Other | Phase PHASE3 | Melanoma (Skin) | UNKNOWN | NCT00002767 |
| Detox-B adjuvant | Other | Phase PHASE3 | Melanoma (Skin) | UNKNOWN | NCT00002767 |
| recombinant interferon alfa | Other | Phase PHASE3 | Melanoma (Skin) | UNKNOWN | NCT00002767 |
| Detox-B adjuvant | Other | Phase PHASE3 | Melanoma (Skin) | UNKNOWN | NCT00002767 |
| Sample collection | Other | Preclinical | Infections, Streptococcal | COMPLETED | NCT01204385 |
| Urine sample | Other | Preclinical | Infections, Streptococcal | COMPLETED | NCT00637351 |
| Blood sample | Other | Preclinical | Infections, Streptococcal | COMPLETED | NCT00637351 |
| Blood sampling | Other | Preclinical | Herpes Zoster | COMPLETED | NCT00501670 |
| Herpes zoster sampling procedure for VZV PCR | Procedure | Preclinical | Herpes Zoster | COMPLETED | NCT00501670 |
| Td (Tetanus diphtheria) vaccine | Other | Preclinical | Diphtheria | COMPLETED | NCT00297856 |
| Boostrix® | Other | Preclinical | Diphtheria | COMPLETED | NCT00297856 |
| Prevnar®: (Wyeth) | Other | Preclinical | Hepatitis B | COMPLETED | NCT00146835 |
| Licensed DTPa containing vaccine | Other | Preclinical | Hepatitis B | COMPLETED | NCT00146835 |
| Pediarix | Other | Preclinical | Hepatitis B | COMPLETED | NCT00146835 |
| pazopanib | Other | Phase PHASE3 | Carcinoma, Renal Cell | COMPLETED | NCT00387764 |
| pazopanib | Other | Phase PHASE3 | Carcinoma, Renal Cell | COMPLETED | NCT00387764 |
| Salmeterol/Fluticasone propionate | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00662805 |
| Salmeterol/Fluticasone propionate | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00662805 |
| Radiation | Other | Phase PHASE3 | Lung Cancer, Non-Small Cell | COMPLETED | NCT00390806 |
| HYCAMTIN, oral capsules | Other | Phase PHASE3 | Lung Cancer, Non-Small Cell | COMPLETED | NCT00390806 |
| Empty Finn Chamber | Other | Approved | Wound Healing | COMPLETED | NCT01762982 |
| Normal Saline Water | Other | Approved | Wound Healing | COMPLETED | NCT01762982 |
| SLS Solution | Other | Approved | Wound Healing | COMPLETED | NCT01762982 |
| 0.13% Benzalkonium Chloride | Other | Approved | Wound Healing | COMPLETED | NCT01762982 |
| CBZ | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01967771 |
| DTG | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01967771 |
| CBZ | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01967771 |
| DTG | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01967771 |
| Ofatumumab | Other | Phase PHASE2 | Lymphoma, Follicular | COMPLETED | NCT00394836 |
| Nicotine | Other | Phase PHASE3 | Smoking Cessation | COMPLETED | NCT01702532 |
| placebo | Other | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT01495000 |
| denosumab | Other | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT01495000 |
| Data collection | Other | Preclinical | Influenza | COMPLETED | NCT01715792 |
| Data collection | Other | Preclinical | Influenza | COMPLETED | NCT01715792 |
| TMC278 LA 600mg intramuscular injection | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01593046 |
| TMC278 LA 1200mg intramuscular injection | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01593046 |
| GSK1265744 LAP 400mg intramuscular injection | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01593046 |
| GSK1265744 LAP 200mg intramuscular injection | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01593046 |
| GSK1265744 LAP 200mg subcutaneous injection | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01593046 |
| GSK1265744 LAP 800mg intramuscular injection | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01593046 |
| GSK1265744 Oral | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01593046 |
| Cyclophosphamide | Other | Phase PHASE2 | Leukaemia, Lymphocytic, Chronic | COMPLETED | NCT00410163 |
| Fludarabine | Other | Phase PHASE2 | Leukaemia, Lymphocytic, Chronic | COMPLETED | NCT00410163 |
| Ofatumumab 1000mg | Other | Phase PHASE2 | Leukaemia, Lymphocytic, Chronic | COMPLETED | NCT00410163 |
| Ofatumumab 500mg | Other | Phase PHASE2 | Leukaemia, Lymphocytic, Chronic | COMPLETED | NCT00410163 |
| Radiation | Other | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT00256815 |
| chemotherapy | Drug | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT00256815 |
| Radiation | Other | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT00256815 |
| chemotherapy | Drug | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT00256815 |
| Beta2-adrenergic agonist Mobile Phone Application | Other | Approved | Asthma | COMPLETED | NCT01710059 |
| Inhaled Corticosteroid Mobile Phone Application | Other | Approved | Asthma | COMPLETED | NCT01710059 |
| Mobile Phone | Other | Approved | Asthma | COMPLETED | NCT01710059 |
| Asthma Supervision | Other | Approved | Asthma | COMPLETED | NCT01710059 |
| Spirometry | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01485159 |
| Spirometry | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01485159 |
| Licensed Japanese Encephalitis (JE) Vaccine | Other | Phase PHASE1 | Dengue Fever | COMPLETED | NCT00384670 |
| Dengue Vaccine Formulation 17 | Other | Phase PHASE1 | Dengue Fever | COMPLETED | NCT00384670 |
| pazopanib monotherapy | Drug | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00849472 |
| surgery | Procedure | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00849472 |
| paclitaxel + pazopanib | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00849472 |
| doxorubicin + cyclophosphamide | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00849472 |
| pazopanib monotherapy | Drug | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00849472 |
| surgery | Procedure | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00849472 |
| paclitaxel + pazopanib | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00849472 |
| doxorubicin + cyclophosphamide | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00849472 |
| No Intervention | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02076269 |
| Sodium Monofluorophosphate | Other | Phase PHASE3 | Dentine Hypersensitivity | COMPLETED | NCT01592864 |
| Stannous Fluoride | Other | Phase PHASE3 | Dentine Hypersensitivity | COMPLETED | NCT01592864 |
| Paroxetine | Other | Phase PHASE3 | Post-Traumatic Stress Disorder | COMPLETED | NCT00839397 |
| Paroxetine | Other | Phase PHASE3 | Post-Traumatic Stress Disorder | COMPLETED | NCT00839397 |
| Drisapersen | Other | Phase PHASE3 | Muscular Dystrophies | WITHDRAWN | NCT01890798 |
| Placebo | Other | Phase PHASE4 | Gastrointestinal Mucosal Damage | COMPLETED | NCT01822665 |
| Paracetamol | Other | Phase PHASE4 | Gastrointestinal Mucosal Damage | COMPLETED | NCT01822665 |
| Ibuprofen | Other | Phase PHASE4 | Gastrointestinal Mucosal Damage | COMPLETED | NCT01822665 |
| Placebo | Other | Phase PHASE4 | Gastrointestinal Mucosal Damage | COMPLETED | NCT01822665 |
| Paracetamol | Other | Phase PHASE4 | Gastrointestinal Mucosal Damage | COMPLETED | NCT01822665 |
| Ibuprofen | Other | Phase PHASE4 | Gastrointestinal Mucosal Damage | COMPLETED | NCT01822665 |
| Data collection | Other | Preclinical | Lung Cancer, Non-Small Cell | COMPLETED | NCT01772225 |
| Data collection | Other | Preclinical | Lung Cancer, Non-Small Cell | COMPLETED | NCT01772225 |
| Data collection | Other | Preclinical | Lung Cancer, Non-Small Cell | COMPLETED | NCT01772225 |
| GSK1120212 | Other | Phase PHASE2 | Cancer | COMPLETED | NCT01037127 |
| Eltrombopag | Other | Phase PHASE1 | Sarcoma, Soft Tissue | TERMINATED | NCT01491594 |
| GSK1120212 | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00920140 |
| Placebo | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT01817790 |
| Fluticasone propionate | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT01817790 |
| Placebo | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT01817790 |
| Fluticasone propionate | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT01817790 |
| Placebo | Other | Phase PHASE4 | Menstrual Migraine | COMPLETED | NCT01329562 |
| Treximet | Other | Phase PHASE4 | Menstrual Migraine | COMPLETED | NCT01329562 |
| GSK1265744 400 mg (5 micro m) | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01754116 |
| GSK1265744 400 mg (1 micro m) | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01754116 |
| GSK1265744 400 mg (200 nm) | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01754116 |
| Midazolam 3 mg oral + GSK1265744 30mg oral | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01754116 |
| GSK1265744 30 mg oral | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01754116 |
| Treatment with zanamivir | Drug | Preclinical | Influenza, Human | COMPLETED | NCT01462487 |
| Treatment with zanamivir | Drug | Preclinical | Influenza, Human | COMPLETED | NCT01462487 |
| Use of sunitinib, bevacizumab, or sorafenib | Other | Preclinical | Carcinoma, Renal Cell | COMPLETED | NCT01449825 |
| Pazopanib use | Other | Preclinical | Carcinoma, Renal Cell | COMPLETED | NCT01449825 |
| Fenofibrate | Other | Phase PHASE4 | Hypertriglyceridemia in Type 4 Hyperlipidemia | TERMINATED | NCT00819910 |
| Placebo (Fenofibrate) | Other | Phase PHASE4 | Hypertriglyceridemia in Type 4 Hyperlipidemia | TERMINATED | NCT00819910 |
| Placebo (Rosiglitazone) | Other | Phase PHASE4 | Hypertriglyceridemia in Type 4 Hyperlipidemia | TERMINATED | NCT00819910 |
| Rosiglitazone | Other | Phase PHASE4 | Hypertriglyceridemia in Type 4 Hyperlipidemia | TERMINATED | NCT00819910 |
| Malaria challenge | Other | Phase PHASE1 | Malaria, Falciparum | COMPLETED | NCT01556945 |
| AS02 adjuvant alone | Other | Phase PHASE1 | Malaria, Falciparum | COMPLETED | NCT01556945 |
| RTS,S/AS02 | Other | Phase PHASE1 | Malaria, Falciparum | COMPLETED | NCT01556945 |
| FMP1/AS02 | Other | Phase PHASE1 | Malaria, Falciparum | COMPLETED | NCT01556945 |
| Micardis placebo | Other | Phase PHASE4 | Stroke | COMPLETED | NCT00153062 |
| Clopidogrel | Other | Phase PHASE4 | Stroke | COMPLETED | NCT00153062 |
| Aggrenox placebo | Other | Phase PHASE4 | Stroke | COMPLETED | NCT00153062 |
| Micardis | Other | Phase PHASE4 | Stroke | COMPLETED | NCT00153062 |
| Clopidogrel placebo | Other | Phase PHASE4 | Stroke | COMPLETED | NCT00153062 |
| Aggrenox | Other | Phase PHASE4 | Stroke | COMPLETED | NCT00153062 |
| Placebo | Other | Phase PHASE4 | Prostate Cancer | COMPLETED | NCT00805701 |
| avodart | Other | Phase PHASE4 | Prostate Cancer | COMPLETED | NCT00805701 |
| Ofatumumab | Other | Phase PHASE4 | Leukaemia, Lymphocytic, Chronic | COMPLETED | NCT00802737 |
| Ofatumumab | Other | Phase PHASE4 | Leukaemia, Lymphocytic, Chronic | COMPLETED | NCT00802737 |
| Ofatumumab | Other | Phase PHASE4 | Leukaemia, Lymphocytic, Chronic | COMPLETED | NCT00802737 |
| Screening for cervical cancer | Other | Preclinical | Uterine Cervical Cancer | UNKNOWN | NCT01393470 |
| Screening for cervical cancer | Other | Preclinical | Uterine Cervical Cancer | UNKNOWN | NCT01393470 |
| Erlotinib | Other | Phase PHASE2 | Cancer | WITHDRAWN | NCT02034097 |
| Foretinib | Other | Phase PHASE2 | Cancer | WITHDRAWN | NCT02034097 |
| 200mg [14C]- GSK2248761 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | WITHDRAWN | NCT01273103 |
| Herceptin | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00470847 |
| Whole Brain Radiation | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00470847 |
| Lapatinib | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00470847 |
| Dolutegravir 50 mg q12h | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02064374 |
| Dolutegravir 50 mg q24h | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02064374 |
| Metformin 500 mg q12h | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02064374 |
| Placebo | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01607398 |
| ADOAIR250 | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01607398 |
| Trastuzumab or Lapatinib | Other | Preclinical | Cancer | COMPLETED | NCT01077648 |
| Trastuzumab or Lapatinib | Other | Preclinical | Cancer | COMPLETED | NCT01077648 |
| Sodium fluoride dentifrice | Other | Phase PHASE2 | Dentine Hypersensitivity | COMPLETED | NCT01691560 |
| Sodium monofluorophosphate dentifrice | Other | Phase PHASE2 | Dentine Hypersensitivity | COMPLETED | NCT01691560 |
| 0% calcium sodium phosphosilicate/sodium monofluorophosphate dentifrice | Other | Phase PHASE2 | Dentine Hypersensitivity | COMPLETED | NCT01691560 |
| 5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice | Other | Phase PHASE2 | Dentine Hypersensitivity | COMPLETED | NCT01691560 |
| MRI | Other | Phase PHASE1 | Heart Failure, Congestive | COMPLETED | NCT01277679 |
| Sodium Monofluorophosphate | Other | Phase PHASE3 | Dentine Hypersensitivity | COMPLETED | NCT01592851 |
| Stannous Fluoride | Other | Phase PHASE3 | Dentine Hypersensitivity | COMPLETED | NCT01592851 |
| Placebo | Other | Approved | Upper Back Pain | COMPLETED | NCT01562548 |
| Guaifenesin | Other | Approved | Upper Back Pain | COMPLETED | NCT01562548 |
| ofatumumab | Other | Phase PHASE2 | Leukaemia, Lymphocytic, Chronic | COMPLETED | NCT00349349 |
| ofatumumab | Other | Phase PHASE2 | Leukaemia, Lymphocytic, Chronic | COMPLETED | NCT00349349 |
| Placebo | Other | Phase PHASE3 | Arthritis, Rheumatoid | TERMINATED | NCT00603525 |
| Ofatumumab | Other | Phase PHASE3 | Arthritis, Rheumatoid | TERMINATED | NCT00603525 |
| Placebo | Other | Phase PHASE3 | Arthritis, Rheumatoid | TERMINATED | NCT00603525 |
| Ofatumumab | Other | Phase PHASE3 | Arthritis, Rheumatoid | TERMINATED | NCT00603525 |
| No intervention | Other | Preclinical | Maximal Rate of Fat Oxidation | COMPLETED | NCT02070055 |
| No intervention | Other | Preclinical | Maximal Rate of Fat Oxidation | COMPLETED | NCT02070055 |
| No intervention | Other | Preclinical | Maximal Rate of Fat Oxidation | COMPLETED | NCT02070055 |
| BONVIVA(ibandronate) injection | Other | Preclinical | Osteoporosis | COMPLETED | NCT01376102 |
| placebo (for meperidine) | Other | Phase PHASE4 | Diagnostic Colonoscopy Screening | COMPLETED | NCT01693185 |
| placebo (for midazolam) | Other | Phase PHASE4 | Diagnostic Colonoscopy Screening | COMPLETED | NCT01693185 |
| placebo (for remifentanil) | Other | Phase PHASE4 | Diagnostic Colonoscopy Screening | COMPLETED | NCT01693185 |
| Meperidine | Other | Phase PHASE4 | Diagnostic Colonoscopy Screening | COMPLETED | NCT01693185 |
| Midazolam | Other | Phase PHASE4 | Diagnostic Colonoscopy Screening | COMPLETED | NCT01693185 |
| Remifentanil | Other | Phase PHASE4 | Diagnostic Colonoscopy Screening | COMPLETED | NCT01693185 |
| Fluticasone Propionate Inhalation Powder | Other | Phase PHASE3 | Asthma | WITHDRAWN | NCT01435902 |
| Fluticasone Furoate/Vilanterol Inhalation Powder | Other | Phase PHASE3 | Asthma | WITHDRAWN | NCT01435902 |
| Placebo | Other | Phase PHASE3 | Smoking | COMPLETED | NCT00985985 |
| Nicotine | Other | Phase PHASE3 | Smoking | COMPLETED | NCT00985985 |
| Placebo | Other | Phase PHASE3 | Smoking | COMPLETED | NCT00985985 |
| Nicotine | Other | Phase PHASE3 | Smoking | COMPLETED | NCT00985985 |
| fluticasone furoate group | Other | Preclinical | Rhinitis, Allergic, Perennial and Seasonal | COMPLETED | NCT01001130 |
| Pravastatin and paroxetine combined | Other | Preclinical | Depression, Postpartum | COMPLETED | NCT01602913 |
| Paroxetine alone | Other | Preclinical | Depression, Postpartum | COMPLETED | NCT01602913 |
| Pravastatin alone | Other | Preclinical | Depression, Postpartum | COMPLETED | NCT01602913 |
| Paroxetine | Other | Preclinical | Social Phobia | COMPLETED | NCT01376271 |
| Referent group: no exposure to any anti-depressant or anti-smoking drug during pregnancy | Drug | Preclinical | Depressive Disorder | COMPLETED | NCT01597661 |
| Exposure to bupropion alone during the first trimester | Other | Preclinical | Depressive Disorder | COMPLETED | NCT01597661 |
| Exposure to any bupropion during the first trimester | Other | Preclinical | Depressive Disorder | COMPLETED | NCT01597661 |
| Referent group: no exposure to any anti-depressant or anti-smoking drug during pregnancy | Drug | Preclinical | Depressive Disorder | COMPLETED | NCT01597661 |
| Exposure to bupropion alone during the first trimester | Other | Preclinical | Depressive Disorder | COMPLETED | NCT01597661 |
| Exposure to any bupropion during the first trimester | Other | Preclinical | Depressive Disorder | COMPLETED | NCT01597661 |
| Benzodiazepine (BZD) use, defined by ATC codes | Other | Preclinical | Anxiety Disorders | COMPLETED | NCT01587833 |
| Prescription drugs with known hepatotoxicity | Drug | Preclinical | Drug-induced Liver Injury | COMPLETED | NCT01584765 |
| Prescription drugs with known hepatotoxicity | Drug | Preclinical | Drug-induced Liver Injury | COMPLETED | NCT01584765 |
| Arzerra | Other | Preclinical | Leukaemia, Lymphocytic, Chronic | COMPLETED | NCT01453062 |
| lapatinib | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00044343 |
| lapatinib | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00044343 |
| Prednisolone, Prednisone or equivalent | Other | Phase PHASE2 | Lymphoma, Follicular | COMPLETED | NCT00494780 |
| Vincristine | Other | Phase PHASE2 | Lymphoma, Follicular | COMPLETED | NCT00494780 |
| Doxorubicin | Other | Phase PHASE2 | Lymphoma, Follicular | COMPLETED | NCT00494780 |
| Cyclophosphamide | Other | Phase PHASE2 | Lymphoma, Follicular | COMPLETED | NCT00494780 |
| Ofatumumab | Other | Phase PHASE2 | Lymphoma, Follicular | COMPLETED | NCT00494780 |
| Prednisolone, Prednisone or equivalent | Other | Phase PHASE2 | Lymphoma, Follicular | COMPLETED | NCT00494780 |
| Vincristine | Other | Phase PHASE2 | Lymphoma, Follicular | COMPLETED | NCT00494780 |
| Doxorubicin | Other | Phase PHASE2 | Lymphoma, Follicular | COMPLETED | NCT00494780 |
| Cyclophosphamide | Other | Phase PHASE2 | Lymphoma, Follicular | COMPLETED | NCT00494780 |
| Ofatumumab | Other | Phase PHASE2 | Lymphoma, Follicular | COMPLETED | NCT00494780 |
| Lapatinib, Vinorelbine | Other | Phase PHASE2 | Neoplasms, Breast | TERMINATED | NCT00709618 |
| Placebo patch | Other | Phase PHASE1 | Herpes Labialis | COMPLETED | NCT01653509 |
| Acyclovir patch | Other | Phase PHASE1 | Herpes Labialis | COMPLETED | NCT01653509 |
| Placebo patch | Other | Phase PHASE1 | Herpes Labialis | COMPLETED | NCT01653509 |
| Acyclovir patch | Other | Phase PHASE1 | Herpes Labialis | COMPLETED | NCT01653509 |
| Placebo | Other | Phase PHASE3 | Neoplasms, Head and Neck | COMPLETED | NCT00424255 |
| Chemoradiation | Other | Phase PHASE3 | Neoplasms, Head and Neck | COMPLETED | NCT00424255 |
| Lapatinib | Other | Phase PHASE3 | Neoplasms, Head and Neck | COMPLETED | NCT00424255 |
| Paclitaxel infusion | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00356811 |
| Lapatinib oral tablets | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00356811 |
| Omega-3 Fatty Acid | Other | Phase PHASE2 | Breast Cancer | TERMINATED | NCT00930527 |
| Omega-3 Fatty Acid | Other | Phase PHASE2 | Breast Cancer | TERMINATED | NCT00930527 |
| no added fluoride in a silica base | Other | Phase PHASE3 | Enamel Erosion | COMPLETED | NCT01641237 |
| sodium fluoride | Other | Phase PHASE3 | Enamel Erosion | COMPLETED | NCT01641237 |
| Filgrastim | Other | Phase PHASE1 | Lung Cancer, Non-Small Cell | WITHDRAWN | NCT01938456 |
| Docetaxel | Other | Phase PHASE1 | Lung Cancer, Non-Small Cell | WITHDRAWN | NCT01938456 |
| Trametinib | Other | Phase PHASE1 | Lung Cancer, Non-Small Cell | WITHDRAWN | NCT01938456 |
| Chlorhexidine Digluconate Mouthwash without Alcohol | Other | Phase PHASE4 | Gingivitis | COMPLETED | NCT01751178 |
| Chlorhexidine Digluconate Mouthwash with Alcohol | Other | Phase PHASE4 | Gingivitis | COMPLETED | NCT01751178 |
| Chlorhexidine Digluconate Mouthwash without Alcohol | Other | Phase PHASE4 | Gingivitis | COMPLETED | NCT01751178 |
| Chlorhexidine Digluconate Mouthwash with Alcohol | Other | Phase PHASE4 | Gingivitis | COMPLETED | NCT01751178 |
| Normal saline placebo | Other | Phase PHASE2 | Purpura, Thrombocytopaenic, Idiopathic | WITHDRAWN | NCT01440361 |
| Belimumab | Other | Phase PHASE2 | Purpura, Thrombocytopaenic, Idiopathic | WITHDRAWN | NCT01440361 |
| Normal saline placebo | Other | Phase PHASE2 | Purpura, Thrombocytopaenic, Idiopathic | WITHDRAWN | NCT01440361 |
| Belimumab | Other | Phase PHASE2 | Purpura, Thrombocytopaenic, Idiopathic | WITHDRAWN | NCT01440361 |
| Fondaparinux Sodium | Other | Preclinical | Cardiovascular Disease | COMPLETED | NCT01390896 |
| fondaparinux | Other | Approved | Kidney Diseases | WITHDRAWN | NCT00483600 |
| No intervention | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00791518 |
| No intervention | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00791518 |
| Bevacizumab | Other | Phase PHASE2 | Cervical Cancer | COMPLETED | NCT00548418 |
| Cisplatin | Other | Phase PHASE2 | Cervical Cancer | COMPLETED | NCT00548418 |
| Topotecan | Other | Phase PHASE2 | Cervical Cancer | COMPLETED | NCT00548418 |
| Other ADA users | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT01767389 |
| DPP-4 inhibitor users | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT01767389 |
| The GLP-1 receptor agonist users | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT01767389 |
| Other ADA users | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT01767389 |
| DPP-4 inhibitor users | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT01767389 |
| The GLP-1 receptor agonist users | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT01767389 |
| vehicle gel | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT01400932 |
| GI148512 | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT01400932 |
| fluticasone and salmeterol | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00116402 |
| sodium chloride | Other | Phase PHASE2 | Pre-eclampsia | COMPLETED | NCT00158743 |
| Anti-digoxin antibody (FAB fragment) | Other | Phase PHASE2 | Pre-eclampsia | COMPLETED | NCT00158743 |
| Placebo | Other | Phase PHASE3 | Dental Caries | COMPLETED | NCT01607411 |
| Fluoride | Other | Phase PHASE3 | Dental Caries | COMPLETED | NCT01607411 |
| Placebo | Other | Phase PHASE3 | Dental Caries | COMPLETED | NCT01607411 |
| Fluoride | Other | Phase PHASE3 | Dental Caries | COMPLETED | NCT01607411 |
| asthma control test | Other | Preclinical | Asthma | COMPLETED | NCT01376219 |
| Breakfast | Other | Phase PHASE1 | Obesity | TERMINATED | NCT01366508 |
| High calorie lunch | Other | Phase PHASE1 | Obesity | TERMINATED | NCT01366508 |
| Spirometry, PEF measurements and diary cards to evaluate control of Asthma | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00858286 |
| Spirometry, PEF measurements and diary cards to evaluate control of Asthma | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00858286 |
| RTS,S with AS02A/AS01B adjuvant | Other | Phase PHASE1 | Malaria | COMPLETED | NCT00075049 |
| matched placebo | Other | Phase PHASE2 | Muscular Dystrophies | COMPLETED | NCT01153932 |
| GSK2402968 | Other | Phase PHASE2 | Muscular Dystrophies | COMPLETED | NCT01153932 |
| Data interpretation | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT01682005 |
| Data interpretation | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT01682005 |
| fondaparinux sodium injection | Other | Phase PHASE1 | Renal Insufficiency | COMPLETED | NCT01121770 |
| Alclometasone dipropionate cream | Other | Phase PHASE2 | Eczema | COMPLETED | NCT02075632 |
| Data collection | Other | Preclinical | Infections, Respiratory Tract | TERMINATED | NCT01292213 |
| Bronchoscopy/ bronchoalveolar lavage samples | Other | Preclinical | Infections, Respiratory Tract | TERMINATED | NCT01292213 |
| Blood sample | Other | Preclinical | Infections, Respiratory Tract | TERMINATED | NCT01292213 |
| Nasopharyngeal swabs | Other | Preclinical | Infections, Respiratory Tract | TERMINATED | NCT01292213 |
| Oropharyngeal swab | Other | Preclinical | Infections, Respiratory Tract | TERMINATED | NCT01292213 |
| Cough swab | Other | Preclinical | Infections, Respiratory Tract | TERMINATED | NCT01292213 |
| Data collection | Other | Preclinical | Infections, Respiratory Tract | TERMINATED | NCT01292213 |
| Bronchoscopy/ bronchoalveolar lavage samples | Other | Preclinical | Infections, Respiratory Tract | TERMINATED | NCT01292213 |
| Blood sample | Other | Preclinical | Infections, Respiratory Tract | TERMINATED | NCT01292213 |
| Nasopharyngeal swabs | Other | Preclinical | Infections, Respiratory Tract | TERMINATED | NCT01292213 |
| Oropharyngeal swab | Other | Preclinical | Infections, Respiratory Tract | TERMINATED | NCT01292213 |
| Cough swab | Other | Preclinical | Infections, Respiratory Tract | TERMINATED | NCT01292213 |
| GSK580299, GSK Biological's HPV vaccine | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00849381 |
| Pramipexole, Amisulpride | Other | Phase PHASE1 | Obsessive-Compulsive Disorder | COMPLETED | NCT00471588 |
| Survey Responses | Other | Preclinical | Epilepsy | COMPLETED | NCT01938560 |
| Placebo | Other | Phase PHASE2 | Caries | COMPLETED | NCT01657877 |
| Sodium monoflurophosphate | Other | Phase PHASE2 | Caries | COMPLETED | NCT01657877 |
| Calcium sodium phosphosilicate | Other | Phase PHASE2 | Caries | COMPLETED | NCT01657877 |
| Placebo | Other | Phase PHASE2 | Caries | COMPLETED | NCT01657877 |
| Sodium monoflurophosphate | Other | Phase PHASE2 | Caries | COMPLETED | NCT01657877 |
| Calcium sodium phosphosilicate | Other | Phase PHASE2 | Caries | COMPLETED | NCT01657877 |
| Non lamotrigine anti-epileptic drug monotherapy | Drug | Preclinical | Epilepsy | COMPLETED | NCT01055327 |
| No anti-epileptic drug exposure | Drug | Preclinical | Epilepsy | COMPLETED | NCT01055327 |
| Lamotrigine monotherapy | Drug | Preclinical | Epilepsy | COMPLETED | NCT01055327 |
| placebo | Other | Phase PHASE2 | Depressive Disorder | COMPLETED | NCT00448058 |
| venlafaxine | Other | Phase PHASE2 | Depressive Disorder | COMPLETED | NCT00448058 |
| GSK372475 | Other | Phase PHASE2 | Depressive Disorder | COMPLETED | NCT00448058 |
| Placebo | Other | Phase PHASE2 | Mild Asthma and Allergic Rhinitis | COMPLETED | NCT01788813 |
| GSK2245035 | Other | Phase PHASE2 | Mild Asthma and Allergic Rhinitis | COMPLETED | NCT01788813 |
| pemetrexed | Other | Phase PHASE2 | Lung Cancer, Small Cell | TERMINATED | NCT01313663 |
| pazopanib | Other | Phase PHASE2 | Lung Cancer, Small Cell | TERMINATED | NCT01313663 |
| pemetrexed | Other | Phase PHASE2 | Lung Cancer, Small Cell | TERMINATED | NCT01313663 |
| pazopanib | Other | Phase PHASE2 | Lung Cancer, Small Cell | TERMINATED | NCT01313663 |
| TYKERB® tablets | Other | Preclinical | Cancer | COMPLETED | NCT00975988 |
| Sodium monofluorophosphate | Other | Phase PHASE3 | Dentine Hypersensitivity | COMPLETED | NCT01827670 |
| Stannous fluoride | Other | Phase PHASE3 | Dentine Hypersensitivity | COMPLETED | NCT01827670 |
| Sodium monofluorophosphate | Other | Phase PHASE3 | Dentine Hypersensitivity | COMPLETED | NCT01827670 |
| Stannous fluoride | Other | Phase PHASE3 | Dentine Hypersensitivity | COMPLETED | NCT01827670 |
| Potassium nitrate | Other | Approved | Dental Erosion | COMPLETED | NCT01657903 |
| Sodium Fluoride | Other | Approved | Dental Erosion | COMPLETED | NCT01657903 |
| Rotarix™ | Other | Phase PHASE2 | Infections, Rotavirus | WITHDRAWN | NCT01110044 |
| Synflorix™ | Other | Phase PHASE2 | Infections, Rotavirus | WITHDRAWN | NCT01110044 |
| Infanrix hexa™ | Other | Phase PHASE2 | Infections, Rotavirus | WITHDRAWN | NCT01110044 |
| 251154 vaccine | Other | Phase PHASE2 | Infections, Rotavirus | WITHDRAWN | NCT01110044 |
| GW572016 | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00062686 |
| GW572016 | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00062686 |
| metoprolol | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT00060918 |
| carvedilol | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT00060918 |
| Moxifloxacin | Other | Phase PHASE1 | Infections, Bacterial | WITHDRAWN | NCT01039610 |
| Linezolid | Other | Phase PHASE1 | Infections, Bacterial | WITHDRAWN | NCT01039610 |
| Placebo | Other | Phase PHASE1 | Infections, Bacterial | WITHDRAWN | NCT01039610 |
| GSK945237 | Other | Phase PHASE1 | Infections, Bacterial | WITHDRAWN | NCT01039610 |
| Moxifloxacin | Other | Phase PHASE1 | Infections, Bacterial | WITHDRAWN | NCT01039610 |
| Linezolid | Other | Phase PHASE1 | Infections, Bacterial | WITHDRAWN | NCT01039610 |
| Placebo | Other | Phase PHASE1 | Infections, Bacterial | WITHDRAWN | NCT01039610 |
| GSK945237 | Other | Phase PHASE1 | Infections, Bacterial | WITHDRAWN | NCT01039610 |
| Placebo | Other | Phase PHASE4 | Ankle Sprain | COMPLETED | NCT01957215 |
| Indomethacin | Other | Phase PHASE4 | Ankle Sprain | COMPLETED | NCT01957215 |
| cisplatin chemotherapy | Drug | Phase PHASE2 | Neoplasms, Head and Neck | COMPLETED | NCT00387127 |
| radiotherapy | Drug | Phase PHASE2 | Neoplasms, Head and Neck | COMPLETED | NCT00387127 |
| Lapatinib oral tablets | Other | Phase PHASE2 | Neoplasms, Head and Neck | COMPLETED | NCT00387127 |
| Cooperstown Cocktail | Other | Phase PHASE1 | Chemotherapy-induced Nausea and Vomiting | COMPLETED | NCT02434861 |
| Sulfasalazine | Other | Phase PHASE1 | Chemotherapy-induced Nausea and Vomiting | COMPLETED | NCT02434861 |
| Digoxin | Other | Phase PHASE1 | Chemotherapy-induced Nausea and Vomiting | COMPLETED | NCT02434861 |
| Rolapitant | Other | Phase PHASE1 | Chemotherapy-induced Nausea and Vomiting | COMPLETED | NCT02434861 |
| Rolapitant | Other | Phase PHASE1 | Chemotherapy-induced Nausea and Vomiting | COMPLETED | NCT02382666 |
| Rolapitant - IV | Other | Phase PHASE1 | Chemotherapy-induced Nausea and Vomiting | COMPLETED | NCT02285647 |
| Rolapitant - Oral | Other | Phase PHASE1 | Chemotherapy-induced Nausea and Vomiting | COMPLETED | NCT02285647 |
| Data collection | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT01636739 |
| Oral Rotarix® | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT01636739 |
| Data collection | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT01636739 |
| Oral Rotarix® | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT01636739 |
| Data collection | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT01636739 |
| Oral Rotarix® | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT01636739 |
| Blood sampling | Other | Phase PHASE4 | Hepatitis B | WITHDRAWN | NCT02135666 |
| Blood sampling | Other | Phase PHASE4 | Hepatitis A | WITHDRAWN | NCT02124785 |
| [18F]PBR111 | Other | Phase PHASE2 | Multiple Sclerosis | TERMINATED | NCT01428505 |
| Placebo | Other | Phase PHASE4 | Hypertriglyceridemia | WITHDRAWN | NCT01180764 |
| Lovaza (Omega-3 acid ethyl esters) | Other | Phase PHASE4 | Hypertriglyceridemia | WITHDRAWN | NCT01180764 |
| Revaxis® | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT01277705 |
| GSK Biologicals' IPV vaccine | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT01277705 |
| Boostrix™ | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT01277705 |
| GSK Biologicals' reduced antigen diphtheria and tetanus toxoids and acellular pertussis- inactivated poliovirus vaccine | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT01277705 |
| Ditanrix™ Adult, TedivaxTM (Td) | Other | Phase PHASE4 | Acellular Pertussis | COMPLETED | NCT01294605 |
| GSK Biologicals' reduced-antigen-content combined diphtheria, tetanus, acellular pertussis and inactivated polio vaccine (dTpa-IPV; BoostrixTM) | Other | Phase PHASE4 | Acellular Pertussis | COMPLETED | NCT01294605 |
| Boostrix™ (dTpa) | Other | Phase PHASE4 | Acellular Pertussis | COMPLETED | NCT01294605 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00920959 |
| FSC 100/50mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00920959 |
| FP 100mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00920959 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00920959 |
| FSC 100/50mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00920959 |
| FP 100mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00920959 |
| Optical Coherence Tomography (C7 XR Dragonfly ) | Other | Phase PHASE1 | Coronary Atherosclerosis | COMPLETED | NCT01642173 |
| Vehicle foam | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT00689481 |
| U0267 Foam | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT00689481 |
| Fluarix | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00380211 |
| Influenza vaccine (A/H3N2, A/H1N1, and B strains) | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00380211 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00748306 |
| GSK2190915 - 100mcg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00748306 |
| rosiglitazone | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00523913 |
| Hepatitis B immunoglobulin (HBIg) | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00240526 |
| Engerix™ -B | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00240526 |
| Placebo | Other | Phase PHASE2 | Rhinitis, Allergic, Perennial and Seasonal | COMPLETED | NCT01957202 |
| levocabastine | Other | Phase PHASE2 | Rhinitis, Allergic, Perennial and Seasonal | COMPLETED | NCT01957202 |
| FF/levocabastine | Other | Phase PHASE2 | Rhinitis, Allergic, Perennial and Seasonal | COMPLETED | NCT01957202 |
| Metformin Large Pack | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01817777 |
| Metformin Small Pack | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01817777 |
| Vilanterol 25 mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01716520 |
| Umeclidinium 62.5 mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01716520 |
| Umeclidinium/Vilanterol 62.5/25 mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01716520 |
| GSK573719 | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01702363 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01636713 |
| GSK573719/VI 125/25 | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01636713 |
| GSK573719/VI 62.5/25 | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01636713 |
| Fluticasone furoate | Other | Phase PHASE3 | Rhinitis | COMPLETED | NCT01622231 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01453296 |
| GW642444 | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01453296 |
| Web-based survey questionnaire | Other | Preclinical | Pertussis | COMPLETED | NCT01890447 |
| Data collection | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT01733849 |
| Stool sample | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT01733849 |
| Data collection | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT01733849 |
| Stool sample | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT01733849 |
| Atovaquone | Other | Phase PHASE1 | Malaria | COMPLETED | NCT01858831 |
| Atovaquone/proguanil HCL | Other | Phase PHASE1 | Malaria | COMPLETED | NCT01858831 |
| ambrisentan | Other | Preclinical | Hypertension, Pulmonary | COMPLETED | NCT00679224 |
| Eltrombopag | Other | Preclinical | Purpura, Thrombocytopaenic, Idiopathic | COMPLETED | NCT00643929 |
| Eltrombopag | Other | Preclinical | Purpura, Thrombocytopaenic, Idiopathic | COMPLETED | NCT00643929 |
| Ropinirole XL (formerly CR) | Other | Phase PHASE3 | Parkinson Disease | COMPLETED | NCT00632736 |
| placebo | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00519376 |
| GW642444H | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00519376 |
| GW642444M | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00519376 |
| placebo | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00519376 |
| GW642444H | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00519376 |
| GW642444M | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00519376 |
| firategrast | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT00469378 |
| Engerix-B | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00383591 |
| Hepatitis B adjuvanted vaccine | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00383591 |
| Ropinirole | Other | Phase PHASE3 | Parkinson Disease | COMPLETED | NCT00381472 |
| Ropinirole | Other | Phase PHASE3 | Parkinson Disease | COMPLETED | NCT00381472 |
| Metformin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00379769 |
| Sulfonylurea | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00379769 |
| Rosiglitazone | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00379769 |
| Paracetamol | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT00370318 |
| Rotarix | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT00370318 |
| Infanrix Hexa | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT00370318 |
| 10 valent pneumococcal conjugate vaccine | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT00370318 |
| Simvastatin + Lovaza | Other | Phase PHASE3 | Hypertriglyceridemia | COMPLETED | NCT00246701 |
| Simvastatin | Other | Phase PHASE3 | Hypertriglyceridemia | COMPLETED | NCT00246701 |
| bupropion and smoking cessation behavioral intervention | Other | Phase PHASE4 | Major Depressive Disorder | COMPLETED | NCT00186446 |
| FLOLAN injection with reformulated diluent | Other | Phase PHASE4 | Cardiovascular Disease | COMPLETED | NCT02705807 |
| FLOLAN injection with currently marketed diluent | Other | Phase PHASE4 | Cardiovascular Disease | COMPLETED | NCT02705807 |
| placebo | Other | Phase PHASE3 | Endothelial Dysfunction | COMPLETED | NCT01067339 |
| darapladib | Other | Phase PHASE3 | Endothelial Dysfunction | COMPLETED | NCT01067339 |
| Placebo | Other | Phase PHASE2 | Systemic Lupus Erythematosus | TERMINATED | NCT01777256 |
| GSK2586184 400 mg | Other | Phase PHASE2 | Systemic Lupus Erythematosus | TERMINATED | NCT01777256 |
| GSK2586184 200 mg | Other | Phase PHASE2 | Systemic Lupus Erythematosus | TERMINATED | NCT01777256 |
| GSK2586184 100 mg | Other | Phase PHASE2 | Systemic Lupus Erythematosus | TERMINATED | NCT01777256 |
| GSK2586184 50 mg | Other | Phase PHASE2 | Systemic Lupus Erythematosus | TERMINATED | NCT01777256 |
| Alpha-glucosidase inhibitor | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01777282 |
| Thiazolidinedione | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01777282 |
| Glinide | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01777282 |
| Biguanide | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01777282 |
| Sulfonylurea | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01777282 |
| Albiglutide | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01777282 |
| Placebo | Other | Phase PHASE1 | Obstetric Labour, Premature | COMPLETED | NCT02377414 |
| Retosiban solution for Infusion | Other | Phase PHASE1 | Obstetric Labour, Premature | COMPLETED | NCT02377414 |
| Zanamivir | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT02377401 |
| Cervarix TM | Other | Phase PHASE1 | Infections, Papillomavirus | COMPLETED | NCT00478621 |
| GSK Biologicals' HPV vaccine (GSK1674330A) | Other | Phase PHASE1 | Infections, Papillomavirus | COMPLETED | NCT00478621 |
| laboratory biomarker analysis | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00482391 |
| paclitaxel | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00482391 |
| lapatinib ditosylate | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00482391 |
| doxorubicin hydrochloride | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00482391 |
| cyclophosphamide | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00482391 |
| trastuzumab | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00482391 |
| laboratory biomarker analysis | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00482391 |
| paclitaxel | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00482391 |
| lapatinib ditosylate | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00482391 |
| doxorubicin hydrochloride | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00482391 |
| cyclophosphamide | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00482391 |
| trastuzumab | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00482391 |
| Tuberculin PPD | Other | Phase PHASE1 | Dermatitis | COMPLETED | NCT01910662 |
| PBS (0.1 mL) | Other | Phase PHASE1 | Dermatitis | COMPLETED | NCT01910662 |
| KLH 5 mg | Other | Phase PHASE1 | Dermatitis | COMPLETED | NCT01910662 |
| KLH 0.1 mg | Other | Phase PHASE1 | Dermatitis | COMPLETED | NCT01910662 |
| VI 100 mcg | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01894386 |
| UMEC 250 mcg | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01894386 |
| UMEC 500 mcg | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01894386 |
| FF 400 mcg | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01894386 |
| VI 100 mcg | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01894386 |
| UMEC 250 mcg | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01894386 |
| UMEC 500 mcg | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01894386 |
| FF 400 mcg | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01894386 |
| Belimumab 200 mg/mL | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT01894360 |
| Belimumab 200 mg/mL | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT01894360 |
| Matching placebo repeat dose IH | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT01818024 |
| Repeat IH dose selected of GSK2862277 from Part 2 | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT01818024 |
| Matching placebo repeat dose IV infusion | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT01818024 |
| Repeat IV dose of GSK2862277 | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT01818024 |
| Matching placebo single dose IH | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT01818024 |
| Single IH dose of GSK2862277 | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT01818024 |
| Matching placebo single dose IV infusion | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT01818024 |
| Single IV dose of GSK2862277 | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT01818024 |
| Rosiglitazone | Other | Phase PHASE3 | Alzheimer's Disease | COMPLETED | NCT00428090 |
| continuous screening | Other | Preclinical | Neoplasms, Prostate | COMPLETED | NCT01371513 |
| continuous screening | Other | Preclinical | Neoplasms, Prostate | COMPLETED | NCT01371513 |
| Paroxetine | Other | Preclinical | Panic Disorder | COMPLETED | NCT01371474 |
| rosiglitazone | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT00381238 |
| Placebo comparator | Other | Phase PHASE1 | Infections, Respiratory Syncytial Virus | COMPLETED | NCT01905215 |
| RSV vaccine GSK3003899A (formulation 6) | Other | Phase PHASE1 | Infections, Respiratory Syncytial Virus | COMPLETED | NCT01905215 |
| RSV vaccine GSK3003898A (formulation 5) | Other | Phase PHASE1 | Infections, Respiratory Syncytial Virus | COMPLETED | NCT01905215 |
| RSV vaccine GSK3003896A (formulation 4) | Other | Phase PHASE1 | Infections, Respiratory Syncytial Virus | COMPLETED | NCT01905215 |
| RSV vaccine GSK3003895A (formulation 3) | Other | Phase PHASE1 | Infections, Respiratory Syncytial Virus | COMPLETED | NCT01905215 |
| RSV vaccine GSK3003893A (formulation 2) | Other | Phase PHASE1 | Infections, Respiratory Syncytial Virus | COMPLETED | NCT01905215 |
| RSV vaccine GSK3003892A (formulation 1) | Other | Phase PHASE1 | Infections, Respiratory Syncytial Virus | COMPLETED | NCT01905215 |
| Rosiglitazone | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT00995995 |
| Dapsone gel | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT00964366 |
| clindamycin and benzoyl peroxide | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT00964366 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00933530 |
| SRT2104 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00933530 |
| Retrospective analysis of already archived samples | Other | Preclinical | Hepatocellular Carcinoma | COMPLETED | NCT00911196 |
| Alendronate | Other | Phase PHASE4 | Osteoporosis | COMPLETED | NCT00327990 |
| Ibandronate | Other | Phase PHASE4 | Osteoporosis | COMPLETED | NCT00327990 |
| Alendronate | Other | Phase PHASE4 | Osteoporosis | COMPLETED | NCT00327990 |
| Ibandronate | Other | Phase PHASE4 | Osteoporosis | COMPLETED | NCT00327990 |
| Extended-release Venlafaxine | Other | Phase PHASE4 | Depressive Disorder, Major | COMPLETED | NCT00316160 |
| Bupropion Hydrochloride Extended-release | Other | Phase PHASE4 | Depressive Disorder, Major | COMPLETED | NCT00316160 |
| Orange juice | Other | Approved | Tooth Wear | COMPLETED | NCT03178968 |
| GSK2315698 | Other | Phase PHASE1 | Amyloidosis | COMPLETED | NCT01406314 |
| Placebo | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT01387217 |
| GSK2018682 | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT01387217 |
| Gemfibrozil | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT01376232 |
| GSK1278863 + food | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT01376232 |
| GSK1278863 | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT01376232 |
| Isotretinoin: Test Medication | Drug | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT02498288 |
| Isotretinoin: Reference Medication 2 | Drug | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT02498288 |
| Isotretinoin: Reference Medication 1 | Drug | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT02498288 |
| Alprazolam 0.5 mg | Other | Phase PHASE1 | Anxiety Disorders | COMPLETED | NCT01745562 |
| Alprazolam 0.5 mg | Other | Phase PHASE1 | Anxiety Disorders | COMPLETED | NCT01745562 |
| GSK1605786 Placebo | Other | Phase PHASE1 | Crohn's Disease | COMPLETED | NCT01611805 |
| GSK1605786 | Other | Phase PHASE1 | Crohn's Disease | COMPLETED | NCT01611805 |
| GSK1605786 Placebo | Other | Phase PHASE1 | Crohn's Disease | COMPLETED | NCT01611805 |
| GSK1605786 | Other | Phase PHASE1 | Crohn's Disease | COMPLETED | NCT01611805 |
| FP HFA MDI 50 mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02113436 |
| FP/ SLM HFA MDI 50/25 mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02113436 |
| MRI | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02207452 |
| Ipratropium | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02207452 |
| Salbutamol | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02207452 |
| He-3 MRI | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02207452 |
| MRI | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02207452 |
| Ipratropium | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02207452 |
| Salbutamol | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02207452 |
| He-3 MRI | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02207452 |
| Placebo to prednisolone | Other | Phase PHASE1 | Inflammation | COMPLETED | NCT01762787 |
| Placebo to aspirin | Other | Phase PHASE1 | Inflammation | COMPLETED | NCT01762787 |
| Prednisolone | Other | Phase PHASE1 | Inflammation | COMPLETED | NCT01762787 |
| Aspirin | Other | Phase PHASE1 | Inflammation | COMPLETED | NCT01762787 |
| Cantharidin solution | Other | Phase PHASE1 | Inflammation | COMPLETED | NCT01762787 |
| GSK2251052 | Other | Phase PHASE1 | Community-acquired Infection | TERMINATED | NCT01702350 |
| GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state | Other | Phase PHASE1 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT01466322 |
| Placebo | Other | Phase PHASE1 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT01431937 |
| GSK2018682 | Other | Phase PHASE1 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT01431937 |
| Plactebo To Match | Other | Phase PHASE1 | Depressive Disorder and Anxiety Disorders | COMPLETED | NCT01424384 |
| GSK424887 | Other | Phase PHASE1 | Depressive Disorder and Anxiety Disorders | COMPLETED | NCT01424384 |
| Citalopram | Other | Phase PHASE1 | Depressive Disorder and Anxiety Disorders | COMPLETED | NCT01424384 |
| Firategrast gastro-retentive solution | Other | Phase PHASE1 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT01416363 |
| Firategrast modified release tablet | Other | Phase PHASE1 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT01416363 |
| Firategrast immediate release tablet | Other | Phase PHASE1 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT01416363 |
| GSK2485852 210 mg +Ritonavir 100mg | Other | Phase PHASE1 | Hepatitis C | TERMINATED | NCT01332552 |
| GSK2485852 210 mg + Ritonavir 100mg | Other | Phase PHASE1 | Hepatitis C | TERMINATED | NCT01332552 |
| GSK2485852 70 mg + Ritonavir 100mg | Other | Phase PHASE1 | Hepatitis C | TERMINATED | NCT01332552 |
| GSK2485852 630 mg | Other | Phase PHASE1 | Hepatitis C | TERMINATED | NCT01332552 |
| placebo | Other | Phase PHASE1 | Hepatitis C | TERMINATED | NCT01332552 |
| GSK2485852 420 mg | Other | Phase PHASE1 | Hepatitis C | TERMINATED | NCT01332552 |
| GSK2485852 70 mg | Other | Phase PHASE1 | Hepatitis C | TERMINATED | NCT01332552 |
| Administration of rosiglitazone/metformin | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT01294553 |
| Artemether + Lumefantrine | Other | Phase PHASE1 | Malaria, Vivax | COMPLETED | NCT02184637 |
| Dihydroartemisinin + Piperaquine tetraphosphate | Other | Phase PHASE1 | Malaria, Vivax | COMPLETED | NCT02184637 |
| Tafenoquine | Other | Phase PHASE1 | Malaria, Vivax | COMPLETED | NCT02184637 |
| Itraconazole capsule | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT02045849 |
| GSK2140944 tablet | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT02045849 |
| GSK2140944 capsule | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT02045849 |
| Placebo | Other | Phase PHASE2 | Depressive Disorder, Major | TERMINATED | NCT00569062 |
| GW856553X | Other | Phase PHASE2 | Depressive Disorder, Major | TERMINATED | NCT00569062 |
| Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose) | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01458054 |
| Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose) | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01458054 |
| Loestrin 1.5/30 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02480881 |
| Oral Contraceptive | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02480881 |
| BMS-663068 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02480881 |
| Loestrin 1.5/30 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02480881 |
| Oral Contraceptive | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02480881 |
| BMS-663068 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02480881 |
| Ursodeoxycholic acid | Other | Phase PHASE2 | Cholestasis, Intrahepatic | COMPLETED | NCT01899703 |
| Placebo | Other | Phase PHASE2 | Cholestasis, Intrahepatic | COMPLETED | NCT01899703 |
| GSK2330672 | Other | Phase PHASE2 | Cholestasis, Intrahepatic | COMPLETED | NCT01899703 |
| Placebo | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00711386 |
| GSK706769 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00711386 |
| Placebo | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00711386 |
| GSK706769 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00711386 |
| Simvastatin | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00504439 |
| Matching placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00504439 |
| SB-656933-AAA | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00504439 |
| Casopitant 50 mg matching placebo | Other | Phase PHASE1 | Nausea and Vomiting, Chemotherapy-Induced | COMPLETED | NCT00460707 |
| Casopitant 50 mg | Other | Phase PHASE1 | Nausea and Vomiting, Chemotherapy-Induced | COMPLETED | NCT00460707 |
| Casopitant 150 mg matching placebo | Other | Phase PHASE1 | Nausea and Vomiting, Chemotherapy-Induced | COMPLETED | NCT00460707 |
| Ketoconazole | Other | Phase PHASE1 | Nausea and Vomiting, Chemotherapy-Induced | COMPLETED | NCT00460707 |
| Casopitant 150 mg | Other | Phase PHASE1 | Nausea and Vomiting, Chemotherapy-Induced | COMPLETED | NCT00460707 |
| Ketoconazole | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT00411866 |
| SB773812 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT00411866 |
| Paxil CR | Other | Phase PHASE1 | Depressive Disorder | COMPLETED | NCT00749359 |
| GSK598809 old formulation | Other | Phase PHASE1 | Substance Dependence | COMPLETED | NCT00728897 |
| GSK598809 new formulation | Other | Phase PHASE1 | Substance Dependence | COMPLETED | NCT00728897 |
| GSK598809 old formulation | Other | Phase PHASE1 | Substance Dependence | COMPLETED | NCT00728897 |
| GSK598809 new formulation | Other | Phase PHASE1 | Substance Dependence | COMPLETED | NCT00728897 |
| phenytoin | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT00627575 |
| atorvastatin | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT00627575 |
| lamotrigine | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT00627575 |
| GI198745 | Other | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT00609596 |
| GI198745 | Other | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT00609596 |
| GW856553 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00599612 |
| Placebo | Other | Phase PHASE1 | Social Phobia | COMPLETED | NCT00555139 |
| alprazolam | Other | Phase PHASE1 | Social Phobia | COMPLETED | NCT00555139 |
| GW876008 tablet | Other | Phase PHASE1 | Social Phobia | COMPLETED | NCT00555139 |
| GSK561679 tablet | Other | Phase PHASE1 | Social Phobia | COMPLETED | NCT00555139 |
| rosiglitazone maleate | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00551564 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00549120 |
| Ipratropium | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00549120 |
| Salbutamol | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00549120 |
| Propranolol | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00549120 |
| fluticasone propionate | Other | Preclinical | Rhinitis, Allergic, Perennial | COMPLETED | NCT01199757 |
| mometasone furoate | Other | Preclinical | Rhinitis, Allergic, Perennial | COMPLETED | NCT01199757 |
| Fluticasone furoate | Other | Preclinical | Rhinitis, Allergic, Perennial | COMPLETED | NCT01199757 |
| Flurbiprofen | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00615212 |
| Rosiglitazone | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00615212 |
| Midazolam | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00615212 |
| GSK376501 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00615212 |
| Salmeterol 50mcg | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00347139 |
| GW642444 (25, 100 & 400 mcg/day) | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00347139 |
| Salbutamol 100 mcg pMDI | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02233803 |
| NEUMOTEX 400 (Budesonide 400 mcg) | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02233803 |
| SYMBICORT forte (BFF 320/9mcg) TURBUHALER inhaler | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02233803 |
| NEUMOTEROL 400 (BFF 400/12 mcg) single capsule inhaler | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02233803 |
| Salbutamol 100 mcg pMDI | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02233803 |
| NEUMOTEX 400 (Budesonide 400 mcg) | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02233803 |
| SYMBICORT forte (BFF 320/9mcg) TURBUHALER inhaler | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02233803 |
| NEUMOTEROL 400 (BFF 400/12 mcg) single capsule inhaler | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02233803 |
| Maraviroc | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02480894 |
| BMS-663068 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02480894 |
| BMS-663068 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02467335 |
| Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00506350 |
| Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00506350 |
| Atorvastatin | Other | Phase PHASE1 | Osteoarthritis | COMPLETED | NCT00411190 |
| Ibuprofen | Other | Phase PHASE1 | Osteoarthritis | COMPLETED | NCT00411190 |
| Acetaminophen | Other | Phase PHASE1 | Osteoarthritis | COMPLETED | NCT00411190 |
| Relacatib | Other | Phase PHASE1 | Osteoarthritis | COMPLETED | NCT00411190 |
| Questionnaire | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02586506 |
| Placebo ELLIPTA inhaler | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02586506 |
| Exenatide | Other | Phase PHASE1 | Obesity | COMPLETED | NCT01857895 |
| Cyclosporine | Other | Phase PHASE1 | Purpura, Thrombocytopenic, Idiopathic | COMPLETED | NCT02281370 |
| Eltrombopag | Other | Phase PHASE1 | Purpura, Thrombocytopenic, Idiopathic | COMPLETED | NCT02281370 |
| Eltrombopag | Other | Phase PHASE1 | Cirrhosis, Liver | COMPLETED | NCT02254434 |
| GSK2110183 IR Tablet | Other | Phase PHASE1 | Cancer | COMPLETED | NCT02040480 |
| GSK2110183 Gelatin Capsule | Other | Phase PHASE1 | Cancer | COMPLETED | NCT02040480 |
| Afuresertib ECT - Fed State | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01827644 |
| Afuresertib HPMC capsule - Fed State | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01827644 |
| Afuresertib GC - Fed State | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01827644 |
| Afuresertib ECT - Fasted State | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01827644 |
| Afuresertib HPMC capsule - Fasted State | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01827644 |
| Afuresertib GC - Fasted State | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01827644 |
| Placebo | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01738451 |
| GSK2118436 75 mg | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01738451 |
| GSK1120212B (Lower DMSO content) | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01725100 |
| GSK1120212B (Standard DMSO content) | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01725100 |
| GSK1120212 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01658553 |
| Telaprevir | Other | Phase PHASE1 | Thrombocytopaenia | COMPLETED | NCT01657552 |
| Boceprevir | Other | Phase PHASE1 | Thrombocytopaenia | COMPLETED | NCT01657552 |
| Eltrombopag | Other | Phase PHASE1 | Thrombocytopaenia | COMPLETED | NCT01657552 |
| Trametinib pediatric formulation | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01647659 |
| Trametinib tablet | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01647659 |
| Trametinib pediatric formulation | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01647659 |
| Trametinib tablet | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01647659 |
| GSK2118436 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01582997 |
| GSK2118436 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01582997 |
| GSK2110183 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01476137 |
| GSK1120212 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01476137 |
| GSK2110183 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01476137 |
| GSK1120212 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01476137 |
| saline | Other | Phase PHASE1 | Nausea and Vomiting, Chemotherapy-Induced | COMPLETED | NCT01449188 |
| moxifloxacin | Other | Phase PHASE1 | Nausea and Vomiting, Chemotherapy-Induced | COMPLETED | NCT01449188 |
| ondansetron | Other | Phase PHASE1 | Nausea and Vomiting, Chemotherapy-Induced | COMPLETED | NCT01449188 |
| Gemcitabine | Other | Phase PHASE1 | Leukaemia, Myelocytic, Acute | COMPLETED | NCT01428427 |
| GSK1120212 | Other | Phase PHASE1 | Leukaemia, Myelocytic, Acute | COMPLETED | NCT01428427 |
| Placebo | Other | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT00903201 |
| SB656933 | Other | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT00903201 |
| PLACEBO | Other | Phase PHASE2 | Ischaemic Attack, Transient | COMPLETED | NCT00833989 |
| GSK249320 | Other | Phase PHASE2 | Ischaemic Attack, Transient | COMPLETED | NCT00833989 |
| Vehicle cream | Other | Phase PHASE3 | Psoriasis | WITHDRAWN | NCT03202004 |
| GSK2894512 1% cream | Other | Phase PHASE3 | Psoriasis | WITHDRAWN | NCT03202004 |
| MAXCLARITY II (0.5% Salicylic Acid) Toner Foam | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT01706263 |
| MAXCLARITY II (2.5% BPO) Foam Treatment | Drug | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT01706263 |
| MAXCLARITY II (2.5% BPO) Foam Cleanser | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT01706263 |
| Cobicistat | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02277600 |
| Darunavir | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02277600 |
| BMS-663068 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02277600 |
| Rabipur | Other | Phase PHASE2 | Malaria | COMPLETED | NCT00360230 |
| GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049 | Other | Phase PHASE2 | Malaria | COMPLETED | NCT00360230 |
| GW685698X | Other | Phase PHASE3 | Rhinitis, Vasomotor | COMPLETED | NCT00117325 |
| Glycopyrronium | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02236611 |
| Umeclidinium | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02236611 |
| Glycopyrronium | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02236611 |
| Umeclidinium | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02236611 |
| Oral BMS-663068 (pro-drug) | Drug | Phase PHASE1 | HIV Infections | COMPLETED | NCT02674581 |
| Oral BMS-663068 (pro-drug) | Drug | Phase PHASE1 | HIV Infections | COMPLETED | NCT02674581 |
| Placebo | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT01767467 |
| Herpes zoster vaccine (GSK 1437173A) | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT01767467 |
| Placebo | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT01767467 |
| Herpes zoster vaccine (GSK 1437173A) | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT01767467 |
| Boostrix | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT01738477 |
| non-drug intervention educational programme | Drug | Preclinical | Cancer | COMPLETED | NCT01462604 |
| Ropinirole | Other | Phase PHASE1 | Parkinson Disease | COMPLETED | NCT01435915 |
| Ropinirole | Other | Phase PHASE1 | Parkinson Disease | COMPLETED | NCT01435915 |
| Ropinirole XL | Other | Phase PHASE1 | Parkinson Disease | COMPLETED | NCT01371682 |
| Cervarix™ | Other | Phase PHASE2 | Infections, Papillomavirus | COMPLETED | NCT00546078 |
| Infanrix™ | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT01000974 |
| Engerix™-B | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT01000974 |
| Rotarix™ | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT01000974 |
| Prevnar 13™ | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT01000974 |
| Pediarix™ | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT01000974 |
| Pentacel™ | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT01000974 |
| ActHIB™ | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT01000974 |
| GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108) | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT01000974 |
| GSK Biological's HPV vaccine GSK580299 (Cervarix™) | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00799825 |
| GSK Biological's HPV vaccine GSK580299 (Cervarix™) | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00799825 |
| Boostrix TM | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00369824 |
| Menactra TM | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00369824 |
| Different formulations of GSK Biologicals' HPV vaccine (580299) | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00369824 |
| HPV-16/18 L1 VLP AS04 (Cervarix TM) | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00345878 |
| Placebo | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00345878 |
| GSK2636771 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01458067 |
| Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02301975 |
| Placebo inhalation powder via ACCUHALER/DISKUS inhaler | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02301975 |
| Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02301975 |
| Placebo inhalation powders via ELLIPTA inhaler | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02301975 |
| Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02301975 |
| Salbutamol MDI | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02299375 |
| Placebo tablets | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02299375 |
| Losmapimod tablets | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02299375 |
| SOC | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02281318 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02281318 |
| Mepolizumab | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02281318 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02105961 |
| Mepolizumab | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02105961 |
| Fluarix™ | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00706563 |
| Vaqta | Other | Phase PHASE4 | Hepatitis A | COMPLETED | NCT00684671 |
| HBVAXPRO | Other | Phase PHASE4 | Hepatitis A | COMPLETED | NCT00684671 |
| Havrix | Other | Phase PHASE4 | Hepatitis A | COMPLETED | NCT00684671 |
| Engerix-B | Other | Phase PHASE4 | Hepatitis A | COMPLETED | NCT00684671 |
| Twinrix | Other | Phase PHASE4 | Hepatitis A | COMPLETED | NCT00684671 |
| Sodium monofluorophosphate | Other | Approved | Dentin Sensitivity | COMPLETED | NCT02924350 |
| Stannous fluoride | Other | Approved | Dentin Sensitivity | COMPLETED | NCT02924350 |
| CLDM 1% gel | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT02557399 |
| ADA 0.1% gel | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT02557399 |
| Duac® fixed dose combination gel | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT02557399 |
| Intravenous Docetaxel | Other | Phase PHASE2 | Mediastinal Neoplasms | TERMINATED | NCT00315211 |
| Intravenous Topotecan | Other | Phase PHASE2 | Mediastinal Neoplasms | TERMINATED | NCT00315211 |
| Current formulation | Other | Phase PHASE1 | Herpes Labialis | COMPLETED | NCT00711776 |
| New formulation | Other | Phase PHASE1 | Herpes Labialis | COMPLETED | NCT00711776 |
| Current formulation | Other | Phase PHASE1 | Herpes Labialis | COMPLETED | NCT00711776 |
| New formulation | Other | Phase PHASE1 | Herpes Labialis | COMPLETED | NCT00711776 |
| Fluviral® | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01626820 |
| TDF/FTC | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | TERMINATED | NCT02415595 |
| EFV | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | TERMINATED | NCT02415595 |
| BMS-955176 | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | TERMINATED | NCT02415595 |
| Influenza vaccine GSK2604409A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01204671 |
| FluarixTM | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01204671 |
| Influenza vaccine GSK2321138A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01204671 |
| Havrix™ Junior | Other | Phase PHASE4 | Influenza | COMPLETED | NCT01196026 |
| Fluarix™ | Other | Phase PHASE4 | Influenza | COMPLETED | NCT01196026 |
| Fluarix | Other | Phase PHASE1 | Influenza | COMPLETED | NCT01096056 |
| Influenza vaccine GSK2186877A formulation 2 | Other | Phase PHASE1 | Influenza | COMPLETED | NCT01096056 |
| Influenza vaccine GSK2186877A formulation 1 | Other | Phase PHASE1 | Influenza | COMPLETED | NCT01096056 |
| Placebo | Other | Phase PHASE3 | Alopecia | COMPLETED | NCT02014584 |
| Dutasteride | Other | Phase PHASE3 | Alopecia | COMPLETED | NCT02014584 |
| GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A | Other | Phase PHASE1 | Leukaemia, Myelocytic, Acute | COMPLETED | NCT01051063 |
| GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A | Other | Phase PHASE1 | Leukaemia, Myelocytic, Acute | COMPLETED | NCT01051063 |
| Pneumococcal vaccine GSK1024850A | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00985465 |
| Sorafenib | Other | Phase PHASE1 | Carcinoma, Hepatocellular | COMPLETED | NCT01258608 |
| Placebo | Other | Phase PHASE1 | Carcinoma, Hepatocellular | COMPLETED | NCT01258608 |
| Mapatumumab | Other | Phase PHASE1 | Carcinoma, Hepatocellular | COMPLETED | NCT01258608 |
| Sorafenib | Other | Phase PHASE1 | Carcinoma, Hepatocellular | COMPLETED | NCT01258608 |
| Placebo | Other | Phase PHASE1 | Carcinoma, Hepatocellular | COMPLETED | NCT01258608 |
| Mapatumumab | Other | Phase PHASE1 | Carcinoma, Hepatocellular | COMPLETED | NCT01258608 |
| Placebo | Other | Phase PHASE3 | Tobacco Dependence | COMPLETED | NCT02355665 |
| Nicotine Spray | Other | Phase PHASE3 | Tobacco Dependence | COMPLETED | NCT02355665 |
| Placebo | Other | Phase PHASE3 | Tobacco Dependence | COMPLETED | NCT02355665 |
| Nicotine Spray | Other | Phase PHASE3 | Tobacco Dependence | COMPLETED | NCT02355665 |
| Saline Solution Sodium Chloride | Other | Approved | Skin Care | COMPLETED | NCT03233009 |
| Experimental Daily Defense Serum N | Other | Approved | Skin Care | COMPLETED | NCT03233009 |
| Experimental Daily Defense Serum G | Other | Approved | Skin Care | COMPLETED | NCT03233009 |
| Experimental Daily Defense Serum C | Other | Approved | Skin Care | COMPLETED | NCT03233009 |
| Experimental Daily Defense Serum A | Other | Approved | Skin Care | COMPLETED | NCT03233009 |
| fluticasone propionate/salmeterol combination DISKUS | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00269087 |
| Prevenar | Other | Phase PHASE2 | Influenza | TERMINATED | NCT01003418 |
| Infanrix™-IPV/Hib | Other | Phase PHASE2 | Influenza | TERMINATED | NCT01003418 |
| GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine | Other | Phase PHASE2 | Influenza | TERMINATED | NCT01003418 |
| Advair 250 - matched | Other | Phase PHASE4 | COPD | COMPLETED | NCT00731770 |
| Placebo | Other | Phase PHASE4 | COPD | COMPLETED | NCT00731770 |
| Placebo- matched | Other | Phase PHASE4 | COPD | COMPLETED | NCT00731770 |
| Advair 250 | Other | Phase PHASE4 | COPD | COMPLETED | NCT00731770 |
| Non fortified beverage Powder | Other | Approved | Growth and Development | COMPLETED | NCT03155269 |
| Fortified Beverage Powder | Other | Approved | Growth and Development | COMPLETED | NCT03155269 |
| Infanrix Hexa (DTPa-HBV-IPV/Hib) | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT01204658 |
| Prevenar 13 | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT01204658 |
| Synflorix | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT01204658 |
| Pneumococcal vaccine GSK 2189242A (HD formulation 2) | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT01204658 |
| Pneumococcal vaccine GSK 2189242A (LD formulation 1) | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT01204658 |
| Collection of tumor and blood samples | Other | Approved | Lung Cancer, Non-Small Cell | TERMINATED | NCT00685750 |
| Folic acid | Other | Phase PHASE1 | Arthritis, Rheumatoid | COMPLETED | NCT03028467 |
| Placebo | Other | Phase PHASE1 | Arthritis, Rheumatoid | COMPLETED | NCT03028467 |
| Methotrexate | Other | Phase PHASE1 | Arthritis, Rheumatoid | COMPLETED | NCT03028467 |
| GSK3196165 Dose 3 | Other | Phase PHASE1 | Arthritis, Rheumatoid | COMPLETED | NCT03028467 |
| GSK3196165 Dose 2 | Other | Phase PHASE1 | Arthritis, Rheumatoid | COMPLETED | NCT03028467 |
| GSK3196165 Dose 1 | Other | Phase PHASE1 | Arthritis, Rheumatoid | COMPLETED | NCT03028467 |
| 1) basiliximab 2) mycophenolate mofetil (MMF) OR azathioprine 3) tacrolimus 4) corticosteroids | Other | Phase PHASE2 | Kidney Transplantation (Status Post) | TERMINATED | NCT02723786 |
| GSK1070806 | Other | Phase PHASE2 | Kidney Transplantation (Status Post) | TERMINATED | NCT02723786 |
| Data collection | Other | Preclinical | Hepatitis A | COMPLETED | NCT02112890 |
| Data collection | Other | Preclinical | Hepatitis A | COMPLETED | NCT02112890 |
| Prevnar13 | Other | Phase PHASE4 | Acellular Pertussis | COMPLETED | NCT02422264 |
| Infanrix hexa | Other | Phase PHASE4 | Acellular Pertussis | COMPLETED | NCT02422264 |
| Albuterol/salbutamol | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02729051 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02729051 |
| UMEC | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02729051 |
| FF/VI | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02729051 |
| FF/UMEC/VI | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02729051 |
| Albuterol/salbutamol | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02729051 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02729051 |
| UMEC | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02729051 |
| FF/VI | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02729051 |
| FF/UMEC/VI | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02729051 |
| Conventional dolutegravir 25 mg tablet | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT03095638 |
| Dispersible dolutegravir 5 mg tablet | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT03095638 |
| Conventional dolutegravir 50 mg tablet | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT03095638 |
| Conventional dolutegravir 10 mg tablet | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT03095638 |
| Saline Solution | Other | Phase PHASE1 | Arthritis, Rheumatoid | COMPLETED | NCT03306589 |
| Granulocyte-Macrophage Colony-Stimulating Factor | Other | Phase PHASE1 | Arthritis, Rheumatoid | COMPLETED | NCT03306589 |
| Lipopolysaccharide | Other | Phase PHASE1 | Arthritis, Rheumatoid | COMPLETED | NCT03306589 |
| Cantharidin | Other | Phase PHASE1 | Arthritis, Rheumatoid | COMPLETED | NCT03306589 |
| Placebo | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT01725139 |
| GSK2126458 | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT01725139 |
| Placebo | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT01725139 |
| GSK2126458 | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT01725139 |
| Decitabine | Other | Phase PHASE2 | Leukemia | TERMINATED | NCT02010645 |
| Eltrombopag | Other | Phase PHASE2 | Leukemia | TERMINATED | NCT02010645 |
| No Adhesive | Other | Phase PHASE4 | Denture Retention | COMPLETED | NCT03709810 |
| Marketed Denture Adhesive (Super Poligrip Max Seal) | Other | Phase PHASE4 | Denture Retention | COMPLETED | NCT03709810 |
| Mechanical ventilation | Other | Approved | Acute Lung Injury | TERMINATED | NCT03212690 |
| Local standard of care | Other | Approved | Acute Lung Injury | TERMINATED | NCT03212690 |
| ACQ-7 | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03184987 |
| Salbutamol | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03184987 |
| FF/UMEC/VI 200/62.5/25 mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03184987 |
| FF/UMEC/VI 100/62.5/25 mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03184987 |
| Matching Placebo | Other | Phase PHASE2 | Cachexia | COMPLETED | NCT03359473 |
| GSK2881078 | Other | Phase PHASE2 | Cachexia | COMPLETED | NCT03359473 |
| Pazopanib | Other | Phase PHASE2 | Advanced and / or Metastatic Liposarcoma | COMPLETED | NCT01692496 |
| Placebo matching atosiban | Other | Phase PHASE3 | Obstetric Labour, Premature | TERMINATED | NCT02292771 |
| Placebo matching retosiban | Other | Phase PHASE3 | Obstetric Labour, Premature | TERMINATED | NCT02292771 |
| Atosiban | Other | Phase PHASE3 | Obstetric Labour, Premature | TERMINATED | NCT02292771 |
| Retosiban | Other | Phase PHASE3 | Obstetric Labour, Premature | TERMINATED | NCT02292771 |
| Ambrisentan | Other | Preclinical | Hypertension, Pulmonary | COMPLETED | NCT01406327 |
| Ambrisentan | Other | Preclinical | Hypertension, Pulmonary | COMPLETED | NCT01406327 |
| Placebo | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT04079790 |
| Gepotidacin | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT04079790 |
| Placebo | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT03020745 |
| GSK3389404 | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT03020745 |
| Blood sampling | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT03368053 |
| HandiHaler | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03478683 |
| MDI | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03478683 |
| ELLIPTA | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03478683 |
| placebo to match tiotropium | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03478683 |
| Placebo to match FF/UMEC/VI | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03478683 |
| tiotropium | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03478683 |
| Placebo to match budesonide/formoterol | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03478683 |
| FF/UMEC/VI | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03478683 |
| albuterol/salbutamol | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03478683 |
| budesonide/formoterol | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03478683 |
| EFV 600 mg | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02178592 |
| DTG 50 mg | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02178592 |
| MenACWY | Other | Phase PHASE2 | Meningitis, Meningococcal | COMPLETED | NCT03433482 |
| MenACWY liquid | Other | Phase PHASE2 | Meningitis, Meningococcal | COMPLETED | NCT03433482 |
| Dostarlimab | Other | Phase PHASE2 | Stage I Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04584255 |
| Niraparib | Other | Phase PHASE2 | Stage I Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04584255 |
| Hypofractionated IMRT | Other | Phase PHASE2 | Endometrial Cancer | RECRUITING | NCT04774419 |
| Dostarlimab | Other | Phase PHASE2 | Endometrial Cancer | RECRUITING | NCT04774419 |
| Intensity modulated radiation therapy (IMRT) | Drug | Phase PHASE2 | Endometrial Cancer | RECRUITING | NCT04774419 |
| Bepirovirsen | Other | Phase PHASE1 | Hepatitis B | TERMINATED | NCT05330455 |
| Placebo to match GSK3965193 | Other | Phase PHASE1 | Hepatitis B | TERMINATED | NCT05330455 |
| GSK3965193 | Other | Phase PHASE1 | Hepatitis B | TERMINATED | NCT05330455 |
| Belantamab mafodotin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05002816 |
| Elotuzumab | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05002816 |
| Intensity Modulated Radiation Therapy (IMRT) | Drug | Phase PHASE2 | Rectal Adenocarcinoma | RECRUITING | NCT04165772 |
| capecitabine or 5-FU | Other | Phase PHASE2 | Rectal Adenocarcinoma | RECRUITING | NCT04165772 |
| TSR-042 or Dostarlimab | Other | Phase PHASE2 | Rectal Adenocarcinoma | RECRUITING | NCT04165772 |
| Imatinib | Other | Phase PHASE3 | Gastrointestinal Stromal Neoplasms | NOT_YET_RECRUITING | NCT07585266 |
| Velzatinib | Other | Phase PHASE3 | Gastrointestinal Stromal Neoplasms | NOT_YET_RECRUITING | NCT07585266 |
| abacavir /3TC plus ritonavir boosted lopinavir | Other | Phase PHASE2 | AIDS-related Kaposi's Sarcoma | COMPLETED | NCT00834457 |
| abacavir/3TC/zidovudine | Other | Phase PHASE2 | AIDS-related Kaposi's Sarcoma | COMPLETED | NCT00834457 |
| abacavir /3TC plus ritonavir boosted lopinavir | Other | Phase PHASE2 | AIDS-related Kaposi's Sarcoma | COMPLETED | NCT00834457 |
| abacavir/3TC/zidovudine | Other | Phase PHASE2 | AIDS-related Kaposi's Sarcoma | COMPLETED | NCT00834457 |
| placebo | Other | Preclinical | Coronary Heart Disease | COMPLETED | NCT01636271 |
| darapladib | Other | Preclinical | Coronary Heart Disease | COMPLETED | NCT01636271 |
| Sumatriptan-naproxen combination | Other | Preclinical | Migraine Disorders | COMPLETED | NCT01059604 |
| Naratriptan | Other | Preclinical | Migraine Disorders | COMPLETED | NCT01059604 |
| Sumatriptan | Other | Preclinical | Migraine Disorders | COMPLETED | NCT01059604 |
| Salbutamol | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT01457261 |
| Salbutamol | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT01457261 |
| Carvedilol and Placebo | Other | Approved | Vascular Disease | TERMINATED | NCT00638222 |
| Carvedilol and Placebo | Other | Approved | Vascular Disease | TERMINATED | NCT00638222 |
| Metoprolol | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT00123604 |
| Carvedilol | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT00123604 |
| Maraviroc | Other | Phase PHASE4 | Human Immunodeficiency Virus | COMPLETED | NCT01866267 |
| Pazopanib (GW786034) | Other | Phase PHASE2 | Lung Cancer, Non-Small Cell | TERMINATED | NCT00549328 |
| Lapatinib and Capecitabine and Vinorelbine | Other | Phase PHASE1 | Metastatic Breast Cancer | TERMINATED | NCT01238029 |
| Zanamivir | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00784784 |
| Fluviral | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00784784 |
| Experimental paracetamol formulation | Other | Phase PHASE1 | Pain | COMPLETED | NCT01592227 |
| Marketed paracetamol | Other | Phase PHASE1 | Pain | COMPLETED | NCT01592227 |
| Experimental paracetamol formulation | Other | Phase PHASE1 | Pain | COMPLETED | NCT01592227 |
| Marketed paracetamol | Other | Phase PHASE1 | Pain | COMPLETED | NCT01592227 |
| Paracetamol formulation 4 | Other | Phase PHASE1 | Analgesia | COMPLETED | NCT01568749 |
| Paracetamol formulation 3 | Other | Phase PHASE1 | Analgesia | COMPLETED | NCT01568749 |
| Paracetamol Formulation 2 | Other | Phase PHASE1 | Analgesia | COMPLETED | NCT01568749 |
| Paracetamol formulation 1 | Other | Phase PHASE1 | Analgesia | COMPLETED | NCT01568749 |
| Paracetamol | Other | Phase PHASE1 | Analgesia | COMPLETED | NCT01568749 |
| Paracetamol formulation 4 | Other | Phase PHASE1 | Analgesia | COMPLETED | NCT01568749 |
| Paracetamol formulation 3 | Other | Phase PHASE1 | Analgesia | COMPLETED | NCT01568749 |
| Paracetamol Formulation 2 | Other | Phase PHASE1 | Analgesia | COMPLETED | NCT01568749 |
| Paracetamol formulation 1 | Other | Phase PHASE1 | Analgesia | COMPLETED | NCT01568749 |
| Paracetamol | Other | Phase PHASE1 | Analgesia | COMPLETED | NCT01568749 |
| Experimental paracetamol formulation | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01540721 |
| Marketed paracetamol | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01540721 |
| Experimental paracetamol formulation | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01540721 |
| Marketed paracetamol | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01540721 |
| Experimental paracetamol formulation | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01540721 |
| Marketed paracetamol | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01540721 |
| Paracetamol | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01476215 |
| Paracetamol slow dissolution suspension | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01476215 |
| Paracetamol medium dissolution suspension | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01476215 |
| Paracetamol fast dissolution suspension | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01476215 |
| Higher dose marketed paracetamol | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01476189 |
| Marketed paracetamol | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01476189 |
| Experimental paracetamol formulation | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01476189 |
| Paracetamol marketed formulation | Other | Phase PHASE1 | Headache, Tension-Type | COMPLETED | NCT01476176 |
| Experimental paracetamol | Other | Phase PHASE1 | Headache, Tension-Type | COMPLETED | NCT01476176 |
| 4 mg nicotine prototype | Other | Phase PHASE1 | Healthy Volunteer Smokers | COMPLETED | NCT00651352 |
| 2 mg nicotine prototype | Other | Phase PHASE1 | Healthy Volunteer Smokers | COMPLETED | NCT00651352 |
| 2 mg nicotine lozenge | Other | Phase PHASE1 | Healthy Volunteer Smokers | COMPLETED | NCT00651352 |
| 4 mg nicotine lozenge | Other | Phase PHASE1 | Healthy Volunteer Smokers | COMPLETED | NCT00651352 |
| Blood sampling | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT00715910 |
| Nimenrix | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT00715910 |
| Data collection | Other | Preclinical | Infections, Papillomavirus | COMPLETED | NCT01153906 |
| paracetamol | Other | Phase PHASE3 | Common Cold | COMPLETED | NCT01686646 |
| paracetamol + caffeine | Other | Phase PHASE3 | Common Cold | COMPLETED | NCT01686646 |
| Seretide 500 Accuhaler | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT00974805 |
| Antibiotic prescription during the study period between January 1, 2004 and December 31, 2009 | Other | Preclinical | Infections, Bacterial | COMPLETED | NCT01587768 |
| corn oil | Other | Approved | Sarcopenia | COMPLETED | NCT01308957 |
| Omega-3 fatty acids | Other | Approved | Sarcopenia | COMPLETED | NCT01308957 |
| Placebo | Other | Phase PHASE1 | Nutritional Status | COMPLETED | NCT02094781 |
| Whey protein only supplement | Other | Phase PHASE1 | Nutritional Status | COMPLETED | NCT02094781 |
| Whey protein and creatine supplement | Other | Phase PHASE1 | Nutritional Status | COMPLETED | NCT02094781 |
| lapatinib + capecitabine | Other | Phase PHASE2 | Metastatic Breast Cancer | COMPLETED | NCT01262469 |
| CCB use | Other | Preclinical | Hypertension | COMPLETED | NCT01587742 |
| GSK2248761 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus I | WITHDRAWN | NCT01283100 |
| GSK1349572 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus I | WITHDRAWN | NCT01283100 |
| Intralipid 20% | Other | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT00738023 |
| Normal saline 0.9% | Other | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT00738023 |
| Rosiglitazone | Other | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT00738023 |
| Lamotrigine novel formulation | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00621842 |
| Lamotrigine regular tablet formulation | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00621842 |
| Sterile water | Other | Phase PHASE2 | Tooth Erosion | COMPLETED | NCT01128972 |
| Sodium monoflurophosphate | Other | Phase PHASE2 | Tooth Erosion | COMPLETED | NCT01128972 |
| Sodium fluoride | Other | Phase PHASE2 | Tooth Erosion | COMPLETED | NCT01128972 |
| NaMFP | Other | Phase PHASE4 | Dental Caries | COMPLETED | NCT01128946 |
| SnF | Other | Phase PHASE4 | Dental Caries | COMPLETED | NCT01128946 |
| NaF | Other | Phase PHASE4 | Dental Caries | COMPLETED | NCT01128946 |
| Placebo | Other | Phase PHASE3 | Dental Caries | COMPLETED | NCT00708305 |
| Sodium Fluoride (NaF) | Other | Phase PHASE3 | Dental Caries | COMPLETED | NCT00708305 |
| NaMFP | Other | Phase PHASE3 | Caries | COMPLETED | NCT00708097 |
| Placebo | Other | Phase PHASE3 | Caries | COMPLETED | NCT00708097 |
| NaF | Other | Phase PHASE3 | Caries | COMPLETED | NCT00708097 |
| Placebo | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT01001767 |
| Lovaza | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT01001767 |
| nelarabine | Other | Preclinical | Leukaemia, Lymphoblastic, Acute | COMPLETED | NCT00866671 |
| Trobalt™ | Other | Preclinical | Epilepsy | COMPLETED | NCT01721213 |
| nicotine | Other | Phase PHASE2 | Smoking Cessation | COMPLETED | NCT01669122 |
| nicotine | Other | Phase PHASE2 | Smoking Cessation | COMPLETED | NCT01669122 |
| Vinorelbine | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT00151086 |
| Estramustine | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT00151086 |
| Cervarix® | Other | Preclinical | Infections, Papillomavirus | COMPLETED | NCT01187927 |
| Cervarix® | Other | Preclinical | Infections, Papillomavirus | COMPLETED | NCT01187927 |
| Sterile water | Other | Phase PHASE2 | Dentine Hypersensitivity | COMPLETED | NCT01115452 |
| 2.5% Potassium nitrate | Other | Phase PHASE2 | Dentine Hypersensitivity | COMPLETED | NCT01115452 |
| 5% Potassium nitrate | Other | Phase PHASE2 | Dentine Hypersensitivity | COMPLETED | NCT01115452 |
| EE/NE Placebo | Other | Phase PHASE1 | Infections, Bacterial | WITHDRAWN | NCT01953809 |
| GSK1322322 Placebo | Other | Phase PHASE1 | Infections, Bacterial | WITHDRAWN | NCT01953809 |
| EE/NE | Other | Phase PHASE1 | Infections, Bacterial | WITHDRAWN | NCT01953809 |
| GSK1322322 | Other | Phase PHASE1 | Infections, Bacterial | WITHDRAWN | NCT01953809 |
| Moxifloxacin | Other | Phase PHASE1 | Infections, Bacterial | WITHDRAWN | NCT01803399 |
| Placebo | Other | Phase PHASE1 | Infections, Bacterial | WITHDRAWN | NCT01803399 |
| GSK1322322 3000 mg | Other | Phase PHASE1 | Infections, Bacterial | WITHDRAWN | NCT01803399 |
| GSK1322322 1200 mg | Other | Phase PHASE1 | Infections, Bacterial | WITHDRAWN | NCT01803399 |
| BCG | Other | Phase PHASE1 | Bladder Cancer | COMPLETED | NCT01498172 |
| MAGE-A3 ASCI | Other | Phase PHASE1 | Bladder Cancer | COMPLETED | NCT01498172 |
| Placebo to Match ROTACAPS | Other | Phase PHASE1 | Asthma | WITHDRAWN | NCT02218762 |
| Fluticasone Propionate/Salmeterol Xinafoate ROTACAPS | Other | Phase PHASE1 | Asthma | WITHDRAWN | NCT02218762 |
| Placebo to Match DISKUS | Other | Phase PHASE1 | Asthma | WITHDRAWN | NCT02218762 |
| Fluticasone Propionate/Salmeterol Xinafoate DISKUS | Other | Phase PHASE1 | Asthma | WITHDRAWN | NCT02218762 |
| Negative control | Other | Approved | Skin Care | COMPLETED | NCT02106403 |
| Reference product | Other | Approved | Skin Care | COMPLETED | NCT02106403 |
| Prototype disinfectant spray formulation | Other | Approved | Skin Care | COMPLETED | NCT02106403 |
| Negative control | Other | Approved | Skin Care | COMPLETED | NCT02106403 |
| Reference product | Other | Approved | Skin Care | COMPLETED | NCT02106403 |
| Prototype disinfectant spray formulation | Other | Approved | Skin Care | COMPLETED | NCT02106403 |
| GW842166X | Other | Phase PHASE1 | Healthy Subjects | WITHDRAWN | NCT00554762 |
| GW842166X | Other | Phase PHASE1 | Healthy Subjects | WITHDRAWN | NCT00536497 |
| lapatinib | Other | Phase PHASE1 | Healthy Subjects | WITHDRAWN | NCT00513253 |
| SB797620 | Other | Phase PHASE1 | Healthy Subjects | WITHDRAWN | NCT00549263 |
| fluticasone propionate/salmeterol 250/50mcg combination, salmeterol 50mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | WITHDRAWN | NCT00411372 |
| Dolutegravir | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01499199 |
| Dolutegravir | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01499199 |
| Dolutegravir | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01499199 |
| Placebo | Other | Phase PHASE4 | Smoking | COMPLETED | NCT00657020 |
| Nicotine | Other | Phase PHASE4 | Smoking | COMPLETED | NCT00657020 |
| GW876008 and GSK561679 | Other | Phase PHASE2 | Irritable Bowel Syndrome | WITHDRAWN | NCT00511563 |
| GW876008 and GSK561679 | Other | Phase PHASE2 | Irritable Bowel Syndrome | WITHDRAWN | NCT00511563 |
| Chlorhexidine digluconate | Other | Phase PHASE4 | Oral Hygiene | COMPLETED | NCT01962493 |
| Sodium fluoride | Other | Phase PHASE4 | Oral Hygiene | COMPLETED | NCT01962493 |
| Sodium bicarbonate/ Sodium Fluoride | Other | Phase PHASE4 | Oral Hygiene | COMPLETED | NCT01962493 |
| Placebo comparator | Other | Phase PHASE2 | Neoplasms, Ovarian | COMPLETED | NCT01227928 |
| Pazopanib | Other | Phase PHASE2 | Neoplasms, Ovarian | COMPLETED | NCT01227928 |
| Placebo comparator | Other | Phase PHASE2 | Neoplasms, Ovarian | COMPLETED | NCT01227928 |
| Pazopanib | Other | Phase PHASE2 | Neoplasms, Ovarian | COMPLETED | NCT01227928 |
| Stool sample collection | Other | Preclinical | Infections, Rotavirus | WITHDRAWN | NCT01978223 |
| Data collection | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT01435967 |
| New users of FLOVENT DISKUS, FLVENT HFA (long-acting bronchodilators (LABD)) | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01763463 |
| New users of ADVAIR DISKUS, ADVAIR HFA (ICS) - containing medications | Drug | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01763463 |
| Eltrombopag olamine | Other | Phase PHASE4 | Purpura, Thrombocytopaenic, Idiopathic | COMPLETED | NCT01098487 |
| Xylitol | Other | Phase PHASE1 | Xerostomia | COMPLETED | NCT01647737 |
| MighTeaFlow | Other | Phase PHASE1 | Xerostomia | COMPLETED | NCT01647737 |
| Fondaparinux | Other | Phase PHASE1 | Ovarian Carcinoma | WITHDRAWN | NCT00659399 |
| nicotine | Other | Phase PHASE1 | Smoking | COMPLETED | NCT01702519 |
| nicotine | Other | Phase PHASE1 | Smoking | COMPLETED | NCT01702519 |
| Placebo | Other | Phase PHASE3 | Influenza | WITHDRAWN | NCT00866580 |
| FluarixTM | Other | Phase PHASE3 | Influenza | WITHDRAWN | NCT00866580 |
| GSK's candidate influenza vaccine 1562902A | Other | Phase PHASE3 | Influenza | WITHDRAWN | NCT00866580 |
| Sodium Fluoride dentifrice | Other | Phase PHASE2 | Dentinal Hypersensitivity | COMPLETED | NCT01831817 |
| Sodium monofluorophosphate dentifrice | Other | Phase PHASE2 | Dentinal Hypersensitivity | COMPLETED | NCT01831817 |
| 0% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice | Other | Phase PHASE2 | Dentinal Hypersensitivity | COMPLETED | NCT01831817 |
| 5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice | Other | Phase PHASE2 | Dentinal Hypersensitivity | COMPLETED | NCT01831817 |
| Paracetamol marketed formulation | Other | Phase PHASE2 | Headache, Tension-Type | TERMINATED | NCT01755702 |
| ibuprofen marketed formulation | Other | Phase PHASE2 | Headache, Tension-Type | TERMINATED | NCT01755702 |
| Experimental paracetamol + caffeine formulation | Other | Phase PHASE2 | Headache, Tension-Type | TERMINATED | NCT01755702 |
| Placebo | Other | Phase PHASE2 | Headache, Tension-Type | TERMINATED | NCT01755702 |
| Fondaparinux | Other | Preclinical | Thrombosis, Venous | COMPLETED | NCT01691495 |
| Inhaled LABA use | Other | Preclinical | Asthma | COMPLETED | NCT01636726 |
| Lamotrigine use | Other | Preclinical | Epilepsy | COMPLETED | NCT01607333 |
| Tricyclic AD (TCAs) and selective serotonin re-uptake inhibitors (SSRIs) antidepressants | Other | Preclinical | Depression, Postpartum | COMPLETED | NCT01587729 |
| Other anti-VEGFs | Other | Preclinical | Carcinoma, Renal Cell | COMPLETED | NCT01446224 |
| Pazopanib | Other | Preclinical | Carcinoma, Renal Cell | COMPLETED | NCT01446224 |
| Fluticasone | Other | Preclinical | Rhinitis | COMPLETED | NCT01420822 |
| Botulinum Toxin Type A | Other | Preclinical | Mumps | COMPLETED | NCT01390922 |
| Botulinum Toxin Type A | Other | Preclinical | Mumps | COMPLETED | NCT01390922 |
| Fondaparinux Sodium | Other | Preclinical | Cardiovascular Disease | COMPLETED | NCT01390883 |
| Fondaparinux Sodium | Other | Preclinical | Cardiovascular Disease | COMPLETED | NCT01390883 |
| Data collection | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT01592838 |
| Serum sample | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT02153333 |
| Data collection | Other | Preclinical | Infections, Papillomavirus | COMPLETED | NCT01498627 |
| Cervarix | Other | Preclinical | Infections, Papillomavirus | COMPLETED | NCT01498627 |
| Data collection | Other | Preclinical | Infections, Papillomavirus | COMPLETED | NCT01498627 |
| Cervarix | Other | Preclinical | Infections, Papillomavirus | COMPLETED | NCT01498627 |
| Health economics questionnaire | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT01253967 |
| Collection of stool samples | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT01253967 |
| Middle ear fluid and urine. | Other | Preclinical | Infections, Streptococcal | WITHDRAWN | NCT01160055 |
| Tympanocenthesis and urine collection | Other | Preclinical | Infections, Streptococcal | WITHDRAWN | NCT01031329 |
| talnetant | Other | Phase PHASE2 | Irritable Colon | COMPLETED | NCT00101985 |
| 683699 | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00101946 |
| 683699 | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00101946 |
| SB683699 | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00097331 |
| Valaciclovir Hydrochloride | Other | Phase PHASE4 | Virus Diseases | COMPLETED | NCT00343278 |
| metoprolol | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT00060931 |
| carvedilol | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT00060931 |
| Lapatanib | Other | Preclinical | Cancer | COMPLETED | NCT01462552 |
| Fluviral 2010/11 Tri-valent Seasonal Influenza vaccine | Other | Phase PHASE2 | Influenza | COMPLETED | NCT01140009 |
| Topotecan | Other | Preclinical | Lung Cancer, Small Cell | COMPLETED | NCT01037023 |
| Topotecan | Other | Preclinical | Lung Cancer, Small Cell | COMPLETED | NCT01037023 |
| Arepanrix | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT01002040 |
| Placebo | Other | Phase PHASE2 | Bladder Cancer | UNKNOWN | NCT00949455 |
| lapatinib ditosylate | Other | Phase PHASE2 | Bladder Cancer | UNKNOWN | NCT00949455 |
| Placebo | Other | Phase PHASE2 | Bladder Cancer | UNKNOWN | NCT00949455 |
| lapatinib ditosylate | Other | Phase PHASE2 | Bladder Cancer | UNKNOWN | NCT00949455 |
| solabegron and oxybutynin | Other | Phase PHASE1 | Overactive Bladder | COMPLETED | NCT00501267 |
| Rilapladib (SB-659032) | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT00387257 |
| GW869682 oral tablets | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00291356 |
| GSK189075 oral tablets | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00291356 |
| valaciclovir HCl granules | Other | Phase PHASE3 | Varicella | COMPLETED | NCT00169416 |
| Investigational Cancer Drug | Drug | Phase PHASE2 | Metastatic Breast Cancer | COMPLETED | NCT00051103 |
| atorvastatin | Other | Preclinical | Atherosclerotic Carotid Disease | COMPLETED | NCT00368589 |
| GW679769 | Other | Phase PHASE2 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00354809 |
| GW679769 | Other | Phase PHASE2 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00280436 |
| GW679769 | Other | Phase PHASE2 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00280436 |
| GW679769 | Other | Preclinical | Depressive Disorder | COMPLETED | NCT00264628 |
| GW679769 | Other | Preclinical | Depressive Disorder | COMPLETED | NCT00264628 |
| placebo | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT00240630 |
| sumatriptan succinate/naproxen sodium | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT00240630 |
| placebo | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT00240630 |
| sumatriptan succinate/naproxen sodium | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT00240630 |
| Ondansetron Hydrochloride | Other | Phase PHASE2 | Nausea and Vomiting, Chemotherapy-Induced | COMPLETED | NCT00104403 |
| Dexamethasone | Other | Phase PHASE2 | Nausea and Vomiting, Chemotherapy-Induced | COMPLETED | NCT00104403 |
| GW679769 | Other | Phase PHASE2 | Nausea and Vomiting, Chemotherapy-Induced | COMPLETED | NCT00104403 |
| GW679769 | Other | Phase PHASE2 | Depressive Disorder, Major | COMPLETED | NCT00102492 |
| Alosetron | Other | Phase PHASE3 | Irritable Colon | COMPLETED | NCT00067561 |
| alosetron | Other | Phase PHASE3 | Irritable Colon | COMPLETED | NCT00067457 |
| Radafaxine | Other | Phase PHASE2 | Depressive Disorder, Major | COMPLETED | NCT00057226 |
| Radafaxine | Other | Phase PHASE2 | Depressive Disorder, Major | COMPLETED | NCT00057213 |
| Radafaxine | Other | Phase PHASE2 | Depressive Disorder, Major | COMPLETED | NCT00057213 |
| Ondansetron | Other | Phase PHASE3 | Cancer | WITHDRAWN | NCT00891761 |
| IV casopitant (active) | Other | Phase PHASE3 | Cancer | WITHDRAWN | NCT00891761 |
| IV casopitant (placebo) | Other | Phase PHASE3 | Cancer | WITHDRAWN | NCT00891761 |
| Dexamethasone | Other | Phase PHASE3 | Cancer | WITHDRAWN | NCT00891761 |
| GSK690693 | Other | Phase PHASE1 | Cancer | WITHDRAWN | NCT00666081 |
| SB-649868 | Other | Phase PHASE1 | Insomnia | WITHDRAWN | NCT00534872 |
| SB-649868 | Other | Phase PHASE1 | Insomnia | WITHDRAWN | NCT00534872 |
| FLIXOTIDE and SERETIDE | Other | Phase PHASE4 | Asthma | WITHDRAWN | NCT00456313 |
| denagliptin (GW823093) | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | WITHDRAWN | NCT00387972 |
| GW679769 | Other | Phase PHASE2 | Incontinence, Urinary and Urinary Bladder, Overactive | TERMINATED | NCT00332319 |
| Iodine I 131 Tositumomab | Other | Phase PHASE3 | Lymphoma, Small Cleaved-Cell, Follicular | WITHDRAWN | NCT00319332 |
| Ibritumomab Tiuxetan | Other | Phase PHASE3 | Lymphoma, Small Cleaved-Cell, Follicular | WITHDRAWN | NCT00319332 |
| Cancer Registry of Norway (database) | Other | Preclinical | Infections, Papillomavirus | TERMINATED | NCT00924794 |
| Etanercept | Other | Phase PHASE4 | Plaque Psoriasis | WITHDRAWN | NCT00832364 |
| Placebo | Other | Phase PHASE4 | Plaque Psoriasis | WITHDRAWN | NCT00832364 |
| Acitretin (also called U0279) | Other | Phase PHASE4 | Plaque Psoriasis | WITHDRAWN | NCT00832364 |
| Etanercept | Other | Phase PHASE4 | Plaque Psoriasis | WITHDRAWN | NCT00832364 |
| Placebo | Other | Phase PHASE4 | Plaque Psoriasis | WITHDRAWN | NCT00832364 |
| Acitretin (also called U0279) | Other | Phase PHASE4 | Plaque Psoriasis | WITHDRAWN | NCT00832364 |
| HuMax-CD20 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | WITHDRAWN | NCT00093314 |
| HuMax-CD20 | Other | Phase PHASE1 | Lymphoma, Follicular | WITHDRAWN | NCT00092274 |
| Non-fortified isocaloric beverage powder | Other | Approved | Growth and Development | COMPLETED | NCT02345187 |
| Beverage powder fortified with Bacopa Monnieri Extract and Multiple Micronutrient supplementation | Other | Approved | Growth and Development | COMPLETED | NCT02345187 |
| fondaparinux | Other | Preclinical | Acute Coronary Syndrome | COMPLETED | NCT01406301 |
| Placebo | Other | Phase PHASE1 | Dentinal Hypersensitivity | COMPLETED | NCT01587950 |
| Potassium Nitrate | Other | Phase PHASE1 | Dentinal Hypersensitivity | COMPLETED | NCT01587950 |
| Placebo | Other | Phase PHASE4 | Post-surgical Dental Pain | COMPLETED | NCT01075243 |
| Paracetamol 650 mg | Other | Phase PHASE4 | Post-surgical Dental Pain | COMPLETED | NCT01075243 |
| Paracetamol 1000 mg | Other | Phase PHASE4 | Post-surgical Dental Pain | COMPLETED | NCT01075243 |
| risperidone | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT00103727 |
| placebo | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT00103727 |
| Talnetant | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT00103727 |
| Carbon Dioxide | Other | Phase PHASE2 | Nasal Congestion | COMPLETED | NCT02113449 |
| Fluoride (0 ppm) | Other | Approved | Oral Hygiene | COMPLETED | NCT02195583 |
| Sodium fluoride (1426 ppm) + zinc base B | Other | Approved | Oral Hygiene | COMPLETED | NCT02195583 |
| Sodium fluoride (1426 ppm) + zinc base A | Other | Approved | Oral Hygiene | COMPLETED | NCT02195583 |
| Sodium fluoride (250 ppm) | Other | Approved | Oral Hygiene | COMPLETED | NCT02195583 |
| Sodium fluoride (1150 ppm) | Other | Approved | Oral Hygiene | COMPLETED | NCT02195583 |
| Sodium fluoride (1426 ppm) | Other | Approved | Oral Hygiene | COMPLETED | NCT02195583 |
| Pre-randomization Dutasteride | Other | Phase PHASE4 | Benign Prostatic Hyperplasia (BPH) | COMPLETED | NCT00939120 |
| Placebo | Other | Phase PHASE4 | Benign Prostatic Hyperplasia (BPH) | COMPLETED | NCT00939120 |
| Tolterodine ER 4mg | Other | Phase PHASE4 | Benign Prostatic Hyperplasia (BPH) | COMPLETED | NCT00939120 |
| 323U66 SR | Other | Phase PHASE2 | Major Depressive Disorder (MDD) | COMPLETED | NCT00330616 |
| 323U66 SR | Other | Phase PHASE2 | Major Depressive Disorder (MDD) | COMPLETED | NCT00330616 |
| GW572016 (Lapatinib) | Other | Phase PHASE3 | Neoplasms, Breast | COMPLETED | NCT00075270 |
| Paclitaxel | Other | Phase PHASE3 | Neoplasms, Breast | COMPLETED | NCT00075270 |
| GW572016 (Lapatinib) | Other | Phase PHASE3 | Neoplasms, Breast | COMPLETED | NCT00075270 |
| Paclitaxel | Other | Phase PHASE3 | Neoplasms, Breast | COMPLETED | NCT00075270 |
| lapatinib (GW572016) | Other | Phase PHASE2 | Neoplasms, Uterine Cervix | COMPLETED | NCT00430781 |
| pazopanib (GW786034) | Other | Phase PHASE2 | Neoplasms, Uterine Cervix | COMPLETED | NCT00430781 |
| Low molecular weight heparin (LMWH) | Other | Preclinical | Thrombosis, Venous | COMPLETED | NCT01064362 |
| Fondaparinux sodium | Other | Preclinical | Thrombosis, Venous | COMPLETED | NCT01064362 |
| Vehicle and Locoid lipocream (R) | Other | Phase PHASE4 | Atopic Dermatitis | WITHDRAWN | NCT00871208 |
| Altabax (R) | Other | Phase PHASE4 | Atopic Dermatitis | WITHDRAWN | NCT00871208 |
| eltrombopag 25 mg tablet | Other | Phase PHASE2 | Liver Diseases | COMPLETED | NCT00861601 |
| eltrombopag 12.5 milligrams (mg) tablet | Other | Phase PHASE2 | Liver Diseases | COMPLETED | NCT00861601 |
| Placebo | Other | Phase PHASE4 | Post-surgical Dental Pain | COMPLETED | NCT01082081 |
| Paracetamol 500 mg | Other | Phase PHASE4 | Post-surgical Dental Pain | COMPLETED | NCT01082081 |
| Paracetamol 1000 mg | Other | Phase PHASE4 | Post-surgical Dental Pain | COMPLETED | NCT01082081 |
| Placebo | Other | Phase PHASE4 | Post-surgical Dental Pain | COMPLETED | NCT01082081 |
| Paracetamol 500 mg | Other | Phase PHASE4 | Post-surgical Dental Pain | COMPLETED | NCT01082081 |
| Paracetamol 1000 mg | Other | Phase PHASE4 | Post-surgical Dental Pain | COMPLETED | NCT01082081 |
| eltrombopag | Other | Phase PHASE4 | Thrombocytopaenia | WITHDRAWN | NCT01055600 |
| eltrombopag | Other | Phase PHASE4 | Thrombocytopaenia | WITHDRAWN | NCT01055600 |
| GW856553 | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT00393146 |
| A/H1N1 vaccine | Other | Preclinical | Narcolepsy | COMPLETED | NCT01394614 |
| Neutrogena Rapid Clear® | Other | Phase PHASE4 | Skin Diseases | COMPLETED | NCT02052752 |
| 3% Benzoyl Peroxide Placebo | Other | Phase PHASE4 | Skin Diseases | COMPLETED | NCT02052752 |
| 3% Benzoyl Peroxide | Other | Phase PHASE4 | Skin Diseases | COMPLETED | NCT02052752 |
| alosetron | Other | Phase PHASE4 | Irritable Colon | COMPLETED | NCT00370032 |
| benzoyl peroxide 2.5% and adapalene 0.1% gel | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT00926367 |
| Clindamycin and benzoyl peroxide | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT00926367 |
| Ascorbic Acid | Other | Phase PHASE4 | Influenza | COMPLETED | NCT01332578 |
| Phenylephrine | Other | Phase PHASE4 | Influenza | COMPLETED | NCT01332578 |
| Paracetamol | Other | Phase PHASE4 | Influenza | COMPLETED | NCT01332578 |
| Investigational Seasonal Affective Disorder (SAD) Drug | Drug | Phase PHASE3 | Seasonal Affective Disorder (SAD) | COMPLETED | NCT00046449 |
| Placebo | Other | Phase PHASE3 | Hyperhidrosis | COMPLETED | NCT01128738 |
| GSK1358820 | Other | Phase PHASE3 | Hyperhidrosis | COMPLETED | NCT01128738 |
| eltrombopag | Other | Phase PHASE2 | Pediatric Patients Undergoing Allogeneic Cord Blood Transplantation. | UNKNOWN | NCT01940562 |
| Pazopanib | Other | Phase PHASE1 | Cancer, Metastatic | TERMINATED | NCT01542047 |
| Carboplatin | Other | Phase PHASE1 | Cancer, Metastatic | TERMINATED | NCT01542047 |
| Pazopanib | Other | Phase PHASE1 | Cancer, Metastatic | TERMINATED | NCT01542047 |
| Carboplatin | Other | Phase PHASE1 | Cancer, Metastatic | TERMINATED | NCT01542047 |
| PARIET 20 mg DR tabs | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02477306 |
| Idiazole 20mg DR tabs | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02477306 |
| GSK548470 300 mg tablet | Other | Phase PHASE3 | Hepatitis B, Chronic | COMPLETED | NCT01475851 |
| lapatinib | Other | Approved | Ductal Carcinoma in Situ | TERMINATED | NCT00857714 |
| Fondaparinux sodium | Other | Preclinical | Ataxia | COMPLETED | NCT01428544 |
| Blood sampling | Other | Phase PHASE3 | Infections, Papillomavirus | WITHDRAWN | NCT02100618 |
| Havrix | Other | Phase PHASE3 | Infections, Papillomavirus | WITHDRAWN | NCT02082639 |
| Cervarix™ | Other | Phase PHASE3 | Infections, Papillomavirus | WITHDRAWN | NCT02082639 |
| Alvimopan | Other | Phase PHASE3 | Ileus | COMPLETED | NCT00388479 |
| Alvimopan | Other | Phase PHASE3 | Ileus | COMPLETED | NCT00388479 |
| Alvimopan | Other | Phase PHASE3 | Ileus | COMPLETED | NCT00388401 |
| Retrospective database study using administrative claims data | Other | Preclinical | Diphtheria | COMPLETED | NCT01890850 |
| Retrospective database study using administrative claims data | Other | Preclinical | Diphtheria | COMPLETED | NCT01890850 |
| GSK1358820 | Other | Phase PHASE3 | Strabismus | COMPLETED | NCT01584843 |
| GSK1358820 | Other | Phase PHASE3 | Strabismus | COMPLETED | NCT01584843 |
| Ofatumumab | Other | Phase PHASE2 | Lymphoma, Large-Cell, Diffuse | COMPLETED | NCT00622388 |
| Ofatumumab | Other | Phase PHASE2 | Lymphoma, Large-Cell, Diffuse | COMPLETED | NCT00622388 |
| Lamotrigine | Other | Phase PHASE2 | Bipolar Disorder | COMPLETED | NCT00176228 |
| Alvimopan | Other | Preclinical | Ileus | COMPLETED | NCT01150760 |
| Creatine | Other | Approved | Sports Nutritional Sciences | COMPLETED | NCT02519751 |
| D3 Creatine | Other | Approved | Sports Nutritional Sciences | COMPLETED | NCT02519751 |
| Experimental: Protesomal Vaccine 2 x 15 µg | Other | Phase PHASE1 | Influenza | COMPLETED | NCT02522754 |
| Experimental: Protesomal Vaccine 2 x 30 µg | Other | Phase PHASE1 | Influenza | COMPLETED | NCT02522754 |
| Experimental: Protesomal Vaccine 1 x 30 µg | Other | Phase PHASE1 | Influenza | COMPLETED | NCT02522754 |
| Placebo Protesomal Vaccine | Other | Phase PHASE1 | Influenza | COMPLETED | NCT02522754 |
| Levocetirizine | Other | Preclinical | Rhinitis, Allergic, Perennial and Seasonal | COMPLETED | NCT01445262 |
| Naratriptan | Other | Preclinical | Migraine Disorders | COMPLETED | NCT01332383 |
| Data collection | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT01636193 |
| Oral Rotarix® | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT01636193 |
| ibandronate [Bonviva/Boniva] | Other | Phase PHASE4 | Post Menopausal Osteoporosis | COMPLETED | NCT00545480 |
| Alvimopan 1 mg/day | Other | Phase PHASE2 | Cancer | TERMINATED | NCT00331045 |
| Alvimopan 0.5 mg/day | Other | Phase PHASE2 | Cancer | TERMINATED | NCT00331045 |
| Placebo | Other | Phase PHASE2 | Cancer | TERMINATED | NCT00331045 |
| alvimopan | Other | Phase PHASE2 | Cancer | TERMINATED | NCT00331045 |
| Alvimopan 1 mg/day | Other | Phase PHASE2 | Cancer | TERMINATED | NCT00331045 |
| Alvimopan 0.5 mg/day | Other | Phase PHASE2 | Cancer | TERMINATED | NCT00331045 |
| Placebo | Other | Phase PHASE2 | Cancer | TERMINATED | NCT00331045 |
| alvimopan | Other | Phase PHASE2 | Cancer | TERMINATED | NCT00331045 |
| Alvimopan 1 mg/day | Other | Phase PHASE2 | Cancer | TERMINATED | NCT00331045 |
| Alvimopan 0.5 mg/day | Other | Phase PHASE2 | Cancer | TERMINATED | NCT00331045 |
| Placebo | Other | Phase PHASE2 | Cancer | TERMINATED | NCT00331045 |
| alvimopan | Other | Phase PHASE2 | Cancer | TERMINATED | NCT00331045 |
| Alviompan | Other | Phase PHASE3 | Bowel Dysfunction | COMPLETED | NCT00259922 |
| Alvimopan | Other | Phase PHASE3 | Bowel Dysfunction | COMPLETED | NCT00259922 |
| Placebo | Other | Phase PHASE3 | Bowel Dysfunction | COMPLETED | NCT00259922 |
| Alviompan | Other | Phase PHASE3 | Bowel Dysfunction | COMPLETED | NCT00259922 |
| Alvimopan | Other | Phase PHASE3 | Bowel Dysfunction | COMPLETED | NCT00259922 |
| Placebo | Other | Phase PHASE3 | Bowel Dysfunction | COMPLETED | NCT00259922 |
| Placebo | Other | Phase PHASE3 | Bowel Dysfunction | COMPLETED | NCT00256932 |
| alvimopan | Other | Phase PHASE3 | Bowel Dysfunction | COMPLETED | NCT00256932 |
| Placebo | Other | Phase PHASE3 | Bowel Dysfunction | COMPLETED | NCT00256932 |
| alvimopan | Other | Phase PHASE3 | Bowel Dysfunction | COMPLETED | NCT00256932 |
| placebo | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00135577 |
| alvimopan | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00135577 |
| placebo | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00135577 |
| alvimopan | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00135577 |
| fluticasone/salmeterol, tiotropium | Other | Phase PHASE4 | COPD | UNKNOWN | NCT02546349 |
| ALTARGO(retapamulin) | Other | Preclinical | Skin Infections, Bacterial | COMPLETED | NCT01445600 |
| Data collection | Other | Preclinical | Herpes Zoster | COMPLETED | NCT01521286 |
| lapatinib | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00105950 |
| pazopanib | Other | Phase PHASE1 | Sarcoma,Soft Tissue | COMPLETED | NCT01985295 |
| Ofatumumab | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | WITHDRAWN | NCT01263418 |
| testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT00853697 |
| Kinrix | Other | Preclinical | Diphtheria | COMPLETED | NCT02447978 |
| Pediarix | Other | Preclinical | Diphtheria | COMPLETED | NCT02447978 |
| Infanrix | Other | Preclinical | Diphtheria | COMPLETED | NCT02447978 |
| iodine I 131 | Other | Phase PHASE1 | Recurrent Thyroid Cancer | COMPLETED | NCT01413113 |
| pazopanib hydrochloride | Other | Phase PHASE1 | Recurrent Thyroid Cancer | COMPLETED | NCT01413113 |
| iodine I 131 | Other | Phase PHASE1 | Recurrent Thyroid Cancer | COMPLETED | NCT01413113 |
| pazopanib hydrochloride | Other | Phase PHASE1 | Recurrent Thyroid Cancer | COMPLETED | NCT01413113 |
| Routine schedule immunisations except monovalent MenC vaccine | Other | Phase PHASE4 | Invasive Meningococcal Disease | COMPLETED | NCT01129518 |
| Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine | Other | Phase PHASE4 | Invasive Meningococcal Disease | COMPLETED | NCT01129518 |
| Routine schedule immunisations except monovalent MenC vaccine | Other | Phase PHASE4 | Invasive Meningococcal Disease | COMPLETED | NCT01129518 |
| Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine | Other | Phase PHASE4 | Invasive Meningococcal Disease | COMPLETED | NCT01129518 |
| Placebo | Other | Phase PHASE1 | Pain | COMPLETED | NCT02602002 |
| Remifentanil | Other | Phase PHASE1 | Pain | COMPLETED | NCT02602002 |
| TURBUHALER | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02195284 |
| MDI | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02195284 |
| DISKUS/ACCUHALER | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02195284 |
| ELLIPTA | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02195284 |
| placebo | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT00062738 |
| Nortriptyline | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT00062738 |
| paroxetine | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT00062738 |
| We will compare the resources used by both groups | Other | Preclinical | Novel H1N1 Influenzal Acute Respiratory Infection | COMPLETED | NCT01485237 |
| Lenalidomide | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01123356 |
| Ofatumumab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01123356 |
| GSK1349572 (Cohort II) | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00950859 |
| GSK1349572 (Cohort I) | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00950859 |
| RTS,S/AS01E | Other | Preclinical | Malaria | UNKNOWN | NCT00872963 |
| Fluticasone plus salmeterol | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00156819 |
| montelukast | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00156819 |
| fluticasone | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00156819 |
| Ofatumumab and Bendamustine | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01010568 |
| Ofatumumab and Bendamustine | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01010568 |
| RIF | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02411435 |
| CAB | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02411435 |
| dolutegravir | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01328041 |
| dolutegravir | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01328041 |
| Matching albiglutide placebo | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | WITHDRAWN | NCT02229240 |
| Albiglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | WITHDRAWN | NCT02229240 |
| Risperidone | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT00364429 |
| Lorazepam | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT00364429 |
| [123]I-CNS 1261 | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT00364429 |
| alvimopan | Other | Phase PHASE3 | Ileus | COMPLETED | NCT00205842 |
| alvimopan | Other | Phase PHASE3 | Ileus | COMPLETED | NCT00205842 |
| Extended Release Lamotrigine | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT00789113 |
| Paracetamol 500 mg | Other | Preclinical | Osteoarthritis | WITHDRAWN | NCT02262702 |
| Paracetamol 665 mg | Other | Preclinical | Osteoarthritis | WITHDRAWN | NCT02262702 |
| Placebo | Other | Phase PHASE1 | Cancer | WITHDRAWN | NCT02292732 |
| ORTHO-NOVUM® tablet 1/35 | Other | Phase PHASE1 | Cancer | WITHDRAWN | NCT02292732 |
| Trametinib 2 mg | Other | Phase PHASE1 | Cancer | WITHDRAWN | NCT02292732 |
| Trametinib 0.5 mg | Other | Phase PHASE1 | Cancer | WITHDRAWN | NCT02292732 |
| Placebo (for cAd3-EBOZ vaccine) | Other | Phase PHASE1 | Ebola Vaccines | COMPLETED | NCT02289027 |
| cAd3-EBOZ vaccine | Other | Phase PHASE1 | Ebola Vaccines | COMPLETED | NCT02289027 |
| Placebo (for cAd3-EBOZ vaccine) | Other | Phase PHASE1 | Ebola Vaccines | COMPLETED | NCT02289027 |
| cAd3-EBOZ vaccine | Other | Phase PHASE1 | Ebola Vaccines | COMPLETED | NCT02289027 |
| Ritonavir | Other | Approved | Healthy | COMPLETED | NCT00614991 |
| Fosamprenavir | Other | Approved | Healthy | COMPLETED | NCT00614991 |
| Raltegravir | Other | Approved | Healthy | COMPLETED | NCT00614991 |
| Lapatinib and Capecitabine | Other | Phase PHASE2 | Neoplasms, Gastrointestinal Tract | COMPLETED | NCT00526669 |
| Lapatinib and Capecitabine | Other | Phase PHASE2 | Neoplasms, Gastrointestinal Tract | COMPLETED | NCT00526669 |
| placebo | Other | Phase PHASE3 | Carcinoma, Renal Cell | COMPLETED | NCT00334282 |
| Pazopanib | Other | Phase PHASE3 | Carcinoma, Renal Cell | COMPLETED | NCT00334282 |
| Beverage: Placebo (sucrose, glucose, fructose, maltodextrin, malic acid, citric acid, vitamin C, artificial blackcurrant flavouring and low-nitrate water) | Other | Approved | Vascular Stiffness | COMPLETED | NCT02459756 |
| Beverage: Spray dried blackcurrant powder dissolved in water | Other | Approved | Vascular Stiffness | COMPLETED | NCT02459756 |
| Beverage: Placebo (sucrose, glucose, fructose, maltodextrin, malic acid, citric acid, vitamin C, artificial blackcurrant flavouring and low-nitrate water) | Other | Approved | Vascular Stiffness | COMPLETED | NCT02459756 |
| Beverage: Spray dried blackcurrant powder dissolved in water | Other | Approved | Vascular Stiffness | COMPLETED | NCT02459756 |
| Beverage: Placebo (sucrose, glucose, fructose, maltodextrin, malic acid, citric acid, vitamin C, artificial blackcurrant flavouring and low-nitrate water) | Other | Approved | Vascular Stiffness | COMPLETED | NCT02459756 |
| Beverage: Spray dried blackcurrant powder dissolved in water | Other | Approved | Vascular Stiffness | COMPLETED | NCT02459756 |
| Vaccine safety surveillance | Other | Preclinical | Influenza | COMPLETED | NCT02567721 |
| Vaccine safety surveillance | Other | Preclinical | Influenza | COMPLETED | NCT02567721 |
| Eltrombopag and Vorinostat | Other | Phase PHASE2 | Follicular Lymphoma | TERMINATED | NCT01500538 |
| Azacitidine and eltrombopag | Other | Phase PHASE2 | Myelodysplastic Syndromes (MDS) | COMPLETED | NCT01488565 |
| Azacitidine and eltrombopag | Other | Phase PHASE2 | Myelodysplastic Syndromes (MDS) | COMPLETED | NCT01488565 |
| Placebo | Other | Phase PHASE2 | Substance Dependence | WITHDRAWN | NCT00793468 |
| Nicotine Replacement Transdermal Patch | Other | Phase PHASE2 | Substance Dependence | WITHDRAWN | NCT00793468 |
| GSK598809 | Other | Phase PHASE2 | Substance Dependence | WITHDRAWN | NCT00793468 |
| Lapatinib and bortezomib | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT01497626 |
| Lapatinib and bortezomib | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT01497626 |
| Lapatinib and bortezomib | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT01497626 |
| Retapamulin (Altabax) | Other | Phase PHASE4 | Impetigo | COMPLETED | NCT01126268 |
| Retapamulin (Altabax) | Other | Phase PHASE4 | Impetigo | COMPLETED | NCT01126268 |
| Lovaza | Other | Approved | Cardiovascular Disease | COMPLETED | NCT01048502 |
| Placebo | Other | Approved | Cardiovascular Disease | COMPLETED | NCT01048502 |
| Fenofibrate (Tricor) tablets | Other | Approved | Cardiovascular Disease | COMPLETED | NCT01048502 |
| Lovaza | Other | Approved | Cardiovascular Disease | COMPLETED | NCT01048502 |
| Placebo | Other | Approved | Cardiovascular Disease | COMPLETED | NCT01048502 |
| Fenofibrate (Tricor) tablets | Other | Approved | Cardiovascular Disease | COMPLETED | NCT01048502 |
| Trastuzumab | Other | Phase PHASE3 | Neoplasms, Breast | COMPLETED | NCT00320385 |
| Lapatinib | Other | Phase PHASE3 | Neoplasms, Breast | COMPLETED | NCT00320385 |
| Trastuzumab | Other | Phase PHASE3 | Neoplasms, Breast | COMPLETED | NCT00320385 |
| Lapatinib | Other | Phase PHASE3 | Neoplasms, Breast | COMPLETED | NCT00320385 |
| SB-497115-GR | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01636778 |
| Placebo | Other | Phase PHASE3 | Chemotherapy-induced Nausea and Vomiting | COMPLETED | NCT01500226 |
| Dexamethasone | Other | Phase PHASE3 | Chemotherapy-induced Nausea and Vomiting | COMPLETED | NCT01500226 |
| Granisetron | Other | Phase PHASE3 | Chemotherapy-induced Nausea and Vomiting | COMPLETED | NCT01500226 |
| Rolapitant | Other | Phase PHASE3 | Chemotherapy-induced Nausea and Vomiting | COMPLETED | NCT01500226 |
| Placebo | Other | Phase PHASE3 | Chemotherapy-induced Nausea and Vomiting | COMPLETED | NCT01500226 |
| Dexamethasone | Other | Phase PHASE3 | Chemotherapy-induced Nausea and Vomiting | COMPLETED | NCT01500226 |
| Granisetron | Other | Phase PHASE3 | Chemotherapy-induced Nausea and Vomiting | COMPLETED | NCT01500226 |
| Rolapitant | Other | Phase PHASE3 | Chemotherapy-induced Nausea and Vomiting | COMPLETED | NCT01500226 |
| Placebo | Other | Phase PHASE3 | Chemotherapy-induced Nausea and Vomiting | COMPLETED | NCT01500213 |
| Dexamethasone | Other | Phase PHASE3 | Chemotherapy-induced Nausea and Vomiting | COMPLETED | NCT01500213 |
| Granisetron | Other | Phase PHASE3 | Chemotherapy-induced Nausea and Vomiting | COMPLETED | NCT01500213 |
| Rolapitant | Other | Phase PHASE3 | Chemotherapy-induced Nausea and Vomiting | COMPLETED | NCT01500213 |
| Placebo | Other | Phase PHASE3 | Chemotherapy-induced Nausea and Vomiting | COMPLETED | NCT01500213 |
| Dexamethasone | Other | Phase PHASE3 | Chemotherapy-induced Nausea and Vomiting | COMPLETED | NCT01500213 |
| Granisetron | Other | Phase PHASE3 | Chemotherapy-induced Nausea and Vomiting | COMPLETED | NCT01500213 |
| Rolapitant | Other | Phase PHASE3 | Chemotherapy-induced Nausea and Vomiting | COMPLETED | NCT01500213 |
| Sirukumab (SC injection with PFS-AI) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02079545 |
| Sirukumab (SC injection with PFS-U) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02079545 |
| Sirukumab (IV infusion) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02079545 |
| Tenofovir disoproxil fumarate | Other | Phase PHASE1 | Lymphoma | WITHDRAWN | NCT01528865 |
| Lamivudine | Other | Phase PHASE1 | Lymphoma | WITHDRAWN | NCT01528865 |
| MMR vaccine / MMRV vaccine | Other | Preclinical | Measles | UNKNOWN | NCT02712203 |
| Lapatinib | Other | Phase PHASE2 | Neurofibromatosis 2 | COMPLETED | NCT00973739 |
| cyclophosphamide | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00429299 |
| epidoxorubicin | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00429299 |
| fluorouracil | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00429299 |
| paclitaxel | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00429299 |
| trastuzumab | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00429299 |
| lapatinib | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00429299 |
| Lovaza (Fish Oils) | Other | Preclinical | Atrial Fibrillation | NO_LONGER_AVAILABLE | NCT00841451 |
| Belimumab 10 mg/kg | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT00724867 |
| Belimumab 1 mg/kg | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT00724867 |
| Belimumab 10 mg/kg | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT00724867 |
| Belimumab 1 mg/kg | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT00724867 |
| Short Acting Beta Agonist (SABA) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02293265 |
| Short Acting Beta Agonist (SABA) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02293265 |
| Placebo | Other | Phase PHASE2 | Thrombocytopaenia | COMPLETED | NCT01147809 |
| Eltrombopag olamine | Other | Phase PHASE2 | Thrombocytopaenia | COMPLETED | NCT01147809 |
| No intervention done | Other | Preclinical | Rotavirus Infections | COMPLETED | NCT01467037 |
| No intervention done | Other | Preclinical | Rotavirus Infections | COMPLETED | NCT01467037 |
| Cumulative corticosteroid exposure | Other | Preclinical | Systemic Lupus Erythematosus | COMPLETED | NCT01616472 |
| liposomal doxorubicin | Other | Phase PHASE1 | Cancer: Solid Tumors | TERMINATED | NCT01110603 |
| paclitaxel | Other | Phase PHASE1 | Cancer: Solid Tumors | TERMINATED | NCT01110603 |
| carboplatin | Other | Phase PHASE1 | Cancer: Solid Tumors | TERMINATED | NCT01110603 |
| MK-4827 | Other | Phase PHASE1 | Cancer: Solid Tumors | TERMINATED | NCT01110603 |
| Placebo | Other | Phase PHASE2 | Migraine Disorders | COMPLETED | NCT00242866 |
| GW274150 | Other | Phase PHASE2 | Migraine Disorders | COMPLETED | NCT00242866 |
| Placebo | Other | Phase PHASE2 | Migraine Disorders | COMPLETED | NCT00242866 |
| GW274150 | Other | Phase PHASE2 | Migraine Disorders | COMPLETED | NCT00242866 |
| Fluoride mouthwash | Other | Approved | Dental Caries | COMPLETED | NCT02399163 |
| Fluoride toothpaste | Other | Approved | Dental Caries | COMPLETED | NCT02399163 |
| Fluoride free toothpaste | Other | Approved | Dental Caries | COMPLETED | NCT02399163 |
| Fluoride mouthwash | Other | Approved | Dental Caries | COMPLETED | NCT02399163 |
| Fluoride toothpaste | Other | Approved | Dental Caries | COMPLETED | NCT02399163 |
| Fluoride free toothpaste | Other | Approved | Dental Caries | COMPLETED | NCT02399163 |
| Unexposed to Arepanrix™ Cohort | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT02367222 |
| Exposed to Arepanrix™ Cohort | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT02367222 |
| ibandronate | Other | Phase PHASE4 | Postmenopausal Osteoporosis | COMPLETED | NCT00545051 |
| Placebo | Other | Phase PHASE4 | Postmenopausal Osteoporosis | COMPLETED | NCT00545051 |
| placebo | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00422903 |
| letrozole | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00422903 |
| lapatinib | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00422903 |
| Cetrizine hydrochloride | Other | Preclinical | Allergic Rhinitis | COMPLETED | NCT02020902 |
| Synflorix™ | Other | Preclinical | Infections, Streptococcal | TERMINATED | NCT01046097 |
| Carvedilol-CR | Other | Phase PHASE2 | Epilepsy | TERMINATED | NCT00524134 |
| Placebo | Other | Phase PHASE3 | Heart Failure | TERMINATED | NCT00944229 |
| LOVAZA (Omega-3) | Other | Phase PHASE3 | Heart Failure | TERMINATED | NCT00944229 |
| Placebo | Other | Phase PHASE3 | Heart Failure | TERMINATED | NCT00944229 |
| LOVAZA (Omega-3) | Other | Phase PHASE3 | Heart Failure | TERMINATED | NCT00944229 |
| inhaled corticosteroid | Other | Phase PHASE4 | Asthma | TERMINATED | NCT00395239 |
| inhaled corticosteroid | Other | Phase PHASE4 | Asthma | TERMINATED | NCT00395239 |
| lapatinib | Other | Phase PHASE3 | Invasive Breast Cancer | UNKNOWN | NCT00486668 |
| trastuzumab | Other | Phase PHASE3 | Invasive Breast Cancer | UNKNOWN | NCT00486668 |
| paclitaxel | Other | Phase PHASE3 | Invasive Breast Cancer | UNKNOWN | NCT00486668 |
| cyclophosphamide | Other | Phase PHASE3 | Invasive Breast Cancer | UNKNOWN | NCT00486668 |
| doxorubicin | Other | Phase PHASE3 | Invasive Breast Cancer | UNKNOWN | NCT00486668 |
| lapatinib | Other | Phase PHASE3 | Invasive Breast Cancer | UNKNOWN | NCT00486668 |
| trastuzumab | Other | Phase PHASE3 | Invasive Breast Cancer | UNKNOWN | NCT00486668 |
| paclitaxel | Other | Phase PHASE3 | Invasive Breast Cancer | UNKNOWN | NCT00486668 |
| cyclophosphamide | Other | Phase PHASE3 | Invasive Breast Cancer | UNKNOWN | NCT00486668 |
| doxorubicin | Other | Phase PHASE3 | Invasive Breast Cancer | UNKNOWN | NCT00486668 |
| Placebo Inhalation Aerosol (MDI) | Other | Preclinical | Asthma | COMPLETED | NCT02135718 |
| ELLIPTA inhaler | Other | Preclinical | Asthma | COMPLETED | NCT02135718 |
| Placebo Inhalation Aerosol (MDI) | Other | Preclinical | Asthma | COMPLETED | NCT02135718 |
| ELLIPTA inhaler | Other | Preclinical | Asthma | COMPLETED | NCT02135718 |
| placebo matching lapatinib | Other | Phase PHASE4 | Cancer | COMPLETED | NCT01328054 |
| lapatinib | Other | Phase PHASE4 | Cancer | COMPLETED | NCT01328054 |
| Arixtra + filter | Other | Phase PHASE3 | Cancer | TERMINATED | NCT00423683 |
| Arixtra alone | Other | Phase PHASE3 | Cancer | TERMINATED | NCT00423683 |
| laboratory biomarker analysis | Other | Phase PHASE2 | Waldenström Macroglobulinemia | TERMINATED | NCT01536067 |
| bortezomib | Other | Phase PHASE2 | Waldenström Macroglobulinemia | TERMINATED | NCT01536067 |
| ofatumumab | Other | Phase PHASE2 | Waldenström Macroglobulinemia | TERMINATED | NCT01536067 |
| laboratory biomarker analysis | Other | Phase PHASE2 | Waldenström Macroglobulinemia | TERMINATED | NCT01536067 |
| bortezomib | Other | Phase PHASE2 | Waldenström Macroglobulinemia | TERMINATED | NCT01536067 |
| ofatumumab | Other | Phase PHASE2 | Waldenström Macroglobulinemia | TERMINATED | NCT01536067 |
| Adding Advair Diskus 100/50mcg (FSC) BID and Singulair 10mg is added to placebo Diskus BID | Other | Approved | Asthma | WITHDRAWN | NCT00385463 |
| Test Product H | Other | Approved | Skin Care | COMPLETED | NCT02792595 |
| Test Product G | Other | Approved | Skin Care | COMPLETED | NCT02792595 |
| Test Product F | Other | Approved | Skin Care | COMPLETED | NCT02792595 |
| Test Product E | Other | Approved | Skin Care | COMPLETED | NCT02792595 |
| Test Product D | Other | Approved | Skin Care | COMPLETED | NCT02792595 |
| Test Product C | Other | Approved | Skin Care | COMPLETED | NCT02792595 |
| Test Product B | Other | Approved | Skin Care | COMPLETED | NCT02792595 |
| Test Product A | Other | Approved | Skin Care | COMPLETED | NCT02792595 |
| Positive Control | Other | Approved | Skin Care | COMPLETED | NCT02792595 |
| Negative Control | Other | Approved | Skin Care | COMPLETED | NCT02792595 |
| Placebo | Other | Phase PHASE1 | Influenza | WITHDRAWN | NCT02177734 |
| Investigational H7N9 vaccine GSK3277509A | Other | Phase PHASE1 | Influenza | WITHDRAWN | NCT02177734 |
| Investigational H7N9 vaccine GSK3277510A | Other | Phase PHASE1 | Influenza | WITHDRAWN | NCT02177734 |
| Placebo | Other | Phase PHASE1 | Influenza | WITHDRAWN | NCT02177734 |
| Investigational H7N9 vaccine GSK3277509A | Other | Phase PHASE1 | Influenza | WITHDRAWN | NCT02177734 |
| Investigational H7N9 vaccine GSK3277510A | Other | Phase PHASE1 | Influenza | WITHDRAWN | NCT02177734 |
| DTG/RPV 50 mg/25 mg: Product Code AR | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02373930 |
| DTG/RPV 50 mg/25 mg: Product Code AK | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02373930 |
| DTG/RPV 50 mg/25 mg: Product Code AQ | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02373930 |
| DTG/RPV 50 mg/25 mg: Product Code AM | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02373930 |
| DTG/RPV 50 mg/25 mg: Product Code AS | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02373930 |
| RPV 25 mg | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02373930 |
| DTG 50 mg | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02373930 |
| DTG/RPV 50 mg/25 mg: Product Code AR | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02373930 |
| DTG/RPV 50 mg/25 mg: Product Code AK | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02373930 |
| DTG/RPV 50 mg/25 mg: Product Code AQ | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02373930 |
| DTG/RPV 50 mg/25 mg: Product Code AM | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02373930 |
| DTG/RPV 50 mg/25 mg: Product Code AS | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02373930 |
| RPV 25 mg | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02373930 |
| DTG 50 mg | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02373930 |
| Placebo | Other | Approved | Tobacco Abuse Smoke | COMPLETED | NCT01216735 |
| Fluticasone | Other | Approved | Tobacco Abuse Smoke | COMPLETED | NCT01216735 |
| Placebo | Other | Approved | Tobacco Abuse Smoke | COMPLETED | NCT01216735 |
| Fluticasone | Other | Approved | Tobacco Abuse Smoke | COMPLETED | NCT01216735 |
| fluticasone/salmeterol | Other | Approved | Asthma | COMPLETED | NCT01231230 |
| Salmeterol | Other | Approved | Asthma | COMPLETED | NCT01231230 |
| placebo inhalation | Other | Approved | Asthma | COMPLETED | NCT01231230 |
| fluticasone | Other | Approved | Asthma | COMPLETED | NCT01231230 |
| Pazopanib | Other | Phase PHASE2 | Dermatofibrosarcomas of DARIER FERRAND(DFSP) | TERMINATED | NCT01059656 |
| Experimental paracetamol formulation | Other | Phase PHASE1 | Healthy Subjects | WITHDRAWN | NCT01381640 |
| Marketed paracetamol | Other | Phase PHASE1 | Healthy Subjects | WITHDRAWN | NCT01381640 |
| Experimental paracetamol formulation | Other | Phase PHASE1 | Healthy Subjects | WITHDRAWN | NCT01381640 |
| Marketed paracetamol | Other | Phase PHASE1 | Healthy Subjects | WITHDRAWN | NCT01381640 |
| docetaxel + trastuzumab + lapatinib | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00450892 |
| docetaxel + trastuzumab | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00450892 |
| docetaxel+lapatinib | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00450892 |
| MMR GlaxoSmithKline | Other | Phase PHASE3 | Measles | COMPLETED | NCT01991899 |
| MMR Bio-Manguinhos | Other | Phase PHASE3 | Measles | COMPLETED | NCT01991899 |
| Data collection | Other | Preclinical | Hepatitis B | COMPLETED | NCT02324218 |
| Data collection | Other | Preclinical | Hepatitis B | COMPLETED | NCT02324218 |
| Recombinant hepatitis B surface antigen | Other | Phase PHASE3 | Hepatitis B | TERMINATED | NCT00120796 |
| Lamivudine | Other | Phase PHASE3 | Hepatitis B | TERMINATED | NCT00120796 |
| Albuterol/Salbutamol | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | WITHDRAWN | NCT02731846 |
| Placebo ELLIPTA inhaler | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | WITHDRAWN | NCT02731846 |
| Umeclidinium 62.5 mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | WITHDRAWN | NCT02731846 |
| Fluticasone furoate 100 mcg + Vilanterol 25 mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | WITHDRAWN | NCT02731846 |
| Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | WITHDRAWN | NCT02731846 |
| Albuterol/Salbutamol | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | WITHDRAWN | NCT02731846 |
| Placebo ELLIPTA inhaler | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | WITHDRAWN | NCT02731846 |
| Umeclidinium 62.5 mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | WITHDRAWN | NCT02731846 |
| Fluticasone furoate 100 mcg + Vilanterol 25 mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | WITHDRAWN | NCT02731846 |
| Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | WITHDRAWN | NCT02731846 |
| Eltrombopag | Other | Preclinical | Purpura, Thrombocytopaenic, Idiopathic | COMPLETED | NCT01064336 |
| Eltrombopag | Other | Preclinical | Purpura, Thrombocytopaenic, Idiopathic | COMPLETED | NCT01064336 |
| Bupropion | Other | Preclinical | Depressive Disorder, Major | COMPLETED | NCT02039960 |
| OPV | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT01457560 |
| DTPa-HBV-IPV/Hib (Infanrix hexa™) | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT01457560 |
| DTPa-HBV-IPV-Hib vaccine (HEXAVAC™) | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT01457547 |
| DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA) | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT01457547 |
| placebo | Other | Phase PHASE2 | Atherosclerosis | COMPLETED | NCT00269048 |
| SB-480848 | Other | Phase PHASE2 | Atherosclerosis | COMPLETED | NCT00269048 |
| ETV 0.5 mg capsule | Other | Phase PHASE3 | Hepatitis B, Chronic | COMPLETED | NCT01480284 |
| GSK548470 300 mg tablet | Other | Phase PHASE3 | Hepatitis B, Chronic | COMPLETED | NCT01480284 |
| Reference product 2 | Other | Approved | Sports Nutritional Sciences | COMPLETED | NCT02458599 |
| Reference product 1 | Other | Approved | Sports Nutritional Sciences | COMPLETED | NCT02458599 |
| Test product | Other | Approved | Sports Nutritional Sciences | COMPLETED | NCT02458599 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT01772199 |
| GSK239512 | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT01772199 |
| Bexxar | Other | Phase PHASE1 | B-cell Lymphoma | COMPLETED | NCT00434629 |
| Placebo balm | Other | Phase PHASE4 | Pain | COMPLETED | NCT02424565 |
| IODEX® balm | Other | Phase PHASE4 | Pain | COMPLETED | NCT02424565 |
| FSC 500/50mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00920543 |
| FSC 250/50mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00920543 |
| FSC 100/50mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00920543 |
| FP 250mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00920543 |
| FP 500mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00920543 |
| FP 100mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00920543 |
| Placebo | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00920543 |
| Rosiglitazone | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00306644 |
| fluticasone furoate | Other | Phase PHASE3 | Hayfever | COMPLETED | NCT00115622 |
| lamotrigine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00071747 |
| lamotrigine | Other | Phase PHASE4 | Bipolar Disorder | COMPLETED | NCT00067938 |
| lamotrigine | Other | Phase PHASE4 | Bipolar Disorder | COMPLETED | NCT00067938 |
| EngerixTM-B | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00880477 |
| DTPa-IPV/Hib vaccine | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00880477 |
| DTPa-HBV-IPV/Hib vaccine | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00880477 |
| Hiberix TM | Other | Phase PHASE3 | Diphtheria | COMPLETED | NCT00879827 |
| Pediarix TM, Infanrix penta TM | Other | Phase PHASE3 | Diphtheria | COMPLETED | NCT00879827 |
| Hiberix TM | Other | Phase PHASE3 | Diphtheria | COMPLETED | NCT00879827 |
| Pediarix TM, Infanrix penta TM | Other | Phase PHASE3 | Diphtheria | COMPLETED | NCT00879827 |
| Placebo | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT00757770 |
| Rotarix | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT00757770 |
| Placebo injection | Other | Phase PHASE3 | Herpes Simplex | COMPLETED | NCT00699764 |
| Herpes simplex candidate vaccine- adjuvanted GSK208141 | Other | Phase PHASE3 | Herpes Simplex | COMPLETED | NCT00699764 |
| HAVRIX | Other | Phase PHASE4 | Acellular Pertussis | TERMINATED | NCT00544271 |
| BOOSTRIX | Other | Phase PHASE4 | Acellular Pertussis | TERMINATED | NCT00544271 |
| INFANRIX | Other | Phase PHASE4 | Acellular Pertussis | TERMINATED | NCT00544271 |
| Combined Hepatitis A and B vaccine | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00197171 |
| Unconjugated Hib vaccine (plain PRP) | Other | Phase PHASE2 | Haemophilus Influenzae Type b | COMPLETED | NCT01061541 |
| Hiberix™ | Other | Phase PHASE2 | Haemophilus Influenzae Type b | COMPLETED | NCT01061541 |
| Tritanrix™-HepB | Other | Phase PHASE2 | Haemophilus Influenzae Type b | COMPLETED | NCT01061541 |
| Hib 2.5 | Other | Phase PHASE2 | Haemophilus Influenzae Type b | COMPLETED | NCT01061541 |
| Tritanrix™-HepB low thio / | Other | Phase PHASE2 | Haemophilus Influenzae Type b | COMPLETED | NCT01061541 |
| Rotavirus (vaccine) | Other | Phase PHASE2 | Rotavirus Infections | COMPLETED | NCT00346892 |
| DTPw-HBV/Hib-MenAC conjugate vaccine | Other | Phase PHASE2 | Haemophilus Influenzae Type b | COMPLETED | NCT00317174 |
| DTPw-HBV/Hib-MenAC conjugate vaccine | Other | Phase PHASE2 | Haemophilus Influenzae Type b | COMPLETED | NCT00317174 |
| Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix | Other | Phase PHASE3 | Hepatitis A | COMPLETED | NCT00197249 |
| placebo | Other | Phase PHASE2 | Infections, Papillomavirus | COMPLETED | NCT00689741 |
| Cervarix | Other | Phase PHASE2 | Infections, Papillomavirus | COMPLETED | NCT00689741 |
| Telzir® | Other | Phase PHASE4 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00240552 |
| fosamprenavir | Other | Phase PHASE4 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00240552 |
| HPV-16/18 L1/AS04 | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00169494 |
| HPV-16/18 L1/AS04 | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00169494 |
| No intervention | Other | Preclinical | Hepatitis B, Chronic | COMPLETED | NCT01128686 |
| Placebo | Other | Phase PHASE4 | Common Cold | COMPLETED | NCT02246166 |
| Test tablet | Other | Phase PHASE4 | Common Cold | COMPLETED | NCT02246166 |
| Rosiglitazone | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00500955 |
| Salmeterol/fluticasone propionate or formoterol/budesonide | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00479739 |
| rosiglitazone | Other | Phase PHASE3 | Neuropathy, Diabetic | COMPLETED | NCT00422955 |
| Varicella (Varilrix®) | Other | Phase PHASE3 | Rubella | COMPLETED | NCT00406211 |
| MMR (Priorix®) | Other | Phase PHASE3 | Rubella | COMPLETED | NCT00406211 |
| MMRV | Other | Phase PHASE3 | Rubella | COMPLETED | NCT00406211 |
| vestipitant/paroxetine | Other | Phase PHASE2 | Social Phobia | COMPLETED | NCT00403962 |
| Fluticasone propionate | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00400855 |
| Salmeterol/fluticasone propionate and fluticasone propionate | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00370591 |
| salmeterol 50mcg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00354874 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00354874 |
| GW642444 | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00354874 |
| paroxetine | Other | Phase PHASE2 | Depressive Disorder and Anxiety Disorders | COMPLETED | NCT00343707 |
| vestipitant | Other | Phase PHASE2 | Depressive Disorder and Anxiety Disorders | COMPLETED | NCT00343707 |
| rosiglitazone | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00329225 |
| frusemide | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00306696 |
| hydrochlorothiazide | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00306696 |
| spironolactone | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00306696 |
| Rosiglitazone | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00306696 |
| lamotrigine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00274677 |
| Placebo | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00274677 |
| Salmeterol/fluticasone propionate 50/500mcg Diskus | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00268177 |
| Salmeterol/fluticasone propionate 50/500mcg Diskus | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00268177 |
| Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3 | Other | Phase PHASE2 | Diphtheria | COMPLETED | NCT00263692 |
| Prophylaxis: Diphtheria, tetanus and pertussis | Other | Phase PHASE3 | Acellular Pertussis | COMPLETED | NCT00263679 |
| ropinirole | Other | Phase PHASE2 | Fibromyalgia Syndrome, Primary | COMPLETED | NCT00256893 |
| ropinirole | Other | Phase PHASE3 | Restless Legs Syndrome | COMPLETED | NCT00225862 |
| GW685698X | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00225823 |
| Fluticasone propionate | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00169546 |
| Salmeterol/fluticasone propionate | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00169546 |
| Fluticasone propionate | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00169546 |
| Salmeterol/fluticasone propionate | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00169546 |
| GW685698X Aqueous Nasal Spray | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00118729 |
| GW685698X Aqueous Nasal Spray | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00118729 |
| GW685698X aqueous nasal spray | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00116883 |
| GW685698X aqueous nasal spray | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00116818 |
| GW685698X | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial and Seasonal | COMPLETED | NCT00109486 |
| GW685698X | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial and Seasonal | COMPLETED | NCT00109486 |
| GW685698X | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00107757 |
| Dutasteride | Other | Phase PHASE4 | Prostatic Hyperplasia | COMPLETED | NCT00062790 |
| lamotrigine | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT00043875 |
| lamotrigine | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT00043875 |
| Engerix™-B | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00697866 |
| HBV-MPL vaccine 208129 | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00697866 |
| Engerix™-B | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00697749 |
| HBV-MPL vaccine 208129 | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00697749 |
| MEDI-517 HPV-16/18 VLP with Al(OH)3 (Formulation 4) | Other | Phase PHASE2 | Infections, Papillomavirus | COMPLETED | NCT00693966 |
| MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 3) | Other | Phase PHASE2 | Infections, Papillomavirus | COMPLETED | NCT00693966 |
| MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 2) | Other | Phase PHASE2 | Infections, Papillomavirus | COMPLETED | NCT00693966 |
| MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 1) | Other | Phase PHASE2 | Infections, Papillomavirus | COMPLETED | NCT00693966 |
| MEDI-517 HPV-16/18 VLP vaccine without adjuvant | Other | Phase PHASE2 | Infections, Papillomavirus | COMPLETED | NCT00693615 |
| MEDI-517 HPV-16/18 VLP vaccine with Al(OH)3 | Other | Phase PHASE2 | Infections, Papillomavirus | COMPLETED | NCT00693615 |
| MEDI-517 HPV-16/18 VLP AS04 vaccine | Other | Phase PHASE2 | Infections, Papillomavirus | COMPLETED | NCT00693615 |
| Rotarix | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT00429481 |
| Rotarix | Other | Phase PHASE2 | Infections, Rotavirus | COMPLETED | NCT00425737 |
| Hepatitis B adjuvanted vaccine | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00383227 |
| Hepatitis B adjuvanted vaccine | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00383227 |
| Infanrix-Hexa | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00366366 |
| Haemophilus influenzae type b- and meningococcal (vaccine) | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT00323050 |
| Meningococcal serogroup B vaccine | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT00137917 |
| Hib-MenC-TT | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT00135486 |
| MenC-TT | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT00135486 |
| MMR vaccine (Priorix) | Other | Phase PHASE4 | Rubella | COMPLETED | NCT00388440 |
| MMR vaccine (Priorix) | Other | Phase PHASE4 | Rubella | COMPLETED | NCT00388440 |
| DTPw-HBV/Hib-MenAC conjugate vaccine | Other | Phase PHASE3 | Diphtheria | COMPLETED | NCT00317161 |
| Placebo | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01580995 |
| Valacyclovir | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01580995 |
| DTPw-HBV/Hib-MenAC conjugate vaccine | Other | Phase PHASE3 | Diphtheria; Haemophilus Influenzae Type b; Hepatitis B; Tetanus; Whole Cell Pertussis | COMPLETED | NCT00317122 |
| Influsplit SSW® | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00306943 |
| Haemophilus influenzae type b- and meningococcal (vaccine) | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00263653 |
| Mencevax ACWY | Other | Phase PHASE4 | Infections, Meningococcal | COMPLETED | NCT00227422 |
| GSK208141 vaccine | Other | Phase PHASE3 | Herpes Simplex | COMPLETED | NCT00224471 |
| Hepatitis B vaccine | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00197158 |
| RTS,S/AS02A | Other | Phase PHASE2 | Malaria | COMPLETED | NCT00197041 |
| Rotavirus | Other | Phase PHASE2 | Infections, Rotavirus | COMPLETED | NCT00139334 |
| Live attenuated rotavirus vaccine | Other | Phase PHASE2 | Infections, Rotavirus | COMPLETED | NCT00137930 |
| Measles, Mumps, Rubella and Chickenpox (live vaccine) | Other | Phase PHASE3 | Mumps | COMPLETED | NCT00127023 |
| Measles, Mumps, Rubella and Chickenpox (live vaccine) | Other | Phase PHASE4 | Mumps | COMPLETED | NCT00126997 |
| Meningococcal Vaccine | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT00126945 |
| Retapamulin 1% | Other | Phase PHASE4 | Atopic Dermatitis | COMPLETED | NCT01064947 |
| Pneumococcal (vaccine) | Other | Phase PHASE2 | Acellular Pertussis | COMPLETED | NCT00307567 |
| lamotrigine extended-release | Other | Phase PHASE3 | Epilepsy | COMPLETED | NCT00264615 |
| lamotrigine extended-release | Other | Phase PHASE3 | Epilepsy | COMPLETED | NCT00264615 |
| Ropinirole Extended Release (XR) | Other | Phase PHASE3 | Restless Legs Syndrome | COMPLETED | NCT00197080 |
| albuterol sulfate inhalation aerosol | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00144846 |
| Live attenuated human rotavirus vaccine | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT00134732 |
| Fluticasone propionate/salmeterol | Other | Phase PHASE4 | Bronchospasm | COMPLETED | NCT00118690 |
| Placebo | Other | Phase PHASE3 | Neoplasms, Prostate | COMPLETED | NCT00056407 |
| Dutasteride | Other | Phase PHASE3 | Neoplasms, Prostate | COMPLETED | NCT00056407 |
| Placebo | Other | Phase PHASE3 | Neoplasms, Prostate | COMPLETED | NCT00056407 |
| Dutasteride | Other | Phase PHASE3 | Neoplasms, Prostate | COMPLETED | NCT00056407 |
| Pneumococcal (vaccine) | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00307554 |
| Measles, Mumps, Rubella and Chickenpox (live vaccine) | Other | Phase PHASE3 | Measles | COMPLETED | NCT00127010 |
| Fluarix | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00345904 |
| Hepatitis B vaccine | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00329576 |
| DTPa-HBV-IPV/Hib vaccine | Other | Phase PHASE3 | Diphtheria | COMPLETED | NCT00316147 |
| HPV-16/18 L1/AS04 | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00290277 |
| Prednisone | Other | Phase PHASE1 | Cancer | WITHDRAWN | NCT02380313 |
| Abiraterone | Other | Phase PHASE1 | Cancer | WITHDRAWN | NCT02380313 |
| Enzalutamide | Other | Phase PHASE1 | Cancer | WITHDRAWN | NCT02380313 |
| Afuresertib | Other | Phase PHASE1 | Cancer | WITHDRAWN | NCT02380313 |
| MMR, Varicella vacc (control) | Other | Phase PHASE2 | Varicella | COMPLETED | NCT00353288 |
| MeMuRu-OKA (study vacc) | Other | Phase PHASE2 | Varicella | COMPLETED | NCT00353288 |
| hepatitis B vaccine | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00335881 |
| Pneumococcal vaccine | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00333450 |
| Neis-Vac-C | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT00327184 |
| Infanrix hexa | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT00327184 |
| Infanrix Penta | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT00327184 |
| Haemophilus influenzae type b- and meningococcal serogroup C (vaccine) | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT00327184 |
| Diphtheria, tetanus, pertussis, hepatitis B, Hib vaccine | Other | Phase PHASE3 | Haemophilus Influenzae Type b | TERMINATED | NCT00316680 |
| Hib-MenAC mixed with Tritanrix™-HepB | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT00197275 |
| Mencevax ACWY | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT00126984 |
| Meningitec | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT00126984 |
| DTPa/Hib containing vaccine | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT00126984 |
| Conjugated meningococcal ACWY-TT (vaccine) | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT00126984 |
| lamotrigine | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00086593 |
| pazopanib in combination with weekly topotecan | Other | Phase PHASE1 | Ovarian Cancer | UNKNOWN | NCT01600573 |
| Placebo | Other | Phase PHASE2 | Sarcoma, Soft Tissue | WITHDRAWN | NCT02367651 |
| Pazopanib 800 mg | Other | Phase PHASE2 | Sarcoma, Soft Tissue | WITHDRAWN | NCT02367651 |
| Pazopanib plus Paclitaxel | Other | Phase PHASE2 | Non-small Cell Lung Cancer | WITHDRAWN | NCT01179269 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00945932 |
| GW870086X | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00945932 |
| diphtheria, tetanus, pertussis & Hib vaccine | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT00379977 |
| hepatitis B vaccine | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00356564 |
| hepatitis B vaccine | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00356564 |
| DTPa-HBV-IPV/Hib vaccine | Other | Phase PHASE3 | Diphtheria | COMPLETED | NCT00320463 |
| Dutasteride | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT00553878 |
| fluticasone propionate/salmeterol | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00369993 |
| Ropinirole | Other | Phase PHASE3 | Restless Legs Syndrome (RLS) | COMPLETED | NCT00363857 |
| Ropinirole | Other | Phase PHASE3 | Restless Legs Syndrome (RLS) | COMPLETED | NCT00363857 |
| Entecavir | Other | Phase PHASE4 | Chronic Hepatitis B | TERMINATED | NCT01627223 |
| Lamivudine | Other | Phase PHASE4 | Chronic Hepatitis B | TERMINATED | NCT01627223 |
| ropinirole Extended Release (XR) | Other | Phase PHASE3 | Restless Legs Syndrome | COMPLETED | NCT00314860 |
| MK-4827 + pegylated liposomal doxorubicin | Other | Phase PHASE1 | Ovarian Cancer | TERMINATED | NCT01227941 |
| Lamictal | Other | Phase PHASE3 | Epilepsy | COMPLETED | NCT01431963 |
| Lamictal | Other | Phase PHASE3 | Epilepsy | COMPLETED | NCT01431963 |
| FluarixTM/ Influsplit SSW® 2010/2011 | Other | Phase PHASE3 | Influenza | TERMINATED | NCT01160237 |
| PandemrixTM | Other | Phase PHASE3 | Influenza | TERMINATED | NCT01160237 |
| Blood sampling | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00929526 |
| Liquid-based cytology (LBC) sampling | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00929526 |
| dietary recommendation for weight maintenance | Other | Approved | Diabetes Mellitus, Type 2 | TERMINATED | NCT00225225 |
| Rosiglitazone | Other | Approved | Diabetes Mellitus, Type 2 | TERMINATED | NCT00225225 |
| Tiotropium + SERETIDE 50/500 | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00325169 |
| placebo | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT00329459 |
| sumatriptan succinate/naproxen sodium | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT00329459 |
| Mencevax™ ACWY | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT00390143 |
| Meningococcal vaccine 134612 | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT00390143 |
| ropinirole dosing for up to 28 days | Other | Phase PHASE1 | Restless Legs Syndrome | COMPLETED | NCT00422994 |
| placebo injection | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00354536 |
| GSK716155 subcutaneous injections | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00354536 |
| GW679769 (casopitant) | Other | Phase PHASE3 | Nausea and Vomiting, Postoperative | COMPLETED | NCT00326248 |
| placebo | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT00240617 |
| sumatriptan succinate/naproxen sodium | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT00240617 |
| placebo | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT00240617 |
| sumatriptan succinate/naproxen sodium | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT00240617 |
| Vilanterol | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01691885 |
| Fluticasone Furoate | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01691885 |
| Boostrix | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT00406562 |
| Ropinirole | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT00460148 |
| Chinese DT vaccine | Other | Phase PHASE3 | Diphtheria | COMPLETED | NCT00452686 |
| Boostrix | Other | Phase PHASE3 | Diphtheria | COMPLETED | NCT00452686 |
| Chinese DT vaccine | Other | Phase PHASE3 | Diphtheria | COMPLETED | NCT00452686 |
| Boostrix | Other | Phase PHASE3 | Diphtheria | COMPLETED | NCT00452686 |
| GSK233705 | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00422604 |
| tiotropium | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00422604 |
| salmeterol | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00422604 |
| GW679769 | Other | Phase PHASE2 | Depressive Disorder, Major | COMPLETED | NCT00413023 |
| Engerix™-B Kinder | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00411697 |
| Darapladib | Other | Phase PHASE1 | Atherosclerosis | COMPLETED | NCT00411073 |
| ADVAIR DISKUS | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00400608 |
| ADVAIR HFA | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00400608 |
| Placebo | Other | Phase PHASE2 | Tinnitus | COMPLETED | NCT00394056 |
| Vestipitant + Paroxetine | Other | Phase PHASE2 | Tinnitus | COMPLETED | NCT00394056 |
| Vestipitant | Other | Phase PHASE2 | Tinnitus | COMPLETED | NCT00394056 |
| ropinirole CR-RLS | Other | Phase PHASE4 | Restless Legs Syndrome (RLS) | COMPLETED | NCT00373542 |
| 10 valent pneumococcal conjugate (vaccine) | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00370227 |
| placebo | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00358488 |
| salmeterol 50mcg | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00358488 |
| salbutamol | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00358488 |
| GSK159797 (10, 15, and 20mcg) | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00358488 |
| Ropinirole Extended Release (XR) | Other | Phase PHASE3 | Restless Legs Syndrome | COMPLETED | NCT00355641 |
| Ropinirole Extended Release (XR) | Other | Phase PHASE3 | Restless Legs Syndrome | COMPLETED | NCT00355641 |
| Fluticasone Propionate/Salmeterol Combination Product | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT00346749 |
| Salmeterol | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT00346749 |
| montelukast | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00296530 |
| fluticasone propionate | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00296530 |
| fluticasone propionate/salmeterol | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00296530 |
| GW677954 | Other | Phase PHASE2 | Metabolic Syndrome X | COMPLETED | NCT00264667 |
| Fluticasone Propionate/Salmeterol Combination Product | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00144911 |
| Salmeterol | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00144911 |
| 2-dose oral live attenuated G1P[8] human rotavirus vaccine | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT00139347 |
| cilomilast | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00103922 |
| cilomilast | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00103922 |
| ibandronate | Other | Phase PHASE4 | Osteoporosis | COMPLETED | NCT02948881 |
| ibandronate | Other | Phase PHASE4 | Osteoporosis | COMPLETED | NCT02948881 |
| ibandronate | Other | Phase PHASE4 | Osteoporosis | COMPLETED | NCT02948881 |
| Vitamin D | Other | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT02014467 |
| Elemental Calcium | Other | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT02014467 |
| Placebo | Other | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT02014467 |
| Denosumab | Other | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT02014467 |
| GSK704838 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00539825 |
| EngerixTM-B | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00774995 |
| SB-480848 (Darapladib) | Other | Phase PHASE1 | Atherosclerosis | COMPLETED | NCT00622830 |
| SB-480848 (Darapladib) | Other | Phase PHASE1 | Atherosclerosis | COMPLETED | NCT00622830 |
| fluticasone propionate | Other | Phase PHASE2 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00612820 |
| GSK256066 | Other | Phase PHASE2 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00612820 |
| fluticasone propionate | Other | Phase PHASE2 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00612820 |
| GSK256066 | Other | Phase PHASE2 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00612820 |
| SB-480848 (darapladib) | Other | Phase PHASE1 | Atherosclerosis | COMPLETED | NCT00704431 |
| SB-480848 (darapladib) | Other | Phase PHASE1 | Atherosclerosis | COMPLETED | NCT00704431 |
| Fluviral® | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00505453 |
| Fluarix™/Influsplit SSW® 2007/2008 | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00476307 |
| Infanrix hexa Vaccine | Other | Phase PHASE2 | Acellular Pertussis | COMPLETED | NCT00376779 |
| 2-dose oral live attenuated G1P[8] human rotavirus vaccine | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT00334607 |
| HPV-16/18 L1 VLP AS04 | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00306241 |
| Rotavirus | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT00197210 |
| HPV 16/18 VLP AS04 | Other | Phase PHASE2 | Infections, Papillomavirus | COMPLETED | NCT00120848 |
| HPV 16/18 VLP AS04 | Other | Phase PHASE2 | Infections, Papillomavirus | COMPLETED | NCT00120848 |
| MK-4827 | Other | Phase PHASE2 | Lymphoma | WITHDRAWN | NCT01244009 |
| Placebo | Other | Phase PHASE2 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00851344 |
| Cetirizine (10mg) | Other | Phase PHASE2 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00851344 |
| GSK835726 (100mg) | Other | Phase PHASE2 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00851344 |
| GSK835726 (50mg) | Other | Phase PHASE2 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00851344 |
| GSK835726 (10mg) | Other | Phase PHASE2 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00851344 |
| Placebo | Other | Phase PHASE2 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00851344 |
| Cetirizine (10mg) | Other | Phase PHASE2 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00851344 |
| GSK835726 (100mg) | Other | Phase PHASE2 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00851344 |
| GSK835726 (50mg) | Other | Phase PHASE2 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00851344 |
| GSK835726 (10mg) | Other | Phase PHASE2 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00851344 |
| Placebo Lyophilized DCC Pen injector | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02660736 |
| Placebo Liquid Auto-injector | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02660736 |
| Albiglutide Lyophilized DCC Pen Injector | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02660736 |
| Albiglutide Liquid Auto-injector | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02660736 |
| Lamotrigine tablets | Other | Preclinical | Epilepsy | COMPLETED | NCT01863602 |
| Alpha-blockers | Other | Preclinical | Prostatic Hyperplasia | COMPLETED | NCT01767363 |
| 5-alpha reductase inhibitors | Other | Preclinical | Prostatic Hyperplasia | COMPLETED | NCT01767363 |
| Lamotrigine | Other | Preclinical | Epilepsy | COMPLETED | NCT01376180 |
| fluticasone propionate/salmeterol 50/250mcg and tiotropium 18mcg | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01762800 |
| tiotropium bromide placebo | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01762800 |
| tiotropium bromide 18mcg | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01762800 |
| fluticasone propionate/salmeterol placebo | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01762800 |
| fluticasone propionate/salmeterol 50/250mcg | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01762800 |
| Lapatinib | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00524303 |
| FEC75 | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00524303 |
| Paclitaxel | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00524303 |
| Trastuzumab | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00524303 |
| Lapatinib | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00524303 |
| FEC75 | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00524303 |
| Paclitaxel | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00524303 |
| Trastuzumab | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00524303 |
| Placebo (saline) | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT01648153 |
| GSK1070806 | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT01648153 |
| placebo | Other | Phase PHASE2 | Retinopathy, Diabetic | COMPLETED | NCT01506895 |
| darapladib | Other | Phase PHASE2 | Retinopathy, Diabetic | COMPLETED | NCT01506895 |
| 20mg Atorvastatin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01495013 |
| 10mg Atorvastatin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01495013 |
| 4mg Glimepiride | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01495013 |
| 3mg Glimepiride | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01495013 |
| 2mg Glimepiride | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01495013 |
| 1mg Glimepiride | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01495013 |
| 4mg Glimepiride/20mg Atorvastatin FDC | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01495013 |
| 3mg Glimepiride/20mg Atorvastatin FDC | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01495013 |
| 2mg Glimepiride/20mg Atorvastatin FDC | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01495013 |
| 1mg Glimepiride/20mg Atorvastatin FDC | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01495013 |
| 4mg Glimepiride/10mg Atorvastatin FDC | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01495013 |
| 3mg Glimepiride/10mg Atorvastatin FDC | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01495013 |
| 2mg Glimepiride/10mg Atorvastatin FDC | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01495013 |
| 1mg Glimepiride/10mg Atorvastatin FDC | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01495013 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01471665 |
| GSK2190915 100mg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01471665 |
| retrospective chart review | Other | Preclinical | Infections, Respiratory Tract | COMPLETED | NCT01353768 |
| Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | COMPLETED | NCT00996593 |
| benzoyl peroxide and adapalene gel (EPIDUO™ Gel) | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT00964223 |
| Clindamycin and benzoyl peroxide gel (Duac® Topical Gel) | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT00964223 |
| benzoyl peroxide and adapalene gel (EPIDUO™ Gel) | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT00964223 |
| Clindamycin and benzoyl peroxide gel (Duac® Topical Gel) | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT00964223 |
| unfractionated heparin (UFH) | Other | Phase PHASE3 | Thrombosis, Venous | COMPLETED | NCT00911157 |
| Fondaparinux sodium | Other | Phase PHASE3 | Thrombosis, Venous | COMPLETED | NCT00911157 |
| Fluticasone Propionate/Salmeterol | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00784550 |
| Tiotropium Bromide | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00784550 |
| vehicle gel | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT00776919 |
| BPO gel | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT00776919 |
| clindamycin gel | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT00776919 |
| clindamycin / benzoyl peroxide gel | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT00776919 |
| GSK573719 | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00732472 |
| Placebo ointment | Other | Phase PHASE3 | Skin Infections, Bacterial | COMPLETED | NCT00684177 |
| Retapamulin Ointment, 1% | Other | Phase PHASE3 | Skin Infections, Bacterial | COMPLETED | NCT00684177 |
| Placebo | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00550407 |
| lamotrigine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00550407 |
| Placebo capsule (PM) | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01248975 |
| Placebo tablets (2) (AM) | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01248975 |
| Montelukast 10mg QD (PM) | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01248975 |
| GSK2190915 100mg QD (AM) | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01248975 |
| GSK2190915 200mg QD (AM) | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01248975 |
| FP/SAL 250/50mcg BID | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01248975 |
| Placebo capsule (PM) | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01248975 |
| Placebo tablets (2) (AM) | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01248975 |
| Montelukast 10mg QD (PM) | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01248975 |
| GSK2190915 100mg QD (AM) | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01248975 |
| GSK2190915 200mg QD (AM) | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01248975 |
| FP/SAL 250/50mcg BID | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01248975 |
| Sampling of blood | Other | Approved | Rheumatoid Arthritis | UNKNOWN | NCT02116504 |
| Varivax | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00345683 |
| M-M-R II | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00345683 |
| Prevnar | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00345683 |
| PedvaxHIB | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00345683 |
| GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014) | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00345683 |
| SB-705498 | Other | Phase PHASE2 | Rhinitis | COMPLETED | NCT01476098 |
| Placebo | Other | Phase PHASE2 | Rhinitis | COMPLETED | NCT01476098 |
| SB-705498 | Other | Phase PHASE2 | Rhinitis | COMPLETED | NCT01439308 |
| Placebo | Other | Phase PHASE2 | Rhinitis | COMPLETED | NCT01439308 |
| SB-705498 | Other | Phase PHASE2 | Rhinitis | COMPLETED | NCT01439308 |
| Placebo | Other | Phase PHASE2 | Rhinitis | COMPLETED | NCT01439308 |
| GW870086 3mg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01245426 |
| GW870086 1mg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01245426 |
| GW870086 Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01245426 |
| GW870086 4mg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01245426 |
| GW870086 2mg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01245426 |
| Placebo | Other | Phase PHASE2 | Obesity | COMPLETED | NCT01195792 |
| GSK1521498 | Other | Phase PHASE2 | Obesity | COMPLETED | NCT01195792 |
| 18F Fluorodeoxylucose (FDG)-PET | Other | Phase PHASE2 | Atherosclerosis | COMPLETED | NCT00695305 |
| placebo | Other | Phase PHASE2 | Atherosclerosis | COMPLETED | NCT00695305 |
| rilapladib | Other | Phase PHASE2 | Atherosclerosis | COMPLETED | NCT00695305 |
| Placebo | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT00674635 |
| GSK3152314A | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT00674635 |
| Placebo | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT00674635 |
| GSK3152314A | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT00674635 |
| Placebo | Other | Phase PHASE2 | Atherosclerosis | COMPLETED | NCT01916720 |
| SB-480848 80 mg | Other | Phase PHASE2 | Atherosclerosis | COMPLETED | NCT01916720 |
| SB-480848 40 mg | Other | Phase PHASE2 | Atherosclerosis | COMPLETED | NCT01916720 |
| Darapladib (SB480848) | Other | Phase PHASE1 | Atherosclerosis | COMPLETED | NCT00551317 |
| SB 480848, tablets | Other | Phase PHASE1 | Atherosclerosis | COMPLETED | NCT00368576 |
| SB 480848, tablets | Other | Phase PHASE1 | Atherosclerosis | COMPLETED | NCT00368576 |
| artemether-lumefantrine | Other | Phase PHASE3 | Malaria, Falciparum | COMPLETED | NCT00344006 |
| chlorproguanil-dapsone-artesunate | Other | Phase PHASE3 | Malaria, Falciparum | COMPLETED | NCT00344006 |
| Avandia | Other | Phase PHASE3 | Insulin Resistance | COMPLETED | NCT00197132 |
| Avandia | Other | Phase PHASE3 | Insulin Resistance | COMPLETED | NCT00197132 |
| LAMICTAL extended-release | Other | Phase PHASE3 | Epilepsy | COMPLETED | NCT00113165 |
| LAMICTAL extended-release | Other | Phase PHASE3 | Epilepsy | COMPLETED | NCT00113165 |
| Chlorproguanil-dapsone-artesunate (CDA) | Other | Phase PHASE2 | Malaria | COMPLETED | NCT00519467 |
| Mobile application | Other | Approved | Asthma | UNKNOWN | NCT02977078 |
| Inhaler casing | Other | Approved | Asthma | UNKNOWN | NCT02977078 |
| Active feedback on monitored inhaler use | Other | Approved | Asthma | UNKNOWN | NCT02977078 |
| GW685698X | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00766090 |
| Placebo Dentifrice | Other | Phase PHASE2 | Dental Erosion | COMPLETED | NCT00752089 |
| NaF Dentifrice | Other | Phase PHASE2 | Dental Erosion | COMPLETED | NCT00752089 |
| NaF/KNO3 Dentifrice | Other | Phase PHASE2 | Dental Erosion | COMPLETED | NCT00752089 |
| NaF/ KNO3/isopentane Dentifrice | Other | Phase PHASE2 | Dental Erosion | COMPLETED | NCT00752089 |
| GW685698/GW642444 | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00731822 |
| GW685698/GW642444 | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00731822 |
| Fluticasone propionate 250 mcg BID | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00452699 |
| Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00452699 |
| Paclitaxel | Other | Phase PHASE2 | Epithelial Ovarian Cancer | COMPLETED | NCT00314678 |
| Cisplatin | Other | Phase PHASE2 | Epithelial Ovarian Cancer | COMPLETED | NCT00314678 |
| Topotecan | Other | Phase PHASE2 | Epithelial Ovarian Cancer | COMPLETED | NCT00314678 |
| Paclitaxel | Other | Phase PHASE2 | Epithelial Ovarian Cancer | COMPLETED | NCT00314678 |
| Cisplatin | Other | Phase PHASE2 | Epithelial Ovarian Cancer | COMPLETED | NCT00314678 |
| Topotecan | Other | Phase PHASE2 | Epithelial Ovarian Cancer | COMPLETED | NCT00314678 |
| Blood sampling | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00240539 |
| Placebo | Other | Phase PHASE3 | Seizures | COMPLETED | NCT00232596 |
| Retigabine | Other | Phase PHASE3 | Seizures | COMPLETED | NCT00232596 |
| placebo FFNS | Other | Phase PHASE4 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00539006 |
| placebo FPNS | Other | Phase PHASE4 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00539006 |
| FFNS | Other | Phase PHASE4 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00539006 |
| FPNS | Other | Phase PHASE4 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00539006 |
| placebo FPNS | Other | Phase PHASE4 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00519636 |
| placebo FFNS | Other | Phase PHASE4 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00519636 |
| FFNS | Other | Phase PHASE4 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00519636 |
| FPNS | Other | Phase PHASE4 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00519636 |
| Cervarix | Other | Phase PHASE2 | Infections, Papillomavirus | COMPLETED | NCT00518336 |
| Collection of cervical specimen | Other | Phase PHASE2 | Infections, Papillomavirus | COMPLETED | NCT00518336 |
| Blood sampling | Other | Phase PHASE2 | Infections, Papillomavirus | COMPLETED | NCT00518336 |
| fluticasone furoate, fexofenadine | Other | Phase PHASE4 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00502775 |
| Fluticasone propionate 250 mcg BID | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00452348 |
| Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00452348 |
| Fluticasone propionate 250 mcg BID | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00452348 |
| Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00452348 |
| Placebo | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT00329745 |
| Rotarix™ | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT00329745 |
| Placebo | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT00241644 |
| Rotarix™ | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT00241644 |
| GSK1120212 | Other | Phase PHASE2 | Melanoma | COMPLETED | NCT01619774 |
| GSK2118436 | Other | Phase PHASE2 | Melanoma | COMPLETED | NCT01619774 |
| Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | COMPLETED | NCT01224821 |
| Belimumab 10 mg/kg | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT00424476 |
| Belimumab 1 mg/kg | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT00424476 |
| Placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT00424476 |
| Itraconazole | Other | Phase PHASE1 | Alzheimer's Disease | WITHDRAWN | NCT02130661 |
| Rilapladib 250 mg | Other | Phase PHASE1 | Alzheimer's Disease | WITHDRAWN | NCT02130661 |
| Rilapladib 25 mg | Other | Phase PHASE1 | Alzheimer's Disease | WITHDRAWN | NCT02130661 |
| BENZOYL PEROXIDE/ ADAPALENE | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT00887484 |
| BENZOYL PEROXIDE/ CLINDAMYCIN | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT00887484 |
| BENZOYL PEROXIDE/ ADAPALENE | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT00887484 |
| BENZOYL PEROXIDE/ CLINDAMYCIN | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT00887484 |
| Placebo | Other | Phase PHASE2 | Infections, Bacterial | COMPLETED | NCT00539994 |
| Retapamulin | Other | Phase PHASE2 | Infections, Bacterial | COMPLETED | NCT00539994 |
| retapamulin | Other | Phase PHASE2 | Infections, Bacterial | COMPLETED | NCT00539994 |
| Lovaza™ | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01252290 |
| placebo | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00606684 |
| GW642444 50mcg | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00606684 |
| GW642444 25mcg | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00606684 |
| GW642444 12.5mcg | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00606684 |
| GW642444 3mcg | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00606684 |
| GW642444 6.25 | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00606684 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00600171 |
| GW642444M | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00600171 |
| Lamotrigine | Other | Phase PHASE3 | Mood Disorders | COMPLETED | NCT00579982 |
| Albiglutide (GSK716155) or exenatide | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00518115 |
| Placebo | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00517634 |
| SFC | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00517634 |
| Cervarix TM | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00456807 |
| Placebo | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00456807 |
| Cervarix TM | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00456807 |
| Placebo | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00456807 |
| Cervarix TM | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00456807 |
| Placebo | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00456807 |
| Engerix™-B | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00456625 |
| Placebo | Other | Phase PHASE3 | Migraine, Without Aura | COMPLETED | NCT00387881 |
| sumatriptan succinate / naproxen sodium | Other | Phase PHASE3 | Migraine, Without Aura | COMPLETED | NCT00387881 |
| Placebo | Other | Phase PHASE3 | Migraine, Without Aura | COMPLETED | NCT00387881 |
| sumatriptan succinate / naproxen sodium | Other | Phase PHASE3 | Migraine, Without Aura | COMPLETED | NCT00387881 |
| Hib conjugate vaccine (ActHIB) | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT00359983 |
| MenHibrix (Hib-MenCY-TT) | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT00359983 |
| Pediarix/Infanrix Penta | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00345579 |
| ActHIB | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00345579 |
| GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014 | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00345579 |
| placebo DISKUS | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00296491 |
| placebo capsule | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00296491 |
| ADVAIR DISKUS | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00296491 |
| placebo nasal | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00296491 |
| fluticasone propionate (FP) | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00296491 |
| montelukast (MON) | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00296491 |
| fluticasone propionate/salmeterol (FSC) | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00296491 |
| lisinopril | Other | Phase PHASE3 | Hypertrophy, Left Ventricular | COMPLETED | NCT00108082 |
| atenolol | Other | Phase PHASE3 | Hypertrophy, Left Ventricular | COMPLETED | NCT00108082 |
| carvedilol MR | Other | Phase PHASE3 | Hypertrophy, Left Ventricular | COMPLETED | NCT00108082 |
| Engerix™-B | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00657657 |
| Engerix™-B | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00240500 |
| Data collection | Other | Preclinical | Infections, Papillomavirus | COMPLETED | NCT01953822 |
| carvedilol controlled release formulation | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00347360 |
| lisinopril | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00347360 |
| Ofatumumab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01681563 |
| Cyclophosphamide | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01681563 |
| Pentostatin | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01681563 |
| lisinopril + placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00624065 |
| carvedilol controlled release/lisinopril | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00624065 |
| placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00603278 |
| GW685698X | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00603278 |
| placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00603278 |
| GW685698X | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00603278 |
| placebo | Other | Phase PHASE4 | Asthma | TERMINATED | NCT00503009 |
| fluticasone propionate | Other | Phase PHASE4 | Asthma | TERMINATED | NCT00503009 |
| fluticasone propionate/salmeterol | Other | Phase PHASE4 | Asthma | TERMINATED | NCT00503009 |
| Vehicle | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT00688519 |
| U0267 | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT00688519 |
| Vehicle | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT00688519 |
| U0267 | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT00688519 |
| lamotrigine, 250 mg/day | Other | Phase PHASE3 | Epilepsy, Partial | COMPLETED | NCT00355082 |
| lamotrigine, 300 mg/day | Other | Phase PHASE3 | Epilepsy, Partial | COMPLETED | NCT00355082 |
| Placebo | Other | Phase PHASE3 | Epilepsy, Tonic-Clonic | COMPLETED | NCT00104416 |
| lamotrigine (LAMICTAL) extended-release | Other | Phase PHASE3 | Epilepsy, Tonic-Clonic | COMPLETED | NCT00104416 |
| Ongoing cART regimen | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02105987 |
| ABC/DTG/3TC FDC | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02105987 |
| Vilanterol | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01573767 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01573767 |
| Fluticasone propionate 100mcg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01573767 |
| CCI18781 | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01498653 |
| GW685698/GW642444 | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01498653 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01436110 |
| Fluticasone propionate 100mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01436110 |
| Fluticasone furoate 50mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01436110 |
| albuterol/salbutamol | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01431950 |
| fluticasone furoate | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01431950 |
| GSK573719/GW642444 Inhalation Powder | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01376388 |
| albiglutide (GSK716155) | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01357889 |
| Tositumomab and Iodine I 131 Tositumomab | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | COMPLETED | NCT00938041 |
| placebo | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00849017 |
| albiglutide uptitration | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00849017 |
| albiglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00849017 |
| placebo to match pioglitazone | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00839527 |
| pioglitazone | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00839527 |
| glimepiride | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00839527 |
| metformin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00839527 |
| albiglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00839527 |
| placebo to match albiglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00839527 |
| lamictal | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00723450 |
| lamictal | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00723450 |
| Rituximab | Other | Phase PHASE3 | Lymphoma, Non-Hodgkin | COMPLETED | NCT00268983 |
| Tositumomab and Iodine I 131 Tositumomab | Other | Phase PHASE3 | Lymphoma, Non-Hodgkin | COMPLETED | NCT00268983 |
| Iodine I 131 Tositumomab Therapeutic Regimen | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | COMPLETED | NCT00268203 |
| Data collection | Other | Preclinical | Influenza | COMPLETED | NCT02019732 |
| Pneumococcal (vaccine) | Other | Phase PHASE2 | Streptococcal Infections | COMPLETED | NCT00169481 |
| cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab. | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | COMPLETED | NCT01663714 |
| cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab. | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | COMPLETED | NCT01663714 |
| placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01475734 |
| albiglutide | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01475734 |
| Fluticasone Furoate/Vilanterol | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01453023 |
| Fluticasone Furoate | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01453023 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01436071 |
| Fluticasone furoate 50mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01436071 |
| Mepolizumab | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01366521 |
| Placebo PM | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01287065 |
| Placebo AM | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01287065 |
| FF(100mcg)/Vilanterol(25mcg) PM | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01287065 |
| FF(100mcg)/Vilanterol(25mcg) AM | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01287065 |
| Fluticasone Furoate Inhalation Powder | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01244984 |
| Fluticasone Furoate/GW642444 Inhalation Powder | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01244984 |
| Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01192191 |
| Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01192191 |
| Placebo Inhalation Powder 2 | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01134042 |
| Placebo Inhalation Powder 1 | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01134042 |
| Fluticasone Propionate Inhalation Powder | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01134042 |
| Fluticasone Furoate Inhalation Powder | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01134042 |
| Fluticasone Furoate/Vilanterol Inhalation Powder | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01134042 |
| Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody) | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | COMPLETED | NCT00996996 |
| Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody) | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | COMPLETED | NCT00996996 |
| 18FML10 | Other | Phase PHASE2 | Cancer | TERMINATED | NCT01428440 |
| 10-week smoking cessation group therapy combined with NicoDerm CQ | Drug | Phase PHASE3 | Tobacco Use Cessation | COMPLETED | NCT00110630 |
| Cabotegravir 30 mg | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02799264 |
| Cabotegravir 30 mg | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02799264 |
| Synflorix™ Data collection | Other | Preclinical | Infections, Streptococcal | COMPLETED | NCT01248988 |
| placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01098461 |
| albiglutide | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01098461 |
| vehicle placebo nasal spray | Other | Phase PHASE4 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00682643 |
| fluticasone furoate nasal spray | Other | Phase PHASE4 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00682643 |
| vehicle placebo nasal spray | Other | Phase PHASE4 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00682643 |
| fluticasone furoate nasal spray | Other | Phase PHASE4 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00682643 |
| Vitamin D supplement | Other | Phase PHASE3 | Fractures, Bone | COMPLETED | NCT01920568 |
| Calcium supplement | Other | Phase PHASE3 | Fractures, Bone | COMPLETED | NCT01920568 |
| Placebo SC | Other | Phase PHASE3 | Fractures, Bone | COMPLETED | NCT01920568 |
| Placebo IV | Other | Phase PHASE3 | Fractures, Bone | COMPLETED | NCT01920568 |
| Zoledronic acid 4 mg | Other | Phase PHASE3 | Fractures, Bone | COMPLETED | NCT01920568 |
| Denosumab 70 mg/mL | Other | Phase PHASE3 | Fractures, Bone | COMPLETED | NCT01920568 |
| Vitamin D supplement | Other | Phase PHASE3 | Fractures, Bone | COMPLETED | NCT01920568 |
| Calcium supplement | Other | Phase PHASE3 | Fractures, Bone | COMPLETED | NCT01920568 |
| Placebo SC | Other | Phase PHASE3 | Fractures, Bone | COMPLETED | NCT01920568 |
| Placebo IV | Other | Phase PHASE3 | Fractures, Bone | COMPLETED | NCT01920568 |
| Zoledronic acid 4 mg | Other | Phase PHASE3 | Fractures, Bone | COMPLETED | NCT01920568 |
| Denosumab 70 mg/mL | Other | Phase PHASE3 | Fractures, Bone | COMPLETED | NCT01920568 |
| SB424323 | Other | Phase PHASE2 | Fibrillation, Atrial | COMPLETED | NCT00240643 |
| Live attenuated human rotavirus vaccine | Other | Phase PHASE3 | Rotavirus Gastroenteritis | COMPLETED | NCT00169455 |
| Placebo ELLIPTA DPI | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02972905 |
| GSK2269557 ELLIPTA DPI | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02972905 |
| Placebo ELLIPTA DPI | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02972905 |
| GSK2269557 ELLIPTA DPI | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02972905 |
| Ritonavir | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02795754 |
| Placebo PIB | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02795754 |
| GSK2838232 IR2 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02795754 |
| GSK2838232 IR1 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02795754 |
| GSK2838232 PIB | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02795754 |
| Ritonavir | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02795754 |
| Placebo PIB | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02795754 |
| GSK2838232 IR2 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02795754 |
| GSK2838232 IR1 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02795754 |
| GSK2838232 PIB | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02795754 |
| Placebo | Other | Phase PHASE2 | Adenomyosis | WITHDRAWN | NCT02794467 |
| Epelsiban | Other | Phase PHASE2 | Adenomyosis | WITHDRAWN | NCT02794467 |
| Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB) | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02738931 |
| Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA) | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02738931 |
| Lamivudine 300 mg tablet | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02738931 |
| Dolutegravir 50 mg tablet | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02738931 |
| Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB) | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02738931 |
| Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA) | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02738931 |
| Lamivudine 300 mg tablet | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02738931 |
| Dolutegravir 50 mg tablet | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02738931 |
| De-ionised water | Other | Approved | Tooth Erosion | COMPLETED | NCT02548156 |
| Orange Juice | Other | Approved | Tooth Erosion | COMPLETED | NCT02548156 |
| Comparator Dentifrice | Other | Approved | Tooth Erosion | COMPLETED | NCT02548156 |
| Reference Dentifrice | Other | Approved | Tooth Erosion | COMPLETED | NCT02548156 |
| Test Dentifrice | Other | Approved | Tooth Erosion | COMPLETED | NCT02548156 |
| Stool samples | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT01339221 |
| ADVAIR™ DISKUS™ 100/50 mcg BID | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01192178 |
| FLOVENT™ DISKUS™ 100 mcg BID | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01192178 |
| Placebo (2) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01147848 |
| Placebo (1) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01147848 |
| Fluticasone propionate/salmeterol Inhalation Powder | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01147848 |
| Fluticasone furoate/Vilanterol Inhalation Powder | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01147848 |
| Vehicle Foam | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01139580 |
| Calcipotriene Foam | Other | Phase PHASE3 | Psoriasis | COMPLETED | NCT01139580 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01128595 |
| Fluticasone Furoate | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01128595 |
| GW642444M | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01128595 |
| FF/GW642444M | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01128595 |
| Prednisolone Oral Capsule | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01086410 |
| Placebo Oral Capsule | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01086410 |
| Fluticasone Furoate/GW642444 Inhalation Powder | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01086410 |
| Placebo Inhalation Powder | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01086410 |
| Prednisolone Oral Capsule | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01086410 |
| Placebo Oral Capsule | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01086410 |
| Fluticasone Furoate/GW642444 Inhalation Powder | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01086410 |
| Placebo Inhalation Powder | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01086410 |
| Vehicle Foam | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT01017146 |
| Tazarotene foam | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT01017146 |
| Tositumomab and Iodine I 131 Tositumomab | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | COMPLETED | NCT00933335 |
| Placebo | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT00843024 |
| Sumatriptan and Naproxen Sodium | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT00843024 |
| ropinirole IR | Other | Phase PHASE3 | Parkinson Disease | COMPLETED | NCT00823836 |
| ropinirole PR/XR | Other | Phase PHASE3 | Parkinson Disease | COMPLETED | NCT00823836 |
| Lamotrigine | Other | Phase PHASE3 | Epilepsy | COMPLETED | NCT00516139 |
| GSK690693 | Other | Phase PHASE1 | Cancer | TERMINATED | NCT00493818 |
| GSK690693 | Other | Phase PHASE1 | Cancer | TERMINATED | NCT00493818 |
| ropinirole controlled-release (REQUIP CR) for RLS | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00363727 |
| ropinirole controlled-release (REQUIP CR) for RLS | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00363727 |
| paroxetine | Other | Phase PHASE4 | Mental Disorders | COMPLETED | NCT00259883 |
| GW786034 | Other | Phase PHASE2 | Carcinoma, Renal Cell | COMPLETED | NCT00256880 |
| Influenza | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00197288 |
| Influenza | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00197288 |
| lisinopril | Other | Phase PHASE3 | Heart Failure, Congestive and Microalbuminuria | TERMINATED | NCT00123903 |
| carvedilol MR | Other | Phase PHASE3 | Heart Failure, Congestive and Microalbuminuria | TERMINATED | NCT00123903 |
| metoprolol xl | Other | Phase PHASE3 | Heart Failure, Congestive and Microalbuminuria | TERMINATED | NCT00123903 |
| lisinopril | Other | Phase PHASE3 | Heart Failure, Congestive and Microalbuminuria | TERMINATED | NCT00123903 |
| carvedilol MR | Other | Phase PHASE3 | Heart Failure, Congestive and Microalbuminuria | TERMINATED | NCT00123903 |
| metoprolol xl | Other | Phase PHASE3 | Heart Failure, Congestive and Microalbuminuria | TERMINATED | NCT00123903 |
| fluticasone propionate powder | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00102765 |
| fluticasone propionate/salmeterol powder | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00102765 |
| lamotrigine | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT00044278 |
| BMS955176 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02715479 |
| Dolutegravir | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02715479 |
| Ritonavir | Other | Phase PHASE1 | Infections, Human Immunodeficiency Virus and Herpesviridae | COMPLETED | NCT01209065 |
| Fosamprenavir | Other | Phase PHASE1 | Infections, Human Immunodeficiency Virus and Herpesviridae | COMPLETED | NCT01209065 |
| GSK1349572 | Other | Phase PHASE1 | Infections, Human Immunodeficiency Virus and Herpesviridae | COMPLETED | NCT01209065 |
| GSK1325760A | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT00424034 |
| ZANTAC (ranitidine) | Other | Phase PHASE2 | Gastroesophageal Reflux Disease | COMPLETED | NCT00405119 |
| NEXIUM (esomeprazole) | Other | Phase PHASE2 | Gastroesophageal Reflux Disease | COMPLETED | NCT00405119 |
| AH23844 (lavoltidine) | Other | Phase PHASE2 | Gastroesophageal Reflux Disease | COMPLETED | NCT00405119 |
| GW685698X Aqueous Nasal Spray | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00197262 |
| GW685698X Aqueous Nasal Spray | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00197262 |
| GW406381 | Other | Phase PHASE3 | Dental Pain | COMPLETED | NCT00114049 |
| GW685698X | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00108914 |
| Tafenoquine SIL | Other | Phase PHASE1 | Malaria, Vivax | COMPLETED | NCT02751294 |
| Tafenoquine dissolution profile X | Other | Phase PHASE1 | Malaria, Vivax | COMPLETED | NCT02751294 |
| Tafenoquine Control | Other | Phase PHASE1 | Malaria, Vivax | COMPLETED | NCT02751294 |
| GSK580416 oral tablets (250 mg) Ketoconazole oral tablets (200 mg) | Other | Phase PHASE1 | Bacterial Infection | TERMINATED | NCT00680485 |
| GW597599 | Other | Phase PHASE2 | Postoperative Nausea and Vomiting | COMPLETED | NCT00600990 |
| fluticasone propionate DISKUS 500mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00549146 |
| fluticasone propionate/salmeterol 250/50 DISKUS combination product | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00549146 |
| Fluticasone propionate/ salmeterol combination 50/500mcg | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00361959 |
| Tiotropium bromide 18mcg | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00361959 |
| Salmeterol/Fluticasone propionate Inhalation Powder (50/100mcg BID) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00328718 |
| montelukast (5mg QD) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00328718 |
| GW679769 oral tablets | Other | Phase PHASE2 | Incontinence, Urinary and Urinary Bladder, Overactive | COMPLETED | NCT00321477 |
| GW679769 | Other | Phase PHASE2 | Postoperative Nausea and Vomiting | COMPLETED | NCT00274690 |
| Salmeterol 50mcg/ Fluticasone Propionate 500mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00268216 |
| Salmeterol | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00115492 |
| Fluticasone Propionate/Salmeterol Combination Product | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00115492 |
| Salmeterol | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00115492 |
| Fluticasone Propionate/Salmeterol Combination Product | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00115492 |
| intravenous ondansetron | Other | Phase PHASE2 | Postoperative Nausea and Vomiting | COMPLETED | NCT00108095 |
| Placebo | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT01602510 |
| Lamotrigine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT01602510 |
| Placebo | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT01602510 |
| Lamotrigine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT01602510 |
| sumatriptan succinate/naproxen sodium | Other | Phase PHASE3 | Migraine | COMPLETED | NCT00329355 |
| rosiglitazone | Other | Phase PHASE3 | Non-insulin-dependent Diabetes Mellitus | COMPLETED | NCT00231387 |
| GSK2798745 milled API without SLS and hypermellose (Tablet C) | Other | Phase PHASE1 | Heart Failure, Congestive | COMPLETED | NCT02925546 |
| GSK2798745 Micronized API with SLS and hypermellose (Tablet B) | Other | Phase PHASE1 | Heart Failure, Congestive | COMPLETED | NCT02925546 |
| GSK2798745 Micronized API without SLS and hypermellose (Tablet A) | Other | Phase PHASE1 | Heart Failure, Congestive | COMPLETED | NCT02925546 |
| Low Dose Methotrexate | Other | Phase PHASE2 | Follicular Lymphoma | TERMINATED | NCT01389076 |
| Bexxar | Other | Phase PHASE2 | Follicular Lymphoma | TERMINATED | NCT01389076 |
| GSK962040 (75 mg) | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT01039805 |
| Placebo | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT01039805 |
| GSK962040 (50 mg) | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT01039805 |
| GSK962040 (75 mg) | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT01039805 |
| Placebo | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT01039805 |
| GSK962040 (50 mg) | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT01039805 |
| clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT01016977 |
| Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT01016977 |
| Dose 1 BD | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00980200 |
| Dose 2 QD | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00980200 |
| placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00980200 |
| Dose 3 QD | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00980200 |
| Dose 4 QD | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00980200 |
| GSK962040 1250 mg | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT00861809 |
| GSK962040 50 mg | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT00861809 |
| Placebo | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT00861809 |
| GSK962040 25 mg | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT00861809 |
| Ketoconazole | Other | Phase PHASE4 | Dermatitis, Seborrheic | COMPLETED | NCT00703846 |
| Placebo | Other | Phase PHASE3 | Fibrillation, Atrial | COMPLETED | NCT00402363 |
| omega-3-acid ethyl esters | Other | Phase PHASE3 | Fibrillation, Atrial | COMPLETED | NCT00402363 |
| Belimumab 10 mg/kg | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT00410384 |
| Belimumab 1 mg/kg | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT00410384 |
| Placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT00410384 |
| Belimumab 10 mg/kg | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT00410384 |
| Belimumab 1 mg/kg | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT00410384 |
| Placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT00410384 |
| GSK961081 | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00478738 |
| Placebo | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT00383162 |
| Combination Product (sumatriptan succinate / naproxen sodium) | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT00383162 |
| Combination Product (sumatriptan succinate/naproxen sodium) | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT00382993 |
| Placebo | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT00382993 |
| GW870086X | Other | Phase PHASE1 | Asthma | COMPLETED | NCT00549497 |
| salmeterol xinafoate | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00102882 |
| fluticasone propionate/salmeterol | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00102882 |
| Placebo | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT01602549 |
| GSK962040 (25 mg tablet) | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT01602549 |
| Placebo | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT01602549 |
| GSK962040 (25 mg tablet) | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT01602549 |
| Placebo | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00367744 |
| Rosiglitazone | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00367744 |
| Placebo | Other | Phase PHASE2 | Nonulcer Dyspepsia | COMPLETED | NCT00358410 |
| GW679769 oral tablets | Other | Phase PHASE2 | Nonulcer Dyspepsia | COMPLETED | NCT00358410 |
| Placebo | Other | Phase PHASE2 | Myasthaenia Gravis | COMPLETED | NCT01480596 |
| Belimumab | Other | Phase PHASE2 | Myasthaenia Gravis | COMPLETED | NCT01480596 |
| Urine sample collection | Other | Preclinical | Infections, Streptococcal | COMPLETED | NCT00523770 |
| Urine sample collection | Other | Preclinical | Infections, Streptococcal | COMPLETED | NCT00523770 |
| Placebo tablets | Other | Phase PHASE3 | Onychomycosis | COMPLETED | NCT00356915 |
| Itraconazole 200mg tablets | Other | Phase PHASE3 | Onychomycosis | COMPLETED | NCT00356915 |
| Itraconazole 100mg capsules | Other | Phase PHASE3 | Onychomycosis | COMPLETED | NCT00356915 |
| Simvastatin | Other | Phase PHASE2 | Pre-diabetes | COMPLETED | NCT00831129 |
| Placebo Rosiglitazone | Other | Phase PHASE2 | Pre-diabetes | COMPLETED | NCT00831129 |
| Rosiglitazone | Other | Phase PHASE2 | Pre-diabetes | COMPLETED | NCT00831129 |
| PLACEBO | Other | Phase PHASE2 | Pain, Neuropathic | COMPLETED | NCT00969059 |
| GW856553 | Other | Phase PHASE2 | Pain, Neuropathic | COMPLETED | NCT00969059 |
| liraglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01128894 |
| albiglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01128894 |
| bicalutamide | Other | Phase PHASE4 | Neoplasms, Prostate | COMPLETED | NCT00470834 |
| placebo | Other | Phase PHASE4 | Neoplasms, Prostate | COMPLETED | NCT00470834 |
| dutasteride | Other | Phase PHASE4 | Neoplasms, Prostate | COMPLETED | NCT00470834 |
| bicalutamide | Other | Phase PHASE4 | Neoplasms, Prostate | COMPLETED | NCT00470834 |
| placebo | Other | Phase PHASE4 | Neoplasms, Prostate | COMPLETED | NCT00470834 |
| dutasteride | Other | Phase PHASE4 | Neoplasms, Prostate | COMPLETED | NCT00470834 |
| 1% clindamycin phosphate gel | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT01915732 |
| Duac™Once Daily Gel | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT01915732 |
| Botulinum toxin type A | Other | Phase PHASE3 | Spasticity, Post-Stroke | COMPLETED | NCT01205451 |
| sitagliptin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01098539 |
| albiglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01098539 |
| tamsulosin 0.4mg once daily for 4 years | Other | Phase PHASE3 | Prostatic Hyperplasia | COMPLETED | NCT00090103 |
| dutasteride 0.5mg once daily for 4 years | Other | Phase PHASE3 | Prostatic Hyperplasia | COMPLETED | NCT00090103 |
| GW572016 (lapatinib) | Other | Phase PHASE2 | Lung Cancer, Non-Small Cell | TERMINATED | NCT00073008 |
| GW572016 (lapatinib) | Other | Phase PHASE2 | Lung Cancer, Non-Small Cell | TERMINATED | NCT00073008 |
| Intravenous etoposide/cisplatin | Other | Phase PHASE3 | Lung Cancer, Small Cell | COMPLETED | NCT00320359 |
| Intravenous topotecan/cisplatin | Other | Phase PHASE3 | Lung Cancer, Small Cell | COMPLETED | NCT00320359 |
| Itraconazole | Other | Phase PHASE1 | Cachexia | COMPLETED | NCT02567773 |
| Placebo | Other | Phase PHASE1 | Cachexia | COMPLETED | NCT02567773 |
| GSK2881078 | Other | Phase PHASE1 | Cachexia | COMPLETED | NCT02567773 |
| Placebo | Other | Phase PHASE3 | Hypertension | TERMINATED | NCT01884675 |
| Ambrisentan 5 mg | Other | Phase PHASE3 | Hypertension | TERMINATED | NCT01884675 |
| DCE-MRI | Other | Phase PHASE2 | Head and Neck Cancer | TERMINATED | NCT00490061 |
| G.E. Healthcare 1.5T MR, systems revision 12.0 M5 | Other | Phase PHASE2 | Head and Neck Cancer | TERMINATED | NCT00490061 |
| Radiotherapy (radiation) | Drug | Phase PHASE2 | Head and Neck Cancer | TERMINATED | NCT00490061 |
| Lapatinib | Other | Phase PHASE2 | Head and Neck Cancer | TERMINATED | NCT00490061 |
| DCE-MRI | Other | Phase PHASE2 | Head and Neck Cancer | TERMINATED | NCT00490061 |
| G.E. Healthcare 1.5T MR, systems revision 12.0 M5 | Other | Phase PHASE2 | Head and Neck Cancer | TERMINATED | NCT00490061 |
| Radiotherapy (radiation) | Drug | Phase PHASE2 | Head and Neck Cancer | TERMINATED | NCT00490061 |
| Lapatinib | Other | Phase PHASE2 | Head and Neck Cancer | TERMINATED | NCT00490061 |
| Fondaparinux 2.5mg or placebo | Other | Phase PHASE3 | Thrombosis, Venous | COMPLETED | NCT00443053 |
| Pazopanib | Other | Phase PHASE2 | Lung Cancer | COMPLETED | NCT01262820 |
| Ritonavir | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus I | COMPLETED | NCT00089583 |
| LEXIVA (GW433908) | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus I | COMPLETED | NCT00089583 |
| fluticasone propionate/salmeterol plus tiotropium bromide | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01751113 |
| tiotropium bromide | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01751113 |
| fluticasone propionate/salmeterol | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01751113 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01498679 |
| GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01498679 |
| Salbutamol/Albuterol | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01641692 |
| GSK573719 (Sub-group cohort) | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01641692 |
| GSK573719 Active treatment or Placebo | Drug | Phase PHASE2 | Asthma | COMPLETED | NCT01641692 |
| Valacyclovir | Other | Phase PHASE4 | Genital Herpes | COMPLETED | NCT01346475 |
| valacyclovir | Other | Phase PHASE4 | Genital Herpes | COMPLETED | NCT01346475 |
| Valacyclovir | Other | Phase PHASE4 | Genital Herpes | COMPLETED | NCT01346475 |
| valacyclovir | Other | Phase PHASE4 | Genital Herpes | COMPLETED | NCT01346475 |
| Pazopanib and paclitaxel | Other | Phase PHASE1 | Ovarian Neoplasm | COMPLETED | NCT01608009 |
| GSK189254 | Other | Phase PHASE2 | Narcolepsy | TERMINATED | NCT00366080 |
| GSK189254 | Other | Phase PHASE2 | Narcolepsy | TERMINATED | NCT00366080 |
| Vaqta | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00603252 |
| HBVAXPRO | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00603252 |
| Havrix | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00603252 |
| Engerix-B | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00603252 |
| Twinrix | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00603252 |
| fluticasone propionate 2 x 100 mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00197106 |
| Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00197106 |
| GSK2118436 | Other | Approved | Papillary Thyroid Carcinoma | COMPLETED | NCT01534897 |
| Stable isotope infusions | Other | Phase PHASE1 | Crohn's Disease | COMPLETED | NCT00583232 |
| Stable isotope infusions | Other | Phase PHASE1 | Crohn's Disease | COMPLETED | NCT00583232 |
| Stable isotope infusions | Other | Phase PHASE1 | Crohn's Disease | COMPLETED | NCT00583232 |
| Placebo | Other | Phase PHASE2 | Glomerulonephritis, Membranous | WITHDRAWN | NCT01762852 |
| Belimumab 10 mg | Other | Phase PHASE2 | Glomerulonephritis, Membranous | WITHDRAWN | NCT01762852 |
| Placebo | Other | Phase PHASE2 | Glomerulonephritis, Membranous | WITHDRAWN | NCT01762852 |
| Belimumab 10 mg | Other | Phase PHASE2 | Glomerulonephritis, Membranous | WITHDRAWN | NCT01762852 |
| GSK1322322 (freebase) tablets FED | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT01648179 |
| GSK1322322 (mesylate salt) Powder for Oral Solution | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT01648179 |
| GSK1322322 (freebase) tablets | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT01648179 |
| GSK1322322 (mesylate salt) Powder for Injection | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT01648179 |
| Mepolizumab | Other | Phase PHASE1 | Churg Strauss Syndrome | COMPLETED | NCT00527566 |
| Mepolizumab | Other | Phase PHASE1 | Churg Strauss Syndrome | COMPLETED | NCT00527566 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02119286 |
| UMEC | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02119286 |
| OCS (prednisone/prednisolone) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01691508 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01691508 |
| Mepolizumab | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01691508 |
| OCS (prednisone/prednisolone) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01691508 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01691508 |
| Mepolizumab | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01691508 |
| GSK2402968 | Other | Phase PHASE3 | Muscular Dystrophies | TERMINATED | NCT01480245 |
| Eicosapentaenoic Acid | Other | Approved | Cancer Cachexia | COMPLETED | NCT00815685 |
| Open label fondaparinux | Other | Phase PHASE4 | Acute Coronary Syndrome | COMPLETED | NCT00790907 |
| Fondaparinux background and low dose heparin | Other | Phase PHASE4 | Acute Coronary Syndrome | COMPLETED | NCT00790907 |
| fondaparinux background and standard dose UFH | Other | Phase PHASE4 | Acute Coronary Syndrome | COMPLETED | NCT00790907 |
| Fluarix vaccine | Other | Phase PHASE4 | Influenza | COMPLETED | NCT00363870 |
| Fluarix vaccine | Other | Phase PHASE4 | Influenza | COMPLETED | NCT00363870 |
| casopitant | Other | Phase PHASE3 | Nausea and Vomiting, Postoperative | COMPLETED | NCT00334152 |
| Ropinirole | Other | Phase PHASE4 | Restless Legs Syndrome | COMPLETED | NCT00329602 |
| Placebo | Other | Phase PHASE4 | Restless Legs Syndrome | COMPLETED | NCT00329602 |
| Nadroparin | Other | Phase PHASE3 | Thrombosis, Venous | COMPLETED | NCT00312013 |
| Novel endpoint determination | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00292552 |
| Olanzapine | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT00259870 |
| SB-773812 | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT00259870 |
| Olanzapine | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT00259870 |
| SB-773812 | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT00259870 |
| Influenza vaccine | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00197223 |
| GW677954 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00196989 |
| Pioglitazone | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00196989 |
| HPV-16/18 L1/AS04 | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00196924 |
| HPV-16/18 L1/AS04 | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00196924 |
| Rotavirus (vaccine) | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT00140686 |
| undecavalent pneumococcal-protein D conjugate vaccine | Other | Phase PHASE3 | Hepatitis A | TERMINATED | NCT00119743 |
| rosiglitazone maleate | Other | Phase PHASE3 | Atherosclerosis | COMPLETED | NCT00116831 |
| Glipizide | Other | Phase PHASE3 | Atherosclerosis | COMPLETED | NCT00116831 |
| rosiglitazone maleate | Other | Phase PHASE3 | Atherosclerosis | COMPLETED | NCT00116831 |
| Glipizide | Other | Phase PHASE3 | Atherosclerosis | COMPLETED | NCT00116831 |
| Placebo | Other | Phase PHASE2 | Thrombocytopaenia | COMPLETED | NCT00102726 |
| SB497115 | Other | Phase PHASE2 | Thrombocytopaenia | COMPLETED | NCT00102726 |
| Placebo Comparator: Placebo | Other | Phase PHASE2 | Nicotine Dependence | COMPLETED | NCT00218465 |
| GW468816 | Other | Phase PHASE2 | Nicotine Dependence | COMPLETED | NCT00218465 |
| Linezolid | Other | Phase PHASE3 | Skin Infections, Bacterial | COMPLETED | NCT00852540 |
| Retpamulin Ointment, 1% | Other | Phase PHASE3 | Skin Infections, Bacterial | COMPLETED | NCT00852540 |
| Linezolid | Other | Phase PHASE3 | Skin Infections, Bacterial | COMPLETED | NCT00852540 |
| Retpamulin Ointment, 1% | Other | Phase PHASE3 | Skin Infections, Bacterial | COMPLETED | NCT00852540 |
| Intermittent compression devices (ICD) | Device | Phase PHASE3 | Venous Thrombosis | TERMINATED | NCT00539942 |
| Arixtra (fondaparinux sodium) | Other | Phase PHASE3 | Venous Thrombosis | TERMINATED | NCT00539942 |
| Placebo | Other | Phase PHASE2 | Carcinoma, Renal Cell | COMPLETED | NCT00244764 |
| GW786034 | Other | Phase PHASE2 | Carcinoma, Renal Cell | COMPLETED | NCT00244764 |
| TVR | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01563328 |
| BCV | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01563328 |
| DTG | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01563328 |
| TVR | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01563328 |
| BCV | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01563328 |
| DTG | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01563328 |
| zanamivir aqueous solution | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT01014988 |
| Pazopanib | Other | Phase PHASE1 | Gynecologic Tumors | COMPLETED | NCT00800345 |
| Oral Topotecan | Other | Phase PHASE1 | Gynecologic Tumors | COMPLETED | NCT00800345 |
| Potassium Iodide (KI) | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | TERMINATED | NCT00490490 |
| External beam radiotherapy (XRT) | Drug | Phase PHASE2 | Lymphoma, Non-Hodgkin | TERMINATED | NCT00490490 |
| Bexxar (tositumomab) | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | TERMINATED | NCT00490490 |
| Potassium Iodide (KI) | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00490009 |
| Diphenhydramine | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00490009 |
| Acetaminophen | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00490009 |
| Bexxar | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00490009 |
| Potassium Iodide (KI) | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00490009 |
| Diphenhydramine | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00490009 |
| Acetaminophen | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00490009 |
| Bexxar | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00490009 |
| lamotrigine | Other | Phase PHASE4 | Bipolar Disorder | COMPLETED | NCT00360126 |
| Clindamycin phosphate and benzoyl peroxide 2.5% gel. | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT01015638 |
| Clindamycin and BPO 5% gel | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT01015638 |
| BW430C (lamotrigine) | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00566020 |
| lamotrigine | Other | Phase PHASE4 | Epilepsy, Tonic-Clonic | COMPLETED | NCT00043901 |
| lamotrigine | Other | Phase PHASE4 | Epilepsy, Tonic-Clonic | COMPLETED | NCT00043901 |
| Placebo | Other | Phase PHASE2 | Cough | COMPLETED | NCT01899768 |
| GSK2339345 | Other | Phase PHASE2 | Cough | COMPLETED | NCT01899768 |
| FP/SAL 100/50 | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01156792 |
| placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01156792 |
| montelukast | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01156792 |
| GSK2190915 300 | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01156792 |
| GSK2190915 100 | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01156792 |
| FP 100 | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01156792 |
| FP/SAL 100/50 | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01156792 |
| placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01156792 |
| montelukast | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01156792 |
| GSK2190915 300 | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01156792 |
| GSK2190915 100 | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01156792 |
| FP 100 | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01156792 |
| Continued Access Arm | Other | Preclinical | Infection, Human Immunodeficiency Virus | NO_LONGER_AVAILABLE | NCT01776996 |
| Placebo Nasal Spray | Other | Phase PHASE2 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00730756 |
| Fluticasone Furoate Nasal Spray | Other | Phase PHASE2 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00730756 |
| Placebo Nasal Spray | Other | Phase PHASE2 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00730756 |
| Fluticasone Furoate Nasal Spray | Other | Phase PHASE2 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00730756 |
| Placebo | Other | Phase PHASE3 | Pain | COMPLETED | NCT02311881 |
| Paracetamol 665 mg SR tablets | Other | Phase PHASE3 | Pain | COMPLETED | NCT02311881 |
| Paracetamol 1000 mg SR tablets | Other | Phase PHASE3 | Pain | COMPLETED | NCT02311881 |
| Pazopanib | Other | Phase PHASE2 | Gastrointestinal Stromal Tumor (GIST) | TERMINATED | NCT01391611 |
| Pazopanib | Other | Phase PHASE2 | Gastrointestinal Stromal Tumor (GIST) | TERMINATED | NCT01391611 |
| lamotrigine | Other | Phase PHASE3 | Bipolar Disorder | COMPLETED | NCT00056277 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT00640328 |
| Ofatumumab 700 | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT00640328 |
| Ofatumumab 300 | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT00640328 |
| Ofatumumab 100 | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT00640328 |
| Blood draw | Other | Phase PHASE4 | Virus Diseases | COMPLETED | NCT02991872 |
| Blood Sampling | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00974363 |
| Placebo | Other | Phase PHASE2 | Fracture Healing | TERMINATED | NCT00548496 |
| SB-751689 | Other | Phase PHASE2 | Fracture Healing | TERMINATED | NCT00548496 |
| Placebo | Other | Phase PHASE2 | Fracture Healing | TERMINATED | NCT00548496 |
| SB-751689 | Other | Phase PHASE2 | Fracture Healing | TERMINATED | NCT00548496 |
| Sodium fluoride | Other | Phase PHASE2 | Oral Hygiene | COMPLETED | NCT02207907 |
| Sodium bicarbonate plus sodium fluoride | Other | Phase PHASE2 | Oral Hygiene | COMPLETED | NCT02207907 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01160224 |
| GW766944 | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01160224 |
| Placebo | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT01009255 |
| GSK239512 | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT01009255 |
| Placebo | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT01009255 |
| GSK239512 | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT01009255 |
| Niraparib | Other | Preclinical | Recurrent Ovarian Cancer | APPROVED_FOR_MARKETING | NCT03025867 |
| Niraparib | Other | Preclinical | Recurrent Ovarian Cancer | APPROVED_FOR_MARKETING | NCT03025867 |
| BMS-955176 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02273947 |
| Placebo | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | TERMINATED | NCT00879970 |
| Vitamin D | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | TERMINATED | NCT00879970 |
| placebo | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | TERMINATED | NCT00879970 |
| rosiglitazone | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | TERMINATED | NCT00879970 |
| pioglitazone | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | TERMINATED | NCT00879970 |
| Placebo | Other | Phase PHASE3 | Purpura, Thrombocytopaenic, Idiopathic | COMPLETED | NCT00370331 |
| eltrombopag | Other | Phase PHASE3 | Purpura, Thrombocytopaenic, Idiopathic | COMPLETED | NCT00370331 |
| ropinirole | Other | Phase PHASE4 | Bipolar Disorder | COMPLETED | NCT00314821 |
| Usual care | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00238888 |
| asthma control awareness | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00238888 |
| Placebo | Other | Phase PHASE3 | Seizures | COMPLETED | NCT00235755 |
| Retigabine | Other | Phase PHASE3 | Seizures | COMPLETED | NCT00235755 |
| adjuvanted influenza vaccine | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00377585 |
| Fluarix | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00377585 |
| 0.76% sodium monofluorophosphate (1000ppm fluoride) | Other | Approved | Dentin Sensitivity | COMPLETED | NCT02705716 |
| 0.454% w/w stannous fluoride (1100ppm fluoride) | Other | Approved | Dentin Sensitivity | COMPLETED | NCT02705716 |
| Placebo | Other | Phase PHASE2 | Transplantation, Organ | COMPLETED | NCT01536379 |
| Belimumab | Other | Phase PHASE2 | Transplantation, Organ | COMPLETED | NCT01536379 |
| Fluticasone Diskus | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01437995 |
| Fluticasone/Salmeterol Diskus | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01437995 |
| SRT2104 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01018017 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01018017 |
| GSK Malaria vaccine 257049 | Other | Phase PHASE2 | Malaria | COMPLETED | NCT00443131 |
| Activated charcoal | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02691325 |
| Placebo ELLIPTA DPI | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02691325 |
| GSK2269557 ELLIPTA DPI | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02691325 |
| Placebo | Other | Phase PHASE2 | Bulimia | TERMINATED | NCT00600743 |
| Instructions to eat normally | Other | Phase PHASE2 | Bulimia | TERMINATED | NCT00600743 |
| Instructions to binge eat | Other | Phase PHASE2 | Bulimia | TERMINATED | NCT00600743 |
| GSKI181771X (CCK-1R agonist) | Other | Phase PHASE2 | Bulimia | TERMINATED | NCT00600743 |
| GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT02612051 |
| Placebo Nebuliser solution | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT02612051 |
| GSK3008348 Nebuliser solution | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT02612051 |
| GR68755 (Alosetron hydrochloride) 1 mg tablet | Other | Phase PHASE2 | Irritable Colon | COMPLETED | NCT01855711 |
| Coumadin | Other | Phase PHASE2 | Deep Vein Thrombosis | COMPLETED | NCT00244725 |
| Warfarin | Other | Phase PHASE2 | Deep Vein Thrombosis | COMPLETED | NCT00244725 |
| Odiparcil | Other | Phase PHASE2 | Deep Vein Thrombosis | COMPLETED | NCT00244725 |
| Coumadin | Other | Phase PHASE2 | Deep Vein Thrombosis | COMPLETED | NCT00244725 |
| Warfarin | Other | Phase PHASE2 | Deep Vein Thrombosis | COMPLETED | NCT00244725 |
| Odiparcil | Other | Phase PHASE2 | Deep Vein Thrombosis | COMPLETED | NCT00244725 |
| Placebo | Other | Phase PHASE2 | Atrophy, Geographic | COMPLETED | NCT01342926 |
| GSK933776 | Other | Phase PHASE2 | Atrophy, Geographic | COMPLETED | NCT01342926 |
| Placebo | Other | Phase PHASE2 | Atrophy, Geographic | COMPLETED | NCT01342926 |
| GSK933776 | Other | Phase PHASE2 | Atrophy, Geographic | COMPLETED | NCT01342926 |
| Placebo | Other | Phase PHASE2 | Atrophy, Geographic | COMPLETED | NCT01342926 |
| GSK933776 | Other | Phase PHASE2 | Atrophy, Geographic | COMPLETED | NCT01342926 |
| Placebo | Other | Phase PHASE1 | Irritable Bowel Syndrome | COMPLETED | NCT02727283 |
| GSK3179106 | Other | Phase PHASE1 | Irritable Bowel Syndrome | COMPLETED | NCT02727283 |
| Lamotrigine | Other | Phase PHASE1 | Bipolar Disorder | COMPLETED | NCT02513654 |
| Innovator | Other | Phase PHASE1 | Cardiovascular Disease | COMPLETED | NCT02502812 |
| Clop F2 | Other | Phase PHASE1 | Cardiovascular Disease | COMPLETED | NCT02502812 |
| Clop F1 | Other | Phase PHASE1 | Cardiovascular Disease | COMPLETED | NCT02502812 |
| Ortho-Cylcen (21)® tablet | Other | Phase PHASE1 | Embryo Transfer | TERMINATED | NCT02213029 |
| Oxytocin | Other | Phase PHASE1 | Embryo Transfer | TERMINATED | NCT02213029 |
| Placebo | Other | Phase PHASE1 | Embryo Transfer | TERMINATED | NCT02213029 |
| Epelsiban | Other | Phase PHASE1 | Embryo Transfer | TERMINATED | NCT02213029 |
| Ortho-Cylcen (21)® tablet | Other | Phase PHASE1 | Embryo Transfer | TERMINATED | NCT02213029 |
| Oxytocin | Other | Phase PHASE1 | Embryo Transfer | TERMINATED | NCT02213029 |
| Placebo | Other | Phase PHASE1 | Embryo Transfer | TERMINATED | NCT02213029 |
| Epelsiban | Other | Phase PHASE1 | Embryo Transfer | TERMINATED | NCT02213029 |
| Placebo | Other | Phase PHASE1 | Influenza | COMPLETED | NCT01934127 |
| Investigational H7N1 vaccine GSK2789868A | Other | Phase PHASE1 | Influenza | COMPLETED | NCT01934127 |
| Investigational H7N1 vaccine GSK2789869A | Other | Phase PHASE1 | Influenza | COMPLETED | NCT01934127 |
| 10-valent pneumococcal vaccine GSK513026 | Other | Phase PHASE1 | Infections, Streptococcal | COMPLETED | NCT00327665 |
| Placebo | Other | Phase PHASE1 | Infections, Streptococcal | COMPLETED | NCT00327665 |
| Pneumo 23™ | Other | Phase PHASE1 | Infections, Streptococcal | COMPLETED | NCT00327665 |
| 11-valent pneumococcal vaccine GSK513026 | Other | Phase PHASE1 | Infections, Streptococcal | COMPLETED | NCT00327665 |
| influenza vaccine Fluarix, Adjuvanted Fluarix | Other | Phase PHASE1 | Influenza | COMPLETED | NCT00318058 |
| Influenza Monovalent Whole virus (H5N1) | Other | Phase PHASE1 | Influenza | COMPLETED | NCT00309647 |
| Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine | Other | Phase PHASE1 | Influenza | COMPLETED | NCT00309647 |
| Reference Montelukast | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT02658422 |
| Test Montelukast | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT02658422 |
| Reference Montelukast | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT02658422 |
| Test Montelukast | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT02658422 |
| GSK2894512 Topical Cream | Other | Phase PHASE1 | Dermatitis, Atopic | COMPLETED | NCT02466152 |
| Placebo | Other | Phase PHASE1 | Autoimmune Diseases | COMPLETED | NCT02293161 |
| GSK2618960 | Other | Phase PHASE1 | Autoimmune Diseases | COMPLETED | NCT02293161 |
| Placebo | Other | Phase PHASE1 | Autoimmune Diseases | COMPLETED | NCT02293161 |
| GSK2618960 | Other | Phase PHASE1 | Autoimmune Diseases | COMPLETED | NCT02293161 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02262689 |
| GSK2256294 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02262689 |
| Placebo | Other | Phase PHASE1 | Tendon Injuries | COMPLETED | NCT02231190 |
| GSK1278863 | Other | Phase PHASE1 | Tendon Injuries | COMPLETED | NCT02231190 |
| CXCL1 | Other | Phase PHASE1 | Infections, Respiratory Syncytial Virus | COMPLETED | NCT02201303 |
| Danirixin | Other | Phase PHASE1 | Infections, Respiratory Syncytial Virus | COMPLETED | NCT02201303 |
| GSK2256294 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02006537 |
| GSK2256294 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02006537 |
| Patch only | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01984801 |
| 0.1% SLS in sterile distilled water | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01984801 |
| 0.5% SLS in sterile distilled water | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01984801 |
| Sterile distilled water | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01984801 |
| 0.3%/1% vehicle gel only | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01984801 |
| 1% GSK1940029 gel | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01984801 |
| 0.3% GSK1940029 gel | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01984801 |
| Patch only | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01984801 |
| 0.1% SLS in sterile distilled water | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01984801 |
| 0.5% SLS in sterile distilled water | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01984801 |
| Sterile distilled water | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01984801 |
| 0.3%/1% vehicle gel only | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01984801 |
| 1% GSK1940029 gel | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01984801 |
| 0.3% GSK1940029 gel | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01984801 |
| Placebo to match testosterone enanthate | Other | Phase PHASE1 | Cachexia | COMPLETED | NCT01962454 |
| Testosterone enanthate | Other | Phase PHASE1 | Cachexia | COMPLETED | NCT01962454 |
| Deuterated Water | Other | Phase PHASE1 | Cachexia | COMPLETED | NCT01962454 |
| Placebo to match testosterone enanthate | Other | Phase PHASE1 | Cachexia | COMPLETED | NCT01962454 |
| Testosterone enanthate | Other | Phase PHASE1 | Cachexia | COMPLETED | NCT01962454 |
| Deuterated Water | Other | Phase PHASE1 | Cachexia | COMPLETED | NCT01962454 |
| 0.3%/1% vehicle gel only | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01938482 |
| 1% GSK1940029 gel | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01938482 |
| 0.3% GSK1940029 gel | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01938482 |
| 0.3%/1% vehicle gel only | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01938482 |
| 1% GSK1940029 gel | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01938482 |
| 0.3% GSK1940029 gel | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01938482 |
| Placebo | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01837316 |
| FF/VI 100/25 mcg | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01837316 |
| Ritonavir | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01802918 |
| Placebo | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01802918 |
| GSK2838232 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01802918 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01762774 |
| GSK2256294 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01762774 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01762774 |
| GSK2256294 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01762774 |
| Placebo | Other | Phase PHASE1 | Infections, Respiratory Tract | COMPLETED | NCT01706315 |
| GSK2140944 | Other | Phase PHASE1 | Infections, Respiratory Tract | COMPLETED | NCT01706315 |
| GSK2126458 and GSK1120212 | Other | Phase PHASE1 | Cancer | TERMINATED | NCT01248858 |
| GSK2126458 | Other | Phase PHASE1 | Solid Tumours | COMPLETED | NCT00972686 |
| Placebo | Other | Phase PHASE4 | Hypertriglyceridemia | COMPLETED | NCT00931879 |
| omega-3-ethyl esters | Other | Phase PHASE4 | Hypertriglyceridemia | COMPLETED | NCT00931879 |
| GSK3074477 FDC - 2 | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT02075619 |
| GSK3074477 FDC - 1 | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT02075619 |
| Amlodipine+Rosuvastatin | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT02075619 |
| Placebo | Other | Phase PHASE1 | Alcoholism | COMPLETED | NCT01738867 |
| Naltrexone (NTX) | Other | Phase PHASE1 | Alcoholism | COMPLETED | NCT01738867 |
| GSK1521498 | Other | Phase PHASE1 | Alcoholism | COMPLETED | NCT01738867 |
| Pneumo 23™ | Other | Phase PHASE1 | Infections, Streptococcal | COMPLETED | NCT00707798 |
| Pneumococcal vaccine GSK2189242A | Other | Phase PHASE1 | Infections, Streptococcal | COMPLETED | NCT00707798 |
| 4 non-adjuvanted pandemic influenza candidate vaccines | Other | Phase PHASE1 | Influenza | COMPLETED | NCT00309634 |
| 4 adjuvanted pandemic influenza candidate vaccines | Other | Phase PHASE1 | Influenza | COMPLETED | NCT00309634 |
| Exercise | Other | Approved | Asthma | COMPLETED | NCT02012400 |
| Adalimumab, solution for injection | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT01899755 |
| Placebo (0.9% w/v Sodium Chloride), solution for injection | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT01899755 |
| GSK2800528, solution for injection | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT01899755 |
| Adalimumab, solution for injection | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT01899755 |
| Placebo (0.9% w/v Sodium Chloride), solution for injection | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT01899755 |
| GSK2800528, solution for injection | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT01899755 |
| GSK2256098 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01138033 |
| Sorbitol | Other | Phase PHASE4 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02634073 |
| Lamivudine | Other | Phase PHASE4 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02634073 |
| Sorbitol | Other | Phase PHASE4 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02634073 |
| Lamivudine | Other | Phase PHASE4 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02634073 |
| Laboratory-based exercise tests | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02619357 |
| Field-based exercise tests | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02619357 |
| Strength exercises | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02619357 |
| SOMNOwatch plus EEG 6 sleep monitor | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02619357 |
| Garmin Vivofit 2 wristband | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02619357 |
| Actigraph GT9x wristband and waistband | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02619357 |
| SenseWear Armband MF | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02619357 |
| SenseWear Armband Gecko | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02619357 |
| Labelled neutrophils and Imaging assessment | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02551614 |
| Saline challenge | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02551614 |
| Lipopolysaccharide challenge | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02551614 |
| Betamethasone valerate 0.1% | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT02548052 |
| Vehicle | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT02548052 |
| GSK2981278 4% | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT02548052 |
| GSK2981278 0.8% | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT02548052 |
| GSK2981278 0.1% | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT02548052 |
| GSK2981278 0.03% | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT02548052 |
| Test 2 Montelukast | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT02322671 |
| Test 1 Montelukast | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT02322671 |
| Reference Montelukast | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT02322671 |
| Ritonavir | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | TERMINATED | NCT02289482 |
| Placebo | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | TERMINATED | NCT02289482 |
| GSK2838232 PIB (API) | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | TERMINATED | NCT02289482 |
| GSK2838232 PIB (SDD) | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | TERMINATED | NCT02289482 |
| GR107719B (Formulation 2) | Other | Phase PHASE1 | Gastritis | COMPLETED | NCT02201316 |
| GR107719B (Formulation 1) | Other | Phase PHASE1 | Gastritis | COMPLETED | NCT02201316 |
| Reference mosapride citrate (GASMOTIN) | Other | Phase PHASE1 | Gastritis | COMPLETED | NCT02201316 |
| GR107719B (Formulation 2) | Other | Phase PHASE1 | Gastritis | COMPLETED | NCT02201316 |
| GR107719B (Formulation 1) | Other | Phase PHASE1 | Gastritis | COMPLETED | NCT02201316 |
| Reference mosapride citrate (GASMOTIN) | Other | Phase PHASE1 | Gastritis | COMPLETED | NCT02201316 |
| GSK1325756 Tablet Matching Placebo | Other | Phase PHASE1 | Infections, Respiratory Tract | COMPLETED | NCT02169583 |
| GSK1325756 Tablet | Other | Phase PHASE1 | Infections, Respiratory Tract | COMPLETED | NCT02169583 |
| GSK1325756 Solution Matching Placebo | Other | Phase PHASE1 | Infections, Respiratory Tract | COMPLETED | NCT02169583 |
| GSK1325756 Solution | Other | Phase PHASE1 | Infections, Respiratory Tract | COMPLETED | NCT02169583 |
| GSK1325756 Tablet Matching Placebo | Other | Phase PHASE1 | Infections, Respiratory Tract | COMPLETED | NCT02169583 |
| GSK1325756 Tablet | Other | Phase PHASE1 | Infections, Respiratory Tract | COMPLETED | NCT02169583 |
| GSK1325756 Solution Matching Placebo | Other | Phase PHASE1 | Infections, Respiratory Tract | COMPLETED | NCT02169583 |
| GSK1325756 Solution | Other | Phase PHASE1 | Infections, Respiratory Tract | COMPLETED | NCT02169583 |
| FDC of candesartan cilexetil 16 mg and HCTZ 12.5mg | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT02094924 |
| GSK587323 | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT02094924 |
| Fluticasone furoate | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02064504 |
| GSK961081 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02064504 |
| Fluticasone furoate | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02064504 |
| GSK961081 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02064504 |
| Darapladib | Other | Phase PHASE1 | Atherosclerosis | COMPLETED | NCT02058641 |
| GSK933776 for IV administration | Other | Phase PHASE1 | Atrophy, Geographic | COMPLETED | NCT02033668 |
| GSK933776 for IM administration | Other | Phase PHASE1 | Atrophy, Geographic | COMPLETED | NCT02033668 |
| GSK933776 for SQ administration | Other | Phase PHASE1 | Atrophy, Geographic | COMPLETED | NCT02033668 |
| Candesartan cilexetil (Reference treatment) | Drug | Phase PHASE1 | Hypertension | COMPLETED | NCT02006589 |
| Candesartan cilexetil (GW615775, Test formulation) | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT02006589 |
| darapladib 160mg | Other | Phase PHASE1 | Atherosclerosis | COMPLETED | NCT02000804 |
| Placebo | Other | Phase PHASE1 | Fibrosis | TERMINATED | NCT01978301 |
| Triamcinolone acetonide | Other | Phase PHASE1 | Fibrosis | TERMINATED | NCT01978301 |
| LEV | Other | Phase PHASE1 | Rhinitis, Allergic, Perennial and Seasonal | COMPLETED | NCT01962467 |
| FF/LEV FDC | Other | Phase PHASE1 | Rhinitis, Allergic, Perennial and Seasonal | COMPLETED | NCT01962467 |
| GSK2140944 (Multiple dose) | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT01934205 |
| GSK2140944 (Single dose) | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT01934205 |
| GSK2140944 (Multiple dose) | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT01934205 |
| GSK2140944 (Single dose) | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT01934205 |
| [14C]Umeclidinium 18.5 mg | Other | Phase PHASE1 | Hyperhidrosis | COMPLETED | NCT01934153 |
| Placebo | Other | Phase PHASE1 | Arthritis, Rheumatoid | TERMINATED | NCT01934101 |
| CHR-5154 | Other | Phase PHASE1 | Arthritis, Rheumatoid | TERMINATED | NCT01934101 |
| Placebo | Other | Phase PHASE1 | Arthritis, Rheumatoid | TERMINATED | NCT01934101 |
| CHR-5154 | Other | Phase PHASE1 | Arthritis, Rheumatoid | TERMINATED | NCT01934101 |
| Matching placebo repeat dose IH | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT01818024 |
| Repeat IH dose selected of GSK2862277 from Part 2 | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT01818024 |
| Matching placebo repeat dose IV infusion | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT01818024 |
| Repeat IV dose of GSK2862277 | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT01818024 |
| Matching placebo single dose IH | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT01818024 |
| Single IH dose of GSK2862277 | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT01818024 |
| Matching placebo single dose IV infusion | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT01818024 |
| Single IV dose of GSK2862277 | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT01818024 |
| Saline placebo | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT01657526 |
| GSK Biologicals' Non-Typeable H. influenzae (GSK2838501A) | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT01657526 |
| GSK Biologicals' Non-Typeable H. influenzae (GSK2838500A) | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT01657526 |
| Radiotherapy | Drug | Phase PHASE1 | Lung Cancer, Non-Small Cell | TERMINATED | NCT00455572 |
| Vinorelbine | Other | Phase PHASE1 | Lung Cancer, Non-Small Cell | TERMINATED | NCT00455572 |
| Cisplatin (CDDP) | Other | Phase PHASE1 | Lung Cancer, Non-Small Cell | TERMINATED | NCT00455572 |
| Immunotherapeutic GSK1572932A | Other | Phase PHASE1 | Lung Cancer, Non-Small Cell | TERMINATED | NCT00455572 |
| unfractionated heparin | Other | Preclinical | Thrombosis, Venous | COMPLETED | NCT01444612 |
| fondaparinux | Other | Preclinical | Thrombosis, Venous | COMPLETED | NCT01444612 |
| enoxaparin | Other | Preclinical | Thrombosis, Venous | COMPLETED | NCT01444612 |
| dalteparin | Other | Preclinical | Thrombosis, Venous | COMPLETED | NCT01444612 |
| unfractionated heparin | Other | Preclinical | Thrombosis, Venous | COMPLETED | NCT01444612 |
| fondaparinux | Other | Preclinical | Thrombosis, Venous | COMPLETED | NCT01444612 |
| enoxaparin | Other | Preclinical | Thrombosis, Venous | COMPLETED | NCT01444612 |
| dalteparin | Other | Preclinical | Thrombosis, Venous | COMPLETED | NCT01444612 |
| Delayed combination therapy | Drug | Preclinical | Benign Prostatic Hyperplasia | COMPLETED | NCT01435954 |
| Early combination therapy | Drug | Preclinical | Benign Prostatic Hyperplasia | COMPLETED | NCT01435954 |
| Delayed Maintenance treatment | Drug | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01431911 |
| Early maintenance treatment | Drug | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01431911 |
| Delayed Maintenance treatment | Drug | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01431911 |
| Early maintenance treatment | Drug | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01431911 |
| Amoxicillin and clavulanate | Other | Preclinical | Otitis Maedia | COMPLETED | NCT01406275 |
| Amoxicillin and clavulanate | Other | Preclinical | Otitis Maedia | COMPLETED | NCT01406275 |
| Anticholinergics (AC) | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01395875 |
| Fluticasone Propionate / Salmeterol Xinafoate Combination (FSC) | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01395875 |
| Salmeterol and Fluticasone | Other | Preclinical | Respiratory Disorders | COMPLETED | NCT01395849 |
| Salmeterol and Fluticasone | Other | Preclinical | Respiratory Disorders | COMPLETED | NCT01395849 |
| Zanamivir hydrate | Other | Preclinical | Influenza, Human | COMPLETED | NCT01390792 |
| Epoprostenol | Other | Preclinical | Cardiovascular Disease | COMPLETED | NCT01387191 |
| Epoprostenol | Other | Preclinical | Cardiovascular Disease | COMPLETED | NCT01387191 |
| Placebo | Other | Phase PHASE1 | Irritable Colon | COMPLETED | NCT00376896 |
| GW876008 20mcg | Other | Phase PHASE1 | Irritable Colon | COMPLETED | NCT00376896 |
| GW876008 200mcg | Other | Phase PHASE1 | Irritable Colon | COMPLETED | NCT00376896 |
| Sodium Monofluorophosphate dentifrice | Other | Approved | Dentin Sensitivity | COMPLETED | NCT02612064 |
| Stannous Fluoride dentifice | Other | Approved | Dentin Sensitivity | COMPLETED | NCT02612064 |
| Sputum collection | Other | Approved | Respiratory Disorders | COMPLETED | NCT01516437 |
| Swab collection | Other | Approved | Respiratory Disorders | COMPLETED | NCT01516437 |
| Blood collection | Other | Approved | Respiratory Disorders | COMPLETED | NCT01516437 |
| 5ARI or AB or Combination Therapy (5ARI + AB) | Drug | Preclinical | Prostatic Hyperplasia | COMPLETED | NCT01390870 |
| 5ARI or AB or Combination Therapy (5ARI + AB) | Drug | Preclinical | Prostatic Hyperplasia | COMPLETED | NCT01390870 |
| tiotropium bromide (TIO) | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01387178 |
| fluticasone propionate/salmeterol 250µg/50µg (FSC) | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01387178 |
| 5ARI + AB | Other | Preclinical | Prostatic Hyperplasia | COMPLETED | NCT01386983 |
| 5ARI | Other | Preclinical | Prostatic Hyperplasia | COMPLETED | NCT01386983 |
| Placebo Nasal Spray | Other | Phase PHASE2 | Sinusitis, Acute | COMPLETED | NCT01018030 |
| FFNS 110 mcg BID | Other | Phase PHASE2 | Sinusitis, Acute | COMPLETED | NCT01018030 |
| FFNS 110 mcg QD | Other | Phase PHASE2 | Sinusitis, Acute | COMPLETED | NCT01018030 |
| Vehicle Foam | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT01017120 |
| Tazarotene Foam | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT01017120 |
| Combination Tablet of Treximet (sumatriptan/naproxen sodium) | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT00488514 |
| Placebo | Other | Phase PHASE1 | Infections, Rotavirus | COMPLETED | NCT01162590 |
| Rotarix ™ | Other | Phase PHASE1 | Infections, Rotavirus | COMPLETED | NCT01162590 |
| Placebo | Other | Phase PHASE1 | Infections, Rotavirus | COMPLETED | NCT01162590 |
| Rotarix ™ | Other | Phase PHASE1 | Infections, Rotavirus | COMPLETED | NCT01162590 |
| Placebo | Other | Phase PHASE1 | Infections, Rotavirus | COMPLETED | NCT01107587 |
| GSK Biologicals' human rotavirus vaccine 444563 | Other | Phase PHASE1 | Infections, Rotavirus | COMPLETED | NCT01107587 |
| ACs | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01381458 |
| FSC | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01381458 |
| ACs | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01381458 |
| FSC | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01381458 |
| 5ARI | Other | Preclinical | Prostatic Hyperplasia | COMPLETED | NCT01376258 |
| Fluticasone | Other | Preclinical | Rhinitis | COMPLETED | NCT01376206 |
| Fluticasone | Other | Preclinical | Rhinitis | COMPLETED | NCT01376206 |
| Lamivudine | Other | Preclinical | Hepatitis B, Chronic | COMPLETED | NCT01376154 |
| Sumatriptan | Other | Preclinical | Migraine Disorders | COMPLETED | NCT01376141 |
| Paroxetine | Other | Preclinical | Panic Disorder | COMPLETED | NCT01376128 |
| GSK2140944 | Other | Phase PHASE2 | Gonorrhea | COMPLETED | NCT02294682 |
| 1 µg TDENV-PIV with AS01E adjuvant | Other | Phase PHASE1 | Dengue Fever | COMPLETED | NCT01702857 |
| 1 µg TDENV-PIV with Alum adjuvant | Other | Phase PHASE1 | Dengue Fever | COMPLETED | NCT01702857 |
| Phosphate buffered saline | Other | Phase PHASE1 | Dengue Fever | COMPLETED | NCT01702857 |
| Biological/Vaccine: 1 µg TDENV-PIV with AS03B adjuvant | Other | Phase PHASE1 | Dengue Fever | COMPLETED | NCT01702857 |
| Biological/Vaccine: 4 µg TDENV-PIV with Alum adjuvant | Other | Phase PHASE1 | Dengue Fever | COMPLETED | NCT01702857 |
| 1 µg TDENV-PIV with AS01E adjuvant | Other | Phase PHASE1 | Dengue Fever | COMPLETED | NCT01702857 |
| 1 µg TDENV-PIV with Alum adjuvant | Other | Phase PHASE1 | Dengue Fever | COMPLETED | NCT01702857 |
| Phosphate buffered saline | Other | Phase PHASE1 | Dengue Fever | COMPLETED | NCT01702857 |
| Biological/Vaccine: 1 µg TDENV-PIV with AS03B adjuvant | Other | Phase PHASE1 | Dengue Fever | COMPLETED | NCT01702857 |
| Biological/Vaccine: 4 µg TDENV-PIV with Alum adjuvant | Other | Phase PHASE1 | Dengue Fever | COMPLETED | NCT01702857 |
| HEC or MEC | Other | Preclinical | Vomiting | COMPLETED | NCT01366599 |
| Soap Free Cleanser and CTGel | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT00891982 |
| CTGel/ BPO Wash | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT00891982 |
| Inhalation profile recorder | Other | Preclinical | Haemorrhage | COMPLETED | NCT02106000 |
| Fluticasone Propionate Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02094937 |
| Fluticasone Furoate Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02094937 |
| Fluticasone Propionate 100 mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02094937 |
| Fluticasone Propionate 250 mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02094937 |
| Fluticasone Furoate 100 mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02094937 |
| Fluticasone Furoate/Vilanterol | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02094937 |
| Fluticasone Propionate Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02094937 |
| Fluticasone Furoate Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02094937 |
| Fluticasone Propionate 100 mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02094937 |
| Fluticasone Propionate 250 mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02094937 |
| Fluticasone Furoate 100 mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02094937 |
| Fluticasone Furoate/Vilanterol | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02094937 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01978119 |
| FSC | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01978119 |
| acne system - benzoyl peroxide 2.5%, Salicyclic Acid 0.5% | Other | Approved | Acne Vulgaris | COMPLETED | NCT01446237 |
| inhaled corticosteroids | Other | Preclinical | Asthma | COMPLETED | NCT01347060 |
| fluticasone propionate/salmeterol xinafoate combination | Other | Preclinical | Asthma | COMPLETED | NCT01347060 |
| inhaled corticosteroids | Other | Preclinical | Asthma | COMPLETED | NCT01347060 |
| fluticasone propionate/salmeterol xinafoate combination | Other | Preclinical | Asthma | COMPLETED | NCT01347060 |
| Ziana gel | Other | Phase PHASE4 | Acne | COMPLETED | NCT00841776 |
| Duac | Other | Phase PHASE4 | Acne | COMPLETED | NCT00841776 |
| Benzoyl peroxide with clindamycin and doxycycline | Other | Phase PHASE4 | Acne | COMPLETED | NCT00837213 |
| Benzoyl peroxide with clindamycin | Other | Phase PHASE4 | Acne | COMPLETED | NCT00837213 |
| Placebo | Other | Phase PHASE1 | Influenza | COMPLETED | NCT01999842 |
| Investigational H7N9 vaccine GSK3206640A | Other | Phase PHASE1 | Influenza | COMPLETED | NCT01999842 |
| Investigational H7N9 vaccine GSK3206641A | Other | Phase PHASE1 | Influenza | COMPLETED | NCT01999842 |
| Asthma treatment with an asthma-related medication and at least one asthma controller medication | Drug | Preclinical | Asthma | COMPLETED | NCT01346852 |
| paclitaxel | Other | Preclinical | Cervical Intraepithelial Neoplasia | COMPLETED | NCT01345279 |
| topotecan | Other | Preclinical | Cervical Intraepithelial Neoplasia | COMPLETED | NCT01345279 |
| cisplatin | Other | Preclinical | Cervical Intraepithelial Neoplasia | COMPLETED | NCT01345279 |
| Anticholinergics | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01337336 |
| fluticasone propionate/salmeterol xinafoate | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01337336 |
| Fluticasone furoate nasal spray | Other | Preclinical | Rhinitis, Allergic, Seasonal | TERMINATED | NCT01337323 |
| Fluticasone furoate nasal spray | Other | Preclinical | Rhinitis, Allergic, Seasonal | TERMINATED | NCT01337323 |
| Placebo | Other | Preclinical | Neoplasms, Prostate | COMPLETED | NCT01337258 |
| Dutasteride | Other | Preclinical | Neoplasms, Prostate | COMPLETED | NCT01337258 |
| Placebo | Other | Preclinical | Neoplasms, Prostate | COMPLETED | NCT01337258 |
| Dutasteride | Other | Preclinical | Neoplasms, Prostate | COMPLETED | NCT01337258 |
| Non-adherent to 5ARI therapy | Drug | Preclinical | Prostatic Hyperplasia | COMPLETED | NCT01334723 |
| Adherent with 5-alpha-reductase inhibitor (5ARI) therapy | Drug | Preclinical | Prostatic Hyperplasia | COMPLETED | NCT01334723 |
| other oral triptans | Other | Preclinical | Migraine Disorders | COMPLETED | NCT01332500 |
| Sumatriptan/Naproxen combination | Other | Preclinical | Migraine Disorders | COMPLETED | NCT01332500 |
| other oral triptans | Other | Preclinical | Migraine Disorders | COMPLETED | NCT01332500 |
| Sumatriptan/Naproxen combination | Other | Preclinical | Migraine Disorders | COMPLETED | NCT01332500 |
| Saline placebo | Other | Phase PHASE1 | Infections, Staphylococcal | COMPLETED | NCT01160172 |
| Staphylococcal investigational vaccine GSK2392019A | Other | Phase PHASE1 | Infections, Staphylococcal | COMPLETED | NCT01160172 |
| Staphylococcal investigational vaccine GSK2392106A | Other | Phase PHASE1 | Infections, Staphylococcal | COMPLETED | NCT01160172 |
| Staphylococcal investigational vaccine GSK2392105A | Other | Phase PHASE1 | Infections, Staphylococcal | COMPLETED | NCT01160172 |
| Staphylococcal investigational vaccine GSK2392103A | Other | Phase PHASE1 | Infections, Staphylococcal | COMPLETED | NCT01160172 |
| No prophylaxis with Relenza | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01156701 |
| Receiving a prescription of Relenza for prophylaxis | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01156701 |
| Gabapentin prescriptions | Other | Preclinical | Renal Pelvis Cancer | COMPLETED | NCT01138124 |
| Nebivolol | Other | Preclinical | Hypertension | COMPLETED | NCT01077661 |
| Nebivolol | Other | Preclinical | Hypertension | COMPLETED | NCT01077661 |
| ofatumumab 100 mg, 1000 mg / vial | Other | Phase PHASE2 | Leukaemia, Lymphocytic, Chronic | COMPLETED | NCT01077622 |
| Sample Collection | Other | Preclinical | Acute Otitis Media | TERMINATED | NCT01072227 |
| Sample Collection | Other | Preclinical | Acute Otitis Media | TERMINATED | NCT01072227 |
| Vehicle Gel | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT00689117 |
| Tretinoin Gel (tretinoin) | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT00689117 |
| Clindamycin Gel (clindamycin ) | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT00689117 |
| CT Gel | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT00689117 |
| Collection of stool samples | Other | Preclinical | Rotavirus Severe Gastroenteritis | COMPLETED | NCT00655187 |
| Collection of information | Other | Preclinical | Rotavirus Severe Gastroenteritis | COMPLETED | NCT00655187 |
| tositumomab | Other | Phase PHASE2 | Lymphoma, B-Cell | COMPLETED | NCT00577629 |
| doxorubicin | Other | Phase PHASE2 | Lymphoma, B-Cell | COMPLETED | NCT00577629 |
| cytarabine | Other | Phase PHASE2 | Lymphoma, B-Cell | COMPLETED | NCT00577629 |
| rituximab | Other | Phase PHASE2 | Lymphoma, B-Cell | COMPLETED | NCT00577629 |
| etoposide | Other | Phase PHASE2 | Lymphoma, B-Cell | COMPLETED | NCT00577629 |
| cyclophosphamide | Other | Phase PHASE2 | Lymphoma, B-Cell | COMPLETED | NCT00577629 |
| Placebo | Other | Phase PHASE1 | Tinea Pedis | COMPLETED | NCT00509275 |
| W0027 | Other | Phase PHASE1 | Tinea Pedis | COMPLETED | NCT00509275 |
| Placebo | Other | Phase PHASE3 | Post-Stroke Spasticity | COMPLETED | NCT00460564 |
| GSK1358820 | Other | Phase PHASE3 | Post-Stroke Spasticity | COMPLETED | NCT00460564 |
| Propofol | Other | Phase PHASE3 | Analgesia | TERMINATED | NCT00436345 |
| Remifentanil | Other | Phase PHASE3 | Analgesia | TERMINATED | NCT00436345 |
| Propofol | Other | Phase PHASE3 | Analgesia | TERMINATED | NCT00436345 |
| Remifentanil | Other | Phase PHASE3 | Analgesia | TERMINATED | NCT00436345 |
| GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A | Other | Phase PHASE1 | Infections, Cytomegalovirus | COMPLETED | NCT00435396 |
| commercially available dutasteride | Other | Phase PHASE2 | Hypogonadism | COMPLETED | NCT00398580 |
| Nanomilled dutasteride | Other | Phase PHASE2 | Hypogonadism | COMPLETED | NCT00398580 |
| Nanomilled testosterone | Other | Phase PHASE2 | Hypogonadism | COMPLETED | NCT00398580 |
| commercially available dutasteride | Other | Phase PHASE2 | Hypogonadism | COMPLETED | NCT00398580 |
| Nanomilled dutasteride | Other | Phase PHASE2 | Hypogonadism | COMPLETED | NCT00398580 |
| Nanomilled testosterone | Other | Phase PHASE2 | Hypogonadism | COMPLETED | NCT00398580 |
| Placebo Comparator | Other | Phase PHASE2 | Dengue | COMPLETED | NCT00370682 |
| T-DEN F-19 | Other | Phase PHASE2 | Dengue | COMPLETED | NCT00370682 |
| T-DEN F17 | Other | Phase PHASE2 | Dengue | COMPLETED | NCT00370682 |
| GW274150 | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT00370435 |
| Cervarix™ | Other | Phase PHASE3 | Papillomavirus Type 16/18 Infection | COMPLETED | NCT00337818 |
| Mtb72F/AS02. | Other | Phase PHASE1 | Tuberculosis (TB) | COMPLETED | NCT00291889 |
| Salmeterol/fluticasone propionate combination | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00291382 |
| Live attenuated human rotavirus vaccine | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT00289172 |
| Duac® Gel / Differin® Gel | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT00160394 |
| GW501516 oral tablets | Other | Phase PHASE2 | Dyslipidaemias | COMPLETED | NCT00158899 |
| Diphteria, tetanus, whole-cell pertussis, hepatitis B & Hib | Other | Phase PHASE2 | Hib Disease | COMPLETED | NCT00158808 |
| Haemophilus Influenza type b vaccine | Other | Phase PHASE4 | Haemophilus Influenzae Type b Disease | COMPLETED | NCT00158795 |
| Mtb72F/AS02A | Other | Phase PHASE2 | Tuberculosis (TB) | COMPLETED | NCT00146744 |
| topotecan | Other | Phase PHASE1 | Lung Cancer, Small Cell | COMPLETED | NCT00046111 |
| Placebo | Other | Phase PHASE2 | Arthroplasty | COMPLETED | NCT00041509 |
| SB-424323 | Other | Phase PHASE2 | Arthroplasty | COMPLETED | NCT00041509 |
| Trametinib (Multiple tablet) | Other | Phase PHASE2 | Cancer | COMPLETED | NCT01943864 |
| Trametinib (single tablet) | Other | Phase PHASE2 | Cancer | COMPLETED | NCT01943864 |
| Existing Maintenance Therapy | Drug | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01551758 |
| FF/VI | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01551758 |
| sodium chloride | Other | Phase PHASE3 | Glabellar Lines | COMPLETED | NCT00408785 |
| Botulinum Toxin Type A | Other | Phase PHASE3 | Glabellar Lines | COMPLETED | NCT00408785 |
| Paclitaxel | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00111787 |
| Lapatinib | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00111787 |
| topotecan | Other | Phase PHASE2 | Lung Cancer, Small Cell | COMPLETED | NCT00043862 |
| Lamotrigine Compressed tablet 25mg | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT01879423 |
| Lamotrigine Dispersible/Chewable tablets 5mg*5 | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT01879423 |
| SRT2104 | Other | Phase PHASE1 | Colitis, Ulcerative | COMPLETED | NCT01453491 |
| Exposure to licensed dose of FPV (+/- 20% of 18mg/kg BID + RTV) | Other | Preclinical | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01077635 |
| Placebo | Other | Phase PHASE3 | Myocardial Infarction | COMPLETED | NCT00729430 |
| Omega-3 Fatty Acids (Fish Oil Supplements) | Other | Phase PHASE3 | Myocardial Infarction | COMPLETED | NCT00729430 |
| Placebo | Other | Phase PHASE3 | Myocardial Infarction | COMPLETED | NCT00729430 |
| Omega-3 Fatty Acids (Fish Oil Supplements) | Other | Phase PHASE3 | Myocardial Infarction | COMPLETED | NCT00729430 |
| Standard therapy | Drug | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT02145468 |
| Placebo twice daily | Other | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT02145468 |
| Losmapimod 7.5 mg twice daily | Other | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT02145468 |
| Standard therapy | Drug | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT02145468 |
| Placebo twice daily | Other | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT02145468 |
| Losmapimod 7.5 mg twice daily | Other | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT02145468 |
| Glucophage 500mg | Other | Phase PHASE2 | Diabetic Foot | COMPLETED | NCT01710527 |
| Metformin 500mg | Other | Phase PHASE2 | Diabetic Foot | COMPLETED | NCT01710527 |
| Telaprevir | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01648140 |
| Ribavirin | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01648140 |
| Pegylated interferon alpha-2a | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01648140 |
| GSK2336805 60 mg | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01648140 |
| GSK2336805 40 mg | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01648140 |
| Orlistat 60 | Other | Preclinical | Obesity | COMPLETED | NCT01332448 |
| Orlistat 120 | Other | Preclinical | Obesity | COMPLETED | NCT01332448 |
| Orlistat 60 | Other | Preclinical | Obesity | COMPLETED | NCT01332448 |
| Orlistat 120 | Other | Preclinical | Obesity | COMPLETED | NCT01332448 |
| Sitagliptin + Metformin | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT01332370 |
| Rosiglitazone + Metformin | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT01332370 |
| Inhaled corticosteroids | Other | Preclinical | Asthma | COMPLETED | NCT01332344 |
| Fluticasone propionate/salmeterol combination | Other | Preclinical | Asthma | COMPLETED | NCT01332344 |
| Herpes simplex candidate (gD) vaccine GSK208141 | Other | Phase PHASE1 | Herpes Simplex | COMPLETED | NCT00698893 |
| Enalapril Maleate 20 mg | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT01822639 |
| Amlodipine 5 mg | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT01822639 |
| GSK2944404 FDC | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT01822639 |
| Cephalexin 250mg/5ml | Other | Phase PHASE1 | Infections, Respiratory Tract | COMPLETED | NCT01767571 |
| Cephalexin 125 mg/5ml | Other | Phase PHASE1 | Infections, Respiratory Tract | COMPLETED | NCT01767571 |
| Carbon-14 radio-labeled SRT2104 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00937872 |
| 250 mg SRT2104 Suspension | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00937872 |
| Placebo | Other | Phase PHASE2 | Rhinitis, Allergic, Perennial and Seasonal | COMPLETED | NCT01949051 |
| Levocabastine | Other | Phase PHASE2 | Rhinitis, Allergic, Perennial and Seasonal | COMPLETED | NCT01949051 |
| Placebo | Other | Phase PHASE2 | Rhinitis, Allergic, Perennial and Seasonal | COMPLETED | NCT01949051 |
| Levocabastine | Other | Phase PHASE2 | Rhinitis, Allergic, Perennial and Seasonal | COMPLETED | NCT01949051 |
| ambrisentan | Other | Phase PHASE3 | Vascular Disease | COMPLETED | NCT01808313 |
| VI 25 mcg | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01899638 |
| UMEC 62.5 mcg | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01899638 |
| UMEC 125 mcg | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01899638 |
| UMEC/VI 62.5/25 mcg | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01899638 |
| UMEC/VI 125/25 mcg | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01899638 |
| Part C: Dose of GSK2618960 decided from Part A and B | Other | Phase PHASE1 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT01808482 |
| Part B: matching placebo | Other | Phase PHASE1 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT01808482 |
| Part B: Dose of GSK2618960 decided from Part A | Other | Phase PHASE1 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT01808482 |
| Part A: matching placebo | Other | Phase PHASE1 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT01808482 |
| Part A: 100 mg/mL GSK2618960 | Other | Phase PHASE1 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT01808482 |
| Part C: Dose of GSK2618960 decided from Part A and B | Other | Phase PHASE1 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT01808482 |
| Part B: matching placebo | Other | Phase PHASE1 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT01808482 |
| Part B: Dose of GSK2618960 decided from Part A | Other | Phase PHASE1 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT01808482 |
| Part A: matching placebo | Other | Phase PHASE1 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT01808482 |
| Part A: 100 mg/mL GSK2618960 | Other | Phase PHASE1 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT01808482 |
| Plerixafor | Other | Phase PHASE1 | Transplantation, Stem Cell | COMPLETED | NCT01802892 |
| Ronacaleret 400 mg | Other | Phase PHASE1 | Transplantation, Stem Cell | COMPLETED | NCT01802892 |
| Ronacaleret 100 mg | Other | Phase PHASE1 | Transplantation, Stem Cell | COMPLETED | NCT01802892 |
| Plerixafor | Other | Phase PHASE1 | Transplantation, Stem Cell | COMPLETED | NCT01802892 |
| Ronacaleret 400 mg | Other | Phase PHASE1 | Transplantation, Stem Cell | COMPLETED | NCT01802892 |
| Ronacaleret 100 mg | Other | Phase PHASE1 | Transplantation, Stem Cell | COMPLETED | NCT01802892 |
| Moxifloxacin Placebo | Other | Phase PHASE1 | Acute Coronary Syndrome | COMPLETED | NCT01756495 |
| Losmapimod matched Placebo | Other | Phase PHASE1 | Acute Coronary Syndrome | COMPLETED | NCT01756495 |
| Moxifloxacin | Other | Phase PHASE1 | Acute Coronary Syndrome | COMPLETED | NCT01756495 |
| Losmapimod | Other | Phase PHASE1 | Acute Coronary Syndrome | COMPLETED | NCT01756495 |
| Moxifloxacin Placebo | Other | Phase PHASE1 | Acute Coronary Syndrome | COMPLETED | NCT01756495 |
| Losmapimod matched Placebo | Other | Phase PHASE1 | Acute Coronary Syndrome | COMPLETED | NCT01756495 |
| Moxifloxacin | Other | Phase PHASE1 | Acute Coronary Syndrome | COMPLETED | NCT01756495 |
| Losmapimod | Other | Phase PHASE1 | Acute Coronary Syndrome | COMPLETED | NCT01756495 |
| Placebo | Other | Phase PHASE1 | Cachexia | COMPLETED | NCT01696604 |
| GSK2849466 | Other | Phase PHASE1 | Cachexia | COMPLETED | NCT01696604 |
| GSK557296 dose 4 | Other | Phase PHASE1 | Embryo Transfer | COMPLETED | NCT01669083 |
| GSK557296 dose 3 | Other | Phase PHASE1 | Embryo Transfer | COMPLETED | NCT01669083 |
| GSK557296 150 mg | Other | Phase PHASE1 | Embryo Transfer | COMPLETED | NCT01669083 |
| GSK557296 10 mg | Other | Phase PHASE1 | Embryo Transfer | COMPLETED | NCT01669083 |
| BOTOX | Other | Preclinical | Spasticity, Post-Stroke | COMPLETED | NCT01332474 |
| GSK2190915A 100mg | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT01286844 |
| GSK2190915A 50mg | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT01286844 |
| GSK2190915A 25mg | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT01286844 |
| GSK2190915A 10mg | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT01286844 |
| GSK2190915A 5mg | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT01286844 |
| oseltamivir | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT01258530 |
| over-encapsulated oseltamivir | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT01258530 |
| Placebo | Other | Preclinical | Thrombocytopaenia | COMPLETED | NCT01236014 |
| Romiplostim | Other | Preclinical | Thrombocytopaenia | COMPLETED | NCT01236014 |
| Eltrombopag | Other | Preclinical | Thrombocytopaenia | COMPLETED | NCT01236014 |
| Placebo | Other | Preclinical | Thrombocytopaenia | COMPLETED | NCT01236014 |
| Romiplostim | Other | Preclinical | Thrombocytopaenia | COMPLETED | NCT01236014 |
| Eltrombopag | Other | Preclinical | Thrombocytopaenia | COMPLETED | NCT01236014 |
| Placebo | Other | Preclinical | Thrombocytopaenia | COMPLETED | NCT01235988 |
| Eltrombopag | Other | Preclinical | Thrombocytopaenia | COMPLETED | NCT01235988 |
| Placebo | Other | Preclinical | Thrombocytopaenia | COMPLETED | NCT01235988 |
| Eltrombopag | Other | Preclinical | Thrombocytopaenia | COMPLETED | NCT01235988 |
| OPSAT-Q | Other | Preclinical | Osteoporosis, Postmenopausal | COMPLETED | NCT01227369 |
| OPSAT-Q | Other | Preclinical | Osteoporosis, Postmenopausal | COMPLETED | NCT01227369 |
| Paclitaxel | Other | Phase PHASE2 | Neoplasms, Breast | WITHDRAWN | NCT01205217 |
| Cyclophosphamide | Other | Phase PHASE2 | Neoplasms, Breast | WITHDRAWN | NCT01205217 |
| Epirubicin | Other | Phase PHASE2 | Neoplasms, Breast | WITHDRAWN | NCT01205217 |
| Trastuzumab | Other | Phase PHASE2 | Neoplasms, Breast | WITHDRAWN | NCT01205217 |
| Lapatinib | Other | Phase PHASE2 | Neoplasms, Breast | WITHDRAWN | NCT01205217 |
| Tafenoquine | Other | Phase PHASE1 | Malaria | COMPLETED | NCT01205178 |
| Primaquine | Other | Phase PHASE1 | Malaria | COMPLETED | NCT01205178 |
| Chloroquine | Other | Phase PHASE1 | Malaria | COMPLETED | NCT01205178 |
| Database analysis | Other | Preclinical | Nosocomial Rotavirus Gastroenteritis | COMPLETED | NCT01202201 |
| 1. Exposure to bupropion during the first trimester | Other | Preclinical | Depressive Disorder | COMPLETED | NCT01165255 |
| 2. Exposure to bupropion outside the first trimester comparison cohort | Other | Preclinical | Depressive Disorder | COMPLETED | NCT01165255 |
| 3. Exposure to other antidepressants during the first trimester comparison cohort | Other | Preclinical | Depressive Disorder | COMPLETED | NCT01165255 |
| Epidemiologic Surveillance System of the Ministry of Health of Panama | Other | Preclinical | Hepatitis | COMPLETED | NCT01159951 |
| Bupropion | Other | Phase PHASE3 | Smoking Cessation | COMPLETED | NCT00440115 |
| Comparison group | Other | Phase PHASE3 | Smoking Cessation | COMPLETED | NCT00440115 |
| Low intensity disease management | Other | Phase PHASE3 | Smoking Cessation | COMPLETED | NCT00440115 |
| High intensity disease management | Other | Phase PHASE3 | Smoking Cessation | COMPLETED | NCT00440115 |
| drug-drug interaction | Drug | Phase PHASE1 | Alzheimer's Disease | TERMINATED | NCT01978327 |
| GSK2647544 | Other | Phase PHASE1 | Alzheimer's Disease | TERMINATED | NCT01978327 |
| Moxifloxacin | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01406262 |
| Albiglutide | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01406262 |
| Fluzone® | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01389479 |
| Fluviral™ | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01389479 |
| Fluzone® | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01389479 |
| Fluviral™ | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01389479 |
| Paroxetine | Other | Preclinical | Mental Disorders | COMPLETED | NCT01371461 |
| Paroxetine | Other | Preclinical | Mental Disorders | COMPLETED | NCT01371448 |
| Paroxetine | Other | Preclinical | Mental Disorders | COMPLETED | NCT01371448 |
| Paroxetine | Other | Preclinical | Mental Disorders | COMPLETED | NCT01371435 |
| Rifabutin | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01231542 |
| Rifampin | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01231542 |
| GSK1349572 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01231542 |
| Rifabutin | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01231542 |
| Rifampin | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01231542 |
| GSK1349572 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01231542 |
| Moxifloxacin placebo | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01209026 |
| Moxifloxacin 400mg | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01209026 |
| Placebo Inhaler | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01209026 |
| Fluticasone furoate (400 mcg)/GW642444 (50mcg) combination | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01209026 |
| Fluticasone furoate (200 mcg)/GW642444 (25mcg) combination | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01209026 |
| ketoconazole (placebo to match) | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01165125 |
| ketoconazole | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01165125 |
| FF / GW642444 | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01165125 |
| simvastatin plus albiglutide | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01147692 |
| GS856553 | Other | Phase PHASE2 | Pain, Neuropathic | COMPLETED | NCT01110057 |
| Placebo | Other | Phase PHASE2 | Pain, Neuropathic | COMPLETED | NCT01110057 |
| Matching placebo | Other | Phase PHASE1 | Arthritis, Rheumatoid | TERMINATED | NCT01077531 |
| Otelixizumab | Other | Phase PHASE1 | Arthritis, Rheumatoid | TERMINATED | NCT01077531 |
| Matching placebo | Other | Phase PHASE1 | Arthritis, Rheumatoid | TERMINATED | NCT01077531 |
| Otelixizumab | Other | Phase PHASE1 | Arthritis, Rheumatoid | TERMINATED | NCT01077531 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00976261 |
| Sitagliptin | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00976261 |
| GSK1614235 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00976261 |
| Carvedilol | Other | Phase PHASE1 | Pulmonary Arterial Hypertension | COMPLETED | NCT00964678 |
| FF/UMEC 400/500 mcg | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01725685 |
| UMEC 500 mcg | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01725685 |
| FF 400 mcg | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01725685 |
| Placebo | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT01673555 |
| GSK1278863 | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT01673555 |
| Paclitaxel | Other | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT01108055 |
| Pazopanib (GW786034) | Other | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT01108055 |
| GSK1349572 formulation AX | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01098513 |
| GSK1349572 formulation AW | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01098513 |
| GSK1349572 formulation AP | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01098513 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01018628 |
| SRT2379 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01018628 |
| Placebo | Other | Phase PHASE1 | Infections, Respiratory Tract | COMPLETED | NCT02202187 |
| GSK2140944 | Other | Phase PHASE1 | Infections, Respiratory Tract | COMPLETED | NCT02202187 |
| Propafenone | Other | Phase PHASE1 | Arrhythmia, Cardiac | COMPLETED | NCT01956487 |
| Placebo for moxifloxaxin | Other | Phase PHASE1 | Malaria, Vivax | COMPLETED | NCT01928914 |
| Placebo for Tafenoquine | Other | Phase PHASE1 | Malaria, Vivax | COMPLETED | NCT01928914 |
| moxifloxacin | Other | Phase PHASE1 | Malaria, Vivax | COMPLETED | NCT01928914 |
| Tafenoquine 1200mg | Other | Phase PHASE1 | Malaria, Vivax | COMPLETED | NCT01928914 |
| Tafenoquine 600mg | Other | Phase PHASE1 | Malaria, Vivax | COMPLETED | NCT01928914 |
| Tafenoquine 300mg | Other | Phase PHASE1 | Malaria, Vivax | COMPLETED | NCT01928914 |
| FDC 5/100 amlodipine /losartan | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT01797926 |
| FDC 5/50 amlodipine/ losartan | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT01797926 |
| Reference Treatment:5 mg amlodipine + 100 mg losartan | Drug | Phase PHASE1 | Hypertension | COMPLETED | NCT01797926 |
| Reference Treatment: 5 mg amlodipine + 50 mg losartan | Drug | Phase PHASE1 | Hypertension | COMPLETED | NCT01797926 |
| Metformin, 1000 mg and Glimepiride, 2 mg extended release tablet coated with release controlling polymers | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01725672 |
| Metformin, 500 mg and Glimepiride, 1 mg extended release tablet coated with release controlling polymers | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01725672 |
| Metformin, 1000 mg and Glimepiride, 2 mg extended release film coated tablet containing release controlling polymers | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01725672 |
| Metformin, 500 mg and Glimepiride, 1 mg extended release film coated tablet containing release controlling polymers | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01725672 |
| Glimepiride, 2 mg immediate release tablet | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01725672 |
| Glimepiride, 1 mg immediate release tablet | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01725672 |
| Metformin, 1000 mg extended release tablet | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01725672 |
| Metformin, 500 mg extended release tablet | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01725672 |
| FF, 250 mcg | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01669070 |
| FF, 200 mcg | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01669070 |
| FF, 100 mcg | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01669070 |
| FF, 50 mcg | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01669070 |
| GSK1322322 1200 mg containing radioactive 14C-GSK1322322 | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT01663389 |
| GSK1322322 1000 mg containing radioactive 14C-GSK1322322 | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT01663389 |
| GSK1322322 1200 mg containing radioactive 14C-GSK1322322 | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT01663389 |
| GSK1322322 1000 mg containing radioactive 14C-GSK1322322 | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT01663389 |
| 1000mg IV GSK1322322J/placebo | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT01610388 |
| 3000mg IV GSK1322322J/placebo | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT01610388 |
| 2000mg IV GSK1322322J/placebo | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT01610388 |
| 1500mg IV GSK1322322/placebo | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT01610388 |
| 1500mg oral GSK1322322/placebo dose | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT01610388 |
| 1000mg IV GSK1322322/placebo | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT01610388 |
| 1000mg oral GSK1322322/placebo | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT01610388 |
| 500mg IV GSK1322322/placebo | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT01610388 |
| Placebo DPI | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01521377 |
| GSK573719/Vilanterol 500/100mcg | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01521377 |
| GSK573719 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01521377 |
| GSK573719/Vilanterol 125/25mcg | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01521377 |
| Moxifloxacin | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01521377 |
| Placebo Moxifloxacin | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01521377 |
| Gabapentin higher dose | Other | Phase PHASE1 | Pain, Neuropathic | COMPLETED | NCT01485185 |
| Placebo (Gaba) | Other | Phase PHASE1 | Pain, Neuropathic | COMPLETED | NCT01485185 |
| Placebo (Dop) | Other | Phase PHASE1 | Pain, Neuropathic | COMPLETED | NCT01485185 |
| Donepezil | Other | Phase PHASE1 | Pain, Neuropathic | COMPLETED | NCT01485185 |
| Gabapentin lower dose | Other | Phase PHASE1 | Pain, Neuropathic | COMPLETED | NCT01485185 |
| Placebo | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT01476046 |
| GSK1995057 single dose | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT01476046 |
| GSK1325756 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01453478 |
| GSK1550188 1mg/kg or 10mg/kg | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT01381536 |
| GW642444 | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01299558 |
| fluticasone furoate | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01299558 |
| fluticasone furoate//GW642444 | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01299558 |
| Dutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg) | Other | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT01254071 |
| digoxin plus albiglutide | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01147718 |
| GSK1070806 | Other | Phase PHASE1 | Inflammatory Bowel Diseases | COMPLETED | NCT01035645 |
| Prednisone/Prednisolone | Other | Phase PHASE3 | Pemphigus | TERMINATED | NCT02613910 |
| Antihistamine (cetirizine or equivalent) | Other | Phase PHASE3 | Pemphigus | TERMINATED | NCT02613910 |
| Acetaminophen/paracetamol | Other | Phase PHASE3 | Pemphigus | TERMINATED | NCT02613910 |
| Ofatumumab | Other | Phase PHASE3 | Pemphigus | TERMINATED | NCT02613910 |
| Prednisone/Prednisolone | Other | Phase PHASE3 | Pemphigus | TERMINATED | NCT02613910 |
| Antihistamine (cetirizine or equivalent) | Other | Phase PHASE3 | Pemphigus | TERMINATED | NCT02613910 |
| Acetaminophen/paracetamol | Other | Phase PHASE3 | Pemphigus | TERMINATED | NCT02613910 |
| Ofatumumab | Other | Phase PHASE3 | Pemphigus | TERMINATED | NCT02613910 |
| GSK2190915 Micronised Tablet | Other | Phase PHASE1 | Asthma | COMPLETED | NCT02224521 |
| GSK2190915 Milled Tablet | Other | Phase PHASE1 | Asthma | COMPLETED | NCT02224521 |
| GSK2190915 Liquid Lipid Capsule (C) | Other | Phase PHASE1 | Asthma | COMPLETED | NCT02224521 |
| GSK2190915 Semi-solid Lipid Capsule (B) | Other | Phase PHASE1 | Asthma | COMPLETED | NCT02224521 |
| GSK2190915 Granule Capsule (A) | Other | Phase PHASE1 | Asthma | COMPLETED | NCT02224521 |
| GSK2190915 Solution. | Other | Phase PHASE1 | Asthma | COMPLETED | NCT02224521 |
| TIO+FSC | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01381406 |
| TIO | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01381406 |
| Drug | Drug | Phase PHASE1 | Mental Disorders | COMPLETED | NCT01371799 |
| Drug | Drug | Phase PHASE1 | Mental Disorders | COMPLETED | NCT01371799 |
| Vilanterol 25 mcg (4 inhalations) | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01213849 |
| Fluticasone furoate 200 mcg (4 inhalations) | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01213849 |
| Fluticasone furoate 100 mcg (4 inhalations) | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01213849 |
| Fluticasone furoate 50 mcg (4 inhalations) | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01213849 |
| GSK1325756 | Other | Phase PHASE1 | Nutritional Status | COMPLETED | NCT01209104 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01209052 |
| GSK1325756 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01209052 |
| Placebo | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01160003 |
| GW870086X | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01160003 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01147861 |
| GSK256073 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01147861 |
| GW573719/GW573719 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01128634 |
| GSK573719 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01128634 |
| Tazarotene (Patch application in Challenge Phase) | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01119651 |
| Vehicle Foam | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01114841 |
| Tazarotene Foam | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01114841 |
| GSK1292263 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01101568 |
| Rosuvastatin | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01101568 |
| Simvastatin | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01101568 |
| Oral contraceptive (Brevicon) | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01077505 |
| albiglutide | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01077505 |
| losmapimod 15 mg | Other | Phase PHASE1 | Cardiovascular Disease | COMPLETED | NCT01039961 |
| losmapimod | Other | Phase PHASE1 | Cardiovascular Disease | COMPLETED | NCT01039961 |
| losmapimod 1 mg | Other | Phase PHASE1 | Cardiovascular Disease | COMPLETED | NCT01039961 |
| Zanamivir | Other | Phase PHASE1 | Influenza A Virus, H1N1 Subtype | COMPLETED | NCT00989404 |
| SRT501 | Other | Phase PHASE1 | Neoplasms, Colorectal | COMPLETED | NCT00920803 |
| Placebo | Other | Phase PHASE1 | Neoplasms, Colorectal | COMPLETED | NCT00920803 |
| Placebo | Other | Phase PHASE1 | Premature Ejaculation | COMPLETED | NCT00861484 |
| GSK958108 | Other | Phase PHASE1 | Premature Ejaculation | COMPLETED | NCT00861484 |
| Placebo | Other | Phase PHASE1 | Premature Ejaculation | COMPLETED | NCT00861484 |
| GSK958108 | Other | Phase PHASE1 | Premature Ejaculation | COMPLETED | NCT00861484 |
| Montelukast 10 mg | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01943942 |
| Montelukast 5 mg chewable tablets | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01863654 |
| GSK221149 750 mg + Food | Other | Phase PHASE1 | Obstetric Labour, Premature | COMPLETED | NCT01627587 |
| GSK221149 750 mg Fasted | Other | Phase PHASE1 | Obstetric Labour, Premature | COMPLETED | NCT01627587 |
| GSK221149 100 mg | Other | Phase PHASE1 | Obstetric Labour, Premature | COMPLETED | NCT01627587 |
| Ketoconazole | Other | Phase PHASE1 | Obstetric Labour, Premature | COMPLETED | NCT01627587 |
| GSK221149 750 mg | Other | Phase PHASE1 | Obstetric Labour, Premature | COMPLETED | NCT01627587 |
| GSK2251052 0.9% saline | Other | Phase PHASE1 | Community-acquired Infection | TERMINATED | NCT01495065 |
| GSK2251052 3000 mg | Other | Phase PHASE1 | Community-acquired Infection | TERMINATED | NCT01495065 |
| GSK2251052 2250 mg | Other | Phase PHASE1 | Community-acquired Infection | TERMINATED | NCT01495065 |
| GSK2251052 1500 mg BID | Other | Phase PHASE1 | Community-acquired Infection | TERMINATED | NCT01495065 |
| GSK2251052 1500 mg | Other | Phase PHASE1 | Community-acquired Infection | TERMINATED | NCT01495065 |
| GSK2251052 750 mg | Other | Phase PHASE1 | Community-acquired Infection | TERMINATED | NCT01495065 |
| GSK2251052 0.9% saline | Other | Phase PHASE1 | Community-acquired Infection | TERMINATED | NCT01495065 |
| GSK2251052 3000 mg | Other | Phase PHASE1 | Community-acquired Infection | TERMINATED | NCT01495065 |
| GSK2251052 2250 mg | Other | Phase PHASE1 | Community-acquired Infection | TERMINATED | NCT01495065 |
| GSK2251052 1500 mg BID | Other | Phase PHASE1 | Community-acquired Infection | TERMINATED | NCT01495065 |
| GSK2251052 1500 mg | Other | Phase PHASE1 | Community-acquired Infection | TERMINATED | NCT01495065 |
| GSK2251052 750 mg | Other | Phase PHASE1 | Community-acquired Infection | TERMINATED | NCT01495065 |
| Placebo | Other | Phase PHASE1 | Sepsis | COMPLETED | NCT01416376 |
| SRT2379 | Other | Phase PHASE1 | Sepsis | COMPLETED | NCT01416376 |
| HBV (Engerix™-B) | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT01457495 |
| DTPa-IPV/Hib (Infanrix-IPV/Hib™) | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT01457495 |
| DTPa-HBV-IPV/Hib (Infanrix-hexa™) | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT01457495 |
| HBV (Engerix™-B) | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT01457495 |
| DTPa-IPV/Hib (Infanrix-IPV/Hib™) | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT01457495 |
| DTPa-HBV-IPV/Hib (Infanrix-hexa™) | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT01457495 |
| Placebo | Other | Phase PHASE1 | Malaria | COMPLETED | NCT00871156 |
| Chloroquine, Tafenoquine | Other | Phase PHASE1 | Malaria | COMPLETED | NCT00871156 |
| Alprazolam 2 mg tablets | Other | Phase PHASE1 | Anxiety Disorders | COMPLETED | NCT01745575 |
| Alprazolam 2mg tablets | Other | Phase PHASE1 | Anxiety Disorders | COMPLETED | NCT01745575 |
| Gabapentin 300 mg | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT01738893 |
| tamsulosin | Other | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT01657851 |
| dutasteride | Other | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT01657851 |
| dutasteride/tamsulosin | Other | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT01657851 |
| Rolipram | Other | Phase PHASE1 | Huntington Disease | COMPLETED | NCT01602900 |
| GSK356278 | Other | Phase PHASE1 | Huntington Disease | COMPLETED | NCT01602900 |
| 10 mg Ezetimibe - wash out period | Other | Phase PHASE1 | Hypercholesterolaemia | COMPLETED | NCT01597700 |
| 10mg Ezetimibe | Other | Phase PHASE1 | Hypercholesterolaemia | COMPLETED | NCT01597700 |
| sibutramine placebo | Other | Phase PHASE1 | Obesity | COMPLETED | NCT01597609 |
| sibutramine | Other | Phase PHASE1 | Obesity | COMPLETED | NCT01597609 |
| sibutramine placebo | Other | Phase PHASE1 | Obesity | COMPLETED | NCT01597609 |
| sibutramine | Other | Phase PHASE1 | Obesity | COMPLETED | NCT01597609 |
| Subcutaneous (SC) single dose | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01563042 |
| Intravenous (IV) single dose | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01563042 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01521390 |
| GSK573719 125 mcg(two strips) | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01521390 |
| GSK573719 125 mcg (one strip) | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01521390 |
| GSK573719 62.5 mcg(two strips) | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01521390 |
| GSK573719 62.5 mcg (one strip) | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01521390 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01521390 |
| GSK573719 125 mcg(two strips) | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01521390 |
| GSK573719 125 mcg (one strip) | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01521390 |
| GSK573719 62.5 mcg(two strips) | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01521390 |
| GSK573719 62.5 mcg (one strip) | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01521390 |
| Lidocaine | Other | Phase PHASE1 | Cough | COMPLETED | NCT01494636 |
| Placebo (0.9% sodium chloride solution) | Other | Phase PHASE1 | Cough | COMPLETED | NCT01494636 |
| GSK2339345 (nebulised) | Other | Phase PHASE1 | Cough | COMPLETED | NCT01494636 |
| GSK2339345 (solution) | Other | Phase PHASE1 | Cough | COMPLETED | NCT01494636 |
| Placebo | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01471327 |
| SB-240563 | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01471327 |
| Placebo | Other | Phase PHASE1 | Bone Marrow Transplantation | COMPLETED | NCT01466335 |
| Ronacaleret (100mg tablet) | Other | Phase PHASE1 | Bone Marrow Transplantation | COMPLETED | NCT01466335 |
| 60 mg GSK2330672 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01416324 |
| 30 mg GSK2330672 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01416324 |
| 10 mg GSK2330672 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01416324 |
| 3 mg GSK2330672 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01416324 |
| 1 mg GSK2330672 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01416324 |
| 0.3 mg GSK2330672 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01416324 |
| 0.1 mg GSK2330672 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01416324 |
| placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01416324 |
| [14C]GW642444 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01286831 |
| GSK1144814 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01209039 |
| No Treatment with UVA and UVB and visible light irradiation | Drug | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01115322 |
| No Treatment with UVA and UVB irradiation | Drug | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01115322 |
| No Treatment without irradiation | Drug | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01115322 |
| Vehicle Foam with UVA and UVB and visible light irradiation | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01115322 |
| Vehicle Foam with UVA and UVB irradiation | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01115322 |
| Vehicle Foam without irradiation | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01115322 |
| Tazarotene Foam with UVA, UVB, and visible light | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01115322 |
| Tazarotene Foam with UVA and UVB irradiation | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01115322 |
| Tazarotene Foam without irradiation | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01115322 |
| Distilled Water | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01112787 |
| Sodium Laural Sulfate | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01112787 |
| Vehicle Foam | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01112787 |
| Tazarotene Foam | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01112787 |
| Ketoconazole | Other | Phase PHASE1 | Gastroparesis | COMPLETED | NCT01039974 |
| GSK962040 | Other | Phase PHASE1 | Gastroparesis | COMPLETED | NCT01039974 |
| Ketoconazole | Other | Phase PHASE1 | Gastroparesis | COMPLETED | NCT01039974 |
| GSK962040 | Other | Phase PHASE1 | Gastroparesis | COMPLETED | NCT01039974 |
| SRT2104 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01031108 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01031108 |
| Placebo | Other | Phase PHASE1 | Onychomycosis | COMPLETED | NCT01014962 |
| Albaconozole | Other | Phase PHASE1 | Onychomycosis | COMPLETED | NCT01014962 |
| GSK1362885 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01013766 |
| GSK1521498 or placebo | Other | Phase PHASE1 | Obesity | COMPLETED | NCT00976105 |
| Zolpidem or placebo - Hypnotic drug given for sleep disorders | Drug | Phase PHASE1 | Obesity | COMPLETED | NCT00976105 |
| 4000mg GSK investigational drug | Drug | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT00828867 |
| 3000mg GSK investigational drug | Drug | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT00828867 |
| 800mg fed GSK investigational drug | Drug | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT00828867 |
| 1500 mg GSK investigational drug | Drug | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT00828867 |
| 2000 mg GSK investigational drug | Drug | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT00828867 |
| 800 mg GSK investigational drug | Drug | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT00828867 |
| 400 mg GSK investigational drug | Drug | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT00828867 |
| 200 mg GSK investigational drug | Drug | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT00828867 |
| 100 mg GSK investigational drug | Drug | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT00828867 |
| Placebo | Other | Phase PHASE4 | Osteoarthritis, Knee | COMPLETED | NCT01105936 |
| Paracetamol | Other | Phase PHASE4 | Osteoarthritis, Knee | COMPLETED | NCT01105936 |
| Placebo | Other | Phase PHASE4 | Osteoarthritis, Knee | COMPLETED | NCT01105936 |
| Paracetamol | Other | Phase PHASE4 | Osteoarthritis, Knee | COMPLETED | NCT01105936 |
| GSK1278863A | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT02348372 |
| GSK1278863A Placebo | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT02348372 |
| Terbinafine 250 mg | Other | Phase PHASE1 | Mycoses | COMPLETED | NCT01772212 |
| Cephalexin 125 mg/5ml | Other | Phase PHASE1 | Infections, Respiratory Tract | COMPLETED | NCT01767532 |
| Minocycline 100mg | Other | Phase PHASE1 | Skin Infections (Acne) | COMPLETED | NCT01755611 |
| Metformin | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01357876 |
| Inhalation Profiling | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01345266 |
| warfarin plus albiglutide | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01147731 |
| SRT2104 | Other | Phase PHASE1 | Sepsis | COMPLETED | NCT01014117 |
| Placebo | Other | Phase PHASE1 | Sepsis | COMPLETED | NCT01014117 |
| GSK2212836 | Other | Phase PHASE1 | Cardiovascular Disease | COMPLETED | NCT00996268 |
| Placebo | Other | Phase PHASE1 | Kidney Disease | COMPLETED | NCT00840320 |
| 1278863 | Other | Phase PHASE1 | Kidney Disease | COMPLETED | NCT00840320 |
| GSK1278863A | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT01319006 |
| GSK1322322 | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT00924911 |
| GSK1521498 or placebo | Other | Phase PHASE1 | Obesity | COMPLETED | NCT00857883 |
| GSK256066 | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00549744 |
| Treatment Period 2 - Oral dose of GSK573719 | Drug | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01362257 |
| Treatment Period 1 - IV dose of GSK573719 | Drug | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01362257 |
| Other maintenance Treatments (OMT) | Drug | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01332461 |
| fluticasone propionate/salmeterol xinafoate combination | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01332461 |
| 5ARI + AB | Other | Preclinical | Prostatic Hyperplasia | COMPLETED | NCT01332435 |
| single dose | Other | Phase PHASE1 | Alcoholism | COMPLETED | NCT01181908 |
| GSK1360707 is a potent re-uptake inhibitor of the neurotransmitters dopamine, norepinephrine and serotonin | Other | Phase PHASE1 | Depressive Disorder | COMPLETED | NCT01153802 |
| GSK573719 (INHALATION POWDER) | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01110018 |
| GSK573719 (SOLUTION) | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01110018 |
| Blood withdrawal | Other | Approved | Immunologic Tests | COMPLETED | NCT01099488 |
| GSK573719 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00976144 |
| GSK1034702 | Other | Phase PHASE1 | Cognitive Disorders | COMPLETED | NCT00937846 |
| Placebo | Other | Phase PHASE1 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT01480271 |
| 4000ng GSK2445053 | Other | Phase PHASE1 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT01480271 |
| 2000ng GSK2445053 | Other | Phase PHASE1 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT01480271 |
| 1000ng GSK2445053 | Other | Phase PHASE1 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT01480271 |
| 400ng GSK2445053 | Other | Phase PHASE1 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT01480271 |
| 200ng GSK2445053 | Other | Phase PHASE1 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT01480271 |
| 100ng GSK2445053 | Other | Phase PHASE1 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT01480271 |
| 20ng GSK2445053 | Other | Phase PHASE1 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT01480271 |
| 2 ng GSK2445053 | Other | Phase PHASE1 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT01480271 |
| 14C GSK2251052 | Other | Phase PHASE1 | Community-acquired Infection | COMPLETED | NCT01475695 |
| Topamax® coated tablet | Other | Phase PHASE1 | Epilepsy, Tonic-Clonic | COMPLETED | NCT01439438 |
| Topiramate coated tablet | Other | Phase PHASE1 | Epilepsy, Tonic-Clonic | COMPLETED | NCT01439438 |
| Placebo | Other | Phase PHASE1 | Gastroparesis | COMPLETED | NCT01294566 |
| GSK1322888 | Other | Phase PHASE1 | Gastroparesis | COMPLETED | NCT01294566 |
| GSK2236805 30mg | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01277692 |
| GSK2236805 5mg | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01277692 |
| GSK2236805 dose to be determined up to 100mg | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01277692 |
| GSK2236805 10mg | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01277692 |
| GSK2236805 200mg | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01277692 |
| GSK2236805 100mg | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01277692 |
| GSK2336805 30mg | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01277692 |
| GSK2336805 10mg | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01277692 |
| GSK2236805 30mg | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01277692 |
| GSK2236805 5mg | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01277692 |
| GSK2236805 dose to be determined up to 100mg | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01277692 |
| GSK2236805 10mg | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01277692 |
| GSK2236805 200mg | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01277692 |
| GSK2236805 100mg | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01277692 |
| GSK2336805 30mg | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01277692 |
| GSK2336805 10mg | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01277692 |
| Placebo | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT01262885 |
| GSK2251052 | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT01262885 |
| placebo | Other | Phase PHASE3 | Cerebrovascular Accident | COMPLETED | NCT01153815 |
| GSK1358820(Botulinum toxin type A) | Other | Phase PHASE3 | Cerebrovascular Accident | COMPLETED | NCT01153815 |
| Prednisolone | Other | Phase PHASE1 | Asthma | TERMINATED | NCT00331058 |
| Bronchoscopsy | Other | Phase PHASE1 | Asthma | TERMINATED | NCT00331058 |
| Prednisolone | Other | Phase PHASE1 | Asthma | TERMINATED | NCT00331058 |
| Bronchoscopsy | Other | Phase PHASE1 | Asthma | TERMINATED | NCT00331058 |
| lapatinib ditosylate | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT00246753 |
| Placebo | Other | Phase PHASE1 | Common Cold | COMPLETED | NCT02832362 |
| Carbomer 980 | Other | Phase PHASE1 | Common Cold | COMPLETED | NCT02832362 |
| Menthol | Other | Phase PHASE1 | Pain | COMPLETED | NCT02201238 |
| Diclofenac sodium | Other | Phase PHASE1 | Pain | COMPLETED | NCT02201238 |
| 0.9% Saline | Other | Phase PHASE1 | Pain | COMPLETED | NCT02169154 |
| 0.2% Sodium Lauryl Sulfate | Other | Phase PHASE1 | Pain | COMPLETED | NCT02169154 |
| 0.09% Menthol | Other | Phase PHASE1 | Pain | COMPLETED | NCT02169154 |
| 3% Menthol | Other | Phase PHASE1 | Pain | COMPLETED | NCT02169154 |
| 1% Diclofenac Sodium | Other | Phase PHASE1 | Pain | COMPLETED | NCT02169154 |
| ipratropium bromide alone or in fixed dose combination with albuterol | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01331694 |
| tiotropium | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01331694 |
| fluticasone/salmeterol combination (FSC) 250/50mcg | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01331694 |
| adefovir dipivoxil | Other | Preclinical | Hepatitis B | COMPLETED | NCT01329419 |
| Dutasteride | Other | Preclinical | Benign Prostatic Hyperplasia | COMPLETED | NCT01299571 |
| Placebo | Other | Phase PHASE2 | Telangiectasia, Hereditary Hemorrhagic | TERMINATED | NCT02204371 |
| Pazopanib | Other | Phase PHASE2 | Telangiectasia, Hereditary Hemorrhagic | TERMINATED | NCT02204371 |
| Fluticasone propionate/salmeterol combination OP MD | Other | Preclinical | Asthma | COMPLETED | NCT01332357 |
| Fluticasone propionate/salmeterol combination ED MD | Other | Preclinical | Asthma | COMPLETED | NCT01332357 |
| Montelukast | Other | Preclinical | Asthma | COMPLETED | NCT01328964 |
| Budesonide | Other | Preclinical | Asthma | COMPLETED | NCT01328964 |
| Fluticasone propionate | Other | Preclinical | Asthma | COMPLETED | NCT01328964 |
| 5ARI | Other | Preclinical | Prostatic Hyperplasia | COMPLETED | NCT01323998 |
| 5ARI | Other | Preclinical | Prostatic Hyperplasia | COMPLETED | NCT01323998 |
| Remifentanil | Other | Preclinical | Analgesia | COMPLETED | NCT01299584 |
| placebo | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT01231464 |
| fluticasone furoate nasal spray | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT01231464 |
| zanamivir | Other | Preclinical | Influenza, Human | COMPLETED | NCT01199744 |
| Cephalexin 1g tablets | Other | Phase PHASE1 | Infections, Respiratory Tract | COMPLETED | NCT01767584 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00933062 |
| SRT2104 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00933062 |
| 2g SRT2104 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00920660 |
| 1g SRT2104 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00920660 |
| 0.5g SRT2104 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00920660 |
| Prednisolone | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00920660 |
| 0.25g SRT2104 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00920660 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00920660 |
| GSK1482160 or placebo | Other | Phase PHASE1 | Pain, Inflammatory | COMPLETED | NCT00849134 |
| Glucagon + GSK1362885 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00823940 |
| Glucagon | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00823940 |
| GSK1362885 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00823940 |
| GSK618334 | Other | Phase PHASE1 | Substance Dependence | COMPLETED | NCT00814957 |
| ascending dose of GSK1292263 | Other | Phase PHASE1 | Dyslipidaemias | COMPLETED | NCT00783549 |
| an undetermined dose of GSK1292263 | Other | Phase PHASE1 | Dyslipidaemias | COMPLETED | NCT00783549 |
| ascending dose of GSK1292263 | Other | Phase PHASE1 | Dyslipidaemias | COMPLETED | NCT00783549 |
| an undetermined dose of GSK1292263 | Other | Phase PHASE1 | Dyslipidaemias | COMPLETED | NCT00783549 |
| GSK1363089 | Other | Phase PHASE1 | Solid Tumours | COMPLETED | NCT00742261 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT00675090 |
| GSK239512 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT00675090 |
| mepolizumab | Other | Phase PHASE3 | Hypereosinophilic Syndrome | TERMINATED | NCT00097370 |
| Mineral Water | Other | Approved | Xerostomia | COMPLETED | NCT02641912 |
| Biotene mouthwash | Other | Approved | Xerostomia | COMPLETED | NCT02641912 |
| Control | Other | Approved | Growth and Development | COMPLETED | NCT02254460 |
| Test | Other | Approved | Growth and Development | COMPLETED | NCT02254460 |
| Control | Other | Approved | Growth and Development | COMPLETED | NCT02254460 |
| Test | Other | Approved | Growth and Development | COMPLETED | NCT02254460 |
| Amoxicillin-Potassium Clavulanate Combination | Other | Phase PHASE3 | Sinusitis, Acute | COMPLETED | NCT01934231 |
| dutasteride | Other | Preclinical | Neoplasms, Prostate | COMPLETED | NCT00883909 |
| GW597599 | Other | Phase PHASE2 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00606697 |
| GR205171 | Other | Phase PHASE2 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00606697 |
| Placebo | Other | Phase PHASE2 | Osteoarthritis | COMPLETED | NCT00479427 |
| GW842166 | Other | Phase PHASE2 | Osteoarthritis | COMPLETED | NCT00479427 |
| Placebo | Other | Phase PHASE2 | Osteoarthritis | COMPLETED | NCT00479427 |
| GW842166 | Other | Phase PHASE2 | Osteoarthritis | COMPLETED | NCT00479427 |
| paroxetine | Other | Phase PHASE2 | Social Phobia | COMPLETED | NCT00397722 |
| GW876008 | Other | Phase PHASE2 | Social Phobia | COMPLETED | NCT00397722 |
| paroxetine | Other | Phase PHASE2 | Social Phobia | COMPLETED | NCT00397722 |
| GW876008 | Other | Phase PHASE2 | Social Phobia | COMPLETED | NCT00397722 |
| Prednisolone | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00379730 |
| Prednisolone | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00379730 |
| Placebo | Other | Phase PHASE3 | Asthma | TERMINATED | NCT02594332 |
| Mepolizumab | Other | Phase PHASE3 | Asthma | TERMINATED | NCT02594332 |
| GSK2140944 Capsule | Other | Phase PHASE1 | Infections, Respiratory Tract | COMPLETED | NCT02000765 |
| GSK2140944 for Injection | Other | Phase PHASE1 | Infections, Respiratory Tract | COMPLETED | NCT02000765 |
| Diltiazem | Other | Phase PHASE1 | Atherosclerosis | COMPLETED | NCT01852565 |
| Darapladib | Other | Phase PHASE1 | Atherosclerosis | COMPLETED | NCT01852565 |
| Diltiazem | Other | Phase PHASE1 | Atherosclerosis | COMPLETED | NCT01852565 |
| Darapladib | Other | Phase PHASE1 | Atherosclerosis | COMPLETED | NCT01852565 |
| Pantoprazole 20 mg gastro-resistant tablet | Other | Phase PHASE1 | Ulcers, Duodenal and Gastric | COMPLETED | NCT01847417 |
| ASA 100 mg tablet | Other | Phase PHASE1 | Ulcers, Duodenal and Gastric | COMPLETED | NCT01847417 |
| Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two | Other | Phase PHASE1 | Ulcers, Duodenal and Gastric | COMPLETED | NCT01847417 |
| Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one | Other | Phase PHASE1 | Ulcers, Duodenal and Gastric | COMPLETED | NCT01847417 |
| Pantoprazole 20 mg gastro-resistant tablet | Other | Phase PHASE1 | Ulcers, Duodenal and Gastric | COMPLETED | NCT01847404 |
| ASA 100 mg tablet | Other | Phase PHASE1 | Ulcers, Duodenal and Gastric | COMPLETED | NCT01847404 |
| Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two | Other | Phase PHASE1 | Ulcers, Duodenal and Gastric | COMPLETED | NCT01847404 |
| Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one | Other | Phase PHASE1 | Ulcers, Duodenal and Gastric | COMPLETED | NCT01847404 |
| Placebo | Other | Phase PHASE1 | Cognitive Disorders | COMPLETED | NCT00950586 |
| Dextromethorphan | Other | Phase PHASE1 | Cognitive Disorders | COMPLETED | NCT00950586 |
| GSK1043702 | Other | Phase PHASE1 | Cognitive Disorders | COMPLETED | NCT00950586 |
| Placebo | Other | Phase PHASE1 | Cognitive Disorders | COMPLETED | NCT00950586 |
| Dextromethorphan | Other | Phase PHASE1 | Cognitive Disorders | COMPLETED | NCT00950586 |
| GSK1043702 | Other | Phase PHASE1 | Cognitive Disorders | COMPLETED | NCT00950586 |
| Placebo | Other | Phase PHASE1 | Rhinitis | COMPLETED | NCT00907933 |
| SB-705498 | Other | Phase PHASE1 | Rhinitis | COMPLETED | NCT00907933 |
| Placebo | Other | Approved | HIV | COMPLETED | NCT00803543 |
| Valacyclovir | Other | Approved | HIV | COMPLETED | NCT00803543 |
| SB756050 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00733577 |
| Caspaicin | Other | Phase PHASE1 | Rhinitis | COMPLETED | NCT00731250 |
| Placebo | Other | Phase PHASE1 | Rhinitis | COMPLETED | NCT00731250 |
| SB-705498 | Other | Phase PHASE1 | Rhinitis | COMPLETED | NCT00731250 |
| GSK372475 | Other | Phase PHASE1 | Depressive Disorder | COMPLETED | NCT00728208 |
| GSK372475 | Other | Phase PHASE1 | Depressive Disorder | COMPLETED | NCT00728208 |
| Mobic 15mg | Other | Approved | Arthritis, Rheumatoid | COMPLETED | NCT01750931 |
| Meloxicam GSK 15mg | Other | Approved | Arthritis, Rheumatoid | COMPLETED | NCT01750931 |
| Empty Patch | Other | Phase PHASE1 | Dermatitis, Atopic | COMPLETED | NCT02637206 |
| Vehicle Cream | Other | Phase PHASE1 | Dermatitis, Atopic | COMPLETED | NCT02637206 |
| GSK2894512 Cream | Other | Phase PHASE1 | Dermatitis, Atopic | COMPLETED | NCT02637206 |
| Blank patch | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01929278 |
| Vehicle gel patch | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01929278 |
| CT Gel (clindamycin 1% and tretinoin 0.025%) | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01929278 |
| Isotretinoin 40 mg | Other | Phase PHASE1 | Skin Infections (Acne) | COMPLETED | NCT01863615 |
| Placebo | Other | Phase PHASE1 | Gastrointestinal Motility | COMPLETED | NCT01366560 |
| Active | Other | Phase PHASE1 | Gastrointestinal Motility | COMPLETED | NCT01366560 |
| GSK2239633 | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01086462 |
| GSK1018921 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT00945503 |
| Foretinib | Other | Phase PHASE1 | Carcinoma, Hepatocellular | COMPLETED | NCT00920192 |
| Ethanol | Other | Phase PHASE1 | Substance Dependence | COMPLETED | NCT00887367 |
| GSK598809 | Other | Phase PHASE1 | Substance Dependence | COMPLETED | NCT00887367 |
| Placebo + GW642444M | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00866515 |
| Ketoconazole + GW642444M | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00866515 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00783003 |
| GSK233705 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00783003 |
| GW642444 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00783003 |
| GSK233705 and GW642444 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00783003 |
| Placebo | Other | Phase PHASE1 | Gastroparesis | COMPLETED | NCT00733551 |
| GSK962040 | Other | Phase PHASE1 | Gastroparesis | COMPLETED | NCT00733551 |
| Paroxetine treatment during 8 weeks | Drug | Phase PHASE1 | Social Phobia | COMPLETED | NCT00470483 |
| Placebo treatment during 8 weeks | Drug | Phase PHASE1 | Social Phobia | COMPLETED | NCT00470483 |
| Indirect cost | Other | Preclinical | COPD | COMPLETED | NCT02750189 |
| Direct cost | Other | Preclinical | COPD | COMPLETED | NCT02750189 |
| Saline | Other | Phase PHASE1 | Infections, Pseudomonas | COMPLETED | NCT01449838 |
| Colistimethate sodium | Other | Phase PHASE1 | Infections, Pseudomonas | COMPLETED | NCT01449838 |
| Placebo | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT01428479 |
| GR121167 Solution | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT01428479 |
| Placebo | Other | Phase PHASE1 | Dermatitis, Atopic | COMPLETED | NCT01381445 |
| Clobetasol Propionate | Other | Phase PHASE1 | Dermatitis, Atopic | COMPLETED | NCT01381445 |
| GW870086 2% | Other | Phase PHASE1 | Dermatitis, Atopic | COMPLETED | NCT01381445 |
| GW870086 0.2% | Other | Phase PHASE1 | Dermatitis, Atopic | COMPLETED | NCT01381445 |
| Placebo | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01371812 |
| GSK2239633 | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01371812 |
| GSK2315698 | Other | Phase PHASE1 | Amyloidosis | COMPLETED | NCT01323985 |
| SB649868 | Other | Phase PHASE1 | Sleep Disorders | COMPLETED | NCT01299597 |
| Simvastatin | Other | Phase PHASE1 | Sleep Disorders | COMPLETED | NCT01299597 |
| Atorvastatin | Other | Phase PHASE1 | Sleep Disorders | COMPLETED | NCT01299597 |
| SB649868 | Other | Phase PHASE1 | Sleep Disorders | COMPLETED | NCT01299597 |
| Simvastatin | Other | Phase PHASE1 | Sleep Disorders | COMPLETED | NCT01299597 |
| Atorvastatin | Other | Phase PHASE1 | Sleep Disorders | COMPLETED | NCT01299597 |
| Inhaled FF 200mcg/GW642444M 25mcg | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01266941 |
| 0.5g SRT2104 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00938275 |
| Lamotrigine | Other | Phase PHASE1 | Bipolar Disorder | TERMINATED | NCT00907985 |
| Vofopitant | Other | Phase PHASE1 | Bipolar Disorder | TERMINATED | NCT00907985 |
| Placebo | Other | Phase PHASE1 | Bipolar Disorder | TERMINATED | NCT00907985 |
| Lamotrigine | Other | Phase PHASE1 | Bipolar Disorder | TERMINATED | NCT00907985 |
| Vofopitant | Other | Phase PHASE1 | Bipolar Disorder | TERMINATED | NCT00907985 |
| Placebo | Other | Phase PHASE1 | Bipolar Disorder | TERMINATED | NCT00907985 |
| Orvepitant | Other | Phase PHASE1 | Depressive Disorder | COMPLETED | NCT00843011 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00803673 |
| 1000mcg | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00803673 |
| 500mcg | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00803673 |
| 100mcg | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00803673 |
| GSK1278863A | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT00750256 |
| GSK1278863A | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT00750256 |
| Placebo | Other | Phase PHASE1 | Cognitive Disorders | COMPLETED | NCT00743405 |
| GSK1034702 | Other | Phase PHASE1 | Cognitive Disorders | COMPLETED | NCT00743405 |
| Placebo | Other | Phase PHASE1 | Cognitive Disorders | COMPLETED | NCT00743405 |
| GSK1034702 | Other | Phase PHASE1 | Cognitive Disorders | COMPLETED | NCT00743405 |
| Placebo | Other | Phase PHASE1 | Cognitive Disorders | COMPLETED | NCT00743405 |
| GSK1034702 | Other | Phase PHASE1 | Cognitive Disorders | COMPLETED | NCT00743405 |
| Rosiglitazone XR | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT00733785 |
| GSK706769 & KALETRA | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00723775 |
| GW642444 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00711126 |
| SB-485232 (interleukin 18), pegylated liposomal doxorubicin | Other | Phase PHASE1 | Neoplasms, Ovarian | COMPLETED | NCT00659178 |
| SB-485232 (interleukin 18), pegylated liposomal doxorubicin | Other | Phase PHASE1 | Neoplasms, Ovarian | COMPLETED | NCT00659178 |
| Placebo | Other | Phase PHASE1 | Cerebrovascular Accident | COMPLETED | NCT00622609 |
| GSK249320A | Other | Phase PHASE1 | Cerebrovascular Accident | COMPLETED | NCT00622609 |
| GSK598809 | Other | Phase PHASE1 | Substance Dependence | COMPLETED | NCT00605241 |
| single dose | Other | Phase PHASE1 | Depressive Disorder and Anxiety Disorders | COMPLETED | NCT00513565 |
| Placebo to match GSK933776 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT00459550 |
| GSK933776 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT00459550 |
| Placebo to match GSK933776 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT00459550 |
| GSK933776 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT00459550 |
| Dabrafenib 75 mg capsule | Other | Phase PHASE1 | Cancer | COMPLETED | NCT02082665 |
| Midazolam 3 mg syrup | Other | Phase PHASE1 | Cancer | COMPLETED | NCT02082665 |
| Rosuvastatin10 mg tablet | Other | Phase PHASE1 | Cancer | COMPLETED | NCT02082665 |
| Rabies vaccine (RabAvert) | Other | Phase PHASE1 | Malaria | COMPLETED | NCT00349713 |
| FMP2.1/AS02A | Other | Phase PHASE1 | Malaria | COMPLETED | NCT00349713 |
| Placebo | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01711463 |
| Fluticasone Furoate/Vilanterol | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01711463 |
| 0.9% sodium chloride | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01545570 |
| GSK2376497 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01545570 |
| 0.9% sodium chloride | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01545570 |
| GSK2376497 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01545570 |
| Rosuvastatin 10 mg | Other | Phase PHASE1 | Crohn's Disease | COMPLETED | NCT01489943 |
| Omeprazole 40 mg | Other | Phase PHASE1 | Crohn's Disease | COMPLETED | NCT01489943 |
| Pioglitazone 15 mg | Other | Phase PHASE1 | Crohn's Disease | COMPLETED | NCT01489943 |
| Midazolam 3 mg | Other | Phase PHASE1 | Crohn's Disease | COMPLETED | NCT01489943 |
| GSK1605786 500 mg | Other | Phase PHASE1 | Crohn's Disease | COMPLETED | NCT01489943 |
| Rosuvastatin 10 mg | Other | Phase PHASE1 | Crohn's Disease | COMPLETED | NCT01489943 |
| Omeprazole 40 mg | Other | Phase PHASE1 | Crohn's Disease | COMPLETED | NCT01489943 |
| Pioglitazone 15 mg | Other | Phase PHASE1 | Crohn's Disease | COMPLETED | NCT01489943 |
| Midazolam 3 mg | Other | Phase PHASE1 | Crohn's Disease | COMPLETED | NCT01489943 |
| GSK1605786 500 mg | Other | Phase PHASE1 | Crohn's Disease | COMPLETED | NCT01489943 |
| Rosuvastatin 10 mg | Other | Phase PHASE1 | Crohn's Disease | COMPLETED | NCT01489943 |
| Omeprazole 40 mg | Other | Phase PHASE1 | Crohn's Disease | COMPLETED | NCT01489943 |
| Pioglitazone 15 mg | Other | Phase PHASE1 | Crohn's Disease | COMPLETED | NCT01489943 |
| Midazolam 3 mg | Other | Phase PHASE1 | Crohn's Disease | COMPLETED | NCT01489943 |
| GSK1605786 500 mg | Other | Phase PHASE1 | Crohn's Disease | COMPLETED | NCT01489943 |
| GSK2269557 matching placebo | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01462617 |
| GSK2269557 | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01462617 |
| GSK2190915 100mg | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01411111 |
| GSK2190915 30mg | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01411111 |
| Rosuvastatin 10 mg | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01411111 |
| Iodine-131 Anti-B1 Antibody | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | COMPLETED | NCT00992758 |
| Iodine-131 Anti-B1 Antibody | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | COMPLETED | NCT00992758 |
| GSK1059615 | Other | Phase PHASE1 | Solid Tumours | TERMINATED | NCT00695448 |
| GSK1059615 | Other | Phase PHASE1 | Solid Tumours | TERMINATED | NCT00695448 |
| ketoconazole | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT01802931 |
| GSK239512 | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT01802931 |
| Darapladib 160 mg | Other | Phase PHASE1 | Atherosclerosis | COMPLETED | NCT01751074 |
| Rosuvastatin 10 mg | Other | Phase PHASE1 | Atherosclerosis | COMPLETED | NCT01751074 |
| Darapladib 160 mg | Other | Phase PHASE1 | Atherosclerosis | COMPLETED | NCT01751074 |
| Rosuvastatin 10 mg | Other | Phase PHASE1 | Atherosclerosis | COMPLETED | NCT01751074 |
| Darapladib 160 mg | Other | Phase PHASE1 | Atherosclerosis | COMPLETED | NCT01711723 |
| Fixed Dose Combination 2: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT01648231 |
| Fixed Dose Combination 1: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT01648231 |
| Reference Treatment: 1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state | Drug | Phase PHASE1 | Hypertension | COMPLETED | NCT01648231 |
| Losmapimod for repeat dose | Other | Phase PHASE1 | Acute Coronary Syndrome | COMPLETED | NCT01648192 |
| Losmapimod for single dose | Other | Phase PHASE1 | Acute Coronary Syndrome | COMPLETED | NCT01648192 |
| GSK1614235 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01607385 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01607385 |
| GSK2330672 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01607385 |
| Placebo (Inhaled) Repeat Dose | Other | Phase PHASE1 | Cough | COMPLETED | NCT01587716 |
| GSK2339345 (Inhaled) Repeat Dose | Other | Phase PHASE1 | Cough | COMPLETED | NCT01587716 |
| Placebo (Inhaled) Single Dose | Other | Phase PHASE1 | Cough | COMPLETED | NCT01587716 |
| GSK2339345 (Inhaled) Single Dose | Other | Phase PHASE1 | Cough | COMPLETED | NCT01587716 |
| GSK2585823 | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01527123 |
| darapladib | Other | Phase PHASE1 | Atherosclerosis | COMPLETED | NCT01154114 |
| GSK1363089 (formerly XL880) | Other | Phase PHASE1 | Solid Tumours | COMPLETED | NCT00743067 |
| Rituximab | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | COMPLETED | NCT00500058 |
| SB-485232 | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | COMPLETED | NCT00500058 |
| BMS-663068 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02164045 |
| Placebo | Other | Phase PHASE1 | Kidney Disease | COMPLETED | NCT00935831 |
| GSK1278863A | Other | Phase PHASE1 | Kidney Disease | COMPLETED | NCT00935831 |
| SB-485232 | Other | Phase PHASE2 | Melanoma | COMPLETED | NCT00107718 |
| SB-485232 | Other | Phase PHASE2 | Melanoma | COMPLETED | NCT00107718 |
| GSK961081 800 microgram Fluticasone Propionate 500 microgram in a blend | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01449799 |
| GSK961081 800 microgram and Fluticasone Propionate 500 microgram separately | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01449799 |
| Fluticasone Propionate 500 microgram dose | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01449799 |
| GSK961081 800 microgram dose | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01449799 |
| Placebo | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00549679 |
| GSK256066 | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00549679 |
| Placebo | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00549679 |
| GSK256066 | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00549679 |
| GSK1363089 | Other | Phase PHASE1 | Solid Tumours | COMPLETED | NCT00742131 |
| Caffeine | Other | Phase PHASE1 | Substance Dependence | COMPLETED | NCT00437632 |
| Placebo | Other | Phase PHASE1 | Substance Dependence | COMPLETED | NCT00437632 |
| GSK598809 | Other | Phase PHASE1 | Substance Dependence | COMPLETED | NCT00437632 |
| SB-681323 | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT00134693 |
| Prednisolone | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT00134693 |
| SB-681323 | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT00134693 |
| Prednisolone | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT00134693 |
| 37-items questionnaire | Other | Preclinical | Pulmonary Arterial Hypertension (PAH) | UNKNOWN | NCT03235401 |
| Simulated Team sport protocol | Other | Approved | Sports Nutritional Sciences | COMPLETED | NCT03083509 |
| High-Intensity stochastic cycling session | Other | Approved | Sports Nutritional Sciences | COMPLETED | NCT03083509 |
| Resistance exercise weight training session | Other | Approved | Sports Nutritional Sciences | COMPLETED | NCT03083509 |
| Placebo | Other | Phase PHASE1 | Premature Ejaculation | COMPLETED | NCT00664365 |
| GSK958108 | Other | Phase PHASE1 | Premature Ejaculation | COMPLETED | NCT00664365 |
| Formulation D | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT00548769 |
| Formulation C | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT00548769 |
| Formulation B | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT00548769 |
| Formulation A | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT00548769 |
| amoxicillin/clavulanate potassium | Other | Phase PHASE1 | Infections, Respiratory Tract | COMPLETED | NCT00354965 |
| Potassium nitrate | Other | Approved | Tooth Erosion | COMPLETED | NCT02533466 |
| Sodium fluoride + potassium nitrate | Other | Approved | Tooth Erosion | COMPLETED | NCT02533466 |
| Nasal spray | Other | Phase PHASE4 | Nasal Congestion | COMPLETED | NCT02275364 |
| Placebo strip | Other | Phase PHASE4 | Nasal Congestion | COMPLETED | NCT02275364 |
| Test strip | Other | Phase PHASE4 | Nasal Congestion | COMPLETED | NCT02275364 |
| placebo | Other | Phase PHASE2 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00972504 |
| Cetirizine 10mg | Other | Phase PHASE2 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00972504 |
| GSK1004723 1000mcg | Other | Phase PHASE2 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00972504 |
| GSK835726 10mg | Other | Phase PHASE2 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00972504 |
| placebo | Other | Phase PHASE2 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00972504 |
| Cetirizine 10mg | Other | Phase PHASE2 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00972504 |
| GSK1004723 1000mcg | Other | Phase PHASE2 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00972504 |
| GSK835726 10mg | Other | Phase PHASE2 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00972504 |
| Carvedilol-IR 10 mg tablet | Other | Phase PHASE1 | Heart Failure, Congestive | COMPLETED | NCT00742508 |
| SK&F-105517-D 40 mg capsule | Other | Phase PHASE1 | Heart Failure, Congestive | COMPLETED | NCT00742508 |
| SK&F-105517-D 20 mg capsule | Other | Phase PHASE1 | Heart Failure, Congestive | COMPLETED | NCT00742508 |
| Carvedilol-immediate release (IR) 2.5 mg tablet | Other | Phase PHASE1 | Heart Failure, Congestive | COMPLETED | NCT00742508 |
| SK&F-105517-D 10 mg capsule | Other | Phase PHASE1 | Heart Failure, Congestive | COMPLETED | NCT00742508 |
| 14C-SB649868 | Other | Phase PHASE1 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00520663 |
| placebo | Other | Phase PHASE1 | Dermatitis | COMPLETED | NCT02447393 |
| cetirizine | Other | Phase PHASE1 | Dermatitis | COMPLETED | NCT02447393 |
| levocetirizine | Other | Phase PHASE1 | Dermatitis | COMPLETED | NCT02447393 |
| Cherry Placebo | Other | Phase PHASE1 | Mental Disorders | COMPLETED | NCT01607086 |
| Cherry lamotrigine ODT | Other | Phase PHASE1 | Mental Disorders | COMPLETED | NCT01607086 |
| Inhaled FF/ GW642444M (200/25mcg) | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01266980 |
| GSK573719 matching Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01013974 |
| GSK573719 1000 μg | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01013974 |
| GSK573719 500 μg | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01013974 |
| GSK573719 250 μg | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01013974 |
| GW685698X | Other | Phase PHASE1 | Asthma | COMPLETED | NCT00972673 |
| Placebo | Other | Phase PHASE1 | Asthma | COMPLETED | NCT00972673 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00964405 |
| GSK233705 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00964405 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00964249 |
| GW642444 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00964249 |
| GSK932121; Rosiglitazone; Rosuvastatin | Other | Phase PHASE1 | Malaria | TERMINATED | NCT00811356 |
| Placebo | Other | Phase PHASE1 | Substance Dependence | COMPLETED | NCT00728052 |
| GSK598809 | Other | Phase PHASE1 | Substance Dependence | COMPLETED | NCT00728052 |
| 400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml | Other | Phase PHASE1 | Infections, Respiratory Tract | COMPLETED | NCT01772238 |
| Fixed dose combination (Lamivudine and Adefovir dipivoxil) | Other | Phase PHASE1 | Hepatitis B, Chronic | COMPLETED | NCT01353742 |
| Adefovir dipivoxil | Other | Phase PHASE1 | Hepatitis B, Chronic | COMPLETED | NCT01353742 |
| Lamivudine | Other | Phase PHASE1 | Hepatitis B, Chronic | COMPLETED | NCT01353742 |
| IMITREX Tablet 100mg | Other | Phase PHASE1 | Migraine Disorders | COMPLETED | NCT00875784 |
| IMITREX® (6mg) | Other | Phase PHASE1 | Migraine Disorders | COMPLETED | NCT00875784 |
| IMITREX® (4mg) | Other | Phase PHASE1 | Migraine Disorders | COMPLETED | NCT00875784 |
| TREXIMA™ | Other | Phase PHASE1 | Migraine Disorders | COMPLETED | NCT00875784 |
| GW685698X & GW642444M | Other | Phase PHASE1 | Asthma | COMPLETED | NCT00538057 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT00527020 |
| Nicotine Lozenges | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT00527020 |
| GSK1018921 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT00527020 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT00527020 |
| Nicotine Lozenges | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT00527020 |
| GSK1018921 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT00527020 |
| Midazolam | Other | Phase PHASE1 | Depressive Disorder | COMPLETED | NCT00511654 |
| GW823296 matching placebo | Other | Phase PHASE1 | Depressive Disorder | COMPLETED | NCT00511654 |
| GW823296 tablet | Other | Phase PHASE1 | Depressive Disorder | COMPLETED | NCT00511654 |
| COC | Other | Phase PHASE1 | Social Phobia | TERMINATED | NCT00508911 |
| GW876008 | Other | Phase PHASE1 | Social Phobia | TERMINATED | NCT00508911 |
| GSK573719 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00475436 |
| GW642444M for 14 days | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00469040 |
| Casopitant/Docetaxel | Other | Phase PHASE1 | Nausea and Vomiting, Chemotherapy-Induced | COMPLETED | NCT00440128 |
| Docetaxel | Other | Phase PHASE1 | Nausea and Vomiting, Chemotherapy-Induced | COMPLETED | NCT00440128 |
| Casopitant | Other | Phase PHASE1 | Vomiting | COMPLETED | NCT00358813 |
| Bronchoscopy | Other | Phase PHASE1 | Asthma | TERMINATED | NCT00327197 |
| Prednisolone | Other | Phase PHASE1 | Asthma | TERMINATED | NCT00327197 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00551811 |
| SB-656933-AAA | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00551811 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00551811 |
| SB-656933-AAA | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00551811 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00515268 |
| GSK256066 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00515268 |
| GSK233705 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00500461 |
| GW869682-Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00494767 |
| GSK189075-Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00494767 |
| GSK189075 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00494767 |
| GW869682 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00494767 |
| RSG XR | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT00468897 |
| RSG XR | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT00468897 |
| GSK233705 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00453687 |
| Placebo | Other | Phase PHASE1 | Substance Dependence | COMPLETED | NCT00437840 |
| GSK598809 | Other | Phase PHASE1 | Substance Dependence | COMPLETED | NCT00437840 |
| Placebo | Other | Phase PHASE1 | Substance Dependence | COMPLETED | NCT00437840 |
| GSK598809 | Other | Phase PHASE1 | Substance Dependence | COMPLETED | NCT00437840 |
| Lamotrigine | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT00412191 |
| Duloxetine Placebo | Other | Phase PHASE1 | Hyperalgesia | COMPLETED | NCT00387413 |
| GSK189254 Placebo | Other | Phase PHASE1 | Hyperalgesia | COMPLETED | NCT00387413 |
| GSK189254 | Other | Phase PHASE1 | Hyperalgesia | COMPLETED | NCT00387413 |
| Duloxetine | Other | Phase PHASE1 | Hyperalgesia | COMPLETED | NCT00387413 |
| Duloxetine Placebo | Other | Phase PHASE1 | Hyperalgesia | COMPLETED | NCT00387413 |
| GSK189254 Placebo | Other | Phase PHASE1 | Hyperalgesia | COMPLETED | NCT00387413 |
| GSK189254 | Other | Phase PHASE1 | Hyperalgesia | COMPLETED | NCT00387413 |
| Duloxetine | Other | Phase PHASE1 | Hyperalgesia | COMPLETED | NCT00387413 |
| Placebo | Other | Phase PHASE2 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00650871 |
| GW679769 | Other | Phase PHASE2 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00650871 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00615576 |
| SB-656933 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00615576 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00615576 |
| SB-656933 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00615576 |
| Placebo | Other | Phase PHASE1 | Gastroparesis | COMPLETED | NCT00562848 |
| GSK962040 | Other | Phase PHASE1 | Gastroparesis | COMPLETED | NCT00562848 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT00500201 |
| SB- 773812 120 mg | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT00500201 |
| SB- 773812 60 mg | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT00500201 |
| Simvastatin | Other | Phase PHASE1 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00495729 |
| Placebo | Other | Phase PHASE1 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00495729 |
| SB-649868 | Other | Phase PHASE1 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00495729 |
| Lamotrigine ODT tablets | Other | Phase PHASE1 | Mental Disorders | COMPLETED | NCT00449774 |
| Lamotrigine IR tablets | Other | Phase PHASE1 | Mental Disorders | COMPLETED | NCT00449774 |
| GW876008 | Other | Phase PHASE2 | Irritable Colon | COMPLETED | NCT00385099 |
| BMS-955176, Moxifloxacin, Placebo (Part 2) | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | TERMINATED | NCT02576119 |
| BMS-955176, Placebo (Part 1) | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | TERMINATED | NCT02576119 |
| Placebo | Other | Approved | Cardiovascular Disease | TERMINATED | NCT01002118 |
| Omega-3 Acid Ethyl Esters | Other | Approved | Cardiovascular Disease | TERMINATED | NCT01002118 |
| Warfarin oral tablets | Other | Phase PHASE1 | Nausea and Vomiting, Chemotherapy-Induced | COMPLETED | NCT00404274 |
| Casopitant (GW679769) oral tablets | Other | Phase PHASE1 | Nausea and Vomiting, Chemotherapy-Induced | COMPLETED | NCT00404274 |
| Warfarin oral tablets | Other | Phase PHASE1 | Nausea and Vomiting, Chemotherapy-Induced | COMPLETED | NCT00404274 |
| Casopitant (GW679769) oral tablets | Other | Phase PHASE1 | Nausea and Vomiting, Chemotherapy-Induced | COMPLETED | NCT00404274 |
| PET | Other | Phase PHASE1 | Depressive Disorder and Anxiety Disorders | COMPLETED | NCT01059578 |
| PLACEBO | Other | Phase PHASE1 | Depressive Disorder and Anxiety Disorders | COMPLETED | NCT01059578 |
| GSK206136 | Other | Phase PHASE1 | Depressive Disorder and Anxiety Disorders | COMPLETED | NCT01059578 |
| PET | Other | Phase PHASE1 | Depressive Disorder and Anxiety Disorders | COMPLETED | NCT01059578 |
| PLACEBO | Other | Phase PHASE1 | Depressive Disorder and Anxiety Disorders | COMPLETED | NCT01059578 |
| GSK206136 | Other | Phase PHASE1 | Depressive Disorder and Anxiety Disorders | COMPLETED | NCT01059578 |
| Placebo | Other | Phase PHASE3 | Atherosclerosis | COMPLETED | NCT00799903 |
| Darapladib | Other | Phase PHASE3 | Atherosclerosis | COMPLETED | NCT00799903 |
| Placebo | Other | Phase PHASE3 | Atherosclerosis | COMPLETED | NCT00799903 |
| Darapladib | Other | Phase PHASE3 | Atherosclerosis | COMPLETED | NCT00799903 |
| Magnesium Stearate | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00702910 |
| GW642444 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00702910 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00702910 |
| Magnesium Stearate | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00702910 |
| GW642444 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00702910 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00702910 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00694902 |
| GSK610677 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00694902 |
| Reference formulation | Other | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT01262989 |
| Test formulation | Other | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT01262989 |
| Dabrafenib | Other | Preclinical | Melanoma | NO_LONGER_AVAILABLE | NCT02416232 |
| Trametinib | Other | Preclinical | Melanoma | NO_LONGER_AVAILABLE | NCT02416232 |
| LAMA | Other | Phase PHASE3 | COPD | COMPLETED | NCT01491802 |
| LAMA/LABA | Other | Phase PHASE3 | COPD | COMPLETED | NCT01491802 |
| capecitabine, lapatinib | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00721630 |
| Placebo | Other | Phase PHASE1 | Arthritis, Rheumatoid | COMPLETED | NCT00539760 |
| GSK1827771 | Other | Phase PHASE1 | Arthritis, Rheumatoid | COMPLETED | NCT00539760 |
| Placebo | Other | Phase PHASE1 | Arthritis, Rheumatoid | COMPLETED | NCT00539760 |
| GSK1827771 | Other | Phase PHASE1 | Arthritis, Rheumatoid | COMPLETED | NCT00539760 |
| Metformin | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01929863 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01929863 |
| GSK2330672 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01929863 |
| Metformin | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01929863 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01929863 |
| GSK2330672 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01929863 |
| placebo | Other | Phase PHASE4 | Erectile Dysfunction | COMPLETED | NCT00379756 |
| LEVITRA (vardenafil) | Other | Phase PHASE4 | Erectile Dysfunction | COMPLETED | NCT00379756 |
| risperidone | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT00049946 |
| talnetant | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT00049946 |
| risperidone | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT00049946 |
| talnetant | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT00049946 |
| Albuterol/salbutamol Metered Dose Inhaler (MDI) | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02257372 |
| ICS/LABA medication | Drug | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02257372 |
| Placebo DPI | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02257372 |
| UMEC DPI | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02257372 |
| Albuterol/salbutamol Metered Dose Inhaler (MDI) | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02257372 |
| ICS/LABA medication | Drug | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02257372 |
| Placebo DPI | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02257372 |
| UMEC DPI | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02257372 |
| Placebo | Other | Phase PHASE2 | Heart Failure, Congestive | COMPLETED | NCT01357850 |
| GSK716155 | Other | Phase PHASE2 | Heart Failure, Congestive | COMPLETED | NCT01357850 |
| Duac Gel | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT00757523 |
| Epiduo Gel | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT00757523 |
| Treatment sequence D | Drug | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT00537654 |
| Treatment sequence C | Drug | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT00537654 |
| Treatment sequence B | Drug | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT00537654 |
| Treatment sequence A | Drug | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT00537654 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00530309 |
| GSK716155 for injection | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00530309 |
| Placebo | Other | Phase PHASE1 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00440323 |
| Zolpidem | Other | Phase PHASE1 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00440323 |
| SB-649868 | Other | Phase PHASE1 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00440323 |
| Placebo | Other | Phase PHASE1 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00440323 |
| Zolpidem | Other | Phase PHASE1 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00440323 |
| SB-649868 | Other | Phase PHASE1 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00440323 |
| Risperidone | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT00269035 |
| SB773812 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT00269035 |
| Risperidone | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT00269035 |
| SB773812 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT00269035 |
| Tritanrix™-HepB/ Hiberix™ | Other | Phase PHASE3 | Whole Cell Pertussis | COMPLETED | NCT00473668 |
| Zilbrix-Hib | Other | Phase PHASE3 | Whole Cell Pertussis | COMPLETED | NCT00473668 |
| Placebo | Other | Phase PHASE1 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00605852 |
| GSK835726 | Other | Phase PHASE1 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00605852 |
| GW685698X | Other | Phase PHASE3 | Vasomotor Rhinitis | COMPLETED | NCT00118703 |
| Placebo | Other | Phase PHASE2 | Sepsis | COMPLETED | NCT00089986 |
| Intravenous GR270773- Phospholipid Emulsion | Other | Phase PHASE2 | Sepsis | COMPLETED | NCT00089986 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01978145 |
| FSC | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01978145 |
| Pazopanib | Other | Phase PHASE2 | Bladder Cancer | TERMINATED | NCT01622660 |
| Gemcitabine | Other | Phase PHASE2 | Bladder Cancer | TERMINATED | NCT01622660 |
| Placebo | Other | Phase PHASE1 | Depressive Disorder and Anxiety Disorders | COMPLETED | NCT00703547 |
| GSK586529 tablets | Other | Phase PHASE1 | Depressive Disorder and Anxiety Disorders | COMPLETED | NCT00703547 |
| GSK586529 capsules | Other | Phase PHASE1 | Depressive Disorder and Anxiety Disorders | COMPLETED | NCT00703547 |
| GI265235 | Other | Phase PHASE4 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00441688 |
| Placebo | Other | Phase PHASE2 | Pain, Neuropathic | COMPLETED | NCT00390845 |
| SB681323 | Other | Phase PHASE2 | Pain, Neuropathic | COMPLETED | NCT00390845 |
| Placebo | Other | Phase PHASE2 | Pain, Neuropathic | COMPLETED | NCT00390845 |
| SB681323 | Other | Phase PHASE2 | Pain, Neuropathic | COMPLETED | NCT00390845 |
| Placebo | Other | Phase PHASE2 | Pain, Neuropathic | COMPLETED | NCT00390845 |
| SB681323 | Other | Phase PHASE2 | Pain, Neuropathic | COMPLETED | NCT00390845 |
| Alvimopan | Other | Phase PHASE3 | Ileus | COMPLETED | NCT00388258 |
| Alvimopan | Other | Phase PHASE3 | Ileus | COMPLETED | NCT00388258 |
| GSK1363089 (formerly XL880) | Other | Phase PHASE2 | Neoplasms, Gastrointestinal Tract | COMPLETED | NCT00725712 |
| Azelaic acid | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT02058628 |
| Clindamycin + BPO | Other | Phase PHASE4 | Acne Vulgaris | COMPLETED | NCT02058628 |
| non-SLS negative control | Other | Approved | Dental Plaque | COMPLETED | NCT02856880 |
| SLS negative control | Other | Approved | Dental Plaque | COMPLETED | NCT02856880 |
| Positive control | Other | Approved | Dental Plaque | COMPLETED | NCT02856880 |
| Test zinc non- IPMP toothpaste | Other | Approved | Dental Plaque | COMPLETED | NCT02856880 |
| Test zinc-IPMP toothpaste | Other | Approved | Dental Plaque | COMPLETED | NCT02856880 |
| Placebo | Other | Phase PHASE3 | Bowel Dysfunction | COMPLETED | NCT00241722 |
| Alvimopan | Other | Phase PHASE3 | Bowel Dysfunction | COMPLETED | NCT00241722 |
| placebo | Other | Phase PHASE2 | Constipation | COMPLETED | NCT00101998 |
| alvimopan | Other | Phase PHASE2 | Constipation | COMPLETED | NCT00101998 |
| placebo | Other | Phase PHASE2 | Constipation | COMPLETED | NCT00101998 |
| alvimopan | Other | Phase PHASE2 | Constipation | COMPLETED | NCT00101998 |
| placebo | Other | Phase PHASE2 | Constipation | COMPLETED | NCT00101998 |
| alvimopan | Other | Phase PHASE2 | Constipation | COMPLETED | NCT00101998 |
| Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas (Tositumomab and Iodine I 131 Tositumomab) | Drug | Phase PHASE1 | Lymphoma, Non-Hodgkin | COMPLETED | NCT01536561 |
| Pazopanib and TH-302 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01485042 |
| Placebo | Other | Phase PHASE3 | Alzheimer's Disease | COMPLETED | NCT00348140 |
| Rosiglitazone Extended Release 8mg | Other | Phase PHASE3 | Alzheimer's Disease | COMPLETED | NCT00348140 |
| Rosiglitazone Extended Release 2mg | Other | Phase PHASE3 | Alzheimer's Disease | COMPLETED | NCT00348140 |
| Placebo NDPI | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01822899 |
| Fluticasone propionate/Salmeterol | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01822899 |
| Placebo ACCUHALER/DISKUS | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01822899 |
| Umeclidinium bromide/Vilanterol | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01822899 |
| Boostrix® | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT01767376 |
| Meningococcal vaccine GSK134612 | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT01767376 |
| Boostrix® | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT01767376 |
| Meningococcal vaccine GSK134612 | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT01767376 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00607906 |
| SB-756050 modified release capsule | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00607906 |
| SB-756050 immediate release capsule | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00607906 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00519480 |
| Metformin | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00519480 |
| GSK189075 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00519480 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00519480 |
| Metformin | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00519480 |
| GSK189075 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00519480 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | TERMINATED | NCT01316939 |
| GSK1605786A | Other | Phase PHASE3 | Crohn's Disease | TERMINATED | NCT01316939 |
| Placebo | Other | Phase PHASE2 | Infections, Urinary Tract | TERMINATED | NCT01381549 |
| imipenem-cilastatin | Other | Phase PHASE2 | Infections, Urinary Tract | TERMINATED | NCT01381549 |
| GSK2251052 | Other | Phase PHASE2 | Infections, Urinary Tract | TERMINATED | NCT01381549 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00555022 |
| Tiotropium bromide | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00555022 |
| GSK1160724 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00555022 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00555022 |
| Tiotropium bromide | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00555022 |
| GSK1160724 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00555022 |
| BMS-663068 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02666053 |
| BMS-663068 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02666053 |
| BMS-663068 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02508064 |
| BMS-663068 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02508064 |
| ACOS clinical questionnaire | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02302417 |
| Spirometry | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02302417 |
| BMS-955176 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02095886 |
| Ambrisentan 5 mg | Other | Phase PHASE3 | Hypertension | TERMINATED | NCT01894022 |
| Ambrisentan 5 mg | Other | Phase PHASE3 | Hypertension | TERMINATED | NCT01894022 |
| GSK561679 | Other | Phase PHASE1 | Depressive Disorder and Anxiety Disorders | COMPLETED | NCT00426608 |
| placebo | Other | Phase PHASE1 | Depressive Disorder and Anxiety Disorders | COMPLETED | NCT00426608 |
| alprazolam | Other | Phase PHASE1 | Depressive Disorder and Anxiety Disorders | COMPLETED | NCT00426608 |
| metyrapone | Other | Phase PHASE1 | Depressive Disorder and Anxiety Disorders | COMPLETED | NCT00426608 |
| GW406381 | Other | Phase PHASE1 | Pain | COMPLETED | NCT00373243 |
| GW406381 | Other | Phase PHASE1 | Pain | COMPLETED | NCT00373243 |
| Placebo HFA | Other | Phase PHASE1 | Asthma | COMPLETED | NCT00370097 |
| FLOVENT (fluticasone propionate) HFA | Other | Phase PHASE1 | Asthma | COMPLETED | NCT00370097 |
| salmeterol/fluticasone propionate 50/250 µg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00351143 |
| salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00351143 |
| salmeterol/fluticasone propionate 50/250 µg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00351143 |
| salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00351143 |
| Valaciclovir | Other | Phase PHASE1 | Herpes Simplex | COMPLETED | NCT00297206 |
| Ropinirole Immediate Release | Other | Phase PHASE1 | Restless Legs Syndrome | COMPLETED | NCT00140712 |
| Ropinirole Immediate Release | Other | Phase PHASE1 | Restless Legs Syndrome | COMPLETED | NCT00140712 |
| paroxetine CR | Other | Phase PHASE4 | Major Depressive Disorder | COMPLETED | NCT00049972 |
| Ropinirole | Other | Preclinical | Restless Legs Syndrome | COMPLETED | NCT01327339 |
| placebo | Other | Phase PHASE2 | Premature Ejaculation | COMPLETED | NCT01021553 |
| GSK557296 | Other | Phase PHASE2 | Premature Ejaculation | COMPLETED | NCT01021553 |
| placebo | Other | Phase PHASE2 | Depressive Disorder, Major | TERMINATED | NCT00880399 |
| orvepitant | Other | Phase PHASE2 | Depressive Disorder, Major | TERMINATED | NCT00880399 |
| placebo | Other | Phase PHASE4 | Atrial Fibrillation | TERMINATED | NCT00791089 |
| LOVAZA | Other | Phase PHASE4 | Atrial Fibrillation | TERMINATED | NCT00791089 |
| LOVAZA Omega 3-acid ethyl esters | Other | Phase PHASE4 | Atrial Fibrillation | TERMINATED | NCT00791089 |
| Cheek swab & blood test | Other | Preclinical | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00453440 |
| GI267119 | Other | Phase PHASE1 | Mental Disorders | COMPLETED | NCT00410371 |
| Lamotrigine | Other | Phase PHASE1 | Mental Disorders | COMPLETED | NCT00410371 |
| Casopitant 50 mg | Other | Phase PHASE1 | Nausea and Vomiting, Chemotherapy-Induced | COMPLETED | NCT00404378 |
| casopitant 100 mg | Other | Phase PHASE1 | Nausea and Vomiting, Chemotherapy-Induced | COMPLETED | NCT00404378 |
| ketoconazole | Other | Phase PHASE1 | Nausea and Vomiting, Chemotherapy-Induced | COMPLETED | NCT00404378 |
| tadalafil | Other | Phase PHASE3 | Hypertension, Pulmonary | COMPLETED | NCT01178073 |
| ambrisentan | Other | Phase PHASE3 | Hypertension, Pulmonary | COMPLETED | NCT01178073 |
| tadalafil | Other | Phase PHASE3 | Hypertension, Pulmonary | COMPLETED | NCT01178073 |
| ambrisentan | Other | Phase PHASE3 | Hypertension, Pulmonary | COMPLETED | NCT01178073 |
| tadalafil | Other | Phase PHASE3 | Hypertension, Pulmonary | COMPLETED | NCT01178073 |
| ambrisentan | Other | Phase PHASE3 | Hypertension, Pulmonary | COMPLETED | NCT01178073 |
| placebo | Other | Phase PHASE4 | Patients With Nasal Polyps | TERMINATED | NCT01013701 |
| fluticasone furoate | Other | Phase PHASE4 | Patients With Nasal Polyps | TERMINATED | NCT01013701 |
| placebo | Other | Phase PHASE4 | Patients With Nasal Polyps | TERMINATED | NCT01013701 |
| fluticasone furoate | Other | Phase PHASE4 | Patients With Nasal Polyps | TERMINATED | NCT01013701 |
| GSK1605786A | Other | Phase PHASE3 | Crohn's Disease | TERMINATED | NCT01318993 |
| GSK1605786A | Other | Phase PHASE3 | Crohn's Disease | TERMINATED | NCT01318993 |
| GW685698X | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00603746 |
| Placebo nasal spray | Other | Phase PHASE4 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00570492 |
| Fluticasone furoate nasal spray | Other | Phase PHASE4 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00570492 |
| GSK618334 matching placebo tablets | Other | Phase PHASE1 | Substance Dependence | COMPLETED | NCT00513279 |
| GSK618334 | Other | Phase PHASE1 | Substance Dependence | COMPLETED | NCT00513279 |
| sitamaquine | Other | Phase PHASE2 | Leishmaniasis, Visceral | COMPLETED | NCT00381394 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT01277666 |
| GSK1605786A | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT01277666 |
| Spirometry | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01516528 |
| GSK1223249 | Other | Phase PHASE1 | Multiple Sclerosis | TERMINATED | NCT01424423 |
| Placebo | Other | Phase PHASE1 | Multiple Sclerosis | TERMINATED | NCT01424423 |
| Lamotrigine | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT01357902 |
| No intervention | Other | Preclinical | Gastroenteritis | COMPLETED | NCT03271593 |
| Cefadroxil tablets manufactured by NP | Other | Phase PHASE4 | Infections, Urinary Tract | COMPLETED | NCT02446496 |
| Cefadroxil tablets manufactured by GSK | Other | Phase PHASE4 | Infections, Urinary Tract | COMPLETED | NCT02446496 |
| pazopanib eye drops | Other | Phase PHASE2 | Macular Degeneration | TERMINATED | NCT01362348 |
| Clindamycin | Other | Phase PHASE4 | Focal Infection, Dental | COMPLETED | NCT02141217 |
| Amoxicillin/clavulanate | Other | Phase PHASE4 | Focal Infection, Dental | COMPLETED | NCT02141217 |
| Ritonavir | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02138084 |
| Rifabutin | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02138084 |
| BMS-663068 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02138084 |
| Ritonavir | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02138084 |
| Rifabutin | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02138084 |
| BMS-663068 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02138084 |
| GSK2788723 | Other | Preclinical | Mucopolysaccharidosis II | COMPLETED | NCT01602601 |
| Idursulfase | Other | Preclinical | Mucopolysaccharidosis II | COMPLETED | NCT01602601 |
| Efavirenz | Other | Phase PHASE1 | Infections, Human Immunodeficiency Virus and Herpesviridae | COMPLETED | NCT01098526 |
| GSK1349572 | Other | Phase PHASE1 | Infections, Human Immunodeficiency Virus and Herpesviridae | COMPLETED | NCT01098526 |
| Efavirenz | Other | Phase PHASE1 | Infections, Human Immunodeficiency Virus and Herpesviridae | COMPLETED | NCT01098526 |
| GSK1349572 | Other | Phase PHASE1 | Infections, Human Immunodeficiency Virus and Herpesviridae | COMPLETED | NCT01098526 |
| GW679769 | Other | Phase PHASE1 | Vomiting | COMPLETED | NCT00359177 |
| Placebo | Other | Phase PHASE1 | Asthma | COMPLETED | NCT00318630 |
| Rosiglitazone | Other | Phase PHASE1 | Asthma | COMPLETED | NCT00318630 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00279019 |
| Tiotropium | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00279019 |
| GSK233705 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00279019 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00279019 |
| Tiotropium | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00279019 |
| GSK233705 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00279019 |
| Intravenous GR270773 - Phospholipid emulsion | Other | Phase PHASE1 | Sepsis | COMPLETED | NCT00158769 |
| Extended-release Bupropion Hydrochloride | Other | Phase PHASE1 | Depressive Disorder | COMPLETED | NCT00069459 |
| Extended-release Bupropion Hydrochloride | Other | Phase PHASE1 | Depressive Disorder | COMPLETED | NCT00069459 |
| Standard of Care | Other | Approved | Sickle Cell Disease | COMPLETED | NCT03293641 |
| Zinc Sulfate Tablets | Other | Approved | Sickle Cell Disease | COMPLETED | NCT03293641 |
| GSK2118436 | Other | Phase PHASE2 | Melanoma | COMPLETED | NCT01153763 |
| Sodium monofluorophosphate Dentifrice | Other | Phase PHASE4 | Dentin Sensitivity | COMPLETED | NCT02773758 |
| Stannous Fluoride Dentifrice | Other | Phase PHASE4 | Dentin Sensitivity | COMPLETED | NCT02773758 |
| Sodium monofluorophosphate Dentifrice | Other | Phase PHASE4 | Dentin Sensitivity | COMPLETED | NCT02773758 |
| Stannous Fluoride Dentifrice | Other | Phase PHASE4 | Dentin Sensitivity | COMPLETED | NCT02773758 |
| Placebo | Other | Phase PHASE1 | Asthma | COMPLETED | NCT00483899 |
| GW870086X | Other | Phase PHASE1 | Asthma | COMPLETED | NCT00483899 |
| Placebo | Other | Phase PHASE1 | Asthma | TERMINATED | NCT00453791 |
| GW805858 | Other | Phase PHASE1 | Asthma | TERMINATED | NCT00453791 |
| Paroxetine controlled release tablet | Other | Phase PHASE1 | Depressive Disorder | COMPLETED | NCT00406003 |
| Placebo | Other | Phase PHASE1 | Bronchospasm | COMPLETED | NCT00400660 |
| GSK615915A | Other | Phase PHASE1 | Bronchospasm | COMPLETED | NCT00400660 |
| Placebo | Other | Phase PHASE1 | Bronchospasm | COMPLETED | NCT00400660 |
| GSK615915A | Other | Phase PHASE1 | Bronchospasm | COMPLETED | NCT00400660 |
| flucloxacillin 500 mg | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT00358371 |
| flucloxacillin 250 mg | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT00358371 |
| Lamotrigine | Other | Phase PHASE1 | Seizure, Absence | COMPLETED | NCT00144872 |
| Placebo GSK2190915 two tablets | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01147744 |
| Placebo fluticasone propionate via ACCUHALER/DISKUS | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01147744 |
| Placebo montelukast | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01147744 |
| Placebo GSK2190915 one tablet | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01147744 |
| Montelukast 10mg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01147744 |
| GSK2190915 30mg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01147744 |
| GSK2190915 300mg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01147744 |
| GSK2190915 10mg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01147744 |
| GSK2190915 100mg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01147744 |
| Fluticasone Propionate 100mcg via ACCUHALER/DISKUS | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01147744 |
| placebo infusion plus physician determined standard of care | Other | Phase PHASE3 | Diabetes Mellitus, Type 1 | COMPLETED | NCT00678886 |
| otelixizumab infusion plus physician determined standard of care | Other | Phase PHASE3 | Diabetes Mellitus, Type 1 | COMPLETED | NCT00678886 |
| PREMARIN | Other | Phase PHASE2 | Menopausal and Female Climacteric States | COMPLETED | NCT00604825 |
| GSK232802 | Other | Phase PHASE2 | Menopausal and Female Climacteric States | COMPLETED | NCT00604825 |
| Other: Placebo | Other | Phase PHASE2 | Menopausal and Female Climacteric States | COMPLETED | NCT00604825 |
| PREMARIN | Other | Phase PHASE2 | Menopausal and Female Climacteric States | COMPLETED | NCT00604825 |
| GSK232802 | Other | Phase PHASE2 | Menopausal and Female Climacteric States | COMPLETED | NCT00604825 |
| Other: Placebo | Other | Phase PHASE2 | Menopausal and Female Climacteric States | COMPLETED | NCT00604825 |
| Dacarbazine (DTIC) | Other | Phase PHASE3 | Cancer | COMPLETED | NCT01227889 |
| GSK2118436 | Other | Phase PHASE3 | Cancer | COMPLETED | NCT01227889 |
| Atenolol | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT00669279 |
| Carvedilol CR | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT00669279 |
| Atenolol | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT00669279 |
| Carvedilol CR | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT00669279 |
| FF/VI | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01573624 |
| FF/GSK573719 | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01573624 |
| Fluarix Tetra | Other | Phase PHASE3 | Influenza | COMPLETED | NCT02369341 |
| Fluarix Tetra | Other | Phase PHASE3 | Influenza | COMPLETED | NCT02369341 |
| Vehicle foam | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT00842153 |
| Clobetasol propionate foam | Other | Phase PHASE4 | Psoriasis | COMPLETED | NCT00842153 |
| Placebo | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00676052 |
| GSK233705 200mcg | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00676052 |
| GSK233705 100mcg | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00676052 |
| GSK233705 50mcg | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00676052 |
| GSK233705 25mcg | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00676052 |
| GSK233705 12.5mcg | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00676052 |
| placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT00575159 |
| GSK189075 | Other | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT00575159 |
| Rosiglitazone | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00501020 |
| Rosiglitazone | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00501020 |
| Amlodipine 5 or 10 mg(oral) | Other | Phase PHASE4 | Uncomplicated Hypertension | COMPLETED | NCT00338338 |
| Lacidipine 4 or 6 mg (oral) | Other | Phase PHASE4 | Uncomplicated Hypertension | COMPLETED | NCT00338338 |
| Rosiglitazone | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00333723 |
| paroxetine | Other | Phase PHASE2 | Depressive Disorder, Major | COMPLETED | NCT00048204 |
| GW597599B | Other | Phase PHASE2 | Depressive Disorder, Major | COMPLETED | NCT00048204 |
| rosiglitazone | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00044460 |
| lamotrigine | Other | Phase PHASE4 | Epilepsy | COMPLETED | NCT00043914 |
| UMEC | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02164539 |
| Sitagliptin 100mg | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01376323 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01376323 |
| GSK256073 25mg | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01376323 |
| GSK256073 10mg | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01376323 |
| GSK256073 5mg | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01376323 |
| GSK256073 1mg | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01376323 |
| Plb | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01328444 |
| GW642444 25 | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01328444 |
| GSK 573719 62.5 | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01328444 |
| GSK 573719 125 | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01328444 |
| GSK573719 + GW642444 62.5/25 | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01328444 |
| GSK 573719 +GW642444 125/25 | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01328444 |
| Global Efficacy questionnaire | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00259909 |
| Acute Short Form 12 version 2 | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00259909 |
| St. George's Respiratory Questionnaire | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00259909 |
| GSK questionnaire | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00259909 |
| 0.3%ZnCl2, 0.5% sodium citrate, 1150ppm F | Other | Approved | Dental Caries | COMPLETED | NCT02751320 |
| 1150ppm F | Other | Approved | Dental Caries | COMPLETED | NCT02751320 |
| 0 ppm F | Other | Approved | Dental Caries | COMPLETED | NCT02751320 |
| 0.85 % w/w phytate,0.3%ZnCl2 0.5% sodium citrate, 1150ppm F | Other | Approved | Dental Caries | COMPLETED | NCT02751320 |
| 0.85 % w/w phytate,1150ppm F | Other | Approved | Dental Caries | COMPLETED | NCT02751320 |
| 0.425 % w/w phytate,1150ppm F | Other | Approved | Dental Caries | COMPLETED | NCT02751320 |
| 0.3%ZnCl2, 0.5% sodium citrate, 1150ppm F | Other | Approved | Dental Caries | COMPLETED | NCT02751320 |
| 1150ppm F | Other | Approved | Dental Caries | COMPLETED | NCT02751320 |
| 0 ppm F | Other | Approved | Dental Caries | COMPLETED | NCT02751320 |
| 0.85 % w/w phytate,0.3%ZnCl2 0.5% sodium citrate, 1150ppm F | Other | Approved | Dental Caries | COMPLETED | NCT02751320 |
| 0.85 % w/w phytate,1150ppm F | Other | Approved | Dental Caries | COMPLETED | NCT02751320 |
| 0.425 % w/w phytate,1150ppm F | Other | Approved | Dental Caries | COMPLETED | NCT02751320 |
| belimumab | Other | Phase PHASE2 | Glomerulonephritis, Membranous | COMPLETED | NCT01610492 |
| Ropinirole | Other | Phase PHASE1 | Restless Legs Syndrome | COMPLETED | NCT00419692 |
| Metformin hydrochloride sustained release/Glimepiride | Other | Approved | Diabetes Mellitus, Type 2 | COMPLETED | NCT01561976 |
| metformin hydrochloride prolonged release | Other | Approved | Diabetes Mellitus, Type 2 | COMPLETED | NCT01561976 |
| Metformin hydrochloride prolonged release | Other | Approved | Diabetes Mellitus, Type 2 | COMPLETED | NCT01561976 |
| new thermo stable formulation of epoprostenol sodium | Other | Phase PHASE4 | Hypertension, Pulmonary | COMPLETED | NCT01462565 |
| current marketed FLOLAN (epoprostenol sodium) | Other | Phase PHASE4 | Hypertension, Pulmonary | COMPLETED | NCT01462565 |
| Sitagliptin | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01128621 |
| GSK1292263 matching placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01128621 |
| GSK1292263 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01128621 |
| GSK1363089 (foretinib) | Other | Phase PHASE2 | Neoplasms, Head and Neck | COMPLETED | NCT00725764 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT01702467 |
| GSK2647544 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT01702467 |
| Meningococcal vaccine GSK134612 | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT01641042 |
| ofatumumab | Other | Phase PHASE2 | Follicular Lymphoma | COMPLETED | NCT01239394 |
| ofatumumab | Other | Phase PHASE2 | Follicular Lymphoma | COMPLETED | NCT01239394 |
| Placebo | Other | Phase PHASE1 | Postpartum Hemorrhage | COMPLETED | NCT02542813 |
| IH oxytocin 600 mcg | Other | Phase PHASE1 | Postpartum Hemorrhage | COMPLETED | NCT02542813 |
| IH oxytocin 400 mcg | Other | Phase PHASE1 | Postpartum Hemorrhage | COMPLETED | NCT02542813 |
| IH oxytocin 200 mcg | Other | Phase PHASE1 | Postpartum Hemorrhage | COMPLETED | NCT02542813 |
| IH oxytocin 50 mcg | Other | Phase PHASE1 | Postpartum Hemorrhage | COMPLETED | NCT02542813 |
| IM oxytocin 10 IU | Other | Phase PHASE1 | Postpartum Hemorrhage | COMPLETED | NCT02542813 |
| Placebo | Other | Phase PHASE1 | Postpartum Hemorrhage | COMPLETED | NCT02542813 |
| IH oxytocin 600 mcg | Other | Phase PHASE1 | Postpartum Hemorrhage | COMPLETED | NCT02542813 |
| IH oxytocin 400 mcg | Other | Phase PHASE1 | Postpartum Hemorrhage | COMPLETED | NCT02542813 |
| IH oxytocin 200 mcg | Other | Phase PHASE1 | Postpartum Hemorrhage | COMPLETED | NCT02542813 |
| IH oxytocin 50 mcg | Other | Phase PHASE1 | Postpartum Hemorrhage | COMPLETED | NCT02542813 |
| IM oxytocin 10 IU | Other | Phase PHASE1 | Postpartum Hemorrhage | COMPLETED | NCT02542813 |
| Salbutamol | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00315744 |
| Fluticasone propionate | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00315744 |
| Salmeterol/fluticasone | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00315744 |
| Sodium Monofluorophosphate | Other | Approved | Gingivitis | COMPLETED | NCT02750943 |
| Stannous Fluoride | Other | Approved | Gingivitis | COMPLETED | NCT02750943 |
| Placebo | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT02019472 |
| sirukumab 50 mg | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT02019472 |
| sirukumab 100 mg | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT02019472 |
| adalimumab 40 mg | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT02019472 |
| air puffs | Other | Preclinical | Dentine Hypersensitivity | COMPLETED | NCT02929043 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00495469 |
| GSK189075 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00495469 |
| TwinrixTM | Other | Phase PHASE1 | Haemophilus Influenzae | TERMINATED | NCT00849069 |
| GSK2231395A | Other | Phase PHASE1 | Haemophilus Influenzae | TERMINATED | NCT00849069 |
| TwinrixTM | Other | Phase PHASE1 | Haemophilus Influenzae | TERMINATED | NCT00849069 |
| GSK2231395A | Other | Phase PHASE1 | Haemophilus Influenzae | TERMINATED | NCT00849069 |
| Metformin | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02202161 |
| Sitagliptin | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02202161 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02202161 |
| GSK2330672 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02202161 |
| Metformin | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02202161 |
| Sitagliptin | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02202161 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02202161 |
| GSK2330672 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02202161 |
| The placebo contained 1 gram of corn oil in each capsule. | Other | Phase PHASE1 | Myocardial Infarction | TERMINATED | NCT01155336 |
| Lovaza® | Other | Phase PHASE1 | Myocardial Infarction | TERMINATED | NCT01155336 |
| Placebo | Other | Phase PHASE3 | Arthritis, Rheumatoid | TERMINATED | NCT00611455 |
| ofatumumab | Other | Phase PHASE3 | Arthritis, Rheumatoid | TERMINATED | NCT00611455 |
| Placebo | Other | Phase PHASE3 | Arthritis, Rheumatoid | TERMINATED | NCT00611455 |
| ofatumumab | Other | Phase PHASE3 | Arthritis, Rheumatoid | TERMINATED | NCT00611455 |
| GW685698X | Other | Phase PHASE1 | Asthma | COMPLETED | NCT00419237 |
| Alendronate | Other | Phase PHASE2 | Osteoporosis | TERMINATED | NCT00471237 |
| Teriparatide | Other | Phase PHASE2 | Osteoporosis | TERMINATED | NCT00471237 |
| Ronacaleret | Other | Phase PHASE2 | Osteoporosis | TERMINATED | NCT00471237 |
| Placebo NDPI | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01879410 |
| Placebo DISKUS | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01879410 |
| FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01879410 |
| UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01879410 |
| Placebo | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01372410 |
| Tiotropium | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01372410 |
| GSK573719 | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01372410 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01336608 |
| Vilanterol | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01336608 |
| Fluticasone Furoate/Vilanterol | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01336608 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01336608 |
| Vilanterol | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01336608 |
| Fluticasone Furoate/Vilanterol | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01336608 |
| Fluticasone Propionate 250mcg/ salmeterol 50mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01323634 |
| Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01323634 |
| tiotropium bromide inhalation powder HandiHaler | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01124422 |
| fluticasone propionate/salmeterol inhalation powder DISKUS 250/50 | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01124422 |
| SEREVENT 50 mcg BID | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01110200 |
| ADVAIR DISKUS 250/50 mg BID | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01110200 |
| Placebo once daily | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01039675 |
| 500mcg/25mcg once daily | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01039675 |
| GSK573179 | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00950807 |
| Placebo | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00950807 |
| Tiotropium | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00950807 |
| Questionnaire | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02586493 |
| Placebo | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02586493 |
| Questionnaire | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02586493 |
| Placebo | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02586493 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02152605 |
| UMEC/VI | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02152605 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02152605 |
| UMEC/VI | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02152605 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01957163 |
| UMEC | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01957163 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01957163 |
| UMEC | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01957163 |
| Placebo | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT01587898 |
| GSK1278863 | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT01587898 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01387230 |
| GSK573719 | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01387230 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01387230 |
| GSK573719 | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01387230 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01159912 |
| Fluticasone furoate | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01159912 |
| Fluticasone propionate | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01159912 |
| Pazopanib | Other | Phase PHASE1 | Macular Degeneration | COMPLETED | NCT01154062 |
| Pazopanib | Other | Phase PHASE1 | Macular Degeneration | COMPLETED | NCT01154062 |
| placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01072149 |
| Fluticasone Furoate (FF)/GW642444 Inhalation Powder | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01072149 |
| placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01072149 |
| Fluticasone Furoate (FF)/GW642444 Inhalation Powder | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01072149 |
| GW642444 Inhalation Powder | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01009463 |
| FF/GW642444 Inhalation Powder | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01009463 |
| GSK1120212 plus everolimus | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00955773 |
| breathing test | Other | Preclinical | Asthma | COMPLETED | NCT03243110 |
| Vehicle cream | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT02564042 |
| GSK2894512 0.5% Cream | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT02564042 |
| GSK2894512 1% Cream | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT02564042 |
| Gemcitabine | Other | Phase PHASE1 | Leukaemia, Myelocytic, Acute | COMPLETED | NCT01428427 |
| GSK1120212 | Other | Phase PHASE1 | Leukaemia, Myelocytic, Acute | COMPLETED | NCT01428427 |
| GSK1120212B | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01416337 |
| GSK1120212 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01416337 |
| GSK1120212 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01387204 |
| GSK1120212 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01371487 |
| GSK1120212 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01371487 |
| GSK2118436 75mg | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01340846 |
| GSK2118436 150mg | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01340846 |
| Gemfibrozil | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01340846 |
| Ketoconazole | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01340846 |
| Warfarin | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01340846 |
| GSK2118436 75mg | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01340846 |
| GSK2118436 150mg | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01340846 |
| Gemfibrozil | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01340846 |
| Ketoconazole | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01340846 |
| Warfarin | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01340846 |
| GSK2118436 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01340833 |
| Gemcitabine | Other | Phase PHASE1 | Solid Tumours | COMPLETED | NCT01324258 |
| GSK1120212 | Other | Phase PHASE1 | Solid Tumours | COMPLETED | NCT01324258 |
| GSK2118436 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01262963 |
| Cisplatin | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01192165 |
| nab-Paclitaxel | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01192165 |
| Carboplatin | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01192165 |
| Pemetrexed | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01192165 |
| Erlotinib | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01192165 |
| Docetaxel | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01192165 |
| Trametinib (GSK1120212) | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01192165 |
| Cisplatin | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01192165 |
| nab-Paclitaxel | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01192165 |
| Carboplatin | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01192165 |
| Pemetrexed | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01192165 |
| Erlotinib | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01192165 |
| Docetaxel | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01192165 |
| Trametinib (GSK1120212) | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01192165 |
| GSK2141795 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01138085 |
| GSK1120212 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01138085 |
| GSK2141795 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01138085 |
| GSK1120212 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01138085 |
| Ofatumumab | Other | Phase PHASE1 | Leukaemia, Lymphocytic, Chronic | COMPLETED | NCT01110031 |
| Ofatumumab | Other | Phase PHASE1 | Leukaemia, Lymphocytic, Chronic | COMPLETED | NCT01110031 |
| lapatinib | Other | Phase PHASE1 | Neoplasms, Breast | COMPLETED | NCT00996762 |
| Pazopanib 3 week | Other | Phase PHASE1 | Carcinoma, Renal Cell | COMPLETED | NCT00992121 |
| Pazopanib 2 week | Other | Phase PHASE1 | Carcinoma, Renal Cell | COMPLETED | NCT00992121 |
| Bevacizumab | Other | Phase PHASE1 | Carcinoma, Renal Cell | COMPLETED | NCT00992121 |
| GSK2141795 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00920257 |
| Placebo | Other | Phase PHASE1 | Myelodysplastic Syndrome | COMPLETED | NCT00903422 |
| eltrombopag olamine | Other | Phase PHASE1 | Myelodysplastic Syndrome | COMPLETED | NCT00903422 |
| paclitaxel | Other | Phase PHASE1 | Lung Cancer, Non-Small Cell | COMPLETED | NCT00866528 |
| pazopanib | Other | Phase PHASE1 | Lung Cancer, Non-Small Cell | COMPLETED | NCT00866528 |
| paclitaxel | Other | Phase PHASE1 | Lung Cancer, Non-Small Cell | COMPLETED | NCT00866528 |
| pazopanib | Other | Phase PHASE1 | Lung Cancer, Non-Small Cell | COMPLETED | NCT00866528 |
| pazopanib | Other | Phase PHASE1 | Solid Tumours | COMPLETED | NCT00732420 |
| topotecan | Other | Phase PHASE1 | Solid Tumours | COMPLETED | NCT00732420 |
| pazopanib | Other | Phase PHASE1 | Solid Tumours | COMPLETED | NCT00732420 |
| topotecan | Other | Phase PHASE1 | Solid Tumours | COMPLETED | NCT00732420 |
| GSK1120212 | Other | Phase PHASE1 | Solid Tumours | COMPLETED | NCT00687622 |
| Ketoconozole tablets | Other | Phase PHASE1 | Macular Degeneration | COMPLETED | NCT00659555 |
| pazopanib eye drops | Other | Phase PHASE1 | Macular Degeneration | COMPLETED | NCT00659555 |
| Ketoconozole tablets | Other | Phase PHASE1 | Macular Degeneration | COMPLETED | NCT00659555 |
| pazopanib eye drops | Other | Phase PHASE1 | Macular Degeneration | COMPLETED | NCT00659555 |
| Lapatinib | Other | Phase PHASE1 | Carcinoma, Renal Cell | COMPLETED | NCT00516672 |
| pazopanib | Other | Phase PHASE1 | Carcinoma, Renal Cell | COMPLETED | NCT00516672 |
| Lapatinib | Other | Phase PHASE1 | Carcinoma, Renal Cell | COMPLETED | NCT00516672 |
| pazopanib | Other | Phase PHASE1 | Carcinoma, Renal Cell | COMPLETED | NCT00516672 |
| Rosiglitazone XR | Other | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT00490568 |
| Topotecan | Other | Phase PHASE1 | Solid Tumours | COMPLETED | NCT00483860 |
| Topotecan | Other | Phase PHASE1 | Solid Tumours | COMPLETED | NCT00483860 |
| Nelarabine injection 1500mg/m2 | Other | Phase PHASE1 | Leukaemia, Lymphoblastic, Acute and Lymphoma, Lymphoblastic | COMPLETED | NCT00406757 |
| Nelarabine injection 1000mg/m2 | Other | Phase PHASE1 | Leukaemia, Lymphoblastic, Acute and Lymphoma, Lymphoblastic | COMPLETED | NCT00406757 |
| Nelarabine injection 650mg/m2 | Other | Phase PHASE1 | Leukaemia, Lymphoblastic, Acute and Lymphoma, Lymphoblastic | COMPLETED | NCT00406757 |
| Nelarabine injection 400mg/m2 | Other | Phase PHASE1 | Leukaemia, Lymphoblastic, Acute and Lymphoma, Lymphoblastic | COMPLETED | NCT00406757 |
| Nelarabine injection 1500mg/m2 | Other | Phase PHASE1 | Leukaemia, Lymphoblastic, Acute and Lymphoma, Lymphoblastic | COMPLETED | NCT00406757 |
| Nelarabine injection 1000mg/m2 | Other | Phase PHASE1 | Leukaemia, Lymphoblastic, Acute and Lymphoma, Lymphoblastic | COMPLETED | NCT00406757 |
| Nelarabine injection 650mg/m2 | Other | Phase PHASE1 | Leukaemia, Lymphoblastic, Acute and Lymphoma, Lymphoblastic | COMPLETED | NCT00406757 |
| Nelarabine injection 400mg/m2 | Other | Phase PHASE1 | Leukaemia, Lymphoblastic, Acute and Lymphoma, Lymphoblastic | COMPLETED | NCT00406757 |
| Probe drugs | Drug | Phase PHASE1 | Carcinoma, Renal Cell | COMPLETED | NCT00401583 |
| GW786034 (pazopanib) | Other | Phase PHASE1 | Carcinoma, Renal Cell | COMPLETED | NCT00401583 |
| Probe drugs | Drug | Phase PHASE1 | Carcinoma, Renal Cell | COMPLETED | NCT00401583 |
| GW786034 (pazopanib) | Other | Phase PHASE1 | Carcinoma, Renal Cell | COMPLETED | NCT00401583 |
| eltrombopag | Other | Phase PHASE1 | Purpura, Thrombocytopaenic, Idiopathic | COMPLETED | NCT00359463 |
| eltrombopag | Other | Phase PHASE1 | Purpura, Thrombocytopaenic, Idiopathic | COMPLETED | NCT00359463 |
| lapatinib | Other | Phase PHASE1 | Neoplasms, Breast | COMPLETED | NCT00359190 |
| lapatinib | Other | Phase PHASE1 | Neoplasms, Breast | COMPLETED | NCT00359190 |
| eltrombopag | Other | Phase PHASE1 | Thrombocytopaenia | COMPLETED | NCT00358540 |
| Calcipotriol | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT00358384 |
| Betamethasone valerate | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT00358384 |
| Pazopanib vehicle | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT00358384 |
| Pazopanib | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT00358384 |
| Rifampin 600 mg OD | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01954043 |
| Rabeprazole 40 mg once daily (OD) | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01954043 |
| Dabrafenib 150 mg twice a day (BID) | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01954043 |
| Ipilimumab | Other | Phase PHASE1 | Solid Tumours | COMPLETED | NCT01767454 |
| Trametinib | Other | Phase PHASE1 | Solid Tumours | COMPLETED | NCT01767454 |
| Dabrafenib | Other | Phase PHASE1 | Solid Tumours | COMPLETED | NCT01767454 |
| rhEPO | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT01587924 |
| GSK1278863 | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT01587924 |
| Regimen D | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01231568 |
| Regimen C | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01231568 |
| Regimen B | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01231568 |
| Regimen A | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01231568 |
| Regimen D | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01231568 |
| Regimen C | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01231568 |
| Regimen B | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01231568 |
| Regimen A | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01231568 |
| Placebo | Other | Phase PHASE1 | Macular Degeneration | COMPLETED | NCT01072214 |
| pazopanib | Other | Phase PHASE1 | Macular Degeneration | COMPLETED | NCT01072214 |
| Eltrombopag | Other | Phase PHASE1 | Purpura, Thrombocytopaenic, Idiopathic | COMPLETED | NCT01072162 |
| Placebo | Other | Phase PHASE1 | Macular Degeneration | COMPLETED | NCT01051700 |
| GW786034 | Other | Phase PHASE1 | Macular Degeneration | COMPLETED | NCT01051700 |
| Placebo | Other | Phase PHASE2 | Depressive Disorder, Major | COMPLETED | NCT00976560 |
| GW856553 | Other | Phase PHASE2 | Depressive Disorder, Major | COMPLETED | NCT00976560 |
| Placebo for moxifloxacin | Other | Phase PHASE1 | Carcinoma, Renal Cell | COMPLETED | NCT00861029 |
| Moxifloxacin | Other | Phase PHASE1 | Carcinoma, Renal Cell | COMPLETED | NCT00861029 |
| Placebo for pazopanib | Other | Phase PHASE1 | Carcinoma, Renal Cell | COMPLETED | NCT00861029 |
| Pazopanib | Other | Phase PHASE1 | Carcinoma, Renal Cell | COMPLETED | NCT00861029 |
| Placebo for moxifloxacin | Other | Phase PHASE1 | Carcinoma, Renal Cell | COMPLETED | NCT00861029 |
| Moxifloxacin | Other | Phase PHASE1 | Carcinoma, Renal Cell | COMPLETED | NCT00861029 |
| Placebo for pazopanib | Other | Phase PHASE1 | Carcinoma, Renal Cell | COMPLETED | NCT00861029 |
| Pazopanib | Other | Phase PHASE1 | Carcinoma, Renal Cell | COMPLETED | NCT00861029 |
| lapatinib plus esomeprazole | Other | Phase PHASE1 | Neoplasms, Breast | COMPLETED | NCT00849329 |
| lapatinib | Other | Phase PHASE1 | Neoplasms, Breast | COMPLETED | NCT00849329 |
| Cisplatin | Other | Phase PHASE1 | Lung Cancer, Non-Small Cell | COMPLETED | NCT00678977 |
| Gemcitabine | Other | Phase PHASE1 | Lung Cancer, Non-Small Cell | COMPLETED | NCT00678977 |
| Pazopanib (GW786034) | Other | Phase PHASE1 | Lung Cancer, Non-Small Cell | COMPLETED | NCT00678977 |
| Radiation therapy | Drug | Phase PHASE1 | Carcinoma, Renal Cell | TERMINATED | NCT00158886 |
| Topotecan | Other | Phase PHASE1 | Carcinoma, Renal Cell | TERMINATED | NCT00158886 |
| PARIET 20 mg DR tabs | Other | Phase PHASE4 | Gastrointestinal Diseases | COMPLETED | NCT02446483 |
| Idiazole 20mg DR tabs | Other | Phase PHASE4 | Gastrointestinal Diseases | COMPLETED | NCT02446483 |
| PARIET 20 mg DR tabs | Other | Phase PHASE4 | Gastrointestinal Diseases | COMPLETED | NCT02446483 |
| Idiazole 20mg DR tabs | Other | Phase PHASE4 | Gastrointestinal Diseases | COMPLETED | NCT02446483 |
| Trimethoprim 100 mg Tablet | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT02371603 |
| Rosuvastatin 10 mg Tablet | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT02371603 |
| Pioglitazone 15 mg Tablet | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT02371603 |
| GSK1278863 25 mg Tablet | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT02371603 |
| Lamotrigine tablets 25/100 mg | Other | Phase PHASE4 | Epilepsy | COMPLETED | NCT02100644 |
| GSK2140944 Capsules | Other | Phase PHASE2 | Infections, Bacterial | COMPLETED | NCT02045797 |
| GSK2140944 Lyophile | Other | Phase PHASE2 | Infections, Bacterial | COMPLETED | NCT02045797 |
| GSK2140944 Capsules | Other | Phase PHASE2 | Infections, Bacterial | COMPLETED | NCT02045797 |
| GSK2140944 Lyophile | Other | Phase PHASE2 | Infections, Bacterial | COMPLETED | NCT02045797 |
| GSK2140944 Capsules | Other | Phase PHASE2 | Infections, Bacterial | COMPLETED | NCT02045797 |
| GSK2140944 Lyophile | Other | Phase PHASE2 | Infections, Bacterial | COMPLETED | NCT02045797 |
| Placebo | Other | Phase PHASE2 | Influenza | COMPLETED | NCT01949090 |
| Investigational H7N1 vaccine GSK2789869A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT01949090 |
| Placebo | Other | Phase PHASE2 | Cerebrovascular Accident | TERMINATED | NCT01808261 |
| GSK249320 100/mg | Other | Phase PHASE2 | Cerebrovascular Accident | TERMINATED | NCT01808261 |
| Placebo | Other | Phase PHASE2 | Dermatitis, Atopic | COMPLETED | NCT01299610 |
| FP 0.05% | Other | Phase PHASE2 | Dermatitis, Atopic | COMPLETED | NCT01299610 |
| GW870086 0.2% | Other | Phase PHASE2 | Dermatitis, Atopic | COMPLETED | NCT01299610 |
| GW870086 2.0% | Other | Phase PHASE2 | Dermatitis, Atopic | COMPLETED | NCT01299610 |
| Argatroban and warfarin | Other | Phase PHASE4 | Coronary Artery Bypass Graft Surgery | TERMINATED | NCT01246011 |
| Etravirine | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | TERMINATED | NCT01199731 |
| GSK2248761 200 mg once daily | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | TERMINATED | NCT01199731 |
| GSK2248761 100 mg once daily | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | TERMINATED | NCT01199731 |
| ofatumumab | Other | Phase PHASE1 | Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular | COMPLETED | NCT00742144 |
| Digoxin | Other | Phase PHASE1 | Neoplasms, Breast | COMPLETED | NCT00650910 |
| lapatinib | Other | Phase PHASE1 | Neoplasms, Breast | COMPLETED | NCT00650910 |
| Digoxin | Other | Phase PHASE1 | Neoplasms, Breast | COMPLETED | NCT00650910 |
| lapatinib | Other | Phase PHASE1 | Neoplasms, Breast | COMPLETED | NCT00650910 |
| pemetrexed | Other | Phase PHASE1 | Lung Cancer, Non-Small Cell | COMPLETED | NCT00619424 |
| erlotinib | Other | Phase PHASE1 | Lung Cancer, Non-Small Cell | COMPLETED | NCT00619424 |
| pazopanib | Other | Phase PHASE1 | Lung Cancer, Non-Small Cell | COMPLETED | NCT00619424 |
| pemetrexed | Other | Phase PHASE1 | Lung Cancer, Non-Small Cell | COMPLETED | NCT00619424 |
| erlotinib | Other | Phase PHASE1 | Lung Cancer, Non-Small Cell | COMPLETED | NCT00619424 |
| pazopanib | Other | Phase PHASE1 | Lung Cancer, Non-Small Cell | COMPLETED | NCT00619424 |
| GW786034, radiolabeled oral | Other | Phase PHASE1 | Carcinoma, Renal Cell | COMPLETED | NCT00478725 |
| GW786034, IV | Other | Phase PHASE1 | Carcinoma, Renal Cell | COMPLETED | NCT00478725 |
| GW786034, oral | Other | Phase PHASE1 | Carcinoma, Renal Cell | COMPLETED | NCT00478725 |
| pazopanib | Other | Phase PHASE1 | Carcinoma, Hepatocellular | COMPLETED | NCT00370513 |
| Pazopanib (GW786034) | Other | Phase PHASE1 | Carcinoma, Renal Cell | COMPLETED | NCT00363194 |
| GW572016 oral tablets | Other | Phase PHASE1 | Neoplasms, Breast | COMPLETED | NCT00169533 |
| lapatinib | Other | Phase PHASE1 | Carcinoma, Renal Cell | COMPLETED | NCT00158782 |
| GW786034 | Other | Phase PHASE1 | Carcinoma, Renal Cell | COMPLETED | NCT00158782 |
| Prednisone /Prednisone placebo | Other | Phase PHASE3 | Polymyalgia Rheumatica | WITHDRAWN | NCT02899026 |
| Placebo to match sirukumab | Other | Phase PHASE3 | Polymyalgia Rheumatica | WITHDRAWN | NCT02899026 |
| Sirukumab | Other | Phase PHASE3 | Polymyalgia Rheumatica | WITHDRAWN | NCT02899026 |
| Vehicle cream | Other | Phase PHASE2 | Dermatitis, Atopic | COMPLETED | NCT02564055 |
| GSK2894512 0.5% Cream | Other | Phase PHASE2 | Dermatitis, Atopic | COMPLETED | NCT02564055 |
| GSK2894512 1% Cream | Other | Phase PHASE2 | Dermatitis, Atopic | COMPLETED | NCT02564055 |
| Pazopanib | Other | Phase PHASE2 | Macular Degeneration | COMPLETED | NCT00612456 |
| Pazopanib | Other | Phase PHASE2 | Macular Degeneration | COMPLETED | NCT00612456 |
| Placebo | Other | Approved | Allergic Asthma | COMPLETED | NCT00214019 |
| Fluticasone | Other | Approved | Allergic Asthma | COMPLETED | NCT00214019 |
| salmeterol | Other | Approved | Allergic Asthma | COMPLETED | NCT00214019 |
| Vehicle (base cream) | Other | Phase PHASE3 | Eczema | COMPLETED | NCT01567995 |
| Clobetasone Butyrate 0.05% Cream | Other | Phase PHASE3 | Eczema | COMPLETED | NCT01567995 |
| GSK2894512 MATCHING VEHICLE CREAM | Other | Phase PHASE1 | Psoriasis | WITHDRAWN | NCT03201978 |
| GSK2894512 1% CREAM | Other | Phase PHASE1 | Psoriasis | WITHDRAWN | NCT03201978 |
| GSK2894512 MATCHING VEHICLE CREAM | Other | Phase PHASE1 | Psoriasis | WITHDRAWN | NCT03201978 |
| GSK2894512 1% CREAM | Other | Phase PHASE1 | Psoriasis | WITHDRAWN | NCT03201978 |
| Irinotecan | Other | Phase PHASE1 | Neoplasms, Colorectal | COMPLETED | NCT00540943 |
| Cetuximab | Other | Phase PHASE1 | Neoplasms, Colorectal | COMPLETED | NCT00540943 |
| Pazopanib | Other | Phase PHASE1 | Neoplasms, Colorectal | COMPLETED | NCT00540943 |
| Irinotecan | Other | Phase PHASE1 | Neoplasms, Colorectal | COMPLETED | NCT00540943 |
| Cetuximab | Other | Phase PHASE1 | Neoplasms, Colorectal | COMPLETED | NCT00540943 |
| Pazopanib | Other | Phase PHASE1 | Neoplasms, Colorectal | COMPLETED | NCT00540943 |
| Havrix™ | Other | Phase PHASE4 | Hepatitis A | COMPLETED | NCT00291876 |
| metformin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00279045 |
| glyburide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00279045 |
| Rosiglitazone | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00279045 |
| radiation therapy | Drug | Phase PHASE1 | Cervical Cancer | COMPLETED | NCT00287911 |
| brachytherapy | Drug | Phase PHASE1 | Cervical Cancer | COMPLETED | NCT00287911 |
| topotecan hydrochloride | Other | Phase PHASE1 | Cervical Cancer | COMPLETED | NCT00287911 |
| cisplatin | Other | Phase PHASE1 | Cervical Cancer | COMPLETED | NCT00287911 |
| 18F-GE-180 | Other | Phase PHASE1 | Arthritis, Rheumatoid | TERMINATED | NCT02350426 |
| 18F-FDG | Other | Phase PHASE1 | Arthritis, Rheumatoid | TERMINATED | NCT02350426 |
| Gadobutrol | Other | Phase PHASE1 | Arthritis, Rheumatoid | TERMINATED | NCT02350426 |
| Linezolid placebo | Other | Phase PHASE2 | Skin Infections, Bacterial | COMPLETED | NCT01209078 |
| GSK1322322 placebo | Other | Phase PHASE2 | Skin Infections, Bacterial | COMPLETED | NCT01209078 |
| Linezolid | Other | Phase PHASE2 | Skin Infections, Bacterial | COMPLETED | NCT01209078 |
| GSK1322322 | Other | Phase PHASE2 | Skin Infections, Bacterial | COMPLETED | NCT01209078 |
| Linezolid placebo | Other | Phase PHASE2 | Skin Infections, Bacterial | COMPLETED | NCT01209078 |
| GSK1322322 placebo | Other | Phase PHASE2 | Skin Infections, Bacterial | COMPLETED | NCT01209078 |
| Linezolid | Other | Phase PHASE2 | Skin Infections, Bacterial | COMPLETED | NCT01209078 |
| GSK1322322 | Other | Phase PHASE2 | Skin Infections, Bacterial | COMPLETED | NCT01209078 |
| Pazopanib | Other | Phase PHASE2 | Macular Degeneration | COMPLETED | NCT00733304 |
| Pazopanib | Other | Phase PHASE2 | Macular Degeneration | COMPLETED | NCT00733304 |
| ofatumumab | Other | Phase PHASE2 | Arthritis, Rheumatoid | TERMINATED | NCT00655824 |
| ofatumumab | Other | Phase PHASE2 | Arthritis, Rheumatoid | TERMINATED | NCT00655824 |
| Placebo dutasteride | Other | Phase PHASE4 | Hypogonadism | COMPLETED | NCT00194675 |
| Testosterone gel | Other | Phase PHASE4 | Hypogonadism | COMPLETED | NCT00194675 |
| Dutasteride | Other | Phase PHASE4 | Hypogonadism | COMPLETED | NCT00194675 |
| Placebo dutasteride | Other | Phase PHASE4 | Hypogonadism | COMPLETED | NCT00194675 |
| Testosterone gel | Other | Phase PHASE4 | Hypogonadism | COMPLETED | NCT00194675 |
| Dutasteride | Other | Phase PHASE4 | Hypogonadism | COMPLETED | NCT00194675 |
| GSK1265744 5mg | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00920426 |
| Placebo | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00920426 |
| GSK1265744 30mg | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00920426 |
| GSK1265744 5mg | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00920426 |
| Placebo | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00920426 |
| GSK1265744 30mg | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00920426 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00500331 |
| pioglitazone | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00500331 |
| GSK189075 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00500331 |
| Lapatinib | Other | Phase PHASE1 | Neoplasms, Breast | COMPLETED | NCT00258050 |
| Midazolam | Other | Phase PHASE1 | Neoplasms, Breast | COMPLETED | NCT00258050 |
| Lapatinib | Other | Phase PHASE1 | Neoplasms, Breast | COMPLETED | NCT00258050 |
| Midazolam | Other | Phase PHASE1 | Neoplasms, Breast | COMPLETED | NCT00258050 |
| docetaxel | Other | Phase PHASE1 | Neoplasms, Breast | COMPLETED | NCT00148902 |
| lapatinib | Other | Phase PHASE1 | Neoplasms, Breast | COMPLETED | NCT00148902 |
| Placebo | Other | Phase PHASE2 | Surgical Procedures | COMPLETED | NCT01920594 |
| GSK1278863 | Other | Phase PHASE2 | Surgical Procedures | COMPLETED | NCT01920594 |
| Placebo | Other | Phase PHASE2 | Acute Coronary Syndrome | COMPLETED | NCT00910962 |
| GW856553 | Other | Phase PHASE2 | Acute Coronary Syndrome | COMPLETED | NCT00910962 |
| Placebo | Other | Phase PHASE2 | Acute Coronary Syndrome | COMPLETED | NCT00910962 |
| GW856553 | Other | Phase PHASE2 | Acute Coronary Syndrome | COMPLETED | NCT00910962 |
| donepezil 5-10mg | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT00710684 |
| Placebo | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT00710684 |
| SB-742457 35mg | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT00710684 |
| SB-742457 15mg | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT00710684 |
| Trametinib tablets | Other | Phase PHASE2 | Solid Tumours | WITHDRAWN | NCT03266159 |
| GSK525762 Besylate tablets | Other | Phase PHASE2 | Solid Tumours | WITHDRAWN | NCT03266159 |
| Trametinib tablets | Other | Phase PHASE2 | Solid Tumours | WITHDRAWN | NCT03266159 |
| GSK525762 Besylate tablets | Other | Phase PHASE2 | Solid Tumours | WITHDRAWN | NCT03266159 |
| Camicinal | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT02210000 |
| Placebo | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT02210000 |
| Placebo IV | Other | Phase PHASE2 | Gastroparesis | TERMINATED | NCT01934192 |
| Placebo NG | Other | Phase PHASE2 | Gastroparesis | TERMINATED | NCT01934192 |
| Metoclopramide 10 mg | Other | Phase PHASE2 | Gastroparesis | TERMINATED | NCT01934192 |
| GSK962040 50 mg | Other | Phase PHASE2 | Gastroparesis | TERMINATED | NCT01934192 |
| GSK2336805 Matching Placebo | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01439373 |
| Ribavirin | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01439373 |
| Pegylated interferon alfa-2a | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01439373 |
| GSK2336805 | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01439373 |
| foretinib (formerly GSK1363089 or XL880) | Other | Phase PHASE2 | Carcinoma, Renal Cell | COMPLETED | NCT00726323 |
| GSK1120212 | Other | Phase PHASE2 | GNA11 Mutation-positive Metastatic Melanoma | WITHDRAWN | NCT01328106 |
| Saline placebo | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00985088 |
| GSK2340273A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00985088 |
| GSK2340274A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00985088 |
| GSK2340273A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00976820 |
| GSK2340274A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00976820 |
| Placebo vaccine (saline) | Other | Phase PHASE2 | Herpes Zoster | COMPLETED | NCT00920218 |
| Herpes Zoster Vaccine 1437173A | Other | Phase PHASE2 | Herpes Zoster | COMPLETED | NCT00920218 |
| FLUTICASONE PROPIONATE | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00843193 |
| INTRAVENOUS PLACEBO | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00843193 |
| INTRAVENOUS GSK679586 | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00843193 |
| Placebo | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00285584 |
| Bupropion | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00285584 |
| Liraglutide | Other | Phase PHASE2 | Obesity | COMPLETED | NCT01725126 |
| Placebo | Other | Phase PHASE2 | Obesity | COMPLETED | NCT01725126 |
| Metformin | Other | Phase PHASE2 | Obesity | COMPLETED | NCT01725126 |
| GSK2890457 | Other | Phase PHASE2 | Obesity | COMPLETED | NCT01725126 |
| Pneumococcal conjugate vaccine GSK1024850A | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00792909 |
| Placebo Injection | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02076178 |
| Placebo Tablet | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02076178 |
| 744 LA Injection | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02076178 |
| 744 Tablet | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02076178 |
| capecitabine | Other | Phase PHASE1 | Neoplasms, Colorectal | COMPLETED | NCT00536809 |
| oxaliplatin | Other | Phase PHASE1 | Neoplasms, Colorectal | COMPLETED | NCT00536809 |
| lapatinib | Other | Phase PHASE1 | Neoplasms, Colorectal | COMPLETED | NCT00536809 |
| Pazopanib | Other | Preclinical | Sarcoma, Soft Tissue | COMPLETED | NCT01995981 |
| Pazopanib | Other | Preclinical | Sarcoma, Soft Tissue | COMPLETED | NCT01995981 |
| Control | Other | Approved | Growth and Development | WITHDRAWN | NCT02551627 |
| Test Product | Other | Approved | Growth and Development | WITHDRAWN | NCT02551627 |
| Placebo | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01753076 |
| Ozanezumab | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01753076 |
| Metformin | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01842620 |
| Infanrix-IPV/Hib | Other | Phase PHASE3 | Diphtheria | WITHDRAWN | NCT03128489 |
| Ixabepilone | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT01012362 |
| Pazopanib | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT01012362 |
| Rotarix™ | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT00938327 |
| Rotarix™ | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT00938327 |
| Placebo | Other | Phase PHASE2 | Virus Diseases | COMPLETED | NCT02485301 |
| GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A) | Other | Phase PHASE2 | Virus Diseases | COMPLETED | NCT02485301 |
| Rifampin | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT00964106 |
| Fluconazole | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT00964106 |
| Ketoconazole | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT00964106 |
| Rosuvastatin | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT00964106 |
| Midazolam | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT00964106 |
| Dextromethorphan | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT00964106 |
| Omeprazole | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT00964106 |
| Flurbiprofen | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT00964106 |
| Rosiglitazone | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT00964106 |
| Caffeine | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT00964106 |
| ranibizumab intravitreal injection | Other | Phase PHASE2 | Macular Degeneration | COMPLETED | NCT01134055 |
| placebo | Other | Phase PHASE2 | Macular Degeneration | COMPLETED | NCT01134055 |
| pazopanib eye drops | Other | Phase PHASE2 | Macular Degeneration | COMPLETED | NCT01134055 |
| Sirukumab | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01604343 |
| Placebo | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01604343 |
| Sirukumab | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01604343 |
| Placebo | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01604343 |
| Placebo with 0.09% menthol gel | Other | Phase PHASE3 | Pain | COMPLETED | NCT02100670 |
| 3% menthol | Other | Phase PHASE3 | Pain | COMPLETED | NCT02100670 |
| 1% diclofenac sodium plus 0.09% menthol | Other | Phase PHASE3 | Pain | COMPLETED | NCT02100670 |
| 1% diclofenac sodium plus 3% menthol | Other | Phase PHASE3 | Pain | COMPLETED | NCT02100670 |
| SB480848 Placebo Tablet | Other | Phase PHASE2 | Atherosclerosis | COMPLETED | NCT00734032 |
| SB480848 160mg EC Tablet | Other | Phase PHASE2 | Atherosclerosis | COMPLETED | NCT00734032 |
| SB480848 80mg EC Tablet | Other | Phase PHASE2 | Atherosclerosis | COMPLETED | NCT00734032 |
| SB480848 40mg EC Tablet | Other | Phase PHASE2 | Atherosclerosis | COMPLETED | NCT00734032 |
| exemestane and pazopanib | Other | Phase PHASE2 | Hormone-receptor Positive Breast Cancer | WITHDRAWN | NCT00615524 |
| ritonavir 100mg OAD | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01449929 |
| darunavir 800mg OAD | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01449929 |
| dolutegravir 50 mg OAD | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01449929 |
| ritonavir 100mg OAD | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01449929 |
| darunavir 800mg OAD | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01449929 |
| dolutegravir 50 mg OAD | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01449929 |
| Safety follow up | Other | Preclinical | Influenza | COMPLETED | NCT00996853 |
| efavirenz | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00951015 |
| GSK1349572 | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00951015 |
| efavirenz | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00951015 |
| GSK1349572 | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00951015 |
| Placebo | Other | Phase PHASE2 | Obstetric Labour, Premature | COMPLETED | NCT00404768 |
| GSK221149A | Other | Phase PHASE2 | Obstetric Labour, Premature | COMPLETED | NCT00404768 |
| Flunisolide | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00346775 |
| Beclomethasone dipropionate | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00346775 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT00065065 |
| Rosiglitazone | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT00065065 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT00065065 |
| Rosiglitazone | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT00065065 |
| Ondansetron | Other | Phase PHASE3 | Nausea and Vomiting, Chemotherapy-Induced | COMPLETED | NCT00601172 |
| Placebo | Other | Phase PHASE3 | Nausea and Vomiting, Chemotherapy-Induced | COMPLETED | NCT00601172 |
| Dexamethasone | Other | Phase PHASE3 | Nausea and Vomiting, Chemotherapy-Induced | COMPLETED | NCT00601172 |
| Casopitant | Other | Phase PHASE3 | Nausea and Vomiting, Chemotherapy-Induced | COMPLETED | NCT00601172 |
| PoliorixTM | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT00920439 |
| Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine | Other | Phase PHASE1 | Dengue | COMPLETED | NCT00322049 |
| Tetravalent live attenuated dengue vaccine | Other | Phase PHASE1 | Dengue | COMPLETED | NCT00322049 |
| Trametinib | Other | Phase PHASE2 | BRAFV600E Melanoma Patients | TERMINATED | NCT01721603 |
| Gamma Knife Radiosurgery | Procedure | Phase PHASE2 | BRAFV600E Melanoma Patients | TERMINATED | NCT01721603 |
| Dabrafenib | Other | Phase PHASE2 | BRAFV600E Melanoma Patients | TERMINATED | NCT01721603 |
| GW685698X 200mcg,GW685698X 200mcg and 400mcg | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00398645 |
| Tiotropium matching placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02207829 |
| Tiotropium | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02207829 |
| Umeclidinium matching placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02207829 |
| Umeclidinium | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02207829 |
| Vilanterol | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02105974 |
| Fluticasone Furoate/Vilanterol | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02105974 |
| Tiotropium 18 mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01899742 |
| Umeclidinium/Vilanterol 62.5/25 mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01899742 |
| Tiotropium 18 mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01777334 |
| Umeclidinium/Vilanterol 62.5/25 mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01777334 |
| Fluticasone Furoate 100 mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01686633 |
| Fluticasone Furoate/ Vilanterol 100/25 mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01686633 |
| Fluticasone Furoate/ Vilanterol 200/25 mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01686633 |
| tiotropium bromide | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01316900 |
| GW642444 | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01316900 |
| GSK573719/GW642444 62.5/25 | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01316900 |
| GSK573719/GW642444 125/25 | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01316900 |
| Fluticasone furoate | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01086384 |
| Fluticasone Furoate/GW642444 | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01086384 |
| Fluticasone furoate | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01086384 |
| Fluticasone Furoate/GW642444 | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01086384 |
| Placebo saline | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01000506 |
| Mepolizumab 75 | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01000506 |
| Mepolizumab 250 | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01000506 |
| Mepolizumab 750 | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01000506 |
| Salbutamol/Albuterol | Other | Phase PHASE4 | Asthma | WITHDRAWN | NCT03363191 |
| Fluticasone Furoate | Other | Phase PHASE4 | Asthma | WITHDRAWN | NCT03363191 |
| Fluticasone Furoate/Vilanterol | Other | Phase PHASE4 | Asthma | WITHDRAWN | NCT03363191 |
| Dissolvable polymer strip containing Novamin (calcium sodium phosphosilicate) | Other | Approved | Dentin Sensitivity | COMPLETED | NCT02937623 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01772134 |
| Fluticasone propionate 250mcg/Salmeterol 50mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01772134 |
| Umeclidinium bromide 125mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01772134 |
| Umeclidinium bromide 62.5mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01772134 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01772134 |
| Fluticasone propionate 250mcg/Salmeterol 50mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01772134 |
| Umeclidinium bromide 125mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01772134 |
| Umeclidinium bromide 62.5mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01772134 |
| Placebo | Other | Phase PHASE2 | Rhinitis | COMPLETED | NCT01424514 |
| SB-705498 | Other | Phase PHASE2 | Rhinitis | COMPLETED | NCT01424514 |
| Placebo only | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01313637 |
| GW642444 25mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01313637 |
| GSK573719 125mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01313637 |
| GSK573719/GW642444 125/25mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01313637 |
| Placebo | Other | Phase PHASE2 | Irritable Bowel Syndrome (IBS) | COMPLETED | NCT00421707 |
| GW876008 | Other | Phase PHASE2 | Irritable Bowel Syndrome (IBS) | COMPLETED | NCT00421707 |
| Placebo | Other | Phase PHASE2 | Depressive Disorder | COMPLETED | NCT00420641 |
| Paroxetine | Other | Phase PHASE2 | Depressive Disorder | COMPLETED | NCT00420641 |
| GSK372475 | Other | Phase PHASE2 | Depressive Disorder | COMPLETED | NCT00420641 |
| Cisplatin | Other | Phase PHASE2 | Cervical Cancer | COMPLETED | NCT00257816 |
| Topotecan | Other | Phase PHASE2 | Cervical Cancer | COMPLETED | NCT00257816 |
| Placebo | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT00396630 |
| Rotarix | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT00396630 |
| Fluoride free dentifrice | Other | Phase PHASE4 | Dental Caries | COMPLETED | NCT01563172 |
| Sodium fluoride / silica and carbopol, 1.5g | Other | Phase PHASE4 | Dental Caries | COMPLETED | NCT01563172 |
| Sodium fluoride / silica and carbopol, 0.5g | Other | Phase PHASE4 | Dental Caries | COMPLETED | NCT01563172 |
| Vehicle | Other | Phase PHASE2 | Hyperhidrosis | COMPLETED | NCT02673619 |
| Umeclidinium | Other | Phase PHASE2 | Hyperhidrosis | COMPLETED | NCT02673619 |
| Placebo | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT02019719 |
| GSK1278863 | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT02019719 |
| Placebo | Other | Phase PHASE4 | Infections, Herpesviridae | COMPLETED | NCT00116844 |
| Valaciclovir | Other | Phase PHASE4 | Infections, Herpesviridae | COMPLETED | NCT00116844 |
| Placebo | Other | Phase PHASE4 | Infections, Herpesviridae | COMPLETED | NCT00116844 |
| Valaciclovir | Other | Phase PHASE4 | Infections, Herpesviridae | COMPLETED | NCT00116844 |
| Placebo Inhaltion Powder | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01165138 |
| Fluticasone Furoate Inhalation Powder | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01165138 |
| Fluticasone furoate/Vilanterol Inhalation Powder | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01165138 |
| Placebo Inhaltion Powder | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01165138 |
| Fluticasone Furoate Inhalation Powder | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01165138 |
| Fluticasone furoate/Vilanterol Inhalation Powder | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01165138 |
| Umeclidinium/Vilanterol 62.5/25 mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02014480 |
| Vilanterol 25 mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02014480 |
| Umeclidinium 62.5 mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02014480 |
| Tiotropium | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01395888 |
| fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI) | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01395888 |
| Salbutamol as needed | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01323621 |
| Double-dummy placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01323621 |
| Fluticasone Propionate 250mcg / salmeterol 50mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01323621 |
| Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01323621 |
| InfanrixTM IPV | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT00891176 |
| InfanrixTM IPV/Hib | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT00891176 |
| InfanrixTM penta | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT00891176 |
| InfanrixTM hexa | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT00891176 |
| NeisVac-CTM | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT00891176 |
| MeningitecTM | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT00891176 |
| PrevenarTM | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT00891176 |
| Pneumococcal conjugate vaccine GSK1024850A | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT00891176 |
| MenitorixTM | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT00891176 |
| Twinrix™ adult | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00289718 |
| Twinrix™ adult | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00289718 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00857857 |
| GW870086X | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00857857 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00857857 |
| GW870086X | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00857857 |
| Intravenous (IV) zanamivir | Other | Phase PHASE3 | Influenza, Human | COMPLETED | NCT01527110 |
| Intravenous (IV) zanamivir | Other | Phase PHASE3 | Influenza, Human | COMPLETED | NCT01527110 |
| tafenoquine | Other | Phase PHASE2 | Malaria | TERMINATED | NCT01290601 |
| Chloroquine + Primaquine | Other | Phase PHASE2 | Malaria | TERMINATED | NCT01290601 |
| Tafenoquine | Other | Phase PHASE2 | Malaria | TERMINATED | NCT01290601 |
| hepatitis A vaccine, DTaP, PCV10 | Other | Phase PHASE4 | Pneumococcal Pneumonia | UNKNOWN | NCT01028326 |
| PCV10 and DTaP | Other | Phase PHASE4 | Pneumococcal Pneumonia | UNKNOWN | NCT01028326 |
| Rabipur | Other | Phase PHASE4 | Virus Diseases | WITHDRAWN | NCT03192371 |
| Fluarix and adjuvanted influenza vaccine | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00386113 |
| Fluarix and adjuvanted influenza vaccine | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00386113 |
| Ispinesib | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00089973 |
| SC belimumab 200 mg | Other | Preclinical | Systemic Lupus Erythematosus | NO_LONGER_AVAILABLE | NCT03125486 |
| Matched placebo 150mg | Other | Phase PHASE1 | Malaria, Vivax | COMPLETED | NCT02658435 |
| Tafenoquine 150 mg | Other | Phase PHASE1 | Malaria, Vivax | COMPLETED | NCT02658435 |
| Albuterol/salbutamol Metered Dose Inhaler (MDI) | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02257385 |
| Indacaterol matching placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02257385 |
| Indacaterol | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02257385 |
| Tiotropium matching placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02257385 |
| Tiotropium | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02257385 |
| UMEC/VI matching placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02257385 |
| UMEC/VI | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02257385 |
| Placebo | Other | Phase PHASE4 | Physical Fitness | COMPLETED | NCT00876018 |
| Nutritional supplement | Other | Phase PHASE4 | Physical Fitness | COMPLETED | NCT00876018 |
| fluticasone furoate (FF) | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00398476 |
| fluticasone propionate (FP) | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00398476 |
| Havrix® | Other | Phase PHASE4 | Hepatitis A | WITHDRAWN | NCT03183492 |
| GSK HIV vaccine 732462 | Other | Phase PHASE1 | AIDS | COMPLETED | NCT01092611 |
| Blood collection | Other | Phase PHASE1 | AIDS | COMPLETED | NCT01092611 |
| Sodium Monofluorophosphate | Other | Phase PHASE3 | Dentine Hypersensitivity | COMPLETED | NCT03072719 |
| Stannous Fluoride | Other | Phase PHASE3 | Dentine Hypersensitivity | COMPLETED | NCT03072719 |
| Sodium Monofluorophosphate | Other | Phase PHASE3 | Dentine Hypersensitivity | COMPLETED | NCT03072719 |
| Stannous Fluoride | Other | Phase PHASE3 | Dentine Hypersensitivity | COMPLETED | NCT03072719 |
| Cefixime reference capsule | Other | Phase PHASE1 | Infections, Bacterial | WITHDRAWN | NCT03329547 |
| Cefixime test capsule | Other | Phase PHASE1 | Infections, Bacterial | WITHDRAWN | NCT03329547 |
| Methotrexate | Other | Phase PHASE2 | Autoimmune Diseases | WITHDRAWN | NCT03239600 |
| Placebo | Other | Phase PHASE2 | Autoimmune Diseases | WITHDRAWN | NCT03239600 |
| GSK2618960 2 mg/kg | Other | Phase PHASE2 | Autoimmune Diseases | WITHDRAWN | NCT03239600 |
| Fluticasone furoate and fexofenadine | Other | Phase PHASE4 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00435461 |
| Herpes Zoster Vaccine GSK 1437173A | Other | Phase PHASE1 | Herpes Zoster | COMPLETED | NCT01086449 |
| Placebo | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01030965 |
| GSK573719 500mcg | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01030965 |
| GSK573719 250mcg | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01030965 |
| GSK573719 125mcg | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01030965 |
| DISKUS™ powder inhalers | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00363480 |
| Salbutamol 100 mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00363480 |
| Salmeterol/Fluticasone 50/250 mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00363480 |
| Paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C | Other | Phase PHASE3 | Infections, Respiratory Tract | WITHDRAWN | NCT02730364 |
| ATACAND | Other | Phase PHASE1 | Cardiovascular Disease | COMPLETED | NCT02254447 |
| Candesartan Cilexetil in formulation 2 | Other | Phase PHASE1 | Cardiovascular Disease | COMPLETED | NCT02254447 |
| Candesartan Cilexetil in formulation 1 | Other | Phase PHASE1 | Cardiovascular Disease | COMPLETED | NCT02254447 |
| Data collection | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT01563146 |
| GSK233705B | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00453479 |
| Data collection | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT01563159 |
| Autologous Stem Cell Rescue | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT00325416 |
| topotecan (TPT) | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT00325416 |
| melphalan | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT00325416 |
| Autologous Stem Cell Rescue | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT00325416 |
| topotecan (TPT) | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT00325416 |
| melphalan | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT00325416 |
| GSK163090 3 mg | Other | Phase PHASE2 | Depressive Disorder | COMPLETED | NCT00896363 |
| GSK163090 Placebo | Other | Phase PHASE2 | Depressive Disorder | COMPLETED | NCT00896363 |
| GSK163090 1 mg | Other | Phase PHASE2 | Depressive Disorder | COMPLETED | NCT00896363 |
| SB-480848 matching placebo | Other | Phase PHASE2 | Atherosclerosis | COMPLETED | NCT00268996 |
| SB-480848 | Other | Phase PHASE2 | Atherosclerosis | COMPLETED | NCT00268996 |
| GSK2340273A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00979602 |
| GSK2340274A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00979602 |
| rosiglitazone maleate/metformin hydrochloride | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00499707 |
| rosiglitazone maleate/metformin hydrochloride | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00499707 |
| salmeterol xinafoate/fluticasone propionate | Other | Phase PHASE4 | Asthma | TERMINATED | NCT00273026 |
| rosiglitazone/metformin | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00241605 |
| DEN 45 mg | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00111800 |
| DEN 30 mg | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00111800 |
| DEN 15 mg | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00111800 |
| DEN 7.5 mg | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00111800 |
| DEN 2.5 mg | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00111800 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00111800 |
| rosiglitazone/metformin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00067951 |
| Placebo | Other | Phase PHASE1 | Nutritional Status | COMPLETED | NCT02058654 |
| Creatine | Other | Phase PHASE1 | Nutritional Status | COMPLETED | NCT02058654 |
| Sirukumab | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01606761 |
| Placebo | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01606761 |
| glyburide | Other | Approved | Type 2 Diabetes Mellitus | COMPLETED | NCT00194896 |
| rosiglitazone | Other | Approved | Type 2 Diabetes Mellitus | COMPLETED | NCT00194896 |
| glyburide | Other | Approved | Type 2 Diabetes Mellitus | COMPLETED | NCT00194896 |
| rosiglitazone | Other | Approved | Type 2 Diabetes Mellitus | COMPLETED | NCT00194896 |
| Placebo | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00372112 |
| GW642444 | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00372112 |
| Placebo (Saline) | Other | Phase PHASE3 | Influenza | COMPLETED | NCT02218697 |
| Pneumovax™ 23 | Other | Phase PHASE3 | Influenza | COMPLETED | NCT02218697 |
| Influsplit™ Tetra (Fluarix™ Tetra) | Other | Phase PHASE3 | Influenza | COMPLETED | NCT02218697 |
| Remifentanil | Other | Phase PHASE4 | Analgesia | TERMINATED | NCT00421720 |
| Sufentanil | Other | Phase PHASE4 | Analgesia | TERMINATED | NCT00421720 |
| Remifentanil | Other | Phase PHASE4 | Analgesia | TERMINATED | NCT00421720 |
| Sufentanil | Other | Phase PHASE4 | Analgesia | TERMINATED | NCT00421720 |
| Pollen allergen extract | Other | Phase PHASE2 | Asthma and Rhinitis | COMPLETED | NCT02446613 |
| Pollen allergen extract | Other | Phase PHASE2 | Asthma and Rhinitis | COMPLETED | NCT02446613 |
| Sodium monofluorophosphate | Other | Approved | Dentine Sensitivity | COMPLETED | NCT02371616 |
| Sodium fluoride | Other | Approved | Dentine Sensitivity | COMPLETED | NCT02371616 |
| Calcium sodium phosphosilicate | Other | Approved | Dentine Sensitivity | COMPLETED | NCT02371616 |
| Atripla placebo | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus I | COMPLETED | NCT01263015 |
| Dolutegravir placebo | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus I | COMPLETED | NCT01263015 |
| Abacavir/Lamivudine Placebo | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus I | COMPLETED | NCT01263015 |
| Abacavir/Lamivudine | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus I | COMPLETED | NCT01263015 |
| Atripla | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus I | COMPLETED | NCT01263015 |
| Dolutegravir | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus I | COMPLETED | NCT01263015 |
| Atripla placebo | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus I | COMPLETED | NCT01263015 |
| Dolutegravir placebo | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus I | COMPLETED | NCT01263015 |
| Abacavir/Lamivudine Placebo | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus I | COMPLETED | NCT01263015 |
| Abacavir/Lamivudine | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus I | COMPLETED | NCT01263015 |
| Atripla | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus I | COMPLETED | NCT01263015 |
| Dolutegravir | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus I | COMPLETED | NCT01263015 |
| CCK (Kinevac) | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02496221 |
| Placebo | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02496221 |
| Albiglutide 50 mg | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02496221 |
| Chemotherapy | Drug | Phase PHASE3 | Melanoma | COMPLETED | NCT01245062 |
| GSK1120212 | Other | Phase PHASE3 | Melanoma | COMPLETED | NCT01245062 |
| Belimumab autoinjector | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT02124798 |
| Placebo | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00289198 |
| BMS-663068 | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT02234882 |
| Rosuvastatin | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT02234882 |
| BMS-955176 | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT02206711 |
| Ortho Cyclen | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02157467 |
| BMS-955176 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02157467 |
| Ortho Cyclen | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02157467 |
| BMS-955176 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02157467 |
| Azathioprine | Other | Phase PHASE3 | Vasculitis | COMPLETED | NCT01663623 |
| Belimumab 10 mg/kg | Other | Phase PHASE3 | Vasculitis | COMPLETED | NCT01663623 |
| Placebo | Other | Phase PHASE3 | Vasculitis | COMPLETED | NCT01663623 |
| Azathioprine | Other | Phase PHASE3 | Vasculitis | COMPLETED | NCT01663623 |
| Belimumab 10 mg/kg | Other | Phase PHASE3 | Vasculitis | COMPLETED | NCT01663623 |
| Placebo | Other | Phase PHASE3 | Vasculitis | COMPLETED | NCT01663623 |
| Ondansetron Oral Disintegrating Tablet | Other | Approved | Gastroenteritis | COMPLETED | NCT00120744 |
| Ondansetron Oral Disintegrating Tablet | Other | Approved | Gastroenteritis | COMPLETED | NCT00120744 |
| Metformin | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00679939 |
| Rosiglitazone | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00679939 |
| Fosamprenavir | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus I | COMPLETED | NCT00094523 |
| Primaquine 15mg (Part2 ) | Other | Phase PHASE2 | Malaria, Vivax | COMPLETED | NCT01376167 |
| Tafenoquine 300mg (Part 2) | Other | Phase PHASE2 | Malaria, Vivax | COMPLETED | NCT01376167 |
| Chloroquine 300mg (Part 2 ) | Other | Phase PHASE2 | Malaria, Vivax | COMPLETED | NCT01376167 |
| Chloroquine 600mg (Part 2 ) | Other | Phase PHASE2 | Malaria, Vivax | COMPLETED | NCT01376167 |
| Primaquine 15mg | Other | Phase PHASE2 | Malaria, Vivax | COMPLETED | NCT01376167 |
| Tafenoquine 600mg | Other | Phase PHASE2 | Malaria, Vivax | COMPLETED | NCT01376167 |
| Tafenoquine 300mg | Other | Phase PHASE2 | Malaria, Vivax | COMPLETED | NCT01376167 |
| Tafenoquine 100mg | Other | Phase PHASE2 | Malaria, Vivax | COMPLETED | NCT01376167 |
| Tafenoquine 50mg | Other | Phase PHASE2 | Malaria, Vivax | COMPLETED | NCT01376167 |
| Chloroquine 300mg | Other | Phase PHASE2 | Malaria, Vivax | COMPLETED | NCT01376167 |
| Chloroquine 600mg | Other | Phase PHASE2 | Malaria, Vivax | COMPLETED | NCT01376167 |
| Primaquine 15mg (Part2 ) | Other | Phase PHASE2 | Malaria, Vivax | COMPLETED | NCT01376167 |
| Tafenoquine 300mg (Part 2) | Other | Phase PHASE2 | Malaria, Vivax | COMPLETED | NCT01376167 |
| Chloroquine 300mg (Part 2 ) | Other | Phase PHASE2 | Malaria, Vivax | COMPLETED | NCT01376167 |
| Chloroquine 600mg (Part 2 ) | Other | Phase PHASE2 | Malaria, Vivax | COMPLETED | NCT01376167 |
| Primaquine 15mg | Other | Phase PHASE2 | Malaria, Vivax | COMPLETED | NCT01376167 |
| Tafenoquine 600mg | Other | Phase PHASE2 | Malaria, Vivax | COMPLETED | NCT01376167 |
| Tafenoquine 300mg | Other | Phase PHASE2 | Malaria, Vivax | COMPLETED | NCT01376167 |
| Tafenoquine 100mg | Other | Phase PHASE2 | Malaria, Vivax | COMPLETED | NCT01376167 |
| Tafenoquine 50mg | Other | Phase PHASE2 | Malaria, Vivax | COMPLETED | NCT01376167 |
| Chloroquine 300mg | Other | Phase PHASE2 | Malaria, Vivax | COMPLETED | NCT01376167 |
| Chloroquine 600mg | Other | Phase PHASE2 | Malaria, Vivax | COMPLETED | NCT01376167 |
| Boostrix | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT02052596 |
| Herpes Zoster vaccine GSK 1437173A | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT02052596 |
| Pazopanib | Other | Phase PHASE2 | Renal Cell Carcinoma | COMPLETED | NCT01361113 |
| Ofatumumab | Other | Phase PHASE2 | Richter's Syndrome | COMPLETED | NCT01171378 |
| Treximet 85Mg-500Mg Tablet | Other | Phase PHASE4 | Workplace Migraine Treatment | COMPLETED | NCT01086358 |
| Triptan | Other | Phase PHASE4 | Workplace Migraine Treatment | COMPLETED | NCT01086358 |
| GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT01954251 |
| Herpes Zoster vaccine GSK 1437173A | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT01954251 |
| Placebo once-daily | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01316887 |
| 125mcg once-daily GSK573719 | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01316887 |
| 125/25 mcg once-daily GSK573719/GW642444 | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01316887 |
| Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine | Other | Phase PHASE2 | Virus Diseases | COMPLETED | NCT02548078 |
| GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A) | Other | Phase PHASE2 | Virus Diseases | COMPLETED | NCT02548078 |
| Ofatumumab/HDMP | Other | Phase PHASE2 | CLL | COMPLETED | NCT01191190 |
| Ofatumumab/HDMP | Other | Phase PHASE2 | CLL | COMPLETED | NCT01191190 |
| Pneumococcal vaccine GSK1024850A | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00758264 |
| Meningococcal vaccine GSK134612 | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00758264 |
| Calcipotriene 0.005% Foam | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT01563068 |
| placebo | Other | Approved | Metabolic Syndrome | COMPLETED | NCT00579436 |
| omega-3 fatty acid | Other | Approved | Metabolic Syndrome | COMPLETED | NCT00579436 |
| placebo | Other | Approved | Metabolic Syndrome | COMPLETED | NCT00579436 |
| omega-3 fatty acid | Other | Approved | Metabolic Syndrome | COMPLETED | NCT00579436 |
| Marketed scopolamine patch | Other | Phase PHASE1 | Motion Sickness | COMPLETED | NCT02839135 |
| Reformulated scopolamine patch | Other | Phase PHASE1 | Motion Sickness | COMPLETED | NCT02839135 |
| Placebo | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00997620 |
| Fluticasone furoate Nasal Spray 110 mcg | Other | Phase PHASE4 | Seasonal Allergic Rhinitis | COMPLETED | NCT00997620 |
| Placebo | Other | Phase PHASE2 | AIDS | COMPLETED | NCT01218113 |
| GSK Biologicals HIV Vaccine 732462 | Other | Phase PHASE2 | AIDS | COMPLETED | NCT01218113 |
| Placebo | Other | Phase PHASE2 | AIDS | COMPLETED | NCT01218113 |
| GSK Biologicals HIV Vaccine 732462 | Other | Phase PHASE2 | AIDS | COMPLETED | NCT01218113 |
| Negative Control | Other | Approved | Denture Retention | COMPLETED | NCT02937870 |
| Reference Product | Other | Approved | Denture Retention | COMPLETED | NCT02937870 |
| Test Product 2 | Other | Approved | Denture Retention | COMPLETED | NCT02937870 |
| Test Product 1 | Other | Approved | Denture Retention | COMPLETED | NCT02937870 |
| GSK2586184 single dose taken without food | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT01687309 |
| GSK2586184 single dose taken with food | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT01687309 |
| Placebo-to-match GSK2586184 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT01687309 |
| GSK2586184 800mg single and repeat dose | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT01687309 |
| Palbociclib | Other | Phase PHASE1 | Cancer | COMPLETED | NCT02065063 |
| Trametinib | Other | Phase PHASE1 | Cancer | COMPLETED | NCT02065063 |
| Data collection | Other | Preclinical | Herpes Zoster | COMPLETED | NCT01873365 |
| Data collection | Other | Preclinical | Herpes Zoster | COMPLETED | NCT01873365 |
| Routine sample collection | Other | Preclinical | Influenza | TERMINATED | NCT01171157 |
| Meningitec™ | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT00427908 |
| Mencevax™ ACWY | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT00427908 |
| GSK Biolgicals' meningococcal vaccine 134612 (Nimenrix) | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT00427908 |
| Influsplit Tetra™ vaccine produced by licensed process (LP) | Other | Phase PHASE3 | Influenza | COMPLETED | NCT02207413 |
| Influsplit Tetra™ vaccine produced by investigational process (IP) | Other | Phase PHASE3 | Influenza | COMPLETED | NCT02207413 |
| Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine | Other | Phase PHASE3 | Rubella | COMPLETED | NCT02058563 |
| Priorix® | Other | Phase PHASE3 | Rubella | COMPLETED | NCT02058563 |
| Engerix™-B Kinder | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT02052661 |
| Standard therapy | Drug | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT01484496 |
| Belimumab 200 mg SC | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT01484496 |
| Placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT01484496 |
| Standard therapy | Drug | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT01484496 |
| Belimumab 200 mg SC | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT01484496 |
| Placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT01484496 |
| Poliorix™ | Other | Phase PHASE3 | Acellular Pertussis | COMPLETED | NCT01449812 |
| Infanrix+Hib™ | Other | Phase PHASE3 | Acellular Pertussis | COMPLETED | NCT01449812 |
| Pegfilgrastim | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01385228 |
| Prednisone | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01385228 |
| Docetaxel | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01385228 |
| Pazopanib | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01385228 |
| Pegfilgrastim | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01385228 |
| Prednisone | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01385228 |
| Docetaxel | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01385228 |
| Pazopanib | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01385228 |
| BoostrixTM Polio | Other | Phase PHASE4 | Acellular Pertussis | COMPLETED | NCT01323959 |
| Poliorix™ | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT01086423 |
| Infanrix Hib™ | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT01086423 |
| Infanrix-IPV/Hib™ | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT01086423 |
| Menjugate | Other | Phase PHASE2 | Tetanus | TERMINATED | NCT00871741 |
| Infanrix hexa | Other | Phase PHASE2 | Tetanus | TERMINATED | NCT00871741 |
| GSK2202083A vaccine | Other | Phase PHASE2 | Tetanus | TERMINATED | NCT00871741 |
| Menjugate | Other | Phase PHASE2 | Tetanus | TERMINATED | NCT00871741 |
| Infanrix hexa | Other | Phase PHASE2 | Tetanus | TERMINATED | NCT00871741 |
| GSK2202083A vaccine | Other | Phase PHASE2 | Tetanus | TERMINATED | NCT00871741 |
| Menjugate™ | Other | Phase PHASE2 | Neisseria Meningitidis | COMPLETED | NCT00871338 |
| Pediacel™ | Other | Phase PHASE2 | Neisseria Meningitidis | COMPLETED | NCT00871338 |
| Menitorix™ | Other | Phase PHASE2 | Neisseria Meningitidis | COMPLETED | NCT00871338 |
| Prevenar™ | Other | Phase PHASE2 | Neisseria Meningitidis | COMPLETED | NCT00871338 |
| GSK2197870A | Other | Phase PHASE2 | Neisseria Meningitidis | COMPLETED | NCT00871338 |
| Tetravac TM | Other | Phase PHASE3 | Acellular Pertussis | COMPLETED | NCT00871000 |
| Priorix Tetra TM 208136 | Other | Phase PHASE3 | Acellular Pertussis | COMPLETED | NCT00871000 |
| Boostrix Polio™ 711866 | Other | Phase PHASE3 | Acellular Pertussis | COMPLETED | NCT00871000 |
| Hiberix™ | Other | Phase PHASE3 | Acellular Pertussis | COMPLETED | NCT00696423 |
| Infanrix™ | Other | Phase PHASE3 | Acellular Pertussis | COMPLETED | NCT00696423 |
| Boostrix-Polio | Other | Phase PHASE4 | Poliomyelitis | COMPLETED | NCT00635128 |
| Infanrix Hexa | Other | Phase PHASE2 | Acellular Pertussis | COMPLETED | NCT00627458 |
| Hiberix | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT00412854 |
| Infanrix | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT00412854 |
| Infanrix™/Hib | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT00412854 |
| Hiberix | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT00412854 |
| Infanrix | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT00412854 |
| Infanrix™/Hib | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT00412854 |
| Ibandronate (SB743830HD) | Other | Phase PHASE4 | Osteoporosis, Postmenopausal | COMPLETED | NCT00405392 |
| DTPa-IPV/Hib vaccine | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00325143 |
| DTPa-HBV-IPV/Hib | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00325143 |
| Mencevax™ ACW | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00317109 |
| Hiberix™ | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00317109 |
| Tritanrix™- HepB | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00317109 |
| Mencevax™ ACWY | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00291343 |
| Hiberix™ | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00291343 |
| Tritanrix™- HepB | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00291343 |
| Tritanrix™-HepB Kft | Other | Phase PHASE3 | Whole Cell Pertussis | COMPLETED | NCT00169442 |
| Polyribosil-Ribitol-Phosphate (PRP) vaccine | Other | Phase PHASE3 | Whole Cell Pertussis | COMPLETED | NCT00169442 |
| Hiberix™ | Other | Phase PHASE3 | Whole Cell Pertussis | COMPLETED | NCT00169442 |
| Tritanrix™-HepB/Hiberix™ | Other | Phase PHASE3 | Whole Cell Pertussis | COMPLETED | NCT00169442 |
| Tritanrix™-HepB/Hiberix™ Kft. | Other | Phase PHASE3 | Whole Cell Pertussis | COMPLETED | NCT00169442 |
| acyclovir | Other | Phase PHASE4 | Genital Herpes | COMPLETED | NCT00527618 |
| valacyclovir | Other | Phase PHASE4 | Genital Herpes | COMPLETED | NCT00527618 |
| GSK233705 | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00376714 |
| rhEPO | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT01977482 |
| Placebo | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT01977482 |
| GSK1278863 | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT01977482 |
| rhEPO | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT01977482 |
| Placebo | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT01977482 |
| GSK1278863 | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT01977482 |
| Varilrix™ | Other | Phase PHASE3 | Varicella | COMPLETED | NCT00969436 |
| Priorix™ | Other | Phase PHASE3 | Varicella | COMPLETED | NCT00969436 |
| GSK Biological's investigational MMRV vaccine 208136 | Other | Phase PHASE3 | Varicella | COMPLETED | NCT00969436 |
| Priorix-Tetra® | Other | Phase PHASE3 | Measles | COMPLETED | NCT00751348 |
| VarilrixTM | Other | Phase PHASE3 | Measles | COMPLETED | NCT00751348 |
| PriorixTM | Other | Phase PHASE3 | Measles | COMPLETED | NCT00751348 |
| GSK Biologicals' trivalent influenza vaccine | Other | Phase PHASE1 | Influenza | COMPLETED | NCT00714285 |
| GSK Biologicals' quadrivalent influenza vaccine | Other | Phase PHASE1 | Influenza | COMPLETED | NCT00714285 |
| Fluarix | Other | Phase PHASE1 | Influenza | COMPLETED | NCT00693706 |
| Trivalent influenza vaccine GSK 138842A | Other | Phase PHASE1 | Influenza | COMPLETED | NCT00693706 |
| GSK Biologicals' Hiberix™ | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00680914 |
| Prevenar | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00680914 |
| Pneumococcal vaccine GSK1024850A (Synflorix) | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00680914 |
| Thiomersal reduced FluAS25 adjuvanted vaccine (GSK576389A) | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00633074 |
| Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A) | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00633074 |
| Thiomersal reduced FluAS25 adjuvanted vaccine (GSK576389A) | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00633074 |
| Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A) | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00633074 |
| Varilrix (inactivated varicella vaccine) | Other | Phase PHASE2 | Varicella | COMPLETED | NCT00568334 |
| Fluarix | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00540592 |
| GlaxoSmithKline Biologicals' influenza vaccine GSK576389A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00540592 |
| GSK Bio's Influenza Vaccine GSK576389A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00538213 |
| Fluarix™ | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00538213 |
| Rotarix | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT00533507 |
| Infanrix hexa | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT00533507 |
| Synflorix | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT00533507 |
| Fluarix [NH 2007/08 season] | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00532298 |
| Fluarix [NH 2006/07 season] | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00532298 |
| GSK Bio's influenza vaccine GSK576389A [NH 2007/08 season] | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00532298 |
| GSK Bio's influenza vaccine GSK576389A [NH 2006/07 season] | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00532298 |
| Twinrix | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00465816 |
| Nimenrix (Meningococcal vaccine 134612) | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00465816 |
| Mencevax™ ACWY | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00464815 |
| Meningococcal vaccine GSK134612 | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00464815 |
| FluarixTM | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00385840 |
| Influenza Vaccine GSK1247446A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00385840 |
| Fluzone | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00383123 |
| Fluarix™ | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00383123 |
| GSK1247446A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00374842 |
| Fluarix™ | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00374842 |
| GSK1247446A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00374842 |
| Fluarix™ | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00374842 |
| Fluarix™ | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00363077 |
| GSK1247446A Group | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00363077 |
| Fluarix TM | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00321763 |
| Candidate Influenza Vaccine GSK1247446A - 3 different formulations | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00321763 |
| FluarixTM | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00321373 |
| Candidate Influenza Vaccine GSK1247446A - 2 different formulations | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00321373 |
| FluarixTM | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00321373 |
| Candidate Influenza Vaccine GSK1247446A - 2 different formulations | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00321373 |
| FluarixTM | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00321373 |
| Candidate Influenza Vaccine GSK1247446A - 2 different formulations | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00321373 |
| Mencevax ACWY | Other | Phase PHASE4 | Infections, Meningococcal | COMPLETED | NCT00290329 |
| Mencevax™ACWY | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT00196976 |
| Meningitec™ | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT00196976 |
| DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™) | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT00196976 |
| DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib) | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT00196976 |
| Conjugated meningococcal ACWY-TT (vaccine) | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT00196976 |
| Placebo | Other | Phase PHASE1 | Influenza | COMPLETED | NCT01659086 |
| Investigational H9N2 vaccine GSK2654909A | Other | Phase PHASE1 | Influenza | COMPLETED | NCT01659086 |
| Investigational H9N2 vaccine GSK2654911A | Other | Phase PHASE1 | Influenza | COMPLETED | NCT01659086 |
| Immunotherapeutic GSK2302032A, different formulations | Other | Phase PHASE1 | Lung Cancer, Non-Small Cell | TERMINATED | NCT01159964 |
| Placebo vaccine | Other | Phase PHASE1 | AIDS | COMPLETED | NCT00814762 |
| HIV Vaccine 732462 | Other | Phase PHASE1 | AIDS | COMPLETED | NCT00814762 |
| Placebo | Other | Phase PHASE2 | Common Cold | COMPLETED | NCT03005067 |
| Carbomer 980 (1146A) | Other | Phase PHASE2 | Common Cold | COMPLETED | NCT03005067 |
| Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet | Other | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT02509104 |
| FDC capsule of dutasteride and tamsulosin | Other | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT02509104 |
| Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet | Other | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT02509104 |
| FDC capsule of dutasteride and tamsulosin | Other | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT02509104 |
| Treatment sequence C | Drug | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT02184585 |
| Treatment sequence B | Drug | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT02184585 |
| Treatment sequence A | Drug | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT02184585 |
| Aerochamber Plus spacer | Other | Phase PHASE1 | Asthma | COMPLETED | NCT02045953 |
| VENTOLIN Mini-Spacer | Other | Phase PHASE1 | Asthma | COMPLETED | NCT02045953 |
| Salbutamol MDI 100mcg with activated charcoal | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01984086 |
| Salbutamol MDI 100mcg without activated charcoal | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01984086 |
| Salbutamol Diskus 200mcg Blister with activated charcoal | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01984086 |
| Salbutamol Diskus 200mcg Blister without activated charcoal | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01984086 |
| Salbutamol Sulphate 250mcg UD-DPI Blister (selected from Part A) | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01984086 |
| Salbutamol Sulphate UD-DPI Blister (selected from Part A) | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01984086 |
| Salbutamol MDI 100mcg | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01984086 |
| Salbutamol Diskus 200mcg Blister | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01984086 |
| Salbutamol Sulphate 200mcg UD-DPI Blister(1% blend) | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01984086 |
| Salbutamol Sulphate 250mcg UD-DPI Blister(1.6% blend) | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01984086 |
| Salbutamol Sulphate 200mcg UD-DPI Blister(1.6% blend) | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01984086 |
| Salbutamol Sulphate 150mcg UD-DPI Blister(1.6% blend) | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01984086 |
| Dutasteride and Tamsulosin | Other | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT01957189 |
| GI198745 0.5 mg | Other | Phase PHASE1 | Alopecia | COMPLETED | NCT01929330 |
| GI198745 0.1 mg | Other | Phase PHASE1 | Alopecia | COMPLETED | NCT01929330 |
| Digoxin + Retigabine | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT01583036 |
| Digoxin Alone | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT01583036 |
| SERETIDE Diskus | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01540708 |
| SERETIDE Rotacaps | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01540708 |
| Harnal-D tablets without water (fasted state) | Other | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT01495026 |
| Harnal-D Tablets with water (fed state) | Other | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT01495026 |
| Harnal-D Tablets with water (fasted state) | Other | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT01495026 |
| Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fed state) | Other | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT01495026 |
| Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state) | Other | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT01495026 |
| Dutasteride (0.5mg, fed state) | Other | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT01495026 |
| Dutasteride (0.5mg, fasted state) | Other | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT01495026 |
| Harnal D Tablets and Harnal Capsules (both comprising 0.2 mg tamsulosin HCl) | Other | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT01471678 |
| FDC product of dutasteride (0.5mg) and tamsulosin HCl (0.2mg) | Other | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT01471678 |
| Dutasteride (0.5mg) | Other | Phase PHASE1 | Prostatic Hyperplasia | COMPLETED | NCT01471678 |
| 400mg Ezogabine/retigabine | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT01462669 |
| 200mg Ezogabine/retigabine | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT01462669 |
| 100mg Ezogabine/retigabine | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT01462669 |
| 50mg Ezogabine/retigabine | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT01462669 |
| Investigational Medicinal Product (IR) | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT01332513 |
| Investigational Medicinal Product (MR5) | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT01332513 |
| Investigational Medicinal Product (MR4) | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT01332513 |
| Investigational Medicinal Product (MR3) | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT01332513 |
| Investigational Medicinal Product (MR2) | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT01332513 |
| Investigational Medicinal Product (MR1) | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT01332513 |
| This study is non-interventional study, so this section is not applicable. | Other | Preclinical | Neoplasms, Metastasis | COMPLETED | NCT01248897 |
| Paroxetine 50 milligrams tablet | Other | Phase PHASE1 | Depressive Disorder | COMPLETED | NCT00938184 |
| Paroxetine 25 milligrams tablet | Other | Phase PHASE1 | Depressive Disorder | COMPLETED | NCT00938184 |
| Paroxetine 12.5 milligrams tablet | Other | Phase PHASE1 | Depressive Disorder | COMPLETED | NCT00938184 |
| Ropinirole CR matching Placebo tablet | Other | Phase PHASE3 | Parkinson Disease | TERMINATED | NCT01929317 |
| Ropinirole CR 8mg tablet | Other | Phase PHASE3 | Parkinson Disease | TERMINATED | NCT01929317 |
| Ropinirole CR 2mg tablet | Other | Phase PHASE3 | Parkinson Disease | TERMINATED | NCT01929317 |
| Cetirizine Placebo | Other | Phase PHASE4 | Rhinitis, Allergic, Perennial and Seasonal | COMPLETED | NCT01916226 |
| Cetirizine | Other | Phase PHASE4 | Rhinitis, Allergic, Perennial and Seasonal | COMPLETED | NCT01916226 |
| FPNS Placebo | Other | Phase PHASE4 | Rhinitis, Allergic, Perennial and Seasonal | COMPLETED | NCT01916226 |
| FPNS | Other | Phase PHASE4 | Rhinitis, Allergic, Perennial and Seasonal | COMPLETED | NCT01916226 |
| Dutasteride 0.5 mg | Other | Phase PHASE3 | Alopecia | COMPLETED | NCT01831791 |
| Ipratropium | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01691482 |
| Albuterol/salbutamol | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01691482 |
| salbutamol | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01687296 |
| placebo tablet | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01687296 |
| placebo inhalation solution | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01687296 |
| oral prednisone | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01687296 |
| fluticasone propionate inhalation solution | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01687296 |
| Amoxil® 500mg/5mL powder for oral suspension | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT01431989 |
| Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT01431989 |
| Paxil CR 25 mg manufactured by GlaxoSmithKline Inc. - Mississauga - Canada | Other | Phase PHASE1 | Depressive Disorder | COMPLETED | NCT01339247 |
| Paxil CR 25 mg manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico | Other | Phase PHASE1 | Depressive Disorder | COMPLETED | NCT01339247 |
| Vehicle / Placebo | Other | Phase PHASE4 | Dermatitis, Chronic | COMPLETED | NCT01323673 |
| clobetasol propionate 0.05% | Other | Phase PHASE4 | Dermatitis, Chronic | COMPLETED | NCT01323673 |
| Reference formulation | Other | Phase PHASE1 | Depressive Disorder | COMPLETED | NCT01316926 |
| Test formulation | Other | Phase PHASE1 | Depressive Disorder | COMPLETED | NCT01316926 |
| Mineral water | Other | Approved | Dentin Sensitivity | COMPLETED | NCT02768194 |
| Sodium monofluorophosphate | Other | Approved | Dentin Sensitivity | COMPLETED | NCT02768194 |
| Stannous fluoride | Other | Approved | Dentin Sensitivity | COMPLETED | NCT02768194 |
| GSK2634673F | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT02052297 |
| GSK2634673F | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT02052297 |
| Cervarix TM | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00552279 |
| metoprolol succinate | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00273052 |
| Carvedilol Phosphate modified release formulation | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00273052 |
| metoprolol succinate | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00273052 |
| Carvedilol Phosphate modified release formulation | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00273052 |
| Boostrix | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT02753413 |
| RSV vaccine GSK3003891A | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT02753413 |
| Albuterol/salbutamol | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02799784 |
| TIO/OLO | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02799784 |
| UMEC/VI | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02799784 |
| Dolutegravir placebo twice daily | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT01568892 |
| Dolutegravir 50 mg twice daily | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT01568892 |
| Dolutegravir placebo twice daily | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT01568892 |
| Dolutegravir 50 mg twice daily | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT01568892 |
| Dolutegravir placebo twice daily | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT01568892 |
| Dolutegravir 50 mg twice daily | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT01568892 |
| Adefor dipivoxil | Other | Phase PHASE4 | Hepatitis B, Chronic | COMPLETED | NCT01205165 |
| DISKUS inhaler | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00355342 |
| Fluticasone Propionate/Salmeterol 250/50 mcg BID | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00355342 |
| Salmeterol 50 mcg BID | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00355342 |
| GSK523338 | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00256867 |
| Boostrix | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT02360475 |
| RSV vaccine GSK3003899A (formulation 3) | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT02360475 |
| RSV vaccine GSK3003898A (formulation 2) | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT02360475 |
| RSV vaccine GSK3003895A (formulation 1) | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT02360475 |
| Boostrix® | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT01755689 |
| Cervarix® | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT01755689 |
| Meningococcal vaccine GSK134612 | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT01755689 |
| Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine | Other | Phase PHASE2 | Malaria | COMPLETED | NCT00380393 |
| GSK malaria vaccine 257049 Vaccine | Other | Phase PHASE2 | Malaria | COMPLETED | NCT00380393 |
| Mencevax™ ACWY | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT00356369 |
| meningococcal ACWY (vaccine) | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT00356369 |
| Placebo | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00719043 |
| Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00719043 |
| A/turkey H5N1 vaccine | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00719043 |
| CervarixTM (GSK580299) | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT01418937 |
| CervarixTM (GSK580299) | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT01418937 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01053988 |
| GW642444 Inhalation Powder | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01053988 |
| FF Inhalation Powder | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01053988 |
| FF/GW642444 Inhalation Powder | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01053988 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01053988 |
| GW642444 Inhalation Powder | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01053988 |
| FF Inhalation Powder | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01053988 |
| FF/GW642444 Inhalation Powder | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01053988 |
| GSK923295 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00504790 |
| Adefovir dipivoxil (ADV) tablets | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT01300234 |
| Tenofovir disoproxil fumarate (TDF) tablets | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT01300234 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00937326 |
| SRT2104 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00937326 |
| Fluoride and Silica | Other | Phase PHASE1 | Gingivitis | WITHDRAWN | NCT01079910 |
| isopropylmethylphenol and Fluoride | Other | Phase PHASE1 | Gingivitis | WITHDRAWN | NCT01079910 |
| Fluoride and Silica | Other | Phase PHASE1 | Gingivitis | WITHDRAWN | NCT01079910 |
| isopropylmethylphenol and Fluoride | Other | Phase PHASE1 | Gingivitis | WITHDRAWN | NCT01079910 |
| Bottled mineral water | Other | Approved | Xerostomia | COMPLETED | NCT03005041 |
| Biotene mouthwash | Other | Approved | Xerostomia | COMPLETED | NCT03005041 |
| Tylenol® Caplets | Other | Approved | Pain | COMPLETED | NCT02504775 |
| Mejoral® 500 Tablets | Other | Approved | Pain | COMPLETED | NCT02504775 |
| Tylenol® Caplets | Other | Approved | Pain | COMPLETED | NCT02504775 |
| Mejoral® 500 Tablets | Other | Approved | Pain | COMPLETED | NCT02504775 |
| PedvaxHIB® | Other | Phase PHASE2 | Neisseria Meningitidis | COMPLETED | NCT00134719 |
| Varivax® | Other | Phase PHASE2 | Neisseria Meningitidis | COMPLETED | NCT00134719 |
| M-M-R®II | Other | Phase PHASE2 | Neisseria Meningitidis | COMPLETED | NCT00134719 |
| Meningitec® | Other | Phase PHASE2 | Neisseria Meningitidis | COMPLETED | NCT00134719 |
| ActHIB® | Other | Phase PHASE2 | Neisseria Meningitidis | COMPLETED | NCT00134719 |
| Prevenar® | Other | Phase PHASE2 | Neisseria Meningitidis | COMPLETED | NCT00134719 |
| Infanrix® Penta | Other | Phase PHASE2 | Neisseria Meningitidis | COMPLETED | NCT00134719 |
| MenHibrix (Hib-MenCY-TT) | Other | Phase PHASE2 | Neisseria Meningitidis | COMPLETED | NCT00134719 |
| GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine) | Other | Phase PHASE1 | Infections, Papillomavirus | COMPLETED | NCT00549900 |
| GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00426361 |
| Boostrix ® Polio | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00426361 |
| Boostrix TM | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00369824 |
| Menactra TM | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00369824 |
| Different formulations of GSK Biologicals' HPV vaccine (580299) | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00369824 |
| Data collection | Other | Preclinical | Infections, Papillomavirus | COMPLETED | NCT01101542 |
| Cervarix. | Other | Preclinical | Infections, Papillomavirus | COMPLETED | NCT01101542 |
| Placebo | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00319098 |
| Fluarix | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00319098 |
| Adjuvanted pandemic influenza candidate vaccine | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00319098 |
| Havrix™ | Other | Phase PHASE4 | Hepatitis A | COMPLETED | NCT00289757 |
| Prilosec (omeprazole) 40mg Delayed-Release capsule | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02453022 |
| Danirixin FB 50 mg IR Tablet | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02453022 |
| Danirixin HBr 50 mg IR Tablet | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02453022 |
| Placebo matching Moxifloxacin | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT02293148 |
| Placebo matching GSK1278863 | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT02293148 |
| Moxifloxacin 400 mg | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT02293148 |
| GSK1278863 500 mg | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT02293148 |
| GSK1278863 75 mg | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT02293148 |
| FF ELLIPTA DPI | Other | Phase PHASE1 | Asthma | COMPLETED | NCT02218723 |
| FF UD-DPI | Other | Phase PHASE1 | Asthma | COMPLETED | NCT02218723 |
| Placebo | Other | Phase PHASE1 | Cachexia | COMPLETED | NCT02045940 |
| GSK2881078 | Other | Phase PHASE1 | Cachexia | COMPLETED | NCT02045940 |
| Placebo | Other | Phase PHASE1 | Colitis, Ulcerative | COMPLETED | NCT01984047 |
| GSK3050002 | Other | Phase PHASE1 | Colitis, Ulcerative | COMPLETED | NCT01984047 |
| Placebo | Other | Phase PHASE1 | Colitis, Ulcerative | COMPLETED | NCT01984047 |
| GSK3050002 | Other | Phase PHASE1 | Colitis, Ulcerative | COMPLETED | NCT01984047 |
| Placebo | Other | Phase PHASE1 | Hepatitis C, Chronic | COMPLETED | NCT01879462 |
| GSK2878175 | Other | Phase PHASE1 | Hepatitis C, Chronic | COMPLETED | NCT01879462 |
| Placebo | Other | Phase PHASE1 | Hepatitis C, Chronic | COMPLETED | NCT01879462 |
| GSK2878175 | Other | Phase PHASE1 | Hepatitis C, Chronic | COMPLETED | NCT01879462 |
| GSK2315698 | Other | Phase PHASE1 | Amyloidosis | COMPLETED | NCT01777243 |
| GSK2398852 | Other | Phase PHASE1 | Amyloidosis | COMPLETED | NCT01777243 |
| GSK2315698 | Other | Phase PHASE1 | Amyloidosis | COMPLETED | NCT01777243 |
| GSK2398852 | Other | Phase PHASE1 | Amyloidosis | COMPLETED | NCT01777243 |
| therapeutic conventional surgery | Procedure | Phase PHASE2 | Estrogen Receptor-positive Breast Cancer | TERMINATED | NCT01394211 |
| pazopanib hydrochloride | Other | Phase PHASE2 | Estrogen Receptor-positive Breast Cancer | TERMINATED | NCT01394211 |
| anastrozole | Other | Phase PHASE2 | Estrogen Receptor-positive Breast Cancer | TERMINATED | NCT01394211 |
| Placebo | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT00708552 |
| Donepezil | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT00708552 |
| SB-742457 | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT00708552 |
| Sodium fluoride | Other | Phase PHASE2 | Oral Hygiene | COMPLETED | NCT02207400 |
| Sodium bicarbonate and sodium fluoride | Other | Phase PHASE2 | Oral Hygiene | COMPLETED | NCT02207400 |
| Data acquisition and analysis | Other | Preclinical | Neoplasms, Urinary Bladder | COMPLETED | NCT01706185 |
| Engerix™-B vaccine | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT01627340 |
| GSK Biologicals' Fluarix™ | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00772889 |
| Influenza vaccine GSK2186877A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00772889 |
| GSK Biologicals' Fluarix | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00765076 |
| GSK Biologicals' influenza vaccine GSK2186877A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00765076 |
| GSK Biologicals' Fluarix | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00765076 |
| GSK Biologicals' influenza vaccine GSK2186877A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00765076 |
| Fluzone | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00764790 |
| Fluarix | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00764790 |
| Influenza A (H5N1) Virus Monovalent Vaccine | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00695669 |
| VARIVAX® | Other | Phase PHASE3 | Hepatitis A | COMPLETED | NCT00197015 |
| M-M-R®II | Other | Phase PHASE3 | Hepatitis A | COMPLETED | NCT00197015 |
| Havrix® | Other | Phase PHASE3 | Hepatitis A | COMPLETED | NCT00197015 |
| Placebo DPI | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02567708 |
| GSK2269557 DPI | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02567708 |
| Placebo DPI | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02567708 |
| GSK2269557 DPI | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02567708 |
| NaCl Placebo | Other | Phase PHASE2 | Respiratory Disorders | COMPLETED | NCT02075541 |
| NTHi-10-AS01E | Other | Phase PHASE2 | Respiratory Disorders | COMPLETED | NCT02075541 |
| NaCl Placebo | Other | Phase PHASE2 | Respiratory Disorders | COMPLETED | NCT02075541 |
| NTHi-10-AS01E | Other | Phase PHASE2 | Respiratory Disorders | COMPLETED | NCT02075541 |
| Placebo | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT02058589 |
| Herpes Zoster vaccine GSK1437173A | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT02058589 |
| Placebo | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT02058589 |
| Herpes Zoster vaccine GSK1437173A | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT02058589 |
| Havrix™ | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01218308 |
| FluLaval® Quadrivalent | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01218308 |
| Saline placebo | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00985673 |
| Seasonal trivalent influenza vaccine (TIV) | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00985673 |
| GSK2340273A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00985673 |
| GSK2340274A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00985673 |
| I-131 Tositumomab therapeutic regimen | Other | Phase PHASE1 | Hodgkin's Disease | COMPLETED | NCT00484874 |
| Boostrix™ | Other | Phase PHASE3 | Diphtheria | COMPLETED | NCT01988857 |
| Pandemic influenza vaccine GSK1562902A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00652743 |
| Pandemic influenza vaccine GSK1562902A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00652743 |
| Mepolizumab | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01842607 |
| SC Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01691521 |
| IV Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01691521 |
| Mepolizumab SC | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01691521 |
| Mepolizumab IV | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01691521 |
| FLOVENT 250mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01462344 |
| FLOVENT 100mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01462344 |
| ADVAIR 250/50mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01462344 |
| ADVAIR 100/50mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01462344 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01313676 |
| vilanterol | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01313676 |
| fluticasone furoate | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01313676 |
| fluticasone furoate/vilanterol | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01313676 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01313650 |
| 25mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01313650 |
| 62.5mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01313650 |
| 62.5/25mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01313650 |
| Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV) | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT01171963 |
| Infanrix™ | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT01171963 |
| Placebo | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT01171963 |
| GSK Biologicals' liquid human rotavirus vaccine 444563 | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT01171963 |
| Placebo | Other | Phase PHASE3 | Parkinson Disease | COMPLETED | NCT01154166 |
| ReQuip PR | Other | Phase PHASE3 | Parkinson Disease | COMPLETED | NCT01154166 |
| Influenza vaccine GSK2340274A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00979407 |
| Influenza vaccine GSK2340272A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00979407 |
| Placebo | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT00963937 |
| Sumatriptan 50 mg | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT00963937 |
| Sumatriptan 25 mg | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT00963937 |
| Prevnar™ | Other | Phase PHASE3 | Hepatitis A | COMPLETED | NCT00197002 |
| GSK Biologicals 2-dose inactivated hepatitis A vaccine (Havrix) | Other | Phase PHASE3 | Hepatitis A | COMPLETED | NCT00197002 |
| GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) | Other | Phase PHASE1 | Leukaemia, Myelocytic, Acute | COMPLETED | NCT00725283 |
| Engerix-B | Other | Phase PHASE1 | Streptococcus Pneumoniae | COMPLETED | NCT00814489 |
| GSK2231395A | Other | Phase PHASE1 | Streptococcus Pneumoniae | COMPLETED | NCT00814489 |
| Fluarix-AS01E | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00318149 |
| Fluarix-AS01B | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00318149 |
| Fluarix-AS50 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00318149 |
| Fluarix-AS25 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00318149 |
| Fluarix | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00318149 |
| Fluarix-AS01E | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00318149 |
| Fluarix-AS01B | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00318149 |
| Fluarix-AS50 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00318149 |
| Fluarix-AS25 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00318149 |
| Fluarix | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00318149 |
| goserelin with bicalutamide and dutasteride and ketoconazole | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00298155 |
| goserelin with bicalutamide and dutasteride | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00298155 |
| goserelin with dutasteride | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00298155 |
| goserelin with bicalutamide and dutasteride and ketoconazole | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00298155 |
| goserelin with bicalutamide and dutasteride | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00298155 |
| goserelin with dutasteride | Other | Phase PHASE2 | Cancer | COMPLETED | NCT00298155 |
| Sodium monofluorophosphate (SMFP) | Other | Approved | Dentin Sensitivity | COMPLETED | NCT02861664 |
| Stannous fluoride (SnF2) | Other | Approved | Dentin Sensitivity | COMPLETED | NCT02861664 |
| Boostrix TM (previous syringe presentation) | Other | Phase PHASE4 | Diphtheria | COMPLETED | NCT01362322 |
| Boostrix TM (new syringe presentation) | Other | Phase PHASE4 | Diphtheria | COMPLETED | NCT01362322 |
| Dutasteride placebo | Other | Phase PHASE3 | Androgenetic Alopecia | COMPLETED | NCT01231607 |
| Finasteride placebo | Other | Phase PHASE3 | Androgenetic Alopecia | COMPLETED | NCT01231607 |
| 0.5mg dutasteride | Other | Phase PHASE3 | Androgenetic Alopecia | COMPLETED | NCT01231607 |
| 0.1mg dutasteride | Other | Phase PHASE3 | Androgenetic Alopecia | COMPLETED | NCT01231607 |
| 0.02mg dutasteride | Other | Phase PHASE3 | Androgenetic Alopecia | COMPLETED | NCT01231607 |
| 1mg Finasteride active | Other | Phase PHASE3 | Androgenetic Alopecia | COMPLETED | NCT01231607 |
| 323U66 SR 150 mg placebo tablet | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT01138007 |
| 323U66 SR 150 mg tablet | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT01138007 |
| Placebo | Other | Phase PHASE1 | Respiratory Syncytial Virus (RSV) | COMPLETED | NCT02298179 |
| RSV F subunit 135 μg MF59 adjuvant | Other | Phase PHASE1 | Respiratory Syncytial Virus (RSV) | COMPLETED | NCT02298179 |
| RSV F subunit 135 μg Aluminum hydroxide adjuvant | Other | Phase PHASE1 | Respiratory Syncytial Virus (RSV) | COMPLETED | NCT02298179 |
| RSV F subunit 135 μg No adjuvant | Other | Phase PHASE1 | Respiratory Syncytial Virus (RSV) | COMPLETED | NCT02298179 |
| RSV F subunit 90 μg MF59 adjuvant | Other | Phase PHASE1 | Respiratory Syncytial Virus (RSV) | COMPLETED | NCT02298179 |
| RSV F subunit 90 μg Aluminum hydroxide adjuvant | Other | Phase PHASE1 | Respiratory Syncytial Virus (RSV) | COMPLETED | NCT02298179 |
| RSV F subunit 90 μg No adjuvant | Other | Phase PHASE1 | Respiratory Syncytial Virus (RSV) | COMPLETED | NCT02298179 |
| RSV F subunit 45 μg MF59 adjuvant | Other | Phase PHASE1 | Respiratory Syncytial Virus (RSV) | COMPLETED | NCT02298179 |
| RSV F subunit 45 μg Aluminum hydroxide adjuvant | Other | Phase PHASE1 | Respiratory Syncytial Virus (RSV) | COMPLETED | NCT02298179 |
| RSV F subunit 45 μg No adjuvant | Other | Phase PHASE1 | Respiratory Syncytial Virus (RSV) | COMPLETED | NCT02298179 |
| Dolutegravir | Other | Preclinical | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02076386 |
| Dolutegravir | Other | Preclinical | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02076386 |
| Requip PR | Other | Phase PHASE3 | Parkinson Disease | COMPLETED | NCT01536574 |
| Requip PR | Other | Phase PHASE3 | Parkinson Disease | COMPLETED | NCT01536574 |
| lactose powder | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01400906 |
| 500 micrograms Fluticasone propionate | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01400906 |
| 100 micrograms Fluticasone propionate | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01400906 |
| Pharmacological Study | Other | Phase PHASE1 | BRAF Gene Mutation | TERMINATED | NCT01907802 |
| Pharmacogenomic Study | Other | Phase PHASE1 | BRAF Gene Mutation | TERMINATED | NCT01907802 |
| Laboratory Biomarker Analysis | Other | Phase PHASE1 | BRAF Gene Mutation | TERMINATED | NCT01907802 |
| Dabrafenib | Other | Phase PHASE1 | BRAF Gene Mutation | TERMINATED | NCT01907802 |
| Pharmacological Study | Other | Phase PHASE1 | BRAF Gene Mutation | TERMINATED | NCT01907802 |
| Pharmacogenomic Study | Other | Phase PHASE1 | BRAF Gene Mutation | TERMINATED | NCT01907802 |
| Laboratory Biomarker Analysis | Other | Phase PHASE1 | BRAF Gene Mutation | TERMINATED | NCT01907802 |
| Dabrafenib | Other | Phase PHASE1 | BRAF Gene Mutation | TERMINATED | NCT01907802 |
| Real-time data capture app | Other | Preclinical | Arthritis, Rheumatoid | COMPLETED | NCT03285191 |
| Numerical rating scale | Other | Preclinical | Arthritis, Rheumatoid | COMPLETED | NCT03285191 |
| Tritanrix/Hiberix vaccine | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00317187 |
| Tritanrix-HepB/Meningitec conjugate vaccine | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00317187 |
| Tritanrix/Hiberix vaccine | Other | Phase PHASE3 | Diphtheria | COMPLETED | NCT00317135 |
| Tritanrix-HepB/Meningitec conjugate vaccine | Other | Phase PHASE3 | Diphtheria | COMPLETED | NCT00317135 |
| Albuterol/salbutamol MDI | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02275052 |
| Placebo DPI | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02275052 |
| UMEC/VI DPI | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02275052 |
| Belimumab plus Late Vaccination | Other | Phase PHASE4 | Systemic Lupus Erythematosus | COMPLETED | NCT01597492 |
| Belimumab plus Early Vaccination | Other | Phase PHASE4 | Systemic Lupus Erythematosus | COMPLETED | NCT01597492 |
| Belimumab plus Late Vaccination | Other | Phase PHASE4 | Systemic Lupus Erythematosus | COMPLETED | NCT01597492 |
| Belimumab plus Early Vaccination | Other | Phase PHASE4 | Systemic Lupus Erythematosus | COMPLETED | NCT01597492 |
| Dutasteride 0.5mg oral tablets | Other | Phase PHASE3 | Alopecia | COMPLETED | NCT00441116 |
| Polio Sabin™ | Other | Phase PHASE2 | Malaria | COMPLETED | NCT00436007 |
| Stamaril™ | Other | Phase PHASE2 | Malaria | COMPLETED | NCT00436007 |
| Rouvax™ | Other | Phase PHASE2 | Malaria | COMPLETED | NCT00436007 |
| Tritanrix™ HepB/Hib | Other | Phase PHASE2 | Malaria | COMPLETED | NCT00436007 |
| GSK 257049 | Other | Phase PHASE2 | Malaria | COMPLETED | NCT00436007 |
| Work productivity and activity impairment questionnaire | Other | Approved | Asthma | COMPLETED | NCT02153346 |
| Valuation of lost productivity questionnaire | Other | Approved | Asthma | COMPLETED | NCT02153346 |
| VACV tablets (Adults or pediatrics) or granules (pediatrics) | Other | Phase PHASE3 | Herpes Simplex | COMPLETED | NCT01602562 |
| Meningitec | Other | Phase PHASE3 | Rubella | COMPLETED | NCT01506193 |
| PriorixTetra™ | Other | Phase PHASE3 | Rubella | COMPLETED | NCT01506193 |
| GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049) | Other | Phase PHASE3 | Malaria | COMPLETED | NCT01323972 |
| Engerix-BTM | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT01277042 |
| GSK580299 (CervarixTM) | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT01277042 |
| Placebo (saline) | Other | Phase PHASE2 | Influenza | COMPLETED | NCT01035749 |
| GSK Biologicals' Influenza investigational vaccine GSK2340273A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT01035749 |
| GSK Biologicals' Influenza investigational vaccine GSK2340274A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT01035749 |
| GSK Biologicals' Pandemic influenza (H1N1) candidate vaccine (GSK2340274A) | Other | Phase PHASE2 | Influenza | COMPLETED | NCT01001169 |
| Control | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00996125 |
| CervarixTM | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00996125 |
| Control | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00996125 |
| CervarixTM | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00996125 |
| Control | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00996125 |
| CervarixTM | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00996125 |
| Chloroquine | Other | Phase PHASE2 | AIDS | COMPLETED | NCT00972725 |
| GSK Biologicals' HIV vaccine (732461) | Other | Phase PHASE2 | AIDS | COMPLETED | NCT00972725 |
| Placebo | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00971425 |
| Fluarix™ | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00971425 |
| Pandemrix (GSK investigational influenza GSK2340272A vaccine) | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00971425 |
| Pneumococcal vaccine GSK2189242A (formulation 2) | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT00896064 |
| Pneumococcal vaccine GSK2189242A (formulation 1) | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT00896064 |
| Local OPV | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00829010 |
| Rotarix | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00829010 |
| measles | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00829010 |
| Tritanrix-HepB/Hib | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00829010 |
| Pneumococcal vaccine GSK1024850A | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00829010 |
| Rotarix | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00808444 |
| Infanrix-IPV/Hib | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00808444 |
| Infanrix hexa | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00808444 |
| Pneumococcal conjugate vaccine GSK1024850A (different lots) | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00808444 |
| Rotarix | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00808444 |
| Infanrix-IPV/Hib | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00808444 |
| Infanrix hexa | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00808444 |
| Pneumococcal conjugate vaccine GSK1024850A (different lots) | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00808444 |
| Fluarix | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00760617 |
| GSK Bio's influenza vaccine GSK2186877A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00760617 |
| Fluarix™ | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00706563 |
| Engerix B | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00652938 |
| HPV Vaccine (GSK580299) Cervarix TM | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00652938 |
| Engerix B | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00652938 |
| HPV Vaccine (GSK580299) Cervarix TM | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00652938 |
| Twinrix ™ Paediatric | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00578227 |
| Cervarix™ | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00578227 |
| Placebo | Other | Phase PHASE1 | Infections, Papillomavirus | COMPLETED | NCT00541970 |
| Cervarix | Other | Phase PHASE1 | Infections, Papillomavirus | COMPLETED | NCT00541970 |
| Engerix™-B Kinder | Other | Phase PHASE4 | Hepatitis B Vaccine | COMPLETED | NCT00519649 |
| Pandemrix ™ | Other | Phase PHASE1 | Influenza | COMPLETED | NCT00510874 |
| Pumarix™ | Other | Phase PHASE1 | Influenza | COMPLETED | NCT00510874 |
| Menactra™ | Other | Phase PHASE4 | Acellular Pertussis | COMPLETED | NCT00282295 |
| Boostrix® | Other | Phase PHASE4 | Acellular Pertussis | COMPLETED | NCT00282295 |
| Nurse case manager support | Other | Approved | COPD | COMPLETED | NCT02275078 |
| Telesystem-Phone self-assessment/reporting system | Other | Approved | COPD | COMPLETED | NCT02275078 |
| COPD self-management using an action plan | Other | Approved | COPD | COMPLETED | NCT02275078 |
| Engerix™-B Kinder | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT01847430 |
| Placebo | Other | Phase PHASE4 | Prostatic Hyperplasia | COMPLETED | NCT01777269 |
| Dutasteride plus tamsulosin | Other | Phase PHASE4 | Prostatic Hyperplasia | COMPLETED | NCT01777269 |
| Placebo | Other | Phase PHASE4 | Prostatic Hyperplasia | COMPLETED | NCT01777269 |
| Dutasteride plus tamsulosin | Other | Phase PHASE4 | Prostatic Hyperplasia | COMPLETED | NCT01777269 |
| Dutasteride/Tamsulosin | Other | Phase PHASE4 | Prostatic Hyperplasia | TERMINATED | NCT01673490 |
| Dutasteride/Tamsulosin | Other | Phase PHASE4 | Prostatic Hyperplasia | TERMINATED | NCT01673490 |
| tamsulosin | Other | Phase PHASE4 | Prostatic Hyperplasia | COMPLETED | NCT01294592 |
| Dutasteride plus tamsulosin | Other | Phase PHASE4 | Prostatic Hyperplasia | COMPLETED | NCT01294592 |
| GSK217744 | Other | Phase PHASE2 | Tetanus | COMPLETED | NCT01248884 |
| Prevenar 13® | Other | Phase PHASE2 | Tetanus | COMPLETED | NCT01248884 |
| Infanrix hexa™ | Other | Phase PHASE2 | Tetanus | COMPLETED | NCT01248884 |
| MencevaxACWY TM | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT01235975 |
| Meningococcal vaccine GSK 134612 | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT01235975 |
| Rotarix TM | Other | Phase PHASE4 | Infections, Rotavirus | COMPLETED | NCT01198769 |
| Boostrix™-US formulation | Other | Phase PHASE4 | Acellular Pertussis | COMPLETED | NCT01147900 |
| Boostrix™ | Other | Phase PHASE4 | Acellular Pertussis | COMPLETED | NCT01147900 |
| Engerix™-B | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT01138098 |
| Rotarix™ | Other | Phase PHASE2 | Tetanus | COMPLETED | NCT01090453 |
| Menjugate® | Other | Phase PHASE2 | Tetanus | COMPLETED | NCT01090453 |
| Infanrix hexa™ | Other | Phase PHASE2 | Tetanus | COMPLETED | NCT01090453 |
| Prevenar 13® | Other | Phase PHASE2 | Tetanus | COMPLETED | NCT01090453 |
| GSK2202083A vaccine | Other | Phase PHASE2 | Tetanus | COMPLETED | NCT01090453 |
| Rotarix™ | Other | Phase PHASE2 | Tetanus | COMPLETED | NCT01090453 |
| Menjugate® | Other | Phase PHASE2 | Tetanus | COMPLETED | NCT01090453 |
| Infanrix hexa™ | Other | Phase PHASE2 | Tetanus | COMPLETED | NCT01090453 |
| Prevenar 13® | Other | Phase PHASE2 | Tetanus | COMPLETED | NCT01090453 |
| GSK2202083A vaccine | Other | Phase PHASE2 | Tetanus | COMPLETED | NCT01090453 |
| Engerix™-B Kinder | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00984139 |
| Engerix™-B Kinder | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00984139 |
| Placebo | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00968890 |
| Fluarix™ | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00968890 |
| Pandemrix (Influenza vaccine GSK2340272A) | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00968890 |
| GSK investigational FluNG vaccine GSK2186877A, fresh lot | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00938392 |
| GSK investigational FluNG vaccine GSK2186877A, aged lot | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00938392 |
| Additional challenge dose | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00875485 |
| Blood sampling | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00875485 |
| GSK1562902A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00812981 |
| HBsAg (Booster injection) | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT00805389 |
| GSK Biologicals' Hepatitis B vaccines (GSK223192A) | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT00805389 |
| Fendrix™ | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT00805389 |
| Engerix-B™ | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT00805389 |
| HBsAg (Booster injection) | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT00805389 |
| GSK Biologicals' Hepatitis B vaccines (GSK223192A) | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT00805389 |
| Fendrix™ | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT00805389 |
| Engerix-B™ | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT00805389 |
| Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00742885 |
| GSK256066 | Other | Phase PHASE2 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00464568 |
| SB-705498 | Other | Phase PHASE2 | Irritable Colon | TERMINATED | NCT00461682 |
| Engerix TM | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00289744 |
| TWINRIX™ ADULT | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00289744 |
| ActHIB™ | Other | Phase PHASE3 | Hepatitis A | COMPLETED | NCT00197236 |
| Infanrix™ | Other | Phase PHASE3 | Hepatitis A | COMPLETED | NCT00197236 |
| Havrix™ | Other | Phase PHASE3 | Hepatitis A | COMPLETED | NCT00197236 |
| Twinrix™ Junior | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00197184 |
| Twinrix™ Adult | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00197184 |
| Engerix-B® | Other | Phase PHASE2 | Malaria | COMPLETED | NCT00197028 |
| TETRActHib™ | Other | Phase PHASE2 | Malaria | COMPLETED | NCT00197028 |
| RTS,S/AS02D | Other | Phase PHASE2 | Malaria | COMPLETED | NCT00197028 |
| Havrix™-based investigational formulation | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00122681 |
| Cervarix™ | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00122681 |
| Meningococcal ACWY Conjugate Vaccine, MenACWY | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT02106390 |
| Meningococcal group B Vaccine, rMenB+OMV NZ | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT02106390 |
| Merck and Company's Varivax | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT00871117 |
| Merck and Company's MMRII | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT00871117 |
| GSK Biologicals'Kinrix® | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT00871117 |
| Control vaccine with physiological saline | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT00707967 |
| Control vaccine with the adjuvant system. | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT00707967 |
| GSK's candidate Mycobacterium tuberculosis vaccine 692342 | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT00707967 |
| Control vaccine with physiological saline | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT00707967 |
| Control vaccine with the adjuvant system. | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT00707967 |
| GSK's candidate Mycobacterium tuberculosis vaccine 692342 | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT00707967 |
| GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 2 | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT00621322 |
| GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 1 | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT00621322 |
| GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 3 | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT00621322 |
| GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 2 | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT00621322 |
| GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 1 | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT00621322 |
| GSK Biologicals' AS01B adjuvant | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT00621322 |
| Meningitec™ | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00326118 |
| Hiberix™ | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00326118 |
| Priorix™ | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00326118 |
| Haemophilus influenzae type b and meningococcal serogroup C (vaccine) | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00326118 |
| Varivax | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00289783 |
| M-M-R II | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00289783 |
| Prevnar | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00289783 |
| Pediarix | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00289783 |
| PedvaxHIB | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00289783 |
| ActHIB | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00289783 |
| GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00289783 |
| Menomune | Other | Phase PHASE2 | Haemophilus Influenzae Type b | COMPLETED | NCT00129129 |
| Prevnar | Other | Phase PHASE2 | Haemophilus Influenzae Type b | COMPLETED | NCT00129129 |
| Pediarix | Other | Phase PHASE2 | Haemophilus Influenzae Type b | COMPLETED | NCT00129129 |
| ActHIB | Other | Phase PHASE2 | Haemophilus Influenzae Type b | COMPLETED | NCT00129129 |
| GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine | Other | Phase PHASE2 | Haemophilus Influenzae Type b | COMPLETED | NCT00129129 |
| Reference (Marketed) Denture Adhesive | Other | Approved | Denture Retention | COMPLETED | NCT02928380 |
| Experimental Denture Adhesive | Other | Approved | Denture Retention | COMPLETED | NCT02928380 |
| Fluoride toothpaste | Other | Approved | Dentin Sensitivity | COMPLETED | NCT02753075 |
| Placebo Oral Rinse | Other | Approved | Dentin Sensitivity | COMPLETED | NCT02753075 |
| Experimental Oral Rinse 2 | Other | Approved | Dentin Sensitivity | COMPLETED | NCT02753075 |
| Experimental Oral Rinse 1 | Other | Approved | Dentin Sensitivity | COMPLETED | NCT02753075 |
| stannous fluoride | Other | Approved | Dentin Sensitivity | COMPLETED | NCT02752958 |
| Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 ) | Other | Approved | Dentin Sensitivity | COMPLETED | NCT02651467 |
| Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5) | Other | Approved | Dentin Sensitivity | COMPLETED | NCT02651467 |
| Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0) | Other | Approved | Dentin Sensitivity | COMPLETED | NCT02651467 |
| Standard fluoride dentifrice | Other | Phase PHASE2 | Dentin Sensitivity | COMPLETED | NCT02226562 |
| Potassium nitrate and sodium fluoride | Other | Phase PHASE2 | Dentin Sensitivity | COMPLETED | NCT02226562 |
| Infanrix™ IPV | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00586612 |
| Prevenar™ | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00586612 |
| Infanrix™ penta | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00586612 |
| Menitorix™ | Other | Phase PHASE3 | Haemophilus Influenzae Type b | COMPLETED | NCT00586612 |
| Infanrix hexa ® | Other | Phase PHASE2 | Haemophilus Influenzae Type b | COMPLETED | NCT00129116 |
| Infanrix penta ® | Other | Phase PHASE2 | Haemophilus Influenzae Type b | COMPLETED | NCT00129116 |
| Menjugate ® | Other | Phase PHASE2 | Haemophilus Influenzae Type b | COMPLETED | NCT00129116 |
| Hib-MenC-TT vaccine | Other | Phase PHASE2 | Haemophilus Influenzae Type b | COMPLETED | NCT00129116 |
| Hib-MenCY-TT vaccine | Other | Phase PHASE2 | Haemophilus Influenzae Type b | COMPLETED | NCT00129116 |
| PRP (Polyribosyl Ribitol Phosphate) | Other | Phase PHASE2 | Haemophilus Influenzae Type b | COMPLETED | NCT00127855 |
| Mencevax® ACWY | Other | Phase PHASE2 | Haemophilus Influenzae Type b | COMPLETED | NCT00127855 |
| Prevenar® | Other | Phase PHASE2 | Haemophilus Influenzae Type b | COMPLETED | NCT00127855 |
| Infanrix® Penta | Other | Phase PHASE2 | Haemophilus Influenzae Type b | COMPLETED | NCT00127855 |
| ActHIB® | Other | Phase PHASE2 | Haemophilus Influenzae Type b | COMPLETED | NCT00127855 |
| Meningitec® | Other | Phase PHASE2 | Haemophilus Influenzae Type b | COMPLETED | NCT00127855 |
| Hib-MenCY-TT vaccine (MenHibrix) | Other | Phase PHASE2 | Haemophilus Influenzae Type b | COMPLETED | NCT00127855 |
| Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine | Other | Phase PHASE3 | Herpes Simplex Infection | COMPLETED | NCT00057330 |
| HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine | Other | Phase PHASE3 | Herpes Simplex Infection | COMPLETED | NCT00057330 |
| Placebo | Other | Phase PHASE4 | Pain | TERMINATED | NCT02974114 |
| Paracetamol | Other | Phase PHASE4 | Pain | TERMINATED | NCT02974114 |
| Paracetamol and caffeine | Other | Phase PHASE4 | Pain | TERMINATED | NCT02974114 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT02712047 |
| Vilanterol (VI) (25 mcg) | Other | Phase PHASE2 | Asthma | COMPLETED | NCT02712047 |
| Fluticasone furoate (FF) (100 mcg) | Other | Phase PHASE2 | Asthma | COMPLETED | NCT02712047 |
| Placebo (primary vaccination study) | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT00420316 |
| Rotarix (primary vaccination study) | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT00420316 |
| Placebo | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00984659 |
| Salmeterol | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00984659 |
| Fluticasone propionate/salmeterol combination product | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00984659 |
| Placebo | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00984659 |
| Salmeterol | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00984659 |
| Fluticasone propionate/salmeterol combination product | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT00984659 |
| Negative Control | Other | Approved | Denture Retention | COMPLETED | NCT03037307 |
| Positive Contol | Other | Approved | Denture Retention | COMPLETED | NCT03037307 |
| Test Product | Other | Approved | Denture Retention | COMPLETED | NCT03037307 |
| Placebo | Other | Phase PHASE1 | Autoimmune Diseases | WITHDRAWN | NCT02671188 |
| GSK3050002 | Other | Phase PHASE1 | Autoimmune Diseases | WITHDRAWN | NCT02671188 |
| Placebo | Other | Phase PHASE1 | Autoimmune Diseases | WITHDRAWN | NCT02671188 |
| GSK3050002 | Other | Phase PHASE1 | Autoimmune Diseases | WITHDRAWN | NCT02671188 |
| Placebo | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT02547974 |
| Formulation 3 (adjuvanted): NTHi/Mcat vaccine GSK3339036A | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT02547974 |
| Formulation 2 (adjuvanted): NTHi/Mcat vaccine GSK3277513A | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT02547974 |
| Formulation 1 (plain): NTHi/Mcat vaccine GSK3277513A | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT02547974 |
| Water | Other | Approved | Growth and Development | COMPLETED | NCT02428127 |
| Calorie matched beverage powder | Other | Approved | Growth and Development | COMPLETED | NCT02428127 |
| Carbohydrate beverage powder | Other | Approved | Growth and Development | COMPLETED | NCT02428127 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02105948 |
| Mepolizumab | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02105948 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02105948 |
| Mepolizumab | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02105948 |
| Fluticaosne Propionate 500mcg/Salmeterol 50mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01342913 |
| Fluticasone Furoate 100mcg/Vilanterol 25mcg | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01342913 |
| GW642444 Inhalation Powder | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01017952 |
| FF/GW642444 Inhalation Powder | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01017952 |
| Tykerb | Other | Phase PHASE1 | Neoplasms, Breast | COMPLETED | NCT00462956 |
| GW572016 oral tablets | Other | Phase PHASE1 | Neoplasms, Breast | COMPLETED | NCT00371488 |
| GW823093C C | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | TERMINATED | NCT00370942 |
| GW823093C B | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | TERMINATED | NCT00370942 |
| GW823093C A | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | TERMINATED | NCT00370942 |
| GW823093C C | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | TERMINATED | NCT00370942 |
| GW823093C B | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | TERMINATED | NCT00370942 |
| GW823093C A | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | TERMINATED | NCT00370942 |
| GW685698X Aqueous Nasal Spray | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00363740 |
| GW685698X Aqueous Nasal Spray | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00363740 |
| GW685698 | Other | Phase PHASE3 | Rhinitis, Allergic, Seasonal | COMPLETED | NCT00358475 |
| Havrix | Other | Phase PHASE4 | Hepatitis A | COMPLETED | NCT01000324 |
| Engerix-B | Other | Phase PHASE4 | Hepatitis A | COMPLETED | NCT01000324 |
| Blood sampling | Other | Phase PHASE4 | Hepatitis A | COMPLETED | NCT01000324 |
| lapatinib | Other | Phase PHASE1 | Prostate Cancer | TERMINATED | NCT00953576 |
| dutasteride | Other | Phase PHASE1 | Prostate Cancer | TERMINATED | NCT00953576 |
| hydrocortisone | Other | Phase PHASE1 | Prostate Cancer | TERMINATED | NCT00953576 |
| ketoconazole | Other | Phase PHASE1 | Prostate Cancer | TERMINATED | NCT00953576 |
| lapatinib | Other | Phase PHASE1 | Prostate Cancer | TERMINATED | NCT00953576 |
| dutasteride | Other | Phase PHASE1 | Prostate Cancer | TERMINATED | NCT00953576 |
| hydrocortisone | Other | Phase PHASE1 | Prostate Cancer | TERMINATED | NCT00953576 |
| ketoconazole | Other | Phase PHASE1 | Prostate Cancer | TERMINATED | NCT00953576 |
| Cervarix™ (HPV-16/18 L1 VLP AS04) | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00492544 |
| GW823093 30mg | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00372957 |
| GW823093 placebo capsule | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00372957 |
| GW823093 15mg | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00372957 |
| GW823093 30mg | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00372957 |
| GW823093 placebo capsule | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00372957 |
| GW823093 15mg | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00372957 |
| Sumatriptan Succinate | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT00356603 |
| Sumatriptan Succinate | Other | Phase PHASE3 | Migraine Disorders | COMPLETED | NCT00356603 |
| Fondaparinux | Other | Phase PHASE3 | Thromboembolism | COMPLETED | NCT00320424 |
| Fondaparinux | Other | Phase PHASE3 | Thrombosis, Venous | COMPLETED | NCT00320398 |
| Aimmugen™ | Other | Phase PHASE2 | Infections, Papillomavirus | COMPLETED | NCT00316693 |
| HPV-16/18 vaccine (Cervarix™) | Other | Phase PHASE2 | Infections, Papillomavirus | COMPLETED | NCT00316693 |
| Placebo | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT02497937 |
| GSK2798745 | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT02497937 |
| GSK Biologicals' - GSK2340272A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT01161160 |
| GSK Biologicals' GSK2340274A (two different formulations) | Other | Phase PHASE2 | Influenza | COMPLETED | NCT01161160 |
| 89Zr-GSK3128349 1 mg | Other | Phase PHASE1 | Drug-Related Side Effects and Adverse Reactions | COMPLETED | NCT02829307 |
| Fluzone® | Other | Phase PHASE2 | Influenza | COMPLETED | NCT01974895 |
| FluLaval® Quadrivalent | Other | Phase PHASE2 | Influenza | COMPLETED | NCT01974895 |
| Fluarix/Influsplit SSW® (2013-2014 season) | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01884519 |
| Fluviral™ | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01878825 |
| Fluarix/Influsplit Tetra® (2013-2014 season) | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01878812 |
| FLULAVAL® QUADRIVALENT | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01440387 |
| FLULAVAL® QUADRIVALENT | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01440387 |
| Havrix™ Junior | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01379937 |
| Havrix™ | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01379937 |
| Influenza vaccine GSK1562902A Formulation 2 | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01379937 |
| Influenza vaccine GSK1562902A Formulation 1 | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01379937 |
| HavrixTM Junior (in subjects of 15 years old or below) or HavrixTM (in subjects above 15 years old) | Other | Phase PHASE4 | Influenza | COMPLETED | NCT01190215 |
| FluarixTM | Other | Phase PHASE4 | Influenza | COMPLETED | NCT01190215 |
| HavrixTM Junior (in subjects of 15 years old or below) or HavrixTM (in subjects above 15 years old) | Other | Phase PHASE4 | Influenza | COMPLETED | NCT01190215 |
| FluarixTM | Other | Phase PHASE4 | Influenza | COMPLETED | NCT01190215 |
| Engerix™-B | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00524576 |
| Retapamulin | Other | Phase PHASE4 | Methicillin-resistant Staphylococcus Aureus | WITHDRAWN | NCT00856089 |
| [14C]-GSK3191607 | Other | Phase PHASE1 | Malaria, Falciparum | COMPLETED | NCT02737007 |
| Bupropion HCl XL tablet 300mg | Other | Phase PHASE1 | Depressive Disorder, Major | COMPLETED | NCT02698553 |
| Bupropion HCl XL tablet 150mg | Other | Phase PHASE1 | Depressive Disorder, Major | COMPLETED | NCT02698553 |
| Epelsiban | Other | Phase PHASE1 | Embryo Transfer | COMPLETED | NCT02257359 |
| Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule | Other | Phase PHASE1 | Urologic Diseases | COMPLETED | NCT02058576 |
| Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg | Other | Phase PHASE1 | Urologic Diseases | COMPLETED | NCT02058576 |
| Placebo capsule | Other | Phase PHASE1 | Bronchiectasis | TERMINATED | NCT02058407 |
| Placebo solution | Other | Phase PHASE1 | Bronchiectasis | TERMINATED | NCT02058407 |
| GSK2793660 capsule | Other | Phase PHASE1 | Bronchiectasis | TERMINATED | NCT02058407 |
| GSK2793660 solution | Other | Phase PHASE1 | Bronchiectasis | TERMINATED | NCT02058407 |
| Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule | Other | Phase PHASE1 | Urologic Diseases | COMPLETED | NCT02052713 |
| Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg | Other | Phase PHASE1 | Urologic Diseases | COMPLETED | NCT02052713 |
| Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule | Other | Phase PHASE1 | Urologic Diseases | COMPLETED | NCT02052713 |
| Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg | Other | Phase PHASE1 | Urologic Diseases | COMPLETED | NCT02052713 |
| Placebo | Other | Phase PHASE1 | Malaria | COMPLETED | NCT00675064 |
| GSK369796 | Other | Phase PHASE1 | Malaria | COMPLETED | NCT00675064 |
| Placebo | Other | Phase PHASE1 | Malaria | COMPLETED | NCT00675064 |
| GSK369796 | Other | Phase PHASE1 | Malaria | COMPLETED | NCT00675064 |
| Trametinib | Other | Phase PHASE1 | Cancer | WITHDRAWN | NCT02939846 |
| Trametinib | Other | Phase PHASE1 | Cancer | WITHDRAWN | NCT02939846 |
| Trametinib | Other | Phase PHASE1 | Melanoma | WITHDRAWN | NCT02447939 |
| Dabrafenib | Other | Phase PHASE1 | Melanoma | WITHDRAWN | NCT02447939 |
| Havrix® | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT01978093 |
| PedvaxHIB® | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT01978093 |
| Prevnar 13® | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT01978093 |
| Rotarix® | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT01978093 |
| Pediarix® | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT01978093 |
| Hib-MenCY-TT (MenHibrix®) | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT01978093 |
| Havrix® | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT01978093 |
| PedvaxHIB® | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT01978093 |
| Prevnar 13® | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT01978093 |
| Rotarix® | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT01978093 |
| Pediarix® | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT01978093 |
| Hib-MenCY-TT (MenHibrix®) | Other | Phase PHASE3 | Neisseria Meningitidis | COMPLETED | NCT01978093 |
| Treatment | Drug | Preclinical | Cancer | TERMINATED | NCT01357863 |
| Anti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer | Drug | Preclinical | Cancer | COMPLETED | NCT01064349 |
| Physiological saline | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT01262976 |
| GSK's investigational vaccine 692342 | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT01262976 |
| Eltrombopag oral tablets | Other | Phase PHASE3 | Idiopathic Thrombocytopenic Purpura | COMPLETED | NCT00828750 |
| capecitabine | Other | Phase PHASE2 | Metastatic Breast Cancer | COMPLETED | NCT00477464 |
| Lapatinib | Other | Phase PHASE2 | Metastatic Breast Cancer | COMPLETED | NCT00477464 |
| Engerix-B vaccine | Other | Phase PHASE2 | Infections, Papillomavirus | COMPLETED | NCT00309166 |
| Cervarix vaccine | Other | Phase PHASE2 | Infections, Papillomavirus | COMPLETED | NCT00309166 |
| GW786034 | Other | Phase PHASE2 | Peritoneal Cancer | COMPLETED | NCT00281632 |
| InfanrixTM | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT01153893 |
| Pneumococcal vaccine GSK1024850A | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT01153893 |
| Infanrix-IPV/Hib | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT01119625 |
| Pneumococcal vaccine GSK1024850A | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT01119625 |
| Infanrix-IPV/Hib | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT01119625 |
| Pneumococcal vaccine GSK1024850A | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT01119625 |
| GSK Biologicals' Hiberix™ | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00911144 |
| Wyeth-Lederle's Prevenar™ | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00911144 |
| GSK Biologicals' Synflorix™ (Pneumococcal vaccine GSK1024850A) | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00911144 |
| MenACWY-CRM (Menveo) | Other | Phase PHASE4 | Meningococcal Disease | COMPLETED | NCT01766206 |
| Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted | Other | Phase PHASE2 | Influenza | COMPLETED | NCT01416571 |
| Fluarix™ YB | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01198756 |
| Fluarix™ VB | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01198756 |
| Quadrivalent seasonal influenza vaccine GSK2282512A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01198756 |
| Influenza vaccine GSK2604409A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01196988 |
| FluarixTM | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01196988 |
| Influenza vaccine GSK2321138A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01196988 |
| Influenza vaccine GSK2604409A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01196988 |
| FluarixTM | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01196988 |
| Influenza vaccine GSK2321138A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01196988 |
| FluLavalTM-YB | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01196975 |
| FluLavalTM-VB | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01196975 |
| Quadrivalent seasonal influenza vaccine GSK2282512A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01196975 |
| GSK pandemic vaccine GSK2340272A | Other | Phase PHASE3 | Influenza | TERMINATED | NCT01014091 |
| FluarixTM | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00992784 |
| GSK investigational vaccine 2186877A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00992784 |
| Fluarix™ | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00985790 |
| Influenza vaccine GSK2321138A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00985790 |
| Fluarix™/Influsplit SSW® | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00920374 |
| Fluarix™/Influsplit SSW® | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00920374 |
| GSK A/turkey H5N1 Influenza vaccine | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00771615 |
| Pediarix® | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00614614 |
| ActHIB® | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00614614 |
| Infanrix® | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00614614 |
| GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix) | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00614614 |
| GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix) | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00614614 |
| Placebo | Other | Phase PHASE2 | Meningococcal Disease | COMPLETED | NCT02285777 |
| Meningococcal ABCWY | Other | Phase PHASE2 | Meningococcal Disease | COMPLETED | NCT02285777 |
| Fluarix | Other | Phase PHASE1 | Influenza | COMPLETED | NCT01096056 |
| Influenza vaccine GSK2186877A formulation 2 | Other | Phase PHASE1 | Influenza | COMPLETED | NCT01096056 |
| Influenza vaccine GSK2186877A formulation 1 | Other | Phase PHASE1 | Influenza | COMPLETED | NCT01096056 |
| Placebo nasal strip | Other | Phase PHASE2 | Congestion, Nasal | COMPLETED | NCT03549130 |
| Breathe Right Tan (small/medium) nasal strips | Other | Phase PHASE2 | Congestion, Nasal | COMPLETED | NCT03549130 |
| Placebo nasal strip | Other | Phase PHASE2 | Congestion, Nasal | COMPLETED | NCT03549130 |
| Breathe Right Tan (small/medium) nasal strips | Other | Phase PHASE2 | Congestion, Nasal | COMPLETED | NCT03549130 |
| Placebo nasal strip | Other | Phase PHASE2 | Congestion, Nasal | COMPLETED | NCT03549117 |
| Breathe Right Tan (small/medium) nasal strips | Other | Phase PHASE2 | Congestion, Nasal | COMPLETED | NCT03549117 |
| Water | Other | Approved | Xerostomia | COMPLETED | NCT03494985 |
| Biotene Moisturizing Mouth Spray | Other | Approved | Xerostomia | COMPLETED | NCT03494985 |
| Biotene Original Oral Rinse | Other | Approved | Xerostomia | COMPLETED | NCT03494985 |
| Experimental Oralbalance Moisturizing Gel | Other | Approved | Xerostomia | COMPLETED | NCT03494985 |
| Varilrix | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01439360 |
| Varivax/ProVarivax | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01439360 |
| Prevenar 13 | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01439360 |
| Havrix Junior | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01439360 |
| Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01439360 |
| Varilrix | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01439360 |
| Varivax/ProVarivax | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01439360 |
| Prevenar 13 | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01439360 |
| Havrix Junior | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01439360 |
| Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01439360 |
| ropinirole controlled release (CR)-RLS | Other | Phase PHASE2 | Restless Legs Syndrome | COMPLETED | NCT00530790 |
| lamictal | Other | Phase PHASE3 | Epilepsy | COMPLETED | NCT00395694 |
| Placebo | Other | Phase PHASE3 | Prostatic Hyperplasia | COMPLETED | NCT00368979 |
| Dutasteride | Other | Phase PHASE3 | Prostatic Hyperplasia | COMPLETED | NCT00368979 |
| Placebo capsule | Other | Phase PHASE2 | Oedema, Pulmonary | COMPLETED | NCT02119260 |
| Placebo suspension | Other | Phase PHASE2 | Oedema, Pulmonary | COMPLETED | NCT02119260 |
| Placebo solution | Other | Phase PHASE2 | Oedema, Pulmonary | COMPLETED | NCT02119260 |
| GSK2798745 capsule | Other | Phase PHASE2 | Oedema, Pulmonary | COMPLETED | NCT02119260 |
| GSK2798745 suspension | Other | Phase PHASE2 | Oedema, Pulmonary | COMPLETED | NCT02119260 |
| GSK2798745 solution | Other | Phase PHASE2 | Oedema, Pulmonary | COMPLETED | NCT02119260 |
| Placebo capsule | Other | Phase PHASE2 | Oedema, Pulmonary | COMPLETED | NCT02119260 |
| Placebo suspension | Other | Phase PHASE2 | Oedema, Pulmonary | COMPLETED | NCT02119260 |
| Placebo solution | Other | Phase PHASE2 | Oedema, Pulmonary | COMPLETED | NCT02119260 |
| GSK2798745 capsule | Other | Phase PHASE2 | Oedema, Pulmonary | COMPLETED | NCT02119260 |
| GSK2798745 suspension | Other | Phase PHASE2 | Oedema, Pulmonary | COMPLETED | NCT02119260 |
| GSK2798745 solution | Other | Phase PHASE2 | Oedema, Pulmonary | COMPLETED | NCT02119260 |
| Placebo capsule | Other | Phase PHASE2 | Oedema, Pulmonary | COMPLETED | NCT02119260 |
| Placebo suspension | Other | Phase PHASE2 | Oedema, Pulmonary | COMPLETED | NCT02119260 |
| Placebo solution | Other | Phase PHASE2 | Oedema, Pulmonary | COMPLETED | NCT02119260 |
| GSK2798745 capsule | Other | Phase PHASE2 | Oedema, Pulmonary | COMPLETED | NCT02119260 |
| GSK2798745 suspension | Other | Phase PHASE2 | Oedema, Pulmonary | COMPLETED | NCT02119260 |
| GSK2798745 solution | Other | Phase PHASE2 | Oedema, Pulmonary | COMPLETED | NCT02119260 |
| Ropinirole prolonged release/extended release(PR/XR) | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT00434304 |
| Placebo | Other | Phase PHASE1 | Amyloidosis | WITHDRAWN | NCT03567499 |
| GSK3039294 | Other | Phase PHASE1 | Amyloidosis | WITHDRAWN | NCT03567499 |
| Placebo | Other | Phase PHASE1 | Amyloidosis | WITHDRAWN | NCT03567499 |
| GSK3039294 | Other | Phase PHASE1 | Amyloidosis | WITHDRAWN | NCT03567499 |
| raltegravir Placebo | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus I | COMPLETED | NCT01227824 |
| TDF/FTC | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus I | COMPLETED | NCT01227824 |
| ABC/3TC | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus I | COMPLETED | NCT01227824 |
| GSK1349572 Placebo | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus I | COMPLETED | NCT01227824 |
| raltegravir | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus I | COMPLETED | NCT01227824 |
| GSK1349572 (dolutegravir) | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus I | COMPLETED | NCT01227824 |
| Prevnar® | Other | Phase PHASE2 | Varicella | COMPLETED | NCT00578175 |
| Havrix® | Other | Phase PHASE2 | Varicella | COMPLETED | NCT00578175 |
| ProQuad® | Other | Phase PHASE2 | Varicella | COMPLETED | NCT00578175 |
| Priorix-Tetra™ (MMRV vaccine 208136) | Other | Phase PHASE2 | Varicella | COMPLETED | NCT00578175 |
| Fluarix™ | Other | Phase PHASE4 | Influenza | COMPLETED | NCT00377611 |
| Fluarix™ | Other | Phase PHASE4 | Influenza | COMPLETED | NCT00377611 |
| umeclidinium bromide (UMEC) | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02164513 |
| vilanterol (VI) | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02164513 |
| fluticasone furoate (FF) | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02164513 |
| MVA-NSmut | Other | Phase PHASE1 | Hepatitis C Infection | COMPLETED | NCT02568332 |
| AdCh3NSmut1 | Other | Phase PHASE1 | Hepatitis C Infection | COMPLETED | NCT02568332 |
| Vehicle | Other | Phase PHASE2 | Hyperhidrosis | COMPLETED | NCT02563899 |
| Umeclidinium | Other | Phase PHASE2 | Hyperhidrosis | COMPLETED | NCT02563899 |
| Vehicle | Other | Phase PHASE2 | Hyperhidrosis | COMPLETED | NCT02563899 |
| Umeclidinium | Other | Phase PHASE2 | Hyperhidrosis | COMPLETED | NCT02563899 |
| PLACEBO | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02130635 |
| GSK2269557 500 MCG | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02130635 |
| GSK2269557 100 MCG | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02130635 |
| PLACEBO | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02130635 |
| GSK2269557 500 MCG | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02130635 |
| GSK2269557 100 MCG | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02130635 |
| rhEPO | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT01977573 |
| GSK1278863 | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT01977573 |
| rhEPO | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT01977573 |
| GSK1278863 | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT01977573 |
| Fluticasone propionate | Other | Phase PHASE4 | Skin Diseases | COMPLETED | NCT01915914 |
| Placebo | Other | Phase PHASE2 | Purpura, Thrombocytopaenic, Idiopathic | COMPLETED | NCT00908037 |
| eltrombopag | Other | Phase PHASE2 | Purpura, Thrombocytopaenic, Idiopathic | COMPLETED | NCT00908037 |
| Tap Water | Other | Approved | Denture Cleansers | COMPLETED | NCT03478644 |
| Experimental Denture Wipe | Other | Approved | Denture Cleansers | COMPLETED | NCT03478644 |
| Placebo (Formulation buffer S9b) | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | WITHDRAWN | NCT03191383 |
| RSV vaccine (GSK3003891A) formulation 3 | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | WITHDRAWN | NCT03191383 |
| RSV vaccine (GSK3003891A) formulation 2 | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | WITHDRAWN | NCT03191383 |
| RSV vaccine (GSK3003891A) formulation 1 | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | WITHDRAWN | NCT03191383 |
| Inhaler Preference Questionnaire Version 2 | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02786927 |
| Inhaler Preference Questionnaire Version 1 | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02786927 |
| Placebo capsules for use in HANDIHALER device | Device | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02786927 |
| Placebo ELLIPTA device | Device | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02786927 |
| Placebo to match oseltamivir | Other | Phase PHASE3 | Influenza, Human | COMPLETED | NCT01231620 |
| Oseltamivir | Other | Phase PHASE3 | Influenza, Human | COMPLETED | NCT01231620 |
| Placebo to match zanamivir | Other | Phase PHASE3 | Influenza, Human | COMPLETED | NCT01231620 |
| Zanamivir | Other | Phase PHASE3 | Influenza, Human | COMPLETED | NCT01231620 |
| Boosted Protease Inhibitor | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00449436 |
| Non-nucleoside reverse transcriptase inhibitor | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00449436 |
| TRIZIVIR | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00449436 |
| ACQ-6 | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT03707678 |
| eDairy | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT03707678 |
| Albuterol/Salbutamol | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT03707678 |
| FP-DPI | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT03707678 |
| Placebo | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT03707678 |
| GSK2245035 | Other | Phase PHASE2 | Asthma | WITHDRAWN | NCT03707678 |
| Real-time data capture app | Other | Preclinical | Osteoarthritis | COMPLETED | NCT03271203 |
| Michigan Hand Outcomes Questionnaire | Other | Preclinical | Osteoarthritis | COMPLETED | NCT03271203 |
| Placebo | Other | Phase PHASE2 | Atherosclerosis | COMPLETED | NCT00633022 |
| LOSMAPIMOD 7.5 MG | Other | Phase PHASE2 | Atherosclerosis | COMPLETED | NCT00633022 |
| Placebo | Other | Phase PHASE2 | Atherosclerosis | COMPLETED | NCT00633022 |
| LOSMAPIMOD 7.5 MG | Other | Phase PHASE2 | Atherosclerosis | COMPLETED | NCT00633022 |
| Herpes zoster vaccine GSK1437173A | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT01751165 |
| Herpes zoster vaccine GSK1437173A | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT01777321 |
| Herpes zoster vaccine GSK1437173A | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT01777321 |
| Sodium monofluorophosphate | Other | Phase PHASE4 | Dentin Sensitivity | COMPLETED | NCT02923895 |
| Stannous fluoride | Other | Phase PHASE4 | Dentin Sensitivity | COMPLETED | NCT02923895 |
| FluarixTM | Other | Phase PHASE4 | Influenza | COMPLETED | NCT00750360 |
| FluarixTM | Other | Phase PHASE4 | Influenza | COMPLETED | NCT00750360 |
| Gemcitabine-Pazopanib | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT01855724 |
| Gemcitabine-Pazopanib | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT01855724 |
| rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine) | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT02446743 |
| Rabies Vaccine | Other | Phase PHASE2 | Plasmodium Falciparum Malaria | COMPLETED | NCT00460525 |
| FMP2.1/AS02A | Other | Phase PHASE2 | Plasmodium Falciparum Malaria | COMPLETED | NCT00460525 |
| Placebo | Other | Phase PHASE2 | Dentin Sensitivity | COMPLETED | NCT03238352 |
| Sodium fluoride | Other | Phase PHASE2 | Dentin Sensitivity | COMPLETED | NCT03238352 |
| Potassium oxalate | Other | Phase PHASE2 | Dentin Sensitivity | COMPLETED | NCT03238352 |
| Retigabine (INN), Ezogabine (USAN) | Other | Phase PHASE3 | Epilepsy | TERMINATED | NCT00310388 |
| DEN vaccine F17 | Other | Phase PHASE1 | Dengue | COMPLETED | NCT01843621 |
| GSK investigational vaccine GSK2340269A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00951041 |
| GSK investigational vaccine GSK2340272A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00951041 |
| GSK investigational vaccine GSK2340269A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00951041 |
| GSK investigational vaccine GSK2340272A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00951041 |
| Falciparum Malaria Protein 11 with AS02A adjuvant | Other | Phase PHASE1 | Malaria | COMPLETED | NCT00312702 |
| Placebo | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00945282 |
| HAART | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00945282 |
| Lopinavir/ritonavir | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00945282 |
| GSK2248761 | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00945282 |
| Poliorix. | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00344318 |
| Polio Sabin. | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00344318 |
| Hiberix | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00344318 |
| Tritanrix-HepB | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00344318 |
| Prevenar | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00344318 |
| Pneumococcal conjugate vaccine GSK1024850A | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00344318 |
| Placebo (for Lamotrigine) | Other | Approved | Facial Neuropathy | COMPLETED | NCT00243152 |
| Lamotrigine | Other | Approved | Facial Neuropathy | COMPLETED | NCT00243152 |
| Poliorix | Other | Phase PHASE1 | Poliomyelitis | COMPLETED | NCT00937404 |
| Infanrix hexa | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00390910 |
| Pneumococcal conjugate vaccine GSK1024850A | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00390910 |
| Ciprofloxacin reference tablet | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT03150082 |
| GR37547 tablet | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT03150082 |
| Ciprofloxacin reference tablet | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT03150082 |
| GR37547 tablet | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT03150082 |
| Havrix | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT00513409 |
| Infanrix Hexa | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT00513409 |
| Synflorix | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT00513409 |
| Water | Other | Approved | Denture Cleansers | COMPLETED | NCT02780661 |
| Denture Cleanser Weekly Use Period | Other | Approved | Denture Cleansers | COMPLETED | NCT02780661 |
| Denture Cleanser Daily Use Period | Other | Approved | Denture Cleansers | COMPLETED | NCT02780661 |
| Quantitative Measure of Speech (Core Phase Only) | Other | Approved | Amyotrophic Lateral Sclerosis | COMPLETED | NCT02447952 |
| Fast Fix electrode patch | Other | Approved | Amyotrophic Lateral Sclerosis | COMPLETED | NCT02447952 |
| Faros Sensor (FS) and LifeInsight Hub | Other | Approved | Amyotrophic Lateral Sclerosis | COMPLETED | NCT02447952 |
| Test head to toe wash | Other | Approved | Skin Care | COMPLETED | NCT02403999 |
| Test bath foam | Other | Approved | Skin Care | COMPLETED | NCT02403999 |
| Test shampoo | Other | Approved | Skin Care | COMPLETED | NCT02403999 |
| Placebo | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT01777295 |
| EngerixTM-B | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT01777295 |
| Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A. | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT01777295 |
| Placebo | Other | Phase PHASE3 | Herpes Simplex | COMPLETED | NCT00224484 |
| Havrix (investigational formulation) | Other | Phase PHASE3 | Herpes Simplex | COMPLETED | NCT00224484 |
| GSK208141 | Other | Phase PHASE3 | Herpes Simplex | COMPLETED | NCT00224484 |
| 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP | Other | Phase PHASE2 | Oral Hygiene | COMPLETED | NCT03267511 |
| 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica | Other | Phase PHASE2 | Oral Hygiene | COMPLETED | NCT03267511 |
| 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP | Other | Phase PHASE2 | Oral Hygiene | COMPLETED | NCT03267511 |
| 5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica | Other | Phase PHASE2 | Oral Hygiene | COMPLETED | NCT03267511 |
| Placebo | Other | Phase PHASE2 | Urinary Bladder Neoplasms | TERMINATED | NCT01435356 |
| recMAGE-A3 + AS15 ASCI | Other | Phase PHASE2 | Urinary Bladder Neoplasms | TERMINATED | NCT01435356 |
| Placebo | Other | Phase PHASE2 | Urinary Bladder Neoplasms | TERMINATED | NCT01435356 |
| recMAGE-A3 + AS15 ASCI | Other | Phase PHASE2 | Urinary Bladder Neoplasms | TERMINATED | NCT01435356 |
| Formoterol Fumarate | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02446418 |
| Budesonide | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02446418 |
| Salmeterol | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02446418 |
| Fluticasone propionate | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02446418 |
| Vilanterol | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02446418 |
| Fluticasone Furoate | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02446418 |
| Prevenar (Wyeth) | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00547248 |
| Poliorix | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00547248 |
| Polio Sabin | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00547248 |
| Hiberix | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00547248 |
| Tritanrix-HepB | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00547248 |
| Synflorix | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00547248 |
| Subject file | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03465332 |
| Doctor's questionnaire | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03465332 |
| Placebo injection | Other | Phase PHASE1 | Infections, Bacterial | TERMINATED | NCT01818011 |
| GSK1322322 for injection | Other | Phase PHASE1 | Infections, Bacterial | TERMINATED | NCT01818011 |
| 13C-GSK1322322 stable isotope powder | Other | Phase PHASE1 | Infections, Bacterial | TERMINATED | NCT01818011 |
| Placebo tablets | Other | Phase PHASE1 | Infections, Bacterial | TERMINATED | NCT01818011 |
| GSK1322322 intended commercial tablets | Other | Phase PHASE1 | Infections, Bacterial | TERMINATED | NCT01818011 |
| GSK1322322 over granulated tablets | Other | Phase PHASE1 | Infections, Bacterial | TERMINATED | NCT01818011 |
| GSK1322322 Initial fit for purpose tablets | Other | Phase PHASE1 | Infections, Bacterial | TERMINATED | NCT01818011 |
| Infanrix IPV/Hib | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00345358 |
| Synflorix | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00345358 |
| Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis). | Other | Phase PHASE3 | Malaria | COMPLETED | NCT01148459 |
| Human Diploid Cell Vaccine (HDCV) or Purified Vero Cell Rabies Vaccine (PVRV, Verorab) (Aventis Pasteur); | Other | Phase PHASE3 | Malaria | COMPLETED | NCT01148459 |
| GSK Biological's Investigational Malaria Vaccine 257049 | Other | Phase PHASE3 | Malaria | COMPLETED | NCT01148459 |
| Influenza investigational vaccine GSK2340274A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00989612 |
| Placebo | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | WITHDRAWN | NCT03015519 |
| Albiglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | WITHDRAWN | NCT03015519 |
| Paracetamol. | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00496015 |
| Meningococcal vaccine GSK134612. | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00496015 |
| Infanrix hexa. | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00496015 |
| Pneumococcal conjugate vaccine GSK1024850A. | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00496015 |
| Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently) | Other | Phase PHASE1 | Hypertension, Pulmonary | COMPLETED | NCT02688387 |
| FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose | Other | Phase PHASE1 | Hypertension, Pulmonary | COMPLETED | NCT02688387 |
| PRFs | Other | Preclinical | Sjogren's Syndrome | COMPLETED | NCT03501420 |
| PSC questionnaire | Other | Preclinical | Sjogren's Syndrome | COMPLETED | NCT03501420 |
| Interview | Other | Preclinical | Sjogren's Syndrome | COMPLETED | NCT03501420 |
| Acetylcysteine 2% solution | Other | Phase PHASE1 | Infections, Respiratory Tract | COMPLETED | NCT02688361 |
| Fluimucil® 2% solution | Other | Phase PHASE1 | Infections, Respiratory Tract | COMPLETED | NCT02688361 |
| Acetylcysteine 2% solution | Other | Phase PHASE1 | Infections, Respiratory Tract | COMPLETED | NCT02688361 |
| Fluimucil® 2% solution | Other | Phase PHASE1 | Infections, Respiratory Tract | COMPLETED | NCT02688361 |
| inhaled corticosteroid with or without a long acting beta2-agonist | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01706198 |
| fluticasone furoate + vilanterol | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01706198 |
| inhaled corticosteroid with or without a long acting beta2-agonist | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01706198 |
| fluticasone furoate + vilanterol | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01706198 |
| Meningitec™ | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00508261 |
| Infanrix™ hexa | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00508261 |
| Meningococcal vaccine GSK134612 | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00508261 |
| Meningococcal conjugate vaccine GSK134612 | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT01777308 |
| 1 µg TDENV-PIV with AS01E1 adjuvant | Other | Phase PHASE1 | Dengue Fever | COMPLETED | NCT01666652 |
| 1 µg TDENV-PIV with Alum adjuvant | Other | Phase PHASE1 | Dengue Fever | COMPLETED | NCT01666652 |
| Phosphate buffered saline | Other | Phase PHASE1 | Dengue Fever | COMPLETED | NCT01666652 |
| 1 µg TDENV-PIV with AS03B1 adjuvant | Other | Phase PHASE1 | Dengue Fever | COMPLETED | NCT01666652 |
| 4 µg TDENV-PIV with Alum adjuvant | Other | Phase PHASE1 | Dengue Fever | COMPLETED | NCT01666652 |
| Health Insurance Database | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT00875641 |
| GSK investigational vaccine GSK2340272A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00992511 |
| lapatinib | Other | Phase PHASE2 | Neoplasms, Breast | COMPLETED | NCT00320411 |
| Havrix | Other | Phase PHASE4 | Hepatitis A | COMPLETED | NCT01037114 |
| Engerix-B | Other | Phase PHASE4 | Hepatitis A | COMPLETED | NCT01037114 |
| Blood sampling | Other | Phase PHASE4 | Hepatitis A | COMPLETED | NCT01037114 |
| bupropion hydrochloride | Other | Phase PHASE2 | Depressive Disorder | COMPLETED | NCT00135512 |
| bupropion hydrochloride | Other | Phase PHASE2 | Depressive Disorder | COMPLETED | NCT00135512 |
| Data Collection | Other | Preclinical | Hepatitis | COMPLETED | NCT03619590 |
| Data Collection | Other | Preclinical | Hepatitis | COMPLETED | NCT03619590 |
| Collection of clinical samples | Other | Phase PHASE3 | Varicella | COMPLETED | NCT00127608 |
| Telephonic interview | Other | Preclinical | Neoplasms | COMPLETED | NCT03336567 |
| Infanrix+Hib | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT01323647 |
| PoliorixTM | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT01323647 |
| Blood sample | Other | Phase PHASE4 | Diphtheria-Tetanus-Acellular Pertussis | TERMINATED | NCT03188458 |
| Saline Solution: Sodium Chloride (NaCl; 0.9%) | Other | Approved | Skin Care | COMPLETED | NCT03183518 |
| Facial micellar cleanser | Other | Approved | Skin Care | COMPLETED | NCT03183518 |
| Saline Solution: Sodium Chloride (NaCl; 0.9%) | Other | Approved | Skin Care | COMPLETED | NCT03175562 |
| Facial micellar cleanser | Other | Approved | Skin Care | COMPLETED | NCT03175562 |
| Placebos | Other | Phase PHASE4 | Depression | COMPLETED | NCT02989727 |
| Lamotrigine | Other | Phase PHASE4 | Depression | COMPLETED | NCT02989727 |
| Placebos | Other | Phase PHASE4 | Depression | COMPLETED | NCT02989727 |
| Lamotrigine | Other | Phase PHASE4 | Depression | COMPLETED | NCT02989727 |
| Tests | Other | Approved | Respiratory Disorders | COMPLETED | NCT01360398 |
| Data collection | Other | Approved | Respiratory Disorders | COMPLETED | NCT01360398 |
| End tidal breath sample | Other | Approved | Respiratory Disorders | COMPLETED | NCT01360398 |
| Urine sample | Other | Approved | Respiratory Disorders | COMPLETED | NCT01360398 |
| Nasopharyngeal swab | Other | Approved | Respiratory Disorders | COMPLETED | NCT01360398 |
| Sputum sample | Other | Approved | Respiratory Disorders | COMPLETED | NCT01360398 |
| Blood sample | Other | Approved | Respiratory Disorders | COMPLETED | NCT01360398 |
| Placebo | Other | Phase PHASE4 | Herpes Genitalis | COMPLETED | NCT00158860 |
| Valaciclovir | Other | Phase PHASE4 | Herpes Genitalis | COMPLETED | NCT00158860 |
| Placebo | Other | Phase PHASE4 | Herpes Genitalis | COMPLETED | NCT00158860 |
| Valaciclovir | Other | Phase PHASE4 | Herpes Genitalis | COMPLETED | NCT00158860 |
| MRI | Other | Approved | Pulmonary Arterial Hypertension | UNKNOWN | NCT03841344 |
| Boostrix | Other | Phase PHASE2 | Shigella Sonnei Infection | COMPLETED | NCT02676895 |
| Menveo | Other | Phase PHASE2 | Shigella Sonnei Infection | COMPLETED | NCT02676895 |
| GVGH S. sonnei (1790GAHB) vaccine 100 μg | Other | Phase PHASE2 | Shigella Sonnei Infection | COMPLETED | NCT02676895 |
| GVGH S. sonnei (1790GAHB) vaccine 25 μg | Other | Phase PHASE2 | Shigella Sonnei Infection | COMPLETED | NCT02676895 |
| Trametinib | Other | Phase PHASE2 | Melanoma | TERMINATED | NCT02314143 |
| Dabrafenib | Other | Phase PHASE2 | Melanoma | TERMINATED | NCT02314143 |
| Placebo | Other | Phase PHASE2 | Dengue | COMPLETED | NCT00239577 |
| Live attenuated tetravalent dengue vaccine | Other | Phase PHASE2 | Dengue | COMPLETED | NCT00239577 |
| Placebo | Other | Phase PHASE2 | Dengue | COMPLETED | NCT00239577 |
| Live attenuated tetravalent dengue vaccine | Other | Phase PHASE2 | Dengue | COMPLETED | NCT00239577 |
| Sunscreen (Reference Product) | Other | Approved | Skin Care | COMPLETED | NCT03103906 |
| Cleanser (Reference Product) | Other | Approved | Skin Care | COMPLETED | NCT03103906 |
| Cream (Test product) | Other | Approved | Skin Care | COMPLETED | NCT03103906 |
| Placebo | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | TERMINATED | NCT01195974 |
| GSK2248761 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | TERMINATED | NCT01195974 |
| YASMIN | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | TERMINATED | NCT01195974 |
| Dolutegravir + Lamivudine FDC Formulation 2 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT03078556 |
| Dolutegravir + Lamivudine FDC Formulation 1 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT03078556 |
| Lamivudine | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT03078556 |
| Dolutegravir | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT03078556 |
| 89Zr-GSK2849330 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT02345174 |
| GSK2849330 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT02345174 |
| 89Zr-GSK2849330 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT02345174 |
| GSK2849330 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT02345174 |
| SERETIDE Diskus | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01494610 |
| SERETIDE Rotacaps | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01494610 |
| Pre- and post-biopsy questionnaire | Other | Approved | Diabetes Mellitus, Type 1 | COMPLETED | NCT02801942 |
| Peripheral blood collection | Other | Approved | Diabetes Mellitus, Type 1 | COMPLETED | NCT02801942 |
| Inguinal lymph node core biopsy | Other | Approved | Diabetes Mellitus, Type 1 | COMPLETED | NCT02801942 |
| Inguinal lymph node fine needle aspirate biopsy | Other | Approved | Diabetes Mellitus, Type 1 | COMPLETED | NCT02801942 |
| Pre- and post-biopsy questionnaire | Other | Approved | Diabetes Mellitus, Type 1 | COMPLETED | NCT02801942 |
| Peripheral blood collection | Other | Approved | Diabetes Mellitus, Type 1 | COMPLETED | NCT02801942 |
| Inguinal lymph node core biopsy | Other | Approved | Diabetes Mellitus, Type 1 | COMPLETED | NCT02801942 |
| Inguinal lymph node fine needle aspirate biopsy | Other | Approved | Diabetes Mellitus, Type 1 | COMPLETED | NCT02801942 |
| Gadobutrol | Other | Phase PHASE1 | Heart Failure, Congestive | COMPLETED | NCT02135861 |
| DCE-MRI scans | Other | Phase PHASE1 | Heart Failure, Congestive | COMPLETED | NCT02135861 |
| Gadobutrol | Other | Phase PHASE1 | Heart Failure, Congestive | COMPLETED | NCT02135861 |
| DCE-MRI scans | Other | Phase PHASE1 | Heart Failure, Congestive | COMPLETED | NCT02135861 |
| Albiglutide matching placebo | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT02465515 |
| Albiglutide 50 mg | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT02465515 |
| Albiglutide 30 mg | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT02465515 |
| Albiglutide matching placebo | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT02465515 |
| Albiglutide 50 mg | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT02465515 |
| Albiglutide 30 mg | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT02465515 |
| Saliva Sample Collection | Other | Preclinical | Healthy | COMPLETED | NCT02188238 |
| hepatitis A inactivated virus vaccine | Other | Phase PHASE3 | Cervical Cancer | COMPLETED | NCT00128661 |
| human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine | Other | Phase PHASE3 | Cervical Cancer | COMPLETED | NCT00128661 |
| Infanrix TM | Other | Phase PHASE4 | Poliomyelitis | COMPLETED | NCT01094171 |
| Poliorix TM | Other | Phase PHASE4 | Poliomyelitis | COMPLETED | NCT01094171 |
| Clinical questionnaire | Other | Preclinical | Wiskott-Aldrich Syndrome | COMPLETED | NCT03399461 |
| Pediatric quality of life (PedsQL) questionnaire | Other | Preclinical | Wiskott-Aldrich Syndrome | COMPLETED | NCT03399461 |
| Sociodemographic questionnaire | Other | Preclinical | Wiskott-Aldrich Syndrome | COMPLETED | NCT03399461 |
| Caregiver interview guide | Other | Preclinical | Wiskott-Aldrich Syndrome | COMPLETED | NCT03399461 |
| Patient Interview guide | Other | Preclinical | Wiskott-Aldrich Syndrome | COMPLETED | NCT03399461 |
| Placebo | Other | Phase PHASE2 | Herpes Zoster | COMPLETED | NCT00434577 |
| Herpes Zoster vaccine GSK1437173A Modified | Other | Phase PHASE2 | Herpes Zoster | COMPLETED | NCT00434577 |
| Herpes Zoster vaccine GSK1437173A High Dose | Other | Phase PHASE2 | Herpes Zoster | COMPLETED | NCT00434577 |
| Herpes Zoster vaccine GSK1437173A Medium Dose | Other | Phase PHASE2 | Herpes Zoster | COMPLETED | NCT00434577 |
| Herpes Zoster vaccine GSK1437173A Low Dose | Other | Phase PHASE2 | Herpes Zoster | COMPLETED | NCT00434577 |
| Placebo | Other | Phase PHASE2 | Herpes Zoster | COMPLETED | NCT00434577 |
| Herpes Zoster vaccine GSK1437173A Modified | Other | Phase PHASE2 | Herpes Zoster | COMPLETED | NCT00434577 |
| Herpes Zoster vaccine GSK1437173A High Dose | Other | Phase PHASE2 | Herpes Zoster | COMPLETED | NCT00434577 |
| Herpes Zoster vaccine GSK1437173A Medium Dose | Other | Phase PHASE2 | Herpes Zoster | COMPLETED | NCT00434577 |
| Herpes Zoster vaccine GSK1437173A Low Dose | Other | Phase PHASE2 | Herpes Zoster | COMPLETED | NCT00434577 |
| Ropinirole CR 3 mg Placebo | Other | Phase PHASE3 | Restless Legs Syndrome | COMPLETED | NCT00256854 |
| Ropinirole CR 2 mg Placebo | Other | Phase PHASE3 | Restless Legs Syndrome | COMPLETED | NCT00256854 |
| Ropinirole CR 3 mg | Other | Phase PHASE3 | Restless Legs Syndrome | COMPLETED | NCT00256854 |
| Ropinirole CR 2 mg | Other | Phase PHASE3 | Restless Legs Syndrome | COMPLETED | NCT00256854 |
| Ropinirole IR 2 mg Placebo | Other | Phase PHASE3 | Restless Legs Syndrome | COMPLETED | NCT00256854 |
| Ropinirole IR 1 mg Placebo | Other | Phase PHASE3 | Restless Legs Syndrome | COMPLETED | NCT00256854 |
| Ropinirole IR 2 mg | Other | Phase PHASE3 | Restless Legs Syndrome | COMPLETED | NCT00256854 |
| Ropinirole IR 1 mg | Other | Phase PHASE3 | Restless Legs Syndrome | COMPLETED | NCT00256854 |
| healthy controls | Other | Phase PHASE2 | Immune Thrombocytopenia | COMPLETED | NCT00902018 |
| Romiplostim | Other | Phase PHASE2 | Immune Thrombocytopenia | COMPLETED | NCT00902018 |
| Eltrombopag | Other | Phase PHASE2 | Immune Thrombocytopenia | COMPLETED | NCT00902018 |
| healthy controls | Other | Phase PHASE2 | Immune Thrombocytopenia | COMPLETED | NCT00902018 |
| Romiplostim | Other | Phase PHASE2 | Immune Thrombocytopenia | COMPLETED | NCT00902018 |
| Eltrombopag | Other | Phase PHASE2 | Immune Thrombocytopenia | COMPLETED | NCT00902018 |
| GSK Biologicals' investigational TB vaccine GSK 692342 | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT01669096 |
| Education program | Other | Approved | COPD | UNKNOWN | NCT03889054 |
| Education program | Other | Approved | COPD | UNKNOWN | NCT03889054 |
| Connected Inhaler System | Other | Phase PHASE3 | Asthma | WITHDRAWN | NCT03376932 |
| Metered Dose Inhaler | Other | Phase PHASE3 | Asthma | WITHDRAWN | NCT03376932 |
| RESPIMAT inhaler | Other | Phase PHASE3 | Asthma | WITHDRAWN | NCT03376932 |
| DISKUS DPI | Other | Phase PHASE3 | Asthma | WITHDRAWN | NCT03376932 |
| ELLIPTA DPI | Other | Phase PHASE3 | Asthma | WITHDRAWN | NCT03376932 |
| Albuterol/salbutamol | Other | Phase PHASE3 | Asthma | WITHDRAWN | NCT03376932 |
| Tiotropium | Other | Phase PHASE3 | Asthma | WITHDRAWN | NCT03376932 |
| FP/SAL | Other | Phase PHASE3 | Asthma | WITHDRAWN | NCT03376932 |
| FF/UMEC/VI | Other | Phase PHASE3 | Asthma | WITHDRAWN | NCT03376932 |
| No Adhesive | Other | Approved | Denture Retention | COMPLETED | NCT03345108 |
| Denture Adhesive (Continuous Strip Application) | Other | Approved | Denture Retention | COMPLETED | NCT03345108 |
| Denture Adhesive Cream (Conventional Application) | Other | Approved | Denture Retention | COMPLETED | NCT03345108 |
| Disintegrating placebo tamsulosin tablet | Other | Phase PHASE3 | Prostatic Hyperplasia | COMPLETED | NCT02058368 |
| Tamsulosin 0.2mg tablets | Other | Phase PHASE3 | Prostatic Hyperplasia | COMPLETED | NCT02058368 |
| Dutasteride placebo capsules | Other | Phase PHASE3 | Prostatic Hyperplasia | COMPLETED | NCT02058368 |
| Dutasteride 0.5mg capsules | Other | Phase PHASE3 | Prostatic Hyperplasia | COMPLETED | NCT02058368 |
| Vilanterol | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01957150 |
| Fluticasone Furoate/Vilanterol | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT01957150 |
| Participants self-administered questionnaire and assessment | Other | Approved | Cognition | TERMINATED | NCT02860169 |
| Clinical questionnaire | Other | Preclinical | Asthma | COMPLETED | NCT03344406 |
| Sociodemographic questionnaire | Other | Preclinical | Asthma | COMPLETED | NCT03344406 |
| Daily diary | Other | Preclinical | Asthma | COMPLETED | NCT03344406 |
| Supplemental asthma items | Other | Preclinical | Asthma | COMPLETED | NCT03344406 |
| E-RS: COPD | Other | Preclinical | Asthma | COMPLETED | NCT03344406 |
| Telephonic interviews | Other | Preclinical | Asthma | COMPLETED | NCT03344406 |
| Clinical questionnaire | Other | Preclinical | Asthma | COMPLETED | NCT03344406 |
| Sociodemographic questionnaire | Other | Preclinical | Asthma | COMPLETED | NCT03344406 |
| Daily diary | Other | Preclinical | Asthma | COMPLETED | NCT03344406 |
| Supplemental asthma items | Other | Preclinical | Asthma | COMPLETED | NCT03344406 |
| E-RS: COPD | Other | Preclinical | Asthma | COMPLETED | NCT03344406 |
| Telephonic interviews | Other | Preclinical | Asthma | COMPLETED | NCT03344406 |
| No treatment | Drug | Approved | Skin Care | COMPLETED | NCT03216265 |
| Positive control (Commercial market place moisturising cream) | Other | Approved | Skin Care | COMPLETED | NCT03216265 |
| Test product (Moisturising cream) | Other | Approved | Skin Care | COMPLETED | NCT03216265 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03136380 |
| GSK1325756H | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03136380 |
| Vehicle ointment | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT03004846 |
| GSK2981278 ointment | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT03004846 |
| ISO 24444:2010 P3 Standard Sunscreen | Other | Approved | Sunscreening Agents | COMPLETED | NCT03136107 |
| Physiogel Daily Defence Protective Day Cream Light | Other | Approved | Sunscreening Agents | COMPLETED | NCT03136107 |
| Placebo | Other | Phase PHASE1 | Tuberculosis | COMPLETED | NCT03075410 |
| GSK3036656 | Other | Phase PHASE1 | Tuberculosis | COMPLETED | NCT03075410 |
| Plasmapheresis | Other | Phase PHASE1 | Renal Transplant Rejection | COMPLETED | NCT02500251 |
| Rituximab | Other | Phase PHASE1 | Renal Transplant Rejection | COMPLETED | NCT02500251 |
| Bortezomib | Other | Phase PHASE1 | Renal Transplant Rejection | COMPLETED | NCT02500251 |
| belimumab | Other | Phase PHASE1 | Renal Transplant Rejection | COMPLETED | NCT02500251 |
| Placebo | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01856309 |
| Sirukumab 50 mg | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01856309 |
| Sirukumab 100 mg | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01856309 |
| Placebo | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01856309 |
| Sirukumab 50 mg | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01856309 |
| Sirukumab 100 mg | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT01856309 |
| lapatinib plus oral vinorelbine | Other | Phase PHASE1 | Metastatic Breast Cancer | COMPLETED | NCT00912275 |
| Influsplit SSW® 2005/2006 | Other | Phase PHASE4 | Influenza | COMPLETED | NCT00372255 |
| Paracetamol | Other | Phase PHASE4 | Infections, Streptococcal | COMPLETED | NCT01235949 |
| Ibuprofen | Other | Phase PHASE4 | Infections, Streptococcal | COMPLETED | NCT01235949 |
| Infanrix-IPV/Hib | Other | Phase PHASE4 | Infections, Streptococcal | COMPLETED | NCT01235949 |
| Infanrix hexa | Other | Phase PHASE4 | Infections, Streptococcal | COMPLETED | NCT01235949 |
| GSK1024850A (SynflorixTM) | Other | Phase PHASE4 | Infections, Streptococcal | COMPLETED | NCT01235949 |
| Azacitidine | Other | Phase PHASE1 | Myelodysplastic Syndrome | TERMINATED | NCT02929498 |
| GSK2879552 | Other | Phase PHASE1 | Myelodysplastic Syndrome | TERMINATED | NCT02929498 |
| 1100 ppm F as NaF (positive control) | Other | Phase PHASE3 | Caries | COMPLETED | NCT03383783 |
| 500 ppm F as NaF (dose-response control) | Other | Phase PHASE3 | Caries | COMPLETED | NCT03383783 |
| 250 ppm F as NaF (dose-response control) | Other | Phase PHASE3 | Caries | COMPLETED | NCT03383783 |
| 0 ppm F (placebo, negative control) | Other | Phase PHASE3 | Caries | COMPLETED | NCT03383783 |
| Data capture app | Other | Preclinical | Nasal Polyps | COMPLETED | NCT03221192 |
| SNOT-22 questionnaire | Other | Preclinical | Nasal Polyps | COMPLETED | NCT03221192 |
| VAS questionnaire | Other | Preclinical | Nasal Polyps | COMPLETED | NCT03221192 |
| Placebo | Other | Phase PHASE2 | Hepatitis | COMPLETED | NCT00287469 |
| Hepatitis E vaccine, recombinant (Sar 56 kDa) | Other | Phase PHASE2 | Hepatitis | COMPLETED | NCT00287469 |
| Data collection | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT01733862 |
| Stannous fluoride (SnF2, 0.454%), RDA~120 | Other | Approved | Extrinsic Dental Stain | COMPLETED | NCT03160703 |
| Sodium Monofluorophosphate (1000 ppm fluoride ), RDA~80 | Other | Approved | Extrinsic Dental Stain | COMPLETED | NCT03160703 |
| Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), abrasive silica (3.5%) | Other | Approved | Extrinsic Dental Stain | COMPLETED | NCT03160703 |
| Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), 2.0% abrasive silica | Other | Approved | Extrinsic Dental Stain | COMPLETED | NCT03160703 |
| Polio Sabin | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT01175083 |
| Tritanrix-HepB/Hib | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT01175083 |
| GSK1024850A (Synflorix) | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT01175083 |
| Stool sample collection | Other | Approved | Infections, Clostridium Difficile | COMPLETED | NCT01716533 |
| Blood sampling | Other | Approved | Infections, Clostridium Difficile | COMPLETED | NCT01716533 |
| Fondaparinux | Other | Phase EARLY_PHASE1 | Deep Venous Thrombosis | COMPLETED | NCT00894283 |
| Enoxaparin | Other | Phase EARLY_PHASE1 | Deep Venous Thrombosis | COMPLETED | NCT00894283 |
| Data collection | Other | Preclinical | Acute Otitis Media | COMPLETED | NCT02742753 |
| Data collection | Other | Preclinical | Acute Otitis Media | COMPLETED | NCT02742753 |
| Data collection | Other | Preclinical | Acute Otitis Media | COMPLETED | NCT02567747 |
| Data collection | Other | Preclinical | Acute Otitis Media | COMPLETED | NCT02567747 |
| Placebo control | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00779766 |
| HPV GSK 580299 vaccine | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00779766 |
| Infanrix hexa | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00370396 |
| Prevenar | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00370396 |
| Synflorix | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00370396 |
| Infanrix hexa | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00370396 |
| Prevenar | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00370396 |
| Synflorix | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00370396 |
| placebo | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00343915 |
| 10 μg Engerix™-B (preservative-free) | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00343915 |
| Engerix™-B (thiomersal-free) 20µg | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00343915 |
| MenACWY-CRM | Other | Phase PHASE3 | Meningococcal Disease | COMPLETED | NCT01682876 |
| MenACWY-CRM | Other | Phase PHASE3 | Meningococcal Disease | COMPLETED | NCT01682876 |
| Fluarix™ | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00540228 |
| Influenza Vaccine GSK1247446A - 4 different formulations | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00540228 |
| Sporozoite challenge | Other | Phase PHASE2 | Malaria | COMPLETED | NCT01366534 |
| GSK Biologicals' malaria vaccine 257049 (3 doses) | Other | Phase PHASE2 | Malaria | COMPLETED | NCT01366534 |
| GSK Biologicals' malaria vaccine 257049 (2 doses) | Other | Phase PHASE2 | Malaria | COMPLETED | NCT01366534 |
| Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01) | Other | Phase PHASE2 | Malaria | COMPLETED | NCT01366534 |
| Stamaril™ | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT01262872 |
| M-Vac™ | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT01262872 |
| Polio Sabin™ | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT01262872 |
| Tritanrix™-HepB/Hib | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT01262872 |
| Prevnar13™ | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT01262872 |
| Synflorix™ | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT01262872 |
| Pneumococcal vaccine GSK 2189242A (HD formulation 2) | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT01262872 |
| Pneumococcal vaccine GSK 2189242A (LD formulation 1) | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT01262872 |
| Control vaccine with the adjuvant system. | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT00397943 |
| Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and physiological saline | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT00397943 |
| Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and adjuvant system | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT00397943 |
| GSK's candidate Mycobacterium tuberculosis vaccine 692342 | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT00397943 |
| Placebo | Other | Phase PHASE1 | Urticaria | COMPLETED | NCT02424799 |
| GSK2646264 1% topical cream | Other | Phase PHASE1 | Urticaria | COMPLETED | NCT02424799 |
| GSK2646264 0.5% topical cream | Other | Phase PHASE1 | Urticaria | COMPLETED | NCT02424799 |
| Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg | Other | Phase PHASE1 | Common Cold | COMPLETED | NCT03415243 |
| Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg | Other | Phase PHASE1 | Common Cold | COMPLETED | NCT03415243 |
| Pirinase Hayfever Relief for Adults 0.05% Nasal Spray | Other | Preclinical | Rhinitis, Allergic, Seasonal | COMPLETED | NCT02856282 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02000817 |
| Otelixizumab | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02000817 |
| GSK1349572 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01068925 |
| GSK1349572 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01068925 |
| Docetaxel | Other | Phase PHASE2 | Lung Cancer, Non-Small Cell | COMPLETED | NCT00065182 |
| Topotecan/Docetaxel combination | Other | Phase PHASE2 | Lung Cancer, Non-Small Cell | COMPLETED | NCT00065182 |
| Blood sample collection | Other | Approved | Dengue | COMPLETED | NCT01391819 |
| Data collection | Other | Approved | Dengue | COMPLETED | NCT01391819 |
| GSK investigational vaccine GSK2340272A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00968526 |
| Meningococcal vaccine GSK134612 | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT00471081 |
| Sporozoite-infected mosquitoes challenge | Other | Phase PHASE2 | Malaria | COMPLETED | NCT01857869 |
| GSK257049 Dosage 2 | Other | Phase PHASE2 | Malaria | COMPLETED | NCT01857869 |
| GSK257049 Dosage 1 | Other | Phase PHASE2 | Malaria | COMPLETED | NCT01857869 |
| GSK investigational vaccine GSK2340272A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00972517 |
| Meningococcal vaccine GSK134612 | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT00718666 |
| Fluviral® | Other | Phase PHASE3 | Influenza Vaccines | COMPLETED | NCT00718120 |
| Prevenar™ | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00652951 |
| Pediacel™ | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00652951 |
| Infanrix™ hexa. | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00652951 |
| GSK Biologicals´ Pneumococcal Conjugate Vaccine GSK1024850A (Synflorix™) | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00652951 |
| Prevenar™ | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00652951 |
| Pediacel™ | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00652951 |
| Infanrix™ hexa. | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00652951 |
| GSK Biologicals´ Pneumococcal Conjugate Vaccine GSK1024850A (Synflorix™) | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00652951 |
| Fluarix™ | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00545025 |
| Influenza Vaccine GSK1247446A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00545025 |
| Blood sampling for assay of persistence of immunogenicity | Other | Phase PHASE2 | Herpes Zoster | COMPLETED | NCT00492648 |
| Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A). | Other | Phase PHASE2 | Influenza | COMPLETED | NCT02719743 |
| MenACWY | Other | Phase PHASE4 | Infections, Meningococcal | COMPLETED | NCT02446691 |
| MenABCWY | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT02212457 |
| Havrix | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT02212457 |
| Saline Placebo | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT02212457 |
| Bexsero | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT02212457 |
| Placebo | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT01587807 |
| LPS | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT01587807 |
| bronchoalveolar lavage | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT01587807 |
| GSK1995057 | Other | Phase PHASE1 | Respiratory Disorders | COMPLETED | NCT01587807 |
| Menjugate™ | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT01098474 |
| Polio Sabin™ | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT01098474 |
| Prevnar™ | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT01098474 |
| Tritanrix™ HB+Hib | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT01098474 |
| GSK's investigational vaccine 692342 | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT01098474 |
| Menjugate™ | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT01098474 |
| Polio Sabin™ | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT01098474 |
| Prevnar™ | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT01098474 |
| Tritanrix™ HB+Hib | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT01098474 |
| GSK's investigational vaccine 692342 | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT01098474 |
| Fluviral | Other | Phase PHASE4 | Influenza Vaccines | COMPLETED | NCT00586469 |
| GVGH Shigella sonnei 1790GAHB vaccine | Other | Phase PHASE1 | Dysentery, Bacillary | COMPLETED | NCT03089879 |
| Questionnaire | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03028207 |
| Medical tests | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03028207 |
| ATRA | Other | Phase PHASE1 | Leukaemia, Myelocytic, Acute | TERMINATED | NCT02177812 |
| GSK2879552 | Other | Phase PHASE1 | Leukaemia, Myelocytic, Acute | TERMINATED | NCT02177812 |
| 5 mg GSK1278863 | Other | Phase PHASE1 | Anaemia | TERMINATED | NCT01406340 |
| No treatment | Drug | Approved | Skin Aging | COMPLETED | NCT03180645 |
| Positive control (Commercial market place moisturising cream) | Other | Approved | Skin Aging | COMPLETED | NCT03180645 |
| Test product (Moisturising cream) | Other | Approved | Skin Aging | COMPLETED | NCT03180645 |
| GSK2849330 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01966445 |
| Placebo (Formulation buffer S9b) | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT02956837 |
| RSV Vaccine (GSK3003891A) formulation 3 | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT02956837 |
| RSV Vaccine (GSK3003891A) formulation 2 | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT02956837 |
| RSV Vaccine (GSK3003891A) formulation 1 | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT02956837 |
| AZ MDI | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02794480 |
| GSK MDI | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02794480 |
| ELLIPTA DPI | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02794480 |
| Synflorix™ | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT01746108 |
| Trametinib | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01938443 |
| GSK2256098 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01938443 |
| Trametinib | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01938443 |
| GSK2256098 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01938443 |
| Placebo via DISKUS / ACCUHALER | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02730351 |
| Placebo via ELLIPTA inhaler | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02730351 |
| Fluticasone propionate 250 mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02730351 |
| Fluticasone furoate/ Vilanterol 100 mcg/25 mcg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02730351 |
| Matching Placebo | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT02647281 |
| GSK3389404 | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT02647281 |
| Matching Placebo | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT02647281 |
| GSK3389404 | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT02647281 |
| Infanrix hexa™ | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT01616459 |
| Prevnar 13™ | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT01616459 |
| Synflorix™ | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT01616459 |
| Pneumococcal conjugate vaccine GSK2830930A | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT01616459 |
| Pneumococcal conjugate vaccine GSK2830929A | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT01616459 |
| Washout | Other | Phase PHASE2 | Dyslipidaemias | COMPLETED | NCT01218204 |
| 10mg ezetimibe | Other | Phase PHASE2 | Dyslipidaemias | COMPLETED | NCT01218204 |
| 800mg GSK1292263 | Other | Phase PHASE2 | Dyslipidaemias | COMPLETED | NCT01218204 |
| 300mg GSK1292263 | Other | Phase PHASE2 | Dyslipidaemias | COMPLETED | NCT01218204 |
| 100mg GSK1292263 | Other | Phase PHASE2 | Dyslipidaemias | COMPLETED | NCT01218204 |
| GSK1292263 Placebo | Other | Phase PHASE2 | Dyslipidaemias | COMPLETED | NCT01218204 |
| 80mg atorvastatin | Other | Phase PHASE2 | Dyslipidaemias | COMPLETED | NCT01218204 |
| 10mg atorvastatin | Other | Phase PHASE2 | Dyslipidaemias | COMPLETED | NCT01218204 |
| GSK Biologicals' DTPa-IPV/Hib vaccine | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00466947 |
| Infanrix hexa | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00466947 |
| Engerix-B | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00466947 |
| Havrix | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00466947 |
| Pneumococcal conjugate vaccine GSK1024850A | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00466947 |
| Yellow fever vaccine | Other | Phase PHASE3 | Malaria | COMPLETED | NCT01345240 |
| Measles vaccine | Other | Phase PHASE3 | Malaria | COMPLETED | NCT01345240 |
| Synflorix™ vaccine | Other | Phase PHASE3 | Malaria | COMPLETED | NCT01345240 |
| Rotarix™ vaccine | Other | Phase PHASE3 | Malaria | COMPLETED | NCT01345240 |
| Polio Sabin™ vaccine | Other | Phase PHASE3 | Malaria | COMPLETED | NCT01345240 |
| Infanrix/Hib™ vaccine | Other | Phase PHASE3 | Malaria | COMPLETED | NCT01345240 |
| Engerix-B™ vaccine | Other | Phase PHASE3 | Malaria | COMPLETED | NCT01345240 |
| GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049 | Other | Phase PHASE3 | Malaria | COMPLETED | NCT01345240 |
| Yellow fever vaccine | Other | Phase PHASE3 | Malaria | COMPLETED | NCT01345240 |
| Measles vaccine | Other | Phase PHASE3 | Malaria | COMPLETED | NCT01345240 |
| Synflorix™ vaccine | Other | Phase PHASE3 | Malaria | COMPLETED | NCT01345240 |
| Rotarix™ vaccine | Other | Phase PHASE3 | Malaria | COMPLETED | NCT01345240 |
| Polio Sabin™ vaccine | Other | Phase PHASE3 | Malaria | COMPLETED | NCT01345240 |
| Infanrix/Hib™ vaccine | Other | Phase PHASE3 | Malaria | COMPLETED | NCT01345240 |
| Engerix-B™ vaccine | Other | Phase PHASE3 | Malaria | COMPLETED | NCT01345240 |
| GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049 | Other | Phase PHASE3 | Malaria | COMPLETED | NCT01345240 |
| Vaginal swab sample | Other | Approved | Streptococcus Agalactiae | COMPLETED | NCT01888471 |
| Blood sample | Other | Approved | Streptococcus Agalactiae | COMPLETED | NCT01888471 |
| Glycerin | Other | Approved | Sunscreening Agents | COMPLETED | NCT03157583 |
| Sunscreen formulation S2 | Other | Approved | Sunscreening Agents | COMPLETED | NCT03157583 |
| P3 Standard, (Expected SPF 16) | Other | Approved | Sunscreening Agents | COMPLETED | NCT03157583 |
| NGBUV000D, (Expected SPF 30) | Other | Approved | Sunscreening Agents | COMPLETED | NCT03157583 |
| NGBUV000C, (Expected SPF 30) | Other | Approved | Sunscreening Agents | COMPLETED | NCT03157583 |
| NGBUV000B, (Expected SPF 30) | Other | Approved | Sunscreening Agents | COMPLETED | NCT03157583 |
| NGBUV000A, (Expected SPF 30) | Other | Approved | Sunscreening Agents | COMPLETED | NCT03157583 |
| Albiglutide liquid auto-injector matching placebo | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02683746 |
| Albiglutide liquid auto-injector | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02683746 |
| Lyophilized albiglutide DCC pen injector matching placebo | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02683746 |
| Lyophilized albiglutide DCC pen injector | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02683746 |
| Placebo To Match Oseltamivir Phosphate | Other | Phase PHASE2 | Virus Diseases | COMPLETED | NCT02469298 |
| Oseltamivir Phosphate | Other | Phase PHASE2 | Virus Diseases | COMPLETED | NCT02469298 |
| Placebo To Match GSK1325756 | Other | Phase PHASE2 | Virus Diseases | COMPLETED | NCT02469298 |
| GSK1325756 (Danirixin) | Other | Phase PHASE2 | Virus Diseases | COMPLETED | NCT02469298 |
| Belimumab | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT00583362 |
| Belimumab | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT00583362 |
| Placebo | Other | Phase PHASE1 | Asthma | COMPLETED | NCT03045887 |
| GSK2292767 500 μg | Other | Phase PHASE1 | Asthma | COMPLETED | NCT03045887 |
| GSK2292767 50 μg | Other | Phase PHASE1 | Asthma | COMPLETED | NCT03045887 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02742766 |
| GSK3008356 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02742766 |
| No strip | Other | Phase PHASE2 | Sleep Disordered Breathing | COMPLETED | NCT03105297 |
| Prototype nasal dilator strip | Other | Phase PHASE2 | Sleep Disordered Breathing | COMPLETED | NCT03105297 |
| No strip | Other | Phase PHASE2 | Sleep Disordered Breathing | COMPLETED | NCT03105297 |
| Prototype nasal dilator strip | Other | Phase PHASE2 | Sleep Disordered Breathing | COMPLETED | NCT03105297 |
| GSK1349572 | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01231529 |
| GSK1349572 | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01231529 |
| Infanrix-IPV/HiberixTM | Other | Phase PHASE3 | Meningococcal Infection | COMPLETED | NCT01340898 |
| SynflorixTM | Other | Phase PHASE3 | Meningococcal Infection | COMPLETED | NCT01340898 |
| Meningococcal vaccine GSK 134612 | Other | Phase PHASE3 | Meningococcal Infection | COMPLETED | NCT01340898 |
| Pazopanib and Paclitaxel | Other | Phase PHASE2 | Stage III Melanoma | COMPLETED | NCT01107665 |
| Matching Placebo | Other | Phase PHASE1 | Irritable Bowel Syndrome | COMPLETED | NCT03154086 |
| GSK3352589 | Other | Phase PHASE1 | Irritable Bowel Syndrome | COMPLETED | NCT03154086 |
| Data collection | Other | Approved | Pertussis | COMPLETED | NCT01597687 |
| Blood collection | Other | Approved | Pertussis | COMPLETED | NCT01597687 |
| Data collection | Other | Approved | Pertussis | COMPLETED | NCT01597687 |
| Blood collection | Other | Approved | Pertussis | COMPLETED | NCT01597687 |
| [18F]-FBA-A20FMDV2 | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT03069989 |
| Placebo | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT03069989 |
| GSK3008348 | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT03069989 |
| Intermittent pazopanib (Arm B) | Other | Phase PHASE2 | Thyroid Carcinoma | COMPLETED | NCT01813136 |
| Continuous pazopanib (Arm A) | Other | Phase PHASE2 | Thyroid Carcinoma | COMPLETED | NCT01813136 |
| Sucralose | Other | Phase PHASE1 | Burns | TERMINATED | NCT03242434 |
| Lactulose and Mannitol solution | Other | Phase PHASE1 | Burns | TERMINATED | NCT03242434 |
| Sucralose | Other | Phase PHASE1 | Burns | TERMINATED | NCT03242434 |
| Lactulose and Mannitol solution | Other | Phase PHASE1 | Burns | TERMINATED | NCT03242434 |
| GSK2269557 750 µg | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03189589 |
| GSK2269557 500 µg | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03189589 |
| Placebo | Other | Phase PHASE1 | Wound Healing | COMPLETED | NCT01831804 |
| GSK1278863 | Other | Phase PHASE1 | Wound Healing | COMPLETED | NCT01831804 |
| Meningococcal B Recombinant vaccine | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT02946385 |
| Meningococcal ABCWY Vaccine | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT02946385 |
| none of intervention was given | Other | Preclinical | HIV-1-infection | UNKNOWN | NCT04063306 |
| Placebo | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT02450552 |
| Ezogabine | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT02450552 |
| Placebo | Other | Phase PHASE2 | Smoking Dependence | COMPLETED | NCT01506908 |
| oral nicotine | Other | Phase PHASE2 | Smoking Dependence | COMPLETED | NCT01506908 |
| Placebo | Other | Phase PHASE2 | Smoking Dependence | COMPLETED | NCT01506908 |
| oral nicotine | Other | Phase PHASE2 | Smoking Dependence | COMPLETED | NCT01506908 |
| Placebo | Other | Phase PHASE2 | Smoking | COMPLETED | NCT01466361 |
| Nicotine higher dose | Other | Phase PHASE2 | Smoking | COMPLETED | NCT01466361 |
| Nicotine lower dose | Other | Phase PHASE2 | Smoking | COMPLETED | NCT01466361 |
| 89Zr-GSK2398852 (89Zr-labeled anti-SAP mAb) | Other | Phase PHASE1 | Amyloidosis | TERMINATED | NCT03417830 |
| GSK2398852 (unlabeled anti-SAP mAb) | Other | Phase PHASE1 | Amyloidosis | TERMINATED | NCT03417830 |
| GSK2315698 (CPHPC) | Other | Phase PHASE1 | Amyloidosis | TERMINATED | NCT03417830 |
| 89Zr-GSK2398852 (89Zr-labeled anti-SAP mAb) | Other | Phase PHASE1 | Amyloidosis | TERMINATED | NCT03417830 |
| GSK2398852 (unlabeled anti-SAP mAb) | Other | Phase PHASE1 | Amyloidosis | TERMINATED | NCT03417830 |
| GSK2315698 (CPHPC) | Other | Phase PHASE1 | Amyloidosis | TERMINATED | NCT03417830 |
| Daprodustat (GSK1278863) | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT03223337 |
| Data collection | Other | Preclinical | Herpes Zoster | COMPLETED | NCT02487472 |
| placebo | Other | Phase PHASE2 | Rhinitis | COMPLETED | NCT01424397 |
| SB-705498 | Other | Phase PHASE2 | Rhinitis | COMPLETED | NCT01424397 |
| placebo | Other | Phase PHASE2 | Rhinitis | COMPLETED | NCT01424397 |
| SB-705498 | Other | Phase PHASE2 | Rhinitis | COMPLETED | NCT01424397 |
| trastuzumab | Other | Phase PHASE2 | Carcinoma, Ductal, Breast | TERMINATED | NCT01891357 |
| lapatinib | Other | Phase PHASE2 | Carcinoma, Ductal, Breast | TERMINATED | NCT01891357 |
| paclitaxel | Other | Phase PHASE2 | Carcinoma, Ductal, Breast | TERMINATED | NCT01891357 |
| Biopsy before and after three weeks of study treatment | Drug | Phase PHASE2 | Carcinoma, Ductal, Breast | TERMINATED | NCT01891357 |
| Trametinib | Other | Phase PHASE2 | Estrogen Receptor Negative | COMPLETED | NCT01964924 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Estrogen Receptor Negative | COMPLETED | NCT01964924 |
| Akt Inhibitor GSK2141795 | Other | Phase PHASE2 | Estrogen Receptor Negative | COMPLETED | NCT01964924 |
| Trametinib | Other | Phase PHASE2 | Estrogen Receptor Negative | COMPLETED | NCT01964924 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Estrogen Receptor Negative | COMPLETED | NCT01964924 |
| Akt Inhibitor GSK2141795 | Other | Phase PHASE2 | Estrogen Receptor Negative | COMPLETED | NCT01964924 |
| GSK3039294 | Other | Phase PHASE1 | Amyloidosis | TERMINATED | NCT02603172 |
| TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution. | Other | Phase PHASE1 | Dengue | COMPLETED | NCT02421367 |
| Combined diphtheria, tetanus and tricomponent acellular pertussis vaccine [Refortrix (Tdap)] | Other | Preclinical | Diphtheria | COMPLETED | NCT02757950 |
| HIV vaccine 732461 | Other | Phase PHASE2 | AIDS | COMPLETED | NCT00434512 |
| Placebo | Other | Phase PHASE1 | Cough | TERMINATED | NCT03372603 |
| GSK2798745 | Other | Phase PHASE1 | Cough | TERMINATED | NCT03372603 |
| Fluticasone propionate | Other | Preclinical | Asthma | COMPLETED | NCT03273946 |
| Nasopharyngeal swab sampling | Other | Approved | Infections, Streptococcal | COMPLETED | NCT02838407 |
| BAL fluid sampling | Other | Approved | Infections, Streptococcal | COMPLETED | NCT02838407 |
| Collection for non-craniotomy | Other | Preclinical | Melanoma | COMPLETED | NCT02058953 |
| Craniotomy scheduled | Other | Preclinical | Melanoma | COMPLETED | NCT02058953 |
| Placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT01345253 |
| Belimumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT01345253 |
| Placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT01345253 |
| Belimumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT01345253 |
| Placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT01345253 |
| Belimumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT01345253 |
| GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A) | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT02979639 |
| Ambrisentan - high dose | Other | Phase PHASE2 | Hypertension, Pulmonary | TERMINATED | NCT01332331 |
| Ambrisentan - low dose | Other | Phase PHASE2 | Hypertension, Pulmonary | TERMINATED | NCT01332331 |
| GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI) | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT01213472 |
| Polio Sabin Oral Polio Vaccine (GSK) | Other | Phase PHASE3 | Malaria | COMPLETED | NCT00866619 |
| TritanrixHepB/Hib | Other | Phase PHASE3 | Malaria | COMPLETED | NCT00866619 |
| Cell-culture rabies vaccine | Other | Phase PHASE3 | Malaria | COMPLETED | NCT00866619 |
| Meningococcal C Conjugate Vaccine | Other | Phase PHASE3 | Malaria | COMPLETED | NCT00866619 |
| Malaria Vaccine 257049 | Other | Phase PHASE3 | Malaria | COMPLETED | NCT00866619 |
| GSK2398852 (anti-SAP mAb) | Other | Phase PHASE2 | Amyloidosis | TERMINATED | NCT03044353 |
| GSK2315698 (CPHPC) | Other | Phase PHASE2 | Amyloidosis | TERMINATED | NCT03044353 |
| PQ4 | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02982187 |
| PQ3 | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02982187 |
| PQ2 | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02982187 |
| PQ1 | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02982187 |
| Placebo HANDIHALER | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02982187 |
| Placebo TURBUHALER | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02982187 |
| Placebo DISKUS | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02982187 |
| Placebo ELLIPTA | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02982187 |
| Meningococcal quadrivalent CRM-197 conjugate vaccine | Other | Preclinical | Meningococcal Disease | COMPLETED | NCT02287688 |
| Pandemic influenza vaccine (GSK1119711A)-formulation 2 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00430521 |
| Pandemic influenza vaccine (GSK1119711A)-formulation 1 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00430521 |
| Pandemic influenza vaccine (GSK1119711A)-formulation 2 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00430521 |
| Pandemic influenza vaccine (GSK1119711A)-formulation 1 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT00430521 |
| Cyclophosphamide | Other | Phase PHASE2 | Neoplasms | WITHDRAWN | NCT03697824 |
| Fludarabine | Other | Phase PHASE2 | Neoplasms | WITHDRAWN | NCT03697824 |
| Pembrolizumab | Other | Phase PHASE2 | Neoplasms | WITHDRAWN | NCT03697824 |
| GSK3377794 | Other | Phase PHASE2 | Neoplasms | WITHDRAWN | NCT03697824 |
| Gynaecological follow-up | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00937950 |
| Placebo control | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT01190176 |
| Cervarix | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT01190176 |
| Gynaecological follow-up | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT01190176 |
| Pneumovax 23™ | Other | Phase PHASE2 | Prophylaxis Invasive Pneumococcal Diseases and Pneumonia | COMPLETED | NCT00307528 |
| Pneumococcal vaccine GSK513026 | Other | Phase PHASE2 | Prophylaxis Invasive Pneumococcal Diseases and Pneumonia | COMPLETED | NCT00307528 |
| Tenofovir disoproxil fumarate | Other | Phase PHASE4 | Hepatitis B, Chronic | COMPLETED | NCT02195518 |
| Tenofovir disoproxil fumarate | Other | Phase PHASE4 | Hepatitis B, Chronic | COMPLETED | NCT02195518 |
| Cervarix | Other | Phase PHASE4 | Human Papillomavirus Infection Leading to Cervical Cancer | TERMINATED | NCT00730847 |
| Cervarix | Other | Phase PHASE4 | Human Papillomavirus Infection Leading to Cervical Cancer | TERMINATED | NCT00730847 |
| Endocrine | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00548184 |
| Trastuzumab | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00548184 |
| Lapatinib | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00548184 |
| Eltrombopag | Other | Phase PHASE2 | Thrombocytopenia | TERMINATED | NCT01821625 |
| Placebo | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT01462357 |
| Gardasil | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT01462357 |
| Cervarix | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT01462357 |
| GSK Biologicals' 208136, new formulation | Other | Phase PHASE2 | Measles | COMPLETED | NCT00892775 |
| Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine) | Other | Phase PHASE2 | Measles | COMPLETED | NCT00892775 |
| GSK Biologicals' 208136, new formulation | Other | Phase PHASE2 | Measles | COMPLETED | NCT00892775 |
| Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine) | Other | Phase PHASE2 | Measles | COMPLETED | NCT00892775 |
| GSK Biologicals' Zilbrix™ Hib | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00678301 |
| GSK Biologicals' Polio Sabin™ | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00678301 |
| GSK Biologicals' Synflorix™ | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00678301 |
| Engerix-B | Other | Phase PHASE4 | Infections, Papillomavirus | COMPLETED | NCT00534638 |
| Cervarix | Other | Phase PHASE4 | Infections, Papillomavirus | COMPLETED | NCT00534638 |
| Vaqta™ | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00289731 |
| HB VAX PRO™ | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00289731 |
| HAVRIX™ | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00289731 |
| Engerix™-B | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00289731 |
| TWINRIX™ | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00289731 |
| GSK investigational vaccine GSK2340269A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00968539 |
| GSK investigational vaccine GSK2340272A | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00968539 |
| Menjugate | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00674583 |
| GSK Biologicals' meningococcal vaccine GSK134612 | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00674583 |
| Meningitec | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00474266 |
| Priorix-Tetra | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00474266 |
| Meningococcal vaccine GSK134612 (Nimenrix) | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00474266 |
| Blood sample collection | Other | Approved | Hepatitis A Vaccine | COMPLETED | NCT02712359 |
| Rotarix | Other | Phase PHASE4 | Rotavirus | COMPLETED | NCT02907216 |
| Squarekids | Other | Phase PHASE4 | Rotavirus | COMPLETED | NCT02907216 |
| Polio Sabin Oral Polio Vaccine (GSK) (MALARIA-055 PRI) | Other | Phase PHASE3 | Malaria | COMPLETED | NCT02207816 |
| TritanrixHepB/Hib (MALARIA-055 PRI) | Other | Phase PHASE3 | Malaria | COMPLETED | NCT02207816 |
| Cell-culture rabies vaccine (MALARIA-055 PRI) | Other | Phase PHASE3 | Malaria | COMPLETED | NCT02207816 |
| Meningococcal C Conjugate Vaccine (MALARIA-055 PRI) | Other | Phase PHASE3 | Malaria | COMPLETED | NCT02207816 |
| Malaria Vaccine 257049 (MALARIA-055 PRI) | Other | Phase PHASE3 | Malaria | COMPLETED | NCT02207816 |
| Blood sampling | Other | Phase PHASE3 | Malaria | COMPLETED | NCT02207816 |
| Data collection | Other | Approved | Pertussis | COMPLETED | NCT02014519 |
| Blood sampling | Other | Approved | Pertussis | COMPLETED | NCT02014519 |
| Rotarix | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT02096263 |
| Prevnar13 | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT02096263 |
| Hiberix | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT02096263 |
| Infanrix | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT02096263 |
| Engerix-B | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT02096263 |
| Pentacel | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT02096263 |
| ActHIB | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT02096263 |
| Pediarix | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT02096263 |
| Infanrix hexa | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT02096263 |
| Rotarix™ | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT01309646 |
| Synflorix™ | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT01309646 |
| Hiberix™ | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT01309646 |
| Infanrix™ IPV | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT01309646 |
| Infanrix™-IPV+Hib | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT01309646 |
| Infanrix™ hexa | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00753649 |
| DTPa | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT01027845 |
| Pneumococcal vaccine GSK1024850A | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT01027845 |
| DTPa | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT01027845 |
| Pneumococcal vaccine GSK1024850A | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT01027845 |
| Daprodustat 6 mg oral tablet | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT03239522 |
| [14C]-GSK1278863 oral solution | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT03239522 |
| [14C]-GSK1278863 solution for IV infusion | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT03239522 |
| Prefilled Safety Syringe | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03014674 |
| Prefilled autoinjector | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03014674 |
| Liquid mepolizumab | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03014674 |
| Lyophilized mepolizumab | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03014674 |
| Iron | Other | Phase PHASE3 | Anaemia | COMPLETED | NCT02829320 |
| GSK1278863 | Other | Phase PHASE3 | Anaemia | COMPLETED | NCT02829320 |
| Mepolizumab | Other | Phase PHASE2 | Asthma | COMPLETED | NCT02377427 |
| Mepolizumab | Other | Phase PHASE2 | Asthma | COMPLETED | NCT02377427 |
| SOC | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02135692 |
| Mepolizumab | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02135692 |
| Placebo | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT01755598 |
| GSK Biologicals' investigational TB vaccine (GSK692342) | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT01755598 |
| Autologous Genetically modified T cells | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT01352286 |
| Nicorette Mini Lozenge | Other | Phase PHASE1 | Tobacco Use Disorder | COMPLETED | NCT03543137 |
| Nicotine Prototype Mini lozenge | Other | Phase PHASE1 | Tobacco Use Disorder | COMPLETED | NCT03543137 |
| Tositumomab and Iodine I 131 Tositumomab followed by CHOP | Other | Phase PHASE2 | Lymphoma, Mantle-Cell | COMPLETED | NCT00992992 |
| Placebo | Other | Phase PHASE3 | Depressive Disorder | COMPLETED | NCT00296517 |
| 323U66 (Bupropion Hydrochloride Sustained Release) | Other | Phase PHASE3 | Depressive Disorder | COMPLETED | NCT00296517 |
| Fortified malt based food | Other | Approved | Growth and Development | COMPLETED | NCT02542865 |
| Niaspan | Other | Phase PHASE2 | Dyslipidaemias | COMPLETED | NCT00903617 |
| Placebo | Other | Phase PHASE2 | Dyslipidaemias | COMPLETED | NCT00903617 |
| GSK256073 | Other | Phase PHASE2 | Dyslipidaemias | COMPLETED | NCT00903617 |
| belimumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT00712933 |
| Treatment F | Drug | Phase PHASE1 | HIV Infections | COMPLETED | NCT03441984 |
| Treatment E | Drug | Phase PHASE1 | HIV Infections | COMPLETED | NCT03441984 |
| Treatment D | Drug | Phase PHASE1 | HIV Infections | COMPLETED | NCT03441984 |
| Treatment C | Drug | Phase PHASE1 | HIV Infections | COMPLETED | NCT03441984 |
| Treatment B | Drug | Phase PHASE1 | HIV Infections | COMPLETED | NCT03441984 |
| Treatment A | Drug | Phase PHASE1 | HIV Infections | COMPLETED | NCT03441984 |
| Treatment F | Drug | Phase PHASE1 | HIV Infections | COMPLETED | NCT03441984 |
| Treatment E | Drug | Phase PHASE1 | HIV Infections | COMPLETED | NCT03441984 |
| Treatment D | Drug | Phase PHASE1 | HIV Infections | COMPLETED | NCT03441984 |
| Treatment C | Drug | Phase PHASE1 | HIV Infections | COMPLETED | NCT03441984 |
| Treatment B | Drug | Phase PHASE1 | HIV Infections | COMPLETED | NCT03441984 |
| Treatment A | Drug | Phase PHASE1 | HIV Infections | COMPLETED | NCT03441984 |
| MAGE-A3 ASCI injections with Poly IC:LC | Other | Phase PHASE2 | Melanoma | TERMINATED | NCT01437605 |
| MAGE-A3 ASCI injections without Poly IC:LC | Other | Phase PHASE2 | Melanoma | TERMINATED | NCT01437605 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT03000686 |
| GSK2586881 | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT03000686 |
| PedvaxHIB® | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT01545375 |
| Prevnar 13® | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT01545375 |
| Placebo | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT01545375 |
| Pneumococcal vaccine GSK2189242A | Other | Phase PHASE2 | Infections, Streptococcal | COMPLETED | NCT01545375 |
| HRV vaccine | Other | Phase PHASE2 | Infections, Rotavirus | COMPLETED | NCT00385320 |
| HRV vaccine | Other | Phase PHASE2 | Infections, Rotavirus | COMPLETED | NCT00385320 |
| RTS,S/AS02D and RTS,S/AS02A | Other | Phase PHASE1 | Malaria | COMPLETED | NCT00197067 |
| GSK Biologicals' 719125 | Other | Phase PHASE1 | Neoplasms, Breast | COMPLETED | NCT00140738 |
| GSK Biologicals' 719125 | Other | Phase PHASE1 | Neoplasms, Breast | COMPLETED | NCT00140738 |
| Rotavirus | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT00140673 |
| Infanrix hexa™ | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT01353703 |
| Infanrix hexa™ | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT01353703 |
| Infanrix hexa™ | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT01153841 |
| Synflorix™( GSK1024850A) | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT01153841 |
| Infanrix hexa™ | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT01153841 |
| Synflorix™( GSK1024850A) | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT01153841 |
| Placebo | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00423046 |
| Gardasil ® (Merck & Co. Inc) | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00423046 |
| GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM) | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00423046 |
| HPV investigational vaccine GSK568893A, different formulations | Other | Phase PHASE2 | Infections, Papillomavirus | COMPLETED | NCT00359619 |
| CervarixTM | Other | Phase PHASE2 | Infections, Papillomavirus | COMPLETED | NCT00359619 |
| GSK Biologicals' combined DTPa-IPV/Hib vaccine | Other | Phase PHASE4 | Diphtheria | COMPLETED | NCT00325156 |
| Pneumococcal (vaccine) | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00307541 |
| Placebo control | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00294047 |
| Cervarix | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00294047 |
| Placebo | Other | Phase PHASE2 | Lung Cancer, Non-Small Cell | COMPLETED | NCT00290355 |
| GSK 249553 vaccine | Other | Phase PHASE2 | Lung Cancer, Non-Small Cell | COMPLETED | NCT00290355 |
| Cervarix™ | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00250276 |
| Cervarix™ | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00250276 |
| Sample collection | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT01177826 |
| Ritonavir | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT01009814 |
| BMS-663068 | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT01009814 |
| Ritonavir | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT01009814 |
| BMS-663068 | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT01009814 |
| Menjugate® | Other | Phase PHASE2 | Tetanus | COMPLETED | NCT00970307 |
| Infanrix hexa™ | Other | Phase PHASE2 | Tetanus | COMPLETED | NCT00970307 |
| 10-valent pneumococcal vaccine (GSK 1024850A) | Other | Phase PHASE2 | Tetanus | COMPLETED | NCT00970307 |
| GSK2202083A vaccine | Other | Phase PHASE2 | Tetanus | COMPLETED | NCT00970307 |
| Prevnar® | Other | Phase PHASE2 | Rubella | COMPLETED | NCT00861744 |
| Havrix® | Other | Phase PHASE2 | Rubella | COMPLETED | NCT00861744 |
| Varivax® | Other | Phase PHASE2 | Rubella | COMPLETED | NCT00861744 |
| M-M-R® II (Merck and Co) | Other | Phase PHASE2 | Rubella | COMPLETED | NCT00861744 |
| GSK Biological's investigational vaccine 209762 | Other | Phase PHASE2 | Rubella | COMPLETED | NCT00861744 |
| Decavac™ | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT00835237 |
| Boostrix® | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT00835237 |
| Decavac™ | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT00835237 |
| Boostrix® | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT00835237 |
| Tritanrix-HepB | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00814710 |
| Hiberix | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00814710 |
| Tritanrix-HepB/Hib | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00814710 |
| Pneumococcal conjugate vaccine GSK1024850A | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00814710 |
| Tritanrix-HepB | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00814710 |
| Hiberix | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00814710 |
| Tritanrix-HepB/Hib | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00814710 |
| Pneumococcal conjugate vaccine GSK1024850A | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00814710 |
| Engerix™ | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00637195 |
| Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™) | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00637195 |
| Blood and urine sampling | Other | Preclinical | Lung Inflammation | UNKNOWN | NCT03312712 |
| Saline Challenge | Other | Preclinical | Lung Inflammation | UNKNOWN | NCT03312712 |
| LPS Challenge | Other | Preclinical | Lung Inflammation | UNKNOWN | NCT03312712 |
| PET/CT scan | Other | Preclinical | Lung Inflammation | UNKNOWN | NCT03312712 |
| Topical emollient (Sun Flower seed oil) | Other | Approved | Child Malnutrition | COMPLETED | NCT02616289 |
| Niraparib Oral Capsules (Unlabeled) | Other | Phase PHASE1 | Cancer | COMPLETED | NCT02476552 |
| Niraparib IV (Labeled) | Other | Phase PHASE1 | Cancer | COMPLETED | NCT02476552 |
| Niraparib Oral Capsules (Labeled) | Other | Phase PHASE1 | Cancer | COMPLETED | NCT02476552 |
| GSK149203A | Other | Approved | Infections, Cytomegalovirus | COMPLETED | NCT01357915 |
| Blood sampling | Other | Approved | Infections, Cytomegalovirus | COMPLETED | NCT01357915 |
| Boostrix™ | Other | Phase PHASE4 | Acellular Pertussis | COMPLETED | NCT00548171 |
| Boostrix™ | Other | Phase PHASE4 | Acellular Pertussis | COMPLETED | NCT00548171 |
| Infanrix hexa | Other | Phase PHASE4 | Diphtheria | COMPLETED | NCT02853929 |
| Infanrix hexa | Other | Phase PHASE4 | Diphtheria | COMPLETED | NCT02853929 |
| Control Dentifrice | Other | Preclinical | Gingivitis | COMPLETED | NCT03703245 |
| Sodium bicarbonate | Other | Preclinical | Gingivitis | COMPLETED | NCT03703245 |
| Engerix-B Kinder | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT02798952 |
| Engerix-B Kinder | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT02798952 |
| Placebo | Other | Phase PHASE4 | Infections, Rotavirus | COMPLETED | NCT00969228 |
| Rotarix ™ | Other | Phase PHASE4 | Infections, Rotavirus | COMPLETED | NCT00969228 |
| Blood sampling | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00877877 |
| Infanrix-IPV+Hib™ | Other | Phase PHASE3 | Acellular Pertussis | COMPLETED | NCT01577732 |
| Synflorix™ | Other | Phase PHASE2 | Tetanus | COMPLETED | NCT01171989 |
| NeisVac-C™ | Other | Phase PHASE2 | Tetanus | COMPLETED | NCT01171989 |
| Menjugate™ | Other | Phase PHASE2 | Tetanus | COMPLETED | NCT01171989 |
| Infanrix hexa™ | Other | Phase PHASE2 | Tetanus | COMPLETED | NCT01171989 |
| GSK2202083A vaccine | Other | Phase PHASE2 | Tetanus | COMPLETED | NCT01171989 |
| Oral Poliovirus vaccine | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT01021293 |
| Poliorix™ | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT01021293 |
| Oral Poliovirus vaccine | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT01021293 |
| Poliorix™ | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT01021293 |
| Saline placebo | Other | Phase PHASE4 | Diphtheria-Tetanus-acellular Pertussis Vaccines | COMPLETED | NCT02377349 |
| Boostrix™ | Other | Phase PHASE4 | Diphtheria-Tetanus-acellular Pertussis Vaccines | COMPLETED | NCT02377349 |
| Sodium monofluorophosphate | Other | Phase PHASE3 | Gingivitis | COMPLETED | NCT04123665 |
| Stannous fluoride | Other | Phase PHASE3 | Gingivitis | COMPLETED | NCT04123665 |
| Belimumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT02119156 |
| Belimumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT02119156 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02555371 |
| Mepolizumab 100mg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02555371 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02555371 |
| Mepolizumab 100mg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02555371 |
| M-M-R II | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT00148941 |
| IPOL | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT00148941 |
| Infanrix | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT00148941 |
| SB213503 lot 3 | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT00148941 |
| SB213503 lot 2 | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT00148941 |
| SB213503 lot 1 | Other | Phase PHASE3 | Tetanus | COMPLETED | NCT00148941 |
| Nelarabine | Other | Phase PHASE1 | Leukemia | COMPLETED | NCT01094860 |
| MenACWY (Menveo) vaccine | Other | Phase PHASE2 | Meningitis, Meningococcal | COMPLETED | NCT03587207 |
| rMenB+OMV NZ (Bexsero) vaccine | Other | Phase PHASE2 | Meningitis, Meningococcal | COMPLETED | NCT03587207 |
| MenABCWY vaccine | Other | Phase PHASE2 | Meningitis, Meningococcal | COMPLETED | NCT03587207 |
| cohort 4 | Other | Phase PHASE1 | Metastatic Pancreatic Cancer | COMPLETED | NCT00439179 |
| cohort 3 | Other | Phase PHASE1 | Metastatic Pancreatic Cancer | COMPLETED | NCT00439179 |
| cohort 2 | Other | Phase PHASE1 | Metastatic Pancreatic Cancer | COMPLETED | NCT00439179 |
| cohort 1 | Other | Phase PHASE1 | Metastatic Pancreatic Cancer | COMPLETED | NCT00439179 |
| cohort 4 | Other | Phase PHASE1 | Metastatic Pancreatic Cancer | COMPLETED | NCT00439179 |
| cohort 3 | Other | Phase PHASE1 | Metastatic Pancreatic Cancer | COMPLETED | NCT00439179 |
| cohort 2 | Other | Phase PHASE1 | Metastatic Pancreatic Cancer | COMPLETED | NCT00439179 |
| cohort 1 | Other | Phase PHASE1 | Metastatic Pancreatic Cancer | COMPLETED | NCT00439179 |
| recMAGE-A3 + AS15 | Other | Phase PHASE2 | Melanoma | COMPLETED | NCT01266603 |
| HDIL-2 | Other | Phase PHASE2 | Melanoma | COMPLETED | NCT01266603 |
| Mencevax-ACWY | Other | Phase PHASE3 | Whole Cell Pertussis | COMPLETED | NCT00228917 |
| Tritanrix-HepB/Hiberix | Other | Phase PHASE3 | Whole Cell Pertussis | COMPLETED | NCT00228917 |
| Tritanrix-HepB/Hib-MenAC | Other | Phase PHASE3 | Whole Cell Pertussis | COMPLETED | NCT00228917 |
| Meningitec | Other | Phase PHASE3 | Whole Cell Pertussis | COMPLETED | NCT00136604 |
| Tritanrix-HepB/Hiberix | Other | Phase PHASE3 | Whole Cell Pertussis | COMPLETED | NCT00136604 |
| Mencevax ACWY | Other | Phase PHASE3 | Whole Cell Pertussis | COMPLETED | NCT00136604 |
| Tritanrix-HepB/Hib-MenAC | Other | Phase PHASE3 | Whole Cell Pertussis | COMPLETED | NCT00136604 |
| Placebo matching OCS capsules | Other | Phase PHASE3 | Hypereosinophilic Syndrome | COMPLETED | NCT02836496 |
| Active OCS capsules (5 mg prednisolone or prednisone) | Other | Phase PHASE3 | Hypereosinophilic Syndrome | COMPLETED | NCT02836496 |
| Placebo matching mepolizumab | Other | Phase PHASE3 | Hypereosinophilic Syndrome | COMPLETED | NCT02836496 |
| Mepolizumab 300 mg | Other | Phase PHASE3 | Hypereosinophilic Syndrome | COMPLETED | NCT02836496 |
| Placebo gel | Other | Phase PHASE1 | Pain | COMPLETED | NCT03497039 |
| Diclofenac Diethylamine (DDEA) gel | Other | Phase PHASE1 | Pain | COMPLETED | NCT03497039 |
| Reference formulation B | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT03408392 |
| Test formulation A | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT03408392 |
| GSK1278863 matching Placebo | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT02689206 |
| GSK1278863 | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT02689206 |
| Escitalopram Matching Placebo | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT02191397 |
| Escitalopram | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT02191397 |
| Bupropion Matching Placebo | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT02191397 |
| Bupropion | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT02191397 |
| GSK2816126 | Other | Phase PHASE1 | Cancer | TERMINATED | NCT02082977 |
| Blood withdrawal | Other | Approved | Immunologic Tests | COMPLETED | NCT01098006 |
| Fluticasone propionate | Other | Phase PHASE2 | Asthma | COMPLETED | NCT03207243 |
| Fluticasone propionate/salmeterol | Other | Phase PHASE2 | Asthma | COMPLETED | NCT03207243 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT03207243 |
| GSK3772847 | Other | Phase PHASE2 | Asthma | COMPLETED | NCT03207243 |
| Cobicistat | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT03045861 |
| GSK2838232 | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT03045861 |
| Placebo via DISKUS | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03034915 |
| Placebo via ELLIPTA | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03034915 |
| Salmeterol 50 mcg via DISKUS | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03034915 |
| UMEC 62.5 mcg via ELLIPTA | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03034915 |
| UMEC/VI 62.5/25 mcg via ELLIPTA | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03034915 |
| Retigabine IR | Other | Phase PHASE3 | Epilepsy | COMPLETED | NCT01777139 |
| Retigabine IR | Other | Phase PHASE3 | Epilepsy | COMPLETED | NCT01777139 |
| Retigabine IR | Other | Phase PHASE3 | Epilepsy | COMPLETED | NCT01336621 |
| Nicorette Mini Lozenge | Other | Phase PHASE1 | Tobacco Use Disorder | COMPLETED | NCT03541044 |
| Nicotine Prototype Mini lozenge | Other | Phase PHASE1 | Tobacco Use Disorder | COMPLETED | NCT03541044 |
| [14C]-GSK2269557 oral solution | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03315559 |
| GSK2269557 via DPI | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03315559 |
| [14C]-GSK2269557 IV infusion | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03315559 |
| ROTAHALER | Other | Phase PHASE1 | Postpartum Hemorrhage | TERMINATED | NCT02999100 |
| IV Oxytocin | Other | Phase PHASE1 | Postpartum Hemorrhage | TERMINATED | NCT02999100 |
| IM Oxytocin | Other | Phase PHASE1 | Postpartum Hemorrhage | TERMINATED | NCT02999100 |
| IH Oxytocin | Other | Phase PHASE1 | Postpartum Hemorrhage | TERMINATED | NCT02999100 |
| Placebo | Other | Phase PHASE1 | HIV | COMPLETED | NCT02425241 |
| CPHPC | Other | Phase PHASE1 | HIV | COMPLETED | NCT02425241 |
| MVA.HIVconsv booster vaccine | Other | Phase PHASE1 | HIV | COMPLETED | NCT02425241 |
| ChAdV63.HIVconsv booster vaccine | Other | Phase PHASE1 | HIV | COMPLETED | NCT02425241 |
| pSG2.HIVconsv DNA vaccine | Other | Phase PHASE1 | HIV | COMPLETED | NCT02425241 |
| Paroxetine IR tablets B | Other | Phase PHASE1 | Anxiety Disorders | COMPLETED | NCT03329573 |
| Paroxetine IR tablets A | Other | Phase PHASE1 | Anxiety Disorders | COMPLETED | NCT03329573 |
| Paroxetine IR tablets B | Other | Phase PHASE1 | Anxiety Disorders | COMPLETED | NCT03329573 |
| Paroxetine IR tablets A | Other | Phase PHASE1 | Anxiety Disorders | COMPLETED | NCT03329573 |
| Calcium folinate | Other | Phase PHASE1 | Toxoplasmosis | COMPLETED | NCT03258762 |
| Pyrimethamine | Other | Phase PHASE1 | Toxoplasmosis | COMPLETED | NCT03258762 |
| Belimumab | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02880852 |
| Belimumab | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02880852 |
| Belimumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT01597622 |
| Belimumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT01597622 |
| Belimumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT01597622 |
| GSK2248761 formulation 2 or 4 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01031472 |
| GSK2248761 formulation 3 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01031472 |
| GSK2248761 reference formulation | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01031472 |
| GSK2248761 formulation 1 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01031472 |
| GSK2248761 formulation 2 or 4 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01031472 |
| GSK2248761 formulation 3 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01031472 |
| GSK2248761 reference formulation | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01031472 |
| GSK2248761 formulation 1 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01031472 |
| H5N1 adjuvanted split virus vaccine (A/Indonesia/05/2005 strain) | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00449670 |
| H5N1 non-adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain) | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00449670 |
| H5N1 adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain) | Other | Phase PHASE3 | Influenza | COMPLETED | NCT00449670 |
| molibresib | Other | Preclinical | Solid Tumours | NO_LONGER_AVAILABLE | NCT03702036 |
| Fluticasone furoate/umeclidinium/vilanterol | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | WITHDRAWN | NCT03949842 |
| Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | WITHDRAWN | NCT03949842 |
| Fluticasone furoate/umeclidinium/vilanterol | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | WITHDRAWN | NCT03949842 |
| Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | WITHDRAWN | NCT03949842 |
| Blood sample collection | Other | Approved | AIDS | COMPLETED | NCT01610427 |
| Itraconazole | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03398421 |
| Nemiralisib | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03398421 |
| Albuterol/Salbutamol | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02483975 |
| Montelukast | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02483975 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02483975 |
| Data collection | Other | Approved | Dengue | TERMINATED | NCT01751139 |
| Blood sample collection | Other | Approved | Dengue | TERMINATED | NCT01751139 |
| Placebo | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT01165229 |
| Herpes Zoster Vaccine GSK1437173A | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT01165229 |
| Encoding of data collected in Zoster 006 and Zoster 022 studies | Other | Preclinical | Herpes Zoster | COMPLETED | NCT03563183 |
| GSK2982772 Immediate Release | Other | Phase PHASE1 | Autoimmune Diseases | COMPLETED | NCT03649412 |
| GSK2982772 Modified Release | Other | Phase PHASE1 | Autoimmune Diseases | COMPLETED | NCT03649412 |
| GSK2982772 Immediate Release | Other | Phase PHASE1 | Autoimmune Diseases | COMPLETED | NCT03649412 |
| GSK2982772 Modified Release | Other | Phase PHASE1 | Autoimmune Diseases | COMPLETED | NCT03649412 |
| Adacel | Other | Phase PHASE3 | Acellular Pertussis | COMPLETED | NCT00489970 |
| Boostrix | Other | Phase PHASE3 | Acellular Pertussis | COMPLETED | NCT00489970 |
| Taking of blood samples | Other | Phase PHASE3 | Acellular Pertussis | COMPLETED | NCT00489970 |
| mepolizumab | Other | Phase PHASE3 | Hypereosinophilia | COMPLETED | NCT00086658 |
| ACQ-7 | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03184987 |
| Salbutamol | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03184987 |
| FF/UMEC/VI 200/62.5/25 mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03184987 |
| FF/UMEC/VI 100/62.5/25 mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03184987 |
| ACQ-7 | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03184987 |
| Salbutamol | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03184987 |
| FF/UMEC/VI 200/62.5/25 mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03184987 |
| FF/UMEC/VI 100/62.5/25 mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03184987 |
| Levocetirizine ODT 5 mg | Other | Phase PHASE1 | Rhinitis | COMPLETED | NCT03555890 |
| Levocetirizine IRT 5 mg | Other | Phase PHASE1 | Rhinitis | COMPLETED | NCT03555890 |
| Levocetirizine ODT 5 mg | Other | Phase PHASE1 | Rhinitis | COMPLETED | NCT03555890 |
| Levocetirizine IRT 5 mg | Other | Phase PHASE1 | Rhinitis | COMPLETED | NCT03555890 |
| Placebo | Other | Phase PHASE3 | Spasticity, Post-Stroke | COMPLETED | NCT03261167 |
| Botulinum toxin A (GSK1358820) | Other | Phase PHASE3 | Spasticity, Post-Stroke | COMPLETED | NCT03261167 |
| Placebo | Other | Phase PHASE3 | Spasticity, Post-Stroke | COMPLETED | NCT03261167 |
| Botulinum toxin A (GSK1358820) | Other | Phase PHASE3 | Spasticity, Post-Stroke | COMPLETED | NCT03261167 |
| Standard cleanser soap | Other | Approved | Dry Skin | COMPLETED | NCT03804710 |
| Developmental moisturizing cream 2 | Other | Approved | Dry Skin | COMPLETED | NCT03804710 |
| Developmental moisturizing cream 1 | Other | Approved | Dry Skin | COMPLETED | NCT03804710 |
| Placebo | Other | Phase PHASE2 | Colitis, Ulcerative | COMPLETED | NCT02903966 |
| GSK2982772 | Other | Phase PHASE2 | Colitis, Ulcerative | COMPLETED | NCT02903966 |
| Placebo | Other | Phase PHASE1 | Pancreatitis, Acute Necrotizing | TERMINATED | NCT03245619 |
| GSK3335065 | Other | Phase PHASE1 | Pancreatitis, Acute Necrotizing | TERMINATED | NCT03245619 |
| Mepolizumab | Other | Phase PHASE3 | Hypereosinophilic Syndrome | COMPLETED | NCT03306043 |
| Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01788228 |
| There is not intervention. | Other | Preclinical | COPD Exacerbation | UNKNOWN | NCT04449419 |
| Linerixibat oral solution | Other | Phase PHASE1 | Cholestasis | COMPLETED | NCT03992014 |
| [14C]-linerixibat intravenous infusion | Other | Phase PHASE1 | Cholestasis | COMPLETED | NCT03992014 |
| Linerixibat tablet | Other | Phase PHASE1 | Cholestasis | COMPLETED | NCT03992014 |
| Gepotidacin | Other | Phase PHASE2 | Infections, Bacterial | COMPLETED | NCT03568942 |
| Insulin | Other | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02284009 |
| Placebo weekly injection | Other | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02284009 |
| Albiglutide weekly injection | Other | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02284009 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02184611 |
| Umeclidinium bromide | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02184611 |
| Vaginal swab | Other | Approved | Infections, Cytomegalovirus | COMPLETED | NCT01251744 |
| Urine sampling | Other | Approved | Infections, Cytomegalovirus | COMPLETED | NCT01251744 |
| Saliva swab | Other | Approved | Infections, Cytomegalovirus | COMPLETED | NCT01251744 |
| Cord blood sample | Other | Approved | Infections, Cytomegalovirus | COMPLETED | NCT01251744 |
| Blood sample | Other | Approved | Infections, Cytomegalovirus | COMPLETED | NCT01251744 |
| Placebo-2 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03243760 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03243760 |
| CCI15106 7.5 mg capsule | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03243760 |
| Not applicable / dataset analysis | Other | Preclinical | Whooping Cough | COMPLETED | NCT03973905 |
| Not applicable / dataset analysis | Other | Preclinical | Whooping Cough | COMPLETED | NCT03973905 |
| Blood sample collection | Other | Approved | Dengue | COMPLETED | NCT02570152 |
| Daprodustat 4 mg tablet | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT03493386 |
| Daprodustat 2 mg tablet | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT03493386 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03235726 |
| CCI15106 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03235726 |
| Inhaler preference questionnaires | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03227445 |
| HandiHaler placebo DPI | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03227445 |
| DISKUS placebo DPI | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03227445 |
| ELLIPTA placebo DPI | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03227445 |
| Inhaler preference questionnaires | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03227445 |
| HandiHaler placebo DPI | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03227445 |
| DISKUS placebo DPI | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03227445 |
| ELLIPTA placebo DPI | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03227445 |
| Placebo | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT02776033 |
| GSK2982772 | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT02776033 |
| Placebo | Other | Phase PHASE1 | Shingles | COMPLETED | NCT02114333 |
| HZ/su vaccine | Other | Phase PHASE1 | Shingles | COMPLETED | NCT02114333 |
| Zostavax | Other | Phase PHASE1 | Shingles | COMPLETED | NCT02114333 |
| Pazopanib | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01466972 |
| Placebo | Other | Phase PHASE3 | Obstetric Labour, Premature | COMPLETED | NCT02292784 |
| Atosiban | Other | Phase PHASE3 | Obstetric Labour, Premature | COMPLETED | NCT02292784 |
| Retosiban | Other | Phase PHASE3 | Obstetric Labour, Premature | COMPLETED | NCT02292784 |
| Placebo | Other | Phase PHASE3 | Obstetric Labour, Premature | COMPLETED | NCT02292784 |
| Atosiban | Other | Phase PHASE3 | Obstetric Labour, Premature | COMPLETED | NCT02292784 |
| Retosiban | Other | Phase PHASE3 | Obstetric Labour, Premature | COMPLETED | NCT02292784 |
| GSK217744 | Other | Phase PHASE2 | Acellular Pertussis | COMPLETED | NCT01453998 |
| Prevenar 13 | Other | Phase PHASE2 | Acellular Pertussis | COMPLETED | NCT01453998 |
| Infanrix hexa | Other | Phase PHASE2 | Acellular Pertussis | COMPLETED | NCT01453998 |
| Rotarix | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT02914184 |
| HRV PCV-free liquid vaccine | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT02914184 |
| Gepotidacin | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT02729038 |
| Albuterol | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02573870 |
| Placebo | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02573870 |
| Batefenterol + Fluticasone Furoate | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02573870 |
| Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil) | Other | Phase PHASE4 | Infections, Papillomavirus | COMPLETED | NCT01031069 |
| GSK Biologicals' HPV vaccine 580299 | Other | Phase PHASE4 | Infections, Papillomavirus | COMPLETED | NCT01031069 |
| Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil) | Other | Phase PHASE4 | Infections, Papillomavirus | COMPLETED | NCT01031069 |
| GSK Biologicals' HPV vaccine 580299 | Other | Phase PHASE4 | Infections, Papillomavirus | COMPLETED | NCT01031069 |
| Obeticholic acid | Other | Phase PHASE1 | Cholestasis | COMPLETED | NCT04053023 |
| GSK2330672 (linerixibat) | Other | Phase PHASE1 | Cholestasis | COMPLETED | NCT04053023 |
| PQ (End of study treatment) | Drug | Phase PHASE3 | Malaria, Vivax | COMPLETED | NCT02802501 |
| ACT plus PQ (Rescue medication) | Drug | Phase PHASE3 | Malaria, Vivax | COMPLETED | NCT02802501 |
| Dihydroartemisinin-piperaquine (DHA-PQP) | Other | Phase PHASE3 | Malaria, Vivax | COMPLETED | NCT02802501 |
| Matched-Placebo for Primaquine | Other | Phase PHASE3 | Malaria, Vivax | COMPLETED | NCT02802501 |
| Primaquine | Other | Phase PHASE3 | Malaria, Vivax | COMPLETED | NCT02802501 |
| Matched-Placebo for Tafenoquine | Other | Phase PHASE3 | Malaria, Vivax | COMPLETED | NCT02802501 |
| Tafenoquine | Other | Phase PHASE3 | Malaria, Vivax | COMPLETED | NCT02802501 |
| S. sonnei 53G challenge strain | Other | Phase PHASE2 | Dysentery, Bacillary | COMPLETED | NCT03527173 |
| Placebo | Other | Phase PHASE2 | Dysentery, Bacillary | COMPLETED | NCT03527173 |
| S.sonnei vaccine | Other | Phase PHASE2 | Dysentery, Bacillary | COMPLETED | NCT03527173 |
| Placebo IV infusion | Other | Phase PHASE3 | Obstetric Labour, Premature | TERMINATED | NCT02377466 |
| Retosiban IV infusion | Other | Phase PHASE3 | Obstetric Labour, Premature | TERMINATED | NCT02377466 |
| Placebo IV infusion | Other | Phase PHASE3 | Obstetric Labour, Premature | TERMINATED | NCT02377466 |
| Retosiban IV infusion | Other | Phase PHASE3 | Obstetric Labour, Premature | TERMINATED | NCT02377466 |
| Placebo | Other | Phase PHASE4 | Post-Traumatic Headache | TERMINATED | NCT01053507 |
| sumatriptan/naproxen sodium | Other | Phase PHASE4 | Post-Traumatic Headache | TERMINATED | NCT01053507 |
| Pembrolizumab | Other | Phase PHASE2 | Neoplasms, Pancreatic | TERMINATED | NCT03681951 |
| GSK3145095 | Other | Phase PHASE2 | Neoplasms, Pancreatic | TERMINATED | NCT03681951 |
| Rescue medication | Drug | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03170232 |
| Metered dose inhaler (MDI) sensor device | Device | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03170232 |
| Placebo | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03170232 |
| Danirixin 35 mg tablets | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03170232 |
| Placebo (ELLIPTA or DISKUS) | Other | Phase PHASE2 | Asthma | COMPLETED | NCT02991859 |
| Budesonide (BUD) Turbuhaler | Other | Phase PHASE2 | Asthma | COMPLETED | NCT02991859 |
| Fluticasone propionate (FP) Dry Powder Inhaler | Other | Phase PHASE2 | Asthma | COMPLETED | NCT02991859 |
| Fluticasone furoate (FF) Dry Powder Inhaler | Other | Phase PHASE2 | Asthma | COMPLETED | NCT02991859 |
| Ezogabine: USAN Retigabine (International Nonproprietary Name) | Other | Phase PHASE3 | Epilepsy | COMPLETED | NCT00310375 |
| Tenofovir Disoproxil Fumarate | Other | Phase PHASE4 | Hepatitis B, Chronic | COMPLETED | NCT03258710 |
| Tenofovir Disoproxil Fumarate | Other | Phase PHASE4 | Hepatitis B, Chronic | COMPLETED | NCT03258710 |
| GSK1265744 30mg | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT02354950 |
| Reference AMB (5 mg) | Other | Phase PHASE1 | Hypertension, Pulmonary | COMPLETED | NCT04095286 |
| AMB new formulation (1 mg) | Other | Phase PHASE1 | Hypertension, Pulmonary | COMPLETED | NCT04095286 |
| Reference AMB (5 mg) | Other | Phase PHASE1 | Hypertension, Pulmonary | COMPLETED | NCT04095286 |
| AMB new formulation (1 mg) | Other | Phase PHASE1 | Hypertension, Pulmonary | COMPLETED | NCT04095286 |
| GSK2857916 | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02064387 |
| GSK2857916 | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02064387 |
| RTS,S/AS01E (SB257049) | Other | Phase PHASE2 | Malaria | COMPLETED | NCT03824236 |
| Assessment of body temperature | Other | Approved | Malaria | COMPLETED | NCT01190202 |
| Blood sampling | Other | Approved | Malaria | COMPLETED | NCT01190202 |
| Arnuity | Other | Preclinical | Asthma | COMPLETED | NCT03595930 |
| GSK1120212 | Other | Phase EARLY_PHASE1 | Breast Cancer | COMPLETED | NCT01467310 |
| 4CMenB | Other | Preclinical | Infections, Meningococcal | COMPLETED | NCT02640677 |
| 4CMenB | Other | Preclinical | Infections, Meningococcal | COMPLETED | NCT02640677 |
| Placebo | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT04079790 |
| Gepotidacin | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT04079790 |
| Stannous Fluoride | Other | Phase PHASE2 | Dentin Hypersensitivity | COMPLETED | NCT03943095 |
| Potassium Nitrate | Other | Phase PHASE2 | Dentin Hypersensitivity | COMPLETED | NCT03943095 |
| Prototype PTB (Combined mode) | Other | Phase PHASE2 | Dental Plaque | COMPLETED | NCT03809910 |
| Prototype PTB (Gum line mode) | Other | Phase PHASE2 | Dental Plaque | COMPLETED | NCT03809910 |
| Reference PTB | Other | Phase PHASE2 | Dental Plaque | COMPLETED | NCT03809910 |
| Reference MTB | Other | Phase PHASE2 | Dental Plaque | COMPLETED | NCT03809910 |
| 5% KNO3 | Other | Phase PHASE3 | Tooth Erosion | COMPLETED | NCT03296072 |
| 0.454% w/w stannous fluoride | Other | Phase PHASE3 | Tooth Erosion | COMPLETED | NCT03296072 |
| 0.254% w/w sodium fluoride and 5% KNO3 | Other | Phase PHASE3 | Tooth Erosion | COMPLETED | NCT03296072 |
| Rifabutin | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT03149848 |
| Cabotegravir | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT03149848 |
| Rifabutin | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT03149848 |
| Cabotegravir | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT03149848 |
| Software of Big Data | Other | Preclinical | Asthma | COMPLETED | NCT03137043 |
| Questionnaire | Other | Preclinical | Asthma | COMPLETED | NCT03137043 |
| Dolutegravir | Other | Approved | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01536873 |
| Gepotidacin Capsule | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT02853435 |
| Gepotidacin HSWG Tablet | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT02853435 |
| Gepotidacin RC Tablet | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT02853435 |
| Gepotidacin Capsule | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT02853435 |
| Gepotidacin HSWG Tablet | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT02853435 |
| Gepotidacin RC Tablet | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT02853435 |
| GSK Biologicals' Recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK1203486A | Other | Phase PHASE2 | Melanoma | TERMINATED | NCT00706238 |
| GSK2586184 400mg | Other | Phase PHASE1 | Colitis, Ulcerative | TERMINATED | NCT02000453 |
| [18F]GSK2647544 IV bolus | Other | Phase PHASE1 | Alzheimer's Disease | TERMINATED | NCT01924858 |
| GSK2647544 oral | Other | Phase PHASE1 | Alzheimer's Disease | TERMINATED | NCT01924858 |
| [18F]GSK2647544 IV bolus | Other | Phase PHASE1 | Alzheimer's Disease | TERMINATED | NCT01924858 |
| GSK2647544 oral | Other | Phase PHASE1 | Alzheimer's Disease | TERMINATED | NCT01924858 |
| GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342) | Other | Phase PHASE2 | Tuberculosis (TB) | COMPLETED | NCT00600782 |
| GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342) | Other | Phase PHASE2 | Tuberculosis (TB) | COMPLETED | NCT00600782 |
| Omalizumab | Other | Phase PHASE4 | Asthma | UNKNOWN | NCT04585997 |
| Mepolizumab | Other | Phase PHASE4 | Asthma | UNKNOWN | NCT04585997 |
| Subjects do not receive study medication in this study 202094 | Drug | Phase PHASE3 | HIV Infections | COMPLETED | NCT02478632 |
| Enzalutamide | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT02215096 |
| GSK2636771 | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT02215096 |
| Enzalutamide | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT02215096 |
| GSK2636771 | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT02215096 |
| Placebo | Other | Phase PHASE2 | Asthma | TERMINATED | NCT03393806 |
| GSK3772847 | Other | Phase PHASE2 | Asthma | TERMINATED | NCT03393806 |
| Placebo | Other | Phase PHASE2 | Asthma | TERMINATED | NCT03393806 |
| GSK3772847 | Other | Phase PHASE2 | Asthma | TERMINATED | NCT03393806 |
| Boostrix | Other | Phase PHASE3 | Diphtheria-Tetanus-acellular Pertussis Vaccines | COMPLETED | NCT03311659 |
| Sporozoite-infected mosquitoes challenge. | Other | Phase PHASE2 | Malaria | COMPLETED | NCT03162614 |
| RTS,S/AS01B | Other | Phase PHASE2 | Malaria | COMPLETED | NCT03162614 |
| RTS,S/AS01E | Other | Phase PHASE2 | Malaria | COMPLETED | NCT03162614 |
| Placebo | Other | Phase PHASE2 | Lung Injury, Acute and Respiratory Distress Syndrome, Adult | TERMINATED | NCT02221037 |
| GSK2862277 | Other | Phase PHASE2 | Lung Injury, Acute and Respiratory Distress Syndrome, Adult | TERMINATED | NCT02221037 |
| Mencevax | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00514904 |
| Nimenrix | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00514904 |
| Placebo for GSK2838232 tablets | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT03234036 |
| Ritonavir 100 mg tablets | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT03234036 |
| GSK2838232 50 mg capsule | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT03234036 |
| GSK2838232 100 mg tablet | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT03234036 |
| Anoro ELLIPTA | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03114969 |
| Incruse ELLIPTA | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03114969 |
| BREEZHALER | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03114969 |
| Spiriva HANDIHALER | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03114969 |
| Seretide DISKUS | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03114969 |
| Symbicort TURBUHALER | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03114969 |
| Relvar ELLIPTA | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03114969 |
| Albuterol/salbutamol | Other | Phase PHASE2 | Asthma | COMPLETED | NCT03012061 |
| Fluticasone Furoate | Other | Phase PHASE2 | Asthma | COMPLETED | NCT03012061 |
| UMEC | Other | Phase PHASE2 | Asthma | COMPLETED | NCT03012061 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT03012061 |
| TETRActHib™ | Other | Phase PHASE2 | Malaria | COMPLETED | NCT00289185 |
| Engerix-B® | Other | Phase PHASE2 | Malaria | COMPLETED | NCT00289185 |
| RTS,S/AS02D | Other | Phase PHASE2 | Malaria | COMPLETED | NCT00289185 |
| Placebo | Other | Phase PHASE2 | Arthritis, Rheumatoid | TERMINATED | NCT02965599 |
| GSK3117391 | Other | Phase PHASE2 | Arthritis, Rheumatoid | TERMINATED | NCT02965599 |
| Exenatide placebo (saline) | Other | Phase PHASE4 | Diabetes Mellitus | TERMINATED | NCT02802514 |
| Exenatide 10microgram | Other | Phase PHASE4 | Diabetes Mellitus | TERMINATED | NCT02802514 |
| Albiglutide matching placebo | Other | Phase PHASE4 | Diabetes Mellitus | TERMINATED | NCT02802514 |
| Albiglutide 50mg | Other | Phase PHASE4 | Diabetes Mellitus | TERMINATED | NCT02802514 |
| retigabine/ezogabine | Other | Phase PHASE3 | Epilepsy | TERMINATED | NCT01668654 |
| otelixizumab | Other | Phase PHASE2 | Diabetes Mellitus, Type 1 | TERMINATED | NCT01222078 |
| Methylprednisolone | Other | Phase PHASE2 | Graves Ophthalmopathy | TERMINATED | NCT01114503 |
| Otelixizumab | Other | Phase PHASE2 | Graves Ophthalmopathy | TERMINATED | NCT01114503 |
| Otelixizumab - high dose | Other | Phase PHASE2 | Graves Ophthalmopathy | TERMINATED | NCT01114503 |
| Otelixizumab - medium high dose | Other | Phase PHASE2 | Graves Ophthalmopathy | TERMINATED | NCT01114503 |
| Otelixizumab - medium low dose | Other | Phase PHASE2 | Graves Ophthalmopathy | TERMINATED | NCT01114503 |
| Otelixizumab - low dose | Other | Phase PHASE2 | Graves Ophthalmopathy | TERMINATED | NCT01114503 |
| Cervico-vaginal secretion (CVS) samples | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00947115 |
| Blood sampling | Other | Phase PHASE3 | Infections, Papillomavirus | COMPLETED | NCT00947115 |
| SB-656933 | Other | Phase PHASE2 | Colitis, Ulcerative | TERMINATED | NCT00748410 |
| Chloroquine | Other | Phase PHASE2 | Malaria, Vivax | COMPLETED | NCT02563496 |
| Tafenoquine | Other | Phase PHASE2 | Malaria, Vivax | COMPLETED | NCT02563496 |
| Ritonavir | Other | Phase PHASE1 | HIV Infection | COMPLETED | NCT00817765 |
| Fosamprenavir | Other | Phase PHASE1 | HIV Infection | COMPLETED | NCT00817765 |
| Posaconazole | Other | Phase PHASE1 | HIV Infection | COMPLETED | NCT00817765 |
| Rifampicin 300 mg | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT02706535 |
| Itraconazole 200 mg | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT02706535 |
| GSK525762 Besylate Tablets | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT02706535 |
| Placebo Al(OH)3 | Other | Phase PHASE3 | Human Papillomavirus (HPV) Infection | COMPLETED | NCT00481767 |
| Cervarix | Other | Phase PHASE3 | Human Papillomavirus (HPV) Infection | COMPLETED | NCT00481767 |
| Placebo Al(OH)3 | Other | Phase PHASE3 | Human Papillomavirus (HPV) Infection | COMPLETED | NCT00481767 |
| Cervarix | Other | Phase PHASE3 | Human Papillomavirus (HPV) Infection | COMPLETED | NCT00481767 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03965533 |
| GSK2831781 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03965533 |
| Placebo | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT00265148 |
| Rosiglitazone | Other | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT00265148 |
| Colgate Cavity Protection | Other | Phase PHASE4 | Gingivitis | COMPLETED | NCT04050722 |
| Sensodyne Repair and Protect | Other | Phase PHASE4 | Gingivitis | COMPLETED | NCT04050722 |
| Blood sampling for antibody determination | Other | Phase PHASE3 | Cervical Intraepithelial Neoplasia | COMPLETED | NCT03355820 |
| Immunotherapeutic GSK2302025A, different formulations | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT01149343 |
| Menjugate | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT01266993 |
| Nimenrix (GSK134612 vaccine) | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT01266993 |
| Pneumococcal conjugate vaccine Prevenar™ (Wyeth Lederle's) | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00907777 |
| Pneumococcal conjugate vaccine GSK 1024850A | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00907777 |
| Saline placebo | Other | Phase PHASE1 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT01435993 |
| GSK1223249 | Other | Phase PHASE1 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT01435993 |
| ACE inhibitors | Other | Phase PHASE4 | Heart Failure, Congestive | COMPLETED | NCT00344513 |
| Beta-blockers including Carvedilol | Other | Phase PHASE4 | Heart Failure, Congestive | COMPLETED | NCT00344513 |
| ACE inhibitors | Other | Phase PHASE4 | Heart Failure, Congestive | COMPLETED | NCT00344513 |
| Beta-blockers including Carvedilol | Other | Phase PHASE4 | Heart Failure, Congestive | COMPLETED | NCT00344513 |
| Physiogel Calming Relief Anti-Redness Serum | Other | Approved | Skin Care | COMPLETED | NCT03640832 |
| Developmental Serum | Other | Approved | Skin Care | COMPLETED | NCT03640832 |
| Stannous Chloride (SnCl2) and 0.15% NaF: 1450 ppm fluoride in total | Other | Approved | Dentin Sensitivity | COMPLETED | NCT03310268 |
| 1400 ppm fluoride as sodium monofluorophosphate (SMFP) | Other | Approved | Dentin Sensitivity | COMPLETED | NCT03310268 |
| 0.454% Stannous fluoride (SnF2) and 0.072% sodium fluoride (NaF): 1450 ppm fluoride in total | Other | Approved | Dentin Sensitivity | COMPLETED | NCT03310268 |
| Treatment Benefit Scale (TBS) | Drug | Phase PHASE3 | Urinary Bladder, Overactive | COMPLETED | NCT02820844 |
| Overactive Bladder Symptom Score (OABSS) | Other | Phase PHASE3 | Urinary Bladder, Overactive | COMPLETED | NCT02820844 |
| King's Health Questionnaire (KHQ) | Other | Phase PHASE3 | Urinary Bladder, Overactive | COMPLETED | NCT02820844 |
| Bladder diary | Other | Phase PHASE3 | Urinary Bladder, Overactive | COMPLETED | NCT02820844 |
| Antibiotic therapy | Drug | Phase PHASE3 | Urinary Bladder, Overactive | COMPLETED | NCT02820844 |
| Placebo | Other | Phase PHASE3 | Urinary Bladder, Overactive | COMPLETED | NCT02820844 |
| GSK1358820 | Other | Phase PHASE3 | Urinary Bladder, Overactive | COMPLETED | NCT02820844 |
| Placebo | Other | Phase PHASE1 | Cancer | COMPLETED | NCT02798978 |
| GSK1795091 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT02798978 |
| Oseltamivir 75 mg | Other | Phase PHASE2 | Virus Diseases | TERMINATED | NCT02927431 |
| Placebo | Other | Phase PHASE2 | Virus Diseases | TERMINATED | NCT02927431 |
| Danirixin 50 mg FBE | Other | Phase PHASE2 | Virus Diseases | TERMINATED | NCT02927431 |
| Danirixin 15 mg FBE | Other | Phase PHASE2 | Virus Diseases | TERMINATED | NCT02927431 |
| olanzapine | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00977301 |
| fosamprenavir/ritonavir | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00977301 |
| ezogabine/retigabine | Other | Phase PHASE4 | Epilepsy | TERMINATED | NCT01607346 |
| Immunotherapeutic GSK2132231A | Other | Phase PHASE2 | Melanoma | COMPLETED | NCT00942162 |
| Normal Saline | Other | Approved | Skin Care | COMPLETED | NCT04007159 |
| Cream | Other | Approved | Skin Care | COMPLETED | NCT04007159 |
| Lotion | Other | Approved | Skin Care | COMPLETED | NCT04007159 |
| Serum | Other | Approved | Skin Care | COMPLETED | NCT04007159 |
| Osimertinib | Other | Phase PHASE1 | Lung Cancer | UNKNOWN | NCT03891615 |
| Niraparib | Other | Phase PHASE1 | Lung Cancer | UNKNOWN | NCT03891615 |
| Osimertinib | Other | Phase PHASE1 | Lung Cancer | UNKNOWN | NCT03891615 |
| Niraparib | Other | Phase PHASE1 | Lung Cancer | UNKNOWN | NCT03891615 |
| GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine) | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00861380 |
| GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine) | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00861380 |
| Pneumococcal conjugate vaccine GSK1024850A | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00861380 |
| GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine) | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00839254 |
| GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine) | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00839254 |
| Pneumococcal conjugate vaccine Synflorix (GSK1024850A) | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00839254 |
| Data collection | Other | Preclinical | Pertussis | COMPLETED | NCT02096276 |
| Placebo Control | Other | Phase PHASE3 | Lung Cancer, Non-Small Cell | TERMINATED | NCT00480025 |
| GSK1572932A Antigen-Specific Cancer Immunotherapeutic | Other | Phase PHASE3 | Lung Cancer, Non-Small Cell | TERMINATED | NCT00480025 |
| Reference Griseofulvin 500 mg | Other | Phase PHASE1 | Antifungal Agents | COMPLETED | NCT04318535 |
| Griseofulvin 250 mg | Other | Phase PHASE1 | Antifungal Agents | COMPLETED | NCT04318535 |
| Griseofulvin 500 mg | Other | Phase PHASE1 | Antifungal Agents | COMPLETED | NCT04318535 |
| Belimumab for SC | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT04136145 |
| Belimumab for IV | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT04136145 |
| Prevenar 13 | Other | Phase PHASE3 | Rotavirus Infection | COMPLETED | NCT03207750 |
| Hiberix | Other | Phase PHASE3 | Rotavirus Infection | COMPLETED | NCT03207750 |
| Pediarix | Other | Phase PHASE3 | Rotavirus Infection | COMPLETED | NCT03207750 |
| Rotarix | Other | Phase PHASE3 | Rotavirus Infection | COMPLETED | NCT03207750 |
| International Prostate Symptom Score (IPSS) screening tool | Other | Phase PHASE4 | Prostatic Hyperplasia | COMPLETED | NCT02757963 |
| Benign prostatic enlargement (BPE)/Benign prostatic obstruction (BPO) screening tool | Other | Phase PHASE4 | Prostatic Hyperplasia | COMPLETED | NCT02757963 |
| Prevnar 13 | Other | Phase PHASE3 | Measles; Mumps; Rubella | COMPLETED | NCT02184572 |
| Havrix | Other | Phase PHASE3 | Measles; Mumps; Rubella | COMPLETED | NCT02184572 |
| Varivax | Other | Phase PHASE3 | Measles; Mumps; Rubella | COMPLETED | NCT02184572 |
| M-M-R II | Other | Phase PHASE3 | Measles; Mumps; Rubella | COMPLETED | NCT02184572 |
| Priorix | Other | Phase PHASE3 | Measles; Mumps; Rubella | COMPLETED | NCT02184572 |
| Prevnar 13 | Other | Phase PHASE3 | Measles | COMPLETED | NCT01681992 |
| Havrix | Other | Phase PHASE3 | Measles | COMPLETED | NCT01681992 |
| Varivax | Other | Phase PHASE3 | Measles | COMPLETED | NCT01681992 |
| M-M-R II | Other | Phase PHASE3 | Measles | COMPLETED | NCT01681992 |
| Priorix | Other | Phase PHASE3 | Measles | COMPLETED | NCT01681992 |
| Placebo | Other | Phase PHASE2 | Respiratory Disorders | COMPLETED | NCT03281876 |
| NTHi Mcat investigational vaccine (GSK3277511A) | Other | Phase PHASE2 | Respiratory Disorders | COMPLETED | NCT03281876 |
| Placebo | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT02504671 |
| Folic acid | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT02504671 |
| MTX | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT02504671 |
| GSK3196165 | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT02504671 |
| Placebo | Other | Phase PHASE4 | Rhinitis, Allergic, Perennial and Seasonal | COMPLETED | NCT02424539 |
| FFNS | Other | Phase PHASE4 | Rhinitis, Allergic, Perennial and Seasonal | COMPLETED | NCT02424539 |
| lapatinib | Other | Phase EARLY_PHASE1 | Vestibular Schwannoma | COMPLETED | NCT00863122 |
| lapatinib | Other | Phase EARLY_PHASE1 | Vestibular Schwannoma | COMPLETED | NCT00863122 |
| Blood Sampling | Other | Phase PHASE4 | Tetanus | COMPLETED | NCT01358825 |
| Super Poligrip Free | Other | Phase PHASE3 | Denture Retention | WITHDRAWN | NCT04473521 |
| Investigational denture adhesive cream | Other | Phase PHASE3 | Denture Retention | WITHDRAWN | NCT04473521 |
| Placebo | Other | Phase PHASE1 | Subarachnoid Hemorrhage, Aneurysmal | COMPLETED | NCT03318783 |
| GSK2256294 | Other | Phase PHASE1 | Subarachnoid Hemorrhage, Aneurysmal | COMPLETED | NCT03318783 |
| pazopanib | Other | Phase PHASE2 | Sarcoma, Soft-tissue | TERMINATED | NCT01543802 |
| Varilrix | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00624819 |
| Havrix | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00624819 |
| Infanrix hexa | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00624819 |
| Prevenar | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00624819 |
| GSK1024805A | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT00624819 |
| Respiratory nasal swab | Other | Preclinical | Influenza | COMPLETED | NCT02979626 |
| Licensed GSK MenACWY vaccine (Menveo) | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT03652610 |
| MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A) | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT03652610 |
| Synflorix™ | Other | Phase PHASE1 | Infections, Streptococcal | COMPLETED | NCT01485406 |
| Pneumococcal vaccine GSK2830930A | Other | Phase PHASE1 | Infections, Streptococcal | COMPLETED | NCT01485406 |
| Synflorix™ | Other | Phase PHASE1 | Infections, Streptococcal | COMPLETED | NCT01485406 |
| Pneumococcal vaccine GSK2830930A | Other | Phase PHASE1 | Infections, Streptococcal | COMPLETED | NCT01485406 |
| Placebo | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT01165177 |
| Herpes Zoster Vaccine GSK1437173A | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT01165177 |
| Placebo | Other | Phase PHASE2 | Dengue | COMPLETED | NCT00350337 |
| Post-transfection F19 | Other | Phase PHASE2 | Dengue | COMPLETED | NCT00350337 |
| Post-transfection F17 | Other | Phase PHASE2 | Dengue | COMPLETED | NCT00350337 |
| Pre-transfection F17 | Other | Phase PHASE2 | Dengue | COMPLETED | NCT00350337 |
| Rabipur (Rabies) Vaccine | Other | Phase PHASE2 | Plasmodium Falciparum | COMPLETED | NCT00197054 |
| RTS, S/AS02A | Other | Phase PHASE2 | Plasmodium Falciparum | COMPLETED | NCT00197054 |
| RTS, S/AS01B | Other | Phase PHASE2 | Plasmodium Falciparum | COMPLETED | NCT00197054 |
| Phosphate buffered saline (PBS) | Other | Phase PHASE1 | Influenza | COMPLETED | NCT03300050 |
| Normal saline | Other | Phase PHASE1 | Influenza | COMPLETED | NCT03300050 |
| AS03-adjuvanted cH8/1N1 IIV | Other | Phase PHASE1 | Influenza | COMPLETED | NCT03300050 |
| cH5/1N1 IIV | Other | Phase PHASE1 | Influenza | COMPLETED | NCT03300050 |
| AS03-adjuvanted cH5/1N1 IIV | Other | Phase PHASE1 | Influenza | COMPLETED | NCT03300050 |
| cH8/1N1 LAIV | Other | Phase PHASE1 | Influenza | COMPLETED | NCT03300050 |
| Meningitec™ | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00955682 |
| Meningococcal vaccine GSK134612 | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT00955682 |
| Salbutamol/albuterol | Other | Phase PHASE1 | Asthma | COMPLETED | NCT03287310 |
| Placebo | Other | Phase PHASE1 | Asthma | COMPLETED | NCT03287310 |
| GSK3511294 | Other | Phase PHASE1 | Asthma | COMPLETED | NCT03287310 |
| hepatitis B vaccine or hepatitis A vaccine | Other | Preclinical | Pneumococcal Infections | COMPLETED | NCT01311024 |
| PCV GSK1024850A | Other | Preclinical | Pneumococcal Infections | COMPLETED | NCT01311024 |
| Prevenar 13 (2-Dose) | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT01641133 |
| Prevenar 13 (Single Dose) | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT01641133 |
| Synflorix (Single Dose) | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT01641133 |
| Synflorix (2-Dose) | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT01641133 |
| Synflorix (3-Dose) | Other | Phase PHASE3 | Infections, Streptococcal | COMPLETED | NCT01641133 |
| Herpes Zoster Vaccine GSK1437173A | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT02690207 |
| Placebo | Other | Phase PHASE3 | Melanoma | TERMINATED | NCT00796445 |
| GSK 2132231A | Other | Phase PHASE3 | Melanoma | TERMINATED | NCT00796445 |
| Data collection | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT00353366 |
| Rotarix | Other | Preclinical | Infections, Rotavirus | COMPLETED | NCT00353366 |
| Standard therapy | Drug | Phase PHASE3 | Lupus Nephritis | COMPLETED | NCT01639339 |
| Belimumab 10 mg/kg plus standard therapy | Drug | Phase PHASE3 | Lupus Nephritis | COMPLETED | NCT01639339 |
| Placebo plus standard therapy | Drug | Phase PHASE3 | Lupus Nephritis | COMPLETED | NCT01639339 |
| Standard therapy | Drug | Phase PHASE3 | Lupus Nephritis | COMPLETED | NCT01639339 |
| Belimumab 10 mg/kg plus standard therapy | Drug | Phase PHASE3 | Lupus Nephritis | COMPLETED | NCT01639339 |
| Placebo plus standard therapy | Drug | Phase PHASE3 | Lupus Nephritis | COMPLETED | NCT01639339 |
| METERED-DOSE INHALER (MDI) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02924688 |
| DISKUS DPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02924688 |
| ELLIPTA DPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02924688 |
| Albuterol/salbutamol | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02924688 |
| Fluticasone/salmeterol (FSC) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02924688 |
| FF/VI (200/25) mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02924688 |
| FF/VI (100/25) mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02924688 |
| FF/UMEC/VI (200/62.5/25) mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02924688 |
| FF/UMEC/VI (200/31.25/25) mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02924688 |
| FF/UMEC/VI (100/62.5/25) mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02924688 |
| FF/UMEC/VI (100/31.25/25) mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02924688 |
| Placebo Nasal Spray Solution | Other | Phase PHASE2 | Asthma | COMPLETED | NCT02833974 |
| GSK2245035 Nasal Spray Solution | Other | Phase PHASE2 | Asthma | COMPLETED | NCT02833974 |
| Inhaled COPD maintenance medication | Drug | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03250689 |
| Rescue medication | Drug | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03250689 |
| Placebo | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03250689 |
| Danirixin | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03250689 |
| Epoetin beta pegol | Other | Phase PHASE3 | Anaemia | COMPLETED | NCT02791763 |
| 6 mg GSK1278863 tablet | Other | Phase PHASE3 | Anaemia | COMPLETED | NCT02791763 |
| 1 to 4 mg tablets of GSK1278863 | Other | Phase PHASE3 | Anaemia | COMPLETED | NCT02791763 |
| Epoetin beta pegol | Other | Phase PHASE3 | Anaemia | COMPLETED | NCT02791763 |
| 6 mg GSK1278863 tablet | Other | Phase PHASE3 | Anaemia | COMPLETED | NCT02791763 |
| 1 to 4 mg tablets of GSK1278863 | Other | Phase PHASE3 | Anaemia | COMPLETED | NCT02791763 |
| Placebo | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT03231943 |
| GSK3640254 | Other | Phase PHASE1 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT03231943 |
| Bronchoscopy | Other | Approved | COPD | COMPLETED | NCT03984799 |
| GSK3326595 | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT04676516 |
| GSK3326595 | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT04676516 |
| Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY) | Other | Phase PHASE4 | Meningitis, Meningococcal | COMPLETED | NCT03493919 |
| rMenB+OMV NZ vaccine | Other | Phase PHASE4 | Meningitis, Meningococcal | COMPLETED | NCT03493919 |
| Placebo | Other | Phase PHASE4 | Herpes Zoster | RECRUITING | NCT07502560 |
| Recombinant zoster vaccine | Other | Phase PHASE4 | Herpes Zoster | RECRUITING | NCT07502560 |
| Dostarlimab | Other | Phase PHASE2 | Stage I Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04584255 |
| Niraparib | Other | Phase PHASE2 | Stage I Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04584255 |
| Hypofractionated IMRT | Other | Phase PHASE2 | Endometrial Cancer | RECRUITING | NCT04774419 |
| Dostarlimab | Other | Phase PHASE2 | Endometrial Cancer | RECRUITING | NCT04774419 |
| Intensity modulated radiation therapy (IMRT) | Drug | Phase PHASE2 | Endometrial Cancer | RECRUITING | NCT04774419 |
| Bepirovirsen | Other | Phase PHASE1 | Hepatitis B | TERMINATED | NCT05330455 |
| Placebo to match GSK3965193 | Other | Phase PHASE1 | Hepatitis B | TERMINATED | NCT05330455 |
| GSK3965193 | Other | Phase PHASE1 | Hepatitis B | TERMINATED | NCT05330455 |
| Belantamab mafodotin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05002816 |
| Elotuzumab | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05002816 |
| Intensity Modulated Radiation Therapy (IMRT) | Drug | Phase PHASE2 | Rectal Adenocarcinoma | RECRUITING | NCT04165772 |
| capecitabine or 5-FU | Other | Phase PHASE2 | Rectal Adenocarcinoma | RECRUITING | NCT04165772 |
| TSR-042 or Dostarlimab | Other | Phase PHASE2 | Rectal Adenocarcinoma | RECRUITING | NCT04165772 |
| Imatinib | Other | Phase PHASE3 | Gastrointestinal Stromal Neoplasms | NOT_YET_RECRUITING | NCT07585266 |
| Velzatinib | Other | Phase PHASE3 | Gastrointestinal Stromal Neoplasms | NOT_YET_RECRUITING | NCT07585266 |
| Placebo | Other | Phase PHASE4 | Herpes Zoster | RECRUITING | NCT07502560 |
| Recombinant zoster vaccine | Other | Phase PHASE4 | Herpes Zoster | RECRUITING | NCT07502560 |
| Depemokimab | Other | Phase PHASE1 | Asthma | COMPLETED | NCT05602025 |
| Primaquine | Other | Phase PHASE2 | Plasmodium Falciparum | COMPLETED | NCT04661579 |
| Artemether / Lumefantrine | Other | Phase PHASE2 | Plasmodium Falciparum | COMPLETED | NCT04661579 |
| Dihydroartemisinin-piperaquine (DHA/Pip) | Other | Phase PHASE2 | Plasmodium Falciparum | COMPLETED | NCT04661579 |
| Abhayrab rabies vaccine | Other | Phase PHASE2 | Plasmodium Falciparum | COMPLETED | NCT04661579 |
| Malaria Vaccine RTS,S/AS01E | Other | Phase PHASE2 | Plasmodium Falciparum | COMPLETED | NCT04661579 |
| Placebo | Other | Phase PHASE4 | Herpes Zoster | RECRUITING | NCT07502560 |
| Recombinant zoster vaccine | Other | Phase PHASE4 | Herpes Zoster | RECRUITING | NCT07502560 |
| Placebo | Other | Phase PHASE1 | Lupus Erythematosus, Cutaneous | COMPLETED | NCT02927457 |
| GSK2646264 1% | Other | Phase PHASE1 | Lupus Erythematosus, Cutaneous | COMPLETED | NCT02927457 |
| Immunotherapeutic GSK2132231A | Other | Phase PHASE2 | Melanoma | COMPLETED | NCT00896480 |
| Gepotidacin | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT03562117 |
| Run In Medication | Drug | Phase PHASE2 | Nasal Polyps | COMPLETED | NCT01362244 |
| Placebo | Other | Phase PHASE2 | Nasal Polyps | COMPLETED | NCT01362244 |
| Mepolizumab | Other | Phase PHASE2 | Nasal Polyps | COMPLETED | NCT01362244 |
| Arnuity Ellipta | Other | Preclinical | Asthma | COMPLETED | NCT03184480 |
| Saliva collection | Other | Approved | Infections, Cytomegalovirus | COMPLETED | NCT01691820 |
| Urine collection | Other | Approved | Infections, Cytomegalovirus | COMPLETED | NCT01691820 |
| Blood collection | Other | Approved | Infections, Cytomegalovirus | COMPLETED | NCT01691820 |
| Placebo- sodium chloride | Other | Phase PHASE1 | Crohn Disease | COMPLETED | NCT03681067 |
| GSK1070806 | Other | Phase PHASE1 | Crohn Disease | COMPLETED | NCT03681067 |
| GSK2330672 | Other | Phase PHASE2 | Cholestasis | COMPLETED | NCT02966834 |
| Placebo | Other | Phase PHASE2 | Cholestasis | COMPLETED | NCT02966834 |
| GSK2330672 | Other | Phase PHASE2 | Cholestasis | COMPLETED | NCT02966834 |
| Placebo | Other | Phase PHASE2 | Cholestasis | COMPLETED | NCT02966834 |
| Fluarix Quadrivalent | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT03275389 |
| Placebo | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT03275389 |
| D-SUIV cH11/1N1 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT03275389 |
| D-SUIV cH5/1N1 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT03275389 |
| D-SUIV cH8/1N1 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT03275389 |
| D-SUIV cH11/1N1+AS01 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT03275389 |
| D-SUIV cH5/1N1+AS01 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT03275389 |
| D-SUIV cH8/1N1+AS01 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT03275389 |
| D-SUIV cH11/1N1+AS03 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT03275389 |
| D-SUIV cH5/1N1+AS03 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT03275389 |
| D-SUIV cH8/1N1+AS03 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT03275389 |
| Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets) | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT03031496 |
| GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets) | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT03031496 |
| Ofatumumab + Fresh Frozen Plasma | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01716208 |
| Herpes Zoster vaccine (GSK 1437173A) | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT02075515 |
| Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™ | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT02045836 |
| Herpes Zoster vaccine GSK 1437173A | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT02045836 |
| Pazopanib | Other | Phase PHASE2 | Germ Cell Tumors | COMPLETED | NCT01743482 |
| Pembrolizumab | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT02528357 |
| GSK3174998 | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT02528357 |
| GSK2330811 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04138043 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04138043 |
| Placebo | Other | Phase PHASE2 | Scleroderma, Systemic | COMPLETED | NCT03041025 |
| GSK2330811 | Other | Phase PHASE2 | Scleroderma, Systemic | COMPLETED | NCT03041025 |
| Placebo | Other | Phase PHASE2 | Scleroderma, Systemic | COMPLETED | NCT03041025 |
| GSK2330811 | Other | Phase PHASE2 | Scleroderma, Systemic | COMPLETED | NCT03041025 |
| Trastuzumab | Other | Phase PHASE2 | Neoplasms, Breast | TERMINATED | NCT01220128 |
| Paclitaxel | Other | Phase PHASE2 | Neoplasms, Breast | TERMINATED | NCT01220128 |
| Epirubicin | Other | Phase PHASE2 | Neoplasms, Breast | TERMINATED | NCT01220128 |
| Doxorubicin | Other | Phase PHASE2 | Neoplasms, Breast | TERMINATED | NCT01220128 |
| Docetaxel | Other | Phase PHASE2 | Neoplasms, Breast | TERMINATED | NCT01220128 |
| Cyclophosphamide | Other | Phase PHASE2 | Neoplasms, Breast | TERMINATED | NCT01220128 |
| Carboplatin AUC | Other | Phase PHASE2 | Neoplasms, Breast | TERMINATED | NCT01220128 |
| 5-Fluorouracil | Other | Phase PHASE2 | Neoplasms, Breast | TERMINATED | NCT01220128 |
| Aromatase inhibitor | Other | Phase PHASE2 | Neoplasms, Breast | TERMINATED | NCT01220128 |
| Placebo | Other | Phase PHASE2 | Neoplasms, Breast | TERMINATED | NCT01220128 |
| GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A | Other | Phase PHASE2 | Neoplasms, Breast | TERMINATED | NCT01220128 |
| Niraparib | Other | Phase PHASE1 | Ovarian Neoplasms | COMPLETED | NCT03359850 |
| Niraparib | Other | Phase PHASE1 | Ovarian Neoplasms | COMPLETED | NCT03359850 |
| Epoetin alfa | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT03029247 |
| Daprodustat | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT03029247 |
| Epoetin alfa | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT03029247 |
| Daprodustat | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT03029247 |
| Mepolizumab | Other | Preclinical | Asthma; Eosinophilic | UNKNOWN | NCT04924478 |
| Sputum and blood sampling | Other | Approved | Respiratory Disorders | COMPLETED | NCT03151395 |
| Sputum and blood sampling | Other | Approved | Respiratory Disorders | COMPLETED | NCT03151395 |
| Placebo | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT02858492 |
| GSK2982772 60 mg | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT02858492 |
| Placebo | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT02858492 |
| GSK2982772 60 mg | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT02858492 |
| Nemiralisib | Other | Phase PHASE2 | Activated PI3K-delta Syndrome | COMPLETED | NCT02593539 |
| GSK2586184 new formulation | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT01953835 |
| Rosuvastatin | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT01953835 |
| Simvastatin | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT01953835 |
| GSK2586184 standard formulation | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT01953835 |
| Placebo (saline) | Other | Phase PHASE1 | Herpes Simplex | TERMINATED | NCT04762511 |
| High dose formulation of HSV vaccine (GSK4108771A) | Other | Phase PHASE1 | Herpes Simplex | TERMINATED | NCT04762511 |
| Medium dose formulation of HSV vaccine (GSK4108771A) | Other | Phase PHASE1 | Herpes Simplex | TERMINATED | NCT04762511 |
| Low dose formulation of HSV vaccine (GSK4108771A) | Other | Phase PHASE1 | Herpes Simplex | TERMINATED | NCT04762511 |
| Lower dose formulation of HSV vaccine (GSK4108771A) | Other | Phase PHASE1 | Herpes Simplex | TERMINATED | NCT04762511 |
| Cyclophosphamide | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT01343043 |
| Fludarabine | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT01343043 |
| NY-ESO-1(c259)T Cells | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT01343043 |
| Routine Treatment | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT02868281 |
| ACT guided Routine Treatment | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT02868281 |
| Saline vials or bags | Other | Phase PHASE3 | Anaemia | COMPLETED | NCT03400033 |
| Epoetin alfa vials | Other | Phase PHASE3 | Anaemia | COMPLETED | NCT03400033 |
| Matching placebo tablets | Other | Phase PHASE3 | Anaemia | COMPLETED | NCT03400033 |
| Daprodustat tablets | Other | Phase PHASE3 | Anaemia | COMPLETED | NCT03400033 |
| PROMIS Physical Function Items | Other | Preclinical | Neoplasms | COMPLETED | NCT03351140 |
| Qualitative Interviews | Other | Preclinical | Neoplasms | COMPLETED | NCT03351140 |
| Standard of care therapy | Drug | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03345407 |
| Albuterol (Salbutamol) MDI or nebules | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03345407 |
| Nemiralisib ELLIPTA 750 µg | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03345407 |
| Nemiralisib ELLIPTA 500 µg | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03345407 |
| Nemiralisib ELLIPTA 250 µg | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03345407 |
| Nemiralisib ELLIPTA 100 µg | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03345407 |
| Nemiralisib ELLIPTA 50 µg | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03345407 |
| Placebo ELLIPTA | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03345407 |
| Standard of care therapy | Drug | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03345407 |
| Albuterol (Salbutamol) MDI or nebules | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03345407 |
| Nemiralisib ELLIPTA 750 µg | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03345407 |
| Nemiralisib ELLIPTA 500 µg | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03345407 |
| Nemiralisib ELLIPTA 250 µg | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03345407 |
| Nemiralisib ELLIPTA 100 µg | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03345407 |
| Nemiralisib ELLIPTA 50 µg | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03345407 |
| Placebo ELLIPTA | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | TERMINATED | NCT03345407 |
| Placebo | Other | Phase PHASE3 | Urinary Bladder, Overactive | COMPLETED | NCT02849418 |
| GSK1358820 | Other | Phase PHASE3 | Urinary Bladder, Overactive | COMPLETED | NCT02849418 |
| Placebo | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT01262898 |
| GSK962040 (125 mg tablet) | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT01262898 |
| GSK962040 (25 mg tablet) | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT01262898 |
| GSK962040 (5 mg tablet) | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT01262898 |
| RELVAR 100 ELLIPTA | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03219255 |
| RELVAR 100 ELLIPTA | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03219255 |
| Placebo Treatment Beverage | Drug | Approved | Nutritional and Metabolic Disease | COMPLETED | NCT01729949 |
| Active Treatment Beverage | Drug | Approved | Nutritional and Metabolic Disease | COMPLETED | NCT01729949 |
| Questionnaire | Other | Preclinical | Multiple Myeloma | UNKNOWN | NCT04727294 |
| 10-valent pneumococcal conjugate vaccine, PCV10 | Other | Preclinical | Pneumococcal Infections | COMPLETED | NCT04912297 |
| 10-valent pneumococcal conjugate vaccine, PCV10 | Other | Preclinical | Pneumococcal Infections | COMPLETED | NCT04912297 |
| Placebo | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02294734 |
| GSK2269557 | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02294734 |
| Placebo | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02294734 |
| GSK2269557 | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02294734 |
| Normal Saline | Other | Approved | Skin Care | COMPLETED | NCT04006795 |
| Cream | Other | Approved | Skin Care | COMPLETED | NCT04006795 |
| Lotion | Other | Approved | Skin Care | COMPLETED | NCT04006795 |
| Serum | Other | Approved | Skin Care | COMPLETED | NCT04006795 |
| Placebo (Normal Saline) | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03674177 |
| GSK3888550A RSV Maternal vaccine formulation 3 | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03674177 |
| GSK3888550A RSV Maternal vaccine formulation 2 | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03674177 |
| GSK3888550A RSV Maternal vaccine formulation 1 | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03674177 |
| Placebo | Other | Phase PHASE2 | Respiratory Disorders | COMPLETED | NCT03443427 |
| NTHi Mcat investigational vaccine (GSK3277511A) | Other | Phase PHASE2 | Respiratory Disorders | COMPLETED | NCT03443427 |
| Fludarabine | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT02588612 |
| Cyclophosphamide | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT02588612 |
| letetresgene autoleucel (GSK3377794) | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT02588612 |
| ELLIPTA | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02522299 |
| DISKUS | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02522299 |
| Placebo | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02522299 |
| GSK2269557 | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02522299 |
| ELLIPTA | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02522299 |
| DISKUS | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02522299 |
| Placebo | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02522299 |
| GSK2269557 | Other | Phase PHASE2 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT02522299 |
| Evaluation of quality of life | Other | Preclinical | Pulmonary Hypertension | COMPLETED | NCT01380054 |
| Safety data collection (following routine vaccination) | Other | Preclinical | Cervical Intraepithelial Neoplasia | COMPLETED | NCT03438006 |
| Standard therapy | Drug | Phase PHASE4 | Systemic Lupus Erythematosus | COMPLETED | NCT01632241 |
| Belimumab 10 mg/kg plus standard therapy | Drug | Phase PHASE4 | Systemic Lupus Erythematosus | COMPLETED | NCT01632241 |
| Placebo plus standard therapy | Drug | Phase PHASE4 | Systemic Lupus Erythematosus | COMPLETED | NCT01632241 |
| Standard therapy | Drug | Phase PHASE4 | Systemic Lupus Erythematosus | COMPLETED | NCT01632241 |
| Belimumab 10 mg/kg plus standard therapy | Drug | Phase PHASE4 | Systemic Lupus Erythematosus | COMPLETED | NCT01632241 |
| Placebo plus standard therapy | Drug | Phase PHASE4 | Systemic Lupus Erythematosus | COMPLETED | NCT01632241 |
| Standard therapy | Drug | Phase PHASE4 | Systemic Lupus Erythematosus | COMPLETED | NCT01632241 |
| Belimumab 10 mg/kg plus standard therapy | Drug | Phase PHASE4 | Systemic Lupus Erythematosus | COMPLETED | NCT01632241 |
| Placebo plus standard therapy | Drug | Phase PHASE4 | Systemic Lupus Erythematosus | COMPLETED | NCT01632241 |
| Abacavir | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00214890 |
| Tenofovir | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00214890 |
| Stamaril | Other | Phase PHASE3 | Malaria | COMPLETED | NCT02699099 |
| MR-Vac | Other | Phase PHASE3 | Malaria | COMPLETED | NCT02699099 |
| Candidate Plasmodium falciparum malaria vaccine | Other | Phase PHASE3 | Malaria | COMPLETED | NCT02699099 |
| Vitamin A | Other | Phase PHASE3 | Malaria | COMPLETED | NCT02699099 |
| lapatinib | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00206427 |
| GW572016 | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00206427 |
| BOTOX | Other | Preclinical | Dysphonia | UNKNOWN | NCT03543150 |
| Iron therapy | Drug | Phase PHASE3 | Anaemia | COMPLETED | NCT03029208 |
| Darbepoetin alfa | Other | Phase PHASE3 | Anaemia | COMPLETED | NCT03029208 |
| Daprodustat | Other | Phase PHASE3 | Anaemia | COMPLETED | NCT03029208 |
| Niraparib | Other | Phase PHASE2 | Metastatic Melanoma | UNKNOWN | NCT03925350 |
| Niraparib | Other | Phase PHASE2 | Metastatic Melanoma | UNKNOWN | NCT03925350 |
| Placebo | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT02927873 |
| RSV (GSK3389245A) high dose formulation vaccine | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT02927873 |
| RSV (GSK3389245A) middle dose formulation vaccine | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT02927873 |
| RSV (GSK3389245A) low dose formulation vaccine | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT02927873 |
| Lovenox 40mg SC Daily | Other | Approved | Venous Thrombosis | TERMINATED | NCT00521885 |
| Arixtra (Fondaparinox) 2.5 mg SC Daily | Other | Approved | Venous Thrombosis | TERMINATED | NCT00521885 |
| Saline placebo | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01310413 |
| Influenza A (H5N1) Virus monovalent vaccine | Other | Phase PHASE3 | Influenza | COMPLETED | NCT01310413 |
| Engerix-B | Other | Preclinical | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT02985450 |
| Engerix-B | Other | Preclinical | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT02985450 |
| Bortezomib and Tositumomab I-131 | Other | Phase PHASE2 | Follicular Lymphoma | TERMINATED | NCT00479167 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04366349 |
| melrilimab (GSK3772847) 140 milligram (mg) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04366349 |
| melrilimab (GSK3772847) 70 milligram (mg) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04366349 |
| Isocarboxazid | Other | Phase EARLY_PHASE1 | Healthy Volunteers | COMPLETED | NCT02323217 |
| Idazoxan | Other | Phase EARLY_PHASE1 | Healthy Volunteers | COMPLETED | NCT02323217 |
| [11C]BU99008 | Other | Phase EARLY_PHASE1 | Healthy Volunteers | COMPLETED | NCT02323217 |
| Mometasone furoate drug formulation (MFF) 2 | Drug | Phase PHASE1 | Hypersensitivity | COMPLETED | NCT02588326 |
| Mometasone furoate drug formulation (MFF) 1 | Drug | Phase PHASE1 | Hypersensitivity | COMPLETED | NCT02588326 |
| Iron therapy | Drug | Phase PHASE3 | Anaemia | COMPLETED | NCT02879305 |
| Placebo | Other | Phase PHASE3 | Anaemia | COMPLETED | NCT02879305 |
| rhEPO | Other | Phase PHASE3 | Anaemia | COMPLETED | NCT02879305 |
| Daprodustat | Other | Phase PHASE3 | Anaemia | COMPLETED | NCT02879305 |
| Iron therapy | Drug | Phase PHASE3 | Anaemia | COMPLETED | NCT02879305 |
| Placebo | Other | Phase PHASE3 | Anaemia | COMPLETED | NCT02879305 |
| rhEPO | Other | Phase PHASE3 | Anaemia | COMPLETED | NCT02879305 |
| Daprodustat | Other | Phase PHASE3 | Anaemia | COMPLETED | NCT02879305 |
| Placebo | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT04126213 |
| RSV MAT 120 µg | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT04126213 |
| RSV MAT 60 µg | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT04126213 |
| Placebo | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT04126213 |
| RSV MAT 120 µg | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT04126213 |
| RSV MAT 60 µg | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT04126213 |
| Lapatinib | Other | Phase PHASE1 | Metastatic Breast Cancer | COMPLETED | NCT00952692 |
| dHER2 + AS15 ASCI | Other | Phase PHASE1 | Metastatic Breast Cancer | COMPLETED | NCT00952692 |
| Maraviroc | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT02778204 |
| Prevenar13 | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT03439657 |
| HZ/su vaccine GSK1437173A | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT03439657 |
| Prevenar13 | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT03439657 |
| HZ/su vaccine GSK1437173A | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT03439657 |
| Pembrolizumab | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT03168438 |
| Cyclophosphamide | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT03168438 |
| Fludarabine | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT03168438 |
| Letetresgene autoleucel with pembrolizumab | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT03168438 |
| Letetresgene autoleucel | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT03168438 |
| Placebo | Other | Phase PHASE2 | Crohns Disease | WITHDRAWN | NCT04151225 |
| GSK2330811 | Other | Phase PHASE2 | Crohns Disease | WITHDRAWN | NCT04151225 |
| Placebo | Other | Phase PHASE2 | Crohns Disease | WITHDRAWN | NCT04151225 |
| GSK2330811 | Other | Phase PHASE2 | Crohns Disease | WITHDRAWN | NCT04151225 |
| PAXIL (Paroxetine hydrochloride ) | Other | Phase PHASE1 | Anxiety Disorders | COMPLETED | NCT04311463 |
| Paroxetine hydrochloride | Other | Phase PHASE1 | Anxiety Disorders | COMPLETED | NCT04311463 |
| Tenofovir disoproxil fumarate | Other | Phase PHASE4 | Hepatitis B, Chronic | COMPLETED | NCT02224456 |
| Placebo | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT04090658 |
| RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT04090658 |
| Placebo | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT04090658 |
| RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT04090658 |
| Placebo matching to gepotidacin | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT04493931 |
| Digoxin | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT04493931 |
| Midazolam | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT04493931 |
| Rifampicin | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT04493931 |
| Cimetidine | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT04493931 |
| Gepotidacin | Other | Phase PHASE1 | Infections, Bacterial | COMPLETED | NCT04493931 |
| Prednisolone | Other | Phase PHASE2 | ANCA Associated Vasculitis | UNKNOWN | NCT03967925 |
| Rituximab | Other | Phase PHASE2 | ANCA Associated Vasculitis | UNKNOWN | NCT03967925 |
| Belimumab | Other | Phase PHASE2 | ANCA Associated Vasculitis | UNKNOWN | NCT03967925 |
| Prednisolone | Other | Phase PHASE2 | ANCA Associated Vasculitis | UNKNOWN | NCT03967925 |
| Rituximab | Other | Phase PHASE2 | ANCA Associated Vasculitis | UNKNOWN | NCT03967925 |
| Belimumab | Other | Phase PHASE2 | ANCA Associated Vasculitis | UNKNOWN | NCT03967925 |
| Lyophilized formulation of GSK's oral live attenuated HRV vaccine | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT03954743 |
| PCV-free liquid formulation of GSK's oral live attenuated HRV vaccine | Other | Phase PHASE3 | Infections, Rotavirus | COMPLETED | NCT03954743 |
| Pazopanib + interferon alpha 2A | Other | Phase PHASE1 | Advanced Renal Cell Carcinoma | COMPLETED | NCT01513187 |
| Pazopanib + interferon alpha 2A | Other | Phase PHASE1 | Advanced Renal Cell Carcinoma | COMPLETED | NCT01513187 |
| Raltegravir Placebo | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01231516 |
| GSK1349572 Placebo | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01231516 |
| Raltegravir | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01231516 |
| GSK1349572 | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01231516 |
| Raltegravir Placebo | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01231516 |
| GSK1349572 Placebo | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01231516 |
| Raltegravir | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01231516 |
| GSK1349572 | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01231516 |
| RSV MAT | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | WITHDRAWN | NCT05229068 |
| RSV MAT | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | WITHDRAWN | NCT05229068 |
| Enoxaparin | Other | Phase PHASE3 | Venous Thromboembolism | TERMINATED | NCT00493896 |
| Fondaparinux | Other | Phase PHASE3 | Venous Thromboembolism | TERMINATED | NCT00493896 |
| Placebo | Other | Phase PHASE3 | Pain | COMPLETED | NCT04052620 |
| Diclofenac diethylamine 1.16% gel | Other | Phase PHASE3 | Pain | COMPLETED | NCT04052620 |
| Diclofenac diethylamine 2.32% gel | Other | Phase PHASE3 | Pain | COMPLETED | NCT04052620 |
| Oximetry | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03018808 |
| anthropometric measures | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03018808 |
| Blood test | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03018808 |
| CAT | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03018808 |
| Medical interview | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03018808 |
| Minimal questionnaire | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03018808 |
| Cream | Other | Approved | Skin Care | COMPLETED | NCT04557371 |
| Lotion | Other | Approved | Skin Care | COMPLETED | NCT04557371 |
| Serum | Other | Approved | Skin Care | COMPLETED | NCT04557371 |
| Carboplatin | Other | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT04762901 |
| Pegfilgrastim | Other | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT04762901 |
| Paclitaxel | Other | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT04762901 |
| Cyclophosphamide | Other | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT04762901 |
| Doxorubicin | Other | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT04762901 |
| Niraparib | Other | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT04762901 |
| GSK2831781 - Open Label phase | Other | Phase PHASE2 | Colitis, Ulcerative | TERMINATED | NCT03893565 |
| Placebo | Other | Phase PHASE2 | Colitis, Ulcerative | TERMINATED | NCT03893565 |
| GSK2831781 - Double Blind Phase | Other | Phase PHASE2 | Colitis, Ulcerative | TERMINATED | NCT03893565 |
| Diagnostic testing | Other | Preclinical | Respiratory Disease | UNKNOWN | NCT05357274 |
| Ofatumumab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01455051 |
| Mepolizumab 100 MG | Other | Preclinical | Severe Asthma | UNKNOWN | NCT04914078 |
| Safety assessment following routine immunization with Boostrix | Other | Preclinical | Whooping Cough | COMPLETED | NCT03463577 |
| GSK3368715 | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT03666988 |
| Best supportive care | Other | Phase PHASE2 | Urothelial Carcinoma | COMPLETED | NCT03945084 |
| Niraparib | Other | Phase PHASE2 | Urothelial Carcinoma | COMPLETED | NCT03945084 |
| Valsartan | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00657241 |
| Carvedilol CR | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00657241 |
| Biospecimen Collection | Other | Phase PHASE1 | Breast Cancer Female | COMPLETED | NCT03518242 |
| Capecitabine | Other | Phase PHASE1 | Breast Cancer Female | COMPLETED | NCT03518242 |
| Methotrexate | Other | Phase PHASE1 | Breast Cancer Female | COMPLETED | NCT03518242 |
| Cyclophosphamide | Other | Phase PHASE1 | Breast Cancer Female | COMPLETED | NCT03518242 |
| Dostarlimab | Other | Phase PHASE2 | HRD | WITHDRAWN | NCT04895046 |
| Niraparib | Other | Phase PHASE2 | HRD | WITHDRAWN | NCT04895046 |
| RSVPreF3 OA investigational vaccine (GSK3844766A) | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT04657198 |
| Mepolizumab 100 MG | Other | Preclinical | Asthma Severe Persistent Uncontrolled | COMPLETED | NCT05441059 |
| Mepolizumab 100 MG | Other | Preclinical | Asthma Severe Persistent Uncontrolled | COMPLETED | NCT05441059 |
| Opinion leader educational letter | Other | Approved | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT01107613 |
| Opinion leader educational letter | Other | Approved | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT01107613 |
| Niraparib | Other | Phase PHASE2 | Breast Cancer | TERMINATED | NCT02826512 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT03292588 |
| Mepolizumab | Other | Phase PHASE2 | Asthma | COMPLETED | NCT03292588 |
| standard follow-up care | Other | Phase PHASE1 | Adult Acute Basophilic Leukemia | TERMINATED | NCT01550185 |
| eltrombopag olamine | Other | Phase PHASE1 | Adult Acute Basophilic Leukemia | TERMINATED | NCT01550185 |
| Placebo | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03636906 |
| GSK's meningococcal group A, C, W-135 and Y conjugate vaccine | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03636906 |
| GSK's pneumococcal polysaccharide conjugate vaccine | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03636906 |
| Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03636906 |
| GSK's multicomponent meningococcal B vaccine | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03636906 |
| RSV (GSK3389245A) higher dose formulation vaccine | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03636906 |
| RSV (GSK3389245A) lower dose formulation vaccine | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03636906 |
| Belantamab mafodotin | Other | Preclinical | RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA | UNKNOWN | NCT05297240 |
| Belantamab mafodotin | Other | Preclinical | RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA | UNKNOWN | NCT05297240 |
| Placebo (Saline solution) | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03814590 |
| RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03814590 |
| RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03814590 |
| RSV Vaccine (GSK3844766A) unadjuvanted high dose | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03814590 |
| RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03814590 |
| RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03814590 |
| RSV Vaccine (GSK3844766A) unadjuvanted medium dose | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03814590 |
| RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03814590 |
| RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03814590 |
| RSV Vaccine (GSK3844766A) unadjuvanted low dose | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03814590 |
| MRI scan | Other | Preclinical | Alzheimer Disease | TERMINATED | NCT05491902 |
| [18F] Flutemetamol PET scan | Other | Preclinical | Alzheimer Disease | TERMINATED | NCT05491902 |
| [C11] Leucine PET scan | Other | Preclinical | Alzheimer Disease | TERMINATED | NCT05491902 |
| Prednisone | Other | Phase PHASE1 | Solid Tumours | TERMINATED | NCT03150056 |
| Enzalutamide | Other | Phase PHASE1 | Solid Tumours | TERMINATED | NCT03150056 |
| Abiraterone | Other | Phase PHASE1 | Solid Tumours | TERMINATED | NCT03150056 |
| GSK525762 | Other | Phase PHASE1 | Solid Tumours | TERMINATED | NCT03150056 |
| Prednisone | Other | Phase PHASE1 | Solid Tumours | TERMINATED | NCT03150056 |
| Enzalutamide | Other | Phase PHASE1 | Solid Tumours | TERMINATED | NCT03150056 |
| Abiraterone | Other | Phase PHASE1 | Solid Tumours | TERMINATED | NCT03150056 |
| GSK525762 | Other | Phase PHASE1 | Solid Tumours | TERMINATED | NCT03150056 |
| Niraparib Oral Product | Other | Phase PHASE1 | Breast Cancer | NOT_YET_RECRUITING | NCT05519670 |
| Dostarlimab | Other | Phase PHASE2 | Ovarian Neoplasms | TERMINATED | NCT03955471 |
| Niraparib | Other | Phase PHASE2 | Ovarian Neoplasms | TERMINATED | NCT03955471 |
| PCV13 | Other | Phase PHASE2 | Pneumococcal Vaccines | COMPLETED | NCT01953510 |
| PCV10 | Other | Phase PHASE2 | Pneumococcal Vaccines | COMPLETED | NCT01953510 |
| PCV13 | Other | Phase PHASE2 | Pneumococcal Vaccines | COMPLETED | NCT01953510 |
| PCV10 | Other | Phase PHASE2 | Pneumococcal Vaccines | COMPLETED | NCT01953510 |
| GSK3228836 | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT04971928 |
| Carboplatin | Other | Phase PHASE1 | Unspecified Adult Solid Tumor - Protocol Specific | TERMINATED | NCT01407562 |
| Paclitaxel | Other | Phase PHASE1 | Unspecified Adult Solid Tumor - Protocol Specific | TERMINATED | NCT01407562 |
| Pazopanib | Other | Phase PHASE1 | Unspecified Adult Solid Tumor - Protocol Specific | TERMINATED | NCT01407562 |
| Placebo | Other | Phase PHASE1 | Klebsiella Pneumoniae Infection | COMPLETED | NCT04959344 |
| Kleb4V low dose + AS03 | Other | Phase PHASE1 | Klebsiella Pneumoniae Infection | COMPLETED | NCT04959344 |
| Kleb4V low dose | Other | Phase PHASE1 | Klebsiella Pneumoniae Infection | COMPLETED | NCT04959344 |
| Kleb4V target dose + AS03 | Other | Phase PHASE1 | Klebsiella Pneumoniae Infection | COMPLETED | NCT04959344 |
| Kleb4V target dose | Other | Phase PHASE1 | Klebsiella Pneumoniae Infection | COMPLETED | NCT04959344 |
| DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02075593 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | NOT_YET_RECRUITING | NCT05581875 |
| Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | NOT_YET_RECRUITING | NCT05581875 |
| Daratumumab | Other | Phase PHASE1 | Multiple Myeloma | NOT_YET_RECRUITING | NCT05581875 |
| Belantamab Mafodotin-Blmf | Other | Phase PHASE1 | Multiple Myeloma | NOT_YET_RECRUITING | NCT05581875 |
| recMAGE-A3 Protein + AS15 Adjuvant | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01380145 |
| recMAGE-A3 Protein + AS15 Adjuvant | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01380145 |
| Trametinib | Other | Phase PHASE2 | Pancreatic Cancer | COMPLETED | NCT02428270 |
| GSK2256098 | Other | Phase PHASE2 | Pancreatic Cancer | COMPLETED | NCT02428270 |
| Trametinib | Other | Phase PHASE2 | Pancreatic Cancer | COMPLETED | NCT02428270 |
| GSK2256098 | Other | Phase PHASE2 | Pancreatic Cancer | COMPLETED | NCT02428270 |
| Eltrombopag | Other | Phase PHASE1 | Myelodysplastic Syndrome (MDS) | TERMINATED | NCT01286038 |
| Eltrombopag | Other | Phase PHASE1 | Myelodysplastic Syndrome (MDS) | TERMINATED | NCT01286038 |
| Placebo | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT00915902 |
| Omega-3-acid ethyl esters | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT00915902 |
| Physician's choice | Other | Phase PHASE3 | Neoplasms, Breast | TERMINATED | NCT01905592 |
| niraparib | Other | Phase PHASE3 | Neoplasms, Breast | TERMINATED | NCT01905592 |
| Physician's choice | Other | Phase PHASE3 | Neoplasms, Breast | TERMINATED | NCT01905592 |
| niraparib | Other | Phase PHASE3 | Neoplasms, Breast | TERMINATED | NCT01905592 |
| Rosiglitazone | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00297063 |
| Diary cards | Other | Approved | Respiratory Syncytial Virus | COMPLETED | NCT01995175 |
| Blood sampling | Other | Approved | Respiratory Syncytial Virus | COMPLETED | NCT01995175 |
| Nasal swab sampling | Other | Approved | Respiratory Syncytial Virus | COMPLETED | NCT01995175 |
| pembrolizumab | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT02657889 |
| niraparib | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT02657889 |
| pembrolizumab | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT02657889 |
| niraparib | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT02657889 |
| Rosiglitazone (BRL49653C) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00432679 |
| Ambrisentan | Other | Phase PHASE2 | Hypertension, Pulmonary | COMPLETED | NCT01342952 |
| Belimumab | Other | Phase PHASE2 | Kidney Transplantation | TERMINATED | NCT03591380 |
| Linerixibat | Other | Phase PHASE1 | Pruritus | COMPLETED | NCT05393076 |
| Feladilimab | Other | Phase PHASE2 | Neoplasms | COMPLETED | NCT05553808 |
| Docetaxel | Other | Phase PHASE2 | Neoplasms | COMPLETED | NCT05553808 |
| Feladilimab | Other | Phase PHASE2 | Neoplasms | COMPLETED | NCT05553808 |
| Docetaxel | Other | Phase PHASE2 | Neoplasms | COMPLETED | NCT05553808 |
| Otilimab | Other | Phase PHASE1 | Arthritis, Rheumatoid | WITHDRAWN | NCT05304130 |
| Otilimab | Other | Phase PHASE1 | Arthritis, Rheumatoid | WITHDRAWN | NCT05304130 |
| ACE-Hemmer-Ratiopharm | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT04964050 |
| Capozide | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT04964050 |
| Captopril | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT04878315 |
| Capoten | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT04878315 |
| Infanrix-IPV data collection | Other | Preclinical | Acellular Pertussis | COMPLETED | NCT01568060 |
| Induced sputum microbiome | Other | Preclinical | Asthma | UNKNOWN | NCT04260282 |
| Polymerase Chain Reaction (PCR) for viruses and bacteria in nasal swab | Other | Preclinical | Asthma | UNKNOWN | NCT04260282 |
| RSVPreF3 OA investigational vaccine | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT05059301 |
| Placebo | Other | Phase PHASE1 | Urinary Tract Infections | COMPLETED | NCT04488770 |
| GSK3882347 | Other | Phase PHASE1 | Urinary Tract Infections | COMPLETED | NCT04488770 |
| Placebo | Other | Phase PHASE1 | Urinary Tract Infections | COMPLETED | NCT04488770 |
| GSK3882347 | Other | Phase PHASE1 | Urinary Tract Infections | COMPLETED | NCT04488770 |
| Safety data collection (following routine vaccination) by a continuous surveillance method. | Other | Preclinical | Neoplasms, Rectal | COMPLETED | NCT03671369 |
| Placebo | Other | Phase PHASE1 | Leishmaniasis | TERMINATED | NCT03874234 |
| GSK3186899 | Other | Phase PHASE1 | Leishmaniasis | TERMINATED | NCT03874234 |
| Dostarlimab | Other | Phase PHASE2 | Gestational Trophoblastic Neoplasia | WITHDRAWN | NCT05405192 |
| Continued Ocrelizumab | Other | Phase PHASE2 | Multiple Sclerosis | TERMINATED | NCT04767698 |
| Short-course Ocrelizumab | Other | Phase PHASE2 | Multiple Sclerosis | TERMINATED | NCT04767698 |
| Belimumab | Other | Phase PHASE2 | Multiple Sclerosis | TERMINATED | NCT04767698 |
| Continued Ocrelizumab | Other | Phase PHASE2 | Multiple Sclerosis | TERMINATED | NCT04767698 |
| Short-course Ocrelizumab | Other | Phase PHASE2 | Multiple Sclerosis | TERMINATED | NCT04767698 |
| Belimumab | Other | Phase PHASE2 | Multiple Sclerosis | TERMINATED | NCT04767698 |
| Experimental | Other | Approved | COPD Exacerbation | UNKNOWN | NCT05762861 |
| Two NRTIs | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT02227238 |
| LPV/RTV | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT02227238 |
| DTG | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT02227238 |
| Two NRTIs | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT02227238 |
| LPV/RTV | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT02227238 |
| DTG | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT02227238 |
| It was an observational study | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT05779384 |
| carvedilol immediate release | Other | Phase PHASE3 | Congestive Heart Failure | COMPLETED | NCT00323037 |
| carvedilol controlled release | Other | Phase PHASE3 | Congestive Heart Failure | COMPLETED | NCT00323037 |
| Trastuzumab | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00841828 |
| Lapatinib | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00841828 |
| Docetaxel | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00841828 |
| Cyclophosphamide | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00841828 |
| Epirubicin | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00841828 |
| Mepolizumab 100 MG | Other | Phase PHASE2 | COPD | UNKNOWN | NCT05320939 |
| dTpa vaccine | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT05169905 |
| RSV MAT vaccine | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT05169905 |
| Fludarabine | Other | Phase PHASE2 | Neoplasms | COMPLETED | NCT02992743 |
| Cyclophosphamide | Other | Phase PHASE2 | Neoplasms | COMPLETED | NCT02992743 |
| letetresgene autoleucel (GSK3377794) | Other | Phase PHASE2 | Neoplasms | COMPLETED | NCT02992743 |
| Niraparib | Other | Phase PHASE2 | Ovarian Neoplasm | COMPLETED | NCT05751629 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Neoplasm | COMPLETED | NCT05751629 |
| Dostarlimab | Other | Phase PHASE2 | Ovarian Neoplasm | COMPLETED | NCT05751629 |
| Niraparib | Other | Phase PHASE2 | Ovarian Neoplasm | COMPLETED | NCT05751629 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Neoplasm | COMPLETED | NCT05751629 |
| Dostarlimab | Other | Phase PHASE2 | Ovarian Neoplasm | COMPLETED | NCT05751629 |
| Ventolin 90Mcg/Actuation Inhalation Aerosol | Other | Phase PHASE4 | COPD | COMPLETED | NCT04606394 |
| Trelegy Ellipta 100/62.5/25Mcg Inh 30D | Other | Phase PHASE4 | COPD | COMPLETED | NCT04606394 |
| Grape fruit juice | Other | Phase PHASE1 | Celiac Disease | COMPLETED | NCT04604795 |
| Water | Other | Phase PHASE1 | Celiac Disease | COMPLETED | NCT04604795 |
| Itraconazole | Other | Phase PHASE1 | Celiac Disease | COMPLETED | NCT04604795 |
| Placebo capsules | Other | Phase PHASE1 | Celiac Disease | COMPLETED | NCT04604795 |
| GSK3915393 Solution for Infusion | Other | Phase PHASE1 | Celiac Disease | COMPLETED | NCT04604795 |
| GSK3915393 Capsules | Other | Phase PHASE1 | Celiac Disease | COMPLETED | NCT04604795 |
| BREEZHALER | Other | Phase PHASE4 | Asthma | COMPLETED | NCT04813354 |
| ELLIPTA | Other | Phase PHASE4 | Asthma | COMPLETED | NCT04813354 |
| BREEZHALER | Other | Phase PHASE4 | Asthma | COMPLETED | NCT04813354 |
| ELLIPTA | Other | Phase PHASE4 | Asthma | COMPLETED | NCT04813354 |
| Nucleos(t)ide therapy | Drug | Phase PHASE2 | Hepatitis B | COMPLETED | NCT04449029 |
| Placebo | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT04449029 |
| GSK3228836 | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT04449029 |
| Nucleos(t)ide therapy | Drug | Phase PHASE2 | Hepatitis B | COMPLETED | NCT04449029 |
| Placebo | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT04449029 |
| GSK3228836 | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT04449029 |
| administration of Bicalutamide, Dutasteride and Tamoxifen | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT00866554 |
| administration of a LHRH agonist and Bicalutamide | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT00866554 |
| CVSQIV | Other | Phase PHASE1 | Influenza | COMPLETED | NCT05252338 |
| CVSQIV | Other | Phase PHASE1 | Influenza | COMPLETED | NCT05252338 |
| CVSQIV | Other | Phase PHASE1 | Influenza | COMPLETED | NCT05252338 |
| Everolimus | Other | Phase PHASE1 | Advanced Cancers | COMPLETED | NCT01430572 |
| Pazopanib | Other | Phase PHASE1 | Advanced Cancers | COMPLETED | NCT01430572 |
| Placebo matching gepotidacin | Other | Phase PHASE3 | Urinary Tract Infections | COMPLETED | NCT04020341 |
| Nitrofurantoin | Other | Phase PHASE3 | Urinary Tract Infections | COMPLETED | NCT04020341 |
| Placebo matching nitrofurantoin | Other | Phase PHASE3 | Urinary Tract Infections | COMPLETED | NCT04020341 |
| Gepotidacin | Other | Phase PHASE3 | Urinary Tract Infections | COMPLETED | NCT04020341 |
| Placebo matching gepotidacin | Other | Phase PHASE3 | Urinary Tract Infections | COMPLETED | NCT04020341 |
| Nitrofurantoin | Other | Phase PHASE3 | Urinary Tract Infections | COMPLETED | NCT04020341 |
| Placebo matching nitrofurantoin | Other | Phase PHASE3 | Urinary Tract Infections | COMPLETED | NCT04020341 |
| Gepotidacin | Other | Phase PHASE3 | Urinary Tract Infections | COMPLETED | NCT04020341 |
| Mepolizumab | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03099096 |
| Mepolizumab | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01691859 |
| Mepolizumab | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01691859 |
| Placebo | Other | Phase PHASE2 | Influenza | COMPLETED | NCT05082688 |
| Influenza Vaccine (Fluarix Tetra Northern Hemisphere 2021 or 2022, GSK) | Other | Phase PHASE2 | Influenza | COMPLETED | NCT05082688 |
| Herpes zoster vaccination (Shingrix, GSK) | Other | Phase PHASE2 | Influenza | COMPLETED | NCT05082688 |
| Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY) | Other | Phase PHASE4 | Meningitis, Meningococcal | COMPLETED | NCT03493919 |
| rMenB+OMV NZ vaccine | Other | Phase PHASE4 | Meningitis, Meningococcal | COMPLETED | NCT03493919 |
| Placebo matching gepotidacin | Other | Phase PHASE3 | Urinary Tract Infections | COMPLETED | NCT04187144 |
| Nitrofurantoin | Other | Phase PHASE3 | Urinary Tract Infections | COMPLETED | NCT04187144 |
| Placebo matching nitrofurantoin | Other | Phase PHASE3 | Urinary Tract Infections | COMPLETED | NCT04187144 |
| Gepotidacin | Other | Phase PHASE3 | Urinary Tract Infections | COMPLETED | NCT04187144 |
| Placebo | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03244059 |
| Belimumab | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03244059 |
| Lapatinib | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT01138384 |
| Foretinib | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT01138384 |
| laboratory biomarker analysis | Other | Phase PHASE1 | Lung Cancer | COMPLETED | NCT01068587 |
| erlotinib hydrochloride | Other | Phase PHASE1 | Lung Cancer | COMPLETED | NCT01068587 |
| MET/VEGFR2 inhibitor Foretinib | Other | Phase PHASE1 | Lung Cancer | COMPLETED | NCT01068587 |
| Infant Diary Card | Other | Approved | Respiratory Syncytial Virus Infections | COMPLETED | NCT03614676 |
| Nasal Swab collection | Other | Approved | Respiratory Syncytial Virus Infections | COMPLETED | NCT03614676 |
| Maternal Diary Card | Other | Approved | Respiratory Syncytial Virus Infections | COMPLETED | NCT03614676 |
| Cord blood sample collection | Other | Approved | Respiratory Syncytial Virus Infections | COMPLETED | NCT03614676 |
| Blood sample collection | Other | Approved | Respiratory Syncytial Virus Infections | COMPLETED | NCT03614676 |
| Infant Diary Card | Other | Approved | Respiratory Syncytial Virus Infections | COMPLETED | NCT03614676 |
| Nasal Swab collection | Other | Approved | Respiratory Syncytial Virus Infections | COMPLETED | NCT03614676 |
| Maternal Diary Card | Other | Approved | Respiratory Syncytial Virus Infections | COMPLETED | NCT03614676 |
| Cord blood sample collection | Other | Approved | Respiratory Syncytial Virus Infections | COMPLETED | NCT03614676 |
| Blood sample collection | Other | Approved | Respiratory Syncytial Virus Infections | COMPLETED | NCT03614676 |
| Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC) | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02831673 |
| Lamivudine (3TC) | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02831673 |
| Dolutegravir (DTG) | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02831673 |
| Alemtuzumab | Other | Phase PHASE2 | CLL | TERMINATED | NCT01465334 |
| High-Dose Methylprednisolone | Other | Phase PHASE2 | CLL | TERMINATED | NCT01465334 |
| Ofatumumab | Other | Phase PHASE2 | CLL | TERMINATED | NCT01465334 |
| Combination of Rituximab with subcutaneous placebo | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT05338190 |
| Combination of Rituximab with subcutaneous belimumab | Other | Phase PHASE3 | Primary Immune Thrombocytopenia (ITP) | RECRUITING | NCT05338190 |
| No rinsing | Other | Approved | Covid19 | COMPLETED | NCT04723446 |
| Oral-B® Gum & Enamel Care -Cetylpyridinium chloride | Other | Approved | Covid19 | COMPLETED | NCT04723446 |
| Colgate Peroxyl® -1.5% Hydrogen peroxide | Other | Approved | Covid19 | COMPLETED | NCT04723446 |
| Corsodyl® Alcohol free -0.2 % Chlorhexidine digluconate | Other | Approved | Covid19 | COMPLETED | NCT04723446 |
| Niraparib | Other | Phase PHASE2 | Mesothelioma | COMPLETED | NCT03207347 |
| Experimental: Nasal LPS spray 100 µg | Other | Approved | Healthy | COMPLETED | NCT02284074 |
| Experimental: Nasal LPS spray 30 µg | Other | Approved | Healthy | COMPLETED | NCT02284074 |
| Experimental: Nasal LPS spray 10 µg | Other | Approved | Healthy | COMPLETED | NCT02284074 |
| Experimental: Nasal LPS spray 1µg | Other | Approved | Healthy | COMPLETED | NCT02284074 |
| Nasal LPS spray | Other | Approved | Healthy | COMPLETED | NCT02284074 |
| Mepolizumab 100 MG | Other | Preclinical | Asthma | UNKNOWN | NCT04641741 |
| Dolutegravir plus lamivudine in a FDC | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT04808973 |
| Placebo | Other | Phase PHASE1 | Autoimmune Diseases | COMPLETED | NCT03590613 |
| GSK2982772 | Other | Phase PHASE1 | Autoimmune Diseases | COMPLETED | NCT03590613 |
| Placebo | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT05045144 |
| Flu Quadrivalent influenza vaccine (15 μg HA) | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT05045144 |
| RSVPreF3(120 μg) | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT05045144 |
| Placebo | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT04789577 |
| AS03A | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT04789577 |
| AS03B | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT04789577 |
| FLU-Q-PAN H7N9 Formulation 3 | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT04789577 |
| FLU-Q-PAN H7N9 Formulation 2 | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT04789577 |
| FLU-Q-PAN H7N9 Formulation 1 | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT04789577 |
| Placebo capsule | Other | Phase PHASE1 | Autoimmune Diseases | COMPLETED | NCT03305419 |
| GSK2982772 capsule | Other | Phase PHASE1 | Autoimmune Diseases | COMPLETED | NCT03305419 |
| Placebo capsule | Other | Phase PHASE1 | Autoimmune Diseases | COMPLETED | NCT03305419 |
| GSK2982772 capsule | Other | Phase PHASE1 | Autoimmune Diseases | COMPLETED | NCT03305419 |
| ritonavir | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00071760 |
| GW433908 | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT00071760 |
| CAR | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT04021290 |
| DTG/3TC FDC | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT04021290 |
| Nirogacestat | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05573802 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05573802 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05573802 |
| Belantamab Mafodotin-Blmf | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05573802 |
| Belantamab mafodotin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04808037 |
| Belantamab mafodotin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04808037 |
| Rifafour e-275 | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT03557281 |
| GSK3036656 | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT03557281 |
| Rifafour e-275 | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT03557281 |
| GSK3036656 | Other | Phase PHASE2 | Tuberculosis | COMPLETED | NCT03557281 |
| Hospitalization | Other | Preclinical | Herpes Zoster | UNKNOWN | NCT05952271 |
| Momelotinib | Other | Preclinical | Myelofibrosis | NO_LONGER_AVAILABLE | NCT05582083 |
| Niraparib | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT05961124 |
| Metoprolol succinate + doxazosin | Other | Phase PHASE4 | Idiopathic Dilated Cardiomyopathy | COMPLETED | NCT01798992 |
| Metoprolol succinate | Other | Phase PHASE4 | Idiopathic Dilated Cardiomyopathy | COMPLETED | NCT01798992 |
| Carvedilol | Other | Phase PHASE4 | Idiopathic Dilated Cardiomyopathy | COMPLETED | NCT01798992 |
| Metoprolol succinate + doxazosin | Other | Phase PHASE4 | Idiopathic Dilated Cardiomyopathy | COMPLETED | NCT01798992 |
| Metoprolol succinate | Other | Phase PHASE4 | Idiopathic Dilated Cardiomyopathy | COMPLETED | NCT01798992 |
| Carvedilol | Other | Phase PHASE4 | Idiopathic Dilated Cardiomyopathy | COMPLETED | NCT01798992 |
| Placebo | Other | Phase PHASE3 | Arthritis, Rheumatoid | TERMINATED | NCT03970837 |
| Tofacitinib | Other | Phase PHASE3 | Arthritis, Rheumatoid | TERMINATED | NCT03970837 |
| GSK3196165 (Otilimab) | Other | Phase PHASE3 | Arthritis, Rheumatoid | TERMINATED | NCT03970837 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | UNKNOWN | NCT05280275 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | UNKNOWN | NCT05280275 |
| Daratumumab | Other | Phase PHASE1 | Multiple Myeloma | UNKNOWN | NCT05280275 |
| Belantamab Mafodotin-Blmf | Other | Phase PHASE1 | Multiple Myeloma | UNKNOWN | NCT05280275 |
| Belantamab mafodotin | Other | Phase PHASE3 | Multiple Myeloma | TERMINATED | NCT04549363 |
| Placebo | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT03699241 |
| BG505 SOSIP.664 gp140, adjuvanted | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT03699241 |
| Indomethacin | Other | Phase PHASE1 | Colitis, Ulcerative | WITHDRAWN | NCT05999708 |
| Placebo | Other | Phase PHASE1 | Colitis, Ulcerative | WITHDRAWN | NCT05999708 |
| GSK4381406 | Other | Phase PHASE1 | Colitis, Ulcerative | WITHDRAWN | NCT05999708 |
| PPSV23 | Other | Phase PHASE1 | Pneumonia, Bacterial | COMPLETED | NCT03803202 |
| PCV13 | Other | Phase PHASE1 | Pneumonia, Bacterial | COMPLETED | NCT03803202 |
| ASP3772 | Other | Phase PHASE1 | Pneumonia, Bacterial | COMPLETED | NCT03803202 |
| Methodology | Other | Approved | Acute Decompensated Heart Failure | COMPLETED | NCT03146754 |
| Passive enhanced safety surveillance | Other | Phase PHASE4 | Influenza, Human | COMPLETED | NCT03688620 |
| Passive enhanced safety surveillance | Other | Phase PHASE4 | Influenza, Human | COMPLETED | NCT03688620 |
| Paclitaxel | Other | Phase PHASE2 | Ovarian Cancer | UNKNOWN | NCT05065021 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Cancer | UNKNOWN | NCT05065021 |
| Dostarlimab | Other | Phase PHASE2 | Ovarian Cancer | UNKNOWN | NCT05065021 |
| Niraparib | Other | Phase PHASE2 | Ovarian Cancer | UNKNOWN | NCT05065021 |
| Paclitaxel | Other | Phase PHASE2 | Ovarian Cancer | UNKNOWN | NCT05065021 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Cancer | UNKNOWN | NCT05065021 |
| Dostarlimab | Other | Phase PHASE2 | Ovarian Cancer | UNKNOWN | NCT05065021 |
| Niraparib | Other | Phase PHASE2 | Ovarian Cancer | UNKNOWN | NCT05065021 |
| Short Acting Beta 2 Agonist | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02889809 |
| Montelukast | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02889809 |
| Placebo | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02889809 |
| Fluticasone furoate | Other | Phase PHASE4 | Asthma | COMPLETED | NCT02889809 |
| HZ/su vaccine | Other | Phase PHASE3 | Herpes Zoster | ACTIVE_NOT_RECRUITING | NCT05371080 |
| 1 µg CoV2 SAM (LNP) | Other | Phase PHASE1 | Virus Diseases | COMPLETED | NCT04758962 |
| Placebo | Other | Phase PHASE2 | Salmonella Infections | RECRUITING | NCT06213506 |
| DTPa-HBV-IPV+Hib | Other | Phase PHASE2 | Salmonella Infections | RECRUITING | NCT06213506 |
| MenACWY | Other | Phase PHASE2 | Salmonella Infections | RECRUITING | NCT06213506 |
| iNTS-GMMA Dose A | Other | Phase PHASE2 | Salmonella Infections | RECRUITING | NCT06213506 |
| iNTS-GMMA Dose B | Other | Phase PHASE2 | Salmonella Infections | RECRUITING | NCT06213506 |
| iNTS-GMMA Dose C | Other | Phase PHASE2 | Salmonella Infections | RECRUITING | NCT06213506 |
| Inactivated polio vaccine | Other | Phase PHASE2 | Salmonella Infections | RECRUITING | NCT06213506 |
| Pneumococcal vaccine | Other | Phase PHASE2 | Salmonella Infections | RECRUITING | NCT06213506 |
| Pentavalent vaccine | Other | Phase PHASE2 | Salmonella Infections | RECRUITING | NCT06213506 |
| Yellow Fever vaccine | Other | Phase PHASE2 | Salmonella Infections | RECRUITING | NCT06213506 |
| Measles and Rubella vaccine | Other | Phase PHASE2 | Salmonella Infections | RECRUITING | NCT06213506 |
| Negative control dentifrice | Other | Phase PHASE2 | Gingivitis | COMPLETED | NCT04737538 |
| Positive control dentifrice | Other | Phase PHASE2 | Gingivitis | COMPLETED | NCT04737538 |
| Experimental Dentrifrice | Other | Phase PHASE2 | Gingivitis | COMPLETED | NCT04737538 |
| 4CMenB (Bexsero®) vaccine | Other | Preclinical | Acquired Immunodeficiency | COMPLETED | NCT04295733 |
| 4CMenB (Bexsero®) vaccine | Other | Preclinical | Acquired Immunodeficiency | COMPLETED | NCT04295733 |
| Placebo | Other | Phase PHASE2 | Arthritis, Rheumatoid | WITHDRAWN | NCT00979771 |
| GSK706769 | Other | Phase PHASE2 | Arthritis, Rheumatoid | WITHDRAWN | NCT00979771 |
| TSR-042 | Other | Phase PHASE2 | Endometrial Cancer | UNKNOWN | NCT03016338 |
| Niraparib | Other | Phase PHASE2 | Endometrial Cancer | UNKNOWN | NCT03016338 |
| TSR-042 | Other | Phase PHASE2 | Endometrial Cancer | UNKNOWN | NCT03016338 |
| Niraparib | Other | Phase PHASE2 | Endometrial Cancer | UNKNOWN | NCT03016338 |
| TSR-042 | Other | Phase PHASE2 | Sarcoma, Clear Cell | TERMINATED | NCT04274023 |
| TSR-042 | Other | Phase PHASE2 | Sarcoma, Clear Cell | TERMINATED | NCT04274023 |
| Screening Platform | Other | Phase PHASE2 | Neoplasms | TERMINATED | NCT05100316 |
| Carboplatin | Other | Phase PHASE1 | Solid Tumor, Adult | TERMINATED | NCT03209401 |
| Niraparib | Other | Phase PHASE1 | Solid Tumor, Adult | TERMINATED | NCT03209401 |
| csDMARD(s) | Other | Phase PHASE3 | Arthritis, Rheumatoid | TERMINATED | NCT04333147 |
| Otilimab (GSK3196165) | Other | Phase PHASE3 | Arthritis, Rheumatoid | TERMINATED | NCT04333147 |
| BQ 123 | Other | Preclinical | Cardiovascular Diseases | COMPLETED | NCT02987465 |
| Noradrenaline | Other | Preclinical | Cardiovascular Diseases | COMPLETED | NCT02987465 |
| Acetylcholine | Other | Preclinical | Cardiovascular Diseases | COMPLETED | NCT02987465 |
| Darbepoetin Alfa | Other | Preclinical | Cardiovascular Diseases | COMPLETED | NCT02987465 |
| Placebo | Other | Phase PHASE2 | Myositis | COMPLETED | NCT02347891 |
| Belimumab | Other | Phase PHASE2 | Myositis | COMPLETED | NCT02347891 |
| Aromatase Inhibitors | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT04240106 |
| Niraparib | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT04240106 |
| Aromatase Inhibitors | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT04240106 |
| Niraparib | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT04240106 |
| Monodose RS01 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT04585009 |
| Matching placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT04585009 |
| GSK3923868 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT04585009 |
| Tenofovir/emtricitabine FDC | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01910402 |
| Ritonavir | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01910402 |
| Atazanavir | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01910402 |
| Dolutegravir/abacavir/lamivudine FDC | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT01910402 |
| no intervention | Other | Preclinical | Chronic Sinusitis | UNKNOWN | NCT06272123 |
| Placebo | Other | Phase PHASE1 | Leishmaniasis | COMPLETED | NCT04504435 |
| GSK3494245 | Other | Phase PHASE1 | Leishmaniasis | COMPLETED | NCT04504435 |
| Prospective observational cohort study | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03957577 |
| Pertussis maternal immunization | Other | Preclinical | Diphtheria | COMPLETED | NCT02569879 |
| Pembrolizumab | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT03709706 |
| Lete-cel | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT03709706 |
| Pembrolizumab | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT03709706 |
| Lete-cel | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT03709706 |
| Descriptive and analytical | Other | Preclinical | Endometrial Cancer | RECRUITING | NCT06206083 |
| MenABCWY-3 | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT04502693 |
| MenABCWY-2 | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT04502693 |
| MenABCWY-1 | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT04502693 |
| Placebo | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT04502693 |
| Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY) | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT04502693 |
| rMenB+OMV NZ vaccine | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT04502693 |
| laboratory experiments before and after mepolizumab treatment | Drug | Preclinical | EGPA - Eosinophilic Granulomatosis With Polyangiitis | RECRUITING | NCT06298448 |
| GSK3174998 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT06160609 |
| Belantamab Mafodotin | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT06160609 |
| GSK3174998 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT06160609 |
| Belantamab Mafodotin | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT06160609 |
| Prednisolone | Other | Phase PHASE3 | Churg-Strauss Syndrome | COMPLETED | NCT03298061 |
| Mepolizumab | Other | Phase PHASE3 | Churg-Strauss Syndrome | COMPLETED | NCT03298061 |
| Shingrix vaccine | Other | Phase EARLY_PHASE1 | Chronic Lymphocytic Leukemia (CLL) | COMPLETED | NCT03771157 |
| Shingrix vaccine | Other | Phase EARLY_PHASE1 | Chronic Lymphocytic Leukemia (CLL) | COMPLETED | NCT03771157 |
| HPV (Types 16, 18) Vaccine, Adsorbed | Other | Phase PHASE4 | Cervical Intraepithelial Neoplasia | COMPLETED | NCT03629886 |
| HPV (Types 16, 18) Vaccine, Adsorbed | Other | Phase PHASE4 | Cervical Intraepithelial Neoplasia | COMPLETED | NCT03629886 |
| Blood sample collection | Other | Approved | Dengue | TERMINATED | NCT02766088 |
| Blood sample collection | Other | Approved | Dengue | TERMINATED | NCT02766088 |
| Placebo | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT04316585 |
| GSK2982772 | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT04316585 |
| GSK3858279 | Other | Phase PHASE1 | Pain | TERMINATED | NCT04114656 |
| Placebo | Other | Phase PHASE1 | Pain | TERMINATED | NCT04114656 |
| Placebo matching to GSK3858279 (SC) | Other | Phase PHASE1 | Pain, Inflammatory | COMPLETED | NCT03485365 |
| Placebo matching to GSK3858279 (SC or IV) | Other | Phase PHASE1 | Pain, Inflammatory | COMPLETED | NCT03485365 |
| GSK3858279 SC | Other | Phase PHASE1 | Pain, Inflammatory | COMPLETED | NCT03485365 |
| GSK3858279 IV | Other | Phase PHASE1 | Pain, Inflammatory | COMPLETED | NCT03485365 |
| Belimumab | Other | Preclinical | Systemic Lupus Erythematosus | UNKNOWN | NCT06327724 |
| Re-irradiation (re-RT) | Other | Phase PHASE1 | Recurrent Glioblastoma | WITHDRAWN | NCT05666349 |
| Niraparib | Other | Phase PHASE1 | Recurrent Glioblastoma | WITHDRAWN | NCT05666349 |
| Placebo | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT03980483 |
| Tofacitinib 5 mg | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT03980483 |
| GSK3196165 (Otilimab) | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT03980483 |
| Placebo | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT03980483 |
| Tofacitinib 5 mg | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT03980483 |
| GSK3196165 (Otilimab) | Other | Phase PHASE3 | Arthritis, Rheumatoid | COMPLETED | NCT03980483 |
| Ferrous sulfate containing the stable iron isotope (58Fe) | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT03457701 |
| Ferrous sulfate containing the stable iron isotope (57Fe) | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT03457701 |
| rhEPO | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT03457701 |
| Daprodustat | Other | Phase PHASE2 | Anaemia | COMPLETED | NCT03457701 |
| L-N-monomethyl arginine acetate (L-NMMA) | Other | Phase PHASE2 | Anaemia | TERMINATED | NCT03446612 |
| Sodium nitroprusside | Other | Phase PHASE2 | Anaemia | TERMINATED | NCT03446612 |
| Acetylcholine | Other | Phase PHASE2 | Anaemia | TERMINATED | NCT03446612 |
| Darbepoetin alfa | Other | Phase PHASE2 | Anaemia | TERMINATED | NCT03446612 |
| Daprodustat | Other | Phase PHASE2 | Anaemia | TERMINATED | NCT03446612 |
| Encepur Adults | Other | Phase PHASE4 | Virus Diseases | COMPLETED | NCT03294135 |
| Iron therapy | Drug | Phase PHASE3 | Anaemia | COMPLETED | NCT03409107 |
| Placebo | Other | Phase PHASE3 | Anaemia | COMPLETED | NCT03409107 |
| Daprodustat (GSK1278863) | Other | Phase PHASE3 | Anaemia | COMPLETED | NCT03409107 |
| Erlotinib | Other | Phase PHASE1 | Lung Adenocarcinoma | COMPLETED | NCT03076164 |
| Trametinib | Other | Phase PHASE1 | Lung Adenocarcinoma | COMPLETED | NCT03076164 |
| Erlotinib | Other | Phase PHASE1 | Lung Adenocarcinoma | COMPLETED | NCT03076164 |
| Trametinib | Other | Phase PHASE1 | Lung Adenocarcinoma | COMPLETED | NCT03076164 |
| GBS Trivalent Vaccine | Other | Phase PHASE2 | Bacterial Infection Due to Streptococcus, Group B | COMPLETED | NCT02690181 |
| Data collection | Other | Preclinical | Influenza, Human | COMPLETED | NCT02663102 |
| Pembrolizumab | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT03848845 |
| belantamab mafodotin | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT03848845 |
| Bevacizumab | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT03250832 |
| FOLFIRI | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT03250832 |
| mFOLFOX6 | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT03250832 |
| Dostarlimab | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT03250832 |
| TSR-033 | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT03250832 |
| Herpes Zoster Vaccine GSK1437173A | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT02735915 |
| lisinopril | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | TERMINATED | NCT00430040 |
| Carvedilol Controlled Release (CR) | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | TERMINATED | NCT00430040 |
| Bintrafusp alfa | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT04349280 |
| Bintrafusp alfa | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT04349280 |
| Rilpivirine extended release suspension for injection (long-acting) | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT04371380 |
| Cabotegravir extended release suspension for injection (long-acting) | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT04371380 |
| Rilpivirine Tablets | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT04371380 |
| Cabotegravir Tablets | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT04371380 |
| Placebo | Other | Phase PHASE1 | Heart Failure | TERMINATED | NCT05044325 |
| GSK3884464 | Other | Phase PHASE1 | Heart Failure | TERMINATED | NCT05044325 |
| NA therapy | Drug | Phase PHASE2 | Hepatitis B | COMPLETED | NCT04676724 |
| PegIFN | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT04676724 |
| GSK3228836 | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT04676724 |
| Investigational [RCA4]: standard (RC) plus amoxicillin/clavulanate (A) for 4 weeks. | Other | Phase PHASE2 | Buruli Ulcer | RECRUITING | NCT05169554 |
| Standard [RC8]: rifampicin plus clarithromycin (RC) therapy for 8 weeks. | Drug | Phase PHASE2 | Buruli Ulcer | RECRUITING | NCT05169554 |
| Daprodustat | Other | Phase PHASE4 | Anemia | COMPLETED | NCT05951192 |
| Niraparib | Other | Phase PHASE2 | Esophageal Cancer | TERMINATED | NCT03840967 |
| Augmentin (ES)-600 | Other | Phase PHASE4 | Otitis Media | COMPLETED | NCT04600752 |
| Augmentin (ES)-600 | Other | Phase PHASE4 | Otitis Media | COMPLETED | NCT04600752 |
| Belimumab | Other | Preclinical | Systemic Lupus Erythematosus | COMPLETED | NCT04570306 |
| RPV | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02120352 |
| HAART | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02120352 |
| RPV Oral Tablets | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02120352 |
| ABC/3TC Oral tablets | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02120352 |
| CAB LA | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02120352 |
| CAB Oral Tablets | Other | Phase PHASE2 | Infection, Human Immunodeficiency Virus | COMPLETED | NCT02120352 |
| Placebo | Other | Phase PHASE2 | COPD | COMPLETED | NCT04075331 |
| Mepolizumab | Other | Phase PHASE2 | COPD | COMPLETED | NCT04075331 |
| MenB vaccine | Other | Phase PHASE3 | Meningitis, Meningococcal | COMPLETED | NCT04707391 |
| MenACWY vaccine | Other | Phase PHASE3 | Meningitis, Meningococcal | COMPLETED | NCT04707391 |
| Placebo | Other | Phase PHASE3 | Meningitis, Meningococcal | COMPLETED | NCT04707391 |
| MenABCWY vaccine | Other | Phase PHASE3 | Meningitis, Meningococcal | COMPLETED | NCT04707391 |
| Placebo | Other | Phase PHASE3 | Neoplasms, Head and Neck | TERMINATED | NCT04128696 |
| Pembrolizumab | Other | Phase PHASE3 | Neoplasms, Head and Neck | TERMINATED | NCT04128696 |
| feladilimab | Other | Phase PHASE3 | Neoplasms, Head and Neck | TERMINATED | NCT04128696 |
| Placebo | Other | Phase PHASE3 | Neoplasms, Head and Neck | TERMINATED | NCT04128696 |
| Pembrolizumab | Other | Phase PHASE3 | Neoplasms, Head and Neck | TERMINATED | NCT04128696 |
| feladilimab | Other | Phase PHASE3 | Neoplasms, Head and Neck | TERMINATED | NCT04128696 |
| Dostarlimab | Other | Phase PHASE2 | Recurrent Cancer | RECRUITING | NCT05855811 |
| Purified Chick-Embryo Cell Rabies Vaccine | Other | Phase PHASE3 | Virus Diseases | COMPLETED | NCT02545517 |
| Blood sampling | Other | Phase PHASE3 | Virus Diseases | COMPLETED | NCT02545517 |
| Rabipur | Other | Phase PHASE3 | Virus Diseases | COMPLETED | NCT02545517 |
| Purified Chick-Embryo Cell Rabies Vaccine | Other | Phase PHASE3 | Virus Diseases | COMPLETED | NCT02545517 |
| Blood sampling | Other | Phase PHASE3 | Virus Diseases | COMPLETED | NCT02545517 |
| Rabipur | Other | Phase PHASE3 | Virus Diseases | COMPLETED | NCT02545517 |
| Dostarlimab | Other | Phase PHASE2 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT04313504 |
| Niraparib | Other | Phase PHASE2 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT04313504 |
| CV2CoV (20 µg) | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05260437 |
| CV2CoV (16 µg) | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05260437 |
| CV2CoV (12 µg) | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05260437 |
| CV2CoV (8 µg) | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05260437 |
| CV2CoV (4 µg) | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05260437 |
| CV2CoV (2 µg) | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05260437 |
| CV2CoV (20 µg) | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05260437 |
| CV2CoV (16 µg) | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05260437 |
| CV2CoV (12 µg) | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05260437 |
| CV2CoV (8 µg) | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05260437 |
| CV2CoV (4 µg) | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05260437 |
| CV2CoV (2 µg) | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05260437 |
| Placebo | Other | Phase PHASE1 | Dermatitis, Atopic | COMPLETED | NCT05590338 |
| GSK1070806 | Other | Phase PHASE1 | Dermatitis, Atopic | COMPLETED | NCT05590338 |
| Sotrovimab | Other | Phase PHASE2 | SARS CoV 2 Infection | COMPLETED | NCT05210101 |
| hepatitis A vaccine | Other | Phase PHASE4 | Hepatitis A | COMPLETED | NCT00139113 |
| Placebo | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT04138056 |
| Boostrix-US | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT04138056 |
| Boostrix-ex-US | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT04138056 |
| RSVPreF3 formulation 2 | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT04138056 |
| RSVPreF3 formulation 3 | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT04138056 |
| Nirapaib | Other | Phase PHASE1 | Metastatic Carcinoma of the Cervix | TERMINATED | NCT03644342 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT04719832 |
| GSK3511294 (Depemokimab) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT04719832 |
| Belantamab mafodotin | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05064358 |
| Placebo | Other | Phase PHASE2 | Dermatitis, Atopic | TERMINATED | NCT05999799 |
| GSK1070806 | Other | Phase PHASE2 | Dermatitis, Atopic | TERMINATED | NCT05999799 |
| Placebo | Other | Phase PHASE2 | Dermatitis, Atopic | TERMINATED | NCT05999799 |
| GSK1070806 | Other | Phase PHASE2 | Dermatitis, Atopic | TERMINATED | NCT05999799 |
| Dostarlimab | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT02715284 |
| Dostarlimab | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT02715284 |
| PCV20 | Other | Phase PHASE1 | Pneumonia, Bacterial | NOT_YET_RECRUITING | NCT07406334 |
| Pn-MAPS30plus | Other | Phase PHASE1 | Pneumonia, Bacterial | NOT_YET_RECRUITING | NCT07406334 |
| Temozolomide | Other | Phase PHASE3 | Glioblastoma | RECRUITING | NCT06388733 |
| Niraparib | Other | Phase PHASE3 | Glioblastoma | RECRUITING | NCT06388733 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | RECRUITING | NCT06961214 |
| Depemokimab | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | RECRUITING | NCT06961214 |
| GSK5471713 | Other | Phase PHASE1 | Neoplasms, Prostate | RECRUITING | NCT07332455 |
| Dexamethasone | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04246047 |
| Bortezomib | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04246047 |
| Daratumumab | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04246047 |
| Belantamab mafodotin | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04246047 |
| Placebo | Other | Phase PHASE4 | Herpes Zoster | RECRUITING | NCT07502560 |
| Recombinant zoster vaccine | Other | Phase PHASE4 | Herpes Zoster | RECRUITING | NCT07502560 |
| Fulvestrant | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT02964507 |
| Placebo | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT02964507 |
| GSK525762 | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT02964507 |
| Niraparib | Other | Phase PHASE1 | Glioma, Malignant | NOT_YET_RECRUITING | NCT06258018 |
| Temodal | Other | Phase PHASE1 | Glioma, Malignant | NOT_YET_RECRUITING | NCT06258018 |
| FLU-QIV | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT04841577 |
| RSVPreF3 OA investigational vaccine | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT04841577 |
| FLU-QIV | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT04841577 |
| RSVPreF3 OA investigational vaccine | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT04841577 |
| CAR | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT02429791 |
| RPV 25 mg | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT02429791 |
| DTG 50 mg | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT02429791 |
| CAR | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT02422797 |
| RPV 25 mg | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT02422797 |
| DTG 50 mg | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT02422797 |
| CAR | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT02422797 |
| RPV 25 mg | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT02422797 |
| DTG 50 mg | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT02422797 |
| Ofatumumab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01243190 |
| NUCALA Injection | Other | Preclinical | Asthma | COMPLETED | NCT03028480 |
| Salbutamol HFA-134a | Other | Phase PHASE1 | Asthma | COMPLETED | NCT05791565 |
| Salbutamol HFA-152a | Other | Phase PHASE1 | Asthma | COMPLETED | NCT05791565 |
| Salbutamol HFA-134a | Other | Phase PHASE1 | Asthma | COMPLETED | NCT05791565 |
| Salbutamol HFA-152a | Other | Phase PHASE1 | Asthma | COMPLETED | NCT05791565 |
| Standard of care | Other | Phase PHASE2 | Severe Acute Respiratory Syndrome | COMPLETED | NCT04376684 |
| Placebo 2 | Other | Phase PHASE2 | Severe Acute Respiratory Syndrome | COMPLETED | NCT04376684 |
| Placebo 1 | Other | Phase PHASE2 | Severe Acute Respiratory Syndrome | COMPLETED | NCT04376684 |
| Otilimab | Other | Phase PHASE2 | Severe Acute Respiratory Syndrome | COMPLETED | NCT04376684 |
| Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A) | Other | Phase PHASE2 | Respiratory Disorders | COMPLETED | NCT03894969 |
| GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E | Other | Phase PHASE2 | Respiratory Disorders | COMPLETED | NCT03894969 |
| Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A) | Other | Phase PHASE2 | Respiratory Disorders | COMPLETED | NCT03894969 |
| GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E | Other | Phase PHASE2 | Respiratory Disorders | COMPLETED | NCT03894969 |
| Pembrolizumab | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT03447314 |
| GSK3359609 | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT03447314 |
| GSK3174998 | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT03447314 |
| GSK1795091 | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT03447314 |
| Pembrolizumab | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT03447314 |
| GSK3359609 | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT03447314 |
| GSK3174998 | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT03447314 |
| GSK1795091 | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT03447314 |
| FLU vaccine | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT05568797 |
| RSVPreF3 OA vaccine | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT05568797 |
| FLU HD vaccine | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT05559476 |
| RSVPreF3 OA investigational vaccine | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT05559476 |
| Adjuvanted Recombinant Zoster Vaccine (RZV) | Other | Phase PHASE4 | Inflammatory Bowel Diseases | WITHDRAWN | NCT06224270 |
| GSK525762 | Other | Phase PHASE2 | Neoplasms | COMPLETED | NCT01943851 |
| Fluorouracil (5FU) | Other | Phase PHASE3 | Neoplasms, Head and Neck | TERMINATED | NCT04428333 |
| Platinum based chemotherapy | Drug | Phase PHASE3 | Neoplasms, Head and Neck | TERMINATED | NCT04428333 |
| Placebo | Other | Phase PHASE3 | Neoplasms, Head and Neck | TERMINATED | NCT04428333 |
| Pembrolizumab | Other | Phase PHASE3 | Neoplasms, Head and Neck | TERMINATED | NCT04428333 |
| Feladilimab | Other | Phase PHASE3 | Neoplasms, Head and Neck | TERMINATED | NCT04428333 |
| Niraparib | Other | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT06161493 |
| ZEN003694 | Other | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT06161493 |
| Niraparib | Other | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT06161493 |
| ZEN003694 | Other | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT06161493 |
| Placebo | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT05677347 |
| GSK3923868 | Other | Phase PHASE1 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT05677347 |
| Sotrovimab | Other | Phase PHASE4 | COVID-19 | COMPLETED | NCT05305651 |
| Belantamab mafodotin 2.5/1.9 mg/kg IV Q4Weeks + Pd (BPd) | Other | Preclinical | Multiple Myeloma | AVAILABLE | NCT03763370 |
| Belantamab mafodotin 2.5 mg/kg IV Q3Weeks + Vd (BVd) | Other | Preclinical | Multiple Myeloma | AVAILABLE | NCT03763370 |
| Belimumab Injection | Other | Phase PHASE3 | Lupus Erythematosus, Systemic | ACTIVE_NOT_RECRUITING | NCT03747159 |
| Auto-injector pen, mepolizumab 100 mg/month | Other | Phase PHASE4 | Asthma | ACTIVE_NOT_RECRUITING | NCT05626777 |
| Pre-filled syringe, mepolizumab 100 mg/month | Other | Phase PHASE4 | Asthma | ACTIVE_NOT_RECRUITING | NCT05626777 |
| Mepolizumab | Other | Phase PHASE1 | Eosinophilic Fasciitis | WITHDRAWN | NCT04305678 |
| Clindamycin | Other | Approved | C. Difficile | NOT_YET_RECRUITING | NCT06702345 |
| Vancomycin | Other | Approved | C. Difficile | NOT_YET_RECRUITING | NCT06702345 |
| encapsulated 10^4 CFU toxigenic. C. difficile spores | Other | Approved | C. Difficile | NOT_YET_RECRUITING | NCT06702345 |
| Standard of care | Other | Phase PHASE3 | Nasal Polyps | COMPLETED | NCT04607005 |
| Placebo | Other | Phase PHASE3 | Nasal Polyps | COMPLETED | NCT04607005 |
| Mepolizumab | Other | Phase PHASE3 | Nasal Polyps | COMPLETED | NCT04607005 |
| Rilpivirine - Injectable Suspension (RPV LA) | Other | Phase PHASE3 | Human Immunodeficiency Virus Type 1 (HIV-1) | COMPLETED | NCT05896748 |
| Cabotegravir - Injectable Suspension (CAB LA) | Other | Phase PHASE3 | Human Immunodeficiency Virus Type 1 (HIV-1) | COMPLETED | NCT05896748 |
| Rilpivirine - Injectable Suspension (RPV LA) | Other | Phase PHASE3 | Human Immunodeficiency Virus Type 1 (HIV-1) | COMPLETED | NCT05896748 |
| Cabotegravir - Injectable Suspension (CAB LA) | Other | Phase PHASE3 | Human Immunodeficiency Virus Type 1 (HIV-1) | COMPLETED | NCT05896748 |
| Arexvy powder and suspension for injection | Other | Phase PHASE2 | RSV Infection | RECRUITING | NCT06597916 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT04718103 |
| GSK3511294 | Other | Phase PHASE3 | Asthma | COMPLETED | NCT04718103 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT04718103 |
| GSK3511294 | Other | Phase PHASE3 | Asthma | COMPLETED | NCT04718103 |
| Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI] | Other | Phase PHASE2 | Endometrial Cancer Stage I | RECRUITING | NCT06278857 |
| Placebo | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT04224701 |
| BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT04224701 |
| standard of care | Other | Phase PHASE2 | Chronic Lymphoid Leukemia in Relapse | ACTIVE_NOT_RECRUITING | NCT05069051 |
| Belimumab 200 MG/ML [Benlysta] | Other | Phase PHASE2 | Chronic Lymphoid Leukemia in Relapse | ACTIVE_NOT_RECRUITING | NCT05069051 |
| standard of care | Other | Phase PHASE2 | Chronic Lymphoid Leukemia in Relapse | ACTIVE_NOT_RECRUITING | NCT05069051 |
| Belimumab 200 MG/ML [Benlysta] | Other | Phase PHASE2 | Chronic Lymphoid Leukemia in Relapse | ACTIVE_NOT_RECRUITING | NCT05069051 |
| Placebo | Other | Phase PHASE1 | Respiratory Tract Infections | COMPLETED | NCT06577597 |
| GSK3923868 | Other | Phase PHASE1 | Respiratory Tract Infections | COMPLETED | NCT06577597 |
| Salbutamol | Other | Phase PHASE4 | Asthma | COMPLETED | NCT04276233 |
| Mepolizumab | Other | Phase PHASE4 | Asthma | COMPLETED | NCT04276233 |
| Salbutamol | Other | Phase PHASE4 | Asthma | COMPLETED | NCT04276233 |
| Mepolizumab | Other | Phase PHASE4 | Asthma | COMPLETED | NCT04276233 |
| Paroxetine | Other | Phase PHASE1 | Anxiety Disorders | COMPLETED | NCT06065735 |
| Paroxetine | Other | Phase PHASE1 | Anxiety Disorders | COMPLETED | NCT06065735 |
| Travel Health (Hepatitis A, Hepatitis B, Typhoid Fever) | Other | Phase PHASE4 | Healthy | COMPLETED | NCT02868970 |
| Herpes Zoster | Other | Phase PHASE4 | Healthy | COMPLETED | NCT02868970 |
| Meningococcal ACWY | Other | Phase PHASE4 | Healthy | COMPLETED | NCT02868970 |
| Tdap (tetanus-diphtheria-acellular pertussis) | Other | Phase PHASE4 | Healthy | COMPLETED | NCT02868970 |
| High-Dose TIV | Other | Phase PHASE4 | Healthy | COMPLETED | NCT02868970 |
| Meningococcal B | Other | Phase PHASE4 | Healthy | COMPLETED | NCT02868970 |
| Travel Health (Hepatitis A, Hepatitis B, Typhoid Fever) | Other | Phase PHASE4 | Healthy | COMPLETED | NCT02868970 |
| Herpes Zoster | Other | Phase PHASE4 | Healthy | COMPLETED | NCT02868970 |
| Meningococcal ACWY | Other | Phase PHASE4 | Healthy | COMPLETED | NCT02868970 |
| Tdap (tetanus-diphtheria-acellular pertussis) | Other | Phase PHASE4 | Healthy | COMPLETED | NCT02868970 |
| High-Dose TIV | Other | Phase PHASE4 | Healthy | COMPLETED | NCT02868970 |
| Meningococcal B | Other | Phase PHASE4 | Healthy | COMPLETED | NCT02868970 |
| Niraparib plus Cabozantinib | Other | Phase PHASE1 | Urothelial Cancer | COMPLETED | NCT03425201 |
| Niraparib plus Cabozantinib | Other | Phase PHASE1 | Urothelial Cancer | COMPLETED | NCT03425201 |
| GSK2857916 with Pomalidomide and Dexamethasone | Other | Phase PHASE1 | Relapsed and/or Refractory Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT03715478 |
| GSK2857916 with Pomalidomide and Dexamethasone | Other | Phase PHASE1 | Relapsed and/or Refractory Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT03715478 |
| Niraparib | Other | Phase PHASE1 | Neoplasms, Breast | COMPLETED | NCT03329937 |
| Niraparib | Other | Phase PHASE1 | Neoplasms, Breast | COMPLETED | NCT03329937 |
| vaccination with 2 doses of Shingrix vaccine | Other | Phase PHASE4 | Systemic Vasculitis | ENROLLING_BY_INVITATION | NCT06763783 |
| Shingrix | Other | Phase PHASE4 | Systemic Vasculitis | ENROLLING_BY_INVITATION | NCT06763783 |
| vaccination with 2 doses of Shingrix vaccine | Other | Phase PHASE4 | Systemic Vasculitis | ENROLLING_BY_INVITATION | NCT06763783 |
| Shingrix | Other | Phase PHASE4 | Systemic Vasculitis | ENROLLING_BY_INVITATION | NCT06763783 |
| GSK3882347 | Other | Phase PHASE1 | Urinary Tract Infections | COMPLETED | NCT05760261 |
| Midazolam | Other | Phase PHASE1 | Urinary Tract Infections | COMPLETED | NCT05760261 |
| Vaxneuvance | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06693895 |
| PCV 20 | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06693895 |
| PCV (pneumococcal conjugate vaccine) 13 | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06693895 |
| Hepatitis A vaccine | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06693895 |
| Measles, mumps, and rubella vaccine | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06693895 |
| Marketed varicella vaccine | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06693895 |
| Investigational varicella vaccine | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06693895 |
| Placebo | Other | Phase PHASE4 | Herpes Zoster | COMPLETED | NCT04869982 |
| RZV | Other | Phase PHASE4 | Herpes Zoster | COMPLETED | NCT04869982 |
| Placebo | Other | Phase PHASE4 | Herpes Zoster | COMPLETED | NCT04869982 |
| RZV | Other | Phase PHASE4 | Herpes Zoster | COMPLETED | NCT04869982 |
| GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine | Other | Phase PHASE1 | Typhoid Fever | COMPLETED | NCT05613205 |
| Sanofi Pasteur's Typhoid Vi polysaccharide vaccine | Other | Phase PHASE1 | Typhoid Fever | COMPLETED | NCT05613205 |
| TYP03B Full Dose with Alum investigational vaccine | Other | Phase PHASE1 | Typhoid Fever | COMPLETED | NCT05613205 |
| TYP03A Low Dose with Alum investigational vaccine | Other | Phase PHASE1 | Typhoid Fever | COMPLETED | NCT05613205 |
| TYP04B Full Dose without Alum investigational vaccine | Other | Phase PHASE1 | Typhoid Fever | COMPLETED | NCT05613205 |
| TYP04A Low Dose without Alum investigational vaccine | Other | Phase PHASE1 | Typhoid Fever | COMPLETED | NCT05613205 |
| Albendazole 400 mg | Other | Phase PHASE1 | Intestinal Diseases | COMPLETED | NCT06201559 |
| Albendazole IP 400 mg | Other | Phase PHASE1 | Intestinal Diseases | COMPLETED | NCT06201559 |
| GSK3511294 | Other | Phase PHASE1 | Asthma | COMPLETED | NCT05140200 |
| GSK3511294 | Other | Phase PHASE1 | Asthma | COMPLETED | NCT05140200 |
| Dostarlimab | Other | Phase PHASE2 | MMR-D/MSI-H Colorectal Cancers | WITHDRAWN | NCT06365970 |
| Niraparib | Other | Phase PHASE2 | MMR-D/MSI-H Colorectal Cancers | WITHDRAWN | NCT06365970 |
| Blenrep | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT05986682 |
| Gardasil 9 | Other | Phase PHASE1 | Cervical Intraepithelial Neoplasia | COMPLETED | NCT05496231 |
| HPV9 Low formulation | Other | Phase PHASE1 | Cervical Intraepithelial Neoplasia | COMPLETED | NCT05496231 |
| HPV9 Medium formulation | Other | Phase PHASE1 | Cervical Intraepithelial Neoplasia | COMPLETED | NCT05496231 |
| HPV9 High formulation | Other | Phase PHASE1 | Cervical Intraepithelial Neoplasia | COMPLETED | NCT05496231 |
| Observational study | Other | Preclinical | Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT05857397 |
| Observational study | Other | Preclinical | Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT05857397 |
| GSK3915393 | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT06625489 |
| Nintedanib | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT06625489 |
| Part A: Placebo | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT06625489 |
| Steroid Taper | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT03312907 |
| Standard therapy (Excluding Immunosuppressants) | Drug | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT03312907 |
| Standard therapy (Including Immunosuppressants) | Drug | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT03312907 |
| Rituximab-placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT03312907 |
| Rituximab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT03312907 |
| Belimumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT03312907 |
| Steroid Taper | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT03312907 |
| Standard therapy (Excluding Immunosuppressants) | Drug | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT03312907 |
| Standard therapy (Including Immunosuppressants) | Drug | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT03312907 |
| Rituximab-placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT03312907 |
| Rituximab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT03312907 |
| Belimumab | Other | Phase PHASE3 | Systemic Lupus Erythematosus | COMPLETED | NCT03312907 |
| Placebo | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | TERMINATED | NCT04605159 |
| RSV MAT | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | TERMINATED | NCT04605159 |
| Placebo | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | TERMINATED | NCT04605159 |
| RSV MAT | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | TERMINATED | NCT04605159 |
| CV0501 (200 μg) | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05477186 |
| CV0501 (100 μg) | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05477186 |
| CV0501 (50 μg) | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05477186 |
| CV0501 (25 μg) | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05477186 |
| CV0501 (12 μg) | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05477186 |
| CV0501 (6 μg) | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05477186 |
| CV0501 (3 μg) | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05477186 |
| Linerixibat | Other | Preclinical | Pruritus | AVAILABLE | NCT05448170 |
| Linerixibat | Other | Preclinical | Pruritus | AVAILABLE | NCT05448170 |
| Ofatumumab + Bendamustine | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT01437709 |
| Ofatumumab (This arm is closed) | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT01437709 |
| Dostarlimab | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT06655818 |
| Belantamab Mafodotin | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT06655818 |
| Vaxneuvance | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06740630 |
| PCV 20 | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06740630 |
| PCV (pneumococcal conjugate vaccine) 13 | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06740630 |
| Hepatitis A vaccine | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06740630 |
| MMR vaccine | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06740630 |
| Marketed varicella vaccine_Lot 2 | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06740630 |
| Marketed varicella vaccine_Lot 1 | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06740630 |
| Investigational varicella vaccine_Lot 3 | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06740630 |
| Investigational varicella vaccine_Lot 2 | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06740630 |
| Investigational varicella vaccine_Lot 1 | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06740630 |
| Vaxneuvance | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06740630 |
| PCV 20 | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06740630 |
| PCV (pneumococcal conjugate vaccine) 13 | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06740630 |
| Hepatitis A vaccine | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06740630 |
| MMR vaccine | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06740630 |
| Marketed varicella vaccine_Lot 2 | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06740630 |
| Marketed varicella vaccine_Lot 1 | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06740630 |
| Investigational varicella vaccine_Lot 3 | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06740630 |
| Investigational varicella vaccine_Lot 2 | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06740630 |
| Investigational varicella vaccine_Lot 1 | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06740630 |
| Observational study | Other | Preclinical | Endometrial Cancer | ACTIVE_NOT_RECRUITING | NCT06014580 |
| cisplatin plus radiotherapy | Drug | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT05784012 |
| Niraparib | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT05784012 |
| Dostarlimab | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT05784012 |
| Zanamivir | Other | Phase PHASE2 | Influenza, Human | RECRUITING | NCT04494412 |
| LV5FU2 | Other | Phase PHASE2 | Pancreas Neoplasms | RECRUITING | NCT06757244 |
| mFOLFIRINOX Treatment Regimen | Drug | Phase PHASE2 | Pancreas Neoplasms | RECRUITING | NCT06757244 |
| Vitamin D3 (Cholecalciferol) | Other | Phase PHASE2 | Pancreas Neoplasms | RECRUITING | NCT06757244 |
| Dostarlimab | Other | Phase PHASE2 | Pancreas Neoplasms | RECRUITING | NCT06757244 |
| Bortezomib | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04484623 |
| Dexamethasone | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04484623 |
| Pomalidomide | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04484623 |
| Belantamab mafodotin | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04484623 |
| Bortezomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT03544281 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT03544281 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT03544281 |
| Belantamab mafodotin | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT03544281 |
| ELLIPTA | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT04923347 |
| FF/UMEC/VI | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT04923347 |
| Placebo | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT05131971 |
| GSK3888130B | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT05131971 |
| Fluarix Tetra Vaccine | Other | Phase PHASE4 | Influenza, Human | COMPLETED | NCT05648357 |
| Niraparib | Other | Phase PHASE2 | Recurrent Endometrial Carcinoma | TERMINATED | NCT05523440 |
| Bevacizumab | Other | Phase PHASE2 | Recurrent Endometrial Carcinoma | TERMINATED | NCT05523440 |
| Niraparib | Other | Phase PHASE2 | Recurrent Endometrial Carcinoma | TERMINATED | NCT05523440 |
| Bevacizumab | Other | Phase PHASE2 | Recurrent Endometrial Carcinoma | TERMINATED | NCT05523440 |
| Augmentin ES | Other | Phase PHASE2 | Infections, Bacterial | WITHDRAWN | NCT05340257 |
| Augmentin ES | Other | Phase PHASE2 | Infections, Bacterial | WITHDRAWN | NCT05340257 |
| HZ/su vaccine | Other | Phase PHASE3 | Respiratory Syncytial Viruses | COMPLETED | NCT05966090 |
| RSVPreF3 OA investigational vaccine | Other | Phase PHASE3 | Respiratory Syncytial Viruses | COMPLETED | NCT05966090 |
| Dostarlimab | Other | Phase PHASE2 | Recurrent Ovarian Cancer | WITHDRAWN | NCT05126342 |
| Niraparib | Other | Phase PHASE2 | Recurrent Ovarian Cancer | WITHDRAWN | NCT05126342 |
| Placebo | Other | Phase PHASE2 | Hepatitis B | RECRUITING | NCT04954859 |
| Bepirovirsen | Other | Phase PHASE2 | Hepatitis B | RECRUITING | NCT04954859 |
| Placebo | Other | Phase PHASE2 | Hepatitis B | RECRUITING | NCT04954859 |
| Bepirovirsen | Other | Phase PHASE2 | Hepatitis B | RECRUITING | NCT04954859 |
| Daprodustat | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT04640311 |
| Daprodustat | Other | Phase PHASE1 | Anaemia | COMPLETED | NCT04640311 |
| Placebo | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | TERMINATED | NCT04980391 |
| RSV MAT | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | TERMINATED | NCT04980391 |
| Mepolizumab | Other | Preclinical | Hypereosinophilic Syndrome | NO_LONGER_AVAILABLE | NCT00244686 |
| Iodine I 131 Tositumomab | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00135200 |
| Iodine I 131 Tositumomab | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00135200 |
| PCV-free liquid formulation of GSK's oral live attenuated HRV | Other | Phase PHASE3 | Gastroenteritis | COMPLETED | NCT06025695 |
| GSK's liquid oral live attenuated HRV | Other | Phase PHASE3 | Gastroenteritis | COMPLETED | NCT06025695 |
| PCV-free liquid formulation of GSK's oral live attenuated HRV | Other | Phase PHASE3 | Gastroenteritis | COMPLETED | NCT06025695 |
| GSK's liquid oral live attenuated HRV | Other | Phase PHASE3 | Gastroenteritis | COMPLETED | NCT06025695 |
| Placebo | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT05219253 |
| HZ/su | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT05219253 |
| Placebo | Other | Phase PHASE1 | Pain | COMPLETED | NCT05174013 |
| GSK3858279 | Other | Phase PHASE1 | Pain | COMPLETED | NCT05174013 |
| Placebo | Other | Phase PHASE1 | Pain | COMPLETED | NCT05174013 |
| GSK3858279 | Other | Phase PHASE1 | Pain | COMPLETED | NCT05174013 |
| Bupropion XL | Other | Phase PHASE3 | Bipolar I Disorder | TERMINATED | NCT00958633 |
| Escitalopram | Other | Phase PHASE3 | Bipolar I Disorder | TERMINATED | NCT00958633 |
| PCV20 | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT05879107 |
| RSVPreF3 OA investigational vaccine | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT05879107 |
| MenACWY-TT vaccine | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT05082285 |
| MenB vaccine | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT05082285 |
| MenABCWY-1Gen vaccine | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT05082285 |
| MenABCWY-2Gen high dose vaccine | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT05082285 |
| MenABCWY-2Gen low dose vaccine | Other | Phase PHASE2 | Infections, Meningococcal | COMPLETED | NCT05082285 |
| Pazopanib | Other | Phase PHASE1 | Glioblastoma Multiforme | RECRUITING | NCT02331498 |
| TSR-042 | Other | Phase PHASE2 | Cervical Cancer | ACTIVE_NOT_RECRUITING | NCT03833479 |
| No Further Treatment | Drug | Phase PHASE2 | Cervical Cancer | ACTIVE_NOT_RECRUITING | NCT03833479 |
| TSR-042 | Other | Phase PHASE2 | Cervical Cancer | ACTIVE_NOT_RECRUITING | NCT03833479 |
| No Further Treatment | Drug | Phase PHASE2 | Cervical Cancer | ACTIVE_NOT_RECRUITING | NCT03833479 |
| Niraparib | Other | Phase PHASE2 | Recurrent Glioblastoma | TERMINATED | NCT05297864 |
| Niraparib | Other | Phase PHASE2 | Recurrent Glioblastoma | TERMINATED | NCT05297864 |
| MenACWY vaccine | Other | Phase PHASE1 | Infections, Meningococcal | COMPLETED | NCT04886154 |
| MenB vaccine | Other | Phase PHASE1 | Infections, Meningococcal | COMPLETED | NCT04886154 |
| Placebo | Other | Phase PHASE1 | Infections, Meningococcal | COMPLETED | NCT04886154 |
| MenABCWY-2Gen high dose vaccine | Other | Phase PHASE1 | Infections, Meningococcal | COMPLETED | NCT04886154 |
| MenABCWY-2Gen low dose vaccine | Other | Phase PHASE1 | Infections, Meningococcal | COMPLETED | NCT04886154 |
| Ipilimumab | Other | Phase PHASE2 | Neoplasms | TERMINATED | NCT06790303 |
| Feladilimab | Other | Phase PHASE2 | Neoplasms | TERMINATED | NCT06790303 |
| Control | Other | Approved | Vitamin Deficiency | COMPLETED | NCT03004807 |
| Centrum Silver Mens' Formula | Other | Approved | Vitamin Deficiency | COMPLETED | NCT03004807 |
| Control | Other | Approved | Vitamin Deficiency | COMPLETED | NCT03004807 |
| Centrum Silver Mens' Formula | Other | Approved | Vitamin Deficiency | COMPLETED | NCT03004807 |
| belimumab | Other | Preclinical | Systemic Lupus Erythematosus | COMPLETED | NCT01532310 |
| Placebo | Other | Phase PHASE1 | Herpes Simplex | COMPLETED | NCT05989672 |
| HSVTI Formulation 2 | Other | Phase PHASE1 | Herpes Simplex | COMPLETED | NCT05989672 |
| HSVTI Formulation 1 | Other | Phase PHASE1 | Herpes Simplex | COMPLETED | NCT05989672 |
| Pegylated liposomal doxorubicin | Other | Phase PHASE2 | Ovarian Neoplasms | RECRUITING | NCT06023862 |
| Paclitaxel | Other | Phase PHASE2 | Ovarian Neoplasms | RECRUITING | NCT06023862 |
| Gemcitabine | Other | Phase PHASE2 | Ovarian Neoplasms | RECRUITING | NCT06023862 |
| Doxorubicin | Other | Phase PHASE2 | Ovarian Neoplasms | RECRUITING | NCT06023862 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Neoplasms | RECRUITING | NCT06023862 |
| Dostarlimab | Other | Phase PHASE2 | Ovarian Neoplasms | RECRUITING | NCT06023862 |
| GSK6097608 | Other | Phase PHASE2 | Neoplasms | COMPLETED | NCT03739710 |
| Dostarlimab | Other | Phase PHASE2 | Neoplasms | COMPLETED | NCT03739710 |
| GSK4428859A | Other | Phase PHASE2 | Neoplasms | COMPLETED | NCT03739710 |
| Ipilimumab | Other | Phase PHASE2 | Neoplasms | COMPLETED | NCT03739710 |
| Feladilimab | Other | Phase PHASE2 | Neoplasms | COMPLETED | NCT03739710 |
| Docetaxel | Other | Phase PHASE2 | Neoplasms | COMPLETED | NCT03739710 |
| Placebo | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT06422767 |
| Bepirovirsen | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT06422767 |
| Marketed MMRV_Lot 1 and Lot 2 vaccine | Other | Phase PHASE2 | Measles; Mumps; Rubella; Chickenpox | COMPLETED | NCT05630846 |
| Investigational M(L)M(L)R(L)V(L)NS vaccine | Other | Phase PHASE2 | Measles; Mumps; Rubella; Chickenpox | COMPLETED | NCT05630846 |
| Investigational MM(H)RVNS vaccine | Other | Phase PHASE2 | Measles; Mumps; Rubella; Chickenpox | COMPLETED | NCT05630846 |
| Investigational MMRV(H)NS vaccine | Other | Phase PHASE2 | Measles; Mumps; Rubella; Chickenpox | COMPLETED | NCT05630846 |
| FF via ELLIPTA DPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03248128 |
| FF/VI via ELLIPTA DPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03248128 |
| GSK5733584 | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06431594 |
| Antiretroviral therapy | Drug | Phase PHASE2 | HIV Infections | COMPLETED | NCT06214052 |
| Matching Placebo | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT06214052 |
| VH4524184 | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT06214052 |
| Antiretroviral therapy | Drug | Phase PHASE2 | HIV Infections | COMPLETED | NCT06214052 |
| Matching Placebo | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT06214052 |
| VH4524184 | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT06214052 |
| Nelistotug | Other | Phase PHASE2 | Neoplasms | COMPLETED | NCT06926673 |
| Belrestotug. | Other | Phase PHASE2 | Neoplasms | COMPLETED | NCT06926673 |
| Dostarlimab | Other | Phase PHASE2 | Neoplasms | COMPLETED | NCT06926673 |
| Dostarlimab | Other | Phase PHASE4 | Neoplasms, Endometrial | NOT_YET_RECRUITING | NCT06897527 |
| trametinib | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT02230553 |
| Lapatinib | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT02230553 |
| Nucleos(t)ide therapy | Drug | Phase PHASE2 | Hepatitis B | COMPLETED | NCT04544956 |
| GSK3228836 | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT04544956 |
| Paclitaxel | Other | Phase PHASE2 | Ovarian Neoplasms | COMPLETED | NCT03574779 |
| Carboplatin | Other | Phase PHASE2 | Ovarian Neoplasms | COMPLETED | NCT03574779 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Neoplasms | COMPLETED | NCT03574779 |
| TSR-042 | Other | Phase PHASE2 | Ovarian Neoplasms | COMPLETED | NCT03574779 |
| Niraparib | Other | Phase PHASE2 | Ovarian Neoplasms | COMPLETED | NCT03574779 |
| Placebo | Other | Phase PHASE3 | Neoplasms, Breast | ACTIVE_NOT_RECRUITING | NCT04915755 |
| Niraparib | Other | Phase PHASE3 | Neoplasms, Breast | ACTIVE_NOT_RECRUITING | NCT04915755 |
| Placebo | Other | Phase PHASE3 | Neoplasms, Breast | ACTIVE_NOT_RECRUITING | NCT04915755 |
| Niraparib | Other | Phase PHASE3 | Neoplasms, Breast | ACTIVE_NOT_RECRUITING | NCT04915755 |
| HZ/su vaccine (GSK1437173A) | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT04176939 |
| Placebo | Other | Phase PHASE3 | Pruritus | COMPLETED | NCT04950127 |
| Linerixibat | Other | Phase PHASE3 | Pruritus | COMPLETED | NCT04950127 |
| F2F22F/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| Control 3 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F23C/DL001Z-NH | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| Control 2 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F23B/DL001Z-NH | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F23A/DL001Z-NH | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F23D/DL001Z-NH | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| Control 1 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F22E/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F22D/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F22C/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F22B/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F22A/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2B22E/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2B22D/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2B22C/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2B22B/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2B22A/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2C22C/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F22F/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| Control 3 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F23C/DL001Z-NH | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| Control 2 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F23B/DL001Z-NH | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F23A/DL001Z-NH | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F23D/DL001Z-NH | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| Control 1 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F22E/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F22D/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F22C/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F22B/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F22A/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2B22E/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2B22D/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2B22C/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2B22B/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2B22A/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2C22C/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F22F/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| Control 3 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F23C/DL001Z-NH | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| Control 2 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F23B/DL001Z-NH | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F23A/DL001Z-NH | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F23D/DL001Z-NH | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| Control 1 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F22E/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F22D/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F22C/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F22B/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2F22A/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2B22E/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2B22D/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2B22C/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2B22B/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2B22A/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| F2C22C/DL001Z | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05823974 |
| Blood sampling | Other | Phase PHASE4 | Malaria | COMPLETED | NCT02251704 |
| Assessment of body temperature | Other | Phase PHASE4 | Malaria | COMPLETED | NCT02251704 |
| Nirogacestat | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT07084896 |
| Belantamab mafodotin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT07084896 |
| Nirogacestat | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT07084896 |
| Belantamab mafodotin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT07084896 |
| Paclitaxel | Other | Phase PHASE2 | Carcinoma | ACTIVE_NOT_RECRUITING | NCT06317311 |
| Carboplatin | Other | Phase PHASE2 | Carcinoma | ACTIVE_NOT_RECRUITING | NCT06317311 |
| Dostarlimab | Other | Phase PHASE2 | Carcinoma | ACTIVE_NOT_RECRUITING | NCT06317311 |
| Placebo | Other | Phase PHASE2 | Chronic Hepatitis B Virus Infection | ACTIVE_NOT_RECRUITING | NCT06537414 |
| Bepirovirsen | Other | Phase PHASE2 | Chronic Hepatitis B Virus Infection | ACTIVE_NOT_RECRUITING | NCT06537414 |
| Daplusiran/Tomligisiran Dose Level 2 | Other | Phase PHASE2 | Chronic Hepatitis B Virus Infection | ACTIVE_NOT_RECRUITING | NCT06537414 |
| Daplusiran/Tomligisiran Dose Level 1 | Other | Phase PHASE2 | Chronic Hepatitis B Virus Infection | ACTIVE_NOT_RECRUITING | NCT06537414 |
| Spirometry | Other | Phase PHASE4 | Asthma | ACTIVE_NOT_RECRUITING | NCT06041386 |
| Mepolizumab | Other | Phase PHASE4 | Asthma | ACTIVE_NOT_RECRUITING | NCT06041386 |
| Chloroquine | Other | Phase PHASE3 | Malaria, Vivax | RECRUITING | NCT06666491 |
| Primaquine | Other | Phase PHASE3 | Malaria, Vivax | RECRUITING | NCT06666491 |
| Tafenoquine | Other | Phase PHASE3 | Malaria, Vivax | RECRUITING | NCT06666491 |
| NgG below HTD investigational vaccine | Other | Phase PHASE1 | Sexually Transmitted Diseases | COMPLETED | NCT05630859 |
| NgG HTD investigational vaccine | Other | Phase PHASE1 | Sexually Transmitted Diseases | COMPLETED | NCT05630859 |
| Placebo | Other | Phase PHASE1 | Sexually Transmitted Diseases | COMPLETED | NCT05630859 |
| NgG high dose investigational vaccine | Other | Phase PHASE1 | Sexually Transmitted Diseases | COMPLETED | NCT05630859 |
| NgG medium dose investigational vaccine | Other | Phase PHASE1 | Sexually Transmitted Diseases | COMPLETED | NCT05630859 |
| NgG low dose investigational vaccine | Other | Phase PHASE1 | Sexually Transmitted Diseases | COMPLETED | NCT05630859 |
| Chemotherapy | Drug | Phase PHASE2 | Lung Cancer, Non-Small Cell | TERMINATED | NCT04581824 |
| Pembrolizumab | Other | Phase PHASE2 | Lung Cancer, Non-Small Cell | TERMINATED | NCT04581824 |
| Dostarlimab | Other | Phase PHASE2 | Lung Cancer, Non-Small Cell | TERMINATED | NCT04581824 |
| Chemotherapy | Drug | Phase PHASE2 | Lung Cancer, Non-Small Cell | TERMINATED | NCT04581824 |
| Pembrolizumab | Other | Phase PHASE2 | Lung Cancer, Non-Small Cell | TERMINATED | NCT04581824 |
| Dostarlimab | Other | Phase PHASE2 | Lung Cancer, Non-Small Cell | TERMINATED | NCT04581824 |
| Strep A Alum Placebo | Other | Phase PHASE1 | Streptococcal Infections | RECRUITING | NCT07085702 |
| High dose Strep A AS37 | Other | Phase PHASE1 | Streptococcal Infections | RECRUITING | NCT07085702 |
| Medium dose Strep A AS37 | Other | Phase PHASE1 | Streptococcal Infections | RECRUITING | NCT07085702 |
| Low dose Strep A AS37 | Other | Phase PHASE1 | Streptococcal Infections | RECRUITING | NCT07085702 |
| High dose Strep A Alum | Other | Phase PHASE1 | Streptococcal Infections | RECRUITING | NCT07085702 |
| Medium dose Strep A Alum | Other | Phase PHASE1 | Streptococcal Infections | RECRUITING | NCT07085702 |
| Low dose Strep A Alum | Other | Phase PHASE1 | Streptococcal Infections | RECRUITING | NCT07085702 |
| ELLIPTA | Other | Phase PHASE3 | Asthma | COMPLETED | NCT04937387 |
| FF/UMEC/VI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT04937387 |
| FF/VI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT04937387 |
| ELLIPTA | Other | Phase PHASE3 | Asthma | COMPLETED | NCT04937387 |
| FF/UMEC/VI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT04937387 |
| FF/VI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT04937387 |
| Radiation | Other | Phase PHASE2 | Pancreatic Cancer | COMPLETED | NCT04409002 |
| Dostarlimab | Other | Phase PHASE2 | Pancreatic Cancer | COMPLETED | NCT04409002 |
| Niraparib | Other | Phase PHASE2 | Pancreatic Cancer | COMPLETED | NCT04409002 |
| Radiation | Other | Phase PHASE2 | Pancreatic Cancer | COMPLETED | NCT04409002 |
| Dostarlimab | Other | Phase PHASE2 | Pancreatic Cancer | COMPLETED | NCT04409002 |
| Niraparib | Other | Phase PHASE2 | Pancreatic Cancer | COMPLETED | NCT04409002 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT04133909 |
| Mepolizumab | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT04133909 |
| Prospective observational cohort study | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT04657211 |
| Dostarlimab | Other | Phase PHASE2 | Endometrial Cancer | NOT_YET_RECRUITING | NCT07115927 |
| Dostarlimab | Other | Phase PHASE2 | Endometrial Cancer | NOT_YET_RECRUITING | NCT07115927 |
| FLU Q-PAN H5N8 750_A | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05975840 |
| FLU Q-PAN H5N8 750_B | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05975840 |
| FLU Q-PAN H5N8 375_A | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05975840 |
| FLU Q-PAN H5N8 375_B | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05975840 |
| FLU Q-PAN H5N8 750_A | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05975840 |
| FLU Q-PAN H5N8 750_B | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05975840 |
| FLU Q-PAN H5N8 375_A | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05975840 |
| FLU Q-PAN H5N8 375_B | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05975840 |
| FLU Q-PAN H5N8 750_A | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05975840 |
| FLU Q-PAN H5N8 750_B | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05975840 |
| FLU Q-PAN H5N8 375_A | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05975840 |
| FLU Q-PAN H5N8 375_B | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05975840 |
| Niraparib | Other | Phase PHASE2 | Endometrial Cancer | COMPLETED | NCT04080284 |
| Prospective observational cohort study | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT04853225 |
| HFA-134A propellant | Other | Phase PHASE1 | Asthma | COMPLETED | NCT06702462 |
| HFA-152A propellant | Other | Phase PHASE1 | Asthma | COMPLETED | NCT06702462 |
| GSK3036656 | Other | Phase PHASE1 | Tuberculosis | COMPLETED | NCT06354257 |
| Microgynon | Other | Phase PHASE1 | Tuberculosis | COMPLETED | NCT06354257 |
| Belantamab | Other | Phase PHASE1 | Autoimmune Diseases | WITHDRAWN | NCT06413511 |
| Nucala | Other | Phase EARLY_PHASE1 | Chronic Spontaneous Urticaria | COMPLETED | NCT03494881 |
| Placebo | Other | Phase PHASE1 | Dermatitis, Atopic | COMPLETED | NCT04975438 |
| GSK1070806 | Other | Phase PHASE1 | Dermatitis, Atopic | COMPLETED | NCT04975438 |
| FF/UMEC/VI | Other | Phase PHASE3 | Asthma | ACTIVE_NOT_RECRUITING | NCT04651777 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT07150104 |
| Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT07150104 |
| Nirogacestat | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT07150104 |
| Belantamab mafodotin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT07150104 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT07150104 |
| Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT07150104 |
| Nirogacestat | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT07150104 |
| Belantamab mafodotin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT07150104 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT07150091 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT07150091 |
| Nirogacestat | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT07150091 |
| Belantamab mafodotin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT07150091 |
| Pomalidomide | Other | Phase PHASE2 | Plasma Cell Myeloma | RECRUITING | NCT05208307 |
| Dexamethasone | Other | Phase PHASE2 | Plasma Cell Myeloma | RECRUITING | NCT05208307 |
| Belantamab Mafodotin | Other | Phase PHASE2 | Plasma Cell Myeloma | RECRUITING | NCT05208307 |
| Pomalidomide | Other | Phase PHASE2 | Plasma Cell Myeloma | RECRUITING | NCT05208307 |
| Dexamethasone | Other | Phase PHASE2 | Plasma Cell Myeloma | RECRUITING | NCT05208307 |
| Belantamab Mafodotin | Other | Phase PHASE2 | Plasma Cell Myeloma | RECRUITING | NCT05208307 |
| Placebo matching Niraparib | Other | Phase PHASE3 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT03981796 |
| Niraparib | Other | Phase PHASE3 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT03981796 |
| Paclitaxel | Other | Phase PHASE3 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT03981796 |
| Carboplatin | Other | Phase PHASE3 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT03981796 |
| Placebo matching dostarlimab | Other | Phase PHASE3 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT03981796 |
| Dostarlimab | Other | Phase PHASE3 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT03981796 |
| Belantamab mafodotin lyophilized powder | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT03525678 |
| Belantamab mafodotin frozen liquid | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT03525678 |
| Belantamab mafodotin | Other | Phase PHASE2 | AL Amyloidosis | COMPLETED | NCT04617925 |
| Placebo | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | ACTIVE_NOT_RECRUITING | NCT06573281 |
| Investigational RSV vaccine 6 | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | ACTIVE_NOT_RECRUITING | NCT06573281 |
| Investigational RSV vaccine 5 | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | ACTIVE_NOT_RECRUITING | NCT06573281 |
| Investigational RSV vaccine 4 | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | ACTIVE_NOT_RECRUITING | NCT06573281 |
| Investigational RSV vaccine 3 | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | ACTIVE_NOT_RECRUITING | NCT06573281 |
| Investigational RSV vaccine 2 | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | ACTIVE_NOT_RECRUITING | NCT06573281 |
| Investigational RSV vaccine 1 | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | ACTIVE_NOT_RECRUITING | NCT06573281 |
| HSVTI_F2 | Other | Phase PHASE1 | Herpes Simplex | COMPLETED | NCT05298254 |
| HSVTI_F1 | Other | Phase PHASE1 | Herpes Simplex | COMPLETED | NCT05298254 |
| Placebo | Other | Phase PHASE1 | Herpes Simplex | COMPLETED | NCT05298254 |
| HSV formulation 3 with adjuvant 2 | Other | Phase PHASE1 | Herpes Simplex | COMPLETED | NCT05298254 |
| HSV formulation 2 with adjuvant 2 | Other | Phase PHASE1 | Herpes Simplex | COMPLETED | NCT05298254 |
| HSV formulation 1 with adjuvant 2 | Other | Phase PHASE1 | Herpes Simplex | COMPLETED | NCT05298254 |
| HSV formulation 3 with adjuvant 1 | Other | Phase PHASE1 | Herpes Simplex | COMPLETED | NCT05298254 |
| HSV formulation 2 with adjuvant 1 | Other | Phase PHASE1 | Herpes Simplex | COMPLETED | NCT05298254 |
| HSV formulation 1 with adjuvant 1 | Other | Phase PHASE1 | Herpes Simplex | COMPLETED | NCT05298254 |
| Non-adjuvanted HSV formulation 3 | Other | Phase PHASE1 | Herpes Simplex | COMPLETED | NCT05298254 |
| Non-adjuvanted HSV formulation 2 | Other | Phase PHASE1 | Herpes Simplex | COMPLETED | NCT05298254 |
| Non-adjuvanted HSV formulation 1 | Other | Phase PHASE1 | Herpes Simplex | COMPLETED | NCT05298254 |
| Placebo | Other | Phase PHASE3 | Nasal Polyps | COMPLETED | NCT05281523 |
| Depemokimab (GSK3511294) | Other | Phase PHASE3 | Nasal Polyps | COMPLETED | NCT05281523 |
| Placebo | Other | Phase PHASE3 | Nasal Polyps | COMPLETED | NCT05281523 |
| Depemokimab (GSK3511294) | Other | Phase PHASE3 | Nasal Polyps | COMPLETED | NCT05281523 |
| Placebo | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT06680375 |
| Licensed COVID-19 mRNA | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT06680375 |
| Licensed Flu Seasonal | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT06680375 |
| SARS-CoV-2 mRNA Dose 2 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT06680375 |
| SARS-CoV-2 mRNA Dose 1 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT06680375 |
| Flu Seasonal mRNA | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT06680375 |
| Flu Seasonal /SARS-CoV-2 mRNA Dose 2 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT06680375 |
| Flu Seasonal /SARS-CoV-2 mRNA Dose 1 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT06680375 |
| Placebo | Other | Phase PHASE3 | Stem Cell Transplant Complications | TERMINATED | NCT04655508 |
| Seretide | Other | Phase PHASE3 | Stem Cell Transplant Complications | TERMINATED | NCT04655508 |
| RSVPreF3 OA investigational vaccine | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT06389487 |
| Placebo | Other | Phase PHASE3 | Neoplasms, Head and Neck | RECRUITING | NCT06256588 |
| Dostarlimab | Other | Phase PHASE3 | Neoplasms, Head and Neck | RECRUITING | NCT06256588 |
| Docetaxel | Other | Phase PHASE3 | Lung Cancer, Non-Small Cell | ACTIVE_NOT_RECRUITING | NCT04655976 |
| Dostarlimab | Other | Phase PHASE3 | Lung Cancer, Non-Small Cell | ACTIVE_NOT_RECRUITING | NCT04655976 |
| Cobolimab | Other | Phase PHASE3 | Lung Cancer, Non-Small Cell | ACTIVE_NOT_RECRUITING | NCT04655976 |
| Docetaxel | Other | Phase PHASE3 | Lung Cancer, Non-Small Cell | ACTIVE_NOT_RECRUITING | NCT04655976 |
| Dostarlimab | Other | Phase PHASE3 | Lung Cancer, Non-Small Cell | ACTIVE_NOT_RECRUITING | NCT04655976 |
| Cobolimab | Other | Phase PHASE3 | Lung Cancer, Non-Small Cell | ACTIVE_NOT_RECRUITING | NCT04655976 |
| RTS,S/AS01E vaccine | Other | Phase PHASE2 | Malaria | RECRUITING | NCT07036159 |
| RTS,S/AS01E vaccine | Other | Phase PHASE2 | Malaria | RECRUITING | NCT07036159 |
| Niraparib | Other | Phase PHASE2 | Ovarian Neoplasms | RECRUITING | NCT04641247 |
| Radiation Therapy | Drug | Phase PHASE1 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT03945721 |
| Niraparib | Other | Phase PHASE1 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT03945721 |
| Placebo | Other | Phase PHASE2 | Bronchiectasis | NOT_YET_RECRUITING | NCT07201051 |
| GSK3862995B | Other | Phase PHASE2 | Bronchiectasis | NOT_YET_RECRUITING | NCT07201051 |
| Ofatumumab | Other | Phase PHASE2 | Leukemia | TERMINATED | NCT01258933 |
| Placebo | Other | Phase PHASE1 | Systemic Lupus Erythematosus | SUSPENDED | NCT06188507 |
| GSK4347859 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | SUSPENDED | NCT06188507 |
| Ethionamide | Other | Phase PHASE2 | Pulmonary Tuberculosis | RECRUITING | NCT05807399 |
| Ethambutol (E) | Other | Phase PHASE2 | Pulmonary Tuberculosis | RECRUITING | NCT05807399 |
| Pretomanid (Pa) | Other | Phase PHASE2 | Pulmonary Tuberculosis | RECRUITING | NCT05807399 |
| Delpazolid (LCB01-0371) | Other | Phase PHASE2 | Pulmonary Tuberculosis | RECRUITING | NCT05807399 |
| Ganfeborole (GSK3036656) | Other | Phase PHASE2 | Pulmonary Tuberculosis | RECRUITING | NCT05807399 |
| Alpibectir (GSK3729098) | Other | Phase PHASE2 | Pulmonary Tuberculosis | RECRUITING | NCT05807399 |
| Moxifloxacin | Other | Phase PHASE2 | Pulmonary Tuberculosis | RECRUITING | NCT05807399 |
| Pyrazinamide | Other | Phase PHASE2 | Pulmonary Tuberculosis | RECRUITING | NCT05807399 |
| Isoniazid | Other | Phase PHASE2 | Pulmonary Tuberculosis | RECRUITING | NCT05807399 |
| Rifampicin | Other | Phase PHASE2 | Pulmonary Tuberculosis | RECRUITING | NCT05807399 |
| BTZ-043 | Other | Phase PHASE2 | Pulmonary Tuberculosis | RECRUITING | NCT05807399 |
| Ethionamide | Other | Phase PHASE2 | Pulmonary Tuberculosis | RECRUITING | NCT05807399 |
| Ethambutol (E) | Other | Phase PHASE2 | Pulmonary Tuberculosis | RECRUITING | NCT05807399 |
| Pretomanid (Pa) | Other | Phase PHASE2 | Pulmonary Tuberculosis | RECRUITING | NCT05807399 |
| Delpazolid (LCB01-0371) | Other | Phase PHASE2 | Pulmonary Tuberculosis | RECRUITING | NCT05807399 |
| Ganfeborole (GSK3036656) | Other | Phase PHASE2 | Pulmonary Tuberculosis | RECRUITING | NCT05807399 |
| Alpibectir (GSK3729098) | Other | Phase PHASE2 | Pulmonary Tuberculosis | RECRUITING | NCT05807399 |
| Moxifloxacin | Other | Phase PHASE2 | Pulmonary Tuberculosis | RECRUITING | NCT05807399 |
| Pyrazinamide | Other | Phase PHASE2 | Pulmonary Tuberculosis | RECRUITING | NCT05807399 |
| Isoniazid | Other | Phase PHASE2 | Pulmonary Tuberculosis | RECRUITING | NCT05807399 |
| Rifampicin | Other | Phase PHASE2 | Pulmonary Tuberculosis | RECRUITING | NCT05807399 |
| BTZ-043 | Other | Phase PHASE2 | Pulmonary Tuberculosis | RECRUITING | NCT05807399 |
| FF/VI | Other | Phase PHASE3 | Asthma | RECRUITING | NCT05757102 |
| ELLIPTA | Other | Phase PHASE3 | Asthma | RECRUITING | NCT05757102 |
| FF/UMEC/VI | Other | Phase PHASE3 | Asthma | RECRUITING | NCT05757102 |
| Belantamab mafodotin | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05064358 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | RECRUITING | NCT06959095 |
| Depemokimab | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | RECRUITING | NCT06959095 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | RECRUITING | NCT06959095 |
| Depemokimab | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | RECRUITING | NCT06959095 |
| laboratory biomarker analysis | Other | Phase PHASE2 | Recurrent Bladder Cancer | TERMINATED | NCT01382706 |
| fluorescence in situ hybridization | Other | Phase PHASE2 | Recurrent Bladder Cancer | TERMINATED | NCT01382706 |
| immunohistochemistry staining method | Other | Phase PHASE2 | Recurrent Bladder Cancer | TERMINATED | NCT01382706 |
| lapatinib ditosylate | Other | Phase PHASE2 | Recurrent Bladder Cancer | TERMINATED | NCT01382706 |
| docetaxel | Other | Phase PHASE2 | Recurrent Bladder Cancer | TERMINATED | NCT01382706 |
| Isatuximab | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT07217184 |
| Belantamab mafodotin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT07217184 |
| Feladilimab | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT07217119 |
| Belantamab mafodotin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT07217119 |
| Bepirovirsen | Other | Phase PHASE1 | Hepatitis B | RECRUITING | NCT07168356 |
| Pre-filled Syringes (PFS) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT04718389 |
| Standard of care (SoC) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT04718389 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT04718389 |
| Benralizumab | Other | Phase PHASE3 | Asthma | COMPLETED | NCT04718389 |
| Mepolizumab | Other | Phase PHASE3 | Asthma | COMPLETED | NCT04718389 |
| GSK3511294 (Depemokimab) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT04718389 |
| Dostarlimab (TSR-042) and TSR-022 (combination) | Other | Phase PHASE2 | Melanoma Stage III | ACTIVE_NOT_RECRUITING | NCT04139902 |
| Dostarlimab (TSR-042) (singly) | Other | Phase PHASE2 | Melanoma Stage III | ACTIVE_NOT_RECRUITING | NCT04139902 |
| Niraparib | Other | Phase PHASE2 | Sarcoma,Soft Tissue | ACTIVE_NOT_RECRUITING | NCT05515575 |
| Prevnar 20 | Other | Phase PHASE2 | Pneumonia, Bacterial | COMPLETED | NCT05412030 |
| Prevnar 13 | Other | Phase PHASE2 | Pneumonia, Bacterial | COMPLETED | NCT05412030 |
| AFX3772 | Other | Phase PHASE2 | Pneumonia, Bacterial | COMPLETED | NCT05412030 |
| IPV | Other | Phase PHASE3 | Gastroenteritis | COMPLETED | NCT06331156 |
| HRV PCV-free | Other | Phase PHASE3 | Gastroenteritis | COMPLETED | NCT06331156 |
| IPV | Other | Phase PHASE3 | Gastroenteritis | COMPLETED | NCT06331156 |
| HRV PCV-free | Other | Phase PHASE3 | Gastroenteritis | COMPLETED | NCT06331156 |
| CV0801 mRNA COVID-19 Vaccine | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05960097 |
| Control vaccine | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05960097 |
| CV0601 mRNA COVID-19 Vaccine | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05960097 |
| CV0701 mRNA COVID-19 Vaccine (High dose) | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05960097 |
| CV0701 mRNA COVID-19 Vaccine (Medium dose) | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05960097 |
| CV0701 mRNA COVID-19 Vaccine (Low dose) | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05960097 |
| CV0801 mRNA COVID-19 Vaccine | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05960097 |
| Control vaccine | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05960097 |
| CV0601 mRNA COVID-19 Vaccine | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05960097 |
| CV0701 mRNA COVID-19 Vaccine (High dose) | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05960097 |
| CV0701 mRNA COVID-19 Vaccine (Medium dose) | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05960097 |
| CV0701 mRNA COVID-19 Vaccine (Low dose) | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05960097 |
| CV0801 mRNA COVID-19 Vaccine | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05960097 |
| Control vaccine | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05960097 |
| CV0601 mRNA COVID-19 Vaccine | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05960097 |
| CV0701 mRNA COVID-19 Vaccine (High dose) | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05960097 |
| CV0701 mRNA COVID-19 Vaccine (Medium dose) | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05960097 |
| CV0701 mRNA COVID-19 Vaccine (Low dose) | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05960097 |
| Placebo | Other | Phase PHASE1 | Asthma | RECRUITING | NCT06433921 |
| Salbutamol HFA-134a | Other | Phase PHASE1 | Asthma | RECRUITING | NCT06433921 |
| Salbutamol HFA-152a | Other | Phase PHASE1 | Asthma | RECRUITING | NCT06433921 |
| Carboplatin | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT02817633 |
| Cisplatin | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT02817633 |
| Pemetrexed | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT02817633 |
| Docetaxel | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT02817633 |
| TSR-033 | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT02817633 |
| TSR-042 | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT02817633 |
| Nivolumab | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT02817633 |
| TSR-022 | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT02817633 |
| Carboplatin | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT02817633 |
| Cisplatin | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT02817633 |
| Pemetrexed | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT02817633 |
| Docetaxel | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT02817633 |
| TSR-033 | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT02817633 |
| TSR-042 | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT02817633 |
| Nivolumab | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT02817633 |
| TSR-022 | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT02817633 |
| Niraparib | Other | Phase PHASE2 | Solid Tumor | TERMINATED | NCT05169437 |
| Belantamab mafodotin | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05002816 |
| Elotuzumab | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05002816 |
| Placebo | Other | Phase PHASE2 | Pain | TERMINATED | NCT05838742 |
| GSK3858279 | Other | Phase PHASE2 | Pain | TERMINATED | NCT05838742 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | NOT_YET_RECRUITING | NCT07227311 |
| Bortezomib | Other | Phase PHASE2 | Multiple Myeloma | NOT_YET_RECRUITING | NCT07227311 |
| Pomalidomide | Other | Phase PHASE2 | Multiple Myeloma | NOT_YET_RECRUITING | NCT07227311 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | NOT_YET_RECRUITING | NCT07227311 |
| Belantamab mafodotin | Other | Phase PHASE2 | Multiple Myeloma | NOT_YET_RECRUITING | NCT07227311 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | NOT_YET_RECRUITING | NCT07227311 |
| Bortezomib | Other | Phase PHASE2 | Multiple Myeloma | NOT_YET_RECRUITING | NCT07227311 |
| Pomalidomide | Other | Phase PHASE2 | Multiple Myeloma | NOT_YET_RECRUITING | NCT07227311 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | NOT_YET_RECRUITING | NCT07227311 |
| Belantamab mafodotin | Other | Phase PHASE2 | Multiple Myeloma | NOT_YET_RECRUITING | NCT07227311 |
| Dostarlimab | Other | Phase PHASE1 | Melanoma | ACTIVE_NOT_RECRUITING | NCT06521567 |
| Cobolimab | Other | Phase PHASE1 | Melanoma | ACTIVE_NOT_RECRUITING | NCT06521567 |
| Comparator 3 | Other | Phase PHASE2 | Influenza, Human | ACTIVE_NOT_RECRUITING | NCT07121192 |
| Comparator 2 | Other | Phase PHASE2 | Influenza, Human | ACTIVE_NOT_RECRUITING | NCT07121192 |
| Comparator 1 | Other | Phase PHASE2 | Influenza, Human | ACTIVE_NOT_RECRUITING | NCT07121192 |
| Flu mRNA (Formulation B) | Other | Phase PHASE2 | Influenza, Human | ACTIVE_NOT_RECRUITING | NCT07121192 |
| Flu mRNA (Formulation A) | Other | Phase PHASE2 | Influenza, Human | ACTIVE_NOT_RECRUITING | NCT07121192 |
| Comparator 3 | Other | Phase PHASE2 | Influenza, Human | ACTIVE_NOT_RECRUITING | NCT07121192 |
| Comparator 2 | Other | Phase PHASE2 | Influenza, Human | ACTIVE_NOT_RECRUITING | NCT07121192 |
| Comparator 1 | Other | Phase PHASE2 | Influenza, Human | ACTIVE_NOT_RECRUITING | NCT07121192 |
| Flu mRNA (Formulation B) | Other | Phase PHASE2 | Influenza, Human | ACTIVE_NOT_RECRUITING | NCT07121192 |
| Flu mRNA (Formulation A) | Other | Phase PHASE2 | Influenza, Human | ACTIVE_NOT_RECRUITING | NCT07121192 |
| Standard of care | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT05917288 |
| Belimumab | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT05917288 |
| Dostarlimab | Other | Phase PHASE2 | Neoplasms, Rectal | ACTIVE_NOT_RECRUITING | NCT06640049 |
| Dostarlimab | Other | Phase PHASE2 | Neoplasms, Rectal | ACTIVE_NOT_RECRUITING | NCT06640049 |
| GSK1070806 | Other | Phase PHASE2 | Dermatitis, Atopic | TERMINATED | NCT06447506 |
| GSK5764227 | Other | Phase PHASE1 | Gastrointestinal Neoplasms | RECRUITING | NCT06885034 |
| Placebo | Other | Phase PHASE2 | Pain | TERMINATED | NCT05838755 |
| GSK3858279 | Other | Phase PHASE2 | Pain | TERMINATED | NCT05838755 |
| TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation | Other | Phase PHASE4 | Copd | COMPLETED | NCT05292053 |
| Placebo | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | RECRUITING | NCT07177339 |
| Depemokimab | Other | Phase PHASE3 | Pulmonary Disease, Chronic Obstructive | RECRUITING | NCT07177339 |
| Placebo | Other | Phase PHASE3 | Hypereosinophilic Syndrome | RECRUITING | NCT05334368 |
| Depemokimab | Other | Phase PHASE3 | Hypereosinophilic Syndrome | RECRUITING | NCT05334368 |
| Carboplatin-Nab-Paclitaxel | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT03307785 |
| Carboplatin-Pemetrexed | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT03307785 |
| TSR-022 | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT03307785 |
| Bevacizumab | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT03307785 |
| Carboplatin-Paclitaxel | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT03307785 |
| TSR-042 | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT03307785 |
| Niraparib | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT03307785 |
| Paclitaxel | Other | Phase PHASE2 | Ovarian Neoplasms | TERMINATED | NCT06964165 |
| Carboplatin | Other | Phase PHASE2 | Ovarian Neoplasms | TERMINATED | NCT06964165 |
| Niraparib | Other | Phase PHASE2 | Ovarian Neoplasms | TERMINATED | NCT06964165 |
| Paclitaxel | Other | Phase PHASE2 | Ovarian Neoplasms | TERMINATED | NCT06964165 |
| Carboplatin | Other | Phase PHASE2 | Ovarian Neoplasms | TERMINATED | NCT06964165 |
| Niraparib | Other | Phase PHASE2 | Ovarian Neoplasms | TERMINATED | NCT06964165 |
| Belimumab (GSK1550188) | Other | Phase PHASE4 | Systemic Lupus Erythematosus | RECRUITING | NCT06411249 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04091126 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04091126 |
| Bortezomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04091126 |
| Belantamab mafodotin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04091126 |
| Chemotherapy | Drug | Phase PHASE2 | Pancreatic Adenocarcinoma | RECRUITING | NCT06333314 |
| Dostarlimab | Other | Phase PHASE2 | Pancreatic Adenocarcinoma | RECRUITING | NCT06333314 |
| MMF maintain | Other | Phase PHASE4 | Rheumatoid Arthritis | ACTIVE_NOT_RECRUITING | NCT05879419 |
| MTX maintain | Other | Phase PHASE4 | Rheumatoid Arthritis | ACTIVE_NOT_RECRUITING | NCT05879419 |
| Placebo | Other | Phase PHASE4 | Rheumatoid Arthritis | ACTIVE_NOT_RECRUITING | NCT05879419 |
| MMF Discontinuation | Other | Phase PHASE4 | Rheumatoid Arthritis | ACTIVE_NOT_RECRUITING | NCT05879419 |
| MTX Discontinuation | Other | Phase PHASE4 | Rheumatoid Arthritis | ACTIVE_NOT_RECRUITING | NCT05879419 |
| Recombinant Herpes Zoster Vaccine (RZV) | Other | Phase PHASE4 | Rheumatoid Arthritis | ACTIVE_NOT_RECRUITING | NCT05879419 |
| Placebo | Other | Phase PHASE3 | Nasal Polyps | COMPLETED | NCT05274750 |
| Depemokimab (GSK3511294) | Other | Phase PHASE3 | Nasal Polyps | COMPLETED | NCT05274750 |
| DB-1324 | Other | Phase PHASE1 | Gastrointestinal Cancer | NOT_YET_RECRUITING | NCT07263594 |
| Vaxneuvance | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06855160 |
| PCV 20 | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06855160 |
| PCV (pneumococcal conjugate vaccine) 13 | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06855160 |
| Hepatitis A vaccine | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06855160 |
| MMR vaccine | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06855160 |
| Marketed varicella vaccine | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06855160 |
| Candidate varicella vaccine | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06855160 |
| Vaxneuvance | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06806137 |
| PCV 20 | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06806137 |
| PCV (pneumococcal conjugate vaccine) 13 | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06806137 |
| Hepatitis A vaccine | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06806137 |
| MMR vaccine | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06806137 |
| Marketed varicella vaccine | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06806137 |
| Investigational varicella vaccine | Other | Phase PHASE3 | Chickenpox | RECRUITING | NCT06806137 |
| Niraparib | Other | Phase PHASE2 | Penile Carcinoma | RECRUITING | NCT05526989 |
| Dostarlimab | Other | Phase PHASE2 | Penile Carcinoma | RECRUITING | NCT05526989 |
| Dostarlimab | Other | Phase PHASE3 | Endometrial Cancer | ACTIVE_NOT_RECRUITING | NCT05201547 |
| Carboplatin-Paclitaxel | Other | Phase PHASE3 | Endometrial Cancer | ACTIVE_NOT_RECRUITING | NCT05201547 |
| Dostarlimab | Other | Phase PHASE3 | Endometrial Cancer | ACTIVE_NOT_RECRUITING | NCT05201547 |
| Carboplatin-Paclitaxel | Other | Phase PHASE3 | Endometrial Cancer | ACTIVE_NOT_RECRUITING | NCT05201547 |
| Serum Institute of India's Measles and rubella vaccine | Other | Phase PHASE1 | Diarrhoea | COMPLETED | NCT05073003 |
| Sanofi Pasteur's Typhoid Vi polysaccharide vaccine | Other | Phase PHASE1 | Diarrhoea | COMPLETED | NCT05073003 |
| GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccine | Other | Phase PHASE1 | Diarrhoea | COMPLETED | NCT05073003 |
| GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine | Other | Phase PHASE1 | Diarrhoea | COMPLETED | NCT05073003 |
| GSK's Meningococcal A, C, Y and W-135 conjugate vaccine | Other | Phase PHASE1 | Diarrhoea | COMPLETED | NCT05073003 |
| altSonflex1-2-3 Dose A | Other | Phase PHASE1 | Diarrhoea | COMPLETED | NCT05073003 |
| altSonflex1-2-3 Dose B | Other | Phase PHASE1 | Diarrhoea | COMPLETED | NCT05073003 |
| altSonflex1-2-3 Dose C | Other | Phase PHASE1 | Diarrhoea | COMPLETED | NCT05073003 |
| altSonflex Placebo | Other | Phase PHASE1 | Diarrhoea | COMPLETED | NCT05073003 |
| Mepolizumab | Other | Phase PHASE3 | Hypereosinophilic Syndrome | COMPLETED | NCT04965636 |
| Placebo | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT04091451 |
| Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A) | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT04091451 |
| Momelotinib treatment | Drug | Phase PHASE2 | VEXAS Syndome | RECRUITING | NCT07098936 |
| FF/UMEC/VI | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT05535972 |
| FF/UMEC/VI | Other | Phase PHASE4 | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT05535972 |
| Placebo | Other | Phase PHASE2 | Respiratory Syncytial Virus (RSV) | RECRUITING | NCT07050732 |
| Arexvy (1 dose total) | Other | Phase PHASE2 | Respiratory Syncytial Virus (RSV) | RECRUITING | NCT07050732 |
| Arexvy (3 doses total) | Other | Phase PHASE2 | Respiratory Syncytial Virus (RSV) | RECRUITING | NCT07050732 |
| Arexvy (2 doses total) | Other | Phase PHASE2 | Respiratory Syncytial Virus (RSV) | RECRUITING | NCT07050732 |
| Placebo | Other | Phase PHASE3 | Chronic Hepatitis B | ACTIVE_NOT_RECRUITING | NCT05630820 |
| Bepirovirsen | Other | Phase PHASE3 | Chronic Hepatitis B | ACTIVE_NOT_RECRUITING | NCT05630820 |
| Herpes Zoster Vaccine GSK1437173A | Other | Phase PHASE3 | Herpes Zoster | COMPLETED | NCT02723773 |
| Placebo | Other | Phase PHASE3 | Chronic Hepatitis B | ACTIVE_NOT_RECRUITING | NCT05630807 |
| Bepirovirsen | Other | Phase PHASE3 | Chronic Hepatitis B | ACTIVE_NOT_RECRUITING | NCT05630807 |
| Placebo | Other | Phase PHASE3 | Chronic Hepatitis B | ACTIVE_NOT_RECRUITING | NCT05630807 |
| Bepirovirsen | Other | Phase PHASE3 | Chronic Hepatitis B | ACTIVE_NOT_RECRUITING | NCT05630807 |
| Dexamethasone | Other | Phase PHASE3 | Multiple Myeloma | NOT_YET_RECRUITING | NCT07285239 |
| Lenalidomide | Other | Phase PHASE3 | Multiple Myeloma | NOT_YET_RECRUITING | NCT07285239 |
| Bortezomib | Other | Phase PHASE3 | Multiple Myeloma | NOT_YET_RECRUITING | NCT07285239 |
| Arm B: Daratumumab Hyaluronidase | Other | Phase PHASE3 | Multiple Myeloma | NOT_YET_RECRUITING | NCT07285239 |
| Arm A: Belantamab Mafodotin | Other | Phase PHASE3 | Multiple Myeloma | NOT_YET_RECRUITING | NCT07285239 |
| Bevacizumab | Other | Phase PHASE1 | Neoplasms | RECRUITING | NCT06551142 |
| Cetuximab | Other | Phase PHASE1 | Neoplasms | RECRUITING | NCT06551142 |
| Durvalumab | Other | Phase PHASE1 | Neoplasms | RECRUITING | NCT06551142 |
| Pembrolizumab | Other | Phase PHASE1 | Neoplasms | RECRUITING | NCT06551142 |
| Atezolizumab | Other | Phase PHASE1 | Neoplasms | RECRUITING | NCT06551142 |
| Carboplatin | Other | Phase PHASE1 | Neoplasms | RECRUITING | NCT06551142 |
| Cisplatin | Other | Phase PHASE1 | Neoplasms | RECRUITING | NCT06551142 |
| GSK5764227 | Other | Phase PHASE1 | Neoplasms | RECRUITING | NCT06551142 |
| Chemotherapy Drugs | Drug | Phase PHASE2 | Ovarian Carcinosarcoma | RECRUITING | NCT03651206 |
| Niraparib + TSR-042 (Dostarlimab) | Other | Phase PHASE2 | Ovarian Carcinosarcoma | RECRUITING | NCT03651206 |
| Niraparib | Other | Phase PHASE2 | Ovarian Carcinosarcoma | RECRUITING | NCT03651206 |
| Chemotherapy Drugs | Drug | Phase PHASE2 | Ovarian Carcinosarcoma | RECRUITING | NCT03651206 |
| Niraparib + TSR-042 (Dostarlimab) | Other | Phase PHASE2 | Ovarian Carcinosarcoma | RECRUITING | NCT03651206 |
| Niraparib | Other | Phase PHASE2 | Ovarian Carcinosarcoma | RECRUITING | NCT03651206 |
| Paclitaxel | Other | Phase PHASE2 | Neoplasms, Endometrial | RECRUITING | NCT07108270 |
| Carboplatin | Other | Phase PHASE2 | Neoplasms, Endometrial | RECRUITING | NCT07108270 |
| Dostarlimab | Other | Phase PHASE2 | Neoplasms, Endometrial | RECRUITING | NCT07108270 |
| CAB LA | Other | Phase PHASE3 | HIV Infections | RECRUITING | NCT06134362 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT05789303 |
| Pomalidomide | Other | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT05789303 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT05789303 |
| Belantamab mafodotin | Other | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT05789303 |
| Skin biopsies | Other | Preclinical | Systemic Sclerosis | COMPLETED | NCT03816189 |
| Blood test | Other | Preclinical | Systemic Sclerosis | COMPLETED | NCT03816189 |
| PCV20 | Other | Phase PHASE1 | Pneumonia, Bacterial | ACTIVE_NOT_RECRUITING | NCT07105722 |
| Pn-MAPS30plus | Other | Phase PHASE1 | Pneumonia, Bacterial | ACTIVE_NOT_RECRUITING | NCT07105722 |
| Placebo | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT06614725 |
| RSVPreF3 OA investigational vaccine | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT06614725 |
| Placebo | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT06614725 |
| RSVPreF3 OA investigational vaccine | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT06614725 |
| Control | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT05276297 |
| GSK3528869A | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT05276297 |
| GSK3228836 | Other | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT05276297 |
| Niraparib-Placebo | Other | Phase PHASE3 | Ovarian Neoplasms | ACTIVE_NOT_RECRUITING | NCT03602859 |
| Dostarlimab-Placebo | Other | Phase PHASE3 | Ovarian Neoplasms | ACTIVE_NOT_RECRUITING | NCT03602859 |
| Standard of care | Other | Phase PHASE3 | Ovarian Neoplasms | ACTIVE_NOT_RECRUITING | NCT03602859 |
| Dostarlimab (TSR-042) | Other | Phase PHASE3 | Ovarian Neoplasms | ACTIVE_NOT_RECRUITING | NCT03602859 |
| Niraparib | Other | Phase PHASE3 | Ovarian Neoplasms | ACTIVE_NOT_RECRUITING | NCT03602859 |
| Niraparib-Placebo | Other | Phase PHASE3 | Ovarian Neoplasms | ACTIVE_NOT_RECRUITING | NCT03602859 |
| Dostarlimab-Placebo | Other | Phase PHASE3 | Ovarian Neoplasms | ACTIVE_NOT_RECRUITING | NCT03602859 |
| Standard of care | Other | Phase PHASE3 | Ovarian Neoplasms | ACTIVE_NOT_RECRUITING | NCT03602859 |
| Dostarlimab (TSR-042) | Other | Phase PHASE3 | Ovarian Neoplasms | ACTIVE_NOT_RECRUITING | NCT03602859 |
| Niraparib | Other | Phase PHASE3 | Ovarian Neoplasms | ACTIVE_NOT_RECRUITING | NCT03602859 |
| 2 NRTIs plus an INI, NNRTI, or PI | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | ACTIVE_NOT_RECRUITING | NCT02951052 |
| Rilpivirine - Injectable Suspension (RPV LA) | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | ACTIVE_NOT_RECRUITING | NCT02951052 |
| Cabotegravir - Injectable Suspension (CAB LA) | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | ACTIVE_NOT_RECRUITING | NCT02951052 |
| Rilpivirine (RPV) tablet | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | ACTIVE_NOT_RECRUITING | NCT02951052 |
| Cabotegravir (CAB) tablet | Other | Phase PHASE3 | Infection, Human Immunodeficiency Virus | ACTIVE_NOT_RECRUITING | NCT02951052 |
| Panitumumab | Other | Phase PHASE2 | Advanced Microsatellite Stable Colorectal Carcinoma | ACTIVE_NOT_RECRUITING | NCT03983993 |
| Niraparib | Other | Phase PHASE2 | Advanced Microsatellite Stable Colorectal Carcinoma | ACTIVE_NOT_RECRUITING | NCT03983993 |
| TYPHIBEV | Other | Phase PHASE2 | Diarrhoea | NOT_YET_RECRUITING | NCT07320716 |
| Infanrix hexa | Other | Phase PHASE2 | Diarrhoea | NOT_YET_RECRUITING | NCT07320716 |
| Menveo | Other | Phase PHASE2 | Diarrhoea | NOT_YET_RECRUITING | NCT07320716 |
| AltSonflex1-2-3 | Other | Phase PHASE2 | Diarrhoea | NOT_YET_RECRUITING | NCT07320716 |
| Enzalutamide | Other | Phase PHASE1 | Neoplasms | RECRUITING | NCT07277270 |
| leucovorin | Other | Phase PHASE1 | Neoplasms | RECRUITING | NCT07277270 |
| Fluorouracil | Other | Phase PHASE1 | Neoplasms | RECRUITING | NCT07277270 |
| Bevacizumab | Other | Phase PHASE1 | Neoplasms | RECRUITING | NCT07277270 |
| GSK5764227 | Other | Phase PHASE1 | Neoplasms | RECRUITING | NCT07277270 |
| Dostarlimab | Other | Phase PHASE2 | Neoplasms, Rectal | ACTIVE_NOT_RECRUITING | NCT05723562 |
| Dostarlimab | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT03843359 |
| GSK3745417 | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT03843359 |
| Salbutamol HFA-134a | Other | Phase PHASE1 | Asthma | COMPLETED | NCT06433908 |
| Salbutamol HFA-152a | Other | Phase PHASE1 | Asthma | COMPLETED | NCT06433908 |
| Salbutamol HFA-134a | Other | Phase PHASE1 | Asthma | COMPLETED | NCT06433908 |
| Salbutamol HFA-152a | Other | Phase PHASE1 | Asthma | COMPLETED | NCT06433908 |
| Mepolizumab | Other | Phase EARLY_PHASE1 | Chronic Rhinosinusitis With Nasal Polyps | RECRUITING | NCT05895929 |
| Placebo | Other | Phase PHASE2 | Systemic Sclerosis Associated Interstitial Lung Disease | RECRUITING | NCT05878717 |
| Belimumab | Other | Phase PHASE2 | Systemic Sclerosis Associated Interstitial Lung Disease | RECRUITING | NCT05878717 |
| Placebo | Other | Phase PHASE2 | Systemic Sclerosis Associated Interstitial Lung Disease | RECRUITING | NCT05878717 |
| Belimumab | Other | Phase PHASE2 | Systemic Sclerosis Associated Interstitial Lung Disease | RECRUITING | NCT05878717 |
| Cobolimab | Other | Phase PHASE2 | Cervical Cancer | ACTIVE_NOT_RECRUITING | NCT06238635 |
| Dostarlimab | Other | Phase PHASE2 | Cervical Cancer | ACTIVE_NOT_RECRUITING | NCT06238635 |
| GSK's HBsAg (20 μg) vaccine adjuvanted with GSK's AS37A adjuvant system (100 μg) | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT05561673 |
| GSK's HBsAg (20 μg) vaccine adjuvanted with GSK's AS37B adjuvant system (50 μg) | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT05561673 |
| GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT05561673 |
| GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT05561673 |
| GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT05561673 |
| GSK3511294 (Depemokimab) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT05243680 |
| Niraparib (Tablet) | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT04544995 |
| Dostarlimab | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT04544995 |
| Niraparib (Tablet for oral suspension) | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT04544995 |
| Placebo | Other | Phase PHASE1 | Hematologic Diseases | TERMINATED | NCT05660265 |
| GSK4172239D | Other | Phase PHASE1 | Hematologic Diseases | TERMINATED | NCT05660265 |
| Combination of Veliparib + Lapatinib | Other | Approved | Metastatic Triple Negative Breast Cancer | COMPLETED | NCT02158507 |
| Combination of Veliparib + Lapatinib | Other | Approved | Metastatic Triple Negative Breast Cancer | COMPLETED | NCT02158507 |
| FOLFOX | Other | Phase PHASE3 | Colonic Neoplasms | RECRUITING | NCT05855200 |
| CAPEOX | Other | Phase PHASE3 | Colonic Neoplasms | RECRUITING | NCT05855200 |
| Dostarlimab | Other | Phase PHASE3 | Colonic Neoplasms | RECRUITING | NCT05855200 |
| Unconjugated belantamab antibody in combination with pomalidomide-dexamethasone backbone, with or without belantamab mafodotin | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05714839 |
| Unconjugated belantamab antibody and belantamab mafodotin | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05714839 |
| Belantamab mafodotin | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05714839 |
| Unconjugated belantamab antibody | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05714839 |
| Niraparib | Other | Phase PHASE2 | Metastatic Cancer | ACTIVE_NOT_RECRUITING | NCT04992013 |
| Intensity Modulated Radiation Therapy (IMRT) | Drug | Phase PHASE2 | Rectal Adenocarcinoma | RECRUITING | NCT04165772 |
| capecitabine or 5-FU | Other | Phase PHASE2 | Rectal Adenocarcinoma | RECRUITING | NCT04165772 |
| TSR-042 or Dostarlimab | Other | Phase PHASE2 | Rectal Adenocarcinoma | RECRUITING | NCT04165772 |
| Trastuzumab | Other | Phase PHASE1 | Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT03368729 |
| Niraparib | Other | Phase PHASE1 | Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT03368729 |
| Benlysta | Other | Preclinical | Systemic Lupus Erythematosus | COMPLETED | NCT03370263 |
| MR-VAC | Other | Phase PHASE2 | Diarrhoea | COMPLETED | NCT06663436 |
| Infanrix hexa | Other | Phase PHASE2 | Diarrhoea | COMPLETED | NCT06663436 |
| TYPHIBEV | Other | Phase PHASE2 | Diarrhoea | COMPLETED | NCT06663436 |
| altSonflex1-2-3 Dose C | Other | Phase PHASE2 | Diarrhoea | COMPLETED | NCT06663436 |
| altSonflex1-2-3 Dose B | Other | Phase PHASE2 | Diarrhoea | COMPLETED | NCT06663436 |
| altSonflex1-2-3 Dose A | Other | Phase PHASE2 | Diarrhoea | COMPLETED | NCT06663436 |
| Hypofractionated IMRT | Other | Phase PHASE2 | Endometrial Cancer | RECRUITING | NCT04774419 |
| Dostarlimab | Other | Phase PHASE2 | Endometrial Cancer | RECRUITING | NCT04774419 |
| Intensity modulated radiation therapy (IMRT) | Drug | Phase PHASE2 | Endometrial Cancer | RECRUITING | NCT04774419 |
| Placebo | Other | Phase PHASE2 | Hepatitis B | ACTIVE_NOT_RECRUITING | NCT06497504 |
| Bepirovirsen | Other | Phase PHASE2 | Hepatitis B | ACTIVE_NOT_RECRUITING | NCT06497504 |
| Placebo | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT06382311 |
| Influenza virus vaccine | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT06382311 |
| Flu Pandemic mRNA_Dose level 6 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT06382311 |
| Flu Pandemic mRNA_Dose level 5 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT06382311 |
| Flu Pandemic mRNA_ Dose level 4 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT06382311 |
| Flu Pandemic mRNA_ Dose level 3. | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT06382311 |
| Flu Pandemic mRNA_Dose level 2 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT06382311 |
| Flu Pandemic mRNA_Dose level 1 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT06382311 |
| Zoster Vaccine Recombinant | Other | Phase PHASE2 | Bone Marrow Transplant | RECRUITING | NCT05775718 |
| Niraparib | Other | Phase PHASE2 | SCLC,Extensive Stage | RECRUITING | NCT05718323 |
| Niraparib | Other | Phase PHASE2 | SCLC,Extensive Stage | RECRUITING | NCT05718323 |
| Resection/Treatment with Niraparib | Drug | Phase EARLY_PHASE1 | Low-grade Glioma | ACTIVE_NOT_RECRUITING | NCT05406700 |
| Niraparib | Other | Phase EARLY_PHASE1 | Low-grade Glioma | ACTIVE_NOT_RECRUITING | NCT05406700 |
| Prevnar 20 | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT03621670 |
| Placebo (saline water) | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT03621670 |
| Varivax | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT03621670 |
| M-M-R II | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT03621670 |
| Rotarix | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT03621670 |
| Hiberix | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT03621670 |
| Pediarix | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT03621670 |
| Prevnar13 | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT03621670 |
| Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ) | Other | Phase PHASE3 | Infections, Meningococcal | COMPLETED | NCT03621670 |
| Dostarlimab | Other | Phase PHASE2 | Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07408063 |
| GSK5764227 | Other | Phase PHASE2 | Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07408063 |
| MMRV | Other | Phase PHASE3 | Measles | NOT_YET_RECRUITING | NCT07406360 |
| MMRVNS | Other | Phase PHASE3 | Measles | NOT_YET_RECRUITING | NCT07406360 |
| PCV20 | Other | Phase PHASE1 | Pneumonia, Bacterial | NOT_YET_RECRUITING | NCT07406347 |
| Pn-MAPS30plus | Other | Phase PHASE1 | Pneumonia, Bacterial | NOT_YET_RECRUITING | NCT07406347 |
| PCV20 | Other | Phase PHASE1 | Pneumonia, Bacterial | NOT_YET_RECRUITING | NCT07406347 |
| Pn-MAPS30plus | Other | Phase PHASE1 | Pneumonia, Bacterial | NOT_YET_RECRUITING | NCT07406347 |
| PCV20 | Other | Phase PHASE1 | Pneumonia, Bacterial | NOT_YET_RECRUITING | NCT07406334 |
| Pn-MAPS30plus | Other | Phase PHASE1 | Pneumonia, Bacterial | NOT_YET_RECRUITING | NCT07406334 |
| Temozolomide | Other | Phase PHASE1 | Advanced Malignant Solid Neoplasm | ACTIVE_NOT_RECRUITING | NCT03830918 |
| Questionnaire Administration | Other | Phase PHASE1 | Advanced Malignant Solid Neoplasm | ACTIVE_NOT_RECRUITING | NCT03830918 |
| Quality-of-Life Assessment | Other | Phase PHASE1 | Advanced Malignant Solid Neoplasm | ACTIVE_NOT_RECRUITING | NCT03830918 |
| Niraparib | Other | Phase PHASE1 | Advanced Malignant Solid Neoplasm | ACTIVE_NOT_RECRUITING | NCT03830918 |
| Atezolizumab | Other | Phase PHASE1 | Advanced Malignant Solid Neoplasm | ACTIVE_NOT_RECRUITING | NCT03830918 |
| Temozolomide | Other | Phase PHASE1 | Advanced Malignant Solid Neoplasm | ACTIVE_NOT_RECRUITING | NCT03830918 |
| Questionnaire Administration | Other | Phase PHASE1 | Advanced Malignant Solid Neoplasm | ACTIVE_NOT_RECRUITING | NCT03830918 |
| Quality-of-Life Assessment | Other | Phase PHASE1 | Advanced Malignant Solid Neoplasm | ACTIVE_NOT_RECRUITING | NCT03830918 |
| Niraparib | Other | Phase PHASE1 | Advanced Malignant Solid Neoplasm | ACTIVE_NOT_RECRUITING | NCT03830918 |
| Atezolizumab | Other | Phase PHASE1 | Advanced Malignant Solid Neoplasm | ACTIVE_NOT_RECRUITING | NCT03830918 |
| Rituximab | Other | Phase PHASE2 | Membranous Nephropathy | RECRUITING | NCT03949855 |
| Placebo for Belimumab | Other | Phase PHASE2 | Membranous Nephropathy | RECRUITING | NCT03949855 |
| Belimumab | Other | Phase PHASE2 | Membranous Nephropathy | RECRUITING | NCT03949855 |
| Belantamab mafodotin 1.0 mg/kg (12 weeks) | Other | Phase PHASE1 | AL Amyloidosis | RECRUITING | NCT05145816 |
| Belantamab mafodotin every 8 weeks or 12 weeks as determined by Part 1 recommended dosages | Other | Phase PHASE1 | AL Amyloidosis | RECRUITING | NCT05145816 |
| Belantamab mafodotin 1.9 mg/kg (12 weeks) | Other | Phase PHASE1 | AL Amyloidosis | RECRUITING | NCT05145816 |
| Belantamab mafodotin 1.4 mg/kg (12 weeks) | Other | Phase PHASE1 | AL Amyloidosis | RECRUITING | NCT05145816 |
| Belantamab mafodotin 1.9 mg/kg (8 weeks) | Other | Phase PHASE1 | AL Amyloidosis | RECRUITING | NCT05145816 |
| Belantamab mafodotin 2.5 mg/kg (8 weeks) | Other | Phase PHASE1 | AL Amyloidosis | RECRUITING | NCT05145816 |
| Nucala | Other | Preclinical | Churg-Strauss Syndrome | COMPLETED | NCT03557060 |
| Linerixibat | Other | Phase PHASE3 | Cholestasis | ACTIVE_NOT_RECRUITING | NCT04167358 |
| Placebo | Other | Phase PHASE1 | Hepatitis B, Chronic | TERMINATED | NCT03866187 |
| MVA-HBV high dose formulation | Other | Phase PHASE1 | Hepatitis B, Chronic | TERMINATED | NCT03866187 |
| MVA-HBV low dose formulation | Other | Phase PHASE1 | Hepatitis B, Chronic | TERMINATED | NCT03866187 |
| HBc-HBs/AS01B-4 high dose formulation | Other | Phase PHASE1 | Hepatitis B, Chronic | TERMINATED | NCT03866187 |
| HBc-HBs/AS01B-4 low dose formulation | Other | Phase PHASE1 | Hepatitis B, Chronic | TERMINATED | NCT03866187 |
| ChAd155-hIi-HBV high dose formulation | Other | Phase PHASE1 | Hepatitis B, Chronic | TERMINATED | NCT03866187 |
| ChAd155-hIi-HBV low dose formulation | Other | Phase PHASE1 | Hepatitis B, Chronic | TERMINATED | NCT03866187 |
| placebo | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT01649765 |
| belimumab 10mg/kg | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT01649765 |
| Salbutamol HFA-152a | Other | Phase PHASE3 | Asthma | COMPLETED | NCT06261957 |
| Salbutamol HFA-134a | Other | Phase PHASE3 | Asthma | COMPLETED | NCT06261957 |
| Salbutamol HFA-152a | Other | Phase PHASE3 | Asthma | COMPLETED | NCT06261957 |
| Salbutamol HFA-134a | Other | Phase PHASE3 | Asthma | COMPLETED | NCT06261957 |
| PED-HZ/su | Other | Phase PHASE1 | Herpes Zoster | RECRUITING | NCT04006808 |
| PED-HZ/su | Other | Phase PHASE1 | Herpes Zoster | RECRUITING | NCT04006808 |
| Pharmacological Study | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT01684397 |
| Pazopanib Hydrochloride | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT01684397 |
| Laboratory Biomarker Analysis | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT01684397 |
| Bevacizumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT01684397 |
| Placebo (saline) | Other | Phase PHASE1 | Cytomegalovirus Infections | COMPLETED | NCT05089630 |
| Pentamer (high)/gB(med)/Adjuvant vaccine | Other | Phase PHASE1 | Cytomegalovirus Infections | COMPLETED | NCT05089630 |
| Pentamer (med)/gB(med)/Adjuvant vaccine | Other | Phase PHASE1 | Cytomegalovirus Infections | COMPLETED | NCT05089630 |
| Pentamer (med)/gB(low)/Adjuvant vaccine | Other | Phase PHASE1 | Cytomegalovirus Infections | COMPLETED | NCT05089630 |
| Pentamer (low)/gB(low)/Adjuvant vaccine | Other | Phase PHASE1 | Cytomegalovirus Infections | COMPLETED | NCT05089630 |
| Whole blood sample | Other | Preclinical | Malaria | COMPLETED | NCT03855995 |
| Placebo | Other | Phase PHASE3 | Lung Diseases, Interstitial | RECRUITING | NCT06572384 |
| Belimumab | Other | Phase PHASE3 | Lung Diseases, Interstitial | RECRUITING | NCT06572384 |
| Vaccine | Other | Phase PHASE1 | Recurrent Vulvovaginal Candidiasis | ACTIVE_NOT_RECRUITING | NCT06190509 |
| Autologous stem cell transplant (ASCT) | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04802356 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04802356 |
| Lenalidomide | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04802356 |
| Bortezomib | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04802356 |
| Belantamab mafodotin | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04802356 |
| Risvutatug rezetecan | Other | Phase EARLY_PHASE1 | Glioblastoma (GBM) | RECRUITING | NCT07268053 |
| Adjuvanted RSVPreF3 vaccine | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | RECRUITING | NCT07092865 |
| Adjuvanted RSVPreF3 vaccine | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | RECRUITING | NCT07092865 |
| Radiation therapy | Drug | Phase EARLY_PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT05076513 |
| Niraparib | Other | Phase EARLY_PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT05076513 |
| Hospital administration of CAB+RPV | Other | Approved | HIV | ACTIVE_NOT_RECRUITING | NCT06468995 |
| Home administration of CAB+RPV | Other | Approved | HIV | ACTIVE_NOT_RECRUITING | NCT06468995 |
| Surveys completion | Other | Approved | HIV | ACTIVE_NOT_RECRUITING | NCT06468995 |
| Fluzone HD | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT06431607 |
| Fluzone HD Quadrivalent | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT06431607 |
| F2H23G/DL001Z | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT06431607 |
| F2H23A/DL001Z-NH | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT06431607 |
| Flu D-TIV | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT06431607 |
| GSK5800544A | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT06431607 |
| FDQ23A-NH (Flu D-QIV) | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT06431607 |
| F2H23H/DL001Z | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT06431607 |
| F2H23B/DL001Z-NH | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT06431607 |
| F2H23D/DL001Z-NH | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT06431607 |
| F2G22B/DL001Z | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT06431607 |
| Fluzone HD | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT06431607 |
| Fluzone HD Quadrivalent | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT06431607 |
| F2H23G/DL001Z | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT06431607 |
| F2H23A/DL001Z-NH | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT06431607 |
| Flu D-TIV | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT06431607 |
| GSK5800544A | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT06431607 |
| FDQ23A-NH (Flu D-QIV) | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT06431607 |
| F2H23H/DL001Z | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT06431607 |
| F2H23B/DL001Z-NH | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT06431607 |
| F2H23D/DL001Z-NH | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT06431607 |
| F2G22B/DL001Z | Other | Phase PHASE2 | Influenza, Human | COMPLETED | NCT06431607 |
| FDQ22A-NH | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05446740 |
| FDQ21A-NH | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05446740 |
| GSK4382276A Dose level 10 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05446740 |
| GSK4382276A Dose level 9 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05446740 |
| GSK4382276A Dose level 8 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05446740 |
| GSK4382276A Dose level 7 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05446740 |
| GSK4382276A Dose level 6 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05446740 |
| GSK4382276A Dose level 5 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05446740 |
| GSK4382276A Dose level 4 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05446740 |
| GSK4382276A Dose level 3 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05446740 |
| GSK4382276A Dose level 2 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05446740 |
| GSK4382276A Dose level 1 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05446740 |
| FDQ22A-NH | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05446740 |
| FDQ21A-NH | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05446740 |
| GSK4382276A Dose level 10 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05446740 |
| GSK4382276A Dose level 9 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05446740 |
| GSK4382276A Dose level 8 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05446740 |
| GSK4382276A Dose level 7 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05446740 |
| GSK4382276A Dose level 6 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05446740 |
| GSK4382276A Dose level 5 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05446740 |
| GSK4382276A Dose level 4 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05446740 |
| GSK4382276A Dose level 3 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05446740 |
| GSK4382276A Dose level 2 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05446740 |
| GSK4382276A Dose level 1 | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT05446740 |
| Doxorubicin | Other | Phase PHASE3 | Neoplasms, Endometrial | NOT_YET_RECRUITING | NCT07286331 |
| Paclitaxel | Other | Phase PHASE3 | Neoplasms, Endometrial | NOT_YET_RECRUITING | NCT07286331 |
| GSK5733584 | Other | Phase PHASE3 | Neoplasms, Endometrial | NOT_YET_RECRUITING | NCT07286331 |
| Doxorubicin | Other | Phase PHASE3 | Neoplasms, Endometrial | NOT_YET_RECRUITING | NCT07286331 |
| Paclitaxel | Other | Phase PHASE3 | Neoplasms, Endometrial | NOT_YET_RECRUITING | NCT07286331 |
| GSK5733584 | Other | Phase PHASE3 | Neoplasms, Endometrial | NOT_YET_RECRUITING | NCT07286331 |
| Belimumab | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT06576271 |
| Placebo matching GSK4527363 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT06576271 |
| GSK4527363 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT06576271 |
| Placebo | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT06317285 |
| GSK3915393 | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT06317285 |
| Placebo | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT06317285 |
| GSK3915393 | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT06317285 |
| Belantamab Mafodotin | Other | Phase PHASE2 | Relapsed Plasmablastic Lymphoma | TERMINATED | NCT04676360 |
| Belantamab Mafodotin | Other | Phase PHASE2 | Relapsed Plasmablastic Lymphoma | TERMINATED | NCT04676360 |
| GSK5926371 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT07371468 |
| GSK5926371 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT07371468 |
| Dexamethasone | Other | Phase PHASE2 | Amyloidosis | NOT_YET_RECRUITING | NCT07224672 |
| Bortezomib | Other | Phase PHASE2 | Amyloidosis | NOT_YET_RECRUITING | NCT07224672 |
| Cyclophosphamide | Other | Phase PHASE2 | Amyloidosis | NOT_YET_RECRUITING | NCT07224672 |
| Belantamab mafodotin | Other | Phase PHASE2 | Amyloidosis | NOT_YET_RECRUITING | NCT07224672 |
| Control | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT05705440 |
| RSVPreF3 vaccine | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT05705440 |
| Transoral Surgery | Procedure | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT01612351 |
| Bilateral Radiation | Other | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT01612351 |
| Ipsilateral Radiation | Other | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT01612351 |
| Cisplatin | Other | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT01612351 |
| Lapatinib | Other | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT01612351 |
| Paclitaxel | Other | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT01612351 |
| Carboplatin | Other | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT01612351 |
| DTG Tablet | Other | Phase PHASE3 | HIV Infections | ACTIVE_NOT_RECRUITING | NCT02938520 |
| ABC/DTG/3TC STR - Tablet | Other | Phase PHASE3 | HIV Infections | ACTIVE_NOT_RECRUITING | NCT02938520 |
| Rilpivirine - Injectable Suspension (RPV LA) | Other | Phase PHASE3 | HIV Infections | ACTIVE_NOT_RECRUITING | NCT02938520 |
| Cabotegravir - Injectable Suspension (CAB LA) | Other | Phase PHASE3 | HIV Infections | ACTIVE_NOT_RECRUITING | NCT02938520 |
| Rilpivirine (RPV) tablet | Other | Phase PHASE3 | HIV Infections | ACTIVE_NOT_RECRUITING | NCT02938520 |
| Cabotegravir (CAB) tablet | Other | Phase PHASE3 | HIV Infections | ACTIVE_NOT_RECRUITING | NCT02938520 |
| DTG Tablet | Other | Phase PHASE3 | HIV Infections | ACTIVE_NOT_RECRUITING | NCT02938520 |
| ABC/DTG/3TC STR - Tablet | Other | Phase PHASE3 | HIV Infections | ACTIVE_NOT_RECRUITING | NCT02938520 |
| Rilpivirine - Injectable Suspension (RPV LA) | Other | Phase PHASE3 | HIV Infections | ACTIVE_NOT_RECRUITING | NCT02938520 |
| Cabotegravir - Injectable Suspension (CAB LA) | Other | Phase PHASE3 | HIV Infections | ACTIVE_NOT_RECRUITING | NCT02938520 |
| Rilpivirine (RPV) tablet | Other | Phase PHASE3 | HIV Infections | ACTIVE_NOT_RECRUITING | NCT02938520 |
| Cabotegravir (CAB) tablet | Other | Phase PHASE3 | HIV Infections | ACTIVE_NOT_RECRUITING | NCT02938520 |
| Standard of Care (SoC) Therapy | Drug | Preclinical | Systemic Lupus Erythematosus | COMPLETED | NCT01729455 |
| Benlysta | Other | Preclinical | Systemic Lupus Erythematosus | COMPLETED | NCT01729455 |
| GSK5460025 | Other | Phase PHASE1 | Neoplasms, Colorectal | RECRUITING | NCT07213609 |
| Placebo | Other | Phase PHASE2 | Asthma | ACTIVE_NOT_RECRUITING | NCT06748053 |
| GSK5784283 | Other | Phase PHASE2 | Asthma | ACTIVE_NOT_RECRUITING | NCT06748053 |
| Placebo | Other | Phase PHASE2 | Asthma | ACTIVE_NOT_RECRUITING | NCT06748053 |
| GSK5784283 | Other | Phase PHASE2 | Asthma | ACTIVE_NOT_RECRUITING | NCT06748053 |
| GSK5764227 | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT05277051 |
| Nelistotug | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT05277051 |
| Belrestotug | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT05277051 |
| Dostarlimab | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT05277051 |
| Remzistotug | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT05277051 |
| Belantamab mafodotin | Other | Phase PHASE2 | Myeloma | ACTIVE_NOT_RECRUITING | NCT04680468 |
| Belantamab mafodotin | Other | Phase PHASE2 | Myeloma | ACTIVE_NOT_RECRUITING | NCT04680468 |
| Inhaled corticosteroids/long-acting beta-2 agonists | Other | Phase PHASE4 | Asthma | ACTIVE_NOT_RECRUITING | NCT06372496 |
| Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate | Other | Phase PHASE4 | Asthma | ACTIVE_NOT_RECRUITING | NCT06372496 |
| Placebo | Other | Phase PHASE2 | Nonalcoholic Fatty Liver Disease | ACTIVE_NOT_RECRUITING | NCT05583344 |
| GSK4532990 | Other | Phase PHASE2 | Nonalcoholic Fatty Liver Disease | ACTIVE_NOT_RECRUITING | NCT05583344 |
| Placebo | Other | Phase PHASE2 | Nonalcoholic Fatty Liver Disease | ACTIVE_NOT_RECRUITING | NCT05583344 |
| GSK4532990 | Other | Phase PHASE2 | Nonalcoholic Fatty Liver Disease | ACTIVE_NOT_RECRUITING | NCT05583344 |
| Licensed COVID-19 Vaccine | Other | Phase PHASE1 | Influenza, Human+COVID-19 | RECRUITING | NCT07464314 |
| Licensed Seasonal Influenza Vaccine | Other | Phase PHASE1 | Influenza, Human+COVID-19 | RECRUITING | NCT07464314 |
| Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine | Other | Phase PHASE1 | Influenza, Human+COVID-19 | RECRUITING | NCT07464314 |
| Licensed COVID-19 Vaccine | Other | Phase PHASE1 | Influenza, Human+COVID-19 | RECRUITING | NCT07464314 |
| Licensed Seasonal Influenza Vaccine | Other | Phase PHASE1 | Influenza, Human+COVID-19 | RECRUITING | NCT07464314 |
| Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine | Other | Phase PHASE1 | Influenza, Human+COVID-19 | RECRUITING | NCT07464314 |
| Placebo | Other | Phase PHASE1 | Non-alcoholic Fatty Liver Disease | RECRUITING | NCT07335198 |
| Efimosfermin alfa | Other | Phase PHASE1 | Non-alcoholic Fatty Liver Disease | RECRUITING | NCT07335198 |
| Placebo | Other | Phase PHASE1 | Non-alcoholic Fatty Liver Disease | RECRUITING | NCT07335198 |
| Efimosfermin alfa | Other | Phase PHASE1 | Non-alcoholic Fatty Liver Disease | RECRUITING | NCT07335198 |
| Comparator 3 | Other | Phase PHASE2 | Influenza, Human | ACTIVE_NOT_RECRUITING | NCT07204964 |
| Comparator 2 | Other | Phase PHASE2 | Influenza, Human | ACTIVE_NOT_RECRUITING | NCT07204964 |
| Comparator 1 | Other | Phase PHASE2 | Influenza, Human | ACTIVE_NOT_RECRUITING | NCT07204964 |
| Flu mRNA(Formulation A) | Other | Phase PHASE2 | Influenza, Human | ACTIVE_NOT_RECRUITING | NCT07204964 |
| Flu mRNA (Formulation B3) | Other | Phase PHASE2 | Influenza, Human | ACTIVE_NOT_RECRUITING | NCT07204964 |
| Flu mRNA (Formulation B1) | Other | Phase PHASE2 | Influenza, Human | ACTIVE_NOT_RECRUITING | NCT07204964 |
| Comparator 3 | Other | Phase PHASE2 | Influenza, Human | ACTIVE_NOT_RECRUITING | NCT07204964 |
| Comparator 2 | Other | Phase PHASE2 | Influenza, Human | ACTIVE_NOT_RECRUITING | NCT07204964 |
| Comparator 1 | Other | Phase PHASE2 | Influenza, Human | ACTIVE_NOT_RECRUITING | NCT07204964 |
| Flu mRNA(Formulation A) | Other | Phase PHASE2 | Influenza, Human | ACTIVE_NOT_RECRUITING | NCT07204964 |
| Flu mRNA (Formulation B3) | Other | Phase PHASE2 | Influenza, Human | ACTIVE_NOT_RECRUITING | NCT07204964 |
| Flu mRNA (Formulation B1) | Other | Phase PHASE2 | Influenza, Human | ACTIVE_NOT_RECRUITING | NCT07204964 |
| None (Observational study) | Other | Preclinical | Lupus Nephritis | RECRUITING | NCT06527872 |
| MMF | Other | Phase PHASE2 | Systemic Sclerosis | RECRUITING | NCT03844061 |
| Placebo Infusion | Other | Phase PHASE2 | Systemic Sclerosis | RECRUITING | NCT03844061 |
| Placebo Subcutaneous Injection | Other | Phase PHASE2 | Systemic Sclerosis | RECRUITING | NCT03844061 |
| Rituximab | Other | Phase PHASE2 | Systemic Sclerosis | RECRUITING | NCT03844061 |
| Belimumab | Other | Phase PHASE2 | Systemic Sclerosis | RECRUITING | NCT03844061 |
| Placebo | Other | Phase PHASE4 | Herpes Zoster | NOT_YET_RECRUITING | NCT07502560 |
| Recombinant zoster vaccine | Other | Phase PHASE4 | Herpes Zoster | NOT_YET_RECRUITING | NCT07502560 |
| Momelotinib | Other | Phase PHASE1 | Myelofibrosis | RECRUITING | NCT07104799 |
| Lenalidomide | Other | Phase PHASE2 | Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT04876248 |
| Belantamab Mafodotin | Other | Phase PHASE2 | Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT04876248 |
| Pom/dex (Pomalidomide plus low dose Dexamethasone) | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04162210 |
| Belantamab mafodotin | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04162210 |
| Placebo | Other | Phase PHASE2 | Liver Diseases, Alcoholic | RECRUITING | NCT06613698 |
| GSK4532990 | Other | Phase PHASE2 | Liver Diseases, Alcoholic | RECRUITING | NCT06613698 |
| CAPEOX | Other | Phase PHASE2 | Neoplasms, Colon | RECRUITING | NCT06567782 |
| Dostarlimab | Other | Phase PHASE2 | Neoplasms, Colon | RECRUITING | NCT06567782 |
| CAPEOX | Other | Phase PHASE2 | Neoplasms, Colon | RECRUITING | NCT06567782 |
| Dostarlimab | Other | Phase PHASE2 | Neoplasms, Colon | RECRUITING | NCT06567782 |
| TSR-022 and TSR-042 | Other | Phase PHASE2 | Adult Primary Liver Cancer | ACTIVE_NOT_RECRUITING | NCT03680508 |
| Sunitinib | Other | Phase PHASE3 | Gastrointestinal Neoplasms | RECRUITING | NCT07218926 |
| IDRX-42 | Other | Phase PHASE3 | Gastrointestinal Neoplasms | RECRUITING | NCT07218926 |
| Sunitinib | Other | Phase PHASE3 | Gastrointestinal Neoplasms | RECRUITING | NCT07218926 |
| IDRX-42 | Other | Phase PHASE3 | Gastrointestinal Neoplasms | RECRUITING | NCT07218926 |
| GSK5533524 | Other | Phase PHASE1 | Neoplasms | RECRUITING | NCT07438782 |
| GSK5533524 | Other | Phase PHASE1 | Neoplasms | RECRUITING | NCT07438782 |
| Placebo | Other | Phase PHASE1 | Colitis, Ulcerative | ACTIVE_NOT_RECRUITING | NCT06681181 |
| GSK4528287 | Other | Phase PHASE1 | Colitis, Ulcerative | ACTIVE_NOT_RECRUITING | NCT06681181 |
| Placebo | Other | Phase PHASE1 | Colitis, Ulcerative | ACTIVE_NOT_RECRUITING | NCT06681181 |
| GSK4528287 | Other | Phase PHASE1 | Colitis, Ulcerative | ACTIVE_NOT_RECRUITING | NCT06681181 |
| rMenB+OMV NZ | Other | Phase PHASE4 | Meningitis, Meningococcal | ACTIVE_NOT_RECRUITING | NCT06113198 |
| Abemaciclib | Other | Phase PHASE2 | Intracranial Meningioma | RECRUITING | NCT02523014 |
| Capivasertib | Other | Phase PHASE2 | Intracranial Meningioma | RECRUITING | NCT02523014 |
| FAK Inhibitor GSK2256098 | Other | Phase PHASE2 | Intracranial Meningioma | RECRUITING | NCT02523014 |
| Vismodegib | Other | Phase PHASE2 | Intracranial Meningioma | RECRUITING | NCT02523014 |
| non-adjuvanted A(H1N1)v influenza vaccine | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT01008813 |
| adjuvanted A(H1N1)v influenza vaccine | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT01008813 |
| non-adjuvanted A(H1N1)v influenza vaccine | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT01008813 |
| adjuvanted A(H1N1)v influenza vaccine | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT01008813 |
| non-adjuvanted A(H1N1)v influenza vaccine | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT01008813 |
| adjuvanted A(H1N1)v influenza vaccine | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT01008813 |
| Shingrix | Other | Phase PHASE3 | Kidney Transplant Recipient Response to Shingrix Vaccine | RECRUITING | NCT04128189 |
| Camlipixant | Other | Phase PHASE2 | Irritable Bowel Syndrome | NOT_YET_RECRUITING | NCT07519395 |
| Placebo | Other | Phase PHASE2 | Irritable Bowel Syndrome | NOT_YET_RECRUITING | NCT07519395 |
| Ruxolitinib | Other | Phase PHASE4 | Myelofibrosis | NOT_YET_RECRUITING | NCT07498205 |
| Momelotinib | Other | Phase PHASE4 | Myelofibrosis | NOT_YET_RECRUITING | NCT07498205 |
| Ruxolitinib | Other | Phase PHASE4 | Myelofibrosis | NOT_YET_RECRUITING | NCT07498205 |
| Momelotinib | Other | Phase PHASE4 | Myelofibrosis | NOT_YET_RECRUITING | NCT07498205 |
| Placebo | Other | Phase PHASE2 | Meningitis, Meningococcal | ACTIVE_NOT_RECRUITING | NCT05087056 |
| MenABCWY vaccine | Other | Phase PHASE2 | Meningitis, Meningococcal | ACTIVE_NOT_RECRUITING | NCT05087056 |
| PCV20 | Other | Phase PHASE1 | Pneumonia, Bacterial | RECRUITING | NCT07428759 |
| Pn-MAPS30plus | Other | Phase PHASE1 | Pneumonia, Bacterial | RECRUITING | NCT07428759 |
| Placebo | Other | Phase PHASE3 | Non-alcoholic Fatty Liver Disease | RECRUITING | NCT07221227 |
| Efimosfermin alfa | Other | Phase PHASE3 | Non-alcoholic Fatty Liver Disease | RECRUITING | NCT07221227 |
| No treatment | Drug | Phase PHASE3 | Stage III Ovarian Cancer | RECRUITING | NCT05659381 |
| Cisplatin | Other | Phase PHASE3 | Stage III Ovarian Cancer | RECRUITING | NCT05659381 |
| No treatment | Drug | Phase PHASE3 | Stage III Ovarian Cancer | RECRUITING | NCT05659381 |
| Cisplatin | Other | Phase PHASE3 | Stage III Ovarian Cancer | RECRUITING | NCT05659381 |
| Saline | Other | Phase PHASE2 | Salmonella Infections | RECRUITING | NCT07286370 |
| Nimenrix | Other | Phase PHASE2 | Salmonella Infections | RECRUITING | NCT07286370 |
| Prevenar 13 | Other | Phase PHASE2 | Salmonella Infections | RECRUITING | NCT07286370 |
| TYPHIBEV | Other | Phase PHASE2 | Salmonella Infections | RECRUITING | NCT07286370 |
| Full dose of iNTS-TCV | Other | Phase PHASE2 | Salmonella Infections | RECRUITING | NCT07286370 |
| Low dose of iNTS-TCV | Other | Phase PHASE2 | Salmonella Infections | RECRUITING | NCT07286370 |
| Placebo | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | RECRUITING | NCT07220109 |
| RSVPreF3 OA vaccine | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | RECRUITING | NCT07220109 |
| RSVPreF3 OA vaccine | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | ACTIVE_NOT_RECRUITING | NCT06534892 |
| Luspatercept | Other | Phase PHASE2 | Primary Myelofibrosis | RECRUITING | NCT06517875 |
| Momelotinib | Other | Phase PHASE2 | Primary Myelofibrosis | RECRUITING | NCT06517875 |
| MMB | Other | Phase PHASE2 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT03441113 |
| Belimumab | Other | Phase PHASE1 | Graft Vs Host Disease | COMPLETED | NCT03207958 |
| Placebo | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT01649765 |
| Belimumab 10 mg/kg | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT01649765 |
| rMenB+OMV NZ vaccine | Other | Phase PHASE3 | Meningitis | COMPLETED | NCT06995430 |
| Placebo | Other | Phase PHASE1 | Urinary Tract Infections | RECRUITING | NCT06702449 |
| Candidate UTI vaccine HTD formulation 2 | Other | Phase PHASE1 | Urinary Tract Infections | RECRUITING | NCT06702449 |
| Candidate UTI vaccine high dose formulation 2 | Other | Phase PHASE1 | Urinary Tract Infections | RECRUITING | NCT06702449 |
| Candidate UTI vaccine high dose formulation 1 | Other | Phase PHASE1 | Urinary Tract Infections | RECRUITING | NCT06702449 |
| Candidate UTI vaccine medium dose formulation 2 | Other | Phase PHASE1 | Urinary Tract Infections | RECRUITING | NCT06702449 |
| Candidate UTI vaccine medium dose formulation 1 | Other | Phase PHASE1 | Urinary Tract Infections | RECRUITING | NCT06702449 |
| Candidate UTI vaccine low dose formulation 2 | Other | Phase PHASE1 | Urinary Tract Infections | RECRUITING | NCT06702449 |
| Candidate UTI vaccine low dose formulation 1 | Other | Phase PHASE1 | Urinary Tract Infections | RECRUITING | NCT06702449 |
| GSK3772701 50 mg | Other | Phase PHASE2 | Malaria, Falciparum | NOT_YET_RECRUITING | NCT07545681 |
| GSK3772701 400 mg | Other | Phase PHASE2 | Malaria, Falciparum | NOT_YET_RECRUITING | NCT07545681 |
| GSK3772701 150 mg | Other | Phase PHASE2 | Malaria, Falciparum | NOT_YET_RECRUITING | NCT07545681 |
| GSK3772701 900 mg | Other | Phase PHASE2 | Malaria, Falciparum | NOT_YET_RECRUITING | NCT07545681 |
| GSK3772701 600 mg | Other | Phase PHASE2 | Malaria, Falciparum | NOT_YET_RECRUITING | NCT07545681 |
| GSK3772701 50 mg | Other | Phase PHASE2 | Malaria, Falciparum | NOT_YET_RECRUITING | NCT07545681 |
| GSK3772701 400 mg | Other | Phase PHASE2 | Malaria, Falciparum | NOT_YET_RECRUITING | NCT07545681 |
| GSK3772701 150 mg | Other | Phase PHASE2 | Malaria, Falciparum | NOT_YET_RECRUITING | NCT07545681 |
| GSK3772701 900 mg | Other | Phase PHASE2 | Malaria, Falciparum | NOT_YET_RECRUITING | NCT07545681 |
| GSK3772701 600 mg | Other | Phase PHASE2 | Malaria, Falciparum | NOT_YET_RECRUITING | NCT07545681 |
| Recombinant Herpes Zoster Vaccine (Shingrix) | Other | Phase PHASE4 | Cardiovascular Disease | NOT_YET_RECRUITING | NCT07485283 |
| Topotecan | Other | Phase PHASE3 | Neoplasms, Lung | RECRUITING | NCT07099898 |
| Ris-Rez | Other | Phase PHASE3 | Neoplasms, Lung | RECRUITING | NCT07099898 |
| Momelotinib | Other | Phase PHASE2 | Myelodysplastic Syndromes | RECRUITING | NCT06847867 |
| Momelotinib | Other | Phase PHASE2 | Myelodysplastic Syndromes | RECRUITING | NCT06847867 |
| Daratumumab | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06679101 |
| Dexamethasone | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06679101 |
| Lenalidomide | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06679101 |
| Belantamab mafodotin | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06679101 |
| Daratumumab | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06679101 |
| Dexamethasone | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06679101 |
| Lenalidomide | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06679101 |
| Belantamab mafodotin | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06679101 |
| Recommendation for the diagnoses and treatment of Severe Asthma | Drug | Preclinical | Severe Asthma | ACTIVE_NOT_RECRUITING | NCT06389058 |
| SOC | Other | Phase PHASE1 | Urinary Tract Infections | NOT_YET_RECRUITING | NCT07371429 |
| Gepotidacin | Other | Phase PHASE1 | Urinary Tract Infections | NOT_YET_RECRUITING | NCT07371429 |
| Depemokimab | Other | Phase PHASE3 | Asthma | RECRUITING | NCT06979323 |
| Dexamethasone | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT06868667 |
| Bortezomib | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT06868667 |
| Daratumumab | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT06868667 |
| Belantamab mafodotin | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT06868667 |
| Dexamethasone | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT06868667 |
| Bortezomib | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT06868667 |
| Daratumumab | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT06868667 |
| Belantamab mafodotin | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT06868667 |
| Dexamethasone | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT06868654 |
| Bortezomib | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT06868654 |
| Daratumumab | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT06868654 |
| Belantamab mafodotin | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT06868654 |
| Niraparib | Other | Phase PHASE4 | Ovarian Cancer | RECRUITING | NCT06412120 |
| GSK5458514 | Other | Phase PHASE1 | Neoplasms, Prostate | RECRUITING | NCT06990880 |
| Belimumab Auto-Injector [Benlysta] | Other | Phase PHASE2 | Autoimmune Hepatitis | RECRUITING | NCT06381453 |
| Niraparib | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT06077877 |
| GSK4524101 | Other | Phase PHASE1 | Neoplasms | ACTIVE_NOT_RECRUITING | NCT06077877 |
| Placebo | Other | Phase PHASE2 | COPD | COMPLETED | NCT04075331 |
| Mepolizumab | Other | Phase PHASE2 | COPD | COMPLETED | NCT04075331 |
| Placebo | Other | Phase PHASE4 | Herpes Zoster | RECRUITING | NCT07502560 |
| Recombinant zoster vaccine | Other | Phase PHASE4 | Herpes Zoster | RECRUITING | NCT07502560 |
Total products: 9402